{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "f2b1d406-70b1-40be-9490-be2ed3e5d55d",
   "metadata": {},
   "outputs": [],
   "source": [
    "import os\n",
    "from langchain.document_loaders import PyPDFLoader\n",
    "from langchain.text_splitter import RecursiveCharacterTextSplitter\n",
    "from langchain.embeddings import HuggingFaceEmbeddings\n",
    "from langchain_community.vectorstores import LanceDB\n",
    "from langchain_community.embeddings import HuggingFaceEmbeddings\n",
    "import lancedb\n",
    "from langchain.chains import RetrievalQA\n",
    "from langchain_openai import ChatOpenAI\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "48f3786f-d47e-4b7a-a6d3-3cf55fef71cd",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Loaded 286 pages\n"
     ]
    }
   ],
   "source": [
    "PDF_PATH = \"Kenya-ARV-Guidelines-2022-Final-1.pdf\"\n",
    "\n",
    "loader = PyPDFLoader(PDF_PATH)\n",
    "documents = loader.load()\n",
    "\n",
    "print(f\"Loaded {len(documents)} pages\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "98dd4b72-0a7f-45fe-8299-98b9e39295e5",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Chunking"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "fbbd212a-64df-4fcb-9b94-a0970806df10",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Created 1013 chunks\n"
     ]
    }
   ],
   "source": [
    "text_splitter = RecursiveCharacterTextSplitter(\n",
    "    chunk_size=800,\n",
    "    chunk_overlap=150,\n",
    "    separators=[\"\\n\\n\", \"\\n\", \".\", \" \"]\n",
    ")\n",
    "\n",
    "chunks = text_splitter.split_documents(documents)\n",
    "print(f\"Created {len(chunks)} chunks\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "0dfead11-828f-468e-86b0-397281847f5c",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[Document(page_content=' \\n \\n', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 0}),\n",
       " Document(page_content='', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 1}),\n",
       " Document(page_content='  \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n2022 Edition  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 2}),\n",
       " Document(page_content=' \\n  \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n© National AIDS & STI Control Program 2022  \\n \\nThis guideline document is a publication of the National AIDS & STI Control Program, Ministry of Health \\nKenya. No part of this publication may be reproduced, distributed, or transmitted in any form or by any \\nmeans, including photocopying or recording, without the prior written permission of the National AIDS and \\nSTI Contro l Program (NASCOP), Ministry of Health Kenya, except for non -commercial uses permitted by \\ncopyright law.  \\n \\nKenya HIV Prevention and Treatment Guidelines, 2022  edition contain relevant information required by \\nhealthcare providers in the use of ARVs as of the date of issue. All reasonable precautions have been taken \\nby NASCOP to verify the information contained in this guideline document.   \\n \\nFor clarifications contact National AIDS and STI Control Program (NASCOP) at P. O. Box 19361 - 00202, \\nNairobi Kenya, T el: +254 (020) 2630867, Email: info@nascop.or.ke, Website: www.nascop.or.ke  \\nThe recommended citation for this document is:  \\nMinistry of Health, National AIDS & STI Control Program. Kenya HIV Prevention and Treatment Guidelines, \\n2022  Edition. Nairobi, Kenya: NASCOP, Aug  2022. Print.  \\n \\n \\n \\nDesign and Layout: Collins Etemesi - NASCOP  \\nISBN: 13 -978 -9966 -038 -31-9\\n', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 3}),\n",
       " Document(page_content=' \\n \\ni Foreword  \\nKenya is committed to achieving the UNAIDS 95 –95–95 testing and treatment targets among \\npeople living with HIV within all sub -populations and age groups.  \\nThe 2022 edition of the ‘Guidelines on Use of Antiretroviral Drugs for Treating and Pr eventing \\nHIV Infection in Kenya’ is an update of the comprehensive HIV prevention, Care and treatment \\nguidelines released in 2018. These guidelines are aligned with the Ministry of Health’s mission of \\nproviding the highest standard of health for all Kenyan s and one of the Government of Kenya’s Big \\nFour Agenda on Universal Health Coverage .  \\nThe theme of the 2022 guidelines is refocusing efforts in the management of Advanced HIV \\nDisease to reduce HIV/AIDS related morbidity and mortality. While Kenya has made tremendous \\nprogress in HIV Prevention, Care and Treatment through introduction of better medicines, \\ndiagnostics and patient centered approaches in service delivery, Advanced HIV Disease continues \\nto be a challenge. These guidelines intend to widen access t o key diagnostics and medicines to \\nmanage the most common causes of illness and death. Further, emphasis on integrated delivery \\nof patient -centered HIV, TB, NCDs, mental health and sexual and reproductive health services has \\nbeen included.  \\nThese guidelines  provide key recommendations on  HIV testing services and linkage to prevention \\nand treatment; initial evaluation and follow up of PLHIV; standard package of care for PLHIV; \\nadherence preparation monitoring and support; antiretroviral therapy in infants, c hildren, \\nadolescents and adults; prevention of mother to child transmission of HIV, Syphilis and Viral \\nHepatitis; TB/HIV coinfection; Hepatitis B & C/HIV co -infection; use of ARVs for post and pre -\\nexposure prophylaxis for HIV uninfected populations; and HI V services for people who inject \\ndrugs.  \\nThe guidelines are an important tool meant to be used by service providers at all levels of the \\nhealth sector in Kenya. They are presented in a simplified manner using a public health approach \\nto HIV prevention and treatment.  \\nIt is my hope that this guidance document provides the much -needed framework and impetus to \\nmove towards universal access for HIV services and the agenda of ending AIDS by 2030 as a key \\nnational health strategic objective.  \\n \\n \\nDr. Patrick Amoth , EBS  \\nAg. Director General for Health , \\nMinistry of Health . \\n', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 4}),\n",
       " Document(page_content=' \\n \\nii Acknowledgement s \\n \\nThe 2022 Guidelines on Use of Antiretroviral Drugs for Treating and Preventing HIV Infection in \\nKenya has been a long -awaited document as the revision was greatly affected by the COVID -19 \\npandemic. The document has been updated through the collaborative effort of multiple \\nstakeholders, both individuals and institutions, that contributed to the extensive consultations \\nled by NASCOP HIV Care and Treatment Program.  \\n \\nWith much appreciation, I acknowledge all the institutions, both local and international, \\ngovernment ministries and departments whose staff spent long hours, both virtually and in \\nperson, in the review, writing and finalization of this document.  \\n \\nI take th is opportunity to appreciate the efforts of the Ministry of Health officers at NASCOP and \\nother institutions who coordinated and provided leadership during the review process. \\nCompliments to the guidelines review secretariat and the special task force who worked tirelessly \\nto ensure that the team produced a great quality document. Particular appreciation to the \\nNASCOP team and numerous TA’s who were instrumental in compiling the evidence review and \\ndeveloping the guidelines. Special thanks to the consultant s; Jeremy Penner, Irene Mukui, and \\nHerb Harwell for their dedication to this process.  \\n \\nFinancial support for the review process, printing and launch of this document was provided by \\nthe Global Fund, UNITAID through CHAI, the US government through the Cent ers for Disease \\nControl and Prevention and ICAP at Columbia University through the USAID -funded RISE -Kenya \\nProject, WHO and UNICEF - Kenya.  \\n \\n \\n \\nDr. Rose Wafula  \\nHead, National AIDS & STI Control Program  \\nMinistry of Health\\n', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 5}),\n",
       " Document(page_content=' \\n \\niii Table of Contents  \\nForeword  ................................ ................................ ................................ ................................ ................................ .......... i \\nAcknowledgements  ................................ ................................ ................................ ................................ ....................  ii \\nTable of Contents  ................................ ................................ ................................ ................................ ........................  iii \\nList of Figures  ................................ ................................ ................................ ................................ ...............................  ix \\nList of Tables  ................................ ................................ ................................ ................................ ................................ ..x \\nAcronyms and Abbreviations  ................................ ................................ ................................ ............................  xiii \\n1. Summary of Key Recommendations  ................................ ................................ ..................  1 \\n1.1 HIV Testing Services (HTS) and Linkage to Treatment and Prevention  ................................ ..... 1 \\n1.2 Initial Evaluation and Follow -up for PLHIV  ................................ ................................ .............................  1 \\n1.3 Standard Package of Care for PLHIV  ................................ ................................ ................................ ...........  2 \\n1.4 Adherence Preparation, Monitoring and Support  ................................ ................................ ................  4 \\n1.5 Antiretroviral Therapy for Infants, Children, Adolescents, and Adults  ................................ ....... 4 \\n1.6 Prevention of Mother to Child Transmission of HIV/Syphilis/HBV  ................................ .............  5 \\n1.7 TB/HIV Co -infection Prevention and Management  ................................ ................................ .............  6 \\n1.8 HBV/HIV and HCV/HIV Co -infection Prevention and Management  ................................ .............  7 \\n1.9 ARVs for Post -exposure Prophylaxis (PEP)  ................................ ................................ .............................  7 \\n1.10 Pre -Exposure Prophylaxis (PrEP)  ................................ ................................ ................................ .............  7 \\n1.11 People Who Inject Drugs (PWID) and HIV  ................................ ................................ ............................  8 \\n2. HIV Testing Services and Linkage to Treatment and Prevention  ...........................  1 \\n2.1 Settings for HIV Testing  ................................ ................................ ................................ ................................ .... 1 \\n2.1.1 Facility -based testing  ................................ ................................ ................................ ................................ ..........................  1 \\n2.1.2 Community –based testing  ................................ ................................ ................................ ................................ ................  2 \\n2.2 HTS strategies  ................................ ................................ ................................ ................................ .......................  2 \\n2.2.1 HIV Self -Testing (HIVST)  ................................ ................................ ................................ ................................ ...................  2 \\n2.2.2 Index Testing  ................................ ................................ ................................ ................................ ................................ ...........  2 \\n2.2.3 Voluntary Counselling and Testing (VCT):  ................................ ................................ ................................ ...............  2 \\n2.2.4 Social Network Strategy (SNS) - ................................ ................................ ................................ ................................ ...... 2 \\n2.3 Package of HI V Testing Services  ................................ ................................ ................................ ...................  5 \\n2.4 Age -Specific HIV Testing Algorithms  ................................ ................................ ................................ ..........  8 \\n2.4.1 Early Infant Diagnosis  ................................ ................................ ................................ ................................ .................  8 \\n2.4.2 Diagnosis of HIV Infection in the Older Child (≥ 18 months), Adolescents and Adults  ............  12 \\n2.4.3 HIV testing for Pregnant Women  ................................ ................................ ................................ .......................  14 \\n2.5 Retesting recommendations for HIV negative pe rsons  ................................ ................................ ... 17 \\n2.6 Inconclusive HIV status  ................................ ................................ ................................ ................................ .. 18 \\n2.7 Approach to Patients on ART with a Discrepant HIV Test Result  ................................ ...............  19 ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 6}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n \\niv 3. Initial Evaluation and Follow up  ................................ ................................ .........................  1 \\n3.1 Introduction  ................................ ................................ ................................ ................................ ...........................  1 \\n3.2 Initial Clinical Evaluation of PLHIV  ................................ ................................ ................................ ..............  1 \\n3.3 Initial Laboratory Evaluation of PLHIV  ................................ ................................ ................................ ...... 4 \\n3.4 Managem ent of Patients Who Present with Advanced HIV Disease  ................................ .............  6 \\n3.5 Follow -up of PLHIV after ART initiation  ................................ ................................ ................................ ... 8 \\n3.5.1 First 6 months after ART initiation  ................................ ................................ ................................ ..............................  9 \\n3.5.2 Differentiated Service Delivery for Patients beyond the 1st 6 months of ART  ................................ ....... 9 \\n3.6 Summary of clinical and laboratory monitoring of PLHIV on ART ................................ .............  11 \\n3.7 Differentiated Care for Chi ldren, Adolescents and Pregnant/ breastfeeding Women  ...... 13 \\n3.8 ART Prescription, Dispensing, and Distribution for clients establishe d on ART  .................  14 \\n4. Standard Package of Care for PLHIV ................................ ................................ ..................  1 \\n4.1 Antiretrovir al Therapy  ................................ ................................ ................................ ................................ ...... 4 \\n4.2 PHDP, GBV/IPV & HIV Education/Counselling  ................................ ................................ ......................  5 \\n4.2.1 Screening for Gender -Based Violence (GBV)/Intimate -Partner Violence (IPV)  ................................ .... 6 \\n4.2.2 HIV Education/Counselling  ................................ ................................ ................................ ................................ ..............  7 \\n4.3 Specific Opportun istic Infection Screening and Prevention  ................................ .............................  8 \\n4.3.1 Cotrimoxazole Preventive Therapy (CPT)  ................................ ................................ ................................ ................  8 \\n4.3.2 Tuberculosis (TB) Prevention and Management for PLHIV  ................................ ................................ ..........  11 \\n4.3.3 Cryptococcal Meningitis (CM) Screening and Treatment  ................................ ................................ ...............  11 \\n4.4 Reproductive Health Services  ................................ ................................ ................................ .....................  15 \\n4.4.1 Sexually Transmitted Infections  ................................ ................................ ................................ ................................ . 15 \\n4.4.2 Family Planning and Pre -Conception Counselling  ................................ ................................ .............................  15 \\n4.4.3 Maternal Healthcare  ................................ ................................ ................................ ................................ .........................  18 \\n4.5 Non -communicable Diseas es Screening and Management  ................................ ............................  18 \\n4.5.1 Metabolic Disorders  ................................ ................................ ................................ ................................ ..........................  18 \\n4.5.2 Cancer Prevention, Early Detection and Management among PLHIV  ................................ ......................  23 \\n4.6 Mental Health Screening and Management  ................................ ................................ ..........................  25 \\n4.6.1 Depre ssion  ................................ ................................ ................................ ................................ ................................ .............  25 \\n4.6.2 Alcohol and Drug Use/Addiction  ................................ ................................ ................................ ................................  28 \\n4.6.3 Anxiety ................................ ................................ ................................ ................................ ................................ .....................  31 \\n4.6.4 Stress and stress management  ................................ ................................ ................................ ................................ .... 32 \\n4.6.5 experiences o f Trauma  ................................ ................................ ................................ ................................ ....................  33 \\n4.6.6 Psychosis  ................................ ................................ ................................ ................................ ................................ ................  34 \\n4.6.7 Self -Care  ................................ ................................ ................................ ................................ ................................ ..................  34 \\n4.6.8 Wellbeing  ................................ ................................ ................................ ................................ ................................ ...............  35 ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 7}),\n",
       " Document(page_content=' \\n \\nv 4.7 Nutritional Services  ................................ ................................ ................................ ................................ .........  36 \\n4.7.1 Nutritional Assessment, Counselling and Support (NACS)  ................................ ................................ ............  36 \\n4.8 Prevention of Other Infections  ................................ ................................ ................................ ...................  40 \\n4.8.1 Immunizations  ................................ ................................ ................................ ................................ ................................ ..... 40 \\n4.8.2 Malaria  ................................ ................................ ................................ ................................ ................................ .....................  42 \\n4.8.3 Safe Water, Sanitation and Hygien e ................................ ................................ ................................ ..........................  42 \\n5. Adherence Preparation, Monitoring and Support  ................................ ........................  1 \\n5.1 Undetectable = Untransmittable (U=U)  ................................ ................................ ................................ ..... 5 \\n5.1.1 Benefits of U=U  ................................ ................................ ................................ ................................ ................................ ....... 5 \\n5.1.2 Considerations for implem entation of U=U within clinical settings  ................................ ............................  5 \\n5.1.3 Messaging to Patients on U=U  ................................ ................................ ................................ ................................ .........  5 \\n5.1.4 How patients can discuss U=U with others  ................................ ................................ ................................ ..............  6 \\n5.1.5 Counselling patients about other prevention combination interventions  ................................ ................  6 \\n5.1.6 Application of U=U in o ther settings  ................................ ................................ ................................ ............................  6 \\n5.2 ART Adherence Preparation and Support  ................................ ................................ ................................  7 \\n5.2.1 Treatment Preparation as Part of HIV Testing Services  ................................ ................................ ....................  7 \\n5.2.2 ART Treatment Preparation  ................................ ................................ ................................ ................................ ............  7 \\n5.2.3 Age -Specific Tr eatment Preparation and Support  ................................ ................................ .............................  13 \\n5.3 Adherence Monitoring, Counselling and Support During the First 3 Months of ART  ........ 20 \\n5.3.1 Adherence Monitoring  ................................ ................................ ................................ ................................ .....................  20 \\n5.3.2 Adherence Counselling and Support During the First 3 Months of ART  ................................ .................  25 \\n5.4 Adherence Monitoring, Counselling and Support for Patients with Suppressed Viral Load \\n< 200 copies/ml  ................................ ................................ ................................ ................................ ...... 29 \\n5.5 Adherence Monitoring, Counselling and Support for Patients with Unsuppressed Viral \\nLoad ≥ 200 copies/ml  ................................ ................................ ................................ ...........................  30 \\n5.5.1 Enhanced Adherence Assessments  ................................ ................................ ................................ ...........................  31 \\n5.5.2 Enhanced Adherence Counselling  ................................ ................................ ................................ ..............................  31 \\n5.6 Treatment Preparation for 2nd Line or 3rd Line ART  ................................ ................................ ..... 34 \\n5.7 Identifying, Tracing, and Supporting Patients who Default from Care  ................................ ..... 35 \\n6. Antiretroviral Therapy in Infants, Children, Adolescents, and Adults  .................  1 \\n6.1 Eligibility for ART  ................................ ................................ ................................ ................................ ................  1 \\n6.2 Timing of ART Initiation  ................................ ................................ ................................ ................................ ... 1 \\n6.3 First -Line ART for Infants, Children, Adolescents and Adults (including Pregnant and \\nBreastfeeding Women)  ................................ ................................ ................................ ...........................  3 \\n6.4 Dosing and Administration of Dolutegravir (DTG) ................................ ................................ ...............  5 \\n6.5 Monitoring and Changing ART  ................................ ................................ ................................ .......................  7 \\n6.5.1 Optimizing Therapy for Patients who have suppressed viral load on First Line ART .........................  7 ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 8}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n \\nvi 6.5.2 Changing ARVs Due to Adverse Drug Reactions  ................................ ................................ ................................ .... 9 \\n6.5.3 Changing ARVs Due to Drug -Drug Interactions  ................................ ................................ ................................ .. 16 \\n6.5.4 Changing ARVs Due to Treatment Failure  ................................ ................................ ................................ .............  17 \\n7. Prevention of Mother to Child Transmission of HIV/Syphilis/Hepatitis B  .........  1 \\n7.1 Antiretroviral Therapy for HIV -positive Pregnant and Breastfeeding Women and Infant \\nProphylaxis  ................................ ................................ ................................ ................................ ...................  3 \\n7.2. Syphilis elimination for Pregnant and Breastfeeding Women and Infant Treatment  .........  5 \\n7.3. Hepatitis B elimination for Pregnant and Breastfeeding Women and Infant Prophylaxis  5 \\n7.4 Infant and Young Child Nutrition in the Context of HIV  ................................ ................................ ..... 7 \\n8. TB/HIV Co -infection, Prevention  and Management  ................................ ....................  1 \\n8.1 TB Screening for PLHIV: Intensified Case Finding (ICF)  ................................ ................................ .... 1 \\n8.2. TB Preventive Therapy (TPT)  ................................ ................................ ................................ .......................  9 \\n8.2.1. Indications for TPT  ................................ ................................ ................................ ................................ ..............................  9 \\n8.2.2. Contraindications to TPT  ................................ ................................ ................................ ................................ ..............  10 \\n8.2.3. Dose and Duration of TPT  ................................ ................................ ................................ ................................ .............  10 \\n8.2.4. Follow -up of Patients on TPT  ................................ ................................ ................................ ................................ ...... 11 \\n8.3. Identifying and Managing Drug Toxicities from TPT  ................................ ................................ ...... 11 \\n8.3.1 Peripheral Neuropathy - Suspected drug: INH  ................................ ................................ ................................ ..... 11 \\n8.3.2 Drug -Induced Liver Injury (DILI) -Suspected drugs include Isoniazid (H), Rifapentine (P), \\nRifampicin (R)  ................................ ................................ ................................ ................................ ................................ .................  12 \\n8.3.3 Managemen t of TPT -associated Rash - Suspected Drugs include Isoniazid (H), Rifapentine (P), \\nRifampicin (R)  ................................ ................................ ................................ ................................ ................................ .................  13 \\n8.4. ART for TB/HIV Co -infect ion ................................ ................................ ................................ ......................  13 \\n9. HBV/HIV and HCV/HIV Co -infection Prevention and Management  .......................  1 \\n9.1 Hepatitis B/HIV Co -infection  ................................ ................................ ................................ ..........................  1 \\n9.1.1 Screening  ................................ ................................ ................................ ................................ ................................ ...................  1 \\n9.1.2 Prevention  ................................ ................................ ................................ ................................ ................................ ................  1 \\n9.1.3 Treatment  ................................ ................................ ................................ ................................ ................................ .................  2 \\n9.2 Hepatitis C/HIV Co -infection  ................................ ................................ ................................ ..........................  5 \\n9.2.1 Screening  ................................ ................................ ................................ ................................ ................................ ...................  5 \\n9.2.2 Prevention  ................................ ................................ ................................ ................................ ................................ ................  6 \\n9.2.3 Treatment of HIV/HCV Co -infection  ................................ ................................ ................................ ............................  6 \\n10. ARVs for Post -exposure Prophylaxis  ................................ ................................ .................  1 \\n10.1 What is P EP? ................................ ................................ ................................ ................................ ........................  1 \\n10.2 Recommended ARVs for PEP  ................................ ................................ ................................ .......................  1 \\n10.3 Eligibility For PEP  ................................ ................................ ................................ ................................ .............  2 \\n10.4 Management and Follow Up ................................ ................................ ................................ .........................  2 ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 9}),\n",
       " Document(page_content=' \\n \\nvii 10.5 Risk reduction cou nselling ................................ ................................ ................................ ............................  4 \\n10.6 Preventing HIV exposure  ................................ ................................ ................................ ...............................  4 \\n11. Pre-Exposure Prophylaxis (PrEP)  ................................ ................................ ......................  1 \\n11.1 Indications for PrEP and Criteria for Eligibility  ................................ ................................ ..................  1 \\n11.1.1 Indications for PrEP  ................................ ................................ ................................ ................................ ..........................  1 \\n11.1.2 HIV Risk Assessment  ................................ ................................ ................................ ................................ ........................  1 \\n11.1.3 Criteria for PrEP Eligibility  ................................ ................................ ................................ ................................ ............  2 \\n11.2 Package of PrEP Service  ................................ ................................ ................................ ................................ . 3 \\n11.2.1 Pre -Initiation Che cklist  ................................ ................................ ................................ ................................ ....................  4 \\n11.2.2 Pre -initiation client education  ................................ ................................ ................................ ................................ ..... 5 \\n11.3 Recommended ARVs for PrEP  ................................ ................................ ................................ .....................  5 \\n11.3.1 Schema for follow up for daily oral PrEP  ................................ ................................ ................................ ................  7 \\n11.3. 2 EVENT DRIVEN PrEP (ON DEMAND PrEP or 2+1+1 PrEP)  ................................ ................................ ...........  7 \\n11.4 Managing Clinical and Laboratory Results on Initial and Follow -up Asse ssment  ...............  9 \\n11.5 Contra -indications to Oral PrEP (daily or ED PrEP)  ................................ ................................ ....... 12 \\n11.6 Criteria for Discontinuing Oral PrEP  ................................ ................................ ................................ ..... 12 \\n11.7 Restarting PrEP  ................................ ................................ ................................ ................................ ...............  12 \\n11.8 Improving adherence to PrEP  ................................ ................................ ................................ ..................  13 \\n11.9 Monitoring Sero -conversion among PrEP users  ................................ ................................ ..............  13 \\n12. People Who Inject Drugs (PWID) and HIV ................................ ................................ ....... 1 \\n12.1 Intro duction  ................................ ................................ ................................ ................................ ........................  1 \\n12.3 ART in HIV positive PWID  ................................ ................................ ................................ .............................  4 \\n13. Annexes  ................................ ................................ ................................ ................................ ........  1 \\nAnnex 1: WHO Clinical Staging of HIV Infection in Infants and Children  ................................ ...........  1 \\nAnnex 2: WHO Clinical Staging of HIV Infection in Adolescents and Adults  ................................ ..... 2 \\nAnnex 3: Normal Developmental Miles tones in Children  ................................ ................................ .........  3 \\nAnnex 4: Tanner Staging of Sexual Maturity in Adolescents  ................................ ................................ ... 4 \\nAnnex 4 A: Tanner Staging of Sexual Maturity in Girls ................................ ................................ ................................ ... 4 \\nAnnex 4 B: Tanner Staging of Sexual Maturity in Boys  ................................ ................................ ................................ .. 4 \\nAnnex 5: Age -Appropriate Disclosure for Child ren and Adolescents  ................................ ..................  5 \\nAnnex 6: Transitioning from Adolescent to Adult HIV Services  ................................ .............................  6 \\nAnnex 7: 2018 HIV Testing Services Algorithm ................................ ................................ .............................  7 \\nAnnex 8: HIV Education and Adherence Counselling Content Guide  ................................ ...................  8 \\nAnnex 9 A: Enhanced Adherence Counselling Content Guide  ................................ ..............................  16 \\nAnnex 9 B: Case Summary Form  ................................ ................................ ................................ .......................  22 \\nAnnex 9 C: Enhanced Adherence Counselling Form  ................................ ................................ .................  24 \\nAnnex 9 D: Home Visit Checklist  ................................ ................................ ................................ .......................  25 ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 10}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n \\nviii Annex 9 E: Management Protocol for Patients Switc hing to 3rd Line ART  ................................ .... 26 \\nAnnex 10 A: Dosing of Solid and Liquid Formulations for Twice -Daily Dosing in Infants and \\nChildren 4 Week s of Age and Older  1 ................................ ................................ .............................  28 \\nAnnex 10 B: Simplified Dosing of Child -Friendly Solid and Oral Liquid Formulations for Once -\\nDaily Dosing in Infants and Children 4 Weeks of Age and Older1 ................................ ..... 29 \\nAnnex 10 C: Drug Dosing of Liquid Formulations for Twice -Daily Dosing in Infants Less than \\n4 Weeks of Age  ................................ ................................ ................................ ................................ .........  30 \\nAnnex 10 D: Simplified Dosing of INH and CTX Prophylaxis for Infants and Children Who Are \\nat Least 4 Weeks of Age  ................................ ................................ ................................ .......................  30 \\nAnn ex 10 E: TB Preventive Therapy dosing  ................................ ................................ ................................ . 31 \\nAnnex 10 F: Ritonavir Dosing for Super -Boosting LPV/r in Children Taking Rifampicin  ....... 34 \\nAnnex 11: Overlapping toxicities between AR Vs ................................ ................................ .......................  35 \\nAnnex 12 A: Use of Nucleoside & Nucleotide Reverse Transcriptase Inhibitors in Adults  ..... 36 \\nAnnex 12 B: Use of Non -Nucleoside Reverse Transcriptase Inhibitors for Adults  .....................  38 \\nAnnex 12 C: Use of Protease Inhibitors in Adults  ................................ ................................ ......................  39 \\nAnnex 12 D: Integrase Strand Transfer Inhibitors - INSTIs  ................................ ................................ .. 40 \\nAnnex 13 A: Drug -Drug Interactions - NNRTIs  ................................ ................................ ...........................  41 \\nAnnex 13 B: Drug -Drug Interactions – PIs ................................ ................................ ................................ .... 45 \\nAnnex 13 C: Drug -Drug Interactions – INSTIs  ................................ ................................ .............................  52 \\nAnnex 14: Health Facility Assessment to Provide Community ART Distribution  .......................  54 \\nAnnex 15: Creatinine Clearance  ................................ ................................ ................................ .........................  55 \\nAnnex 16: Immune Reconstitution Inflammatory Syndrome  ................................ ..............................  56 \\nAnnex 17: HTS Adult Screening Tool Enhancement  ................................ ................................ .................  59 \\nAnnex 18: List of Contributors and Affiliation  ................................ ................................ ............................  60 \\nAnnex 19: List of Participating Organizations and Agencies  ................................ ................................  62 \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 11}),\n",
       " Document(page_content=' \\n \\nix List of Figures  \\nFigure 2.1 Algorithm for Early Infant Diagnosis in Infants and Children < 18 months of age  ................................ .. 9 \\nFigure 2.2: Birth Testing Algor ithm  ................................ ................................ ................................ ................................ ....................  11 \\nFigure 2.3: HIV Testing Services Algorithm  ................................ ................................ ................................ ................................ .... 13 \\nFigure 2.4 Dual HIV/syphilis Testing Algorithm  ................................ ................................ ................................ ..........................  15 \\nFigure 2.5: Managing Patients on ART Who Present with a New Negative HIV Antibody Test  ............................  20 \\nFigure 4.1: Routine Screening for Cryptococcal Meningitis for HIV -infected Adults and Adolescents  .............  14 \\nFigure 4.2: Generalized Anxiety Disorder Assessment (GAD -7) ................................ ................................ ..........................  32 \\nFigure 4.3: Management of Severe Acute Malnutrition in Children  ................................ ................................ ....................  38 \\nFigure 4.4: Management of Malnutrition in Adults with HIV  ................................ ................................ ................................ . 39 \\nFigure 5.1: Adherence Preparation, Monitoring and Support  until Viral Load after 3 Months on ART  ...............  2 \\nFigure 5.2: Adherence Counselling and Education for Patients Preparing to Initiate 2nd Line or 3rd Line \\nART  ................................ ................................ ................................ ................................ ................................ ................................ .....................  34 \\nFigure 5.3: Ident ifying, Tracing and Supporting Patients who Default from Care  ................................ .......................  35 \\nFigure 6.1: Optimizing ART Regimens for Children and adolescents <15 years Weighing < 30 kg on First \\nLine ART  ................................ ................................ ................................ ................................ ................................ ................................ ..............  8 \\nFigure 6.2: Optimizing ART Regimens for Children and Adolescents Weighing ≥ 30 kg  or ≥ 15 years old on \\nFirst Line ART  ................................ ................................ ................................ ................................ ................................ ................................ ... 9 \\nFigure 6.3: General Principles for Managing Adverse Drug Reactions  ................................ ................................ ..............  11 \\nFigure 6.4: Managing Single Drug Substitutions for ART  ................................ ................................ ................................ .........  12 \\nFigure 6.5: Managing TDF -Associated Kidney Toxicity  ................................ ................................ ................................ ............  13 \\nFigure 6.6: Viral Load Monitoring of Patients on ART (1st Line or 2nd Line)  ................................ ...............................  18 \\nFigure 8.1: TB diagnosis - GeneXpert Ultra algorithm  ................................ ................................ ................................ ...................  5 \\nFigure 8.2: Use of TB -LAM for Diagnosis of TB among PLHIV  ................................ ................................ ................................ .. 8 \\nFigure 11.1 : Package of Service for PrEP  ................................ ................................ ................................ ................................ ............  3 \\nFigure 11.2: Schema for Follow -up for Daily Oral PrEP  ................................ ................................ ................................ ...............  7 \\nFigure 11.3 Schema for Event -Driven PrEP  ................................ ................................ ................................ ................................ ....... 8 \\nFigure 11.4 Schema for Initiation and Follow -up for Event -driven PrEP  ................................ ................................ ...........  8 \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 12}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n \\nx List of Tables  \\nTable 2.1: HTS Recommendations for Different Populations and Settings  ................................ ................................ ........ 3 \\nTable 2.2: Summary of HIV Testing Services Package  ................................ ................................ ................................ ..................  6 \\nTable 2.3: Presumptive Diagnosis of HIV in children <18 months while awaiting DNA PCR Results  ................  10 \\nTable 2 .4: Approaches to Improve Linkage to Treatment and Prevention Services  ................................ ..................  16 \\nTable 2.5: Recommendations for Retesting HIV Negative C lients  ................................ ................................ .......................  18 \\nTable 3.1: Initial Clinical Evaluation for PLHIV (History and Physical Examination)  ................................ ...................  2 \\nTable 3.2: Baseline Laboratory Investigatio ns for PLHIV  ................................ ................................ ................................ ...........  4 \\nTable 3.3: Differentiated Care Based on Initial Patient Presentation  ................................ ................................ ...................  7 \\nTable 3.4: Management of patients who are presenting well: WHO Stage 1 or 2, and CD4 count > 200 \\ncell/mm3  ................................ ................................ ................................ ................................ ................................ ................................ ............  8 \\nTable 3.5: Differentiated Follow -up of Patients Beyond the First 6 Months of ART  ................................ ......................  9 \\nTable 3.6: Summary of Clinical and Laboratory Monitoring for PLHIV1 ................................ ................................ ..........  11 \\nTable 4.1: Components of the Standard Package of Care for PLHIV  ................................ ................................ ......................  2 \\nTable 4.2: Domains and Components for PHDP Serv ices ................................ ................................ ................................ ............  5 \\nTable 4.2a: Components of screening for GBV/IPV (LIVES)  ................................ ................................ ................................ ...... 7 \\nTable 4.3: Co -trimoxazole Preventive therapy  ................................ ................................ ................................ ................................ . 8 \\nTable 4.4: Daily Dose of Cotrimoxazole Preventive Therapy  ................................ ................................ ................................ .... 9 \\nTable 4.5: Management of Drug -Associated Skin Rash  ................................ ................................ ................................ ................  9 \\nTable 4.6a: Standard Cotrimoxazole Desensitization Regimen (8 days)  ................................ ................................ ..........  10 \\nTable 4.6b: Rapid Cotrimoxazole Desensitization Regimen (6 hours)  ................................ ................................ ..............  10 \\nTable 4.7: Treatment of Cryptococcal Meningitis  ................................ ................................ ................................ ........................  12 \\nTable 4.8: Contraceptive Methods for PLHIV Based on WHO 2018 Medical Eligibility Criteria  ...........................  16 \\nTable 4.9: Pr e-Conception Counselling Messages and Services for PLHIV  ................................ ................................ ...... 17 \\nTable 4.10: Lifestyle Modifications to Prevent and Manage Cardiovascu lar Disease in PLHIV  ............................  19 \\nTable 4.11 : Hypertension Screening, Diagnosis, and Initial Management for Adult PLHIV  ................................ .... 20 \\nTable 4.12: Type 2 Diabetes Mellitus Screening, Dia gnosis, and Initial Management for PLHIV  .........................  21 \\nTable 4.12: Dyslipidemia Screening, Diagnosis, and Initial Management for PLHIV  ................................ ..................  22 \\nTable 4.13: Chronic Kidney Disease Screening, Diagnosis, and Initial Management for PLHIV  ...........................  23 \\nTable 4.15: Patient Health Questionnaire -9 (PHQ -9) for Depression Screening  ................................ ..........................  26 \\nTable 4.16: CRAFFT Screening Interview for Adolescents  ................................ ................................ ................................ ...... 28 \\nTable 4.17: CAGE -AID Screening Questions for Adults  ................................ ................................ ................................ .............  29 \\nTable 4.18: Addiction Support Based on Stages of Change  ................................ ................................ ................................ ..... 30 \\nTable 4.19: Interpretation of MUAC Results for Children and Pregnant/Lactating Women  ................................ .. 37 \\nTable 4.20: Interpretation of Z -scores for Children  ................................ ................................ ................................ ....................  37 \\nTable 4.21: Interpretation of BMI Results for Adults  ................................ ................................ ................................ .................  40 \\nTable 4.22: Kenya Expanded Program on Immunizations 2016 Schedule  ................................ ................................ ...... 40 ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 13}),\n",
       " Document(page_content=' \\n \\nxi Table 4.23: Vaccinations in Adolescents and Adults Living wit h HIV  ................................ ................................ ................  41 \\nTable 5.1: Treatment Preparation and Adherence Counselling Guide  ................................ ................................ .................  7 \\nTable 5.2: Components of HIV Education (see Annex 8 for detai led content guide)  ................................ ..................  10 \\nTable 5.3: Adherence Support and Retention Interventions  ................................ ................................ ................................ .. 11 \\nTable 5.4: ART Readiness Assessment Form  ................................ ................................ ................................ ................................ . 13 \\nTable 5 .5: Age -appropriate Involvement of Child/Adolescent in HIV Education and Adherence Counselling\\n ................................ ................................ ................................ ................................ ................................ ................................ ..............................  15 \\nTable 5.6: Unique Considerations for Caregivers, Children and Adolescents  ................................ ................................  16 \\nTable 5.7: Treatment Preparation and Support for Chil dren (≤ 9 years) and Caregivers  ................................ ....... 17 \\nTable 5.8: Treatment Preparation and Support for Adolescents (10 -19 years)  ................................ ...........................  18 \\nTable 5.9: Treatment Preparation and Support for Adults  ................................ ................................ ................................ ..... 19 \\nTable 5.10: Adherence Monitoring Strategies  ................................ ................................ ................................ ...............................  21 \\nTable 5.11: Morisky Medication Adherence Scale (MMAS -4) ................................ ................................ ................................  23 \\nTable 5.12: Morisky Medication Adherence Scale (MMAS -8) ................................ ................................ ................................  24 \\nTable 5.13: Adherence Rate Based on Pill Counts  ................................ ................................ ................................ .......................  25 \\nTable 5.14: Adherence Counselling and Support During the First 3 Months of ART  ................................ .................  26 \\nTable 5.15: Assessment for Barriers to Adherence  ................................ ................................ ................................ .....................  27 \\nTable 5.16: Adherence Counselling and Support for Patients with Viral Load < 50 copies/ml  ............................  29 \\nTable 5.17 Viral Load Monitoring Cut -Offs  ................................ ................................ ................................ ................................ ..... 30 \\nTable 5.18: Components of Enhanced Adherence Co unselling Sessions (Annex 9A for detailed content \\nguide)  ................................ ................................ ................................ ................................ ................................ ................................ .................  32 \\nTable 6.1: Special Considerat ions for Timing of ART Initiation  ................................ ................................ ...............................  2 \\nTable 6.2: Preferred First -line ART Regimens and Dosing for Children, Adolescents and Adults 1 .......................  3 \\nTable 6.3: Use of Alternative ARVs in First -Line Regimens 1 ................................ ................................ ................................ .... 4 \\nTable 6.4: Dosing and Administration of Dolutegravir  ................................ ................................ ................................ ................  5 \\nTable 6.5: Common Significant Adverse Drug Reactions  ................................ ................................ ................................ .........  10 \\nTable 6.6: ARV, CTX and Fluconazole Adjustments in Renal and Hepatic Impairment1 ................................ ...........  14 \\nTable 6.7: Management of AZT -Associated Bone Marrow Suppression  ................................ ................................ ...........  15 \\nTable 6.8: Management of Drug -Related Hepatotoxicity  ................................ ................................ ................................ .........  15 \\nTable 6.9: Diagnosis and Management of Abacavir Hypersensitivity Reaction  ................................ ............................  16 \\nTable 6.10: Recommended Second -line ART Regimens in Infants, Children, Adolescents and Adults, \\nexcluding TB/HIV co -infection 1 ................................ ................................ ................................ ................................ ...........................  19 \\nTable 6.11: Possible Third -line ART in Children, Adolescents and Adults  ................................ ................................ ...... 21 \\nTable 7.1: Essential Package of Antenatal Care  ................................ ................................ ................................ ...............................  1 \\nTable 7.2: Summary of Use of ART for HIV Positive Pregnant and Breastfeeding Women  ................................ ........ 3 \\nTable 7.3: ARV Prophylaxis for HIV -Exposed Infants  ................................ ................................ ................................ ...................  6 \\nTable 7.4: Dosing of ARVs for Infant Prophylaxis from Birth to 12 Weeks of Age  ................................ ..........................  7 \\nTable 7.5: NVP Dosing for Infant Prophylaxi s beyond 12 Weeks of Age *  ................................ ................................ ..........  7 \\nTable 7.6: AZT Dosing for Infant Prophylaxis beyond 12 Weeks of Age *  ................................ ................................ ..........  7 ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 14}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n \\nxii Table 7.7: Complementary Foods for Children 6 -24 Months Old  ................................ ................................ ...........................  9 \\nTable 8.1: TB Diagnosis in Children <10 Years Old  ................................ ................................ ................................ ........................  6 \\nTable 8.2: Drug Susceptible TB Treatment Regimen for Children, Adolescents and Adults  ................................ ...... 7 \\nTable 8.3: Recommended TPT Regimens for PLHIV  ................................ ................................ ................................ ..................  10 \\nTable 8.4: Grading and Management of DILI  ................................ ................................ ................................ ................................ .. 12 \\nTable 8.5: Management of TPT -Associated Skin Rash  ................................ ................................ ................................ ...............  13 \\nTable 8.6: Preferred ART Regimens for TB/HIV Co -infection for Patients Newly Initiating 1st Line ART 1 ... 14 \\nTable 8.7: Preferred ART Regimens for Patients who Develop TB while Virally Suppressed on 1st Line ART \\n1,2 ................................ ................................ ................................ ................................ ................................ ................................ ..........................  15 \\nTable 8.8: Recommended ART Regimens for Patients who Develop TB while Failing 1st Line ART 1 ..............  16 \\nTable 9.1: Hepatitis B Vaccination Schedule for HIV -positive Adolescents and Adults  ................................ ...............  2 \\nTable 9.2: Summary of Initial Clinical and Laboratory Evaluation in HIV/HBV Co -infection  ................................ ... 3 \\nTable 9.3: Dose Adjustment of TDF and  3TC in Patients with Impaired Renal Function 1 ................................ .........  4 \\nTable 9.4: Summary of Initial Clinical and Laboratory Evaluation in HIV/HCV Co -infection  ................................ ... 6 \\nTable 9.5: Recommended DAA for the Treatment of HCV among PLHIV  ................................ ................................ ............  7 \\nTable 10.1: Recommended ARVs for PEP  ................................ ................................ ................................ ................................ ...........  1 \\nTable 10.2: Recommendations for PEP Management and Follow -up ................................ ................................ ...................  3 \\nTable 10.3 Considerations for special circumstances  ................................ ................................ ................................ ...................  4 \\nTable 11:1 HIV Screening questions  ................................ ................................ ................................ ................................ .....................  2 \\nTable 11.2: Pre -Initiation Assessment Checklist  ................................ ................................ ................................ .............................  4 \\nTable 11.3: Client Education Checklist  ................................ ................................ ................................ ................................ .................  5 \\nTable 11.4: Antiretrovirals for Use in PrEP  ................................ ................................ ................................ ................................ ....... 6 \\nTable 11. 5 Initial & follow up laboratory test  ................................ ................................ ................................ ................................ ... 9 \\nTable 11.6: Managing Clinical and Laboratory Results on Initial and Follow -up Assessment  ..............................  10 \\nTable 11.7: Summary of PrEP Initial and Follow -up Assessment  ................................ ................................ ........................  11 \\nTable 11.7 Cont: Summary of PrEP Initial and Follow -up Assessment  ................................ ................................ .............  12 \\nTable 12.1: Comprehensive Package of Harm Reduction for PWID  ................................ ................................ ......................  2 \\nTable 12.2: Summary of ART Recommendations for PWID  ................................ ................................ ................................ ....... 5 ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 15}),\n",
       " Document(page_content=' \\n \\nxiii Acronyms and Abbreviations  \\nAbbreviations and Names of Antiretroviral Drugs  Other Acronyms and Abbreviations  \\n3TC  Lamivudine  HTS  HIV Testing Services  \\nABC  Abacavir  ICF  Intensified Case Finding  \\nATV  Atazanavir  IEC  Information, Education and Communication  \\nATV/r  Atazanavir/ritonavir  INH  Isoniazid  \\nAZT  Zidovudine  INSTI  Integrase Strand Transfer Inhibitor  \\nDRV  Darunavir  IPD  In-Patient Department  \\nDRV/r  Darunavir/ritonavir  IPT  Isoniazid Preventive Therapy  \\nDTG  Dolutegravir  IPV Intimate Partner Violence  \\nEFV  Efavirenz  IRIS  Immune Reconstitution Inflammatory \\nSyndrome  \\nETR  Etravirine  ITN  Insecticide Treated Mosquito Nets  \\nFTC  Emtricitabine  IUD  Intrauterine Device  \\nLPV  Lopinavir  KEPI  Kenya Expanded Program of Immunization  \\nLPV/r  Lopinavir/ritonavir  KS  Kaposi’s Sarcoma  \\nNVP        Nevirapine  LEEP  Loop Electrosurgical Excision Procedure  \\nRAL                                Raltegravir  L&D  Labor And Delivery  \\nRTV  Ritonavir  LIVES  Listen, Inquiry, Validate, Enhance Safety and \\nSupport  \\nTDF  Tenofovir Disoproxil Fumarate  LLV  Low Level Viremia  \\nOther Acronyms and Abbreviations  LRF  Laboratory Requisition Form  \\nACE -I Angiotensin -Converting Enzyme Inhibitor  LP Lumbar Puncture  \\nADR  Adverse Drug Reaction  MAC  Mycobacterium Avium Complex  \\nAIDS  Acquired Immunodeficiency Syndrome  MAT  Medically Assisted Therapy  \\nALT  Alanine Transaminase  MCH  Maternal Child Health  \\nALP  Alkaline Phosphatase  MNCH/FP  Maternal, Neonatal and Child Health/Family \\nPlanning  \\nAHI Acute Hiv Infection  MDT  Multi -Disciplinary Team  \\nANC  Antenatal Care  MEC  Medical Eligibility Criteria  \\nA&E  Accident And Emergency  MOH  Ministry of Health  \\nARB  Angiotensin -Receptor Blocker  MSM  Men Who Have Sex with Men  \\nART  Antiretroviral Therapy  MUAC  Mid -Upper Arm Circumference  \\nARV  Antiretroviral Drug(S)  NACS  Nutritional Assessment, Counselling and \\nSupport  \\nAST  Aspartate Transaminase  NASCOP  National AIDS And STI Control Program  \\nBD Twice Daily  NCD  Non -Communicable Diseases  \\nBF Breastfeeding  NHRL  National H IV Reference Laboratory  \\nBMI  Body Mass Index  NNRTI  Non -Nucleoside Reverse Transcriptase \\nInhibitor  \\nBP Blood Pressure  NRTI  Nucleoside Reverse Transcriptase Inhibitor  \\nCAG  Community Art Groups  NSP  Needle and Syringe Programmes  \\nCCC  Comprehensive Care Centre  NRTI  Nucleotide Reverse Transcriptase Inhibitor  \\nCrCl  Creatinine Clearance  OD  Once Daily  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 16}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n \\nxiv CHV  Community Health Volunteer  OI  Opportunistic Infection  \\nCITC  Client -Initiated HIV Testing and Counselling  OPD  Outpatient Department  \\nCM Cryptococcal Meningitis  OST  Opioid Substitution Therapy  \\nCMV  Cytomegalovirus  OVC  Orphans And Vulnerable Children  \\nCNS  Central Nervous System  PCP  Pneumocystis Jirovecii Pneumonia  \\nCPT  Cotrimoxazole Preventive Therapy  PCR  Polymerase Chain Reaction  \\nCrCl  Creatinine Clearance  PEP  Post -Exposure Prophylaxis  \\nCTX  Cotrimoxazole  PrEP  Pre-Exposure Prophylaxis  \\nCYP450  Cytochrome P450  PGL  Persistent Generalized Lymphadenopathy  \\nDAAs  Direct Acting Antiviral Therapies  PHQ -9  Patient Health Questionnaire -9 \\nDBS  Dried Blood Spot  PHDP  Positive Health, Dignity, and Prevention  \\nDICEs  Drop -In-Centres  PI  Protease Inhibitor  \\nDMS  Director of Medical Services  PITC  Provider Initiated HIV Testing and Counselling  \\nDNA  Deoxyribonucleic acid  PLHIV  People Living With HIV  \\nDOT  Directly observed therapy  PLLV  Persistent Low-level Viremia  \\nDS Double strength  PML                                 Progressive Multifocal Leukoencephalopathy  \\nDRT  Drug Resistance Testing  PMTCT                           Prevention of mother -to-child transmission  \\nED - PrEP  Event Driven PrEP  PPE                                  Papular Pruritic Eruptions  \\nEDTA  Ethylenediaminetetraacetic acid  PrEP  Pre-exposure Prophylaxis  \\nECP  Emergency contraceptive pill  PTB  Pulmonary Tuberculosis  \\nEID  Early Infant Diagnosis  PWID  People Who Inject Drugs  \\neMTCT  Elimination of Mother to Child Transmission  NHCSC  National HIV Clinical Support Centre  \\nEPTB  Extra -pulmonary Tuberculosis  RAST  Rapid Assessment Tool  \\nFDA  Food and Drug Administration  RNA  Ribonucleic Acid \\nFBC  Full Blood Count  RPR  Rapid Plasma Reagin  \\nFBS Fasting Blood Sugar  sCrAg  Serum Cryptococcal Antigen  \\nFDC  Fixed Dose Combination  SRH  Sexual and Reproductive Health  \\nFLP  Fasting Lipid Profile  SS  Single Strength  \\nFP  Family Planning  STI  Sexually Transmitted Infection  \\nFTC  Emtriciatabine  TB  Tuberculosis  \\nGIT  Gastro -intestinal tract  TB LAM  Tuberculosis Lipoarabinomannan  \\nGOK  Government of Kenya  TDF  Tenofovir  \\nGBV  Gender -Based Violence  TT Tetanus Toxoid  \\nHb  Hemoglobin  TWG  Technical Working Group  \\nHBV  Hepatitis B virus  ULN  Upper Limit of Normal  \\nHBsAg  Hepatitis B Surface Antigen  UTI Urinary Tract Infection  \\nHCV  Hepatitis C Virus  VIA  Visual Inspection with Acetic Acid  \\nHCW  Health Care Worker  VILI  Visual Inspection with Lugol’s Iodine  \\nHEI  HIV Exposed Infant  VL  Viral Load  \\nHIV  Human immunodeficiency Virus  VMMC  Voluntary Medical Male Circumcision  \\nHIVST  HIV Self-testing  WHO  World Health Organization  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 17}),\n",
       " Document(page_content='  \\nSummary of Key Recommendations  \\n1 - 1   \\n1. Summary of Key Recommendations  \\n \\n1.1 HIV Testing Services (HTS) and Linkage to Treatment and Prevention  \\n• HIV testing should be voluntary and conducted ethically in an environment where \\nConsent, Confidentiality, Counselling, Correct results, Connection (linkage) and Creating \\nan enabling environment can be assured  \\n• To optimize access to testing services, HIV testing can be conducted in 2 different settings:  \\n▪ Facility -based  \\n▪ Community -based  \\n• Targeted HIV testing is recommended which involves index client listing of contacts, HIV \\nself-testing and use of HTS screening tool to identify people at risk of HIV infection as \\neligible for testing  \\n• Serial testing, using ap proved rapid HIV antibody testing kits, is used to diagnose HIV \\ninfection in children older than 18 months, adolescents, and adults. An HIV -positive \\ndiagnosis will be made using three consecutive reactive assays  \\n \\n1.2 Initial Evaluation and Follow -up for PLHIV  \\n● Initial clinical evaluation of PLHIV entails CD4 monitoring, which is recommended for:  \\n▪ Baseline investigation for all PLHIV  \\n▪ Any patient with suspected treatment failure  \\n▪ Any patient returning to care after interrupting treatment for > 3 months  \\n▪ Any patient on fluconazole maintenance therapy or on dapsone as prophylaxis, to \\ndetermine when prophylaxis can be discontinued  \\n● Advanced HIV Disease is defined as:  \\n▪ Adults, adolescents, and children five years and older as having a CD4 cell count of \\nless than 200 cells/mm3 or \\n▪ WHO clinical stage 3 or 4 disease  \\n▪ All children younger than five years  \\n● All PLHIV presenting with Advanced HIV Disease (AHD) should be offered a package of \\ncare that includes timely initiation of ART, screening, diagnosis, prophyl axis, and \\nmanagement  of opportunistic infections.  \\n● Frequency of routine VL monitoring:  \\n▪ For PCR positive HEIs: at baseline (at the time of ART initiation)  \\n▪ Age 0 -24 years old: 3 months after ART initiation, and then every 6 months  \\n▪ Age ≥ 25 years old: 3 months after ART initiation, then at month 12, and then annually  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 18}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n1 - 2  ▪ Pregnant or breastfeeding: at confirmation of pregnancy (if already on ART) or 3 \\nmonths after ART initiation (if ART initiated during pregnancy/breastfeeding), and \\nthen every 6 months until c omplete cessation of breastfeeding  \\n▪ Before any drug substitution (if no VL result available from the prior 6 months)  \\n▪ Three months after any regimen modification (including single -drug substitution)  \\n● PLHIV should receive differentiated care based on initial e valuation (advanced vs. well) \\nand follow up (established vs not established on ART)  \\n \\n1.3 Standard Package of Care for PLHIV  \\nConsists of 8 components:  \\n1. Antiretroviral Therapy  \\n▪ All PLHIV are eligible for ART irrespective of CD4 cell count or percentage, WHO \\nclinical stage, age, pregnancy status, or comorbidities  \\n▪ ART should be initiated as soon as the patient is ready to start, preferably within \\ntwo weeks from time of HIV diagnosis (except for patients with cryptococcal \\nmeningitis or TB meningi tis) \\n2. Positive Health, Dignity, and Prevention, GBV/IPV & HIV Education and Counselling  \\n▪ All patients should be counselled and supported for disclosure of HIV status; \\npartner/ family testing and engagement; condom use; family planning; sexually \\ntransmitted infections screening; treatment adherence; and pre -exposure \\nprophylaxis for HIV -negative sexual partners  \\n▪ All females aged 15 -49 years and emancipated minors accessing HIV care services \\nshould be screened for Intimate Partner Violence (IPV) as p art of the standard \\npackage of care  \\n▪ All PLHIV should be provided with HIV education and counselling  \\n3. Screening for and Prevention of Specific Opportunistic Infections  \\nCotrimoxazole Preventive Therapy (CPT) is no longer recommended as life -long \\nprophylaxis, and is only recommended in the following sub populations, unless they \\nhave an allergy to sulfur drugs or develop toxicity from CPT  \\n● All HIV Exposed Infants  \\n● HIV infected children < 15 years of age  \\n● All PLHIV > 15 years of age:  \\no Living in malaria -endemic zones  (Refer to the National Guidelines for the \\nDiagnosis, Treatment and Prevention of Malaria in Kenya for the current Kenya \\nMalaria endemicity map)  \\no Presenting with WHO stage 3 or 4 event, or meeting the AHD criteria  \\no Suspected treatment fa ilure  \\n● All Pregnant and Breast -feeding women  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 19}),\n",
       " Document(page_content='  \\nSummary of Key Recommendations  \\n1 - 3  ▪ When dapsone (as a substitute for CPT) is being used as PCP prophylaxis, it is only \\nrecommended for patients in WHO Stage 4 and/or absolute CD4 count ≤ 200 \\ncells/mm3 (or CD4% ≤ 25% for children ≤ 5 years old), and should be discontinued \\nonce a patient achieves viral suppression and a sustained CD4 count of > 200 \\ncell/mm3 (or > 25% for children ≤ 5 years old) for at least 6 months  \\n▪ All PLHIV should be screened for TB at  every visit using the Intensified Case Finding \\n(ICF) tool and assessed for TB Preventive Therapy (TPT) if screened negative for TB  \\n▪ All adolescent and adult PLHIV with a baseline CD4 count of ≤ 200 cells/mm3 should \\nbe screened for cryptococcal infection us ing the serum CrAg test  \\n4. Reproductive Health Services  \\n▪ All PLHIV should be screened for STI at every clinic visit  \\n▪ Pregnancy status should be determined for all women of reproductive age at every \\nvisit and their contraception need determined and met  \\n▪ All HIV p ositive women between the ages of 18 - 65 years should be screened for \\ncervical cancer (HPV testing conducted every 2 years or Annually if using VIA -VILI)  \\n5. Screening for and Management of Non -Communicable Diseases  \\n▪ All PLHIV should be screened for hypertension, diabetes mellitus, dyslipidaemia, \\nand renal disease annually.  \\n▪ Routine screening should be provided for early detection of cervical cancer, breast \\ncancer, bowel cancer, and prostate cancer  \\n6. Mental Health Screening and Management  \\n▪ All PLHIV should receive basic screening for depression  and anxiety  before initiating \\nART, and annually thereafter, and whenever there is a clinical suspicion  \\n▪ All PLHIV should be provided for and linked with support structures to maintain \\ngeneral well -being  addressi ng issues that could affect their mental health  \\n▪ All adults and adolescents should be screened for alcohol and drug use before \\ninitiating ART and regularly during follow -up \\n▪ All caregivers should also receive baseline and follow -up screening for depression \\nand alcohol/drug use  \\n7. Nutrition Services  \\n▪ All PLHIV should receive nutritional assessment, counselling, and support tailored \\nto the individual needs of the patients  \\n▪ All infants irrespective of HIV status should be exclusively breastfed for the first 6 \\nmonths  of life, with timely introduction of appropriate complementary foods after \\n6 months, and continued breastfeeding up to 24 months or beyond  \\n8. Prevention of Other Infections  \\n▪ PLHIV (including children) should receive vaccinations as recommended by the \\nNational  Vaccines and Immunization Program  \\n▪ All PLHIV should receive vaccination for COVID -19 following national guidelines for \\nage and dosing  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 20}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n1 - 4  1.4 Adherence Preparation, Monitoring and Support  \\n• The adherence preparation, monitoring, and support that a patient requires should be \\ntailored to their level of adherence and the stage of ART initiation and follow -up \\n• All patients with durable viral suppression (2 consecutive viral load results with < 50 \\ncopies) should be offered messaging on Undetectable=Untrans mittable (U=U).  \\n• Whenever possible, follow -up should be provided by the same care provider or team of \\ncare providers (e.g., same clinician and counsellor) at every visit. This is particularly \\nimportant during the first 3 months in care  \\n• For all children/adol escents, the level of disclosure should be assessed at the first visit. \\nOngoing care should include a plan for age -appropriate disclosure  \\n• All patients are at risk of new or worsening barriers to adherence, so adherence \\nmonitoring, counselling and support s hould continue despite viral suppression  \\n• Every service delivery point that is providing ARVs for patients (whether ART, PEP, or \\nPrEP) must have a functional system for identifying patients who miss appointments and \\nfor taking action within 24 hours of a mi ssed appointment  \\n• In patients failing ART, do not change regimens until the reason/s for treatment failure \\nhave been identified and addressed (which should be done urgently using a case -\\nmanagement approach)  \\n1.5 Antiretroviral Therapy for Infants, Children, Adolescents, and Adults  \\n• The goal of ART is to suppress viral replication with the aim of reducing the patient’s VL \\nto undetectable levels (Viral Load <50 copies/LD L) \\n• All individuals with confirmed HIV infection are eligible for ART, irrespective of CD4 \\ncount/%, WHO clinical stage, age, pregnancy or breastfeeding status, co -infection status, \\nrisk group, or any other criteria, provided that the individual is willing and ready to start \\nART  \\n• ART should be started in all patients as soon as possible, even on the  same day as \\nconfirming their HIV diagnosis (and preferably within 2 weeks)  \\n• Preferred first -line ART for infants, children, adolescents and adults  \\n▪ Birth to 4 weeks: AZT + 3TC + NVP  \\n▪ > 4 weeks to < 15 years old  \\n▪ < 30 kg: ABC + 3TC + DTG  \\n▪ ≥ 30 kg: TDF + 3TC + DTG  \\n▪ ≥ 15 years old: TDF + 3TC + DTG  \\n• Children and adolescents who are virally suppressed but are NOT on the preferred first -\\nline ART regimen should be assessed for transition and transitioned to the preferred \\nregimen  \\n• Treatment failure is suspected when a pa tient has a VL ≥ 100 0 copies/ml after at least 3 \\nmonths of using ART. Treatment failure is only confirmed when VL is ≥ 1,000 copies/ml \\nafter assessing for and addressing poor adherence or other reasons for high VL, and then \\nrepeating VL after at least 3 mo nths of excellent adherence to allow for viral re -\\nsuppression  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 21}),\n",
       " Document(page_content='  \\nSummary of Key Recommendations  \\n1 - 5  • Persistent low -level viremia ( pLLV) is defined as having VL 200 - 999 copies/ml on two \\nor more consecutive measures. These patients are at increased risk of progression to \\ntreatment failure, dev elopment of ARV resistance and death and therefore require a \\nsimilar case management approach as patients with an initial VL ≥ 1,000 copies/ml  \\n• All PLHIV with a detectable VL ≥ 200 copies/ ml (unsuppressed) : assess for and address \\npotential reasons for virem ia, including intensifying adherence support, and repeat the \\nVL after 3 months of excellent adherence  \\n▪ If the repeat VL is < 200  copies/ml ( suppres sed) then continue routine \\nmonitoring  \\n▪ If the repeat VL is ≥ 1,000 copies/ml (suspected treatment failure), prepare for \\nchange to an effective regimen (Figure 5.2 and Table 6.10)  \\n▪ If the repeat VL is 200 - 999 copies/ml (low level viremia),  reassess adherence \\nand other causes of viremia and repeat VL after another 3 months of excellent \\nadherence  \\n1.6 Pre vention of Mother to Child Transmission of HIV/Syphilis/HBV  \\n• Prevention of mother -to-child transmission (PMTCT) of HIV,  Syphilis and Hepatitis B  \\n(triple elimination ) should be offered as part of a comprehensive package of fully \\nintegrated, routine antenatal  care interventions  \\n• All pregnant women, unless known positive, should be counseled and tested for HIV, \\nSyphilis (using the HIV -Syphilis dual test) and HBV during their first ANC visit, and if \\nnegative a repeat HIV -Syphilis dual test should be performed in the 3rd trimester.  \\n• Lifelong ART should be initiated in all pregnant and breastfeeding women living \\nwith HIV, regardless of gestational age, WHO clinical stage or CD4 count  \\n• ART should be started as soon as possible, ideally on the same day HIV diagnosis is  made, \\nwith ongoing enhanced adherence support  \\n• The preferred first line ART regimen for pregnant and breastfeeding women is TDF + 3TC \\n+ DTG  \\n• For pregnant and breastfeeding women newly initiated on ART, obtain VL 3 months after \\ninitiation, and then every 6 m onths until complete cessation of breastfeeding  \\n• For HIV positive women already on ART at the time of confirming pregnancy or \\nbreastfeeding, obtain a VL irrespective of when prior VL was done, and then every 6 \\nmonths until complete cessation of breastfeeding  \\n• For pregnant or breastfeeding women with a VL ≥ 200 copies/m l (unsuppressed ): assess \\nfor and address potential reasons for viremia, including intensifying adherence support, \\nand repeat the VL after 3 months of excellent adherence  \\n▪ If the repea t VL is < 200  copies/ml (suppressed) then continue routine \\nmonitoring  \\n▪ If the repeat VL is ≥ 1,000 copies/ml (treatment failure), prepare for change to \\nan effective regimen  \\n▪ If the repeat VL is 200  - 999 copies/ml ( low level viremia ), reassess adherence \\nand other causes of viremia and consult the Regional or National TWG  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 22}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n1 - 6  • All HIV exposed infants (HEI) should be tested with DNA PCR within 6 weeks of age or \\nfirst contact thereafter; if negative then another DNA PCR at 6 months, and if negative \\nthen  repeat DNA PCR at 12 months.  \\n• All HEI should receive infant ARV prophylaxis consisting of 6 weeks of AZT + NVP and \\nthereafter NVP should be continued until 6 weeks after complete cessation of \\nbreastfeeding  \\n• All infants irrespective of HIV status should be exclusively breastfed for the first 6 months \\nof life, with timely introduction of appropriate complementary foods after 6 months, and \\ncontinued breastfeeding up to 24 months or beyond  \\n \\n1.7 TB/HIV Co -infection Prevention and Management  \\n• All healthcare settings should implement TB infection control recommendations to \\nreduce the risk of transmission of TB among patients, visitors and staff  \\n• Symptom -based TB screening using the ICF tool MUST be performed for all PLHIV at \\nevery clinic visit  \\n▪ Patien ts who screen negative should be assessed for and provided with TB \\npreventive therapy (TPT)  \\n▪ Patients who screen positive (presumptive TB) must complete definitive diagnostic \\npathways  \\n• The GeneXpert Ultra MTB/Rif test is the preferred test for diagnosis of T B and \\nrifampicin resistance in all presumptive TB cases  \\n• TB-LAM can be used as an adjunct rapid point -of-care diagnostic test for PLHIV: with \\nadvanced HIV disease (WHO stage 3 or 4 or CD4 count ≤ 200 cells/mm3 (or CD4% ≤ 25% \\nfor children ≤ 5 years)) with presumptive TB, or; any danger signs of severe illness, or; \\ncurrently admitted to hospital  \\n• Patients diagnosed with TB/HIV co -infection should start anti -TB treatment immediately \\nand initiate ART as soon as anti -TB medications are tolerated, preferably within 2 weeks \\n(unless they have TB meningitis, in which case ART should be deferred for 4 to 8 weeks)  \\n• Patients with TB/HIV co -infection who are already on ART should start anti -TB treatment \\nimmediately and continu e ART, making any required adjustments to the ART regimen \\nbased on known drug -drug interactions and monitoring toxicity  \\n• Always assess for ART failure in patients who develop TB after being on ART for ≥ 6 \\nmonths  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 23}),\n",
       " Document(page_content='  \\nSummary of Key Recommendations  \\n1 - 7  1.8 HBV/HIV and HCV/HIV Co -infection Preve ntion and Management  \\n• All HIV positive adolescents and adults should be screened for HBV infection, using serum \\nHBsAg, as part of initial evaluation; children who did not complete routine childhood \\nimmunizations should also be screened for HBV and vaccinat ed if negative.  \\n• PLHIV without evidence of hepatitis B infection (HBsAg negative) should be vaccinated \\nagainst hepatitis B  \\n• The recommended first -line ART for adults with HIV/HBV co -infection is TDF+ 3TC + DTG  \\n• HCV serology should be offered to individuals at  risk of HCV infection  \\n• Direct acting antiviral therapies (DAAs) for treatment of HCV have simplified the \\nmanagement of HIV/HCV co -infection  \\n \\n1.9 ARVs for Post -exposure Prophylaxis (PEP)  \\n• PEP should be offered as soon as possible (< 72 hours) after high -risk exposure  \\n• The recommended ARV agents for PEP are  \\n▪  <15 years old  \\n▪ < 30 kg: ABC + 3TC + DTG  \\n▪ ≥ 30 kg: TDF + 3TC + DTG  \\n▪ ≥ 15 years old  \\n▪ TDF + 3TC + DTG  \\n \\n1.10 Pre -Exposure Prophylaxis (PrEP)  \\n• PrEP should be offered to HIV negative individuals at substantial ongoing risk of HIV \\ninfection (including the seronegative partner in a discordant relationship)  \\n•  PrEP works if taken as prescribed . However, it does not prevent other STIs or unintended \\npregnancies, therefore, additional protection should be of fered.  \\n• PrEP should only be offered to clients  ≥15 years of age who are sexually active after \\neligibility assessment using  the following parameters:  \\n▪ Laboratory: HIV negative  \\n▪ Medical (for oral PrEP): no contraindication to TDF; no severe renal diseases; wei ght \\n≥ 30 kg  \\n▪ Client readiness: client must be willing to take PrEP as prescribed, and adhere to \\nassociated follow up and HIV testing (at enrollment, at month 1 and thereafter every \\n3 months)  \\n• The recommended ARV regimen for Oral PrEP is TDF/FTC (alternative  TDF/3TC), \\navailable in two dosing strategies:  \\n▪ Daily oral PrEP: TDF (300 mg) + FTC (200 mg) once daily  \\n▪ Event -driven PrEP : Event driven PrEP is where oral PrEP is used in men having sex \\nwith men when an isolated sexual act is anticipated. The dose is two pills of TDF/FTC \\ntaken between 2 and 24 hours (preferably closer to 24h) before the anticipated \\nsexual act; then, a third pill taken 24 hours after the first two pills; and then a fourth \\npill taken 24 hours after the third pill (“2+1+1”).  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 24}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n1 - 8  1.11 People Who I nject Drugs (PWID) and HIV  \\n• PWID should be offered regular HIV testing and counselling and be linked to   \\ncomprehensive HIV treatment and prevention services including harm reduction \\ncounselling and support  \\n• The recommended first -line ART for adult PWID is T DF + 3TC + DTG  \\n• PWID should be offered screening, diagnosis, treatment and prevention of STIs as part of \\ncomprehensive HIV prevention and care  \\n• PWID should have the same access to TB prevention, screening and treatment services as \\nother populations at risk o f or living with HIV  \\n• PWID should be screened for HBV (by HBsAg) and HCV (by HCV serology) at first contact  \\n• All PWID should be linked to Needle and Syringe Programs (NSP) to access sterile \\ninjecting equipment  \\n• All PWID should be linked to Medically Assisted Therapy (MAT)  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 25}),\n",
       " Document(page_content='  \\nHIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 1   \\n2. HIV Testing Services and Linkage to Treatment \\nand Prevention  \\nHIV testing services (HTS) provide the first critical link to comprehensive HIV treatment and \\nprevention services such as voluntary medical male circumcision (VMMC), pre -exposure \\nprophylaxis (PrEP), post -exposure prophylaxis (P EP) and other combination HIV prevention \\nservices. In addition, this initial step also provides opportunities to offer other interventions such \\nas sexual and reproductive health services (SRH), TB screening and referral, and substance abuse \\nscreening and r eferral.  \\nHIV testing should be voluntary and conducted ethically in an environment where the six Cs \\nprinciples of Consent, Confidentiality, Counselling, Correct results, Connection (linkage) to care and \\nother appropriate post -test services and creating an  enabling environment are adhered to . \\nTargeted HIV testing  is the major strategic shift, involving index client listing of contacts, HIV self -\\ntesting and use of HIV screening tools to identify people at risk of HIV infection as eligible for \\ntesting, except in the case of PMTCT and key populations.  \\n2.1 Settings fo r HIV Testing  \\nIn Kenya, HTS is delivered in two broad settings: facility -based and community -based settings  \\n2.1.1 Facility -based testing  \\n● The HTS screening tool should be used to facilitate prioritization of testing for persons at risk \\nof HIV infection; those diagnosed with sexually transmitted infections, with multiple sexual \\npartners, key populations, and those with possible or known HIV exposures, such as sexual or \\nneedle sharing partner of a person living with HIV or of a person of unknown HIV status  \\n● Providers should undertake a thorough risk assessment using the validated NASCOP screening \\ntools (Annex 17) to identify clients at risk and those eligible for a HIV test.  \\n● HTS should be offered only to clients who consent  \\n● Clients who are not eli gible for testing should receive HIV prevention messages and be offered \\nservices as appropriate  \\n● Clients who test HIV positive should be linked to care while those who test negative should be \\nlinked to HIV prevention services  \\n● Patients starting HIV care shou ld receive disclosure counselling and support, and be offered \\nfamily, sexual and needle -sharing partner testing  \\nAs much as possible, HIV testing services should be integrated into care pathways at all service \\ndelivery points including adult and pediatric i npatient units, outpatient units, maternal and child \\nhealth clinics, SRH/family planning clinics, TB clinics, specialty clinics, gender -based violence \\n(GBV) care units and service delivery points for key and priority populations.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 26}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 2  2.1.2 Community –based t esting  \\nTargeted community based HTS offers additional opportunities to identify and link people to HIV \\ntreatment and prevention. This setting is especially important for testing children and partners of \\nindex clients through index testing , as well as  outreach to key and priority populations, orphans, \\nand vulnerable children (OVCs), adolescents, youth and targeted testing in workplaces.  \\n2.2 HTS strategies  \\nThe major HTS strategies to identify people living with HIV but unaware of their status are:  \\n2.2.1 HIV Self -Testing (HIVST)  \\n● HIVST allows individuals to collect their own specimen, perform the test, and interpret the \\nresults on their own, conducted either within a health facility, at home or in any other \\nconvenient place.  \\nHIVST can be  conducted with o r without direct assistance by a trained person.  \\n● HIVST is a screening test and is not sufficient to make an HIV -positive diagnosis. A reactive \\n(positive) self -test result should therefore be confirmed using the validated national testing \\nalgorithm by an H TS-trained service provider.  \\n● HIVST should be performed using MoH approved HIV rapid diagnostic test kits that are either \\nblood -based or oral fluid based.  \\n● HIVST may have the greatest benefit in reaching specific populations such as partners of newly \\ndiagnosed PLHIV; partners of pregnant women attending antenatal care (ANC); contacts of \\npatients treated for STIs; hard -to-reach populations such as men, adolescents, and young \\npeople, as well as key populations, such as MSM and sex workers.  \\nHIVST is a scr eening test and does not provide a diagnosis.  \\nAll reactive (positive) self -test results must be confirmed in a health facility according to \\nnationally set standards  \\n2.2.2 Index Testing  referred to as partner testing/partner notification services, is an approach \\nwhereby the exposed contacts (i.e., sexual partners, biological children and anyone with whom a \\nneedle was shared) of an HIV -positive person (i.e., index client), are elicited and offered HIV testing \\nservices  \\n2.2.3 Voluntary Counselling and Testin g (VCT):  This involves provision of targeted HIV \\ntesting to clients who willingly present to HTS facilities for testing for diverse reasons, including \\nself-assessed risk.  \\n2.2.4 Social Network Strategy (SNS) - this involves offering to index clients self -guided options \\nto informally extend links to HIV testing and other services to a broader set of social -, sexual -, \\nand injecting -network members who have an elevated risk of HIV infection. The index client for \\nSNS can either be PLHIV or HIV negative persons wi th increased risk for HIV infection . \\nProviding targeted HTS for different populations and in different settings increases opportunities \\nfor access to knowledge of HIV status and to a range of HIV treatment and prevention services. \\nTable 2.1 summarizes key recommendations for HTS for different sub -populations.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 27}),\n",
       " Document(page_content='  \\nHIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 3  Table 2.1: HTS R ecommendations for Different Populations and Settings  \\nPopulation  Recommendation  \\nBirth testing of \\ninfants born to \\nknown HIV - \\npositive mothers \\n(Figure 2.2)  ● Birth testing (HIV testing of infants at birth or at first contact within 2 weeks after \\nbirth) can be conducted where feasible and in settings wher e return of results is \\nfeasible within 24 hours and ART  can be initiated immediately*). Infants tested at \\nbirth must be tested at the 6 weeks immunization visit regardless of the results of \\nthe initial test at birth.  \\n● Infants with an initial positive HIV D NA PCR result should be presumed to be HIV \\ninfected and started on ART in line with national guidelines, with a new sample for \\nconfirmatory HIV DNA PCR and baseline viral load taken at the time of ART \\ninitiation (ART initiation is based on the initial HIV DNA PCR result)  \\nInfants and \\nchildren aged less \\nthan 18 months \\n(Figure 2.1)  ● HIV exposure status of all infants should be established at first contact.  \\n● To establish HIV exposure status of a child less than 18 months of age, conduct HIV \\nantibody testing for mothers with unknown status or who previously tested \\nnegative during antenatal care at the 6 -week immunization visit or first contact. If \\nthe mother declines to be tested or is not available for testing, then conduct a rapid \\nHIV antibo dy test for the child to determine exposure (if antibody test is positive \\nthis confirms HIV exposure)  \\n● When HIV exposure is confirmed, ARV prophylaxis should be started immediately.  \\n● All HEIs should have DNA PCR testing at the 6 -week immunization visit or fi rst \\ncontact thereafter.  \\n● Infants with an initial positive HIV DNA PCR result should be presumed to be HIV \\ninfected and started on ART in line with national guidelines, with a new sample for \\nconfirmatory HIV DNA PCR and baseline viral load taken at the time of ART \\ninitiation (ART initiation is based on the initial HIV DNA PCR result)  \\n● All HEI with initial HIV negative results should continue infant ARV prophylaxis \\nand be followed as HEIs, including additional PCR testing at 6 months and 12 \\nmonths, and antibody  testing at 18 months and every 6 months during \\nbreastfeeding, and at 6 weeks after complete cessation of breastfeeding  \\nChildren older \\nthan 18 months \\ntill age 9 years \\n(Figure 2.3)  ● Conduct HIV testing and counselling for all children of adults living with HIV as \\nsoon as possible after confirming the HIV positive status of the adult. Within health \\nfacilities, testing should be conducted at in -patient wards, nutrition clinics, and all \\nhigh HIV burden settings.  \\nAdolescents and \\nyoung people  \\n(10 - 24 years) \\n(Figure 2.3)  ● Targeted HIV testing services should be offered to adolescents and young people \\nwho are screened and found eligible for HIV test. HIV prevention services should \\nbe offered to clients who test negative while those who test positive should be \\nlinked to HIV care.  \\n● Adolescents aged above 10 years, should be tested with the written consent of a \\nparent or guardian, and are also required to give assent.  \\n● Adolescents who are e mancipated minors irrespective of age, can give their own \\nconsent.  \\n● All adolescents should be counselled on the potential benefits and risks of \\ndisclosure of their HIV status and empowered and supported to determine if, \\nwhen, how and to whom to disclose.  \\n● For sexually active adolescents, HIV testing and counselling should be offered to \\ntheir partners and children where appropriate.  \\n● All uncircumcised adolescent males who test HIV negative should be counselled \\nabout the prevention benefits of VMMC and linked t o VMMC services if they agree  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 28}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 4  Table 2.1 Cont.  \\nPregnant and \\nbreastfeeding \\nwomen  ● During the first ANC visit, HIV testing of pregnant women should be done \\nusing a dual test for HIV and syphilis, unless the woman is known to be living \\nwith HIV.  \\n● Women who test negative for both HIV and Syphilis should be offered a repeat \\nHIV-Syphilis dua l test in the third trimester.  \\n● Prevention services should be offered to all pregnant and breastfeeding \\nwomen who test HIV negative. They should be screened for eligibility and \\nwillingness for PrEP.  \\n● At labor and delivery, HIV testing should be done for all women with \\nunknown HIV status and those who previously tested negative (even if tested \\nnegative in the third trimester).  \\n● All breastfeeding mothers (unless known HIV positive) should be counselled \\nand tested at the 6 -week infant immunization visit. The HIV  test (if negative) \\nshould be repeated every 6 months until complete cessation of breastfeeding.  \\n● For mothers considered to be at high risk of HIV infection, retesting \\npostnatally should be done every 3 months; these include mothers \\ncategorized as key popul ation; in a HIV discordant relationship, or having \\nongoing sexual or injecting behavior that places her at risk, including new or \\nmultiple sexual partners.  \\n● Mothers should be counselled on the schedule for repeat HIV testing in \\npregnancy and postnatal as p art of routine ANC and postnatal education.  \\n● All pregnant and breastfeeding women who are not tested, opt -out or decline \\nHIV testing during the first contact should be offered HIV counselling and \\ntesting in subsequent visits with appropriate referral and li nkage for \\nprevention, care, and support services.  \\n● All HIV positive pregnant and breastfeeding women enrolled into care should \\nreceive counselling and support (assisted disclosure), case management and \\nfollow -up. It should also include linkage to general ca re for ANC, delivery and \\npost -natal care  \\n● All spouses/partners as well as children of pregnant and breastfeeding \\nwomen testing HIV positive should be offered HIV testing and counselling.  \\nSexual partners & \\nchildren of index \\nclients (HIV positive \\nperson who is newly \\ndiagnosed or already \\nin HIV care)  ● All PLHIV enrolled into HIV care should receive disclosure counselling and \\nbe supported to disclose their HIV status (assisted disclosure)  \\n● HIV testing and counselling (facility -based or community -based) should be \\nencouraged for all partners including  sexual partners, needle sharing \\npartners, and children of index clients, with appropriate linkage to \\ntreatment and prevention services.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 29}),\n",
       " Document(page_content='  \\nHIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 5  Table 2.1 Cont.  \\nKey and vulnerable \\npopulations  ● Conduct HIV testing and counselling for all clients from key and vulnerable \\npopulations presenting to the health facility irrespective of the reason for \\ntheir visit, or through targeted outreach and testing at key and vulnerable \\npopulation service delivery points (e.g., drop -in centers).  \\n● Key populations that test negati ve should be retested quarterly.  \\n● Link all who test HIV positive to treatment and prevention services.  \\n● Prevention services should be recommended, including consistent and \\ncorrect use of condoms and use of sterile needles and syringes.  They should \\nbe scree ned for eligibility and willingness for PrEP.  \\n● All uncircumcised males who test HIV negative should be counselled on the \\nprevention benefits of VMMC and linked to VMMC services if they consent  \\nTargeted HIV testing \\nand counselling of \\nadults  ● All adults eligible for testing should be offered HTS and encouraged to know \\ntheir HIV status and the status of their partners.  \\n● For those that test negative, re -testing is recommended if there is a new risk \\nexposure.  \\n● HIV positive adults should be counseled for  immediate ART initiation.  \\n● Link all adults identified as HIV positive to treatment and prevention services.  \\n● Clients who are not eligible for testing should receive HIV prevention \\nmessages and be offered services, as appropriate.  \\n● All males who test HIV nega tive should be counselled on the prevention \\nbenefits of VMMC and linked to VMMC services if they consent  \\n \\n2.3 Package of HIV Testing Services  \\nAn HIV testing and counselling session consists of:  \\n● A pre -test session  \\n● HIV testing  \\n● Assessment for other health -related conditions or needs (while HIV tests are running)  \\n● A post -test session (including index testing)  \\n● Referral and linkage to other appropriate health services (as part of the post -test session)  \\nThe HIV testing service package is summarized in Tab le 2.2.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 30}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 6  Table 2.2: Summary of HIV Testing Services Package  \\nPre- Test Counselling  \\nPre-test counselling may be provided to an individual or a couple presenting for HTS.  Group information \\ncan also be offered during pre -test.  \\nThe objectives of the pre -test counselling session are to:  \\n− Provide information on the benefits of knowing one’s H IV status, including outcomes for people \\non ART and undetectable = Untransmittable  (U=U).  \\n− Provide an explanation for the HIV testing process including time the session will take, \\nconfidentiality, and interpretation of test results  \\n− Obtain informed consent for HIV testing.  \\n− Explore the client’s risk of HIV infection.  \\n− Discuss the importance of disclosure to partners and other family members.  \\n− Explain the benefits of couple testing and partner services/index testing.  \\nProvide information on available post -test se rvices, including referrals for prevention or HIV care services  \\nPerform test.  \\nThe goal of HIV testing is to:  \\n• Provide accurate HIV diagnosis as per the nationally approved testing algorithm  \\n• Provide same day HIV test results  \\nDuring the 15 minutes as you wait for the test results:  \\n− Discuss Combination Prevention e.g., PrEP, PEP, Risk Reduction, STI treatment, condom \\ninformation and demonstration, VMMC, Elimination of Mother to Child Transmission of HIV \\n(eMTCT)  \\n− Screen, provide information and referrals for; Intimate Partner Violence (IPV), STI and cancer \\nscreening, Tuberculosis (TB), Family planning/c ontraceptive needs, etc.  \\n− Establishing number of sexual contacts and biological children for the purpose of index testing.  \\n− Document in the HTS, Lab, referral and linkage register (MOH 362).  \\nDiscuss further on index testing and HIVST as you perform the secon d and the third test, as per the national \\nalgorithm, for the clients who test positive with the screening test  \\nPost -test counselling  \\n− Check if the client is ready for results and help them to interpret.  \\n− Check what the client understands by the results.  \\n− Allow the client to share his/her initial reactions and verbalize their initial feelings.  \\n− Explore and acknowledge client’s immediate feelings and concerns.  \\nOffer necessary support  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 31}),\n",
       " Document(page_content='  \\nHIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 7  Table 2.2 Cont.  \\nNEGATIVE RESULT  \\n− Explain test results.  \\n− Review implications of being HIV negative.  \\n− Support clients to develop a risk reduction \\nplan (see HTS operational manual)  \\n− Provide information on methods to prevent \\nHIV acquisition.  \\n− Provide male and/or female condoms, \\nlubricant, and guidance on their use.  \\n− Emphasize on importance of knowing the \\nstatus of sexual partners and information \\nabout the availability of partner and couples \\ntesting services.  \\n− Referral and linkage to relevant HIV \\nprevention services  \\nExplain the need for repeat testing for people \\nwho tes t negative but report risky behavior \\nwithin the prior  4 weeks (i.e., unprotected sex \\nwith a partner of unknown status or Known HIV \\npositive status); if they test HIV negative again \\nafter 4 weeks  and are at  ongoing risk of HIV \\nacquisition , they should be ad vised to return for \\ntesting every 3 months  POSITIVE RESULT  \\n− Review implications of being HIV positive.  \\n− Help the index client to cope with emotions arising \\nfrom the diagnosis.  \\n− Discuss immediate concerns and help for the client \\nto decide who in his or her social network may be \\navailable to provide immediate support.  \\n− Discuss positive living.  \\n− Provide clear information on ART and its benefits \\nfor maintaining health and reducing the  risk of HIV \\ntransmission, as well as where and how to access \\nART  \\n− Refer clients who turn HIV positive to CCC for \\nlinkage to treatment.  \\n− Revisit index testing and HIVST to determine \\npartner notification plan/approach (refer to HTS \\noperational manual and APN S operational Manual).  \\n− Discussion of the risks and benefits of disclosure to \\npartners; couples counselling should be offered to \\nsupport mutual disclosure.  \\nEncourage and offer HIV testing for sexual partners, \\ninjecting partners, biological children, and oth er family \\nmembers, which can be done through couples testing, \\nfamily testing and/or assisted partner notification \\nservice.  \\nAssessment of other health related conditions  \\nAssess risk for sexually transmitted infections (STIs) and opportunistic infections that would also require \\nmanagement  \\nReferral and linkage to care  \\nObtain accurate locator information from the index client (physical location, phone number)  \\nPhysically escort the client for re -testing and linkage to ART  \\nDocument the outcomes of partner follow up(s)  \\nPost -Test Counseling in the Era of Test -and -Treat  \\nPost -test counselling should, at a minimum, include three key messages that being the ART treatment \\npreparation process for all PLHIV:  \\n− Treatment (called antiretroviral therapy or ART) is available and is recommended for everyone \\nwith HIV.  \\n− Starting treatment as soon as possible (preferably within two weeks from testing positive for \\nHIV) reduces the chance of your illness getting worse or of passing HIV to others. If  you take your \\nART properly and do not miss pills you can expect to live a long and productive life  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 32}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 8  2.4 Age -Specific HIV Testing Algorithms  \\n2.4.1  Early Infant Diagnosis  \\n2.4.1.1 Confirmation of HIV infection in HIV Exposed Infants and Children < 18 Months Old  \\nHIV expo sure  of an infant or child can occur in utero, at labour and delivery and through breast \\nmilk. Confirmation of HIV infection should immediately follow.  \\nAll HIV exposed infants (HEI) should be tested with DNA PCR within 6 weeks of age or first contact \\nthere after; if negative then another DNA PCR at 6 months, and if negative then repeat DNA PCR at \\n12 months.  \\nIf the HEI develops symptoms suggestive of HIV as per WHO staging criteria, an additional DNA \\nPCR test should be conducted immediately.  \\nAn antibody test  should be performed for all HEI at 18 months of age and every 6 months thereafter \\nduring breastfeeding, and at 6 weeks after complete cessation of breastfeeding (Figure 2.1).  \\n \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 33}),\n",
       " Document(page_content='  \\nHIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 9  \\nEstablish  HIV   of Infants  and  Children\\n< 18 months\\n•  Mother known HIV \\n•  HTS  for mothers  with  unkn own HIV \\n•  Rapid antibod y test on infant/child  if mother s HIV cannot  be \\nEstablish HIV infection for HIV Exposed Child at 6 weeks or at first \\ncontact  (includes child with negative DNA PCR result at birth)\\n• Collect a DBS for HIV DNA PCR test 1\\n• Start/continue infant  ARV prophylaxis\\n• Start CPT At L&D, MNCH/F P, \\nIPD, A&E,  CCC & \\nHIV DNA PCR test NEGATIVE\\nChild HIV -exposed\\n• Continue HEI follow -upHIV DNA PCR test POSITIVE\\nChild presumed HIV infected\\n• Discontinue infant ARV prophylaxis\\n• Start ART\\n• Offer comprehensive care including \\ncontinuation of CPT\\n• Collect new sample for confirmatory HIV DNA \\nPCR, baseline viral load and CD4%.  1Conduct DNA PCR  at 6 months of age or soonest contact \\nthereafter (or earlier if child develops symptoms \\nsuggestive of HIV -as per WHO staging criteria)1\\nConfirmatory HIV DNA \\nPCR test POSITIVE\\nChild confirmed HIV \\ninfected\\n• Continue ART and \\ncomprehensive care \\nand routine under -5 \\ncareConfirmatory HIV DNA PCR \\ntest NEGATIVE\\nChild presumed HIV infected\\n• Continue ART \\n• Collect and send a DBS \\nto NHRL and manage \\nas per the results from \\nNHRLHIV DNA PCR result NEGATIVE\\nChild HIV -exposed\\n• Continue HEI follow -up\\n• Conduct DNA PCR at 12 months of age  or \\nsoonest contact till 18 months of age (or earlier if \\nchild develops symptoms suggestive of HIV -as \\nper WHO staging criteria) 1\\nHIV DNA PCR result NEGATIVE\\nChild HIV -exposed\\n• Continue HEI follow -up\\n• Continue routine under -5 care\\n• Conduct HIV Antibody test at 18 months of age \\n• If breast feeding, do HIV antibody test every 6 months while breast \\nfeeding and 6 weeks after complete cessation of breastfeeding \\nIf HIV antibody test  is negative\\nChild HIV negative \\n• Stop CPT * \\n• Review at age 2 years and document vital status \\n• Continue routine  unde r-5 If HIV antibody test  is positive \\nChild confirmed HIV infected\\n• Start  ompre hensive  \\n• Continue CPT\\n• Continue routine  unde r-5 \\n1 Where Point of Care DNA PCR is available - EID should be done using the whole blood at the facility. \\nFor baseline viral load testing – If available, use point of care machine for viral load; If there is no point of care \\nmachine to do viral load - Take a plasma and send it to the VL testing laboratory\\n* Only after final antibody test negativeChild is HIV unexposed\\n  \\nFigure 2.1 Algorithm for Early Infant Diagnosis in Infants and Children < 18 months of age   \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 34}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 10  Presumptive Diagnosis of Severe HIV Disease in Children under 18 Months  \\nOccasionally, children less than 18 months of age present to hospital with severe illness; and a rapid \\nHIV antibody test confirm s HIV exposure. Lack of immediate availability of HIV DNA PCR results \\nfor confirmation of HIV could result in undue delay in starting life -saving ART. In such children, a \\npresumptive diagnosis of HIV infection can be made using the criteria in Table 2.3. A RT can be \\ninitiated while awaiting HIV DNA PCR results to confirm HIV infection.  \\nTable 2.3: Presumptive Diagnosis of HIV in children <18 months while awaiting DNA PCR \\nResults  \\nHIV antibody test positive AND symptomatic with;  \\n 2 or more of the following:  \\n● Oral candidiasis/thrush  \\n● Severe pneumonia  \\n● Severe sepsis  \\nOR any of the of following:  \\n● Any WHO Clinical Stage 4 condition  \\n● Recent maternal death (if likely to have been HIV -related) or advanced HIV disease in \\nmother  \\n● Child’s CD4% < 2 5% \\n \\n2.4.1.2  Birth Testing  \\nBirth testing is defined as HIV testing (with DNA PCR) at birth or around birth for infants born to \\nHIV-positive mothers. Birth testing has the potential to improve survival for infants who are \\ninfected during pregnancy, around labour and delivery by ident ifying them early for rapid ART \\ninitiation. Do not use cord blood for birth testing as this could result in false positive results.  \\nA DNA PCR test can be offered at birth or around birth where feasible.  \\nALL children initially tested at birth should be rete sted at 6 weeks of age and the EID \\nalgorithm followed (Figure 2.2.)  \\nConsiderations for providing birth testing:  \\nBirth testing may be prioritized for newborns who are at high risk of HIV acquisition including \\nthose born to:  \\n● Mothers who seroconvert during p regnancy.  \\n● Mothers who have unsuppressed or unknown viral loads during delivery.  \\n● Mothers who received a HIV positive diagnosis for the first time at or after 28 weeks \\ngestation or during labour and delivery  \\n● Mother on ART for less than 12 weeks prior to delivery  \\nBirth testing should be offered where this is feasible:  \\n● DNA PCR results can be returned the same  day e.g., where on site point of care is available.  \\n● ART regimens recommended for neonates as per national guidelines are available and can \\nbe initiated immed iately.  \\n● Follow -up of the newborn is done to ensure no lost to follow -up. ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 35}),\n",
       " Document(page_content='  \\nHIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 11  \\nInfant of known HIV positive mothers at birth (or \\nwithin 2 weeks of birth)\\n• Collect DBS for DNA PCR\\n• Start infant ARV prophylaxis immediately after \\nbirth.  \\nHIV DNA PCR positive HIV DNA PCR Negative \\n• Initiate ART immediately\\n• Book for follow up at 2 weeks of age. \\n• Offer comprehensive care for HIV infected child. \\n• Collect new sample for confirmatory HIV DNA \\nPCR, baseline viral load and CD4%.• Continue infant ARV prophylaxis and follow up \\nfor HIV exposed infants. \\n• Repeat DNA PCR test at 6 weeks. Follow the EID \\nalgorithm. \\nConfirmatory DNA PCR positive/ \\ndetectable Viral load \\n• Continue ART \\n• Provide comprehensive care. Confirmatory DNA PCR negative \\n• Continue ART \\n• Collect DBS for repeat PCR at 6 weeks of age \\nand manage as per EID algorithm \\n• Collect new sample send to NHRL. Manage as \\nper NHRL results \\nFigure 2.2: Birth Testing Algorithm  \\n \\n2.4.1.3  Use of Point of Care testing for Children  \\nPoint -of-care testing occurs at the health facility where care is being provided, with results being \\nreturned to the patient or caregiver on the same day as sample collection. Point of care DNA PCR \\ntesting for early infant diagnosis of HIV can reduce the turnaround time for testing and return of \\nresults and allow imme diate initiation of ART among infants.  Point of care DNA PCR testing can be \\nused to diagnose HIV infection as well as to confirm positive results.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 36}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 12  2.4.2  Diagnosis of HIV Infection in the Older Child (≥ 18 months), Adolescents and \\nAdults  \\n● Serial testing,  using approved rapid HIV antibody testing kits, is used to diagnose HIV infection \\nin children older than 18 months, adolescents, and adults, and (refer to Figure 2.3)  \\n● An HIV -positive diagnosis will be made using three consecutive reactive assays . This thr ee-\\ntest strategy as well as retesting aims to ensure that at least a 99% Positive Predictive Value \\n(PPV) is maintained, and false positive misdiagnosis is avoided.  \\n● Offer adequate information to all clients and obtain consent prior to the HIV test (verbal \\nconsent is adequate but should be documented by the health care worker in client records). \\nFor children below the age of 14 year who are not emancipated minors, a written consent from \\nthe guardian is recommended.  \\n● Individuals 15 years and older and emancipa ted minors can provide self -consent.  \\n● Clients who test positive should be linked to care and treatment. Counselling support, index \\nand family testing should be offered to these clients.  \\n● Clients who test negative should be counselled on HIV risk reduction b ehaviors and linked to \\ncombination HIV prevention services (such as VMMC, RH/FP, condoms, PrEP, etc.) depending \\non individual risk profile. Table 2.5 provides recommendations for re -testing those who test \\nHIV negative.  \\nHIV testing algorithm for children >1 8months, adolescents and adults.  \\nFigure 2.3 illustrates the serial testing algorithm. An HIV -positive diagnosis will be made using \\nthree consecutive reactive assays (Figure 2.3). All individuals are first tested on Assay 1 (A1). \\nAnyone with a non -reactive test result (A1−) is reported HIV -negative.  Individuals who are \\nreactive on Assay 1 (A1+) will then be tested on a separate and distinct Assay 2 (A2). Individuals \\nwho are reactive on both Assay 1 and Assay 2 (A1+; A2+) will then be tested on a separate an d \\ndistinct Assay 3 (A3). A positive HIV diagnosis is given when Assay 3 is reactive (A1+; A2+; A3+).  \\nIf Assay 3 is nonreactive (A1+; A2+; A3−), the status should be reported as HIV -inconclusive, and \\nthe individual should be asked to return in 14 days for retesting.   \\nIndividuals who are reactive on Assay 1 but non -reactive on Assay 2 (A1+; A2−) should be repeated \\non Assay 1. If repeat Assay 1 is non -reactive (A1+; A2−; repeat A1 –), the status should be reported \\nas HIV -negative.  If repeat Assay 1 is reactive (A1+; A2 –; repeat A1+), the status should be reported \\nas HIV -inconclusive, and the individual asked  to return in 14 days for retesting.   All clients with \\nHIV positive results will be referred to a Comprehensive Care Clinic for retesting prior to \\ninitiation of ART  \\nNOTE:  The three -test algorithm will be implemented after identification of the specific \\nassay. Meanwhile, the current algorithm continues being in use (Annex 7). Guidance will \\nbe issued before implementation.  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 37}),\n",
       " Document(page_content='  \\nHIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 13  \\nHIV TEST A1\\nNON -REACTIVE REACTIVE\\nREPORT NEGATIVE HIV TEST A2\\nNON -REACTIVE REACTIVE\\nHIV TEST A1 HIV TEST A3\\nNON -REACTIVE REACTIVE NON -REACTIVE REACTIVE\\nREPORT NEGATIVE\\nREPORT INCONCLUSIVE AND \\nRETEST IN 14 DAYS. \\nREPORT HIV POSITIVE AND REFER TO THE SECOND TESTER AT CCC/MCH\\nHIV TEST A1\\nNON -REACTIVE REACTIVE\\nREPORT INCONCLUSIVE AND \\nRETEST IN 14 DAYSHIV TEST A2\\nNON -REACTIVE REACTIVE\\nHIV TEST A1 HIV TEST A3\\nNON -REACTIVE REACTIVE NON -REACTIVE REACTIVE\\nREPORT NEGATIVEREPORT INCONCLUSIVE AND \\nRETEST IN 14 DAYSINITIATE ART\\nNote: \\n• The use of DNA PCR as a supplemental assay is no longer recommended\\n• For inconclusive HIV status, if reactivity remains the same after 14 days the individual should be \\nreported as HIV -negative and advised to retest after 3 months \\nFigure 2.3: HIV Testing Services Algorithm  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 38}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 14  Results interpretation  \\nRESULTS  INTERPRETATION  \\nA1- HIV-NEGATIVE  \\nA1+; A2+; A3+  HIV-POSITIVE  \\nA1+; A2 -; Repeat A1+  HIV-INCONCLUSIVE (retest after 14 days). If reactivity \\nremains the same after 14 days, the individual should be \\nreported as HIV -negative   \\nA1+; A2 -; Repeat A1 - HIV-NEGATIVE  \\nA1+; A2+; A3 - HIV- INCONCLUSIVE (Retest after 14 days). If reactivity \\nremains the same after 14 days, the individual should be \\nreported as HIV -negative  \\n \\n2.4.3  HIV testing for Pregnant Women  \\nFor pregnant women, the HIV/syphilis dual test should be used as the A1 test (Figure 2.4). The dual \\ntest kit is recommended for:  \\n● Pregnant women during their first ANC, unless the woman is known to be living with HIV.  \\n● For those who test negative for both HIV and Syphilis repeat testing should be conducted \\nin the third trimester using the HIV and syphilis dual test.  \\n● Partners accompanying pregnant women for the first -time during ANC  \\nHIV/Syphilis dual test should not be used for retesting women on ART or with  known positive HIV \\nstatus, or women diagnosed with syphilis during pregnancy.  \\nSee Figure 2.4 for the full algorithm when considering HIV and syphilis (TP) results concurrently.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 39}),\n",
       " Document(page_content='  \\nHIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 15  \\nTEST A1 (HIV/Syphillis)\\nHIV TEST A1 SYPHILIS TEST A1\\nREPORT NEGATIVE HIV TEST A2\\nNON -REACTIVE REACTIVE\\nHIV TEST A1 HIV TEST A3\\nNON -REACTIVE REACTIVE NON -REACTIVE REACTIVE\\nREPORT NEGATIVE REPORT INCONCLUSIVE \\nRETEST IN 14 DAYS.\\nREPORT HIV POSITIVE AND REFER TO THE SECOND TESTER AT CCC/MCH\\nHIV TEST A1\\nNON -REACTIVE REACTIVE\\nREPORT INCONCLUSIVE AND \\nRETEST IN 14 DAYSHIV TEST A2\\nNON -REACTIVE REACTIVE\\nHIV TEST A1 HIV TEST A3\\nNON -REACTIVE REACTIVE NON -REACTIVE REACTIVE\\nREPORT NEGATIVE REPORT INCONCLUSIVE AND \\nRETEST IN 14 DAYSINITIATE ARTNON -REACTIVE REACTIVE NON -REACTIVE REACTIVE\\nREPORT NEGATIVEREPORT POSITIVE AND \\nTREAT FOR SYPHILLIS\\nNote: \\n• The use of DNA PCR as a supplemental assay is no longer recommended\\n• For inconclusive HIV status, if reactivity remains the same after 14 days the individual should be \\nreported as HIV -negative and advised to retest after 3 months \\nFigure 2.4 Dual HIV/syphilis Testing Algorithm  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 40}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 16  RESULTS  INTERPRETATION  \\nA1 HIV -, Syphilis Test (TP) - HIV negative, syphilis negative  \\nA1 HIV -, Syphilis Test (TP)+  HIV negative, syphilis positive  \\nA1 HIV+, Syphilis Test (TP) - Syphilis negative and proceed with A2 for HIV  \\nA1 HIV+, Syphilis Test (TP)+  Syphilis positive and proceed with A2 for HIV  \\nA1 (HIV+); A2+; A3+  HIV-positive  \\nA1(HIV+); A2 -; Repeat A1+  HIV-inconclusive (retest after 14 days). If reactivity remains the same \\nafter 14 days, the individual should be reported as HIV -negative  \\nA1(HIV+); A2 -; Repeat A1 - HIV-negative  \\nA1(HIV+); A2+; A3 - HIV- inconclusive (retest after 14 days). If reactivity remains the same \\nafter 14 days, the individual should be reported as HIV -negative  \\nTable 2.4: Approaches to Improve Linkage to Treatment and Prevention Services  \\nkey area  Action  \\nInformation  ● Quality post -test counselling should include information about the nature and \\navailability of additional HIV -related services, description of the next steps in \\ntreatment and prevention including entire treatment plan and follow -up visits \\nand schedule.  \\n● The benefits of immediate assessment and early initiation of ART should be \\nemphasized.  \\n● Involve the patient in the decision -making process regarding treatment and \\nprevention (espe cially where and when to start ART)  \\nDisclosure  ● Disclosure to a trusted ‘significant other’ promotes linkage and adherence to \\ntreatment.  \\n● Encourage and help the patient to discuss HIV status with a trusted friend or close \\nrelative.  \\n● Encourage adolescents to identify and invite a supportive adult or friend to \\nsupport them.  \\n● For children, HIV status should be disclosed to children by age 12 years and the \\nprocess can start when a child is as young as 7 years old.  The health care provider \\nor the pa rent/caregiver/guardian can disclose to the child with appropriate \\nguidance and training. The aim of disclosure to children is to start to involve them \\nin the management of their own health and reduce stigma associated with HIV  \\nBarriers to \\nLinkage  ● During post -test counselling, identify and address any barriers to linkage  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 41}),\n",
       " Document(page_content='  \\nHIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 17  Table 2.4 Cont.  \\nSystems to \\nFacilitate \\nLinkage  ● The HTS provider is responsible for linkage into care.  \\n● Same day enrolment into care is expected. monitor linkage to treatment initiation \\nwithin 14 days of diagnosis, however allow follow up of clients to 90 days of a \\nHIV-positive diagnosis  \\n● For HIV negative clients link to HIV prevention services based on assessed risk  \\n● Linkage should be done to on -site treatment and prev ention services through \\npatient escorts. Where this is not possible (due to patient preference or the \\nservices are not available), the testing facility should book the appointment with \\nthe receiving facility and follow -up to ensure the patient registers at  the receiving \\nfacility. Provide the patient with referral information, referral form and contact \\ndetails of the facility.  \\n● Deploy retention and loss -to-follow up tracking system to ensure linkage is \\nsuccessful. These include enlisting the help of peer or b uddy systems, SMS \\nreminders, phone calls and community outreach workers to escort HIV positive \\nclients to enrolment.  \\n● Early preparation and assessment for ART, with early initiation of ART \\nstrengthens engagement in care.  \\nCare \\nCoordination \\nand \\nIntegration  ● Coordinate and treat mother -baby pairs, partners, and families together. \\nIntegrate common services offered to PLHIV (TB diagnosis and treatment, \\nSRH/FP, cervical cancer screening, nutrition etc.)  \\n● Where referrals are necessary, such referrals should be coor dinated \\n(communication and documentation between referring and receiving service \\ndelivery points)  \\nLinkage Register  ● Maintain a linkage register at all testing points in the facility and community.  \\n● Track and report on progress with linkage monthly  \\n● Discuss linkage at MDT meetings.  \\n \\n2.5 Retesting recommendations for HIV negative persons  \\nRetesting in this context refers to testing that occurs later after the initial test is negative.  \\nThe purpose of retesting is to:  \\n● Monitor the effectiveness of HIV prevention interventions  \\n● identify and treat new HIV infections as early as possible when prevention efforts fail.  \\nThe following are the recommendations for HIV retesting in different populations and settings in \\nKenya:  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 42}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 18  Table 2.5: Recommendations for Retesting HIV Negative Clients  \\nScenario/population  Recommendation for retesting  \\nGeneral population  All general population to be screened every 2 years \\nusing the approved NASCOP HTS screening tool and \\nthose eligible get tested  \\nKey populations (FSW, MsM, TG, \\nPWID)  Re-test every 3 months  \\nNegative partner in discordant  \\n \\n Retest HIV negative partner at the initiation of ART for the \\nHIV positive partner, at 6months and 12 months once \\nviral suppression is achieved.  \\nRetest a nnually if the positive partner remains virally \\nsuppressed.  \\nPregnant women  Test in first trimester or first contact; Re -test in the third \\ntrimester and, during labour and delivery.  \\nBreastfeeding mothers  Re-test 6 weeks after delivery, at 6 months then every 6 \\nmonths until complete cessation of breast feeding.  \\nFor mothers considered to be at high risk of HIV \\ninfection, retesting postnatally should be done every 3 \\nmonths  \\nPersons who had a most recent \\n(e.g., less than one month) high \\nrisk exposure to  HIV  Test at initial presentation and re -test at 4 weeks, after \\nwhich National testing guidelines apply  \\nSTI symptomatic patients or \\npatients with symptoms \\nsuggestive of acute HIV  Test at initial presentation and re -test at 4 weeks, after \\nwhich national te sting guidelines apply  \\nIndividuals on Pre -exposure \\nprophylaxis (PrEP)  Test at initiation of PrEP; Retest at month one, and then \\nevery 3 months  \\n2.6 Inconclusive HIV status  \\nAn HIV -inconclusive test status means that individuals had discrepant results on the test (for \\nexample, first test reactive, second test nonreactive, third test reactive) and so could not be given \\nan HIV -positive or HIV -negative diagnosis.  \\nInconclusive results are rare, but they may occur when  \\ni) cross -reactivity exists between kits or patient -related factors,  \\nii) the tester or test kit makes an error; and/or  \\niii) individuals are seroconverting and in the window period, when infection cannot be \\ndeterm ined.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 43}),\n",
       " Document(page_content='  \\nHIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 19  The window period is the time from exposure to HIV infection to when the body produces enough \\nHIV antibodies to be detected by an HIV antibody test. This time can vary across different types of \\ntests, where some tests may be able to detect antibodies earli er than another test, which can lead \\nto discrepant test results.  \\nAll people with an inconclusive HIV status should be encouraged to return in 14 days for retesting. \\nReceiving inconclusive results could be confusing and stressful for clients and may be dif ficult for \\nthe provider to explain. During post -test counselling, the provider needs to take time to explain \\ncarefully what an HIV -inconclusive status means, stating that it is neither HIV -positive nor HIV -\\nnegative, and that retesting in 14 days is needed to establish the correct diagnosis. Because \\ndefinitive diagnosis cannot be made on the day of testing, and immediate referral to HIV care or \\nART initiation is not appropriate, providers need to help clients make a clear plan for follow -up and \\nschedule an a ppointment for retesting. Also, clients should be informed about prevention options \\nand how to stay HIV -negative, as well as about the availability and benefits of ART.  \\nThose suspected of having an acute HIV infection1 – for example, if they report or pre sent with \\nsymptoms associated with acute HIV infection – should be followed up closely. This is a period of \\nhigh infectiousness due to high viral load, and clients need to be informed how to protect their \\npartners. Individuals at high ongoing risk of HIV c an be informed about PrEP and encouraged to \\ndiscuss options depending on their final HIV status when they come back for retesting.  \\n \\n2.7 Approach to Patients on ART with a Discrepant HIV Test Result  \\nHIV testing should not be performed to patients who are al ready enrolled into HIV care and \\non ART.  However, some patients self -refer for HIV antibody testing without disclosing that they \\nare known HIV positive and on ART. Figure 2.5 provides recommendations on managing patients \\nwho have a non -reactive antibody te st while on ART.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 44}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 20  \\nEducation/counselling  for patients who are on ART and present with a new negative HIV antibody test\\n• The new HIV antibody test may be a  false negative    the patient may still be HIV -infected but their antibody \\nlevels may be suppressed as a result of effective ART. This is more common for patients who start ART very \\nsoon after HIV infection\\n• Those with prior history of detectable viral loads, positive DNA PCR results, or low CD4 counts are almost \\nalways truly HIV positive\\n• Continue their ART until a special test is performed (a new sample for DNA PCR) at the National HIV \\nReference Laboratory (NHRL)\\n• Stopping ART before HIV status is confirmed could result in a rapid rise in viral load, decline in CD4, and \\nincreased risk of developing an opportunistic infection or dying\\n• Draw a sample for DNA PCR  and send to the NHRL  (preferably a whole blood EDTA sample following \\ncold -chain protocols within 24 hours of collection; DBS is acceptable if EDTA is not possible)\\n• Specify that this is a sample for confirming HIV status  of a patient who is on ART, and provide the dates \\nand results for all prior antibody tests, DNA PCR tests, and RNA viral load tests in the request form\\nIf HIV DNA PCR sample is positive\\n• This confirms the patient is HIV positive\\n• Provide additional counseling on the \\nreasons why the antibody test may have \\nbeen falsely negative and discourage the \\npatient from any repeat antibody testing\\n• Emphasize that the patient  s ART is \\nworking and the need for continued \\nexcellent adherenceIf HIV DNA PCR sample is negative\\n• The patient may be HIV negative, or it could be that the \\npatient is  HIV positive but the HIV DNA levels have been \\nsuppressed below the testing limit (this is more common if \\na DBS sample was used)\\n• Inform the patient that they may still be HIV positive and \\nneed to be monitored closely for an additional 6 months \\nbefore confirming they are HIV negative\\n• Inform the patient that ART should be stopped immediately\\n• They should return for HIV viral load performed at 1 \\nmonth, 3 months, and 6 months after stopping ART \\n(samples for HIV viral load should be sent to the designated \\nVL/EID network laboratory assigned to the requesting \\nfacility with all past details) \\nFigure 2.5: Managing Patients on ART Who Present with a New Negative HIV Antibody Test', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 45}),\n",
       " Document(page_content='  \\nInitial Evaluation and Follow up  \\n3 - 1   \\n3. Initial Evaluation and Follow up  \\n \\n3.1 Introduction  \\nAll PLHIV are eligible for ART irrespective of CD4 cell count or percentage, WHO clinical  stage, age, \\npregnancy status, or comorbidities. ART should be initiated as soon as the patient is ready to start, \\npreferably within two weeks from time of HIV diagnosis.  \\nIn order to provide targeted services based on clinical presentation, during the init ial evaluation \\nall PLHIV should be categorized as presenting with advanced HIV disease (AHD) or as presenting \\nwell (Table 3.3). Patients with advanced disease require more intensive evaluation for and \\nmanagement of OIs, and once ART is started, they are at  higher risk of developing immune \\nreconstitution inflammatory syndrome (IRIS, Annex 16).  \\nSimilarly, after at least 6 months on ART, PLHIV should be categorized as being either established \\nor not established on ART (clinically, virologically, and psychosoci ally) to best meet the specific \\nneeds of each patient for treatment and follow -up and improve patient outcomes through provision \\nof targeted differentiated care. Differentiated care minimizes inconvenience and unnecessary \\nfrequent follow -up, thus reducing costs and time related to clinic visits. It also allows resources to \\nbe focused on those patients who require additional attention.  \\n3.2 Initial Clinical Evaluation of PLHIV  \\nAll patients enrolling into HIV care should have a complete medical history taken, a thorough \\nphysical examination and appropriate laboratory investigations. Findings from this initial \\nevaluation should be documented legibly in a retrievable health record management format \\n(electronic or paper -based) to facilitate long -term follow -up of the patient. Table 3.1 summarizes \\nimportant aspects of the initial medical history and physical examination for PLHIV.  \\nThe initial visit provides the opportunity to establish a meaningful patient -provider relationship; \\nthe clinician should elicit concerns  and expectations with open, non -judgmental, and clear \\ncommunication.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 46}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 2  Table 3.1: Initial Clinical Evaluation for PLHIV (History and Physical Examination)  \\nHistory  Details for History taking  \\nCurrent and past \\nmedical history  ● Presenting complaints/current symptoms  \\no Also inquire about symptoms due to co -existing HIV -related and non -HIV-\\nrelated disease and co -morbidities that will require immediate intervention  \\n● History of TB and TB contacts  \\nComplete the Intensified Case Finding (ICF) tool  \\n● Date of first positive HIV test  \\n● Past and current co -morbidities (e.g., TB, cryptococcal meningitis, hypertension, \\ndiabetes, kidney, and liver disease)  \\no Document history of TB  \\n● Current medications,  \\no Establish current medications (prescription, non -prescription, and \\nherbal) likely to interact with ARVs  \\no Document ARV exposure history including previous or current ARV use \\n(including for PMTCT, PEP, PrEP, and ART)  \\n● Drug allergies, especially sulpha allergy  \\n● History of hospitalizations  \\no Establish reasons for hospitalizations  \\n● Family history of chronic disease or cancer  \\nEstablish nutritional history and adequacy of nutritional intake and household food \\nsecurity  \\nPsychosocial \\nhistory  ● Education, employment, family, marital status  \\n● Establish possible presence of mental health concerns  \\no Including past treatment for mental illnesses and any current \\nsymptoms of depression  \\n● Assess for disclosure and presence of self -stigma  \\no Encourage disclosure to trusted close relations and sexual partners  \\n● Substance use screening including alcohol, tobacco, miraa (khat), marijuana, \\nnarcotics, injection drug use (use the CRAFFT screening tool for adolescents and \\nthe CAGE -AID screening tool for adults to screen for alcohol and drug use \\ndisorders – see Tables 4.15 and 4.16)  \\n● Establish and document social support structures  \\n● Link to additional facility and community support resources, including \\npsychosocial support groups, peer mentors, harm reduction services for PWIDs, \\netc. \\nElicit and begin to address possible barriers to adherence  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 47}),\n",
       " Document(page_content='  \\nInitial Evaluation and Follow up  \\n3 - 3  Table 3.1 Cont.  \\nSexual and \\nreproductive \\nhistory  History  \\n● History of STIs  \\n● Current symptoms of STIs  \\n● Sexual practices  \\no Determine HIV status and disclosure to sexual partner(s)  \\no ART status of sexual partner/s  \\n● Pregnancy history and age of all living children  \\n● Menstrual history, family planning and plans for pregnancy  \\n● History of cervical cancer screening  \\n● Vaccination history (including COVID -19 vaccine)  \\nDiscuss:  \\n● Secondary prevention and avoidance of re -infection with STIs  \\n● Pregnancy intention and contraception needs  \\nEncourage contact tracing and HIV testing for sexual partners and all children < 15 \\nyears of age of HIV -infected women or whose mothers’ HIV status is unknown  \\nVital signs, and \\nanthropometric \\nmeasurements  ● Measure and record weight, height, MUAC (in children and pregnant women), \\ntemperature, pulse rate, BP, respiratory rate, and pulse oximetry  \\n● Calculate BMI as: Weight (kg)/ Height2(m); Use z -scores for children  \\n● Monitor growth trends for children  \\nGeneral \\nexamination  Examine the following:  \\n● Conjunctiva and palms for pallor or jaundice; swollen lymph nodes (cervical, \\naxillary, inguinal); mouth for Kaposi’s sarcoma (KS) lesions, oral hairy \\nleucoplakia, candidiasis, tooth decay; skin (for drug eruptions, herpes zoster, \\ndermatitis, pruritic papular eruptions (PPE), folliculitis, fungal infections, \\nmolluscum, and KS)  \\n● Assess developmental milestones for children  \\nSystemic \\nexamination  ● Central Nervous System  \\n● Mental State Examination (for mental status)  \\n● Abdomen   \\n● Respiratory  \\n● Cardiovascular  \\n● Genitourinary/ anorectal system (for ulcers, discharge, condylomata/warts, \\nprostate examination for men ≥ 45 years of age). Speculum examination with \\ncervical cancer screening for females  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 48}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 4  Table 3.1 Cont.  \\nSummary  List differential diagnosis and management plan for each problem (including \\ninvestigations, treatment, referrals, and follow -up) \\n● Assign and document the WHO Clinical Stage and manage presenting \\nillnesses  \\n● Growth and developmental milestone must be assessed and used for WHO \\nstaging in children  \\nDifferentiate between patients with advanced disease versus those who are clinically \\nwell, to guide acuity of follow -up \\n3.3 Initial Laboratory Evaluation of PLHIV  \\nThe comprehensiveness of laboratory tests will depend on presence and/or type of suspected \\nconcurrent illness. Table 3.2 summarizes the recommended baseline laboratory investigations for \\nall PLHIV. Additional investigations should be based on clinical indicati on. ART should not be \\ndelayed if a laboratory test is not available.  \\nTable 3.2: Baseline Laboratory Investigations for PLHIV  \\nHIV  \\nSpecific  Test  Comments  \\n● Confirm and \\ndocument positive \\nHIV test result  ● Positive status should be reconfirmed prior to ART \\ninitiation for all patients  \\n● Refer to current HIV testing algorithm  \\nCD4 cell count  ● For all patients  (CD4% for children ≤ 5 years old)  \\n● If CD4 ≤ 200 cells/mm3 in PLHIV >5 years, th en \\nlaboratories should automatically perform a serum \\ncryptococcal antigen (sCrAg) on the same sample to screen \\nfor cryptococcal infection  \\n● TB-LAM should also be conducted   \\nViral load (HIV -1 RNA)  ● Baseline viral load (VL) is recommended for infants after \\n1st PCR test is positive. Specimen for baseline VL can be \\ndrawn at the time of initiating ART; obtaining a VL should \\nnot delay ART initiation  \\nSerum Cryptococcal  \\nAntigen (sCrAg)  ● Obtain serum CrAg If CD4 ≤ 200 cells/mm3 in patients >5 \\nyears  as reflex testing by the laboratory  \\n● If positive, manage as per the cryptococcal meningitis \\nscreening algorithm (Figure 4.1)  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 49}),\n",
       " Document(page_content='  \\nInitial Evaluation and Follow up  \\n3 - 5  Table 3.2 Cont.  \\nOthers  Hb (preferably full  \\nblood count if available)  ● All patients especially if on AZT  \\n●  \\nPregnancy Test  ● Pregnancy status should be determined for all women of \\nreproductive age (based on history of last menstrual period, \\nand if uncertain, irregular, or delayed then a urine pregnancy \\ntest should be performed)  \\nTB- LAM  ● Conduct TB -LAM  on a urine sample if CD4 ≤ 200 cells/mm3 \\nin PLHIV >5 years, and if CD4% ≤ 25% in children < 5 years  \\n● Seriously ill patients  \\nUrinalysis (for protein  \\n& glucose)  ● All patients  \\nCreatinine  o All patients, especially those starting TDF. Calculate \\nCreatinine Clearance (CrCl), (Annex 15)  \\nSyphilis serology \\n(VDRL, TPHA, or RPR)  ● All patients with a history of being sexually active  \\nGlucose  ● All patients  \\nPlasma lipid profile  ● All patients  \\nHBsAg  ● All adolescent and adult patients (plus children who did not \\ncomplete routine childhood immunizations)  \\nHCV antibody  ● PWID or for patients with history of injection drug use  \\nALT  ● Not recommended as baseline investigation unless there is a \\nspecific clinical reason (e.g., patient with history of hepatitis, \\nsigns or symptoms of liver disease, or risk of liver disease - \\nalcoholics, HBV or HCV infection, hepatotoxic drugs such as \\nfluconazole, etc.)  \\nHPV testing  ● For women of reproductive age between 25 -49 years \\nconducted at baseline and every two years (refer to cancer \\nscreening guidelines)  \\n \\nIt is not possible for ALL facilities providing ART to offer all the laboratory tests recommended for \\nHIV treatment. If a facility does not have on -site capacity to carry out any test, arrangements \\nshould be made to transport specimens to a local or regional reference laboratory.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 50}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 6  3.4 Management of Patients Who Present with Advanced HIV Disease  \\nThe World hea lth organization (WHO) defines AHD for adults, adolescents, and children five years \\nand older as having a CD4 cell count of less than 200 cells/mm3 or WHO clinical stage III or IV \\ndisease. All children younger than five years living with HIV who are not al ready receiving ART and \\nnot clinically stable are considered to have AHD.  \\nAdvanced HIV Disease can occur in various settings including PLHIV newly presenting to care, \\nthose returning to care after treatment interruption and those on ART who have experienc ed \\ntreatment failure.  \\nPLHIV with AHD have immune suppression with reduced ability to fight opportunistic infections \\n(OI), other infectious and non -infectious diseases, and are therefore at increased risk of morbidity \\nand mortality. AHD is also associated with increased health -care costs, use of more health -care \\nservices and more frequent monitoring needs. Leading causes of mortality among adults with AHD \\ninclude immune reconstitution inflammatory syndrome, tuberculosis (TB), severe bacterial \\ninfections, cryptococcal disease, histoplasmosis, toxoplasmosis, and Pneumocystis Jirovecii \\npneumonia amongst others.  \\nCD4 testing criteria to diagnose AHD and determine eligibility for package for care:   \\n• New clients initiating ART:  \\no CD4 testing should be c onducted as a baseline test for ALL PLHIV  \\n• Patients who are treatment experienced:  \\no PLHIV ≥5 years of age and who had previously initiated ART and are reinitiating after >3 \\nmonths).  \\no Individuals who have documented persistent unsuppressed viral load (two viral load VL \\n>1,000 within 3 -6 months).  \\nPackage of Care for AHD  \\nAll PLHIV presenting  with Advanced HIV Disease (AHD) should be offered a package of care that \\nincludes timely initiation of ART, screening, diagnosis, prophylaxis, and management of \\nopportunistic infections.  \\nTable 3.3 provides a summary of definitions of well versus advanced disease and package of care \\nfor each at enrolment.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 51}),\n",
       " Document(page_content='  \\nInitial Evaluation and Follow up  \\n3 - 7  Table 3.3: Differentiated Care Based on Initial Patient Presentation  \\nAdults, adolescents, and children ≥ 5 years who Present with Advanced HIV Disease: WHO Stage \\n3 or 4, or CD4 count ≤ 200 cell/mm3  \\nAll children younger than five years at enrollment into care  \\nPackage of Care  ● Standard Package of Care (Chapter 4)  \\n● Intensive management of presenting illnesses and malnutrition  \\n● Priority for identification, management, and prevention of OIs, \\nincluding.  \\no GeneXpert ultra for TB diagnosis for all PLHIV with presumptive TB \\n(Figure 8.1)  \\no TB-LAM (Figure 8.2), in addition to GeneXpert ultra, for PLHIV with \\npresumptive TB who  \\n▪ Have CD4 ≤ 200 cells/mm3 and if CD4% ≤ 25% in children < 5 \\nyears  \\n▪ Have signs of severe illness, or  \\n▪ Are currently admitted to hospital  \\no Cryptococcal antigen screening for adolescents and adults with CD4 \\n≤ 200 cells/mm3 or clinical suspicion of meningitis (any age) (Figure \\n4.1)  \\no Cotrimoxazole Preventive Therapy (CPT)  \\no TB Preventiv e Therapy (TPT)  \\n● Immediate ART initiation unless they are suspected to have TB, TB \\nmeningitis, or cryptococcal meningitis;( Table 6.1)  \\n● Close monitoring for development of immune reconstitution \\ninflammatory syndrome (Annex 16)  \\nFocus of ART Preparation \\nCounselling  ● Immediate ART start is required to prevent further damage to the \\nimmune system.  \\n● Starting ART soon will decrease risk of disease progression, including \\nwasting and other infections  \\nFrequency of  \\nFollow -up ● Weekly follow -up until ART initiation, and then at week 2 and 4 after \\nART initiation, and then monthly until confirmed viral suppression.  \\n● More frequent visits or hospitalization may be required to stabilize \\nacute medical conditions and address psychosocial and other concerns  \\n● Referral for management of co -morbidities or concurrent infections \\nmay also be needed  \\nManagement of Opportunistic Infections in Patients with AHD  \\nCryptococcal Disease (CM)  \\nCryptococcal disease is one of the most important opportunistic infections among peop le living \\nwith AHD and is a major contributor to mortality.  \\nEarly diagnosis and treatment of cryptococcal meningitis is key to reducing mortality from \\ncryptococcal disease. Health -care professionals should have a low threshold for suspecting \\ncryptococcal meningitis among people with advanced HIV disease.  \\nScreening, prevention and treatment of  cryptococcal meningitis is described in Section 4.33.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 52}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 8  Tuberculosis (TB)  \\nTB is the most frequent life -threatening OI and a leading cause of death among PLHIV. TB remains \\nthe leading cause of mortality among PLHIV, despite substantial scale -up of ART, accounting for \\n30% of the AIDS -related deaths reported.  \\nScreening, prevention  and treatment of TB is described in Chapter 8.  \\nTable 3. 4: Management of patients who are presenting well : WHO Stage 1 or 2, and CD4 count \\n> 200 cell/mm3  \\nAdults, adolescents, and children ≥ 5 years who Present Well: WHO Stage 1 or 2, and CD4 count > \\n200 cell/mm3 \\nFocus of ART Preparation \\nCounselling  ● ART is the most important treatment to maintain good health and an \\nactive life  \\n● Starting ART soon will decrease risk of developing wasting and other \\ninfections  \\n● ART will reduce the risk of transmitting HIV to others  \\nFrequency of  \\nFollow -up ● Weekly follow -up until ART initiation, and then at week 2 and 4 after \\nART initiation, and then monthly until confirmed viral suppression  \\n● Additional visits as required to address any medical or psychosocial \\nconcerns  \\nAdults, adolescents, and children ≥ 5 years who Present Well: WHO Stage 1 or 2, and CD4 count > \\n200 cell/mm3 \\nLocation of Services  • Management at any ART service delivery point; all facility levels   \\n• Initial management and ART initiation by trained and experienced HCW  \\nFocus of Treatment \\nPreparation Counselling  • ART is the most important treatment to maintain good health and an \\nactive life  \\n• Starting ART soon will decrease risk of developing wasting and other \\ninfections  \\n• ART will reduce the risk of transmitting HIV to others  \\n \\n3.5 Follow -up of PLHIV after ART initiation   \\nFollow -up of patients on ART is determined by the duration the patient has been on treatment, how \\nwell they understand the treatment and their response to AR T. Follow -up includes scheduled \\nclinical appointments, unscheduled clinical assessments for patients with concerns/complaints, \\nroutine and as -needed laboratory monitoring.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 53}),\n",
       " Document(page_content='  \\nInitial Evaluation and Follow up  \\n3 - 9  3.5.1 First 6 months after ART initiation  \\nAfter ART initiation, patients need to be monitored closely for development of adverse drug events, \\nidentify and address barriers to adherence, and development of IRIS. A reasonable follow -up \\nschedule for most patients is 2 weeks and 4 weeks after ART initiation (Table 3. 5 and 3. 6).  \\nWhen possi ble, follow -up for a particular patient should be provided by the same care provider or \\nteam of care providers (e.g., same clinician and same counsellor) at every visit. This is particularly \\nimportant during the first 6 months in care.   \\n3.5.2 Differentiat ed Service Delivery for Patients beyond the 1st 6 months of ART  \\nFollow up of patients beyond 6 months of ART is described in table 3. 5. It also  provides the criteria \\nfor determining if a patient is established on ART.  \\nIn summary:  \\n● Patients who are not established on ART require closer follow -up.  \\n● Patients who are established on ART require less frequent facility follow -up, with up \\nto six months b etween clinical appointments  \\n \\nTable 3. 5: Differentiated Follow -up of Patients Beyond the First 6 Months of ART  \\nPatients NOT established on ART  \\nPatients with any of the following:  \\n● On treatment for < 6 months  \\n● Any active OIs (including TB) in the previous 6 months  \\n● Poor or questionable adherence to scheduled clinic visits in the previous 6 months.  \\n● Most recent VL ≥ 200 copies/ml  \\n● Children < 2 years  \\nPackage of \\nCare  ● Standard Package of Care  \\n● Case management to address reason/s for not being established on ART  \\nFocus of \\nCounselling  ● ART is the most important treatment to maintain good health and an active life  \\n● ART will reduce the risk of transmitting HIV to others   \\nFrequency of \\nFollow -up ● Every 1 -3 months, based on clinical judgment  \\n● Additional visits as required to address any medical or psychosocial concerns  \\n● If VL is detectable at 3 months they will need additional assessments for \\nand management of the reason/s for detectable viral load, with close \\nfollow -up until viral suppression is achieved (Chapter 5).  \\n● Patients with confirmed viral suppression can be followed up every 3 -6 \\nmonths based on patient preference and clinician judgment, with \\nadditional unscheduled visits any time the patient has a concern.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 54}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 10  Table 3. 5 Cont.  \\nPatients Established on ART  \\nPatients established on ART must have achieved ALL the following  \\n● On their current ART regimen for ≥ 6 months  \\n● Currently no active Illness or in the previous 6 months (patients with well controlled chronic \\nconditions should not be excluded)  \\n● Adherent to scheduled clinic visits for the previous 6 months  \\n● VL ≤200 copies/ml (LDL) within the last 6 months  \\nNote:  \\n● This definition should be applied to all populations, including those receiving second - \\nand third -line regimens, those with controlled comorbidities, children above 2 years *, \\nadolescents, pregnant and breastfeeding women, and key populations.  \\n● The client’s category can change at any time so there is a need for a reassessment at each \\nvisit. Clients should be categorized at every visit and managed based on their status.  \\nPackage of \\nCare  ● Standard Package of Care  \\n● Re-assessment of criteria at every clinical visit  \\nLocation of  \\nServices  ● Clinical review and ART prescription from any ART service delivery point; all \\nfacility levels  \\n● Distribution of ART between clinical appointments, which can be facility -based \\nor community -based  \\nFocus of  \\nCounselling  ● Encourage patient to continue with what is working  \\n● Reminders that any significant life event or change in daily routine could \\ninterfere with adherence  \\nFrequency of  \\nFollow -up ● Clinic appointments to be made at 6 months intervals  \\n● ART should be offered as refills lasting 3 months,  (through fast -track pick -up at \\nfacility or through community -based distribution). Patients on injectab le \\ncontraception should be provided FP through a fast -tracked process between \\nclinic follow -up visits; oral contraceptives and condoms should be distributed \\nwith ART  \\n● Additional visits as required to address any medical or psychosocial concerns  \\n● Closer follow -up may be arranged based on patient preference  \\n*  Children below 2 years are excluded as they require frequent dose adjustment  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 55}),\n",
       " Document(page_content='  \\nInitial Evaluation and Follow up  \\n3 - 11  3.6 Summary of clinical and laboratory monitoring of PLHIV on ART  \\nTable 3. 6 summarizes the recommended minimum routine follow -up schedule for PLHIV.  \\nAdditional clinical and laboratory follow -up should be performed whenever clinically indicated  \\nTable 3. 6: Summary of Clinical and Laboratory Monitoring for PLHIV1 \\n Initial  \\nVisit  ART  \\npreparation  Week  \\n(After \\nART)   \\nMonths (after ART)   \\n≥ 6 months  \\n \\nAppointment2,3   \\nEvery week4  \\n2  \\n4  \\n2  \\n3  \\n4  \\n5  \\n6 Every 1 -6 \\nmonths \\ndepending \\non stability  \\nHistory and \\nphysical exam5 ✔  ✔  ✔  ✔  ✔  ✔  ✔  ✔  ✔  At each \\nclinical visit  \\nAdherence \\nassessment and \\nsupport6 ✔  ✔  ✔  ✔  ✔  ✔  ✔  ✔  ✔  At each visit  \\nTB Screening  ✔  Every visit, using ICF screening tool  \\nCD4 count  ✔  ● Baseline, and then only if patient develops treatment failure (to assess \\nfor risk of OIs), or if defaults from care (off ART) for at least 6 months  \\n● For patients on prophylaxis using dapsone (documented CTX allergy), \\nrepeat CD4 every 6 months until CD4 >200 cells/mm3 for two \\nconsecutive measures 6 months apart and VL undetectable, after which \\ndapsone and CD4 monitoring can be discontinued  \\nHIV Viral Load   ● For PCR positive HEIs: baseline at the time of ART initiation  \\n● Age 0 -24 years: at month 3, then every 6 months  \\n● Age ≥ 25 years: at month 3, then month 12, then annually thereafter if \\nsuppressed  \\n● For all: before any drug substitution for patients on ART for a t least 6 \\nmonths with no valid VL, at month 3 after regimen modification, and \\nthen as per population group  \\n● Any patient with a detectable VL during routine monitoring, follow viral \\nload monitoring algorithm (Figure 6.6)  \\nHIV Viral Load \\n(pregnant/ \\nbreastfeeding)   ● If on ART at time of confirming pregnancy: VL done at confirmation of \\npregnancy (regardless of when previously done), then every 6 months \\nuntil complete cessation of breastfeeding  \\n● If starting ART during pregnancy or breastfeeding, VL at 3 months after \\ninitiation, and then every 6 months until complete cessation of \\nbreastfeeding  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 56}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 12  Table 3. 6 Cont.  \\nCrAg  ✔  Baseline for adults and adolescents with CD4 ≤ 200 cells/mm3 (as reflex \\ntesting by laboratory), then only if there is clinical suspicion of CM  \\nHb ✔  Baseline, then symptom directed; if on AZT, baseline then weeks 2, 4, and \\n12 \\nPregnancy \\nStatus  ✔  At every visit for women of reproductive age (by history +/ - urine \\npregnancy test)  \\nUrinalysis \\n(protein & \\nglucose)  ✔  Baseline, then annually if on TDF  \\nCreatinine  ✔  Baseline, then annually if on TDF  \\nGlucose  ✔  Baseline, then annually  \\nPlasma lipid \\nprofile  ✔  Baseline, then annually  \\nHBsAg  ✔  Baseline, followed by immunization for all patients who screen \\nnegative (after viral suppression is confirmed)  \\nSyphilis \\nserology \\n(VDRL, \\nTPHA, or \\nRPR)  ✔  Baseline, then annually in those at risk and as part of routine ANC profile  \\nDrug \\nResistance  \\nTesting   DRT recommended once treatment failure confirmed on a DTG - or PI -based \\n1st line regimen, or confirmed treatment failure on 2nd line or subsequent \\nregimens  \\nALT   Not recommended for routine baseline or follow -up unless specific clinical \\nindication  \\nCervical \\nCancer  All women should be screened for cervical cancer following the national guidelines.  \\nUsing HPV screening conducted every 2 years for HIV positive women in their \\nreproductive age (or annually if using VIA -VILI)  \\nHCV  Baseline for PWIDs or with a history of injection drug use  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 57}),\n",
       " Document(page_content='  \\nInitial Evaluation and Follow up  \\n3 - 13  Table 3. 6 Cont.  \\n1 Recommended investigation should not delay ART initiation.  \\n 2This is the recommended appointment schedule. Clinicians and patients should be encouraged to \\nschedule additional appointments as needed. Patients should be encouraged to return to the HIV \\nclinic for unscheduled appointment whenever  an acute issue arises, instead of seeking care at \\nanother facility. Early after initiation of ART, and after any regimen modification , every \\nappointment should include:  \\n− Continued adherence counselling and support (started at the initial visit)  \\n− Assessment of adherence and correct storage of medication  \\n−  Assessment for and management of early side effects of the drugs, and patient counselling \\non the same  \\n3 Patients who are adherent and virally suppressed at month 3, may not need subsequent \\nmonthly appointments until month 6.  \\n4 All PLHIV qualify for ART and should be initiated as soon as possible including same day and \\nwithin 2 weeks. For patients who do not  start ART on the same day as enrolment into HIV care, \\nthey should be followed up every week until ART initiation to address whatever issues are \\ndelaying ART initiation, for ongoing management of acute medical issues and for treatment \\npreparation and ART r eadiness assessment.  \\n4Refer to table 3.1 for detailed history and physical examinations.  \\n5children and adolescents, weight and height should be measured and recorded at every visit, \\nwith weight -based dosing of ARVs confirmed at every visit.  \\nIn adults, weig ht and height should be measured at the initial visit to determine nutritional status \\nand calculate the BMI, and thereafter, weight should be measured at every visit.  \\n6The first 2 -4 visits are critical for assessing and supporting adherence to ART, managi ng adverse \\ndrug reactions, and treating any acute illnesses including IRIS. Adherence should be assessed at \\nevery contact with the clinic. See Chapter 5 for specific adherence preparation, monitoring and \\nsupport procedures for each visit  \\nRequired laboratory tests are highly recommended for patient monitoring, but are not a pre -\\nrequisite for ART initiation.  \\nTargeted laboratory tests may be necessary to identify and manage inter -current diseases or \\nadverse drug reactions.  \\n3.7 Differentiated Care for Children, Adolescents and Pregnant/ breastfeeding \\nWomen  \\nChildren, adolescents, pregnant and breastfeeding women, and key populations face unique \\nchallenges in retention  and viral suppression and  hence may benefit more from different iated \\nservice delivery models  adapted to their needs.  \\nChildren:  Children’s care is dependent on family and care giver dynamics. Family centered \\napproaches to care where clinic visits for parents/caregivers and the child are synchronized, \\nshould be used.  A ssessment and categorization to determine establishment on ART should be \\nconducted for pairs and follow -up tailored to their situations. Weight -based dose adjustments \\nshould be incorporated in both the facility and community models (e.g., by using portable  weighing \\nscales if out of the health facility) to determine optimal doses for ARVs at each review.  Aligning \\nappointments with school calendar should be considered to avert disruption of treatment and \\nlearning of the child.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 58}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 14  Adolescents:  Adolescents requi re psychosocial support, ongoing adherence assessments and \\ncounselling which should be aligned with clinic visits, community follow -up as well as school \\ncalendar.  Considerations should be factored in during the clinical encounters with more focus to \\nthose  with adherence and viral suppression challenges. Adolescents and Youth Friendly services \\nthat incorporate life skills and extracurricular activities should be integrated where feasible.  \\nPregnant/breastfeeding women:  Pregnant and breastfeeding women who h ave been established \\non ART should have their HIV clinic appointments synchronized with Antenatal Care visits and with \\nfollow -up of the HIV -exposed infant. Those initiated on ART during pregnancy may need close \\nfollow up to support them in adherence, reten tion and achieving viral suppression. Breast feeding \\nwomen and their babies will have their clinical visit aligned with the immunization clinics schedule. \\nPsychosocial support groups are encouraged for both pregnant and breastfeeding mothers \\nincluding peer  to peer support.  \\n3.8 ART Prescription, Dispensing, and Distribution for clients established on \\nART  \\nPatients who are established on ART should be offered ART  refills of up to 3 months. The refill of \\nother associated commodities such as cotrimoxazole, TPT a nd condoms should be aligned to the \\nART refill schedule. Clients established on ART should receive their ART, CPT, family planning, and \\nany other chronic medicines through a distribution system that minimizes the burden on them \\n(travel costs, waiting times , inconvenience) and burden on the health facility (personnel time, \\nspace constraints, etc.). This must be on a voluntary basis (i.e., the client can choose to remain in \\nstandard care if they prefer).  \\nThe health facility is responsible for ART prescription , dispensing, and distribution for all patients \\nenrolled into care. ART distribution for patients established on ART can take place at the health \\nfacility or through a community distribution system, depending on patient preference and health \\nfacility syste ms and resources. The point of ART dispensing should be based on client ability \\nto access treatment with ease.  Models for ART refills include:  \\n● Facility -based  \\no Fast track facility -based refills  \\no Facility -based ART distribution groups  \\n● Community -based  \\no Community -based ART distribution groups  \\no Community ART distribution points  \\no Community pharmacy distribution  \\nFacility -based Fast Track System for ART Refills  \\nThe facility -based fast track system for ART  refills is a simple model implemented at the health \\nfacility. The client is still required to come to the clinic every 3 months for ART refill, however the \\nrefill appointments require minimal or no waiting time at the clinic.   Refer to DSD operational \\nmanual for detailed information on community models.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 59}),\n",
       " Document(page_content='  \\nInitial Evaluation and Follow up  \\n3 - 15  Facility -based ART Distribution Group  \\nFacility -based ART Distribution Groups are a model for ART distribution, whereby a group of \\nPLHIVs meet at a designated location within their health facility for drug refills and dispense \\ndrugs to their peers within the group while ensuring peer support and treatment literacy.  ART \\nrefills are done through the group every 3 months and  each client is required to attend their \\nclinical review appointment e very 6 months.   \\nThis model may provide clients with psychosocial support if they are not already part of a support \\ngroup. This may also be more convenient for clients who are in urban settings and would not wish \\nto be enrolled in a community -based group. F acility -based groups can be peer or HCW led.  \\nCommunity -based ART Distribution Models  \\nClients may receive ART refills through community -based distribution. All clients may also benefit \\nfrom home visits such as for adherence monitoring and support, on a case -by-case basis.  \\nClients can receive their ART refill through community -based models such as:  \\n● Community -based ART distribution groups  \\n● Community ART distribution points  \\n● Community pharmacy distribution  \\nBefore implementing a community -based ART distribution program, a health facility should work \\nwith the CHMT to design a program that meets the criteria listed in Annex 14, and the plan \\napproved by the County HIV Technical Working Group before implementation. Refer to DSD \\noperational manual for det ailed information on community models.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 60}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 16   ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 61}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 1   \\n4. Standard Package of Care for PLHIV  \\n \\nAll PLHIV should receive a package of services that are known to promote health, improve the \\nquality of life, prevent further HIV transmission, and prevent HIV disease progression and \\nmortality.  \\nThe standard package of care for PLHIV in cludes: antiretroviral therapy; Positive Health, Dignity \\nand Prevention (PHDP) services; screening and providing support in cases of gender -based \\nviolence (GBV) or intimate -partner violence (IPV); HIV education/counselling; screening and \\nprevention of spec ific opportunistic infections; reproductive health services; screening for and \\nmanagement of non -communicable diseases; mental health screening and management; \\nnutritional services; and prevention of other infections (Table 4.1).  \\nThe standard package of ca re should always be applied using a patient - and family -\\ncentered approach  in PLHIV management.  Patient -centered care includes: considering the \\nindividual patient’s health needs; eliciting and addressing the patient’s concerns and expectations; \\ninvolving th e patient’s (and their family and friends as appropriate) in decision -making, and; \\nrespecting the patient’s values and preferences. Family -centered care identifies, engages and \\nprovides care to all HIV -positive family members, prevents new infections among  family members \\nat risk, and promotes family support and awareness.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 62}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 2  Table 4.1: Components of the Standard Package of Care for PLHIV  \\nComponent of Standard Package of Care Sub components  \\nAntiretroviral therapy (ART)  ● ART initiation  \\n● Adherence assessment, counselling and support  \\n● Monitoring (clinical and laboratory)  \\nPositive health, dignity and prevention \\n(PHDP); gender -based violence (GBV) \\nand intimate -partner violence (IPV) \\nscreening; and HIV \\neducation/counselling  ● Disclosure  \\n● Index testing  \\n● Condom use  \\n● Family planning  \\n● STI screening, prevention, and treatment  \\n● Adherence counselling and support  \\n● Pre-exposure prophylaxis for HIV -negative sexual partners  \\n● GBV/IPV screening and support  \\n● HIV education/counselling  \\nSpecific opportunistic infection screening \\nand prevention  ● Cotrimoxazole preventive therapy  \\n● Tuberculosis (TB)  \\no Intensified case finding  \\no TB preventive therapy  \\no ART for TB/HIV co -infected patients  \\n● Cryptococcal meningitis  \\nReproductive health services  ● Sexually transmitted infections screening and management  \\n● Family planning and pre -conception services  \\n● Maternal healthcare  \\n● Cervical cancer screening  \\nNon -communicable diseases (NCD) \\nscreening and management  ● Hypertension  \\n● Diabetes mellitus  \\n● Dyslipidemia  \\n● Chronic kidney disease  \\n● Other NCDs  \\nMental health screening and management  ● Depression  \\n● Anxiety  \\n● Stress  \\n● Trauma  \\n● Alcohol and drug use/addiction  \\n● Self-care and wellbeing  \\nNutritional services  ● Assessment  \\n● Counselling and education  \\n● Management and support  \\nPrevention of other infections  ● Immunizations  \\n● Malaria  \\n● Safe water, sanitation and hygiene  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 63}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 3  Table 4.1 Cont.  \\nStandard Package of Care for HIV -Exposed and HIV -Infected Infants  \\n● Determine HIV status at first contact through HTS/EID and link to HIV care  \\n● Provide ARV prophylaxis for all HEIs and ART for all HIV -infected children ( confirming correct \\nweight -based dosing of ARVs at every visit ); perform clinical and laboratory assessment  \\n● Provide nutritional assessment, counselling and support (NACS, Section 4. 7) and monitor growth and \\ndevelopment of the child (Annex 3)  \\n● Ensure that all immunizations are provided following the national schedule (Section 4.8.1)  \\n● Clinical assessment at every visit, treat infections early, identify, manage and report adverse drug \\nreactions aggressively and refer appropriately where specialized care is required.  \\n● Screen for opportunistic infections and provide prophylaxis (cotrimoxazole, TB Preventive Therapy \\n(TPT), deworm every 6 months (starting at 1 year of age) and provide supplemen tal Vitamin A every 6 \\nmonths (starting at age 6 months)  \\n● Educate the caregiver on all aspects of care for the child including infant feeding, immunizations, \\npersonal hygiene, HIV education/counselling, adherence, availability of support for child disclosure , \\nand follow -up requirements  \\n● Adherence assessment, counselling and support  \\n● Provide age -appropriate psychosocial support for the family and child and refer to community -based \\nsupport programs as appropriate  \\n● Ensure that the caregiver and family members are r eceiving appropriate care, support and treatment  \\n● Provide intensive case management for mother/infant pair until 2 years postpartum; identify \\ndefaulters and prioritize this population for tracking  \\n● Enroll in Orphans and Vulnerable Children (OVC) program for social protection and other services.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 64}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 4  Table 4.1 Cont.  \\nStandard Package of Care for Adolescents Living with HIV  \\nClinical care  \\n● Provide immediate linkage to HIV care  \\n● Provide ART to all HIV -infected adolescents  \\n● Perform clinical and laboratory assessment  \\n● Clinical assessment at every visit, treat infections early and refer appropriately where specialized care \\nis required  \\n● Screen for opportunistic infections and provide prophylaxis (cotrimoxazole, TPT)  \\n● Provide NACS and monitor growth and  development  \\n● Provide/refer for HPV vaccine  \\nAdherence and psychosocial support  \\n● Perform a baseline and regular subsequent psychosocial assessment  \\n● Assess for and support disclosure of HIV status to the adolescent (Annex 5)  \\n● Enroll in age -appropriate psychosoci al support groups  \\n● Provide treatment literacy  \\n● Provide life skills counselling  \\n● Provide adherence counselling  \\n● Support appropriate transition into adult HIV treatment and prevention  \\n \\nPrevention of HIV transmission  \\n● Encourage index testing and support for disclosure  \\n● Assess for and manage drug and alcohol use  \\n● Perform a sexual risk assessment and STI screening and treatment, and linkage of sexual partner to \\nPrEP where applicable  \\n● Assess for and manage IPV  \\n● Provide reproductive health services, including pregnan cy screening, pregnancy intention assessment, \\nfamily planning and linkage to PMTCT for pregnant adolescents  \\nReferrals, linkages and support for continuum of care  \\n● Provide intra -facility & inter -facility referrals as needed for specialized care  \\n● Link with youth community groups, targeting youth both in and out of school  \\nOther services  \\nlegal centers, paralegal services, gender -based violence recovery centers, educational institutions, \\nbursary/scholarship programs, income generating activities, constituency development funds, vocational \\ntraining centers for skills development, etc.  \\n4.1 Antiretroviral Therapy  \\nART is recommended for all PLHIV, regardless of WHO stage, CD4 count, age, pregnancy status, \\nor comorbidities/co -infections. O nce a diagnosis of HIV infection is confirmed, ART should be \\ninitiated as soon as possible (preferably within 2 weeks), once patient readiness has been \\ndetermined. Other sections of these guidelines deal with initial evaluation and monitoring \\n(Chapter 3), patient preparation and adherence support (Chapter 5), and specific recommended \\nART regimens (Chapter 6).  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 65}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 5  4.2 PHDP, GBV/IPV & HIV Education/Counselling  \\nPHDP (Positive Health, Dignity and prevention) is a framework that emphasizes the health and \\nrights of P LHIV, including reducing risk of onward transmission of HIV.  Within PHDP are 7 core \\ndomains of services that should be provided at the health facility to PLHIV and caregivers (Table \\n4.2). Complementary community -based PHDP should also be implemented.  \\nTabl e 4.2: Domains and Components for PHDP Services  \\nPHDP Domain  Components  \\nDisclosure of HIV status  ● Assessment of disclosure status, particularly to sexual partners  \\n● Assisted disclosure  \\nNote: for children and adolescents, it is also necessary to evaluate for and \\nsupport age -appropriate HIV disclosure to the child/adolescent (Annex 5)  \\nIndex testing and \\nengagement  ● HIV testing of sexual and drug injecting partners  \\n● HIV testing of other family members at risk  \\n● Enrolment of positive partners/family members into HIV care  \\n● Engagement of negative partners and family members in care and \\nsupport for index patient, and PrEP as appropriate  \\nCondom use  ● Risk reduction counseling  \\n● Correct and consistent condom use  \\n● Provision of condoms at every visit  \\nFamily planning  ● Assessment of pregnancy intention  \\n● Pre-conception counselling  \\n● Dual contraception until ready for pregnancy  \\n(See Section 4.4.2 for specific clinical guidelines)  \\nSexually transmitted \\ninfections (STI)  ● Screening for symptoms of STIs  \\n● Prevention of STIs  \\n(See Section 4.4.1 for specific clinical guidelines)  \\nTreatment adherence  ● Benefits/importance of:  \\no Adherence to clinical care  \\no Adherence to ART  \\n● Messaging on Undetectable=Untransmissible (U=U)  \\n (Chapter 5)  \\nPre-exposure prophylaxis  ● Assess HIV -negative sexual partners for PrEP  \\n(Chapter 11)  \\nAdditional services that should be offered to PLHIV beyond the above components include screening for GBV and IPV \\nand HIV education/counseling services.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 66}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 6  4.2.1 Screening for Gender -Based Violence (GBV)/Intimate -Partner Violence (IPV)  \\nNational data (KDHS 2014) shows that 45% of women and 44 % of men aged 15 -49 years have \\nexperienced physical violence since age 15.; 14% of women and 6% of men age 15 -49 report \\nhaving experienced sexual violence at least once in their lifetime.  To identify these survivors \\nscreening is recommended. WHO recommends that facilities should meet the minimum \\nrequirement before starting to routinely screening clients.  \\nThe minimum require ments are:   \\n• A protocol or Standard Operating Procedure exists for providing post -GBV and Violence \\nAgainst Children  services  \\n• A questionnaire, with standard questions where providers can document responses,  \\n• Providers offer first -line support (LIVES)  \\n• Providers have received training on how to ask about GBV and Violence Against Children  \\n• Private setting, confidentiality ensured  \\n• A system for referrals or linkages to other services within the facility is in place  \\nIf any of these minimum requirements is mis sing, GBV and Violence Against Children  services are \\nconsidered inadequate, and providers should ensure to have these systems in place before \\nconducting routine enquiry or universal screening  \\nAll clients accessing HIV care services should be screened for a ny form of violence \\nincluding  IPV as part of the standard package of care for PLHIV.  \\nThe following script can be used for screening:  \\n “Many people do not realize that violence can lead to various serious health problems. Many \\npeople have problems with thei r husbands, partners or other people in their lives. Sometimes the \\npeople who love us can hurt us. Has this ever happened to you?”  \\nHas your partner ever:  \\n1. Insulted you or made you feel bad about yourself?  \\n2. Belittled or humiliated you in front of other people?   \\n3. Did things to scare or intimidate you on purpose  \\n4. Threatened to hurt you or someone you care about?  \\n5. Slapped you or thrown something at you that could hurt you?  \\n6. Kicked, dragged, beat you up?  \\n7. Chocked or  burned you on purpose?  \\n8. Threatened to use or actually used a gun, knife or other weapon against you?  \\n9. Physically forced you to have sexual intercourse when you did not want?  \\n10. Did you ever have sexual intercourse you did not want because you were afraid of w hat \\nhe might do?  \\n11. Forced you to do something sexual that you found degrading or humiliating?  \\nIf a survivor answers yes to any of these questions provide them with LIVES and do a mental \\nassessment  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 67}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 7  Table 4.2a: Components of screening for GBV/IPV (LIVES)  \\nListen  Listen to the client closely, with empathy and without judging  \\nInquire  Assess and respond to the client’s various needs and concerns  \\nValidate  Show the client that you understand and believe them. Assure the client that they \\nare not to blame  \\nEnhance safety  Discuss a plan to protect the client from further harm if violence occurs again  \\nSupport  Support the client by helping them to access information, services and social \\nsupport  \\nSupportive messages that may be helpful include:  \\n● “What happened to you is not your fault”  \\n● “Many women/men are in the same situation as you”  \\n● “You are not to blame.”  \\n● “Everybody deserves to feel safe at home if you feel like you are in immediate danger, we can \\ninvolve the police or local administration “  \\nMen, the  elderly, and children suffer different forms of violence and should be assessed if there \\nis any clinical suspicion. Key populations are particularly vulnerable to abuse, including MSM, \\ntransgender, and prisoners. For children art and play therapy is used during history taking and \\npsychological assessment.  \\n4.2.2 HIV Education/Counselling  \\nAll PLHIV and caregivers should receive focused education about HIV and its treatment to \\nempower them to succeed in management of the infection. Self -management is critica l to the \\nsuccessful treatment of any chronic illness, including HIV. Key messages for HIV education and \\nadherence counselling are described in Chapter 5 of these guidelines.  \\nIn addition, psychosocial counselling and support for PLHIV and caregivers should include:  \\n● Mitigation of fear, anger, self -stigma and discrimination  \\n● Alleviation of grief, bewilderment and stress among partners and family members  \\n● Behavior changes in support of healthy living and prevention of further HIV transmission  \\n● Skills -building on how to live a healthy and productive life  \\n● Identification and treatment of depression and substance abuse  \\nHIV education and counselling can be offered in multiple settings, including: facility -based \\nindividual, couples, family, and/or gro up counselling, and through community -based counselling \\nand peer support groups.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 68}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 8  4.3 Specific Opportunistic Infection Screening and Prevention  \\n4.3.1 Cotrimoxazole Preventive Therapy (CPT)  \\nCPT is no longer recommended as life -long prophylaxis, and is only recommended in the \\nfollowing sub populations, unless they have an allergy to sulfur drugs or develop toxicity from \\nCPT:  \\n● HIV exposed infants  \\n● HIV infected children and adolescents <15 years of age  \\n● PLHIV > 15 years of age:  \\no Living in malaria -endemic zones * \\no Presenting with WHO stage 3 or 4 event, or meeting the criteria AHD  \\no Suspected treatment failure  \\n● All Pregnant and Breast -feeding women  \\nFor HIV exposed and infected infants, CPT should start at 6 weeks of age. CPT is effective in AHD, \\nand preventing specific OIs for patients with low CD4 counts (PCP and toxoplasmosis), as well as \\nreducing the risk of common bacterial infections, sepsis, diarrhea illness and malaria.  \\n*Refer to the National Guidelines for the Diagnosis, Treatment and Prevention of Malaria in Kenya for the \\ncurrent Kenya Malaria endemicity map  \\nTable 4.3: Co -trimoxazole Preventive therapy  \\nSub -Population  Starting/Restarting criteria  Ending criteria  \\nHIV exposed Infants  All infants, starting 4 -6 weeks \\nafter birth  Child is confirmed HIV -negative  \\n \\nHIV-infected children \\nand adolescents ≤ 15 \\nyears old  All children  Attains 15 years of age  \\nPLHIV > 15 years old  Suspected treatment failure  \\nWHO Clinical Stage 3 and 4  Clinically stable:  \\no On ART for at least 12 months  \\no Showing no signs or symptoms of \\nWHO Clinical Stage 2,3 or 4  \\nHIV-positive \\nPregnant and \\nbreastfeeding women  All Clinically stable:  \\no On ART for at least 12 months  \\no Showing no signs or symptoms of \\nWHO Clinical Stage 2,3 or 4  \\no Not pregnant or breastfeeding  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 69}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 9  Table 4.4: Daily Dose of Cotrimoxazole Preventive Therapy  \\nWeight (kg)  If using oral suspension  \\n(240mg per 5ml)  If using single \\nstrength tablet 480 \\nmg (SS)  If using double strength \\ntablet 960 mg (DS)  \\n1 – 4 2.5 ml  ¼ SS tab  -- \\n5 – 8 5 ml  ½ SS tab  ¼ DS tab  \\n9 – 16 10 ml  1 SS tab  ½ DS tab  \\n17 – 30 15 ml  2 SS tabs  1 DS tab  \\n> 30  20 ml  2 SS tabs  1 DS tab  \\nAdult (any weight)   2 SS tabs  1 DS tab  \\nNote: If CrCl 15 -30 ml/min then use 50% of normal recommended dose; if CrCl < 15 ml/min then CTX should \\nbe avoided  \\nDuring pregnancy, CPT should be initiated irrespective of the gestational age and should \\ncontinue throughout pregnancy and breastfeeding. Additional intermittent preventive \\ntherapy (sulfadoxi ne-pyrimethamine (SP)) for malaria is not required for women already \\non CPT.  \\nCotrimoxazole can cause anaemia and neutropenia in some patients, as well as a skin rash.  \\nManagement of Patients with Cotrimoxazole Allergy  \\n● A rash may occasionally develop, usually about 7 -14 days following initiation of CPT. It \\nis often a relatively mild maculopapular rash with or without pruritus. Infrequently, rash \\nmay develop with severe exfoliation of the skin and Stevens -Johnson syndrome. Rash \\nseverity should b e assessed, with management based on severity (Table 4.5)  \\n● Desensitization is effective in the majority of patients with mild to moderate rash (Table \\n4.6a). The rapid desensitization regimen (Table 4.6 b) can be used in situations where \\ntreatment for PCP is needed  \\nTable 4.5: Management of Drug -Associated Skin Rash  \\nSeverity  Characteristics  Action  \\nMild  Dry; erythema +/ - fine \\npapules; pruritus; affecting \\n< 50% of body surface area  Continue CTX; close monitoring; symptomatic treatment with \\nantihistamines +/ - topical steroids (NOT oral steroids)  \\nModerate  Dry; erythema +/ - fine \\npapules; pruritus; affecting \\n≥ 50% of body surface area  Stop CTX; symptomatic treatment with antihistamines +/ - \\ntopical steroids (NOT oral steroids); trial of desensitization \\nafter symptoms completely resolved  \\nSevere  Mucosal involvement;  \\nblistering; associated fever; \\nany % of body surface area  Stop CTX; admission to hospital for supportive management (IV \\nfluids, wound care, pain control, infection control, monitoring \\nfor super -infection); patient should NEVER be re -challenged \\nwith CTX or other sulfa -containing drugs;  document and \\nreport adverse event and issue patient alert card  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 70}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 10   \\n \\n Cotrimoxazole Desensitization Protocols (for patients who have fully recovered from \\nmoderate reaction)  \\nTable 4.6a: Standard Cotrimoxazole \\nDesensitization Regimen (8 days)  Table 4.6b: Rapid Cotrimoxazole \\nDesensitization Regimen (6 hours)  \\n \\nDay  \\nDose of TMP/SMX Suspension  \\n(40/200 mg per 5ml)  \\nDay 1 0.5 ml  \\nDay 2 1 ml \\nDay 3 2 ml \\nDay 4 3 ml \\nDay 5 4 ml \\nDay 6 5 ml \\nDay 7 1 SS tablet  \\nDay 8 2 SS tablets/1 DS tablet per day  \\nNote: For children, continue up until they have \\nreached their recommended weight -based dosage  \\n  \\nHour  \\nDose of TMP/SMX Suspension \\n(40/200  mg per 5ml) \\nHour 0 0.5 ml \\nHour 1 1 ml \\nHour 2 2 ml \\nHour 3 3 ml \\nHour 4 4 ml \\nHour 5 5 ml \\nHour 6 1 SS tablet \\nNote: The rapid desensitization protocol should \\nnot be used for children because the cumulative \\ndosage will be too high  \\n \\n \\nDapsone as a Substitute for CPT  \\nIn situations of severe allergy to cotrimoxazole or when desensitization is not successful, \\ndapsone can be used instead of CTX. It is primarily effective as prophylaxis against PCP but does \\nnot have the other prophylactic benefits of cotrimoxazole.  \\nNote:  \\nDapsone will contribute to anaemia in most patients, and causes haemolytic anaemia in some \\npatients, so pati ents should have a baseline Hb before starting dapsone and Hb monitored every \\n1-2 weeks for the first couple of months.  \\nWhen dapsone (as a substitute for CPT) is being used as PCP prophylaxis, it is only \\nrecommended for patients in WHO Stage 4 and/or with  absolute CD4 count ≤ 200 \\ncells/mm3 (or CD4 % ≤ 25% for children ≤ 5 years old), and should be discontinued once \\na patient achieves a sustained CD4 count of > 200 cells/mm3 (or > 25% for children ≤ 5 \\nyears old) for at least 6 months.  \\nDapsone is NOT recomme nded during breastfeeding.  \\nDose of Dapsone  \\n● Available as 25 mg and 100 mg tabs  \\n● Children: 2 mg/kg once daily (maximum dose: 100 mg) OR 4 mg/kg once weekly \\n(maximum dose: 200 mg)  \\n● Adults: 100 mg once daily  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 71}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 11  4.3.2 Tuberculosis (TB) Prevention and Management for PLHIV  \\nAll PLHIV should be screened for TB at every visit using the Intensified Case Finding (ICF) tool.  \\nAll PLHIV older than 12 months of age who screen negative for TB should be provided with TB \\nPreventive Therapy (TPT) unless they have a s pecific contraindication.  All patients who receive \\na full course of TPT should have this clearly documented in their file (Section 8.2)  \\nFor PLHIV who have presumptive TB, GeneXpert ultra is the preferred testing platform to \\nconfirm the diagnosis, with TB -LAM used as an adjunct bedside test when indicated, while \\nawaiting GeneXpert ultra -results. All PLHIV qualify for ART, including patients with HIV/TB co -\\ninfection.  \\nChapter 8 provides specific guidelines for ICF, TPT, use of GeneXpert ultra and TB -LAM, and ART \\nfor patients with TB/HIV co -infection.  \\n4.3.3 Cryptococcal Meningitis (CM) Screening and Treatment  \\nAll adult and adolescent PLHIV with a baseline CD4 count of ≤ 200 cells/mm3   should be \\nscreened for cryptococcal infection (Figure 4.1). This should be a  reflex test performed by the \\nlaboratory as soon as the low CD4 count is noted, rather than requiring the clinician to order a \\nspecial test for screening.  \\nPLHIV, including children and adolescents, should receive cryptococcal screening if clinically \\nsuspec ted. For patients who are symptomatic for meningitis but screen serum CrAg negative, \\nalternative diagnoses for sub -acute meningitis should be explored, such as TB meningitis. All \\npatients with clinical meningitis should be assessed and managed at a facilit y that can perform \\nlumbar punctures.  \\nWhenever performing CSF CrAg for patients with symptomatic meningitis, CSF GeneXpert \\nultra for TB should be performed at the same time, as well as urine for TB -LAM . \\nFluconazole use during first trimester of pregnancy in creases the risk of birth defects. All \\npregnant women who screen positive with serum CrAg should be offered a lumbar puncture \\n(irrespective of symptoms) to determine if they have cryptococcal meningitis. If the CSF CrAg is \\npositive, they should be treated with 2 weeks of amphotericin B for induction (without \\nfluconazole), while consulting Uliza!  Hotline (0726 460 000; ulizanascop@gmail.com) to discuss \\nconsolidation/maintenance. Pregnant women with negative CSF CrAg should start ART \\nimmediately (without pre -emptive fluconazole therapy) and be monitored for symptoms of CM.  \\nTable 4. 7 provides detailed guidance on the use of amphotericin, fluconazole, flucytosine (once \\navailable), and therapeutic lumbar punctures for the treatment of symptomatic cryptococcal \\nmen ingitis  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 72}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 12  Table 4. 7: Treatment of Cryptococcal Meningitis  \\nTarget \\npopulation  Regimen  Induction (2 \\nweeks)1,2 Consolidation \\n(8 weeks)  Maintenance  When to start  \\nART  \\nAdults  Preferred  Ampho B 1.0 \\nmg/kg/day + \\nFluconazole \\n1,200 mg/day  Fluconazole6  \\n800 mg/day  Fluconazole 200 \\nmg/day for at \\nleast 1 year and \\nuntil CD4 count  \\n> 200 cells/mm3 \\nfor two measures  \\n6 months apart \\nAND VL is \\nundetectable  Defer ART until \\nafter completing  \\n5 weeks of CM \\ntreatment and \\nsymptoms have \\nresolved  Alternative  Fluconazole,3,4,5,6  \\n1,600 mg daily  Fluconazole6 \\n800 mg daily  \\nChildren and \\nadolescents  Preferred  Ampho B 1.0 \\nmg/kg/day + \\nFluconazole 12 \\nmg/kg/day (up \\nto max 800 \\nmg/day)  Fluconazole 6 -\\n12 mg/kg/day \\nup to  \\n800 mg/day  Fluconazole  \\n6mg/kg/day up \\nto 200 mg/day  \\nAlternative  Fluconazole3,4,5 \\n12 mg/kg/day \\n(up to max \\n1,600 mg/  \\nday)  Fluconazole 12 \\nmg/kg/day up \\nto \\n800 mg/day  Fluconazole  \\n6mg/kg/day up \\nto 200 mg/day  \\n1Amphotericin B should always be used for induction when available. If it is not possible to complete 2 weeks \\nof induction with ampho due to availability, toxicity or monitoring, then use a shorter duration of ampho and \\ncomplete the 14 -day induction period with the alternative regimen  \\n2Once available, flucytosine may become part of the  preferred and alternative induction regimens, given \\n100mg/kg per day divided into four doses per day  \\n3Fluconazole requires a dose adjustment for impaired renal function; when CrCl ≤ 50 ml/min then use 50% \\nof the standard recommended dose  \\n4Fluconazole shou ld not be used with rifabutin -based TB treatment  \\n5When using high -dose fluconazole check ALT after one week of treatment and based on symptoms \\nthereafter  \\n6Fluconazole is contraindicated in the first trimester of pregnancy. Amphotericin can be used. Please consult \\nexpert or National or Regional TWG.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 73}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 13  Managing and Monitoring for Amphotericin B Therapy  \\nAdults  \\n• Give 1 L of normal saline with 20 mmol of KCl over 2 -4 hours before each controlled \\ninfusion of Ampho B given with 1 litre of 5% dextrose. Add one to two tablets of 8 mEq \\nKCl orally twice daily. An additional one 8 mEq KCl tablets twice daily may be added in \\nthe second week. Include magnesium supplementation at 250 mg tablets of magnesium \\ntrisilicate twice daily (or 4 mEq tablets of magnesium chloride t wice daily)  \\nAdolescents and Children  \\n• Give 1 L of normal saline with 20 mmol of KCl over 2 -4 hours before each controlled \\ninfusion of Ampho B. Darrows or Ringer’s solutions can also be used  \\nNote: Avoid KCl replacement in patients with pre -existing renal imp airment or \\nhyperkalemia  \\n \\nManaging hypokalaemia and raised creatinine levels  \\n• Obtain a routine baseline and twice weekly potassium and creatinine:  \\n- If K < 3.3 mmol/L, administer 1 L of normal saline with KCl 40 mmol in normal saline \\nor 1 -2 tablets of 8mEq KCl every 8 hours. Add magnesium. Monitor potassium daily  \\n- If creatinine level increases > 2 -fold from baseline, omit dose of Ampho B, increase \\nhydration to 1 L every 8 hours. If there’s improvement, re -start Ampho B at 0.7 \\nmg/kg/day on alternate days. If n o improvement, discontinue Ampho B, give \\nfluconazole 1,600 mg/day to complete induction. Monitor creatinine daily  \\nTherapeutic lumbar punctures are a critical component of the management of CM and \\nshould be standard of care:  \\n• For all patients with symptomati c CM: perform daily therapeutic lumbar punctures:  \\n- If opening pressure is ≤ 40 cm: draw off enough CSF to reduce pressure to 20 cm  \\n- If opening pressure is > 40 cm: draw off enough CSF to reduce pressure by 50%  \\n- Continue daily LPs until pressure is normal for 3 consecutive days  \\n- Restart LPs if symptoms return  \\nIf measuring intracranial pressure is not possible (even using a giving set and tape measure), \\nthen perform daily therapeutic LPs until severe headache subsides, removing 10 -20 ml of CSF \\neach tim e \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 74}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 14  \\nNewly diagnosed HIV -infected adult or adolescent\\nCD4   200 cells/mm3\\nAutomatic/reflex CrAg \\nscreening\\nSerum CrAg POSITIVE Serum CrAg NEGATIVE\\nSymptom Screen: Progressive headache, fever, \\nmalaise, neck pain, confusion\\nSymptomatic: Admit and do \\nLumbar puncture to obtain CSF \\nfor CrAg and geneXpert• Asymptomatic1: Offer presumptive treatment for possible early CM with \\nfluconazole 1,600 mg per day for 2 weeks, followed by fluconazole 800 \\nmg per day for 8 weeks, followed by fluconazole 200 mg per day for at \\nleast 1 year and until CD4 count >200 cells/mm3 for two measures 6 \\nmonths apart and VL is undetectable (LDL <200copies/ml )\\n• Defer ART for 5 weeks2\\n• Monitor closely and perform LP if symptoms develop\\nNB: Lumber puncture for CSF CrAg is strongly recommended for pregnant \\nwomen irrespective of symptoms3\\nCSF CrAg positive: Treat for cryptococcal \\nmeningitis with amphotericin, fluconazole \\nand therapeutic LPs (Annex 7)\\nDefer ART until completed 5 weeks of \\ntreatment and has resolution of \\nsymptoms2• CSF CrAg negative: Offer pre -emptive therapy for non -meningeal \\ndisease with fluconazole 800 mg per day for 2 weeks, followed by \\nfluconazole 400 mg per day for 8 weeks, followed by fluconazole \\n200 mg for at least 1 year and until CD4 count >200 cells/mm3 for \\ntwo measures 6 months apart and VL is undetectable (LDL \\n<200copies/ml )\\n• Defer ART until completed 5 weeks of treatment and has \\nresolution of symptoms2\\nLP is recommended for all sCrAg positive patients irrespective of symptoms with management based on LP results. If \\nLP is not available to rule out meningeal disease then patients should be treated for possible CM, even if \\nasymptomatic\\nPatients with cryptococcal meningitis are at high risk of developing life-threatening IRIS;  deferring ART has \\nshown to improve survival for these specific \\nFluconazole use during pregnancy increases the risk of birth defects. All pregnant women who screen positive with \\nserum CrAg should be offered a lumbar puncture (irrespective of symptoms) to determine if they have cryptococcal \\nmeningitis\\nNote: \\n• Fluconazole requires a dose adjustment for impaired renal function; when CrCl      ml/min then use 50% of the \\nstandard recommended dose\\n• Fluconazole should not be used with rifabutin -based TB treatment\\n• When using high -dose fluconazole check ALT after one week of treatment and based on symptoms thereafter• No cryptococcal treatment required\\n• Initiate ART within 2 weeks \\nFigure 4.1: Routine Screening for Cryptococcal Meningitis for HIV -infected Adults and Adolescents  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 75}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 15  4.4 Reproductive Health Services  \\n4.4.1 Sexually Transmitted Infections  \\nScreening for syphilis using VDRL, TPHA, or RPR should be performed as a baseline investigation \\nfor all adolescent and adult PLHIV. Pregnant women should be screened for Syphilis during the \\nfirst ANC visit and 3rd trimester.  \\n \\nAll PLHIV should be assessed for symptoms of STIs using the National Algorithm s for Treating \\nCommon STI Syndromes (Kenya National guidelines for management and control of STIs, 2018. \\nAnnex 4). Sexual partners should be treated as well.  \\n \\nRisk reduction counselling and provision of condoms is an integral part of STI treatment.  \\n \\nPatien ts who have persistent signs and symptoms of STIs after syndromic treatment should \\nundergo diagnostic evaluation for definitive diagnosis and treatment.  \\n \\nAt initial diagnosis of HIV, all sex workers should be treated for presumptive gonorrhoea and \\nchlamydi a (following treatment recommendations of vaginal/urethral discharge syndrome as \\nper national STI guidelines), with presumptive treatment every quarter.  \\n \\n4.4.2 Family Planning and Pre -Conception Counselling  \\nPregnancy status should be determined for all wom en of reproductive age at every visit (based \\non history of last menstrual period and, if uncertain, irregular, or delayed, then a urine pregnancy \\ntest should be performed).  \\n \\nPregnancy intention should be determined for all women of reproductive age and the ir partners \\nso that appropriate family planning or pre -conception counselling can be provided.  \\n \\nFor patients who do not have an immediate desire to become pregnant, dual contraception \\n(defined as condoms plus another form of effective contraception) should  be provided \\nimmediately with follow -up appointments scheduled to ensure no interruption in contraception \\nprovision. Table 4.8  outlines contraception options for PLHIV based on the ARVs they are using.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 76}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 16  Table 4.8 : Contraceptive Methods for PLHIV Based on  WHO 2018 Medical Eligibility Criteria  \\nContraceptive Method  ARVs Being Used  Anti -TB \\nNRTI \\n(any)  NNRTI  \\nPI/r \\n(any)  INSTI  \\nRifampicin or \\nRifabutin  EFV \\nor \\nNVP  ETR  RAL  DTG*  \\nIM medroxyprogesterone (DMPA; Depo \\nProvera)  1 1 1 1 1 - 1 \\nNorethisterone enanthate (NET -EN; \\nnorethindrone)  1 2 1 2 1 - 2 \\nImplants  1 2 1 2 1 - 2 \\nCombined oral contraceptive (pill)  1 2 1 2 1 - 3 \\nIntrauterine \\ndevice (IUD)  Initiation  ● Category 2 for asymptomatic or mild HIV disease (WHO Stage 1 \\nor 2, or any WHO Stage once they are stable on ART)  \\n● Category 3 for women with advanced and symptomatic HIV \\ndisease UNTIL they are stable on ART and asymptomatic  \\nContinuation  Category 2 for all women regardless of symptomatic HIV (do not \\nrequire IUD to be removed)  \\nCondoms  No restrictions; use encouraged in combination with a hormonal \\ncontraception method or IUD as part of dual FP to prevent STI/HIV \\ntransmission  \\nEmergency contraceptive pill (ECP)  No restrictions; can be started up to 5 days after intercourse  \\nSterilization  No reason to deny; delay in case of acute HIV -related infection  \\nFertility awareness -based (FAB) methods  Can use if menstrual cycle is regular, although reliability is not as \\ngood as hormonal contraceptive methods or IUD. Encoura ge to use \\nin combination with condoms to prevent STI/HIV transmission  \\nLactational amenorrhoea method (LAM)  Effective for women who are less than 6 months post -partum, are \\nexclusively breastfeeding, and have not resumed menses. Encourage \\nto use in combinat ion with condoms to prevent STI/HIV \\ntransmission  \\nSpermicides and diaphragm  Use is not recommended; may increase risk of HIV transmission  \\nCategory 1: No restriction for the use of the contraceptive method  \\nCategory 2: Advantages of using the method generally outweigh the theoretical or proven risks  \\nCategory 3: The theoretical or proven risks usually outweigh the advantages of using the method  \\n*DTG was not included in the WHO 2018 MEC Guidelines, however, drug interactions between DTG and \\nhormonal con traception have not been identified  \\nFor patients who intend to become pregnant, the key pre -conception messages and services are \\npresented in Table 4. 9. \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 77}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 17  Table 4. 9: Pre -Conception Counselling Messages and Services for PLHIV  \\nScenario  Key Counselling Messag es Pre-conception Services (in \\naddition to the Standard Package of \\nCare for PLHIV)  \\nAll \\nwomen/couples \\nwith intention to \\nconceive  ● All PLHIV qualify for ART, with \\ninitiation preferably within 2 weeks \\nof HIV diagnosis  \\n● Deferring pregnancy until confirmed \\nviral suppression reduces risk of \\nvertical transmission to the baby, \\nimproves infant outcomes, and \\nreduces risk of cross -transmission to \\nthe sexual partner  \\n● Unprotected sex should be limited to \\ndays when ovulation is expected \\n(based on basal tempe rature \\nmonitoring, fertility calendar based \\non menstrual cycles, and/or fertility \\ncalendar app)  \\n● Routine ANC and delivery by a \\nskilled birth attendant improves \\noutcomes for mother and baby  ● ART for all PLHIV, including those \\nintending to become pregnant  \\n● Baseline investigations  \\no Hb (with management of \\nanaemia)  \\no Syphilis screening  \\no Cervical cancer screening  \\n● STI symptom screening  \\n● Nutritional assessment, \\ncounselling, and support  \\n● Folic acid supplementation  \\n● Standard VL monitoring (Figure \\n6.6)  \\n● PrEP for the HIV -negative partner  \\nAdditional \\nmessages for \\ndiscordant \\ncouples: male \\npartner HIV \\npositive  ● Defer unprotected sex until confirmed viral suppression in the HIV positive \\npartner  \\n● Discuss use of PrEP for the HIV-negative partner (Chapter 11)  \\n● In situations where viral suppression is challenging, consider specialist referral \\nfor additional options such as sperm washing and artificial insemination  \\nAdditional \\nmessages for \\ndiscordant \\ncouples: female \\npartner HIV \\npositive  ● Defer unprotected sex until confirmed viral suppression in the HIV -positive \\npartner  \\n● Discuss use of PrEP for the HIV -negative partner (Chapter 11)  \\n● Discuss self -insemination during the peri -ovulatory period, where \\nappropriate/as preferred  \\n● In situations where viral suppression is challenging, consider specialist referral \\nfor additional options such as artificial insemination  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 78}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 18  4.4.3 Maternal Healthcare  \\nMaternal healthcare begins with preconception counselling (Table 4. 9), and continues \\nthroughout pregnancy and breastfeeding. The standard package of antenatal and postnatal \\nservices in the context of HIV is described in Chapter 7 of these guidelines.  \\n4.5 Non -communicable Diseases Screening and Management  \\n4.5.1 Metabolic Disorders  \\nScreening, prevention and management of specific NCDs are included in the standard package of \\ncare for PLHIV because of their associated high morbidity and mortality. PLHIV are at higher risk \\nfor cardiovascular, liver and kidney disease because o f the chronic inflammatory state associated \\nwith HIV infection itself, and also as a side -effect of some of the ARVs.  \\nThe modifiable risk factors for cardiovascular disease include tobacco use and exposure to \\ntobacco smoke, unhealthy diets, overweight/obe sity, physical inactivity, harmful use of alcohol, \\nhypertension, diabetes, hyperlipidemia, infections such as rheumatic fever and HIV. Advancing \\nage, sex, race/ethnicity and family history are non -modifiable risk factors associated with \\ncardiovascular dise ases  \\nHIV and other chronic diseases require health systems that support chronic care and  \\nadherence; their management should be integrated at the health facility, including at the \\nprimary care level.  \\nLifestyle modifications are always the first line of prev ention and management for \\nhypertension, diabetes mellitus (DM), and dyslipidaemia (Table 4. 10). These are \\nrecommended for all patients to prevent these NCDs and should be integrated into routine HIV \\ntreatment and prevention. Recommendations for screening, diagnosis, and initial management \\nof hypertension, type 2 DM, dyslipidaemia, and chronic kidney disease (CKD) are provided in \\nTables 4.1 1-4.14. \\nFor comprehensive guidelines on prevention, diagnosis and management of diabetes and \\ncardiovascular diseases, re fer to Kenya National Clinical Guidelines for the Management of \\nDiabetes  and Kenya National Guidelines for Cardiovascular Diseases Management , respectively.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 79}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 19  Table 4. 10: Lifestyle Modifications to Prevent and Manage Cardiovascular Disease in PLHIV  \\nSmoking Cessation  \\n● Smoking cessation has multiple short -term and long -term benefits, including  \\no Reduced premature aging/wrinkling of skin  \\no Improved fitness and quicker recovery from common infections  \\no Reduced risk of respiratory infections and chronic lung disease  \\no Reduced risk of high blood pressure, diabetes, kidney disease, heart disease, and stroke  \\no Improved infant outcomes (for pregnant women)  \\no Reduced risk of cancers: lung, bladder, breast, mouth, throat, esophagus  \\no Better response to ART (better viral suppression)  \\no Reduced risk of developing TB or dying from TB  \\n● Tobacco dependence treatment and cessation programs should combine behavioral/counseling \\nsupport with pharmacotherapy treatment where necessary and available. For further details on \\ncessation interventions, refer to the Kenya National Guidelines for Tobacco Dependence \\nTreatment  \\nRefer to Table 4.1 8 for tips to assist a client to quit smoking  \\n \\nDietary Changes and Weight Loss  \\n● Weight loss to maintain a healthy BMI (nutritionists to be engaged in patient care)  \\n● Drink 8 glasses of water per day  \\n● Reduce/abstain from alcohol  \\n● Cut down sugar intake  \\n● Cut down red meat intake  \\n● Cut down consumption of fatty foods, fat for flavoring, and fried foods  \\n● Increase intake of whole grain s, vegetables, fruit, and beans  \\n● Increase intake of fish  \\n● Consume less than 5 g (just under a teaspoon) of salt per day  \\n \\nPhysical Activity  \\n● Active lifestyle with moderate -intensity physical activity  \\n● 30 minutes of aerobic activity such as brisk walking, at least 5 days per week  \\n \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 80}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 20  Table 4.1 1: Hypertension Screening, Diagnosis, and Initial Management for Adult PLHIV  \\nScreening  \\n● BP should be measured and recorded for every adult at every visit  \\nDiagnosis  \\n● Hypertension requiring intervention is defined as BP ≥ 140/90 mmHg on at least 3 different occasions  \\nAdditional Investigations for patients with hypertension  \\n● Urinalysis: to assess for kidney disease and diabetes  \\n● Creatinine, Na, K: to assess for kidney disease  \\n● Blood glucose: to assess for diabetes  \\n● Full blood count: anaemia may indicate chronic kidney disease  \\n● Lipid profile: dyslipidemia is a cardiovascular risk factor  \\n● ECG: to assess for cardiac pathology including cardiomegaly, ventricular dysfunction, ischemic heart \\ndisease, etc.  \\nManagement (treatment target is BP < 140/90 mmHg)  \\n● If baseline BP is 120 -139/80 -89 (pre -hypertension)  \\no Lifestyle modification, along with monthly BP monitoring  \\n \\n● If baseline BP is 140 -159/90 -99 \\no Lifestyle modification (Table 4.9) for up to 6 months, along with monthly BP monitoring  \\no If does not meet treatment target with lifestyle modifications, then add drugs to lifestyle \\nmodification  \\no In PLHIV without  kidney disease or diabetes, first -line antihypertensive therapy is a thiazide \\ndiuretic s uch as hydrochlorothiazide starting at 12.5 mg OD (maximum dose 25 mg OD) OR a \\ncalcium channel blocker such as amlodipine starting at 2.5 mg OD (maximum 10 mg OD)  \\no In PLHIV with kidney disease or diabetes the first antihypertensive should be an ACE -I or ARB  \\nsuch as enalapril 2.5 -10 mg OD (maximum dose is 20 mg BD); or, losartan 50 mg OD (maximum \\ndose is 100 mg OD), with referral to a physician if available  \\no Introduce one drug at a time. If the target blood pressure is not reached within one month after \\ninitia ting therapy, the dosage of the initial medication should be increased. Titrate to maximum \\nrecommended dosage (if tolerated) before adding an additional drug  \\no If inadequate response once dose has been titrated, an additional agent may be required e.g., \\nhydr ochlorothiazide starting at 12.5 mg OD (maximum dose 25 mg OD)  \\no If inadequate response to two agents, consider consultation with or referral to a physician  \\no Note: Calcium -channel blockers have known drug interactions with PIs and NNRTIs and \\nshould be used with caution (Annex 13). ACE -I and thiazide diuretics do not have significant \\ninteractions with ARVs  \\n \\n● If baseline BP ≥ 160/100 mmHg  \\no Initiate lifestyle modifications and introduce anti -hypertensive medications concurrently  \\n \\n \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 81}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 21  Table 4.1 2: Type 2 Diabetes Mellitus Screening, Diagnosis, and Initial Management for PLHIV  \\nScreening  \\n● Blood glucose (fasting or random) should be evaluated at baseline for all PLHIV, then annually if \\nbaseline screening is normal; urine dipstick for protein and glucose can be used if blood glucose \\ntesting is not available  \\nDiagnosis  \\n● Diabetes Mellitus is defined as fasting blood sugar ≥ 7.0 mmol/L, or random blood sugar ≥ 11.1 \\nmmol/L, or HbA1c > 6.5%, or oral glucose tolerance test ≥ 11.1 mmol/L  \\n● Abnormal results should be repeated to confirm the diagnosis, particularly for patients without \\nsymptoms of diabetes (such as polyuria, polydipsia, polyphagia, weight loss)  \\n \\nManagement (treatment target is HbA1c ≤ 7.0% or FBS 4 -7 mmol/L)  \\n● For patients with pre -diabetes (abnormal results but does not meet criteria above for diabetes) \\nmonitor FBS or HbA1c every 3 months and encourage lifestyle modifications (Table 4. 10) \\n \\n● For patients with diabetes, monitor HbA1c (or FBS if HbA1c is not available) every 3 months  \\n \\n● Lifestyle modification (weight loss, nutritional support to manage portion sizes and calculate \\nglycaemic index of various foods to hel p with control of blood sugar) for 3 -6 months  \\n \\n● If does not meet treatment target with lifestyle modifications then add drugs  \\no Metformin  \\n▪ Obtain baseline Creatinine; do NOT use metformin if creatinine clearance < 45 ml/min  \\n▪ Start with low dose (500 mg OD or BD) and titrate up every 1 -2 weeks until reaches 1 g BD (or \\nmaximum tolerated dose if less than 1 g BD)  \\n▪ Note:  DTG may increase metformin plasma levels: monitor blood glucose levels; dose reduction \\nof metformin may be required, and maximum daily dose of met formin should be 1g  \\no If does not meet treatment targets with metformin for 3 -6 months at maximum tolerated dose then \\nconsider adding drug from another class (such as sulphonylureas (gliclazide)) and/or specialist \\nconsultation. Some patients may require insu lin. \\no At every visit: A thorough history (to elicit features of hypoglycemia, other cardiovascular disease \\nrisk factors, neuropathy, diabetic foot ulcers) and a physical exam (for BP, neuropathy, foot ulcers)  \\n \\n● Additional routine screening for patients with diabetes  \\no Annual ophthalmology examination for diabetic retinopathy  \\no Annual urinalysis: start on an ACE -I/ARB if proteinuria develops (even if BP normal)  \\nNote : patients with DM are at increased risk of developing TB  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 82}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 22  Table 4.12: Dyslipidemia Screening, Diagnosis, and Initial Management for PLHIV  \\nScreening  \\n● Fasting lipid profile should be evaluated at baseline for all PLHIV, then annually if baseline screening \\nis normal  \\nDiagnosis  \\n● Dyslipidemia is defined as high fasting total cholesterol (>5.2 mmol/L), LDL (>3.4 mmol/L) or \\ntriglycerides (>2.2 mmol/L)  \\nManagement  \\n● Lifestyle modification for 3 -6 months (Table 4. 10) \\n● If the patient is on an ARV known to cause or exacerbate dyslipidemia (primarily LPV/r & EFV) then \\nconsider a single -drug substitution to a more lipid -friendly drug (such as ATV/r or DTG) as the \\ntreatment of choice before adding a lipid -lowering drug. Rule out treatment failure before making \\nsingle -drug substitutions (Figure 6.4)  \\n● If patient does not meet treatment  target with lifestyle modifications, then add drugs  \\no Atorvastatin: starting dose of 10 mg OD (maximum dose 20 mg once daily if patient is on a PI/r; \\nmaximum dose 80 mg once daily if not on a PI/r)  \\no Simvastatin and lovastatin are contraindicated in the presence of PI/r  \\no Allow at least 3 months before repeating fasting lipids and titrating dose  \\nOnce targets achieved can monitor lipids every 6 -12 months  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 83}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 23  Table 4.13: Chronic Kidney Disease Screening, Diagnosis, and Initial Management for PLHIV  \\nScreening  \\n● Urinalysis (for protein) and serum creatinine should be evaluated at baseline for all PLHIV and \\nmonitored annually  \\nDiagnosis  \\n● Impaired renal function is defined as creatinine clearance < 90 ml/min, or dipstick proteinuria ≥ 1 \\n(see Annex 15 for CrCl calculations)  \\n● Abnormal results should be repeated to confirm diagnosis  \\n● Chronic kidney disease is defined as evidence of kidney damage that persists for at least three \\nmonths  \\nManagement  \\n● Management depends on the cause of the renal impairment; additional investigations and/or \\nspecialist consultation may be required  \\n● Consultations with a physician is recommended  \\n● Treat dehydration promptly and aggressively  \\n● If on TDF -containing regimen, substitute with another ARV if C rCl<50 ml/min (see Section 6.5), \\nwith the exception of patients with HBV/HIV co -infection (Table 9.3 for renal dose adjustments of \\nTDF and 3TC for patients with HIV/HBV co -infection)  \\n● Avoid nephrotoxic drugs (e.g., aminoglycosides and NSAIDS)  \\n● Evaluate for a nd treat hypertension  \\n● All NRTIs except ABC require dose adjustments for renal impairment, depending on the severity \\n(Table 6.6 for specific dose adjustments). NNRTIs, PIs, and INSTIs do not require dose adjustments \\nfor impaired renal function  \\nNote: DTG may  cause a small rise in serum creatinine levels but this does NOT represent a \\ndecline in renal function, close monitoring is recommended.  \\nPatients at higher risk for renal disease and for developing TDF -associated renal toxicity include \\nthose with: pre-existing renal disease, hypertension, diabetes mellitus, severe wasting (weight \\nbelow 60 kg in adults), age > 45 years, WHO stage 3 or 4, CD4 < 200 cells/mm3, high HIV viral \\nload, and concomitant nephrotoxic agents.  \\nGlomerular disease directly related to HIV infection, commonly known as HIV -associated \\nnephropathy (HIVAN) is an important cause of chronic kidney disease among PLHIV.  \\nPrevention, early identification, and management of kidney disease is important to reduce \\nthe burden of dialysis and other c omplications.  \\n4.5.2 Cancer Prevention, Early Detection and Management among PLHIV  \\nPLHIV have a substantially higher risk for many cancers, mainly due to a weakened immune \\nsystem which impairs control of oncogenic viral infections. A high prevalence of thes e infections \\nand other modifiable risk factors (such as smoking, alcohol use, unhealthy diet and physical \\ninactivity) contributes to the elevated risk. PLHIV are far more likely than the general population \\nto be diagnosed with Kaposi Sarcoma, non -Hodgkin l ymphoma and other cancers (cervical, anal, \\nliver, lung and oral/throat) hence the importance of prioritizing screening and early diagnosis \\nprograms in this group.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 84}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 24  4.5.2.1 Specific Interventions for Cancer Control in PLHIV  \\nFour interventions are important f or cancer control among PLHIV:  \\n● Achieve viral suppression:  uncontrolled viral replication is a major risk factor for \\ncancer. All PLHIV should initiate ART, and be supported and monitored to achieve long -\\nterm viral suppression in order to reduce risk for can cer, and to improve treatment \\noutcomes for many cancers  \\n● Primary prevention through avoidance of modifiable risk factors  \\no Smoking cessation  \\no Avoidance of harmful use of alcohol  \\no Regular physical activity  \\no Healthy diets  \\no Vaccination: vaccination against Human Papillomavirus for girls 9 -14 years old are \\neligible in Kenya, Hepatitis B Vaccine for newborns and high -risk groups  \\n● Secondary prevention through screening and early diagnosis  \\no Screening: application of simple tests to detect cancer in asymptomatic individuals  \\n▪ Cervical cancer: all women LHIV who have been sexually active up to 49 years \\nold (25 -49 years in the general population), through either visual inspection \\nwith acetic acid (VIA) or PAP smear annually, or HPV testing every 2 years  \\n▪ Breast cancer: mammogram annually from 40 -55 years; mammogram every \\ntwo years from 56 -74 years; screening for younger women can be performed \\non an individual basis based on family history or other risk factors. Clinical \\nbreast exam can be used where mammogr am is not available  \\n▪ Prostate cancer: serum prostate specific antigen (PSA) annually for men 40 \\nyears and above; digital rectal examination can be used if PSA is not available, \\nand for all men with urinary symptoms  \\n▪ Colorectal cancer: fecal occult blood test ing of stool (guaiac or FIT) annually for \\neveryone 45 -75 years old, or colonoscopy every 10 years  \\n▪ Oral cancer: visual examination for everyone above 40 years with history of \\ntobacco use, known HPV infection or immunosuppression  \\no Early diagnosis: prompt diag nosis of cancer in symptomatic individuals  \\n▪ Breast: lump, asymmetry, skin changes, nipple changes, blood -stained \\ndischarge  \\n▪ Cervix: post -coital bleeding, excessive vaginal discharge  \\n▪ Colon and rectum: change in bowel habits, unexplained weight loss, anemia, \\nblood in stool  \\n▪ Oral: white or red lesions, growth, ulceration  \\n▪ Naso -pharynx: nosebleed, permanent blocked nose, deafness, lymph nodes in \\nupper neck  \\n▪ Larynx: persistent hoarseness of voice  \\n▪ Stomach: upper abdominal pain, indigestion, weight loss  \\n▪ Skin: irregular growths, lesions, or non -healing sores  \\n▪ Bladder: painful or frequent urination, blood in urine  \\n▪ Prostate: difficulty (long time) in urination, frequent nocturnal urination  \\n▪ Retinoblastoma: white spot in the pupil, convergent strabismus (in a child)  \\n▪ Testis: swelling of one testicle  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 85}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 25  ● Tertiary prevention : Cancer management, prevention of complications and treatment \\nof side effects and secondary cancers  \\nNote: For screening, diagnosis, and management recommendations refer to national \\nguidelines for prevent ion and management of cancers. For individual patient \\nmanagement, referral to regional and national hospitals with capacity for comprehensive \\noncology services may be warranted.  \\n4.6 Mental Health Screening and Management  \\nPLHIV are susceptible to psychological disturbances due to HIV itself and perceptions regarding \\nHIV in their environment. Some of the most common psychological disturbances include \\ndepression and suicide, anxiety, internalized stigma, post -traumatic stress disorder, cognitive \\ndifficulties such as dementia, and perceived lack of social support. Any of these can significantly \\ninterfere with a patient’s sense of well -being and their adherence. Depression and alcohol/drug \\naddiction are the most significant and are reviewed in this sect ion. For any patient with other \\nsuspected mental health disorders, such as anxiety, psychosis or post -traumatic stress disorder, \\nconsider formal screening and/or referral to a specialist.  \\n4.6.1 Depression  \\nDepression is one of the most common psychiatric il lnesses in the world, and chronic illness \\n(including HIV) is a strong risk factor for depression. PLHIV are 3 -6 times more likely to suffer \\nfrom depression than the general population, with significant disability and poorer treatment \\noutcomes if it is not identified and managed. Depression can be a significant contributing factor \\nto poor adherence and HIV treatment failure.  \\nAll PLHIV should receive basic screening for depression upon enrollment and thereafter \\nannually using the following two questions:  \\n● Duri ng the past two weeks have you often been bothered by feeling down, depressed, or \\nhopeless?  \\n● During the past two weeks have you often been bothered by little interest or pleasure in \\ndoing things?  \\nAll patients who answer “yes” to either or both of the questi ons above, and all patients with a \\ndetectable viral load after 3 or more months on ART (whether or not they had achieved viral \\nsuppression in the past), should undergo a more thorough screening for depression using the \\nPHQ -9 screening tool, with management  guided by the PHQ -9 score (Table 4.1 5). \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 86}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 26  Table 4.1 5: Patient Health Questionnaire -9 (PHQ -9) for Depression Screening  \\nPHQ -9 Depression Screening                               Name:  _________________________    Date: __________________  \\nAsk the patient the questions below for each of the 9 symptoms and circle the response for each question. After asking all \\nquestions, add the points for each column  at the bottom. The total score is the sum of the column totals. Interpretation \\nand management recommendations are provided at the bottom of the table.  \\nQuestion:  “Over the last 2 weeks, how often have you been \\nbothered by any of the following problems?”  Not at all  Several days  More than \\nhalf the days  Nearly every \\nday \\n 1. Little interest or pleasure in doing things  0 1 2 3 \\n2. Feeling down, depressed, or hopeless  0 1 2 3 \\n3. Trouble falling or staying asleep, or sleeping too much  0 1 2 3 \\n4. Feeling tired or having little energy  0 1 2 3 \\n5. Poor appetite or overeating  0 1 2 3 \\n6. Feeling bad about yourself, or that you are a failure, or that \\nyou have let yourself or your family down  0 1 2 3 \\n7. Trouble concentrating on things (linked with patient’s usual \\nactivities, such as reading the newspaper or listening to a radio \\nprogram)  0 1 2 3 \\n8. Moving or speaking so slowly that other people could have \\nnoticed. Or the opposite, being so fidgety or restless that you \\nhave been moving around a lot m ore than usual  0 1 2 3 \\n9. Thoughts that you would be better off dead or of hurting \\nyourself in some way  0 1 2 3 \\nTotal ____ = (add the points from each column)  0 +___  +___  +___  \\n \\nInterpretation of PHQ -9 Score and Recommended Management  \\nTotal Score  Provisional \\nDiagnosis  Recommended Management  \\n0-4 Depression unlikely  Repeat screening in future if new concerns that depression has developed  \\n5-9 Mild depression  ● Provide counselling support and continue to monitor; refer to mental \\nhealth team if available  \\n● If patient is on EFV, substitute with a different ARV after ruling out \\ntreatment failure (Figure 6.4)  \\n10-14 Moderate depression*  ● Provide supportive counselling (refer to a psychologist if available)  \\n● If patient is on EFV, substitute with a different ARV after ruling out \\ntreatment failure (Figure 6.4)  \\nand  \\n● Begin antidepressant medication (or, if unfamiliar with use of \\nantidepressants, then refer to an experienced clinician)  \\nand  \\n● Refer to a medical officer, psychiatrist, or mental health team if available  15-19 Moderate -severe \\ndepression*  \\n20-27 Severe depression*  \\n*Symptoms should be present for at least 2 weeks for a diagnosis of depression and before considering treatment with \\nantidepressant medication. Severe depression may require patients to start on anti -depressants immediately  \\nDepression is a known adverse drug reaction with EFV although it is often mild and temporary. Patients on \\nEFV who develop any persistent symptoms of depression should be switched to another ARV aft er ruling \\nout treatment failure (Figure 6.4).  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 87}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 27  Supportive Counselling for Depression  \\nPatients with mild depression should receive supportive counselling, which includes  \\n● Psycho -education on the following key messages  \\no Depression is common and can happen to anyone  \\no Depressed people often have exaggerated negative opinions about themselves, \\ntheir life and their future  \\no Effective treatment is possible  \\n● Counseling on self -management  \\no Continuing ART as prescribed  \\no Continuing activities that they used to find interesting/pleasurable  \\no Maintaining a regular sleep cycle  \\no Keeping physically active  \\no Participating in community/social events  \\no Returning to clinic if any thoughts of self -harm occur  \\n● Addressing psychosocial stressors  \\no Explore potential stressors in the patient ’s life  \\no Assist in problem -solving to reduce stressors  \\no Assess for and manage intimate partner violence  \\n● Reactivation of or referral to social networks, including peer support groups  \\n● Regular follow -up until symptoms improves and are stable  \\n \\nPharmacological Management of Depression  \\nPatients with moderate depression or worse should be treated with supportive counselling plus \\nan anti -depressant medication.  \\nFluoxetine is an antidepressant and does not have significant drug interactions with ARVs.  \\n● Starting dose for an adult is usually 20 mg once taken daily in the morning (can start with a \\nlower dose for patients who frequently have side -effects from medications). Dose can be \\ntitrated up by 20 mg every 2 -4 weeks as needed, up to a maximum of 80 mg p er day.  \\n● Common side -effects include GI upset, headaches, insomnia, and disturbances of the \\nmenstrual cycle. These usually resolve after 1 -2 weeks of continued use.  \\n● Full effect is not achieved until around 4 weeks of continued use. Once symptoms of \\ndepres sion resolve, antidepressants should be continued for at least another 6 months.  \\n● If/when the patient is ready to discontinue antidepressant therapy it should be discontinued \\nas a weekly taper (e.g., if the maintenance dose is 60mg then taper to 40mg, then 30mg, then \\n20mg, then 10mg and then stop), with close monitoring for recurrence of symptoms.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 88}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 28  4.6.2 Alcohol and Drug Use/Addiction  \\nAlcohol and other drug use are common among the general population and among PLHIV. \\nAlcohol and drug use can be a significant contributing factor to poor adherence and HIV \\ntreatment failure.  \\nAll adults and adolescents should be screened for alcohol and drug use before initiating ART and \\nevery year using the following three questions:  \\n● During the past 12 months, did you  drink any alcohol (more than a few sips)?  \\n● During the past 12 months, did you smoke any marijuana?  \\n● During the past 12 months, did you use anything else to get high?  \\nPatients who answer “yes” to any of the questions above, and all patients with a detectable  viral \\nload after 3 or more months on ART (whether or not they had achieved viral suppression in the \\npast), should undergo a more thorough screening.  \\nFor adolescents, use the CRAFFT screening tool (Table 4.1 6). For adults, use the CAGE -AID \\nscreening tool (Table 4.1 7). Anyone who screens positive on these tools should have further \\nassessment and management by clinical staff, ideally with experience in managing alcohol and \\ndrug use disorders. Table 4.1 8 gives some general guidance on management of addictions . The \\nNational Protocol for Treatment of Substance Use Disorders in Kenya provides more in -depth \\nguidance.   \\nTable 4.1 6: CRAFFT Screening Interview for Adolescents  \\nCRAFFT Screening for Alcohol and Drug Use Disorders for Adolescents  \\nAsk the patient the six questions below. Each question requires a yes/no response. Answering Yes to two \\nor more questions indicates an alcohol or drug use problem and requires further assessment and \\nmanagement.  \\n“I’m going to ask you a few questions that I ask all my patients . Please be honest. I will keep your \\nanswers confidential”  \\nQuestion  No Yes \\n1. Have you ever ridden in a Car driven by someone (including yourself) \\nwho was “high” or had been using alcohol or drugs?    \\n2. Do you ever use alcohol or drugs to Relax, feel better about yourself, or \\nfit in?    \\n3. Do you ever use Alcohol or drugs while you are alone?    \\n4. Do you ever Forget things you did while using alcohol or drugs?    \\n5. Do your Family or Friends ever tell you that you should cut down on \\nyour drinking or drug use?    \\n6. Have you ever gotten into Trouble while you were using alcohol or \\ndrugs?    \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 89}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 29  Table 4.1 7: CAGE -AID Screening Questions for Adults  \\nCAGE -AID Screening for Alcohol and Drug Use Disorders for Adults  \\nAsk the patient the four questions below. Each question requires a yes/no response. Answering Yes to two \\nor more questions indicates an alcohol or drug use problem and requires further assessment and \\nmanagement.  \\n“I’m going to ask you a few questions that I ask all my patients. Please be honest. I will keep your \\nanswers confidential”  \\nQuestion  No Yes \\n1. Have you felt you should Cut down on your drinking or drug use?    \\n2. Have people ever Annoyed you by criticizing your drinking or drug use?    \\n3. Have you ever felt bad or Guilty about your drinking or drug use?    \\n4. Have you ever had a drink or used drugs first thing in the morning to \\nsteady your nerves or to get rid of a hangover ( Eye opener)?    \\nIf referral to the mental health team is not immediately possible for those who screen positive, or as a \\nstarting point in supporting a patient while referral is being made, an assessment of whether the patient \\nwants to quit and targeted messages/support based on their stage of quitting may be benefi cial (Table \\n4.17). The National Protocol for Treatment of Substance Use Disorders in Kenya provides additional \\nresources for assessments and interventions.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 90}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 30  Table 4.1 8: Addiction Support Based on Stages of Change  \\nStage of Change  Counselling Approach  \\nPre-contemplation: not \\ncurrently considering \\nquitting; no immediate \\ndesire to quit  ● Acknowledge that not everyone is ready to think about quitting  \\n● Clarify that it is their decision  \\n● Listen to them describe the benefits they get from their alcohol or drug \\nuse (their motivation for continuing to use)  \\n● Explore why other people might think it is a good idea to quit  \\nContemplation: not sure if \\nhe/she wants to quit, or \\nthinking about quitting but \\nwith no immediate plan to \\nquit  ● Acknowledge that not everyone is ready to quite immediately  \\n● Clarify that it is their decision  \\n● Listen to them describe the benefits they get from the alcohol or drug use \\n(their motivation for continuing to use)  \\n● Listen to them describe the negative effects o f their alcohol or drug use \\n(their motivation for considering quitting)  \\n● Discuss any ideas they have on how they could go about quitting  \\nPreparation: would like to \\nquit within the next month  ● Congratulate them on their decision to quit  \\n● Listen to them describe the benefits they expect to get from quitting  \\n● Discuss any plan they have to try quitting  \\n● Discuss the challenges they may face with quitting  \\n● Problem -solve with them on overcoming challenges, including identifying \\nsupport systems  \\n● Encourage small ste ps towards quitting (e.g., avoiding situations that \\ntrigger use)  \\n● Acknowledge that they have the strength to succeed  \\nAction: actively trying to \\nquit, or has recently quit \\n(within past 6 months)  ● Listen to their experience with quitting  \\n● Congratulate them on the steps they have taken so far  \\n● Problem -solve with them on overcoming challenges, including identifying \\nsupport systems  \\n● Review the long -term benefits of quitting  \\nMaintenance: has quit (more \\nthan 6 months ago) and \\nwants to remain abstinent  ● Congratulate them on their success so far  \\n● Discuss potential for relapse and how to deal with it  \\n● Review the long -term benefits of maintaining abstinence from drug or \\nalcohol use  \\nRelapse  ● Acknowledge that relapse is common  \\n● Evaluate what triggered the relapse  \\n● Reassess motivation to quit and barriers to quitting  \\n● Problem -solve with them on overcoming challenges and what additional \\nsupport systems and strategies can be used  \\nAs indicated in the introduction of this section on mental health (Section 4.6), the following are \\nkey areas of concern in mental ill health and there needs to be a high index of suspicion in order \\nto identify these often -debilitating conditions that negatively affect an individual’s ability to cope \\nwith the tasks  of daily living. The last to items in this section contribute towards building \\nresilience which positively affects an individual’s mental health enabling them to positively \\ninteract with their environments   and live more meaningful lives.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 91}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 31  4.6.3 Anxiety  \\nAnxiety and other anxiety related disorders are mental health conditions that are often \\ncharacterized by experiences of one or several of the following:  \\n− Feelings of nervousness  \\n− Fear, or worry that interfere with the ability to sleep or otherwise function  \\n− A lack of appetite  \\n− Tremulousness and or frank trembling  \\n− Sweating and clamminess  of hands  \\n− Other symptoms may include a racing heart (rapid heartbeat ), difficulty breathing,  \\nheadaches, difficulty falling asleep, and difficulty concentrating.  \\nConcerns around anxiety, especially within the context of living with HIV or caring for persons \\nliving with HIV may reveal themselves during the history taking. These manifestations need to be \\ntaken seriously and addressed with sincerity and compassion.  \\nMany of these may require basic reassurance and support or even just a listening ear during the \\nevaluation session. These will go a long way in alleviating many patient’s anxieties and conc erns. \\nA quick screening tool can be used to assess whether the anxiety demonstrated or identified may \\nrequire further attention.  \\nThe Generalized Anxiety Disorder Assessment (GAD -7) is a seven -item instrument that is used to \\nmeasure or assess the severity of generalized anxiety disorder (GAD). Each item asks the \\nindividual to rate the severity of his or her symptoms over the past two weeks.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 92}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 32  \\nOver the last 2 weeks,  how \\noften have you been bothered \\nby the following problemsNot at all Several daysMore than half \\nthe daysNearly every \\nday\\n1. Feeling nervous, anxious or \\non edge\\n2. Not being able to stop or \\ncontrol worrying\\n3. Worrying too much about \\ndifferent things\\n4. Trouble Relaxing\\n5. Being so restless that it is \\nhard to sit still\\n6. Becoming easily annoyed or \\nirritable\\n7. Feeling afraid as if \\nsomething awful might \\nhappen\\n0 +1 +2 +3\\n0 +1 +2 +3\\n0 +1 +2 +3\\n0 +1 +2 +3\\n0 +1 +2 +3\\n0 +1 +2 +3\\n0 +1 +2 +3 \\nFigure 4.2: Generalized Anxiety Disorder Assessment (GAD -7) \\nThe following cut -offs correla te with level of anxiety severity:  \\n• Score 0 -4: Minimal Anxiety  \\n• Score 5 -9: Mild Anxiety  \\n• Score 10 -14: Moderate Anxiety  \\n• Score greater than 15: Severe Anxiety  \\nTreatment options can then be explored including referral to psychologists, psychiatrists for \\npossible  psychotherapy and medication if required  \\n4.6.4 Stress and stress management  \\nThis is a feeling of emotional or physical tension. The symptoms include ache and pains, \\npalpitations, exhaustion, insomnia, headache,  dizziness or shaking, digestive problems, we ak \\nimmune system, muscles tension or jaw tension.  \\nMany patients may experience these symptoms individually or in clusters and they interfere with \\nthe lives they are living. Sources of stress may be from difficulties in understanding issues around \\nHIV, from  addressing different concerns within themselves, from their significant others, from ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 93}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 33  their workplaces. These issues could be social, financial or environmental concerns and may be \\nsevere enough to negatively impact their lives. The stress may be so severe  as to be observed by \\nanyone interacting with the individual and may manifest in their behaviour and the symptoms \\nthey complain about. It is important for the health care worker to be calm, and assured as they \\naddress the patient’s concerns around stress. Further, a  screening tool can be used to assess the \\nneed for referral to more specialized mental health workers to provide much needed support.  \\n4.6.5 experiences of Trauma  \\nTrauma results from exposure to an incident or series of events that are emotionally disturbing \\nor life -threatening with lasting adverse effects on the individual’s functioning and mental, \\nphysical, social, emotional, and/or spiritual well -being. Past traumatic experiences in PLHIV must \\nbe addressed for their wellbeing.  \\nAssessi ng for Trauma - Primary Care PTSD Screen for DSM -5 (PC -PTSD -5) \\nThe Primary Care PTSD Screen for DSM -5 (PC -PTSD -5) is a screening tool designed to identify \\npersons with probable PTSD. Results of the screening should be considered \"positive\" if the \\nrespondent  answers \"yes\" to any 3 items in the questions listed below. Those screening positive \\nshould have further assessment with a structured interview for PTSD, preferably performed by a \\nmental health professional who has experience in diagnosing PTSD.  \\n“Sometim es things happen to people that are unusually or especially frightening, horrible, or \\ntraumatic. ” For example:  \\n1. A serious accident or fire  \\n2. A physical or sexual assault or abuse  \\n3. An earthquake or flood  \\n4. A war  \\n5. Seeing someone be killed or seriously injured  \\n7. Having a loved one die through homicide or suicide  \\n“If you have ever experienced this type of event, please answer the following in the past month, \\nhave you ” \\n• Had nightmares about the event(s) or thought about the event(s) when you did not want \\nto? \\n• Tried hard not to think about the event(s) or went out of your way to avoid situations that \\nreminded you of the event(s)?  \\n• Been constantly on guard, watchful, or easily startled?  \\n• Felt numb or detached from people, activities, or your surroundings?  \\n• Felt guil ty or unable to stop blaming yourself or others for the events(s) or any problems \\nthe event(s) may have caused?  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 94}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 34  4.6.6 Psychosis  \\nPsychosis is a mental disorder characterized by a disconnection from reality.  \\nPsychosis may occur as a result of a psychiatri c illness such as schizophrenia. In other instances, \\nit may be caused by a health condition, medication or drug use.  \\nSigns and Symptoms of psychosis  \\n• Marked behavioural changes  \\n• Neglecting usual responsibilities related to work, school, domestic or social activities  \\n• Agitated, aggressive behaviour, decreased or increased activity  \\n• Fixed false beliefs not shared by others in the person’s culture  \\n• Hearing voices or seeing things that are not there  \\n• Lack of realization that one is having mental health problems  \\nTreatment may include medication and talk therapy.  \\n4.6.7 Self -Care  \\nOverall, in the context of mental health, taking up self -care strategies will help individuals live \\nboth more responsibly, and more satisfactorily as this helps boost both physical and mental \\nhealth.  \\nSelf-care strategies include the following;  \\n− Getting regular exercise  \\n− Eating healthy, regular meals and staying well hydrated  \\n− Making sleep a priority. Many people struggle with this but just getting regular sleep with \\na constant waking and sleeping time contribute tremendously to good self-care  as well as \\ngood, well rested physical and mental health  \\n− Taking up a relaxing activity  \\n− Setting goals and priorities.  \\nThis allows for being realistic in one’s expectation in life and formulat ing realistic strategies to \\nachieve one’s goals  \\nPracticing gratitude  \\nReminding oneself that things that one is grateful for. The more specific one is, the easier it is to \\neven be grateful for them. Listing them down is a good way of getting such clarity  \\nFocusing on positivity  \\nThe calls for appreciating the good and positive things that have happened, are going on and are \\nplanned for in one’s life. The things to look forward to. This strategy also calls for the identification \\nand challenging of negative and unhelpful thoughts. Good friends and counsellors, as well as other \\nhealth workers with mental health skills can assist in this.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 95}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 35  Staying connected  \\nThis is extremely important. Increasingly in the present world disconnection is leading to more \\nand more phy sical and mental ill health. Staying connected with family and friends as well as \\nspiritual support systems enable  one to better manage their lives as they work towards being as \\nmentally healthy as possible.  \\n4.6.8 Wellbeing  \\nAccording to the WHO, mental hea lth is a state of well -being in which an individual realizes his or \\nher own abilities, can cope with the normal stresses of life, can work productively and is able to \\nmake a contribution to his or her community.  \\nSupport structures for wellbeing:  \\nThe suppor t structures for wellbeing are available at different levels of implementation which are:  \\n• Individual counselling  \\n• Group therapy  \\n• Networks of organizations providing support to different categories of populations in \\ndifferent age sets such as adolescents, me n, women etc.  \\nHealth workers in facilities should take the initiative to set up/ maintain these structures and \\nestablish referral systems for clients in need of these services. Referral for PLHIV should include \\nservices that address issues that potentially could affect the mental health of PLHIV such as social \\nand financial issues.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 96}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 36  4.7 Nutritional Services  \\nGood nutrition is a critical component of management of HIV because it contributes to: reducing \\nrisk and frequency of other infections; delaying progression from HIV infection to AIDS; a healthy \\nappearance and weight; gaining strength, maintaining and building muscle, and having energy to \\nremain active, and reducing side effects of ART.  \\n4.7.1 Nutritional Assessment, Counselling  and Support (NACS)  \\nAll PLHIV should receive nutritional assessment, counselling, and support  \\nAll PLHIV should receive nutritional assessment, counselling, and support tailored to the \\nindividual needs of the patients, including:  \\n● Nutrition assessment and diagnosis (timed with routine clinic visits, preferably monthly for \\nthe first year of life, and then quarterly up to 14 years old, and then every 3 -6 months)  \\no Anthropometric (Tables 4.1 9, 4.20 and 4.2 1 provide interpretation and required acti ons \\nfor anthropometric results for children and adults)  \\no Biochemical (investigations as listed in Table 3.2 for baseline and Table 3.5 for follow -up \\ninvestigations)  \\no Clinical (physical examination as described in Table 3.1 for initial evaluation)  \\no Dietary (24 -hour recall for food type/frequency and household food security)  \\no Environmental and psychosocial  \\no Functional (ability to care for self, bedridden, etc.)  \\n● Counselling and education  \\no Benefits of maintaining good nutritional status for a person living with HIV \\no Mother infant and young child nutrition (MIYCN) including exclusive breastfeeding  \\no Reassuring the client that it is possible to  \\no Attain/maintain good nutritional status  \\no Look well and live a healthy life  \\no Identifying locally available foods they can access given their own context, food safety \\nand food preparation  \\no Helping the client to plan meals and snacks with a variety of foods in order to meet their \\nenergy and nutrient needs and treatment plans  \\no Identifying any constraints, the client may face and f ind ways to minimize them  \\no Helping the client to understand the potential side effects and food interactions of the \\nmedicines they are taking, and help the client identify ways to manage these side effects  \\no Exploring with the client the cause(s) of poor appetite and appropriate responses (type \\nof food, disease, pain, depression, anxiety, or side effects of medications)  \\no Counsel on critical nutrition practices  \\nMessages: Critical Nutrition Practices (CNPs)  \\n1. Have periodic nutritional status assessments  \\n2. Increase energy intake through a balanced diet  \\n3. Maintain high levels of sanitation and food hygiene  \\n4. Practice positive living behaviors  \\n5. Carry out physical activity or exercises  \\n6. Drink plenty of clean, safe water  \\n7. Seek prompt treat ment for all opportunistic infections and manage diet -related symptoms  \\n8. Manage drug -food interactions and side effects  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 97}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 37  Support  \\no Therapeutic and supplementary foods to treat clinical malnutrition (food by prescription, \\ntherapeutic feeds, fortified blended flour): Figures 4. 3 and 4. 4 provide malnutrition \\nmanagement recommendations for adults and children; Table 4. 10 provides specific \\nnutritional recommendations for patients with non -communicable diseases  \\no Exclusive breastfeeding for the first 6 months of life; complementary foods for children \\naged 6 - 24 months with continued breastfeeding to prevent malnutrition (Table 7.7 \\nprovides complementary feeding recommendations)  \\no Micronutrient supplements to prevent vitamin and mineral deficiencie s \\no Food security and linkage to HIV sensitive social protection such as household food \\nsupport, home -based care, agricultural extension services, and economic strengthening \\nand livelihood support  \\nSome aspects of nutrition support (such as prescription of th erapeutic and supplementary foods) \\nshould be provided by a trained healthcare professional, however all aspects should be promoted \\nand supported at the community level.  \\nTable 4.1 9: Interpretation of MUAC Results for Children and Pregnant/Lactating Women  \\nMUAC Level by Age (cm)  Classification  Action to Take  \\n6-59 \\nmonths  5-9 yrs.  10-17 yrs.  \\n< 11.5  < 13.5  < 14.5 cm  Severe acute \\nmalnutrition  Irrespective of clinical signs, admission \\n(referral) for stabilization/therapeutic \\nrehabilitation  \\n11.5–12.5  13.5 -14.5  14.5 -18.5  Moderate acute \\nmalnutrition  Admission for supplementary feeding is \\nrecommended  \\n12.6–13.5    Mild acute \\nmalnutrition  Nutritional education and counselling  \\n> 13.5    Normal  Education and counselling of caregivers  \\nPregnant and Breastfeeding Women  \\n≤ 23  Malnourished  Provide nutritional support (Figure 4.3)  \\n> 23  Normal  Education and counselling  \\nTable 4. 20: Interpretation of Z -scores for Children  \\nRatio  Indicator   Z-score  Severity  \\nWeight/Age  Underweight  < - 3 Severe  \\nHeight/Age  Stunting  - 3 to - 2 Moderate  \\nWeight/Height  Wasting*  > - 2 to - 1 Mild  \\n> - 1 Normal  \\n*Children with weight/height z -score of -2 or less should be supported with therapeutic/supplementary \\nfoods    ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 98}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 38   \\nScreening\\nMeasure  anthropometry and check bilateral\\nPitting oedema\\nMedical History and Physical examination:\\n-  Evaluate nutritional status and health condition\\n-  Check for medical complications\\n-  Perform appetite test\\nIf SAM without  medical \\ncomplication and passed appetite \\ntestIf SAM with  medical complication \\nand/or failed  appetite test\\nMedical complication developed, decreased \\nappetite, weight loss or stagnant weight, \\noedema increase or no decreaseAdmission to \\nOutpatient careAdmission to \\nInpatient care\\nReferral for continuing treatment in out patient \\ncare:\\nAppetite returning (passed appetite test)\\nOedema decreasing,\\nMedical complication resolvingTreatment Treatment\\nSAM Treatment completed (based on discharge criteria):\\nDischarge to home or refer for supplementary feeding and other services\\n that address underlying causes of malnutritionTREATMENTADMISSION\\n \\nFigure 4. 3: Management of Severe Acute Malnutrition in Children  \\n Other medical complications that necessitate hospitalization  \\nIn addition to severe bilateral pitting oedema (+++), marasmic \\nkwashiorkor and poor appetite, the following complications \\nnecessitate inpatient care:  \\n✔ Intractable vomiting  \\n✔ Convulsions  \\n✔ Lethargy  \\n✔ Unconsciousness  \\n✔ Lower respiratory tract infection  \\n✔ High fever  \\n✔ Severe dehydration  \\n✔ Severe anaemia  \\n✔ Hypoglycaemia  \\n✔ Hypothermia  \\n✔ Eye signs of vitamin A deficiency  \\n✔ Skin lesions  \\nThe following complications require referral of patient for further \\nmedical evaluation:  \\n✔ No appetite (failed appetite test)  \\n✔ IMCI danger signs  \\n✔ Increase in or newly developed bilateral pitting oedema  \\n✔ Weight loss because of diarrhoea (r e-feeding or of other \\norigin)  \\n✔ Weight loss for three consecutive weeks  \\n✔ Static weight (no weight gain) for five consecutive weeks  \\n✔ Other signs of failure to respond to treatment  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 99}),\n",
       " Document(page_content=' Standard Package of Care for PLHIV  \\n 4 - 39 \\nA. Weight loss score\\n<5% – Low Risk\\n5-10% – Moderate Risk\\n>10% – High RiskUnplanned % weight loss in the last 1 -3mnthsB. Opportunistic Infections score\\nNo opportunistic infection\\nSub acute OI – Moderate Risk\\nAcute OI – High RiskOpportunistic infections statusC. Food intake score\\nAdequate Intake\\nLow intake – Moderate Intake\\nNausea/Vomiting Non/Fasted \\nfor >5 days – High RiskFood Intake/barriersD. Food Security score\\nLittle or No H/H Hunger = 0 -1\\nModerate H/H Hunger= 2 -3 (High Risk)\\nSevere H/H Hunger= 4 -6 (High Risk)Household hunger score a\\nPregnant & Postpartum women\\nMUAC (cm)<19\\n(SAM)\\n19.0 - 20.9\\n(MAM)\\n21.0 - 23.1\\n(HIGH \\nRISK)\\n>23.1\\n(NORMAL)Nutritional anemia (Hb < 11g/dl) – \\ndeficiency  of iron, folate, Vit. B12;\\nBitot spots due to Vitamin A \\ndeficiency; Pellagra due to vitamin \\nB1 deficiencyMicronutrient deficiency/diseases Other Adults\\nBMI (Kg/m2) b< 16\\n(SAM)\\n16 – 18.5\\n(MAM)\\n18.6 - 21.9\\n(HIGH \\nRISK)\\n22 – 24. \\n(NORMAL)\\nSEVERE MALNUTRITION (SAM)\\nSAM with medical complications \\nand cannot eat ( Clinical status or \\nfailed appetite test)\\nActions  c\\ni. Initiate Phase I therapeutic \\nfeeding until stable (Inpatient – \\nrescue phase feeding)Clinically stable, able to eat and \\ngood appetite\\nActions  c\\n i.  Initiate Phase II therapeutic \\nfeeding for nutritional \\nreconstitution\\nii.  Nutrition counselling & \\neducation\\niii.  Review (in or out patients) \\nweekly\\niv.  Transition to supplemental \\nfeeding upon recovery from \\nSAMActions  c\\ni. Nutrition counselling & \\neducation\\nii. Initiate supplemental \\nfeeding\\niii.  Multiple micronutrient \\nsupplementation\\niv.  Review monthly\\nv.  Post -discharge review every \\n2-3monthsMODERATE MALNUTRITION \\n(MAM)\\nActions  c\\ni.  Nutrition \\ncounselling & \\neducation\\nii.  Repeat nutrition \\nscreening every 2 -3 \\nmonthsNORMAL/LOW RISK\\nActions  c\\ni.   Nutrition counselling & \\neducation\\nii.   Multiple micronutrient \\nsupplementation\\niii.   Review nutrition status \\nand risk factors every \\n2-4 weeks until stable\\niv.  Repeat nutrition \\nscreening every 2 -3 \\nmonths once stable\\n v.  For pregnant or \\npostpartum mothers \\nenroll on FBPNORMAL/HIGH RISK\\nRefer food insecure \\nclients for livelihood\\na Refer to household food security assessment tool\\nb For overweight and obese, refer for counselling\\nc Implement local clinical policy and protocol\\nNUTRITIONAL \\nINTERVENTIONSNUTRITIONAL \\nDAIGNOSISNUTRITIONAL \\nASSESSMENT\\nRefer non responders for \\nfurther clinical assessment \\nand management \\nFigure 4. 4: Management of Malnutrition in Adults with HIV', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 100}),\n",
       " Document(page_content='  \\nGuidelines on Use of Antiretroviral Drugs for Tre ating and Preventing HIV Infection in Kenya  \\n \\n4 - 40 Table 4.2 1: Interpretation of BMI Results for Adults  \\nBMI Level  Classification  Action to Take  \\n< 16 Severe \\nmalnutrition  • Refer for facility -based therapeutic intervention; rehabilitation with \\ntherapeutic foods; counselling on intake issues and possible metabolic issues  \\n• Screen for TB  \\n16.0 –18.4 Mild/moderate \\nmalnutrition  ● Nutritional counselling and supplementary feeding  \\n● Screen for TB  \\n18.5 –25.0 Normal/ \\nrecommended  Nutritional counselling, consistent exercise to build muscles  \\n25.1 –30 Overweight  Nutritional counselling to reduce energy intake; aerobic physical activity to \\nreduce weight  \\n>30 Obese  Counselling to change lifestyle and reduce energy intake; aerobic physical activity \\nto reduce weight  \\n4.8 Prevention of Other Infections  \\n4.8.1 Immunizations  \\nAll children, regardless of HIV status, should be immunized following the full KEPI schedule, \\nwith a few exceptions for infants with severe immunosup pression (Table 4.2 2). For infants \\nliving with HIV and HEIs, an earlier dose of measles vaccines should be given at 6 months of age.  \\nTable 4.2 2: Kenya Expanded Program on Immunizations 2016 Schedule  \\nAge  Vaccines  \\nBirth  OPV1, BCG2 \\n6 weeks  OPV3, Pentavalent (DPT -HepB -HiB), Pneumococcal (PCV10), Rotavirus  \\n10 weeks  OPV3, Pentavalent (DPT -HepB -HiB), Pneumococcal (PCV10), Rotavirus  \\n14 weeks  IPV, Pentavalent (DPT -HepB -HiB), Pneumococcal (PCV10)  \\n6 months  Measles/Rubella (MR) - for HIV exposed and infected infants; Vitamin A  \\n9 months  Measles/Rubella (MR); Vitamin A; Yellow Fever4 \\n18 months  Measles/Rubella (MR); Vitamin A  \\n10 years (girls only)  HPV (2 doses at 6 months apart in the general population; 3 doses for \\nPLHIV, at month 0, 1 -2, and 6)  \\n11-12 years  Tdap (tetanus, diphtheria and pertussis)  \\n1Give OPV to all infants at birth or within the first two weeks of life. If missed in the neonatal period and the child \\nhas symptoms of advanced HIV disease (WHO Stage 3 or 4) or severe immunosuppressio n (CD4% < 25%) then \\ndefer BCG until virally suppressed on ART and with immune system recovery  \\n2Give BCG to all infants at birth or within the first two weeks of life. If missed in the neonatal period and the child \\nhas symptoms of advanced HIV disease (WHO Stage 3 or 4) or severe immunosuppression (CD4% < 25%) then \\ndefer BCG until virally suppressed on ART and with immune system recovery . Do not give BCG vaccine to babies \\nborn to smear positive mothers. Investigate to rule out TB, give TPT then vaccination d one two weeks after \\ncompletion of TPT  \\n3If HIV+ with symptoms of advanced HIV disease (WHO Stage 3 or 4) or severe immunosuppression (CD4% < 25%) \\nthen use IPV instead of OPV  \\n4Yellow fever vaccine is only routinely used in certain counties as specified by National Vaccines and Immunization \\nProgram; defer yellow fever vaccine if symptoms of advanced HIV disease (WHO Stage 3 or 4) or severe \\nimmunosuppression (CD4% < 25%), until virally suppressed on ART and with immune system recovery  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 101}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 41 PLHIV may have an inadequate response to immunizations, particularly before they achieve full \\nviral suppression. The ideal timing, dose, and frequency of re -immunizations for children on ART \\nare not well known. Providers will receive specific guidance or r evaccination from the National \\nVaccines and Immunization Program and NASCOP.  \\nRecommended vaccinations for adolescents and adults living with HIV are listed in Table 4.2 3. \\nTable 4.2 3: Vaccinations in Adolescents and Adults Living with HIV  \\nInfection  Vaccine  Live  \\n(Y/N)  Course  Comments  \\nCOVID -19 Various  N Variable  Follow national guidelines on dosing for the \\nspecific vaccine available  \\nHepatitis B  Subunit  N 4 doses (at  \\n0, 1, 2 and 6 \\nmonths)  Use double dose if non -adjuvanted; use standard \\ndose if adjuvanted  \\nPneumococcus  Conjugate  N 1 dose (PCV  \\n13)  \\nPreferable to polysaccharide  \\nPolysaccharide  N 1 dose  Use if >65 years and with co -morbidity other \\nthan HIV  \\nHuman \\nPapillomavirus \\n(HPV)  Virus -like \\nparticles   \\nN 3 doses (at \\nmonths 0, 1 -\\n2, and 6)  All girls at 9 -14 years old  \\nInfluenza  Inactivated  N 1 dose  Annually  \\nHepatitis A  Inactivated  N 2 - 3 doses  3 doses if CD4 count < 350 cells/mm3 at 0, 1 and \\n6 months. If CD4 count > 350 cells/mm3, give 2 \\ndoses at 0 and 6 months. For those at continued \\nrisk, one booster dose every 10 years  \\nAdditional Vaccines for Special Circumstances  \\nYellow fever  Live attenuated  Y 1 dose  Use only in patients <60 yrs of age and  CD4 > \\n200 cells/mm3 \\nTyphoid  Polysaccharide  N 1 dose  Give the ViCPS parenteral. Repeat every 3 years  \\nCholera  Subunit  N 2 doses  As indicated (usually in epidemics). 2 oral doses \\nof the non -replicating vaccine given 1 -6 weeks \\napart with a single booster dose at 2 years from \\nprimary vaccination  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 102}),\n",
       " Document(page_content='  \\nGuidelines on Use of Antiretroviral Drugs for Tre ating and Preventing HIV Infection in Kenya  \\n \\n4 - 42 4.8.2 Malaria  \\nChildren and adults living with HIV suffer heavier parasitaemia and more malaria morbidity with \\nadvanced HIV disease. Further, people with advanced immunosuppression are at risk of failure \\nof anti -malarial treatment. In pregnancy, there is increased risk of placental malaria,  severe \\nanaemia, premature delivery and perinatal mortality. Drug interactions between ARVs and \\nantimalarial drugs may further complicate management.  \\nRecommendations for malaria prevention for PLHIV include:  \\n● Offer cotrimoxazole preventive therapy (CPT) for  protection against malaria infection \\n(Table 4. 3: Co-trimoxazole Preventive therapy)  \\n● In areas of stable malaria transmission, PLHIV should have access to insecticide treated \\nmosquito nets (ITNs) or indoor residual spraying to reduce exposure to mosquito bi tes \\nand therefore malaria transmission  \\n● PLHIV travelling from non -malarious zones to malaria endemic areas should sleep under \\nITNs  \\n● Pregnant women with HIV living in areas of stable malaria transmission who are not able \\nto take CPT should be given at least t hree doses of sulfadoxine -pyrimethamine (SP) \\nintermittent preventive treatment for malaria as part of routine antenatal care  \\nNote:  SP should not be given to women who are taking CPT  \\n● PLHIV on CPT who develop fever should not be treated for an unconfirmed presumptive \\ndiagnosis of malaria. Laboratory confirmation of malaria should be obtained prior to \\ninitiation of anti -malarial therapy  \\n● PLHIV with malaria should receive standard antimalarial therapy according to national \\nguidelines.  Those on CPT should not be given sulfa -containing anti -malarial drugs. \\nPatients on ART receiving anti -malarial therapy should be monitored closely for adverse \\ndrug reactions  \\n4.8.3 Safe Water, Sanitation and Hygiene  \\nDiarrheal illnesses are common causes of morbidity and  mortality among PLHIV. These diseases \\nare often due to lack of access to safe drinking water, improper disposal of human and animal \\nwaste, and poor personal hygiene, leading to contamination of food and water.  \\nRecommendations for prevention of faecal -oral ly spread illnesses include:  \\n● Offer CPT for protection against some GI infections (Table 4.3: Co -trimoxazole \\nPreventive therapy)  \\n● Hand washing with soap and water after handling human or animal faeces, after using \\nthe toilet, and before food preparation or eating  \\n● Facilities for proper disposal of human waste.  \\n● Training on household -based water treatment methods and water storage containers \\nthat prevent direct hand contact with drinking water  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 103}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 1  \\n5. Adherence Preparation, Monitoring and \\nSupport  \\n \\nThe individual and population benefits of ART are dependent on high levels of adherence to the \\nprescribed medication, the accompanying medical advice and the follow -up plans. Adherence -\\nenhancing strategies should be implemented beginning at the point of HIV di agnosis (as part of \\npost -test counselling and linkage), continued during initial evaluation, and thereafter during the \\nentire follow -up period for ART.  \\n \\nTo avoid treatment failure and the need to switch patients to 2nd or 3rd line ART, it is key to have \\nan adherence support strategy in place before ART initiation, anticipating common and individual \\nbarriers to good adherence. Prevention of treatment failure starts at the time of HIV diagnosis. \\nThis is particularly important with the current recommendation t hat all PLHIV qualify for ART, \\nand ART should be initiated within 2 weeks of diagnosis. Adherence preparation must begin at \\ntime of HIV testing, and close follow -up is required after ART initiation.  \\n \\nThe adherence preparation, monitoring, and support that a patient requires should be tailored to \\ntheir level of adherence, the stage of ART initiation, and the follow -up stage that they are at (Figure \\n5.1).  \\n \\nWhenever possible, follow -up should be provided by the same care provider or team of care \\nproviders (e.g ., same clinician and same counsellor) at each visit. This is particularly important \\nduring the first few months of HIV care.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 104}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 2 \\nHTS post -test counselling: key treatment preparation messages for all patients who test positive\\n• Treatment is available and recommended for everyone with HIV\\n• Starting treatment early reduces your chance of becoming ill or infecting your sexual partner(s)\\n• With good adherence you can live a long and productive life\\nEnrolment Visit\\n• HIV education and adherence preparation for all patients/caregivers (Table 5.1)\\n• ART Readiness Assessment for all patients/caregivers (Table 5.4), along with \\nindividualized adherence support plan\\nReady to start ART Not ready to start ART\\n• Initiate ART\\n• Baseline investigations if not already completed\\n• Provide standard package of care and differentiated \\ncare based on initial presentation (advanced disease vs \\nwell)\\n• Book follow -up appointment for week 2 and 4 to \\nreview adherence and side -effects\\n• Continue adherence support plan• Weekly appointments  to review clinical \\nstatus, barriers to ART initiation, and provide \\nongoing HIV education and counselling\\n• Provide standard package of care\\n• Re-assessment of ART readiness at every \\nvisit, until ready (target is within 2 weeks)\\nFollow -up with adherence monitoring at every \\nvisit (Table 5.10) and counselling based on \\nlevel of adherence (Table 5.14) until first VL at \\n3 months\\nVL undetectable ( LDL <200copies/ml )\\n• Ongoing adherence assessment and \\ncounselling (Table 5.16)\\n• Continue routine VL monitoring as per \\nthe population groupVL       copies/ml\\n• Suspect poor adherence\\n• Assess for barriers to adherence (Table 5.15)\\n• Follow VL algorithm with enhanced \\nadherence assessment and interventions and \\nassessment for other causes of viremia \\n(Figure 6.6) \\nFigure 5.1: Adherence Preparation, Monitoring and Support until Viral Load after 3 Months on \\nART  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 105}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 3 Adherence is most difficult during the first few months of treatment: the patient is not yet in the \\nhabit of taking their medications every day, they are not familiar with common side -effects, and \\nthey have more challenges with disclosure and stigma,  all of which can interfere with adherence. \\nPoor adherence within the first few months of therapy is also the most risky period for \\ndevelopment of resistance mutations, when the viral load is still high.  \\n \\nFor these reasons, adherence preparation, monitorin g and support must be emphasized \\nduring the first few months of ART until the patient achieves full virological suppression,  \\nafter which adherence monitoring and support can continue at lower intensity.  \\n \\nPatient preparation and counselling should be a coll aborative process between the provider and \\nthe patient or caregiver, to enable the patient to initiate and continue lifelong treatment. This is \\nbest done when the same adherence counsellor follows an individual patient throughout the \\npreparation, initiatio n, and early ART period.  \\n \\nART can be initiated concurrently with the first adherence counselling session, even during \\nthe enrolment visit, especially for infants and for pregnant women. This may also apply to \\npatients with a good understanding of HIV and A RT and strong motivation for immediate \\nART initiation.  \\n \\nEach member of the multidisciplinary team should have the requisite training to provide \\ntreatment education and offer appropriate support to address potential barriers to adherence. \\nTreatment preparat ion and support can be offered at triage, consultation, pharmacy or any other \\nclinic station where confidentiality and privacy are assured and providers are adequately trained. \\nIt should also be incorporated into health talks, peer support group activities , and group \\ncounselling sessions.  \\n \\nBefore commencement of a counseling session, the counselor should ensure that adequate space is available \\nto conduct the counseling, that confidentiality can be maintained, and that tools such as psychosocial \\nassessment f orms, treatment literacy flip charts, PHDP flip charts, and tools to document the counseling \\nsessions are available.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 106}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 4 Persons living positively (adolescent and adult peer educators who can share personal \\nexperiences when needed) should be engaged to support patient education as indicated in the \\noperational guidance below.  \\nOperational Guidance: Meaningful Involvement of People Living with HIV  \\nFor best patient outcomes, PLHIV themselves should be engaged to lead facility -based and \\ncommunity -based HIV ed ucation and support systems. They are often referred to as “peer \\neducators”, “mentor mothers”, and “lay health workers” in these roles. PLHIV have successfully and \\nsignificantly contributed to: improving identification of people at risk for HIV or infected  with HIV; \\nincreasing linkage from testing to treatment; reducing onward transmission of HIV; providing \\npsychosocial support, and improving adherence and retention to care and ART.  \\n \\nIdentifying PLHIV to offer peer -led patient support:  \\n● PLHIV on ART for ≥ 1  year  \\n● Good adherence and undetectable VL  \\n● Positive attitude and interest in supporting peers  \\n \\nPreparing and supporting PLHIV to play a role in patient support systems:  \\n● Must be trained for the role they are expected to provide  \\n● Must have job aids and IEC material appropriate for their role  \\n● Must be supervised by healthcare professionals  \\n \\nPotential roles for PLHIV include  \\n● Supporting HIV self -testing  \\n● Providing HIV testing services  \\n● Acting as peer linkage supporters  \\n● Leading or contributing to facility -based or community -based support groups  \\n● Providing individual or group HIV education  \\n● Providing individual or group adherence counselling  \\n● Distribution of ART refills for stable patients  \\n \\nCompensation for PLHIV who contribute to patient support systems  \\n● Recognition (e.g., ID badges; certificates of service; acknowledgement at community forums)  \\n● Training opportunities with certification  \\n● Financial compensation (e.g., salaries; stipends; transportation allowances)  \\n● Priority consideration for em ployment opportunities  \\n \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 107}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 5 5.1 Undetectable = Untransmittable (U=U)  \\nART adherence resulting to durable viral suppression eliminates risk of sexual transmission of \\nHIV and is key to HIV epidemic control. Adoption of the Undetectable equals Untransmittable \\n(U=U) campaign is posed to revolutionize HIV treatment among PLHIV and fortify treatment -for-\\nprevention strategies. Multiple studies have showed that durable viral suppression of <50 \\ncopies/ml eliminates risk of sexual transmission of HIV. (Table 5. 17 Viral load cut -offs)  \\nThe framework of U=U offers a unique opportunity to dismantle HIV stigma and discrimination, \\nemphasizes the critical importance of antiretroviral therapy (ART), daily adherence, and \\ncontinuous engagement in medical care for  PLHIV.  \\nDefinitions:  \\n● Durably Undetectable: 2 consecutive viral load results of <50 copies/ml  \\n● Untransmittable: The finding established by various clinical trials and observational \\nstudies, that people who maintain an undetectable viral load have minimal HIV virus in their \\nblood and other body fluids secretions that they have “effectively no risk” of passing HIV to \\nothers through sex.  \\n5.1.1 Benefits of U=U  \\n● Diminish stigma associated with having HIV  \\n● Reduce barriers to HIV testing and treatment  \\n● Incre ase interest in starting and staying on ART  \\n● Improve self -esteem by removing the fear of being contagious  \\n● Support healthy sexuality regardless of HIV status  \\n● Reduce sex partners’ concerns  \\n5.1.2 Considerations for implementation of U=U within clinical setting s \\n● Viral load monitoring as per the recommended intervals for various populations  \\n● Continuous adherence monitoring and support at all clinical visits  \\n● STI screening at all visits  \\n● Messaging on U=U should be provided for all PLHIV as part of treatment literacy  \\n5.1.3 Messaging to Patients on U=U  \\n● Keeping your HIV undetectable helps you live a long and healthy life  \\n● To get your HIV to an undetectable level and to keep it undetectable, take antiretroviral \\nmedicines as prescribed  \\n● It may take up to 6 months o f taking HIV treatment medicines to bring your HIV viral load \\ndown to an undetectable level  \\n● If you are durably suppressed and you are taking your medications as prescribed, you can \\nbe sure you will not pass HIV through sex  \\n● People who keep their HIV at an undetectable level will not pass HIV to others through sex  \\n● If you stop taking HIV medicines, your HIV can rebound to a detectable level within 1 to 2 \\nweeks, and you may pass HIV to your sex partners  \\n● Keeping your HIV at durably suppressed level helps you sa fely conceive a child with your \\npartner  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 108}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 6 5.1.4 How patients can discuss U=U with others  \\n● Counsel patients to share information about the research on U=U as follows:  \\no In recent research studies that involved thousands of couples, no one who was on \\nHIV treatment and whose HIV was durably undetectable passed HIV to their HIV -\\nnegative sex partner  \\n● Advise patients that they can share the following personal information with current or \\npotential sex partners:  \\no When they last had a viral load test and if their viral load was undetectable  \\n● Individuals should tell their partner(s) that their HIV is undetectable only if they have \\ntaken HIV medicines consistently since their last test with an undetectable viral load  \\n5.1.5 Counselling patients about other preven tion combination interventions  \\n● PrEP:  PrEP is a safe and effective daily pill that prevents HIV infection. The partner without \\nHIV may decide to take PrEP if they:  \\no Are unsure that their partner’s HIV viral load is undetectable, especially if their \\npartner has only recently started ART  \\no Have mo re than 1 sexual partner  \\no Feel more secure with the added perception of protection provided by PrEP  \\n● PEP:  After a possible HIV exposure (e.g., Occupational exposure or if a sex partner with HIV \\nhas not consistently taken ART and is not virally suppressed), t he immediate initiation of \\nemergency PEP can prevent HIV infection  \\n● Condom use:  Condoms protect against other STIs, such as gonorrhea, chlamydia, and \\nsyphilis, and help prevent pregnancy.  \\nCounsel patients to find a prevention strategy that works for them:  \\n● If an individual who does not have HIV is unsure if their partner has an undetectable level of \\nvirus or is anxious about acquiring HIV, care providers should encourage that person to \\nchoose a prevention strategy that works for them, whether that is use of P rEP, emergency \\nPEP, condoms, or a combination of these strategies  \\nNote: Care providers should emphasize that no one should ever be compelled to have \\nsex without condoms  \\n5.1.6 Application of U=U in other settings  \\n● Breastfeeding:  Studies demonstrate that ART greatly reduces the risk of transmission \\nthrough breast milk. However, research has not established that people whose HIV is \\nundetectable do not transmit virus during breastfeeding. Prophylaxis should be provided \\nto HIV expose d infants during the breastfeeding period as per the guidelines regardless \\nof the viral load status  \\n● Injection drug use:  Studies demonstrate that ART greatly reduces the risk of \\ntransmission through sharing of injection drug use. However, research has not \\nestablished that people whose HIV is undetectable do not transmit virus through needle \\nsharing. All people who inject drugs should only use their own needles and not share \\nneedles or other paraphernalia with others  \\n● Needle stick injuries:  Research has not es tablished that people with undetectable viral \\nload do not transmit HIV to people who are stuck by needles containing their blood. HIV \\nPEP should be provided as per the guidelines  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 109}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 7 5.2 ART Adherence Preparation and Support  \\nPreparation for ART begins at the t ime of HIV diagnosis and continues until initiation of ART.  \\n5.2.1 Treatment Preparation as Part of HIV Testing Services  \\nWith the current treatment guidelines recommendation that all PLHIV qualify for ART, post -test \\ncounselling by the HTS provider should no w include three key messages that begin the ART \\ntreatment preparation process for all PLHIV  \\n● Treatment (called antiretroviral therapy (ART)) is available and is recommended for \\neveryone with HIV  \\n● Starting treatment as soon as possible (preferably within two weeks of testing positive \\nfor HIV) reduces the chance of your illness getting worse or of passing HIV to others  \\n● If you take your ART properly and do not miss pills you can expect to live a long and \\nproductive life  \\n \\n5.2.2 ART Treatment Preparatio n \\nART treatment preparation involves HIV education and counselling, including identifying likely \\nbarriers to adherence, a discussion of strategies and support systems to overcome possible \\nbarriers to adherence, and an individualized adherence plan, as summ arized in Table 5.1. The \\neducation and counseling sessions should be documented in patient charts.  \\nTable 5.1: Treatment Preparation and Adherence Counselling Guide  \\nHIV Education  \\n• Ask the patient what they know about HIV  \\n• Ask the patient what they know about treatment for HIV  \\n• Correct/clarify as needed, ensuring you cover:  \\no Modes of transmission and importance of testing partners/children  \\no HIV effect on the immune system and health  \\no HIV viral load and its relationship to health and to HIV transmission  \\no Goals of ART  \\no Relationship between adherence and viral suppression, treatment failure, and drug \\nresistance  \\no Consequences of drug resistance  \\n• Ensure the patient understands by asking them to explain it back to you  \\nBarriers to Adherence  \\n• Ask the patient what they think will be most difficult about taking ART every day  \\n• As the patient what they think will be most difficult about attending all clinic appointments  \\n• Discuss common reasons patients have trouble with excellent adherence and identify which may \\nbe most relevant for them, including:  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 110}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 8 Table 5.1 Cont.  \\n● Patient Factors  \\no Stigma and non -disclosure (having to hide \\ntheir ARV pill -taking)  \\no Lack of support systems  \\no Alcohol or drug use  \\no Depression or other psychiatric illness  \\no Loss or grief  \\no Cognitive disorders  \\no Change in daily routine  \\no Chaotic lifestyle; no consistent daily \\nroutine  \\no Forgetting to take pills  \\no Feeling better so does not think the ART is \\nneeded any more  \\no Feeling too sick to take ART  \\no Age (adolescents - impulsive, more \\nsusceptible to social pressure; children – \\ncaregiver dependent)  ● Provider/System Factors  \\no Side effects (many patients have side \\neffects when they first start their ART, \\nincluding nausea, headaches, and \\ndifficulty sleeping.  These side effects \\nalmost always resolve with continued \\nuse)  \\no Pill burden  \\no Poor patient -provider relationship  \\no Inadequate HIV education  \\no Cost of care (direct and indirect)  \\no ARV supply -chain limitations (stock -outs, \\nor low stock levels resulting in small refill \\nquantities)  \\nIndividualized Adherence Plan  \\n● Ask the patient what they can do to ensure excellent adherence  \\n● Ensure the adherence plan incorporates details of the patient’s specific ART regimen:  \\no Number of pills, frequency, food requirements/restrictions  \\no Common side effects  \\no Important drug interactions  \\n● Work with the patient to make an individualized adherence plan, which may include:  \\no Disclosing their HIV status to a close friend or family member who can help support their \\ntreatment; bringing their treatment buddy to clinic with them or to a session with a \\ncounsellor to learn more about HIV  \\no Disclosing their HIV status to household members so they do not have to hide pill -taking  \\no Combining pill taking with a consistent activity in their daily routine  \\no Keeping the ARVs in a place that they are lik ely to see every day  \\no Setting a daily alarm on their phone/watch/clock  \\no Connecting with a support group for additional counseling/education/support  \\no Getting treatment for alcohol or drug use  \\no Getting treatment for depression or other psychiatric illness  \\n● Discuss what to do if:  \\no Develops side effects  \\n▪ Discuss common and serious adverse events for their specific regimen  \\n▪ Encourage patient to return to clinic for any side effects rather than stopping ART  \\no Forgets to take a dose: take it late rather than skipping the dose completely  \\no Travels without their ART: go to the nearest health facility or call clinic for guidance  \\n● Ask the patient to summarize their individualized adherence plan  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 111}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 9 Table 5.1 Cont.  \\nOngoing Support at Subsequent Visits  \\n● Review the patient’s HIV knowledge  \\n● Review the patient’s motivation to take ART  \\n● Elicit any concerns the patient may have about their ART, side effects, visit schedule, or health  \\n● Review the ART dosing schedule and ask about any missed pills  \\n● Explore barriers to adherence that were previously identified or new ones that have developed  \\n● Explore any recent or expected changes in their life or daily routine  \\n● Discuss their individualized adherence plan and if any changes are required  \\n \\nHIV Education and Counselling  \\nHIV education should be a standard component of the enrolment visit. Prior to ART initiation, all \\npatients/caregivers must be provided with enough information to make an informed choice about \\nART initiation and adherence (Table 5.2), including for patients who initiate ART during the \\nenrolment visit. A detailed content guide for HIV education and adherence counselling is provided \\nin Annex 8. This information can be provided through group or individual counselling. The ART \\nReadiness Assessment an d the management plan should be completed for each patient \\nindividually (Table 5.4).  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 112}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 10 Table 5.2: Components of HIV Education (see Annex 8 for detailed content guide)  \\nComponent  Questions to be Covered  \\n \\nHIV ● What is HIV  \\n● How is HIV transmitted  \\n● Why should partners and family members be tested for HIV  \\n \\nViral load  ● What is viral load  \\n● How often is viral load measured  \\n● What do viral load measurements mean, including the goal of achieving viral suppression  \\n \\n \\nCD4 cells  ● What are CD4 cells  \\n● How are CD4 cells affected by HIV  \\n● What happens when CD4 cells decrease  \\n● How often is CD4 cell count measured  \\n \\n \\n \\nAntiretroviral \\ntherapy (ART)  ● What is ART  \\n● What are the benefits of ART  \\n● When is ART started  \\n● Does ART cure HIV  \\n● Can you still give HIV to others while taking ART  \\n● How long is ART taken  \\n \\n \\nTreatment failure  ● What happens if you stop taking ART  \\n● What happens if you do not take ART regularly  \\n● What happens if the viral load increases  \\n● What happens in treatment failure  \\n \\nART side effects  ● What are the side -effects of ART  \\n● What should you do if you notice any side effects  \\n \\n \\n \\nAdherence  ● What is adherence  \\n● How should ART be taken  \\n● What usually interferes with good adherence  \\n● What might make it difficult for you to take your ART as prescribed  \\n● What can help you take ART as prescribed  \\n● What happens if you miss an appointment  \\nOther medications  ●  What other medications will you take, in addition to ART (e.g., CPT, TPT)  \\n \\nNutrition  ● Why is nutrition important  \\n● What can you do to improve your nutrition  \\n \\nFollow -up ● How often will you need to come for clinic visits?  \\n● What will we be checking for during your clinic visits  \\nAdherence Support  \\nPsychosocial support for PLHIV and their families is essential for their well -being and good health \\noutcomes. HIV affects virtually every aspect of one’s life, as well as the lives of those close to them. \\nPLHIV need psychological and social support to deal with various issues that are common to \\nchronic illness as well as those that are unique to HIV. These include sti gma, bereavement, self -\\nimage, loss of earning capacity, life skills, and chronic illness, among others. Providing \\npsychosocial support entails identifying any needs that they may have and addressing them. In \\nsome cases, some of these needs can be anticipat ed and addressed even before they come to play \\nin the individual’s life.  \\nThe individualized patient management plan should include establishing appropriate adherence \\nsupport interventions (Table 5.3).  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 113}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 11 Table 5.3: Adherence Support and Retention Intervention s \\nStandard Adherence Support Interventions  \\nStructural \\ninterventions  ● Conduct a baseline psychosocial assessment to explore the various aspects of \\nthe client’s life that may influence their adherence to treatment and \\nprevention, and their general well -being. This teases out issues that need to \\nbe explored in detail during the counselling session e.g., disclosure, family \\nplanning, living circumstances etc.  \\n● Use a multidisciplinary team approach to develop and implement treatment \\nplans for each patien t \\n● Engage peer educators to lead HIV education and support services  \\n● Adequately prepare and assess the patient’s readiness to initiate and continue \\nwith ART  \\n● Implement a system for identifying and taking action when patients miss an \\nappointment  \\n● Formalize a sy stem for providing health talks and treatment literacy classes \\nfor patients  \\n● Formalize a system for linking patients to community -based resources, \\nincluding: community support groups, religious groups, CBOs, groups \\nsupporting income -generating activities, o rganizations providing food \\nsupport, NEPHAK, child welfare societies, community health volunteers/units, \\nschools, children’s homes etc.  \\n \\nHIV \\neducation \\nand \\ncounselling  ● Remind the patient about HIV disease, how ART works, the importance of \\nhigh -level adherence and the consequences of non -adherence  \\no Risk of ill health caused by HIV  \\no Role of ART in restoring and maintaining good health  \\no Link between adherence and viral load, CD4 and health  \\no Side effects of medications and how to avoid, recognize and manage them. \\nManage side effects aggressively  \\no Address misconceptions and beliefs about HIV and ART  \\n● Discuss and agree on a treatment plan with the patient. Gain commitment \\nfrom the patient to follow through  \\n● Discuss use of alcohol and drugs and  how to prevent these from affecting the \\ntreatment plan  \\n● It is important to maintain a non -judgmental attitude, establish trust with \\nparents/caregivers, and involve the child as they mature  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 114}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 12 Table 5.3 Cont.  \\nDisclosure and \\nstigma  ● Respect patient privacy and confidentiality  \\n● Discuss with the patient the role of disclosure to close family \\nmembers/trusted friend in promoting adherence  \\n● Offer to facilitate disclosure  \\n● For children/adolescents, discuss age -appropriate disclosure with the \\ncaregiver and off er to support the process (Annex 5)  \\n● Conduct stigma assessment and support appropriately  \\n \\nTreatment \\nsupporter  ● Encourage the patient to identify a treatment supporter/buddy who will \\nprovide the patient with encouragement and social support and even remind \\nthe patient to take medication  \\n● Invite the treatment supporter to at least one of the adherence counselling \\nsessions  \\n● Obtain consent from the patient to contact the treatment supporter if needed  \\nSupport group  ● Link the patient to psychosocial support groups and other community -based \\nsupport mechanisms (preferably through direct introduction)  \\no Support groups give confidence and encouragement and promote positive \\nattitude towards HIV status and may promote disclosure  \\no Support groups offer opportunities for additional counselling and \\nexperience sharing and are an avenue for developing/strengthening life \\nskills  \\no Some support groups engage in economic empowerment activities  \\no Support groups can be used for ART distribution to improve  convenience \\nto the patient  \\n● Develop population -specific support groups when possible (e.g., youth \\ngroups with peer educators for adolescents; children’s clubs; caregiver \\nsupport groups)  \\n● MDT members should be patrons to the support groups, to guide activiti es in \\nline with intended objectives  \\n \\nSMS reminder \\nsystem  ● Enroll patients into an automated SMS reminder system with their consent  \\n● Review the type of messages the patient may receive, the frequency of \\nmessages, and any actions the patient should take when receiving the \\nmessage  \\n● Ensure the system and messages maintain patient privacy and confidentiality  \\nOther reminder \\nstrategies  ● Encourage patient/caregiver to set a specific time of day to take ART, and to \\nassociate ART time with a specific event/s in their daily schedule  \\n● Encourage patient/caregiver to set an alarm on their phone  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 115}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 13 5.2.3 Age -Specific Treatment Preparation and Support  \\nTreatment preparation must be customized to the patient’s age, gender, needs and clinical status: \\nfor patients who present with advanced/symptomatic disease, the focus is on getting better; for \\npatients who present clinically well, the focus is on staying healthy. Specific needs for children, \\nadolescents, caregivers, pregnant and breastfeeding women and men should also be taken into \\nconsideration.  \\nThe HIV education and counselling sessions should be provided at every visit until the patient is \\nready and wi lling to start ART, as determined using the ART Readiness Assessment Form (Table \\n5.4). Each repeat session should begin with a review of what the patient remembers from the \\nprevious session as well as any key issues the counsellor documented in the patient ’s chart, so the \\nsession can be customized to meet their needs. ART preparation should not take more than 1 -2 \\nweeks except for special circumstances such as with uncontrolled mental health issues or \\nuntreated drug addictions. However, once the patient has initiated ART, continued HIV education, \\ncounselling and adherence support must be provided. The counselling sessions should preferably \\nbe conducted by the same counsellor, peer educator, social worker, nurse, community health \\nvolunteer, and/or clinician wh o is professionally certified to counsel based on a certified \\ncurriculum, and they possess the requisite competencies to provide quality counselling. In order \\nto prepare children and adolescents for ART, the counsellor should be trained in providing \\npsycho social support to this age group.  \\nTable 5.4: ART Readiness Assessment Form  \\nCriteria  Y N* \\nA. Psychosocial/Knowledge Criteria (applies to patients and caregivers)  \\n1. Understands the nature of HIV infection and benefits of ART?    \\n2. Has screened negative for alcohol or other drug use disorder, or is stable on \\ntreatment (see Section 4.6)    \\n3. Has screened negative for depression or other psychiatric illness, or is stable on \\ntreatment (see Section 4.6)    \\n4. Is willing to disclose/has disclosed HIV status, ideally to a family member or close \\nfriend?    \\n5. Has received demonstration of how to take/administer ART and other prescribed \\nmedication?    \\n6. Has received information on predictable side effects of ART and understands what \\nsteps to take in case of these side effects?    \\n7. For patients dependent on a caregiver: is the caregiver committed to long -term \\nsupport of the patient, daily administration of ART, and meets the criteria above?    \\n8. Other likely barriers to adherence have been identified and there is a plan in place \\nto address them (e.g., frequent travel for work, plan to deal with unexpected travel, \\ndistance from clinic, etc.)?    \\n9. Has the Patient/caregiver provided accurate locator information and contact details?    \\n10. Patient/caregiver feels ready to start ART today?    \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 116}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 14 Table 5.4 Cont.  \\nB. Support Systems Criteria (applies to patients and caregivers)  \\n1. Has identified convenient time/s of day for taking ART, and/or associated \\ndose/s with daily event/s?    \\n2. Treatment supporter has been identified and engaged in HIV education, or will \\nattend next counselling session?    \\n3. Is aware of support group meeting time/s?    \\n4. If facility has SMS reminder system: Has enrolled into SMS reminder system?    \\n5. Other support systems are in place or planned (e.g., setting phone alarm, pill box)?    \\nC. Medical Criteria (applies to patients)  \\n1. Newly diagnosed with TB: defer ART until patient tolerates anti -TB medication; \\ninitiate ART as soon as possible preferably within 2 weeks; for TB meningitis \\ndelay ART for 4 to 8 weeks); monitor closely for IRIS    \\n2. Newly diagnosed cryptococcal meningitis (CM), or symptoms consistent with CM \\n(progressive headache, fever, malaise, neck pain, confusion): defer ART until \\ncompleted 5 weeks of CM treatment, or until ruling out CM as the cause of \\nsymptoms; monitor closely f or IRIS    \\n*If the response to any of the psychosocial criteria or support systems criteria is “No”: develop a \\nstrategy to address the issue as quickly as possible and consider assigning a case manager. ART \\nmay be initiated with adequate adherence support while the criteria is being addressed, on a \\ncase -by-case basis  \\n \\nAt each visit up until ART initiation, every patient should be assessed for readiness to \\nstart ART (Table 5.4), with the patient/caregiver allowed to make the final decision on \\nwhether and when to start ART.  \\nSpecial Considerations when Counselling Children and Adolescents  \\nChildren and adolescents depend on caregivers to support their adherence so there are special \\nconsiderations for adherence preparation and support. All topics covered in the HIV Education \\nand Adherence Counselling sessions (Table 5.2 and Annex 8) should be covered with the \\ncaregiver, with involvement of the child/adolescent as appropriate based on the stage of \\ndisclosure and their developmental stage (Tab le 5.5).  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 117}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 15 Table 5.5: Age -appropriate Involvement of Child/Adolescent in HIV Education and \\nAdherence Counselling  \\nAge  Counselling Approach  \\n< 6 years old  The counselling sessions will focus on engaging all of the child’s \\ncaregivers  \\n6-12 years old  Both the caregiver and the child will be involved. The counselling will \\nfocus on the caregiver; younger children can be given a paper and pen \\nand asked to draw their family, school, etc., and talk about their \\nexperiences. Disclosure of HIV status to the child s hould commence by 5 \\nyears of age and be completed by 10 -12 years of age (Annex 5)  \\n> 12 years old with \\ncaregiver present  Most of the counselling can focus on the adolescent, who is often fully \\nresponsible for medication administration. However, it is neces sary to \\nkeep the caregiver coming and involved in supporting the adolescent. A \\nrecommended approach is to start with the caregiver alone, then see the \\ncaregiver and adolescent together, and then see the adolescent alone. \\nUse the HEADSSS tool* to facilitate  discussion  \\n> 12 years old \\nwithout the \\ncaregiver present  Use the HEADSSS tool* to facilitate discussion. Negotiate involvement \\nof a treatment supporter  \\n* HEADSSS assesses: Home; Education/Employment; Activities; Drugs; Sexuality; \\nSuicide/depression/self -image; Safety  \\n \\nIn addition to the standard HIV Education and Adherence Counselling topics, unique issues need \\nto be addressed for caregivers, children and adolescents (Table 5.6).  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 118}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 16 Table 5.6: Unique Considerations for Caregivers, Children and Adolescents  \\nCaregiver Barriers to Adherence  \\n• Frequently changing or multiple simultaneous caregivers  \\n• Loss or grief  \\n• Absent or sick caregiver  \\n• Poor understanding of HIV management due to inadequate counselling, elderly, or illiterate \\ncaregiver  \\n• Depression, alcohol and other drug use  \\n• Living far from the health facility  \\n• Economically unstable  \\n• Lack of affection between caregiver and child  \\n• Lack of support systems for the caregiver  \\nChild/Adolescent Barriers to Adherence  \\n• Level of disclosure (is the child/adolescent aware of their HIV status?)  \\n• Lack of understanding of disease/treatment  \\n• Developmental stage and emotional state  \\n• Child refusal to swallow medicine (do not allow refusal to take medicines: all activities should \\nbe stopped for the child until the dose is swallowed)  \\n• Stigmatization and discrimination  \\n• Low self -esteem  \\n• Depression  \\n• Defiance related to a troublesome caregiver -child relationship  \\n• Inadequate structures at school (day or boarding) to support adherence  \\n• Lack of support systems for the child/adolescent  \\nTreatment Barriers to Adherence  \\n• Large volumes of syrups  \\n• Bad taste of syrups  \\n• Pill burden  \\n• Confusing regimens combining syrups and tablets  \\n• Side effects  \\n• Dose adjustment requirements as the child grows  \\nFor all children/adolescents, the level of disclosure should be assessed at first visit and the \\nmanagement plan should include a plan for age -appropriate disclosure (Annex 5). Treatment \\npreparation and support se ssions should be customized to the patient’s age (Tables 5.7 -5.9).  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 119}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 17 Table 5.7: Treatment Preparation and Support for Children (≤   years) and Caregivers  \\nVisit  Standard of Care  \\nAt \\nenrolment \\ninto care  \\n Use the 5As (Assess, Assist, Advice, Agree, Arrange)  \\n• Perform a psychosocial assessment at enrolment to evaluate for possible \\npsychological, emotional and social adherence boosters and barriers  \\n• Assess growth and developmental milestones (Annex 3) to rule out growth \\nretardation, developmental challenges such as autism, deafness and any other \\nphysical challenge. Any child with developmental challenges should be referred for \\nappropriate care  \\n• Identify the primary caregiver as soon as possible after diagnosis of HIV in a child. In \\nthe absence of a caregiver, link the child to a community health volunteer or a peer \\neducator while a more permanent solution is sought, and link with Department of \\nChildren and Social Protection  \\n• The child and their caregiver, if also infected, should be enrolled in the sa me clinic, \\nand have appointments booked on the same clinic day for family -centered care  \\n• Provide HIV education and counselling to caregiver (and child as appropriate for age, \\nTable 5.5) as outlined in Table 5.2  \\n• Identify and establish appropriate adherence s upport interventions (Table 5.3), \\nincluding linkage to pediatric and caregiver support groups  \\n• Discuss benefits of disclosure of HIV status of the child and formulate a disclosure \\nplan for children aged 5 years and above (Annex 5)  \\n• Conduct readiness assessme nt to initiate ART (Table 5.4); ART should be initiated \\nsame day or the date of initiation agreed upon  \\n• Review ART dosing and timing (including having the caregiver demonstrate how they \\nmeasure and administer the ART)  \\n• Conclude the session by agreeing on a t reatment and follow -up plan  \\n• Where ART is initiated book the child to return within two weeks. Those unwilling to \\ninitiate should return weekly for further counselling on barriers to initiation  \\n• Identify referral needs and link as appropriate  \\n• Document sessi on in the patient’s chart  \\nTwo weeks \\nafter ART \\nInitiation  \\n • Review and reinforce the messages delivered at enrolment; confirm the caregiver’s \\nunderstanding of key messages  \\n• Review ART dosing, timing and reminders (including having the caregiver \\ndemonstrate how they measure and administer the ART)  \\n• Explore any barriers to adherence  \\n• Revisit benefits of disclosure and the individualized age -appropriate disclosure plan  \\n• Identify referral needs and link as appropriate  \\n• Document the session in the patien t’s chart  \\nFour weeks \\nafter ART \\nInitiation, \\nand further \\nfollow -up \\nvisits  \\n • Review and reinforce the messages delivered in previous sessions; confirm the \\ncaregiver’s understanding of key messages  \\n• Review ART dosing, timing and reminders (including having the caregiver \\ndemonstrate how they measure and administer the ART)  \\n• Explore any barriers to adherence  \\n• Revisit benefits of disclosure and the individualized age -appropriate disclosure plan  \\n• Identify referral needs and link as appropriate  \\n• Document the session in the patient’s chart  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 120}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 18 Table 5.8: Treatment Preparation and Support for Adolescents (10 -19 years)  \\nVisit  Standard of care  \\nAt \\nenrolment \\ninto care  Use the 5As (Assess, Assist, Advice, Agree, Arrange)  \\n• Perform a psychosocial assessment at enrolment to evaluate for possible psychological, \\nemotional and social adherence boosters and barriers  \\n• Assess growth and developmental milestones to rule out growth retardation, \\ndevelopmental challenges such as autism, deafness and any other physical challenge. \\nAny adolescent with developmental challenges should be referred for appropriate care  \\n• Identify the primary caregiver as soon as possible after diagnosis of HIV in an \\nadolescent. Adolescents older than 15 years and emancipated minors may not have or \\nmay not want the presence of a caregiver. In this case, the clinical team should explore \\nalternative options to support the adolescent until they are ready to disclose to their \\ncaregivers/guardian or identify someone to disclose to. The alterna tive options include \\nadolescent mentors, peer educators, social worker, nurses or community health \\nvolunteers as may be appropriate.  An adolescent can have both private and joint \\nsessions with the caregiver when deemed appropriate  \\n• The health provider shou ld explore Sexual and Reproductive Health (SRH) \\nunderstanding, fears and needs of the adolescent and prioritize interventions as \\nappropriate. SRH counseling should be introduced in a one -to-one session with the \\nadolescent. The care giver can be excused fro m the sexual and reproductive health \\nsession to enable adolescent to open up during the session  \\n• The adolescent and their caregiver, if also infected, should be enrolled in the same \\nclinic, and have appointments booked on the same clinic day for family -cent ered care  \\n• Provide HIV education and counselling to caregiver (and adolescent as appropriate for \\nage, Table 5.5) as outlined in Table 5.2  \\n• Identify and establish appropriate adherence support interventions (Table 5.3), \\nincluding linkage to adolescent and car egiver support groups  \\n• Discuss with the caregiver the benefits of disclosure of HIV status to the adolescent (if \\nnot aware of status) and formulate a disclosure plan for adolescents (see Annex 5 for \\nage-appropriate disclosure)  \\n• Conduct readiness assessment to initiate ART (Table 5.4); ART should be initiated \\nsame day or the date of initiation agreed upon  \\n• Review ART dosing and timing (including having the adolescent and/or caregiver \\ndemonstrate how they measure and administer the ART)  \\n• Conclude the session by agreeing on a treatment and follow -up plan  \\n• Where ART is initiated, book the adolescent to return within two weeks. Those \\nunwilling to initiate should return weekly for further counselling on barriers to \\ninitiation  \\n• Identify referral needs and li nk as appropriate  \\n• Document session in the patient’s chart  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 121}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 19 Table 5.8 Cont.  \\nTwo \\nweeks \\nafter ART \\ninitiation  • Review and reinforce the messages delivered at enrolment; confirm the adolescent’s \\nand/or caregiver’s understanding of key messages  \\n• Review ART dosing, timing and reminders (including having the adolescent and/or \\ncaregiver demonstrate how they measure and administer the ART)  \\n• Explore any barriers to adherence, including issues related to the school environment  \\n• Review support systems (including adol escent support group)  \\n• Revisit benefits of disclosure and the individualized age -appropriate disclosure plan  \\n• Review SRH needs  \\n• Identify referral needs and link as appropriate  \\n• Document the session in the patient’s chart  \\nFour \\nweeks \\nafter ART \\ninitiation, \\nand \\nfurther \\nfollow -up \\nvisits  \\n • Review and reinforce the messages delivered in previous sessions; confirm the \\nadolescent’s and/or caregiver’s understanding of key messages  \\n• Review ART dosing, timing and reminders (including having the adolescent a nd/or \\ncaregiver demonstrate how they measure and administer the ART)  \\n• Explore any barriers to adherence, including issues related to the school environment  \\n• Review support systems (including adolescent support group)  \\n• Revisit benefits of disclosure and the in dividualized age -appropriate disclosure plan  \\n• Review SRH needs  \\n• Link to psychosocial support group  \\n• Identify referral needs and link as appropriate  \\n• Document the session in the patient’s chart  \\nTable 5.9: Treatment Preparation and Support for Adults  \\nVisit  Standard of care  \\nAt \\nenrolment \\ninto HIV \\ncare  \\n Use the 5As (Assess, Assist, Advice, Agree, Arrange)  \\n● Perform a psychosocial assessment to evaluate adherence boosters and barriers e.g., \\nmental, emotional and social status assessments; refer for appropriate care if mental \\ndisorder diagnosed  \\n● Identify a treatment buddy (family member, friend, peer educator, community health \\nvolunteer, etc.) and involve them in HIV education and adherence counselling  \\n● Provide HIV education and counselling to patient  \\n● Identify and establish appropriate adherence support interventions (Table 5.3), \\nincluding linkage to a support g roup  \\n● Discuss benefits of disclosure of HIV status to a trusted family member/friend; how to \\ndisclose; and establish a disclosure plan  \\n● Discuss importance of child and sexual partner testing as well as assisted partner \\nnotification services (aPNS)  \\n● Discus pr evention methods such as condoms, PrEP, PEP, STI screening and treatment  \\n● Conduct an assessment of readiness to initiate ART (Table 5.4); ART should be initiated \\nsame day or the date of initiation agreed upon  \\n● Review ART dosing and timing  \\n● Conclude the sessi on by agreeing on a treatment and follow -up plan  \\n● Where ART is initiated, book the patient to return within two weeks. Those unwilling \\nto initiate should return weekly for further counselling on barriers to initiation  \\n● Document session in the patient’s cha rt ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 122}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 20 Table 5.9 Cont.  \\nTwo weeks \\nafter ART \\ninitiation  ● Review and reinforce the messages delivered at enrolment; confirm the patient’s \\nunderstanding of key messages  \\n● Review ART dosing, timing and reminders  \\n● Explore any barriers to adherence  \\n● Review support systems  \\n● Revisit benefits of disclosure, the disclosure plan and progress in aPNS  \\n● Document the session in the patient’s chart  \\nFour weeks \\nafter ART \\ninitiation, \\nand further \\nfollow -up \\nvisits  ● Review and reinforce the messages delivered in previous sessions; confirm the \\npatient’s understanding of key messages  \\n● Review ART dosing, timing and reminders  \\n● Explore any barriers to adherence  \\n● Review support systems  \\n● Revisit benefits of disclosure the disclosure plan,  and progress in aPNS  \\n● Document the session in the patient’s chart  \\n \\n5.3 Adherence Monitoring, Counselling and Support During the First 3 Months \\nof ART  \\n5.3.1 Adherence Monitoring  \\nOnce ART has been initiated, adherence should be assessed non-judgmentally by a trained \\nprovider during each visit (Table 5.10).  The objectives of this assessment are to evaluate and \\nreinforce the patient’s adherence to ART, to elicit any barriers to the same, and to develop a plan \\nwith the patient/caregiver to address any of the barriers identified. These may include incorrect \\nknowledge of HIV infection and ART, unsupportive psychosocial factors, difficult home or school \\nenvironment, substance use and poor motivation for taking medication. Patients/caregivers ne ed \\nto be counselled on the importance of being honest about their adherence in order for the \\nhealthcare team to serve them better.  \\nAdherence monitoring requires a combination of interventions. At every clinical visit, the MMAS -\\n4 should be administered as w ell as pill counts. MMAS -8 should be administered any time a \\nhealthcare worker suspects adherence problem (e.g., patients with suspected or confirmed \\ntreatment failure; patient who misses an appointment).  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 123}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 21 Table 5.10: Adherence Monitoring Strategies  \\nAdher ence \\nMonitoring \\nStrategy  Technique  Frequency  \\nSubjective (self -reported adherence)  \\nMorisky \\nMedication \\nAdherence Scale -4 Use Table 5.11 to assess adherence using a \\nstandardized questionnaire, and take action \\nas required  Every patient, every visit  \\nMorisky \\nMedication \\nAdherence Scale -8 Use Table 5.12 to assess adherence using a \\nstandardized questionnaire, and take action \\nas required  Any time a healthcare worker \\nsuspects adherence problems \\n(e.g., patients with suspected or \\nconfirmed treatment failure; \\npatient who misses an \\nappointment)  \\nAdherence \\nMonitoring \\nStrategy  Technique  Frequency  \\nObjective  \\n \\n \\n \\nPill counts  Ask the patient to bring all their pills with \\nthem to follow -up visits. Calculate how many \\npills should be remaining based on the \\nprevious prescription date and amount \\nprescribed, and compare to how many pills \\nare actually remaining. Excess pills are \\nassumed to be missed doses. Use Table 5.13 to \\ncalculate adherence rate and take action as \\nrequired  ● At every visit until confirmed \\nviral suppression  \\n● Any time a healthcare worker \\nsuspects adherence problems  \\n \\nPharmacy refill \\nrecords  Compare drug pick -up date with expected \\ndate of pick -up (based on number of pills \\ndispensed at last visit). If drug pick -up date is \\nlater than expected, it is assumed the patient \\nis missing doses equivalent to the number of \\ndays late  ● At every drug pick -up \\n● Any time a healthcare worker \\nsuspects adherence problems  \\nViral load  Follow the viral load monitoring algorithm \\n(Figure 6.6). Undetectable VL is the best \\nconfirmation of adequate adherence  ● Age 0 -24 years: at 3 months after \\nART initiation and then every 6 \\nmonths  \\n● Age ≥ 25 years: at month 3 after \\nART initiation and month 12 \\nthen annually  \\n● For pregnant and breastfeeding \\nwomen: at fir st ANC visit if \\nalready on ART, or 3 months \\nafter ART initiation if starting \\nART during pregnancy, and then \\nevery 6 months  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 124}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 22 Table 5:10 Cont.  \\n \\n \\nHome visit  Observe where and how a patient stores and takes \\ntheir medications and assess if they have extra \\nmedications because of missed doses. Home visits \\nmay also provide a better understanding of a \\npatient’s living situation and specific barriers to \\nadherence. Unscheduled home visits may be more \\nrevealing, but should only be conducted if the  patient \\nconsente d to home visits previously (preferably at \\nthe time of enrolment or initiation)  For patients with suspected or \\nconfirmed treatment failure, \\npatients who default from care, \\nor any time the MDT feels a \\nhome visit will contribute to \\npatient management  \\n \\nAccurately assessing adherence requires clinicians to develop a collaborative and non -\\njudgmental relationship with patients.  This is best done when one provider follows an \\nindividual patient longitudinally. The key to asking patients about their adherence is not in the \\nspecifics of the tool used but in taking the time to ask about adherence regularly and doing so in \\nan open and truly inquisitive manner. Otherwise, many patients will simply state what they \\nbelieve the clinician wants to hear: perfe ct adherence.  \\nEvery provider in each ART service delivery point should receive training and gain confidence in \\nassessing adherence and providing adherence support and counselling to the majority of patients \\nwho do not have significant barriers to adherence . However, patients with significant adherence \\nchallenges and multiple barriers to adherence should be referred to providers with additional \\ntraining and time to offer dedicated and enhanced adherence support and counselling. Involving \\nexperienced colleagu es at the same health facility should be done as soon as a concern is \\nidentified, and the patient should be discussed by the MDT to generate as many solutions as \\npossible. Consultation with Mental Health Teams or regional or national mentors may be require d \\nfor complex situations.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 125}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 23 Table 5.11: Morisky Medication Adherence Scale (MMAS -4) \\nMMAS -4: Ask the patient each question below. Circle the corresponding score for each response. \\nAfter completion of all questions, add up all the points that you have circle d for the total score.  \\nQuestion  Yes No \\n1. Do you ever forget to take your medicine?  1 0 \\n2. Are you careless at times about taking your medicine?  1 0 \\n3. Sometimes if you feel worse when you take the medicine, do you stop taking it?  1 0 \\n4. When you feel better do you sometimes stop taking your medicine?  1  0 \\nTotal Score (sum of all items)   \\nInterpretation of MMAS -4 Score  \\nMMAS -4 \\nScore  Adherence \\nRating  Action Required  \\n0 Good  Continue with routine monitoring, counselling and support  \\n \\n \\n1-2  \\n \\nInadequate  ● Discuss as an MDT  \\n● Assign a case manager  \\n● Assess for and address barriers to adherence (Table 5.15)  \\n● Engage treatment supporter in adherence counselling sessions  \\n● Follow up in 2 -4 weeks  \\n \\n \\n3-4  \\n \\nPoor  ● Discuss as an MDT  \\n● Assign a case manager  \\n● Assess for and address barriers to adherence (Table 5.15)  \\n● Engage treatment supporter in adherence counselling sessions  \\n● Implement DOTs  \\n● Follow up in 1 -2 weeks  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 126}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 24 Table 5.12: Morisky Medication Adherence Scale (MMAS -8) \\nMMAS -8: Ask the patient each question below. Circle the corresponding score for each \\nresponse. After completion of all questions, add up all the points that you have circled for the \\ntotal score.  \\nQuestion  Yes No \\n1. Do you ever forget to take your medicine?  1 0 \\n2. Are you careless at times about taking your medicine?  1 0 \\n3. Sometimes if you feel worse when you take the medicine, do you stop taking it?  1 0 \\n4. When you feel better do you sometimes stop taking your medicine?  1 0 \\n5. Did you take your medicine yesterday?  0 1 \\n6. When you feel like your symptoms are under control, do you sometimes stop \\ntaking your medicine?   \\n1  \\n0 \\n7. Taking medication every day is a real inconvenience for some people. Do you ever \\nfeel under pressure about sticking to your treatment plan?   \\n1  \\n0 \\n8. How often do you have difficulty remembering to take all your medications? \\n(Please circle the correct number)  \\n  A. Never/Rarely  \\n  B. Once in a while  \\n  C. Sometimes  \\n  D. Usually  \\n  E. All the time  Points: A. 0  \\nB. ¼ C. ½ D. ¾ \\nE. 1 \\nTotal Score (sum of all items)  \\nInterpretation of MMAS -8 Score  \\nMMAS -8 Score  Adherence Rating  Action Required  \\n0 Good  Continue with routine monitoring, counselling and support  \\n \\n \\n1-2  \\n \\nInadequate  ● Discuss as an MDT  \\n● Assign a case manager  \\n● Assess for and address barriers to adherence (Table 5.15)  \\n● Engage treatment supporter in adherence counselling \\nsessions  \\n● Follow up in 2 -4 weeks  \\n \\n \\n \\n3-8  \\n \\n \\nPoor  ● Discuss as an MDT  \\n● Assign a case manager  \\n● Assess for and address barriers to adherence (Table 5.15)  \\n● Engage treatment supporter in adherence counselling \\nsessions  \\n● Implement DOTs  \\n● Follow up in 1 -2 weeks  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 127}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 25 Table 5.13: Adherence Rate Based on Pill Counts  \\nMissed Doses per Month  % Of \\nMedications \\nTaken  Adherence  \\nRating  Action Required (see Table 5.10 for \\nmore details)  For once -\\ndaily \\nregimen  For BD  \\nregimen  \\n1 dose  1-3 doses  ≥ 95%  Good  Continue with routine monitoring, \\ncounselling and support  \\n2-4 doses  4-8 doses  85-94%  Inadequate  ● Discuss as an MDT  \\n● Assign a case manager  \\n● Assess for and address barriers to \\nadherence (Table 5.15)  \\n● Engage treatment supporter in \\nadherence counselling sessions  \\n● Follow up in 2 -4 weeks  \\n≥ 5 doses  ≥ 9 doses  < 85%  Poor  ● Discuss as an MDT  \\n● Assign a case manager  \\n● Assess for and address barriers to \\nadherence (Table 5.15)  \\n● Engage treatment supporter in \\nadherence counselling sessions  \\n● Implement DOTs  \\n● Follow up in 1 -2 weeks  \\n \\n5.3.2 Adherence Counselling and Support During the First 3 Months of ART  \\nAll patients recently initiated on ART need careful adherence monitoring and support to \\nensure they achieve virological suppression.  This is particularly important in the context of \\nrapid ART initiation. The intensity of counselling and support are dependent on the patients’ level \\nof adherence as assessed by the methods described i n section 5.2.1.  \\nTable 5.14 summarizes adherence counselling and support for patients from the time of ART \\ninitiation until the 3 -month viral load results are available. For patients who have inadequate or \\npoor adherence, Table 5.15 describes the assessmen t for barriers to adherence.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 128}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 26 Table 5.14: Adherence Counselling and Support During the First 3 Months of ART  \\nNo adherence concerns (based on adherence assessment and healthcare team opinion)  \\nCounselling: Group or \\nIndividual, at every visit (can be \\ndone by any member of the \\nhealthcare team, including the \\nclinician)  ● Review patient/caregiver HIV knowledge (Table 5.2, Annex 8) \\nand address any gaps  \\n● Review patient/caregiver understanding of ART \\nadministration (dosing, timing, frequency) and address any \\ngaps  \\n● Elicit any concerns the patient/caregiver has about ART, other \\nmedications, visit schedule, or health. Address any concerns or \\nengage another care team member who can address them  \\n● Explore any major recent or expected changes in the \\npatient’s/caregiver ’s life or daily routine that could disrupt \\nadherence  \\n● Update patient locator and contact information  \\nSupport  ● Encourage the patient/caregiver to continue with the support \\nsystems discussed and implemented already  \\n● Encourage introduction of additional standard support \\nsystems (Table 5.3), including supporting disclosure as needed  \\nInadequate or poor adherence (based on adherence assessment or healthcare team opinion)  \\nCounselling: Individual, at \\nevery visit until adherence is \\ngood (preferably by someone \\ntrained on adherence \\ncounselling)  ● Assess for and address potential barriers to adherence \\n(Table  5.15)  \\n● Review patient/caregiver HIV knowledge (Table 5.2, Annex 8) \\nand address any gaps  \\n● Review patient/caregiver understanding of ART administration \\n(dosing, timing, frequency) and address any gaps  \\n● Elicit any concerns the patient/caregiver has about ART, other \\nmedications, visit schedule, or health. Address any concerns or \\nengage another care team member who can addr ess them  \\n● Explore any major recent or expected changes in the \\npatient’s/caregiver’s life or daily routine that could disrupt \\nadherence  \\n● Update patient locator and contact information  \\nSupport  ● Review effectiveness of support systems they already have in \\nplace  \\n● Encourage introduction of additional standard and enhanced \\nsupport systems (Table 5.3), including supporting disclosure as \\nneeded, assigning a case manager and considering DOTs  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 129}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 27 Table 5.15: Assessment for Barriers to Adherence  \\nTheme  Assessment  \\nAwareness of  \\nHIV status  ● Has the patient/caregiver accepted HIV status?  \\n● For children/adolescents: is age -appropriate disclosure underway/complete?  \\n \\n \\nUnderstanding  \\nof HIV infection \\nand ART  ● How HIV affects the body and risk of transmission to sexual partners and \\nchildren during pregnancy and breastfeeding  \\n● ART and how it works  \\n● Understanding of side effects and what to do in case of side effects  \\no “Have you experienced any side effect since your last visit? Has this \\naffected the way you take your medicine?”  \\n● Benefits of adherence  \\n● Consequences of non -adherence including drug resistance and treatment \\nfailure  \\n \\nDaily routine  ● Review the patient’s/caregiver’s daily routine: “Tell me about your typical day”  \\n● Review how the patient takes medicine or how the caregiver administers it  \\no “Please tell me how you take each of your medicines?”  \\no “How does taking your medicine fit into your daily routine?”  \\n● If the patient’s/caregiver’s daily routine conflicts with medication schedule, \\nwork with t hem to find a new medication schedule that will be more \\nappropriate  \\n● Remind the patient/caregiver to take/give missed or delayed doses as soon as \\nhe/she remembers (up to 12 hours late if on a once -daily regimen, or up to 6 \\nhours late if on a twice - daily re gimen). The next dose should be taken at the \\nusual time  \\n● “What do you do in case of visits or travel?”  \\n● Remind the patient/caregiver to plan travel well, pack sufficient medicine; but \\nshould their medication get finished before they return, advise them to vi sit the \\nclosest ART centre and show their appointment card to get a refill  \\n● For orphans it is critical to assess who the primary caregiver is and their \\ncommitment  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 130}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 28 Table 5.15 Cont.  \\n \\n \\nPsychosocial \\ncircumstance  Home environment:  \\n● “Who do you live with?”  \\n● “Who is aware of your HIV status? Are there people in your life with whom you’ve \\ndiscussed your HIV status and ART use?”  \\no Discuss the usefulness of enlisting the support of family members, friends \\nor a treatment supporter/buddy in reminding them to take medication (for \\nchildren/adolescents, this includes teachers and/or supportive peers at \\nschool); offer assisted disclosure  \\no Encourage the patient to identify and bring a treatment supporter during \\nthe next visit  \\n● Support system (treatment buddy, psychos ocial support groups, etc.)  \\n● Any recent losses, grief  \\n● Changes in relationships with family members/friends  \\n● Screen the patient/caregiver for alcohol and substance abuse (Tables 4.15 and \\n4.16)  \\no Discuss impact on ability to remember to take medication  \\no Explore m otivation to stop and offer support/referral  \\no Encourage limiting use and planning ahead so as not to forget to take \\nmedication  \\n● Screen for intimate partner violence (Section 4.2.1)  \\n● Stigma and discrimination  \\no “Does it bother you people might find out about your HIV status?”  \\no “Do you feel that people treat you differently when they know your HIV \\nstatus?”  \\n● Discuss if stigma is interfering with taking medication on time or with keeping \\nclinic appointments  \\n● Beliefs: has the patient tried faith healing? Has th e patient ever stopped using \\nmedication because of religious beliefs?  \\nMental Health  \\nScreening  ● Screen patient/caregiver for depression using the PHQ -9 (Table 4.14) and \\nmanage/refer as required  \\n● Screen for other psychiatric conditions such as anxiety, post -traumatic stress \\ndisorder or psychosis, or refer to a mental health worker for assessment  \\nReferrals  ● Establish if the patient has been referred to other services (including nutrition, \\npsychosocial support services, other medical clinics, substance use treatment, \\netc.)  \\n● Did he/she attend the appointments? What was his/her experience? Do the \\nreferrals need to be re -organized?  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 131}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 29 5.4 Adherence Monitoring, Counselling and Support for Patients with  \\nSuppressed Viral Load < 200 copies/ml  \\nOnce a patient has confirmed viral suppression (with VL < 50 copies/ml or below the Lower \\nDetection Limit (LDL)) this is confirmation of adequate adherence to ART. The patient can be \\nreassured that they will do well if they continue to adhere. Ho wever, all patients are at risk of new \\nor worsening barriers to adherence, so adherence monitoring, counselling and support should \\ncontinue despite viral suppression, but at a lower intensity and frequency unless concerns are \\nidentified (Table 5.16). These  patients should also be educated on and assessed for qualification \\nas “stable patient” services such as less frequent facility visits, fast -track or community -based ART \\ndistribution, etc. (Table 3.5).  \\nTable 5.16: Adherence Counselling and Support for Pati ents with Viral Load < 50 copies/ml  \\nNo adherence concerns (based on adherence assessment or healthcare team opinion)  \\nCounselling: Group or \\nindividual, every visit \\n(can be done by any \\nmember of the \\nhealthcare team, \\nincluding the clinician)  • Elicit any concerns the patient/caregiver has about ART, other \\nmedications, visit schedule, or health. Address any concerns or engage \\nanother care team member who can address them  \\n• Explore any major recent or expected changes in the \\npatient’s/caregiver’s life or daily  routine that could disrupt adherence  \\n• Update patient locator and contact information  \\nSupport  • Encourage the patient/caregiver to continue with the support systems \\nthat are in place already  \\nInadequate or poor adherence (based on adherence assessment or healthcare team opinion)  \\nCounselling: Individual, \\nat every visit until \\nadherence is good \\n(preferably by someone \\ntrained on adherence \\ncounselling)  • Assess for and address potential barriers to adherence (Table \\n5.15)  \\n• Review patient/caregiver HIV knowledge (Table 5.2, Annex 8) and \\naddress any gaps  \\n• Review patient/caregiver understanding of ART administration \\n(dosing, timing, frequency) and address any gaps  \\n• Elicit any concerns the patient/caregiver has about ART, other \\nmedicatio ns, visit schedule, or health. Address any concerns or engage \\nanother care team member who can address them  \\n• Explore any major recent or expected changes in the \\npatient’s/caregiver’s life or daily routine that could disrupt adherence  \\n• Update patient locator and contact information  \\nSupport  • Review effectiveness of support systems the patient already has in \\nplace  \\n• Encourage introduction of additional standard and enhanced support \\nsystems (Table 5.3), including supporting disclosure as needed, \\nassigning a case manager and considering DOTs  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 132}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 30 Table 5.17 Viral Load Monitoring Cut -Offs  \\nClinical \\nDefinition  Category  Lab Value  Interpretation  Guidance  \\n• Suppressed  • LDL  \\n \\n \\n• Low Risk \\nLLV  • <50 \\nCopies/ml  \\n \\n• 50 – 199 \\nCopies/ml.  • Treatment Goal  \\n \\n \\n• Stable Client, \\nUntransmissible  • Continue Management  \\n \\n \\n• Continue management, \\nremind client of \\ntreatment goal  \\n• Enroll  in DSD  \\n \\n• Unsuppressed  • High Risk \\nLLV  • 200 -199 \\nCopies/ml  • Increased risk \\nof progression \\nto treatment \\nfailure  • Step down from DSD, \\ninstitute EAC, repeat VL \\nafter 3 months of \\nexcellent adherence  \\n \\n• Suspected \\nTreatment \\nFailure  • ≥1000 \\nCopies/ml  • Client at \\nincreased risk \\nof morbidity \\nand mortality  • Enroll Client in \\nspecialized clinic if \\navailable  \\n• Conduct EAC  \\n• Refer to VL algorithm  \\n \\n \\n5.5 Adherence Monitoring, Counselling and Support for Patients with \\nUnsuppressed Viral Load ≥ 200 copies/ml  \\nTreatment failure should be suspected whenever a patient has been on ART for at least 3 months \\nand has: a viral load ≥ 200 copies/ml; a decline in CD4 count or; a ny new or worsening clinical \\ncondition. Treatment failure is confirmed as per the viral load monitoring algorithm (Figure 6.6). \\nPoor adherence is often the most important factor in developing treatment failure, though there \\ncan be other causes. Adherence m ust be thoroughly assessed and all issues must be addressed \\nbefore switching patients to the next line of ART. Do not change regimens until the reason/s \\nfor treatment failure have been identified and addressed, and a repeat VL is ≥ 1,000 \\ncopies/ml after 3 months of excellent adherence . For patients with high -risk  persistent low -\\nlevel viremia (VL 200 - 999 copies/ml after additional assessment and intervention), consult the \\nRegional or National HIV Clinical TWG (Uliza Hotline 0726 460 000; \\nhttps://nh csc.nascop.org/clinicalform ). \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 133}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 31 5.5.1 Enhanced Adherence Assessments  \\nAs soon as treatment failure is suspected the patient/caregiver should be discussed by the facility \\nmulti -disciplinary team to develop a plan for assessing barriers to adherence (includin g \\nscheduling a home visit), and assessing other potential causes of treatment failure (e.g., \\ninadequate dosing/dose adjustments, drug -drug interactions, drug -food interactions, impaired \\nabsorption e.g., chronic severe diarrhoea).  \\nAll patients with suspecte d or confirmed treatment failure should have a thorough assessment of \\npotential barriers to adherence (Table 5.15).  \\nIf the patient has a caregiver, treatment buddy, and/or spouse/partner who is enrolled in HIV \\ncare, that person’s file should also be review ed to confirm their most recent viral load results and \\nadherence.  \\n5.5.2 Enhanced Adherence Counselling  \\nAdherence assessment and enhanced adherence counselling should begin as soon as a detectable \\nviral load ( ≥ 200 copies/ml) is received, preferably within 2 weeks.  \\nThe goal of Enhanced Adherence Counselling is to assess possible barriers to adherence in a non -\\njudgmental way and to help the patient construct an adherence plan with concrete objectives. It \\nis important not to focus solely on k nowledge of HIV and ART but also to review psychological, \\nemotional, and socio -economic factors that may contribute to poor adherence. In addition, \\nexploring the patient’s motivation for taking medication often highlights reasons for poor \\nadherence.  \\nAt lea st three sessions of Enhanced Adherence Counselling, spaced 2 -4 weeks apart, are \\nrecommended as the minimum number of sessions, but additional sessions can be added as \\nneeded (Table 5.1 8). If the adherence is evaluated as adequate, a repeat viral load is d one after \\nthree months of excellent adherence, and another Enhanced Adherence Counselling session is \\nconducted to discuss the viral load results. A detailed content guide for Enhanced Adherence \\nCounselling is provided in Annex 9.  \\nIt is preferable to have t he patient go through all adherence counselling sessions with the same \\ncounsellor in order to provide continuity, and that the session is documented to ensure follow -up \\nof all issues identified.  \\nIf adequate adherence cannot be achieved then consult with a senior clinician, discuss as an MDT, \\nor consult the Regional or National TWG.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 134}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 32 Table 5.1 8: Components of Enhanced Adherence Counselling Sessions (Annex 9A for detailed \\ncontent guide)  \\nEnhanced Adherence Counselling Sessions: Overview  \\n \\nSession 1  • Review understanding of viral load (VL) and discuss why the patient’s VL is \\nhigh  \\n• Review common cognitive, behavioral, emotional and socio -economic barriers \\nto adherence  \\no Stigma and non -disclosure  \\no Loss or grief  \\no Treatment literacy  \\no Medications: dosage, timing, storage  \\no Side effects  \\no Discuss risk reduction (e.g., for substance abuse)  \\no Motivation  \\no Mental health screening (screen for depression using PHQ -9, Table 4.14)  \\no Discuss patient’s support systems  \\n● Assist patient to develop adherence plan to address the ide ntified issues  \\n \\nSession 2  ● Review adherence plan from the first session and discuss any challenges  \\n● Identify other possible gaps and issues emerging  \\n● Assist patient to modify the adherence plan to address the identified issues  \\n \\n \\nSession 3  ● Review adherence plan from the first and second session and discuss any \\nchallenges  \\n● Identify other possible gaps and issues emerging  \\n● Assist patient to modify the adherence plan to address the identified issues  \\n● Decision on repeat VL based on current adherence  \\no If the adherence is good: plan repeat VL testing after three months of good \\nadherence and explain possible ways forward, emphasizing role of the \\npatient and the health facility  \\no If adherence challenges persist: consult with a senior clinician, discuss as \\nan MD T, or consult the Regional or National TWG before repeating the VL  \\n \\nSession to \\nDiscuss \\nRepeat Viral \\nLoad Results  ● Discuss result of the second VL test  \\n● Plan the way forward:  \\no If VL now < 200 copies/ml: continue current regimen with ongoing \\nenhanced adherence; repeat VL after 6 months  \\no If VL ≥ 1,000: prepare patient for change of regimen (Figure 5.2)  \\no If VL is 200 -999 copies/ml: perform another assessment for causes for \\nviremia and address any issues identified; repeat viral load after an \\nadditional 3 months of excellent adherence  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 135}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 33 Table 5.1 8 Cont.  \\nOther Enhanced Adherence Support Interventions (for patients failing or at high -risk of failing \\ntreatment)  \\nCase \\nmanagement  • Assign a case manager to all children and adolescents (those not achieving \\noptimum treatment outcomes); pregnant women, orphans, patients with alcohol \\nand substance abuse, patients with mental illness, patients with suspected or \\nconfirmed treatment failure, and any patients who the healthcare team feels has \\npoor adheren ce or is at high risk of defaulting from care  \\n• The case manager is the link between the patient and the MDT  \\n• Roles  of the case managers include:  \\no Coordinating multidisciplinary management for patients under case \\nmanagement  \\no Following up on appointment -keeping for their patients  \\no Organizing patient reminders (SMS, calling the day before) and other support \\nsystems  \\no Ensuring appropriate defaulter tracing  \\no Coordinating home visits to their patients  \\nDirectly \\nobserved \\ntherapy  • Patients with suspected treatment failure should have DOTs to ensure good \\nadherence before a viral load is repeated to confirm treatment failure  \\n• DOTs involve a healthcare provider, family member, treatment supporter or any \\ntrained peer observing the patient ingesting th eir prescribed ART on a daily basis  \\n• DOTs can be tapered off once the patient adopts consistent adherence -enhancing \\nbehaviours  and barriers to adherence are overcome  \\nHome visits  • Observe where and how a patient stores and takes their medications, and assess if \\nthey have extra medications because of missed doses  \\n• Home visits may also provide a better understanding of a patient’s living situation \\nand specific barriers to adherence  \\n• Unscheduled home visits may be more revealing, but should only be conducted if \\nthe patient consented to home visits previously (preferably at the time of enrolment  \\nor initiation)  \\nMonthly “high \\nviral load” \\nclinics  • Patients with suspected treatment failure should be booked for dedicated monthly \\nhigh viral load clinics  \\n• Children and adolescents in school who are unable to attend clinic monthly may \\nattend dedicated monthly clinics during mid -term and school holidays (at least \\nevery 6 weeks)  \\n• Comprehensive clinical and psychosocial evaluation should be conducted at e ach \\nvisit, appropriate investigations done and any opportunistic infections treated  \\n• Enhanced adherence counseling sessions should be conducted at each visit  \\n• Support groups for patients with viremia can be timed with “high viral load” clinic \\ndays  \\nSpecial \\nsupport \\ngroups  • For health facilities with several patients who are failing treatment or who are on \\n2nd line ART, special support groups can be established so these patients can work \\nthrough their adherence challenges together  \\n• Community support groups can also be engaged and linked to the facility for \\nsupporting patients with adherence challenges  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 136}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 34 Adherence support systems will need to be adapted to patients’ specific needs and the context \\n(Table 5.1 8). Special attention needs to be given to children, a dolescents, pregnant and \\nbreastfeeding women, patients with mental health disorders and substance users.  \\n5.6 Treatment Preparation for 2nd Line or 3rd Line ART  \\nAfter confirming treatment failure and making the decision to start 2nd line or 3rd line ART (ba sed \\non discussion as an MDT, and in consultation with the Regional or National HIV Clinical TWG), the \\npatient requires targeted counselling and education to prepare them for the new regimen and to \\nsupport ongoing adherence (Figure 5.2).  \\nReview patient file\\nAssess patient  s \\nknowledge and \\nunderstanding\\nProvide patient education\\nConstruct adherence plan\\nEnsure monthly \\ncounselling follow -up \\nsessionsEnsure a monthly follow -up counselling session during \\nclinic visits for the first 6months after initiating the new \\nregimen\\n• Follow up on problems identified during the previous \\nsessions\\n• Assess patient  s adherence and explore any reasons for \\npoor adherence. Identify strategies to overcome these \\nbarriers\\nRepeat VL after 3 months on new regimen\\n• If VL undetectable: adherence counselling every \\n3months\\n• If VL is detectable: discuss as MDT and consult Clinical \\nTWG• Confirm patient  s willingness to start new regimen\\n• Ensure that the patient understands the treatment plan \\n(drug regimen, dosing schedule, dietary restrictions, \\npotential side effects, what to do when missing doses or \\nexperiencing side effects)\\n• Prepare for situations that could impair good \\nadherence, and encourage disclosure of poor adherence\\n• Plan sessions with the pharmacist on medication \\nadherence, and nutritionist on nutritional aspects• Strengthen key messages on HIV and viral load\\n• Provide information on 2nd/3rd line ART: more complex \\nto take (more pills, twice -a-day dosing), very limited \\noptions if this fails\\n• Provide simple take -home IEC materials on 2nd  or 3rd  \\nline ART management• HIV, viral load and ART\\n• The importance of good adherence and potential \\nproblems of non -adherence\\n• Reasons for switching to 2nd or 3rd line ART: treatment \\nfailure with repeated high viral load• Review the patient file and all problems identified \\nduring Enhanced Adherence Counselling sessions\\n• Confirm all the barriers to adherence have been \\naddressed during Enhanced Adherence Counselling, if \\nnot – address remaining barriers before considering \\nchanging regimens\\n \\n \\nFigure 5.2: Adherence Counselling and Education for Patients Preparing to Initiate 2nd Line or \\n3rd Line ART  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 137}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 35 5.7 Identifying, Tracing, and Supporting Patients who Default from Care  \\nEvery service delivery point that is providing ARVs for patients (whether ART, PEP, or PrEP) must \\nhave a functional system for identifying patients who miss appointments and for taking action \\nwithin 24 hours of a missed appointment (Figure 5.3).  \\nEnter date of next appointment/TCA for each patient into the \\nappointment diary\\n• As patients arrive at the service delivery point their name should be \\nchecked off in the appointment diary for that day\\n• All patients who had appointments booked for the day but did not \\nattend clinic should be recorded in the patient follow -up register\\n• Patient/caregiver should be called within 24 hours of missed \\nappointment\\n• If no response, treatment buddy should be called\\n• Several attempts at phone tracing should be made if no response \\ninitially\\n• Update the patient follow -up register with phone call findings\\nPatient does not return \\nwithin time agreed upon \\nduring phone call, but still \\nable to reach by phonePatient returns to clinic \\nwithin 7 days, or returns \\non date agreed during \\nphone callUnable to reach by phone, \\nand does not return to \\nclinic within 7 daysPatient dead, transferred \\nout, or declines further \\ncontact: update patient \\nrecords/ registers with \\noutcome\\nReturns to clinic\\n• Assess for and address potential barriers to adherence \\n(Table 5.14) \\n• Review patient/caregiver HIV knowledge (Table 5.1, \\nAnnex 6) and address any gaps\\n• Elicit any concerns the patient/caregiver has about ART, \\nother medications, visit schedule, or health. Address any \\nconcerns or engage another care team member who can \\naddress them\\n• Explore any major recent or expected changes in the \\npatient s/caregiver  s life or daily routine that could disrupt \\nadherence\\n• Review effectiveness of facility and community support \\nsystems the patient already has in place\\n• Encourage introduction of additional standard  and \\nenhanced support systems (Table 5.2), including \\nsupporting disclosure as needed, assigning a case manager \\nand considering DOTs\\n• Review ART Readiness Assessment Form for re -initiation \\nof ART• Prioritized home visit, based on\\no Patient type (pregnant and \\nbreastfeeding women, child, co -\\nmorbidity)\\no Proximity to clinic\\n• Complete the home visit form\\n• Update the patient follow -up register with \\nhome visit findings\\n• Update appointment diary if agrees to \\nreturn to clinic\\nUnable to trace or does not return to clinic on \\nscheduled appointment date\\n• Discuss as MDT and develop follow -up/ \\nmanagement plan\\n• Update patient records/registers with \\noutcome\\n \\nFigure 5.3: Ident ifying, Tracing and Supporting Patients who Default from Care  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 138}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 36  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 139}),\n",
       " Document(page_content='  \\nAntiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 1  \\n6. Antiretroviral Therapy in Infants, Children, \\nAdolescents, and Adults  \\nART, while very effective in managing HIV disease, does not cure HIV infection. The goal of ART is \\nto suppress viral replication with the aim of reducing the  patient’s VL to undetectable levels. \\nUninterrupted ART with ongoing strict adherence will help maintain undetectable VL levels \\nthereby preventing damage to the body’s immune system, reducing AIDS -related morbidity and \\nmortality and the risk of sexual and vertical transmission of HIV.  \\n6.1 Eligibility for ART  \\nAll individuals with confirmed HIV infection are eligible for ART irrespective of CD4 \\ncount, WHO clinical stage, age, pregnancy or breastfeeding status, co -infection status, \\nrisk group, or any other cri teria.  \\n6.2 Timing of ART Initiation  \\nART should be started in all patients as soon as possible, preferably within 2 weeks of \\nconfirmation of HIV status, and even on the same day as testing positive for HIV if they are ready.  \\nART Readiness Criteria (Table 5.4) can be used to help determine any issues that need to be \\naddressed around the time of ART initiation. Same -day ART initiation (on the same day as testing \\nHIV-positive) has additional benefits for HIV prevention (e.g., for pregnant and breastfee ding \\nwomen, and the HIV positive partner in a discordant relationship), and is associated with \\nimproved retention, viral suppression, and survival. Special considerations for timing of ART \\ninitiation are listed in Table 6.1.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 140}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 2 Table 6.1: Special Considerat ions for Timing of ART Initiation  \\nPopulation  Timing of ART Initiation  Additional Notes  \\nPregnant and \\nbreastfeeding \\nwomen  Support ART initiation on the \\nsame day as testing positive for \\nHIV Intensive adherence counselling, \\nsupport and close follow -up \\nrequired because of limited time for \\npatient preparation  \\nInfants (< 12 months \\nold)  Support ART initiation on the \\nsame day as testing positive for \\nHIV. Treatment should \\ncommence following a first \\npositive PCR test. ALWAYS take a \\nsample for a confirmatory PCR \\ntest as soon as the first positive \\nPCR result is received, but do not \\ndelay ART initiation for the \\nsecond PCR result  Intensive adherence counselling, \\nsupport and close follow -up \\nrequired because of limited time for \\ncaregiver preparation  \\nPatients with strong \\nmotivation to start \\nART immediately  Support ART initiation as soon as \\nthe patient feels ready, preferably \\non the same day as testing \\npositive for HIV  Intensive adherence counselling, \\nsupport and close follow -up \\nrequired because of limited time for \\npatient preparation  \\nPatients with newly \\ndiagnosed TB  Start anti -TB treatment \\nimmediately and initiate ART as \\nsoon as anti -TB medications are \\ntolerated, preferably within 2 \\nweeks. For TB meningitis delay \\nART for 4 to 8 weeks  Monitor closely for IRIS (Annex 16)  \\nPatients with \\ncryptococcal \\nmeningitis  Defer ART until after completing \\n5 weeks of CM treatment  Monitor closely for IRIS (Annex 16)  \\n \\nPatients for whom \\nadherence will be \\nparticularly \\nchallenging  Start ART as soon as possible \\nwhile implementing additional \\nsupport systems (e.g., optional \\nenrolment of a PWID into a MAT \\nprogram; psychiatric treatment \\nfor a patient with mental illness; \\nenrolment into an OVC program \\nfor orphans etc.)  A case manager should be assigned \\nto all patients with complex \\nadherence challenges  \\nAll other patients  Start ART as soon as possible, \\npreferably within 2 weeks, \\nand even on the same day as \\ntesting positive for HIV if they \\nare ready  Continued adherence monitoring \\nand support is recommended after \\nART initiation for all patients  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 141}),\n",
       " Document(page_content='  \\nAntiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 3 6.3 First -Line ART for Infants, Children, Adolescents and Adults (including \\nPregnant and Breastfeeding Women)  \\nThe recommendations below apply to patients who are starting ART for the first time. Preferred \\nand alternative first line regimens are shown in Tables  6.2 and 6.3. ARVs for infant prophylaxis \\nare presented in the PMTCT chapter in Tables 7.3 to 7.6.  \\nAll patients must have their weight documented at every visit. Children and adolescents \\nless than 15 years must have correct weight -based dosing of ARVs conf irmed at every visit.  \\nInfants and children depend on their caregivers for adherence to medication. Caregivers should \\nbe adequately prepared for their role of administering ARVs to infants and children, including \\naddressing anticipated challenges such as dr ug palatability. It can be helpful for more than one \\ncaregiver to be informed about a child’s HIV status and receive instruction on administration of \\nART.  \\nCaregivers should always be shown and then asked to demonstrate how to measure and \\nadminister ARVs.  This should be done both at the time of prescribing the ART (by the clinician) \\nand at the time of dispensing the ART. Clinicians should ensure that the caregiver accompanying \\na child for clinical review is the same caregiver responsible for day -to-day ART a dministration.  \\nTable 6.2: Preferred First -line ART Regimens and Dosing for Children, Adolescents and \\nAdults 1 \\nAge  Weight  Preferred \\nRegimen  Dosing2 (correct weight -based dosing must \\nbe confirmed at every visit)  \\nBirth to 4 \\nweeks  Any  AZT + 3TC + NVP3 Refer to Annex 10 for weight -based dosing  \\n> 4 weeks to \\n< 15 years  < 30 kg  ABC + 3TC + DTG4 Refer to Annex 10 for weight -based dosing  \\n≥ 30 kg  TDF + 3TC + \\nDTG5,6 TDF/3TC/DTG (300/300/50mg): 1 tab once \\ndaily  \\n≥ 15 years  Any  TDF + 3TC + \\nDTG5,6 TDF/3TC/DTG (300/300/50mg): 1 tab once \\ndaily  \\n1 Patients currently on first -line regimens that are not included in the indicated preferred (Table 6.2) \\nor alternative (Table 6.3) regimens should be considered for regimen optimization as per Section \\n6.5.1  \\n2 See Annex 10 for weight -based dosing of all single -drug and fixed -dose combination formulations  \\n3 Infants who initiate ART at less than 4 weeks of age should initiate on AZT+3TC+NVP irrespective of \\nprevious ART exposure; metabolism of other ARVs is not well known for this age group. As soon as \\nthese infants become 4 weeks old, they should switch to ABC/3TC+DTG (dosing included in Annex \\n10). Consult the Regional or National HIV Clinical TWG (Uliza Hotline 0726 460 000, \\nulizanascop@gmail.com) in case of pre -term infants  \\n4 Once adolescents reach 30 kg, if virally suppressed they should be considered for transition as per \\nFigure 6.2  \\n5 TAF may become the preferred NRTI once fixed -dose combinations are available  \\n6 DTG/3TC dual therapy may be considered for HBV -negative pa tients once fixed -dose combinations \\nare available  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 142}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 4 Table 6.3: Use of Alternative ARVs in First -Line Regimens 1 \\nAge  Weight  Scenario and ARV \\nAffected  Alternative ARV to Use  \\nBirth to 4 \\nweeks   \\nAny  NVP: Develops \\nhypersensitivity reaction  Use RAL granules or LPV/r granules \\n(over 2 weeks of age) or defer ART until \\n4 weeks of age, then start ABC+3TC+DTG  \\nAZT: Infant Hb < 9.5 g/dL  Defer ART until 4 weeks of age, then \\nstart ABC+3TC+DTG  \\n> 4 weeks \\nto < 15 \\nyears   \\n \\n< 30 kg  ABC: Develops ABC \\nhypersensitivity reaction2 Use AZT (if Hb ≥ 9.5 g/dL); if Hb < 9.5 \\ng/dL consults Regional or National HIV \\nClinical TWG (call Uliza Hotline 0726 \\n460 000; ulizanascop@gmail.com)  \\nDTG: Unable to tolerate  Use LPV/r at standard weight -based BD \\ndosing, if 4-in-1 available this is \\npreferred  \\nDTG: Currently on \\nrifampicin -containing \\nanti -TB \\nmedications  Increase DTG dosing frequency to twice \\ndaily for duration of rifampicin -\\ncontaining TB treatment and for an \\nadditional 2 weeks after TB treatment is \\ncompleted, then revert to once daily \\ndosing3 \\n \\n \\n \\n≥ 30 kg  \\n \\n TDF: Impaired renal \\nfunction (CrCl ≤ 50 \\nml/min)  Use ABC4,5 or TAF (once available)  \\nDTG: Unable to tolerate  Use EFV (for PWID use ATV/r)  \\nDTG: Currently on \\nrifampicin -containing \\nanti -TB \\nmedications  Give TDF/3TC/DTG FDC morning + DTG \\n50mg evening for duration of rifampicin -\\ncontaining TB treatment and for an \\nadditional 2 weeks after TB treatment is \\ncompleted, then revert to TDF/3TC/DTG \\nFDC OD 3 \\n≥ 15 years  Any  TDF: Impaired renal \\nfunction (CrCl ≤ 50 \\nml/min)  Use ABC4,5 or TAF (once available)  \\nDTG: Unable to tolerate  Use EFV (for PWID use ATV/r)  \\nDTG: Currently on \\nrifampicin -containing \\nanti -TB \\nmedications  Give TDF/3TC/DTG FDC morning + DTG \\n50mg evening for duration of rifampicin -\\ncontaining TB treatment and for an \\nadditional 2 weeks after TB treatment is \\ncompleted, then revert to TDF/3TC/DTG \\nFDC OD 3 \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 143}),\n",
       " Document(page_content='  \\nAntiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 5 Table 6.3 Cont.  \\n1 For other scenarios that are not covered in this table, discuss as an MDT and consult the Regional or \\nNational HIV Clinical TWG (Uliza Hotline 0726 460 000; https://nhcsc.nascop.org/clinicalform ) \\n2 ABC hypersensitivity reaction (AHR) is rare in the Kenyan population. Table 6.9 provides the \\ndefinition and management of AHR  \\n3 The additional 2 weeks of higher -dose DTG is to counter the ongoing liver enzyme induction effect \\nof rifampicin, which continues for a short period after TB treatment is completed  \\n4 TAF may become the preferred NRTI once fixed -dose combinations are available  \\n5 DTG/3TC dual therapy may be considered for HBV -negative patients once fixed -dose combinations \\nare available  \\n6.4 Dosing and Administration of Dolutegravir (DTG)  \\nDTG is preferred in first line ART (in combination with other ARVs) for children, adolescents and \\nadults. DTG is well tolerated, highly efficacious, has a high genetic barrier to resistance and fewer \\ndrug -drug interactions.  \\nTable 6.4: Dosing and Administration of  Dolutegravir  \\nRecommended Dosing of DTG  \\n● < 20 kg body weight: Use weight -based dosing with dispersible 10mg DTG tablets as per Annex 10  \\n● ≥ 20 kg body weight: DTG 50 mg film -coated tablet once daily, preferably as a morning dose. It is also \\navailable as part of FDC. Those unable to swallow the film coated tablets whole refer to Annex 10  \\n● For patients taking rifampicin: Increase DTG dosing frequency to twice daily for duration of \\nrifampicin -containing TB treatment and for an additional 2 weeks after TB treatment is completed, \\nthen revert to once daily. (The additional 2 weeks of higher -dose DTG is to counter the ongoing liver \\nenzyme induction effect of rifampicin, which continues for a short period after TB treatment is \\ncompleted)  \\n● For patients w ith suspected or confirmed INSTI resistance (e.g., patients with prior history of failing a \\nRAL -based regimen): use DTG twice daily  \\n● DTG can be taken with or without food  \\nCommon Side Effects of DTG  \\n● The most common side effects of DTG are headache, nausea and diarrhea. These side effects usually \\nresolve after continued use for 1 -2 weeks. It is critical to inform patients / caregivers about these \\npotential side effects and their temporary nature, and encourage them to continue their ART and \\nconsult a HCW if concerned.  \\n● Some patients on DTG are more likely to develop insomnia. This may be reduced by taking DTG as a \\nmorning dose, or by taking DTG with a low -fat meal or on an empty stomach.  \\n● DTG may cause a small rise in serum creatinine levels bu t this does NOT represent a true decline in \\nrenal function.  \\n● Integrase inhibitors, including DTG, are associated with increased weight gain. Counsel patients about \\nhealthy eating and physical activity and the benefits of maintaining a healthy weight.  \\n● All ad verse events should be reported through the national pharmacovigilance mechanism. \\n(http://www.pv.pharmacyboardkenya.org/ ) ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 144}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 6 Table 6.4 Cont.  \\nPregnancy Safety of DTG  \\n● DTG is safe during pregnancy and breastfeeding. Pregnancy intention should be discussed with all \\nwomen initiating ART regardless of regimen. Women who do not wish to become pregnant should be \\noffered appropriate family planning counseling and methods.  \\nImportant Drug Interactions with DTG  \\n● Rifampicin  \\no Rifampicin lowers DTG levels: increase DTG to 50 mg twice daily for patients on rifampicin who \\nare > 20 kg in body weight. Children <20 kg taking DTG who require rifampicin should increase \\ntheir weight -appropriate DTG dose to twice daily.  \\no There are no significant drug interactions between DTG and other currently used anti -TB \\nmedications (including for MDR -TB) \\n● Mineral supplements, including: antacids containing calcium, zinc, magnesium or aluminum; iron \\nsupplements; prenatal vitamins (which contain iron and calcium)  \\no These supplements decrease the absorption of DTG: administer DTG at least 2 hours before or 6 \\nhours after taking any of these supplements  \\no Dose separation is not required for calcium and iron supplements (including prenatal vitamins) if \\nDTG is taken with a meal  \\no It is critical to educate patients about this important drug interact ion because many patients get \\nthese supplements and antacids over -the-counter without informing their healthcare provider  \\n● Carbamazepine, phenobarbital, phenytoin  \\no These anticonvulsants decrease DTG levels: use a different anticonvulsant if available  \\no If DTG must be co -administered with these drugs then increase to DTG to twice daily, although \\nthere is little data to guide this  \\no If valproic acid is available this can be used with DTG without dose adjustment  \\n● Metformin  \\no DTG increases levels of metformin; the levels of DTG are not affected: use a lower dose of \\nmetformin (often 50% of usual dose) and monitor glycemic control. Use a maximum daily dose of \\nmetformin 1 g  \\n● Other drug -drug interactions with DTG  \\no See Annex 13C  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 145}),\n",
       " Document(page_content='  \\nAntiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 7 6.5 Monitoring and Changing ART  \\nThe objectives of clinical and laboratory monitoring during ART are to identify and treat inter -\\ncurrent illnesses, assess for and manage adverse drug reactions, and evaluate response to \\ntreatment. Routine laboratory monitoring recommendations are described in Table 3.5; however, \\nadditional investigations should be ordered whenever there is clinical suspicion for which a \\nlaboratory test result may alter patient management.  \\nIndications for changing ART include optimizing therapy for patients who have undetectable viral \\nload, managing adverse drug reactions or toxicity, drug -drug interactions, co -morbidities and \\ntreatment failure.  \\n6.5.1 Optimizing Therapy for Patients who have suppressed viral load on First Line \\nART  \\nPatients who are virally suppressed o n first line ART may benefit from regimen optimization even \\nif they are currently tolerating their regimen well and have no drug -drug interactions requiring a \\nchange. Regimen modifications may be done for age/weight transitions among children and \\nadolescen ts <15 years and to simplify a regimen, prevent long -term toxicity and improve cost -\\neffectiveness. Dolutegravir has been shown to have superior tolerability and efficacy compared to \\nefavirenz and lopinavir and is now preferred as part of first line ART for  children, adolescents and \\nadults. While most adults in Kenya have switched over to a DTG -containing regimen, proactive \\nswitching of children is now also recommended with the availability of a pediatric dispersible \\ndolutegravir tablet.  \\nChildren and adolesc ents with suppressed viral load on first line ART and not on the \\nrecommended first line regimen as per Table 6.2 should be considered for optimization as \\nper Figures 6.1 and 6.2, such as when children grow and enter a new weight band.  This also \\nincludes PL HIV who recently initiated non -standard therapy (less than 3 months ago, before the \\nfirst VL is due). Decisions on regimen modification should be made following discussion with the \\npatient/caregiver.  \\nAlways discuss the possibility of new side effects when changing to a new ARV,  particularly \\nside effects common to all ARVs (headache, nausea, diarrhea) and any side effects specific to the \\nnew ARV. Reassure patients that most side effects resolve with continued use after 1 -2 weeks.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 146}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 8 \\nChildren weighing < 30  kg on a first line ART regimen OTHER than ABC/3TC + DTG\\nVL within last 6 months < \\n200 copies/ml (LDL)\\nNo VL result within last 6 \\nmonths\\nVL within last 6 months   \\n200 copies/ml\\nCollect sample for VL\\nVL   200 copies/ml\\n• Switch to ABC/3TC + DTG using the \\nweight -based dosing from Annex 10A -B\\n• Schedule clinical appointment at 2 weeks \\nafter regimen change to review \\nadherence, side effects and any other \\nconcerns\\n• Repeat VL 3 months after regimen \\nmodification followed by routine viral \\nload monitoring\\n• Switch regimen while assessing for reasons for viremia and \\nproviding enhanced adherence counselling\\n• If current regimen contains ABC: Switch to \\nAZT/3TC + DTG\\n• If current regimen contains AZT: Switch to \\nABC/3TC + DTG\\n• Use the weight -based dosing from Annex 10A -B\\n• For all patients on PI/r or DTG containing regimens: \\nsummarize case for TWG and take sample for DRT  – do not \\nwait for DRT results for making the regimen modification\\n• Schedule clinical appointment at 2 weeks after regimen \\nchange to review adherence, side effects and any other \\nconcerns\\n• Repeat VL 3 months after regimen modification\\n• If VL still   200  copies/ml then consult the \\nregional or national TWG\\n• If VL now < 200  copies/ml then continue routine \\nviral load monitoring\\nOn ART for < 3 months\\n On ART for     months\\nVL < 200 copies/ml  (LDL) \\nFigure 6.1: Optimizing ART Regimens for Children and adolescents <15 years Weighing < 30 kg \\non First Line ART  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 147}),\n",
       " Document(page_content='  \\nAntiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 9 \\nChildren and adolescents weighing      kg or       years old on a first line ART regimen OTHER \\nthan TDF/3TC/DTG\\nVL within last 6 months \\n< 200 copies/ml (LDL)\\nNo VL result within last 6 \\nmonths\\nVL within last 6 months   \\n200  copies/ml\\nCollect sample for VL\\nVL       copies/ml\\n• Switch to TDF/3TC/DTG (300/300/\\n50mg) 1 tab once daily\\n• Schedule clinical appointment at 2 weeks \\nafter regimen change to review \\nadherence, side effects and any other \\nconcerns\\n• Repeat VL 3 months after regimen \\nmodification followed by routine viral \\nload monitoring\\n• Switch regimen while assessing for reasons for viremia \\nand providing enhanced adherence counselling\\n• Switch to TDF/3TC/DTG (300/300/50mg) 1 tab once \\ndaily\\n• For all patients on PI/r or DTG containing regimens: \\nsummarize case for TWG and take sample for DRT  – do \\nnot wait for DRT results for making the regimen \\nmodification\\n• Schedule clinical appointment at 2 weeks after regimen \\nchange to review adherence, side effects and any other \\nconcerns\\n• Repeat VL 3 months after regimen modification\\n• If VL still       copies/ml then consult the \\nregional or national TWG\\n• If VL now < 200 copies/ml then continue routine \\nviral load monitoring\\nOn ART for < 3 months\\n On ART for     months\\nVL < 200 copies/ml (LDL) \\nFigure 6.2: Optimizing ART Regimens for Children and Adolescents Weighing ≥ 30 kg or ≥ 15 years \\nold on First Line ART  \\n6.5.2 Changing ARVs Due to Adverse Drug Reactions  \\nPatients starting ART should be educated on the potential side effects of ART and all ot her \\nprescribed medication.  ADRs can have a significant impact on patient adherence and must be \\nidentified early and managed aggressively. All ADRs should be reported to the Pharmacy and \\nPoisons Board using existing pharmacovigilance tools \\n(http://www.pv.pharmacyboardkenya.org/ ). Pharmacovigilance is particularly important for \\nmonitoring ADRs associated with any new ARVs that enter the national supply chain, as rare \\nADRs may appear in routine care, whi ch were not observed in the highly selected patients \\nparticipating in clinical trials.  \\nThe most common significant ADRs associated with ARVs that may require a drug substitution \\nare summarized in Table 6.5. General principles for managing ADRs are outlined  in Figure 6.3. \\nManaging specific ADRs is described in Tables 6.6 to 6.9.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 148}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 10  Table 6.5: Common Significant Adverse Drug Reactions  \\nARV \\nAgent   Adverse Drug Reaction   High Risk Situations/Comments  \\n NRTIs  \\n  ABC  ABC hypersensitivity \\nreaction (see Table 6.9)  Do not re -challenge  \\n \\n \\n \\nAZT  Anaemia, neutropenia  \\n(See Table 6.7)  Risk factors: CD4 count < 200 cells/mm3; BMI < 18.5 (or \\nbody weight < 50 kg); anaemia at baseline; concurrent use \\nof other drugs with similar ADR (cotrimoxazole, \\ngancyclovir, ribavirin)  \\nLactic acidosis  Risk factors: Pregnancy; obesity  \\nLipoatrophy  Risk factors: Low CD4 count  \\nTDF  Renal dysfunction  \\n(See Figure 6.5)  Risk factors: Underlying renal disease; age > 60 years; BMI \\n< 18.5 (or body weight < 50 kg); diabetes; hypertension; \\nconcomitant PI use or nephrotoxic drug  \\nAvoid in patients with CrCl< 50ml/minute unless no \\nsuitable alternative such as required to treat HIV/HBV co -\\ninfection if TAF is not available  \\nTAF  Weight gain  Risk factors: women; concomitant use of INSTIs  \\nProvide advice on healthy eating and physical activity to \\nmaintain a healthy weight (Table 4.9)  \\nNNRTIs  \\nAll \\nNNRTIs  Rash  \\n(NVP>>EFV>ETR)  Manage rash as per Table 4.4 \\n \\nEFV  CNS side -effects  Risk factors: Pre -existing psychiatric disorder  \\nGynaecomastia  Switch from EFV to an alternative, and consult if \\ngynecomastia does not improve  \\nNVP  Hepatotoxicity  \\n(See Table 6.8)  N/A.  \\nPIs \\nAll PIs \\nboosted \\nwith  \\nRTV  GI intolerance \\n(LPV/r>DRV/r>ATV/r)  Consult for recommendation on alternative regimen (R -\\nTWG or Uliza Hotline 0726 460 000, \\nhttps://nhcsc.nascop.org/clinicalform ) \\nDyslipidaemia \\n(LPV/r>DRV/r>ATV/r)  Risk factors: Obesity; sedentary lifestyle; diet high in \\nsaturated fats and cholesterol  \\nATV/r  Hyperbilirubinemia  This only requires drug substitution if cosmetic effect of \\njaundice is likely to interfere with patient adherence  \\nDRV/r  Rash/hypersensitivity  Risk factors: sulfa allergy  \\nINSTIs  \\nAll \\nINSTIs  Weight gain  Risk factors: women; concomitant use of TAF  \\nProvide advice on healthy eating and physical activity to \\nmaintain a healthy weight  \\nRash/hypersensitivity  Consult (Uliza Hotline 0726 460 000, \\nhttps://nhcsc.nascop.org/clinicalform ) \\n DTG   Insomnia   Give in the morning; if no improvement then try giving \\nwith low fat meal or on empty stomach  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 149}),\n",
       " Document(page_content='  \\nAntiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 11  \\nAlternative explanations for toxicity must be excluded before concluding a reaction is secondary to an ARV.\\nConsider other medications and herbal remedies and diseases including opportunistic infections, immune \\nreconstitution inflammatory syndrome (IRIS), or other illnesses\\n2. Evaluate concurrent medications & any concurrent new \\nor pre -existing condition Establish whether adverse \\nevent is due to:  \\n• other drugs or drug -drug interaction\\n• other medical condition\\n• Inter -current illness or IRIS\\nAdverse Drug Reaction \\nidentifiedPresentation due to other \\nmedical condition\\n3.  Determine seriousness of adverse event Manage condition, continue ART\\nLife-threatening  \\n(Grade 4) Severe\\n(Grade 3) Moderate \\n(Grade 2)Mild \\n(Grade 1)\\nImmediately discontinue\\nALL drugs, including ARVs  \\nand manage the medical \\nevent. The patient often \\nrequires hospitalization \\nWhen the patient is stabilised, \\nreintroduce ARVs using a \\nmodified regimen (substitute \\nthe offending drug) *Substitute the offending \\ndrug without \\ndiscontinuing ART *. \\nMonitor the patient \\ncloselyContinue ARVs as long as \\nfeasible,  offer \\nsymptomatic relief if \\nappropriate. If no \\nimprovement consider \\nsingle drug substitution*Continue ARVs, offer \\nsymptomatic relief (if \\nappropriate)\\nPatients identified with ADR, review the patient progress at every clinic visit and \\ndocument their outcomes \\nReport suspected/confirmed adverse drug events by filling the Pharmacovigilance\\nform or online at www.pv.pharmacykenya.org1. Patient/caregiver \\nreports  possible \\nadverse eventHistory or clinical \\nassessment suggest \\nadverse eventLab tests indicate \\npossible problem \\nrelated to ART\\n1. At every clinic  visit the patient on ART should be monitored clinically for toxicities using history \\n(history of symptoms that suggest toxicity) and physical examination (relevant signs). Patients should be asked \\nspecifically about ADR known to be associated with their current ART. laboratory assessment may be \\nused to confirm specific  \\n2.  Evaluate concurrent medications and establish whether the toxicity is attributable to an ARV, or to a non-ARV \\nmedication taken at the same time. Consider  other disease processes concurrent infectious processes or \\n3.  All toxicities should be graded. Manage the adverse event according to \\n* Follow single-drug substitution algorithm (Figu re \\n \\nFigure 6.3: General Principles for Managing Adverse Drug Reactions  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 150}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 12  \\nPatients with specific reason for stopping an ARV  1\\nVL within last 6 months < \\n200 copies/ml\\nNo VL result within last 6 \\nmonths 1\\nVL within last 6 months   \\n200 copies/ml\\nCollect sample for VL\\nVL       copies/ml\\n• Proceed with single drug substitution\\n• Schedule clinical appointment at 2 weeks after regimen change \\nto review adherence, side effects and any other concerns\\n• Repeat VL 3 months after regimen modification followed by \\nroutine viral load monitoring\\n• Do NOT  change the current regimen unless \\nimmediate change required for clinical reasons1\\n• Follow viral load monitoring algorithm (Figure 6.6)\\nOn ART for < 3 months\\n On ART for     months\\nVL < 200 copies/ml \\n1 If an ARV must be changed for clinical reasons (adverse \\ndrug reaction; drug -drug interaction; co -morbidity; etc) \\nbefore viral load results available, Urgently consult Uliza \\nHotline (0726 460 000) or Regional or National TWG\\n \\nFigure 6.4: Managing Single Drug Substitutions for ART  \\n \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 151}),\n",
       " Document(page_content='  \\nAntiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 13 \\nAt every clinic visit, assess for risk of kidney disease:\\n•  Age > 60 years\\n•  Concurrent HIV associated diseases (such as TB and other OIs)\\n•  Concurrent diabetes, hypertension, viral hepatitis\\n•  Concomitant use of nephrotoxic drugs (e.g. aminoglycosides, \\namphotericin and boosted PIs)\\n•  Wasting, low BMI\\n•  CD4 count < 200 cells/mm3\\nIf any risk factor present\\nObtain a dip stick urinalysis and serum creatinine and calculate \\ncreatinine clearance (CrCl in ml/min, see Annex 15)1\\n4,5CrCl   29\\nAVOID: if there is no \\nsuitable alternative; give \\nTDF 300 mg every 72 \\nhours, monitor CrCl \\nmonthly 2CrCl    90 \\nTDF 300 mg OD: re -\\nassess creatinine and CrCl \\nat 1 month, 3 months and \\nbi-annually thereafter if \\nnormal3CrCl = 50 -89\\nTDF 300 mg OD, monitor \\nmore closely for decline in \\nrenal function (monthly \\nduring the first year, and 3 \\nmonthly thereafter if CrCl \\nremains stable4,5CrCl = 30 -49\\nAVOID: if there is no \\nsuitable alternative; give \\nTDF 300 mg every 48 \\nhours, monitor closely \\nwith monthly CrCl for the \\nfirst year, and 3 monthly \\nthereafter if stable\\n1 DTG may cause a small rise in serum creatinine levels but this does NOT represent a true decline in renal function\\n2 Obtain biannual serum Cr and CrCl in patients at risk of renal disease and a CrCl      ml/min\\n3 Patients with a CrCl      ml/min do not require TDF dose adjustment.\\n4 Avoid the use of TDF in patients with CrCl < 50ml/min unless in HIV/HBV coinfection (in which case TAF or TDF should \\nbe used). If HBV  negative and on first line ART, substitute TDF with  ABC, TAF or DTG + 3TC dual therapy. If prior ART \\ntreatment failure or any other scenario consult the Regional or National HIV Clinical TWG (Uliza Hotline 0726 460 000).  \\n5 3TC also requires dose adjustment once CrCl < 50 ml/min\\n* For patients with decreased renal function, assess for other causes of renal impairment and refer to physician for review \\nFigure 6.5: Managing TDF -Associated Kidney Toxicity  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 152}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 14 Table 6.6: ARV, CTX and Fluconazole Adjustments in Renal and Hepatic Impairment1 \\nDrug  CrCl (ml/min)  Haemodialysis  Liver impairment  \\n15 - 50 <15  \\n \\nABC   \\nNo change  Reduce adult dose to 200 mg BD for \\nmoderate to severe liver impairment. \\nAVOID in severe hepatic impairment  \\nAZT  No change  300 mg/day  300 mg/day  Reduce dose by 50% or double \\ninterval of administration in \\nmoderate to severe impairment  \\nTDF2 AVOID unless \\nHBV+2 AVOID unless \\nHBV+2 300 mg every 7 \\ndays  No change  \\nTAF  No change  AVOID unless \\nHBV+2 No dose adjustment - \\nAdminister after \\ndialysis  No change  \\n3TC  150 mg OD  150 mg OD  75 mg OD  No change  \\nLPV  No change  No change, use with caution in \\nmoderate to severe impairment  RTV  \\nATV  \\nDRV  \\nRAL  No change  \\n No change in mild to moderate \\nimpairment. Use with caution in \\nsevere impairment  DTG  \\nEFV  No change  \\n Use with caution in mild to moderate \\nliver impairment. AVOID in severe \\nimpairment  \\nNVP  No change  AVOID  \\nETV  No change  Use with caution in severe liver \\nimpairment  \\nCTX  If CrCl > 30 ml/min then no dose adjustment \\nrequired; if 15 -30 ml/min then use 50% of normal \\nrecommended dose; if CrCl < 15 ml/min then CTX \\nshould be avoided  Use with caution in mild to moderate \\nliver impairment. AVOID in severe \\nimpairment  \\nFluconazole  If CrCl ≤ 50 ml/min then use 50% of normal \\nrecommended dose (no dose adjustment required \\nfor CrCl > 50 ml/min)  Use with caution  \\n1 Patients with evidence of renal or hepatic impairment should have access to regular monitoring of renal \\nand liver function  \\n2 TDF and renal impairment:  \\n● In acute kidney injury (AKI), interrupt TDF administration until the cause of AKI is established and \\ncorrected.  \\n● Avoid the use of TDF in patients with CrCl < 50ml/min unless in HIV/HBV coinfection (in which case \\nTAF or TDF should be used). For patients wit h HBV co -infection, the benefit of TDF or TAF for treating \\nHBV often outweighs the risks of renal impairment, so more severe levels of renal impairment are \\ntolerated. See Table 9.3 for TDF and TAF dose adjustments for patients with HBV/HIV co -infection. \\nThese patients should be managed in consultation with an experienced clinician  \\n● If HBV negative and on first line ART, substitute TDF with ABC, TAF or DTG + 3TC dual therapy, \\nfollowing the single drug substitution algorithm (Figure 6.4). If prior ART treatmen t failure or any other \\nscenario consult the Regional or National HIV Clinical TWG (Uliza Hotline 0726 460 000; \\nhttps://nhcsc.nascop.org/clinicalform ) \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 153}),\n",
       " Document(page_content='  \\nAntiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 15 Table 6.7: Management of AZT -Associated Bone Marrow Suppression  \\nTest  Result  Action  \\n \\nHb (g/dL)  > 8.5 (and decrease \\nfrom pre -AZT \\nbaseline)  Retain AZT, repeat Hb at week 1, 2, 4 and 12 (if accessing \\nfollow -up Hb is difficult then consider substituting to an \\nalternative ARV immediately)  \\n≤ 8.5  Switch from AZT to an alternative ARV  \\n \\nNeutrophils  \\n(x 109/L) 1.0 – 1.5 (and decrease \\nfrom pre -AZT baseline, \\nif available)  If receiving cotrimoxazole consider withholding unless \\nessential. Retain AZT, repeat at week 1, 2, 4 and 12 (if \\naccessing follow -up neutrophils is difficult then \\nconsider s witching to an alternative ARV immediately)  \\n≤ 1.0  Switch from AZT to an alternative ARV  \\nNote:  \\n● Patients with baseline Hb of < 9.5 g/dL should not be initiated on AZT; patients who develop \\nanaemia while on AZT should be managed as per this table  \\n● AZT -associated bone marrow suppression occurs early in the course of treatment, usually within \\n3 months of initiating ART  \\n● All patients with anaemia and/or neutropenia, whether on AZT or not, should be evaluated for \\nother likely causes of anaemia/neutropenia and managed appropriately  \\n \\nTable 6.8: Management of Drug -Related Hepatotoxicity  \\nALT  <2.5 x Upper Limit of Normal (ULN)  2.5 – 5 x ULN  > 5 x ULN  \\nAction  Retain regimen, repeat in 2 weeks  Retain regimen, \\nrepeat in 1 week  Discontinue offending drug/s  \\nConsult senior clinician for \\nnext step  \\nNote: All patients with acute increase in liver enzymes should be evaluated for other likely causes of \\nhepatitis/hepatotoxicity and managed appropriately  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 154}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 16 Table 6.9: Diagnosis and Management of Abacavir Hypersensitivity Reaction  \\nDiagnosis  \\nWithin 3 weeks of initiating an ABC -containing regimen , patient develops any 2 of the following \\nsymptom groups concurrently  \\n• Fever  \\n• Erythematous and/or pruritic rash  \\n• Respiratory symptoms (shortness of breath and/or sore throat and/or cough)  \\n• GI symptoms: nausea and/or vomiting and/or diarrhea  \\n• Extreme fatigue and/or body pain preventing normal activities  \\nAND: there is not a more likely alternative explanation for the symptoms  \\nManagement  \\n• Stop ABC immediately and substitute with an alternative ARV  \\n• Patient must NEVER be re -challenged with ABC – a single dose could result in a fatal \\nhypersensitivity reaction  \\n• Clearly mark file and educate patient about avoiding ABC in future  \\n• Issue an Adverse Event alert card  \\nNote:  \\n• ABC hypersensitivity reaction is rare in our population: always consider other more likely possible \\ndiagnoses  \\n• Symptoms generally get worse within hours after each dose of ABC  \\n \\n \\n6.5.3 Changing ARVs Due to Drug -Drug Interactions  \\nPatients must be asked about other medications (including non -prescription and herbal \\nmedicine) they are taking at every visit. Some common drugs have specific drug -drug interactions \\nthat may require dose adjustment or substitution o f the ARV or the other interacting drugs. \\nCommon medications that interact with specific ARVs include: rifampicin, rifabutin, antacids, \\nmultivitamin/mineral supplements, methadone, several anti -fungal, anti -convulsant, calcium -\\nchannel blockers, some anti -depressants, some statins, and some anti -malarial. Annex 13 \\nprovides common drug -drug interactions and management recommendations. It is \\nrecommended practice to check for interactions whenever a new medicine is started.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 155}),\n",
       " Document(page_content='  \\nAntiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 17 6.5.4 Changing ARVs Due to Treatmen t Failure  \\nViral load is the test of choice for monitoring response to ART and identifying treatment failure. \\nFirst VL should be performed 3 months after ART initiation for all PLHIV.   \\nTreatment failure should be suspected when a new or recurrent HIV -associ ated condition \\nindicating severe immunodeficiency (WHO stage III or IV condition) develops after at least 6 \\nmonths on ART. Treatment failure should always be confirmed with VL testing.  \\nFrequency of routine VL monitoring for specific populations is:  \\n● Age 0-24 years old: at 3 months after ART initiation and then every 6 months  \\n● Age ≥ 25 years old: at 3 months after ART initiation, then at month 12 and then \\nannually  \\n● Pregnant or breastfeeding: at confirmation of pregnancy (if already on ART) or 3 \\nmonths after ART initiation (if ART initiated during pregnancy/ breastfeeding), and \\nthen every 6 months until cessation of breastfeeding  \\n● Before making any drug substitution (if no VL results from the prior 6 months)  \\n● Three months after any regimen modification (includin g single -drug substitutions), \\nand then as per population group  \\n● For any patient with a detectable VL follow the viral load monitoring algorithm \\n(Figure 6.6)  \\n \\nInterpreting Viral Load Results and Defining Treatment Failure (Figure 6.6)  \\nThe goal for ART is t o achieve sustained viral suppression defined as below the Lower Detection \\nLimit (LDL), < 50 copies/ml is considered as suppressed.  See Table 5.17  \\nPersistent low -level viremia (PLLV) is defined as having between 200 -999 copies/ml on \\ntwo consecutive measures.  These patients are at increased risk of progression to treatment \\nfailure, development of resistance and death and therefore require a similar case management \\napproach as patients with VL ≥ 1,000 copies/ml, and consultation with the Re gional or National \\nHIV Clinical TWG (Uliza Hotline 0726 460 000; https://nhcsc.nascop.org/clinicalform ).  \\nTreatment failure is suspected when a patient has a high VL ≥ 1,000 copies/ml after at least \\n3 months of using ART.  Treatment failure is only confirmed when VL is ≥ 1,000 copies/ml after \\nassessing for and addressing poor adherence or other reasons for high VL, and then repeating VL \\nafter at least 3 months of enhanced adherence to allow for viral re -suppression.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 156}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 18 \\nSchedule for routine viral load testing1 \\n• Age 0 -24 years old: at month 3, then every 6 months \\n• Age      years old: at month 3, then month 12 and then annually \\n• Pregnant or breastfeeding: at confirmation of pregnancy (if already on ART) or 3 months after ART initiation (if ART initiate d during \\npregnancy/breastfeeding), and then every 6 months until complete cessation of breastfeeding \\n• Before any drug substitution (if no VL result available from the prior 6 months) \\n• Three months after any regimen modification (including single -drug substitutions) \\nVL < 200 copies/ml\\n VL 200 – 999 copies/ml\\n VL         copies/ml\\nIncreased risk of progression to \\ntreatment failure\\nSuspected treatment \\nfailure\\n• Discuss patient in MDT \\n• Assign a case manager \\n• Assess for and address likely causes of non -adherence2 \\n• Provide enhanced adherence support/intervention as appropriate (Section \\n5.4 of guidelines for enhanced adherence protocol) \\n• Assess for other causes of viremia and manage as needed3 \\n• Support daily witnessed ingestion by treatment buddy or healthcare worker\\n• After 3 months of excellent adherence, repeat VL \\nVL < 200 copies/ml (LDL)\\nVL 200 – 999 copies/ml\\nVL         copies/ml\\n• Continue ART regimen\\n• Routine adherence \\ncounselling and monitoring\\n• Routine VL monitoring\\n• Reassess adherence and other \\ncauses of viremia2,3\\n• Repeat VL after another 3 months of \\nexcellent adherence\\nConfirms treatment failure: \\n• Begin treatment preparation for new regimen and \\ncontinue failing regimen until adherence \\npreparation completed \\n• Continue enhanced adherence support \\n• Take sample for CD4 count and assess for and \\nmanage any OIs \\n• If failing a DTG or PI based regimen a DRT is \\nrecommended in consult ation with the  regional or \\nNational HIV Clinical TWG or call Uliza Hotline \\n       (0726 460 000)  \\n• Schedule clinical appointment at 2 weeks after \\nregimen change to review adherence, side effects \\nand any other concerns \\n• Repeat VL 3 months after regimen modification \\nConsult Regional or National HIV \\nClinical TWG or call Uliza Hotline \\n(0726 460 000)\\nVL 200 – 999 copies/ml\\n1. As part of treatment preparation, patients should be informed that \\nviral load is the recommended method of monitoring ART. VL results \\nshould always be discussed with patients, even when they are \\nundetectable. Goals of treatment and definition of success should be \\ndiscussed and adherence messaging reinforced \\n2. Common causes of poor adherence include: stigma, non -disclosure, \\ntravel, toxicities, alcohol or drug use, mental health disorder, religious \\nbeliefs, inadequate treatment preparation, chaotic lifestyle, lack of \\nsupport systems, and poor patient -provider relationship \\n3. Other common causes of treatment failure (beyond adherence) \\ninclude: inadequate dosing/dose adjustments, drug -drug \\ninteractions, drug -food interactions, impaired absorption (e.g. \\nchronic severe diarrhoea)  \\n Figure 6.6: Viral Load Monitoring of Patients on ART (1st Line or 2nd Line)  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 157}),\n",
       " Document(page_content='  \\nAntiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 19 Non -adherence is the most frequent cause of treatment failure. As per the viral load \\nmonitoring algorithm, adherence issues must be addressed BEFORE confirming \\ntreatment failure.  \\nDaily witnessed ingestion by a treatment buddy or healthcare worker is recommended to confirm \\nexcellent adherence before repeating the VL. All adherence issues must be resolved before \\nswitching to a new regimen otherwise the patient will quickly fail the n ew regimen as well, and \\nsoon run out of viable ART options. An exception to this may be when the regimen itself is \\nthe primary cause of poor adherence  (e.g., side effects from one of the ARVs are not \\nmanageable such as severe diarrhea with LPV/r that does not improve with symptom \\nmanagement), in which case the regimen may need to be modified to allow for perfect adherence. \\nThis should be done in consultation with the Regional or National HIV Clinical TWG.  \\nChapter 5 provides detailed guidance on adherence pr eparation, assessment, and support.  \\nTable 6.10: Recommended Second -line ART Regimens in Infants, Children, Adolescents and \\nAdults, excluding TB/HIV co -infection 1 \\nWeight/scenario  First -line ART  Second -line ART  \\n \\n< 30 kg  ABC (or AZT) + 3TC + DTG  DRT -based second -line2,3  \\nABC + 3TC + LPV/r  Take sample for DRT and change to AZT + \\n3TC + DTG while awaiting DRT results; \\nmodify based on DRT results if indicated  \\nAZT + 3TC + LPV/r  Take sample for DRT and change to ABC \\n+ 3TC + DTG while awaiting DRT results; \\nmodify based on DRT results if indicated  \\nABC + 3TC + EFV  AZT + 3TC + DTG  \\nAZT + 3TC + EFV  ABC + 3TC + DTG  \\n \\n≥ 30 kg or ≥ 15 \\nyears old  TDF (or ABC) + 3TC + DTG (or PI/r)  DRT -based second -line2 \\nTDF (or ABC) + 3TC + EFV  TDF + 3TC +  DTG  \\nAZT + 3TC + EFV  TDF + 3TC + DTG  \\nPregnant and \\nBreastfeeding \\nwomen  TDF (or ABC) + 3TC + DTG  Take sample for DRT and change to TDF \\n+ 3TC + ATV/r while awaiting DRT \\nresults; modify based on DRT results if \\nindicated  \\nTDF (or ABC) + 3TC + PI/r  Take sample for DRT and change to TDF \\n+ 3TC + DTG while awaiting DRT results; \\nmodify based on DRT results if indicated  \\nTDF (or ABC) + 3TC + EFV  TDF + 3TC + DTG  \\nAZT + 3TC + EFV  TDF + 3TC + DTG  \\nHIV/HBV Co -\\ninfection  Always maintain TDF in order to treat the HBV as well as HIV  \\nTB/HIV Co -\\ninfection  Refer to Table 8.8: Recommended ART Regimens for Patients who Develop TB \\nwhile Failing  1st Line ART  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 158}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 20 Table 6.10 Cont.  \\n1. If any drug in the recommended 2nd line regimen is contraindicated or previously not tolerated, \\nconsult the Regional or National HIV Clinical TWG (Uliza Hotline 0726 460 000; \\nhttps://nhcsc.nascop.org/clinicalform ). Such patients may require DRT to select agents for the \\nsecond -line ART. Add itional drugs may be recommended on a case -by-case basis, including DRV/r, \\nATV/r, RAL, or ETR  \\n2. Patients failing DTG -based or PI -based first -line regimens should have a Drug Resistance Test \\n(DRT) ordered as soon as treatment failure is confirmed. The patient  summary and DRT results \\nshould be sent to the Regional or National HIV Clinical TWG \\n(https://nhcsc.nascop.org/clinicalform ) or call Uliza Hotline (0726 460 000) to determine the \\nmost suitable second -line regimen for the patient. The DRT results will be us ed to determine if \\nthere is true DTG or PI failure or if there is an underlying problem with non -adherence. Daily \\nwitnessed ingestion is recommended prior to performing DRT  \\nImportant Considerations for First -line Treatment Failure in Children  \\n● Second -line ART in infants and children is more complex to manage. These children and \\ntheir caregivers should undergo thorough clinical and psychosocial assessment to rule \\nout inter -current illness or non -adherence as the reason for a high viral load  \\n● All c hildren failing first -line should be discussed in the MDT and preferably with an \\nexperienced ART provider prior to change of ART to second -line. However, this should \\nnot cause undue delay in switching a failing regimen  \\n● The choices for infants and children failing an alternative first -line regimen are limited \\nand may need to be discussed with the Regional or National HIV Clinical TWG. Some of \\nthese children will require HIV DRT to determine the most suitable second -line regimen  \\nImportant considerations for s econd -line ART Treatment Failure  \\n● Patients failing second -line ART have limited options. ARVs used to construct a third -line \\nregimen are often more expensive, will have increased pill burden and more side effects. \\nThese factors will exacerbate pre -existing poor adherence  \\n● Second -line treatment failure should be confirmed by viral load testing following the \\nviral load monitoring algorithm (Figure 6.6)  \\no After the first detectable VL ( \\uf065 50 copies/ml), assess for and address all causes of \\npoor adherence, and assess for all other possible causes of viremia.  \\no These patients should be discussed at an MDT session. Repeat the VL after 3 months \\nof excellent adherence (preferably with daily witn essed ingestion of the ARVs by a \\ntreatment buddy, relative, CHV, etc.).  \\no If the second VL is still \\uf065 50 copies/ml then continue the failing second -line regimen \\nwhile reassessing adherence and other causes of viremia, implementing adherence \\nsupport systems as needed, and then repeat the VL after another 3 months.  \\no If viremia continues then consult the Regional or National HIV Clinical TWG (Uliza \\nHotline 0726 460 000; https://nhcsc.nascop.org/clinicalform ) using the national \\ncase summary form (Annex 9B). These patients will likely require DRT in order for \\nthe TWG to design the most suitable third -line regimen  \\n● Patients failing second -line ART require thorough assessment for barriers to adherence \\nand ongoing enhanced adherence support including  \\no Assigning a case manager  \\no More frequent adherence counselling by a trained counsellor  \\no Assessment and treatment of mental health and substance use disorders  \\no Provision of adherence support such as modified directly observed therapy, a \\ntreatment supporter, hom e visits etc.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 159}),\n",
       " Document(page_content='  \\nAntiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 21 Table 6.11: Possible Third -line ART in Children, Adolescents and Adults  \\n Possible 3rd Line Regimen  Comment  \\n \\nChildren  DTG + 3TC + DRV/r  Third line ART selection is based on DRT \\nresults  \\nNote that the Regional or National \\nHIV Clinical TWG may recommend \\nreusing some of the ARVs the \\npatient has already failed, even \\nwhen resistance is present  DTG + AZT + 3TC + DRV/r  \\nDTG + ABC (or TDF) + 3TC + DRV/r  \\nETV + 3TC + DRV/r  \\nAdults  DTG + 3TC + DRV/r  \\nDTG + AZT + 3TC + DRV/r  \\nDTG + TDF + 3TC + DRV/r  \\nDTG + TDF (or AZT) + 3TC  \\nETV + 3TC + DRV/r  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 160}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 22   ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 161}),\n",
       " Document(page_content='  \\nPrevention of Mother to Child Transmission of HIV/Syphilis/Hepatitis B  \\n  7 - 1  \\n7. Prevention of Mother to Child Transmission of \\nHIV/Syphilis/Hepatitis B  \\nRoutine antenatal care (ANC) offers an important opportunity to provide high quality combined \\nHIV prevention throug h targeted health education and counselling; HIV testing for the woman, \\npartners and family members; linkage to HIV prevention and treatment; and to discuss and plan \\nfor future conception and contraception needs. Prevention of mother -to-child transmission of HIV \\n(PMTCT)/Syphilis/Hepatitis B should be offered as part of a comprehensive package of fully \\nintegrated, routine antenatal care interventions (Table 7.1).  \\nTable 7.1: Essential Package of Antenatal Care  \\nIntervention  Recommendation/Description  \\n \\nGroup & \\nIndividual \\nEducation  Include information on importance of at least 8  ANC visits, details of ANC services \\n(including health checks and treatment of any illness, medical tests including HIV, \\nsyphilis testing and hepatitis B, monitoring of maternal and fetal wellbeing, etc.), \\nnutrition, personal care, recognizing and responding to danger signs during \\npregnancy, birth preparedness including skilled birth attendance, post -natal care \\nincluding immunization, family pla nning and maternal and infant nutrition, HIV \\nprevention and treatment (HTS, preventing new infections during pregnancy \\nincluding PrEP where appropriate, ART for those who are HIV positive, monitoring of \\nART and ARV prophylaxis and follow -up for HEIs) and t riple elimination (preventing \\nHIV/ syphilis/hepatitis B transmission from mother to child).  \\nCounselling  ● Pre-conception – Women in reproductive age who are known to be HIV positive \\nshould have pregnancy intention assessment visit at every visit. If they desire to \\nbecome pregnant, pregnancy should be planned i.e., attain viral load suppression, \\nimmune reconsti tution and have Iron and Folic Acid Supplementation (IFAS) \\nadministered prior to conception.  \\n● Women who are newly diagnosed with HIV and/or newly initiating ART require \\nmore intensive adherence counseling and HIV education, which may include a case \\nmanager  and/or mentor mother  \\n● Birth preparedness: support the pregnant woman and her partner to develop an \\nindividual birth plan that includes place of delivery with skilled attendants, \\nemergency transport, birth companionship and readiness for infant care  \\n● Pregnan cy danger signs: offer information on returning to ANC as soon as possible \\nin case they develop fever, lower abdominal pain, severe headache, swollen feet, \\nconvulsions and per vaginal bleeding.  \\n● Maternal, infant and young child nutrition (MIYCN): All pregn ant women should \\nreceive information on proper nutrition during pregnancy and breastfeeding, safe \\ninfant feeding and optimal nutrition practices. Promote exclusive breastfeeding for \\nthe first 6 months irrespective of HIV status, followed by complementary f eeding \\n(Table 7.7). During pregnancy, provide iron, folate and multivitamins; monitor for \\nanemia, advise on adequate caloric intake (HIV positive women require an \\nadditional 10% of recommended daily allowance (RDA))  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 162}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n7 - 2 Table 7.1 Cont.  \\nCounselling  ● HIV testing services  \\no All pregnant women (unless known HIV positive) should be counselled and \\ntested for HIV, syphilis and Hepatitis B during their first ANC visit and if \\nnegative, repeat HIV and syphilis testing in the third trimester.  \\no All pre gnant and breastfeeding mothers with continued HIV risk (Key \\npopulations) should be counseled and tested for HIV every 3 months until post -\\ncessation of breastfeeding.  \\no Pregnant and breastfeeding mothers should be educated and offered a self -test \\nkit for th eir sexual partner(s)  \\no At Labour and delivery, HIV testing should be done for all women with \\nunknown HIV status or that previously tested negative, even if tested during \\nthe third trimester  \\no All breastfeeding mothers (unless known HIV positive) should be co unselled \\nand tested at the 6 -week infant immunization visit. The HIV test (if negative) \\nshould be repeated every 6 months until complete cessation of breastfeeding. \\nNote:  key population mothers (FSWs and PWIDs) get retested every 3 months \\n(Table 2.5)  \\no Women should be counselled about the schedule for repeat HIV testing in \\npregnancy and postnatally as part of routine ANC and postnatal education  \\no All pregnant and breastfeeding women who are not tested, opt -out or decline \\nHIV, Syphilis or Hepatitis testing during the first contact should be offered \\ncounselling and testing in subsequent visits with appropriate linkage and \\nreferral for prevention, care and support services. Daily Witnessed Ingestion \\n(DWI) is advised to support Viral suppression for newly initi ated clients and \\nthose whose regimens are being switched. This is to support viral suppression \\namong women with high viral load.  \\no All HIV positive pregnant and breastfeeding women enrolled into care should \\nreceive counselling and support (including assiste d disclosure), case \\nmanagement linkage and follow -up for comprehensive treatment and \\nprevention (including lifelong ART)  \\no All Syphilis and Hepatitis B positive clients should be given appropriate care as \\ndefined in Table 7.3 “triple elimination”.  \\no All partn ers of pregnant and breastfeeding women should be offered HIV \\ntesting and counselling and all biological children if the mother is HIV positive  \\n● All pregnant and breastfeeding women should receive information on risk \\nreduction, including PrEP where appropri ate \\n● Post -partum contraception: counsel on contraception methods and help patient \\ndevelop a plan for effective contraception from 6 -weeks post -partum to avoid \\nunplanned pregnancies  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 163}),\n",
       " Document(page_content='  \\nPrevention of Mother to Child Transmission of HIV/Syphilis/Hepatitis B  \\n  7 - 3 7.1 Antiretroviral Therapy for HIV -positive Pregnant and Breastfeeding \\nWomen and Infant Prophylaxis  \\nThe goal of ART for HIV positive pregnant women is two -fold: to restore and maintain the \\nmother’s immune function and therefore general health, and secondly, to prevent transmission \\nof HIV in utero, at labour and delivery and during breastfeeding. To achieve this goal, the mother \\nmust take effective antiretroviral therapy to achieve viral suppression.  Table 7.2 summarizes \\nrecommendations for use of ART for HIV positive pregnant women.  \\nTable 7.2: Summary of Use of A RT for HIV Positive Pregnant and Breastfeeding Women  \\nOverall recommendations  \\nWhen to start  ART should be initiated in all pregnant and breastfeeding women living with HIV, \\nregardless of gestation, WHO clinical stage and at any CD4 cell count and continued \\nlifelong. ART should be started, ideally, on same day as HIV diagnosis after \\nreadiness asse ssment with ongoing enhanced adherence support including \\ncommunity -based case management and support.  \\nWhat to start with \\n(first -line ART)  TDF/3TC/DTG  \\nInfant \\nprophylaxis  ● AZT+NVP for 6 weeks, NVP should be continued until 6 weeks after complete \\ncessation of breastfeeding  \\nFor more comprehensive information Refer to Table 7.3  \\nMonitoring       Viral load  monitoring during pregnancy and breast -feeding (Figure 6.6)  \\n● Whenever possible, use same -day point -of-care methods for viral load \\ntesting of pregnant and breastfeeding women to expedite the return of \\nresults and clinical decision -making. If this is not available, viral load \\nspecimens and results for pregnant and breastfeeding women should be \\ngiven priority across the laboratory referral process  (including specimen \\ncollection, testing and return of results).  \\n● For pregnant and breastfeeding women newly initiated on ART, obtain VL 3 \\nmonths after initiation, and then every 6 months until complete cessation of \\nbreastfeeding  \\n● For HIV positive women already on ART at the time of confirming pregnancy \\nor breastfeeding, obtain a VL irrespective of when prior VL was done, and \\nthen every 6 months until complete cessation of breastfeeding  \\n● For pregnant or breastfeeding women with a VL ≥ 50 copies/ml: assess for \\nand address potential reasons for viremia, including intensifying adherence \\nsupport, repeat the VL after 3 months of excellent adherence, including \\ndaily witnessed ingestion, where feasible and appropriate  \\no If the repeat VL is 200 - 999 copies/ml consul t the Regional or National \\nHIV Clinical TWG  \\no If the repeat VL is ≥ 1,000 copies/ml, change to an effective regimen. \\nRefer to Table 6.10  \\no If the repeat VL is < 200 copies/ml (LDL) then continue routine \\nmonitoring  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 164}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n7 - 4 Table 7.2 Cont.  \\nScenario  \\nPre-conception planning \\nfor women already on \\nART (not yet pregnant)  Maintain ART  \\nCarry out a VL test if not done in the prior six months to confirm viral \\nsuppression (Figure 6.6)  \\nRefer to Table 4.8 for pre -conception care for women on ART who desire \\npregnancy, including laboratory screening, TT immunization, folate, etc.  \\nOn ART at the time of \\nconfirming \\npregnancy/breastfeeding  Maintain ART.  \\nCarry out a VL at first identification of pregnancy, irrespective of when a \\nprior viral load was done, to confirm viral suppression (Figure 6.6)  \\nManage the baby as HEI (Figure 2.1 for EID, and Table 7.3 for infant \\nprophylaxis)  \\nNot on ART at the time of \\nconfirming pregnancy  Prepare the patient and start on ART as soon as possible.  \\nART initiation should occur preferably on the same day HIV infection is \\nconfirmed. Perform VL 3 months after ART initiation.  \\nPregnant and breastfeeding women with a history of treatment \\ninterruption returning to care should have reasons for interruption \\nassessed and preferentially re -started on a DTG -containing regimen \\nunless the reason for interruption was DTG intolerance or failure. Viral \\nload monitoring in this case should be done after 3 months of initiation \\nand 6 months thereafter until cessation of breastfeeding . Additional \\nadherence support should be made available.  \\nNot on ART during \\nlabour and delivery  Start on ART during labour.  \\nAfter delivery, continue treatment preparation and adherence support and \\ncontinue ART  \\nManage the baby as HEI (Figure 2.1 for EID, a nd Table 7.3 for infant \\nprophylaxis)  \\nNot on ART during \\npost -\\npartum/breastfeeding  Prepare (readiness assessment) and start on ART as soon as possible \\npreferably on the same day HIV infection is confirmed.  \\nManage the baby as HEI (Figure 2.1 for EID, and Table 7.3 for infant \\nprophylaxis). Adherence support for both mother and infant, con sider \\ndaily witnessed ingestion (DWI) support.  \\nManaging labour and \\ndelivery  Minimize vaginal examinations, use aseptic techniques to conduct delivery, \\navoid artificial rupture of membranes, monitor labour and avoid prolonged \\nlabour by use of the partograph, avoid unnecessary genital tract trauma  \\nNote that certain patient groups e.g., recent HIV infections, pregnant adolescent girls and young \\nwomen, women with previous children with HIV infection, patients with high viral load at time of \\npregnancy  confirmation, patients with poor social support systems, patients with history of \\ndefault from care and those with active co -morbidities etc. may require additional adherence and \\npsychosocial support  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 165}),\n",
       " Document(page_content='  \\nPrevention of Mother to Child Transmission of HIV/Syphilis/Hepatitis B  \\n  7 - 5 7.2. Syphilis elimination for Pregnant and Breastfeed ing Women and Infant \\nTreatment  \\nThe country has adopted triple elimination of HIV, Syphilis and Hepatitis B among pregnant and \\nbreastfeeding women. It is recommended that all pregnant women attending ANC and not aware \\nof their HIV status require a dual HIV syphilis test during their first trimester and a second HIV \\nSyphilis test in the 3rd trimester if the initial test was negative.   \\nAll women who test positive for syphilis at any point during pregnancy and breastfeeding should \\nbe treated with the appropria te regimen. (Table 7.3). All babies born of mothers who test positive \\nfor syphilis are suspected to be exposed to syphilis and should also be treated with the correct \\nregimen (Table 7.3). Ensure to perform contact tracing for all the sexual contacts and en sure they \\nare treated for syphilis.  \\nSymptoms of congenital syphilis may not become apparent for several weeks or months after \\nbirth.  \\n7.3. Hepatitis B elimination for Pregnant and Breastfeeding Women and Infant \\nProphylaxis  \\nRequires routine testing of pregnant women to identify women in need of antiviral treatment for \\ntheir own health and additional interventions to reduce Mother to Child Transmission of viral \\nhepatitis B.  \\nRegular screening should be done by incorporation of viral hepatitis screening as  part of the ANC \\nprofile. This is recommended for Hepatitis B & C which pose a big risk to both the mother and \\nfetus.  \\nFor pregnant and breastfeeding women who are found to be positive for HBsAg, offer appropriate \\ntreatment options of ARVs containing TDF/3TC or FTC containing regimens. This treatment also \\nacts as prophylaxis for HBV transmission from mother to child. All pregnant and breastfeeding \\nwomen without evidence of hepatitis B infection (HBsAg negative) should be vaccinated against \\nhepatitis B. (Chapter 9).  \\nHIV positive infants without evidence of infection should be vaccinated against Hepatitis B.  \\nInfants born of mothers who test positive for HBsAG should be treated using Hepatitis B \\nImmunoglobulin (Table 7.3).  \\nRefer to Chapter 9 f or management of HIV/HBV coinfection.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 166}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n7 - 6 Table 7.3: ARV Prophylaxis for HIV -Exposed Infants  \\nInfant Scenario  Infant Prophylaxis  Maternal Scenarios  \\nHIV Exposed \\nInfant  ● Infant prophylaxis  \\no AZT+NVP for 6 weeks, NVP + cotrimoxazole should be \\ncontinued until 6 weeks after complete cessation of \\nbreastfeeding  \\no Infant prophylaxis can be discontinued after a minimum \\nof 12 weeks on NVP if the child is not breastfeeding (death \\nof mother or separation with mother)  \\no The infant prophylaxis regimen applies to all infants \\nirrespective of age when identifying HIV exposure (e.g., \\nmother diagnosed HIV -positive in the  postpartum  period)  \\n● DBS or whole blood for PCR at 6 weeks or first contact, \\nfollowing EID algorithm (Figure 2.1)  \\n● Birth testing (Figure 2.2) may be conducted in sites \\nwhere point of care has been implemented and when \\nmedically indicated  If mother not on ART, initiate \\nART as soon as possible \\n(preferably same day)  \\nIf mother is on ART for ≥ 3 \\nmonths and the VL is ≥ 50 \\ncopies/ml, intensify adherence, \\nrepeat the VL  \\n \\nIf VL <50 copies/ml, continue \\ncurrent regimen  \\nFollow Viral load algorithm \\nFigure 6.6  \\nTRIPLE ELIMINATION  \\nCONDITION in \\nmother  INFANT MANAGEMENT  MATERNAL MANAGEMENT  \\nSyphilis -VDRL \\nor diagnosed \\nwith Dual kit  Crystalline Penicillin 50,000 IU/kg BD (if <7 days) or TDS if \\n(>7 days old) for a total of 10 days.  Penicillin G 2.4 MU IM Stat or \\nCeftriaxone 1gm IM daily for 8 -10 \\ndays in case of penicillin allergy.  \\nCongenital \\nsyphilis    \\nHepatitis B – \\nHbsAg test  Hepatitis B immunoglobulin 0.5ml IM within 12 hours after \\nbirth. Hepatitis B vaccine 0.5ml three doses at birth, 1 month \\nand 6 months.  Refer to viral hepatitis \\nmanagement guidelines  \\nNote: If child has contraindication or unable to tolerate NVP or AZT then give the tolerated drug up to complete \\ncessation of breastfeeding. If the infant is on AZT prophylaxis, give up to a minimum of 12 we eks or until maternal viral \\nload is suppressed. In situations where neither AZT nor NVP are tolerated 3TC may be used as a third option if available.  \\nHIV exposed infants with TB infection, infant prophylaxis should include AZT plus 3TC fixed dose (60/30 mg ). For 12 \\nweeks or until maternal viral load is suppressed (3 -5.9 – 1 tab BD, 6 -9.9kg 1.5tab BD, 10 -13.9 kg 2 tabs BD).  For more \\ndetails, refer to Annex 10 A.  \\nAfter TB treatment, revert to NVP until 6 weeks post cessation of breastfeeding,  \\nHB monitoring should be done to all HEIs on AZT prophylaxis as per the recommendations (Table 6.7: management of \\nAZT associated bone marrow suppression)  \\nGroups considered higher risk for mother to child transmission who may need additional adherence and \\npsych ological support include:  \\n● All new HIV positives irrespective of time identified  \\n● HIV positive adolescent Girls and Young Women (AGYW) <19 yrs. including OVC  \\n● VL >200 copies/ml  \\n● Clients with stigma, declining treatment, poor adherence   \\n● PMTCT client with previous HIV infected infant  \\n● Client with active comorbidities - DM, OIs, malnourished (low MUAC), mental health etc.  \\n● Clients who sero -convert during ANC/PNC follow up  \\n● Poor socio -economic and family support structures   \\n● Those who drop of f ART  \\n● Key population – FSW, PWID  \\nAlcohol use and brewers/sellers  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 167}),\n",
       " Document(page_content='  \\nPrevention of Mother to Child Transmission of HIV/Syphilis/Hepatitis B  \\n  7 - 7 Table 7.4: Dosing of ARVs for Infant Prophylaxis from Birth to 12 Weeks of Age  \\nAge/Weight  Dosing of NVP (10mg/ml) OD  Dosing of AZT (10mg/ml) BD  \\nBirth to 6 weeks  \\nBirth weight < 2,000 g  2 mg/kg per dose, OD  4 mg/kg per dose, BD  \\nBirth weight 2,000 -2,499 g  10 mg (1 ml), OD  10 mg (1 ml), BD  \\nBirth weight ≥ 2,500 g  15 mg (1.5 ml), OD  15 mg (1.5 ml), BD  \\n> 6 weeks to 12 weeks of age*  \\nAny weight  20 mg (2 ml), OD  60 mg (6 ml), BD  \\n> 12 weeks (Table 7.5 and 7.6)  \\n*Dose adjustment required once child reaches 6 weeks of age  \\nIf older infant beyond 6 weeks of age is newly identified as HIV exposed infant, should be given \\nAZT+NVP for 6 weeks, NVP + cotrimoxazole should be continued until 6 weeks after complete \\ncessation of breastfeeding  \\nTable 7.5: NVP Dosing for Infant Prophylaxis beyond 12 Weeks of Age *  \\nAge  Dosing of NVP (10mg/ml) Once Daily  \\n12 weeks – 6 months  25 mg (2.5 ml), OD  \\n7 months – 9 months  30 mg (3 ml), OD  \\n10 months – 12 months  40 mg (4 ml), OD  \\n> 12 months  Consult the Regional or National HIV Clinical TWG (Uliza \\nHotline 0726 460 000; \\nhttps://nhcsc.nascop.org/clinicalform ) \\n* If child presents to facility late and has to be on AZT and NVP beyond 12 weeks of age \\nTable 7.6: AZT Dosing for Infant Prophylaxis beyond 12 Weeks of Age *  \\nWeight  Dosing of AZT: (10mg/ml syrup) Twice Daily  \\n3.0-5.9 kg  6 ml, BD  \\n6.0-9.9 kg  9 ml, BD  \\n10.0 -13.9 kg  12 ml, BD  \\n14.0 -19.9 kg  15 ml, BD  \\n* If child presents to facility late and has to be on AZT and NVP beyond 12 weeks of age  \\n7.4 Infant and Young Child Nutrition in the Context of HIV  \\n● Exclusive breastfeeding  involves giving the baby only breast milk with no other liquids \\n(including water) or solids for the first six months of life. Giving of vitamins, mineral \\nsupplements or medicines are permitted if prescribed.  \\n● Mixed feeding  is giving other liquids and/or foods together with breast milk to infants \\nunder 6 months of age and is not recommended.  Mixed feeding during thi s period is \\nassociated with significantly higher risk of mother -to-child HIV transmission, diarrhoeal \\nand respiratory tract illnesses, among other consequences and should be prevented  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 168}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n7 - 8 ● All infants irrespective of HIV status should be exclusively breastfed f or the first 6 months \\nof life, with timely introduction of appropriate complementary foods after 6 months, and \\ncontinued breastfeeding up to 24 months or beyond.  \\n● Should mothers be physically separated from their infants (back to work), support them \\nto sust ain lactation and to exclusively breastfeed including mentorship on expressing \\nbreast milk (refer to current MIYCN Policy)  \\n● All mothers, irrespective of HIV status, should be encouraged and supported to \\nexclusively breastfeed for the first six months and co ntinue breastfeeding with \\nappropriate complementary feeding after 6 months, for a period of 24 months or beyond. \\nBreastfeeding should ONLY stop once a nutritionally adequate and safe diet without \\nbreast milk can be sustained.  \\n● HIV positive mothers and HIV p ositive infants should always be on ART and given extra \\nattention for adherence support, VL monitoring and optimal retention in care  \\n● Breastfeeding mothers who do not know their HIV status or who previously tested HIV \\nnegative should be encouraged to be ret ested for HIV at the 6 -week immunization visit, \\nand then every 6 months thereafter until complete cessation of breastfeeding (Table 2.5)  \\n● Access for HIV testing and STI/HIV prevention interventions should be reinforced for \\npartners of pregnant and breastfee ding women  \\n● Mothers who are diagnosed with HIV while breastfeeding should immediately start \\nappropriate ART, giving extra attention to adherence support, VL monitoring, and optimal \\nretention in care. The infant should immediately start ARV prophylaxis and r eceive PCR \\ntesting (Table 7.3).  \\n● Mothers who decide to stop breastfeeding at any time should stop gradually within one \\nmonth (and only when a nutritionally adequate and safe diet without breast milk can be \\nsustained), and HIV positive mothers and HIV positi ve infants should continue with ART. \\nContinued breastfeeding is recommended for HIV positive infants for as long as the \\nmother is willing and able to do so.  \\n● In special medical circumstances, determined by clinicians, where an infant cannot \\nbreastfeed, refe r to current MIYCN Policy and Breast Milk Substitute (BMS) Regulation \\nand Control Act, 2012.  \\n● Complimentary feeding means giving other foods to complement breast milk after six \\nmonths of exclusive breastfeeding. Complimentary feeds provide additional nutrit ional \\nvalue to meet the child’s increasing nutritional needs for growth (Table 7.7). \\nFurthermore, complementary feeding helps the child to gradually become accustomed \\nto eating family foods while breastfeeding continues to be an important source of \\nnutrien ts. It is worth noting that breastfeeding continues to have child growth/survival \\nbenefits for up to two years or longer. Emphasis should be made on consuming all the \\nseven (7) food groups for children in various meals.  \\no Cereal/tubers and roots  \\no Beans, pulses and nuts  \\no Dairy and dairy products  \\no Eggs and Flesh (meat/poultry/insects/organ meat)  \\no Vitamin A rich food (orange/yellow fruits) and green vegetables  \\no Fats and high sugar foods  \\n● Other fruits and vegetables    ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 169}),\n",
       " Document(page_content='  \\nPrevention of Mother to Child Transmission of HIV/Syphilis/Hepatitis B  \\n  7 - 9 Table 7.7: Complementary Foods for Children 6 -24 Months Old  \\nFoods to Offer  \\nAge  Texture  Frequency  Amount of food per meal  \\n6 \\nmonths  Start with thick porridge or \\nwell mashed foods  \\n 2 times per day  2 tablespoons each feed, \\nincreasing to 3 tablespoons \\nin the 3rd to 4th week  \\n7-8 \\nmonths  Mashed/pureed family foods  \\nBy 8 months can begin \\nfinger foods  3 meals per day, plus \\nfrequent breastfeeds  \\n Increase amount gradually \\nto ½ of a 250 ml cup  \\nUse a separate plate/bowl  \\n9-11 \\nmonths  Finely chopped or mashed \\nfoods, and foods that baby \\ncan pick up  3 meals and 1 snack, \\nplus frequent \\nbreastfeeds  ¾ of a 250 ml cup/bowl  \\nUse a separate plate/bowl  \\n12-23 \\nmonths  Cut food into small, soft \\npieces that child can pick up, \\nchew and swallow \\ncomfortably  3 meals and 2 snacks, \\nplus breastfeeds  One 250ml cup/bowl  \\nUse a separate plate/bowl  \\n24-59 \\nmonths  Cut food into small, soft \\npieces that child can pick up, \\nchew and swallow \\ncomfortably  3 meals and 2 snacks, \\nplus breastfeeds if still \\nbreastfeeding  1 ½ - 2 cups of 250ml \\ncup/bowl  \\nUse a separate plate/bowl  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 170}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n7 - 10  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 171}),\n",
       " Document(page_content=' \\nTB/HIV Co -infection, Prevention and Management  \\n8 - 1 \\n  \\n8. TB/HIV Co -infection, Prevention and \\nManagement  \\n \\nTB is a leading cause of morbidity and mortality among people living with HIV. Reducing this \\nburden of illness requires identifying TB early, providing pre -emptive and preventive  treatment \\nfor TB, and providing optimal treatment for both HIV and TB. Timely initiation of ART in \\ncombination with TB Preventive Therapy are effective ways to reduce the burden of TB in PLHIV.  \\nAll PLHIV should receive counselling about the risk of acquir ing TB, strategies for reducing \\nexposure to TB, recognizing clinical manifestations of TB and seeking care promptly, the risk of \\ntransmission of TB to others and TB preventive therapy to prevent TB disease.  \\nHealthcare settings present suitable conditions f or transmission of TB, particularly among \\nvulnerable individuals like PLHIV. All healthcare settings should develop and implement TB \\ninfection control guidelines to reduce the risk of transmission of TB between patients, visitors \\nand staff.  \\n8.1 TB Screenin g for PLHIV: Intensified Case Finding (ICF)  \\nTB screening and prevention services should be offered at every clinical visit. Symptom -based \\nTB screening using the ICF tool MUST be performed at every clinic visit to rule out active TB; \\npatients who screen pos itive (presumptive TB cases) must complete definitive diagnostic \\npathways (Figure 8.1 and Table 8.1) and patients who screen negative should be evaluated for \\nTB preventive therapy (TPT).  \\nActive Case Finding (ACF) differs from ICF. ICF refers to TB screenin g among PLHIV, whereas \\nActive TB case finding (ACF) refers to special efforts made by the NTP or other partners that go \\nbeyond passive TB case finding at health facilities, in which communities or population groups \\nthat are underserved or at higher risk of  TB are actively reached for providing access to care, \\nincluding screening and testing   ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 172}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n8 - 2      Intensified Case Finding Screening Questions       \\n●  If “Yes” to any question, take a detailed history, examine the patient and do sputum examination \\n(sputum smear or GeneXpert)  \\n● If “No” to questions 1 -5 above, consider TPT eligibility and work up for TB Preventive Therapy and \\nrepeat screening on subsequent visits  \\n● Questions 5 and 6 do not apply to adults  \\nThe following are the intensified case finding screening questions:  \\n● Cough of any duration (Y/N)  \\n● Fever (Y/N)  \\n● Noticeable weight loss/ Failure to thrive/ Poor weight gain (Y/N)  \\n● Night sweats (Y/N)  \\n● Reduced playfulness/ Lethargy/ Irritability (Y/N)  \\n● Contact with a TB case (Y/ N)  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 173}),\n",
       " Document(page_content=' \\nTB/HIV Co -infection, Prevention and Management  \\n \\n8 - 3 \\n \\nIf yes, to any of the signs and symptoms above the patient requires a clinical review If no to all the signs and symptoms above\\nTake a comprehensive history and thorough examination. Decide on classification as a presumptive TB case\\nIs the client/patient a presumptive TB case?\\nIs a sample available for TB testing? • Evaluate and manage for other conditions\\n• Consider TB preventive therapy (TPT) as per LTBI guidelines\\nIs the GeneXpert available on site?\\n• Consider a CXR3\\n• Consider clinical \\ndiagnosis of TB\\nIs smear microscopy available on site?\\n• Obtain a sample1 for GeneXpert\\n• TB LAM should be considered for \\neligible PLHIV2\\no Positive TB LAM test – initiate \\nDS TB treatment. Review once \\nGeneXpert results received\\no NB: A negative TB LAM test \\ndoes not rule out TB• If yes, collect 2 samples; one for smear microscopy and an additional sample for \\nGeneXpert\\n• If smear microscopy is positive, start DS TB treatment and review the patient once \\nGeneXpert results as received\\n• TB LAM should be considered for eligible PLHIV2\\no Positive TB LAM test – initiate DS TB treatment. Evaluate once GeneXpert results \\nreceived\\no NB: A negative TB LAM test does not rule out TB• If not available, collect and refer sample for \\nGeneXpert\\n• TB LAM should be considered for eligible PLHIV2\\n• Positive TB LAM test – initiate DS TB treatment. \\nEvaluate once GeneXpert results received\\n• NB: A negative TB LAM test does not rule out TB\\nGene Xpert ResultsDoes the client have any of the following symptoms?\\n4. Unintended weight loss\\n5. Chest Pain\\n6. BMI less than 18.5 or Z score   -21. Cough of any duration\\n2. Hotness of Body\\n3. Drenching night sweats\\nYES NOYES NOYES NOYES NOYES NOis the initial  test  for TB a has no smear  \\nSHOULD  BE USED  as sample  is & for \\nTB LAM  should  be used  among  PLHIV  as per TB LAM  SHOULD  be used  as an to  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 174}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n8 - 4 \\nMTB Detected\\nRifampicin Resistance Detected \\n(RR)MTB Detected\\nRifampicin Resistance not \\nDetected (TR)MTB not Detected \\n(N)MTB Detected 1\\nRifampicin Resistance \\ninditerminate (TI)MTB \\nDetected \\nTrace4Invalid/\\nError\\n1. Collect another \\nsample and repeat \\nGeneXpert test.\\n2. Treat as per the \\nrepeat results1. Collect a sample for FL & SL LPA, \\nculture and 1st and 2nd line DST\\n2. Conduct baseline work up on DR \\nTB treatment\\n3. Comprehensive review by a DR \\nTB clinical review team.\\n4. Start DR TB treatment as per the \\nguidelines.Patients at high risk of DR TB \\ngroups\\n1. Collect a sample of FL & SL \\nLPA, culture and 1st and 2nd \\nLine DST\\n2. Start DS TB treatment while \\nawaiting DST results.Patients at low  \\nrisk of DR TB \\ngroups\\n1. Start DS TB \\ntreatments.• If already on TB treatment (smear \\npositive, TB LAM positive), continue until \\nother diagnostic test results received and \\nreviewed even if MTB Not Detected\\n• NTM is likely if smear microscopy was \\npositive, and MTB not detected on \\nGeneXpert\\n- Send a sample for culture for definitive \\ndiagnosis of NTM\\n- Continue with TB treatment until \\nculture results received and reviewed\\n• Evaluate for other respiratory illnesses \\ne.g. asthma, pneumonias, COPD, \\nbronchiectasis and cancer as other \\npossible conditions\\n• Obtain a CXR and review with CXR3 report \\nand treat for TB as applicable\\n• Consider EPTB\\n• Refer for further evaluation when a \\ndefinitive diagnosis is yet to be found\\n• Consider repeat GeneXpert1. Treat as DS TB\\n2. Immediately \\ncollect another \\nsample and \\nrepeat GeneXpert \\n(Ultra) test\\n3. Collect a sample \\nfor FL & SL LPA, \\nculture and 1st \\nand 2nd line DST\\n4. Revise regimen \\nbased on DST \\nresults.Based on DST results, DR \\nTB clinical team to adjust \\nregimen as necessary.Revised treatment based on DST \\nresults Follow up as per guidelines\\n• Follow up as per DR TB treatment \\nguidelines\\n• Mandatory clinical review meetings \\nfor Patients\\n• Monthly smears and cultures are \\nmandatory during the treatment \\nduration.Follow up:\\n1. Clinical improvement assessment\\n2. Smear microscopy at months 2/3,5,6\\n3. If drug resistance is detected, treat \\nfor DR TB as per guidelines.DR TB DS TBGene Xpert Results \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 175}),\n",
       " Document(page_content=' \\nTB/HIV Co -infection, Prevention and Management  \\n \\n8 - 5 \\n \\nFootnotes\\n1 Samples for GeneXpert, sputum, CSF, Pleural aspirate, \\nPeriloneal fluid, synovial fluid, Gastric Aspirate, \\nNasopharyngeal aspirate, FNA, Lymph node biopsy, Pus, \\nstool\\n2 Indications for use of TB -LAM, as an adjunct test to \\nGeneXpert:\\n• PLHIV with advanced disease (WHO stage 3 or 4 or \\nCD4 count  200 cells/mm3 (or 25% for children \\n 5years old) with presumed TB\\n• PLHIV that have any danger signs of severe illness: \\nrespiratory rate ˃30breaths per minute, \\ntemperature ˃39°C, heart rate˃120beats per minute, \\nunable to walk unaided\\n• Currently admitted to hospital\\n3 All CHEST X -rays should be reported and the reports \\nreviewed by the clinician for definitive management. \\nRefer to the CXR algorithm for TB diagnosis\\n4 MTB detected Trace – Results from sample with few \\nbacilli (paucibacillary TB).  Rifampicin resistance status.\\nHIV Testing, using the HTS algorithm 1, is \\nrecommended during TB screening and diagnosis.\\nScreening for diabetes is recommended among all \\nadult patients with TB disease\\nKey\\nCBR - Chest X -ray\\nDR TB - Drug Resistant TB\\nDS TB - Drug Susceptible TB\\nDST - Drug Susceptibility \\nTesting\\nEPTB   - Extra Pulmonary TB\\nFL - First LineLPA Line Probe Assay\\nMTB Mycobacteria \\nTuberculosis\\nNTM Non -Tuberculous \\nMycobacteria\\nTST Tuberculin Skin test\\nSL Second lineDR TB risk classification among \\npatients\\nHigh risk for DR TB*\\n1. All previously treated TB \\npatients: treatment failures, \\nrelapses, treatment after loss to \\nfollow up\\n2. Contacts  of Drug Resistant TB \\npatients\\n3. TB patients with a positive \\nsmear result at month 2 or \\nmonth 5 of TB treatment\\n4. Patient who develops TB \\nsymptoms while on IPT or has \\nhad previous IPT exposure\\n5. Healthcare workers with 18 \\nsymptoms\\n6. Prisoners with TB symptoms\\n7. Refugees with TB symptoms\\nLow risk for DR TB\\nAll presumptive TB cases who are \\nNOT  in the high risk group\\n*ALL the high risk patients MUST  \\nbe prioritized to receive DST, \\nGeneXpert, FL and SL LPA, \\nculture and FL and SL DST.DS TB follow up and DR TB surveillance\\nPOSITIVE SMEAR \\nRESULT ATAction\\nMonth 2/3 • Evaluate for adherence, and other causes of delayed conversion\\n• Request for all the following drug susceptibility tests (DST); GeneXpert, FL, LPA and \\nSL, LPA, Culture and FL and SL DST\\n• Continue with RHZE for one more month, or longer if DST results not received by then\\n• Adjust treatment regimen based on DST results\\n• Repeat smear microscopy at end of month 3. If smear positive continue with RHZE and \\nreview DST results and inform the SCTLC immediately\\n• Do not proceed to the continuation phase (RH) without a DST result confirming \\nsusceptibility to RH (rifampicin and isoniazid)\\nMonth 5 or \\nMonth 6• Declare treatment failure and stop anti -TB treatment\\n• Review by the sub county and county TB clinical review teams\\n• Evaluate for adherence, other causes of delayed conversion and treatment failure\\n• Request for GeneXpert, FL LPA and SL LPA, culture and FL and SL DST\\n• Review DST results and re -initiate treatment based on DST results and other clinical \\nfindings\\nDS TB follow up and DR TB surveillance\\nSmear Positive or \\nculture positive \\nat months 3 or \\nlater• Evaluate for adherence, and  other causes of delay conversion\\n• Request for the following drug susceptibility tests (DSTI) (GeneXpert, Culture and \\nFirst Line (FL) and SL DST, FL LPA and SL LPA) depending on the initial resistance \\npattern\\no Review by the sub county and county clinical review teams\\n▪ Evaluate for adherence, other causes of reversion and treatment failure\\n▪ Review the DST results\\no Declare failure if at the end of the extended intensive phase  (refer to DR TB \\nguidelines)\\no Send a case summary to the national clinical team after review by the county clinical \\nteam\\n• Do not proceed to the continuation phase (depending on treatment regimen) without a \\nDST result\\n• Declare treatment failure\\no Review by the sub county and county clinical review teams\\n▪ Evaluate for adherence, other causes of reversion and treatment failure\\n▪ Review the DST results\\n• Send a case summary to the national clinical team after review by the county clinical \\nteamMOH/DNTLDP/TBSDXALG/01\\nSeptember 2020Smear Positive \\nsmears and/or \\ncultures during \\ncontinuation \\nphase \\nFigure 8.1: TB diagnosis - GeneXpert Ultra algorithm', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 176}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 8 - 6 Table 8.1: TB Diagnosis in Children <10 Years Old  \\nALGORITHM FOR PULMONARY TB DIAGNOSIS IN CHILDREN  \\nHistory of \\npresenting \\nillness  For all children presenting to a health facility ask for the following suggestive \\nsymptoms  \\n● Cough  \\n● Fever  \\n● Poor weight gain  \\n● Lethargy or reduced playfulness  \\nSuspect TB if the child has two or more of these suggestive symptoms  \\nAsk for history of contact with adult/adolescent with chronic cough or TB within the \\nlast 2 years  \\nClinical \\nevaluation  Examine the child and check for:  \\n● Temperature > 37.5o (fever)  \\n● Weight (to confirm poor weight gain, weight loss) – check growth monitoring \\ncurve)  \\n● Respiratory rate (fast breathing)  \\n● Respiratory system examination – any abnormal findings  \\nExamine other systems for abnormal signs suggestive of extra -pulmonary TB#  \\nInvesti gation\\ns Obtain specimen’ for Xpert MTB/RIF (and culture when indicated**)  \\nDo a chest Xray (where available)  \\nDo a Mantoux test** (where available)  \\nDo a HIV test  \\nDo other tests to diagnose extra -pulmonary TB where suspected#  \\nDiagnosis  Bacteriologically  \\nConfirmed TB:  \\nDiagnosis if \\nspecimen is \\npositive for MTB  Clinical Diagnosis of PTB:  \\nChild has two or more of the following suggestive symptoms  \\n● Persistent cough, fever, poor weight gain, lethargy  \\nPLUS, two or more of the following:  \\n● Positive contact, abnormal respiratory signs, abnormal, \\npositive Mantoux  \\nNote: If the child has clinical signs suggestive of EPTB, refer to \\nEPTB diagnostic table*  \\nTreatment  Treat for TB as follows:  \\n● All children with bacteriologically confirmed TB \\n● All children with a clinical diagnosis of TB  \\nNB: In children who do not have an Xpert result, or their Xpert results is negative, but \\nthey have clinical signs and symptoms suggestive of TB they should be treated for TB  \\nAll forms of TB (Except TB meningitis, bone and joint TB) Treat for 6 months (2 RH ZE/ \\n4 RH)  \\nTB meningitis, bone and joint TB: Treat for 12 months ( 2 RHZE/ 10 RH)  \\n*Specimen may include: Expectorated sputum (child > 5 years), induced sputum, nasopharyngeal \\naspirate and gastric aspirate. Attempt to obtain specimen in every child  \\n**Do a cultu re and DST for the following children:  \\n1. Rifampicin resistance detected by the Xpert test  \\n2. Refugees and children in contact with anyone who has Drug Resistant TB  \\n3. Those not responding to TB treatment  \\n4. Those with indeterminate Xpert results  \\n***This may include IGRA in facilities where it is available  \\n#Use IMCI guidelines to classify severity of disease   \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 177}),\n",
       " Document(page_content=' \\nTB/HIV Co -infection, Prevention and Management  \\n \\n8 - 7 \\n Table 8.2: Drug Susceptible TB Treatment Regimen for Children, Adolescents and Adults  \\nTB disease category  Recommended regimen  \\nIntensive phase        Continuation phase  \\nAll forms of TB except TB meningitis, bone \\nand joint TB (osteoarticular TB)  2 RHZE  4 RH  \\nTB meningitis   \\nOsteoarticular TB  2 RHZE  10 RH  \\nDrug resistant TB  Refer to a DRTB Clinical Team  \\n● Follow up smears should be done for all bacteriologically confirmed pulmonary TB cases at end of \\nmonth 2, 5 and 6 of TB treatment using smear microscopy  \\n● Follow up of RR TB and DR TB should be done as per PMDT guidelines  \\n● Patients taking isoniazid containing regimen should also be given Pyridoxine (Vitamin B6) daily for \\nthe duration of treatment to reduce the risk of developing peripheral neuropathy (see Annex 10 for \\npyridoxine dosing)  \\nOnce TB treatment is started it should be completed; unless another definitive diagnosis (like lung \\ncancer) is established and TB is ruled out.  \\n \\n \\n \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 178}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 8 - 8  \\nTB-LAM is a rapid point -of-care urine dip -stick test that can be performed at the bedside. LAM stands for \\nlipoarabinomannan, which  can be detected in urine when it sheds off of the TB  cell wall . \\nGeneXpert is the recommended initial diagnostic test for people with presumptive TB.\\nTB-LAM SHOULD NOT be used as an alternative test to GeneXpert, but can be performed  to help diagnose TB while \\nwaiting for GeneXpert test results. TB -LAM cannot detect resistance to rifampicin.\\nIndications for use of TB -LAM, as an adjunct test to GeneXpert:\\n• PLHIV with advanced disease (WHO stage 3 or 4 or CD4 count       cells/mm3 (or       for children     \\nyears old)) with presumed TB \\n• PLHIV that have any danger signs of severe illness: respiratory rate >30 breaths per minute, temperature >39°C, \\nheart rate >120 beats per minute, unable to walk unaided\\n• Currently admitted to hospital \\nLF-LAM Negative LF-LAM Positive\\nTB is not ruled out \\n• Evaluate the clinical response after 3–5 days of \\nantibiotic treatment, while awaiting GeneXpert \\nresultsTB is likely\\n• Initiate TB treatment\\n• Conduct additional investigations for TB \\nand other HIV related diseases as \\nappropriate\\n• Continue TB treatment even if GeneXpert \\nresults come back negative\\nClinical improvementClinical worsening or no \\nimprovement\\nTB is unlikely\\n• Conduct additional investigations for TB and \\nother opportunistic illnesses\\n• Complete the course of parenteral antibiotics\\nNote: \\n• If GeneXpert results are positive for TB, \\ninitiate TB treatment irrespective of TB -LAM \\nresults or clinical improvement \\n• If GeneXpert results are negative for TB, \\nconsider TPTTB is likely\\n• Start TB treatment if patient is seriously \\nill or if GeneXpert results come back \\npositive (irrespective of TB -LAM results)\\n• Conduct additional investigations for TB \\nand other HIV -related diseases\\n• Complete the course of parenteral \\nantibiotics\\n \\nFigure 8.2: Use of TB-LAM for Diagnosis of TB among PLHIV  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 179}),\n",
       " Document(page_content='  \\nTB/HIV Co -infection, Prevention and Management  \\n \\n8 - 9 8.2. TB Preventive Therapy (TPT)  \\nThis section summarizes the current national recommendations for treatment of latent TB \\ninfections (LTBI) in the PLHIV population. These are in line with the updated World Health \\nOrganization guidelines which include the use of shorter, safer LTBI treatment options for an \\nexpanded at -risk population. For further guidance, refer to the national guidelines on LTBI \\nmanagement.  \\n8.2.1. Indications for TPT  \\nTPT should be provided to those p atients in whom TB is excluded (using the ICF tool) and meet \\nthe eligibility criteria to initiate TPT. The following client categories are eligible for TPT who \\nscreen negative for active TB  \\n● All PLHIV above 12 months of age (children, adolescents and adults  including pregnant \\nand breastfeeding women)  \\n● All household contacts of persons with bacteriologically confirmed pulmonary TB            \\n● Prisoners and staff working in prison setting            \\n● Health care workers and other staff in health care setting  \\n● Other clinical risk groups as defined in LTBI guidelines  \\n*Neonates born to mothers with TB, or exposed to close contacts with TB should be given TPT \\nonce TB disease has been ruled out. BCG should be given 2 weeks after completion of TPT or anti -\\nTB treatment  \\nSummary of recommendations for TPT among the PLHIV  \\n● PLHIV are at a much higher risk of getting TB disease compared to the general population  \\n● TB preventive therapy should be given to all PLHIV above 12 months of age who do not \\nhave active TB disease. This should be done irrespective of immune status, ART status, \\nprevious history of TB and pregnancy status.  \\n● Children aged <12 months living with HIV who are household contacts of a person with \\nbacteriologically confirmed pulmonary TB, and whom act ive TB has been ruled out \\nshould receive TB preventive therapy.  \\n● TPT may be given immediately following successful completion of TB treatment among \\nthe PLHIV.  \\n● Repeat TPT is not recommended among PLHIV except if a PLHIV becomes a \\nhousehold contact of a perso n with bacteriologically confirmed pulmonary TB  \\n● PLHIV aged 15 years and above should be provided with 3 months of weekly Rifapentine \\nand Isoniazid (3HP), while those less than 15 years are given 6 months of daily INH (6H)  \\n● In PLHIV on PI/r -based ART, pregna nt women and those who do not tolerate 3HP should \\nbe given six months of daily INH (6H)  \\n● For eligible patients previously treated for TB, initiate TPT upon completion of their TB \\ntreatment.  \\n      \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 180}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 8 - 10 8.2.2. Contraindications to TPT  \\nPatients with the following should not receive TPT until the underlying issue(s) are \\naddressed  \\n● Active tuberculosis disease  \\n● Active hepatitis (acute or chronic)  \\n● Chronic alcohol abuse      \\n● Symptoms of peripheral neuropathy  \\n \\n8.2.3. Dose and Duration of TPT  \\nTable 8.3: Recommended TPT Regimens for PLHIV  \\nTarget populations  TPT Regimen  \\n● Adult PLHIV excluding patients \\non PI/r -based ARV regimens  Rifapentine and Isoniazid (3HP)  \\nOnce weekly for three months  \\n          (12 doses)  \\n● Adult PLHIV on PI/r -based ARV \\nregimens  \\n● All CALHIV aged below 15 years  \\n● Any patient with intolerance or \\ncontraindication to 3HP  \\n● Pregnant women  Isoniazid (6H)  \\nOnce daily for 6 months  \\n● The 3RH (rifampicin and isoniazid) regimen is not recommended for PLHIV due \\nto drug - drug interactions  \\n● All TPT regimens should be given with Vitamin B6 (pyridoxine), if available, to \\nreduce the risk of developing peripheral neuropathy  \\n● Comprehensive health  education and adherence counselling should be \\nconducted prior to initiation of TPT  \\n● Dosing of TPT is in Annex 10  \\n \\n● Children should be weighed at each visit and correct weight -based dosing confirmed.  \\n● Clients on 3HP should receive weekly dose of pyridoxine, Those on Rifapentine and \\nIsoniazid regimen should be given pyridoxine once a week  \\n● The 3RH (rifampicin and isoniazid) regimen is not recommended for PLHIV due \\nto drug -drug interactions. 3RH is used in HIV negative populations   \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 181}),\n",
       " Document(page_content='  \\nTB/HIV Co -infection, Prevention and Management  \\n \\n8 - 11 8.2.4. Follow -up of Patients on TPT  \\nPatients on TPT should be followed up on a monthly basis and their return -to-clinic dates \\nharmonized with any other routine schedules. During each clinic visit, conduct the following;  \\n● Symptom screening for active TB disease and update status  \\n● Assess and reinforce adherence to treatment  \\n● If a patient screens positive for TB while on TPT, stop TPT and manage according to \\nNational TB guidelines  \\n● Assess for any adverse drug reactions at each visit and intervene appropriately  \\n● Provide/update TPT appointment card  \\n● Document and update the relevant recording and reporting tools, e.g., ICF/TPT cards, \\nContact Management/TPT register  \\n● Document outcome of TPT use e.g., completion in the relevant tools and/or EMR  \\n*Baseline liver function tests are not mandatory for patients initiating TPT. These may, however, be \\nconsidered on an individual ba sis, especially for patients taking other medications for chronic \\nmedical conditions or symptomatic patients suspected to have active hepatitis  \\n \\n8.3. Identifying and Managing Drug Toxicities from TPT  \\nThe management of drug toxicities should be based on severity, with appropriate grading of \\nindividual patients. The most common adverse drug reactions associated with TPT are peripheral \\nneuropathy, drug -induced liver injury (DILI), and rash.  \\n8.3.1 Periphe ral Neuropathy - Suspected drug: INH        \\nDiagnosis of Peripheral Neuropathy  \\n● Symptoms include: burning sensation, numbness, or tingling, usually starting at the feet \\non both sides  \\n● May have decreased sensation on examination  \\n● May develop weakness in severe cases  \\n● May be potentiated by other neurotoxic drugs, alcoholism, metabolic disease (e.g., \\ndiabetes), malnutrition and infections  \\n● Rarely severe enough to require drug withdrawal  \\nManagement of INH -induced Peripheral Neuropathy  \\n● Increase the dose of pyridoxine to 100 mg per day  \\n● For children give double the standard weight -based dose  \\n● Assess for other causes of peripheral neuropathy (e.g., diabetes, thyroid disorder, B12 \\ndeficiency, syphilis, etc.)  \\n● Relief of symptoms can be achieved with analgesics, tricyclic antidepressants \\n(amitriptyline, nortriptyline), anticonvulsants (carbamazepine, phenytoin)  \\n● If symptoms do not improve, or there is any worsening, then discontinue TPT; symptoms \\nmay persist even  after discontinuing TPT  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 182}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 8 - 12 8.3.2 Drug -Induced Liver Injury (DILI) -Suspected drugs include Isoniazid (H), \\nRifapentine (P), Rifampicin (R)  \\n● Elevation of liver enzymes may occur in the first weeks of treatment  \\n● In asymptomatic patients, serum liver enzyme lev els do not need to be monitored \\nroutinely   \\n● All clients with gastrointestinal symptoms (nausea and vomiting, liver tenderness, \\nhepatomegaly or jaundice) should have their liver function assessed  \\n● Patients should be screened for other causes of liver injury  (the hepatitis viruses -A, B, C)  \\n● Table 8.4 shows the grading of liver injury and management of DILI  \\n● Once the drugs are discontinued, no attempt should be made to reintroduce these drugs \\nuntil liver functions have normalized  \\n● An expert with experience in managing DILI should be involved in the further \\nmanagement of such cases  \\nDiagnosis of DILI  \\n● Jaundice, a bdominal pain, nausea, vomiting, anorexia, etc.  \\n● Abnormal liver enzymes  \\n \\nTable 8.4: Grading and Management of DILI  \\n Grade 1: Mild  Grade 2: Moderate  Grade 3: Severe  Grade 4: Life \\nthreatening  \\nALT (SGPT)  1.25 – 2.5 x ULN  2.6 – 5.0 x ULN  5.1 – 10.0 x ULN  > 10.0 x ULN  \\nAST (SGOT)  1.25 – 2.5 x ULN  2.6 – 5.0 x ULN  5.1 – 10.0 x ULN  > 10.0 x ULN  \\n  \\n  \\n  \\nACTION  Continue treatment \\nregimen;  \\npatients should have \\nweekly followed up \\nuntil resolution \\n(return to baseline) \\nor stabilization of \\nAST/ALT elevation  Continue treatment \\nregimen;  \\npatients should have \\nweekly followed up \\nuntil resolution \\n(return to baseline) \\nor stabilization of \\nAST/ALT elevation  Stop all drugs, \\nincluding TPT \\ndrugs;  \\nmeasure LFTs \\nweekly;  \\nTPT should not  \\nbe reintroduced \\nafter severe DILI1 Stop all drugs, \\nincluding TPT drugs;  \\nmeasure LFTs weekly. \\nTPT should not  be \\nreintroduced after life \\nthreatening DILI1 \\n \\n \\n1. PLHIV who develop DILI during treatment of active TB disease, may have anti -TBs reintroduced \\nafter toxicity is resolved in consultation with a senior clinician  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 183}),\n",
       " Document(page_content='  \\nTB/HIV Co -infection, Prevention and Management  \\n \\n8 - 13 8.3.3 Management of TPT -associated Rash - Suspected Drugs include Isoniazid (H), \\nRifapentin e (P), Rifampicin (R)  \\n● A rash may occasionally develop, usually within a few days following initiation of TPT. It \\nis often a relatively mild maculopapular rash with or without pruritus.  \\n● Flu-like and other systemic hypersensitivity reactions are rare amongst children. \\nHypersensitivity reactions in adults are usually mild and self -limiting  \\n● Rarely, rash may develop with severe exfoliation of the skin and Stevens -Johnson \\nsyndrome  \\n● Rash severity should be assessed and managed appropriately as shown in table  8.5  \\n \\nTable 8.5: Management of TPT -Associated Skin Rash  \\nSeverity  Characteristics  Action  \\nMild  Dry; erythema +/ - fine \\npapules; pruritus; affecting \\n< 50% of body surface area  Continue TPT; close monitoring; symptomatic \\ntreatment with antihistamines +/ - topical steroids \\n(NOT oral steroids)  \\nModerate  Dry; erythema +/ - fine \\npapules; pruritus; affecting \\n≥ 50% of body surface area  Stop TPT; symptomatic treatment with \\nantihistamines +/ - topical steroids (NOT oral \\nsteroids); trial of desensitization after symptoms \\ncompletely resolved  \\nSevere  Mucosal involvement;  \\nblistering; associated \\nfever; any % of body \\nsurface area  Stop TPT; admission to hospital for supportive \\nmanagement (IV fluids, wound care, pain control, \\ninfection control, monitoring for super -infection); \\npatient should NEVER be re -challenged;  \\ndocument and report adverse event and issue \\npatient alert card  \\n \\n8.4. ART for TB/HIV Co -infection  \\nAs with all PLHIV, those who are diagnosed with TB/HIV co -infection should be on ART and CPT \\nas part of the comprehensive package of care for PLHIV.  \\nTiming of ART for TB/HIV Co -infection  \\n● Patients who are not yet on ART  \\no Start TB treatment immediately  \\no Initiate ART as soon as anti -TB medications are tolerated, preferably within 2 \\nweeks  \\no For TB meningitis delay ART for 4 to 8 weeks  \\no Monitor closely for IRIS (Annex 16)  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 184}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 8 - 14 ● Patients who are already on ART  \\no Start TB treatment immedi ately  \\no Continue ART, assessing for treatment failure and making any required \\nadjustments to the ART regimen based on drug -drug interactions (Table 8.7)  \\no Monitor closely for IRIS (Annex 16)  \\n● Patient being treated concurrently for TB and HIV require close monitoring for \\ntoxicity  \\n● MDR TB and HIV co -infection should be managed in settings where close toxicity \\nmonitoring and follow up by experienced clinicians or multi -disciplinary team is \\npossible       \\nPreferred ART regimens for patients with TB/HIV co -infecti on are summarized in Tables 8.6 - 8.8. \\nTable 8.6: Preferred ART Regimens for TB/HIV Co -infection for Patients Newly Initiating 1st \\nLine ART 1 \\nAge  Weight  1st Line ART if TB/HIV Co -infection  \\nBirth to 4 \\nweeks  Any  Start anti -TB treatment immediately; start ART after 4 weeks \\nof age, once tolerating anti -TB drugs (follow the regimen \\nrecommendations for children ≥ 4 weeks old)  \\n> 4 weeks to < \\n15 years  < 30 kg  ● ABC + 3TC + DTG  \\n● Increase DTG dosing frequency to twice daily for duration \\nof rifampicin -containing TB treatment and for an additional \\n2 weeks after TB treatment is completed, then revert to \\nonce daily dosing  \\n≥ 30 kg  ● Give TDF/3TC/DTG FDC morning + DTG 50mg evening for \\nduration of rifampicin -containing TB treatment and for an \\nadditional 2 weeks after TB treatment is completed, then \\nrevert to TDF/3TC/DTG FDC once daily  \\n≥ 15 years  Any  ● Give TDF/3TC/DTG FDC morning + DTG 50mg evening for \\nduration of rifampicin -containing TB treatment and for an \\nadditional 2 weeks after TB treatmen t is completed, then \\nrevert to TDF/3TC/DTG FDC once daily  \\n1 Refer to Annex 10 for weight -based ARV dosing  \\n \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 185}),\n",
       " Document(page_content='  \\nTB/HIV Co -infection, Prevention and Management  \\n \\n8 - 15 Table 8.7: Preferred ART Regimens for Patients who Develop TB while Virally Suppressed on \\n1st Line ART 1,2 \\nCurrent \\nRegimen3  Recommended Substitution  \\nPI/r -based4 All ages  ● Switch from PI/r to DTG and continue this regimen even after \\ncompleting TB treatment. Follow DTG dosing as below  \\n● If it is not possible to switch to DTG:  \\no Children < 30 kg requiring PI/r -based ART should receive \\nLPV/r with additional ritonavir super -boosting for the duration \\nof rifampicin -based TB therapy, reverting to standard LPV/r \\ndosing 2 weeks after completing TB treatment  \\no Patients ≥ 30 kg who cannot switch to DTG should be switched \\nto EFV -based ART and maintained on EFV -based ART after \\ncompletion of TB treatment  \\nRAL -based  All ages Switch from RAL to double -dose DTG dosing during TB treatment and \\nmaintain on DTG after completion of TB treatment  \\nDTG -based  All ages   \\nAdminister the double -dose of DTG (i.e., the standard weight -based \\ndose of DTG given twice daily) while taking rifampicin containing TB \\ntreatment. Two weeks after completion of TB treatment revert to the \\nrecommended DTG dose once daily.  \\n1 Always assess for HIV treatment failure in patients who develop TB after being on ART for ≥ 6 \\nmonths. For patients failing 1st line ART refer to Table 8.8 for recommended 2nd line regimens  \\n2 For patients on 2nd line ART, subsequent regimens, or nonstandard drugs who require regimen \\nchange because of TB treatment, consult the Regional or National HIV Clinical TWG (Uliza Hotline \\n0726  460 000; https://nhcsc.nascop.org/clinicalform ) \\n3 NRTIs in the patient’s current regimen do not require any adjustments with anti -TB treatment  \\n4 Use “super -boosted” LPV/r by adding additional ritonavir to manage the drug interaction between \\nLPV/r and rifampicin (see Annex 10 for dosing recommendations)  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 186}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 8 - 16 Table 8.8: Recommended ART Regimens for Patients who Develop TB while Failing 1st Line \\nART 1 \\nAge/  \\nScenario  First -line \\nART  Second -line ART  \\n< 30 kg \\nbody \\nweight  LPV/r -\\nbased 1st \\nline ● Start anti -TB immediately.  \\n● Change to DTG -based second -line immediately. Increase DTG dosing \\nfrequency to twice daily for duration of rifampicin -containing TB \\ntreatment and for an additional 2 weeks after TB treatment is completed, \\nthen revert to once daily dosin g  \\n● Immediately collect a sample for DRT2 \\n● Assess for and address reasons for treatment failure.  \\n● If unable to switch to DTG then use super -boosted LPV/r3 \\nABC (or \\nAZT) + \\n3TC + \\nDTG  ● Start anti -TB immediately  \\n● Increase DTG dosing frequency to twice daily for duration of rifampicin -\\ncontaining TB treatment and for an additional 2 weeks after TB treatment \\nis completed, then revert to once daily dosing.  \\n● Follow the viral load monitoring algorithm (Figure 6.6), inclu ding \\nassessing for and addressing reasons for treatment failure, and collecting \\nDRT. Consult the Regional or National TWG to constitute a second -line \\nregimen based on DRT results  \\n≥ 30 kg or \\n≥ 15 years \\nold TDF (or \\nABC or \\nAZT) + 3TC \\n+ DTG  ● Start anti -TB immediately  \\n● Give TDF/3TC/DTG FDC morning + DTG 50mg evening for duration of \\nrifampicin -containing TB treatment and for an additional 2 weeks after \\nTB treatment is completed, then revert to TDF/3TC/DTG FDC once daily  \\n● Follow the viral load monitoring algorithm (Figure 6.6), including \\nassessing for and addressing reasons for treatment failure, and collecting \\nDRT. Consult the Regional or National TWG to constitute a second -line \\nregimen based on DRT results  \\nTDF (or \\nABC or \\nAZT) + \\n3TC + EFV  ● Start anti -TB immediately  \\n● Continue current regimen while following the viral load monitoring \\nalgorithm (Figure 6.6), including assessing for and addressing reasons for \\ntreatment failure.  \\n● Once treatment failure is confirmed and patient ready to switch to 2nd \\nline, switch to TDF + 3TC + DTG (maintain the TDF, even if the patient was \\nalready on a TDF -containing regimen), increasing the DTG dose to twice \\ndaily for the duration of rifampicin -based TB therapy, switching back to \\nstandard DTG dose 2 weeks after rifampin is discontinued.  \\nPI/r -\\nbased 1st \\nline ● Start anti -TB immediately  \\n● Switch to TDF+3TC+DTG immediately. Give TDF/3TC/DTG FDC morning \\n+ DTG 50mg evening for duration of rifampicin -containing TB treatment \\nand for an additional 2 weeks after TB treatment is completed, then revert \\nto TDF/3TC/DTG FDC once daily  \\n● Immediately collect a sample for DRT2  \\n● Assess for and address reasons for treatment failure.  \\nPregnant or \\nBreastfeeding  Follow the same recommendations as for ≥ 30 kg or ≥ 15 years old.   \\nHIV/HBV \\nCo-infection  Always maintain TDF or TAF in second -line instead of switching to a different NRTI and \\ninstead of adding an additional NRTI  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 187}),\n",
       " Document(page_content='  \\nTB/HIV Co -infection, Prevention and Management  \\n \\n8 - 17 Table 8.8 Cont.  \\n1. For patients on 2nd line ART, subsequent regimens, drug intolerance, or nonstandard drugs who require \\nregimen change because of TB treatment, consult the Regional or National HIV Clinical TWG (Uliza Hotline \\n0726 460 000; https://nhcsc.nascop.org/clinicalform ) \\n2. Contact  the Regional or National HIV Clinical TWG (Uliza Hotline 0726 460 000; \\nhttps://nhcsc.nascop.org/clinicalform ) for guidance on urgent collection of DRT samples  \\n3. Use “super -boosted” LPV/r by adding additional ritonavir to manage the drug interaction between LPV/r \\nand rifampicin (see Annex 10 for dosing recommendations). Two weeks after TB treatment is completed \\nthe child should go back to standard LPV/r dosing.  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 188}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 8 - 18 ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 189}),\n",
       " Document(page_content='  \\nTB/HIV Co -infection, Prevention and Management  \\n \\n9 - 1  \\n9. HBV/HIV and HCV/HIV Co -infection \\nPrevention and Management  \\n9.1 Hepatitis B/HIV Co -infection  \\nHIV and Hepatitis -B Virus (HBV) share infection transmission routes.  Acute HBV infection in HIV \\npositive people is associated with increased risk of chronicity, reduced chances of spontaneous \\nclearance, higher rates of replication and reactivation and therefore increased incidence of \\nchronic liver disease, cirrhosis and hep atocellular carcinoma (HCC). Additionally, HIV/HBV co -\\ninfection has been associated with rapid HIV disease progression and poorer HIV treatment \\noutcomes.  Other complications of HIV/HBV co -infection include increased incidence of drug -\\nrelated hepatotoxicit y, drug -drug interactions and ART -related immune reconstitution hepatitis.  \\n9.1.1 Screening  \\nAll adolescents and adults living with HIV (plus children who did not complete routine childhood \\nimmunizations) should be screened for HBV infection, using HBsAg, as part of initial evaluation. \\nTo promote population -wide prevention, hepatitis B prevention should be integrated into \\nroutine HIV prevention and care programs. In this setting, other indications for HBsAg screening \\ncould include  \\n▪ Household and sexual contacts of HBsAg positive individuals  \\n▪ Pregnant women  \\n▪ Persons who inject drugs (PWID)  \\n▪ Men who have sex with men  \\n▪ Sex workers  \\n▪ Persons with multiple sexual partners  \\n▪ Prisoners  \\n▪ Blood donors  \\n▪ Unvaccinated healthcare providers  \\n \\nPLHIV on follow -up who presen t with signs of liver disease (jaundice, ascites, abnormal liver on \\npalpation, other signs of cirrhosis) or unexplained and persistent ALT elevation should also be \\nscreened for HBV as part of their work -up. \\n9.1.2 Prevention  \\nA. Vaccination : HBV vaccination reduces the risk of new (incident) HBV infection in PLHIV and \\nalso reduces the risk of new infections becoming chronic. Therefore;  \\n● HIV positive infants, children, adolescents and adults without evidence of hepatitis B \\ninfection (HBsAg negative)  should be vaccinated against hepatitis B (Table 9.1)  \\n● HIV exposed infants (HEI) should also receive hepatitis B vaccination as part of childhood \\nimmunization (Table 4.21)  \\n● As a strategy to reduce the population level burden of HBV infection, HIV prevention and \\ntreatment settings should integrate HBV prevention through vaccination. Thus, HBV \\nvaccination is recommended for the following groups who test HBsAg negative.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 190}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 9 - 2 o Babies and young children (through EPI and catch -up immunization for those who \\nmissed EPI vac cination)  \\no Household contacts of HBsAg positive people  \\no Sexual contacts of HBsAg positive people  \\no People on haemodialysis  \\no PWID  \\no Individuals with chronic liver disease and/or hepatitis C  \\no Inmates and prison personnel  \\no Healthcare workers  \\nTable 9.1: Hepatitis B Vaccination Schedule for HIV -positive Adolescents and Adults  \\nVaccine  Dose (intramuscular)  Schedule  \\nNon -adjuvanted formulation  Double the standard dose   \\n0, 1, 2, and 6 months  Adjuvanted formulation  Standard dose  \\n*Booster vaccination is not required for persons who have completed the full vaccination schedule  \\nB. General preventive measures:  General measures for infection prevention adopted by \\nPLHIV and in healthcare settings are effective in preventing HBV transmission. The se \\ninclude  \\n● Hand hygiene  \\n● Use of personal protective equipment  \\n● Medical waste management including safe disposal of used sharps  \\n● Disinfection and sterilization  \\n● General health advice against sharing of personal effects like towels, tooth -brushes, \\nrazors, combs and other grooming equipment  \\n● Harm reduction counselling and services for PWID as outlined in Chapter 12  \\n● Safer sex practices  \\n9.1.3 Treatment  \\nA. When to start ART  \\nAll HIV infected patients who are co -infected with hepatitis B should be started on ART \\nirrespective of CD4 cell count, WHO clinical stage or stage of liver disease  \\n \\nThe general recommendations for treatment preparation, adherence counselling and support \\nand monitoring of therapy for PLHIV apply. However, because HBV positive patients are at higher \\nrisk of hepatotoxicity, closer monitoring of liver function (with ALT) is advised. Table 9.2 \\nprovides a summary of areas of focus during initial evaluation for HIV/HBV co -infected patients \\ninitiating therapy.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 191}),\n",
       " Document(page_content='  \\nTB/HIV Co -infection, Prevention and Management  \\n \\n9 - 3 B. Recommended first -line ART in HIV/HBV co -infection  \\nThe recommended first -line ART in adolescents and adults with HIV/HBV co -infection \\nis TDF + 3TC + DTG, including for women and adolescent girls of childbearing potential  \\n \\nTreatment with both TDF (or TAF) and 3TC is recommended as 3TC without TDF or TAF will \\nresult in rapid emergence of resistance. In case of renal impairment (as assessed by creatinine \\nclearance), the dose of TDF and 3TC should be adjusted (Table 9.3).  \\nTable 9.2: Summary of Initial Clinical and Labora tory Evaluation in HIV/HBV Co -infection  \\n Findings  Action  \\nHistory  Alcohol use, cigarette \\nsmoking, intravenous drug \\nuse, risky sexual practices, \\nanorexia, right upper \\nquadrant pain, jaundice, early \\nsatiety, haematemesis, dark \\nstool, bleeding, pruritus  Assess, counsel and support to stop taking \\nalcohol; counsel and support smoking \\ncessation; counsel and provide or refer for \\nharm reduction interventions  \\ndiscuss or refer to a consultant for additional \\nevaluation and management  \\nPhysical \\nexamination  Enlarged liver, enlarged \\nspleen, ascites, scratch marks  Evidence of established chronic liver disease, \\ncloser follow -up due to increased risk of \\nhepatotoxicity.  \\ndiscuss or refer to a consultant for additional \\nevaluation and management  \\nALT  If elevated, may point to \\nactive liver disease. Exclude \\nother causes of elevation of \\nliver enzymes  Every effort should be made to assess for \\nother liver function (albumin and INR), \\nespecially in symptomatic patients. However, \\nthis should not delay initiation of ART  \\nCreatinine  Calculate creatinine clearance  In HIV/HBV co -infection, TDF is indicated \\neven in patients with CrCl < 50 ml/min. In \\nsuch patients, avoid FDCs. Instead administer \\nthe ART as single drugs to allow for dosage \\nadjustment as shown in Table 9.3  \\nComorbidities  HCV antibody, random blood \\nsugar, lipid profile, alcoholic \\nand non -alcoholic liver \\ndisease, hepatocellular \\ncarcinoma (family history)  Consult/Refer the patient for additional \\ninvestigations where these are suspected  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 192}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 9 - 4 Table 9.3: Dose Adjustment of TDF and 3TC in Patients with Impaired Renal Function 1 \\nDrug  Creatinine clearance (ml/min)  Haemodialysis  \\n50 - 80 30-49 10-29 \\nTDF 33 mg/g \\ngranules  \\n(=1scoop)  245 mg (7.5 scoops of \\ngranules or 245mg \\nfilm -coated tablet) \\nonce daily  132 mg (4 \\nscoops of \\ngranules) once \\ndaily  65 mg (2 scoops \\nof granules once \\ndaily  16.5 mg (0.5 scoop) \\nafter each 4 hr session \\nof dialysis  \\n \\nTDF 300 mg  Unchanged: 300 mg \\nonce daily  300 mg every  \\n48 hrs  300 mg every 72 to 96 hours (twice \\nweekly). For patients getting hemodialysis, \\nadminister 300 mg once weekly after \\ncompletion of dialysis sessions 2 \\n3TC 300mg  Unchanged: 300 mg \\nonce daily or 150 mg \\nBD  150 mg once \\ndaily  150 mg once \\ndaily  50 mg first dose,  \\n25 mg once daily  \\n1 Patients with impaired renal function in whom the benefits of continued use of TDF outweighs the \\nrisks (such as in the management of HIV/HBV co -infection) should be managed with input from a \\nspecialist in internal/paediatric or renal medicine  \\n2 Assuming 3 haemodialysis sessions per week, each of approximately 4 hours duration or after 12 \\nhours cumulative haemodialysis  \\n \\nC. Follow -up/Monitoring  \\nFollow -up of HIV/HBV co -infected patients should be as for all other patients on ART. However, \\nconsider more frequent monitoring (using ALT) for patients with active liver disease (jaundice, \\nliver cirrhosis and features of portal hypertension) at baseline.  The presence of co -infection also \\nincreases the risk of drug -related hepatotoxicity from all classes of ARVs by 3 -5 times, especially \\nwhen anti -TB and ART are given simultaneously. Also, hepatic flare -up (AST > 5 times normal \\nvalue) can occur, often in th e initial 3 months.  \\nNote:  ALT elevations 5 -10 times normal can be tolerated in the first 3 months of ART as \\nlong as the patient is not severely symptomatic, remains stable without progression, and \\nthere is no evidence of synthetic dysfunction (INR normal,  glucose normal, albumin \\nnormal).  \\nPatients with persistently elevated ALT levels during follow -up should be referred to a \\nspecialist. Subsequent laboratory monitoring after baseline should be conducted every 6 \\nmonths. Patients should be counselled and supp orted to abstain from consuming alcohol.  \\nD. Stopping treatment, /treatment interruptions  \\nTDF -containing ART should not be stopped in a patient with HIV/HBV co -infection as this may \\nresult in a flare -up of the hepatitis. If the regimen must be stopped and another alternative for \\nsuppressing hepatitis B cannot be found, liver enzymes should be monitored and treatment re -\\ninstated as soon as possible.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 193}),\n",
       " Document(page_content='  \\nTB/HIV Co -infection, Prevention and Management  \\n \\n9 - 5 E. Second line for HIV/ HBV co -infected  \\nMaintain TDF + 3TC in the ART regimen for patients switc hing from TDF -based -therapy.  So, for \\nexample, if a patient with HIV/HBV co -infection fails TDF/3TC/EFV in first -line, they should \\nswitch to TDF/3TC/DTG in second -line.  \\nHIV/HBV co -infected patients failing second -line ART should be discussed in the MDT and  \\ndiscussed with the Regional or National HIV Clinical TWG (Uliza Hotline 0726 460 000.)  \\n9.2 Hepatitis C/HIV Co -infection  \\nIn Kenya, the prevalence of HCV infection is high in PWID (estimated to be 12 -16%). The \\nprevalence in the general population and among PLHIV is low (estimated to be < 3%), but likely \\nto be higher in HIV infected PWID due to shared routes of transmission. HIV/ HCV co -infection is \\nassociated with  \\n• Rapid progression of liver fibrosis  \\n• Higher risk of deteriorating liver disease even in the pres ence of controlled HIV disease  \\n• Worsened hepatotoxicity as a result of ART and other drugs used in the treatment of \\ncomorbidities  \\nThus, HIV -positive persons at risk of HCV co -infection should be identified and offered HCV \\ntreatment. The recent introduction of direct acting antiviral therapies (DAAs) for treatment of \\nHCV has simplified the management of HIV/HCV co -infection, making it possible to manage \\nuncomplicated HIV/HCV infection safely even in primary care settings.  \\nHowever, treatment for H CV is a rapidly evolving field of therapeutics. Providers are encouraged \\nto seek regular updates on the subject and, when in doubt, to discuss individual cases with \\nexperienced providers.  \\n9.2.1 Screening  \\nHCV serology should be offered to individuals at ri sk of HCV infection. These include  \\n● People who inject or use intranasal drugs  \\n● Persons who have had tattoos, body piercing or scarification procedures from \\nsettings with doubtful infection prevention precautions  \\n● Children born to HCV positive mothers  \\nUp to 30 % of individuals who are infected with HCV spontaneously clear the infection. To confirm \\nchronic HCV infection, HCV positive individuals should be offered nucleic acid HCV RNA testing \\nto establish presence of chronic HCV infection.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 194}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 9 - 6 9.2.2 Prevention  \\nGeneral measures for prevention of blood -borne infections are effective in preventing HCV \\ntransmission.  \\n● Recommendations for healthcare settings  \\nTraining of healthcare providers on:  \\no Hand hygiene: including surgical hand preparation, hand -washing and use of gloves  \\no Safe handling and disposal of sharps and waste  \\no Effective disinfection and sterilization  \\no Provision of safe blood and blood products  \\n● Recommendations for PWID  \\no Harm reduction counselling and support (Table 12.1)  \\n● Recommendations for prevention of sexual transmission  \\no Correct and consistent condom use  \\no Access to prevention services for sex workers and other people at risk (including \\nscreening and treatment of STIs, frequent testing for HIV and HCV testing)  \\n \\n9.2.3 Treatment of HIV/HCV Co -infection  \\nTable 9.4: Summary of Initial Clinical and Laboratory Evaluation in HIV/HCV Co -infection  \\n Findings  Action  \\nHistory  Alcohol use, cigarette smoking, \\nintravenous drug use, risky sexual \\npractices, anorexia, right upper quadrant \\npain, jaundice, early satiety, haematemesis, \\ndark stool, bleeding, pruritus  Assess, counsel and support to stop \\ntaking alcohol; counsel and support \\nsmoking cessation; counsel provide \\nand refer for harm reduction \\ninterventions  \\nPhysical \\nexamination  Enlarged liver, enlarged spleen, ascites, \\nscratch marks  Evidence of established chronic liver \\ndisease, closer follow -up due to \\nincreased risk of hepatotoxicity, \\ndiscuss or refer to a consultant for \\nadditional evaluation and management  \\nHCV RNA PCR  For confirmation of chronic HCV  \\ninfection  If available, at baseline  \\nHCV genotype  May be important for selecting appropriate \\nDAA regimen. (Current regimens pan -\\ngenotypic, so HCV genotype testing not \\nrequired)   \\nALT  If elevated, may point to active liver \\ndisease. Exclude other causes of elevation \\nof liver enzymes  Every effort should be made to assess \\nfor liver function (albumin and INR), \\nespecially in symptomatic patients. \\nHowever, this should not delay \\ninitiation of ART  \\nComorbidities  HBV, random blood su gar, lipid profile, \\nalcoholic and non -alcoholic liver disease,  \\nhepatocellular carcinoma (family history)  Consult/Refer the patient for \\nadditional investigations where these \\nare suspected  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 195}),\n",
       " Document(page_content='  \\nTB/HIV Co -infection, Prevention and Management  \\n \\n9 - 7 Table 9.5: Recommended DAA for the Treatment of HCV among PLHIV  \\nGenotype  DAA Regimen*  Duration of treatment  \\n1 and 4  Sofosbuvir + Ledipasvir (Harvoni)  12 weeks  \\nAll Sofosbuvir + Velpatasvir (Epclusa)  12 weeks  \\n* DAA regimen availability continues to evolve; this table just shows the most readily available regimens at \\ntime of publication. Always start DAA HCV therapy, and review most recent drug -drug interactions with \\nARVs.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 196}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 9 - 8  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 197}),\n",
       " Document(page_content='  \\nARVs for Post -exposure Prophylaxis  \\n10 - 1  \\n10. ARVs for Post -exposure Prophylaxis  \\n \\n \\nAn ARV regimen, with preferably three -drugs, should be offered as post exposure prophylaxis as \\nsoon as possible (preferably within 72 hours) after an exposure.  \\n  \\n10.1 What is PEP?  \\nPost -exposure prophylaxis (PEP) is short -term use of antiretroviral treatment to reduce the \\nlikelihood of HIV infection after potential exposure.  \\nPeople can be accidentally exposed to HIV through healthcare work or due to exposures outside \\nhealthcare setting, for example, through unprotected sex or sexual assault among adults and \\nchildren. Healthcare workers are at increased risk of exposure to HIV through contact with \\ncontaminated blood and other body fluids  containing HIV through needle stick injuries and \\ninjuries by other sharp objects or through non -intact skin and mucous membranes.  \\n10.2 Recommended ARVs for PEP  \\nThree -drug regimens are preferred for PEP. However, if the person is unable to tolerate the thi rd \\ndrug, (usually the PI/r), two drugs  can be used.  \\nTable 10.1: Recommended ARVs for PEP  \\nAge  Weight  Preferred  Alternate  \\n \\n \\n<15 years  < 30kg  ABC + 3TC + DTG  ● AZT + 3TC + DTG  \\n● AZT+3TC and LPV/r may be used \\nas the third drug  \\n≥ 30 kg  TDF + 3TC /FTC + DTG  ● TDF+3TC/FTC and ATV/r may be \\nused as alternative third drug  \\n≥ 15 years  Any weight  TDF + 3TC/FTC + DTG  ● TDF+3TC/FTC and ATV/r may be \\nused as alternative third drug  \\n.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 198}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 10 - 2 10.3 Eligibility For PEP  \\nPEP should always be offered as soon as possible, preferably within 72 hours, after an exposure.  \\nPersons who present after 72 hours should be provided with other appropriate services including \\ncounselling and support.  \\nEligibilit y assessment for PEP is based on the type of exposure, HIV status of source where \\npossible and timing of seeking care.  \\nThe following include the eligibility criteria for PEP.  \\n● Exposed individual is HIV negative at baseline.  \\n● Exposure must have occurred within the past 72 hours.  \\n● Exposure to bodily fluids pose a significant risk (exposure and/or material):  \\n▪ Type of exposure:  mucous membrane (i.e.  sexual exposure; splashes to eye, nose, or \\noral cavity), non -intact skin, percutaneous injury or paren teral exposures  \\n▪ Material : blood, blood -stained body fluids, breast milk; semen; vaginal secretions; \\nsynovial, pleural, pericardial, amniotic fluids; CSF, and HIV cultures in laboratories  \\nExposures that do not require HIV PEP include:  \\n● When the exposed individual is already HIV positive.  \\n● Exposures to bodily fluids that do not pose a significant risk, i.e., tears, non -blood -stained \\nsaliva, urine, and sweat.  \\n10.4 Management and Follow Up  \\nPatients should be counselled and encouraged to complete the full course of PEP once a decision \\nhas been made to initiate PEP.  \\nFor occupational exposure, immediate care of the exposure site includes washing the site with \\nsoap and water and allow the wound  to bleed freely for several minutes  \\nNOTE: Do not do anything that will increase tissue damage such as squeezing, scrubbing, or \\ncutting the site further . \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 199}),\n",
       " Document(page_content='  \\nARVs for Post -exposure Prophylaxis  \\n10 - 3 Table 10.2: Recommendations for PEP Management and Follow -up \\nConsiderations  Recommendation  \\nManagement at initial \\ncontact  ● Counsel on risks and benefits of PEP and obtain verbal consent for HIV \\ntesting.  \\n● Voluntary testing for both exposed and source individuals  \\n● Offer PEP as soon as high -risk exposure is established and the exposed \\nindividual tests HIV-negative at baseline (if HIV testing not feasible, \\noffer 1 -2 days of PEP to cover until HIV test performed)  \\n● Provide first aid in case of broken skin or other type of wound  \\nTime of initiation  As soon as possible after exposure, but no later than after 72 hours  \\nDuration of PEP  28 days (dispense all 28 days of treatment at the first visit if tested HIV negative)  \\nDose of PEP  Same as indicated for treatment; use weight -based dosing for children  \\nLaboratory \\ninvestigation at \\nbaseline  ● Conduct creatine testing (if TDF -containing regimen) and Hb (if AZT -\\ncontaining regimen), however PEP should be offered even when lab tests \\nare not available. Do not delay administration of PEP while waiting for lab \\nresults.  \\n● HBsAg testing is recommended. Do not del ay administration of PEP while \\nwaiting for lab results. If negative provide HBV vaccination  \\n● Pregnancy testing for women of childbearing potential in case of sexual \\nassault.  \\nFollow -up ● Follow up client at 7 days, 14 days, 28 days, and 12 weeks after starting \\nPEP  \\n● Assess for and manage side effects due to PEP  \\n● Follow -up HIV testing should be done at the completion of PEP and if \\nnegative, test again at 12 weeks  \\n● Link to HIV treatment if positive  \\nCounselling  Counselling at baseline should include:  \\n● Adherence counselling  \\n● Information on side effects  \\n● Risk reduction counselling  \\n● Trauma and mental health counselling  \\n● Specific support for sexual assault  \\nOther services for \\nsexual assault  ● STI prophylactic treatment to all (treat for vaginal/urethral discharge \\nsyndrome following the national STI algorithms)  \\n● Emergency contraception for non -pregnant women  \\n● Tetanus toxoid for any physical injury of skin or mucous membranes  \\n● Documentation of clinic evidence of assault and collection of foren sic \\nevidence  \\nRefer to post -rape care guidelines for additional details  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 200}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 10 - 4 10.5 Risk reduction counselling  \\nTo reduce the risk of further HIV transmission, it is necessary to prevent transmission to sexual \\npartners and the children of breastfeeding mothers. R isk reduction counselling should form part \\nof each consultation with the individual. Measures to reduce transmission to another person may \\ninclude:  \\n● The use of condoms and safe injecting practices to prevent secondary transmission  \\n● Avoiding blood donation until confirmed HIV negative at 12 weeks post exposure  \\nTable 10.3 Considerations for special circumstances  \\nCircumstance   Recommendation  \\nBreastfeeding women  • Breastfeeding is not a contraindication for PEP  \\n• The risks and benefits of continuing breastfeeding while HIV \\ntransmission risk is unknown and should be discussed with the \\nmother  \\nChildren  • HIV testing approaches for children should be in line with national \\nguidelines and age appropriate  \\n• Informed consent from the caregiver is needed  \\nAdolescents  • Requiring parental consent for adolescents can be a barrier to HIV \\ntesting, particularly in cases of sexual assault  \\n• HIV testing should be performed in accordance with national \\nguidelines and consenting requirements  \\n \\n10.6 Preventing HIV exposure  \\nTo avoid or minimize the risk of exposure to HIV the following infection prevention control (IPC) \\nmeasures are recommended:  \\n• Precautions should be taken when handling contaminated body fluids including the use \\nof appropriate barriers such as gloves, gowns, and goggles.  \\n• Care with sharps including minimizing blind surgical procedures and proper handling \\nand disposal o f sharps.  \\n• Safe disposal of contaminated waste  \\n• Safe handling of soiled linen.  \\n• Adequate disinfection procedures  \\n• Universal Hepatitis B vaccination of non -immune at -risk groups including HCWs, police, \\nprison staff and rescue workers.  \\nIn cases that do not requi re PEP, the exposed person should be counselled about limiting future \\nexposure risk.  \\n \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 201}),\n",
       " Document(page_content='  \\nPre-Exposure Prophylaxis (PrEP)  \\n11 - 1  \\n11. Pre-Exposure Prophylaxis (PrEP)  \\n \\nPre-exposure prophylaxis (PrEP) is the use of antiretroviral medication to prevent the acquisition \\nof HIV infection by an uninfected person at ongoing risk of acquiring HIV infection.  \\nPrEP is recommended for use as follows:  \\n• Daily Oral PrEP for all indivi duals, irrespective of gender or sexual orientation who are at risk \\nof HIV infection.  \\n• Event -Driven (ED) PrEP is currently recommended for all people born male who are not \\ntaking exogenous estradiol -based gender affirming hormones  \\n11.1 Indications for PrEP and Criteria for Eligibility   \\n11.1.1 Indications for PrEP  \\nPrEP is indicated for;  \\n● HIV uninfected persons at ongoing risk of HIV acquisition  \\n● Some risk situations that place one at ongoing risk include individuals or sexual partner/s \\nwho is/are:  \\no HIV positive and: not on ART, or on ART < 6 months, on ART with viral non -suppression, \\nor on ART with suspected poor adherence  \\no In sero -discordant relat ionships trying to conceive  \\no Of unknown HIV status and at high -risk of HIV infection  \\no Engaging in transactional sex or sex work  \\no With history of recent or current sexually transmitted infections  \\no With recurrent use of Post -Exposure Prophylaxis  \\no With a history of sex whilst under the influence of alcohol or recreational drugs  \\no Inconsistent or no condom use or unable to negotiate condom use during intercourse \\nwith persons of unknown HIV status  \\no Using injection drugs where needles and/or syringes are  shared  \\n11.1.2 HIV Risk Assessment  \\nClients accessing health services should be screened for HIV risk and additionally provided with \\ninformation on HIV prevention options available including the availability of PrEP. This is in \\naddition to the use of HIV testing services (HTS), as clients ar e assessed for HIV risk before testing.  \\nThe risk assessment questions are enquiry of behavioural practices that may expose an individual \\nto HIV (Table 11.2).  \\n A simple Risk Assessment Tool (RAST) is provided to guide the provider in generating a \\nconversat ion about HIV risk. Screening for HIV risk should be integrated within other service \\ndelivery points. HIV negative individuals who answer “yes” to any of the screening questions \\nshould be engaged in a discussion about the risks and benefits of PrEP. The cl ient then is evaluated \\nfor eligibility to receive PrEP.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 202}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 11 - 2 Table 11:1 HIV Screening questions  \\nScreening question refer to the past 6 months & include;  \\n• “Have you had sex with more than one person?”  \\n• “Have you had sex without a condom?”  \\n• “Have you had sex with a nyone whose HIV status you do not know?”  \\n• “Are any of your partners at risk of HIV?”  \\n• “Have you had sex with a person who has HIV?”  \\n• “Have you received a new diagnosis of a sexually transmitted infection?”  \\n• “Do you desire pregnancy?”  \\n• “Have you used or wanted t o use PEP or PrEP for sexual exposure to HIV?”  \\n• “Have you injected drugs that were not prescribed by healthcare provider? If yes, did \\nyou use syringes, needles or other drug preparation equipment that had already been \\nused by another person?”  \\n• “Have you rece ived money, housing, food or gifts in exchange for sex?”  \\n• “Have you been forced to have sex against your will?”  \\n• “Have you been physically assaulted, including assault by a sexual partner?”  \\n11.1.3 Criteria for PrEP Eligibility  \\nTo be eligible for PrEP, individuals identified to be at risk of HIV infection from Risk Assessment \\nmust meet ALL the following criteria prior to initiating PrEP.  \\n● Confirmed HIV negative status through rapid antibody testing following the HTS algorithm.  \\n● Determine if the client is w illing to take PrEP as prescribed. (This is done by adherence \\neducation and counselling on the PrEP regimen to be given, and assessing the client’s \\nreadiness to follow the regimen.)  \\n● Does not have a current or recent (within the past one month) illness consistent with acute \\nHIV infection (fever, sore throat, muscle or joint pains, swollen glands, diarrhoea or headache) \\nin combination with a preceding high -risk exposure for HIV.  \\n● No contraindication to use of any of the ARVs recommended for PrEP e. g., TDF +/ - FTC (or \\n3TC) for those who choose oral PrEP.  \\n● Renal or liver disease  \\no Clients with renal and liver disease should receive further clinical and laboratory tests, \\nto determine the renal/liver function and extent of disease.  \\nOther important factors  for screening  \\n1. Gender based violence (GBV) screening:  All clients accessing PrEP must be screened for \\ngender -based violence, especially intimate partner violence (IPV), and appropriate \\nintervention offered or client linked to appropriate.  \\n2. Mental Status Assessment:  Psychological issues that may influence adherence should be \\nassessed and addressed. It is important to carry out basic mental health evaluation and \\noffer appropriate referral as necessary.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 203}),\n",
       " Document(page_content='  \\nPre-Exposure Prophylaxis (PrEP)  \\n11 - 3 HIV self -test (HIVST) should not be used as a de finitive HIV test for PrEP initiation and \\nfollow up monitoring.  \\n11.2 Package of PrEP Service  \\nPrEP should be offered as part of the comprehensive prevention package which includes \\nbehavioural, bio medical and structural components. Integration of PrEP serv ices is \\nrecommended within different service delivery points, including in the community, ANC and FP \\nclinics.  \\n \\n Client  seeking  any service  from the facility /Communit y\\n(See section  on PrEP Integration)\\n \\n \\n \\n \\nSCREEN  for ongoing  risk for HIV \\nTEST for HIV  \\n  \\nHIV Positive – link/refer\\nAdditional Screening:\\nGBV/HIV\\n \\n \\n \\n \\n \\n \\n \\n \\n \\n1 \\n \\nFigure 11.1 : Package of Service for PrEP  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 204}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 11 - 4 11.2.1 Pre -Initiation Checklist  \\nThis checklist is intended to help the service provider ensure all necessary screening and \\nassessments are done prior to PrEP initiation  \\nTable 11.2: Pre -Initiation Assessment Checklist  \\nITEM  Y/N  \\nScreening and Support for GBV   \\nHIV Testing   \\nCheck symptoms of acute viral infection in last 6 weeks   \\nBehavior risk assessment   \\nSubstance use and mental health screening   \\nPartner information   \\nPre-initiation education and understanding of PrEP   \\nClient readiness and willingness to adhere to prescribed PrEP and follow -up schedule   \\nSTI screening and treatment   \\nFor women  \\n✔ Pregnancy test, pregnancy intention and / or breastfeeding  \\n✔ Screen for contraception use using appropriate contraceptive screening tool   \\n✔ Highlight the need for condom use   \\nDiscussed plans for continually accessing PrEP   \\nAdditional laboratory tests (Availability of these test should not delay initiation of PrEP)  \\n✔ Serum creatinine and creatinine clearance  \\n✔ HBsAg  \\n✔ HCV serology  \\nNB:  absence of these tests should not hinder initiation   \\nMedication history and potential drug interactions   \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 205}),\n",
       " Document(page_content='  \\nPre-Exposure Prophylaxis (PrEP)  \\n11 - 5 11.2.2 Pre -initiation client education  \\nThe following components should be discussed prior to PrEP initiation:  \\nTable 11.3: Client Education Checklist  \\nTopic  Check  \\n✔ Explain how PrEP works as part of combination HIV prevention  ✔  \\n✔ Explain the need for baseline and follow -up tests including regular HIV testing  ✔  \\n✔ Explain PrEP use: include the following: (refer to the different types of PrEP \\navailable for details)  \\no The medications used (show the client the pills or other PrEP options  \\no How the medications are used (frequency of dosing for the various options)  \\no Number of doses required to achieve efficacy (7 doses for daily oral PrEP, \\nloading dose for event driven oral PrEP)  \\no What to do when doses are missed (continue for daily doses)  \\no Discontinuation of PrEP, how and when it can be discontinued.  \\no Side effects and what to do in case these are experienced (including when to \\nconsult the clinician)   ✔  \\n✔ Discuss what to do in case client experiences symptoms of seroconversion (acute \\nHIV infect ion)   \\n✔ Discuss the Limitations of PrEP  \\no PrEP reduces but does not eliminate the risk of acquiring HIV.  \\no PrEP does not prevent pregnancies and STIs.   ✔  \\n✔ Risk reduction counselling and support education  \\no Managing mental health needs  \\no Couple counselling  \\no Access to, and consistent use of condoms and lubricants  \\no Access to and need for frequent HIV testing.  \\no Early access to ART  \\no VMMC  \\no STI screening and treatment  \\no Harm reduction for PWID  ✔  \\n \\n11.3 Recommended ARVs for PrEP  \\nThe preferred ARV regimen is Tenofovir 300mg/ Emtricitabine 200mg (TDF/FTC) given as one \\nfixed dose combination (FDC) tablet orally daily.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 206}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 11 - 6 Table 11.4: Antiretrovirals for Use in PrEP  \\nPrEP Dosing \\nStrategies  Preferred  Alternative  \\nDaily Oral PrEP  TDF/FTC (300 mg/200 mg) as FDC \\nonce daily  TDF/3TC (300 mg/300 mg) as FDC once \\ndaily  \\nEvent Driven Oral \\nPrEP    TDF/FTC (300 mg/200 mg) as FDC \\n– two pills taken between 2 and 24 \\nhours in advance of anticipated sex; \\nthen, a third pill 24 hours after the \\nfirst two pills and a fourth pill 48 \\nhours after the first two pills; 2 -1-1 TDF/3TC (300 mg/300 mg) as FDC – \\ntwo pills taken between 2 and 24 hours \\nin advance of anticipated sex; then, a \\nthird pill 24 hours after the first two \\npills and a fourth pill 48 hours after the \\nfirst two pills ; 2-1-1 \\n*Recommended Long -acting Products: These products are at different stages of approval and availability \\nin Kenya. The Ministry of Health will issue specific implementation guidelines when they become \\navailable.  \\n*Long Acting \\nCabotegravir \\nInjection  Initiation injections: 600 mg \\nIntramuscular (IM) x 2 doses given \\n1 month apart (the second \\ninitiation injection can be given up \\nto 7 days before or after the date \\nscheduled to receive injection)  \\nTHEN  \\nContinuation injections: 600 mg  IM \\nevery 2months   \\n*Dapivirine \\nvaginal ring  Dapivirine vaginal ring, 25mg, \\ninserted vaginally every 28 days.   \\nThe drugs can be taken with or without food, and can be stored at room temperature.  \\nPrescription intervals for daily oral PrEP  \\nThe first prescription should be for 30 days to allow for the first follow -up visit during which a \\nrepeat HIV test should be conducted, and adherence, tolerability and adverse effects assessed.   \\nDuring the one -month visit, if no major concerns are noted, PrEP should be prescribed for 2 \\nmonths and thereafter 3 -monthly. Clients with sub -optimal adherence and or other major \\nconcerns should be given monthly follow up visit.  \\nRemind individuals using daily oral PrEP that it takes 7 doses (equivalent to 7 days) o f \\ncontinuous PrEP use to achieve adequate levels of the ARVs in tissues for it to be \\neffective. During these days, safer sex practices should be encouraged (including \\nabstinence and condom use). This only applies for individuals born female. Those born \\nmal e can have protective levels as soon as 2 hours before sex but ideally 24 hours. This \\nis true even for people intending to take daily oral PrEP for ongoing exposure.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 207}),\n",
       " Document(page_content='  \\nPre-Exposure Prophylaxis (PrEP)  \\n11 - 7 11.3.1 Schema for follow up for daily oral PrEP  \\nInitial Visit/First Contact\\nPerform a risk assessment to determine if PrEP is indicated:\\n• Discuss effective PrEP use and Clarify misinformation\\n• Perform Initial clinical and laboratory assessment:\\no Baseline HIV test and rule out symptoms of Acute \\nHIV infection.\\no Screen for STIs and risk of renal disease/Hepatitis \\nB/C infectionIf HIV Negative and meets eligibility for PrEP\\n• Offer adherence counselling and support. \\n• Prescribe 30 -day supply of PrEP (TDF 300 mg/FTC \\n200 mg OD) \\n• Discuss combination prevention and risk reduction.\\n• Offer other HIV prevention services e.g., condoms as \\nappropriate.\\n30 Day review\\n• Assess for adherence and offer adherence counselling and support.\\n• Ask about any side effects. Find out how the client is coping with the side effects if any. Reassure if minor.\\n• Assess for STIs, risk of acute HIV infection, and perform pregnancy test in women. \\n• Assess for risk of kidney disease, if available, obtain serum creatinine and calculate creatinine clearance \\n• Discuss risk reduction and provide condoms.\\n• Perform a repeat HIV test. (Discontinue PrEP for those who test positive and link to care for ART initiation) \\nGive a 60-day PrEP prescription for drug refill of PrEP. Schedule the 3 -month return visit.\\n3 monthly reviews \\n• Assess for adherence and offer adherence counselling and support. \\n• Ask about any side effects\\n• Assess for STIs, (and pregnancy in women) and acute HIV infection. \\n• Perform HIV test every 3 months (HIV self -test may be used followed by a \\nconfirmatory test in health facilities for those testing positive) \\n• Discuss risk reduction and provide condoms.\\nDo serum creatinine and calculate creatinine clearance within 3 months after initiation \\nand thereafter annually as recommended.\\n \\nFigure 11.2: Schema for Follow -up for Daily Oral PrEP  \\n \\n11.3.2 EVENT DRIVEN PrEP (ON DEMAND PrEP or 2+1+1 PrEP)  \\nWhat is event driven?  \\nAn “Event” refers to a sexual act. Event driven PrEP is where oral PrEP is to be used when an  \\nisolated sexual act is anticipated.   \\nEvent -Driven PrEP is recommended for all people assigned male at birth not taking exogenous \\nestradiol -based gender affirming hormones  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 208}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 11 - 8 \\n \\nFigure 11.3 Schema for Event -Driven PrEP  \\nWhen is ED -PrEP considered most appropriate?  \\nEvent driven PrEP is most appropriate for men who:  \\n• Have infrequent sex (for example, sex less than 2 times per week on average).  \\n• Can plan for sex at least 2 hours in advance or who can delay sex for at least 2 hours.  \\n• Would find ED -PrEP more convenient  \\nClients on Event driven PrEP require follow up. Figure 11.4  shows the schema for follow up of \\nevent driven PrEP.  \\nAssess HIV risk and determine eligibility for oral PrEP\\nOffer PrEP and discuss dosing options.\\nDaily dosing if risk is more frequent \\nthan 2 times per week and sex cannot \\nbe predicted or delayed by 2 hours.Men who have sex with men on PrEP \\ncan switch from daily dosing to ED -\\nPrEP (and vice -versa)Event -driven dosing if sex can be \\npredicted (particularly for infrequent \\nsex)\\nFollow -up visit (1 month after initiation and/or every 3 months) \\n✓ Provide HIV testing and screen for STIs\\n✓ Offer counselling by discussing adherence dosing strategy during use, and if PrEP user \\ntransitions from one dosing strategy to another. \\n✓ Assess if HIV risk is likely to persist in the next few weeks and months. \\n✓ May require more active support in continuing PrEP, whichever dosing strategy is chosen.\\n \\nFigure 11.4 Schema for Initiation and Follow -up for Event -driven PrEP  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 209}),\n",
       " Document(page_content='  \\nPre-Exposure Prophylaxis (PrEP)  \\n11 - 9 Changing between ED PrEP and daily oral PrEP  \\nMen can be offered the two dosing options: daily oral PrEP or Event driven PrEP.  \\n• Daily dosing is appropriate for those whose occurrence of sex cannot be predicted and for \\nthose whose potential exposures to HIV  are more frequent than 2 times per week, such \\nthat ED -PrEP would be taken so frequently that it would effectively resemble daily PrEP.  \\n• If sex continues beyond one day, a user of ED -PrEP can stay protected by taking another \\npill each day as long as sex co ntinues and stopping 2 days after the last sex act.  \\n• On the other hand, if an individual starts daily oral PrEP, but then sex becomes infrequent \\nand predictable, ED -PrEP can be used instead.  \\n \\n11.4 Managing Clinical and Laboratory Results on Initial and Fol low -up \\nAssessment  \\nTable 11.5 Initial & follow up laboratory test  \\nLaboratory Test  Guidelines for clients initiating \\nPrEP  Guidelines for clients on \\nfollow up  \\nHIV Rapid Test  Before initiating PrEP as per the National \\nHTS algorithm  At Month 1, Month 3, thereafter \\nevery 3months  \\nCreatinine Test  Test within 1 -3 months of PrEP Initiation  If client >50years – Screen every \\n6-12months  \\nClients of any age with renal \\ncomorbidity: recommended before  \\ninitiating PrEP  Screen every 6 -12months  \\nHepatitis B Surface \\nAntigen (HBsAg)  Test once within 3 months of initiating PrEP. If negative, offer/refer for \\nimmunization   \\nHepatitis C Virus \\nSerology  Test once within 3months of PrEP \\ninitiation  Every 12 months for persons at \\nhigh risk of Hepatitis C infection  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 210}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 11 - 10 Table 11.6: Managing Clinical and Laboratory Results on Initial and Follow -up Assessment  \\nScreening  Action  \\nHIV -positive at \\ninitial evaluation  Do not start PrEP, counsel and link to care and treatment  \\nHIV -positive after \\ninitiation of PrEP  Discontinue PrEP, counsel and link to care and treatment. Take DBS or plasma \\nsample for drug resistance testing.  \\n \\nPositive STI Screen  Thorough genitourinary and anorectal examination, urine dipstick for urethritis, \\nserological testing for syphilis, full STI evaluation if resources available (refer to \\nSTI algorithm). Refer to guidelines on syndromic management of STIs.  \\nHBsAg -negative  Offer HBV vaccination  \\n \\nHBsAg -positive  This is not a contraindication to oral PrEP.  However, will require monitoring of \\nliver function and referral for management of liver disease.  \\nNB: TDF -based daily or event -driven oral PrEP can be safely offered to \\npersons with HBV infection.  \\nHepatitis C - \\nNegative  Continue PrEP and follow Hepatitis C testing algorithm.  \\nHepatitis C - \\nPositive  Continue PrEP, refer for Hepatitis C confirmatory testing and management with \\ndirectly acting antivirals (DAAs).  \\nFlu-like illness after \\ninitiating PrEP  Continue PrEP, test for HIV at first contact and after 28 days, and if negative,  \\ncontinue with usual follow -up \\n \\n \\n \\n \\n \\n \\n \\nSide effects of PrEP  GIT - nausea, vomiting, weight loss: these are often mild, self -limiting and occur \\nduring the first 1 -2 months. Provide supportive counselling, offer symptomatic \\ntreatment e.g., anti -emetics like metoclopramide 10 mg 8 hourly for 3 to 5 days.  \\nRenal – individuals may experience transient increase in creatinine, and rarely \\nproteinuria and Fanconi’s syndrome (presenting as polyuria, bone pain and \\nweakness). Measure creatinine (and ca lculate estimated creatinine clearance) at \\ninitiation of PrEP and annually thereafter (or whenever indicated (symptom \\ndirected)).  \\nIf creatinine clearance (eGFR) < 50 ml/min do not start PrEP, recheck after 2 \\nweeks. Refer for evaluation of underlying renal  disease.  \\nIf the renal function returns to normal, reassess for PrEP and initiate/ continue \\nPrEP.  \\nPrEP should not be prescribed for individuals using nephrotoxic drugs like \\nacyclovir, aminoglycosides, retinoids etc. instead, offer alternative HIV \\nprevent ion services.  \\n \\nPregnancy or \\nBreastfeeding  \\n Pregnancy and breastfeeding are not contraindications to provision of PrEP.  \\nPregnant or breastfeeding women whose sexual partners are HIV positive or are \\nat high risk of HIV infection may benefit from PrEP as part of combination \\nprevention of HIV infection.  \\nPrEP is also indicated for HIV -negative women in sero -different partnersh ips \\nwho wish to conceive. PrEP in these situations can be prescribed during the pre -\\nconception period and throughout pregnancy to reduce risk of sexual HIV \\ninfection.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 211}),\n",
       " Document(page_content='  \\nPre-Exposure Prophylaxis (PrEP)  \\n11 - 11 Table 11.7: Summary of PrEP Initial and Follow -up Assessment  \\nVisit  Action  \\nFirst (Screening Visit) \\nClinician Visit  • HIV testing and counselling.  \\n• Evaluate for eligibility, willingness and readiness to take PrEP.  \\n• Educate about the risks, benefits, and limitations of different PrEP \\noptions  \\n• Educate client about recognizing symptoms of Acute  HIV Infection (AHI) \\nand what to do if such symptoms occur (i.e., urgently return for HIV \\ntesting)  \\n• Conduct behavior risk assessment  \\n• STI screening and treatment  \\n• Pregnancy, contraceptive use and counselling (for women); if pregnancy \\nsuspected, obtain a preg nancy test. However, pregnancy is not a \\ncontraindication to PrEP.  \\n• Adherence counselling  \\n• Discuss combination prevention.  \\n• Laboratory test; serum creatinine test and calculate Creatinine Clearance \\n(CrCl), HBsAg, pregnancy test, Hepatitis C (baseline investigations should \\nnot delay initiation of PrEP)  \\nIf no contraindication to TDF and the client is eligible and ready, \\nprescribe TDF/FTC one tablet once daily for 30 days (alternative \\nTDF/3TC one tablet once daily for 30 days, or TDF 300 mg once daily for \\n30 days); agree on a follow -up date before the prescription is finished  \\nVisit 2 (Month 1) \\nCounsellor/Clinician \\nVisit  • Counsellor/ Clinician visit  \\n• Assess for side effects and adverse effects  \\n• Safety monitoring clinical assessment/ Review lab results  \\n• Conduct a HIV test as per the national algorithm  \\n• Behavioral risk assessment .  \\n• Review for PrEP continuation or discontinuation  \\n• Adherence and risk reduction counselling  \\n• Give a prescription for PrEP for 2 months.  \\n• Offer HBV vaccination if available and HBsAg negative (follow HBV \\nvaccination schedule complete series  \\nFollow up visits - \\nMonths 3, 6,  , 12, 15.….  \\nClinician/Counsellor -\\nled visits  • HIV testing and counselling  \\n• HIV risk assessment   \\n• Review for PrEP continuation or discontinuation  \\n• Assess for side effects and adverse effects  \\n• Safety monitoring clinical assessment/ Review lab results  \\n• Adherence and risk reduction counselling  \\n• Give a prescription for PrEP for 3 months  \\n• Refill PrEP prescription  \\n• Serum creatinine and creatinine clearance  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 212}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 11 - 12 Table 11.7 Cont: Summary of PrEP Initial and Follow -up Assessment  \\nDuring every visit  \\n• Assess adherence  \\n• Reassess risk of HIV infection and offer risk reduction counselling  \\n• HIV testing should be repeated at month 1 and thereafter, every 3 months (this applies for both \\ndaily and Event driven PrEP)  \\n• Assess for adverse effects   \\n11.5 Contra -indications to Oral PrEP (daily or ED PrEP)  \\n• HIV infection or suspected acute HIV infection (i.e., flu -like symptoms in the last 4 weeks in \\ncombination with a preceding h igh-risk exposure for HIV)  \\n• Adolescents < 35 kg or age < 15 years  \\n• Impaired renal function (estimated creatinine clearance of <50 ml/min)  \\n• Unable or unwilling to adhere to prescribed PrEP or follow -up schedule.  \\n11.6 Criteria for Discontinuing Oral PrEP  \\nPrEP should be discontinued if ANY of the following criteria are met.  \\n● Positive HIV test during follow up.  \\n● Change in risk status (no ongoing risk)  \\n● Renal dysfunction with creatinine clearance below 50 ml/min  \\n● Client request to stop.  \\n● Sustained non -adherence.  \\nDiscontinuing daily oral PrEP:   Users discontinuing PrEP due to no ongoing risk or requesting \\nto stop should continue PrEP for at least 7 days after the last potential exposure to HIV. Reasons \\nfor discontinuation should be documented in the client’s record.  \\nDiscontinuing event –driven PrEP:  Event -driven PrEP can be stopped after two daily doses \\nfollowing the last sexual exposure.  \\n11.7 Restarting PrEP  \\nAny client restarting PrEP regardless of the preferred method should be assessed for HIV status \\nand a rapid HI V test conducted:  \\n● Daily Oral PrEP : Clients who stop PrEP for more than 7 days and wishes to restart should \\nbe assessed for resumption of PrEP similar to the assessment done for an initial (first) visit. \\nImportantly, conduct a HIV test before re -starting PrEP. If a high -risk exposure occurre d in \\nthe previous 7 days (i.e., acute HIV infection is suspected), defer PrEP and obtain repeat HIV \\ntest after 4 weeks; if negative, PrEP can be prescribed if the other criteria are fulfilled. The \\nuse of condoms should be recommended during the waiting per iod.  \\n● Event driven Oral PrEP :  Clients who have stopped PrEP for more than a week and who are \\nrestarting ED -PrEP should commence with a double dose (two pills) of PrEP as new \\ninitiators. Risk assessment should be conducted. If a high -risk exposure occurred  in the \\nprevious 7 days (i.e., acute HIV infection is suspected), defer PrEP and obtain repeat HIV \\ntest after 4 weeks; if negative, PrEP can be prescribed if the other criteria are fulfilled. The \\nuse of condoms should be recommended during the waiting peri od.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 213}),\n",
       " Document(page_content='  \\nPre-Exposure Prophylaxis (PrEP)  \\n11 - 13 11.8 Improving adherence to PrEP  \\nApproaches to improve adherence include:  \\n● Encourage ring users to keep ring in place continuously through the 28 -day period from \\ninitial insertion  \\n● Disclosure of PrEP use to a partner or trusted person  \\n● Use of reminder de vices like a cell phone alarm.  \\n● SMS reminders where available and feasible  \\n● Exploring and mitigation of other barriers to adherence  \\n● Peer support  \\n11.9 Monitoring Sero -conversion among PrEP users  \\nPrEP substantially reduce the risk of HIV acquisition.  The effi cacy of PrEP is correlated with \\nadherence.  Sero -conversion during use of PrEP should be monitored critically as it is increasing \\nthe risk of developing drug resistance if clients continue the use of PrEP while HIV infected.  \\nFactors that lead to HIV seroco nversion among PrEP sero -converters include:  \\n● Inconsistency in use of PrEP (non -adherence).  \\n● Social -behavioral factors e.g., poverty, HIV stigma and relationship status that may affect \\nthe ability to use PrEP as prescribed.  \\n● Possible infections with drug res istant strains  \\n \\nWhat should be done upon identification of a PrEP sero -converter?  \\nHIV testing among PrEP should be conducted consistently as per the algorithm. Identification of \\nnew HIV positive diagnosis among PrEP users should be followed with:  \\n● Immediate discontinuation of PrEP  \\n● Counselling of client on positive results  \\n● Linkage to care and ART (immediate ART initiation).  \\n● Assessment of barriers to adherence that may affect use of ART.  \\n● Document sero -conversion in client file, PrEP registers, and monthly reporting as \\nrequired.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 214}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 11 - 14  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 215}),\n",
       " Document(page_content='  \\nPeople Who Inject Drugs (PWID) and HIV  \\n12 - 1  \\n12. People Who Inject Drugs (PWID) and HIV  \\n \\n12.1 Introduction  \\nThe use of ART for HIV treatment in key populations should follow the same general principles \\nand recommendations as for all adults. Individuals within key populations groups may experience \\ndiscrimination and marginali zation that can impede their access to health care, including \\ntreatment for HIV, and frequently present late for treatment. It is important to ensure that people \\nfrom key populations have equitable access to HIV treatment and care.  Programs should ensure \\nthat missed opportunities are minimized and every single encounter with key populations is \\noptimally used. ART service delivery includes decentralization of HIV care and treatment and \\nintegration of ART services into other clinical services such as Medical ly Assisted Therapy and \\ndrop -in centers where appropriate capacity exists.  \\nPeople who inject drugs (PWID) are at increased risk of HIV infection. In Kenya, the HIV \\nprevalence among PWID is up to 4 times that of the general population. PWID also suffer a hi gher \\nburden of viral hepatitis (HBV and HCV), TB and sexually transmitted infections irrespective of \\ntheir HIV status. Despite this, PWID have limited access to HIV treatment and prevention services.  \\nEvery effort should be made to implement evidence -inform ed interventions in the comprehensive \\npackage of measures targeting PWID, either in combination or (depending on site capacity) singly, \\nwith linkage to comprehensive care (Table 12.1).  \\nPackage of care for PWID  \\nPWID have complex needs related to drug dependency, psychosocial and medical \\ncomplications of injection and other substance use. When they require ART, anti -TB, or any \\nother therapy, they are at increased risk of adverse drug reactions, drug -drug interactions and \\nnon-adherence.  These patients a re best comprehensively managed by providers who have \\nreceived specific training in the management of injection drug users. Once identified, PWID \\nshould be counselled and linked to programs with the capacity to offer comprehensive care for \\nsuch patients.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 216}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 12 - 2 Table 12.1: Comprehensive Package of Harm Reduction for PWID  \\nIntervention  Comment/Recommendations  \\nHIV testing services  PWID are at high risk of HIV infection, are likely to be diagnosed late and \\ntherefore have poorer treatment outcomes following ART i nitiation.  \\n● PWID should be offered HIV testing and counselling and be linked to \\ncomprehensive HIV treatment and prevention services including \\nharm reduction counselling and support.  \\n● Retest for HIV every 3 months if there is ongoing risk.  \\n● HIV self -testing should be integrated into drop -in centers (DICEs) \\nthrough both assisted and non -assisted approaches after initial \\ntesting by a provider.  \\n● HTS should also be offered to sexual partners  of PWID.   \\n \\nTargeted information, \\neducation, and \\ncommunication for PWID \\nand their sexual partners  PWID and sexual partners should be provided with information and \\ncounselling on risks related to drug use and risky sexual behavior. PWID \\nshould be informed of where and what harm -reduction services are \\navailable, and linked to appropriate services.  \\nPeer -based networks are effective in improving access and retention to \\nharm reduction care  \\n \\n \\nCondom provision  The correct and consistent use of condoms with condom -compatible \\nlubricants is recommended for all PWID to prevent unintended pregnancy \\nand sexual transmission of HIV and other STIs.  \\n \\n \\nPrevention and treatment of \\nsexually transmitted \\ninfections  PWID may be at higher risk of STIs due to sex work or other risky sex \\npractices.  \\nSTIs, especially genital ulcer diseases increase the risk of HIV infection and \\ntransmission and are often a sign of unsafe sexual behavior or risk of HIV \\ntransmission.  \\nScreening, dia gnosis, treatment, and prevention of STIs should be offered \\nroutinely as part of comprehensive HIV prevention and care for PWID.  \\n \\n \\nPrevention, diagnosis, and \\ntreatment of TB  Independent of HIV infection, PWID have an increased risk of TB. HIV \\ninfection f urther increases this risk.  \\n● All PWID should be screened regularly for active TB using the \\nsymptom -based screening algorithm at each contact with healthcare \\nworkers.  \\n● Once active TB is ruled out, TPT should be provided to PWID living \\nwith HIV as per National guidelines for TPT.  \\n● PWID w ith active TB should receive standard TB treatment as per the \\nNational guidelines and be supported to complete treatment.  \\n● Anticipate and manage complications due to viral hepatitis or renal \\nimpairment.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 217}),\n",
       " Document(page_content='  \\nPeople Who Inject Drugs (PWID) and HIV  \\n12 - 3 Table 12.1 Cont.  \\nPrevention, vaccination, \\ndiagnosis, and treatment for \\nviral hepatitis  Hepatitis B and C disproportionately affect PWID due to overlapping risk \\nfactors of sexual transmission and sharing needles, syringes, and other \\ndrug use items.  \\nHarm reduction and behavioral interv entions are also effective in \\nreducing risk of infection/transmission of HBV and HCV.  \\n● Peer interventions should be offered to people who inject drugs to \\nreduce the incidence of viral hepatitis  \\n● PWID should be screened for HBV (by HBsAg) and HCV (by HCV \\nsero logy) at first contact  \\n● Hepatitis B  \\no Hepatitis B vaccination is recommended for those who are \\nHBsAg negative. A higher -dose HBV vaccine should be used \\nwith the rapid regimen (day 0, 7, 21, and a booster at 12 \\nmonths). If the rapid regimen is not available, the standard \\nregimen should be offered. For PWID who are HIV positive, they \\nshould follow the dosing schedule in Table. 9.1  \\no HBV/HIV co -infected PWID should be started on TDF - or TAF - \\ncontaining ART (the current recommended first line is \\nTDF/3TC/ DTG) in addition to harm -reduction interventions to \\noptimize adherence and treatment outcomes.  \\n● Hepatitis C  \\no HCV/HIV co -infected PWID should be initiated on ART.  \\no Specific HCV antiviral therapy should be provided in \\nconsultation with expertise in the management of HCV infection \\n(refer to national guidelines on management of viral hepatitis)  \\n  \\nNeedle and syringe \\nprogrammes (NSPs)  NSPs help decrease drug -related risk behaviors, reduce quantity of \\ncontaminated needles in circulation, reduce risk of new HIV infections and \\nimprove referrals and linkage to HTS and HIV treatment and prevention \\nservices.  \\nNSPs are effective means for intr oducing combination prevention to PWID \\nincluding HTS, STI screening and treatment, condoms provision, OST, and \\nHIV treatment and prevention.  \\nAll PWID should be linked to NSPs to access sterile injecting \\nequipment  \\n \\nOpioid substitution therapy \\n(OST)  OST usi ng methadone or another suitable alternative is effective in the \\ntreatment of opioid dependency, reducing risk behaviors related to drug \\nuse and therefore reducing HIV transmission and improving PWIDs’ \\nadherence to ART  \\nIdentify and link all PWID who have o pioid dependence for opioid \\nsubstitution therapy  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 218}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 12 - 4 Table 12.1 Cont.  \\nAntiretroviral therapy \\n(refer to Table 12.2 for \\ndetails)  • ART is effective in managing HIV infection in PWID. However, poor \\nadherence may interfere with ART success. Intensive support is \\nrequired including OST, enhanced counselling techniques and daily \\nwitnessed ingestion (DWI) when available.  \\n• Close monitoring of ART is necessary because of risk of drug -drug \\ninteractions, renal and liver toxicity.  \\n• HIV-positive PWID should be off ered comprehensive HIV treatment \\nand prevention services including ART. When ART is provided with \\nadditional targeted support, PWID can achieve and maintain viral \\nsuppression.  \\n• Oral PrEP is recommended as an additional prevention choice for \\nPWID at substant ial risk of HIV infection as part of combination \\nprevention and harm reduction approaches.  \\nCommunity outreach  PWID face barriers to accessing formal facility -based health services due \\nto stigma, discrimination, and fear of victimization among other factors.  \\nOutreach either directly from the facility or through collaborations with \\ncommunity -based groups is an effe ctive means of delivering harm -\\nreduction interventions in addition to HIV treatment and prevention \\nservices.  \\nPeer -led, community -based approaches are particularly useful in \\nimproving adherence and retention.  \\n \\n12.3 ART in HIV positive PWID  \\nAntiretroviral  therapy is part of the comprehensive care package for PWID living with HIV. ART \\nservice provision should follow the same general principles and recommendations as for all \\nadults.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 219}),\n",
       " Document(page_content='  \\nPeople Who Inject Drugs (PWID) and HIV  \\n12 - 5 Table 12.2: Summary of ART Recommendations for PWID  \\nCare and Support  Recom mendation/Additional Information  \\nWhen to start ART in \\nHIV positive PWID  ART should be initiated in all individuals with HIV regardless of WHO clinical \\nstage or CD4 cell count  \\nWhat to start (first -line \\nART)  Irrespective of OST, PWID with HIV infection should be initiated on a first -line \\nregimen of TDF + 3TC + DTG  including women of childbearing potential.  \\nTDF + 3TC + ATV/r may be offered as an alternative where DTG cannot be used. \\n(Table 6.3)  \\nTB Co -infecti on  ART should be started as soon as possible within two weeks of initiating TB \\ntreatment, regardless of CD4 cell count.  \\nFor PWID with TB/HIV co -infection on DTG, give TDF/3TC/DTG FDC given in \\nthe am + DTG 50mg given in the pm for duration of rifampicin -containing TB \\ntreatment and for an additional 2 weeks after TB treatment is completed, then \\nrevert to TDF/3TC/DTG FDC once daily.  \\nSecond -line \\nART  Patients failing DTG -based first line ART (including PWID) should be managed \\nas per the viral load  monitoring algorithm (Figure 6.6), including performing a \\nDRT for selection of a second -line regimen (Table 6.10)  \\nTreatment preparation \\nand adherence \\ncounselling and \\nsupport  Injection drug use is not a contra -indication to ART initiation. OST, though \\nimp ortant in contributing to the success of ART in PWID, should not be a pre -\\nrequisite to initiation of ART. However, these patients benefit from additional \\npreparation and support to increase their chances of successful treatment \\nincluding:  \\n● Harm reduction in terventions  \\n● Thorough baseline assessment for important comorbid conditions like \\nAdvanced HIV Disease (AHD) including TB, hepatitis, renal impairment \\nand depression or other psychiatric disorders  \\n● Negotiation for, and access to daily witnessed ingestion (DWI ). \\n● Community outreach and support  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 220}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 12 - 6 Table 12.1 Cont.  \\nPreventing and \\nmanaging drug -drug \\ninteractions  Selection of drugs should take into consideration possible drug to drug \\ninteractions and their effects on opioids, OST and ART. Any interaction that \\nreduces the levels of methadone may induce withdrawal symptoms and \\nrequire an increased dose of methadone.  \\n● ARV interactions with methadone and opioids  \\no NRTIs  \\n▪ TDF, TAF, 3TC, FTC: no significant interactions  \\n▪ AZT levels are increased, with higher risk of AZT toxicity.  \\n▪ ABC levels are decreased, and methadone levels are \\ndecreased.  \\no NNRTIs  \\n▪ EFV: methadone levels are decreased and may induce \\nwithdrawal symptoms.  \\no PI/r: all boosted PIs decrease methadone levels.  \\n▪ LPV/r and methadone increase risk for prolonged QT \\nsyndrome and sudden cardiac death.  \\no INSTIs: no significant interactions  \\n● ARV interactions with buprenorphine  \\no ATV/r and DRV/r increase concentrations of buprenorphine or \\nits active metabolites and may increase risk of toxicity.  \\no EFV decreases buprenorphine levels substantially.  \\no No known significant interactions with other ARVs  \\n● Rifampicin and Rifapentine decrease levels of methadone and \\nbuprenorphine and may induce withdrawal symptoms.  \\n● INH can be used safely with methadone or bupr enorphine  \\n● Management of Drug -Drug Interactions (Annex 13)  \\n \\nMonitoring ART  ● PWID on ART require more frequent monitoring and support to ensure \\nadherence to treatment and harm reduction interventions, assessment for \\nand management of adverse drug reactions or drug -drug interactions  \\n● Ongoing monitoring should also include screening for other illicit \\nsubstance/drug use.  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 221}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 1  \\n13. Annexes  \\n \\nAnnex 1: WHO Clinical Staging of HIV Infection in Infants and Children  \\nStage I  \\n• Asymptomatic  \\n• Persistent generalized lymphadenopathy  \\n• (PGL)  \\n• Unexplained, asymptomatic \\nhepatosplenomegaly  Stage II  \\n• Papular pruritic eruptions (PPE)  \\n• Seborrheic dermatitis  \\n• Fungal nail infections  \\n• Angular cheilitis  \\n• Linear gingival erythema  \\n• Extensive HPV or molluscum infection (>5% of \\nbody area/face)  \\n• Recurrent oral ulcerations (>2 episodes/ in 6 \\nmonths)  \\n• Parotid enlargement  \\n• Herpes zoster (>1 episode/12 months)  \\n• Recurrent or chronic upper respiratory infection \\n(URI): otitis media, otorrhea, sinusitis (>2 \\nepisodes/6 months)  \\nStage III  \\n• Unexplained moderate malnutrition ( -\\n2SD or Z score) not responding to \\nstandard therapy  \\n• Unexplained persistent diarrhoea (>14 \\ndays)  \\n• Unexplained persistent fever  \\n• (Intermittent or constant, > 1 mo.)  \\n• Oral candidiasis (outside neonatal \\nperiod)  \\n• Oral hairy Leucoplakia  \\n• Pulmonary tuberculosis  \\n• Severe recurrent presumed bacterial \\npneumonia (>2 episodes/12 months)  \\n• Acute necrotizing ulcerative gingivitis/  \\n• periodontitis  \\n• Lymphoid interstitial pneumonitis (LIP)  \\n• Unexplained anaemia (<8g/dL), \\nneutropenia (<1,000/mm3), or \\nthrombocytopenia (<30,000/mm3) for \\n>1 mo.  \\n• HIV-related cardiomyopathy  \\n• HIV-related nephropathy  Stage IV  \\n• Unexplained severe wasting or severe malnutrition \\n(-3 \\nSD or Z score) not responding to standard \\ntherapy  \\n• Pneumocystis pneumonia  \\n• Recurrent severe bacterial infections (>2 \\nepisodes/12 months, excluding pneumonia)  \\n• Chronic orolabial or cutaneous HSV (lasting > 1 \\nmo.)  \\n• Extra -pulmonary tuberculosis  \\n• Kaposi’s sarcoma  \\n• Oesophageal candidiasis  \\n• CNS toxoplasmosis  \\n• Cryptococcal meningitis  \\n• Any disseminated endemic mycosis  \\n• Cryptosporidiosis or Isosporiasis (with \\ndiarrhoea > 1 month)  \\n• CMV infection of organ other than liver, spleen, \\nlymph nodes (and onset age >1 month)  \\n• Disseminated mycobacterial disease other \\nthan tuberculosis  \\n• Candida of trachea, bronchi or lungs  \\n• Acquired recto -vesicular fistula  \\n• Cerebral or B -cell non -Hodgkin’s lymphoma  \\n• Progressive multifocal leukoencephalopathy PML)  \\n• HIV encephalopathy  \\nNOTE: WHO Clinical Staging should be carried out only on children confirmed (by serology or DNA PCR) \\nto be HIV infected  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 222}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 2 Annex 2: WHO Clinical Staging of HIV Infection in Adolescents and Adults  \\nStage 1  \\n• Asymptomatic  \\n• Persistent Generalized  \\nLymphadenopathy (PGL)  Stage 2  \\n• Moderate unexplained weight loss (< 10% of presumed \\nor measured body weight)  \\n• Minor mucocutaneous manifestations (seborrheic \\ndermatitis, papular pruritic eruptions, fungal nail \\ninfections, recurrent oral ulcerations, angular cheilitis)  \\n• Herpes zoster  \\n• Recurrent upper respiratory tract infections (sinusitis, \\ntonsillitis, bronchitis, otitis m edia, pharyngitis)  \\nStage 3  \\n• Unexplained severe weight loss \\n(over  \\n• 10% of presumed or measured \\nbody weight)  \\n• Unexplained chronic diarrhoea for \\nlonger than one month  \\n• Unexplained persistent fever \\n(intermittent or constant for longer \\nthan one month)  \\n• Persistent oral candidiasis  \\n• Oral hairy leukoplakia  \\n• Pulmonary tuberculosis  \\n• Severe bacterial infections (e.g., \\npneumonia, empyema, \\npyomyositis, bone or joint \\ninfection, meningitis, bacteraemia)  \\n• Acute necrotizing ulcerative \\nstomatitis, gingivitis or \\nperiodontitis  \\n• Unexplained anaemia (below 8 \\ng/dl), neutropenia (below 0.5 x \\n109/l) and/or chronic \\nthrombocytopenia (below 50 x 109 \\n/l) Stage 4  \\nConditions where a presumptive diagnosis can be made \\nusing clinical signs or simple investigations:  \\n•   HIV wastin g syndrome  \\n•   Pneumocystis jirovecipneumonia (PCP)  \\n•   Recurrent severe bacterial pneumonia (≥ 2 episodes \\nwithin 1 year)  \\n•   Cryptococcal meningitis  \\n•   Toxoplasmosis of the brain  \\n•   Chronic orolabial, genital or ano -rectal herpes simplex \\ninfection for > 1 month  \\n•   Kaposi’s sarcoma (KS)  \\n•   HIV encephalopathy  \\n•   Extra pulmonary tuberculosis (EPTB) Conditions \\nwhere confirmatory diagnostic testing is  \\nnecessary:  \\n•   Cryptosporidiosis, with diarrhoea > 1 month  \\n•   Isosporiasis  \\n•   Cryptococco sis (extra pulmonary)  \\n•   Disseminated non -tuberculous mycobacterial infection  \\n•   Cytomegalovirus (CMV) retinitis or infection of the \\norgans (other than liver, spleen, or lymph nodes)  \\n•   Progressive multifocal leukoencephalopathy (PML)  \\n•   Any disseminated mycosis (e.g., histoplasmosis, \\ncoccidiomycosis)  \\n•   Candidiasis of the esophagus or airways  \\n•   Non -typhoid salmonella (NTS) septicaemia  \\n•   Lymphoma cerebral or B cell Non -Hodgkin’s Lymphoma  \\n•   Invasive cervical cancer  \\n•   Visceral leishmaniasis  \\n•   Symptomatic HIV -associated nephropathy or HIV  \\nassociated cardiomyopathy  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 223}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 3 Annex 3: Normal Developmental Milestones in Children  \\nAGE  GROSS MOTOR  FINE MOTOR  WARNING SIGNS  \\n3 Months  Supine:  \\n● Pull to sit:  \\n● 45 o head lag still present  \\nSitting: Propped up  \\n● Flexed/C -Position  \\n● Hold head steady  \\nProne:  \\n● Bears weight on flexed arms  \\n● Lifts head 45 o turn head to side  Eyes:  \\n● Follow through 90 o in lying  \\nHands:  \\n● Open for longer  \\n● Shake a rattle when it is placed \\nin the hand (not intentional)  \\n● Mouthing begins  ● No visual fixation or following \\nasymmetry of tone or movement.  \\n● Floppy/stiff  \\n● Consistent fisting  \\n● Unstable to turn or lift head  \\n● Failure to smile  \\n● Poor sucking & swallowing  \\n6 Months  \\n Supine:  \\n● Pull to sit, no more head lag  \\n● Plays with feet  \\n● Rolls from back to tummy  \\nSitting:  \\n● Unaided supported by arms  \\nStanding:  \\n● Bears weight on legs, equal both sides  \\nProne:  \\n● Props self on straight arms, legs \\nextended, toes turned outwards  Eyes:  \\n● Follow through 180 o in lying  \\n● Focus on small objects  \\nHands:  \\n● Hands on midline  \\n● Banging blocks against the table \\nreaches and attains objects at \\nwill Holds and actively plays \\nwith rattle  ● Floppiness  \\n● No head control  \\n● Failure to use both hands  \\n●  Asymmetrical movement squint  \\n● Failure to turn to sound  \\n● Poor response to people  \\n9 Months  Sitting:  \\n● Sits without support lean forward  \\n● And sit up again without losing balance  \\nStanding:  \\n● Remain standing for a few seconds by \\nholding onto an object, falls down again  \\nProne:  \\n● Baby starts to crawl  Eyes:  \\n● Extremely accurate vision  \\nHands:  \\n● Can pick up and button  \\n● Holds a block in each hand  \\n● Points  ● Unable to sit  \\n● Failure to use both hands  \\n● Fisting  \\n● Squint  \\n● Persistence of primitive reflexes  \\n12 Months  \\n Sitting:  \\n● Turns around to reach nearby toys  \\n● Sits down unaided from standing  \\nStanding: (Walking)  \\n● Walks forward if held by one hand  \\n● Walks around furniture sideways -cruising  \\nProne: (crawling)  \\n● Crawls  \\n● Pulls up to standing by holding onto object  Eyes:  \\n● Looks for toys when out of sight  \\nHands:  \\n● Able to pick up a button with thumb and \\nindex finger (pincer grasp)  \\n● Release on request  \\n● Hold with 1 hand and play with the other  \\n● Throws things into a container and take \\nit out again  ● Unable to bear \\nweight on legs  \\n● Not yet crawling and \\npulling to stand  \\n● Abnormal grasp  \\n● Failure to  respond to \\nsound  \\n● Unable to start with \\nsolids independently  \\n15 Months  \\n Sitting:  \\n● Stand up from sitting  \\n● Will climb on a chair and sit down  \\nStanding: (Walking)  \\n● Bend over to pick up an object  \\n● Squat and stand up again  \\n● Walks alone, broad base with arms in the airs  \\nProne: (crawling)  \\n● Able to crawl fast and manage obstacles e.g., stairs  Eyes:  \\n● Hold crayon in a fist when \\nscribbling  \\n● Turn pages of a book roughly  \\n● Hold 2 small toys in 1 hand  \\n● Put lid back on container  ● Unable to bear \\nweight on legs  \\n● Not yet wal king  \\n● Abnormal grasp  \\n● Abnormal posture: \\nfloppy/spastic  \\n● Failure to respond to \\nsound  \\n● Not yet talking  \\n18 Months  ● Walking with more confidence  \\n● Walk, squat and pick up something, \\nstand up and walk again  \\n● Starts running, often falls  \\n● Take few steps backwards  \\n● Runs and change direction easily  \\n● Jump off step with 2 feet together  \\n● Stand and kick a ball  \\n● Able to throw a ball  ● Build a 3 -cube tower  \\n● Scribbles  \\n● Holds the crayon in a fist  \\n● Turn pages of a book  \\n● Page through a book page by page  \\n● Obvious hand preference  \\n● Uses lines: I, _,0  \\n● Completes 3 -piece puzzle  \\n● Remove a sweet wrapper with little help  ● Failure to walk  \\n● Unable to pick up small \\nobjects e.g., buttons  \\n● Abnormal posture  \\n● Not yet talking  \\n● Unable to understand \\nsimple commands  \\n● Poor co -ordination  \\n36 Months  ● Walk forward and backward  \\n● Walks on tip toes  \\n● Walks on straight line  \\n● Jump 2 feet together  \\n● Able to climb on chair  \\n● Catch a big ball (hugging against chest)  \\n● Holds ball above head and throws  \\n● Runs and kicks ball  ● Copies the following shapes: _, I, O, T \\n● Start coloring in, go over the lines  \\n● Pencil grip:  \\n● Holding crayon to draw (still developing)  \\n● Builds a 9 -block tower  \\n● Thread big beads on a shoelace  \\n● Draw a man: at least 4 parts  ● Using only single \\nwords  \\n● Ataxia  \\n   \\n \\n \\n \\n \\n \\n \\n', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 224}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 4 Annex 4: Tanner Staging of Sexual Maturity in Adolescents  Annex 4 A: Tanner Staging of Sexual Maturity in Girls  \\nAge Range  \\n(Year)  \\n0-15 \\n8-15 \\n10-15 \\n10-17 \\n12-18 Tanner Staging in  \\n Annex 4 B: Tanner Staging of Sexual Maturity in Boys  \\nAge Range  \\n(Year)  \\n0-15 \\n \\n10-15 \\n \\n10-16 \\n \\nVariable  \\n(12-17) \\n13-18 Tanner Staging in  \\n \\n \\n', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 225}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 5 Annex 5: Age -Appropriate Disclosure for Children and Adolescents  \\nAge \\nCharacteristics  Stage of \\nDisclosure  Provider Actions  \\n0 - 4 years  No disclosure  At this stage no disclosure is done since the child is too young \\nto understand about HIV  \\n5 - 8 years  Partial disclosure  At this age the child can understand a lot. Define the virus as a \\ngerm and the CD4 as the soldier in the body that keeps fighting \\nand one has to take the drugs to strengthen the soldiers in the \\nbody  \\n9 to 12 years  Full disclosure  Full disclosure is important since most children at this stage \\nare able to understand more about HIV and would have heard \\nabout HIV as part of formal education at school  \\nFollow the following stages in the disclosure process  \\nStage 1  \\nAssessing the child’s social support system to ensure \\navailability of sufficient support once disclosure is completed  \\nStage 2  \\nAssess the child’s prior knowledge about HIV including \\ninformation given at school, any myths and misconceptions. \\nOffer or reinforce accurate information  \\nStage 3  \\nUse an imaginary exercise or story to assess child’s reaction to \\ndisclosure of HIV status  \\nStage 4  \\nTell the child about their HIV status. Support parents to \\ndisclose to the child and clarify the mode of infect ion. Address \\nimmediate reactions and concerns a child might have  \\nPost -disclosure  \\n(1-2 weeks after \\nfull disclosure)  Find out from the parent/guardian if they have observed \\nanything after disclosure, e.g., change in behavior  \\n• Introduce the child to tell their story and emerge as a hero \\n(a comic book may be a useful aid)  \\n• Link the child to a support group or with an older child \\nwho has been disclosed to  \\nNB: Find out how the child is doing at every visit after full \\ndisclosure  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 226}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 6 Annex 6: Transitioning from Adolescent to Adult HIV Services  \\nInitiate transition process for all children in \\npaediatric clinic who have attained 10 years of ageGoal 1 : for age 10 -12 years (early -adolescence)\\n•  Full disclosure\\n•  Understanding of the HIV\\n•  Understanding of HIV prevention measures\\n•  Link to an adolescent support group Has adolescent attained 13years and achieved Goal 1 \\nabove?\\nYes: Client is 13years and has achieved \\ngoals at early adolescence continue to \\ngoal 2No: Client is 13years and has \\nnot achieved goals 1 at early \\nadolescence\\nGoal 2 : for age 13 -16 years (mid -adolescence)\\n•  Understanding of the medication and adherence\\n•  Encourage appointment keeping\\n•  Should be a member of a support group\\nHas adolescent attained 17years and achieved Goal 2 above?No: Client is 17 years and has not \\nachieved goals at mid adolescence\\nYes: Client is 17 years and has achieved goals at mid adolescence\\nGoal 3 : for age 17 -19 years (late -adolescence)\\n• Demonstrated understanding importance of medication adherence in last 2 -3 visits\\n• Prompt appointment keeping for 6months\\nHas adolescent attained 19years and achieved Goal 3 above?\\n Client chooses to transition\\n Transfer medical records\\n Orient adolescent in adult clinic\\n Follow up of transitioned adolescentsClient declines to transition\\n Continue psychosocial support to client as you prepare for transition to \\nadult clinic\\n \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 227}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 7 Annex 7: 2018 HIV Testing Services Algorithm  \\nSCREENING\\nNON REACTIVE REACTIVE\\nREPORT NEGATIVE CONFIRMATORY TEST\\nNON REACTIVE REACTIVE\\nINCONCLUSIVE REPORT POSITIVE\\nREFER TO THE COMPREHENSIVE CARE CLINIC\\nSCREENING TEST SCREENING TEST\\nNON REACTIVE REACTIVE NON REACTIVE\\nCONFIRMATORY TEST\\nNON REACTIVE REACTIVE\\nREPORT INCONCLUSIVE REPORT POSITIVECollect DBS and \\nsend to laboratory \\nfor DNA PCRINCONCLUSIVE\\nRequest for retest \\nafter 2 weeks at \\nCCC\\nIf the result is still \\ninconclusive, \\ncollect DBS and \\nsend to the \\nlaboratory for DNA \\nPCREnroll to care and \\ntreatment \\nNB:  The use of TIE BREAKER is no longer recommendedRetesting in MCH, wards or \\nsettings without CCCs: To be \\ndone by a different service \\nprovider on a second \\nspecimen\\nREPORT NEGATIVE\\n \\n \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 228}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 8 Annex 8: HIV Education and Adherence Counselling Content Guide  \\nHIV Education and Adherence Counselling  \\nNote: for children/adolescents, the script below should be modified towards the caregiver  \\nSection 1: Introductions, climate setting, and review of objectives for the session  \\n• Ensure privacy and confidentiality  \\n• Introductions of all pa rticipants  \\n• Present the key message for each section using simple terms that the patient will understand, \\nusing analogies as appropriate  \\n• Use IEC material when available  \\n• Ask the patient if they have any questions at the end of each section, and then ask them to explain the \\nmain points back to you to confirm understanding  \\n• If this is a follow -up session, review what they remember from previous sessions and adapt the \\nsession  to address their needs  \\nSection 2: HIV  \\n• What is HIV  \\n− HIV stands for “Human Immunodeficiency Virus”  \\n− HIV is a virus that attacks the body’s immune system.  The immune system protects the \\nbody from infections  \\n• How is HIV transmitted  \\n− Sexual contact  \\n− Needles  \\n− Exchange of blood and bodily fluids  \\n− Mother -to-child transmission  \\n• Why should family members be tested for HIV  \\n− Sexual partners are at risk for already having HIV  \\n− All children born to HIV positive mothers are at risk for already having HIV  \\n− Encouraging partners/children to test for HIV now is the best way to identify HIV early, so \\nthey can also get into treatment  \\n− Starting treatment early will help them live long and productive lives  \\n− Whether they test positive or negative, they can be an impor tant source of support for your \\nown treatment  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 229}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 9 Annex 8: Cont.  \\nSection 3: Viral load  \\n• What is viral load  \\n- Viral load is the amount of HIV in your body  \\n- When your viral load is high it means you have a lot of HIV in your body; this causes damage to \\nyour body  \\n- Viral load is measured by a blood test  \\n \\n• How often is viral load measured  \\n- Viral load is measured after being on treatment for 3 months  \\n- After 3 months of treatment, we expect the amount of virus in your body to be undetectable; if \\nyour VL is detectable then we have to discuss the reasons  \\n- Having an “undetectable” VL means the test cannot measure the virus in your blood because \\nyour ART is working, but it does not mean you are no longer infected with HIV  \\n- Repeat viral load tests are done dependin g on how you are doing; if you are doing well on \\ntreatment then the viral load is measured again every 6 months (for children/adolescents and \\npregnant/breastfeeding) or annually  \\n- For HEI with positive PCR, we also measure viral load at the start of treatmen t \\n \\n• What do viral load measurements mean  \\n- After being on treatment for 3 or more months, your viral load should be undetectable  \\n- If your viral load is undetectable, it means your treatment is working well and you should \\ncontinue taking it the same; the virus is not damaging your body any more  \\n- If your viral load is detectable, it means your treatment is not working properly, usually because \\nyou have been missing some of your pills; the virus is damaging your body and you and the clinic \\nteam will need to work together to figure out how to fix the problem  \\nSection 4: CD4 cells  \\n• What are CD4 cells  \\n- CD4 cells are the immune cells that protect the body from infections  \\n- CD4 cells are measured through a blood test, called CD4 count. For adults a normal CD4 count is \\nabove 500  \\n \\n• How are CD4 cells affected by HIV  \\n- HIV attacks and destroys CD4 cells  \\n- After years of constant attack from HIV, the CD4 count falls  \\n \\n• What happens when CD4 cells decrease  \\n- When the CD4 count falls too low (usually below 200), diseases called “opportunistic infections” \\nare able to infect the body because the body cannot defend itself  \\n- Common opportunistic infections include: tuberculosis, pneumonia, skin problems, white spots \\nin the mouth, and chronic diarrhoea  \\n \\n• How often is CD4 count measured  \\n- CD4 count is measured for all patients at the beginning of treatment, to see if you are likely to get \\nany opportunistic infections  \\n- Once you start treatment for HIV, we do not need to check CD4 count frequently, but we will use \\nthe VL tes t to monitor your response to anti -retroviral treatment  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 230}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 10 Annex 8: Cont.  \\nSection 5: Antiretroviral therapy (ART)  \\n• What is ART:  \\n- ART is a combination of 3 or more different medicines  \\n- ART fights HIV, lowering the amount of virus in the body allowing the body to protect \\nitself against opportunistic infections  \\n- When the virus level is low then the CD4 count can increase  \\n- Increased CD4 count means the body is able to protect itself against opportunistic infections  \\n \\n• What are the benefits of ART:  \\n- After a few weeks of taking ART, you will begin to regain appetite and weight (if it has been \\naffected)  \\n- Many people report an increase in their energy levels and general sense of well being  \\n- People can often return to work or school or care for their families  \\n- With ART,  people with HIV can live a long and healthy life if they take it properly  \\n \\n• When is ART started:  \\n- Everybody with HIV should start ART  \\n- Even if your CD4 count is high, the virus is doing damage inside of you and needs to be \\ncontrolled  \\n- ART should be started as soon as you are ready, preferably within 2 weeks  \\n- The longer you wait to start ART, the more time the virus can damage your body, increasing \\nyour chances of getting sick or even dying  \\n- Sometimes ART is started a few weeks later if you have certain infections, or if you do not \\nthink you are ready to take them properly  \\n \\n• Does ART cure HIV:  \\n- ART does not cure HIV  \\n- ART lowers the amount of virus in your body so your body can protect itself from infections  \\n- It does not remove the virus completely  \\n \\n• Can you still give HIV to others while taking ART:  \\n- Transmission of HIV is very unlikely once your viral load is undetectable  \\n- You should practice safer sex to reduce the risk for other infections as well, including \\ndisclosure of HIV status to sexual partners and consistent and correct condom use  \\n \\n• How long is ART taken for:  \\n- ART is a life -long treatment  \\n- Once you start ART, you need to take it every day for the rest of your life (either once a day, \\nor twice a day, depending on which drugs you are on)  \\n- You must take the ART as prescribed and never miss a dose otherwise the treatment might \\nfail and the drugs stop working against the virus  \\n \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 231}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 11 Annex 8: Cont.  \\nSection 6: Treatment failure  \\n• What happens if you stop taking ART:  \\n- When you stop taking ART the virus begins to increase in your body very quickly  \\n- The virus goes back to the same high level it was at before you started ART  \\n• What happens if you do not take ART regularly:  \\n- The virus begins to increase to high levels again  \\n• What happens if t he viral load increases:  \\n- When the virus is allowed to increase again, it will also affect your immunity and reduce your CD4 count \\nputting you at risk of opportunistic infections  \\n- When the virus is allowed to increase again, it can change and get stronger, a nd becomes resistance to \\nthe ART  \\n- When the virus becomes resistant, the ART does not work against the virus anymore  \\n- The risk of resistance increases by not taking the ART correctly and by starting and stopping the \\nmedications several times  \\n- When resistance o ccurs, this is called treatment failure  \\n• What happens in treatment failure:  \\n- The ART no longer works because the virus has become resistant to it  \\n- If treatment fails, it is necessary to use stronger, more expensive ART, but it still may not work as well  \\n- With the stronger ART you may need to take more pills every day, and you may have more side effects  \\n- If you become resistant to the new ART as well, then there may not be any drugs that can work for you, \\nand the virus will increase quickly and your CD4 coun t will go way down  \\n- It is essential that you take your ART every day as prescribed so that you do not develop treatment \\nfailure, and can live a long and healthy life  \\nSection 7: ART side effects  \\n• What are the side -effects of ART:  \\n- Sometimes people can get side effects from taking ART  \\n- Side effects vary from person to person  \\n- Some people have none while other experience mild effects which are unpleasant but often manageable  \\n- Most side effects occur within the first few weeks of starting ART and then improve aft er a few weeks or \\nmonths  \\n- Some common side effects include:  \\n● Headache  \\n● Loss of appetite  \\n● Skin rash  \\n● Fatigue  \\n● Nausea, vomiting, diarrhoea  \\n● Muscle pains  \\n• What do you do if you notice any side effects:  \\n- If you develop any side effects, you should continue taking your ART as prescribed, without missing any \\ndoses, until you discuss with the clinician  \\n- If the side effects are mild then you can continue taking your ART without missing any doses, and then \\ndiscuss the side effects with the clinician at your next appointment  \\n- If the side effects are bothering you too much then return to the clinic immediately, even if you do not \\nhave a scheduled appointment, to discuss what to do next; you can also call the clinic if you are not able \\nto make it yourself immediately  \\n- Severe side effects include rash all over your body, or rash in your mouth or eyes, constant vomiting, \\ninability to eat or retain food, or anything else that makes you think you should stop the ART. If this \\noccurs then contact the clinic immediately  \\n- The cl inician will help you manage the side effects, and occasionally the ART may need to be changed  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 232}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 12 Annex 8: Cont.  \\nSection 8: Adherence  \\n• What is adherence  \\n- Following a care plan as agreed with the healthcare team  \\n- Attending clinic appointments as scheduled  \\n- Picking up medicines and taking them as prescribed  \\n- Getting lab tests according to the recommended schedule  \\n- Following nutritional recommendations  \\n• How should ART be taken  \\n- You must take the correct dosage. If you take less than the dose prescribed the treatment will \\nnot be effective and will result in resistance and treatment failure. Never share your ART with \\nsomeone else  \\n- For children, the dosage keeps changing as they grow and gain weight  \\n- You must take ART the correct time of day:  \\n• If your ART is supposed to be taken once per day, then pick a time when it will usually be \\nconvenient for you to remember, e.g., with breakfast every day.  \\n• If your ART is supposed to be taken twice per day, then you should set a convenient time to \\ntake your dr ugs approximately 12 hours apart (e.g., 8.00 am and 8.00 pm every day). It \\ndoes not have to be exactly 12 hours apart if your schedule does not allow; the most \\nimportant thing is to take them twice per day every day (e.g., you can take it at 6.00 am and \\n8.00 pm every day)  \\n- If you miss a dose of ART then take your dose as soon as you remember, as long as it is not \\nwithin a couple of hours of your next dose, and then return to your regular schedule. Do not \\ntake a double -dose of ART to make up for a missed dose  \\n- You must take ART according to dietary restrictions. Some ART should be taken with food, for \\nsome it does not matter, and a few require that you have an empty stomach. These dietary \\nrestrictions will be explained to you once your ART regimen is  selected  \\n- It is essential to take ART as prescribed and not miss any doses  \\n- Some medications (prescription, non -prescription, and herbal) interact with ART and make \\nthem ineffective. Be sure to tell your clinician and pharmacist the names of all the medicat ions \\n(including traditional/herbal) that you are taking, and any time you are given new medications. \\nAvoid use of alcohol  \\n• What usually interferes with good adherence (can apply to the patient or to the caregiver)  \\n- Stigma: it is hard to take ART correctly if you need to hide it because you are worried about \\npeople finding out you have HIV  \\n- Disclosure: it is hard to take ART correctly if the people closest to you, particularly family \\nmembers and close friends, do not know you have HIV  \\n- Change in rout ine: if your daily routine suddenly changes it may be difficult to remember to \\ntake your ART at the usual time  \\n- Travel: frequent travel, or unexpected travel (such as for a funeral) may interfere with taking \\nART, particularly if you do not have enough drugs  with you for the entire trip  \\n- Alcohol and drug use: it is hard to remember to take ART when under the influence of alcohol \\nor other drugs  \\n- Caregiver changes: every time a child has a new caregiver, that person needs to learn about \\nhow and why ART is taken  \\n- Side effects: when people get side effects from ART they sometimes stop or reduce the amount \\nof ART they are taking, hoping it will reduce the side effects  \\n- Pill burden/palatability: sometime the number of pills (or taste of syrups for children) makes it \\ndifficult to take ART correctly  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 233}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 13 Annex 8: Cont.  \\n- Distance: choosing an HIV clinic that is far away from your home can make it difficult to come to \\nappointments and pick drugs regularly  \\n- HIV knowledge: when people do not understand what HIV is, and why ART is important, they \\nmay not take their drugs properly. This also applies to children and adolescents, if they have \\nnot been told they have HIV and taught what it means  \\n- Mental health disorders: depression and other mental illnesses can make it difficult to t ake ART \\ncorrectly  \\n- Religious beliefs: some people stop taking ART after faith -healing, although there has never \\nbeen a case of someone being cured of HIV this way  \\n• What might make it difficult for you individually to take your ART as prescribed  \\n- Ask the patie nt: “Based on what you have learned so far, what challenges do you think you will \\nhave taken  ART correctly, every day, for the rest of your life?”  \\n- Discuss strategies to manage any expected barriers to adherence  \\n• What can help you take ART as prescribed  \\n- Disclosure: It is easier to take your ART properly when the people close to you know your HIV \\nstatus, so you do not have to try and hide your ART or miss doses to avoid being seen. Family \\nand friends can also provide additional support once they  are aware you have HIV and \\nunderstand more about it. We can help you disclose your HIV status to important family \\nmembers or friends when you are ready  \\n- Treatment supporter: Having a “treatment buddy” can help you take your ART correctly; ask a \\nfriend, par tner, or family member to remind you to take your ART. If possible, invite that \\nperson with you to some of your clinic appointments and counselling sessions so they can learn \\nabout ART, the importance of good adherence, side effects, etc.  \\n- SMS reminder syst em (if SMS reminder system in place at the facility): Receiving a regular SMS, \\ne.g., every week, can help you take your ART correctly. We enroll all our patients into this \\nservice for SMS reminders at our clinic, unless you do not want to receive them. The  messages \\nsimply ask how you are doing, and do not mention HIV, ART, the clinic, or anything else that \\nmay reveal your HIV status to others  \\n- Support group: Joining a support group will help you learn from other people how they \\novercome challenges in living with HIV and taking ART correctly. Some support groups also \\nhave economic activities to help increase your income. We have support groups based at the \\nhealth facility, and there are also support groups in the community  \\n- Other reminders:  \\n- Set a specific time of day to take your ART  \\n- Associate your ART with a specific event/s in your daily schedule (e.g., when you eat \\nbreakfast and dinner)  \\n- Set an alarm on your phone or watch  \\n• What happens if you miss an appointment?  \\n• The healthcare team will be concerned about you, and will try to contact you by phone  \\n- Confirm patient phone number and consent to call if misses an appointment or any urgent \\nlab results  \\n• If we cannot contact you by phone, we will try to call your treatment buddy  \\n- Confirm treatment buddy name and phone number, and consent to call if needed  \\n• If we cannot reach you or your treatment buddy, we may try and visit you at home, if we have \\nyour permission  \\n- Confirm locator information and consent to perform home visits if needed  \\n• Once you are back in care, we will work with you to figure out what caused you to miss an \\nappointment and how it can be prevented in the future  \\n• You will not be punished for missing an appointment  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 234}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 14 Annex 8: Cont.  \\nSection 9: Other medications  \\n• What other medications will you take, in addition to ART:  \\n- CPT: all PLHIV should take cotrimoxazole preventive therapy once per day, in order to reduce \\nthe chance of getting other infections such as pneumonia, malaria, and diarrhoea  \\n- TPT: all PLHIV should receive 6 months of isoniazid preventive therapy (or another \\napproved TPT regimen), unless they have active TB disease, in order to prevent \\ndevelopment of TB  \\n• Other medications may be recommended for specific conditions  \\nSection 10: Nutrition  \\n• Why is nutrition important:  \\n- When the viral load is high, your body uses a lot of energy trying to fight the virus  \\n- If your nutrition is poor, you have more chance of getting other infections as well  \\n- You need to eat well so your body has everything it needs to fight HIV, and look healthy  \\n• What can you do to improve your nutrition?  \\n- Eat a balanced diet from a variety of foods.  \\n- Try not to eat a lot of sugar, red meat, or fatty/fried foods  \\n- Try to eat plenty of whole grains, vegetables, fruit, beans, and fish  \\n- Drink plenty of clean safe water  \\n- Physical activity and exercise is encouraged.  \\nSection 11: Follow -up \\n• How often will you need to come to the clinic  \\n- Before starting ART: you should come to the clinic at least every week in order to get you prepared \\nfor ART so you can start as soon as possible  \\n- Soon after starting ART: after you start ART you should come to the clinic in 2 weeks in order to \\nsee if you have had any trouble taking your pills or have developed any side effects; then you can \\nbe seen after another two weeks for the same; then every month until your first viral load test  \\n- Once you have been on ART for a while: if your first viral load (after 3 months) is undetectable \\nthen you can be seen every 1 -6 months depending on other factors  that will be discussed with the \\nclinician  \\n- Unscheduled visits: if you ever have any concerns, feel unwell, or need to speak with any of the \\nclinic team then you can call or come to the clinic, even if you do not have an appointment \\nscheduled for that day  \\n• What will we be checking for during your clinic visits  \\n- At each visit you will be asked if you have had any illnesses since the last visit, if you have had any \\ntrouble taking your ART, and if you are experiencing any side effects. You may need a physic al \\nexam or blood tests at some visits  \\nSection 12: ART readiness assessment  \\n• Are you ready to start ART today?  \\n- Complete the ART Readiness Assessment (Table 5.4) for each patient to see if they should \\nstart ART today, and if not, to identify what issues need to be addressed before starting \\nART  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 235}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 15 Annex 8: Cont.  \\nSection 13: Management plan  \\n• Which investigations will you have today  \\n- See Table 3.2 and Table 3.5 for recommended baseline and follow -up investigations \\nrespectively  \\n• Which medications will you start today  \\n- May include: ART; CPT; TPT; other  \\n• What else is required as you start or as you prepare to start ART  \\n- May include: assisted disclosure; support group referral; engagement of a treatment \\nbuddy; drug and alcohol counselling; depression management; referrals; other  \\n- For patients not starting ART today, management plan should include specific \\nstrategies to address any issues preventing/delaying ART initiation  \\n• When should you return to the clinic  \\n- Book appointment date  for next visit, preferably with the same healthcare worker  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 236}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 16 Annex 9 A: Enhanced Adherence Counselling Content Guide  \\nEnhanced Adherence Counselling for Patients with Suspected or Confirmed Treatment Failure  \\nNote: for children/adolescents, the script below should be modified towards the caregiver  \\nSession 1  \\n• Assess patient’s understanding of ‘viral load’, ‘high viral load’ and ‘suppressed viral load’. Ask \\nthe patient to explain what each of these terms mean. Provide education if patient requires \\nmore explanation  \\n• Provide VL result and explanation of result:  \\n“You have a detectable viral load. There are several possible reasons for this such as problems with \\nadherence, dosing of your medications, interactions wit h other drugs or foods, or possible drug \\nresistance. It is very important for us to work with you determine which may apply to you.”  \\n• How does the patient feel concerning the result?  \\n• Explain the process of enhanced adherence:  \\n“Patients with a high viral load come for at least 3 adherence counselling sessions to discuss what \\nmight cause a high viral and to look for solutions on how adherence can be improved. Another \\nviral load test will be done after 3 months of good adherence to see if the ART can b e continued or \\nif we need to change treatment.”  \\n• Check whether the patient had previous problems with adherence and/or missed \\nappointments  \\n• Ask:  \\n“Why do you think your viral load is high?”  \\n• Sometimes the patient already knows why his/her VL is detectable. Sta rt by giving them a \\nchance to provide their own explanation. Often, they will admit that they are struggling with \\ntheir adherence  \\n• If they really don’t know why their VL is high you can say:  \\n“We notice that when people sometimes forget to take their ART everyday it gives the virus a chance \\nto multiply. Do you think that you sometimes forget your pills?”  \\nAssess for Possible Barriers to Adherence  \\nCognitive Barriers (HIV and ART knowledge)  \\n• Assess patient’s knowledge about HIV and ART; correct any misconceptions  \\n“What is HIV?”  \\n“What is the immune system and CD4 cells?”  \\n“What is ART and how does it work?”  \\n“Why is it important to be adherent? And how?”  \\n“Why do you have to come for follow -up appointments? What should you bring?”  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 237}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 17 Annex 9A: Cont.  \\nBehavioural Barriers  \\n• Review how the patient takes drugs  \\n“Please explain how you take your drugs, and at what time?”  \\n“How does treatment fit in your daily routines?”  \\n• Establish with the patient whether the time they are meant to take their medication is \\nappropriate or whether the time is a problem. For example, if the patient has chosen 9 pm, \\nbut is already asleep in bed by 9 pm, then that is not a good dosing time. If the time is a \\nproblem, then determine a new, more appropriate time with the patient based on their \\nschedule  \\n• Remind the patient/caregiver that a missed dose should be taken as soon as he/she \\nremembers (up to a couple of hours before the next scheduled dose). The next dose should \\nbe taken at the usual time  \\n“What reminder tools do you use? (e.g., mobile phone alarm)” “What do you do in case of visits, and \\ntravel?”  \\n• Travelling is always a risk for poor adherence or default from treatment. Encourage the patient \\nto plan, to make sure they have enough medication on hand  before and to remember to pack \\nit \\n• Make sure that all relevant information is on the patient’s appointment card and explain that \\nif they are ever away from home and they are about to run out of medication that they must go \\nto the closest ART clinic and sho w their appointment card  \\n“What do you do in case of side effects?”  \\n• Ask the patient if s/he has any side effects from the ARVs, and if they sometimes find it \\ndifficult to take ARVs  \\n• Due to the side effects, ask how s/he manages side effects and if it influences the way s/he \\ntakes the drugs.  \\n“What are the most difficult situations for you to take drugs?”  \\n• Check for alcohol or drug use. Ask the patient in a casual way (not in an accusing way) if they \\nsometimes use substances; emphasize treatment planning in case they do  \\n• “Taking alcohol or drugs sometimes makes it difficult for us to remember to take treatment. If \\npossible, it is best to limit your use, but if you are planning to take any alcohol or drugs, it is \\nimportant to plan ahead so that you don’t for get to take your treatment”  \\n“If you feel your alcohol or drug use is affecting your adherence, are you ready to be referred to some \\nprofessionals that may help you work on that problem?”  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 238}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 18 Annex 9A: Cont.  \\n● Emotional Barriers  \\n• Review the patient’s motivation:  \\n“How do you feel about taking drugs every day?” \\n“What are your ambitions in life?”  \\n• You can use motivation cards for this: Ask the patient to think of his or her own personal \\ngoals/dreams for the future. What are the 3 most important things they  still want to achieve? \\nHave them write them in their own words on a notecard. Encourage the patient to read the \\nnotecard every day, preferably right before they take their medication  \\n• Mental health screening:  \\n- Depression is an important reason of non -adherence.  All patients with suspected or \\nconfirmed treatment failure should be screened for depression using the PHQ -9 tool \\n(Table 4.14)  \\n- The patient may be in any of the five stages of grief (because of their HIV diagnosis or for \\nother reasons): deni al and isolation; anger; bargaining; depression, or; acceptance. This \\nneeds to be assessed and addressed  \\nSocio -economical Barriers  \\n• Review the patient’s disclosure of their HIV status  \\n“Do you have any people in your life who you can talk to about your HIV status and ART?”  \\n• Discuss how the patient can enlist the support of their family, friends, and/or co -workers in \\nreminding them to take their medication if they have not already done so  \\n• Support from a treatment buddy: if the patient came with treatment buddy, assess their input \\ntowards adherence. If patient did not come with treatment buddy, explain the role of a treatment \\nbuddy and encourage the patient to come with a person they trust next visit  \\n• Support in family/community/support group: expl ore support systems, in addition to the \\ntreatment buddy, that the patient is currently using and options that the patient can start using. \\nDiscuss the advantages of joining a support group and any reasons the patient is hesitant to join  \\n• Profession, income generating resources: review the patient’s and family’s sources of income \\nand how well they cover their needs  \\n• Specific barriers to come to health centre on regular basis: ask the patient if they have any \\nchallenges getting to the clinic on regular basis. Help the patient develop strategies to overcome \\nthose challenges  \\n• Stigma and discrimination  \\n“Are you ever worried about people finding out your HIV status \\naccidentally?” “Do you feel like people treat you differently when they know \\nyour HIV status?”  \\n• Discuss if stigma is making it difficult for them to take their medications on time, or for them \\nto attend clinic appointments  \\n• Religious beliefs: find out if the patient has tried faith healing, or if they have ever stopped taking \\ntheir medicine because of their religious beliefs  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 239}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 19 Annex 9A: Cont.  \\nReferrals and Networking  \\n• Review the patient’s file to determine if they have been referred to other services. This includes \\nreferrals to social services, support groups, psychology services, nutrition services, medical \\nclinics, substance abuse groups, etc.  \\n• Ask the patient if they attended the appointments, check in on their experience with the \\nreferral services and re -organize referrals as necessary  \\n• Determine if the patient could benefit from a home visit  \\nDevelop Adherence Plan  \\n• Go through each of the adherence challenges identified during the session and assist the \\npatient to develop a plan that addresses each of the issues. It is important to let the patient \\ncome up with the solutions so that they can own them  \\n• Some examples of addressing adherence challenges:  \\n- Behavioural barriers: using a reminder tool; using a pill box; redefining the medication \\nschedule to fit with the patient’s daily schedule; keeping an emergency dose of drugs when \\naway from home  \\n- Refer to clinician in case of side effects  \\n- Socio -economical barriers: move on to disclosure process; identify a treatment buddy; join a \\nsupport group; refer to CBO/NGO to learn about income generating activities  \\n- Emotional barriers: emotional support or refer to clinician for mental health management  \\nAgree on a follow -up date for the next session  \\n \\nSession 2 (usually 2 weeks after Session 1, preferably with the same provider)  \\nReview Adherence Plan  \\n• Ask the patient if he/she thinks adherence has improved since the last visit. Enquire in a \\nfriendly way if any doses have been missed  \\n• Review the patient’s barriers to adherence documented during the first session and if \\nstrategies identified have been taken up. If  not, discuss why  \\nIdentify Any New Issues  \\n• Discuss specific reasons why the patient may have missed their pills or a clinic \\nappointment since the last counselling session, and determine if it is a new issue that \\nwasn’t addressed during the first session  \\n• Discuss if other issues have come up because of implementing the adherence plan (e.g., \\nperhaps the disclosure process had unintended results)  \\nReferrals and Networking  \\n• Follow -up on any referrals made during the previous session  \\n• Determine if the patient could benefit from a home visit  \\nDevelop Adherence Plan  \\n• Go through each of the adherence challenges identified during the session and assist the patient \\nto modify their original adherence plan to address each of the issues. It is important to let the \\npatient come up with the solutions so that they own them  \\n• Give another short motivational speech on how you believe in the patient! You know they can \\ndo this! Together you will make sure that they suppress their viral load!!  \\n• Agree on a follow -up date fo r the next session  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 240}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 20 Annex 9A: Cont.  \\nSession 3 (usually 2 weeks after Session 2, preferably with the same provider)  \\nReview Adherence Plan  \\n• Ask the patient if he/she thinks adherence has improved since the last visit. Enquire in a \\nfriendly way if any doses have been missed  \\n• Review the patient’s barriers to adherence documented during the first session and if \\nstrategies identified have been taken up. If not, discuss why  \\n \\nIdentify Any New Issues  \\n• Discuss specific reasons why the patient may have missed their pills or a clinic appointment \\nsince the last counselling session, and determine if it is a new issue that wasn’t addressed \\nduring the first session  \\n• Discuss if other issues have come up because of implementing the adherence plan (e.g., perhaps \\nthe disclosure process had unintended results)  \\n \\nReferrals and Networking  \\n• Follow -up on any referrals made during the previous session  \\n• Determine if the patient could benefit from a home visit  \\n \\nDevelop Adherence Plan  \\n• Go through each of the adherence challenges identified during the session and assist the patient \\nto modify their original adherence plan to address each of the issues. It is important to let the \\npatient come up with the solutions so that they own them  \\n• Give another short motivati onal speech on how you believe in the patient! You know they \\ncan do this! Together you will make sure that they suppress their viral load!!  \\n• Agree on a follow -up date for the next session  \\n \\nRepeat Viral Load  \\n• If the adherence is good: plan for the next VL testing after 3 months and explain possible ways \\nforward, emphasizing the roles of the patient, the support systems and the health facility. You \\ncan continue follow -up adherence counselling sessions during the 3 -month period if you and \\nthe patient think th ere would be a benefit to them  \\n“If your results come back and your VL is undetectable then you will be able to continue with same ART. \\nIf your viral load is still greater than 1,000 copies/ml then you will need to switch to a new regimen, \\nprobably after do ing some additional testing to see which regimen may work best for you. If your viral \\nload is detectable but less than 1,000 copies/ml we will discuss options, including changing regimens \\nor continuing to monitor.” (Adapt to individual patient/context)  \\n• If adherence challenges persist: plan further Enhanced Adherence Counselling Sessions before \\nrepeating the VL  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 241}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 21 Annex 9A: Cont.  \\nSession to Discuss Repeat Viral Load Results (after the repeat VL results are back, preferably with \\nthe same provider)  \\nDiscuss Viral Load Results  \\n• If suppressed (VL < 50 copies/ml) CONGRATULATE the patient!!!  \\n- Explain the way forward: will continue with same ART regimen and repeat the VL again in 6 \\nmonths  \\n• If viral load is ≥ 1,000 copies/ml  \\n- Explain the way forward: will probably need to switch to a new ART regimen after discussing \\nas an MDT, and additional testing to see which regimen may work for the patient  \\n- Summarize the case with the MDT; if the patient cannot switch to standard 2nd line ART, or \\nis failin g 2nd line ART, forward to the Regional or National HIV Clinical Technical Working \\nGroup for next steps  \\n• If viral load is 50 - 999 copies/ml  \\n- Explain the way forward: will reassess barriers to adherence, support systems, and other \\nreasons for viremia; once reason/s for viremia have been addressed then will repeat the viral \\nload after another 3 months of excellent adherence  \\n \\n \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 242}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 22 Annex 9 B: Case Summary Form  \\n \\n \\nMINISTRY OF HEALTH  \\nNATIONAL AIDS AND STI CONTROL PROGRAMME  \\nCLINICAL SUMMARY FORM  \\nName of \\nFacility   MFL \\nCode   \\nPatient CCC \\nno.  \\n(Do not write \\nname )  Date   \\nPatient \\nDetails  Date of Birth:                  Enrollment Date:  \\n \\nGender:   Current Weight (Kg):                      Height (cm):  \\nClinician’s \\nName   \\nFacility \\nContacts  Tel:  Email:  \\n \\nWhat is the primary reason for this consultation:  \\n \\nClinical Evaluation: history, physical, diagnostics, working diagnosis ( excluding the information in \\nthe table below  \\n \\n \\n \\n \\n \\n \\nComplete the table below chronologically, including all ART regimens and laboratory results (and \\nany previous history available for transfer -in patients)  \\nDate  CD4  HB CrCl/  \\neGFR  Viral \\nLoad  Weight  \\n(z-score/BMI \\nfor children)  ARV \\nRegimen  Reason for \\nSwitch  New OI or other \\nclinical event  \\n         \\n         \\n         \\n         \\n         \\n         \\n \\n  \\n', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 243}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 23 Annex 9 B: Cont.  \\nAdherence and Treatment Failure Evaluation  \\nParameters of Evaluation  Findings  \\n● Number and findings of adherence counseling/assessment \\nsessions done in the last 3 -6 months including the following:  \\no Findings from MMAS -8 \\no Adherence barriers identified  \\no Recommendations   \\nNumber of home visits conducted in last 3 -6 months, and findings   \\nDescribe support structures (e.g., treatment buddy, support group \\nattendance, caregivers) in place for this patient   \\nEvidence of adherence concerns (e.g., missed appointments, pill counts)   \\nDescribe daily witnessed ingestion done in last 3 -6 months (Who performed \\nit, which tool was used, how long was session done etc.)   \\nDescribe likely root cause/s of poor adherence for this patie nt (e.g., stigma, \\ndisclosure, side effects, alcohol or other drugs, mental health issues, \\ncaregiver changes, religious beliefs, inadequate preparation, etc.)   \\nEvaluation for other causes of treatment failure, e.g.:  \\n● Inadequate dosing/dose adjustments (particularly for children)  \\n● Drug -drug interactions  \\n● Drug -food interactions  \\n● Impaired absorption (e.g., chronic severe diarrhea)   \\nOther Relevant ART History  \\nComment on treatment interruptions, if any   \\nHas Drug Resistance Testing been done for this patient? If yes, state date \\ndone and attach the detailed results   \\nHas facility multidisciplinary team discussed the patient’s case? If yes, \\ncomment on date, deliberations and recommendations (indicate how \\ntreatment failure was established and con firmed, proposed regimen and \\ndosage, current source of drugs if patient already on 3rd line)   \\nMDT members who participated in the case discussion (names and titles)   \\n \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 244}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 24 Annex 9 C: Enhanced Adherence Counselling Form  \\nENHANCED ADHERENCE COUNSELLING FORM  \\n(To be completed by the counsellor)  \\n• Start each session by reviewing the adherence barriers and action plan from the previous session  \\n• For each session assess major barriers to adherence (cognitive, behavioral, emotional, socio -economic)  \\nSession #:   Date:   Adherence % (from pill count):   MMAS -8 Score:   \\nTreatment \\nmotivation:   \\n \\n \\n \\n \\n \\n \\n \\nBarriers to \\nadherence:   \\n \\n \\n \\nYour impression about patient’s \\ncurrent adherence:    ▢ Excellent                ▢ Unsure            ▢ Inadequate  \\nAdherence plan:   \\n \\n \\n \\n \\n \\n \\nNext appointment date:   \\n \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 245}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 25 Annex 9 D: Home Visit Checklist  \\nHOME VISIT CHECKLIST  \\nPatient Name  Tel No:  Sex: M            F     \\nFamily Member  Tel No:  Sex: M            F     \\nPhysical Landmark:   File No.  \\n \\nThis checklist is not all -inclusive but highlights critical areas that can affect adherence.  \\n Areas to Assess and Discuss  Comments  \\nI Is the patient independent in the activities of daily living (e.g., \\nfeeding, grooming, toileting) l  \\n2 Are the patient’s basic needs being met (e.g., clothing, shelter, food) l  \\n3 Has the patient disclosed their HIV status to other household members   \\n4 How are the patient’s ARVs stored and taken?   \\n5 Does the patient receive social support from household members   \\n6 Does the patient receive social support in the community e.g., linked to \\nOVC, income generating activities, community -based support group, CBO, \\ncash transfer program?   \\n7 Is the patient linked to non -clinical services (e.g., spiritual, legal \\nor nutritional)    \\n8 Does the patient have mental health issues that need to be addressed (use \\nPHQ9 to screen for depression), or use drugs or alcohol?   \\n9 Is the patient suffering from a stressful situation or significant loss/grief?   \\n10 Is the patient having any side -effects from the medications?   \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 246}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 26 Annex 9 E: Management Protocol for Patients Switching to 3rd Line ART  \\nManagement Protocol for patients switching to 3rd line ART  \\n \\nPre – Initiation MDT Meeting  \\n• Confirm what 3rd line ARV regimen is prescribed, its availability and the management plan  \\n• Assign a case manager to patient  \\nInitiation of 3rd Line ART  \\n• Triage  \\no Record vital signs and take actions as needed  \\n \\n• Adherence support  \\no Conduct patient education on the new ART regimen: Treatment goals, dosing, drug \\ninteractions and potential side effects and adverse events  \\no Conduct adherence assessment and counselling  \\no Link patient to adherence support systems  \\n \\n• Clinical assessment  \\no Take history and conduct physical examination  \\no Complete clinical encounter form and MOH 257 (Green Card)  \\no Manage any co -infection and co -morbidities  \\no Review for potential drug interactions and contraindications  \\no Conduct adherence assessment and review adherence support systems including \\ndaily witnessed ingestion plan  \\no Reinforce patient education messages on new regimen  \\n▪ Currently limited future treatment options  \\n▪ Need for perfect adherence (>95%)  \\n▪ Dosing schedule and timing  \\n▪ Potential side effects and what the patient should do  \\no Prescribe new regimen  for 2 weeks  \\no Confirm dosing as per the weight (for ≤15)  \\no Continue other medication e.g., CPT, OI treatment etc.  \\n \\n• Dispensing  \\no Confirm ARV dosing as per the weight (for ≤15)  \\no Conduct medication use counselling  \\no Dispense 3rd Line ARVs for 2 weeks  \\no Check for possible drug interaction  \\n \\n• Community follow up  \\no Link all patients to support group, CHV/CHA  \\no Plan for home visits as required  \\n \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 247}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 27 Annex 9 E: cont.  \\nPatient Follow Up after Treatment Initiation  \\n● Frequency  \\no First follow -up should be within 2 weeks of initiation of 3rd line ART  \\no Subsequent visits should be monthly (or more frequent) until confirmed viral sup - \\npression at 6 months  \\no Thereafter, follow -up can be 1 -3 monthly  \\n \\n● Triage  \\no Record vital signs and take action as needed  \\n \\n● Adherence Support (adherence should be reinforced during every clinic visit, in addition to \\nenhanced adherence counselling sessions)  \\no Review and address knowledge deficits on new regimen  \\no Confirm understanding of adherence, conduct adherence assessment, and reinforce key \\nadherence messages  \\no Document reasons for missed doses and manage obstacles to perfect adherence. Review \\nand reinforce adherence support systems  \\n \\n● Clinical Assessment  \\no Take history and conduct physical examination  \\no Complete Clinical Encounter Form and MOH 257 (blue card)  \\no Manage any co -infections and co -morbidities  \\no Evaluate for potential drug interactions  \\no Evaluate for and manage any drug side effects and adverse events  \\no Conduct adherence assessment and review adherence  support systems  \\no Reinforce patient education messages on new regimen  \\n▪ Review and address knowledge gaps on ART regimen  \\n▪ Need for perfect adherence (>95%)  \\n▪ Dosing schedule and timing  \\n▪ Potential side effects and what the patient should do  \\no Prescribe 3rd line ARVs  \\n \\n● Viral load should be conducted 3 months after change of regimen  \\n \\n● Dispensing  \\no Confirm ARV dosing as per the weight  \\no Conduct medication use counselling  \\no Dispense 3rd line ARVs  \\n \\n● Community Follow up  \\no Review linkage to community adherence support systems  \\no Conduct home visits as required  \\no Continue DOTS  \\n \\n● NOTE: 3rd line annual report with viral load, adherence, and outcomes to be sent to NASCOP  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 248}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 28 Annex 10 A: Dosing of Solid and Liquid Formulations for Twice -Daily Dosing in Infants and Children 4 Weeks of Age \\nand Older  1\\n \\nDrug  Strength of tablets  Number of tablets by weight band morning and evening  Strength of adult \\ntablet  Number of tablets \\nby weight band  \\n3–5.9 kg  6–9.9 kg  10–13.9 kg  14–19.9 kg  20–24.9 kg  25–34.9 kg  \\nAM PM AM PM AM PM AM PM AM PM AM PM \\nAZT/3TC  Tablet (dispersible) 60/30 mg  1 1 1.5 1.5 2 2 2.5 2.5 3 3 300 /150 mg  1 1 \\nAZT/3TC/NVP2 Tablet (dispersible) 60/30 mg/50 mg  1 1 1.5 1.5 2 2 2.5 2.5 3 3 300 /150 /200 mg  1 1 \\nABC/3TC  Tablet (dispersible) 120/60 mg  0.5 0.5 0.5 1 1 1 1 1.5 1.5 1.5 600 /300 mg  0.5 0.5 \\nABC/3TC/LPV/r  30/15/40/10 mg  2 2 3 3 4 4 5 5 6 6    \\nSOLID SINGLE FORMULATIONS  \\nAZT  Tablet (dispersible) 60 mg  1 1 1.5 1.5 2 2 2.5 2.5 3 3 300 mg 1 1 \\nABC  Tablet (dispersible) 60 mg  1 1 1.5 1.5 2 2 2.5 2.5 3 3 300 mg  1 1 \\nNVP2 Tablet (dispersible) 50 mg  1 1 1.5 1.5 2 2 2.5 2.5 3 3 200 mg  1 1 \\nTablet 200 mg  – – – – 0.5 0.5 1 0.5 1 0.5 200 mg  1 1 \\n \\nLPV/r3 Tablet 100/25 mg  – – – – 2 1 2 2 2 2 100/25 mg  3 3 \\nTablet 200/50 mg  – – – – – – 1 1 1 1 200/50 mg  2 1 \\nGranules4 40/10 mg per sachet  2 2 3 3 4 4 5 5 6 6    \\nDRV5 Tablet 75 mg  – – – – 3 3 5 5 5 5    \\n \\nRAL6 Chewable tablets 25 mg  – – – – 3 3 4 4 6 6 400 mg  1 1 \\nChewable tablets 100 mg  – – – – – – 1 1 1.5 1.5 400 mg  1 1 \\nGranules (100 mg/sachet)  0.25  0.25  0.5 0.5 – – – – – –  – – \\nLIQUID SINGLE FORMULATIONS  \\nAZT  10 mg/ml  6 ml  6 ml  9 ml  9 ml  12 ml  12 ml  – – – – – – – \\nABC  20 mg/ml  3 ml  3 ml  4 ml  4 ml  6 ml  6 ml  – – – – – – – \\n3TC  10 mg/ml  3 ml  3 ml  4 ml  4 ml  6 ml  6 ml  – – – – – – – \\nNVP2 10 mg/ml  5 ml  5 ml  8 ml  8 ml  10 ml  10 ml  – – – – – – – \\nDRV5 100 mg/ml  – – – – 2.5 ml  2.5 ml  3.5 ml  3.5 ml  – –    \\nNotes  1 For infants younger than 4 weeks of age refer to Table 10C for more accurate dosing information  \\n2 NVP dose escalation with half dose for 2 weeks when initiating ART is still recommended for infants > 2 weeks of age and not already on NVP prophylaxis to avoid toxicity from high initial \\nNVP levels. HEI already on NVP prophylaxis who are confirmed positive can initiate full dose (twice daily) NVP without dose escalation  \\n3 The LPV/r heat -stable tablet formulation must be swallowed whole and should not be split, chewed, dissolved or crushed. The adult 200/50 mg tablet may be used for patients 14 -24.9kg (1 \\ntab am and 1 tab pm) and for patients 25 -34.9kg (2 tabs am and 1 tab pm) who are able to swallow them whole. The 100/25 mg tablet is smaller than the adult formulatio n and may be used \\nby children of lower weight  bands able to swallow tablets whole.  \\n4 LPV/r granule formulation can be used in infants over 2 weeks of age. Transition to tablets as soon as a child is able to swa llow tablets whole. The 4 -in-1 ABC/3TC/LPV/r may be used after \\n1 month of age if the combin ation is appropriate and once it becomes available.  \\n5 DRV must be administered with 0.5 ml of RTV 80 mg/mL oral suspension if less than 15 kg and with RTV 50 mg solid formulation in children 15 to 30 kg  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 249}),\n",
       " Document(page_content='  \\nAnnexes  \\n13 - 29 6RAL granules are approved for use in newborn childre n, however the administration procedure is complex and the formulation has very limited availability. If this RAL must be use d, consult \\nthe regional/national clinical support center  \\n Annex 10 B: Simplified Dosing of Child -Friendly Solid and Oral Liquid For mulations for Once -Daily Dosing in \\nInfants and Children 4 Weeks of Age and Older1 \\nDrug  Strength of tablet  Number of tablets or capsules by weight band once \\ndaily  Strength of adult \\ntablet  Number of tablets or capsules \\nby weight band once daily  \\n3–5.9 \\nkg 6–9.9 \\nkg 10–13.9 \\nkg 14–19.9 \\nkg 20–24.9 kg   25–34.9 kg  \\nEFV2 Tablet (scored) 200 mg  – – 1 1.5 1.5 200 mg  2 \\nABC/3TC  Tablet (dispersible) 120/60 \\nmg 1 1.5 2 2.5 3 600 mg/300 mg  1 \\nDTG  Tablet (dispersible) 10 mg  0.5 1.5 2 2.5 33   \\nDTG  Tablet 50 mg  - - - - 1 50 mg  1 \\nDTG/TDF/  \\n3TC   - - - - - 50/300/300  1 \\nATV4 Capsules 100 mg  – – 1 2 2 300 mg  2 (100 mg) or 1 (300 mg)  \\n \\nTDF5 Oral powder 40 mg/scoop  – – 3 – –  \\n300 mg  1 (200 mg) d or 1 (300 mg)  \\nTablets 150 mg or 200 mg  – – – 1 (150 mg)  1 (200 mg)  \\nNotes  1For infants younger than 4 weeks of age refer to Table 10C for more accurate dosing information  \\n2EFV is not recommended for children younger than 3 years and weighing less than 10 kg. Where there are no suitable alternativ es, EFV may be used in children le ss than 3 years \\nweighing more than 3.5 kg (3.5 -5 kg two 50 mg capsules; 5 -7.5 kg three 50 mg capsules; 7.5 -15 kg one 200 mg capsule).  \\n3 DTG dispersible tablets have higher bioavailability than film tablets and doses are not interchangeable. Children can tr ansition to the 50 mg film tablet once they reach 20 kg. If unable to \\nswallow the tablets whole, the dispersible tablets may be given at a dose of 30 mg daily.  \\n4ATV is only approved for use in children 3 months and older. ATV single strength capsules shoul d be administered with RTV 100 mg for all weight bands. ATV powder formulation \\nenables administration of ATV to infants and children as young as 3 months. Infants and children 5 -10 kg should be given 200 mg of ATV powder (4 packets, 50 mg/ packet) with 80 \\nmg of RTV oral solution (1 ml)  \\n5TDF is can be used in children 2 years and older. Target dose: 8 mg/kg or 200 mg/m2 (maximum 300 m  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 250}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 30 Annex 10 C: Drug Dosing of Liquid Formulations for Twice -Daily Dosing in Infants Less than 4 Weeks of Age  \\nDrug  Strength of oral liquid  2-3 kg  3-4 kg  4-5 kg  \\nAZT  10 mg/mL  1 mL  1.5 mL  2 mL  \\nNVP1 10 mg/mL  1.5 mL  2 mL  3 mL  \\n3TC  10 mg/mL  0.5 mL  0.8 mL  1 mL  \\nNotes  1 NVP for treatment can be initiated with twice daily dosing for infants < 2 weeks of age (they do not require once -daily lead -in dosing)  \\n \\nAnnex 10 D: Simplified Dosing of INH and CTX Prophylaxis for Infants and Children Who Are at Least 4 Weeks of \\nAge \\nDrug  Strength of tablet or oral \\nliquid  Number of tablets or ml by weight band once daily  Strength of adult \\ntablet  Number of tablets \\nby weight band  \\n \\n3–5.9 kg   \\n6–9.9 kg   \\n10–13.9 kg   \\n14–19.9 kg   \\n20–24.9 kg    \\n25–34.9 kg  \\nINH  100 mg  0.5 1 1.5 2 2.5 300 mg 1 \\nCTX  Suspension 200/40 per 5 ml  2.5 ml  5 ml  5 ml  10 ml  10 ml  – – \\nTablets (dispersible) 100/20 mg  1 2 2 4 4 – – \\nTablets (scored) 400/80 mg  – 0.5 0.5 1 1 400 mg/80 mg  2 \\nTablets (scored) 800/160 mg  – – – 0.5 0.5 800 mg/160 mg  1    \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 251}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 31 Annex 10 E: TB Preventive Therapy dosing  \\nA. Daily INH for 6 months (6H)  \\nWeight (Kg)  Dose (mg)  Number of 100mg INH tablets  Number of 300mg (Adult) tablet  \\n<5 50 ½ tablet  - \\n5.1-9.9 100  1 tablet  - \\n10-13.9  150  1½ tablet  ½ tablet  \\n 14-19.9  200  2 tablets  - \\n20-24.9  250  2 ½ tablets  - \\n≥25  300  3 tablets  1 tablet  \\nAdult  300  3 tablets  1 tablet  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 252}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 32 Annex 10 E: Cont.  \\nB1. Daily INH for 6 months (6H)  \\nWeight (Kg)  Number of tablets (RH \\n75/50mg  How to reconstitute the medicine  \\nLess than 2  ¼  Dissolve one (1) tablet of RH in 20 ml of safe drinking water. Once fully \\ndissolved. Give 5ml (¼) of this solution measured with a syringe.  \\n2-2.9 ½  Dissolve one (1) tablet of RH is 20 ml of safe drinking water. Once fully \\ndissolved, give 10ml (½) of this solution measure d with a syringe.  \\n3-3.9 ¾  Dissolve one (1) tablet of RH in 20 ml of safe drinking water. Once fully \\ndissolved, give 15 ml (¾) of this solution measured with a syringe.  \\nAfter giving the child their dose for that day, discard the rest of the solution. Pre pare a fresh solution. Prepare a fresh solution every day.  \\n4-7.9 1 Dissolve the tablet(s) of RH in 20mls of safe drinking water.  \\n \\nOnce fully dissolved, give ALL this solution to the child  8-11.9  2 \\n12-15.9  3 \\n16-24.9  4 \\nB2. Daily RH for 3 months (3RH) for children ≥25kgs (To use adult formulation)  \\nWeight (Kg)  Number of tablets (RH 150/75mg)  \\n25-39.9  2 \\n40-54.9  3 \\n55kg and above  4 \\nC.  Weekly 3HP (3HP) (For adults and adolescents ≥15 years)  \\n3HP products  No of Tablets  \\nRifapentine 150mg tabs  6 \\nIsoniazid 300mg tabs  3 \\nRifapentine 300mg+Isoniazid 200mg (FDC)  3 \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 253}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 33 Annex 10 E: Cont.  \\nD. Dosage of Pyrldoxine (Vitamin B6)  \\nWeight (Kgs)  Dosage In mg  Number of 25mg tablets  Number of 50mg tablets  \\n<5 6.25mg  ½ Tablet 3 times a week, alternate days  - \\n5.0-79 12.5mg  Half a tablet  - \\n8.0-14.9  25mg  One tablet  Half of 50mg tablet  \\n15kg and above  50mg  Two tablets  One 50mg tablet  \\nAdults  50mg  Two tablets  One 50mg tablet  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 254}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 34 Annex 10 F: Ritonavir Dosing for Super -Boosting LPV/r in Children Taking Rifampicin  \\nDosing for RTV super -boosting of LPV/r for children receiving rifampicin -containing TB treatment*  \\nDrug  Strength of paediatric \\ntablets or oral liquid  Number of tablets or MLS by weight -band morning (AM) and evening (PM)  Strength of \\nadult tablet  Number of tablets \\nby weight band  \\n3–5.9 kg  6–9.9 kg  10–13.9 kg  14–19.9 kg  20–24.9 kg   25–34.9 kg  \\nAM PM AM PM AM PM AM PM AM PM  AM PM \\nFor children able to swallow tablets  \\nLPV/rb Tablet 100/25 mg  – – – – 2 1 2 2 2 2 100/25 mg  3 3 \\nRTV  Tablet 100 mg  – – – – 1 1 1 2 1 2  \\n \\n100 mg   \\n2  \\n2 Tablet 50 mg  – – – – 2 2 3 3 3 3 \\nTablet 25 mg  – – – – 4 4 6 6 6 6 \\nFor children unable to swallow tablets  \\nLPV/r  Oral solution 80/20 mg/ml  1 ml  1 ml  1.5 \\nml 1.5 ml  2 ml  2 ml  2.5 \\nml 2.5 \\nml 3 ml  3 ml  - - - \\nPellets 40 mg/10 mg  2 2 3 3 4 4 5 5 6 6 - - - \\nGranules 40 mg/10 mg \\nsachet  2 2 3 3 4 4 5 5 6 6 - - - \\nRTVe Oral solution 80 mg/ml  0.8 ml  0.8 ml  1.2 ml  1.2 ml  1.5 ml  1.5 ml  2 ml  2 ml  2.3 ml  2.3 ml  - - - \\nPowder 100 mg/packet  - - 1 1 1 1 1 2 1 2 - - - \\na Suggested RT V dose for super -boosting to achieve the same dose as LPV in mg, in a ratio equal or approaching to 1:1. This dosing approach is supported by a study which explored this \\napproach in young children receiving LPV/r12. \\nb the LPV/r heat -stable t ablet formulation must be swallowed whole and should not be split, chewed, dissolved or crushed. Adult 200 / 50 tablet could be used for patients 14 -24.9kg (1 \\ntab am and 1 tab pm) and for patients 25 -34.9kg (2 tab am and 1 tab pm).  \\nc LPV/r liquid requires a cold chain during transport and storage.  \\nd LPV/r pellets formulation should not be used in infants younger than 3 months. More details on the administration of LPV/r pe llets can be found at \\nhttps://www.who.int/hiv/pub/toolkits/iattfactsheet -lopinavir -ritonavir/en/. The dosing schedule provided applies to equivalent solid dosage forms that may become available such as \\nLPV/r granules, which are approved by US FDA for use from 2 weeks of life.  \\n  e RT V oral solution dosing is ba sed on the dosing tested in the trial that supports the use of super boosting', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 255}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 35 Annex 11: Overlapping toxicities between ARVs  \\nBone marrow \\nsuppression  Peripheral \\nneuropathy  Pancreatitis  Nephrotoxicity  Hepatotoxicity  Rash  Diarrhoea  Ocular effects  \\nAmphotericin B \\nCotrimoxazole \\nDapsone Flucytosine \\nGanciclovir \\nHydroxyurea \\nInterferon - \\nPrimaquine \\nPyrimethamine \\nZidovudine  Didanosine \\nIsoniazid \\nVincristine  Didanosine \\nLamivudine  \\n(esp. in \\nchildren)  \\nStavudine \\nCotrimoxazole \\nRitonavir \\nPentamidine  Acyclovir  \\nAdefo vir high dose \\nAminoglycosides \\nAmphotericin B \\nCidofovir  \\nFoscarnet \\nPentamidine \\nTenofovir  Abacavir  \\nAtazanavir \\nAtovaquone \\nCotrimoxazole \\nDapsone \\nEfavirenz \\nNevirapine \\nSulfadiazine \\nVoriconazole  Abacavir \\nAtazanavir \\nAtovaquone \\nCotrimoxazole \\nDapsone \\nEfavirenz \\nNevirapine \\nSulfadiazine \\nVoriconazole  Atovaquone \\nClindamycin \\nLPV/r Ritonavir  Cidofovir Ethambutol \\nLinezolid Rifabutin \\nVoriconazole  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 256}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 36 Annex 12 A: Use of Nucleoside & Nucleotide Reverse Transcriptase Inhibitors \\nin Adults  \\nDrug name  Dose (in \\nadults)  Dietary \\nrestrictions  Major side effects  Comments  \\nZidovudine  \\n(AZT or ZDV)  \\n \\nAvailable in 300mg \\ntablets and as FDC \\nwith 3TC and 3TC/ \\nNVP  300mg/  \\ndose BD  No food \\nrestrictions  Bone marrow suppression), \\nincluding anaemia; \\ngranulocytopenia; headache; \\ngastrointestinal intolerance; \\nmyopathy; myositis; liver toxicity; \\ndiscoloured nails; lactic acidosis \\nand severe  \\nhepatomegaly with steatosis (fatal \\ncases have been reported)  Monitor for anaemia in  the \\nfirst 3 months of treatment  \\nLamivudine (3TC) \\nAvailable in 150mg  \\ntablet and as FDC \\nwith AZT and \\nAZT/NVP, D4T and \\nD4T/NVP and with \\nTDF and TDF/ EFV  150mg/ \\ndose BD \\nOR 300 \\nmg/dose \\nOD No food \\nrestrictions  Headache; fatigue; nausea; \\ndiarrhoea; skin rash; pancreatitis; \\nperipheral neuropathy; \\nhepatotoxicity/ hepatitis; lactic \\nacidosis and severe hepatomegaly \\nwith steatosis (rare fatal cases \\nhave been reported).  A well -tolerated drug. \\nAdjust dose in renal \\nimpairment.  \\nAlso active against hepatitis B. \\nIdeally, patients should be  \\nscreened for hepatitis B virus  \\n(HBV) before starting therapy; \\nexacerbation of hepatitis B has \\nbeen reported in patients on \\ndiscontinuation of 3TC.  \\nAbacavir (ABC) \\nAvailable in 300mg  \\ntablets and in \\ncombination with  \\n3TC and DTG  300mg/  \\ndose BD  \\n or 600mg \\nOD No food \\nrestrictions. \\nAlcohol \\nincreases \\nABC levels \\nby 41%  Hypersensitivity reaction \\n(potentially fatal) whose \\nsymptoms include fever, \\nfatigue, malaise, nausea, \\nvomiting, diarrhoea  \\nand abdominal pain or \\nrespiratory symptoms such as \\nshortness of breath, \\nlymphadenopathy, ulceration of \\nmucous  \\nmembranes and skin rash. Patients \\nsuspected of having \\nhypersensitivity reaction should \\nhave ABC stopped and never be \\nrestarted. Pancreatitis; lactic \\nacidosis with hepatic steatosis is \\nrare  Educate patient on \\nhypersensitivity reaction. \\nOnce hypersensitivity has \\noccurred, the patient should \\nnever be re -challenged with \\nABC.  \\n \\nAvoid alcohol while on ABC.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 257}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 37 Table 12 A: Cont.  \\nDrug name  Dose (in \\nadults)  Dietary \\nrestrictions  Major side effects  Comments  \\nEmtricitabine  \\n(FTC)  \\n \\nAvailable in 200mg \\ncapsules and as FDC \\nwith TDF and \\nTDF/EFV  200mg/  \\ndose OD  No food \\nrestrictions  Well tolerated. Lactic \\nacidosis and severe \\nhepatomegaly with \\nsteatosis (fatal cases have \\nbeen reported); headache; \\ndiarrhoea; nausea; rash; \\nskin discoloration  Effective against hepatitis B. \\nIdeally, patients should be \\nscreened for chronic hepatitis B \\nvirus (HBV) before starting \\ntherapy; exacerbation of Hepatitis \\nB has been reported in patients on \\ndiscontinuation of FTC  \\nDecrease dosage in patients with \\nrenal impairment Monitor renal \\nfunction if combined with TDF.  \\nWhen used in combination with \\nTDF, should not be given to \\npatients with a creatinine \\nclearance of <30ml/min. Should \\nnot be used with or aft er failure of \\n3TC  \\nTenofovir \\ndisoproxil fumarate \\n(TDF)  \\n \\nAvailable in 300mg \\ntablets and as FDC \\nwith 3TC and 3TC/ \\nEFV  300mg/  \\ndose OD  No food \\nrestrictions  Lactic acidosis and severe \\nhepatomegaly with \\nsteatosis (fatal cases have \\nbeen reported with \\nnucleoside analogues); \\nrenal toxicity; Pancreatitis  Should not be used with ddI. \\nShould never be used in triple \\nnucleoside combinations  \\nwith 3TC+ddI/ABC.  Renal function \\nshould be monitored while on TDF  \\nIdeally, patients should be \\nscreened for chronic hepatitis B \\nvirus (HBV) before starting \\ntherapy; Exacerbation of hepatitis \\nB has been reported in patients on \\ndiscontinuation of TDF  \\nWhen used in combination with \\n3TC, should not be given to \\npatients with a creatinine \\nclearance of <30ml/min.  \\nWhen used with ATV levels of ATV \\nreduced significantly therefore \\ncombine with RTV  \\nTenofovir \\nalafenamide (TAF)  \\n \\nVarious co -\\nformulations \\navailable or being \\ndeveloped  As TAF 25 \\nmg alone or \\nas part of \\nco-\\nformulated \\nFDC  No food \\nrestrictions  Well tolerated. GIT upsets, \\nraised serum creatinine, \\nproteinuria and renal \\ntoxicity (but to a lesser \\ndegree than TDF)  RTV and cobicistat increase TAF \\nlevels. DRV decreases TAF levels. \\nBoosted PI increase TAF levels but \\nthe PI levels are not affected.  \\nAvoid co -administration with \\nrifabutin, rifampicin and phenytoin  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 258}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 38 Annex 12 B: Use of Non -Nucleoside Reverse Transcriptase Inhibitors for Adults  \\nDrug name  Dose (in \\nadults)  Dietary \\nrestrictions  Major side effects  Comments  \\nEfavirenz (EFV) \\nAvailable in 200mg  \\n& 600mg tablets \\nand as FDC with \\nTDF/3TC  600mg \\nOD Best \\ntaken  \\nat \\nbedtime  Preferably \\ntaken on an \\nempty \\nstomach.  \\nCan be given \\nwith food, \\nbut avoid \\nhigh fat  \\nmeals which \\nincrease \\nabsorption.  CNS symptoms \\n(somnolence, insomnia, \\nabnormal dreams, \\nconfusion, \\nhallucination, amnesia, \\netc. Avoid in patients \\nwith history of \\npsychiatric disease);  \\nSkin rash; avoid use in \\nduring the first \\ntrimester  Can be used with rifampicin in TB \\npatients  \\nEtravirine (ETR) \\nAvailable in tablets  \\nof 200 mg   \\n200 mg \\nBD  \\nTake with \\nfood  Severe but rare: SJS and \\nerythema multiforme \\nCommon & minor: \\nRash, nausea, vomiting, \\ndiarrhoea, abdominal \\npain, hepatotoxicity, \\ndyslipidaemia and CNS \\ndisturbances (less than \\nEFV)  Avoid concurrent use with \\nrifampicin, and boosted tipranavir.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 259}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 39 Annex 12 C: Use of Protease Inhibitors in Adults  \\nDrug name  Dose (in \\nadults)  Dietary \\nrestrictions  Major side effects  Comments  \\nLopinavir/ritonav\\nir (LPV/r) \\nAvailable as \\n200mg  \\n+ 50mg RTV  [LPV 400 mg \\n+ RTV  \\n100 mg] 2 \\ntablets BD  Take with food. \\nModerate  \\nfat increases \\nbioavailability.  GI intolerance; \\nnausea; vomiting; \\ndiarrhoea  Tablets should be \\nswallowed whole  \\nAtazanavir  \\n(ATV)  \\n \\nAvailable in  \\n100mg, 150mg, \\n200 mg capsules  \\n \\nAvailable as FDC  \\nwith RTV  ATV 300mg / \\nRTV 100mg \\nOD Take with food. \\nTake 2 hours \\nbefore or 1  \\nhour after \\nantacids and \\nbuffered \\nmedications \\nsuch as buffered \\nddI (reduced \\nATV \\nconcentrations  \\nif administered \\ntogether)  Jaundice; headache; \\nfever; depression; \\nnausea; diarrhoea \\nand vomiting; \\nparaesthesia; \\nspontaneous \\nbleeding episodes \\nin haemop hiliacs.  Indirect \\nhyperbilirubinaemia. \\nWhen used with TDF \\nshould always be given \\nwith RTV. Experienced \\npatients should also be \\ngiven ATV/RTV.  \\nRitonavir  \\n(RTV)  \\n \\nAvailable as 100mg \\ncapsules  \\nCapsules should be \\nrefrigerated until \\ndispensed; stable \\nat room (up to \\n25ºC) for 30 days  Recommended \\nfor use as a \\nbooster of \\nother PIs  Administration \\nwith food \\nincreases \\nabsorption and \\nhelps reduce \\ngastrointestinal \\nside effects.  Exacerbation of liver \\ndisease; fat \\nredistribution and \\nlipid abnormalities; \\ndiarrhoea; \\nabdom inal \\ndiscomfort; \\nheadache; nausea; \\nparaesthesia;  \\nskin rash; \\nspontaneous \\nbleeding episodes in \\nhaemophiliacs.  Potent CYP450 inhibitor, \\nthus its use as a booster \\nof other PIs  \\nDarunavir (DRV)  DRV 600 \\nmg/ RTV \\n100 mg BID \\nOR \\n \\nDRV 800 \\nmg/ RTV 100 \\nmg OD (only \\nif PI naïve)  Take with a \\nmeal to limit \\nADR  GIT upsets, rash, \\ndyslipidaemia, \\nhepatitis. Caution \\nin patients with \\nsulphur allergy.  Metabolized by CYP3A \\nand is an inhibitor of \\nCYP3A. Contains sulphur \\nmoiety. Monitor liver \\nfunctions especially in \\npatients at risk  or with \\npre-existing liver  \\ndisease.  May cause \\nhormonal contraceptive \\nfailure.  \\n   \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 260}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 40 Annex 12 D: Integrase Strand Transfer Inhibitors - INSTIs  \\nDrug name  Dose (in adults)  Dietary \\nrestrictions  Major side effects  Comments  \\nDolutegravir \\n(DTG) Available \\nas DTG 50mg, \\n10mg dispersible \\ntablet  \\n \\nOr FDCs:  \\nABC/3TC/DTG \\n(600/300/50mg)  \\n \\nand \\n \\nTDF/3TC/DTG \\n(300/300/50mg)  50 mg once daily  \\n \\nIf co - \\nadministering with \\nEFV, \\ncarbamazepine, or \\nrifampicin, use \\nDTG 50 mg BD  \\n \\nIf suspected or \\nconfirmed INSTI \\nresistance use DTG \\n50 mg BD  No food \\nrestrictions  Rare - \\nHypersensitivity; \\nHepatotoxicity \\nespecially in those  \\nwith HBV and HCV  \\ninfection, fatigue  \\n \\nInsomnia, headache, \\ndiarrhea, nausea is \\ncommon but usually \\nminor and resolve \\nwith continued use  Interacts with  carbamazepine, \\nphenobarbital and phenytoin, \\nuse alternative \\nanticonvulsants.  \\n \\nAdminister DTG at least 2 \\nhours before or 6 hours after \\ntaking supplements or \\nantacids containing Mg, Al, Fe, \\nCa and Zn. For Ca or Fe, if DTG \\nis taken with a meal then dose \\nsepa ration is not required  \\nRaltegravir (RAL)  ADULT and CHILD \\nover 16 years, 400 \\nmg BD  No food \\nrestrictions  Nausea, vomiting, \\ndiarrhoea, \\nflatulence, \\nconstipation  \\nSevere skin (SJS \\nand TEN) and \\nhypersensitivity \\nreactions have \\nbeen reported  Contraindicated in \\nbreast - feeding mothers  \\nSafety in paediatric patients \\nhas not been established  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 261}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 41 Annex 13 A: Drug -Drug Interactions - NNRTIs  \\nDrugs Affected  Nevirapine (NVP)  Efavirenz (EFV)  \\nANTIRETROVIRALS  \\nDolutegravir  Co-administration not recommended because NVP \\ndecreases levels of DTG  Co-administration not recommended because EFV decreases \\nlevels of DTG.  If must be used together then increase DTG to \\n50 mg BD when co -administered with EFV  \\nRaltegravir  No interaction or not studied  Efavirenz decreases RAL plasma levels but it is unlikely to be \\nclinically sign ificant  \\nAtazanavir/ritonavir  Co-administration not recommended because ATV/r may \\nincrease the serum concentration of NVP leading to \\nincreased risk of toxicity, and NVP decreases the serum \\nconcentration of ATV/r which may lead to resistance and \\ntreatment failure  Co-administration not recommended because EFV decreases \\nthe serum concentration of ATV/r which may lead to \\nresistance and treatment failure  \\nLopinavir/ritonavir  Co-administration not recommended because NVP \\ndecreases levels of LPV/r  AVOID : this combination increased risk of prolonged -QT \\nsyndrome and sudden cardiac death  \\nDarunavir/ ritonavir  No significant interaction when NVP is combined with \\nritonavir -boosted darunavir  Co-administration not recommended because DRV/r may \\nincrease the seru m concentration of EFV leading to increased \\nrisk of toxicity, and EFV decreases the serum concentration of \\nDRV/r which may lead to resistance and treatment failure  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 262}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 42 Annex 13 A: Cont.  \\nANTIFUNGALS  \\nKetoconazole  Levels: ketoconazole ↓ 63%  \\nNVP ↑ 15 – 30%  \\nDose: Not recommended  No data  \\nVoriconazole  Metabolism of Voriconazole may be induced by NVP. \\nVoriconazole may inhibit NNRTI metabolism. Frequently \\nmonitor for NNRTI toxicity and antifungal outcome  Levels: EFV ↑ 44%  \\nVoriconazole ↓ 77%  \\nThis combination is not recommended  \\nFluconazole  NVP Levels: Cmax, AUC, and Cmin ↑ 100%  \\nFluconazole Levels: No change  \\nRisk of hepatotoxicity may increase with this combination. If \\nconcomitant use is necessary, recommend monitoring NVP \\ntoxicity  No clinically significant changes in EFV or \\nFluconazole concentrations  \\nANTI -MYCOBACTERIALS  \\nRifampicin  Levels: NVP ↓ 20% -58%. Virologic consequences are uncertain; \\nthe potential for additive hepatotoxicity exists. Use of this \\ncombination is not recommended; however, if used, co \\nadministration should be done with careful monitoring  Levels: EFV ↓ 25%.  \\nDose: Consider ↑ EFV to 800 mg QD  \\nClarithromycin  Levels: NVP ↑ 26%. Clarithromycin ↓ 30%. Monitor for efficacy \\nor use alternative agent  Levels: Clarithromycin ↓ 39%.  \\nMonitor for efficacy or use alternative agent  \\nBedaquiline (BDQ)  No dose adjustment required  Do not co -administer  \\nDelamanid (DLM)  No interaction expected  No interaction  \\nORAL CONTRACEPTIVES  \\n Levels: ethinyl estradiol approx. 20%. Use alternative or \\nadditional methods.  Levels: Ethinyl estradiol   37%. No data on other \\ncomponents. Use alternative or additional methods  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 263}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 43 Annex 13 A: Cont.  \\nLIPID -LOWERING AGENTS  \\nSimvastatin  \\nLovastatin  No data  Levels: Simvastatin AUC    by 58%; EFV unchanged  \\nDose: Adjust simvastatin dose according to lipid responses, \\nnot to exceed the maximum recommended dose  \\nAtorvastatin  No data  Levels: Atorvastatin AUC   43%; EFV unchanged.  \\nDose: Adjust atorvastatin dose according to lipid responses, \\nnot to exceed the maximum recommended dose  \\nPravastatin  No data  No data  \\nANTI -HYPERTENSIVES   \\nAngiotensin -converting enzyme \\ninhibitors (ACEIs): E.g.  - Enalapril, \\nLisinopril  No known interactions  No known interactions  \\nAngiotensin II receptor blockers \\n(ARBs): e.g., Losartan, Telmisartan  Telmisartan, Candesartan: None  \\nLosartan: Potential interactions with all NNRTIs, net effect \\nof interaction difficult to predict, use with caution  Telmisartan, Candesartan: None  \\nLosartan: Potential interactions with all NNRTIs, net effect \\nof interaction difficult to predict, use with caution  \\nBeta blockers: e.g., Atenolol, \\nCarvedilol and Propranolol  No known interactions  No known interactions  \\nCalcium channel blockers (CCBs): \\ne.g., Nifedipine, Amlodipine and \\nFelodipine  Potential interaction with all NNRTIs: Metabolism of CCBs \\nis induced by EFV or NVP, blunting antihypertensive \\neffect: higher starting dose of CCB may be required  Potential intera ction with all NNRTIs: Metabolism of CCBs \\nis induced by EFV or NVP, blunting antihypertensive effect: \\nhigher starting dose of CCB may be required  \\nDiuretics: E.g., HCTZ, Indapamide. \\nFurosemide and Spironolactone  No known interactions  No known interactions  \\nOthers: Alpha blockers:  \\nMethyldopa, Hydralazine   No known interactions  No known interactions  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 264}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 44 Annex 13 A: Cont.  \\nANTICONVULSANTS  \\nCarbamazepine Phenobarbital \\nPhenytoin  Unknown  \\nUse with caution.  \\nMonitor anticonvulsant levels  Use with caution  \\nMonitor anticonvulsant levels  \\nMETHADONE  Levels: NVP unchanged. Methadone significantly. \\nOpiate withdrawal common when this combination \\nis used. Increased methadone dose often necessary. \\nTitrate methadone dose to effect  Levels: Methadone   60%  \\nOpiate withdrawal common, increase methadone dose often \\nnecessary. Titrate methadone dose to effect  \\nMISCELLANEOUS  No data  Monitor warfarin when used concomitantly  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 265}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 45 Annex 13 B: Drug -Drug Interactions – PIs \\nDrugs Affected  Atazanavir (ATV)  Ritonavir  \\n(RTV)  Darunavir (DRV)  Lopinavir (LPV)  \\nANTIRETROVIRALS  \\nEFV  Co-administration not \\nrecommended because EFV \\ndecreases the serum \\nconcentration of ATV/r which \\nmay lead to resistance and \\ntreatment failure  See interaction with specific \\nritonavir -boosted PI  Co-administration not \\nrecommended because DRV/r \\nmay increase the serum \\nconcentration of EFV leading to \\nincreased risk of toxicity, and EFV \\ndecreases the serum \\nconcentration of DRV/r which \\nmay lead to resistance and \\ntreatment failure  AVOID: this combination \\nincreased risk of \\nprolonged -QT syndrome \\nand sudden cardiac death  \\nETR  No significant interaction  See interaction with specific \\nritonavir -boosted PI  No significant interaction  \\n No significant interaction  \\nDTG  No significant interaction  See interaction with specific \\nritonavir -boosted PI  No significant interaction  No significant interaction  \\nRAL  ATV/r may increase RAL levels \\nbut interaction in not clinically \\nsignificant  See interaction with specific \\nritonavir -boosted PI  No sign ificant interaction  No significant interaction  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 266}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 46 Annex 13 B: Cont.  \\nANTIFUNGALS  \\nItraconazole  Limited data, minimal effect  No data, but potential for bi - \\ndirectional inhibition between \\nItraconazole and RTV, monitor for \\ntoxicities  \\n \\nDose: dose adjustment for patients \\nreceiving  \\n>400 mg Itraconazole may be \\nneeded, or consider monitoring \\nItraconazole level  ↑ Levels of azoles and DRV  ↑ Levels: itraconazole when \\nadministered with LPV/r  \\n \\nDose: itraconazole  \\n– consider not to exceed \\n200 mg/day or monitor \\nlevel and toxicity  \\nKetoconazole  Limited data, minimal effect  Levels: Ketoconazole ↑ 3X \\nDose: Use with caution; do not \\nexceed 200 mg ketoconazole daily  ↑ levels of azoles and DRV  Levels: LPV AUC ↓ \\n13% Azole ↑ 3-fold.  \\nDose: Use with caution; do \\nnot exceed 200 mg \\nketoconazole daily  \\nANTI -MYCOBACTERIALS  \\nRifampicin  Atazanavir AUC: decreased 72%; \\nCmax: decreased  \\n53%; Cmin:  \\ndecreased 98%  Levels: RTV ↓ 35%.  \\n \\nDose: No change. Increased liver \\ntoxicity possible. Co-administration \\nmay lead to loss of virologic response \\nis RTV sole PI. Alternate anti - \\nmycobacterial agents, such as \\nrifabutin, should be considered  ↓ levels of DRV  Levels: LPV AUC ↓ \\n75%. Should not be co \\nadministered as  \\na safe and effective dose of \\nLPV/ r that can be given \\nwith rifampicin has not \\nbeen established  \\nRifapentine  Do NOT co -administer  Do NOT co -administer  Do NOT co -administer  Do NOT co -administer  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 267}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 47 Annex 13 B: Cont.  \\nClarithromycin  Clarithromycin AUC:  \\nincreased 94%;  Levels; Clarithromycin  \\n↑ 77%  \\n \\nDose: Adjust clarithromycin \\ndose for moderate and severe \\nrenal impairment  ↑ levels of clarithromycin by  \\n59%  Levels: ↑  \\nClarithromycin AUC 77%  \\nDose: Adjust clarithromycin \\ndose for moderate and \\nsevere renal impairment  \\nBedaquiline \\n(BDQ)  Increases BDQ exposure and \\nincreases risk of prolonged QT \\nsyndrome, monitor for increased \\ntoxic effects by frequent ECG and \\ntransaminases assessment  Increases BDQ exposure, \\nmonitor for increased toxic \\neffects by frequent ECG and \\ntransamin ases assessment  Increases BDQ exposure, \\nmonitor for increased toxic \\neffects by frequent ECG and \\ntransaminases assessment  Do NOT co -administer \\nbecause of increased risk of \\nprolonged QT syndrome  \\n \\nIncreases BDQ exposure, \\nmonitor for increased toxic \\neffects  \\nDelamanid \\n(DLM)  Increases DLM exposure, monitor \\nfor increased toxic effects by \\nfrequent ECG and transaminases \\nassessment  Increases DLM exposure, \\nmonitor for increased toxic \\neffects by frequent ECG and \\ntransaminases assessment  Increases DLM exposur e, \\nmonitor for increased toxic \\neffects by frequent ECG and \\ntransaminases assessment  Do NOT co -administer \\nbecause of increased risk of \\nprolonged QT syndrome  \\n \\nIncreases DLM exposure, \\nmonitor for increased toxic \\neffects  \\nORAL CONTRACEPTIVES  \\n Ethinyl estradiol  \\nAUC: ↓ Levels: Ethinyl estradiol  \\n↓ 40%.  \\n \\nUse alternative or additional \\nmethod  Ethinyl estradiol  \\nAUC:  ↓ 44%  Levels: Ethinyl estradiol  \\n↓ 42%  \\nUse alternative or \\nadditional method  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 268}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 48 Annex 13 B: Cont.  \\nLIPID -LOWERING AGENTS  \\nSimvastatin  \\nLovastatin  Avoid co - administration  Levels: potential  \\nfor large increase in statin \\nlevels. Avoid concomitant use  Avoid  Levels: Potential  \\nfor large increase in statin \\nlevels  \\nAvoid concomitant use  \\nAtorvastatin  Minimal interaction  Levels:  450% ↑ \\nwhen administered with \\nSQV/RTV combination. Use \\nlowest possible starting dose of \\natorvastatin with careful \\nmonitoring  ↑ AUC four -fold  Atorvastatin AUC ↑ \\n5.88 -fold. Use lowest possible \\nstarting  \\ndose of atorvastatin with \\ncareful monitoring  \\nPravastatin  Minimal interaction  Levels: 50% ↓ when \\nadministered  \\nwith SQV/RTV  \\ncombination  \\n \\nDose: Pravastatin dosage \\nadjustment based on lipid \\nresponse  ↑ AUC 81%  Pravastatin AUC  \\n↑ 33%; no dosage adjustment \\nnecessary  \\nANTI -HYPERTENSIVES  \\nAngiotensin -\\nconverting enzyme \\ninhibitors (ACEIs): \\nE.g. - Enalapril, \\nLisinopril  No known interactions  No known interactions  No known interactions  No known interactions  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 269}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 49 Annex 13 B: Cont.  \\nAngiotensin II \\nreceptor blockers \\n(ARBs): e.g., \\nLosartan, \\nTelmisartan  Telmisartan, Candesartan:  \\nNone  \\nLosartan: Potential \\ninteractions with all PIs, net \\neffect of interaction difficult \\nto predict, use with caution  Telmisartan, Candesartan:  None  \\nLosartan: Potential interactions \\nwith all PIs, net effect of \\ninteraction difficult to predict, \\nuse with caution  Telmisartan, Candesartan:  None  \\nLosartan: Potential interactions \\nwith all PIs, net effect of \\ninteraction difficult to predict, \\nuse with caution  Telmisartan, Candesartan:  \\nNone  \\nLosartan: Potential \\ninteractions with all PIs, net \\neffect of interaction difficult to \\npredict, use with caution  \\nBeta blockers: e.g., \\nAtenolol, Carvedilol \\nand Propranolol  Potential increase in B -\\nblocker effect, careful dose \\nadjustment and ECG where \\nindicated  Potential increase in B -blocker \\neffect, careful dose adjustment \\nand ECG where indicated  Potential increase in B -blocker \\neffect, careful dose adjustment \\nand ECG where indicated  Potential increase in B -blocker \\neffect, careful dose adjustment \\nand ECG where indicated  \\nCalcium channel \\nblockers (CCBs): e.g., \\nNifedipine, \\nAmlodipine and \\nFelodipine  Potential interaction with all \\nPIs: Metabolism of CCBs \\ninhibited, increasing \\nantihypertensive effect: \\nlower starting dose  of CCB \\nmay be required, monitor for \\nexcessive reduction in BP  Potential interaction with all \\nPIs: Metabolism of CCBs \\ninhibited, increasing \\nantihypertensive effect: lower \\nstarting dose of CCB may be \\nrequired, monitor for excessive \\nreduction in BP  Potential  interaction with all \\nPIs: Metabolism of CCBs \\ninhibited, increasing \\nantihypertensive effect: lower \\nstarting dose of CCB may be \\nrequired, monitor for excessive \\nreduction in BP  Potential interaction with all \\nPIs: Metabolism of CCBs \\ninhibited, increasing \\nanti hypertensive effect: lower \\nstarting dose of CCB may be \\nrequired, monitor for excessive \\nreduction in BP  \\nDiuretics: E.g., HCTZ, \\nIndapamide. \\nFurosemide and \\nSpironolactone  No known interactions  No known interactions  No known interactions  No known interactions  \\nOthers: Alpha \\nblockers:  \\nMethyldopa, \\nHydralazine   No known interactions  No known interactions  No known interactions  No known interactions  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 270}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 50 Annex 13 B: Cont.  \\nANTICONVULSANTS  \\nCarbamazepine \\nPhenobarbital \\nPhenytoin  Reduce ATV levels  Carbamazepine; ↑ \\nserum levels when  \\nco-administered with  \\nRTV  \\n \\nUse with caution  \\n \\nMonitor anticonvulsant levels  Avoid  Many possible  \\ninteractions: Carbamazepine:  \\n↑ levels when  \\nco-administered with RTV. Use \\nwith caution. Monitor \\nanticonvulsant levels. \\nPhenytoin : levels of LPV, RTV, \\nand ↓ levels of Phenytoin when \\nadministered together  \\nAvoid concomitant use or \\nmonitor LPV level  \\nOTHER DRUG  \\nMethadone  No interaction with unboosted \\nATV Increased metabolism of \\nmethadone with boosted ATV  Methadone ↓ 37%. Monitor and \\ntitrate dose if needed  \\n \\nMay require ↑  \\nmethadone dose  ↓ levels of methadone by 16%  Methadone AUC  \\n↑ 53%. Opiate withdrawal may \\noccur  \\nMonitor and titrate dose if \\nneeded.  \\nMay require ↑  \\nmethadone dose  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 271}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 51 Annex 13 B: Cont.  \\nERECTILE DYSFUNCTION AGENTS  \\nSildenafil  Use reduced dose of sildenafil  Sildenafil AUC ↑ 11-fold. Use \\ncautiously Start with reduced \\ndose of 25 mg every  \\n48 hours and monitor for \\nadverse effects   Sildenafil AUC ↑ 11- fold in \\ncombination with RTV. Do not \\nexceed 25 mg every  \\n48 hours  \\nMiscellaneous  Decreased GI absorption of \\natazanavir due to reduced acidity  Theophylline ↓ 47%  \\nmonitor theophylline levels  \\n \\nRTV 100 mg bid significantly \\nincrease systemic exposure  \\nof inhaled (oral or nasal \\nfluticasone, may predispose \\npatients to systemic  \\ncorticosteroid effects. Co -\\nadministration not \\nrecommended unless benefit of \\nfluticasone outweighs the risk  Warfarin levels   ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 272}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 52 Annex 13 C: Drug -Drug Interactions – INSTIs  \\nDrugs Affected  Dolutegravir (DTG)  Raltegravir (RAL)  \\nEfavirenz  Co-administration not recommended because \\nEFV decreases levels of DTG.  If must be used \\ntogether then increase DTG to 50 mg BD when \\nco-administered with EFV.  Efavirenz decreases RAL \\nplasma levels but it is unlikely \\nto be clinically significant  \\nEtravirine  Co-administration not recommended because \\nETR decreases levels of DTG, unless used in \\ncombination with a PI/r (which counteracts the \\ninteraction between DTG and ETR)  \\n \\nIf must be used together without a PI/r then \\nincrease DTG to 50 mg BD when co -\\nadministered with ETR. If used together with a \\nPI/r then standard dose DTG is sufficient  Etravirine decreases RAL \\nplasma levels so co -\\nadministration when using \\nonce -daily RAL is not \\nrecommended.  Co -\\nadministration when using \\nstandard BD RAL dosing is \\nacceptable  \\nRifampicin  Increase DTG to 50 mg BD when co -\\nadministered with rifampicin (for children, use \\ndouble the standard weight -based DTG dose by \\nadministering twice daily).  \\n \\nThere is no known drug interaction between \\nDTG and rifabutin.  Increase RAL to 800 mg BD \\nwhen co -administered with \\nrifampicin (for children, use \\ndouble the standard weight -\\nbased RAL dose).  \\n \\nRifabutin may alter RA L \\nplasma levels but it is unlikely \\nto be clinical significant.  \\nRifapentine  Potential decreased DTG levels when co -\\nadministered with once -weekly rifapentine – no \\ndose adjustment required unless viral load \\nbecomes detectable, in which case increase DTG \\nto twice daily until two weeks after completion \\nof rifapentine -based TPT  Potential increased RAL \\nlevels when co -administered \\nwith once -weekly rifapentine \\n– no dose adjustment \\nrequired but monitor for RAL \\ntoxicity  \\nBedaquiline (BDQ)  No interactions expected  No interactions expected  \\nDelamanid (DLM)  No interactions expected  No interactions expected  \\nMetformin  DTG may increase metformin plasma levels so \\nmetformin dose may need to be decreased. Limit \\ndaily metformin dose to 1,000mg.  \\n \\nDTG does NOT require a dose adjustment is when \\nused with metformin.  No interaction  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 273}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 53 Annex 13 C: Cont.  \\nDrugs Affected  Dolutegravir (DTG)  Raltegravir (RAL)  \\nAnticonvulsants  \\n-Carbamazepine  \\n-Phenobarbital  \\n-Phenytoin  Avoid use of DTG with carbamazepine, \\nphenobarbital, or phenytoin because they \\ndecrease DTG plasma levels.  \\n \\nIf the DTG must be used in combination with any \\nof these anticonvulsants than increase DTG dose \\nto 50mg BD and monitor viral load.  No interaction  \\nMineral \\nsupplements and \\nantacids \\ncontaining cations \\n(e.g., calcium, iron, \\nzinc, magnesium, \\naluminum), \\nincluding prenatal \\nvitamins  Administer DTG at least 2 hours before or 6 \\nhours after taking any of these supplements \\n(note: if taking DTG with a meal then it is safe to \\ntake at th e same time as prenatal vitamins, \\ncalcium, or iron)  \\n \\nThere are no drug -drug interactions between \\nDTG and proton pump inhibitors or H2 blockers \\nused for gastritis.  Do not use calcium, \\nmagnesium and aluminum \\ncontaining antacids with RAL.  \\nMethadone  No inter action  No interaction  \\n \\n \\n \\n \\n \\n \\n \\n \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 274}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 54 Annex 14: Health Facility Assessment to Provide Community ART Distribution  \\nHealth Facility Assessment to Provide Community ART Distribution*  \\nFacility name:  MFL code:  Date of assessment:  \\nHealth system domains for community ART distribution  Yes/No  \\nLeadership:  \\nHas the facility identified a focal person to oversee community -based ART distribution?   \\nFinance:  \\nDoes the facility have resources to implement and monitor community -based ART distribution?   \\nHuman Resources for Health:  \\nHas the facility identified appropriate personnel to distribute ART (peer educators, lay \\ncounselors and /or Community Health Volunteers)?   \\nDoes the facility have capacity to train ART distributors?   \\nService Delivery:  \\nHas the facility achieved a routine viral load monitoring uptake of ≥ 90%?   \\nHas the facility established a facility -based system for fast -track ART distribution?   \\nCommodity Management:  \\nDoes the facility have ≥ three months of ART available on site?   \\nHas the facility identified a focal person to pre -pack and label ART for community distribution?   \\nHealth Information Systems:  \\nDoes the facility have an established system to monitor patient level outcomes, specifically \\nretention, loss to follow -up, mortalities an d viral load suppression?   \\nIs the facility able to establish recording and reporting systems for community ART?   \\nAssessors’ recommendations:  \\n \\nFinal assessment outcome:  \\nFacility can initiate community ART distribution ▢  \\nFacility to implement assessors’ recommendations and be re -assessed thereafter ▢  \\nNames of assessors:  Signature of \\nassessors:  Name of health facility manager: \\nSignature of health facility manager:  \\n*None of these criteria are absolute requirements for implementation of community -based ART \\ndistribution; implementation can be considered even if some criteria are not met, as long as a plan is in \\nplace to address and monitor gaps  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 275}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 55 \\n Annex 15: Creatinine Clearance  \\nFormula for calculating creatinine clearance for adults : \\n \\n \\n \\n \\nFormula for calculating creatinine clearance for children and adolescents (up to 19 years \\nold):  \\n \\neGFR = k x height (cm)/ serum creatinine (mg/dL)  \\n \\nk = 0.45 for infants < 1 year old  \\nk = 0.55 for children (1 – 10 years)  \\nk = 0.55 for female adolescents (11 -19 years)  \\nk = 0.70 for male adolescents (11 -19 years)  \\n \\n', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 276}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 56 Annex 16: Immune Reconstitution Inflammatory Syndrome  \\nImmune Reconstitution Inflammatory Syndrome (IRIS)  \\nDefinition:  \\nIRIS is a paradoxical inflammatory reaction against a foreign antigen (alive or dead) in patients who \\nhave started ART with reconstitution (improved functioning) of their immune system. The immune \\nsystem, once it regains some function, is now able to respond against the foreign antigen.  \\nClassification:  \\n● Unmasked IRIS: appearance of a previously undiagnosed opportunistic infection (OI) following \\nART initiation (or switch of ART to a suppressive regimen)  \\n● Paradoxical IRIS: worsening of a previously diagnosed disease after ART initiation (or switch of \\nART to a suppressive regimen)  \\nRisk Factors for IRIS:  \\n● 10-20% of patients who start ART with advanced immunosuppression (refer to Chapter 3) \\nexperience clinical deterioration during the first few months due to IRIS  \\n● High risk patients include:  \\no Advanced immunosuppression (WHO Stage 3 or 4, or CD4 count ≤ 200 cell/mm3 ( or CD4% ≤ \\n25% for children ≤ 5 years old))  \\no Patients with a diagnosed opportunistic infection like TB, MAC, CMV, and PCP  \\no Low baseline CD4 (CD4 count ≤ 50 cell/mm3 or CD4% ≤ 10%)  \\no High baseline viral load  \\no Substantial increase in CD4 count and drop in viral load after starting ART  \\nPatient evaluation:  \\nIn addition to the clinical evaluation for PLHIV outlined in Table 3.1, emphasis should be placed on the \\nfollowing areas during the patient evaluation:  \\nHistory:  \\nSymptoms and current ARV history:  \\n• Specific systemic symptomatology  \\n• Date of ARV initiation  \\n• Regimen  \\n• Reason for substitution / switch from previous ART if not first line  \\n• Adherence to ART and other ongoing treatment  \\n• HIV viral load  \\n• CD4 count  \\nPrior History:  \\n• ARV toxicity  \\n• Drug -drug interaction  \\n• CD4 count  \\n• HIV viral load  History of treatment of opportunistic infections:  \\n• Date of initiation of treatment  \\n• Duration of therapy  \\n• Clinical response to treatment  \\n• Adherence to the OI treatment  \\n• Any default to treatment  \\n• Resistance to treatment  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 277}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 57 Annex 16: Cont.  \\nPhysical Examination:  \\nVital signs assessment:  Temperature, Heart Rate, Blood Pressure, Respiratory rate  \\nConduct a detailed systemic examination:  \\n• Emphasis should be placed on the system(s) which are primarily affected (Table 3.1)  \\n \\nInvestigations  \\n• All patients with advanced HIV disease should be screened for common OIs including TB, \\ncryptococcal meningitis and other common OIs depending of their presenting signs and \\nsymptoms  \\n. \\nDiagnosis of IRIS  \\n● IRIS should be suspected any time a patient has clinical deterioration weeks to months after \\nstarting ART (or switching to a suppressive ART regimen)  \\n● Clinical deterioration usually occurs within 4 -8 weeks of initiation or change of ART (but can be \\nmonths afterwards)  \\n● IRIS has varied clinical presentations due to multiple possible pathogens that the immune system \\nmay be reacting to, and various immune system reactions; there are generally clinical \\nmanifestations consistent with an inflammatory condition  \\n● A high level of suspicion is required when making a diagnosis of IRIS, which is generally one of \\nexclusion  \\n● Rule out the possibility of drug reaction, patient non -adherence to OI treatment, persistently active \\ninfection and/or drug resistance to OI treatment  \\n● There could be localized tissue inflammation with or without systemic inflammatory response  \\n \\nMajor and Minor Presentations of IRIS  \\nMajor presentation  Minor presentation  \\nTuberculosis (TB)  \\nMycobacterium avium complex (MAC)  \\nCryptococcal meningitis  \\nCytomegalovirus (CMV) retinitis  \\nHepatitis B or C virus  \\nProgressive multifocal leukoencephalopathy \\n(PML)  \\nKaposi’s sarcoma  \\nCerebral toxoplasmosis  \\nAutoimmune diseases  Herpes simplex virus (HSV) and varicella \\nzoster virus (VZV)  \\nNonspecific dermatologic complic ations such \\nas folliculitis, oral and genital warts  \\n \\n   \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 278}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 58 Annex 16: Cont.  \\nManagement of IRIS  \\nIRIS management is dependent on severity of symptoms and the following general guidance is \\nrecommended:  \\nSeverity of \\nIRIS  Definition  Management  \\nMild  • Resolves over time \\nin most patients  \\n• Symptomatic \\ntreatment is often \\nsufficient  \\n • Treat the OI and manage the associated \\nsymptoms  \\n• Treat IRIS -associated inflammation:  \\no NSAIDS for discomfort associated with mild \\ninflammation / fevers  \\no Inhaled steroids for bronchospasm or \\ncough associated with mild pulmonary \\ninflammation  \\n• Surgical intervention:  \\no Drainage of abscesses  \\no Excision of inflamed and painful lymph \\nnodes  \\nSevere  • Threatens a \\npatient’s \\nfunctional state  \\n• Cause permanent \\ndisability  \\n• Potentially lead to \\ndeath  \\nExamples:  \\n• Decline in \\npulmonary \\ncapacity from TB \\nor MAC infection  \\n• Neurologic \\ncomplications \\nfrom cryptococcal \\ninfection  \\n• Loss of vision from \\nCMV retinitis \\ninfection  • Treat the OI and manage the associated \\nsymptoms  \\n• Manage t he IRIS -associated inflammation:  \\no If NOT KS: give 1 to 2 mg/kg prednisone for \\n1 to 2 weeks. Follow with a period of \\nindividualized tapering of the dose  \\no Do not use corticosteroids for the \\nmanagement of KS -related IRIS  \\n• Closely monitor patients on corticosteroid \\ntherapy for:  \\no Hyperglycemia  \\no Hypertension  \\no Mental status changes  \\no Avascular necrosis  \\no Worsening of an existing infection  \\no Predisposition to a new infection (e.g., TB \\nand CMV)  \\n    \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 279}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 59 Annex 17: HTS Adult Screening Tool Enhancement  \\n  \\nCounty: …………………………………………. Sub -County Name: ………………………………….  \\n \\nFacility Name:……………………………… Facility MFL Code: ……………………………………  \\n1 Today’s Date                                              Gender                                             AGE  \\n \\n………………………….                            \\n2 Have you ever tested for HIV Before?  \\nIf yes, what was the HIV result?         Positive                      Negative  \\nIf positive, Date of ART initiation. ……………………. (Not eligible for testing)  \\nIf Negative, when is the most recent HIV test?   Months              Years  \\n \\n3 If negative or status unknown, determine  behavioural risk of HIV acquisition  by \\nasking the following questions:  \\n• Unprotected sex within the last 3 months  \\n• Unknown status of the sexual partners  \\n• New sexual partner within the last 3 months  \\n• Multiple sexual partners  \\n• intergenerational relationships  \\n• Symptoms of sexually transmitted infection (refer to MoH syndromic \\nchart) or history of STI  \\n• Pregnancy for females  \\n• Assessing h istory of recurrent illnesses without resolution of symptoms, \\nacute or chronic febrile illness (symptoms ≥ 14 days) and any other \\nconditions suggestive of HIV  \\n4 Possible Risk exposures:  \\n• Defilement  \\n• Traditional /non -medical procedures e.g., scarification, plastic tooth \\nextraction , Circumcision, uvulectomy etc.  \\n5 If Risk noted or clinical assessment suggest HIV, eligible for testing  \\n6. If No risk noted and assessment does not suggest, not eligible  \\nName  Institutions  \\n \\n  \\n M\\nM\\nM  F \\n  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 280}),\n",
       " Document(page_content=\" Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 60 Annex 1 8: List of Contributors and Affiliation  \\n  Name  Affiliation    Name  Affiliation  \\n1 Abraham Katana  CDC  61 Jonah Magare  MOH NASCOP  \\n2 Adrian Gardner  Moi University  62 Jonah Maswai   DoD  \\n3 Agnes Langat  CDC  63 Jonah Onentiah  MOH NASCOP  \\n4 Alice Njoroge  Kajiado County  64 Jonathan Mwangi  CDC  \\n5 Ambrose Juma  MOH NASCOP  65 Joseph Mbuthia  Mater Hospital  \\n6 Anne Marie \\nMacharia  KNH  66 Joseph Nkuranga  UON  \\n7 Anthony Wachira  MOH NASCOP  67 Judith Lusike  CHAI  \\n8 Appolonia Aoko  CDC  68 Julius Kisio  Murang'a County  \\n9 Barbara Mambo  MOH NASCOP  69 Julius Oliech  CDC  \\n10 Brandwell Mwangi  CHAI  70 Justine Odionyi  EGPAF  \\n11 Brenda Opanga  MOH NASCOP  71 Justus Ogada  CHAI  \\n12 Celestine \\nImuuraget  DOD  72 Kenneth Masamaro  CDC  \\n13 Christine Kisia  WHO  73 Lazarus Momanyi  MOH NASCOP  \\n14 Claver Kimathi  Isiolo County  74 Lennah Nyabiage  CDC  \\n15 Collins Etemesi  MOH NASCOP  75 Leonard Kingwara  MOH NHRL  \\n16 Dalton Wamalwa  UON  76 Leonard Soo  USAID  \\n17 Daniel Kimani  CDC  77 Loice Achieng Ombajo  UON  \\n18 Daniel Were  JHPIEGO  78 Margaret Ndubi  UNAIDS  \\n19 Davis Karambi  CHAI  79 Mary Mugambi  MOH NASCOP  \\n20 Deborah Carpenter  CDC  80 Mary Nyangasi  MOH NCCP  \\n21 Deborah Goldstein  USAID  81 Marybeth Maritim  UON  \\n22 Deborah Ikonge  MOH NASCOP  82 Maureen Inimah  MOH NASCOP  \\n23 Dennis Osiemo  USAID  83 Maureen Syowai  ICAP at Columbia \\nUniversity  \\n24 Diana Marangu  UoN  84 Mike Ekisa  Kakamega County  \\n25 Dinah Mamai   CHS  85 Muthoni Karanja  DOD  \\n26 Dorcus Abuya  UNICEF  86 Nancy Bowen  MOH NHRL  \\n27 Doreen Muriithi  JHPIEGO  87 Nandita Sugandhi  ICAP at Columbia \\nUniversity  \\n28 Dorothy Mwagae  MOH NASCOP  88 Natella Rakhmanina  EGPAF  \\n29 Douglas Gaitho  AKUH  89 Nelson Otwoma  NEPHAK  \\n30 Dunstan Achwoka  USAID  90 Newton Omale  MOH NASCOP  \\n31 Edith Apondi  AMPATH Plus  91 Odylia Muhenje  CDC  \\n32 Elaine Abrams   ICAP at Columbia \\nUniversity  92 Pacific Akinyi  MOH NASCOP  \\n33 Elizabeth Irungu  JHPIEGO  93 Patricia Oluoch  USAID  \\n34 Elizabeth Katiku  CDC  94 Patricia Ongwen  JHPIEGO  \", metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 281}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 61 35 Elizabeth Mueni  NMS  95 Philip Kimani  CHAI  \\n36 Elizabeth Onyango  MOH NCD  96 Rogers Simiyu  EGPAF  \\n37 Elizabeth Washika  MOH NASCOP  97 Rose Ayugi  MOH NASCOP  \\n38 Emma Momanyi  CIHEB  98 Rose Wafula  MOH NASCOP  \\n39 Eric Mutua  MOH NASCOP  99 Ruby Fayorsey                  ICAP at Columbia \\nUniversity  \\n40 Evelyn Ngugi  CDC  100  Ruth Kamau  MOH NASCOP  \\n41 Everline Ashiono  USAID Dumisha Afya  101  Ruth Korir  Mathari Hospital  \\n42 Felicistas Makokha  NyaWest RTWG  102  Ruth Musyoki  MOH NASCOP  \\n43 Francis Ndwiga  MOH NASCOP  103  Ruth Nduati  UoN  \\n44 Frank Basiye  CDC  104  Salome Okutoyi  USAID  \\n45 George Siberry  USAID  105  Sarafuina Sikwata  MOH NASCOP  \\n46 Grace Rabut  MOH NASCOP  106  Sarah Masyuko  MOH NASCOP  \\n47 Helen Chun  CDC  107  Shobha Vakil                     ICAP at Columbia \\nUniversity  \\n48 Herb Herwell  CHAI  108  Sospeter Gitonga  MOH NASCOP  \\n49 Herman Wayenga  CDC  109  Steve Oyule  DoD  \\n50 Immaculate \\nMutisya  CDC  110  Susan Njogo  ARC Kenya  \\n51 Irene Mukui  DnDI  111  Teresa Simiyu  USAID  \\n52 Isabella Yonga  USAID  112  Terezah Alwar  UNICEF  \\n53 Ivy Kasirye  WHO  113  Vakil, Shobha  ICAP  \\n54 Jafred Mwangi  MOH NASCOP  114  Valeria Makory  MOH NASCOP  \\n55 James Wagude  NyaWest RTWG  115  Valerie Obare  MOH NASCOP  \\n56 Janet Muema  MOH NASCOP  116  Veronica Irungu  CHS  \\n57 Japheth Gituku  MOH NASCOP  117  Virginia Karanja  CHS  \\n58 Jeremy Penner  UBC  118  Wangui Kamau  KNH  \\n59 Joan -Paula Bor  MOH NCCP  119  Wanjiku Ndegwa  MOH NASCOP  \\n60 John Mungai  CHAI  120  Winifred Nyanya  MOH NASCOP  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 282}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 62 Annex 19: List of Participating Organizations and Agencies  \\nContributing Organizations  \\nCenter for Health Solutions  \\nAga Khan University Hospital  \\nAMPATH Plus  \\nARC Kenya  \\nCenter for Disease Control  \\nCIHEB Kenya  \\nClinton Health Access Initiative  \\nCouncil of Governors  \\nDepartment of Defence  \\nDnDI  \\nEGPAF  \\nICAP at Columbia University  \\nJHPIEGO  \\nKenyatta Nati onal Hospital  \\nMater Hospital  Mathari National TRH  \\nMOH Department of NCD  \\nMOH Division of NCCP  \\nMOH NASCOP  \\nMOH NHRL  \\nMOH NLTP  \\nMoi University  \\nNairobi Metropolis Services  \\nNEPHAK  \\nUCSF  \\nUNICEF  \\nUniversity of British Columbia  \\nUniversity of Nairobi  \\nUSAID  \\nWorld Health Organization  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 283}),\n",
       " Document(page_content=' \\n63 - 264   \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 284}),\n",
       " Document(page_content=' \\n  \\n', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 285})]"
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "documents"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "d7ee6b4d-196c-46af-961c-998bf7ce1250",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n2022 Edition', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 2}),\n",
       " Document(page_content='© National AIDS & STI Control Program 2022  \\n \\nThis guideline document is a publication of the National AIDS & STI Control Program, Ministry of Health \\nKenya. No part of this publication may be reproduced, distributed, or transmitted in any form or by any \\nmeans, including photocopying or recording, without the prior written permission of the National AIDS and \\nSTI Contro l Program (NASCOP), Ministry of Health Kenya, except for non -commercial uses permitted by \\ncopyright law.  \\n \\nKenya HIV Prevention and Treatment Guidelines, 2022  edition contain relevant information required by \\nhealthcare providers in the use of ARVs as of the date of issue. All reasonable precautions have been taken \\nby NASCOP to verify the information contained in this guideline document.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 3}),\n",
       " Document(page_content='by NASCOP to verify the information contained in this guideline document.   \\n \\nFor clarifications contact National AIDS and STI Control Program (NASCOP) at P. O. Box 19361 - 00202, \\nNairobi Kenya, T el: +254 (020) 2630867, Email: info@nascop.or.ke, Website: www.nascop.or.ke  \\nThe recommended citation for this document is:  \\nMinistry of Health, National AIDS & STI Control Program. Kenya HIV Prevention and Treatment Guidelines, \\n2022  Edition. Nairobi, Kenya: NASCOP, Aug  2022. Print.  \\n \\n \\n \\nDesign and Layout: Collins Etemesi - NASCOP  \\nISBN: 13 -978 -9966 -038 -31-9', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 3}),\n",
       " Document(page_content='i Foreword  \\nKenya is committed to achieving the UNAIDS 95 –95–95 testing and treatment targets among \\npeople living with HIV within all sub -populations and age groups.  \\nThe 2022 edition of the ‘Guidelines on Use of Antiretroviral Drugs for Treating and Pr eventing \\nHIV Infection in Kenya’ is an update of the comprehensive HIV prevention, Care and treatment \\nguidelines released in 2018. These guidelines are aligned with the Ministry of Health’s mission of \\nproviding the highest standard of health for all Kenyan s and one of the Government of Kenya’s Big \\nFour Agenda on Universal Health Coverage .  \\nThe theme of the 2022 guidelines is refocusing efforts in the management of Advanced HIV \\nDisease to reduce HIV/AIDS related morbidity and mortality. While Kenya has made tremendous', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 4}),\n",
       " Document(page_content='Disease to reduce HIV/AIDS related morbidity and mortality. While Kenya has made tremendous \\nprogress in HIV Prevention, Care and Treatment through introduction of better medicines, \\ndiagnostics and patient centered approaches in service delivery, Advanced HIV Disease continues \\nto be a challenge. These guidelines intend to widen access t o key diagnostics and medicines to \\nmanage the most common causes of illness and death. Further, emphasis on integrated delivery \\nof patient -centered HIV, TB, NCDs, mental health and sexual and reproductive health services has \\nbeen included.  \\nThese guidelines  provide key recommendations on  HIV testing services and linkage to prevention \\nand treatment; initial evaluation and follow up of PLHIV; standard package of care for PLHIV;', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 4}),\n",
       " Document(page_content='and treatment; initial evaluation and follow up of PLHIV; standard package of care for PLHIV; \\nadherence preparation monitoring and support; antiretroviral therapy in infants, c hildren, \\nadolescents and adults; prevention of mother to child transmission of HIV, Syphilis and Viral \\nHepatitis; TB/HIV coinfection; Hepatitis B & C/HIV co -infection; use of ARVs for post and pre -\\nexposure prophylaxis for HIV uninfected populations; and HI V services for people who inject \\ndrugs.  \\nThe guidelines are an important tool meant to be used by service providers at all levels of the \\nhealth sector in Kenya. They are presented in a simplified manner using a public health approach \\nto HIV prevention and treatment.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 4}),\n",
       " Document(page_content='health sector in Kenya. They are presented in a simplified manner using a public health approach \\nto HIV prevention and treatment.  \\nIt is my hope that this guidance document provides the much -needed framework and impetus to \\nmove towards universal access for HIV services and the agenda of ending AIDS by 2030 as a key \\nnational health strategic objective.  \\n \\n \\nDr. Patrick Amoth , EBS  \\nAg. Director General for Health , \\nMinistry of Health .', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 4}),\n",
       " Document(page_content='ii Acknowledgement s \\n \\nThe 2022 Guidelines on Use of Antiretroviral Drugs for Treating and Preventing HIV Infection in \\nKenya has been a long -awaited document as the revision was greatly affected by the COVID -19 \\npandemic. The document has been updated through the collaborative effort of multiple \\nstakeholders, both individuals and institutions, that contributed to the extensive consultations \\nled by NASCOP HIV Care and Treatment Program.  \\n \\nWith much appreciation, I acknowledge all the institutions, both local and international, \\ngovernment ministries and departments whose staff spent long hours, both virtually and in \\nperson, in the review, writing and finalization of this document.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 5}),\n",
       " Document(page_content='person, in the review, writing and finalization of this document.  \\n \\nI take th is opportunity to appreciate the efforts of the Ministry of Health officers at NASCOP and \\nother institutions who coordinated and provided leadership during the review process. \\nCompliments to the guidelines review secretariat and the special task force who worked tirelessly \\nto ensure that the team produced a great quality document. Particular appreciation to the \\nNASCOP team and numerous TA’s who were instrumental in compiling the evidence review and \\ndeveloping the guidelines. Special thanks to the consultant s; Jeremy Penner, Irene Mukui, and \\nHerb Harwell for their dedication to this process.  \\n \\nFinancial support for the review process, printing and launch of this document was provided by', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 5}),\n",
       " Document(page_content='Financial support for the review process, printing and launch of this document was provided by \\nthe Global Fund, UNITAID through CHAI, the US government through the Cent ers for Disease \\nControl and Prevention and ICAP at Columbia University through the USAID -funded RISE -Kenya \\nProject, WHO and UNICEF - Kenya.  \\n \\n \\n \\nDr. Rose Wafula  \\nHead, National AIDS & STI Control Program  \\nMinistry of Health', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 5}),\n",
       " Document(page_content='iii Table of Contents  \\nForeword  ................................ ................................ ................................ ................................ ................................ .......... i \\nAcknowledgements  ................................ ................................ ................................ ................................ ....................  ii \\nTable of Contents  ................................ ................................ ................................ ................................ ........................  iii \\nList of Figures  ................................ ................................ ................................ ................................ ...............................  ix', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 6}),\n",
       " Document(page_content='List of Tables  ................................ ................................ ................................ ................................ ................................ ..x \\nAcronyms and Abbreviations  ................................ ................................ ................................ ............................  xiii \\n1. Summary of Key Recommendations  ................................ ................................ ..................  1 \\n1.1 HIV Testing Services (HTS) and Linkage to Treatment and Prevention  ................................ ..... 1 \\n1.2 Initial Evaluation and Follow -up for PLHIV  ................................ ................................ .............................  1', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 6}),\n",
       " Document(page_content='1.2 Initial Evaluation and Follow -up for PLHIV  ................................ ................................ .............................  1 \\n1.3 Standard Package of Care for PLHIV  ................................ ................................ ................................ ...........  2 \\n1.4 Adherence Preparation, Monitoring and Support  ................................ ................................ ................  4 \\n1.5 Antiretroviral Therapy for Infants, Children, Adolescents, and Adults  ................................ ....... 4 \\n1.6 Prevention of Mother to Child Transmission of HIV/Syphilis/HBV  ................................ .............  5', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 6}),\n",
       " Document(page_content='1.6 Prevention of Mother to Child Transmission of HIV/Syphilis/HBV  ................................ .............  5 \\n1.7 TB/HIV Co -infection Prevention and Management  ................................ ................................ .............  6 \\n1.8 HBV/HIV and HCV/HIV Co -infection Prevention and Management  ................................ .............  7 \\n1.9 ARVs for Post -exposure Prophylaxis (PEP)  ................................ ................................ .............................  7 \\n1.10 Pre -Exposure Prophylaxis (PrEP)  ................................ ................................ ................................ .............  7', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 6}),\n",
       " Document(page_content='1.11 People Who Inject Drugs (PWID) and HIV  ................................ ................................ ............................  8 \\n2. HIV Testing Services and Linkage to Treatment and Prevention  ...........................  1 \\n2.1 Settings for HIV Testing  ................................ ................................ ................................ ................................ .... 1 \\n2.1.1 Facility -based testing  ................................ ................................ ................................ ................................ ..........................  1 \\n2.1.2 Community –based testing  ................................ ................................ ................................ ................................ ................  2', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 6}),\n",
       " Document(page_content='2.2 HTS strategies  ................................ ................................ ................................ ................................ .......................  2 \\n2.2.1 HIV Self -Testing (HIVST)  ................................ ................................ ................................ ................................ ...................  2 \\n2.2.2 Index Testing  ................................ ................................ ................................ ................................ ................................ ...........  2 \\n2.2.3 Voluntary Counselling and Testing (VCT):  ................................ ................................ ................................ ...............  2', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 6}),\n",
       " Document(page_content='2.2.4 Social Network Strategy (SNS) - ................................ ................................ ................................ ................................ ...... 2 \\n2.3 Package of HI V Testing Services  ................................ ................................ ................................ ...................  5 \\n2.4 Age -Specific HIV Testing Algorithms  ................................ ................................ ................................ ..........  8 \\n2.4.1 Early Infant Diagnosis  ................................ ................................ ................................ ................................ .................  8 \\n2.4.2 Diagnosis of HIV Infection in the Older Child (≥ 18 months), Adolescents and Adults  ............  12', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 6}),\n",
       " Document(page_content='2.4.2 Diagnosis of HIV Infection in the Older Child (≥ 18 months), Adolescents and Adults  ............  12 \\n2.4.3 HIV testing for Pregnant Women  ................................ ................................ ................................ .......................  14 \\n2.5 Retesting recommendations for HIV negative pe rsons  ................................ ................................ ... 17 \\n2.6 Inconclusive HIV status  ................................ ................................ ................................ ................................ .. 18 \\n2.7 Approach to Patients on ART with a Discrepant HIV Test Result  ................................ ...............  19', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 6}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n \\niv 3. Initial Evaluation and Follow up  ................................ ................................ .........................  1 \\n3.1 Introduction  ................................ ................................ ................................ ................................ ...........................  1 \\n3.2 Initial Clinical Evaluation of PLHIV  ................................ ................................ ................................ ..............  1 \\n3.3 Initial Laboratory Evaluation of PLHIV  ................................ ................................ ................................ ...... 4', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 7}),\n",
       " Document(page_content='3.4 Managem ent of Patients Who Present with Advanced HIV Disease  ................................ .............  6 \\n3.5 Follow -up of PLHIV after ART initiation  ................................ ................................ ................................ ... 8 \\n3.5.1 First 6 months after ART initiation  ................................ ................................ ................................ ..............................  9 \\n3.5.2 Differentiated Service Delivery for Patients beyond the 1st 6 months of ART  ................................ ....... 9 \\n3.6 Summary of clinical and laboratory monitoring of PLHIV on ART ................................ .............  11 \\n3.7 Differentiated Care for Chi ldren, Adolescents and Pregnant/ breastfeeding Women  ...... 13', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 7}),\n",
       " Document(page_content='3.7 Differentiated Care for Chi ldren, Adolescents and Pregnant/ breastfeeding Women  ...... 13 \\n3.8 ART Prescription, Dispensing, and Distribution for clients establishe d on ART  .................  14 \\n4. Standard Package of Care for PLHIV ................................ ................................ ..................  1 \\n4.1 Antiretrovir al Therapy  ................................ ................................ ................................ ................................ ...... 4 \\n4.2 PHDP, GBV/IPV & HIV Education/Counselling  ................................ ................................ ......................  5 \\n4.2.1 Screening for Gender -Based Violence (GBV)/Intimate -Partner Violence (IPV)  ................................ .... 6', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 7}),\n",
       " Document(page_content='4.2.1 Screening for Gender -Based Violence (GBV)/Intimate -Partner Violence (IPV)  ................................ .... 6 \\n4.2.2 HIV Education/Counselling  ................................ ................................ ................................ ................................ ..............  7 \\n4.3 Specific Opportun istic Infection Screening and Prevention  ................................ .............................  8 \\n4.3.1 Cotrimoxazole Preventive Therapy (CPT)  ................................ ................................ ................................ ................  8 \\n4.3.2 Tuberculosis (TB) Prevention and Management for PLHIV  ................................ ................................ ..........  11', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 7}),\n",
       " Document(page_content='4.3.2 Tuberculosis (TB) Prevention and Management for PLHIV  ................................ ................................ ..........  11 \\n4.3.3 Cryptococcal Meningitis (CM) Screening and Treatment  ................................ ................................ ...............  11 \\n4.4 Reproductive Health Services  ................................ ................................ ................................ .....................  15 \\n4.4.1 Sexually Transmitted Infections  ................................ ................................ ................................ ................................ . 15 \\n4.4.2 Family Planning and Pre -Conception Counselling  ................................ ................................ .............................  15', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 7}),\n",
       " Document(page_content='4.4.3 Maternal Healthcare  ................................ ................................ ................................ ................................ .........................  18 \\n4.5 Non -communicable Diseas es Screening and Management  ................................ ............................  18 \\n4.5.1 Metabolic Disorders  ................................ ................................ ................................ ................................ ..........................  18 \\n4.5.2 Cancer Prevention, Early Detection and Management among PLHIV  ................................ ......................  23 \\n4.6 Mental Health Screening and Management  ................................ ................................ ..........................  25', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 7}),\n",
       " Document(page_content='4.6 Mental Health Screening and Management  ................................ ................................ ..........................  25 \\n4.6.1 Depre ssion  ................................ ................................ ................................ ................................ ................................ .............  25 \\n4.6.2 Alcohol and Drug Use/Addiction  ................................ ................................ ................................ ................................  28 \\n4.6.3 Anxiety ................................ ................................ ................................ ................................ ................................ .....................  31', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 7}),\n",
       " Document(page_content='4.6.4 Stress and stress management  ................................ ................................ ................................ ................................ .... 32 \\n4.6.5 experiences o f Trauma  ................................ ................................ ................................ ................................ ....................  33 \\n4.6.6 Psychosis  ................................ ................................ ................................ ................................ ................................ ................  34 \\n4.6.7 Self -Care  ................................ ................................ ................................ ................................ ................................ ..................  34', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 7}),\n",
       " Document(page_content='4.6.8 Wellbeing  ................................ ................................ ................................ ................................ ................................ ...............  35', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 7}),\n",
       " Document(page_content='v 4.7 Nutritional Services  ................................ ................................ ................................ ................................ .........  36 \\n4.7.1 Nutritional Assessment, Counselling and Support (NACS)  ................................ ................................ ............  36 \\n4.8 Prevention of Other Infections  ................................ ................................ ................................ ...................  40 \\n4.8.1 Immunizations  ................................ ................................ ................................ ................................ ................................ ..... 40', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 8}),\n",
       " Document(page_content='4.8.2 Malaria  ................................ ................................ ................................ ................................ ................................ .....................  42 \\n4.8.3 Safe Water, Sanitation and Hygien e ................................ ................................ ................................ ..........................  42 \\n5. Adherence Preparation, Monitoring and Support  ................................ ........................  1 \\n5.1 Undetectable = Untransmittable (U=U)  ................................ ................................ ................................ ..... 5', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 8}),\n",
       " Document(page_content='5.1 Undetectable = Untransmittable (U=U)  ................................ ................................ ................................ ..... 5 \\n5.1.1 Benefits of U=U  ................................ ................................ ................................ ................................ ................................ ....... 5 \\n5.1.2 Considerations for implem entation of U=U within clinical settings  ................................ ............................  5 \\n5.1.3 Messaging to Patients on U=U  ................................ ................................ ................................ ................................ .........  5', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 8}),\n",
       " Document(page_content='5.1.4 How patients can discuss U=U with others  ................................ ................................ ................................ ..............  6 \\n5.1.5 Counselling patients about other prevention combination interventions  ................................ ................  6 \\n5.1.6 Application of U=U in o ther settings  ................................ ................................ ................................ ............................  6 \\n5.2 ART Adherence Preparation and Support  ................................ ................................ ................................  7 \\n5.2.1 Treatment Preparation as Part of HIV Testing Services  ................................ ................................ ....................  7', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 8}),\n",
       " Document(page_content='5.2.2 ART Treatment Preparation  ................................ ................................ ................................ ................................ ............  7 \\n5.2.3 Age -Specific Tr eatment Preparation and Support  ................................ ................................ .............................  13 \\n5.3 Adherence Monitoring, Counselling and Support During the First 3 Months of ART  ........ 20 \\n5.3.1 Adherence Monitoring  ................................ ................................ ................................ ................................ .....................  20 \\n5.3.2 Adherence Counselling and Support During the First 3 Months of ART  ................................ .................  25', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 8}),\n",
       " Document(page_content='5.3.2 Adherence Counselling and Support During the First 3 Months of ART  ................................ .................  25 \\n5.4 Adherence Monitoring, Counselling and Support for Patients with Suppressed Viral Load \\n< 200 copies/ml  ................................ ................................ ................................ ................................ ...... 29 \\n5.5 Adherence Monitoring, Counselling and Support for Patients with Unsuppressed Viral \\nLoad ≥ 200 copies/ml  ................................ ................................ ................................ ...........................  30 \\n5.5.1 Enhanced Adherence Assessments  ................................ ................................ ................................ ...........................  31', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 8}),\n",
       " Document(page_content='5.5.2 Enhanced Adherence Counselling  ................................ ................................ ................................ ..............................  31 \\n5.6 Treatment Preparation for 2nd Line or 3rd Line ART  ................................ ................................ ..... 34 \\n5.7 Identifying, Tracing, and Supporting Patients who Default from Care  ................................ ..... 35 \\n6. Antiretroviral Therapy in Infants, Children, Adolescents, and Adults  .................  1 \\n6.1 Eligibility for ART  ................................ ................................ ................................ ................................ ................  1', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 8}),\n",
       " Document(page_content='6.2 Timing of ART Initiation  ................................ ................................ ................................ ................................ ... 1 \\n6.3 First -Line ART for Infants, Children, Adolescents and Adults (including Pregnant and \\nBreastfeeding Women)  ................................ ................................ ................................ ...........................  3 \\n6.4 Dosing and Administration of Dolutegravir (DTG) ................................ ................................ ...............  5 \\n6.5 Monitoring and Changing ART  ................................ ................................ ................................ .......................  7', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 8}),\n",
       " Document(page_content='6.5.1 Optimizing Therapy for Patients who have suppressed viral load on First Line ART .........................  7', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 8}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n \\nvi 6.5.2 Changing ARVs Due to Adverse Drug Reactions  ................................ ................................ ................................ .... 9 \\n6.5.3 Changing ARVs Due to Drug -Drug Interactions  ................................ ................................ ................................ .. 16 \\n6.5.4 Changing ARVs Due to Treatment Failure  ................................ ................................ ................................ .............  17 \\n7. Prevention of Mother to Child Transmission of HIV/Syphilis/Hepatitis B  .........  1 \\n7.1 Antiretroviral Therapy for HIV -positive Pregnant and Breastfeeding Women and Infant', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 9}),\n",
       " Document(page_content='7.1 Antiretroviral Therapy for HIV -positive Pregnant and Breastfeeding Women and Infant \\nProphylaxis  ................................ ................................ ................................ ................................ ...................  3 \\n7.2. Syphilis elimination for Pregnant and Breastfeeding Women and Infant Treatment  .........  5 \\n7.3. Hepatitis B elimination for Pregnant and Breastfeeding Women and Infant Prophylaxis  5 \\n7.4 Infant and Young Child Nutrition in the Context of HIV  ................................ ................................ ..... 7 \\n8. TB/HIV Co -infection, Prevention  and Management  ................................ ....................  1', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 9}),\n",
       " Document(page_content='8. TB/HIV Co -infection, Prevention  and Management  ................................ ....................  1 \\n8.1 TB Screening for PLHIV: Intensified Case Finding (ICF)  ................................ ................................ .... 1 \\n8.2. TB Preventive Therapy (TPT)  ................................ ................................ ................................ .......................  9 \\n8.2.1. Indications for TPT  ................................ ................................ ................................ ................................ ..............................  9 \\n8.2.2. Contraindications to TPT  ................................ ................................ ................................ ................................ ..............  10', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 9}),\n",
       " Document(page_content='8.2.3. Dose and Duration of TPT  ................................ ................................ ................................ ................................ .............  10 \\n8.2.4. Follow -up of Patients on TPT  ................................ ................................ ................................ ................................ ...... 11 \\n8.3. Identifying and Managing Drug Toxicities from TPT  ................................ ................................ ...... 11 \\n8.3.1 Peripheral Neuropathy - Suspected drug: INH  ................................ ................................ ................................ ..... 11 \\n8.3.2 Drug -Induced Liver Injury (DILI) -Suspected drugs include Isoniazid (H), Rifapentine (P),', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 9}),\n",
       " Document(page_content='8.3.2 Drug -Induced Liver Injury (DILI) -Suspected drugs include Isoniazid (H), Rifapentine (P), \\nRifampicin (R)  ................................ ................................ ................................ ................................ ................................ .................  12 \\n8.3.3 Managemen t of TPT -associated Rash - Suspected Drugs include Isoniazid (H), Rifapentine (P), \\nRifampicin (R)  ................................ ................................ ................................ ................................ ................................ .................  13 \\n8.4. ART for TB/HIV Co -infect ion ................................ ................................ ................................ ......................  13', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 9}),\n",
       " Document(page_content='9. HBV/HIV and HCV/HIV Co -infection Prevention and Management  .......................  1 \\n9.1 Hepatitis B/HIV Co -infection  ................................ ................................ ................................ ..........................  1 \\n9.1.1 Screening  ................................ ................................ ................................ ................................ ................................ ...................  1 \\n9.1.2 Prevention  ................................ ................................ ................................ ................................ ................................ ................  1', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 9}),\n",
       " Document(page_content='9.1.3 Treatment  ................................ ................................ ................................ ................................ ................................ .................  2 \\n9.2 Hepatitis C/HIV Co -infection  ................................ ................................ ................................ ..........................  5 \\n9.2.1 Screening  ................................ ................................ ................................ ................................ ................................ ...................  5 \\n9.2.2 Prevention  ................................ ................................ ................................ ................................ ................................ ................  6', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 9}),\n",
       " Document(page_content='9.2.3 Treatment of HIV/HCV Co -infection  ................................ ................................ ................................ ............................  6 \\n10. ARVs for Post -exposure Prophylaxis  ................................ ................................ .................  1 \\n10.1 What is P EP? ................................ ................................ ................................ ................................ ........................  1 \\n10.2 Recommended ARVs for PEP  ................................ ................................ ................................ .......................  1', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 9}),\n",
       " Document(page_content='10.3 Eligibility For PEP  ................................ ................................ ................................ ................................ .............  2 \\n10.4 Management and Follow Up ................................ ................................ ................................ .........................  2', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 9}),\n",
       " Document(page_content='vii 10.5 Risk reduction cou nselling ................................ ................................ ................................ ............................  4 \\n10.6 Preventing HIV exposure  ................................ ................................ ................................ ...............................  4 \\n11. Pre-Exposure Prophylaxis (PrEP)  ................................ ................................ ......................  1 \\n11.1 Indications for PrEP and Criteria for Eligibility  ................................ ................................ ..................  1', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 10}),\n",
       " Document(page_content='11.1 Indications for PrEP and Criteria for Eligibility  ................................ ................................ ..................  1 \\n11.1.1 Indications for PrEP  ................................ ................................ ................................ ................................ ..........................  1 \\n11.1.2 HIV Risk Assessment  ................................ ................................ ................................ ................................ ........................  1 \\n11.1.3 Criteria for PrEP Eligibility  ................................ ................................ ................................ ................................ ............  2', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 10}),\n",
       " Document(page_content='11.2 Package of PrEP Service  ................................ ................................ ................................ ................................ . 3 \\n11.2.1 Pre -Initiation Che cklist  ................................ ................................ ................................ ................................ ....................  4 \\n11.2.2 Pre -initiation client education  ................................ ................................ ................................ ................................ ..... 5 \\n11.3 Recommended ARVs for PrEP  ................................ ................................ ................................ .....................  5', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 10}),\n",
       " Document(page_content='11.3.1 Schema for follow up for daily oral PrEP  ................................ ................................ ................................ ................  7 \\n11.3. 2 EVENT DRIVEN PrEP (ON DEMAND PrEP or 2+1+1 PrEP)  ................................ ................................ ...........  7 \\n11.4 Managing Clinical and Laboratory Results on Initial and Follow -up Asse ssment  ...............  9 \\n11.5 Contra -indications to Oral PrEP (daily or ED PrEP)  ................................ ................................ ....... 12 \\n11.6 Criteria for Discontinuing Oral PrEP  ................................ ................................ ................................ ..... 12', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 10}),\n",
       " Document(page_content='11.7 Restarting PrEP  ................................ ................................ ................................ ................................ ...............  12 \\n11.8 Improving adherence to PrEP  ................................ ................................ ................................ ..................  13 \\n11.9 Monitoring Sero -conversion among PrEP users  ................................ ................................ ..............  13 \\n12. People Who Inject Drugs (PWID) and HIV ................................ ................................ ....... 1 \\n12.1 Intro duction  ................................ ................................ ................................ ................................ ........................  1', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 10}),\n",
       " Document(page_content='12.3 ART in HIV positive PWID  ................................ ................................ ................................ .............................  4 \\n13. Annexes  ................................ ................................ ................................ ................................ ........  1 \\nAnnex 1: WHO Clinical Staging of HIV Infection in Infants and Children  ................................ ...........  1 \\nAnnex 2: WHO Clinical Staging of HIV Infection in Adolescents and Adults  ................................ ..... 2 \\nAnnex 3: Normal Developmental Miles tones in Children  ................................ ................................ .........  3', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 10}),\n",
       " Document(page_content='Annex 3: Normal Developmental Miles tones in Children  ................................ ................................ .........  3 \\nAnnex 4: Tanner Staging of Sexual Maturity in Adolescents  ................................ ................................ ... 4 \\nAnnex 4 A: Tanner Staging of Sexual Maturity in Girls ................................ ................................ ................................ ... 4 \\nAnnex 4 B: Tanner Staging of Sexual Maturity in Boys  ................................ ................................ ................................ .. 4 \\nAnnex 5: Age -Appropriate Disclosure for Child ren and Adolescents  ................................ ..................  5', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 10}),\n",
       " Document(page_content='Annex 5: Age -Appropriate Disclosure for Child ren and Adolescents  ................................ ..................  5 \\nAnnex 6: Transitioning from Adolescent to Adult HIV Services  ................................ .............................  6 \\nAnnex 7: 2018 HIV Testing Services Algorithm ................................ ................................ .............................  7 \\nAnnex 8: HIV Education and Adherence Counselling Content Guide  ................................ ...................  8 \\nAnnex 9 A: Enhanced Adherence Counselling Content Guide  ................................ ..............................  16', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 10}),\n",
       " Document(page_content='Annex 9 A: Enhanced Adherence Counselling Content Guide  ................................ ..............................  16 \\nAnnex 9 B: Case Summary Form  ................................ ................................ ................................ .......................  22 \\nAnnex 9 C: Enhanced Adherence Counselling Form  ................................ ................................ .................  24 \\nAnnex 9 D: Home Visit Checklist  ................................ ................................ ................................ .......................  25', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 10}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n \\nviii Annex 9 E: Management Protocol for Patients Switc hing to 3rd Line ART  ................................ .... 26 \\nAnnex 10 A: Dosing of Solid and Liquid Formulations for Twice -Daily Dosing in Infants and \\nChildren 4 Week s of Age and Older  1 ................................ ................................ .............................  28 \\nAnnex 10 B: Simplified Dosing of Child -Friendly Solid and Oral Liquid Formulations for Once -\\nDaily Dosing in Infants and Children 4 Weeks of Age and Older1 ................................ ..... 29 \\nAnnex 10 C: Drug Dosing of Liquid Formulations for Twice -Daily Dosing in Infants Less than', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 11}),\n",
       " Document(page_content='Annex 10 C: Drug Dosing of Liquid Formulations for Twice -Daily Dosing in Infants Less than \\n4 Weeks of Age  ................................ ................................ ................................ ................................ .........  30 \\nAnnex 10 D: Simplified Dosing of INH and CTX Prophylaxis for Infants and Children Who Are \\nat Least 4 Weeks of Age  ................................ ................................ ................................ .......................  30 \\nAnn ex 10 E: TB Preventive Therapy dosing  ................................ ................................ ................................ . 31 \\nAnnex 10 F: Ritonavir Dosing for Super -Boosting LPV/r in Children Taking Rifampicin  ....... 34', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 11}),\n",
       " Document(page_content='Annex 10 F: Ritonavir Dosing for Super -Boosting LPV/r in Children Taking Rifampicin  ....... 34 \\nAnnex 11: Overlapping toxicities between AR Vs ................................ ................................ .......................  35 \\nAnnex 12 A: Use of Nucleoside & Nucleotide Reverse Transcriptase Inhibitors in Adults  ..... 36 \\nAnnex 12 B: Use of Non -Nucleoside Reverse Transcriptase Inhibitors for Adults  .....................  38 \\nAnnex 12 C: Use of Protease Inhibitors in Adults  ................................ ................................ ......................  39 \\nAnnex 12 D: Integrase Strand Transfer Inhibitors - INSTIs  ................................ ................................ .. 40', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 11}),\n",
       " Document(page_content='Annex 12 D: Integrase Strand Transfer Inhibitors - INSTIs  ................................ ................................ .. 40 \\nAnnex 13 A: Drug -Drug Interactions - NNRTIs  ................................ ................................ ...........................  41 \\nAnnex 13 B: Drug -Drug Interactions – PIs ................................ ................................ ................................ .... 45 \\nAnnex 13 C: Drug -Drug Interactions – INSTIs  ................................ ................................ .............................  52 \\nAnnex 14: Health Facility Assessment to Provide Community ART Distribution  .......................  54', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 11}),\n",
       " Document(page_content='Annex 14: Health Facility Assessment to Provide Community ART Distribution  .......................  54 \\nAnnex 15: Creatinine Clearance  ................................ ................................ ................................ .........................  55 \\nAnnex 16: Immune Reconstitution Inflammatory Syndrome  ................................ ..............................  56 \\nAnnex 17: HTS Adult Screening Tool Enhancement  ................................ ................................ .................  59 \\nAnnex 18: List of Contributors and Affiliation  ................................ ................................ ............................  60', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 11}),\n",
       " Document(page_content='Annex 18: List of Contributors and Affiliation  ................................ ................................ ............................  60 \\nAnnex 19: List of Participating Organizations and Agencies  ................................ ................................  62', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 11}),\n",
       " Document(page_content='ix List of Figures  \\nFigure 2.1 Algorithm for Early Infant Diagnosis in Infants and Children < 18 months of age  ................................ .. 9 \\nFigure 2.2: Birth Testing Algor ithm  ................................ ................................ ................................ ................................ ....................  11 \\nFigure 2.3: HIV Testing Services Algorithm  ................................ ................................ ................................ ................................ .... 13 \\nFigure 2.4 Dual HIV/syphilis Testing Algorithm  ................................ ................................ ................................ ..........................  15', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 12}),\n",
       " Document(page_content='Figure 2.5: Managing Patients on ART Who Present with a New Negative HIV Antibody Test  ............................  20 \\nFigure 4.1: Routine Screening for Cryptococcal Meningitis for HIV -infected Adults and Adolescents  .............  14 \\nFigure 4.2: Generalized Anxiety Disorder Assessment (GAD -7) ................................ ................................ ..........................  32 \\nFigure 4.3: Management of Severe Acute Malnutrition in Children  ................................ ................................ ....................  38 \\nFigure 4.4: Management of Malnutrition in Adults with HIV  ................................ ................................ ................................ . 39', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 12}),\n",
       " Document(page_content='Figure 5.1: Adherence Preparation, Monitoring and Support  until Viral Load after 3 Months on ART  ...............  2 \\nFigure 5.2: Adherence Counselling and Education for Patients Preparing to Initiate 2nd Line or 3rd Line \\nART  ................................ ................................ ................................ ................................ ................................ ................................ .....................  34 \\nFigure 5.3: Ident ifying, Tracing and Supporting Patients who Default from Care  ................................ .......................  35 \\nFigure 6.1: Optimizing ART Regimens for Children and adolescents <15 years Weighing < 30 kg on First', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 12}),\n",
       " Document(page_content='Figure 6.1: Optimizing ART Regimens for Children and adolescents <15 years Weighing < 30 kg on First \\nLine ART  ................................ ................................ ................................ ................................ ................................ ................................ ..............  8 \\nFigure 6.2: Optimizing ART Regimens for Children and Adolescents Weighing ≥ 30 kg  or ≥ 15 years old on \\nFirst Line ART  ................................ ................................ ................................ ................................ ................................ ................................ ... 9', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 12}),\n",
       " Document(page_content='Figure 6.3: General Principles for Managing Adverse Drug Reactions  ................................ ................................ ..............  11 \\nFigure 6.4: Managing Single Drug Substitutions for ART  ................................ ................................ ................................ .........  12 \\nFigure 6.5: Managing TDF -Associated Kidney Toxicity  ................................ ................................ ................................ ............  13 \\nFigure 6.6: Viral Load Monitoring of Patients on ART (1st Line or 2nd Line)  ................................ ...............................  18', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 12}),\n",
       " Document(page_content='Figure 6.6: Viral Load Monitoring of Patients on ART (1st Line or 2nd Line)  ................................ ...............................  18 \\nFigure 8.1: TB diagnosis - GeneXpert Ultra algorithm  ................................ ................................ ................................ ...................  5 \\nFigure 8.2: Use of TB -LAM for Diagnosis of TB among PLHIV  ................................ ................................ ................................ .. 8 \\nFigure 11.1 : Package of Service for PrEP  ................................ ................................ ................................ ................................ ............  3', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 12}),\n",
       " Document(page_content='Figure 11.2: Schema for Follow -up for Daily Oral PrEP  ................................ ................................ ................................ ...............  7 \\nFigure 11.3 Schema for Event -Driven PrEP  ................................ ................................ ................................ ................................ ....... 8 \\nFigure 11.4 Schema for Initiation and Follow -up for Event -driven PrEP  ................................ ................................ ...........  8', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 12}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n \\nx List of Tables  \\nTable 2.1: HTS Recommendations for Different Populations and Settings  ................................ ................................ ........ 3 \\nTable 2.2: Summary of HIV Testing Services Package  ................................ ................................ ................................ ..................  6 \\nTable 2.3: Presumptive Diagnosis of HIV in children <18 months while awaiting DNA PCR Results  ................  10 \\nTable 2 .4: Approaches to Improve Linkage to Treatment and Prevention Services  ................................ ..................  16', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 13}),\n",
       " Document(page_content='Table 2 .4: Approaches to Improve Linkage to Treatment and Prevention Services  ................................ ..................  16 \\nTable 2.5: Recommendations for Retesting HIV Negative C lients  ................................ ................................ .......................  18 \\nTable 3.1: Initial Clinical Evaluation for PLHIV (History and Physical Examination)  ................................ ...................  2 \\nTable 3.2: Baseline Laboratory Investigatio ns for PLHIV  ................................ ................................ ................................ ...........  4 \\nTable 3.3: Differentiated Care Based on Initial Patient Presentation  ................................ ................................ ...................  7', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 13}),\n",
       " Document(page_content='Table 3.4: Management of patients who are presenting well: WHO Stage 1 or 2, and CD4 count > 200 \\ncell/mm3  ................................ ................................ ................................ ................................ ................................ ................................ ............  8 \\nTable 3.5: Differentiated Follow -up of Patients Beyond the First 6 Months of ART  ................................ ......................  9 \\nTable 3.6: Summary of Clinical and Laboratory Monitoring for PLHIV1 ................................ ................................ ..........  11 \\nTable 4.1: Components of the Standard Package of Care for PLHIV  ................................ ................................ ......................  2', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 13}),\n",
       " Document(page_content='Table 4.2: Domains and Components for PHDP Serv ices ................................ ................................ ................................ ............  5 \\nTable 4.2a: Components of screening for GBV/IPV (LIVES)  ................................ ................................ ................................ ...... 7 \\nTable 4.3: Co -trimoxazole Preventive therapy  ................................ ................................ ................................ ................................ . 8 \\nTable 4.4: Daily Dose of Cotrimoxazole Preventive Therapy  ................................ ................................ ................................ .... 9', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 13}),\n",
       " Document(page_content='Table 4.5: Management of Drug -Associated Skin Rash  ................................ ................................ ................................ ................  9 \\nTable 4.6a: Standard Cotrimoxazole Desensitization Regimen (8 days)  ................................ ................................ ..........  10 \\nTable 4.6b: Rapid Cotrimoxazole Desensitization Regimen (6 hours)  ................................ ................................ ..............  10 \\nTable 4.7: Treatment of Cryptococcal Meningitis  ................................ ................................ ................................ ........................  12 \\nTable 4.8: Contraceptive Methods for PLHIV Based on WHO 2018 Medical Eligibility Criteria  ...........................  16', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 13}),\n",
       " Document(page_content='Table 4.8: Contraceptive Methods for PLHIV Based on WHO 2018 Medical Eligibility Criteria  ...........................  16 \\nTable 4.9: Pr e-Conception Counselling Messages and Services for PLHIV  ................................ ................................ ...... 17 \\nTable 4.10: Lifestyle Modifications to Prevent and Manage Cardiovascu lar Disease in PLHIV  ............................  19 \\nTable 4.11 : Hypertension Screening, Diagnosis, and Initial Management for Adult PLHIV  ................................ .... 20 \\nTable 4.12: Type 2 Diabetes Mellitus Screening, Dia gnosis, and Initial Management for PLHIV  .........................  21 \\nTable 4.12: Dyslipidemia Screening, Diagnosis, and Initial Management for PLHIV  ................................ ..................  22', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 13}),\n",
       " Document(page_content='Table 4.12: Dyslipidemia Screening, Diagnosis, and Initial Management for PLHIV  ................................ ..................  22 \\nTable 4.13: Chronic Kidney Disease Screening, Diagnosis, and Initial Management for PLHIV  ...........................  23 \\nTable 4.15: Patient Health Questionnaire -9 (PHQ -9) for Depression Screening  ................................ ..........................  26 \\nTable 4.16: CRAFFT Screening Interview for Adolescents  ................................ ................................ ................................ ...... 28 \\nTable 4.17: CAGE -AID Screening Questions for Adults  ................................ ................................ ................................ .............  29', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 13}),\n",
       " Document(page_content='Table 4.18: Addiction Support Based on Stages of Change  ................................ ................................ ................................ ..... 30 \\nTable 4.19: Interpretation of MUAC Results for Children and Pregnant/Lactating Women  ................................ .. 37 \\nTable 4.20: Interpretation of Z -scores for Children  ................................ ................................ ................................ ....................  37 \\nTable 4.21: Interpretation of BMI Results for Adults  ................................ ................................ ................................ .................  40 \\nTable 4.22: Kenya Expanded Program on Immunizations 2016 Schedule  ................................ ................................ ...... 40', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 13}),\n",
       " Document(page_content='xi Table 4.23: Vaccinations in Adolescents and Adults Living wit h HIV  ................................ ................................ ................  41 \\nTable 5.1: Treatment Preparation and Adherence Counselling Guide  ................................ ................................ .................  7 \\nTable 5.2: Components of HIV Education (see Annex 8 for detai led content guide)  ................................ ..................  10 \\nTable 5.3: Adherence Support and Retention Interventions  ................................ ................................ ................................ .. 11 \\nTable 5.4: ART Readiness Assessment Form  ................................ ................................ ................................ ................................ . 13', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 14}),\n",
       " Document(page_content='Table 5 .5: Age -appropriate Involvement of Child/Adolescent in HIV Education and Adherence Counselling\\n ................................ ................................ ................................ ................................ ................................ ................................ ..............................  15 \\nTable 5.6: Unique Considerations for Caregivers, Children and Adolescents  ................................ ................................  16 \\nTable 5.7: Treatment Preparation and Support for Chil dren (≤ 9 years) and Caregivers  ................................ ....... 17 \\nTable 5.8: Treatment Preparation and Support for Adolescents (10 -19 years)  ................................ ...........................  18', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 14}),\n",
       " Document(page_content='Table 5.8: Treatment Preparation and Support for Adolescents (10 -19 years)  ................................ ...........................  18 \\nTable 5.9: Treatment Preparation and Support for Adults  ................................ ................................ ................................ ..... 19 \\nTable 5.10: Adherence Monitoring Strategies  ................................ ................................ ................................ ...............................  21 \\nTable 5.11: Morisky Medication Adherence Scale (MMAS -4) ................................ ................................ ................................  23', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 14}),\n",
       " Document(page_content='Table 5.12: Morisky Medication Adherence Scale (MMAS -8) ................................ ................................ ................................  24 \\nTable 5.13: Adherence Rate Based on Pill Counts  ................................ ................................ ................................ .......................  25 \\nTable 5.14: Adherence Counselling and Support During the First 3 Months of ART  ................................ .................  26 \\nTable 5.15: Assessment for Barriers to Adherence  ................................ ................................ ................................ .....................  27 \\nTable 5.16: Adherence Counselling and Support for Patients with Viral Load < 50 copies/ml  ............................  29', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 14}),\n",
       " Document(page_content='Table 5.16: Adherence Counselling and Support for Patients with Viral Load < 50 copies/ml  ............................  29 \\nTable 5.17 Viral Load Monitoring Cut -Offs  ................................ ................................ ................................ ................................ ..... 30 \\nTable 5.18: Components of Enhanced Adherence Co unselling Sessions (Annex 9A for detailed content \\nguide)  ................................ ................................ ................................ ................................ ................................ ................................ .................  32', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 14}),\n",
       " Document(page_content='Table 6.1: Special Considerat ions for Timing of ART Initiation  ................................ ................................ ...............................  2 \\nTable 6.2: Preferred First -line ART Regimens and Dosing for Children, Adolescents and Adults 1 .......................  3 \\nTable 6.3: Use of Alternative ARVs in First -Line Regimens 1 ................................ ................................ ................................ .... 4 \\nTable 6.4: Dosing and Administration of Dolutegravir  ................................ ................................ ................................ ................  5', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 14}),\n",
       " Document(page_content='Table 6.5: Common Significant Adverse Drug Reactions  ................................ ................................ ................................ .........  10 \\nTable 6.6: ARV, CTX and Fluconazole Adjustments in Renal and Hepatic Impairment1 ................................ ...........  14 \\nTable 6.7: Management of AZT -Associated Bone Marrow Suppression  ................................ ................................ ...........  15 \\nTable 6.8: Management of Drug -Related Hepatotoxicity  ................................ ................................ ................................ .........  15 \\nTable 6.9: Diagnosis and Management of Abacavir Hypersensitivity Reaction  ................................ ............................  16', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 14}),\n",
       " Document(page_content='Table 6.9: Diagnosis and Management of Abacavir Hypersensitivity Reaction  ................................ ............................  16 \\nTable 6.10: Recommended Second -line ART Regimens in Infants, Children, Adolescents and Adults, \\nexcluding TB/HIV co -infection 1 ................................ ................................ ................................ ................................ ...........................  19 \\nTable 6.11: Possible Third -line ART in Children, Adolescents and Adults  ................................ ................................ ...... 21 \\nTable 7.1: Essential Package of Antenatal Care  ................................ ................................ ................................ ...............................  1', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 14}),\n",
       " Document(page_content='Table 7.2: Summary of Use of ART for HIV Positive Pregnant and Breastfeeding Women  ................................ ........ 3 \\nTable 7.3: ARV Prophylaxis for HIV -Exposed Infants  ................................ ................................ ................................ ...................  6 \\nTable 7.4: Dosing of ARVs for Infant Prophylaxis from Birth to 12 Weeks of Age  ................................ ..........................  7 \\nTable 7.5: NVP Dosing for Infant Prophylaxi s beyond 12 Weeks of Age *  ................................ ................................ ..........  7 \\nTable 7.6: AZT Dosing for Infant Prophylaxis beyond 12 Weeks of Age *  ................................ ................................ ..........  7', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 14}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n \\nxii Table 7.7: Complementary Foods for Children 6 -24 Months Old  ................................ ................................ ...........................  9 \\nTable 8.1: TB Diagnosis in Children <10 Years Old  ................................ ................................ ................................ ........................  6 \\nTable 8.2: Drug Susceptible TB Treatment Regimen for Children, Adolescents and Adults  ................................ ...... 7 \\nTable 8.3: Recommended TPT Regimens for PLHIV  ................................ ................................ ................................ ..................  10', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 15}),\n",
       " Document(page_content='Table 8.4: Grading and Management of DILI  ................................ ................................ ................................ ................................ .. 12 \\nTable 8.5: Management of TPT -Associated Skin Rash  ................................ ................................ ................................ ...............  13 \\nTable 8.6: Preferred ART Regimens for TB/HIV Co -infection for Patients Newly Initiating 1st Line ART 1 ... 14 \\nTable 8.7: Preferred ART Regimens for Patients who Develop TB while Virally Suppressed on 1st Line ART', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 15}),\n",
       " Document(page_content='Table 8.7: Preferred ART Regimens for Patients who Develop TB while Virally Suppressed on 1st Line ART \\n1,2 ................................ ................................ ................................ ................................ ................................ ................................ ..........................  15 \\nTable 8.8: Recommended ART Regimens for Patients who Develop TB while Failing 1st Line ART 1 ..............  16 \\nTable 9.1: Hepatitis B Vaccination Schedule for HIV -positive Adolescents and Adults  ................................ ...............  2 \\nTable 9.2: Summary of Initial Clinical and Laboratory Evaluation in HIV/HBV Co -infection  ................................ ... 3', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 15}),\n",
       " Document(page_content='Table 9.2: Summary of Initial Clinical and Laboratory Evaluation in HIV/HBV Co -infection  ................................ ... 3 \\nTable 9.3: Dose Adjustment of TDF and  3TC in Patients with Impaired Renal Function 1 ................................ .........  4 \\nTable 9.4: Summary of Initial Clinical and Laboratory Evaluation in HIV/HCV Co -infection  ................................ ... 6 \\nTable 9.5: Recommended DAA for the Treatment of HCV among PLHIV  ................................ ................................ ............  7 \\nTable 10.1: Recommended ARVs for PEP  ................................ ................................ ................................ ................................ ...........  1', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 15}),\n",
       " Document(page_content='Table 10.2: Recommendations for PEP Management and Follow -up ................................ ................................ ...................  3 \\nTable 10.3 Considerations for special circumstances  ................................ ................................ ................................ ...................  4 \\nTable 11:1 HIV Screening questions  ................................ ................................ ................................ ................................ .....................  2 \\nTable 11.2: Pre -Initiation Assessment Checklist  ................................ ................................ ................................ .............................  4', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 15}),\n",
       " Document(page_content='Table 11.3: Client Education Checklist  ................................ ................................ ................................ ................................ .................  5 \\nTable 11.4: Antiretrovirals for Use in PrEP  ................................ ................................ ................................ ................................ ....... 6 \\nTable 11. 5 Initial & follow up laboratory test  ................................ ................................ ................................ ................................ ... 9 \\nTable 11.6: Managing Clinical and Laboratory Results on Initial and Follow -up Assessment  ..............................  10', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 15}),\n",
       " Document(page_content='Table 11.6: Managing Clinical and Laboratory Results on Initial and Follow -up Assessment  ..............................  10 \\nTable 11.7: Summary of PrEP Initial and Follow -up Assessment  ................................ ................................ ........................  11 \\nTable 11.7 Cont: Summary of PrEP Initial and Follow -up Assessment  ................................ ................................ .............  12 \\nTable 12.1: Comprehensive Package of Harm Reduction for PWID  ................................ ................................ ......................  2 \\nTable 12.2: Summary of ART Recommendations for PWID  ................................ ................................ ................................ ....... 5', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 15}),\n",
       " Document(page_content='xiii Acronyms and Abbreviations  \\nAbbreviations and Names of Antiretroviral Drugs  Other Acronyms and Abbreviations  \\n3TC  Lamivudine  HTS  HIV Testing Services  \\nABC  Abacavir  ICF  Intensified Case Finding  \\nATV  Atazanavir  IEC  Information, Education and Communication  \\nATV/r  Atazanavir/ritonavir  INH  Isoniazid  \\nAZT  Zidovudine  INSTI  Integrase Strand Transfer Inhibitor  \\nDRV  Darunavir  IPD  In-Patient Department  \\nDRV/r  Darunavir/ritonavir  IPT  Isoniazid Preventive Therapy  \\nDTG  Dolutegravir  IPV Intimate Partner Violence  \\nEFV  Efavirenz  IRIS  Immune Reconstitution Inflammatory \\nSyndrome  \\nETR  Etravirine  ITN  Insecticide Treated Mosquito Nets  \\nFTC  Emtricitabine  IUD  Intrauterine Device  \\nLPV  Lopinavir  KEPI  Kenya Expanded Program of Immunization', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 16}),\n",
       " Document(page_content='FTC  Emtricitabine  IUD  Intrauterine Device  \\nLPV  Lopinavir  KEPI  Kenya Expanded Program of Immunization  \\nLPV/r  Lopinavir/ritonavir  KS  Kaposi’s Sarcoma  \\nNVP        Nevirapine  LEEP  Loop Electrosurgical Excision Procedure  \\nRAL                                Raltegravir  L&D  Labor And Delivery  \\nRTV  Ritonavir  LIVES  Listen, Inquiry, Validate, Enhance Safety and \\nSupport  \\nTDF  Tenofovir Disoproxil Fumarate  LLV  Low Level Viremia  \\nOther Acronyms and Abbreviations  LRF  Laboratory Requisition Form  \\nACE -I Angiotensin -Converting Enzyme Inhibitor  LP Lumbar Puncture  \\nADR  Adverse Drug Reaction  MAC  Mycobacterium Avium Complex  \\nAIDS  Acquired Immunodeficiency Syndrome  MAT  Medically Assisted Therapy  \\nALT  Alanine Transaminase  MCH  Maternal Child Health', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 16}),\n",
       " Document(page_content='AIDS  Acquired Immunodeficiency Syndrome  MAT  Medically Assisted Therapy  \\nALT  Alanine Transaminase  MCH  Maternal Child Health  \\nALP  Alkaline Phosphatase  MNCH/FP  Maternal, Neonatal and Child Health/Family \\nPlanning  \\nAHI Acute Hiv Infection  MDT  Multi -Disciplinary Team  \\nANC  Antenatal Care  MEC  Medical Eligibility Criteria  \\nA&E  Accident And Emergency  MOH  Ministry of Health  \\nARB  Angiotensin -Receptor Blocker  MSM  Men Who Have Sex with Men  \\nART  Antiretroviral Therapy  MUAC  Mid -Upper Arm Circumference  \\nARV  Antiretroviral Drug(S)  NACS  Nutritional Assessment, Counselling and \\nSupport  \\nAST  Aspartate Transaminase  NASCOP  National AIDS And STI Control Program  \\nBD Twice Daily  NCD  Non -Communicable Diseases', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 16}),\n",
       " Document(page_content='Support  \\nAST  Aspartate Transaminase  NASCOP  National AIDS And STI Control Program  \\nBD Twice Daily  NCD  Non -Communicable Diseases  \\nBF Breastfeeding  NHRL  National H IV Reference Laboratory  \\nBMI  Body Mass Index  NNRTI  Non -Nucleoside Reverse Transcriptase \\nInhibitor  \\nBP Blood Pressure  NRTI  Nucleoside Reverse Transcriptase Inhibitor  \\nCAG  Community Art Groups  NSP  Needle and Syringe Programmes  \\nCCC  Comprehensive Care Centre  NRTI  Nucleotide Reverse Transcriptase Inhibitor  \\nCrCl  Creatinine Clearance  OD  Once Daily', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 16}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n \\nxiv CHV  Community Health Volunteer  OI  Opportunistic Infection  \\nCITC  Client -Initiated HIV Testing and Counselling  OPD  Outpatient Department  \\nCM Cryptococcal Meningitis  OST  Opioid Substitution Therapy  \\nCMV  Cytomegalovirus  OVC  Orphans And Vulnerable Children  \\nCNS  Central Nervous System  PCP  Pneumocystis Jirovecii Pneumonia  \\nCPT  Cotrimoxazole Preventive Therapy  PCR  Polymerase Chain Reaction  \\nCrCl  Creatinine Clearance  PEP  Post -Exposure Prophylaxis  \\nCTX  Cotrimoxazole  PrEP  Pre-Exposure Prophylaxis  \\nCYP450  Cytochrome P450  PGL  Persistent Generalized Lymphadenopathy  \\nDAAs  Direct Acting Antiviral Therapies  PHQ -9  Patient Health Questionnaire -9', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 17}),\n",
       " Document(page_content='DAAs  Direct Acting Antiviral Therapies  PHQ -9  Patient Health Questionnaire -9 \\nDBS  Dried Blood Spot  PHDP  Positive Health, Dignity, and Prevention  \\nDICEs  Drop -In-Centres  PI  Protease Inhibitor  \\nDMS  Director of Medical Services  PITC  Provider Initiated HIV Testing and Counselling  \\nDNA  Deoxyribonucleic acid  PLHIV  People Living With HIV  \\nDOT  Directly observed therapy  PLLV  Persistent Low-level Viremia  \\nDS Double strength  PML                                 Progressive Multifocal Leukoencephalopathy  \\nDRT  Drug Resistance Testing  PMTCT                           Prevention of mother -to-child transmission  \\nED - PrEP  Event Driven PrEP  PPE                                  Papular Pruritic Eruptions  \\nEDTA  Ethylenediaminetetraacetic acid  PrEP  Pre-exposure Prophylaxis', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 17}),\n",
       " Document(page_content='EDTA  Ethylenediaminetetraacetic acid  PrEP  Pre-exposure Prophylaxis  \\nECP  Emergency contraceptive pill  PTB  Pulmonary Tuberculosis  \\nEID  Early Infant Diagnosis  PWID  People Who Inject Drugs  \\neMTCT  Elimination of Mother to Child Transmission  NHCSC  National HIV Clinical Support Centre  \\nEPTB  Extra -pulmonary Tuberculosis  RAST  Rapid Assessment Tool  \\nFDA  Food and Drug Administration  RNA  Ribonucleic Acid \\nFBC  Full Blood Count  RPR  Rapid Plasma Reagin  \\nFBS Fasting Blood Sugar  sCrAg  Serum Cryptococcal Antigen  \\nFDC  Fixed Dose Combination  SRH  Sexual and Reproductive Health  \\nFLP  Fasting Lipid Profile  SS  Single Strength  \\nFP  Family Planning  STI  Sexually Transmitted Infection  \\nFTC  Emtriciatabine  TB  Tuberculosis', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 17}),\n",
       " Document(page_content='FLP  Fasting Lipid Profile  SS  Single Strength  \\nFP  Family Planning  STI  Sexually Transmitted Infection  \\nFTC  Emtriciatabine  TB  Tuberculosis  \\nGIT  Gastro -intestinal tract  TB LAM  Tuberculosis Lipoarabinomannan  \\nGOK  Government of Kenya  TDF  Tenofovir  \\nGBV  Gender -Based Violence  TT Tetanus Toxoid  \\nHb  Hemoglobin  TWG  Technical Working Group  \\nHBV  Hepatitis B virus  ULN  Upper Limit of Normal  \\nHBsAg  Hepatitis B Surface Antigen  UTI Urinary Tract Infection  \\nHCV  Hepatitis C Virus  VIA  Visual Inspection with Acetic Acid  \\nHCW  Health Care Worker  VILI  Visual Inspection with Lugol’s Iodine  \\nHEI  HIV Exposed Infant  VL  Viral Load  \\nHIV  Human immunodeficiency Virus  VMMC  Voluntary Medical Male Circumcision  \\nHIVST  HIV Self-testing  WHO  World Health Organization', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 17}),\n",
       " Document(page_content='Summary of Key Recommendations  \\n1 - 1   \\n1. Summary of Key Recommendations  \\n \\n1.1 HIV Testing Services (HTS) and Linkage to Treatment and Prevention  \\n• HIV testing should be voluntary and conducted ethically in an environment where \\nConsent, Confidentiality, Counselling, Correct results, Connection (linkage) and Creating \\nan enabling environment can be assured  \\n• To optimize access to testing services, HIV testing can be conducted in 2 different settings:  \\n▪ Facility -based  \\n▪ Community -based  \\n• Targeted HIV testing is recommended which involves index client listing of contacts, HIV \\nself-testing and use of HTS screening tool to identify people at risk of HIV infection as \\neligible for testing', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 18}),\n",
       " Document(page_content='self-testing and use of HTS screening tool to identify people at risk of HIV infection as \\neligible for testing  \\n• Serial testing, using ap proved rapid HIV antibody testing kits, is used to diagnose HIV \\ninfection in children older than 18 months, adolescents, and adults. An HIV -positive \\ndiagnosis will be made using three consecutive reactive assays  \\n \\n1.2 Initial Evaluation and Follow -up for PLHIV  \\n● Initial clinical evaluation of PLHIV entails CD4 monitoring, which is recommended for:  \\n▪ Baseline investigation for all PLHIV  \\n▪ Any patient with suspected treatment failure  \\n▪ Any patient returning to care after interrupting treatment for > 3 months  \\n▪ Any patient on fluconazole maintenance therapy or on dapsone as prophylaxis, to', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 18}),\n",
       " Document(page_content='▪ Any patient on fluconazole maintenance therapy or on dapsone as prophylaxis, to \\ndetermine when prophylaxis can be discontinued  \\n● Advanced HIV Disease is defined as:  \\n▪ Adults, adolescents, and children five years and older as having a CD4 cell count of \\nless than 200 cells/mm3 or \\n▪ WHO clinical stage 3 or 4 disease  \\n▪ All children younger than five years  \\n● All PLHIV presenting with Advanced HIV Disease (AHD) should be offered a package of \\ncare that includes timely initiation of ART, screening, diagnosis, prophyl axis, and \\nmanagement  of opportunistic infections.  \\n● Frequency of routine VL monitoring:  \\n▪ For PCR positive HEIs: at baseline (at the time of ART initiation)  \\n▪ Age 0 -24 years old: 3 months after ART initiation, and then every 6 months', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 18}),\n",
       " Document(page_content='▪ Age 0 -24 years old: 3 months after ART initiation, and then every 6 months  \\n▪ Age ≥ 25 years old: 3 months after ART initiation, then at month 12, and then annually', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 18}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n1 - 2  ▪ Pregnant or breastfeeding: at confirmation of pregnancy (if already on ART) or 3 \\nmonths after ART initiation (if ART initiated during pregnancy/breastfeeding), and \\nthen every 6 months until c omplete cessation of breastfeeding  \\n▪ Before any drug substitution (if no VL result available from the prior 6 months)  \\n▪ Three months after any regimen modification (including single -drug substitution)  \\n● PLHIV should receive differentiated care based on initial e valuation (advanced vs. well) \\nand follow up (established vs not established on ART)  \\n \\n1.3 Standard Package of Care for PLHIV  \\nConsists of 8 components:  \\n1. Antiretroviral Therapy  \\n▪ All PLHIV are eligible for ART irrespective of CD4 cell count or percentage, WHO', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 19}),\n",
       " Document(page_content='Consists of 8 components:  \\n1. Antiretroviral Therapy  \\n▪ All PLHIV are eligible for ART irrespective of CD4 cell count or percentage, WHO \\nclinical stage, age, pregnancy status, or comorbidities  \\n▪ ART should be initiated as soon as the patient is ready to start, preferably within \\ntwo weeks from time of HIV diagnosis (except for patients with cryptococcal \\nmeningitis or TB meningi tis) \\n2. Positive Health, Dignity, and Prevention, GBV/IPV & HIV Education and Counselling  \\n▪ All patients should be counselled and supported for disclosure of HIV status; \\npartner/ family testing and engagement; condom use; family planning; sexually \\ntransmitted infections screening; treatment adherence; and pre -exposure \\nprophylaxis for HIV -negative sexual partners', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 19}),\n",
       " Document(page_content='transmitted infections screening; treatment adherence; and pre -exposure \\nprophylaxis for HIV -negative sexual partners  \\n▪ All females aged 15 -49 years and emancipated minors accessing HIV care services \\nshould be screened for Intimate Partner Violence (IPV) as p art of the standard \\npackage of care  \\n▪ All PLHIV should be provided with HIV education and counselling  \\n3. Screening for and Prevention of Specific Opportunistic Infections  \\nCotrimoxazole Preventive Therapy (CPT) is no longer recommended as life -long \\nprophylaxis, and is only recommended in the following sub populations, unless they \\nhave an allergy to sulfur drugs or develop toxicity from CPT  \\n● All HIV Exposed Infants  \\n● HIV infected children < 15 years of age  \\n● All PLHIV > 15 years of age:', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 19}),\n",
       " Document(page_content='● All HIV Exposed Infants  \\n● HIV infected children < 15 years of age  \\n● All PLHIV > 15 years of age:  \\no Living in malaria -endemic zones  (Refer to the National Guidelines for the \\nDiagnosis, Treatment and Prevention of Malaria in Kenya for the current Kenya \\nMalaria endemicity map)  \\no Presenting with WHO stage 3 or 4 event, or meeting the AHD criteria  \\no Suspected treatment fa ilure  \\n● All Pregnant and Breast -feeding women', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 19}),\n",
       " Document(page_content='Summary of Key Recommendations  \\n1 - 3  ▪ When dapsone (as a substitute for CPT) is being used as PCP prophylaxis, it is only \\nrecommended for patients in WHO Stage 4 and/or absolute CD4 count ≤ 200 \\ncells/mm3 (or CD4% ≤ 25% for children ≤ 5 years old), and should be discontinued \\nonce a patient achieves viral suppression and a sustained CD4 count of > 200 \\ncell/mm3 (or > 25% for children ≤ 5 years old) for at least 6 months  \\n▪ All PLHIV should be screened for TB at  every visit using the Intensified Case Finding \\n(ICF) tool and assessed for TB Preventive Therapy (TPT) if screened negative for TB  \\n▪ All adolescent and adult PLHIV with a baseline CD4 count of ≤ 200 cells/mm3 should \\nbe screened for cryptococcal infection us ing the serum CrAg test  \\n4. Reproductive Health Services', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 20}),\n",
       " Document(page_content='be screened for cryptococcal infection us ing the serum CrAg test  \\n4. Reproductive Health Services  \\n▪ All PLHIV should be screened for STI at every clinic visit  \\n▪ Pregnancy status should be determined for all women of reproductive age at every \\nvisit and their contraception need determined and met  \\n▪ All HIV p ositive women between the ages of 18 - 65 years should be screened for \\ncervical cancer (HPV testing conducted every 2 years or Annually if using VIA -VILI)  \\n5. Screening for and Management of Non -Communicable Diseases  \\n▪ All PLHIV should be screened for hypertension, diabetes mellitus, dyslipidaemia, \\nand renal disease annually.  \\n▪ Routine screening should be provided for early detection of cervical cancer, breast \\ncancer, bowel cancer, and prostate cancer', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 20}),\n",
       " Document(page_content='▪ Routine screening should be provided for early detection of cervical cancer, breast \\ncancer, bowel cancer, and prostate cancer  \\n6. Mental Health Screening and Management  \\n▪ All PLHIV should receive basic screening for depression  and anxiety  before initiating \\nART, and annually thereafter, and whenever there is a clinical suspicion  \\n▪ All PLHIV should be provided for and linked with support structures to maintain \\ngeneral well -being  addressi ng issues that could affect their mental health  \\n▪ All adults and adolescents should be screened for alcohol and drug use before \\ninitiating ART and regularly during follow -up \\n▪ All caregivers should also receive baseline and follow -up screening for depression \\nand alcohol/drug use  \\n7. Nutrition Services', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 20}),\n",
       " Document(page_content='▪ All caregivers should also receive baseline and follow -up screening for depression \\nand alcohol/drug use  \\n7. Nutrition Services  \\n▪ All PLHIV should receive nutritional assessment, counselling, and support tailored \\nto the individual needs of the patients  \\n▪ All infants irrespective of HIV status should be exclusively breastfed for the first 6 \\nmonths  of life, with timely introduction of appropriate complementary foods after \\n6 months, and continued breastfeeding up to 24 months or beyond  \\n8. Prevention of Other Infections  \\n▪ PLHIV (including children) should receive vaccinations as recommended by the \\nNational  Vaccines and Immunization Program  \\n▪ All PLHIV should receive vaccination for COVID -19 following national guidelines for \\nage and dosing', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 20}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n1 - 4  1.4 Adherence Preparation, Monitoring and Support  \\n• The adherence preparation, monitoring, and support that a patient requires should be \\ntailored to their level of adherence and the stage of ART initiation and follow -up \\n• All patients with durable viral suppression (2 consecutive viral load results with < 50 \\ncopies) should be offered messaging on Undetectable=Untrans mittable (U=U).  \\n• Whenever possible, follow -up should be provided by the same care provider or team of \\ncare providers (e.g., same clinician and counsellor) at every visit. This is particularly \\nimportant during the first 3 months in care  \\n• For all children/adol escents, the level of disclosure should be assessed at the first visit.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 21}),\n",
       " Document(page_content='important during the first 3 months in care  \\n• For all children/adol escents, the level of disclosure should be assessed at the first visit. \\nOngoing care should include a plan for age -appropriate disclosure  \\n• All patients are at risk of new or worsening barriers to adherence, so adherence \\nmonitoring, counselling and support s hould continue despite viral suppression  \\n• Every service delivery point that is providing ARVs for patients (whether ART, PEP, or \\nPrEP) must have a functional system for identifying patients who miss appointments and \\nfor taking action within 24 hours of a mi ssed appointment  \\n• In patients failing ART, do not change regimens until the reason/s for treatment failure \\nhave been identified and addressed (which should be done urgently using a case -', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 21}),\n",
       " Document(page_content='have been identified and addressed (which should be done urgently using a case -\\nmanagement approach)  \\n1.5 Antiretroviral Therapy for Infants, Children, Adolescents, and Adults  \\n• The goal of ART is to suppress viral replication with the aim of reducing the patient’s VL \\nto undetectable levels (Viral Load <50 copies/LD L) \\n• All individuals with confirmed HIV infection are eligible for ART, irrespective of CD4 \\ncount/%, WHO clinical stage, age, pregnancy or breastfeeding status, co -infection status, \\nrisk group, or any other criteria, provided that the individual is willing and ready to start \\nART  \\n• ART should be started in all patients as soon as possible, even on the  same day as \\nconfirming their HIV diagnosis (and preferably within 2 weeks)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 21}),\n",
       " Document(page_content='confirming their HIV diagnosis (and preferably within 2 weeks)  \\n• Preferred first -line ART for infants, children, adolescents and adults  \\n▪ Birth to 4 weeks: AZT + 3TC + NVP  \\n▪ > 4 weeks to < 15 years old  \\n▪ < 30 kg: ABC + 3TC + DTG  \\n▪ ≥ 30 kg: TDF + 3TC + DTG  \\n▪ ≥ 15 years old: TDF + 3TC + DTG  \\n• Children and adolescents who are virally suppressed but are NOT on the preferred first -\\nline ART regimen should be assessed for transition and transitioned to the preferred \\nregimen  \\n• Treatment failure is suspected when a pa tient has a VL ≥ 100 0 copies/ml after at least 3 \\nmonths of using ART. Treatment failure is only confirmed when VL is ≥ 1,000 copies/ml \\nafter assessing for and addressing poor adherence or other reasons for high VL, and then', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 21}),\n",
       " Document(page_content='after assessing for and addressing poor adherence or other reasons for high VL, and then \\nrepeating VL after at least 3 mo nths of excellent adherence to allow for viral re -\\nsuppression', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 21}),\n",
       " Document(page_content='Summary of Key Recommendations  \\n1 - 5  • Persistent low -level viremia ( pLLV) is defined as having VL 200 - 999 copies/ml on two \\nor more consecutive measures. These patients are at increased risk of progression to \\ntreatment failure, dev elopment of ARV resistance and death and therefore require a \\nsimilar case management approach as patients with an initial VL ≥ 1,000 copies/ml  \\n• All PLHIV with a detectable VL ≥ 200 copies/ ml (unsuppressed) : assess for and address \\npotential reasons for virem ia, including intensifying adherence support, and repeat the \\nVL after 3 months of excellent adherence  \\n▪ If the repeat VL is < 200  copies/ml ( suppres sed) then continue routine \\nmonitoring  \\n▪ If the repeat VL is ≥ 1,000 copies/ml (suspected treatment failure), prepare for', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 22}),\n",
       " Document(page_content='monitoring  \\n▪ If the repeat VL is ≥ 1,000 copies/ml (suspected treatment failure), prepare for \\nchange to an effective regimen (Figure 5.2 and Table 6.10)  \\n▪ If the repeat VL is 200 - 999 copies/ml (low level viremia),  reassess adherence \\nand other causes of viremia and repeat VL after another 3 months of excellent \\nadherence  \\n1.6 Pre vention of Mother to Child Transmission of HIV/Syphilis/HBV  \\n• Prevention of mother -to-child transmission (PMTCT) of HIV,  Syphilis and Hepatitis B  \\n(triple elimination ) should be offered as part of a comprehensive package of fully \\nintegrated, routine antenatal  care interventions  \\n• All pregnant women, unless known positive, should be counseled and tested for HIV,', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 22}),\n",
       " Document(page_content='integrated, routine antenatal  care interventions  \\n• All pregnant women, unless known positive, should be counseled and tested for HIV, \\nSyphilis (using the HIV -Syphilis dual test) and HBV during their first ANC visit, and if \\nnegative a repeat HIV -Syphilis dual test should be performed in the 3rd trimester.  \\n• Lifelong ART should be initiated in all pregnant and breastfeeding women living \\nwith HIV, regardless of gestational age, WHO clinical stage or CD4 count  \\n• ART should be started as soon as possible, ideally on the same day HIV diagnosis is  made, \\nwith ongoing enhanced adherence support  \\n• The preferred first line ART regimen for pregnant and breastfeeding women is TDF + 3TC \\n+ DTG  \\n• For pregnant and breastfeeding women newly initiated on ART, obtain VL 3 months after', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 22}),\n",
       " Document(page_content='+ DTG  \\n• For pregnant and breastfeeding women newly initiated on ART, obtain VL 3 months after \\ninitiation, and then every 6 m onths until complete cessation of breastfeeding  \\n• For HIV positive women already on ART at the time of confirming pregnancy or \\nbreastfeeding, obtain a VL irrespective of when prior VL was done, and then every 6 \\nmonths until complete cessation of breastfeeding  \\n• For pregnant or breastfeeding women with a VL ≥ 200 copies/m l (unsuppressed ): assess \\nfor and address potential reasons for viremia, including intensifying adherence support, \\nand repeat the VL after 3 months of excellent adherence  \\n▪ If the repea t VL is < 200  copies/ml (suppressed) then continue routine \\nmonitoring', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 22}),\n",
       " Document(page_content='and repeat the VL after 3 months of excellent adherence  \\n▪ If the repea t VL is < 200  copies/ml (suppressed) then continue routine \\nmonitoring  \\n▪ If the repeat VL is ≥ 1,000 copies/ml (treatment failure), prepare for change to \\nan effective regimen  \\n▪ If the repeat VL is 200  - 999 copies/ml ( low level viremia ), reassess adherence \\nand other causes of viremia and consult the Regional or National TWG', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 22}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n1 - 6  • All HIV exposed infants (HEI) should be tested with DNA PCR within 6 weeks of age or \\nfirst contact thereafter; if negative then another DNA PCR at 6 months, and if negative \\nthen  repeat DNA PCR at 12 months.  \\n• All HEI should receive infant ARV prophylaxis consisting of 6 weeks of AZT + NVP and \\nthereafter NVP should be continued until 6 weeks after complete cessation of \\nbreastfeeding  \\n• All infants irrespective of HIV status should be exclusively breastfed for the first 6 months \\nof life, with timely introduction of appropriate complementary foods after 6 months, and \\ncontinued breastfeeding up to 24 months or beyond  \\n \\n1.7 TB/HIV Co -infection Prevention and Management', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 23}),\n",
       " Document(page_content='continued breastfeeding up to 24 months or beyond  \\n \\n1.7 TB/HIV Co -infection Prevention and Management  \\n• All healthcare settings should implement TB infection control recommendations to \\nreduce the risk of transmission of TB among patients, visitors and staff  \\n• Symptom -based TB screening using the ICF tool MUST be performed for all PLHIV at \\nevery clinic visit  \\n▪ Patien ts who screen negative should be assessed for and provided with TB \\npreventive therapy (TPT)  \\n▪ Patients who screen positive (presumptive TB) must complete definitive diagnostic \\npathways  \\n• The GeneXpert Ultra MTB/Rif test is the preferred test for diagnosis of T B and \\nrifampicin resistance in all presumptive TB cases  \\n• TB-LAM can be used as an adjunct rapid point -of-care diagnostic test for PLHIV: with', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 23}),\n",
       " Document(page_content='rifampicin resistance in all presumptive TB cases  \\n• TB-LAM can be used as an adjunct rapid point -of-care diagnostic test for PLHIV: with \\nadvanced HIV disease (WHO stage 3 or 4 or CD4 count ≤ 200 cells/mm3 (or CD4% ≤ 25% \\nfor children ≤ 5 years)) with presumptive TB, or; any danger signs of severe illness, or; \\ncurrently admitted to hospital  \\n• Patients diagnosed with TB/HIV co -infection should start anti -TB treatment immediately \\nand initiate ART as soon as anti -TB medications are tolerated, preferably within 2 weeks \\n(unless they have TB meningitis, in which case ART should be deferred for 4 to 8 weeks)  \\n• Patients with TB/HIV co -infection who are already on ART should start anti -TB treatment \\nimmediately and continu e ART, making any required adjustments to the ART regimen', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 23}),\n",
       " Document(page_content='immediately and continu e ART, making any required adjustments to the ART regimen \\nbased on known drug -drug interactions and monitoring toxicity  \\n• Always assess for ART failure in patients who develop TB after being on ART for ≥ 6 \\nmonths', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 23}),\n",
       " Document(page_content='Summary of Key Recommendations  \\n1 - 7  1.8 HBV/HIV and HCV/HIV Co -infection Preve ntion and Management  \\n• All HIV positive adolescents and adults should be screened for HBV infection, using serum \\nHBsAg, as part of initial evaluation; children who did not complete routine childhood \\nimmunizations should also be screened for HBV and vaccinat ed if negative.  \\n• PLHIV without evidence of hepatitis B infection (HBsAg negative) should be vaccinated \\nagainst hepatitis B  \\n• The recommended first -line ART for adults with HIV/HBV co -infection is TDF+ 3TC + DTG  \\n• HCV serology should be offered to individuals at  risk of HCV infection  \\n• Direct acting antiviral therapies (DAAs) for treatment of HCV have simplified the \\nmanagement of HIV/HCV co -infection', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 24}),\n",
       " Document(page_content='• Direct acting antiviral therapies (DAAs) for treatment of HCV have simplified the \\nmanagement of HIV/HCV co -infection  \\n \\n1.9 ARVs for Post -exposure Prophylaxis (PEP)  \\n• PEP should be offered as soon as possible (< 72 hours) after high -risk exposure  \\n• The recommended ARV agents for PEP are  \\n▪  <15 years old  \\n▪ < 30 kg: ABC + 3TC + DTG  \\n▪ ≥ 30 kg: TDF + 3TC + DTG  \\n▪ ≥ 15 years old  \\n▪ TDF + 3TC + DTG  \\n \\n1.10 Pre -Exposure Prophylaxis (PrEP)  \\n• PrEP should be offered to HIV negative individuals at substantial ongoing risk of HIV \\ninfection (including the seronegative partner in a discordant relationship)  \\n•  PrEP works if taken as prescribed . However, it does not prevent other STIs or unintended \\npregnancies, therefore, additional protection should be of fered.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 24}),\n",
       " Document(page_content='pregnancies, therefore, additional protection should be of fered.  \\n• PrEP should only be offered to clients  ≥15 years of age who are sexually active after \\neligibility assessment using  the following parameters:  \\n▪ Laboratory: HIV negative  \\n▪ Medical (for oral PrEP): no contraindication to TDF; no severe renal diseases; wei ght \\n≥ 30 kg  \\n▪ Client readiness: client must be willing to take PrEP as prescribed, and adhere to \\nassociated follow up and HIV testing (at enrollment, at month 1 and thereafter every \\n3 months)  \\n• The recommended ARV regimen for Oral PrEP is TDF/FTC (alternative  TDF/3TC), \\navailable in two dosing strategies:  \\n▪ Daily oral PrEP: TDF (300 mg) + FTC (200 mg) once daily  \\n▪ Event -driven PrEP : Event driven PrEP is where oral PrEP is used in men having sex', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 24}),\n",
       " Document(page_content='▪ Daily oral PrEP: TDF (300 mg) + FTC (200 mg) once daily  \\n▪ Event -driven PrEP : Event driven PrEP is where oral PrEP is used in men having sex \\nwith men when an isolated sexual act is anticipated. The dose is two pills of TDF/FTC \\ntaken between 2 and 24 hours (preferably closer to 24h) before the anticipated \\nsexual act; then, a third pill taken 24 hours after the first two pills; and then a fourth \\npill taken 24 hours after the third pill (“2+1+1”).', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 24}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n1 - 8  1.11 People Who I nject Drugs (PWID) and HIV  \\n• PWID should be offered regular HIV testing and counselling and be linked to   \\ncomprehensive HIV treatment and prevention services including harm reduction \\ncounselling and support  \\n• The recommended first -line ART for adult PWID is T DF + 3TC + DTG  \\n• PWID should be offered screening, diagnosis, treatment and prevention of STIs as part of \\ncomprehensive HIV prevention and care  \\n• PWID should have the same access to TB prevention, screening and treatment services as \\nother populations at risk o f or living with HIV  \\n• PWID should be screened for HBV (by HBsAg) and HCV (by HCV serology) at first contact', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 25}),\n",
       " Document(page_content='other populations at risk o f or living with HIV  \\n• PWID should be screened for HBV (by HBsAg) and HCV (by HCV serology) at first contact  \\n• All PWID should be linked to Needle and Syringe Programs (NSP) to access sterile \\ninjecting equipment  \\n• All PWID should be linked to Medically Assisted Therapy (MAT)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 25}),\n",
       " Document(page_content='HIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 1   \\n2. HIV Testing Services and Linkage to Treatment \\nand Prevention  \\nHIV testing services (HTS) provide the first critical link to comprehensive HIV treatment and \\nprevention services such as voluntary medical male circumcision (VMMC), pre -exposure \\nprophylaxis (PrEP), post -exposure prophylaxis (P EP) and other combination HIV prevention \\nservices. In addition, this initial step also provides opportunities to offer other interventions such \\nas sexual and reproductive health services (SRH), TB screening and referral, and substance abuse \\nscreening and r eferral.  \\nHIV testing should be voluntary and conducted ethically in an environment where the six Cs', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 26}),\n",
       " Document(page_content='screening and r eferral.  \\nHIV testing should be voluntary and conducted ethically in an environment where the six Cs \\nprinciples of Consent, Confidentiality, Counselling, Correct results, Connection (linkage) to care and \\nother appropriate post -test services and creating an  enabling environment are adhered to . \\nTargeted HIV testing  is the major strategic shift, involving index client listing of contacts, HIV self -\\ntesting and use of HIV screening tools to identify people at risk of HIV infection as eligible for \\ntesting, except in the case of PMTCT and key populations.  \\n2.1 Settings fo r HIV Testing  \\nIn Kenya, HTS is delivered in two broad settings: facility -based and community -based settings  \\n2.1.1 Facility -based testing', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 26}),\n",
       " Document(page_content='In Kenya, HTS is delivered in two broad settings: facility -based and community -based settings  \\n2.1.1 Facility -based testing  \\n● The HTS screening tool should be used to facilitate prioritization of testing for persons at risk \\nof HIV infection; those diagnosed with sexually transmitted infections, with multiple sexual \\npartners, key populations, and those with possible or known HIV exposures, such as sexual or \\nneedle sharing partner of a person living with HIV or of a person of unknown HIV status  \\n● Providers should undertake a thorough risk assessment using the validated NASCOP screening \\ntools (Annex 17) to identify clients at risk and those eligible for a HIV test.  \\n● HTS should be offered only to clients who consent', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 26}),\n",
       " Document(page_content='tools (Annex 17) to identify clients at risk and those eligible for a HIV test.  \\n● HTS should be offered only to clients who consent  \\n● Clients who are not eli gible for testing should receive HIV prevention messages and be offered \\nservices as appropriate  \\n● Clients who test HIV positive should be linked to care while those who test negative should be \\nlinked to HIV prevention services  \\n● Patients starting HIV care shou ld receive disclosure counselling and support, and be offered \\nfamily, sexual and needle -sharing partner testing  \\nAs much as possible, HIV testing services should be integrated into care pathways at all service \\ndelivery points including adult and pediatric i npatient units, outpatient units, maternal and child', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 26}),\n",
       " Document(page_content='delivery points including adult and pediatric i npatient units, outpatient units, maternal and child \\nhealth clinics, SRH/family planning clinics, TB clinics, specialty clinics, gender -based violence \\n(GBV) care units and service delivery points for key and priority populations.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 26}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 2  2.1.2 Community –based t esting  \\nTargeted community based HTS offers additional opportunities to identify and link people to HIV \\ntreatment and prevention. This setting is especially important for testing children and partners of \\nindex clients through index testing , as well as  outreach to key and priority populations, orphans, \\nand vulnerable children (OVCs), adolescents, youth and targeted testing in workplaces.  \\n2.2 HTS strategies  \\nThe major HTS strategies to identify people living with HIV but unaware of their status are:  \\n2.2.1 HIV Self -Testing (HIVST)  \\n● HIVST allows individuals to collect their own specimen, perform the test, and interpret the', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 27}),\n",
       " Document(page_content='2.2.1 HIV Self -Testing (HIVST)  \\n● HIVST allows individuals to collect their own specimen, perform the test, and interpret the \\nresults on their own, conducted either within a health facility, at home or in any other \\nconvenient place.  \\nHIVST can be  conducted with o r without direct assistance by a trained person.  \\n● HIVST is a screening test and is not sufficient to make an HIV -positive diagnosis. A reactive \\n(positive) self -test result should therefore be confirmed using the validated national testing \\nalgorithm by an H TS-trained service provider.  \\n● HIVST should be performed using MoH approved HIV rapid diagnostic test kits that are either \\nblood -based or oral fluid based.  \\n● HIVST may have the greatest benefit in reaching specific populations such as partners of newly', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 27}),\n",
       " Document(page_content='blood -based or oral fluid based.  \\n● HIVST may have the greatest benefit in reaching specific populations such as partners of newly \\ndiagnosed PLHIV; partners of pregnant women attending antenatal care (ANC); contacts of \\npatients treated for STIs; hard -to-reach populations such as men, adolescents, and young \\npeople, as well as key populations, such as MSM and sex workers.  \\nHIVST is a scr eening test and does not provide a diagnosis.  \\nAll reactive (positive) self -test results must be confirmed in a health facility according to \\nnationally set standards  \\n2.2.2 Index Testing  referred to as partner testing/partner notification services, is an approach \\nwhereby the exposed contacts (i.e., sexual partners, biological children and anyone with whom a', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 27}),\n",
       " Document(page_content='whereby the exposed contacts (i.e., sexual partners, biological children and anyone with whom a \\nneedle was shared) of an HIV -positive person (i.e., index client), are elicited and offered HIV testing \\nservices  \\n2.2.3 Voluntary Counselling and Testin g (VCT):  This involves provision of targeted HIV \\ntesting to clients who willingly present to HTS facilities for testing for diverse reasons, including \\nself-assessed risk.  \\n2.2.4 Social Network Strategy (SNS) - this involves offering to index clients self -guided options \\nto informally extend links to HIV testing and other services to a broader set of social -, sexual -, \\nand injecting -network members who have an elevated risk of HIV infection. The index client for', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 27}),\n",
       " Document(page_content='and injecting -network members who have an elevated risk of HIV infection. The index client for \\nSNS can either be PLHIV or HIV negative persons wi th increased risk for HIV infection . \\nProviding targeted HTS for different populations and in different settings increases opportunities \\nfor access to knowledge of HIV status and to a range of HIV treatment and prevention services. \\nTable 2.1 summarizes key recommendations for HTS for different sub -populations.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 27}),\n",
       " Document(page_content='HIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 3  Table 2.1: HTS R ecommendations for Different Populations and Settings  \\nPopulation  Recommendation  \\nBirth testing of \\ninfants born to \\nknown HIV - \\npositive mothers \\n(Figure 2.2)  ● Birth testing (HIV testing of infants at birth or at first contact within 2 weeks after \\nbirth) can be conducted where feasible and in settings wher e return of results is \\nfeasible within 24 hours and ART  can be initiated immediately*). Infants tested at \\nbirth must be tested at the 6 weeks immunization visit regardless of the results of \\nthe initial test at birth.  \\n● Infants with an initial positive HIV D NA PCR result should be presumed to be HIV \\ninfected and started on ART in line with national guidelines, with a new sample for', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 28}),\n",
       " Document(page_content='infected and started on ART in line with national guidelines, with a new sample for \\nconfirmatory HIV DNA PCR and baseline viral load taken at the time of ART \\ninitiation (ART initiation is based on the initial HIV DNA PCR result)  \\nInfants and \\nchildren aged less \\nthan 18 months \\n(Figure 2.1)  ● HIV exposure status of all infants should be established at first contact.  \\n● To establish HIV exposure status of a child less than 18 months of age, conduct HIV \\nantibody testing for mothers with unknown status or who previously tested \\nnegative during antenatal care at the 6 -week immunization visit or first contact. If \\nthe mother declines to be tested or is not available for testing, then conduct a rapid \\nHIV antibo dy test for the child to determine exposure (if antibody test is positive', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 28}),\n",
       " Document(page_content='HIV antibo dy test for the child to determine exposure (if antibody test is positive \\nthis confirms HIV exposure)  \\n● When HIV exposure is confirmed, ARV prophylaxis should be started immediately.  \\n● All HEIs should have DNA PCR testing at the 6 -week immunization visit or fi rst \\ncontact thereafter.  \\n● Infants with an initial positive HIV DNA PCR result should be presumed to be HIV \\ninfected and started on ART in line with national guidelines, with a new sample for \\nconfirmatory HIV DNA PCR and baseline viral load taken at the time of ART \\ninitiation (ART initiation is based on the initial HIV DNA PCR result)  \\n● All HEI with initial HIV negative results should continue infant ARV prophylaxis \\nand be followed as HEIs, including additional PCR testing at 6 months and 12', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 28}),\n",
       " Document(page_content='and be followed as HEIs, including additional PCR testing at 6 months and 12 \\nmonths, and antibody  testing at 18 months and every 6 months during \\nbreastfeeding, and at 6 weeks after complete cessation of breastfeeding  \\nChildren older \\nthan 18 months \\ntill age 9 years \\n(Figure 2.3)  ● Conduct HIV testing and counselling for all children of adults living with HIV as \\nsoon as possible after confirming the HIV positive status of the adult. Within health \\nfacilities, testing should be conducted at in -patient wards, nutrition clinics, and all \\nhigh HIV burden settings.  \\nAdolescents and \\nyoung people  \\n(10 - 24 years) \\n(Figure 2.3)  ● Targeted HIV testing services should be offered to adolescents and young people', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 28}),\n",
       " Document(page_content='Adolescents and \\nyoung people  \\n(10 - 24 years) \\n(Figure 2.3)  ● Targeted HIV testing services should be offered to adolescents and young people \\nwho are screened and found eligible for HIV test. HIV prevention services should \\nbe offered to clients who test negative while those who test positive should be \\nlinked to HIV care.  \\n● Adolescents aged above 10 years, should be tested with the written consent of a \\nparent or guardian, and are also required to give assent.  \\n● Adolescents who are e mancipated minors irrespective of age, can give their own \\nconsent.  \\n● All adolescents should be counselled on the potential benefits and risks of \\ndisclosure of their HIV status and empowered and supported to determine if, \\nwhen, how and to whom to disclose.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 28}),\n",
       " Document(page_content='disclosure of their HIV status and empowered and supported to determine if, \\nwhen, how and to whom to disclose.  \\n● For sexually active adolescents, HIV testing and counselling should be offered to \\ntheir partners and children where appropriate.  \\n● All uncircumcised adolescent males who test HIV negative should be counselled \\nabout the prevention benefits of VMMC and linked t o VMMC services if they agree', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 28}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 4  Table 2.1 Cont.  \\nPregnant and \\nbreastfeeding \\nwomen  ● During the first ANC visit, HIV testing of pregnant women should be done \\nusing a dual test for HIV and syphilis, unless the woman is known to be living \\nwith HIV.  \\n● Women who test negative for both HIV and Syphilis should be offered a repeat \\nHIV-Syphilis dua l test in the third trimester.  \\n● Prevention services should be offered to all pregnant and breastfeeding \\nwomen who test HIV negative. They should be screened for eligibility and \\nwillingness for PrEP.  \\n● At labor and delivery, HIV testing should be done for all women with \\nunknown HIV status and those who previously tested negative (even if tested \\nnegative in the third trimester).', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 29}),\n",
       " Document(page_content='unknown HIV status and those who previously tested negative (even if tested \\nnegative in the third trimester).  \\n● All breastfeeding mothers (unless known HIV positive) should be counselled \\nand tested at the 6 -week infant immunization visit. The HIV  test (if negative) \\nshould be repeated every 6 months until complete cessation of breastfeeding.  \\n● For mothers considered to be at high risk of HIV infection, retesting \\npostnatally should be done every 3 months; these include mothers \\ncategorized as key popul ation; in a HIV discordant relationship, or having \\nongoing sexual or injecting behavior that places her at risk, including new or \\nmultiple sexual partners.  \\n● Mothers should be counselled on the schedule for repeat HIV testing in', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 29}),\n",
       " Document(page_content='multiple sexual partners.  \\n● Mothers should be counselled on the schedule for repeat HIV testing in \\npregnancy and postnatal as p art of routine ANC and postnatal education.  \\n● All pregnant and breastfeeding women who are not tested, opt -out or decline \\nHIV testing during the first contact should be offered HIV counselling and \\ntesting in subsequent visits with appropriate referral and li nkage for \\nprevention, care, and support services.  \\n● All HIV positive pregnant and breastfeeding women enrolled into care should \\nreceive counselling and support (assisted disclosure), case management and \\nfollow -up. It should also include linkage to general ca re for ANC, delivery and \\npost -natal care  \\n● All spouses/partners as well as children of pregnant and breastfeeding', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 29}),\n",
       " Document(page_content='post -natal care  \\n● All spouses/partners as well as children of pregnant and breastfeeding \\nwomen testing HIV positive should be offered HIV testing and counselling.  \\nSexual partners & \\nchildren of index \\nclients (HIV positive \\nperson who is newly \\ndiagnosed or already \\nin HIV care)  ● All PLHIV enrolled into HIV care should receive disclosure counselling and \\nbe supported to disclose their HIV status (assisted disclosure)  \\n● HIV testing and counselling (facility -based or community -based) should be \\nencouraged for all partners including  sexual partners, needle sharing \\npartners, and children of index clients, with appropriate linkage to \\ntreatment and prevention services.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 29}),\n",
       " Document(page_content='HIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 5  Table 2.1 Cont.  \\nKey and vulnerable \\npopulations  ● Conduct HIV testing and counselling for all clients from key and vulnerable \\npopulations presenting to the health facility irrespective of the reason for \\ntheir visit, or through targeted outreach and testing at key and vulnerable \\npopulation service delivery points (e.g., drop -in centers).  \\n● Key populations that test negati ve should be retested quarterly.  \\n● Link all who test HIV positive to treatment and prevention services.  \\n● Prevention services should be recommended, including consistent and \\ncorrect use of condoms and use of sterile needles and syringes.  They should \\nbe scree ned for eligibility and willingness for PrEP.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 30}),\n",
       " Document(page_content='correct use of condoms and use of sterile needles and syringes.  They should \\nbe scree ned for eligibility and willingness for PrEP.  \\n● All uncircumcised males who test HIV negative should be counselled on the \\nprevention benefits of VMMC and linked to VMMC services if they consent  \\nTargeted HIV testing \\nand counselling of \\nadults  ● All adults eligible for testing should be offered HTS and encouraged to know \\ntheir HIV status and the status of their partners.  \\n● For those that test negative, re -testing is recommended if there is a new risk \\nexposure.  \\n● HIV positive adults should be counseled for  immediate ART initiation.  \\n● Link all adults identified as HIV positive to treatment and prevention services.  \\n● Clients who are not eligible for testing should receive HIV prevention', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 30}),\n",
       " Document(page_content='● Clients who are not eligible for testing should receive HIV prevention \\nmessages and be offered services, as appropriate.  \\n● All males who test HIV nega tive should be counselled on the prevention \\nbenefits of VMMC and linked to VMMC services if they consent  \\n \\n2.3 Package of HIV Testing Services  \\nAn HIV testing and counselling session consists of:  \\n● A pre -test session  \\n● HIV testing  \\n● Assessment for other health -related conditions or needs (while HIV tests are running)  \\n● A post -test session (including index testing)  \\n● Referral and linkage to other appropriate health services (as part of the post -test session)  \\nThe HIV testing service package is summarized in Tab le 2.2.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 30}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 6  Table 2.2: Summary of HIV Testing Services Package  \\nPre- Test Counselling  \\nPre-test counselling may be provided to an individual or a couple presenting for HTS.  Group information \\ncan also be offered during pre -test.  \\nThe objectives of the pre -test counselling session are to:  \\n− Provide information on the benefits of knowing one’s H IV status, including outcomes for people \\non ART and undetectable = Untransmittable  (U=U).  \\n− Provide an explanation for the HIV testing process including time the session will take, \\nconfidentiality, and interpretation of test results  \\n− Obtain informed consent for HIV testing.  \\n− Explore the client’s risk of HIV infection.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 31}),\n",
       " Document(page_content='confidentiality, and interpretation of test results  \\n− Obtain informed consent for HIV testing.  \\n− Explore the client’s risk of HIV infection.  \\n− Discuss the importance of disclosure to partners and other family members.  \\n− Explain the benefits of couple testing and partner services/index testing.  \\nProvide information on available post -test se rvices, including referrals for prevention or HIV care services  \\nPerform test.  \\nThe goal of HIV testing is to:  \\n• Provide accurate HIV diagnosis as per the nationally approved testing algorithm  \\n• Provide same day HIV test results  \\nDuring the 15 minutes as you wait for the test results:  \\n− Discuss Combination Prevention e.g., PrEP, PEP, Risk Reduction, STI treatment, condom', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 31}),\n",
       " Document(page_content='During the 15 minutes as you wait for the test results:  \\n− Discuss Combination Prevention e.g., PrEP, PEP, Risk Reduction, STI treatment, condom \\ninformation and demonstration, VMMC, Elimination of Mother to Child Transmission of HIV \\n(eMTCT)  \\n− Screen, provide information and referrals for; Intimate Partner Violence (IPV), STI and cancer \\nscreening, Tuberculosis (TB), Family planning/c ontraceptive needs, etc.  \\n− Establishing number of sexual contacts and biological children for the purpose of index testing.  \\n− Document in the HTS, Lab, referral and linkage register (MOH 362).  \\nDiscuss further on index testing and HIVST as you perform the secon d and the third test, as per the national \\nalgorithm, for the clients who test positive with the screening test  \\nPost -test counselling', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 31}),\n",
       " Document(page_content='algorithm, for the clients who test positive with the screening test  \\nPost -test counselling  \\n− Check if the client is ready for results and help them to interpret.  \\n− Check what the client understands by the results.  \\n− Allow the client to share his/her initial reactions and verbalize their initial feelings.  \\n− Explore and acknowledge client’s immediate feelings and concerns.  \\nOffer necessary support', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 31}),\n",
       " Document(page_content='HIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 7  Table 2.2 Cont.  \\nNEGATIVE RESULT  \\n− Explain test results.  \\n− Review implications of being HIV negative.  \\n− Support clients to develop a risk reduction \\nplan (see HTS operational manual)  \\n− Provide information on methods to prevent \\nHIV acquisition.  \\n− Provide male and/or female condoms, \\nlubricant, and guidance on their use.  \\n− Emphasize on importance of knowing the \\nstatus of sexual partners and information \\nabout the availability of partner and couples \\ntesting services.  \\n− Referral and linkage to relevant HIV \\nprevention services  \\nExplain the need for repeat testing for people \\nwho tes t negative but report risky behavior \\nwithin the prior  4 weeks (i.e., unprotected sex', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 32}),\n",
       " Document(page_content='Explain the need for repeat testing for people \\nwho tes t negative but report risky behavior \\nwithin the prior  4 weeks (i.e., unprotected sex \\nwith a partner of unknown status or Known HIV \\npositive status); if they test HIV negative again \\nafter 4 weeks  and are at  ongoing risk of HIV \\nacquisition , they should be ad vised to return for \\ntesting every 3 months  POSITIVE RESULT  \\n− Review implications of being HIV positive.  \\n− Help the index client to cope with emotions arising \\nfrom the diagnosis.  \\n− Discuss immediate concerns and help for the client \\nto decide who in his or her social network may be \\navailable to provide immediate support.  \\n− Discuss positive living.  \\n− Provide clear information on ART and its benefits \\nfor maintaining health and reducing the  risk of HIV', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 32}),\n",
       " Document(page_content='− Discuss positive living.  \\n− Provide clear information on ART and its benefits \\nfor maintaining health and reducing the  risk of HIV \\ntransmission, as well as where and how to access \\nART  \\n− Refer clients who turn HIV positive to CCC for \\nlinkage to treatment.  \\n− Revisit index testing and HIVST to determine \\npartner notification plan/approach (refer to HTS \\noperational manual and APN S operational Manual).  \\n− Discussion of the risks and benefits of disclosure to \\npartners; couples counselling should be offered to \\nsupport mutual disclosure.  \\nEncourage and offer HIV testing for sexual partners, \\ninjecting partners, biological children, and oth er family \\nmembers, which can be done through couples testing, \\nfamily testing and/or assisted partner notification \\nservice.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 32}),\n",
       " Document(page_content='members, which can be done through couples testing, \\nfamily testing and/or assisted partner notification \\nservice.  \\nAssessment of other health related conditions  \\nAssess risk for sexually transmitted infections (STIs) and opportunistic infections that would also require \\nmanagement  \\nReferral and linkage to care  \\nObtain accurate locator information from the index client (physical location, phone number)  \\nPhysically escort the client for re -testing and linkage to ART  \\nDocument the outcomes of partner follow up(s)  \\nPost -Test Counseling in the Era of Test -and -Treat  \\nPost -test counselling should, at a minimum, include three key messages that being the ART treatment \\npreparation process for all PLHIV:', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 32}),\n",
       " Document(page_content='Post -test counselling should, at a minimum, include three key messages that being the ART treatment \\npreparation process for all PLHIV:  \\n− Treatment (called antiretroviral therapy or ART) is available and is recommended for everyone \\nwith HIV.  \\n− Starting treatment as soon as possible (preferably within two weeks from testing positive for \\nHIV) reduces the chance of your illness getting worse or of passing HIV to others. If  you take your \\nART properly and do not miss pills you can expect to live a long and productive life', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 32}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 8  2.4 Age -Specific HIV Testing Algorithms  \\n2.4.1  Early Infant Diagnosis  \\n2.4.1.1 Confirmation of HIV infection in HIV Exposed Infants and Children < 18 Months Old  \\nHIV expo sure  of an infant or child can occur in utero, at labour and delivery and through breast \\nmilk. Confirmation of HIV infection should immediately follow.  \\nAll HIV exposed infants (HEI) should be tested with DNA PCR within 6 weeks of age or first contact \\nthere after; if negative then another DNA PCR at 6 months, and if negative then repeat DNA PCR at \\n12 months.  \\nIf the HEI develops symptoms suggestive of HIV as per WHO staging criteria, an additional DNA \\nPCR test should be conducted immediately.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 33}),\n",
       " Document(page_content='If the HEI develops symptoms suggestive of HIV as per WHO staging criteria, an additional DNA \\nPCR test should be conducted immediately.  \\nAn antibody test  should be performed for all HEI at 18 months of age and every 6 months thereafter \\nduring breastfeeding, and at 6 weeks after complete cessation of breastfeeding (Figure 2.1).', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 33}),\n",
       " Document(page_content='HIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 9  \\nEstablish  HIV   of Infants  and  Children\\n< 18 months\\n•  Mother known HIV \\n•  HTS  for mothers  with  unkn own HIV \\n•  Rapid antibod y test on infant/child  if mother s HIV cannot  be \\nEstablish HIV infection for HIV Exposed Child at 6 weeks or at first \\ncontact  (includes child with negative DNA PCR result at birth)\\n• Collect a DBS for HIV DNA PCR test 1\\n• Start/continue infant  ARV prophylaxis\\n• Start CPT At L&D, MNCH/F P, \\nIPD, A&E,  CCC & \\nHIV DNA PCR test NEGATIVE\\nChild HIV -exposed\\n• Continue HEI follow -upHIV DNA PCR test POSITIVE\\nChild presumed HIV infected\\n• Discontinue infant ARV prophylaxis\\n• Start ART\\n• Offer comprehensive care including \\ncontinuation of CPT\\n• Collect new sample for confirmatory HIV DNA', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 34}),\n",
       " Document(page_content='• Start ART\\n• Offer comprehensive care including \\ncontinuation of CPT\\n• Collect new sample for confirmatory HIV DNA \\nPCR, baseline viral load and CD4%.  1Conduct DNA PCR  at 6 months of age or soonest contact \\nthereafter (or earlier if child develops symptoms \\nsuggestive of HIV -as per WHO staging criteria)1\\nConfirmatory HIV DNA \\nPCR test POSITIVE\\nChild confirmed HIV \\ninfected\\n• Continue ART and \\ncomprehensive care \\nand routine under -5 \\ncareConfirmatory HIV DNA PCR \\ntest NEGATIVE\\nChild presumed HIV infected\\n• Continue ART \\n• Collect and send a DBS \\nto NHRL and manage \\nas per the results from \\nNHRLHIV DNA PCR result NEGATIVE\\nChild HIV -exposed\\n• Continue HEI follow -up\\n• Conduct DNA PCR at 12 months of age  or \\nsoonest contact till 18 months of age (or earlier if', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 34}),\n",
       " Document(page_content='Child HIV -exposed\\n• Continue HEI follow -up\\n• Conduct DNA PCR at 12 months of age  or \\nsoonest contact till 18 months of age (or earlier if \\nchild develops symptoms suggestive of HIV -as \\nper WHO staging criteria) 1\\nHIV DNA PCR result NEGATIVE\\nChild HIV -exposed\\n• Continue HEI follow -up\\n• Continue routine under -5 care\\n• Conduct HIV Antibody test at 18 months of age \\n• If breast feeding, do HIV antibody test every 6 months while breast \\nfeeding and 6 weeks after complete cessation of breastfeeding \\nIf HIV antibody test  is negative\\nChild HIV negative \\n• Stop CPT * \\n• Review at age 2 years and document vital status \\n• Continue routine  unde r-5 If HIV antibody test  is positive \\nChild confirmed HIV infected\\n• Start  ompre hensive  \\n• Continue CPT\\n• Continue routine  unde r-5', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 34}),\n",
       " Document(page_content='Child confirmed HIV infected\\n• Start  ompre hensive  \\n• Continue CPT\\n• Continue routine  unde r-5 \\n1 Where Point of Care DNA PCR is available - EID should be done using the whole blood at the facility. \\nFor baseline viral load testing – If available, use point of care machine for viral load; If there is no point of care \\nmachine to do viral load - Take a plasma and send it to the VL testing laboratory\\n* Only after final antibody test negativeChild is HIV unexposed\\n  \\nFigure 2.1 Algorithm for Early Infant Diagnosis in Infants and Children < 18 months of age', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 34}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 10  Presumptive Diagnosis of Severe HIV Disease in Children under 18 Months  \\nOccasionally, children less than 18 months of age present to hospital with severe illness; and a rapid \\nHIV antibody test confirm s HIV exposure. Lack of immediate availability of HIV DNA PCR results \\nfor confirmation of HIV could result in undue delay in starting life -saving ART. In such children, a \\npresumptive diagnosis of HIV infection can be made using the criteria in Table 2.3. A RT can be \\ninitiated while awaiting HIV DNA PCR results to confirm HIV infection.  \\nTable 2.3: Presumptive Diagnosis of HIV in children <18 months while awaiting DNA PCR \\nResults  \\nHIV antibody test positive AND symptomatic with;  \\n 2 or more of the following:', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 35}),\n",
       " Document(page_content='Results  \\nHIV antibody test positive AND symptomatic with;  \\n 2 or more of the following:  \\n● Oral candidiasis/thrush  \\n● Severe pneumonia  \\n● Severe sepsis  \\nOR any of the of following:  \\n● Any WHO Clinical Stage 4 condition  \\n● Recent maternal death (if likely to have been HIV -related) or advanced HIV disease in \\nmother  \\n● Child’s CD4% < 2 5% \\n \\n2.4.1.2  Birth Testing  \\nBirth testing is defined as HIV testing (with DNA PCR) at birth or around birth for infants born to \\nHIV-positive mothers. Birth testing has the potential to improve survival for infants who are \\ninfected during pregnancy, around labour and delivery by ident ifying them early for rapid ART \\ninitiation. Do not use cord blood for birth testing as this could result in false positive results.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 35}),\n",
       " Document(page_content='initiation. Do not use cord blood for birth testing as this could result in false positive results.  \\nA DNA PCR test can be offered at birth or around birth where feasible.  \\nALL children initially tested at birth should be rete sted at 6 weeks of age and the EID \\nalgorithm followed (Figure 2.2.)  \\nConsiderations for providing birth testing:  \\nBirth testing may be prioritized for newborns who are at high risk of HIV acquisition including \\nthose born to:  \\n● Mothers who seroconvert during p regnancy.  \\n● Mothers who have unsuppressed or unknown viral loads during delivery.  \\n● Mothers who received a HIV positive diagnosis for the first time at or after 28 weeks \\ngestation or during labour and delivery  \\n● Mother on ART for less than 12 weeks prior to delivery', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 35}),\n",
       " Document(page_content='gestation or during labour and delivery  \\n● Mother on ART for less than 12 weeks prior to delivery  \\nBirth testing should be offered where this is feasible:  \\n● DNA PCR results can be returned the same  day e.g., where on site point of care is available.  \\n● ART regimens recommended for neonates as per national guidelines are available and can \\nbe initiated immed iately.  \\n● Follow -up of the newborn is done to ensure no lost to follow -up.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 35}),\n",
       " Document(page_content='HIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 11  \\nInfant of known HIV positive mothers at birth (or \\nwithin 2 weeks of birth)\\n• Collect DBS for DNA PCR\\n• Start infant ARV prophylaxis immediately after \\nbirth.  \\nHIV DNA PCR positive HIV DNA PCR Negative \\n• Initiate ART immediately\\n• Book for follow up at 2 weeks of age. \\n• Offer comprehensive care for HIV infected child. \\n• Collect new sample for confirmatory HIV DNA \\nPCR, baseline viral load and CD4%.• Continue infant ARV prophylaxis and follow up \\nfor HIV exposed infants. \\n• Repeat DNA PCR test at 6 weeks. Follow the EID \\nalgorithm. \\nConfirmatory DNA PCR positive/ \\ndetectable Viral load \\n• Continue ART \\n• Provide comprehensive care. Confirmatory DNA PCR negative \\n• Continue ART', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 36}),\n",
       " Document(page_content='Confirmatory DNA PCR positive/ \\ndetectable Viral load \\n• Continue ART \\n• Provide comprehensive care. Confirmatory DNA PCR negative \\n• Continue ART \\n• Collect DBS for repeat PCR at 6 weeks of age \\nand manage as per EID algorithm \\n• Collect new sample send to NHRL. Manage as \\nper NHRL results \\nFigure 2.2: Birth Testing Algorithm  \\n \\n2.4.1.3  Use of Point of Care testing for Children  \\nPoint -of-care testing occurs at the health facility where care is being provided, with results being \\nreturned to the patient or caregiver on the same day as sample collection. Point of care DNA PCR \\ntesting for early infant diagnosis of HIV can reduce the turnaround time for testing and return of \\nresults and allow imme diate initiation of ART among infants.  Point of care DNA PCR testing can be', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 36}),\n",
       " Document(page_content='results and allow imme diate initiation of ART among infants.  Point of care DNA PCR testing can be \\nused to diagnose HIV infection as well as to confirm positive results.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 36}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 12  2.4.2  Diagnosis of HIV Infection in the Older Child (≥ 18 months), Adolescents and \\nAdults  \\n● Serial testing,  using approved rapid HIV antibody testing kits, is used to diagnose HIV infection \\nin children older than 18 months, adolescents, and adults, and (refer to Figure 2.3)  \\n● An HIV -positive diagnosis will be made using three consecutive reactive assays . This thr ee-\\ntest strategy as well as retesting aims to ensure that at least a 99% Positive Predictive Value \\n(PPV) is maintained, and false positive misdiagnosis is avoided.  \\n● Offer adequate information to all clients and obtain consent prior to the HIV test (verbal \\nconsent is adequate but should be documented by the health care worker in client records).', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 37}),\n",
       " Document(page_content='consent is adequate but should be documented by the health care worker in client records). \\nFor children below the age of 14 year who are not emancipated minors, a written consent from \\nthe guardian is recommended.  \\n● Individuals 15 years and older and emancipa ted minors can provide self -consent.  \\n● Clients who test positive should be linked to care and treatment. Counselling support, index \\nand family testing should be offered to these clients.  \\n● Clients who test negative should be counselled on HIV risk reduction b ehaviors and linked to \\ncombination HIV prevention services (such as VMMC, RH/FP, condoms, PrEP, etc.) depending \\non individual risk profile. Table 2.5 provides recommendations for re -testing those who test \\nHIV negative.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 37}),\n",
       " Document(page_content='on individual risk profile. Table 2.5 provides recommendations for re -testing those who test \\nHIV negative.  \\nHIV testing algorithm for children >1 8months, adolescents and adults.  \\nFigure 2.3 illustrates the serial testing algorithm. An HIV -positive diagnosis will be made using \\nthree consecutive reactive assays (Figure 2.3). All individuals are first tested on Assay 1 (A1). \\nAnyone with a non -reactive test result (A1−) is reported HIV -negative.  Individuals who are \\nreactive on Assay 1 (A1+) will then be tested on a separate and distinct Assay 2 (A2). Individuals \\nwho are reactive on both Assay 1 and Assay 2 (A1+; A2+) will then be tested on a separate an d \\ndistinct Assay 3 (A3). A positive HIV diagnosis is given when Assay 3 is reactive (A1+; A2+; A3+).', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 37}),\n",
       " Document(page_content='distinct Assay 3 (A3). A positive HIV diagnosis is given when Assay 3 is reactive (A1+; A2+; A3+).  \\nIf Assay 3 is nonreactive (A1+; A2+; A3−), the status should be reported as HIV -inconclusive, and \\nthe individual should be asked to return in 14 days for retesting.   \\nIndividuals who are reactive on Assay 1 but non -reactive on Assay 2 (A1+; A2−) should be repeated \\non Assay 1. If repeat Assay 1 is non -reactive (A1+; A2−; repeat A1 –), the status should be reported \\nas HIV -negative.  If repeat Assay 1 is reactive (A1+; A2 –; repeat A1+), the status should be reported \\nas HIV -inconclusive, and the individual asked  to return in 14 days for retesting.   All clients with \\nHIV positive results will be referred to a Comprehensive Care Clinic for retesting prior to \\ninitiation of ART', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 37}),\n",
       " Document(page_content='HIV positive results will be referred to a Comprehensive Care Clinic for retesting prior to \\ninitiation of ART  \\nNOTE:  The three -test algorithm will be implemented after identification of the specific \\nassay. Meanwhile, the current algorithm continues being in use (Annex 7). Guidance will \\nbe issued before implementation.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 37}),\n",
       " Document(page_content='HIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 13  \\nHIV TEST A1\\nNON -REACTIVE REACTIVE\\nREPORT NEGATIVE HIV TEST A2\\nNON -REACTIVE REACTIVE\\nHIV TEST A1 HIV TEST A3\\nNON -REACTIVE REACTIVE NON -REACTIVE REACTIVE\\nREPORT NEGATIVE\\nREPORT INCONCLUSIVE AND \\nRETEST IN 14 DAYS. \\nREPORT HIV POSITIVE AND REFER TO THE SECOND TESTER AT CCC/MCH\\nHIV TEST A1\\nNON -REACTIVE REACTIVE\\nREPORT INCONCLUSIVE AND \\nRETEST IN 14 DAYSHIV TEST A2\\nNON -REACTIVE REACTIVE\\nHIV TEST A1 HIV TEST A3\\nNON -REACTIVE REACTIVE NON -REACTIVE REACTIVE\\nREPORT NEGATIVEREPORT INCONCLUSIVE AND \\nRETEST IN 14 DAYSINITIATE ART\\nNote: \\n• The use of DNA PCR as a supplemental assay is no longer recommended\\n• For inconclusive HIV status, if reactivity remains the same after 14 days the individual should be', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 38}),\n",
       " Document(page_content='• For inconclusive HIV status, if reactivity remains the same after 14 days the individual should be \\nreported as HIV -negative and advised to retest after 3 months \\nFigure 2.3: HIV Testing Services Algorithm', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 38}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 14  Results interpretation  \\nRESULTS  INTERPRETATION  \\nA1- HIV-NEGATIVE  \\nA1+; A2+; A3+  HIV-POSITIVE  \\nA1+; A2 -; Repeat A1+  HIV-INCONCLUSIVE (retest after 14 days). If reactivity \\nremains the same after 14 days, the individual should be \\nreported as HIV -negative   \\nA1+; A2 -; Repeat A1 - HIV-NEGATIVE  \\nA1+; A2+; A3 - HIV- INCONCLUSIVE (Retest after 14 days). If reactivity \\nremains the same after 14 days, the individual should be \\nreported as HIV -negative  \\n \\n2.4.3  HIV testing for Pregnant Women  \\nFor pregnant women, the HIV/syphilis dual test should be used as the A1 test (Figure 2.4). The dual \\ntest kit is recommended for:  \\n● Pregnant women during their first ANC, unless the woman is known to be living with HIV.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 39}),\n",
       " Document(page_content='test kit is recommended for:  \\n● Pregnant women during their first ANC, unless the woman is known to be living with HIV.  \\n● For those who test negative for both HIV and Syphilis repeat testing should be conducted \\nin the third trimester using the HIV and syphilis dual test.  \\n● Partners accompanying pregnant women for the first -time during ANC  \\nHIV/Syphilis dual test should not be used for retesting women on ART or with  known positive HIV \\nstatus, or women diagnosed with syphilis during pregnancy.  \\nSee Figure 2.4 for the full algorithm when considering HIV and syphilis (TP) results concurrently.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 39}),\n",
       " Document(page_content='HIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 15  \\nTEST A1 (HIV/Syphillis)\\nHIV TEST A1 SYPHILIS TEST A1\\nREPORT NEGATIVE HIV TEST A2\\nNON -REACTIVE REACTIVE\\nHIV TEST A1 HIV TEST A3\\nNON -REACTIVE REACTIVE NON -REACTIVE REACTIVE\\nREPORT NEGATIVE REPORT INCONCLUSIVE \\nRETEST IN 14 DAYS.\\nREPORT HIV POSITIVE AND REFER TO THE SECOND TESTER AT CCC/MCH\\nHIV TEST A1\\nNON -REACTIVE REACTIVE\\nREPORT INCONCLUSIVE AND \\nRETEST IN 14 DAYSHIV TEST A2\\nNON -REACTIVE REACTIVE\\nHIV TEST A1 HIV TEST A3\\nNON -REACTIVE REACTIVE NON -REACTIVE REACTIVE\\nREPORT NEGATIVE REPORT INCONCLUSIVE AND \\nRETEST IN 14 DAYSINITIATE ARTNON -REACTIVE REACTIVE NON -REACTIVE REACTIVE\\nREPORT NEGATIVEREPORT POSITIVE AND \\nTREAT FOR SYPHILLIS\\nNote: \\n• The use of DNA PCR as a supplemental assay is no longer recommended', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 40}),\n",
       " Document(page_content='REPORT NEGATIVEREPORT POSITIVE AND \\nTREAT FOR SYPHILLIS\\nNote: \\n• The use of DNA PCR as a supplemental assay is no longer recommended\\n• For inconclusive HIV status, if reactivity remains the same after 14 days the individual should be \\nreported as HIV -negative and advised to retest after 3 months \\nFigure 2.4 Dual HIV/syphilis Testing Algorithm', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 40}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 16  RESULTS  INTERPRETATION  \\nA1 HIV -, Syphilis Test (TP) - HIV negative, syphilis negative  \\nA1 HIV -, Syphilis Test (TP)+  HIV negative, syphilis positive  \\nA1 HIV+, Syphilis Test (TP) - Syphilis negative and proceed with A2 for HIV  \\nA1 HIV+, Syphilis Test (TP)+  Syphilis positive and proceed with A2 for HIV  \\nA1 (HIV+); A2+; A3+  HIV-positive  \\nA1(HIV+); A2 -; Repeat A1+  HIV-inconclusive (retest after 14 days). If reactivity remains the same \\nafter 14 days, the individual should be reported as HIV -negative  \\nA1(HIV+); A2 -; Repeat A1 - HIV-negative  \\nA1(HIV+); A2+; A3 - HIV- inconclusive (retest after 14 days). If reactivity remains the same \\nafter 14 days, the individual should be reported as HIV -negative', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 41}),\n",
       " Document(page_content='after 14 days, the individual should be reported as HIV -negative  \\nTable 2.4: Approaches to Improve Linkage to Treatment and Prevention Services  \\nkey area  Action  \\nInformation  ● Quality post -test counselling should include information about the nature and \\navailability of additional HIV -related services, description of the next steps in \\ntreatment and prevention including entire treatment plan and follow -up visits \\nand schedule.  \\n● The benefits of immediate assessment and early initiation of ART should be \\nemphasized.  \\n● Involve the patient in the decision -making process regarding treatment and \\nprevention (espe cially where and when to start ART)  \\nDisclosure  ● Disclosure to a trusted ‘significant other’ promotes linkage and adherence to \\ntreatment.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 41}),\n",
       " Document(page_content='Disclosure  ● Disclosure to a trusted ‘significant other’ promotes linkage and adherence to \\ntreatment.  \\n● Encourage and help the patient to discuss HIV status with a trusted friend or close \\nrelative.  \\n● Encourage adolescents to identify and invite a supportive adult or friend to \\nsupport them.  \\n● For children, HIV status should be disclosed to children by age 12 years and the \\nprocess can start when a child is as young as 7 years old.  The health care provider \\nor the pa rent/caregiver/guardian can disclose to the child with appropriate \\nguidance and training. The aim of disclosure to children is to start to involve them \\nin the management of their own health and reduce stigma associated with HIV  \\nBarriers to', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 41}),\n",
       " Document(page_content='in the management of their own health and reduce stigma associated with HIV  \\nBarriers to \\nLinkage  ● During post -test counselling, identify and address any barriers to linkage', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 41}),\n",
       " Document(page_content='HIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 17  Table 2.4 Cont.  \\nSystems to \\nFacilitate \\nLinkage  ● The HTS provider is responsible for linkage into care.  \\n● Same day enrolment into care is expected. monitor linkage to treatment initiation \\nwithin 14 days of diagnosis, however allow follow up of clients to 90 days of a \\nHIV-positive diagnosis  \\n● For HIV negative clients link to HIV prevention services based on assessed risk  \\n● Linkage should be done to on -site treatment and prev ention services through \\npatient escorts. Where this is not possible (due to patient preference or the \\nservices are not available), the testing facility should book the appointment with \\nthe receiving facility and follow -up to ensure the patient registers at  the receiving', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 42}),\n",
       " Document(page_content='the receiving facility and follow -up to ensure the patient registers at  the receiving \\nfacility. Provide the patient with referral information, referral form and contact \\ndetails of the facility.  \\n● Deploy retention and loss -to-follow up tracking system to ensure linkage is \\nsuccessful. These include enlisting the help of peer or b uddy systems, SMS \\nreminders, phone calls and community outreach workers to escort HIV positive \\nclients to enrolment.  \\n● Early preparation and assessment for ART, with early initiation of ART \\nstrengthens engagement in care.  \\nCare \\nCoordination \\nand \\nIntegration  ● Coordinate and treat mother -baby pairs, partners, and families together. \\nIntegrate common services offered to PLHIV (TB diagnosis and treatment,', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 42}),\n",
       " Document(page_content='Integrate common services offered to PLHIV (TB diagnosis and treatment, \\nSRH/FP, cervical cancer screening, nutrition etc.)  \\n● Where referrals are necessary, such referrals should be coor dinated \\n(communication and documentation between referring and receiving service \\ndelivery points)  \\nLinkage Register  ● Maintain a linkage register at all testing points in the facility and community.  \\n● Track and report on progress with linkage monthly  \\n● Discuss linkage at MDT meetings.  \\n \\n2.5 Retesting recommendations for HIV negative persons  \\nRetesting in this context refers to testing that occurs later after the initial test is negative.  \\nThe purpose of retesting is to:  \\n● Monitor the effectiveness of HIV prevention interventions', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 42}),\n",
       " Document(page_content='The purpose of retesting is to:  \\n● Monitor the effectiveness of HIV prevention interventions  \\n● identify and treat new HIV infections as early as possible when prevention efforts fail.  \\nThe following are the recommendations for HIV retesting in different populations and settings in \\nKenya:', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 42}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 18  Table 2.5: Recommendations for Retesting HIV Negative Clients  \\nScenario/population  Recommendation for retesting  \\nGeneral population  All general population to be screened every 2 years \\nusing the approved NASCOP HTS screening tool and \\nthose eligible get tested  \\nKey populations (FSW, MsM, TG, \\nPWID)  Re-test every 3 months  \\nNegative partner in discordant  \\n \\n Retest HIV negative partner at the initiation of ART for the \\nHIV positive partner, at 6months and 12 months once \\nviral suppression is achieved.  \\nRetest a nnually if the positive partner remains virally \\nsuppressed.  \\nPregnant women  Test in first trimester or first contact; Re -test in the third \\ntrimester and, during labour and delivery.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 43}),\n",
       " Document(page_content='suppressed.  \\nPregnant women  Test in first trimester or first contact; Re -test in the third \\ntrimester and, during labour and delivery.  \\nBreastfeeding mothers  Re-test 6 weeks after delivery, at 6 months then every 6 \\nmonths until complete cessation of breast feeding.  \\nFor mothers considered to be at high risk of HIV \\ninfection, retesting postnatally should be done every 3 \\nmonths  \\nPersons who had a most recent \\n(e.g., less than one month) high \\nrisk exposure to  HIV  Test at initial presentation and re -test at 4 weeks, after \\nwhich National testing guidelines apply  \\nSTI symptomatic patients or \\npatients with symptoms \\nsuggestive of acute HIV  Test at initial presentation and re -test at 4 weeks, after \\nwhich national te sting guidelines apply  \\nIndividuals on Pre -exposure', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 43}),\n",
       " Document(page_content='which national te sting guidelines apply  \\nIndividuals on Pre -exposure \\nprophylaxis (PrEP)  Test at initiation of PrEP; Retest at month one, and then \\nevery 3 months  \\n2.6 Inconclusive HIV status  \\nAn HIV -inconclusive test status means that individuals had discrepant results on the test (for \\nexample, first test reactive, second test nonreactive, third test reactive) and so could not be given \\nan HIV -positive or HIV -negative diagnosis.  \\nInconclusive results are rare, but they may occur when  \\ni) cross -reactivity exists between kits or patient -related factors,  \\nii) the tester or test kit makes an error; and/or  \\niii) individuals are seroconverting and in the window period, when infection cannot be \\ndeterm ined.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 43}),\n",
       " Document(page_content='HIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 19  The window period is the time from exposure to HIV infection to when the body produces enough \\nHIV antibodies to be detected by an HIV antibody test. This time can vary across different types of \\ntests, where some tests may be able to detect antibodies earli er than another test, which can lead \\nto discrepant test results.  \\nAll people with an inconclusive HIV status should be encouraged to return in 14 days for retesting. \\nReceiving inconclusive results could be confusing and stressful for clients and may be dif ficult for \\nthe provider to explain. During post -test counselling, the provider needs to take time to explain', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 44}),\n",
       " Document(page_content='the provider to explain. During post -test counselling, the provider needs to take time to explain \\ncarefully what an HIV -inconclusive status means, stating that it is neither HIV -positive nor HIV -\\nnegative, and that retesting in 14 days is needed to establish the correct diagnosis. Because \\ndefinitive diagnosis cannot be made on the day of testing, and immediate referral to HIV care or \\nART initiation is not appropriate, providers need to help clients make a clear plan for follow -up and \\nschedule an a ppointment for retesting. Also, clients should be informed about prevention options \\nand how to stay HIV -negative, as well as about the availability and benefits of ART.  \\nThose suspected of having an acute HIV infection1 – for example, if they report or pre sent with', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 44}),\n",
       " Document(page_content='Those suspected of having an acute HIV infection1 – for example, if they report or pre sent with \\nsymptoms associated with acute HIV infection – should be followed up closely. This is a period of \\nhigh infectiousness due to high viral load, and clients need to be informed how to protect their \\npartners. Individuals at high ongoing risk of HIV c an be informed about PrEP and encouraged to \\ndiscuss options depending on their final HIV status when they come back for retesting.  \\n \\n2.7 Approach to Patients on ART with a Discrepant HIV Test Result  \\nHIV testing should not be performed to patients who are al ready enrolled into HIV care and \\non ART.  However, some patients self -refer for HIV antibody testing without disclosing that they', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 44}),\n",
       " Document(page_content='on ART.  However, some patients self -refer for HIV antibody testing without disclosing that they \\nare known HIV positive and on ART. Figure 2.5 provides recommendations on managing patients \\nwho have a non -reactive antibody te st while on ART.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 44}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 20  \\nEducation/counselling  for patients who are on ART and present with a new negative HIV antibody test\\n• The new HIV antibody test may be a  false negative    the patient may still be HIV -infected but their antibody \\nlevels may be suppressed as a result of effective ART. This is more common for patients who start ART very \\nsoon after HIV infection\\n• Those with prior history of detectable viral loads, positive DNA PCR results, or low CD4 counts are almost \\nalways truly HIV positive\\n• Continue their ART until a special test is performed (a new sample for DNA PCR) at the National HIV \\nReference Laboratory (NHRL)\\n• Stopping ART before HIV status is confirmed could result in a rapid rise in viral load, decline in CD4, and', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 45}),\n",
       " Document(page_content='Reference Laboratory (NHRL)\\n• Stopping ART before HIV status is confirmed could result in a rapid rise in viral load, decline in CD4, and \\nincreased risk of developing an opportunistic infection or dying\\n• Draw a sample for DNA PCR  and send to the NHRL  (preferably a whole blood EDTA sample following \\ncold -chain protocols within 24 hours of collection; DBS is acceptable if EDTA is not possible)\\n• Specify that this is a sample for confirming HIV status  of a patient who is on ART, and provide the dates \\nand results for all prior antibody tests, DNA PCR tests, and RNA viral load tests in the request form\\nIf HIV DNA PCR sample is positive\\n• This confirms the patient is HIV positive\\n• Provide additional counseling on the \\nreasons why the antibody test may have', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 45}),\n",
       " Document(page_content='• This confirms the patient is HIV positive\\n• Provide additional counseling on the \\nreasons why the antibody test may have \\nbeen falsely negative and discourage the \\npatient from any repeat antibody testing\\n• Emphasize that the patient  s ART is \\nworking and the need for continued \\nexcellent adherenceIf HIV DNA PCR sample is negative\\n• The patient may be HIV negative, or it could be that the \\npatient is  HIV positive but the HIV DNA levels have been \\nsuppressed below the testing limit (this is more common if \\na DBS sample was used)\\n• Inform the patient that they may still be HIV positive and \\nneed to be monitored closely for an additional 6 months \\nbefore confirming they are HIV negative\\n• Inform the patient that ART should be stopped immediately', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 45}),\n",
       " Document(page_content='before confirming they are HIV negative\\n• Inform the patient that ART should be stopped immediately\\n• They should return for HIV viral load performed at 1 \\nmonth, 3 months, and 6 months after stopping ART \\n(samples for HIV viral load should be sent to the designated \\nVL/EID network laboratory assigned to the requesting \\nfacility with all past details) \\nFigure 2.5: Managing Patients on ART Who Present with a New Negative HIV Antibody Test', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 45}),\n",
       " Document(page_content='Initial Evaluation and Follow up  \\n3 - 1   \\n3. Initial Evaluation and Follow up  \\n \\n3.1 Introduction  \\nAll PLHIV are eligible for ART irrespective of CD4 cell count or percentage, WHO clinical  stage, age, \\npregnancy status, or comorbidities. ART should be initiated as soon as the patient is ready to start, \\npreferably within two weeks from time of HIV diagnosis.  \\nIn order to provide targeted services based on clinical presentation, during the init ial evaluation \\nall PLHIV should be categorized as presenting with advanced HIV disease (AHD) or as presenting \\nwell (Table 3.3). Patients with advanced disease require more intensive evaluation for and \\nmanagement of OIs, and once ART is started, they are at  higher risk of developing immune', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 46}),\n",
       " Document(page_content='management of OIs, and once ART is started, they are at  higher risk of developing immune \\nreconstitution inflammatory syndrome (IRIS, Annex 16).  \\nSimilarly, after at least 6 months on ART, PLHIV should be categorized as being either established \\nor not established on ART (clinically, virologically, and psychosoci ally) to best meet the specific \\nneeds of each patient for treatment and follow -up and improve patient outcomes through provision \\nof targeted differentiated care. Differentiated care minimizes inconvenience and unnecessary \\nfrequent follow -up, thus reducing costs and time related to clinic visits. It also allows resources to \\nbe focused on those patients who require additional attention.  \\n3.2 Initial Clinical Evaluation of PLHIV', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 46}),\n",
       " Document(page_content='be focused on those patients who require additional attention.  \\n3.2 Initial Clinical Evaluation of PLHIV  \\nAll patients enrolling into HIV care should have a complete medical history taken, a thorough \\nphysical examination and appropriate laboratory investigations. Findings from this initial \\nevaluation should be documented legibly in a retrievable health record management format \\n(electronic or paper -based) to facilitate long -term follow -up of the patient. Table 3.1 summarizes \\nimportant aspects of the initial medical history and physical examination for PLHIV.  \\nThe initial visit provides the opportunity to establish a meaningful patient -provider relationship; \\nthe clinician should elicit concerns  and expectations with open, non -judgmental, and clear \\ncommunication.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 46}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 2  Table 3.1: Initial Clinical Evaluation for PLHIV (History and Physical Examination)  \\nHistory  Details for History taking  \\nCurrent and past \\nmedical history  ● Presenting complaints/current symptoms  \\no Also inquire about symptoms due to co -existing HIV -related and non -HIV-\\nrelated disease and co -morbidities that will require immediate intervention  \\n● History of TB and TB contacts  \\nComplete the Intensified Case Finding (ICF) tool  \\n● Date of first positive HIV test  \\n● Past and current co -morbidities (e.g., TB, cryptococcal meningitis, hypertension, \\ndiabetes, kidney, and liver disease)  \\no Document history of TB  \\n● Current medications,  \\no Establish current medications (prescription, non -prescription, and', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 47}),\n",
       " Document(page_content='o Document history of TB  \\n● Current medications,  \\no Establish current medications (prescription, non -prescription, and \\nherbal) likely to interact with ARVs  \\no Document ARV exposure history including previous or current ARV use \\n(including for PMTCT, PEP, PrEP, and ART)  \\n● Drug allergies, especially sulpha allergy  \\n● History of hospitalizations  \\no Establish reasons for hospitalizations  \\n● Family history of chronic disease or cancer  \\nEstablish nutritional history and adequacy of nutritional intake and household food \\nsecurity  \\nPsychosocial \\nhistory  ● Education, employment, family, marital status  \\n● Establish possible presence of mental health concerns  \\no Including past treatment for mental illnesses and any current \\nsymptoms of depression', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 47}),\n",
       " Document(page_content='● Establish possible presence of mental health concerns  \\no Including past treatment for mental illnesses and any current \\nsymptoms of depression  \\n● Assess for disclosure and presence of self -stigma  \\no Encourage disclosure to trusted close relations and sexual partners  \\n● Substance use screening including alcohol, tobacco, miraa (khat), marijuana, \\nnarcotics, injection drug use (use the CRAFFT screening tool for adolescents and \\nthe CAGE -AID screening tool for adults to screen for alcohol and drug use \\ndisorders – see Tables 4.15 and 4.16)  \\n● Establish and document social support structures  \\n● Link to additional facility and community support resources, including \\npsychosocial support groups, peer mentors, harm reduction services for PWIDs, \\netc.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 47}),\n",
       " Document(page_content='psychosocial support groups, peer mentors, harm reduction services for PWIDs, \\netc. \\nElicit and begin to address possible barriers to adherence', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 47}),\n",
       " Document(page_content='Initial Evaluation and Follow up  \\n3 - 3  Table 3.1 Cont.  \\nSexual and \\nreproductive \\nhistory  History  \\n● History of STIs  \\n● Current symptoms of STIs  \\n● Sexual practices  \\no Determine HIV status and disclosure to sexual partner(s)  \\no ART status of sexual partner/s  \\n● Pregnancy history and age of all living children  \\n● Menstrual history, family planning and plans for pregnancy  \\n● History of cervical cancer screening  \\n● Vaccination history (including COVID -19 vaccine)  \\nDiscuss:  \\n● Secondary prevention and avoidance of re -infection with STIs  \\n● Pregnancy intention and contraception needs  \\nEncourage contact tracing and HIV testing for sexual partners and all children < 15 \\nyears of age of HIV -infected women or whose mothers’ HIV status is unknown  \\nVital signs, and', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 48}),\n",
       " Document(page_content='years of age of HIV -infected women or whose mothers’ HIV status is unknown  \\nVital signs, and \\nanthropometric \\nmeasurements  ● Measure and record weight, height, MUAC (in children and pregnant women), \\ntemperature, pulse rate, BP, respiratory rate, and pulse oximetry  \\n● Calculate BMI as: Weight (kg)/ Height2(m); Use z -scores for children  \\n● Monitor growth trends for children  \\nGeneral \\nexamination  Examine the following:  \\n● Conjunctiva and palms for pallor or jaundice; swollen lymph nodes (cervical, \\naxillary, inguinal); mouth for Kaposi’s sarcoma (KS) lesions, oral hairy \\nleucoplakia, candidiasis, tooth decay; skin (for drug eruptions, herpes zoster, \\ndermatitis, pruritic papular eruptions (PPE), folliculitis, fungal infections, \\nmolluscum, and KS)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 48}),\n",
       " Document(page_content='dermatitis, pruritic papular eruptions (PPE), folliculitis, fungal infections, \\nmolluscum, and KS)  \\n● Assess developmental milestones for children  \\nSystemic \\nexamination  ● Central Nervous System  \\n● Mental State Examination (for mental status)  \\n● Abdomen   \\n● Respiratory  \\n● Cardiovascular  \\n● Genitourinary/ anorectal system (for ulcers, discharge, condylomata/warts, \\nprostate examination for men ≥ 45 years of age). Speculum examination with \\ncervical cancer screening for females', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 48}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 4  Table 3.1 Cont.  \\nSummary  List differential diagnosis and management plan for each problem (including \\ninvestigations, treatment, referrals, and follow -up) \\n● Assign and document the WHO Clinical Stage and manage presenting \\nillnesses  \\n● Growth and developmental milestone must be assessed and used for WHO \\nstaging in children  \\nDifferentiate between patients with advanced disease versus those who are clinically \\nwell, to guide acuity of follow -up \\n3.3 Initial Laboratory Evaluation of PLHIV  \\nThe comprehensiveness of laboratory tests will depend on presence and/or type of suspected \\nconcurrent illness. Table 3.2 summarizes the recommended baseline laboratory investigations for', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 49}),\n",
       " Document(page_content='concurrent illness. Table 3.2 summarizes the recommended baseline laboratory investigations for \\nall PLHIV. Additional investigations should be based on clinical indicati on. ART should not be \\ndelayed if a laboratory test is not available.  \\nTable 3.2: Baseline Laboratory Investigations for PLHIV  \\nHIV  \\nSpecific  Test  Comments  \\n● Confirm and \\ndocument positive \\nHIV test result  ● Positive status should be reconfirmed prior to ART \\ninitiation for all patients  \\n● Refer to current HIV testing algorithm  \\nCD4 cell count  ● For all patients  (CD4% for children ≤ 5 years old)  \\n● If CD4 ≤ 200 cells/mm3 in PLHIV >5 years, th en \\nlaboratories should automatically perform a serum \\ncryptococcal antigen (sCrAg) on the same sample to screen \\nfor cryptococcal infection', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 49}),\n",
       " Document(page_content='laboratories should automatically perform a serum \\ncryptococcal antigen (sCrAg) on the same sample to screen \\nfor cryptococcal infection  \\n● TB-LAM should also be conducted   \\nViral load (HIV -1 RNA)  ● Baseline viral load (VL) is recommended for infants after \\n1st PCR test is positive. Specimen for baseline VL can be \\ndrawn at the time of initiating ART; obtaining a VL should \\nnot delay ART initiation  \\nSerum Cryptococcal  \\nAntigen (sCrAg)  ● Obtain serum CrAg If CD4 ≤ 200 cells/mm3 in patients >5 \\nyears  as reflex testing by the laboratory  \\n● If positive, manage as per the cryptococcal meningitis \\nscreening algorithm (Figure 4.1)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 49}),\n",
       " Document(page_content='Initial Evaluation and Follow up  \\n3 - 5  Table 3.2 Cont.  \\nOthers  Hb (preferably full  \\nblood count if available)  ● All patients especially if on AZT  \\n●  \\nPregnancy Test  ● Pregnancy status should be determined for all women of \\nreproductive age (based on history of last menstrual period, \\nand if uncertain, irregular, or delayed then a urine pregnancy \\ntest should be performed)  \\nTB- LAM  ● Conduct TB -LAM  on a urine sample if CD4 ≤ 200 cells/mm3 \\nin PLHIV >5 years, and if CD4% ≤ 25% in children < 5 years  \\n● Seriously ill patients  \\nUrinalysis (for protein  \\n& glucose)  ● All patients  \\nCreatinine  o All patients, especially those starting TDF. Calculate \\nCreatinine Clearance (CrCl), (Annex 15)  \\nSyphilis serology', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 50}),\n",
       " Document(page_content='Creatinine  o All patients, especially those starting TDF. Calculate \\nCreatinine Clearance (CrCl), (Annex 15)  \\nSyphilis serology \\n(VDRL, TPHA, or RPR)  ● All patients with a history of being sexually active  \\nGlucose  ● All patients  \\nPlasma lipid profile  ● All patients  \\nHBsAg  ● All adolescent and adult patients (plus children who did not \\ncomplete routine childhood immunizations)  \\nHCV antibody  ● PWID or for patients with history of injection drug use  \\nALT  ● Not recommended as baseline investigation unless there is a \\nspecific clinical reason (e.g., patient with history of hepatitis, \\nsigns or symptoms of liver disease, or risk of liver disease - \\nalcoholics, HBV or HCV infection, hepatotoxic drugs such as \\nfluconazole, etc.)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 50}),\n",
       " Document(page_content='signs or symptoms of liver disease, or risk of liver disease - \\nalcoholics, HBV or HCV infection, hepatotoxic drugs such as \\nfluconazole, etc.)  \\nHPV testing  ● For women of reproductive age between 25 -49 years \\nconducted at baseline and every two years (refer to cancer \\nscreening guidelines)  \\n \\nIt is not possible for ALL facilities providing ART to offer all the laboratory tests recommended for \\nHIV treatment. If a facility does not have on -site capacity to carry out any test, arrangements \\nshould be made to transport specimens to a local or regional reference laboratory.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 50}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 6  3.4 Management of Patients Who Present with Advanced HIV Disease  \\nThe World hea lth organization (WHO) defines AHD for adults, adolescents, and children five years \\nand older as having a CD4 cell count of less than 200 cells/mm3 or WHO clinical stage III or IV \\ndisease. All children younger than five years living with HIV who are not al ready receiving ART and \\nnot clinically stable are considered to have AHD.  \\nAdvanced HIV Disease can occur in various settings including PLHIV newly presenting to care, \\nthose returning to care after treatment interruption and those on ART who have experienc ed \\ntreatment failure.  \\nPLHIV with AHD have immune suppression with reduced ability to fight opportunistic infections', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 51}),\n",
       " Document(page_content='treatment failure.  \\nPLHIV with AHD have immune suppression with reduced ability to fight opportunistic infections \\n(OI), other infectious and non -infectious diseases, and are therefore at increased risk of morbidity \\nand mortality. AHD is also associated with increased health -care costs, use of more health -care \\nservices and more frequent monitoring needs. Leading causes of mortality among adults with AHD \\ninclude immune reconstitution inflammatory syndrome, tuberculosis (TB), severe bacterial \\ninfections, cryptococcal disease, histoplasmosis, toxoplasmosis, and Pneumocystis Jirovecii \\npneumonia amongst others.  \\nCD4 testing criteria to diagnose AHD and determine eligibility for package for care:   \\n• New clients initiating ART:', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 51}),\n",
       " Document(page_content='pneumonia amongst others.  \\nCD4 testing criteria to diagnose AHD and determine eligibility for package for care:   \\n• New clients initiating ART:  \\no CD4 testing should be c onducted as a baseline test for ALL PLHIV  \\n• Patients who are treatment experienced:  \\no PLHIV ≥5 years of age and who had previously initiated ART and are reinitiating after >3 \\nmonths).  \\no Individuals who have documented persistent unsuppressed viral load (two viral load VL \\n>1,000 within 3 -6 months).  \\nPackage of Care for AHD  \\nAll PLHIV presenting  with Advanced HIV Disease (AHD) should be offered a package of care that \\nincludes timely initiation of ART, screening, diagnosis, prophylaxis, and management of \\nopportunistic infections.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 51}),\n",
       " Document(page_content='includes timely initiation of ART, screening, diagnosis, prophylaxis, and management of \\nopportunistic infections.  \\nTable 3.3 provides a summary of definitions of well versus advanced disease and package of care \\nfor each at enrolment.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 51}),\n",
       " Document(page_content='Initial Evaluation and Follow up  \\n3 - 7  Table 3.3: Differentiated Care Based on Initial Patient Presentation  \\nAdults, adolescents, and children ≥ 5 years who Present with Advanced HIV Disease: WHO Stage \\n3 or 4, or CD4 count ≤ 200 cell/mm3  \\nAll children younger than five years at enrollment into care  \\nPackage of Care  ● Standard Package of Care (Chapter 4)  \\n● Intensive management of presenting illnesses and malnutrition  \\n● Priority for identification, management, and prevention of OIs, \\nincluding.  \\no GeneXpert ultra for TB diagnosis for all PLHIV with presumptive TB \\n(Figure 8.1)  \\no TB-LAM (Figure 8.2), in addition to GeneXpert ultra, for PLHIV with \\npresumptive TB who  \\n▪ Have CD4 ≤ 200 cells/mm3 and if CD4% ≤ 25% in children < 5 \\nyears  \\n▪ Have signs of severe illness, or', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 52}),\n",
       " Document(page_content='presumptive TB who  \\n▪ Have CD4 ≤ 200 cells/mm3 and if CD4% ≤ 25% in children < 5 \\nyears  \\n▪ Have signs of severe illness, or  \\n▪ Are currently admitted to hospital  \\no Cryptococcal antigen screening for adolescents and adults with CD4 \\n≤ 200 cells/mm3 or clinical suspicion of meningitis (any age) (Figure \\n4.1)  \\no Cotrimoxazole Preventive Therapy (CPT)  \\no TB Preventiv e Therapy (TPT)  \\n● Immediate ART initiation unless they are suspected to have TB, TB \\nmeningitis, or cryptococcal meningitis;( Table 6.1)  \\n● Close monitoring for development of immune reconstitution \\ninflammatory syndrome (Annex 16)  \\nFocus of ART Preparation \\nCounselling  ● Immediate ART start is required to prevent further damage to the \\nimmune system.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 52}),\n",
       " Document(page_content='Focus of ART Preparation \\nCounselling  ● Immediate ART start is required to prevent further damage to the \\nimmune system.  \\n● Starting ART soon will decrease risk of disease progression, including \\nwasting and other infections  \\nFrequency of  \\nFollow -up ● Weekly follow -up until ART initiation, and then at week 2 and 4 after \\nART initiation, and then monthly until confirmed viral suppression.  \\n● More frequent visits or hospitalization may be required to stabilize \\nacute medical conditions and address psychosocial and other concerns  \\n● Referral for management of co -morbidities or concurrent infections \\nmay also be needed  \\nManagement of Opportunistic Infections in Patients with AHD  \\nCryptococcal Disease (CM)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 52}),\n",
       " Document(page_content='may also be needed  \\nManagement of Opportunistic Infections in Patients with AHD  \\nCryptococcal Disease (CM)  \\nCryptococcal disease is one of the most important opportunistic infections among peop le living \\nwith AHD and is a major contributor to mortality.  \\nEarly diagnosis and treatment of cryptococcal meningitis is key to reducing mortality from \\ncryptococcal disease. Health -care professionals should have a low threshold for suspecting \\ncryptococcal meningitis among people with advanced HIV disease.  \\nScreening, prevention and treatment of  cryptococcal meningitis is described in Section 4.33.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 52}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 8  Tuberculosis (TB)  \\nTB is the most frequent life -threatening OI and a leading cause of death among PLHIV. TB remains \\nthe leading cause of mortality among PLHIV, despite substantial scale -up of ART, accounting for \\n30% of the AIDS -related deaths reported.  \\nScreening, prevention  and treatment of TB is described in Chapter 8.  \\nTable 3. 4: Management of patients who are presenting well : WHO Stage 1 or 2, and CD4 count \\n> 200 cell/mm3  \\nAdults, adolescents, and children ≥ 5 years who Present Well: WHO Stage 1 or 2, and CD4 count > \\n200 cell/mm3 \\nFocus of ART Preparation \\nCounselling  ● ART is the most important treatment to maintain good health and an \\nactive life', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 53}),\n",
       " Document(page_content='200 cell/mm3 \\nFocus of ART Preparation \\nCounselling  ● ART is the most important treatment to maintain good health and an \\nactive life  \\n● Starting ART soon will decrease risk of developing wasting and other \\ninfections  \\n● ART will reduce the risk of transmitting HIV to others  \\nFrequency of  \\nFollow -up ● Weekly follow -up until ART initiation, and then at week 2 and 4 after \\nART initiation, and then monthly until confirmed viral suppression  \\n● Additional visits as required to address any medical or psychosocial \\nconcerns  \\nAdults, adolescents, and children ≥ 5 years who Present Well: WHO Stage 1 or 2, and CD4 count > \\n200 cell/mm3 \\nLocation of Services  • Management at any ART service delivery point; all facility levels', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 53}),\n",
       " Document(page_content='200 cell/mm3 \\nLocation of Services  • Management at any ART service delivery point; all facility levels   \\n• Initial management and ART initiation by trained and experienced HCW  \\nFocus of Treatment \\nPreparation Counselling  • ART is the most important treatment to maintain good health and an \\nactive life  \\n• Starting ART soon will decrease risk of developing wasting and other \\ninfections  \\n• ART will reduce the risk of transmitting HIV to others  \\n \\n3.5 Follow -up of PLHIV after ART initiation   \\nFollow -up of patients on ART is determined by the duration the patient has been on treatment, how \\nwell they understand the treatment and their response to AR T. Follow -up includes scheduled \\nclinical appointments, unscheduled clinical assessments for patients with concerns/complaints,', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 53}),\n",
       " Document(page_content='clinical appointments, unscheduled clinical assessments for patients with concerns/complaints, \\nroutine and as -needed laboratory monitoring.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 53}),\n",
       " Document(page_content='Initial Evaluation and Follow up  \\n3 - 9  3.5.1 First 6 months after ART initiation  \\nAfter ART initiation, patients need to be monitored closely for development of adverse drug events, \\nidentify and address barriers to adherence, and development of IRIS. A reasonable follow -up \\nschedule for most patients is 2 weeks and 4 weeks after ART initiation (Table 3. 5 and 3. 6).  \\nWhen possi ble, follow -up for a particular patient should be provided by the same care provider or \\nteam of care providers (e.g., same clinician and same counsellor) at every visit. This is particularly \\nimportant during the first 6 months in care.   \\n3.5.2 Differentiat ed Service Delivery for Patients beyond the 1st 6 months of ART', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 54}),\n",
       " Document(page_content='important during the first 6 months in care.   \\n3.5.2 Differentiat ed Service Delivery for Patients beyond the 1st 6 months of ART  \\nFollow up of patients beyond 6 months of ART is described in table 3. 5. It also  provides the criteria \\nfor determining if a patient is established on ART.  \\nIn summary:  \\n● Patients who are not established on ART require closer follow -up.  \\n● Patients who are established on ART require less frequent facility follow -up, with up \\nto six months b etween clinical appointments  \\n \\nTable 3. 5: Differentiated Follow -up of Patients Beyond the First 6 Months of ART  \\nPatients NOT established on ART  \\nPatients with any of the following:  \\n● On treatment for < 6 months  \\n● Any active OIs (including TB) in the previous 6 months', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 54}),\n",
       " Document(page_content='Patients with any of the following:  \\n● On treatment for < 6 months  \\n● Any active OIs (including TB) in the previous 6 months  \\n● Poor or questionable adherence to scheduled clinic visits in the previous 6 months.  \\n● Most recent VL ≥ 200 copies/ml  \\n● Children < 2 years  \\nPackage of \\nCare  ● Standard Package of Care  \\n● Case management to address reason/s for not being established on ART  \\nFocus of \\nCounselling  ● ART is the most important treatment to maintain good health and an active life  \\n● ART will reduce the risk of transmitting HIV to others   \\nFrequency of \\nFollow -up ● Every 1 -3 months, based on clinical judgment  \\n● Additional visits as required to address any medical or psychosocial concerns  \\n● If VL is detectable at 3 months they will need additional assessments for', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 54}),\n",
       " Document(page_content='● If VL is detectable at 3 months they will need additional assessments for \\nand management of the reason/s for detectable viral load, with close \\nfollow -up until viral suppression is achieved (Chapter 5).  \\n● Patients with confirmed viral suppression can be followed up every 3 -6 \\nmonths based on patient preference and clinician judgment, with \\nadditional unscheduled visits any time the patient has a concern.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 54}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 10  Table 3. 5 Cont.  \\nPatients Established on ART  \\nPatients established on ART must have achieved ALL the following  \\n● On their current ART regimen for ≥ 6 months  \\n● Currently no active Illness or in the previous 6 months (patients with well controlled chronic \\nconditions should not be excluded)  \\n● Adherent to scheduled clinic visits for the previous 6 months  \\n● VL ≤200 copies/ml (LDL) within the last 6 months  \\nNote:  \\n● This definition should be applied to all populations, including those receiving second - \\nand third -line regimens, those with controlled comorbidities, children above 2 years *, \\nadolescents, pregnant and breastfeeding women, and key populations.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 55}),\n",
       " Document(page_content='adolescents, pregnant and breastfeeding women, and key populations.  \\n● The client’s category can change at any time so there is a need for a reassessment at each \\nvisit. Clients should be categorized at every visit and managed based on their status.  \\nPackage of \\nCare  ● Standard Package of Care  \\n● Re-assessment of criteria at every clinical visit  \\nLocation of  \\nServices  ● Clinical review and ART prescription from any ART service delivery point; all \\nfacility levels  \\n● Distribution of ART between clinical appointments, which can be facility -based \\nor community -based  \\nFocus of  \\nCounselling  ● Encourage patient to continue with what is working  \\n● Reminders that any significant life event or change in daily routine could \\ninterfere with adherence  \\nFrequency of', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 55}),\n",
       " Document(page_content='● Reminders that any significant life event or change in daily routine could \\ninterfere with adherence  \\nFrequency of  \\nFollow -up ● Clinic appointments to be made at 6 months intervals  \\n● ART should be offered as refills lasting 3 months,  (through fast -track pick -up at \\nfacility or through community -based distribution). Patients on injectab le \\ncontraception should be provided FP through a fast -tracked process between \\nclinic follow -up visits; oral contraceptives and condoms should be distributed \\nwith ART  \\n● Additional visits as required to address any medical or psychosocial concerns  \\n● Closer follow -up may be arranged based on patient preference  \\n*  Children below 2 years are excluded as they require frequent dose adjustment', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 55}),\n",
       " Document(page_content='Initial Evaluation and Follow up  \\n3 - 11  3.6 Summary of clinical and laboratory monitoring of PLHIV on ART  \\nTable 3. 6 summarizes the recommended minimum routine follow -up schedule for PLHIV.  \\nAdditional clinical and laboratory follow -up should be performed whenever clinically indicated  \\nTable 3. 6: Summary of Clinical and Laboratory Monitoring for PLHIV1 \\n Initial  \\nVisit  ART  \\npreparation  Week  \\n(After \\nART)   \\nMonths (after ART)   \\n≥ 6 months  \\n \\nAppointment2,3   \\nEvery week4  \\n2  \\n4  \\n2  \\n3  \\n4  \\n5  \\n6 Every 1 -6 \\nmonths \\ndepending \\non stability  \\nHistory and \\nphysical exam5 ✔  ✔  ✔  ✔  ✔  ✔  ✔  ✔  ✔  At each \\nclinical visit  \\nAdherence \\nassessment and \\nsupport6 ✔  ✔  ✔  ✔  ✔  ✔  ✔  ✔  ✔  At each visit  \\nTB Screening  ✔  Every visit, using ICF screening tool', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 56}),\n",
       " Document(page_content='Adherence \\nassessment and \\nsupport6 ✔  ✔  ✔  ✔  ✔  ✔  ✔  ✔  ✔  At each visit  \\nTB Screening  ✔  Every visit, using ICF screening tool  \\nCD4 count  ✔  ● Baseline, and then only if patient develops treatment failure (to assess \\nfor risk of OIs), or if defaults from care (off ART) for at least 6 months  \\n● For patients on prophylaxis using dapsone (documented CTX allergy), \\nrepeat CD4 every 6 months until CD4 >200 cells/mm3 for two \\nconsecutive measures 6 months apart and VL undetectable, after which \\ndapsone and CD4 monitoring can be discontinued  \\nHIV Viral Load   ● For PCR positive HEIs: baseline at the time of ART initiation  \\n● Age 0 -24 years: at month 3, then every 6 months  \\n● Age ≥ 25 years: at month 3, then month 12, then annually thereafter if \\nsuppressed', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 56}),\n",
       " Document(page_content='● Age 0 -24 years: at month 3, then every 6 months  \\n● Age ≥ 25 years: at month 3, then month 12, then annually thereafter if \\nsuppressed  \\n● For all: before any drug substitution for patients on ART for a t least 6 \\nmonths with no valid VL, at month 3 after regimen modification, and \\nthen as per population group  \\n● Any patient with a detectable VL during routine monitoring, follow viral \\nload monitoring algorithm (Figure 6.6)  \\nHIV Viral Load \\n(pregnant/ \\nbreastfeeding)   ● If on ART at time of confirming pregnancy: VL done at confirmation of \\npregnancy (regardless of when previously done), then every 6 months \\nuntil complete cessation of breastfeeding  \\n● If starting ART during pregnancy or breastfeeding, VL at 3 months after', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 56}),\n",
       " Document(page_content='until complete cessation of breastfeeding  \\n● If starting ART during pregnancy or breastfeeding, VL at 3 months after \\ninitiation, and then every 6 months until complete cessation of \\nbreastfeeding', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 56}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 12  Table 3. 6 Cont.  \\nCrAg  ✔  Baseline for adults and adolescents with CD4 ≤ 200 cells/mm3 (as reflex \\ntesting by laboratory), then only if there is clinical suspicion of CM  \\nHb ✔  Baseline, then symptom directed; if on AZT, baseline then weeks 2, 4, and \\n12 \\nPregnancy \\nStatus  ✔  At every visit for women of reproductive age (by history +/ - urine \\npregnancy test)  \\nUrinalysis \\n(protein & \\nglucose)  ✔  Baseline, then annually if on TDF  \\nCreatinine  ✔  Baseline, then annually if on TDF  \\nGlucose  ✔  Baseline, then annually  \\nPlasma lipid \\nprofile  ✔  Baseline, then annually  \\nHBsAg  ✔  Baseline, followed by immunization for all patients who screen \\nnegative (after viral suppression is confirmed)  \\nSyphilis \\nserology \\n(VDRL,', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 57}),\n",
       " Document(page_content='negative (after viral suppression is confirmed)  \\nSyphilis \\nserology \\n(VDRL, \\nTPHA, or \\nRPR)  ✔  Baseline, then annually in those at risk and as part of routine ANC profile  \\nDrug \\nResistance  \\nTesting   DRT recommended once treatment failure confirmed on a DTG - or PI -based \\n1st line regimen, or confirmed treatment failure on 2nd line or subsequent \\nregimens  \\nALT   Not recommended for routine baseline or follow -up unless specific clinical \\nindication  \\nCervical \\nCancer  All women should be screened for cervical cancer following the national guidelines.  \\nUsing HPV screening conducted every 2 years for HIV positive women in their \\nreproductive age (or annually if using VIA -VILI)  \\nHCV  Baseline for PWIDs or with a history of injection drug use', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 57}),\n",
       " Document(page_content='Initial Evaluation and Follow up  \\n3 - 13  Table 3. 6 Cont.  \\n1 Recommended investigation should not delay ART initiation.  \\n 2This is the recommended appointment schedule. Clinicians and patients should be encouraged to \\nschedule additional appointments as needed. Patients should be encouraged to return to the HIV \\nclinic for unscheduled appointment whenever  an acute issue arises, instead of seeking care at \\nanother facility. Early after initiation of ART, and after any regimen modification , every \\nappointment should include:  \\n− Continued adherence counselling and support (started at the initial visit)  \\n− Assessment of adherence and correct storage of medication  \\n−  Assessment for and management of early side effects of the drugs, and patient counselling \\non the same', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 58}),\n",
       " Document(page_content='−  Assessment for and management of early side effects of the drugs, and patient counselling \\non the same  \\n3 Patients who are adherent and virally suppressed at month 3, may not need subsequent \\nmonthly appointments until month 6.  \\n4 All PLHIV qualify for ART and should be initiated as soon as possible including same day and \\nwithin 2 weeks. For patients who do not  start ART on the same day as enrolment into HIV care, \\nthey should be followed up every week until ART initiation to address whatever issues are \\ndelaying ART initiation, for ongoing management of acute medical issues and for treatment \\npreparation and ART r eadiness assessment.  \\n4Refer to table 3.1 for detailed history and physical examinations.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 58}),\n",
       " Document(page_content='preparation and ART r eadiness assessment.  \\n4Refer to table 3.1 for detailed history and physical examinations.  \\n5children and adolescents, weight and height should be measured and recorded at every visit, \\nwith weight -based dosing of ARVs confirmed at every visit.  \\nIn adults, weig ht and height should be measured at the initial visit to determine nutritional status \\nand calculate the BMI, and thereafter, weight should be measured at every visit.  \\n6The first 2 -4 visits are critical for assessing and supporting adherence to ART, managi ng adverse \\ndrug reactions, and treating any acute illnesses including IRIS. Adherence should be assessed at \\nevery contact with the clinic. See Chapter 5 for specific adherence preparation, monitoring and \\nsupport procedures for each visit', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 58}),\n",
       " Document(page_content='every contact with the clinic. See Chapter 5 for specific adherence preparation, monitoring and \\nsupport procedures for each visit  \\nRequired laboratory tests are highly recommended for patient monitoring, but are not a pre -\\nrequisite for ART initiation.  \\nTargeted laboratory tests may be necessary to identify and manage inter -current diseases or \\nadverse drug reactions.  \\n3.7 Differentiated Care for Children, Adolescents and Pregnant/ breastfeeding \\nWomen  \\nChildren, adolescents, pregnant and breastfeeding women, and key populations face unique \\nchallenges in retention  and viral suppression and  hence may benefit more from different iated \\nservice delivery models  adapted to their needs.  \\nChildren:  Children’s care is dependent on family and care giver dynamics. Family centered', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 58}),\n",
       " Document(page_content='service delivery models  adapted to their needs.  \\nChildren:  Children’s care is dependent on family and care giver dynamics. Family centered \\napproaches to care where clinic visits for parents/caregivers and the child are synchronized, \\nshould be used.  A ssessment and categorization to determine establishment on ART should be \\nconducted for pairs and follow -up tailored to their situations. Weight -based dose adjustments \\nshould be incorporated in both the facility and community models (e.g., by using portable  weighing \\nscales if out of the health facility) to determine optimal doses for ARVs at each review.  Aligning \\nappointments with school calendar should be considered to avert disruption of treatment and \\nlearning of the child.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 58}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 14  Adolescents:  Adolescents requi re psychosocial support, ongoing adherence assessments and \\ncounselling which should be aligned with clinic visits, community follow -up as well as school \\ncalendar.  Considerations should be factored in during the clinical encounters with more focus to \\nthose  with adherence and viral suppression challenges. Adolescents and Youth Friendly services \\nthat incorporate life skills and extracurricular activities should be integrated where feasible.  \\nPregnant/breastfeeding women:  Pregnant and breastfeeding women who h ave been established \\non ART should have their HIV clinic appointments synchronized with Antenatal Care visits and with', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 59}),\n",
       " Document(page_content='on ART should have their HIV clinic appointments synchronized with Antenatal Care visits and with \\nfollow -up of the HIV -exposed infant. Those initiated on ART during pregnancy may need close \\nfollow up to support them in adherence, reten tion and achieving viral suppression. Breast feeding \\nwomen and their babies will have their clinical visit aligned with the immunization clinics schedule. \\nPsychosocial support groups are encouraged for both pregnant and breastfeeding mothers \\nincluding peer  to peer support.  \\n3.8 ART Prescription, Dispensing, and Distribution for clients established on \\nART  \\nPatients who are established on ART should be offered ART  refills of up to 3 months. The refill of', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 59}),\n",
       " Document(page_content='ART  \\nPatients who are established on ART should be offered ART  refills of up to 3 months. The refill of \\nother associated commodities such as cotrimoxazole, TPT a nd condoms should be aligned to the \\nART refill schedule. Clients established on ART should receive their ART, CPT, family planning, and \\nany other chronic medicines through a distribution system that minimizes the burden on them \\n(travel costs, waiting times , inconvenience) and burden on the health facility (personnel time, \\nspace constraints, etc.). This must be on a voluntary basis (i.e., the client can choose to remain in \\nstandard care if they prefer).  \\nThe health facility is responsible for ART prescription , dispensing, and distribution for all patients', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 59}),\n",
       " Document(page_content='standard care if they prefer).  \\nThe health facility is responsible for ART prescription , dispensing, and distribution for all patients \\nenrolled into care. ART distribution for patients established on ART can take place at the health \\nfacility or through a community distribution system, depending on patient preference and health \\nfacility syste ms and resources. The point of ART dispensing should be based on client ability \\nto access treatment with ease.  Models for ART refills include:  \\n● Facility -based  \\no Fast track facility -based refills  \\no Facility -based ART distribution groups  \\n● Community -based  \\no Community -based ART distribution groups  \\no Community ART distribution points  \\no Community pharmacy distribution  \\nFacility -based Fast Track System for ART Refills', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 59}),\n",
       " Document(page_content='o Community ART distribution points  \\no Community pharmacy distribution  \\nFacility -based Fast Track System for ART Refills  \\nThe facility -based fast track system for ART  refills is a simple model implemented at the health \\nfacility. The client is still required to come to the clinic every 3 months for ART refill, however the \\nrefill appointments require minimal or no waiting time at the clinic.   Refer to DSD operational \\nmanual for detailed information on community models.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 59}),\n",
       " Document(page_content='Initial Evaluation and Follow up  \\n3 - 15  Facility -based ART Distribution Group  \\nFacility -based ART Distribution Groups are a model for ART distribution, whereby a group of \\nPLHIVs meet at a designated location within their health facility for drug refills and dispense \\ndrugs to their peers within the group while ensuring peer support and treatment literacy.  ART \\nrefills are done through the group every 3 months and  each client is required to attend their \\nclinical review appointment e very 6 months.   \\nThis model may provide clients with psychosocial support if they are not already part of a support \\ngroup. This may also be more convenient for clients who are in urban settings and would not wish', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 60}),\n",
       " Document(page_content='group. This may also be more convenient for clients who are in urban settings and would not wish \\nto be enrolled in a community -based group. F acility -based groups can be peer or HCW led.  \\nCommunity -based ART Distribution Models  \\nClients may receive ART refills through community -based distribution. All clients may also benefit \\nfrom home visits such as for adherence monitoring and support, on a case -by-case basis.  \\nClients can receive their ART refill through community -based models such as:  \\n● Community -based ART distribution groups  \\n● Community ART distribution points  \\n● Community pharmacy distribution  \\nBefore implementing a community -based ART distribution program, a health facility should work', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 60}),\n",
       " Document(page_content='● Community pharmacy distribution  \\nBefore implementing a community -based ART distribution program, a health facility should work \\nwith the CHMT to design a program that meets the criteria listed in Annex 14, and the plan \\napproved by the County HIV Technical Working Group before implementation. Refer to DSD \\noperational manual for det ailed information on community models.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 60}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 16', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 61}),\n",
       " Document(page_content='Standard Package of Care for PLHIV  \\n4 - 1   \\n4. Standard Package of Care for PLHIV  \\n \\nAll PLHIV should receive a package of services that are known to promote health, improve the \\nquality of life, prevent further HIV transmission, and prevent HIV disease progression and \\nmortality.  \\nThe standard package of care for PLHIV in cludes: antiretroviral therapy; Positive Health, Dignity \\nand Prevention (PHDP) services; screening and providing support in cases of gender -based \\nviolence (GBV) or intimate -partner violence (IPV); HIV education/counselling; screening and \\nprevention of spec ific opportunistic infections; reproductive health services; screening for and \\nmanagement of non -communicable diseases; mental health screening and management;', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 62}),\n",
       " Document(page_content='management of non -communicable diseases; mental health screening and management; \\nnutritional services; and prevention of other infections (Table 4.1).  \\nThe standard package of ca re should always be applied using a patient - and family -\\ncentered approach  in PLHIV management.  Patient -centered care includes: considering the \\nindividual patient’s health needs; eliciting and addressing the patient’s concerns and expectations; \\ninvolving th e patient’s (and their family and friends as appropriate) in decision -making, and; \\nrespecting the patient’s values and preferences. Family -centered care identifies, engages and \\nprovides care to all HIV -positive family members, prevents new infections among  family members \\nat risk, and promotes family support and awareness.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 62}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 2  Table 4.1: Components of the Standard Package of Care for PLHIV  \\nComponent of Standard Package of Care Sub components  \\nAntiretroviral therapy (ART)  ● ART initiation  \\n● Adherence assessment, counselling and support  \\n● Monitoring (clinical and laboratory)  \\nPositive health, dignity and prevention \\n(PHDP); gender -based violence (GBV) \\nand intimate -partner violence (IPV) \\nscreening; and HIV \\neducation/counselling  ● Disclosure  \\n● Index testing  \\n● Condom use  \\n● Family planning  \\n● STI screening, prevention, and treatment  \\n● Adherence counselling and support  \\n● Pre-exposure prophylaxis for HIV -negative sexual partners  \\n● GBV/IPV screening and support  \\n● HIV education/counselling', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 63}),\n",
       " Document(page_content='● Pre-exposure prophylaxis for HIV -negative sexual partners  \\n● GBV/IPV screening and support  \\n● HIV education/counselling  \\nSpecific opportunistic infection screening \\nand prevention  ● Cotrimoxazole preventive therapy  \\n● Tuberculosis (TB)  \\no Intensified case finding  \\no TB preventive therapy  \\no ART for TB/HIV co -infected patients  \\n● Cryptococcal meningitis  \\nReproductive health services  ● Sexually transmitted infections screening and management  \\n● Family planning and pre -conception services  \\n● Maternal healthcare  \\n● Cervical cancer screening  \\nNon -communicable diseases (NCD) \\nscreening and management  ● Hypertension  \\n● Diabetes mellitus  \\n● Dyslipidemia  \\n● Chronic kidney disease  \\n● Other NCDs  \\nMental health screening and management  ● Depression  \\n● Anxiety  \\n● Stress', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 63}),\n",
       " Document(page_content='● Dyslipidemia  \\n● Chronic kidney disease  \\n● Other NCDs  \\nMental health screening and management  ● Depression  \\n● Anxiety  \\n● Stress  \\n● Trauma  \\n● Alcohol and drug use/addiction  \\n● Self-care and wellbeing  \\nNutritional services  ● Assessment  \\n● Counselling and education  \\n● Management and support  \\nPrevention of other infections  ● Immunizations  \\n● Malaria  \\n● Safe water, sanitation and hygiene', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 63}),\n",
       " Document(page_content='Standard Package of Care for PLHIV  \\n4 - 3  Table 4.1 Cont.  \\nStandard Package of Care for HIV -Exposed and HIV -Infected Infants  \\n● Determine HIV status at first contact through HTS/EID and link to HIV care  \\n● Provide ARV prophylaxis for all HEIs and ART for all HIV -infected children ( confirming correct \\nweight -based dosing of ARVs at every visit ); perform clinical and laboratory assessment  \\n● Provide nutritional assessment, counselling and support (NACS, Section 4. 7) and monitor growth and \\ndevelopment of the child (Annex 3)  \\n● Ensure that all immunizations are provided following the national schedule (Section 4.8.1)  \\n● Clinical assessment at every visit, treat infections early, identify, manage and report adverse drug', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 64}),\n",
       " Document(page_content='● Clinical assessment at every visit, treat infections early, identify, manage and report adverse drug \\nreactions aggressively and refer appropriately where specialized care is required.  \\n● Screen for opportunistic infections and provide prophylaxis (cotrimoxazole, TB Preventive Therapy \\n(TPT), deworm every 6 months (starting at 1 year of age) and provide supplemen tal Vitamin A every 6 \\nmonths (starting at age 6 months)  \\n● Educate the caregiver on all aspects of care for the child including infant feeding, immunizations, \\npersonal hygiene, HIV education/counselling, adherence, availability of support for child disclosure , \\nand follow -up requirements  \\n● Adherence assessment, counselling and support', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 64}),\n",
       " Document(page_content='and follow -up requirements  \\n● Adherence assessment, counselling and support  \\n● Provide age -appropriate psychosocial support for the family and child and refer to community -based \\nsupport programs as appropriate  \\n● Ensure that the caregiver and family members are r eceiving appropriate care, support and treatment  \\n● Provide intensive case management for mother/infant pair until 2 years postpartum; identify \\ndefaulters and prioritize this population for tracking  \\n● Enroll in Orphans and Vulnerable Children (OVC) program for social protection and other services.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 64}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 4  Table 4.1 Cont.  \\nStandard Package of Care for Adolescents Living with HIV  \\nClinical care  \\n● Provide immediate linkage to HIV care  \\n● Provide ART to all HIV -infected adolescents  \\n● Perform clinical and laboratory assessment  \\n● Clinical assessment at every visit, treat infections early and refer appropriately where specialized care \\nis required  \\n● Screen for opportunistic infections and provide prophylaxis (cotrimoxazole, TPT)  \\n● Provide NACS and monitor growth and  development  \\n● Provide/refer for HPV vaccine  \\nAdherence and psychosocial support  \\n● Perform a baseline and regular subsequent psychosocial assessment  \\n● Assess for and support disclosure of HIV status to the adolescent (Annex 5)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 65}),\n",
       " Document(page_content='● Perform a baseline and regular subsequent psychosocial assessment  \\n● Assess for and support disclosure of HIV status to the adolescent (Annex 5)  \\n● Enroll in age -appropriate psychosoci al support groups  \\n● Provide treatment literacy  \\n● Provide life skills counselling  \\n● Provide adherence counselling  \\n● Support appropriate transition into adult HIV treatment and prevention  \\n \\nPrevention of HIV transmission  \\n● Encourage index testing and support for disclosure  \\n● Assess for and manage drug and alcohol use  \\n● Perform a sexual risk assessment and STI screening and treatment, and linkage of sexual partner to \\nPrEP where applicable  \\n● Assess for and manage IPV  \\n● Provide reproductive health services, including pregnan cy screening, pregnancy intention assessment,', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 65}),\n",
       " Document(page_content='● Assess for and manage IPV  \\n● Provide reproductive health services, including pregnan cy screening, pregnancy intention assessment, \\nfamily planning and linkage to PMTCT for pregnant adolescents  \\nReferrals, linkages and support for continuum of care  \\n● Provide intra -facility & inter -facility referrals as needed for specialized care  \\n● Link with youth community groups, targeting youth both in and out of school  \\nOther services  \\nlegal centers, paralegal services, gender -based violence recovery centers, educational institutions, \\nbursary/scholarship programs, income generating activities, constituency development funds, vocational \\ntraining centers for skills development, etc.  \\n4.1 Antiretroviral Therapy', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 65}),\n",
       " Document(page_content='training centers for skills development, etc.  \\n4.1 Antiretroviral Therapy  \\nART is recommended for all PLHIV, regardless of WHO stage, CD4 count, age, pregnancy status, \\nor comorbidities/co -infections. O nce a diagnosis of HIV infection is confirmed, ART should be \\ninitiated as soon as possible (preferably within 2 weeks), once patient readiness has been \\ndetermined. Other sections of these guidelines deal with initial evaluation and monitoring \\n(Chapter 3), patient preparation and adherence support (Chapter 5), and specific recommended \\nART regimens (Chapter 6).', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 65}),\n",
       " Document(page_content='Standard Package of Care for PLHIV  \\n4 - 5  4.2 PHDP, GBV/IPV & HIV Education/Counselling  \\nPHDP (Positive Health, Dignity and prevention) is a framework that emphasizes the health and \\nrights of P LHIV, including reducing risk of onward transmission of HIV.  Within PHDP are 7 core \\ndomains of services that should be provided at the health facility to PLHIV and caregivers (Table \\n4.2). Complementary community -based PHDP should also be implemented.  \\nTabl e 4.2: Domains and Components for PHDP Services  \\nPHDP Domain  Components  \\nDisclosure of HIV status  ● Assessment of disclosure status, particularly to sexual partners  \\n● Assisted disclosure  \\nNote: for children and adolescents, it is also necessary to evaluate for and', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 66}),\n",
       " Document(page_content='● Assisted disclosure  \\nNote: for children and adolescents, it is also necessary to evaluate for and \\nsupport age -appropriate HIV disclosure to the child/adolescent (Annex 5)  \\nIndex testing and \\nengagement  ● HIV testing of sexual and drug injecting partners  \\n● HIV testing of other family members at risk  \\n● Enrolment of positive partners/family members into HIV care  \\n● Engagement of negative partners and family members in care and \\nsupport for index patient, and PrEP as appropriate  \\nCondom use  ● Risk reduction counseling  \\n● Correct and consistent condom use  \\n● Provision of condoms at every visit  \\nFamily planning  ● Assessment of pregnancy intention  \\n● Pre-conception counselling  \\n● Dual contraception until ready for pregnancy', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 66}),\n",
       " Document(page_content='Family planning  ● Assessment of pregnancy intention  \\n● Pre-conception counselling  \\n● Dual contraception until ready for pregnancy  \\n(See Section 4.4.2 for specific clinical guidelines)  \\nSexually transmitted \\ninfections (STI)  ● Screening for symptoms of STIs  \\n● Prevention of STIs  \\n(See Section 4.4.1 for specific clinical guidelines)  \\nTreatment adherence  ● Benefits/importance of:  \\no Adherence to clinical care  \\no Adherence to ART  \\n● Messaging on Undetectable=Untransmissible (U=U)  \\n (Chapter 5)  \\nPre-exposure prophylaxis  ● Assess HIV -negative sexual partners for PrEP  \\n(Chapter 11)  \\nAdditional services that should be offered to PLHIV beyond the above components include screening for GBV and IPV \\nand HIV education/counseling services.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 66}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 6  4.2.1 Screening for Gender -Based Violence (GBV)/Intimate -Partner Violence (IPV)  \\nNational data (KDHS 2014) shows that 45% of women and 44 % of men aged 15 -49 years have \\nexperienced physical violence since age 15.; 14% of women and 6% of men age 15 -49 report \\nhaving experienced sexual violence at least once in their lifetime.  To identify these survivors \\nscreening is recommended. WHO recommends that facilities should meet the minimum \\nrequirement before starting to routinely screening clients.  \\nThe minimum require ments are:   \\n• A protocol or Standard Operating Procedure exists for providing post -GBV and Violence \\nAgainst Children  services', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 67}),\n",
       " Document(page_content='• A protocol or Standard Operating Procedure exists for providing post -GBV and Violence \\nAgainst Children  services  \\n• A questionnaire, with standard questions where providers can document responses,  \\n• Providers offer first -line support (LIVES)  \\n• Providers have received training on how to ask about GBV and Violence Against Children  \\n• Private setting, confidentiality ensured  \\n• A system for referrals or linkages to other services within the facility is in place  \\nIf any of these minimum requirements is mis sing, GBV and Violence Against Children  services are \\nconsidered inadequate, and providers should ensure to have these systems in place before \\nconducting routine enquiry or universal screening', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 67}),\n",
       " Document(page_content='considered inadequate, and providers should ensure to have these systems in place before \\nconducting routine enquiry or universal screening  \\nAll clients accessing HIV care services should be screened for a ny form of violence \\nincluding  IPV as part of the standard package of care for PLHIV.  \\nThe following script can be used for screening:  \\n “Many people do not realize that violence can lead to various serious health problems. Many \\npeople have problems with thei r husbands, partners or other people in their lives. Sometimes the \\npeople who love us can hurt us. Has this ever happened to you?”  \\nHas your partner ever:  \\n1. Insulted you or made you feel bad about yourself?  \\n2. Belittled or humiliated you in front of other people?   \\n3. Did things to scare or intimidate you on purpose', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 67}),\n",
       " Document(page_content='2. Belittled or humiliated you in front of other people?   \\n3. Did things to scare or intimidate you on purpose  \\n4. Threatened to hurt you or someone you care about?  \\n5. Slapped you or thrown something at you that could hurt you?  \\n6. Kicked, dragged, beat you up?  \\n7. Chocked or  burned you on purpose?  \\n8. Threatened to use or actually used a gun, knife or other weapon against you?  \\n9. Physically forced you to have sexual intercourse when you did not want?  \\n10. Did you ever have sexual intercourse you did not want because you were afraid of w hat \\nhe might do?  \\n11. Forced you to do something sexual that you found degrading or humiliating?  \\nIf a survivor answers yes to any of these questions provide them with LIVES and do a mental \\nassessment', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 67}),\n",
       " Document(page_content='Standard Package of Care for PLHIV  \\n4 - 7  Table 4.2a: Components of screening for GBV/IPV (LIVES)  \\nListen  Listen to the client closely, with empathy and without judging  \\nInquire  Assess and respond to the client’s various needs and concerns  \\nValidate  Show the client that you understand and believe them. Assure the client that they \\nare not to blame  \\nEnhance safety  Discuss a plan to protect the client from further harm if violence occurs again  \\nSupport  Support the client by helping them to access information, services and social \\nsupport  \\nSupportive messages that may be helpful include:  \\n● “What happened to you is not your fault”  \\n● “Many women/men are in the same situation as you”  \\n● “You are not to blame.”', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 68}),\n",
       " Document(page_content='● “What happened to you is not your fault”  \\n● “Many women/men are in the same situation as you”  \\n● “You are not to blame.”  \\n● “Everybody deserves to feel safe at home if you feel like you are in immediate danger, we can \\ninvolve the police or local administration “  \\nMen, the  elderly, and children suffer different forms of violence and should be assessed if there \\nis any clinical suspicion. Key populations are particularly vulnerable to abuse, including MSM, \\ntransgender, and prisoners. For children art and play therapy is used during history taking and \\npsychological assessment.  \\n4.2.2 HIV Education/Counselling  \\nAll PLHIV and caregivers should receive focused education about HIV and its treatment to', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 68}),\n",
       " Document(page_content='4.2.2 HIV Education/Counselling  \\nAll PLHIV and caregivers should receive focused education about HIV and its treatment to \\nempower them to succeed in management of the infection. Self -management is critica l to the \\nsuccessful treatment of any chronic illness, including HIV. Key messages for HIV education and \\nadherence counselling are described in Chapter 5 of these guidelines.  \\nIn addition, psychosocial counselling and support for PLHIV and caregivers should include:  \\n● Mitigation of fear, anger, self -stigma and discrimination  \\n● Alleviation of grief, bewilderment and stress among partners and family members  \\n● Behavior changes in support of healthy living and prevention of further HIV transmission  \\n● Skills -building on how to live a healthy and productive life', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 68}),\n",
       " Document(page_content='● Skills -building on how to live a healthy and productive life  \\n● Identification and treatment of depression and substance abuse  \\nHIV education and counselling can be offered in multiple settings, including: facility -based \\nindividual, couples, family, and/or gro up counselling, and through community -based counselling \\nand peer support groups.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 68}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 8  4.3 Specific Opportunistic Infection Screening and Prevention  \\n4.3.1 Cotrimoxazole Preventive Therapy (CPT)  \\nCPT is no longer recommended as life -long prophylaxis, and is only recommended in the \\nfollowing sub populations, unless they have an allergy to sulfur drugs or develop toxicity from \\nCPT:  \\n● HIV exposed infants  \\n● HIV infected children and adolescents <15 years of age  \\n● PLHIV > 15 years of age:  \\no Living in malaria -endemic zones * \\no Presenting with WHO stage 3 or 4 event, or meeting the criteria AHD  \\no Suspected treatment failure  \\n● All Pregnant and Breast -feeding women  \\nFor HIV exposed and infected infants, CPT should start at 6 weeks of age. CPT is effective in AHD,', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 69}),\n",
       " Document(page_content='● All Pregnant and Breast -feeding women  \\nFor HIV exposed and infected infants, CPT should start at 6 weeks of age. CPT is effective in AHD, \\nand preventing specific OIs for patients with low CD4 counts (PCP and toxoplasmosis), as well as \\nreducing the risk of common bacterial infections, sepsis, diarrhea illness and malaria.  \\n*Refer to the National Guidelines for the Diagnosis, Treatment and Prevention of Malaria in Kenya for the \\ncurrent Kenya Malaria endemicity map  \\nTable 4.3: Co -trimoxazole Preventive therapy  \\nSub -Population  Starting/Restarting criteria  Ending criteria  \\nHIV exposed Infants  All infants, starting 4 -6 weeks \\nafter birth  Child is confirmed HIV -negative  \\n \\nHIV-infected children \\nand adolescents ≤ 15 \\nyears old  All children  Attains 15 years of age', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 69}),\n",
       " Document(page_content='after birth  Child is confirmed HIV -negative  \\n \\nHIV-infected children \\nand adolescents ≤ 15 \\nyears old  All children  Attains 15 years of age  \\nPLHIV > 15 years old  Suspected treatment failure  \\nWHO Clinical Stage 3 and 4  Clinically stable:  \\no On ART for at least 12 months  \\no Showing no signs or symptoms of \\nWHO Clinical Stage 2,3 or 4  \\nHIV-positive \\nPregnant and \\nbreastfeeding women  All Clinically stable:  \\no On ART for at least 12 months  \\no Showing no signs or symptoms of \\nWHO Clinical Stage 2,3 or 4  \\no Not pregnant or breastfeeding', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 69}),\n",
       " Document(page_content='Standard Package of Care for PLHIV  \\n4 - 9  Table 4.4: Daily Dose of Cotrimoxazole Preventive Therapy  \\nWeight (kg)  If using oral suspension  \\n(240mg per 5ml)  If using single \\nstrength tablet 480 \\nmg (SS)  If using double strength \\ntablet 960 mg (DS)  \\n1 – 4 2.5 ml  ¼ SS tab  -- \\n5 – 8 5 ml  ½ SS tab  ¼ DS tab  \\n9 – 16 10 ml  1 SS tab  ½ DS tab  \\n17 – 30 15 ml  2 SS tabs  1 DS tab  \\n> 30  20 ml  2 SS tabs  1 DS tab  \\nAdult (any weight)   2 SS tabs  1 DS tab  \\nNote: If CrCl 15 -30 ml/min then use 50% of normal recommended dose; if CrCl < 15 ml/min then CTX should \\nbe avoided  \\nDuring pregnancy, CPT should be initiated irrespective of the gestational age and should \\ncontinue throughout pregnancy and breastfeeding. Additional intermittent preventive', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 70}),\n",
       " Document(page_content='continue throughout pregnancy and breastfeeding. Additional intermittent preventive \\ntherapy (sulfadoxi ne-pyrimethamine (SP)) for malaria is not required for women already \\non CPT.  \\nCotrimoxazole can cause anaemia and neutropenia in some patients, as well as a skin rash.  \\nManagement of Patients with Cotrimoxazole Allergy  \\n● A rash may occasionally develop, usually about 7 -14 days following initiation of CPT. It \\nis often a relatively mild maculopapular rash with or without pruritus. Infrequently, rash \\nmay develop with severe exfoliation of the skin and Stevens -Johnson syndrome. Rash \\nseverity should b e assessed, with management based on severity (Table 4.5)  \\n● Desensitization is effective in the majority of patients with mild to moderate rash (Table', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 70}),\n",
       " Document(page_content='● Desensitization is effective in the majority of patients with mild to moderate rash (Table \\n4.6a). The rapid desensitization regimen (Table 4.6 b) can be used in situations where \\ntreatment for PCP is needed  \\nTable 4.5: Management of Drug -Associated Skin Rash  \\nSeverity  Characteristics  Action  \\nMild  Dry; erythema +/ - fine \\npapules; pruritus; affecting \\n< 50% of body surface area  Continue CTX; close monitoring; symptomatic treatment with \\nantihistamines +/ - topical steroids (NOT oral steroids)  \\nModerate  Dry; erythema +/ - fine \\npapules; pruritus; affecting \\n≥ 50% of body surface area  Stop CTX; symptomatic treatment with antihistamines +/ - \\ntopical steroids (NOT oral steroids); trial of desensitization \\nafter symptoms completely resolved  \\nSevere  Mucosal involvement;', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 70}),\n",
       " Document(page_content='topical steroids (NOT oral steroids); trial of desensitization \\nafter symptoms completely resolved  \\nSevere  Mucosal involvement;  \\nblistering; associated fever; \\nany % of body surface area  Stop CTX; admission to hospital for supportive management (IV \\nfluids, wound care, pain control, infection control, monitoring \\nfor super -infection); patient should NEVER be re -challenged \\nwith CTX or other sulfa -containing drugs;  document and \\nreport adverse event and issue patient alert card', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 70}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 10   \\n \\n Cotrimoxazole Desensitization Protocols (for patients who have fully recovered from \\nmoderate reaction)  \\nTable 4.6a: Standard Cotrimoxazole \\nDesensitization Regimen (8 days)  Table 4.6b: Rapid Cotrimoxazole \\nDesensitization Regimen (6 hours)  \\n \\nDay  \\nDose of TMP/SMX Suspension  \\n(40/200 mg per 5ml)  \\nDay 1 0.5 ml  \\nDay 2 1 ml \\nDay 3 2 ml \\nDay 4 3 ml \\nDay 5 4 ml \\nDay 6 5 ml \\nDay 7 1 SS tablet  \\nDay 8 2 SS tablets/1 DS tablet per day  \\nNote: For children, continue up until they have \\nreached their recommended weight -based dosage  \\n  \\nHour  \\nDose of TMP/SMX Suspension \\n(40/200  mg per 5ml) \\nHour 0 0.5 ml \\nHour 1 1 ml \\nHour 2 2 ml \\nHour 3 3 ml \\nHour 4 4 ml \\nHour 5 5 ml \\nHour 6 1 SS tablet', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 71}),\n",
       " Document(page_content='Dose of TMP/SMX Suspension \\n(40/200  mg per 5ml) \\nHour 0 0.5 ml \\nHour 1 1 ml \\nHour 2 2 ml \\nHour 3 3 ml \\nHour 4 4 ml \\nHour 5 5 ml \\nHour 6 1 SS tablet \\nNote: The rapid desensitization protocol should \\nnot be used for children because the cumulative \\ndosage will be too high  \\n \\n \\nDapsone as a Substitute for CPT  \\nIn situations of severe allergy to cotrimoxazole or when desensitization is not successful, \\ndapsone can be used instead of CTX. It is primarily effective as prophylaxis against PCP but does \\nnot have the other prophylactic benefits of cotrimoxazole.  \\nNote:  \\nDapsone will contribute to anaemia in most patients, and causes haemolytic anaemia in some \\npatients, so pati ents should have a baseline Hb before starting dapsone and Hb monitored every', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 71}),\n",
       " Document(page_content='patients, so pati ents should have a baseline Hb before starting dapsone and Hb monitored every \\n1-2 weeks for the first couple of months.  \\nWhen dapsone (as a substitute for CPT) is being used as PCP prophylaxis, it is only \\nrecommended for patients in WHO Stage 4 and/or with  absolute CD4 count ≤ 200 \\ncells/mm3 (or CD4 % ≤ 25% for children ≤ 5 years old), and should be discontinued once \\na patient achieves a sustained CD4 count of > 200 cells/mm3 (or > 25% for children ≤ 5 \\nyears old) for at least 6 months.  \\nDapsone is NOT recomme nded during breastfeeding.  \\nDose of Dapsone  \\n● Available as 25 mg and 100 mg tabs  \\n● Children: 2 mg/kg once daily (maximum dose: 100 mg) OR 4 mg/kg once weekly \\n(maximum dose: 200 mg)  \\n● Adults: 100 mg once daily', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 71}),\n",
       " Document(page_content='Standard Package of Care for PLHIV  \\n4 - 11  4.3.2 Tuberculosis (TB) Prevention and Management for PLHIV  \\nAll PLHIV should be screened for TB at every visit using the Intensified Case Finding (ICF) tool.  \\nAll PLHIV older than 12 months of age who screen negative for TB should be provided with TB \\nPreventive Therapy (TPT) unless they have a s pecific contraindication.  All patients who receive \\na full course of TPT should have this clearly documented in their file (Section 8.2)  \\nFor PLHIV who have presumptive TB, GeneXpert ultra is the preferred testing platform to \\nconfirm the diagnosis, with TB -LAM used as an adjunct bedside test when indicated, while \\nawaiting GeneXpert ultra -results. All PLHIV qualify for ART, including patients with HIV/TB co -\\ninfection.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 72}),\n",
       " Document(page_content='awaiting GeneXpert ultra -results. All PLHIV qualify for ART, including patients with HIV/TB co -\\ninfection.  \\nChapter 8 provides specific guidelines for ICF, TPT, use of GeneXpert ultra and TB -LAM, and ART \\nfor patients with TB/HIV co -infection.  \\n4.3.3 Cryptococcal Meningitis (CM) Screening and Treatment  \\nAll adult and adolescent PLHIV with a baseline CD4 count of ≤ 200 cells/mm3   should be \\nscreened for cryptococcal infection (Figure 4.1). This should be a  reflex test performed by the \\nlaboratory as soon as the low CD4 count is noted, rather than requiring the clinician to order a \\nspecial test for screening.  \\nPLHIV, including children and adolescents, should receive cryptococcal screening if clinically', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 72}),\n",
       " Document(page_content='special test for screening.  \\nPLHIV, including children and adolescents, should receive cryptococcal screening if clinically \\nsuspec ted. For patients who are symptomatic for meningitis but screen serum CrAg negative, \\nalternative diagnoses for sub -acute meningitis should be explored, such as TB meningitis. All \\npatients with clinical meningitis should be assessed and managed at a facilit y that can perform \\nlumbar punctures.  \\nWhenever performing CSF CrAg for patients with symptomatic meningitis, CSF GeneXpert \\nultra for TB should be performed at the same time, as well as urine for TB -LAM . \\nFluconazole use during first trimester of pregnancy in creases the risk of birth defects. All \\npregnant women who screen positive with serum CrAg should be offered a lumbar puncture', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 72}),\n",
       " Document(page_content='pregnant women who screen positive with serum CrAg should be offered a lumbar puncture \\n(irrespective of symptoms) to determine if they have cryptococcal meningitis. If the CSF CrAg is \\npositive, they should be treated with 2 weeks of amphotericin B for induction (without \\nfluconazole), while consulting Uliza!  Hotline (0726 460 000; ulizanascop@gmail.com) to discuss \\nconsolidation/maintenance. Pregnant women with negative CSF CrAg should start ART \\nimmediately (without pre -emptive fluconazole therapy) and be monitored for symptoms of CM.  \\nTable 4. 7 provides detailed guidance on the use of amphotericin, fluconazole, flucytosine (once \\navailable), and therapeutic lumbar punctures for the treatment of symptomatic cryptococcal \\nmen ingitis', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 72}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 12  Table 4. 7: Treatment of Cryptococcal Meningitis  \\nTarget \\npopulation  Regimen  Induction (2 \\nweeks)1,2 Consolidation \\n(8 weeks)  Maintenance  When to start  \\nART  \\nAdults  Preferred  Ampho B 1.0 \\nmg/kg/day + \\nFluconazole \\n1,200 mg/day  Fluconazole6  \\n800 mg/day  Fluconazole 200 \\nmg/day for at \\nleast 1 year and \\nuntil CD4 count  \\n> 200 cells/mm3 \\nfor two measures  \\n6 months apart \\nAND VL is \\nundetectable  Defer ART until \\nafter completing  \\n5 weeks of CM \\ntreatment and \\nsymptoms have \\nresolved  Alternative  Fluconazole,3,4,5,6  \\n1,600 mg daily  Fluconazole6 \\n800 mg daily  \\nChildren and \\nadolescents  Preferred  Ampho B 1.0 \\nmg/kg/day + \\nFluconazole 12 \\nmg/kg/day (up \\nto max 800 \\nmg/day)  Fluconazole 6 -\\n12 mg/kg/day \\nup to', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 73}),\n",
       " Document(page_content='adolescents  Preferred  Ampho B 1.0 \\nmg/kg/day + \\nFluconazole 12 \\nmg/kg/day (up \\nto max 800 \\nmg/day)  Fluconazole 6 -\\n12 mg/kg/day \\nup to  \\n800 mg/day  Fluconazole  \\n6mg/kg/day up \\nto 200 mg/day  \\nAlternative  Fluconazole3,4,5 \\n12 mg/kg/day \\n(up to max \\n1,600 mg/  \\nday)  Fluconazole 12 \\nmg/kg/day up \\nto \\n800 mg/day  Fluconazole  \\n6mg/kg/day up \\nto 200 mg/day  \\n1Amphotericin B should always be used for induction when available. If it is not possible to complete 2 weeks \\nof induction with ampho due to availability, toxicity or monitoring, then use a shorter duration of ampho and \\ncomplete the 14 -day induction period with the alternative regimen  \\n2Once available, flucytosine may become part of the  preferred and alternative induction regimens, given', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 73}),\n",
       " Document(page_content='2Once available, flucytosine may become part of the  preferred and alternative induction regimens, given \\n100mg/kg per day divided into four doses per day  \\n3Fluconazole requires a dose adjustment for impaired renal function; when CrCl ≤ 50 ml/min then use 50% \\nof the standard recommended dose  \\n4Fluconazole shou ld not be used with rifabutin -based TB treatment  \\n5When using high -dose fluconazole check ALT after one week of treatment and based on symptoms \\nthereafter  \\n6Fluconazole is contraindicated in the first trimester of pregnancy. Amphotericin can be used. Please consult \\nexpert or National or Regional TWG.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 73}),\n",
       " Document(page_content='Standard Package of Care for PLHIV  \\n4 - 13  Managing and Monitoring for Amphotericin B Therapy  \\nAdults  \\n• Give 1 L of normal saline with 20 mmol of KCl over 2 -4 hours before each controlled \\ninfusion of Ampho B given with 1 litre of 5% dextrose. Add one to two tablets of 8 mEq \\nKCl orally twice daily. An additional one 8 mEq KCl tablets twice daily may be added in \\nthe second week. Include magnesium supplementation at 250 mg tablets of magnesium \\ntrisilicate twice daily (or 4 mEq tablets of magnesium chloride t wice daily)  \\nAdolescents and Children  \\n• Give 1 L of normal saline with 20 mmol of KCl over 2 -4 hours before each controlled \\ninfusion of Ampho B. Darrows or Ringer’s solutions can also be used', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 74}),\n",
       " Document(page_content='infusion of Ampho B. Darrows or Ringer’s solutions can also be used  \\nNote: Avoid KCl replacement in patients with pre -existing renal imp airment or \\nhyperkalemia  \\n \\nManaging hypokalaemia and raised creatinine levels  \\n• Obtain a routine baseline and twice weekly potassium and creatinine:  \\n- If K < 3.3 mmol/L, administer 1 L of normal saline with KCl 40 mmol in normal saline \\nor 1 -2 tablets of 8mEq KCl every 8 hours. Add magnesium. Monitor potassium daily  \\n- If creatinine level increases > 2 -fold from baseline, omit dose of Ampho B, increase \\nhydration to 1 L every 8 hours. If there’s improvement, re -start Ampho B at 0.7 \\nmg/kg/day on alternate days. If n o improvement, discontinue Ampho B, give \\nfluconazole 1,600 mg/day to complete induction. Monitor creatinine daily', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 74}),\n",
       " Document(page_content='fluconazole 1,600 mg/day to complete induction. Monitor creatinine daily  \\nTherapeutic lumbar punctures are a critical component of the management of CM and \\nshould be standard of care:  \\n• For all patients with symptomati c CM: perform daily therapeutic lumbar punctures:  \\n- If opening pressure is ≤ 40 cm: draw off enough CSF to reduce pressure to 20 cm  \\n- If opening pressure is > 40 cm: draw off enough CSF to reduce pressure by 50%  \\n- Continue daily LPs until pressure is normal for 3 consecutive days  \\n- Restart LPs if symptoms return  \\nIf measuring intracranial pressure is not possible (even using a giving set and tape measure), \\nthen perform daily therapeutic LPs until severe headache subsides, removing 10 -20 ml of CSF \\neach tim e', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 74}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 14  \\nNewly diagnosed HIV -infected adult or adolescent\\nCD4   200 cells/mm3\\nAutomatic/reflex CrAg \\nscreening\\nSerum CrAg POSITIVE Serum CrAg NEGATIVE\\nSymptom Screen: Progressive headache, fever, \\nmalaise, neck pain, confusion\\nSymptomatic: Admit and do \\nLumbar puncture to obtain CSF \\nfor CrAg and geneXpert• Asymptomatic1: Offer presumptive treatment for possible early CM with \\nfluconazole 1,600 mg per day for 2 weeks, followed by fluconazole 800 \\nmg per day for 8 weeks, followed by fluconazole 200 mg per day for at \\nleast 1 year and until CD4 count >200 cells/mm3 for two measures 6 \\nmonths apart and VL is undetectable (LDL <200copies/ml )\\n• Defer ART for 5 weeks2\\n• Monitor closely and perform LP if symptoms develop', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 75}),\n",
       " Document(page_content='months apart and VL is undetectable (LDL <200copies/ml )\\n• Defer ART for 5 weeks2\\n• Monitor closely and perform LP if symptoms develop\\nNB: Lumber puncture for CSF CrAg is strongly recommended for pregnant \\nwomen irrespective of symptoms3\\nCSF CrAg positive: Treat for cryptococcal \\nmeningitis with amphotericin, fluconazole \\nand therapeutic LPs (Annex 7)\\nDefer ART until completed 5 weeks of \\ntreatment and has resolution of \\nsymptoms2• CSF CrAg negative: Offer pre -emptive therapy for non -meningeal \\ndisease with fluconazole 800 mg per day for 2 weeks, followed by \\nfluconazole 400 mg per day for 8 weeks, followed by fluconazole \\n200 mg for at least 1 year and until CD4 count >200 cells/mm3 for \\ntwo measures 6 months apart and VL is undetectable (LDL \\n<200copies/ml )', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 75}),\n",
       " Document(page_content='200 mg for at least 1 year and until CD4 count >200 cells/mm3 for \\ntwo measures 6 months apart and VL is undetectable (LDL \\n<200copies/ml )\\n• Defer ART until completed 5 weeks of treatment and has \\nresolution of symptoms2\\nLP is recommended for all sCrAg positive patients irrespective of symptoms with management based on LP results. If \\nLP is not available to rule out meningeal disease then patients should be treated for possible CM, even if \\nasymptomatic\\nPatients with cryptococcal meningitis are at high risk of developing life-threatening IRIS;  deferring ART has \\nshown to improve survival for these specific \\nFluconazole use during pregnancy increases the risk of birth defects. All pregnant women who screen positive with', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 75}),\n",
       " Document(page_content='Fluconazole use during pregnancy increases the risk of birth defects. All pregnant women who screen positive with \\nserum CrAg should be offered a lumbar puncture (irrespective of symptoms) to determine if they have cryptococcal \\nmeningitis\\nNote: \\n• Fluconazole requires a dose adjustment for impaired renal function; when CrCl      ml/min then use 50% of the \\nstandard recommended dose\\n• Fluconazole should not be used with rifabutin -based TB treatment\\n• When using high -dose fluconazole check ALT after one week of treatment and based on symptoms thereafter• No cryptococcal treatment required\\n• Initiate ART within 2 weeks \\nFigure 4.1: Routine Screening for Cryptococcal Meningitis for HIV -infected Adults and Adolescents', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 75}),\n",
       " Document(page_content='Standard Package of Care for PLHIV  \\n4 - 15  4.4 Reproductive Health Services  \\n4.4.1 Sexually Transmitted Infections  \\nScreening for syphilis using VDRL, TPHA, or RPR should be performed as a baseline investigation \\nfor all adolescent and adult PLHIV. Pregnant women should be screened for Syphilis during the \\nfirst ANC visit and 3rd trimester.  \\n \\nAll PLHIV should be assessed for symptoms of STIs using the National Algorithm s for Treating \\nCommon STI Syndromes (Kenya National guidelines for management and control of STIs, 2018. \\nAnnex 4). Sexual partners should be treated as well.  \\n \\nRisk reduction counselling and provision of condoms is an integral part of STI treatment.  \\n \\nPatien ts who have persistent signs and symptoms of STIs after syndromic treatment should', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 76}),\n",
       " Document(page_content='Patien ts who have persistent signs and symptoms of STIs after syndromic treatment should \\nundergo diagnostic evaluation for definitive diagnosis and treatment.  \\n \\nAt initial diagnosis of HIV, all sex workers should be treated for presumptive gonorrhoea and \\nchlamydi a (following treatment recommendations of vaginal/urethral discharge syndrome as \\nper national STI guidelines), with presumptive treatment every quarter.  \\n \\n4.4.2 Family Planning and Pre -Conception Counselling  \\nPregnancy status should be determined for all wom en of reproductive age at every visit (based \\non history of last menstrual period and, if uncertain, irregular, or delayed, then a urine pregnancy \\ntest should be performed).', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 76}),\n",
       " Document(page_content='on history of last menstrual period and, if uncertain, irregular, or delayed, then a urine pregnancy \\ntest should be performed).  \\n \\nPregnancy intention should be determined for all women of reproductive age and the ir partners \\nso that appropriate family planning or pre -conception counselling can be provided.  \\n \\nFor patients who do not have an immediate desire to become pregnant, dual contraception \\n(defined as condoms plus another form of effective contraception) should  be provided \\nimmediately with follow -up appointments scheduled to ensure no interruption in contraception \\nprovision. Table 4.8  outlines contraception options for PLHIV based on the ARVs they are using.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 76}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 16  Table 4.8 : Contraceptive Methods for PLHIV Based on  WHO 2018 Medical Eligibility Criteria  \\nContraceptive Method  ARVs Being Used  Anti -TB \\nNRTI \\n(any)  NNRTI  \\nPI/r \\n(any)  INSTI  \\nRifampicin or \\nRifabutin  EFV \\nor \\nNVP  ETR  RAL  DTG*  \\nIM medroxyprogesterone (DMPA; Depo \\nProvera)  1 1 1 1 1 - 1 \\nNorethisterone enanthate (NET -EN; \\nnorethindrone)  1 2 1 2 1 - 2 \\nImplants  1 2 1 2 1 - 2 \\nCombined oral contraceptive (pill)  1 2 1 2 1 - 3 \\nIntrauterine \\ndevice (IUD)  Initiation  ● Category 2 for asymptomatic or mild HIV disease (WHO Stage 1 \\nor 2, or any WHO Stage once they are stable on ART)  \\n● Category 3 for women with advanced and symptomatic HIV \\ndisease UNTIL they are stable on ART and asymptomatic', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 77}),\n",
       " Document(page_content='● Category 3 for women with advanced and symptomatic HIV \\ndisease UNTIL they are stable on ART and asymptomatic  \\nContinuation  Category 2 for all women regardless of symptomatic HIV (do not \\nrequire IUD to be removed)  \\nCondoms  No restrictions; use encouraged in combination with a hormonal \\ncontraception method or IUD as part of dual FP to prevent STI/HIV \\ntransmission  \\nEmergency contraceptive pill (ECP)  No restrictions; can be started up to 5 days after intercourse  \\nSterilization  No reason to deny; delay in case of acute HIV -related infection  \\nFertility awareness -based (FAB) methods  Can use if menstrual cycle is regular, although reliability is not as \\ngood as hormonal contraceptive methods or IUD. Encoura ge to use \\nin combination with condoms to prevent STI/HIV transmission', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 77}),\n",
       " Document(page_content='good as hormonal contraceptive methods or IUD. Encoura ge to use \\nin combination with condoms to prevent STI/HIV transmission  \\nLactational amenorrhoea method (LAM)  Effective for women who are less than 6 months post -partum, are \\nexclusively breastfeeding, and have not resumed menses. Encourage \\nto use in combinat ion with condoms to prevent STI/HIV \\ntransmission  \\nSpermicides and diaphragm  Use is not recommended; may increase risk of HIV transmission  \\nCategory 1: No restriction for the use of the contraceptive method  \\nCategory 2: Advantages of using the method generally outweigh the theoretical or proven risks  \\nCategory 3: The theoretical or proven risks usually outweigh the advantages of using the method', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 77}),\n",
       " Document(page_content='Category 3: The theoretical or proven risks usually outweigh the advantages of using the method  \\n*DTG was not included in the WHO 2018 MEC Guidelines, however, drug interactions between DTG and \\nhormonal con traception have not been identified  \\nFor patients who intend to become pregnant, the key pre -conception messages and services are \\npresented in Table 4. 9.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 77}),\n",
       " Document(page_content='Standard Package of Care for PLHIV  \\n4 - 17  Table 4. 9: Pre -Conception Counselling Messages and Services for PLHIV  \\nScenario  Key Counselling Messag es Pre-conception Services (in \\naddition to the Standard Package of \\nCare for PLHIV)  \\nAll \\nwomen/couples \\nwith intention to \\nconceive  ● All PLHIV qualify for ART, with \\ninitiation preferably within 2 weeks \\nof HIV diagnosis  \\n● Deferring pregnancy until confirmed \\nviral suppression reduces risk of \\nvertical transmission to the baby, \\nimproves infant outcomes, and \\nreduces risk of cross -transmission to \\nthe sexual partner  \\n● Unprotected sex should be limited to \\ndays when ovulation is expected \\n(based on basal tempe rature \\nmonitoring, fertility calendar based \\non menstrual cycles, and/or fertility \\ncalendar app)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 78}),\n",
       " Document(page_content='(based on basal tempe rature \\nmonitoring, fertility calendar based \\non menstrual cycles, and/or fertility \\ncalendar app)  \\n● Routine ANC and delivery by a \\nskilled birth attendant improves \\noutcomes for mother and baby  ● ART for all PLHIV, including those \\nintending to become pregnant  \\n● Baseline investigations  \\no Hb (with management of \\nanaemia)  \\no Syphilis screening  \\no Cervical cancer screening  \\n● STI symptom screening  \\n● Nutritional assessment, \\ncounselling, and support  \\n● Folic acid supplementation  \\n● Standard VL monitoring (Figure \\n6.6)  \\n● PrEP for the HIV -negative partner  \\nAdditional \\nmessages for \\ndiscordant \\ncouples: male \\npartner HIV \\npositive  ● Defer unprotected sex until confirmed viral suppression in the HIV positive \\npartner', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 78}),\n",
       " Document(page_content='discordant \\ncouples: male \\npartner HIV \\npositive  ● Defer unprotected sex until confirmed viral suppression in the HIV positive \\npartner  \\n● Discuss use of PrEP for the HIV-negative partner (Chapter 11)  \\n● In situations where viral suppression is challenging, consider specialist referral \\nfor additional options such as sperm washing and artificial insemination  \\nAdditional \\nmessages for \\ndiscordant \\ncouples: female \\npartner HIV \\npositive  ● Defer unprotected sex until confirmed viral suppression in the HIV -positive \\npartner  \\n● Discuss use of PrEP for the HIV -negative partner (Chapter 11)  \\n● Discuss self -insemination during the peri -ovulatory period, where \\nappropriate/as preferred  \\n● In situations where viral suppression is challenging, consider specialist referral', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 78}),\n",
       " Document(page_content='appropriate/as preferred  \\n● In situations where viral suppression is challenging, consider specialist referral \\nfor additional options such as artificial insemination', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 78}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 18  4.4.3 Maternal Healthcare  \\nMaternal healthcare begins with preconception counselling (Table 4. 9), and continues \\nthroughout pregnancy and breastfeeding. The standard package of antenatal and postnatal \\nservices in the context of HIV is described in Chapter 7 of these guidelines.  \\n4.5 Non -communicable Diseases Screening and Management  \\n4.5.1 Metabolic Disorders  \\nScreening, prevention and management of specific NCDs are included in the standard package of \\ncare for PLHIV because of their associated high morbidity and mortality. PLHIV are at higher risk \\nfor cardiovascular, liver and kidney disease because o f the chronic inflammatory state associated', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 79}),\n",
       " Document(page_content='for cardiovascular, liver and kidney disease because o f the chronic inflammatory state associated \\nwith HIV infection itself, and also as a side -effect of some of the ARVs.  \\nThe modifiable risk factors for cardiovascular disease include tobacco use and exposure to \\ntobacco smoke, unhealthy diets, overweight/obe sity, physical inactivity, harmful use of alcohol, \\nhypertension, diabetes, hyperlipidemia, infections such as rheumatic fever and HIV. Advancing \\nage, sex, race/ethnicity and family history are non -modifiable risk factors associated with \\ncardiovascular dise ases  \\nHIV and other chronic diseases require health systems that support chronic care and  \\nadherence; their management should be integrated at the health facility, including at the \\nprimary care level.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 79}),\n",
       " Document(page_content='adherence; their management should be integrated at the health facility, including at the \\nprimary care level.  \\nLifestyle modifications are always the first line of prev ention and management for \\nhypertension, diabetes mellitus (DM), and dyslipidaemia (Table 4. 10). These are \\nrecommended for all patients to prevent these NCDs and should be integrated into routine HIV \\ntreatment and prevention. Recommendations for screening, diagnosis, and initial management \\nof hypertension, type 2 DM, dyslipidaemia, and chronic kidney disease (CKD) are provided in \\nTables 4.1 1-4.14. \\nFor comprehensive guidelines on prevention, diagnosis and management of diabetes and \\ncardiovascular diseases, re fer to Kenya National Clinical Guidelines for the Management of', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 79}),\n",
       " Document(page_content='cardiovascular diseases, re fer to Kenya National Clinical Guidelines for the Management of \\nDiabetes  and Kenya National Guidelines for Cardiovascular Diseases Management , respectively.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 79}),\n",
       " Document(page_content='Standard Package of Care for PLHIV  \\n4 - 19  Table 4. 10: Lifestyle Modifications to Prevent and Manage Cardiovascular Disease in PLHIV  \\nSmoking Cessation  \\n● Smoking cessation has multiple short -term and long -term benefits, including  \\no Reduced premature aging/wrinkling of skin  \\no Improved fitness and quicker recovery from common infections  \\no Reduced risk of respiratory infections and chronic lung disease  \\no Reduced risk of high blood pressure, diabetes, kidney disease, heart disease, and stroke  \\no Improved infant outcomes (for pregnant women)  \\no Reduced risk of cancers: lung, bladder, breast, mouth, throat, esophagus  \\no Better response to ART (better viral suppression)  \\no Reduced risk of developing TB or dying from TB', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 80}),\n",
       " Document(page_content='o Better response to ART (better viral suppression)  \\no Reduced risk of developing TB or dying from TB  \\n● Tobacco dependence treatment and cessation programs should combine behavioral/counseling \\nsupport with pharmacotherapy treatment where necessary and available. For further details on \\ncessation interventions, refer to the Kenya National Guidelines for Tobacco Dependence \\nTreatment  \\nRefer to Table 4.1 8 for tips to assist a client to quit smoking  \\n \\nDietary Changes and Weight Loss  \\n● Weight loss to maintain a healthy BMI (nutritionists to be engaged in patient care)  \\n● Drink 8 glasses of water per day  \\n● Reduce/abstain from alcohol  \\n● Cut down sugar intake  \\n● Cut down red meat intake  \\n● Cut down consumption of fatty foods, fat for flavoring, and fried foods', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 80}),\n",
       " Document(page_content='● Cut down sugar intake  \\n● Cut down red meat intake  \\n● Cut down consumption of fatty foods, fat for flavoring, and fried foods  \\n● Increase intake of whole grain s, vegetables, fruit, and beans  \\n● Increase intake of fish  \\n● Consume less than 5 g (just under a teaspoon) of salt per day  \\n \\nPhysical Activity  \\n● Active lifestyle with moderate -intensity physical activity  \\n● 30 minutes of aerobic activity such as brisk walking, at least 5 days per week', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 80}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 20  Table 4.1 1: Hypertension Screening, Diagnosis, and Initial Management for Adult PLHIV  \\nScreening  \\n● BP should be measured and recorded for every adult at every visit  \\nDiagnosis  \\n● Hypertension requiring intervention is defined as BP ≥ 140/90 mmHg on at least 3 different occasions  \\nAdditional Investigations for patients with hypertension  \\n● Urinalysis: to assess for kidney disease and diabetes  \\n● Creatinine, Na, K: to assess for kidney disease  \\n● Blood glucose: to assess for diabetes  \\n● Full blood count: anaemia may indicate chronic kidney disease  \\n● Lipid profile: dyslipidemia is a cardiovascular risk factor  \\n● ECG: to assess for cardiac pathology including cardiomegaly, ventricular dysfunction, ischemic heart', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 81}),\n",
       " Document(page_content='● ECG: to assess for cardiac pathology including cardiomegaly, ventricular dysfunction, ischemic heart \\ndisease, etc.  \\nManagement (treatment target is BP < 140/90 mmHg)  \\n● If baseline BP is 120 -139/80 -89 (pre -hypertension)  \\no Lifestyle modification, along with monthly BP monitoring  \\n \\n● If baseline BP is 140 -159/90 -99 \\no Lifestyle modification (Table 4.9) for up to 6 months, along with monthly BP monitoring  \\no If does not meet treatment target with lifestyle modifications, then add drugs to lifestyle \\nmodification  \\no In PLHIV without  kidney disease or diabetes, first -line antihypertensive therapy is a thiazide \\ndiuretic s uch as hydrochlorothiazide starting at 12.5 mg OD (maximum dose 25 mg OD) OR a', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 81}),\n",
       " Document(page_content='diuretic s uch as hydrochlorothiazide starting at 12.5 mg OD (maximum dose 25 mg OD) OR a \\ncalcium channel blocker such as amlodipine starting at 2.5 mg OD (maximum 10 mg OD)  \\no In PLHIV with kidney disease or diabetes the first antihypertensive should be an ACE -I or ARB  \\nsuch as enalapril 2.5 -10 mg OD (maximum dose is 20 mg BD); or, losartan 50 mg OD (maximum \\ndose is 100 mg OD), with referral to a physician if available  \\no Introduce one drug at a time. If the target blood pressure is not reached within one month after \\ninitia ting therapy, the dosage of the initial medication should be increased. Titrate to maximum \\nrecommended dosage (if tolerated) before adding an additional drug  \\no If inadequate response once dose has been titrated, an additional agent may be required e.g.,', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 81}),\n",
       " Document(page_content='o If inadequate response once dose has been titrated, an additional agent may be required e.g., \\nhydr ochlorothiazide starting at 12.5 mg OD (maximum dose 25 mg OD)  \\no If inadequate response to two agents, consider consultation with or referral to a physician  \\no Note: Calcium -channel blockers have known drug interactions with PIs and NNRTIs and \\nshould be used with caution (Annex 13). ACE -I and thiazide diuretics do not have significant \\ninteractions with ARVs  \\n \\n● If baseline BP ≥ 160/100 mmHg  \\no Initiate lifestyle modifications and introduce anti -hypertensive medications concurrently', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 81}),\n",
       " Document(page_content='Standard Package of Care for PLHIV  \\n4 - 21  Table 4.1 2: Type 2 Diabetes Mellitus Screening, Diagnosis, and Initial Management for PLHIV  \\nScreening  \\n● Blood glucose (fasting or random) should be evaluated at baseline for all PLHIV, then annually if \\nbaseline screening is normal; urine dipstick for protein and glucose can be used if blood glucose \\ntesting is not available  \\nDiagnosis  \\n● Diabetes Mellitus is defined as fasting blood sugar ≥ 7.0 mmol/L, or random blood sugar ≥ 11.1 \\nmmol/L, or HbA1c > 6.5%, or oral glucose tolerance test ≥ 11.1 mmol/L  \\n● Abnormal results should be repeated to confirm the diagnosis, particularly for patients without \\nsymptoms of diabetes (such as polyuria, polydipsia, polyphagia, weight loss)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 82}),\n",
       " Document(page_content='symptoms of diabetes (such as polyuria, polydipsia, polyphagia, weight loss)  \\n \\nManagement (treatment target is HbA1c ≤ 7.0% or FBS 4 -7 mmol/L)  \\n● For patients with pre -diabetes (abnormal results but does not meet criteria above for diabetes) \\nmonitor FBS or HbA1c every 3 months and encourage lifestyle modifications (Table 4. 10) \\n \\n● For patients with diabetes, monitor HbA1c (or FBS if HbA1c is not available) every 3 months  \\n \\n● Lifestyle modification (weight loss, nutritional support to manage portion sizes and calculate \\nglycaemic index of various foods to hel p with control of blood sugar) for 3 -6 months  \\n \\n● If does not meet treatment target with lifestyle modifications then add drugs  \\no Metformin', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 82}),\n",
       " Document(page_content='● If does not meet treatment target with lifestyle modifications then add drugs  \\no Metformin  \\n▪ Obtain baseline Creatinine; do NOT use metformin if creatinine clearance < 45 ml/min  \\n▪ Start with low dose (500 mg OD or BD) and titrate up every 1 -2 weeks until reaches 1 g BD (or \\nmaximum tolerated dose if less than 1 g BD)  \\n▪ Note:  DTG may increase metformin plasma levels: monitor blood glucose levels; dose reduction \\nof metformin may be required, and maximum daily dose of met formin should be 1g  \\no If does not meet treatment targets with metformin for 3 -6 months at maximum tolerated dose then \\nconsider adding drug from another class (such as sulphonylureas (gliclazide)) and/or specialist \\nconsultation. Some patients may require insu lin.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 82}),\n",
       " Document(page_content='consider adding drug from another class (such as sulphonylureas (gliclazide)) and/or specialist \\nconsultation. Some patients may require insu lin. \\no At every visit: A thorough history (to elicit features of hypoglycemia, other cardiovascular disease \\nrisk factors, neuropathy, diabetic foot ulcers) and a physical exam (for BP, neuropathy, foot ulcers)  \\n \\n● Additional routine screening for patients with diabetes  \\no Annual ophthalmology examination for diabetic retinopathy  \\no Annual urinalysis: start on an ACE -I/ARB if proteinuria develops (even if BP normal)  \\nNote : patients with DM are at increased risk of developing TB', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 82}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 22  Table 4.12: Dyslipidemia Screening, Diagnosis, and Initial Management for PLHIV  \\nScreening  \\n● Fasting lipid profile should be evaluated at baseline for all PLHIV, then annually if baseline screening \\nis normal  \\nDiagnosis  \\n● Dyslipidemia is defined as high fasting total cholesterol (>5.2 mmol/L), LDL (>3.4 mmol/L) or \\ntriglycerides (>2.2 mmol/L)  \\nManagement  \\n● Lifestyle modification for 3 -6 months (Table 4. 10) \\n● If the patient is on an ARV known to cause or exacerbate dyslipidemia (primarily LPV/r & EFV) then \\nconsider a single -drug substitution to a more lipid -friendly drug (such as ATV/r or DTG) as the \\ntreatment of choice before adding a lipid -lowering drug. Rule out treatment failure before making', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 83}),\n",
       " Document(page_content='treatment of choice before adding a lipid -lowering drug. Rule out treatment failure before making \\nsingle -drug substitutions (Figure 6.4)  \\n● If patient does not meet treatment  target with lifestyle modifications, then add drugs  \\no Atorvastatin: starting dose of 10 mg OD (maximum dose 20 mg once daily if patient is on a PI/r; \\nmaximum dose 80 mg once daily if not on a PI/r)  \\no Simvastatin and lovastatin are contraindicated in the presence of PI/r  \\no Allow at least 3 months before repeating fasting lipids and titrating dose  \\nOnce targets achieved can monitor lipids every 6 -12 months', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 83}),\n",
       " Document(page_content='Standard Package of Care for PLHIV  \\n4 - 23  Table 4.13: Chronic Kidney Disease Screening, Diagnosis, and Initial Management for PLHIV  \\nScreening  \\n● Urinalysis (for protein) and serum creatinine should be evaluated at baseline for all PLHIV and \\nmonitored annually  \\nDiagnosis  \\n● Impaired renal function is defined as creatinine clearance < 90 ml/min, or dipstick proteinuria ≥ 1 \\n(see Annex 15 for CrCl calculations)  \\n● Abnormal results should be repeated to confirm diagnosis  \\n● Chronic kidney disease is defined as evidence of kidney damage that persists for at least three \\nmonths  \\nManagement  \\n● Management depends on the cause of the renal impairment; additional investigations and/or \\nspecialist consultation may be required  \\n● Consultations with a physician is recommended', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 84}),\n",
       " Document(page_content='specialist consultation may be required  \\n● Consultations with a physician is recommended  \\n● Treat dehydration promptly and aggressively  \\n● If on TDF -containing regimen, substitute with another ARV if C rCl<50 ml/min (see Section 6.5), \\nwith the exception of patients with HBV/HIV co -infection (Table 9.3 for renal dose adjustments of \\nTDF and 3TC for patients with HIV/HBV co -infection)  \\n● Avoid nephrotoxic drugs (e.g., aminoglycosides and NSAIDS)  \\n● Evaluate for a nd treat hypertension  \\n● All NRTIs except ABC require dose adjustments for renal impairment, depending on the severity \\n(Table 6.6 for specific dose adjustments). NNRTIs, PIs, and INSTIs do not require dose adjustments \\nfor impaired renal function', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 84}),\n",
       " Document(page_content='(Table 6.6 for specific dose adjustments). NNRTIs, PIs, and INSTIs do not require dose adjustments \\nfor impaired renal function  \\nNote: DTG may  cause a small rise in serum creatinine levels but this does NOT represent a \\ndecline in renal function, close monitoring is recommended.  \\nPatients at higher risk for renal disease and for developing TDF -associated renal toxicity include \\nthose with: pre-existing renal disease, hypertension, diabetes mellitus, severe wasting (weight \\nbelow 60 kg in adults), age > 45 years, WHO stage 3 or 4, CD4 < 200 cells/mm3, high HIV viral \\nload, and concomitant nephrotoxic agents.  \\nGlomerular disease directly related to HIV infection, commonly known as HIV -associated \\nnephropathy (HIVAN) is an important cause of chronic kidney disease among PLHIV.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 84}),\n",
       " Document(page_content='nephropathy (HIVAN) is an important cause of chronic kidney disease among PLHIV.  \\nPrevention, early identification, and management of kidney disease is important to reduce \\nthe burden of dialysis and other c omplications.  \\n4.5.2 Cancer Prevention, Early Detection and Management among PLHIV  \\nPLHIV have a substantially higher risk for many cancers, mainly due to a weakened immune \\nsystem which impairs control of oncogenic viral infections. A high prevalence of thes e infections \\nand other modifiable risk factors (such as smoking, alcohol use, unhealthy diet and physical \\ninactivity) contributes to the elevated risk. PLHIV are far more likely than the general population \\nto be diagnosed with Kaposi Sarcoma, non -Hodgkin l ymphoma and other cancers (cervical, anal,', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 84}),\n",
       " Document(page_content='to be diagnosed with Kaposi Sarcoma, non -Hodgkin l ymphoma and other cancers (cervical, anal, \\nliver, lung and oral/throat) hence the importance of prioritizing screening and early diagnosis \\nprograms in this group.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 84}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 24  4.5.2.1 Specific Interventions for Cancer Control in PLHIV  \\nFour interventions are important f or cancer control among PLHIV:  \\n● Achieve viral suppression:  uncontrolled viral replication is a major risk factor for \\ncancer. All PLHIV should initiate ART, and be supported and monitored to achieve long -\\nterm viral suppression in order to reduce risk for can cer, and to improve treatment \\noutcomes for many cancers  \\n● Primary prevention through avoidance of modifiable risk factors  \\no Smoking cessation  \\no Avoidance of harmful use of alcohol  \\no Regular physical activity  \\no Healthy diets  \\no Vaccination: vaccination against Human Papillomavirus for girls 9 -14 years old are', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 85}),\n",
       " Document(page_content='o Regular physical activity  \\no Healthy diets  \\no Vaccination: vaccination against Human Papillomavirus for girls 9 -14 years old are \\neligible in Kenya, Hepatitis B Vaccine for newborns and high -risk groups  \\n● Secondary prevention through screening and early diagnosis  \\no Screening: application of simple tests to detect cancer in asymptomatic individuals  \\n▪ Cervical cancer: all women LHIV who have been sexually active up to 49 years \\nold (25 -49 years in the general population), through either visual inspection \\nwith acetic acid (VIA) or PAP smear annually, or HPV testing every 2 years  \\n▪ Breast cancer: mammogram annually from 40 -55 years; mammogram every \\ntwo years from 56 -74 years; screening for younger women can be performed', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 85}),\n",
       " Document(page_content='▪ Breast cancer: mammogram annually from 40 -55 years; mammogram every \\ntwo years from 56 -74 years; screening for younger women can be performed \\non an individual basis based on family history or other risk factors. Clinical \\nbreast exam can be used where mammogr am is not available  \\n▪ Prostate cancer: serum prostate specific antigen (PSA) annually for men 40 \\nyears and above; digital rectal examination can be used if PSA is not available, \\nand for all men with urinary symptoms  \\n▪ Colorectal cancer: fecal occult blood test ing of stool (guaiac or FIT) annually for \\neveryone 45 -75 years old, or colonoscopy every 10 years  \\n▪ Oral cancer: visual examination for everyone above 40 years with history of \\ntobacco use, known HPV infection or immunosuppression', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 85}),\n",
       " Document(page_content='▪ Oral cancer: visual examination for everyone above 40 years with history of \\ntobacco use, known HPV infection or immunosuppression  \\no Early diagnosis: prompt diag nosis of cancer in symptomatic individuals  \\n▪ Breast: lump, asymmetry, skin changes, nipple changes, blood -stained \\ndischarge  \\n▪ Cervix: post -coital bleeding, excessive vaginal discharge  \\n▪ Colon and rectum: change in bowel habits, unexplained weight loss, anemia, \\nblood in stool  \\n▪ Oral: white or red lesions, growth, ulceration  \\n▪ Naso -pharynx: nosebleed, permanent blocked nose, deafness, lymph nodes in \\nupper neck  \\n▪ Larynx: persistent hoarseness of voice  \\n▪ Stomach: upper abdominal pain, indigestion, weight loss  \\n▪ Skin: irregular growths, lesions, or non -healing sores', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 85}),\n",
       " Document(page_content='▪ Stomach: upper abdominal pain, indigestion, weight loss  \\n▪ Skin: irregular growths, lesions, or non -healing sores  \\n▪ Bladder: painful or frequent urination, blood in urine  \\n▪ Prostate: difficulty (long time) in urination, frequent nocturnal urination  \\n▪ Retinoblastoma: white spot in the pupil, convergent strabismus (in a child)  \\n▪ Testis: swelling of one testicle', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 85}),\n",
       " Document(page_content='Standard Package of Care for PLHIV  \\n4 - 25  ● Tertiary prevention : Cancer management, prevention of complications and treatment \\nof side effects and secondary cancers  \\nNote: For screening, diagnosis, and management recommendations refer to national \\nguidelines for prevent ion and management of cancers. For individual patient \\nmanagement, referral to regional and national hospitals with capacity for comprehensive \\noncology services may be warranted.  \\n4.6 Mental Health Screening and Management  \\nPLHIV are susceptible to psychological disturbances due to HIV itself and perceptions regarding \\nHIV in their environment. Some of the most common psychological disturbances include \\ndepression and suicide, anxiety, internalized stigma, post -traumatic stress disorder, cognitive', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 86}),\n",
       " Document(page_content='depression and suicide, anxiety, internalized stigma, post -traumatic stress disorder, cognitive \\ndifficulties such as dementia, and perceived lack of social support. Any of these can significantly \\ninterfere with a patient’s sense of well -being and their adherence. Depression and alcohol/drug \\naddiction are the most significant and are reviewed in this sect ion. For any patient with other \\nsuspected mental health disorders, such as anxiety, psychosis or post -traumatic stress disorder, \\nconsider formal screening and/or referral to a specialist.  \\n4.6.1 Depression  \\nDepression is one of the most common psychiatric il lnesses in the world, and chronic illness \\n(including HIV) is a strong risk factor for depression. PLHIV are 3 -6 times more likely to suffer', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 86}),\n",
       " Document(page_content='(including HIV) is a strong risk factor for depression. PLHIV are 3 -6 times more likely to suffer \\nfrom depression than the general population, with significant disability and poorer treatment \\noutcomes if it is not identified and managed. Depression can be a significant contributing factor \\nto poor adherence and HIV treatment failure.  \\nAll PLHIV should receive basic screening for depression upon enrollment and thereafter \\nannually using the following two questions:  \\n● Duri ng the past two weeks have you often been bothered by feeling down, depressed, or \\nhopeless?  \\n● During the past two weeks have you often been bothered by little interest or pleasure in \\ndoing things?  \\nAll patients who answer “yes” to either or both of the questi ons above, and all patients with a', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 86}),\n",
       " Document(page_content='doing things?  \\nAll patients who answer “yes” to either or both of the questi ons above, and all patients with a \\ndetectable viral load after 3 or more months on ART (whether or not they had achieved viral \\nsuppression in the past), should undergo a more thorough screening for depression using the \\nPHQ -9 screening tool, with management  guided by the PHQ -9 score (Table 4.1 5).', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 86}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 26  Table 4.1 5: Patient Health Questionnaire -9 (PHQ -9) for Depression Screening  \\nPHQ -9 Depression Screening                               Name:  _________________________    Date: __________________  \\nAsk the patient the questions below for each of the 9 symptoms and circle the response for each question. After asking all \\nquestions, add the points for each column  at the bottom. The total score is the sum of the column totals. Interpretation \\nand management recommendations are provided at the bottom of the table.  \\nQuestion:  “Over the last 2 weeks, how often have you been \\nbothered by any of the following problems?”  Not at all  Several days  More than \\nhalf the days  Nearly every \\nday', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 87}),\n",
       " Document(page_content='bothered by any of the following problems?”  Not at all  Several days  More than \\nhalf the days  Nearly every \\nday \\n 1. Little interest or pleasure in doing things  0 1 2 3 \\n2. Feeling down, depressed, or hopeless  0 1 2 3 \\n3. Trouble falling or staying asleep, or sleeping too much  0 1 2 3 \\n4. Feeling tired or having little energy  0 1 2 3 \\n5. Poor appetite or overeating  0 1 2 3 \\n6. Feeling bad about yourself, or that you are a failure, or that \\nyou have let yourself or your family down  0 1 2 3 \\n7. Trouble concentrating on things (linked with patient’s usual \\nactivities, such as reading the newspaper or listening to a radio \\nprogram)  0 1 2 3 \\n8. Moving or speaking so slowly that other people could have \\nnoticed. Or the opposite, being so fidgety or restless that you', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 87}),\n",
       " Document(page_content='program)  0 1 2 3 \\n8. Moving or speaking so slowly that other people could have \\nnoticed. Or the opposite, being so fidgety or restless that you \\nhave been moving around a lot m ore than usual  0 1 2 3 \\n9. Thoughts that you would be better off dead or of hurting \\nyourself in some way  0 1 2 3 \\nTotal ____ = (add the points from each column)  0 +___  +___  +___  \\n \\nInterpretation of PHQ -9 Score and Recommended Management  \\nTotal Score  Provisional \\nDiagnosis  Recommended Management  \\n0-4 Depression unlikely  Repeat screening in future if new concerns that depression has developed  \\n5-9 Mild depression  ● Provide counselling support and continue to monitor; refer to mental \\nhealth team if available  \\n● If patient is on EFV, substitute with a different ARV after ruling out', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 87}),\n",
       " Document(page_content='health team if available  \\n● If patient is on EFV, substitute with a different ARV after ruling out \\ntreatment failure (Figure 6.4)  \\n10-14 Moderate depression*  ● Provide supportive counselling (refer to a psychologist if available)  \\n● If patient is on EFV, substitute with a different ARV after ruling out \\ntreatment failure (Figure 6.4)  \\nand  \\n● Begin antidepressant medication (or, if unfamiliar with use of \\nantidepressants, then refer to an experienced clinician)  \\nand  \\n● Refer to a medical officer, psychiatrist, or mental health team if available  15-19 Moderate -severe \\ndepression*  \\n20-27 Severe depression*  \\n*Symptoms should be present for at least 2 weeks for a diagnosis of depression and before considering treatment with', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 87}),\n",
       " Document(page_content='20-27 Severe depression*  \\n*Symptoms should be present for at least 2 weeks for a diagnosis of depression and before considering treatment with \\nantidepressant medication. Severe depression may require patients to start on anti -depressants immediately  \\nDepression is a known adverse drug reaction with EFV although it is often mild and temporary. Patients on \\nEFV who develop any persistent symptoms of depression should be switched to another ARV aft er ruling \\nout treatment failure (Figure 6.4).', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 87}),\n",
       " Document(page_content='Standard Package of Care for PLHIV  \\n4 - 27  Supportive Counselling for Depression  \\nPatients with mild depression should receive supportive counselling, which includes  \\n● Psycho -education on the following key messages  \\no Depression is common and can happen to anyone  \\no Depressed people often have exaggerated negative opinions about themselves, \\ntheir life and their future  \\no Effective treatment is possible  \\n● Counseling on self -management  \\no Continuing ART as prescribed  \\no Continuing activities that they used to find interesting/pleasurable  \\no Maintaining a regular sleep cycle  \\no Keeping physically active  \\no Participating in community/social events  \\no Returning to clinic if any thoughts of self -harm occur  \\n● Addressing psychosocial stressors', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 88}),\n",
       " Document(page_content='o Participating in community/social events  \\no Returning to clinic if any thoughts of self -harm occur  \\n● Addressing psychosocial stressors  \\no Explore potential stressors in the patient ’s life  \\no Assist in problem -solving to reduce stressors  \\no Assess for and manage intimate partner violence  \\n● Reactivation of or referral to social networks, including peer support groups  \\n● Regular follow -up until symptoms improves and are stable  \\n \\nPharmacological Management of Depression  \\nPatients with moderate depression or worse should be treated with supportive counselling plus \\nan anti -depressant medication.  \\nFluoxetine is an antidepressant and does not have significant drug interactions with ARVs.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 88}),\n",
       " Document(page_content='an anti -depressant medication.  \\nFluoxetine is an antidepressant and does not have significant drug interactions with ARVs.  \\n● Starting dose for an adult is usually 20 mg once taken daily in the morning (can start with a \\nlower dose for patients who frequently have side -effects from medications). Dose can be \\ntitrated up by 20 mg every 2 -4 weeks as needed, up to a maximum of 80 mg p er day.  \\n● Common side -effects include GI upset, headaches, insomnia, and disturbances of the \\nmenstrual cycle. These usually resolve after 1 -2 weeks of continued use.  \\n● Full effect is not achieved until around 4 weeks of continued use. Once symptoms of \\ndepres sion resolve, antidepressants should be continued for at least another 6 months.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 88}),\n",
       " Document(page_content='depres sion resolve, antidepressants should be continued for at least another 6 months.  \\n● If/when the patient is ready to discontinue antidepressant therapy it should be discontinued \\nas a weekly taper (e.g., if the maintenance dose is 60mg then taper to 40mg, then 30mg, then \\n20mg, then 10mg and then stop), with close monitoring for recurrence of symptoms.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 88}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 28  4.6.2 Alcohol and Drug Use/Addiction  \\nAlcohol and other drug use are common among the general population and among PLHIV. \\nAlcohol and drug use can be a significant contributing factor to poor adherence and HIV \\ntreatment failure.  \\nAll adults and adolescents should be screened for alcohol and drug use before initiating ART and \\nevery year using the following three questions:  \\n● During the past 12 months, did you  drink any alcohol (more than a few sips)?  \\n● During the past 12 months, did you smoke any marijuana?  \\n● During the past 12 months, did you use anything else to get high?  \\nPatients who answer “yes” to any of the questions above, and all patients with a detectable  viral', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 89}),\n",
       " Document(page_content='Patients who answer “yes” to any of the questions above, and all patients with a detectable  viral \\nload after 3 or more months on ART (whether or not they had achieved viral suppression in the \\npast), should undergo a more thorough screening.  \\nFor adolescents, use the CRAFFT screening tool (Table 4.1 6). For adults, use the CAGE -AID \\nscreening tool (Table 4.1 7). Anyone who screens positive on these tools should have further \\nassessment and management by clinical staff, ideally with experience in managing alcohol and \\ndrug use disorders. Table 4.1 8 gives some general guidance on management of addictions . The \\nNational Protocol for Treatment of Substance Use Disorders in Kenya provides more in -depth \\nguidance.   \\nTable 4.1 6: CRAFFT Screening Interview for Adolescents', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 89}),\n",
       " Document(page_content='guidance.   \\nTable 4.1 6: CRAFFT Screening Interview for Adolescents  \\nCRAFFT Screening for Alcohol and Drug Use Disorders for Adolescents  \\nAsk the patient the six questions below. Each question requires a yes/no response. Answering Yes to two \\nor more questions indicates an alcohol or drug use problem and requires further assessment and \\nmanagement.  \\n“I’m going to ask you a few questions that I ask all my patients . Please be honest. I will keep your \\nanswers confidential”  \\nQuestion  No Yes \\n1. Have you ever ridden in a Car driven by someone (including yourself) \\nwho was “high” or had been using alcohol or drugs?    \\n2. Do you ever use alcohol or drugs to Relax, feel better about yourself, or \\nfit in?    \\n3. Do you ever use Alcohol or drugs while you are alone?', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 89}),\n",
       " Document(page_content='fit in?    \\n3. Do you ever use Alcohol or drugs while you are alone?    \\n4. Do you ever Forget things you did while using alcohol or drugs?    \\n5. Do your Family or Friends ever tell you that you should cut down on \\nyour drinking or drug use?    \\n6. Have you ever gotten into Trouble while you were using alcohol or \\ndrugs?', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 89}),\n",
       " Document(page_content='Standard Package of Care for PLHIV  \\n4 - 29  Table 4.1 7: CAGE -AID Screening Questions for Adults  \\nCAGE -AID Screening for Alcohol and Drug Use Disorders for Adults  \\nAsk the patient the four questions below. Each question requires a yes/no response. Answering Yes to two \\nor more questions indicates an alcohol or drug use problem and requires further assessment and \\nmanagement.  \\n“I’m going to ask you a few questions that I ask all my patients. Please be honest. I will keep your \\nanswers confidential”  \\nQuestion  No Yes \\n1. Have you felt you should Cut down on your drinking or drug use?    \\n2. Have people ever Annoyed you by criticizing your drinking or drug use?    \\n3. Have you ever felt bad or Guilty about your drinking or drug use?', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 90}),\n",
       " Document(page_content='3. Have you ever felt bad or Guilty about your drinking or drug use?    \\n4. Have you ever had a drink or used drugs first thing in the morning to \\nsteady your nerves or to get rid of a hangover ( Eye opener)?    \\nIf referral to the mental health team is not immediately possible for those who screen positive, or as a \\nstarting point in supporting a patient while referral is being made, an assessment of whether the patient \\nwants to quit and targeted messages/support based on their stage of quitting may be benefi cial (Table \\n4.17). The National Protocol for Treatment of Substance Use Disorders in Kenya provides additional \\nresources for assessments and interventions.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 90}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 30  Table 4.1 8: Addiction Support Based on Stages of Change  \\nStage of Change  Counselling Approach  \\nPre-contemplation: not \\ncurrently considering \\nquitting; no immediate \\ndesire to quit  ● Acknowledge that not everyone is ready to think about quitting  \\n● Clarify that it is their decision  \\n● Listen to them describe the benefits they get from their alcohol or drug \\nuse (their motivation for continuing to use)  \\n● Explore why other people might think it is a good idea to quit  \\nContemplation: not sure if \\nhe/she wants to quit, or \\nthinking about quitting but \\nwith no immediate plan to \\nquit  ● Acknowledge that not everyone is ready to quite immediately  \\n● Clarify that it is their decision', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 91}),\n",
       " Document(page_content='with no immediate plan to \\nquit  ● Acknowledge that not everyone is ready to quite immediately  \\n● Clarify that it is their decision  \\n● Listen to them describe the benefits they get from the alcohol or drug use \\n(their motivation for continuing to use)  \\n● Listen to them describe the negative effects o f their alcohol or drug use \\n(their motivation for considering quitting)  \\n● Discuss any ideas they have on how they could go about quitting  \\nPreparation: would like to \\nquit within the next month  ● Congratulate them on their decision to quit  \\n● Listen to them describe the benefits they expect to get from quitting  \\n● Discuss any plan they have to try quitting  \\n● Discuss the challenges they may face with quitting', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 91}),\n",
       " Document(page_content='● Discuss any plan they have to try quitting  \\n● Discuss the challenges they may face with quitting  \\n● Problem -solve with them on overcoming challenges, including identifying \\nsupport systems  \\n● Encourage small ste ps towards quitting (e.g., avoiding situations that \\ntrigger use)  \\n● Acknowledge that they have the strength to succeed  \\nAction: actively trying to \\nquit, or has recently quit \\n(within past 6 months)  ● Listen to their experience with quitting  \\n● Congratulate them on the steps they have taken so far  \\n● Problem -solve with them on overcoming challenges, including identifying \\nsupport systems  \\n● Review the long -term benefits of quitting  \\nMaintenance: has quit (more \\nthan 6 months ago) and \\nwants to remain abstinent  ● Congratulate them on their success so far', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 91}),\n",
       " Document(page_content='Maintenance: has quit (more \\nthan 6 months ago) and \\nwants to remain abstinent  ● Congratulate them on their success so far  \\n● Discuss potential for relapse and how to deal with it  \\n● Review the long -term benefits of maintaining abstinence from drug or \\nalcohol use  \\nRelapse  ● Acknowledge that relapse is common  \\n● Evaluate what triggered the relapse  \\n● Reassess motivation to quit and barriers to quitting  \\n● Problem -solve with them on overcoming challenges and what additional \\nsupport systems and strategies can be used  \\nAs indicated in the introduction of this section on mental health (Section 4.6), the following are \\nkey areas of concern in mental ill health and there needs to be a high index of suspicion in order', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 91}),\n",
       " Document(page_content='key areas of concern in mental ill health and there needs to be a high index of suspicion in order \\nto identify these often -debilitating conditions that negatively affect an individual’s ability to cope \\nwith the tasks  of daily living. The last to items in this section contribute towards building \\nresilience which positively affects an individual’s mental health enabling them to positively \\ninteract with their environments   and live more meaningful lives.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 91}),\n",
       " Document(page_content='Standard Package of Care for PLHIV  \\n4 - 31  4.6.3 Anxiety  \\nAnxiety and other anxiety related disorders are mental health conditions that are often \\ncharacterized by experiences of one or several of the following:  \\n− Feelings of nervousness  \\n− Fear, or worry that interfere with the ability to sleep or otherwise function  \\n− A lack of appetite  \\n− Tremulousness and or frank trembling  \\n− Sweating and clamminess  of hands  \\n− Other symptoms may include a racing heart (rapid heartbeat ), difficulty breathing,  \\nheadaches, difficulty falling asleep, and difficulty concentrating.  \\nConcerns around anxiety, especially within the context of living with HIV or caring for persons \\nliving with HIV may reveal themselves during the history taking. These manifestations need to be', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 92}),\n",
       " Document(page_content='living with HIV may reveal themselves during the history taking. These manifestations need to be \\ntaken seriously and addressed with sincerity and compassion.  \\nMany of these may require basic reassurance and support or even just a listening ear during the \\nevaluation session. These will go a long way in alleviating many patient’s anxieties and conc erns. \\nA quick screening tool can be used to assess whether the anxiety demonstrated or identified may \\nrequire further attention.  \\nThe Generalized Anxiety Disorder Assessment (GAD -7) is a seven -item instrument that is used to \\nmeasure or assess the severity of generalized anxiety disorder (GAD). Each item asks the \\nindividual to rate the severity of his or her symptoms over the past two weeks.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 92}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 32  \\nOver the last 2 weeks,  how \\noften have you been bothered \\nby the following problemsNot at all Several daysMore than half \\nthe daysNearly every \\nday\\n1. Feeling nervous, anxious or \\non edge\\n2. Not being able to stop or \\ncontrol worrying\\n3. Worrying too much about \\ndifferent things\\n4. Trouble Relaxing\\n5. Being so restless that it is \\nhard to sit still\\n6. Becoming easily annoyed or \\nirritable\\n7. Feeling afraid as if \\nsomething awful might \\nhappen\\n0 +1 +2 +3\\n0 +1 +2 +3\\n0 +1 +2 +3\\n0 +1 +2 +3\\n0 +1 +2 +3\\n0 +1 +2 +3\\n0 +1 +2 +3 \\nFigure 4.2: Generalized Anxiety Disorder Assessment (GAD -7) \\nThe following cut -offs correla te with level of anxiety severity:  \\n• Score 0 -4: Minimal Anxiety  \\n• Score 5 -9: Mild Anxiety', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 93}),\n",
       " Document(page_content='The following cut -offs correla te with level of anxiety severity:  \\n• Score 0 -4: Minimal Anxiety  \\n• Score 5 -9: Mild Anxiety  \\n• Score 10 -14: Moderate Anxiety  \\n• Score greater than 15: Severe Anxiety  \\nTreatment options can then be explored including referral to psychologists, psychiatrists for \\npossible  psychotherapy and medication if required  \\n4.6.4 Stress and stress management  \\nThis is a feeling of emotional or physical tension. The symptoms include ache and pains, \\npalpitations, exhaustion, insomnia, headache,  dizziness or shaking, digestive problems, we ak \\nimmune system, muscles tension or jaw tension.  \\nMany patients may experience these symptoms individually or in clusters and they interfere with', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 93}),\n",
       " Document(page_content='immune system, muscles tension or jaw tension.  \\nMany patients may experience these symptoms individually or in clusters and they interfere with \\nthe lives they are living. Sources of stress may be from difficulties in understanding issues around \\nHIV, from  addressing different concerns within themselves, from their significant others, from', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 93}),\n",
       " Document(page_content='Standard Package of Care for PLHIV  \\n4 - 33  their workplaces. These issues could be social, financial or environmental concerns and may be \\nsevere enough to negatively impact their lives. The stress may be so severe  as to be observed by \\nanyone interacting with the individual and may manifest in their behaviour and the symptoms \\nthey complain about. It is important for the health care worker to be calm, and assured as they \\naddress the patient’s concerns around stress. Further, a  screening tool can be used to assess the \\nneed for referral to more specialized mental health workers to provide much needed support.  \\n4.6.5 experiences of Trauma  \\nTrauma results from exposure to an incident or series of events that are emotionally disturbing', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 94}),\n",
       " Document(page_content='4.6.5 experiences of Trauma  \\nTrauma results from exposure to an incident or series of events that are emotionally disturbing \\nor life -threatening with lasting adverse effects on the individual’s functioning and mental, \\nphysical, social, emotional, and/or spiritual well -being. Past traumatic experiences in PLHIV must \\nbe addressed for their wellbeing.  \\nAssessi ng for Trauma - Primary Care PTSD Screen for DSM -5 (PC -PTSD -5) \\nThe Primary Care PTSD Screen for DSM -5 (PC -PTSD -5) is a screening tool designed to identify \\npersons with probable PTSD. Results of the screening should be considered \"positive\" if the \\nrespondent  answers \"yes\" to any 3 items in the questions listed below. Those screening positive', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 94}),\n",
       " Document(page_content='respondent  answers \"yes\" to any 3 items in the questions listed below. Those screening positive \\nshould have further assessment with a structured interview for PTSD, preferably performed by a \\nmental health professional who has experience in diagnosing PTSD.  \\n“Sometim es things happen to people that are unusually or especially frightening, horrible, or \\ntraumatic. ” For example:  \\n1. A serious accident or fire  \\n2. A physical or sexual assault or abuse  \\n3. An earthquake or flood  \\n4. A war  \\n5. Seeing someone be killed or seriously injured  \\n7. Having a loved one die through homicide or suicide  \\n“If you have ever experienced this type of event, please answer the following in the past month, \\nhave you ”', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 94}),\n",
       " Document(page_content='“If you have ever experienced this type of event, please answer the following in the past month, \\nhave you ” \\n• Had nightmares about the event(s) or thought about the event(s) when you did not want \\nto? \\n• Tried hard not to think about the event(s) or went out of your way to avoid situations that \\nreminded you of the event(s)?  \\n• Been constantly on guard, watchful, or easily startled?  \\n• Felt numb or detached from people, activities, or your surroundings?  \\n• Felt guil ty or unable to stop blaming yourself or others for the events(s) or any problems \\nthe event(s) may have caused?', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 94}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 34  4.6.6 Psychosis  \\nPsychosis is a mental disorder characterized by a disconnection from reality.  \\nPsychosis may occur as a result of a psychiatri c illness such as schizophrenia. In other instances, \\nit may be caused by a health condition, medication or drug use.  \\nSigns and Symptoms of psychosis  \\n• Marked behavioural changes  \\n• Neglecting usual responsibilities related to work, school, domestic or social activities  \\n• Agitated, aggressive behaviour, decreased or increased activity  \\n• Fixed false beliefs not shared by others in the person’s culture  \\n• Hearing voices or seeing things that are not there  \\n• Lack of realization that one is having mental health problems  \\nTreatment may include medication and talk therapy.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 95}),\n",
       " Document(page_content='• Lack of realization that one is having mental health problems  \\nTreatment may include medication and talk therapy.  \\n4.6.7 Self -Care  \\nOverall, in the context of mental health, taking up self -care strategies will help individuals live \\nboth more responsibly, and more satisfactorily as this helps boost both physical and mental \\nhealth.  \\nSelf-care strategies include the following;  \\n− Getting regular exercise  \\n− Eating healthy, regular meals and staying well hydrated  \\n− Making sleep a priority. Many people struggle with this but just getting regular sleep with \\na constant waking and sleeping time contribute tremendously to good self-care  as well as \\ngood, well rested physical and mental health  \\n− Taking up a relaxing activity  \\n− Setting goals and priorities.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 95}),\n",
       " Document(page_content='good, well rested physical and mental health  \\n− Taking up a relaxing activity  \\n− Setting goals and priorities.  \\nThis allows for being realistic in one’s expectation in life and formulat ing realistic strategies to \\nachieve one’s goals  \\nPracticing gratitude  \\nReminding oneself that things that one is grateful for. The more specific one is, the easier it is to \\neven be grateful for them. Listing them down is a good way of getting such clarity  \\nFocusing on positivity  \\nThe calls for appreciating the good and positive things that have happened, are going on and are \\nplanned for in one’s life. The things to look forward to. This strategy also calls for the identification \\nand challenging of negative and unhelpful thoughts. Good friends and counsellors, as well as other', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 95}),\n",
       " Document(page_content='and challenging of negative and unhelpful thoughts. Good friends and counsellors, as well as other \\nhealth workers with mental health skills can assist in this.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 95}),\n",
       " Document(page_content='Standard Package of Care for PLHIV  \\n4 - 35  Staying connected  \\nThis is extremely important. Increasingly in the present world disconnection is leading to more \\nand more phy sical and mental ill health. Staying connected with family and friends as well as \\nspiritual support systems enable  one to better manage their lives as they work towards being as \\nmentally healthy as possible.  \\n4.6.8 Wellbeing  \\nAccording to the WHO, mental hea lth is a state of well -being in which an individual realizes his or \\nher own abilities, can cope with the normal stresses of life, can work productively and is able to \\nmake a contribution to his or her community.  \\nSupport structures for wellbeing:  \\nThe suppor t structures for wellbeing are available at different levels of implementation which are:', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 96}),\n",
       " Document(page_content='Support structures for wellbeing:  \\nThe suppor t structures for wellbeing are available at different levels of implementation which are:  \\n• Individual counselling  \\n• Group therapy  \\n• Networks of organizations providing support to different categories of populations in \\ndifferent age sets such as adolescents, me n, women etc.  \\nHealth workers in facilities should take the initiative to set up/ maintain these structures and \\nestablish referral systems for clients in need of these services. Referral for PLHIV should include \\nservices that address issues that potentially could affect the mental health of PLHIV such as social \\nand financial issues.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 96}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 36  4.7 Nutritional Services  \\nGood nutrition is a critical component of management of HIV because it contributes to: reducing \\nrisk and frequency of other infections; delaying progression from HIV infection to AIDS; a healthy \\nappearance and weight; gaining strength, maintaining and building muscle, and having energy to \\nremain active, and reducing side effects of ART.  \\n4.7.1 Nutritional Assessment, Counselling  and Support (NACS)  \\nAll PLHIV should receive nutritional assessment, counselling, and support  \\nAll PLHIV should receive nutritional assessment, counselling, and support tailored to the \\nindividual needs of the patients, including:', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 97}),\n",
       " Document(page_content='All PLHIV should receive nutritional assessment, counselling, and support tailored to the \\nindividual needs of the patients, including:  \\n● Nutrition assessment and diagnosis (timed with routine clinic visits, preferably monthly for \\nthe first year of life, and then quarterly up to 14 years old, and then every 3 -6 months)  \\no Anthropometric (Tables 4.1 9, 4.20 and 4.2 1 provide interpretation and required acti ons \\nfor anthropometric results for children and adults)  \\no Biochemical (investigations as listed in Table 3.2 for baseline and Table 3.5 for follow -up \\ninvestigations)  \\no Clinical (physical examination as described in Table 3.1 for initial evaluation)  \\no Dietary (24 -hour recall for food type/frequency and household food security)  \\no Environmental and psychosocial', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 97}),\n",
       " Document(page_content='o Dietary (24 -hour recall for food type/frequency and household food security)  \\no Environmental and psychosocial  \\no Functional (ability to care for self, bedridden, etc.)  \\n● Counselling and education  \\no Benefits of maintaining good nutritional status for a person living with HIV \\no Mother infant and young child nutrition (MIYCN) including exclusive breastfeeding  \\no Reassuring the client that it is possible to  \\no Attain/maintain good nutritional status  \\no Look well and live a healthy life  \\no Identifying locally available foods they can access given their own context, food safety \\nand food preparation  \\no Helping the client to plan meals and snacks with a variety of foods in order to meet their \\nenergy and nutrient needs and treatment plans', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 97}),\n",
       " Document(page_content='o Helping the client to plan meals and snacks with a variety of foods in order to meet their \\nenergy and nutrient needs and treatment plans  \\no Identifying any constraints, the client may face and f ind ways to minimize them  \\no Helping the client to understand the potential side effects and food interactions of the \\nmedicines they are taking, and help the client identify ways to manage these side effects  \\no Exploring with the client the cause(s) of poor appetite and appropriate responses (type \\nof food, disease, pain, depression, anxiety, or side effects of medications)  \\no Counsel on critical nutrition practices  \\nMessages: Critical Nutrition Practices (CNPs)  \\n1. Have periodic nutritional status assessments  \\n2. Increase energy intake through a balanced diet', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 97}),\n",
       " Document(page_content='Messages: Critical Nutrition Practices (CNPs)  \\n1. Have periodic nutritional status assessments  \\n2. Increase energy intake through a balanced diet  \\n3. Maintain high levels of sanitation and food hygiene  \\n4. Practice positive living behaviors  \\n5. Carry out physical activity or exercises  \\n6. Drink plenty of clean, safe water  \\n7. Seek prompt treat ment for all opportunistic infections and manage diet -related symptoms  \\n8. Manage drug -food interactions and side effects', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 97}),\n",
       " Document(page_content='Standard Package of Care for PLHIV  \\n4 - 37  Support  \\no Therapeutic and supplementary foods to treat clinical malnutrition (food by prescription, \\ntherapeutic feeds, fortified blended flour): Figures 4. 3 and 4. 4 provide malnutrition \\nmanagement recommendations for adults and children; Table 4. 10 provides specific \\nnutritional recommendations for patients with non -communicable diseases  \\no Exclusive breastfeeding for the first 6 months of life; complementary foods for children \\naged 6 - 24 months with continued breastfeeding to prevent malnutrition (Table 7.7 \\nprovides complementary feeding recommendations)  \\no Micronutrient supplements to prevent vitamin and mineral deficiencie s \\no Food security and linkage to HIV sensitive social protection such as household food', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 98}),\n",
       " Document(page_content='o Food security and linkage to HIV sensitive social protection such as household food \\nsupport, home -based care, agricultural extension services, and economic strengthening \\nand livelihood support  \\nSome aspects of nutrition support (such as prescription of th erapeutic and supplementary foods) \\nshould be provided by a trained healthcare professional, however all aspects should be promoted \\nand supported at the community level.  \\nTable 4.1 9: Interpretation of MUAC Results for Children and Pregnant/Lactating Women  \\nMUAC Level by Age (cm)  Classification  Action to Take  \\n6-59 \\nmonths  5-9 yrs.  10-17 yrs.  \\n< 11.5  < 13.5  < 14.5 cm  Severe acute \\nmalnutrition  Irrespective of clinical signs, admission \\n(referral) for stabilization/therapeutic \\nrehabilitation', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 98}),\n",
       " Document(page_content='malnutrition  Irrespective of clinical signs, admission \\n(referral) for stabilization/therapeutic \\nrehabilitation  \\n11.5–12.5  13.5 -14.5  14.5 -18.5  Moderate acute \\nmalnutrition  Admission for supplementary feeding is \\nrecommended  \\n12.6–13.5    Mild acute \\nmalnutrition  Nutritional education and counselling  \\n> 13.5    Normal  Education and counselling of caregivers  \\nPregnant and Breastfeeding Women  \\n≤ 23  Malnourished  Provide nutritional support (Figure 4.3)  \\n> 23  Normal  Education and counselling  \\nTable 4. 20: Interpretation of Z -scores for Children  \\nRatio  Indicator   Z-score  Severity  \\nWeight/Age  Underweight  < - 3 Severe  \\nHeight/Age  Stunting  - 3 to - 2 Moderate  \\nWeight/Height  Wasting*  > - 2 to - 1 Mild  \\n> - 1 Normal', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 98}),\n",
       " Document(page_content='Weight/Age  Underweight  < - 3 Severe  \\nHeight/Age  Stunting  - 3 to - 2 Moderate  \\nWeight/Height  Wasting*  > - 2 to - 1 Mild  \\n> - 1 Normal  \\n*Children with weight/height z -score of -2 or less should be supported with therapeutic/supplementary \\nfoods', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 98}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 38   \\nScreening\\nMeasure  anthropometry and check bilateral\\nPitting oedema\\nMedical History and Physical examination:\\n-  Evaluate nutritional status and health condition\\n-  Check for medical complications\\n-  Perform appetite test\\nIf SAM without  medical \\ncomplication and passed appetite \\ntestIf SAM with  medical complication \\nand/or failed  appetite test\\nMedical complication developed, decreased \\nappetite, weight loss or stagnant weight, \\noedema increase or no decreaseAdmission to \\nOutpatient careAdmission to \\nInpatient care\\nReferral for continuing treatment in out patient \\ncare:\\nAppetite returning (passed appetite test)\\nOedema decreasing,\\nMedical complication resolvingTreatment Treatment', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 99}),\n",
       " Document(page_content='care:\\nAppetite returning (passed appetite test)\\nOedema decreasing,\\nMedical complication resolvingTreatment Treatment\\nSAM Treatment completed (based on discharge criteria):\\nDischarge to home or refer for supplementary feeding and other services\\n that address underlying causes of malnutritionTREATMENTADMISSION\\n \\nFigure 4. 3: Management of Severe Acute Malnutrition in Children  \\n Other medical complications that necessitate hospitalization  \\nIn addition to severe bilateral pitting oedema (+++), marasmic \\nkwashiorkor and poor appetite, the following complications \\nnecessitate inpatient care:  \\n✔ Intractable vomiting  \\n✔ Convulsions  \\n✔ Lethargy  \\n✔ Unconsciousness  \\n✔ Lower respiratory tract infection  \\n✔ High fever  \\n✔ Severe dehydration  \\n✔ Severe anaemia  \\n✔ Hypoglycaemia  \\n✔ Hypothermia', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 99}),\n",
       " Document(page_content='✔ Unconsciousness  \\n✔ Lower respiratory tract infection  \\n✔ High fever  \\n✔ Severe dehydration  \\n✔ Severe anaemia  \\n✔ Hypoglycaemia  \\n✔ Hypothermia  \\n✔ Eye signs of vitamin A deficiency  \\n✔ Skin lesions  \\nThe following complications require referral of patient for further \\nmedical evaluation:  \\n✔ No appetite (failed appetite test)  \\n✔ IMCI danger signs  \\n✔ Increase in or newly developed bilateral pitting oedema  \\n✔ Weight loss because of diarrhoea (r e-feeding or of other \\norigin)  \\n✔ Weight loss for three consecutive weeks  \\n✔ Static weight (no weight gain) for five consecutive weeks  \\n✔ Other signs of failure to respond to treatment', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 99}),\n",
       " Document(page_content='Standard Package of Care for PLHIV  \\n 4 - 39 \\nA. Weight loss score\\n<5% – Low Risk\\n5-10% – Moderate Risk\\n>10% – High RiskUnplanned % weight loss in the last 1 -3mnthsB. Opportunistic Infections score\\nNo opportunistic infection\\nSub acute OI – Moderate Risk\\nAcute OI – High RiskOpportunistic infections statusC. Food intake score\\nAdequate Intake\\nLow intake – Moderate Intake\\nNausea/Vomiting Non/Fasted \\nfor >5 days – High RiskFood Intake/barriersD. Food Security score\\nLittle or No H/H Hunger = 0 -1\\nModerate H/H Hunger= 2 -3 (High Risk)\\nSevere H/H Hunger= 4 -6 (High Risk)Household hunger score a\\nPregnant & Postpartum women\\nMUAC (cm)<19\\n(SAM)\\n19.0 - 20.9\\n(MAM)\\n21.0 - 23.1\\n(HIGH \\nRISK)\\n>23.1\\n(NORMAL)Nutritional anemia (Hb < 11g/dl) – \\ndeficiency  of iron, folate, Vit. B12;', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 100}),\n",
       " Document(page_content='(SAM)\\n19.0 - 20.9\\n(MAM)\\n21.0 - 23.1\\n(HIGH \\nRISK)\\n>23.1\\n(NORMAL)Nutritional anemia (Hb < 11g/dl) – \\ndeficiency  of iron, folate, Vit. B12;\\nBitot spots due to Vitamin A \\ndeficiency; Pellagra due to vitamin \\nB1 deficiencyMicronutrient deficiency/diseases Other Adults\\nBMI (Kg/m2) b< 16\\n(SAM)\\n16 – 18.5\\n(MAM)\\n18.6 - 21.9\\n(HIGH \\nRISK)\\n22 – 24. \\n(NORMAL)\\nSEVERE MALNUTRITION (SAM)\\nSAM with medical complications \\nand cannot eat ( Clinical status or \\nfailed appetite test)\\nActions  c\\ni. Initiate Phase I therapeutic \\nfeeding until stable (Inpatient – \\nrescue phase feeding)Clinically stable, able to eat and \\ngood appetite\\nActions  c\\n i.  Initiate Phase II therapeutic \\nfeeding for nutritional \\nreconstitution\\nii.  Nutrition counselling & \\neducation\\niii.  Review (in or out patients) \\nweekly', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 100}),\n",
       " Document(page_content='feeding for nutritional \\nreconstitution\\nii.  Nutrition counselling & \\neducation\\niii.  Review (in or out patients) \\nweekly\\niv.  Transition to supplemental \\nfeeding upon recovery from \\nSAMActions  c\\ni. Nutrition counselling & \\neducation\\nii. Initiate supplemental \\nfeeding\\niii.  Multiple micronutrient \\nsupplementation\\niv.  Review monthly\\nv.  Post -discharge review every \\n2-3monthsMODERATE MALNUTRITION \\n(MAM)\\nActions  c\\ni.  Nutrition \\ncounselling & \\neducation\\nii.  Repeat nutrition \\nscreening every 2 -3 \\nmonthsNORMAL/LOW RISK\\nActions  c\\ni.   Nutrition counselling & \\neducation\\nii.   Multiple micronutrient \\nsupplementation\\niii.   Review nutrition status \\nand risk factors every \\n2-4 weeks until stable\\niv.  Repeat nutrition \\nscreening every 2 -3 \\nmonths once stable\\n v.  For pregnant or', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 100}),\n",
       " Document(page_content='and risk factors every \\n2-4 weeks until stable\\niv.  Repeat nutrition \\nscreening every 2 -3 \\nmonths once stable\\n v.  For pregnant or \\npostpartum mothers \\nenroll on FBPNORMAL/HIGH RISK\\nRefer food insecure \\nclients for livelihood\\na Refer to household food security assessment tool\\nb For overweight and obese, refer for counselling\\nc Implement local clinical policy and protocol\\nNUTRITIONAL \\nINTERVENTIONSNUTRITIONAL \\nDAIGNOSISNUTRITIONAL \\nASSESSMENT\\nRefer non responders for \\nfurther clinical assessment \\nand management \\nFigure 4. 4: Management of Malnutrition in Adults with HIV', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 100}),\n",
       " Document(page_content='Guidelines on Use of Antiretroviral Drugs for Tre ating and Preventing HIV Infection in Kenya  \\n \\n4 - 40 Table 4.2 1: Interpretation of BMI Results for Adults  \\nBMI Level  Classification  Action to Take  \\n< 16 Severe \\nmalnutrition  • Refer for facility -based therapeutic intervention; rehabilitation with \\ntherapeutic foods; counselling on intake issues and possible metabolic issues  \\n• Screen for TB  \\n16.0 –18.4 Mild/moderate \\nmalnutrition  ● Nutritional counselling and supplementary feeding  \\n● Screen for TB  \\n18.5 –25.0 Normal/ \\nrecommended  Nutritional counselling, consistent exercise to build muscles  \\n25.1 –30 Overweight  Nutritional counselling to reduce energy intake; aerobic physical activity to \\nreduce weight', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 101}),\n",
       " Document(page_content='25.1 –30 Overweight  Nutritional counselling to reduce energy intake; aerobic physical activity to \\nreduce weight  \\n>30 Obese  Counselling to change lifestyle and reduce energy intake; aerobic physical activity \\nto reduce weight  \\n4.8 Prevention of Other Infections  \\n4.8.1 Immunizations  \\nAll children, regardless of HIV status, should be immunized following the full KEPI schedule, \\nwith a few exceptions for infants with severe immunosup pression (Table 4.2 2). For infants \\nliving with HIV and HEIs, an earlier dose of measles vaccines should be given at 6 months of age.  \\nTable 4.2 2: Kenya Expanded Program on Immunizations 2016 Schedule  \\nAge  Vaccines  \\nBirth  OPV1, BCG2 \\n6 weeks  OPV3, Pentavalent (DPT -HepB -HiB), Pneumococcal (PCV10), Rotavirus', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 101}),\n",
       " Document(page_content='Age  Vaccines  \\nBirth  OPV1, BCG2 \\n6 weeks  OPV3, Pentavalent (DPT -HepB -HiB), Pneumococcal (PCV10), Rotavirus  \\n10 weeks  OPV3, Pentavalent (DPT -HepB -HiB), Pneumococcal (PCV10), Rotavirus  \\n14 weeks  IPV, Pentavalent (DPT -HepB -HiB), Pneumococcal (PCV10)  \\n6 months  Measles/Rubella (MR) - for HIV exposed and infected infants; Vitamin A  \\n9 months  Measles/Rubella (MR); Vitamin A; Yellow Fever4 \\n18 months  Measles/Rubella (MR); Vitamin A  \\n10 years (girls only)  HPV (2 doses at 6 months apart in the general population; 3 doses for \\nPLHIV, at month 0, 1 -2, and 6)  \\n11-12 years  Tdap (tetanus, diphtheria and pertussis)  \\n1Give OPV to all infants at birth or within the first two weeks of life. If missed in the neonatal period and the child', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 101}),\n",
       " Document(page_content='1Give OPV to all infants at birth or within the first two weeks of life. If missed in the neonatal period and the child \\nhas symptoms of advanced HIV disease (WHO Stage 3 or 4) or severe immunosuppressio n (CD4% < 25%) then \\ndefer BCG until virally suppressed on ART and with immune system recovery  \\n2Give BCG to all infants at birth or within the first two weeks of life. If missed in the neonatal period and the child \\nhas symptoms of advanced HIV disease (WHO Stage 3 or 4) or severe immunosuppression (CD4% < 25%) then \\ndefer BCG until virally suppressed on ART and with immune system recovery . Do not give BCG vaccine to babies \\nborn to smear positive mothers. Investigate to rule out TB, give TPT then vaccination d one two weeks after \\ncompletion of TPT', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 101}),\n",
       " Document(page_content='born to smear positive mothers. Investigate to rule out TB, give TPT then vaccination d one two weeks after \\ncompletion of TPT  \\n3If HIV+ with symptoms of advanced HIV disease (WHO Stage 3 or 4) or severe immunosuppression (CD4% < 25%) \\nthen use IPV instead of OPV  \\n4Yellow fever vaccine is only routinely used in certain counties as specified by National Vaccines and Immunization \\nProgram; defer yellow fever vaccine if symptoms of advanced HIV disease (WHO Stage 3 or 4) or severe \\nimmunosuppression (CD4% < 25%), until virally suppressed on ART and with immune system recovery', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 101}),\n",
       " Document(page_content='Standard Package of Care for PLHIV  \\n4 - 41 PLHIV may have an inadequate response to immunizations, particularly before they achieve full \\nviral suppression. The ideal timing, dose, and frequency of re -immunizations for children on ART \\nare not well known. Providers will receive specific guidance or r evaccination from the National \\nVaccines and Immunization Program and NASCOP.  \\nRecommended vaccinations for adolescents and adults living with HIV are listed in Table 4.2 3. \\nTable 4.2 3: Vaccinations in Adolescents and Adults Living with HIV  \\nInfection  Vaccine  Live  \\n(Y/N)  Course  Comments  \\nCOVID -19 Various  N Variable  Follow national guidelines on dosing for the \\nspecific vaccine available  \\nHepatitis B  Subunit  N 4 doses (at  \\n0, 1, 2 and 6', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 102}),\n",
       " Document(page_content='specific vaccine available  \\nHepatitis B  Subunit  N 4 doses (at  \\n0, 1, 2 and 6 \\nmonths)  Use double dose if non -adjuvanted; use standard \\ndose if adjuvanted  \\nPneumococcus  Conjugate  N 1 dose (PCV  \\n13)  \\nPreferable to polysaccharide  \\nPolysaccharide  N 1 dose  Use if >65 years and with co -morbidity other \\nthan HIV  \\nHuman \\nPapillomavirus \\n(HPV)  Virus -like \\nparticles   \\nN 3 doses (at \\nmonths 0, 1 -\\n2, and 6)  All girls at 9 -14 years old  \\nInfluenza  Inactivated  N 1 dose  Annually  \\nHepatitis A  Inactivated  N 2 - 3 doses  3 doses if CD4 count < 350 cells/mm3 at 0, 1 and \\n6 months. If CD4 count > 350 cells/mm3, give 2 \\ndoses at 0 and 6 months. For those at continued \\nrisk, one booster dose every 10 years  \\nAdditional Vaccines for Special Circumstances', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 102}),\n",
       " Document(page_content='doses at 0 and 6 months. For those at continued \\nrisk, one booster dose every 10 years  \\nAdditional Vaccines for Special Circumstances  \\nYellow fever  Live attenuated  Y 1 dose  Use only in patients <60 yrs of age and  CD4 > \\n200 cells/mm3 \\nTyphoid  Polysaccharide  N 1 dose  Give the ViCPS parenteral. Repeat every 3 years  \\nCholera  Subunit  N 2 doses  As indicated (usually in epidemics). 2 oral doses \\nof the non -replicating vaccine given 1 -6 weeks \\napart with a single booster dose at 2 years from \\nprimary vaccination', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 102}),\n",
       " Document(page_content='Guidelines on Use of Antiretroviral Drugs for Tre ating and Preventing HIV Infection in Kenya  \\n \\n4 - 42 4.8.2 Malaria  \\nChildren and adults living with HIV suffer heavier parasitaemia and more malaria morbidity with \\nadvanced HIV disease. Further, people with advanced immunosuppression are at risk of failure \\nof anti -malarial treatment. In pregnancy, there is increased risk of placental malaria,  severe \\nanaemia, premature delivery and perinatal mortality. Drug interactions between ARVs and \\nantimalarial drugs may further complicate management.  \\nRecommendations for malaria prevention for PLHIV include:  \\n● Offer cotrimoxazole preventive therapy (CPT) for  protection against malaria infection \\n(Table 4. 3: Co-trimoxazole Preventive therapy)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 103}),\n",
       " Document(page_content='● Offer cotrimoxazole preventive therapy (CPT) for  protection against malaria infection \\n(Table 4. 3: Co-trimoxazole Preventive therapy)  \\n● In areas of stable malaria transmission, PLHIV should have access to insecticide treated \\nmosquito nets (ITNs) or indoor residual spraying to reduce exposure to mosquito bi tes \\nand therefore malaria transmission  \\n● PLHIV travelling from non -malarious zones to malaria endemic areas should sleep under \\nITNs  \\n● Pregnant women with HIV living in areas of stable malaria transmission who are not able \\nto take CPT should be given at least t hree doses of sulfadoxine -pyrimethamine (SP) \\nintermittent preventive treatment for malaria as part of routine antenatal care  \\nNote:  SP should not be given to women who are taking CPT', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 103}),\n",
       " Document(page_content='intermittent preventive treatment for malaria as part of routine antenatal care  \\nNote:  SP should not be given to women who are taking CPT  \\n● PLHIV on CPT who develop fever should not be treated for an unconfirmed presumptive \\ndiagnosis of malaria. Laboratory confirmation of malaria should be obtained prior to \\ninitiation of anti -malarial therapy  \\n● PLHIV with malaria should receive standard antimalarial therapy according to national \\nguidelines.  Those on CPT should not be given sulfa -containing anti -malarial drugs. \\nPatients on ART receiving anti -malarial therapy should be monitored closely for adverse \\ndrug reactions  \\n4.8.3 Safe Water, Sanitation and Hygiene  \\nDiarrheal illnesses are common causes of morbidity and  mortality among PLHIV. These diseases', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 103}),\n",
       " Document(page_content='4.8.3 Safe Water, Sanitation and Hygiene  \\nDiarrheal illnesses are common causes of morbidity and  mortality among PLHIV. These diseases \\nare often due to lack of access to safe drinking water, improper disposal of human and animal \\nwaste, and poor personal hygiene, leading to contamination of food and water.  \\nRecommendations for prevention of faecal -oral ly spread illnesses include:  \\n● Offer CPT for protection against some GI infections (Table 4.3: Co -trimoxazole \\nPreventive therapy)  \\n● Hand washing with soap and water after handling human or animal faeces, after using \\nthe toilet, and before food preparation or eating  \\n● Facilities for proper disposal of human waste.  \\n● Training on household -based water treatment methods and water storage containers', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 103}),\n",
       " Document(page_content='● Facilities for proper disposal of human waste.  \\n● Training on household -based water treatment methods and water storage containers \\nthat prevent direct hand contact with drinking water', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 103}),\n",
       " Document(page_content='Adherence Preparation, Monitoring and Support  \\n5 - 1  \\n5. Adherence Preparation, Monitoring and \\nSupport  \\n \\nThe individual and population benefits of ART are dependent on high levels of adherence to the \\nprescribed medication, the accompanying medical advice and the follow -up plans. Adherence -\\nenhancing strategies should be implemented beginning at the point of HIV di agnosis (as part of \\npost -test counselling and linkage), continued during initial evaluation, and thereafter during the \\nentire follow -up period for ART.  \\n \\nTo avoid treatment failure and the need to switch patients to 2nd or 3rd line ART, it is key to have \\nan adherence support strategy in place before ART initiation, anticipating common and individual', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 104}),\n",
       " Document(page_content='an adherence support strategy in place before ART initiation, anticipating common and individual \\nbarriers to good adherence. Prevention of treatment failure starts at the time of HIV diagnosis. \\nThis is particularly important with the current recommendation t hat all PLHIV qualify for ART, \\nand ART should be initiated within 2 weeks of diagnosis. Adherence preparation must begin at \\ntime of HIV testing, and close follow -up is required after ART initiation.  \\n \\nThe adherence preparation, monitoring, and support that a patient requires should be tailored to \\ntheir level of adherence, the stage of ART initiation, and the follow -up stage that they are at (Figure \\n5.1).  \\n \\nWhenever possible, follow -up should be provided by the same care provider or team of care', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 104}),\n",
       " Document(page_content='5.1).  \\n \\nWhenever possible, follow -up should be provided by the same care provider or team of care \\nproviders (e.g ., same clinician and same counsellor) at each visit. This is particularly important \\nduring the first few months of HIV care.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 104}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 2 \\nHTS post -test counselling: key treatment preparation messages for all patients who test positive\\n• Treatment is available and recommended for everyone with HIV\\n• Starting treatment early reduces your chance of becoming ill or infecting your sexual partner(s)\\n• With good adherence you can live a long and productive life\\nEnrolment Visit\\n• HIV education and adherence preparation for all patients/caregivers (Table 5.1)\\n• ART Readiness Assessment for all patients/caregivers (Table 5.4), along with \\nindividualized adherence support plan\\nReady to start ART Not ready to start ART\\n• Initiate ART\\n• Baseline investigations if not already completed\\n• Provide standard package of care and differentiated', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 105}),\n",
       " Document(page_content='• Initiate ART\\n• Baseline investigations if not already completed\\n• Provide standard package of care and differentiated \\ncare based on initial presentation (advanced disease vs \\nwell)\\n• Book follow -up appointment for week 2 and 4 to \\nreview adherence and side -effects\\n• Continue adherence support plan• Weekly appointments  to review clinical \\nstatus, barriers to ART initiation, and provide \\nongoing HIV education and counselling\\n• Provide standard package of care\\n• Re-assessment of ART readiness at every \\nvisit, until ready (target is within 2 weeks)\\nFollow -up with adherence monitoring at every \\nvisit (Table 5.10) and counselling based on \\nlevel of adherence (Table 5.14) until first VL at \\n3 months\\nVL undetectable ( LDL <200copies/ml )\\n• Ongoing adherence assessment and', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 105}),\n",
       " Document(page_content='level of adherence (Table 5.14) until first VL at \\n3 months\\nVL undetectable ( LDL <200copies/ml )\\n• Ongoing adherence assessment and \\ncounselling (Table 5.16)\\n• Continue routine VL monitoring as per \\nthe population groupVL       copies/ml\\n• Suspect poor adherence\\n• Assess for barriers to adherence (Table 5.15)\\n• Follow VL algorithm with enhanced \\nadherence assessment and interventions and \\nassessment for other causes of viremia \\n(Figure 6.6) \\nFigure 5.1: Adherence Preparation, Monitoring and Support until Viral Load after 3 Months on \\nART', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 105}),\n",
       " Document(page_content='Adherence Preparation, Monitoring and Support  \\n5 - 3 Adherence is most difficult during the first few months of treatment: the patient is not yet in the \\nhabit of taking their medications every day, they are not familiar with common side -effects, and \\nthey have more challenges with disclosure and stigma,  all of which can interfere with adherence. \\nPoor adherence within the first few months of therapy is also the most risky period for \\ndevelopment of resistance mutations, when the viral load is still high.  \\n \\nFor these reasons, adherence preparation, monitorin g and support must be emphasized \\nduring the first few months of ART until the patient achieves full virological suppression,  \\nafter which adherence monitoring and support can continue at lower intensity.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 106}),\n",
       " Document(page_content='after which adherence monitoring and support can continue at lower intensity.  \\n \\nPatient preparation and counselling should be a coll aborative process between the provider and \\nthe patient or caregiver, to enable the patient to initiate and continue lifelong treatment. This is \\nbest done when the same adherence counsellor follows an individual patient throughout the \\npreparation, initiatio n, and early ART period.  \\n \\nART can be initiated concurrently with the first adherence counselling session, even during \\nthe enrolment visit, especially for infants and for pregnant women. This may also apply to \\npatients with a good understanding of HIV and A RT and strong motivation for immediate \\nART initiation.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 106}),\n",
       " Document(page_content='patients with a good understanding of HIV and A RT and strong motivation for immediate \\nART initiation.  \\n \\nEach member of the multidisciplinary team should have the requisite training to provide \\ntreatment education and offer appropriate support to address potential barriers to adherence. \\nTreatment preparat ion and support can be offered at triage, consultation, pharmacy or any other \\nclinic station where confidentiality and privacy are assured and providers are adequately trained. \\nIt should also be incorporated into health talks, peer support group activities , and group \\ncounselling sessions.  \\n \\nBefore commencement of a counseling session, the counselor should ensure that adequate space is available', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 106}),\n",
       " Document(page_content='counselling sessions.  \\n \\nBefore commencement of a counseling session, the counselor should ensure that adequate space is available \\nto conduct the counseling, that confidentiality can be maintained, and that tools such as psychosocial \\nassessment f orms, treatment literacy flip charts, PHDP flip charts, and tools to document the counseling \\nsessions are available.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 106}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 4 Persons living positively (adolescent and adult peer educators who can share personal \\nexperiences when needed) should be engaged to support patient education as indicated in the \\noperational guidance below.  \\nOperational Guidance: Meaningful Involvement of People Living with HIV  \\nFor best patient outcomes, PLHIV themselves should be engaged to lead facility -based and \\ncommunity -based HIV ed ucation and support systems. They are often referred to as “peer \\neducators”, “mentor mothers”, and “lay health workers” in these roles. PLHIV have successfully and \\nsignificantly contributed to: improving identification of people at risk for HIV or infected  with HIV;', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 107}),\n",
       " Document(page_content='significantly contributed to: improving identification of people at risk for HIV or infected  with HIV; \\nincreasing linkage from testing to treatment; reducing onward transmission of HIV; providing \\npsychosocial support, and improving adherence and retention to care and ART.  \\n \\nIdentifying PLHIV to offer peer -led patient support:  \\n● PLHIV on ART for ≥ 1  year  \\n● Good adherence and undetectable VL  \\n● Positive attitude and interest in supporting peers  \\n \\nPreparing and supporting PLHIV to play a role in patient support systems:  \\n● Must be trained for the role they are expected to provide  \\n● Must have job aids and IEC material appropriate for their role  \\n● Must be supervised by healthcare professionals  \\n \\nPotential roles for PLHIV include  \\n● Supporting HIV self -testing', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 107}),\n",
       " Document(page_content='● Must be supervised by healthcare professionals  \\n \\nPotential roles for PLHIV include  \\n● Supporting HIV self -testing  \\n● Providing HIV testing services  \\n● Acting as peer linkage supporters  \\n● Leading or contributing to facility -based or community -based support groups  \\n● Providing individual or group HIV education  \\n● Providing individual or group adherence counselling  \\n● Distribution of ART refills for stable patients  \\n \\nCompensation for PLHIV who contribute to patient support systems  \\n● Recognition (e.g., ID badges; certificates of service; acknowledgement at community forums)  \\n● Training opportunities with certification  \\n● Financial compensation (e.g., salaries; stipends; transportation allowances)  \\n● Priority consideration for em ployment opportunities', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 107}),\n",
       " Document(page_content='Adherence Preparation, Monitoring and Support  \\n5 - 5 5.1 Undetectable = Untransmittable (U=U)  \\nART adherence resulting to durable viral suppression eliminates risk of sexual transmission of \\nHIV and is key to HIV epidemic control. Adoption of the Undetectable equals Untransmittable \\n(U=U) campaign is posed to revolutionize HIV treatment among PLHIV and fortify treatment -for-\\nprevention strategies. Multiple studies have showed that durable viral suppression of <50 \\ncopies/ml eliminates risk of sexual transmission of HIV. (Table 5. 17 Viral load cut -offs)  \\nThe framework of U=U offers a unique opportunity to dismantle HIV stigma and discrimination, \\nemphasizes the critical importance of antiretroviral therapy (ART), daily adherence, and', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 108}),\n",
       " Document(page_content='emphasizes the critical importance of antiretroviral therapy (ART), daily adherence, and \\ncontinuous engagement in medical care for  PLHIV.  \\nDefinitions:  \\n● Durably Undetectable: 2 consecutive viral load results of <50 copies/ml  \\n● Untransmittable: The finding established by various clinical trials and observational \\nstudies, that people who maintain an undetectable viral load have minimal HIV virus in their \\nblood and other body fluids secretions that they have “effectively no risk” of passing HIV to \\nothers through sex.  \\n5.1.1 Benefits of U=U  \\n● Diminish stigma associated with having HIV  \\n● Reduce barriers to HIV testing and treatment  \\n● Incre ase interest in starting and staying on ART  \\n● Improve self -esteem by removing the fear of being contagious', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 108}),\n",
       " Document(page_content='● Incre ase interest in starting and staying on ART  \\n● Improve self -esteem by removing the fear of being contagious  \\n● Support healthy sexuality regardless of HIV status  \\n● Reduce sex partners’ concerns  \\n5.1.2 Considerations for implementation of U=U within clinical setting s \\n● Viral load monitoring as per the recommended intervals for various populations  \\n● Continuous adherence monitoring and support at all clinical visits  \\n● STI screening at all visits  \\n● Messaging on U=U should be provided for all PLHIV as part of treatment literacy  \\n5.1.3 Messaging to Patients on U=U  \\n● Keeping your HIV undetectable helps you live a long and healthy life  \\n● To get your HIV to an undetectable level and to keep it undetectable, take antiretroviral \\nmedicines as prescribed', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 108}),\n",
       " Document(page_content='● To get your HIV to an undetectable level and to keep it undetectable, take antiretroviral \\nmedicines as prescribed  \\n● It may take up to 6 months o f taking HIV treatment medicines to bring your HIV viral load \\ndown to an undetectable level  \\n● If you are durably suppressed and you are taking your medications as prescribed, you can \\nbe sure you will not pass HIV through sex  \\n● People who keep their HIV at an undetectable level will not pass HIV to others through sex  \\n● If you stop taking HIV medicines, your HIV can rebound to a detectable level within 1 to 2 \\nweeks, and you may pass HIV to your sex partners  \\n● Keeping your HIV at durably suppressed level helps you sa fely conceive a child with your \\npartner', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 108}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 6 5.1.4 How patients can discuss U=U with others  \\n● Counsel patients to share information about the research on U=U as follows:  \\no In recent research studies that involved thousands of couples, no one who was on \\nHIV treatment and whose HIV was durably undetectable passed HIV to their HIV -\\nnegative sex partner  \\n● Advise patients that they can share the following personal information with current or \\npotential sex partners:  \\no When they last had a viral load test and if their viral load was undetectable  \\n● Individuals should tell their partner(s) that their HIV is undetectable only if they have \\ntaken HIV medicines consistently since their last test with an undetectable viral load', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 109}),\n",
       " Document(page_content='taken HIV medicines consistently since their last test with an undetectable viral load  \\n5.1.5 Counselling patients about other preven tion combination interventions  \\n● PrEP:  PrEP is a safe and effective daily pill that prevents HIV infection. The partner without \\nHIV may decide to take PrEP if they:  \\no Are unsure that their partner’s HIV viral load is undetectable, especially if their \\npartner has only recently started ART  \\no Have mo re than 1 sexual partner  \\no Feel more secure with the added perception of protection provided by PrEP  \\n● PEP:  After a possible HIV exposure (e.g., Occupational exposure or if a sex partner with HIV \\nhas not consistently taken ART and is not virally suppressed), t he immediate initiation of \\nemergency PEP can prevent HIV infection', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 109}),\n",
       " Document(page_content='has not consistently taken ART and is not virally suppressed), t he immediate initiation of \\nemergency PEP can prevent HIV infection  \\n● Condom use:  Condoms protect against other STIs, such as gonorrhea, chlamydia, and \\nsyphilis, and help prevent pregnancy.  \\nCounsel patients to find a prevention strategy that works for them:  \\n● If an individual who does not have HIV is unsure if their partner has an undetectable level of \\nvirus or is anxious about acquiring HIV, care providers should encourage that person to \\nchoose a prevention strategy that works for them, whether that is use of P rEP, emergency \\nPEP, condoms, or a combination of these strategies  \\nNote: Care providers should emphasize that no one should ever be compelled to have \\nsex without condoms', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 109}),\n",
       " Document(page_content='Note: Care providers should emphasize that no one should ever be compelled to have \\nsex without condoms  \\n5.1.6 Application of U=U in other settings  \\n● Breastfeeding:  Studies demonstrate that ART greatly reduces the risk of transmission \\nthrough breast milk. However, research has not established that people whose HIV is \\nundetectable do not transmit virus during breastfeeding. Prophylaxis should be provided \\nto HIV expose d infants during the breastfeeding period as per the guidelines regardless \\nof the viral load status  \\n● Injection drug use:  Studies demonstrate that ART greatly reduces the risk of \\ntransmission through sharing of injection drug use. However, research has not \\nestablished that people whose HIV is undetectable do not transmit virus through needle', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 109}),\n",
       " Document(page_content='established that people whose HIV is undetectable do not transmit virus through needle \\nsharing. All people who inject drugs should only use their own needles and not share \\nneedles or other paraphernalia with others  \\n● Needle stick injuries:  Research has not es tablished that people with undetectable viral \\nload do not transmit HIV to people who are stuck by needles containing their blood. HIV \\nPEP should be provided as per the guidelines', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 109}),\n",
       " Document(page_content='Adherence Preparation, Monitoring and Support  \\n5 - 7 5.2 ART Adherence Preparation and Support  \\nPreparation for ART begins at the t ime of HIV diagnosis and continues until initiation of ART.  \\n5.2.1 Treatment Preparation as Part of HIV Testing Services  \\nWith the current treatment guidelines recommendation that all PLHIV qualify for ART, post -test \\ncounselling by the HTS provider should no w include three key messages that begin the ART \\ntreatment preparation process for all PLHIV  \\n● Treatment (called antiretroviral therapy (ART)) is available and is recommended for \\neveryone with HIV  \\n● Starting treatment as soon as possible (preferably within two weeks of testing positive \\nfor HIV) reduces the chance of your illness getting worse or of passing HIV to others', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 110}),\n",
       " Document(page_content='for HIV) reduces the chance of your illness getting worse or of passing HIV to others  \\n● If you take your ART properly and do not miss pills you can expect to live a long and \\nproductive life  \\n \\n5.2.2 ART Treatment Preparatio n \\nART treatment preparation involves HIV education and counselling, including identifying likely \\nbarriers to adherence, a discussion of strategies and support systems to overcome possible \\nbarriers to adherence, and an individualized adherence plan, as summ arized in Table 5.1. The \\neducation and counseling sessions should be documented in patient charts.  \\nTable 5.1: Treatment Preparation and Adherence Counselling Guide  \\nHIV Education  \\n• Ask the patient what they know about HIV  \\n• Ask the patient what they know about treatment for HIV', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 110}),\n",
       " Document(page_content='HIV Education  \\n• Ask the patient what they know about HIV  \\n• Ask the patient what they know about treatment for HIV  \\n• Correct/clarify as needed, ensuring you cover:  \\no Modes of transmission and importance of testing partners/children  \\no HIV effect on the immune system and health  \\no HIV viral load and its relationship to health and to HIV transmission  \\no Goals of ART  \\no Relationship between adherence and viral suppression, treatment failure, and drug \\nresistance  \\no Consequences of drug resistance  \\n• Ensure the patient understands by asking them to explain it back to you  \\nBarriers to Adherence  \\n• Ask the patient what they think will be most difficult about taking ART every day  \\n• As the patient what they think will be most difficult about attending all clinic appointments', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 110}),\n",
       " Document(page_content='• As the patient what they think will be most difficult about attending all clinic appointments  \\n• Discuss common reasons patients have trouble with excellent adherence and identify which may \\nbe most relevant for them, including:', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 110}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 8 Table 5.1 Cont.  \\n● Patient Factors  \\no Stigma and non -disclosure (having to hide \\ntheir ARV pill -taking)  \\no Lack of support systems  \\no Alcohol or drug use  \\no Depression or other psychiatric illness  \\no Loss or grief  \\no Cognitive disorders  \\no Change in daily routine  \\no Chaotic lifestyle; no consistent daily \\nroutine  \\no Forgetting to take pills  \\no Feeling better so does not think the ART is \\nneeded any more  \\no Feeling too sick to take ART  \\no Age (adolescents - impulsive, more \\nsusceptible to social pressure; children – \\ncaregiver dependent)  ● Provider/System Factors  \\no Side effects (many patients have side \\neffects when they first start their ART, \\nincluding nausea, headaches, and', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 111}),\n",
       " Document(page_content='o Side effects (many patients have side \\neffects when they first start their ART, \\nincluding nausea, headaches, and \\ndifficulty sleeping.  These side effects \\nalmost always resolve with continued \\nuse)  \\no Pill burden  \\no Poor patient -provider relationship  \\no Inadequate HIV education  \\no Cost of care (direct and indirect)  \\no ARV supply -chain limitations (stock -outs, \\nor low stock levels resulting in small refill \\nquantities)  \\nIndividualized Adherence Plan  \\n● Ask the patient what they can do to ensure excellent adherence  \\n● Ensure the adherence plan incorporates details of the patient’s specific ART regimen:  \\no Number of pills, frequency, food requirements/restrictions  \\no Common side effects  \\no Important drug interactions', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 111}),\n",
       " Document(page_content='o Number of pills, frequency, food requirements/restrictions  \\no Common side effects  \\no Important drug interactions  \\n● Work with the patient to make an individualized adherence plan, which may include:  \\no Disclosing their HIV status to a close friend or family member who can help support their \\ntreatment; bringing their treatment buddy to clinic with them or to a session with a \\ncounsellor to learn more about HIV  \\no Disclosing their HIV status to household members so they do not have to hide pill -taking  \\no Combining pill taking with a consistent activity in their daily routine  \\no Keeping the ARVs in a place that they are lik ely to see every day  \\no Setting a daily alarm on their phone/watch/clock  \\no Connecting with a support group for additional counseling/education/support', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 111}),\n",
       " Document(page_content='o Setting a daily alarm on their phone/watch/clock  \\no Connecting with a support group for additional counseling/education/support  \\no Getting treatment for alcohol or drug use  \\no Getting treatment for depression or other psychiatric illness  \\n● Discuss what to do if:  \\no Develops side effects  \\n▪ Discuss common and serious adverse events for their specific regimen  \\n▪ Encourage patient to return to clinic for any side effects rather than stopping ART  \\no Forgets to take a dose: take it late rather than skipping the dose completely  \\no Travels without their ART: go to the nearest health facility or call clinic for guidance  \\n● Ask the patient to summarize their individualized adherence plan', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 111}),\n",
       " Document(page_content='Adherence Preparation, Monitoring and Support  \\n5 - 9 Table 5.1 Cont.  \\nOngoing Support at Subsequent Visits  \\n● Review the patient’s HIV knowledge  \\n● Review the patient’s motivation to take ART  \\n● Elicit any concerns the patient may have about their ART, side effects, visit schedule, or health  \\n● Review the ART dosing schedule and ask about any missed pills  \\n● Explore barriers to adherence that were previously identified or new ones that have developed  \\n● Explore any recent or expected changes in their life or daily routine  \\n● Discuss their individualized adherence plan and if any changes are required  \\n \\nHIV Education and Counselling  \\nHIV education should be a standard component of the enrolment visit. Prior to ART initiation, all', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 112}),\n",
       " Document(page_content='HIV Education and Counselling  \\nHIV education should be a standard component of the enrolment visit. Prior to ART initiation, all \\npatients/caregivers must be provided with enough information to make an informed choice about \\nART initiation and adherence (Table 5.2), including for patients who initiate ART during the \\nenrolment visit. A detailed content guide for HIV education and adherence counselling is provided \\nin Annex 8. This information can be provided through group or individual counselling. The ART \\nReadiness Assessment an d the management plan should be completed for each patient \\nindividually (Table 5.4).', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 112}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 10 Table 5.2: Components of HIV Education (see Annex 8 for detailed content guide)  \\nComponent  Questions to be Covered  \\n \\nHIV ● What is HIV  \\n● How is HIV transmitted  \\n● Why should partners and family members be tested for HIV  \\n \\nViral load  ● What is viral load  \\n● How often is viral load measured  \\n● What do viral load measurements mean, including the goal of achieving viral suppression  \\n \\n \\nCD4 cells  ● What are CD4 cells  \\n● How are CD4 cells affected by HIV  \\n● What happens when CD4 cells decrease  \\n● How often is CD4 cell count measured  \\n \\n \\n \\nAntiretroviral \\ntherapy (ART)  ● What is ART  \\n● What are the benefits of ART  \\n● When is ART started  \\n● Does ART cure HIV', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 113}),\n",
       " Document(page_content='Antiretroviral \\ntherapy (ART)  ● What is ART  \\n● What are the benefits of ART  \\n● When is ART started  \\n● Does ART cure HIV  \\n● Can you still give HIV to others while taking ART  \\n● How long is ART taken  \\n \\n \\nTreatment failure  ● What happens if you stop taking ART  \\n● What happens if you do not take ART regularly  \\n● What happens if the viral load increases  \\n● What happens in treatment failure  \\n \\nART side effects  ● What are the side -effects of ART  \\n● What should you do if you notice any side effects  \\n \\n \\n \\nAdherence  ● What is adherence  \\n● How should ART be taken  \\n● What usually interferes with good adherence  \\n● What might make it difficult for you to take your ART as prescribed  \\n● What can help you take ART as prescribed  \\n● What happens if you miss an appointment', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 113}),\n",
       " Document(page_content='● What can help you take ART as prescribed  \\n● What happens if you miss an appointment  \\nOther medications  ●  What other medications will you take, in addition to ART (e.g., CPT, TPT)  \\n \\nNutrition  ● Why is nutrition important  \\n● What can you do to improve your nutrition  \\n \\nFollow -up ● How often will you need to come for clinic visits?  \\n● What will we be checking for during your clinic visits  \\nAdherence Support  \\nPsychosocial support for PLHIV and their families is essential for their well -being and good health \\noutcomes. HIV affects virtually every aspect of one’s life, as well as the lives of those close to them. \\nPLHIV need psychological and social support to deal with various issues that are common to', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 113}),\n",
       " Document(page_content='PLHIV need psychological and social support to deal with various issues that are common to \\nchronic illness as well as those that are unique to HIV. These include sti gma, bereavement, self -\\nimage, loss of earning capacity, life skills, and chronic illness, among others. Providing \\npsychosocial support entails identifying any needs that they may have and addressing them. In \\nsome cases, some of these needs can be anticipat ed and addressed even before they come to play \\nin the individual’s life.  \\nThe individualized patient management plan should include establishing appropriate adherence \\nsupport interventions (Table 5.3).', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 113}),\n",
       " Document(page_content='Adherence Preparation, Monitoring and Support  \\n5 - 11 Table 5.3: Adherence Support and Retention Intervention s \\nStandard Adherence Support Interventions  \\nStructural \\ninterventions  ● Conduct a baseline psychosocial assessment to explore the various aspects of \\nthe client’s life that may influence their adherence to treatment and \\nprevention, and their general well -being. This teases out issues that need to \\nbe explored in detail during the counselling session e.g., disclosure, family \\nplanning, living circumstances etc.  \\n● Use a multidisciplinary team approach to develop and implement treatment \\nplans for each patien t \\n● Engage peer educators to lead HIV education and support services  \\n● Adequately prepare and assess the patient’s readiness to initiate and continue \\nwith ART', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 114}),\n",
       " Document(page_content='● Adequately prepare and assess the patient’s readiness to initiate and continue \\nwith ART  \\n● Implement a system for identifying and taking action when patients miss an \\nappointment  \\n● Formalize a sy stem for providing health talks and treatment literacy classes \\nfor patients  \\n● Formalize a system for linking patients to community -based resources, \\nincluding: community support groups, religious groups, CBOs, groups \\nsupporting income -generating activities, o rganizations providing food \\nsupport, NEPHAK, child welfare societies, community health volunteers/units, \\nschools, children’s homes etc.  \\n \\nHIV \\neducation \\nand \\ncounselling  ● Remind the patient about HIV disease, how ART works, the importance of \\nhigh -level adherence and the consequences of non -adherence', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 114}),\n",
       " Document(page_content='counselling  ● Remind the patient about HIV disease, how ART works, the importance of \\nhigh -level adherence and the consequences of non -adherence  \\no Risk of ill health caused by HIV  \\no Role of ART in restoring and maintaining good health  \\no Link between adherence and viral load, CD4 and health  \\no Side effects of medications and how to avoid, recognize and manage them. \\nManage side effects aggressively  \\no Address misconceptions and beliefs about HIV and ART  \\n● Discuss and agree on a treatment plan with the patient. Gain commitment \\nfrom the patient to follow through  \\n● Discuss use of alcohol and drugs and  how to prevent these from affecting the \\ntreatment plan  \\n● It is important to maintain a non -judgmental attitude, establish trust with', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 114}),\n",
       " Document(page_content='treatment plan  \\n● It is important to maintain a non -judgmental attitude, establish trust with \\nparents/caregivers, and involve the child as they mature', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 114}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 12 Table 5.3 Cont.  \\nDisclosure and \\nstigma  ● Respect patient privacy and confidentiality  \\n● Discuss with the patient the role of disclosure to close family \\nmembers/trusted friend in promoting adherence  \\n● Offer to facilitate disclosure  \\n● For children/adolescents, discuss age -appropriate disclosure with the \\ncaregiver and off er to support the process (Annex 5)  \\n● Conduct stigma assessment and support appropriately  \\n \\nTreatment \\nsupporter  ● Encourage the patient to identify a treatment supporter/buddy who will \\nprovide the patient with encouragement and social support and even remind \\nthe patient to take medication  \\n● Invite the treatment supporter to at least one of the adherence counselling \\nsessions', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 115}),\n",
       " Document(page_content='the patient to take medication  \\n● Invite the treatment supporter to at least one of the adherence counselling \\nsessions  \\n● Obtain consent from the patient to contact the treatment supporter if needed  \\nSupport group  ● Link the patient to psychosocial support groups and other community -based \\nsupport mechanisms (preferably through direct introduction)  \\no Support groups give confidence and encouragement and promote positive \\nattitude towards HIV status and may promote disclosure  \\no Support groups offer opportunities for additional counselling and \\nexperience sharing and are an avenue for developing/strengthening life \\nskills  \\no Some support groups engage in economic empowerment activities  \\no Support groups can be used for ART distribution to improve  convenience \\nto the patient', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 115}),\n",
       " Document(page_content='o Support groups can be used for ART distribution to improve  convenience \\nto the patient  \\n● Develop population -specific support groups when possible (e.g., youth \\ngroups with peer educators for adolescents; children’s clubs; caregiver \\nsupport groups)  \\n● MDT members should be patrons to the support groups, to guide activiti es in \\nline with intended objectives  \\n \\nSMS reminder \\nsystem  ● Enroll patients into an automated SMS reminder system with their consent  \\n● Review the type of messages the patient may receive, the frequency of \\nmessages, and any actions the patient should take when receiving the \\nmessage  \\n● Ensure the system and messages maintain patient privacy and confidentiality  \\nOther reminder', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 115}),\n",
       " Document(page_content='message  \\n● Ensure the system and messages maintain patient privacy and confidentiality  \\nOther reminder \\nstrategies  ● Encourage patient/caregiver to set a specific time of day to take ART, and to \\nassociate ART time with a specific event/s in their daily schedule  \\n● Encourage patient/caregiver to set an alarm on their phone', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 115}),\n",
       " Document(page_content='Adherence Preparation, Monitoring and Support  \\n5 - 13 5.2.3 Age -Specific Treatment Preparation and Support  \\nTreatment preparation must be customized to the patient’s age, gender, needs and clinical status: \\nfor patients who present with advanced/symptomatic disease, the focus is on getting better; for \\npatients who present clinically well, the focus is on staying healthy. Specific needs for children, \\nadolescents, caregivers, pregnant and breastfeeding women and men should also be taken into \\nconsideration.  \\nThe HIV education and counselling sessions should be provided at every visit until the patient is \\nready and wi lling to start ART, as determined using the ART Readiness Assessment Form (Table', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 116}),\n",
       " Document(page_content='ready and wi lling to start ART, as determined using the ART Readiness Assessment Form (Table \\n5.4). Each repeat session should begin with a review of what the patient remembers from the \\nprevious session as well as any key issues the counsellor documented in the patient ’s chart, so the \\nsession can be customized to meet their needs. ART preparation should not take more than 1 -2 \\nweeks except for special circumstances such as with uncontrolled mental health issues or \\nuntreated drug addictions. However, once the patient has initiated ART, continued HIV education, \\ncounselling and adherence support must be provided. The counselling sessions should preferably \\nbe conducted by the same counsellor, peer educator, social worker, nurse, community health', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 116}),\n",
       " Document(page_content='be conducted by the same counsellor, peer educator, social worker, nurse, community health \\nvolunteer, and/or clinician wh o is professionally certified to counsel based on a certified \\ncurriculum, and they possess the requisite competencies to provide quality counselling. In order \\nto prepare children and adolescents for ART, the counsellor should be trained in providing \\npsycho social support to this age group.  \\nTable 5.4: ART Readiness Assessment Form  \\nCriteria  Y N* \\nA. Psychosocial/Knowledge Criteria (applies to patients and caregivers)  \\n1. Understands the nature of HIV infection and benefits of ART?    \\n2. Has screened negative for alcohol or other drug use disorder, or is stable on \\ntreatment (see Section 4.6)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 116}),\n",
       " Document(page_content='2. Has screened negative for alcohol or other drug use disorder, or is stable on \\ntreatment (see Section 4.6)    \\n3. Has screened negative for depression or other psychiatric illness, or is stable on \\ntreatment (see Section 4.6)    \\n4. Is willing to disclose/has disclosed HIV status, ideally to a family member or close \\nfriend?    \\n5. Has received demonstration of how to take/administer ART and other prescribed \\nmedication?    \\n6. Has received information on predictable side effects of ART and understands what \\nsteps to take in case of these side effects?    \\n7. For patients dependent on a caregiver: is the caregiver committed to long -term \\nsupport of the patient, daily administration of ART, and meets the criteria above?', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 116}),\n",
       " Document(page_content='support of the patient, daily administration of ART, and meets the criteria above?    \\n8. Other likely barriers to adherence have been identified and there is a plan in place \\nto address them (e.g., frequent travel for work, plan to deal with unexpected travel, \\ndistance from clinic, etc.)?    \\n9. Has the Patient/caregiver provided accurate locator information and contact details?    \\n10. Patient/caregiver feels ready to start ART today?', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 116}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 14 Table 5.4 Cont.  \\nB. Support Systems Criteria (applies to patients and caregivers)  \\n1. Has identified convenient time/s of day for taking ART, and/or associated \\ndose/s with daily event/s?    \\n2. Treatment supporter has been identified and engaged in HIV education, or will \\nattend next counselling session?    \\n3. Is aware of support group meeting time/s?    \\n4. If facility has SMS reminder system: Has enrolled into SMS reminder system?    \\n5. Other support systems are in place or planned (e.g., setting phone alarm, pill box)?    \\nC. Medical Criteria (applies to patients)  \\n1. Newly diagnosed with TB: defer ART until patient tolerates anti -TB medication;', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 117}),\n",
       " Document(page_content='C. Medical Criteria (applies to patients)  \\n1. Newly diagnosed with TB: defer ART until patient tolerates anti -TB medication; \\ninitiate ART as soon as possible preferably within 2 weeks; for TB meningitis \\ndelay ART for 4 to 8 weeks); monitor closely for IRIS    \\n2. Newly diagnosed cryptococcal meningitis (CM), or symptoms consistent with CM \\n(progressive headache, fever, malaise, neck pain, confusion): defer ART until \\ncompleted 5 weeks of CM treatment, or until ruling out CM as the cause of \\nsymptoms; monitor closely f or IRIS    \\n*If the response to any of the psychosocial criteria or support systems criteria is “No”: develop a \\nstrategy to address the issue as quickly as possible and consider assigning a case manager. ART', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 117}),\n",
       " Document(page_content='strategy to address the issue as quickly as possible and consider assigning a case manager. ART \\nmay be initiated with adequate adherence support while the criteria is being addressed, on a \\ncase -by-case basis  \\n \\nAt each visit up until ART initiation, every patient should be assessed for readiness to \\nstart ART (Table 5.4), with the patient/caregiver allowed to make the final decision on \\nwhether and when to start ART.  \\nSpecial Considerations when Counselling Children and Adolescents  \\nChildren and adolescents depend on caregivers to support their adherence so there are special \\nconsiderations for adherence preparation and support. All topics covered in the HIV Education \\nand Adherence Counselling sessions (Table 5.2 and Annex 8) should be covered with the', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 117}),\n",
       " Document(page_content='and Adherence Counselling sessions (Table 5.2 and Annex 8) should be covered with the \\ncaregiver, with involvement of the child/adolescent as appropriate based on the stage of \\ndisclosure and their developmental stage (Tab le 5.5).', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 117}),\n",
       " Document(page_content='Adherence Preparation, Monitoring and Support  \\n5 - 15 Table 5.5: Age -appropriate Involvement of Child/Adolescent in HIV Education and \\nAdherence Counselling  \\nAge  Counselling Approach  \\n< 6 years old  The counselling sessions will focus on engaging all of the child’s \\ncaregivers  \\n6-12 years old  Both the caregiver and the child will be involved. The counselling will \\nfocus on the caregiver; younger children can be given a paper and pen \\nand asked to draw their family, school, etc., and talk about their \\nexperiences. Disclosure of HIV status to the child s hould commence by 5 \\nyears of age and be completed by 10 -12 years of age (Annex 5)  \\n> 12 years old with \\ncaregiver present  Most of the counselling can focus on the adolescent, who is often fully', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 118}),\n",
       " Document(page_content='> 12 years old with \\ncaregiver present  Most of the counselling can focus on the adolescent, who is often fully \\nresponsible for medication administration. However, it is neces sary to \\nkeep the caregiver coming and involved in supporting the adolescent. A \\nrecommended approach is to start with the caregiver alone, then see the \\ncaregiver and adolescent together, and then see the adolescent alone. \\nUse the HEADSSS tool* to facilitate  discussion  \\n> 12 years old \\nwithout the \\ncaregiver present  Use the HEADSSS tool* to facilitate discussion. Negotiate involvement \\nof a treatment supporter  \\n* HEADSSS assesses: Home; Education/Employment; Activities; Drugs; Sexuality; \\nSuicide/depression/self -image; Safety', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 118}),\n",
       " Document(page_content='of a treatment supporter  \\n* HEADSSS assesses: Home; Education/Employment; Activities; Drugs; Sexuality; \\nSuicide/depression/self -image; Safety  \\n \\nIn addition to the standard HIV Education and Adherence Counselling topics, unique issues need \\nto be addressed for caregivers, children and adolescents (Table 5.6).', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 118}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 16 Table 5.6: Unique Considerations for Caregivers, Children and Adolescents  \\nCaregiver Barriers to Adherence  \\n• Frequently changing or multiple simultaneous caregivers  \\n• Loss or grief  \\n• Absent or sick caregiver  \\n• Poor understanding of HIV management due to inadequate counselling, elderly, or illiterate \\ncaregiver  \\n• Depression, alcohol and other drug use  \\n• Living far from the health facility  \\n• Economically unstable  \\n• Lack of affection between caregiver and child  \\n• Lack of support systems for the caregiver  \\nChild/Adolescent Barriers to Adherence  \\n• Level of disclosure (is the child/adolescent aware of their HIV status?)  \\n• Lack of understanding of disease/treatment  \\n• Developmental stage and emotional state', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 119}),\n",
       " Document(page_content='• Lack of understanding of disease/treatment  \\n• Developmental stage and emotional state  \\n• Child refusal to swallow medicine (do not allow refusal to take medicines: all activities should \\nbe stopped for the child until the dose is swallowed)  \\n• Stigmatization and discrimination  \\n• Low self -esteem  \\n• Depression  \\n• Defiance related to a troublesome caregiver -child relationship  \\n• Inadequate structures at school (day or boarding) to support adherence  \\n• Lack of support systems for the child/adolescent  \\nTreatment Barriers to Adherence  \\n• Large volumes of syrups  \\n• Bad taste of syrups  \\n• Pill burden  \\n• Confusing regimens combining syrups and tablets  \\n• Side effects  \\n• Dose adjustment requirements as the child grows', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 119}),\n",
       " Document(page_content='• Pill burden  \\n• Confusing regimens combining syrups and tablets  \\n• Side effects  \\n• Dose adjustment requirements as the child grows  \\nFor all children/adolescents, the level of disclosure should be assessed at first visit and the \\nmanagement plan should include a plan for age -appropriate disclosure (Annex 5). Treatment \\npreparation and support se ssions should be customized to the patient’s age (Tables 5.7 -5.9).', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 119}),\n",
       " Document(page_content='Adherence Preparation, Monitoring and Support  \\n5 - 17 Table 5.7: Treatment Preparation and Support for Children (≤   years) and Caregivers  \\nVisit  Standard of Care  \\nAt \\nenrolment \\ninto care  \\n Use the 5As (Assess, Assist, Advice, Agree, Arrange)  \\n• Perform a psychosocial assessment at enrolment to evaluate for possible \\npsychological, emotional and social adherence boosters and barriers  \\n• Assess growth and developmental milestones (Annex 3) to rule out growth \\nretardation, developmental challenges such as autism, deafness and any other \\nphysical challenge. Any child with developmental challenges should be referred for \\nappropriate care  \\n• Identify the primary caregiver as soon as possible after diagnosis of HIV in a child. In', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 120}),\n",
       " Document(page_content='appropriate care  \\n• Identify the primary caregiver as soon as possible after diagnosis of HIV in a child. In \\nthe absence of a caregiver, link the child to a community health volunteer or a peer \\neducator while a more permanent solution is sought, and link with Department of \\nChildren and Social Protection  \\n• The child and their caregiver, if also infected, should be enrolled in the sa me clinic, \\nand have appointments booked on the same clinic day for family -centered care  \\n• Provide HIV education and counselling to caregiver (and child as appropriate for age, \\nTable 5.5) as outlined in Table 5.2  \\n• Identify and establish appropriate adherence s upport interventions (Table 5.3), \\nincluding linkage to pediatric and caregiver support groups', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 120}),\n",
       " Document(page_content='• Identify and establish appropriate adherence s upport interventions (Table 5.3), \\nincluding linkage to pediatric and caregiver support groups  \\n• Discuss benefits of disclosure of HIV status of the child and formulate a disclosure \\nplan for children aged 5 years and above (Annex 5)  \\n• Conduct readiness assessme nt to initiate ART (Table 5.4); ART should be initiated \\nsame day or the date of initiation agreed upon  \\n• Review ART dosing and timing (including having the caregiver demonstrate how they \\nmeasure and administer the ART)  \\n• Conclude the session by agreeing on a t reatment and follow -up plan  \\n• Where ART is initiated book the child to return within two weeks. Those unwilling to \\ninitiate should return weekly for further counselling on barriers to initiation', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 120}),\n",
       " Document(page_content='initiate should return weekly for further counselling on barriers to initiation  \\n• Identify referral needs and link as appropriate  \\n• Document sessi on in the patient’s chart  \\nTwo weeks \\nafter ART \\nInitiation  \\n • Review and reinforce the messages delivered at enrolment; confirm the caregiver’s \\nunderstanding of key messages  \\n• Review ART dosing, timing and reminders (including having the caregiver \\ndemonstrate how they measure and administer the ART)  \\n• Explore any barriers to adherence  \\n• Revisit benefits of disclosure and the individualized age -appropriate disclosure plan  \\n• Identify referral needs and link as appropriate  \\n• Document the session in the patien t’s chart  \\nFour weeks \\nafter ART \\nInitiation, \\nand further \\nfollow -up \\nvisits', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 120}),\n",
       " Document(page_content='• Document the session in the patien t’s chart  \\nFour weeks \\nafter ART \\nInitiation, \\nand further \\nfollow -up \\nvisits  \\n • Review and reinforce the messages delivered in previous sessions; confirm the \\ncaregiver’s understanding of key messages  \\n• Review ART dosing, timing and reminders (including having the caregiver \\ndemonstrate how they measure and administer the ART)  \\n• Explore any barriers to adherence  \\n• Revisit benefits of disclosure and the individualized age -appropriate disclosure plan  \\n• Identify referral needs and link as appropriate  \\n• Document the session in the patient’s chart', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 120}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 18 Table 5.8: Treatment Preparation and Support for Adolescents (10 -19 years)  \\nVisit  Standard of care  \\nAt \\nenrolment \\ninto care  Use the 5As (Assess, Assist, Advice, Agree, Arrange)  \\n• Perform a psychosocial assessment at enrolment to evaluate for possible psychological, \\nemotional and social adherence boosters and barriers  \\n• Assess growth and developmental milestones to rule out growth retardation, \\ndevelopmental challenges such as autism, deafness and any other physical challenge. \\nAny adolescent with developmental challenges should be referred for appropriate care  \\n• Identify the primary caregiver as soon as possible after diagnosis of HIV in an', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 121}),\n",
       " Document(page_content='• Identify the primary caregiver as soon as possible after diagnosis of HIV in an \\nadolescent. Adolescents older than 15 years and emancipated minors may not have or \\nmay not want the presence of a caregiver. In this case, the clinical team should explore \\nalternative options to support the adolescent until they are ready to disclose to their \\ncaregivers/guardian or identify someone to disclose to. The alterna tive options include \\nadolescent mentors, peer educators, social worker, nurses or community health \\nvolunteers as may be appropriate.  An adolescent can have both private and joint \\nsessions with the caregiver when deemed appropriate  \\n• The health provider shou ld explore Sexual and Reproductive Health (SRH)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 121}),\n",
       " Document(page_content='sessions with the caregiver when deemed appropriate  \\n• The health provider shou ld explore Sexual and Reproductive Health (SRH) \\nunderstanding, fears and needs of the adolescent and prioritize interventions as \\nappropriate. SRH counseling should be introduced in a one -to-one session with the \\nadolescent. The care giver can be excused fro m the sexual and reproductive health \\nsession to enable adolescent to open up during the session  \\n• The adolescent and their caregiver, if also infected, should be enrolled in the same \\nclinic, and have appointments booked on the same clinic day for family -cent ered care  \\n• Provide HIV education and counselling to caregiver (and adolescent as appropriate for \\nage, Table 5.5) as outlined in Table 5.2', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 121}),\n",
       " Document(page_content='• Provide HIV education and counselling to caregiver (and adolescent as appropriate for \\nage, Table 5.5) as outlined in Table 5.2  \\n• Identify and establish appropriate adherence support interventions (Table 5.3), \\nincluding linkage to adolescent and car egiver support groups  \\n• Discuss with the caregiver the benefits of disclosure of HIV status to the adolescent (if \\nnot aware of status) and formulate a disclosure plan for adolescents (see Annex 5 for \\nage-appropriate disclosure)  \\n• Conduct readiness assessment to initiate ART (Table 5.4); ART should be initiated \\nsame day or the date of initiation agreed upon  \\n• Review ART dosing and timing (including having the adolescent and/or caregiver \\ndemonstrate how they measure and administer the ART)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 121}),\n",
       " Document(page_content='• Review ART dosing and timing (including having the adolescent and/or caregiver \\ndemonstrate how they measure and administer the ART)  \\n• Conclude the session by agreeing on a treatment and follow -up plan  \\n• Where ART is initiated, book the adolescent to return within two weeks. Those \\nunwilling to initiate should return weekly for further counselling on barriers to \\ninitiation  \\n• Identify referral needs and li nk as appropriate  \\n• Document session in the patient’s chart', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 121}),\n",
       " Document(page_content='Adherence Preparation, Monitoring and Support  \\n5 - 19 Table 5.8 Cont.  \\nTwo \\nweeks \\nafter ART \\ninitiation  • Review and reinforce the messages delivered at enrolment; confirm the adolescent’s \\nand/or caregiver’s understanding of key messages  \\n• Review ART dosing, timing and reminders (including having the adolescent and/or \\ncaregiver demonstrate how they measure and administer the ART)  \\n• Explore any barriers to adherence, including issues related to the school environment  \\n• Review support systems (including adol escent support group)  \\n• Revisit benefits of disclosure and the individualized age -appropriate disclosure plan  \\n• Review SRH needs  \\n• Identify referral needs and link as appropriate  \\n• Document the session in the patient’s chart  \\nFour \\nweeks \\nafter ART \\ninitiation,', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 122}),\n",
       " Document(page_content='• Identify referral needs and link as appropriate  \\n• Document the session in the patient’s chart  \\nFour \\nweeks \\nafter ART \\ninitiation, \\nand \\nfurther \\nfollow -up \\nvisits  \\n • Review and reinforce the messages delivered in previous sessions; confirm the \\nadolescent’s and/or caregiver’s understanding of key messages  \\n• Review ART dosing, timing and reminders (including having the adolescent a nd/or \\ncaregiver demonstrate how they measure and administer the ART)  \\n• Explore any barriers to adherence, including issues related to the school environment  \\n• Review support systems (including adolescent support group)  \\n• Revisit benefits of disclosure and the in dividualized age -appropriate disclosure plan  \\n• Review SRH needs  \\n• Link to psychosocial support group', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 122}),\n",
       " Document(page_content='• Review SRH needs  \\n• Link to psychosocial support group  \\n• Identify referral needs and link as appropriate  \\n• Document the session in the patient’s chart  \\nTable 5.9: Treatment Preparation and Support for Adults  \\nVisit  Standard of care  \\nAt \\nenrolment \\ninto HIV \\ncare  \\n Use the 5As (Assess, Assist, Advice, Agree, Arrange)  \\n● Perform a psychosocial assessment to evaluate adherence boosters and barriers e.g., \\nmental, emotional and social status assessments; refer for appropriate care if mental \\ndisorder diagnosed  \\n● Identify a treatment buddy (family member, friend, peer educator, community health \\nvolunteer, etc.) and involve them in HIV education and adherence counselling  \\n● Provide HIV education and counselling to patient', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 122}),\n",
       " Document(page_content='volunteer, etc.) and involve them in HIV education and adherence counselling  \\n● Provide HIV education and counselling to patient  \\n● Identify and establish appropriate adherence support interventions (Table 5.3), \\nincluding linkage to a support g roup  \\n● Discuss benefits of disclosure of HIV status to a trusted family member/friend; how to \\ndisclose; and establish a disclosure plan  \\n● Discuss importance of child and sexual partner testing as well as assisted partner \\nnotification services (aPNS)  \\n● Discus pr evention methods such as condoms, PrEP, PEP, STI screening and treatment  \\n● Conduct an assessment of readiness to initiate ART (Table 5.4); ART should be initiated \\nsame day or the date of initiation agreed upon  \\n● Review ART dosing and timing', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 122}),\n",
       " Document(page_content='same day or the date of initiation agreed upon  \\n● Review ART dosing and timing  \\n● Conclude the sessi on by agreeing on a treatment and follow -up plan  \\n● Where ART is initiated, book the patient to return within two weeks. Those unwilling \\nto initiate should return weekly for further counselling on barriers to initiation  \\n● Document session in the patient’s cha rt', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 122}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 20 Table 5.9 Cont.  \\nTwo weeks \\nafter ART \\ninitiation  ● Review and reinforce the messages delivered at enrolment; confirm the patient’s \\nunderstanding of key messages  \\n● Review ART dosing, timing and reminders  \\n● Explore any barriers to adherence  \\n● Review support systems  \\n● Revisit benefits of disclosure, the disclosure plan and progress in aPNS  \\n● Document the session in the patient’s chart  \\nFour weeks \\nafter ART \\ninitiation, \\nand further \\nfollow -up \\nvisits  ● Review and reinforce the messages delivered in previous sessions; confirm the \\npatient’s understanding of key messages  \\n● Review ART dosing, timing and reminders  \\n● Explore any barriers to adherence  \\n● Review support systems', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 123}),\n",
       " Document(page_content='● Review ART dosing, timing and reminders  \\n● Explore any barriers to adherence  \\n● Review support systems  \\n● Revisit benefits of disclosure the disclosure plan,  and progress in aPNS  \\n● Document the session in the patient’s chart  \\n \\n5.3 Adherence Monitoring, Counselling and Support During the First 3 Months \\nof ART  \\n5.3.1 Adherence Monitoring  \\nOnce ART has been initiated, adherence should be assessed non-judgmentally by a trained \\nprovider during each visit (Table 5.10).  The objectives of this assessment are to evaluate and \\nreinforce the patient’s adherence to ART, to elicit any barriers to the same, and to develop a plan \\nwith the patient/caregiver to address any of the barriers identified. These may include incorrect', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 123}),\n",
       " Document(page_content='with the patient/caregiver to address any of the barriers identified. These may include incorrect \\nknowledge of HIV infection and ART, unsupportive psychosocial factors, difficult home or school \\nenvironment, substance use and poor motivation for taking medication. Patients/caregivers ne ed \\nto be counselled on the importance of being honest about their adherence in order for the \\nhealthcare team to serve them better.  \\nAdherence monitoring requires a combination of interventions. At every clinical visit, the MMAS -\\n4 should be administered as w ell as pill counts. MMAS -8 should be administered any time a \\nhealthcare worker suspects adherence problem (e.g., patients with suspected or confirmed \\ntreatment failure; patient who misses an appointment).', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 123}),\n",
       " Document(page_content='Adherence Preparation, Monitoring and Support  \\n5 - 21 Table 5.10: Adherence Monitoring Strategies  \\nAdher ence \\nMonitoring \\nStrategy  Technique  Frequency  \\nSubjective (self -reported adherence)  \\nMorisky \\nMedication \\nAdherence Scale -4 Use Table 5.11 to assess adherence using a \\nstandardized questionnaire, and take action \\nas required  Every patient, every visit  \\nMorisky \\nMedication \\nAdherence Scale -8 Use Table 5.12 to assess adherence using a \\nstandardized questionnaire, and take action \\nas required  Any time a healthcare worker \\nsuspects adherence problems \\n(e.g., patients with suspected or \\nconfirmed treatment failure; \\npatient who misses an \\nappointment)  \\nAdherence \\nMonitoring \\nStrategy  Technique  Frequency  \\nObjective', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 124}),\n",
       " Document(page_content='confirmed treatment failure; \\npatient who misses an \\nappointment)  \\nAdherence \\nMonitoring \\nStrategy  Technique  Frequency  \\nObjective  \\n \\n \\n \\nPill counts  Ask the patient to bring all their pills with \\nthem to follow -up visits. Calculate how many \\npills should be remaining based on the \\nprevious prescription date and amount \\nprescribed, and compare to how many pills \\nare actually remaining. Excess pills are \\nassumed to be missed doses. Use Table 5.13 to \\ncalculate adherence rate and take action as \\nrequired  ● At every visit until confirmed \\nviral suppression  \\n● Any time a healthcare worker \\nsuspects adherence problems  \\n \\nPharmacy refill \\nrecords  Compare drug pick -up date with expected \\ndate of pick -up (based on number of pills \\ndispensed at last visit). If drug pick -up date is', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 124}),\n",
       " Document(page_content='records  Compare drug pick -up date with expected \\ndate of pick -up (based on number of pills \\ndispensed at last visit). If drug pick -up date is \\nlater than expected, it is assumed the patient \\nis missing doses equivalent to the number of \\ndays late  ● At every drug pick -up \\n● Any time a healthcare worker \\nsuspects adherence problems  \\nViral load  Follow the viral load monitoring algorithm \\n(Figure 6.6). Undetectable VL is the best \\nconfirmation of adequate adherence  ● Age 0 -24 years: at 3 months after \\nART initiation and then every 6 \\nmonths  \\n● Age ≥ 25 years: at month 3 after \\nART initiation and month 12 \\nthen annually  \\n● For pregnant and breastfeeding \\nwomen: at fir st ANC visit if \\nalready on ART, or 3 months \\nafter ART initiation if starting \\nART during pregnancy, and then', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 124}),\n",
       " Document(page_content='women: at fir st ANC visit if \\nalready on ART, or 3 months \\nafter ART initiation if starting \\nART during pregnancy, and then \\nevery 6 months', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 124}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 22 Table 5:10 Cont.  \\n \\n \\nHome visit  Observe where and how a patient stores and takes \\ntheir medications and assess if they have extra \\nmedications because of missed doses. Home visits \\nmay also provide a better understanding of a \\npatient’s living situation and specific barriers to \\nadherence. Unscheduled home visits may be more \\nrevealing, but should only be conducted if the  patient \\nconsente d to home visits previously (preferably at \\nthe time of enrolment or initiation)  For patients with suspected or \\nconfirmed treatment failure, \\npatients who default from care, \\nor any time the MDT feels a \\nhome visit will contribute to \\npatient management', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 125}),\n",
       " Document(page_content='confirmed treatment failure, \\npatients who default from care, \\nor any time the MDT feels a \\nhome visit will contribute to \\npatient management  \\n \\nAccurately assessing adherence requires clinicians to develop a collaborative and non -\\njudgmental relationship with patients.  This is best done when one provider follows an \\nindividual patient longitudinally. The key to asking patients about their adherence is not in the \\nspecifics of the tool used but in taking the time to ask about adherence regularly and doing so in \\nan open and truly inquisitive manner. Otherwise, many patients will simply state what they \\nbelieve the clinician wants to hear: perfe ct adherence.  \\nEvery provider in each ART service delivery point should receive training and gain confidence in', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 125}),\n",
       " Document(page_content='Every provider in each ART service delivery point should receive training and gain confidence in \\nassessing adherence and providing adherence support and counselling to the majority of patients \\nwho do not have significant barriers to adherence . However, patients with significant adherence \\nchallenges and multiple barriers to adherence should be referred to providers with additional \\ntraining and time to offer dedicated and enhanced adherence support and counselling. Involving \\nexperienced colleagu es at the same health facility should be done as soon as a concern is \\nidentified, and the patient should be discussed by the MDT to generate as many solutions as \\npossible. Consultation with Mental Health Teams or regional or national mentors may be require d \\nfor complex situations.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 125}),\n",
       " Document(page_content='Adherence Preparation, Monitoring and Support  \\n5 - 23 Table 5.11: Morisky Medication Adherence Scale (MMAS -4) \\nMMAS -4: Ask the patient each question below. Circle the corresponding score for each response. \\nAfter completion of all questions, add up all the points that you have circle d for the total score.  \\nQuestion  Yes No \\n1. Do you ever forget to take your medicine?  1 0 \\n2. Are you careless at times about taking your medicine?  1 0 \\n3. Sometimes if you feel worse when you take the medicine, do you stop taking it?  1 0 \\n4. When you feel better do you sometimes stop taking your medicine?  1  0 \\nTotal Score (sum of all items)   \\nInterpretation of MMAS -4 Score  \\nMMAS -4 \\nScore  Adherence \\nRating  Action Required  \\n0 Good  Continue with routine monitoring, counselling and support', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 126}),\n",
       " Document(page_content='MMAS -4 \\nScore  Adherence \\nRating  Action Required  \\n0 Good  Continue with routine monitoring, counselling and support  \\n \\n \\n1-2  \\n \\nInadequate  ● Discuss as an MDT  \\n● Assign a case manager  \\n● Assess for and address barriers to adherence (Table 5.15)  \\n● Engage treatment supporter in adherence counselling sessions  \\n● Follow up in 2 -4 weeks  \\n \\n \\n3-4  \\n \\nPoor  ● Discuss as an MDT  \\n● Assign a case manager  \\n● Assess for and address barriers to adherence (Table 5.15)  \\n● Engage treatment supporter in adherence counselling sessions  \\n● Implement DOTs  \\n● Follow up in 1 -2 weeks', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 126}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 24 Table 5.12: Morisky Medication Adherence Scale (MMAS -8) \\nMMAS -8: Ask the patient each question below. Circle the corresponding score for each \\nresponse. After completion of all questions, add up all the points that you have circled for the \\ntotal score.  \\nQuestion  Yes No \\n1. Do you ever forget to take your medicine?  1 0 \\n2. Are you careless at times about taking your medicine?  1 0 \\n3. Sometimes if you feel worse when you take the medicine, do you stop taking it?  1 0 \\n4. When you feel better do you sometimes stop taking your medicine?  1 0 \\n5. Did you take your medicine yesterday?  0 1 \\n6. When you feel like your symptoms are under control, do you sometimes stop \\ntaking your medicine?   \\n1  \\n0', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 127}),\n",
       " Document(page_content='6. When you feel like your symptoms are under control, do you sometimes stop \\ntaking your medicine?   \\n1  \\n0 \\n7. Taking medication every day is a real inconvenience for some people. Do you ever \\nfeel under pressure about sticking to your treatment plan?   \\n1  \\n0 \\n8. How often do you have difficulty remembering to take all your medications? \\n(Please circle the correct number)  \\n  A. Never/Rarely  \\n  B. Once in a while  \\n  C. Sometimes  \\n  D. Usually  \\n  E. All the time  Points: A. 0  \\nB. ¼ C. ½ D. ¾ \\nE. 1 \\nTotal Score (sum of all items)  \\nInterpretation of MMAS -8 Score  \\nMMAS -8 Score  Adherence Rating  Action Required  \\n0 Good  Continue with routine monitoring, counselling and support  \\n \\n \\n1-2  \\n \\nInadequate  ● Discuss as an MDT  \\n● Assign a case manager', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 127}),\n",
       " Document(page_content='0 Good  Continue with routine monitoring, counselling and support  \\n \\n \\n1-2  \\n \\nInadequate  ● Discuss as an MDT  \\n● Assign a case manager  \\n● Assess for and address barriers to adherence (Table 5.15)  \\n● Engage treatment supporter in adherence counselling \\nsessions  \\n● Follow up in 2 -4 weeks  \\n \\n \\n \\n3-8  \\n \\n \\nPoor  ● Discuss as an MDT  \\n● Assign a case manager  \\n● Assess for and address barriers to adherence (Table 5.15)  \\n● Engage treatment supporter in adherence counselling \\nsessions  \\n● Implement DOTs  \\n● Follow up in 1 -2 weeks', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 127}),\n",
       " Document(page_content='Adherence Preparation, Monitoring and Support  \\n5 - 25 Table 5.13: Adherence Rate Based on Pill Counts  \\nMissed Doses per Month  % Of \\nMedications \\nTaken  Adherence  \\nRating  Action Required (see Table 5.10 for \\nmore details)  For once -\\ndaily \\nregimen  For BD  \\nregimen  \\n1 dose  1-3 doses  ≥ 95%  Good  Continue with routine monitoring, \\ncounselling and support  \\n2-4 doses  4-8 doses  85-94%  Inadequate  ● Discuss as an MDT  \\n● Assign a case manager  \\n● Assess for and address barriers to \\nadherence (Table 5.15)  \\n● Engage treatment supporter in \\nadherence counselling sessions  \\n● Follow up in 2 -4 weeks  \\n≥ 5 doses  ≥ 9 doses  < 85%  Poor  ● Discuss as an MDT  \\n● Assign a case manager  \\n● Assess for and address barriers to \\nadherence (Table 5.15)  \\n● Engage treatment supporter in', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 128}),\n",
       " Document(page_content='● Assign a case manager  \\n● Assess for and address barriers to \\nadherence (Table 5.15)  \\n● Engage treatment supporter in \\nadherence counselling sessions  \\n● Implement DOTs  \\n● Follow up in 1 -2 weeks  \\n \\n5.3.2 Adherence Counselling and Support During the First 3 Months of ART  \\nAll patients recently initiated on ART need careful adherence monitoring and support to \\nensure they achieve virological suppression.  This is particularly important in the context of \\nrapid ART initiation. The intensity of counselling and support are dependent on the patients’ level \\nof adherence as assessed by the methods described i n section 5.2.1.  \\nTable 5.14 summarizes adherence counselling and support for patients from the time of ART', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 128}),\n",
       " Document(page_content='Table 5.14 summarizes adherence counselling and support for patients from the time of ART \\ninitiation until the 3 -month viral load results are available. For patients who have inadequate or \\npoor adherence, Table 5.15 describes the assessmen t for barriers to adherence.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 128}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 26 Table 5.14: Adherence Counselling and Support During the First 3 Months of ART  \\nNo adherence concerns (based on adherence assessment and healthcare team opinion)  \\nCounselling: Group or \\nIndividual, at every visit (can be \\ndone by any member of the \\nhealthcare team, including the \\nclinician)  ● Review patient/caregiver HIV knowledge (Table 5.2, Annex 8) \\nand address any gaps  \\n● Review patient/caregiver understanding of ART \\nadministration (dosing, timing, frequency) and address any \\ngaps  \\n● Elicit any concerns the patient/caregiver has about ART, other \\nmedications, visit schedule, or health. Address any concerns or \\nengage another care team member who can address them', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 129}),\n",
       " Document(page_content='medications, visit schedule, or health. Address any concerns or \\nengage another care team member who can address them  \\n● Explore any major recent or expected changes in the \\npatient’s/caregiver ’s life or daily routine that could disrupt \\nadherence  \\n● Update patient locator and contact information  \\nSupport  ● Encourage the patient/caregiver to continue with the support \\nsystems discussed and implemented already  \\n● Encourage introduction of additional standard support \\nsystems (Table 5.3), including supporting disclosure as needed  \\nInadequate or poor adherence (based on adherence assessment or healthcare team opinion)  \\nCounselling: Individual, at \\nevery visit until adherence is \\ngood (preferably by someone \\ntrained on adherence', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 129}),\n",
       " Document(page_content='Counselling: Individual, at \\nevery visit until adherence is \\ngood (preferably by someone \\ntrained on adherence \\ncounselling)  ● Assess for and address potential barriers to adherence \\n(Table  5.15)  \\n● Review patient/caregiver HIV knowledge (Table 5.2, Annex 8) \\nand address any gaps  \\n● Review patient/caregiver understanding of ART administration \\n(dosing, timing, frequency) and address any gaps  \\n● Elicit any concerns the patient/caregiver has about ART, other \\nmedications, visit schedule, or health. Address any concerns or \\nengage another care team member who can addr ess them  \\n● Explore any major recent or expected changes in the \\npatient’s/caregiver’s life or daily routine that could disrupt \\nadherence  \\n● Update patient locator and contact information', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 129}),\n",
       " Document(page_content='patient’s/caregiver’s life or daily routine that could disrupt \\nadherence  \\n● Update patient locator and contact information  \\nSupport  ● Review effectiveness of support systems they already have in \\nplace  \\n● Encourage introduction of additional standard and enhanced \\nsupport systems (Table 5.3), including supporting disclosure as \\nneeded, assigning a case manager and considering DOTs', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 129}),\n",
       " Document(page_content='Adherence Preparation, Monitoring and Support  \\n5 - 27 Table 5.15: Assessment for Barriers to Adherence  \\nTheme  Assessment  \\nAwareness of  \\nHIV status  ● Has the patient/caregiver accepted HIV status?  \\n● For children/adolescents: is age -appropriate disclosure underway/complete?  \\n \\n \\nUnderstanding  \\nof HIV infection \\nand ART  ● How HIV affects the body and risk of transmission to sexual partners and \\nchildren during pregnancy and breastfeeding  \\n● ART and how it works  \\n● Understanding of side effects and what to do in case of side effects  \\no “Have you experienced any side effect since your last visit? Has this \\naffected the way you take your medicine?”  \\n● Benefits of adherence  \\n● Consequences of non -adherence including drug resistance and treatment \\nfailure', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 130}),\n",
       " Document(page_content='● Benefits of adherence  \\n● Consequences of non -adherence including drug resistance and treatment \\nfailure  \\n \\nDaily routine  ● Review the patient’s/caregiver’s daily routine: “Tell me about your typical day”  \\n● Review how the patient takes medicine or how the caregiver administers it  \\no “Please tell me how you take each of your medicines?”  \\no “How does taking your medicine fit into your daily routine?”  \\n● If the patient’s/caregiver’s daily routine conflicts with medication schedule, \\nwork with t hem to find a new medication schedule that will be more \\nappropriate  \\n● Remind the patient/caregiver to take/give missed or delayed doses as soon as \\nhe/she remembers (up to 12 hours late if on a once -daily regimen, or up to 6', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 130}),\n",
       " Document(page_content='he/she remembers (up to 12 hours late if on a once -daily regimen, or up to 6 \\nhours late if on a twice - daily re gimen). The next dose should be taken at the \\nusual time  \\n● “What do you do in case of visits or travel?”  \\n● Remind the patient/caregiver to plan travel well, pack sufficient medicine; but \\nshould their medication get finished before they return, advise them to vi sit the \\nclosest ART centre and show their appointment card to get a refill  \\n● For orphans it is critical to assess who the primary caregiver is and their \\ncommitment', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 130}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 28 Table 5.15 Cont.  \\n \\n \\nPsychosocial \\ncircumstance  Home environment:  \\n● “Who do you live with?”  \\n● “Who is aware of your HIV status? Are there people in your life with whom you’ve \\ndiscussed your HIV status and ART use?”  \\no Discuss the usefulness of enlisting the support of family members, friends \\nor a treatment supporter/buddy in reminding them to take medication (for \\nchildren/adolescents, this includes teachers and/or supportive peers at \\nschool); offer assisted disclosure  \\no Encourage the patient to identify and bring a treatment supporter during \\nthe next visit  \\n● Support system (treatment buddy, psychos ocial support groups, etc.)  \\n● Any recent losses, grief', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 131}),\n",
       " Document(page_content='the next visit  \\n● Support system (treatment buddy, psychos ocial support groups, etc.)  \\n● Any recent losses, grief  \\n● Changes in relationships with family members/friends  \\n● Screen the patient/caregiver for alcohol and substance abuse (Tables 4.15 and \\n4.16)  \\no Discuss impact on ability to remember to take medication  \\no Explore m otivation to stop and offer support/referral  \\no Encourage limiting use and planning ahead so as not to forget to take \\nmedication  \\n● Screen for intimate partner violence (Section 4.2.1)  \\n● Stigma and discrimination  \\no “Does it bother you people might find out about your HIV status?”  \\no “Do you feel that people treat you differently when they know your HIV \\nstatus?”  \\n● Discuss if stigma is interfering with taking medication on time or with keeping', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 131}),\n",
       " Document(page_content='status?”  \\n● Discuss if stigma is interfering with taking medication on time or with keeping \\nclinic appointments  \\n● Beliefs: has the patient tried faith healing? Has th e patient ever stopped using \\nmedication because of religious beliefs?  \\nMental Health  \\nScreening  ● Screen patient/caregiver for depression using the PHQ -9 (Table 4.14) and \\nmanage/refer as required  \\n● Screen for other psychiatric conditions such as anxiety, post -traumatic stress \\ndisorder or psychosis, or refer to a mental health worker for assessment  \\nReferrals  ● Establish if the patient has been referred to other services (including nutrition, \\npsychosocial support services, other medical clinics, substance use treatment, \\netc.)  \\n● Did he/she attend the appointments? What was his/her experience? Do the', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 131}),\n",
       " Document(page_content='etc.)  \\n● Did he/she attend the appointments? What was his/her experience? Do the \\nreferrals need to be re -organized?', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 131}),\n",
       " Document(page_content='Adherence Preparation, Monitoring and Support  \\n5 - 29 5.4 Adherence Monitoring, Counselling and Support for Patients with  \\nSuppressed Viral Load < 200 copies/ml  \\nOnce a patient has confirmed viral suppression (with VL < 50 copies/ml or below the Lower \\nDetection Limit (LDL)) this is confirmation of adequate adherence to ART. The patient can be \\nreassured that they will do well if they continue to adhere. Ho wever, all patients are at risk of new \\nor worsening barriers to adherence, so adherence monitoring, counselling and support should \\ncontinue despite viral suppression, but at a lower intensity and frequency unless concerns are \\nidentified (Table 5.16). These  patients should also be educated on and assessed for qualification', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 132}),\n",
       " Document(page_content='identified (Table 5.16). These  patients should also be educated on and assessed for qualification \\nas “stable patient” services such as less frequent facility visits, fast -track or community -based ART \\ndistribution, etc. (Table 3.5).  \\nTable 5.16: Adherence Counselling and Support for Pati ents with Viral Load < 50 copies/ml  \\nNo adherence concerns (based on adherence assessment or healthcare team opinion)  \\nCounselling: Group or \\nindividual, every visit \\n(can be done by any \\nmember of the \\nhealthcare team, \\nincluding the clinician)  • Elicit any concerns the patient/caregiver has about ART, other \\nmedications, visit schedule, or health. Address any concerns or engage \\nanother care team member who can address them  \\n• Explore any major recent or expected changes in the', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 132}),\n",
       " Document(page_content='another care team member who can address them  \\n• Explore any major recent or expected changes in the \\npatient’s/caregiver’s life or daily  routine that could disrupt adherence  \\n• Update patient locator and contact information  \\nSupport  • Encourage the patient/caregiver to continue with the support systems \\nthat are in place already  \\nInadequate or poor adherence (based on adherence assessment or healthcare team opinion)  \\nCounselling: Individual, \\nat every visit until \\nadherence is good \\n(preferably by someone \\ntrained on adherence \\ncounselling)  • Assess for and address potential barriers to adherence (Table \\n5.15)  \\n• Review patient/caregiver HIV knowledge (Table 5.2, Annex 8) and \\naddress any gaps  \\n• Review patient/caregiver understanding of ART administration', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 132}),\n",
       " Document(page_content='• Review patient/caregiver HIV knowledge (Table 5.2, Annex 8) and \\naddress any gaps  \\n• Review patient/caregiver understanding of ART administration \\n(dosing, timing, frequency) and address any gaps  \\n• Elicit any concerns the patient/caregiver has about ART, other \\nmedicatio ns, visit schedule, or health. Address any concerns or engage \\nanother care team member who can address them  \\n• Explore any major recent or expected changes in the \\npatient’s/caregiver’s life or daily routine that could disrupt adherence  \\n• Update patient locator and contact information  \\nSupport  • Review effectiveness of support systems the patient already has in \\nplace  \\n• Encourage introduction of additional standard and enhanced support \\nsystems (Table 5.3), including supporting disclosure as needed,', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 132}),\n",
       " Document(page_content='place  \\n• Encourage introduction of additional standard and enhanced support \\nsystems (Table 5.3), including supporting disclosure as needed, \\nassigning a case manager and considering DOTs', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 132}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 30 Table 5.17 Viral Load Monitoring Cut -Offs  \\nClinical \\nDefinition  Category  Lab Value  Interpretation  Guidance  \\n• Suppressed  • LDL  \\n \\n \\n• Low Risk \\nLLV  • <50 \\nCopies/ml  \\n \\n• 50 – 199 \\nCopies/ml.  • Treatment Goal  \\n \\n \\n• Stable Client, \\nUntransmissible  • Continue Management  \\n \\n \\n• Continue management, \\nremind client of \\ntreatment goal  \\n• Enroll  in DSD  \\n \\n• Unsuppressed  • High Risk \\nLLV  • 200 -199 \\nCopies/ml  • Increased risk \\nof progression \\nto treatment \\nfailure  • Step down from DSD, \\ninstitute EAC, repeat VL \\nafter 3 months of \\nexcellent adherence  \\n \\n• Suspected \\nTreatment \\nFailure  • ≥1000 \\nCopies/ml  • Client at \\nincreased risk \\nof morbidity \\nand mortality  • Enroll Client in \\nspecialized clinic if', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 133}),\n",
       " Document(page_content='Treatment \\nFailure  • ≥1000 \\nCopies/ml  • Client at \\nincreased risk \\nof morbidity \\nand mortality  • Enroll Client in \\nspecialized clinic if \\navailable  \\n• Conduct EAC  \\n• Refer to VL algorithm  \\n \\n \\n5.5 Adherence Monitoring, Counselling and Support for Patients with \\nUnsuppressed Viral Load ≥ 200 copies/ml  \\nTreatment failure should be suspected whenever a patient has been on ART for at least 3 months \\nand has: a viral load ≥ 200 copies/ml; a decline in CD4 count or; a ny new or worsening clinical \\ncondition. Treatment failure is confirmed as per the viral load monitoring algorithm (Figure 6.6). \\nPoor adherence is often the most important factor in developing treatment failure, though there \\ncan be other causes. Adherence m ust be thoroughly assessed and all issues must be addressed', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 133}),\n",
       " Document(page_content='can be other causes. Adherence m ust be thoroughly assessed and all issues must be addressed \\nbefore switching patients to the next line of ART. Do not change regimens until the reason/s \\nfor treatment failure have been identified and addressed, and a repeat VL is ≥ 1,000 \\ncopies/ml after 3 months of excellent adherence . For patients with high -risk  persistent low -\\nlevel viremia (VL 200 - 999 copies/ml after additional assessment and intervention), consult the \\nRegional or National HIV Clinical TWG (Uliza Hotline 0726 460 000; \\nhttps://nh csc.nascop.org/clinicalform ).', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 133}),\n",
       " Document(page_content='Adherence Preparation, Monitoring and Support  \\n5 - 31 5.5.1 Enhanced Adherence Assessments  \\nAs soon as treatment failure is suspected the patient/caregiver should be discussed by the facility \\nmulti -disciplinary team to develop a plan for assessing barriers to adherence (includin g \\nscheduling a home visit), and assessing other potential causes of treatment failure (e.g., \\ninadequate dosing/dose adjustments, drug -drug interactions, drug -food interactions, impaired \\nabsorption e.g., chronic severe diarrhoea).  \\nAll patients with suspecte d or confirmed treatment failure should have a thorough assessment of \\npotential barriers to adherence (Table 5.15).  \\nIf the patient has a caregiver, treatment buddy, and/or spouse/partner who is enrolled in HIV', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 134}),\n",
       " Document(page_content='potential barriers to adherence (Table 5.15).  \\nIf the patient has a caregiver, treatment buddy, and/or spouse/partner who is enrolled in HIV \\ncare, that person’s file should also be review ed to confirm their most recent viral load results and \\nadherence.  \\n5.5.2 Enhanced Adherence Counselling  \\nAdherence assessment and enhanced adherence counselling should begin as soon as a detectable \\nviral load ( ≥ 200 copies/ml) is received, preferably within 2 weeks.  \\nThe goal of Enhanced Adherence Counselling is to assess possible barriers to adherence in a non -\\njudgmental way and to help the patient construct an adherence plan with concrete objectives. It \\nis important not to focus solely on k nowledge of HIV and ART but also to review psychological,', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 134}),\n",
       " Document(page_content='is important not to focus solely on k nowledge of HIV and ART but also to review psychological, \\nemotional, and socio -economic factors that may contribute to poor adherence. In addition, \\nexploring the patient’s motivation for taking medication often highlights reasons for poor \\nadherence.  \\nAt lea st three sessions of Enhanced Adherence Counselling, spaced 2 -4 weeks apart, are \\nrecommended as the minimum number of sessions, but additional sessions can be added as \\nneeded (Table 5.1 8). If the adherence is evaluated as adequate, a repeat viral load is d one after \\nthree months of excellent adherence, and another Enhanced Adherence Counselling session is \\nconducted to discuss the viral load results. A detailed content guide for Enhanced Adherence \\nCounselling is provided in Annex 9.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 134}),\n",
       " Document(page_content='conducted to discuss the viral load results. A detailed content guide for Enhanced Adherence \\nCounselling is provided in Annex 9.  \\nIt is preferable to have t he patient go through all adherence counselling sessions with the same \\ncounsellor in order to provide continuity, and that the session is documented to ensure follow -up \\nof all issues identified.  \\nIf adequate adherence cannot be achieved then consult with a senior clinician, discuss as an MDT, \\nor consult the Regional or National TWG.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 134}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 32 Table 5.1 8: Components of Enhanced Adherence Counselling Sessions (Annex 9A for detailed \\ncontent guide)  \\nEnhanced Adherence Counselling Sessions: Overview  \\n \\nSession 1  • Review understanding of viral load (VL) and discuss why the patient’s VL is \\nhigh  \\n• Review common cognitive, behavioral, emotional and socio -economic barriers \\nto adherence  \\no Stigma and non -disclosure  \\no Loss or grief  \\no Treatment literacy  \\no Medications: dosage, timing, storage  \\no Side effects  \\no Discuss risk reduction (e.g., for substance abuse)  \\no Motivation  \\no Mental health screening (screen for depression using PHQ -9, Table 4.14)  \\no Discuss patient’s support systems', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 135}),\n",
       " Document(page_content='o Motivation  \\no Mental health screening (screen for depression using PHQ -9, Table 4.14)  \\no Discuss patient’s support systems  \\n● Assist patient to develop adherence plan to address the ide ntified issues  \\n \\nSession 2  ● Review adherence plan from the first session and discuss any challenges  \\n● Identify other possible gaps and issues emerging  \\n● Assist patient to modify the adherence plan to address the identified issues  \\n \\n \\nSession 3  ● Review adherence plan from the first and second session and discuss any \\nchallenges  \\n● Identify other possible gaps and issues emerging  \\n● Assist patient to modify the adherence plan to address the identified issues  \\n● Decision on repeat VL based on current adherence', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 135}),\n",
       " Document(page_content='● Assist patient to modify the adherence plan to address the identified issues  \\n● Decision on repeat VL based on current adherence  \\no If the adherence is good: plan repeat VL testing after three months of good \\nadherence and explain possible ways forward, emphasizing role of the \\npatient and the health facility  \\no If adherence challenges persist: consult with a senior clinician, discuss as \\nan MD T, or consult the Regional or National TWG before repeating the VL  \\n \\nSession to \\nDiscuss \\nRepeat Viral \\nLoad Results  ● Discuss result of the second VL test  \\n● Plan the way forward:  \\no If VL now < 200 copies/ml: continue current regimen with ongoing \\nenhanced adherence; repeat VL after 6 months  \\no If VL ≥ 1,000: prepare patient for change of regimen (Figure 5.2)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 135}),\n",
       " Document(page_content='enhanced adherence; repeat VL after 6 months  \\no If VL ≥ 1,000: prepare patient for change of regimen (Figure 5.2)  \\no If VL is 200 -999 copies/ml: perform another assessment for causes for \\nviremia and address any issues identified; repeat viral load after an \\nadditional 3 months of excellent adherence', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 135}),\n",
       " Document(page_content='Adherence Preparation, Monitoring and Support  \\n5 - 33 Table 5.1 8 Cont.  \\nOther Enhanced Adherence Support Interventions (for patients failing or at high -risk of failing \\ntreatment)  \\nCase \\nmanagement  • Assign a case manager to all children and adolescents (those not achieving \\noptimum treatment outcomes); pregnant women, orphans, patients with alcohol \\nand substance abuse, patients with mental illness, patients with suspected or \\nconfirmed treatment failure, and any patients who the healthcare team feels has \\npoor adheren ce or is at high risk of defaulting from care  \\n• The case manager is the link between the patient and the MDT  \\n• Roles  of the case managers include:  \\no Coordinating multidisciplinary management for patients under case \\nmanagement', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 136}),\n",
       " Document(page_content='• Roles  of the case managers include:  \\no Coordinating multidisciplinary management for patients under case \\nmanagement  \\no Following up on appointment -keeping for their patients  \\no Organizing patient reminders (SMS, calling the day before) and other support \\nsystems  \\no Ensuring appropriate defaulter tracing  \\no Coordinating home visits to their patients  \\nDirectly \\nobserved \\ntherapy  • Patients with suspected treatment failure should have DOTs to ensure good \\nadherence before a viral load is repeated to confirm treatment failure  \\n• DOTs involve a healthcare provider, family member, treatment supporter or any \\ntrained peer observing the patient ingesting th eir prescribed ART on a daily basis  \\n• DOTs can be tapered off once the patient adopts consistent adherence -enhancing', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 136}),\n",
       " Document(page_content='• DOTs can be tapered off once the patient adopts consistent adherence -enhancing \\nbehaviours  and barriers to adherence are overcome  \\nHome visits  • Observe where and how a patient stores and takes their medications, and assess if \\nthey have extra medications because of missed doses  \\n• Home visits may also provide a better understanding of a patient’s living situation \\nand specific barriers to adherence  \\n• Unscheduled home visits may be more revealing, but should only be conducted if \\nthe patient consented to home visits previously (preferably at the time of enrolment  \\nor initiation)  \\nMonthly “high \\nviral load” \\nclinics  • Patients with suspected treatment failure should be booked for dedicated monthly \\nhigh viral load clinics', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 136}),\n",
       " Document(page_content='Monthly “high \\nviral load” \\nclinics  • Patients with suspected treatment failure should be booked for dedicated monthly \\nhigh viral load clinics  \\n• Children and adolescents in school who are unable to attend clinic monthly may \\nattend dedicated monthly clinics during mid -term and school holidays (at least \\nevery 6 weeks)  \\n• Comprehensive clinical and psychosocial evaluation should be conducted at e ach \\nvisit, appropriate investigations done and any opportunistic infections treated  \\n• Enhanced adherence counseling sessions should be conducted at each visit  \\n• Support groups for patients with viremia can be timed with “high viral load” clinic \\ndays  \\nSpecial \\nsupport \\ngroups  • For health facilities with several patients who are failing treatment or who are on', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 136}),\n",
       " Document(page_content='days  \\nSpecial \\nsupport \\ngroups  • For health facilities with several patients who are failing treatment or who are on \\n2nd line ART, special support groups can be established so these patients can work \\nthrough their adherence challenges together  \\n• Community support groups can also be engaged and linked to the facility for \\nsupporting patients with adherence challenges', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 136}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 34 Adherence support systems will need to be adapted to patients’ specific needs and the context \\n(Table 5.1 8). Special attention needs to be given to children, a dolescents, pregnant and \\nbreastfeeding women, patients with mental health disorders and substance users.  \\n5.6 Treatment Preparation for 2nd Line or 3rd Line ART  \\nAfter confirming treatment failure and making the decision to start 2nd line or 3rd line ART (ba sed \\non discussion as an MDT, and in consultation with the Regional or National HIV Clinical TWG), the \\npatient requires targeted counselling and education to prepare them for the new regimen and to \\nsupport ongoing adherence (Figure 5.2).  \\nReview patient file\\nAssess patient  s \\nknowledge and \\nunderstanding', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 137}),\n",
       " Document(page_content='support ongoing adherence (Figure 5.2).  \\nReview patient file\\nAssess patient  s \\nknowledge and \\nunderstanding\\nProvide patient education\\nConstruct adherence plan\\nEnsure monthly \\ncounselling follow -up \\nsessionsEnsure a monthly follow -up counselling session during \\nclinic visits for the first 6months after initiating the new \\nregimen\\n• Follow up on problems identified during the previous \\nsessions\\n• Assess patient  s adherence and explore any reasons for \\npoor adherence. Identify strategies to overcome these \\nbarriers\\nRepeat VL after 3 months on new regimen\\n• If VL undetectable: adherence counselling every \\n3months\\n• If VL is detectable: discuss as MDT and consult Clinical \\nTWG• Confirm patient  s willingness to start new regimen\\n• Ensure that the patient understands the treatment plan', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 137}),\n",
       " Document(page_content='TWG• Confirm patient  s willingness to start new regimen\\n• Ensure that the patient understands the treatment plan \\n(drug regimen, dosing schedule, dietary restrictions, \\npotential side effects, what to do when missing doses or \\nexperiencing side effects)\\n• Prepare for situations that could impair good \\nadherence, and encourage disclosure of poor adherence\\n• Plan sessions with the pharmacist on medication \\nadherence, and nutritionist on nutritional aspects• Strengthen key messages on HIV and viral load\\n• Provide information on 2nd/3rd line ART: more complex \\nto take (more pills, twice -a-day dosing), very limited \\noptions if this fails\\n• Provide simple take -home IEC materials on 2nd  or 3rd  \\nline ART management• HIV, viral load and ART\\n• The importance of good adherence and potential', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 137}),\n",
       " Document(page_content='line ART management• HIV, viral load and ART\\n• The importance of good adherence and potential \\nproblems of non -adherence\\n• Reasons for switching to 2nd or 3rd line ART: treatment \\nfailure with repeated high viral load• Review the patient file and all problems identified \\nduring Enhanced Adherence Counselling sessions\\n• Confirm all the barriers to adherence have been \\naddressed during Enhanced Adherence Counselling, if \\nnot – address remaining barriers before considering \\nchanging regimens\\n \\n \\nFigure 5.2: Adherence Counselling and Education for Patients Preparing to Initiate 2nd Line or \\n3rd Line ART', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 137}),\n",
       " Document(page_content='Adherence Preparation, Monitoring and Support  \\n5 - 35 5.7 Identifying, Tracing, and Supporting Patients who Default from Care  \\nEvery service delivery point that is providing ARVs for patients (whether ART, PEP, or PrEP) must \\nhave a functional system for identifying patients who miss appointments and for taking action \\nwithin 24 hours of a missed appointment (Figure 5.3).  \\nEnter date of next appointment/TCA for each patient into the \\nappointment diary\\n• As patients arrive at the service delivery point their name should be \\nchecked off in the appointment diary for that day\\n• All patients who had appointments booked for the day but did not \\nattend clinic should be recorded in the patient follow -up register\\n• Patient/caregiver should be called within 24 hours of missed \\nappointment', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 138}),\n",
       " Document(page_content='attend clinic should be recorded in the patient follow -up register\\n• Patient/caregiver should be called within 24 hours of missed \\nappointment\\n• If no response, treatment buddy should be called\\n• Several attempts at phone tracing should be made if no response \\ninitially\\n• Update the patient follow -up register with phone call findings\\nPatient does not return \\nwithin time agreed upon \\nduring phone call, but still \\nable to reach by phonePatient returns to clinic \\nwithin 7 days, or returns \\non date agreed during \\nphone callUnable to reach by phone, \\nand does not return to \\nclinic within 7 daysPatient dead, transferred \\nout, or declines further \\ncontact: update patient \\nrecords/ registers with \\noutcome\\nReturns to clinic\\n• Assess for and address potential barriers to adherence \\n(Table 5.14)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 138}),\n",
       " Document(page_content='contact: update patient \\nrecords/ registers with \\noutcome\\nReturns to clinic\\n• Assess for and address potential barriers to adherence \\n(Table 5.14) \\n• Review patient/caregiver HIV knowledge (Table 5.1, \\nAnnex 6) and address any gaps\\n• Elicit any concerns the patient/caregiver has about ART, \\nother medications, visit schedule, or health. Address any \\nconcerns or engage another care team member who can \\naddress them\\n• Explore any major recent or expected changes in the \\npatient s/caregiver  s life or daily routine that could disrupt \\nadherence\\n• Review effectiveness of facility and community support \\nsystems the patient already has in place\\n• Encourage introduction of additional standard  and \\nenhanced support systems (Table 5.2), including', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 138}),\n",
       " Document(page_content='systems the patient already has in place\\n• Encourage introduction of additional standard  and \\nenhanced support systems (Table 5.2), including \\nsupporting disclosure as needed, assigning a case manager \\nand considering DOTs\\n• Review ART Readiness Assessment Form for re -initiation \\nof ART• Prioritized home visit, based on\\no Patient type (pregnant and \\nbreastfeeding women, child, co -\\nmorbidity)\\no Proximity to clinic\\n• Complete the home visit form\\n• Update the patient follow -up register with \\nhome visit findings\\n• Update appointment diary if agrees to \\nreturn to clinic\\nUnable to trace or does not return to clinic on \\nscheduled appointment date\\n• Discuss as MDT and develop follow -up/ \\nmanagement plan\\n• Update patient records/registers with \\noutcome', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 138}),\n",
       " Document(page_content='scheduled appointment date\\n• Discuss as MDT and develop follow -up/ \\nmanagement plan\\n• Update patient records/registers with \\noutcome\\n \\nFigure 5.3: Ident ifying, Tracing and Supporting Patients who Default from Care', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 138}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 36', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 139}),\n",
       " Document(page_content='Antiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 1  \\n6. Antiretroviral Therapy in Infants, Children, \\nAdolescents, and Adults  \\nART, while very effective in managing HIV disease, does not cure HIV infection. The goal of ART is \\nto suppress viral replication with the aim of reducing the  patient’s VL to undetectable levels. \\nUninterrupted ART with ongoing strict adherence will help maintain undetectable VL levels \\nthereby preventing damage to the body’s immune system, reducing AIDS -related morbidity and \\nmortality and the risk of sexual and vertical transmission of HIV.  \\n6.1 Eligibility for ART  \\nAll individuals with confirmed HIV infection are eligible for ART irrespective of CD4', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 140}),\n",
       " Document(page_content='6.1 Eligibility for ART  \\nAll individuals with confirmed HIV infection are eligible for ART irrespective of CD4 \\ncount, WHO clinical stage, age, pregnancy or breastfeeding status, co -infection status, \\nrisk group, or any other cri teria.  \\n6.2 Timing of ART Initiation  \\nART should be started in all patients as soon as possible, preferably within 2 weeks of \\nconfirmation of HIV status, and even on the same day as testing positive for HIV if they are ready.  \\nART Readiness Criteria (Table 5.4) can be used to help determine any issues that need to be \\naddressed around the time of ART initiation. Same -day ART initiation (on the same day as testing \\nHIV-positive) has additional benefits for HIV prevention (e.g., for pregnant and breastfee ding', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 140}),\n",
       " Document(page_content='HIV-positive) has additional benefits for HIV prevention (e.g., for pregnant and breastfee ding \\nwomen, and the HIV positive partner in a discordant relationship), and is associated with \\nimproved retention, viral suppression, and survival. Special considerations for timing of ART \\ninitiation are listed in Table 6.1.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 140}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 2 Table 6.1: Special Considerat ions for Timing of ART Initiation  \\nPopulation  Timing of ART Initiation  Additional Notes  \\nPregnant and \\nbreastfeeding \\nwomen  Support ART initiation on the \\nsame day as testing positive for \\nHIV Intensive adherence counselling, \\nsupport and close follow -up \\nrequired because of limited time for \\npatient preparation  \\nInfants (< 12 months \\nold)  Support ART initiation on the \\nsame day as testing positive for \\nHIV. Treatment should \\ncommence following a first \\npositive PCR test. ALWAYS take a \\nsample for a confirmatory PCR \\ntest as soon as the first positive \\nPCR result is received, but do not \\ndelay ART initiation for the \\nsecond PCR result  Intensive adherence counselling,', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 141}),\n",
       " Document(page_content='PCR result is received, but do not \\ndelay ART initiation for the \\nsecond PCR result  Intensive adherence counselling, \\nsupport and close follow -up \\nrequired because of limited time for \\ncaregiver preparation  \\nPatients with strong \\nmotivation to start \\nART immediately  Support ART initiation as soon as \\nthe patient feels ready, preferably \\non the same day as testing \\npositive for HIV  Intensive adherence counselling, \\nsupport and close follow -up \\nrequired because of limited time for \\npatient preparation  \\nPatients with newly \\ndiagnosed TB  Start anti -TB treatment \\nimmediately and initiate ART as \\nsoon as anti -TB medications are \\ntolerated, preferably within 2 \\nweeks. For TB meningitis delay \\nART for 4 to 8 weeks  Monitor closely for IRIS (Annex 16)  \\nPatients with \\ncryptococcal', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 141}),\n",
       " Document(page_content='weeks. For TB meningitis delay \\nART for 4 to 8 weeks  Monitor closely for IRIS (Annex 16)  \\nPatients with \\ncryptococcal \\nmeningitis  Defer ART until after completing \\n5 weeks of CM treatment  Monitor closely for IRIS (Annex 16)  \\n \\nPatients for whom \\nadherence will be \\nparticularly \\nchallenging  Start ART as soon as possible \\nwhile implementing additional \\nsupport systems (e.g., optional \\nenrolment of a PWID into a MAT \\nprogram; psychiatric treatment \\nfor a patient with mental illness; \\nenrolment into an OVC program \\nfor orphans etc.)  A case manager should be assigned \\nto all patients with complex \\nadherence challenges  \\nAll other patients  Start ART as soon as possible, \\npreferably within 2 weeks, \\nand even on the same day as \\ntesting positive for HIV if they', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 141}),\n",
       " Document(page_content='All other patients  Start ART as soon as possible, \\npreferably within 2 weeks, \\nand even on the same day as \\ntesting positive for HIV if they \\nare ready  Continued adherence monitoring \\nand support is recommended after \\nART initiation for all patients', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 141}),\n",
       " Document(page_content='Antiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 3 6.3 First -Line ART for Infants, Children, Adolescents and Adults (including \\nPregnant and Breastfeeding Women)  \\nThe recommendations below apply to patients who are starting ART for the first time. Preferred \\nand alternative first line regimens are shown in Tables  6.2 and 6.3. ARVs for infant prophylaxis \\nare presented in the PMTCT chapter in Tables 7.3 to 7.6.  \\nAll patients must have their weight documented at every visit. Children and adolescents \\nless than 15 years must have correct weight -based dosing of ARVs conf irmed at every visit.  \\nInfants and children depend on their caregivers for adherence to medication. Caregivers should', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 142}),\n",
       " Document(page_content='Infants and children depend on their caregivers for adherence to medication. Caregivers should \\nbe adequately prepared for their role of administering ARVs to infants and children, including \\naddressing anticipated challenges such as dr ug palatability. It can be helpful for more than one \\ncaregiver to be informed about a child’s HIV status and receive instruction on administration of \\nART.  \\nCaregivers should always be shown and then asked to demonstrate how to measure and \\nadminister ARVs.  This should be done both at the time of prescribing the ART (by the clinician) \\nand at the time of dispensing the ART. Clinicians should ensure that the caregiver accompanying \\na child for clinical review is the same caregiver responsible for day -to-day ART a dministration.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 142}),\n",
       " Document(page_content='a child for clinical review is the same caregiver responsible for day -to-day ART a dministration.  \\nTable 6.2: Preferred First -line ART Regimens and Dosing for Children, Adolescents and \\nAdults 1 \\nAge  Weight  Preferred \\nRegimen  Dosing2 (correct weight -based dosing must \\nbe confirmed at every visit)  \\nBirth to 4 \\nweeks  Any  AZT + 3TC + NVP3 Refer to Annex 10 for weight -based dosing  \\n> 4 weeks to \\n< 15 years  < 30 kg  ABC + 3TC + DTG4 Refer to Annex 10 for weight -based dosing  \\n≥ 30 kg  TDF + 3TC + \\nDTG5,6 TDF/3TC/DTG (300/300/50mg): 1 tab once \\ndaily  \\n≥ 15 years  Any  TDF + 3TC + \\nDTG5,6 TDF/3TC/DTG (300/300/50mg): 1 tab once \\ndaily  \\n1 Patients currently on first -line regimens that are not included in the indicated preferred (Table 6.2)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 142}),\n",
       " Document(page_content='daily  \\n1 Patients currently on first -line regimens that are not included in the indicated preferred (Table 6.2) \\nor alternative (Table 6.3) regimens should be considered for regimen optimization as per Section \\n6.5.1  \\n2 See Annex 10 for weight -based dosing of all single -drug and fixed -dose combination formulations  \\n3 Infants who initiate ART at less than 4 weeks of age should initiate on AZT+3TC+NVP irrespective of \\nprevious ART exposure; metabolism of other ARVs is not well known for this age group. As soon as \\nthese infants become 4 weeks old, they should switch to ABC/3TC+DTG (dosing included in Annex \\n10). Consult the Regional or National HIV Clinical TWG (Uliza Hotline 0726 460 000, \\nulizanascop@gmail.com) in case of pre -term infants', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 142}),\n",
       " Document(page_content='10). Consult the Regional or National HIV Clinical TWG (Uliza Hotline 0726 460 000, \\nulizanascop@gmail.com) in case of pre -term infants  \\n4 Once adolescents reach 30 kg, if virally suppressed they should be considered for transition as per \\nFigure 6.2  \\n5 TAF may become the preferred NRTI once fixed -dose combinations are available  \\n6 DTG/3TC dual therapy may be considered for HBV -negative pa tients once fixed -dose combinations \\nare available', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 142}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 4 Table 6.3: Use of Alternative ARVs in First -Line Regimens 1 \\nAge  Weight  Scenario and ARV \\nAffected  Alternative ARV to Use  \\nBirth to 4 \\nweeks   \\nAny  NVP: Develops \\nhypersensitivity reaction  Use RAL granules or LPV/r granules \\n(over 2 weeks of age) or defer ART until \\n4 weeks of age, then start ABC+3TC+DTG  \\nAZT: Infant Hb < 9.5 g/dL  Defer ART until 4 weeks of age, then \\nstart ABC+3TC+DTG  \\n> 4 weeks \\nto < 15 \\nyears   \\n \\n< 30 kg  ABC: Develops ABC \\nhypersensitivity reaction2 Use AZT (if Hb ≥ 9.5 g/dL); if Hb < 9.5 \\ng/dL consults Regional or National HIV \\nClinical TWG (call Uliza Hotline 0726 \\n460 000; ulizanascop@gmail.com)  \\nDTG: Unable to tolerate  Use LPV/r at standard weight -based BD', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 143}),\n",
       " Document(page_content='Clinical TWG (call Uliza Hotline 0726 \\n460 000; ulizanascop@gmail.com)  \\nDTG: Unable to tolerate  Use LPV/r at standard weight -based BD \\ndosing, if 4-in-1 available this is \\npreferred  \\nDTG: Currently on \\nrifampicin -containing \\nanti -TB \\nmedications  Increase DTG dosing frequency to twice \\ndaily for duration of rifampicin -\\ncontaining TB treatment and for an \\nadditional 2 weeks after TB treatment is \\ncompleted, then revert to once daily \\ndosing3 \\n \\n \\n \\n≥ 30 kg  \\n \\n TDF: Impaired renal \\nfunction (CrCl ≤ 50 \\nml/min)  Use ABC4,5 or TAF (once available)  \\nDTG: Unable to tolerate  Use EFV (for PWID use ATV/r)  \\nDTG: Currently on \\nrifampicin -containing \\nanti -TB \\nmedications  Give TDF/3TC/DTG FDC morning + DTG \\n50mg evening for duration of rifampicin -\\ncontaining TB treatment and for an', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 143}),\n",
       " Document(page_content='anti -TB \\nmedications  Give TDF/3TC/DTG FDC morning + DTG \\n50mg evening for duration of rifampicin -\\ncontaining TB treatment and for an \\nadditional 2 weeks after TB treatment is \\ncompleted, then revert to TDF/3TC/DTG \\nFDC OD 3 \\n≥ 15 years  Any  TDF: Impaired renal \\nfunction (CrCl ≤ 50 \\nml/min)  Use ABC4,5 or TAF (once available)  \\nDTG: Unable to tolerate  Use EFV (for PWID use ATV/r)  \\nDTG: Currently on \\nrifampicin -containing \\nanti -TB \\nmedications  Give TDF/3TC/DTG FDC morning + DTG \\n50mg evening for duration of rifampicin -\\ncontaining TB treatment and for an \\nadditional 2 weeks after TB treatment is \\ncompleted, then revert to TDF/3TC/DTG \\nFDC OD 3', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 143}),\n",
       " Document(page_content='Antiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 5 Table 6.3 Cont.  \\n1 For other scenarios that are not covered in this table, discuss as an MDT and consult the Regional or \\nNational HIV Clinical TWG (Uliza Hotline 0726 460 000; https://nhcsc.nascop.org/clinicalform ) \\n2 ABC hypersensitivity reaction (AHR) is rare in the Kenyan population. Table 6.9 provides the \\ndefinition and management of AHR  \\n3 The additional 2 weeks of higher -dose DTG is to counter the ongoing liver enzyme induction effect \\nof rifampicin, which continues for a short period after TB treatment is completed  \\n4 TAF may become the preferred NRTI once fixed -dose combinations are available  \\n5 DTG/3TC dual therapy may be considered for HBV -negative patients once fixed -dose combinations', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 144}),\n",
       " Document(page_content='5 DTG/3TC dual therapy may be considered for HBV -negative patients once fixed -dose combinations \\nare available  \\n6.4 Dosing and Administration of Dolutegravir (DTG)  \\nDTG is preferred in first line ART (in combination with other ARVs) for children, adolescents and \\nadults. DTG is well tolerated, highly efficacious, has a high genetic barrier to resistance and fewer \\ndrug -drug interactions.  \\nTable 6.4: Dosing and Administration of  Dolutegravir  \\nRecommended Dosing of DTG  \\n● < 20 kg body weight: Use weight -based dosing with dispersible 10mg DTG tablets as per Annex 10  \\n● ≥ 20 kg body weight: DTG 50 mg film -coated tablet once daily, preferably as a morning dose. It is also \\navailable as part of FDC. Those unable to swallow the film coated tablets whole refer to Annex 10', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 144}),\n",
       " Document(page_content='available as part of FDC. Those unable to swallow the film coated tablets whole refer to Annex 10  \\n● For patients taking rifampicin: Increase DTG dosing frequency to twice daily for duration of \\nrifampicin -containing TB treatment and for an additional 2 weeks after TB treatment is completed, \\nthen revert to once daily. (The additional 2 weeks of higher -dose DTG is to counter the ongoing liver \\nenzyme induction effect of rifampicin, which continues for a short period after TB treatment is \\ncompleted)  \\n● For patients w ith suspected or confirmed INSTI resistance (e.g., patients with prior history of failing a \\nRAL -based regimen): use DTG twice daily  \\n● DTG can be taken with or without food  \\nCommon Side Effects of DTG', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 144}),\n",
       " Document(page_content='RAL -based regimen): use DTG twice daily  \\n● DTG can be taken with or without food  \\nCommon Side Effects of DTG  \\n● The most common side effects of DTG are headache, nausea and diarrhea. These side effects usually \\nresolve after continued use for 1 -2 weeks. It is critical to inform patients / caregivers about these \\npotential side effects and their temporary nature, and encourage them to continue their ART and \\nconsult a HCW if concerned.  \\n● Some patients on DTG are more likely to develop insomnia. This may be reduced by taking DTG as a \\nmorning dose, or by taking DTG with a low -fat meal or on an empty stomach.  \\n● DTG may cause a small rise in serum creatinine levels bu t this does NOT represent a true decline in \\nrenal function.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 144}),\n",
       " Document(page_content='● DTG may cause a small rise in serum creatinine levels bu t this does NOT represent a true decline in \\nrenal function.  \\n● Integrase inhibitors, including DTG, are associated with increased weight gain. Counsel patients about \\nhealthy eating and physical activity and the benefits of maintaining a healthy weight.  \\n● All ad verse events should be reported through the national pharmacovigilance mechanism. \\n(http://www.pv.pharmacyboardkenya.org/ )', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 144}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 6 Table 6.4 Cont.  \\nPregnancy Safety of DTG  \\n● DTG is safe during pregnancy and breastfeeding. Pregnancy intention should be discussed with all \\nwomen initiating ART regardless of regimen. Women who do not wish to become pregnant should be \\noffered appropriate family planning counseling and methods.  \\nImportant Drug Interactions with DTG  \\n● Rifampicin  \\no Rifampicin lowers DTG levels: increase DTG to 50 mg twice daily for patients on rifampicin who \\nare > 20 kg in body weight. Children <20 kg taking DTG who require rifampicin should increase \\ntheir weight -appropriate DTG dose to twice daily.  \\no There are no significant drug interactions between DTG and other currently used anti -TB \\nmedications (including for MDR -TB)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 145}),\n",
       " Document(page_content='o There are no significant drug interactions between DTG and other currently used anti -TB \\nmedications (including for MDR -TB) \\n● Mineral supplements, including: antacids containing calcium, zinc, magnesium or aluminum; iron \\nsupplements; prenatal vitamins (which contain iron and calcium)  \\no These supplements decrease the absorption of DTG: administer DTG at least 2 hours before or 6 \\nhours after taking any of these supplements  \\no Dose separation is not required for calcium and iron supplements (including prenatal vitamins) if \\nDTG is taken with a meal  \\no It is critical to educate patients about this important drug interact ion because many patients get \\nthese supplements and antacids over -the-counter without informing their healthcare provider', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 145}),\n",
       " Document(page_content='these supplements and antacids over -the-counter without informing their healthcare provider  \\n● Carbamazepine, phenobarbital, phenytoin  \\no These anticonvulsants decrease DTG levels: use a different anticonvulsant if available  \\no If DTG must be co -administered with these drugs then increase to DTG to twice daily, although \\nthere is little data to guide this  \\no If valproic acid is available this can be used with DTG without dose adjustment  \\n● Metformin  \\no DTG increases levels of metformin; the levels of DTG are not affected: use a lower dose of \\nmetformin (often 50% of usual dose) and monitor glycemic control. Use a maximum daily dose of \\nmetformin 1 g  \\n● Other drug -drug interactions with DTG  \\no See Annex 13C', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 145}),\n",
       " Document(page_content='Antiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 7 6.5 Monitoring and Changing ART  \\nThe objectives of clinical and laboratory monitoring during ART are to identify and treat inter -\\ncurrent illnesses, assess for and manage adverse drug reactions, and evaluate response to \\ntreatment. Routine laboratory monitoring recommendations are described in Table 3.5; however, \\nadditional investigations should be ordered whenever there is clinical suspicion for which a \\nlaboratory test result may alter patient management.  \\nIndications for changing ART include optimizing therapy for patients who have undetectable viral \\nload, managing adverse drug reactions or toxicity, drug -drug interactions, co -morbidities and \\ntreatment failure.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 146}),\n",
       " Document(page_content='load, managing adverse drug reactions or toxicity, drug -drug interactions, co -morbidities and \\ntreatment failure.  \\n6.5.1 Optimizing Therapy for Patients who have suppressed viral load on First Line \\nART  \\nPatients who are virally suppressed o n first line ART may benefit from regimen optimization even \\nif they are currently tolerating their regimen well and have no drug -drug interactions requiring a \\nchange. Regimen modifications may be done for age/weight transitions among children and \\nadolescen ts <15 years and to simplify a regimen, prevent long -term toxicity and improve cost -\\neffectiveness. Dolutegravir has been shown to have superior tolerability and efficacy compared to \\nefavirenz and lopinavir and is now preferred as part of first line ART for  children, adolescents and', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 146}),\n",
       " Document(page_content='efavirenz and lopinavir and is now preferred as part of first line ART for  children, adolescents and \\nadults. While most adults in Kenya have switched over to a DTG -containing regimen, proactive \\nswitching of children is now also recommended with the availability of a pediatric dispersible \\ndolutegravir tablet.  \\nChildren and adolesc ents with suppressed viral load on first line ART and not on the \\nrecommended first line regimen as per Table 6.2 should be considered for optimization as \\nper Figures 6.1 and 6.2, such as when children grow and enter a new weight band.  This also \\nincludes PL HIV who recently initiated non -standard therapy (less than 3 months ago, before the \\nfirst VL is due). Decisions on regimen modification should be made following discussion with the', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 146}),\n",
       " Document(page_content='first VL is due). Decisions on regimen modification should be made following discussion with the \\npatient/caregiver.  \\nAlways discuss the possibility of new side effects when changing to a new ARV,  particularly \\nside effects common to all ARVs (headache, nausea, diarrhea) and any side effects specific to the \\nnew ARV. Reassure patients that most side effects resolve with continued use after 1 -2 weeks.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 146}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 8 \\nChildren weighing < 30  kg on a first line ART regimen OTHER than ABC/3TC + DTG\\nVL within last 6 months < \\n200 copies/ml (LDL)\\nNo VL result within last 6 \\nmonths\\nVL within last 6 months   \\n200 copies/ml\\nCollect sample for VL\\nVL   200 copies/ml\\n• Switch to ABC/3TC + DTG using the \\nweight -based dosing from Annex 10A -B\\n• Schedule clinical appointment at 2 weeks \\nafter regimen change to review \\nadherence, side effects and any other \\nconcerns\\n• Repeat VL 3 months after regimen \\nmodification followed by routine viral \\nload monitoring\\n• Switch regimen while assessing for reasons for viremia and \\nproviding enhanced adherence counselling\\n• If current regimen contains ABC: Switch to \\nAZT/3TC + DTG', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 147}),\n",
       " Document(page_content='providing enhanced adherence counselling\\n• If current regimen contains ABC: Switch to \\nAZT/3TC + DTG\\n• If current regimen contains AZT: Switch to \\nABC/3TC + DTG\\n• Use the weight -based dosing from Annex 10A -B\\n• For all patients on PI/r or DTG containing regimens: \\nsummarize case for TWG and take sample for DRT  – do not \\nwait for DRT results for making the regimen modification\\n• Schedule clinical appointment at 2 weeks after regimen \\nchange to review adherence, side effects and any other \\nconcerns\\n• Repeat VL 3 months after regimen modification\\n• If VL still   200  copies/ml then consult the \\nregional or national TWG\\n• If VL now < 200  copies/ml then continue routine \\nviral load monitoring\\nOn ART for < 3 months\\n On ART for     months\\nVL < 200 copies/ml  (LDL)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 147}),\n",
       " Document(page_content='• If VL now < 200  copies/ml then continue routine \\nviral load monitoring\\nOn ART for < 3 months\\n On ART for     months\\nVL < 200 copies/ml  (LDL) \\nFigure 6.1: Optimizing ART Regimens for Children and adolescents <15 years Weighing < 30 kg \\non First Line ART', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 147}),\n",
       " Document(page_content='Antiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 9 \\nChildren and adolescents weighing      kg or       years old on a first line ART regimen OTHER \\nthan TDF/3TC/DTG\\nVL within last 6 months \\n< 200 copies/ml (LDL)\\nNo VL result within last 6 \\nmonths\\nVL within last 6 months   \\n200  copies/ml\\nCollect sample for VL\\nVL       copies/ml\\n• Switch to TDF/3TC/DTG (300/300/\\n50mg) 1 tab once daily\\n• Schedule clinical appointment at 2 weeks \\nafter regimen change to review \\nadherence, side effects and any other \\nconcerns\\n• Repeat VL 3 months after regimen \\nmodification followed by routine viral \\nload monitoring\\n• Switch regimen while assessing for reasons for viremia \\nand providing enhanced adherence counselling\\n• Switch to TDF/3TC/DTG (300/300/50mg) 1 tab once \\ndaily', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 148}),\n",
       " Document(page_content='and providing enhanced adherence counselling\\n• Switch to TDF/3TC/DTG (300/300/50mg) 1 tab once \\ndaily\\n• For all patients on PI/r or DTG containing regimens: \\nsummarize case for TWG and take sample for DRT  – do \\nnot wait for DRT results for making the regimen \\nmodification\\n• Schedule clinical appointment at 2 weeks after regimen \\nchange to review adherence, side effects and any other \\nconcerns\\n• Repeat VL 3 months after regimen modification\\n• If VL still       copies/ml then consult the \\nregional or national TWG\\n• If VL now < 200 copies/ml then continue routine \\nviral load monitoring\\nOn ART for < 3 months\\n On ART for     months\\nVL < 200 copies/ml (LDL) \\nFigure 6.2: Optimizing ART Regimens for Children and Adolescents Weighing ≥ 30 kg or ≥ 15 years \\nold on First Line ART', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 148}),\n",
       " Document(page_content='VL < 200 copies/ml (LDL) \\nFigure 6.2: Optimizing ART Regimens for Children and Adolescents Weighing ≥ 30 kg or ≥ 15 years \\nold on First Line ART  \\n6.5.2 Changing ARVs Due to Adverse Drug Reactions  \\nPatients starting ART should be educated on the potential side effects of ART and all ot her \\nprescribed medication.  ADRs can have a significant impact on patient adherence and must be \\nidentified early and managed aggressively. All ADRs should be reported to the Pharmacy and \\nPoisons Board using existing pharmacovigilance tools \\n(http://www.pv.pharmacyboardkenya.org/ ). Pharmacovigilance is particularly important for \\nmonitoring ADRs associated with any new ARVs that enter the national supply chain, as rare', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 148}),\n",
       " Document(page_content='monitoring ADRs associated with any new ARVs that enter the national supply chain, as rare \\nADRs may appear in routine care, whi ch were not observed in the highly selected patients \\nparticipating in clinical trials.  \\nThe most common significant ADRs associated with ARVs that may require a drug substitution \\nare summarized in Table 6.5. General principles for managing ADRs are outlined  in Figure 6.3. \\nManaging specific ADRs is described in Tables 6.6 to 6.9.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 148}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 10  Table 6.5: Common Significant Adverse Drug Reactions  \\nARV \\nAgent   Adverse Drug Reaction   High Risk Situations/Comments  \\n NRTIs  \\n  ABC  ABC hypersensitivity \\nreaction (see Table 6.9)  Do not re -challenge  \\n \\n \\n \\nAZT  Anaemia, neutropenia  \\n(See Table 6.7)  Risk factors: CD4 count < 200 cells/mm3; BMI < 18.5 (or \\nbody weight < 50 kg); anaemia at baseline; concurrent use \\nof other drugs with similar ADR (cotrimoxazole, \\ngancyclovir, ribavirin)  \\nLactic acidosis  Risk factors: Pregnancy; obesity  \\nLipoatrophy  Risk factors: Low CD4 count  \\nTDF  Renal dysfunction  \\n(See Figure 6.5)  Risk factors: Underlying renal disease; age > 60 years; BMI \\n< 18.5 (or body weight < 50 kg); diabetes; hypertension;', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 149}),\n",
       " Document(page_content='(See Figure 6.5)  Risk factors: Underlying renal disease; age > 60 years; BMI \\n< 18.5 (or body weight < 50 kg); diabetes; hypertension; \\nconcomitant PI use or nephrotoxic drug  \\nAvoid in patients with CrCl< 50ml/minute unless no \\nsuitable alternative such as required to treat HIV/HBV co -\\ninfection if TAF is not available  \\nTAF  Weight gain  Risk factors: women; concomitant use of INSTIs  \\nProvide advice on healthy eating and physical activity to \\nmaintain a healthy weight (Table 4.9)  \\nNNRTIs  \\nAll \\nNNRTIs  Rash  \\n(NVP>>EFV>ETR)  Manage rash as per Table 4.4 \\n \\nEFV  CNS side -effects  Risk factors: Pre -existing psychiatric disorder  \\nGynaecomastia  Switch from EFV to an alternative, and consult if \\ngynecomastia does not improve  \\nNVP  Hepatotoxicity  \\n(See Table 6.8)  N/A.  \\nPIs', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 149}),\n",
       " Document(page_content='Gynaecomastia  Switch from EFV to an alternative, and consult if \\ngynecomastia does not improve  \\nNVP  Hepatotoxicity  \\n(See Table 6.8)  N/A.  \\nPIs \\nAll PIs \\nboosted \\nwith  \\nRTV  GI intolerance \\n(LPV/r>DRV/r>ATV/r)  Consult for recommendation on alternative regimen (R -\\nTWG or Uliza Hotline 0726 460 000, \\nhttps://nhcsc.nascop.org/clinicalform ) \\nDyslipidaemia \\n(LPV/r>DRV/r>ATV/r)  Risk factors: Obesity; sedentary lifestyle; diet high in \\nsaturated fats and cholesterol  \\nATV/r  Hyperbilirubinemia  This only requires drug substitution if cosmetic effect of \\njaundice is likely to interfere with patient adherence  \\nDRV/r  Rash/hypersensitivity  Risk factors: sulfa allergy  \\nINSTIs  \\nAll \\nINSTIs  Weight gain  Risk factors: women; concomitant use of TAF', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 149}),\n",
       " Document(page_content='DRV/r  Rash/hypersensitivity  Risk factors: sulfa allergy  \\nINSTIs  \\nAll \\nINSTIs  Weight gain  Risk factors: women; concomitant use of TAF  \\nProvide advice on healthy eating and physical activity to \\nmaintain a healthy weight  \\nRash/hypersensitivity  Consult (Uliza Hotline 0726 460 000, \\nhttps://nhcsc.nascop.org/clinicalform ) \\n DTG   Insomnia   Give in the morning; if no improvement then try giving \\nwith low fat meal or on empty stomach', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 149}),\n",
       " Document(page_content='Antiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 11  \\nAlternative explanations for toxicity must be excluded before concluding a reaction is secondary to an ARV.\\nConsider other medications and herbal remedies and diseases including opportunistic infections, immune \\nreconstitution inflammatory syndrome (IRIS), or other illnesses\\n2. Evaluate concurrent medications & any concurrent new \\nor pre -existing condition Establish whether adverse \\nevent is due to:  \\n• other drugs or drug -drug interaction\\n• other medical condition\\n• Inter -current illness or IRIS\\nAdverse Drug Reaction \\nidentifiedPresentation due to other \\nmedical condition\\n3.  Determine seriousness of adverse event Manage condition, continue ART\\nLife-threatening  \\n(Grade 4) Severe\\n(Grade 3) Moderate', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 150}),\n",
       " Document(page_content='medical condition\\n3.  Determine seriousness of adverse event Manage condition, continue ART\\nLife-threatening  \\n(Grade 4) Severe\\n(Grade 3) Moderate \\n(Grade 2)Mild \\n(Grade 1)\\nImmediately discontinue\\nALL drugs, including ARVs  \\nand manage the medical \\nevent. The patient often \\nrequires hospitalization \\nWhen the patient is stabilised, \\nreintroduce ARVs using a \\nmodified regimen (substitute \\nthe offending drug) *Substitute the offending \\ndrug without \\ndiscontinuing ART *. \\nMonitor the patient \\ncloselyContinue ARVs as long as \\nfeasible,  offer \\nsymptomatic relief if \\nappropriate. If no \\nimprovement consider \\nsingle drug substitution*Continue ARVs, offer \\nsymptomatic relief (if \\nappropriate)\\nPatients identified with ADR, review the patient progress at every clinic visit and', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 150}),\n",
       " Document(page_content='symptomatic relief (if \\nappropriate)\\nPatients identified with ADR, review the patient progress at every clinic visit and \\ndocument their outcomes \\nReport suspected/confirmed adverse drug events by filling the Pharmacovigilance\\nform or online at www.pv.pharmacykenya.org1. Patient/caregiver \\nreports  possible \\nadverse eventHistory or clinical \\nassessment suggest \\nadverse eventLab tests indicate \\npossible problem \\nrelated to ART\\n1. At every clinic  visit the patient on ART should be monitored clinically for toxicities using history \\n(history of symptoms that suggest toxicity) and physical examination (relevant signs). Patients should be asked \\nspecifically about ADR known to be associated with their current ART. laboratory assessment may be \\nused to confirm specific', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 150}),\n",
       " Document(page_content='specifically about ADR known to be associated with their current ART. laboratory assessment may be \\nused to confirm specific  \\n2.  Evaluate concurrent medications and establish whether the toxicity is attributable to an ARV, or to a non-ARV \\nmedication taken at the same time. Consider  other disease processes concurrent infectious processes or \\n3.  All toxicities should be graded. Manage the adverse event according to \\n* Follow single-drug substitution algorithm (Figu re \\n \\nFigure 6.3: General Principles for Managing Adverse Drug Reactions', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 150}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 12  \\nPatients with specific reason for stopping an ARV  1\\nVL within last 6 months < \\n200 copies/ml\\nNo VL result within last 6 \\nmonths 1\\nVL within last 6 months   \\n200 copies/ml\\nCollect sample for VL\\nVL       copies/ml\\n• Proceed with single drug substitution\\n• Schedule clinical appointment at 2 weeks after regimen change \\nto review adherence, side effects and any other concerns\\n• Repeat VL 3 months after regimen modification followed by \\nroutine viral load monitoring\\n• Do NOT  change the current regimen unless \\nimmediate change required for clinical reasons1\\n• Follow viral load monitoring algorithm (Figure 6.6)\\nOn ART for < 3 months\\n On ART for     months\\nVL < 200 copies/ml', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 151}),\n",
       " Document(page_content='• Follow viral load monitoring algorithm (Figure 6.6)\\nOn ART for < 3 months\\n On ART for     months\\nVL < 200 copies/ml \\n1 If an ARV must be changed for clinical reasons (adverse \\ndrug reaction; drug -drug interaction; co -morbidity; etc) \\nbefore viral load results available, Urgently consult Uliza \\nHotline (0726 460 000) or Regional or National TWG\\n \\nFigure 6.4: Managing Single Drug Substitutions for ART', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 151}),\n",
       " Document(page_content='Antiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 13 \\nAt every clinic visit, assess for risk of kidney disease:\\n•  Age > 60 years\\n•  Concurrent HIV associated diseases (such as TB and other OIs)\\n•  Concurrent diabetes, hypertension, viral hepatitis\\n•  Concomitant use of nephrotoxic drugs (e.g. aminoglycosides, \\namphotericin and boosted PIs)\\n•  Wasting, low BMI\\n•  CD4 count < 200 cells/mm3\\nIf any risk factor present\\nObtain a dip stick urinalysis and serum creatinine and calculate \\ncreatinine clearance (CrCl in ml/min, see Annex 15)1\\n4,5CrCl   29\\nAVOID: if there is no \\nsuitable alternative; give \\nTDF 300 mg every 72 \\nhours, monitor CrCl \\nmonthly 2CrCl    90 \\nTDF 300 mg OD: re -\\nassess creatinine and CrCl \\nat 1 month, 3 months and \\nbi-annually thereafter if', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 152}),\n",
       " Document(page_content='hours, monitor CrCl \\nmonthly 2CrCl    90 \\nTDF 300 mg OD: re -\\nassess creatinine and CrCl \\nat 1 month, 3 months and \\nbi-annually thereafter if \\nnormal3CrCl = 50 -89\\nTDF 300 mg OD, monitor \\nmore closely for decline in \\nrenal function (monthly \\nduring the first year, and 3 \\nmonthly thereafter if CrCl \\nremains stable4,5CrCl = 30 -49\\nAVOID: if there is no \\nsuitable alternative; give \\nTDF 300 mg every 48 \\nhours, monitor closely \\nwith monthly CrCl for the \\nfirst year, and 3 monthly \\nthereafter if stable\\n1 DTG may cause a small rise in serum creatinine levels but this does NOT represent a true decline in renal function\\n2 Obtain biannual serum Cr and CrCl in patients at risk of renal disease and a CrCl      ml/min\\n3 Patients with a CrCl      ml/min do not require TDF dose adjustment.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 152}),\n",
       " Document(page_content='3 Patients with a CrCl      ml/min do not require TDF dose adjustment.\\n4 Avoid the use of TDF in patients with CrCl < 50ml/min unless in HIV/HBV coinfection (in which case TAF or TDF should \\nbe used). If HBV  negative and on first line ART, substitute TDF with  ABC, TAF or DTG + 3TC dual therapy. If prior ART \\ntreatment failure or any other scenario consult the Regional or National HIV Clinical TWG (Uliza Hotline 0726 460 000).  \\n5 3TC also requires dose adjustment once CrCl < 50 ml/min\\n* For patients with decreased renal function, assess for other causes of renal impairment and refer to physician for review \\nFigure 6.5: Managing TDF -Associated Kidney Toxicity', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 152}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 14 Table 6.6: ARV, CTX and Fluconazole Adjustments in Renal and Hepatic Impairment1 \\nDrug  CrCl (ml/min)  Haemodialysis  Liver impairment  \\n15 - 50 <15  \\n \\nABC   \\nNo change  Reduce adult dose to 200 mg BD for \\nmoderate to severe liver impairment. \\nAVOID in severe hepatic impairment  \\nAZT  No change  300 mg/day  300 mg/day  Reduce dose by 50% or double \\ninterval of administration in \\nmoderate to severe impairment  \\nTDF2 AVOID unless \\nHBV+2 AVOID unless \\nHBV+2 300 mg every 7 \\ndays  No change  \\nTAF  No change  AVOID unless \\nHBV+2 No dose adjustment - \\nAdminister after \\ndialysis  No change  \\n3TC  150 mg OD  150 mg OD  75 mg OD  No change  \\nLPV  No change  No change, use with caution in \\nmoderate to severe impairment  RTV  \\nATV', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 153}),\n",
       " Document(page_content='3TC  150 mg OD  150 mg OD  75 mg OD  No change  \\nLPV  No change  No change, use with caution in \\nmoderate to severe impairment  RTV  \\nATV  \\nDRV  \\nRAL  No change  \\n No change in mild to moderate \\nimpairment. Use with caution in \\nsevere impairment  DTG  \\nEFV  No change  \\n Use with caution in mild to moderate \\nliver impairment. AVOID in severe \\nimpairment  \\nNVP  No change  AVOID  \\nETV  No change  Use with caution in severe liver \\nimpairment  \\nCTX  If CrCl > 30 ml/min then no dose adjustment \\nrequired; if 15 -30 ml/min then use 50% of normal \\nrecommended dose; if CrCl < 15 ml/min then CTX \\nshould be avoided  Use with caution in mild to moderate \\nliver impairment. AVOID in severe \\nimpairment  \\nFluconazole  If CrCl ≤ 50 ml/min then use 50% of normal', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 153}),\n",
       " Document(page_content='liver impairment. AVOID in severe \\nimpairment  \\nFluconazole  If CrCl ≤ 50 ml/min then use 50% of normal \\nrecommended dose (no dose adjustment required \\nfor CrCl > 50 ml/min)  Use with caution  \\n1 Patients with evidence of renal or hepatic impairment should have access to regular monitoring of renal \\nand liver function  \\n2 TDF and renal impairment:  \\n● In acute kidney injury (AKI), interrupt TDF administration until the cause of AKI is established and \\ncorrected.  \\n● Avoid the use of TDF in patients with CrCl < 50ml/min unless in HIV/HBV coinfection (in which case \\nTAF or TDF should be used). For patients wit h HBV co -infection, the benefit of TDF or TAF for treating \\nHBV often outweighs the risks of renal impairment, so more severe levels of renal impairment are', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 153}),\n",
       " Document(page_content='HBV often outweighs the risks of renal impairment, so more severe levels of renal impairment are \\ntolerated. See Table 9.3 for TDF and TAF dose adjustments for patients with HBV/HIV co -infection. \\nThese patients should be managed in consultation with an experienced clinician  \\n● If HBV negative and on first line ART, substitute TDF with ABC, TAF or DTG + 3TC dual therapy, \\nfollowing the single drug substitution algorithm (Figure 6.4). If prior ART treatmen t failure or any other \\nscenario consult the Regional or National HIV Clinical TWG (Uliza Hotline 0726 460 000; \\nhttps://nhcsc.nascop.org/clinicalform )', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 153}),\n",
       " Document(page_content='Antiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 15 Table 6.7: Management of AZT -Associated Bone Marrow Suppression  \\nTest  Result  Action  \\n \\nHb (g/dL)  > 8.5 (and decrease \\nfrom pre -AZT \\nbaseline)  Retain AZT, repeat Hb at week 1, 2, 4 and 12 (if accessing \\nfollow -up Hb is difficult then consider substituting to an \\nalternative ARV immediately)  \\n≤ 8.5  Switch from AZT to an alternative ARV  \\n \\nNeutrophils  \\n(x 109/L) 1.0 – 1.5 (and decrease \\nfrom pre -AZT baseline, \\nif available)  If receiving cotrimoxazole consider withholding unless \\nessential. Retain AZT, repeat at week 1, 2, 4 and 12 (if \\naccessing follow -up neutrophils is difficult then \\nconsider s witching to an alternative ARV immediately)  \\n≤ 1.0  Switch from AZT to an alternative ARV  \\nNote:', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 154}),\n",
       " Document(page_content='consider s witching to an alternative ARV immediately)  \\n≤ 1.0  Switch from AZT to an alternative ARV  \\nNote:  \\n● Patients with baseline Hb of < 9.5 g/dL should not be initiated on AZT; patients who develop \\nanaemia while on AZT should be managed as per this table  \\n● AZT -associated bone marrow suppression occurs early in the course of treatment, usually within \\n3 months of initiating ART  \\n● All patients with anaemia and/or neutropenia, whether on AZT or not, should be evaluated for \\nother likely causes of anaemia/neutropenia and managed appropriately  \\n \\nTable 6.8: Management of Drug -Related Hepatotoxicity  \\nALT  <2.5 x Upper Limit of Normal (ULN)  2.5 – 5 x ULN  > 5 x ULN  \\nAction  Retain regimen, repeat in 2 weeks  Retain regimen, \\nrepeat in 1 week  Discontinue offending drug/s', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 154}),\n",
       " Document(page_content='Action  Retain regimen, repeat in 2 weeks  Retain regimen, \\nrepeat in 1 week  Discontinue offending drug/s  \\nConsult senior clinician for \\nnext step  \\nNote: All patients with acute increase in liver enzymes should be evaluated for other likely causes of \\nhepatitis/hepatotoxicity and managed appropriately', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 154}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 16 Table 6.9: Diagnosis and Management of Abacavir Hypersensitivity Reaction  \\nDiagnosis  \\nWithin 3 weeks of initiating an ABC -containing regimen , patient develops any 2 of the following \\nsymptom groups concurrently  \\n• Fever  \\n• Erythematous and/or pruritic rash  \\n• Respiratory symptoms (shortness of breath and/or sore throat and/or cough)  \\n• GI symptoms: nausea and/or vomiting and/or diarrhea  \\n• Extreme fatigue and/or body pain preventing normal activities  \\nAND: there is not a more likely alternative explanation for the symptoms  \\nManagement  \\n• Stop ABC immediately and substitute with an alternative ARV  \\n• Patient must NEVER be re -challenged with ABC – a single dose could result in a fatal \\nhypersensitivity reaction', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 155}),\n",
       " Document(page_content='• Patient must NEVER be re -challenged with ABC – a single dose could result in a fatal \\nhypersensitivity reaction  \\n• Clearly mark file and educate patient about avoiding ABC in future  \\n• Issue an Adverse Event alert card  \\nNote:  \\n• ABC hypersensitivity reaction is rare in our population: always consider other more likely possible \\ndiagnoses  \\n• Symptoms generally get worse within hours after each dose of ABC  \\n \\n \\n6.5.3 Changing ARVs Due to Drug -Drug Interactions  \\nPatients must be asked about other medications (including non -prescription and herbal \\nmedicine) they are taking at every visit. Some common drugs have specific drug -drug interactions \\nthat may require dose adjustment or substitution o f the ARV or the other interacting drugs.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 155}),\n",
       " Document(page_content='that may require dose adjustment or substitution o f the ARV or the other interacting drugs. \\nCommon medications that interact with specific ARVs include: rifampicin, rifabutin, antacids, \\nmultivitamin/mineral supplements, methadone, several anti -fungal, anti -convulsant, calcium -\\nchannel blockers, some anti -depressants, some statins, and some anti -malarial. Annex 13 \\nprovides common drug -drug interactions and management recommendations. It is \\nrecommended practice to check for interactions whenever a new medicine is started.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 155}),\n",
       " Document(page_content='Antiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 17 6.5.4 Changing ARVs Due to Treatmen t Failure  \\nViral load is the test of choice for monitoring response to ART and identifying treatment failure. \\nFirst VL should be performed 3 months after ART initiation for all PLHIV.   \\nTreatment failure should be suspected when a new or recurrent HIV -associ ated condition \\nindicating severe immunodeficiency (WHO stage III or IV condition) develops after at least 6 \\nmonths on ART. Treatment failure should always be confirmed with VL testing.  \\nFrequency of routine VL monitoring for specific populations is:  \\n● Age 0-24 years old: at 3 months after ART initiation and then every 6 months  \\n● Age ≥ 25 years old: at 3 months after ART initiation, then at month 12 and then', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 156}),\n",
       " Document(page_content='● Age ≥ 25 years old: at 3 months after ART initiation, then at month 12 and then \\nannually  \\n● Pregnant or breastfeeding: at confirmation of pregnancy (if already on ART) or 3 \\nmonths after ART initiation (if ART initiated during pregnancy/ breastfeeding), and \\nthen every 6 months until cessation of breastfeeding  \\n● Before making any drug substitution (if no VL results from the prior 6 months)  \\n● Three months after any regimen modification (includin g single -drug substitutions), \\nand then as per population group  \\n● For any patient with a detectable VL follow the viral load monitoring algorithm \\n(Figure 6.6)  \\n \\nInterpreting Viral Load Results and Defining Treatment Failure (Figure 6.6)  \\nThe goal for ART is t o achieve sustained viral suppression defined as below the Lower Detection', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 156}),\n",
       " Document(page_content='The goal for ART is t o achieve sustained viral suppression defined as below the Lower Detection \\nLimit (LDL), < 50 copies/ml is considered as suppressed.  See Table 5.17  \\nPersistent low -level viremia (PLLV) is defined as having between 200 -999 copies/ml on \\ntwo consecutive measures.  These patients are at increased risk of progression to treatment \\nfailure, development of resistance and death and therefore require a similar case management \\napproach as patients with VL ≥ 1,000 copies/ml, and consultation with the Re gional or National \\nHIV Clinical TWG (Uliza Hotline 0726 460 000; https://nhcsc.nascop.org/clinicalform ).  \\nTreatment failure is suspected when a patient has a high VL ≥ 1,000 copies/ml after at least', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 156}),\n",
       " Document(page_content='Treatment failure is suspected when a patient has a high VL ≥ 1,000 copies/ml after at least \\n3 months of using ART.  Treatment failure is only confirmed when VL is ≥ 1,000 copies/ml after \\nassessing for and addressing poor adherence or other reasons for high VL, and then repeating VL \\nafter at least 3 months of enhanced adherence to allow for viral re -suppression.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 156}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 18 \\nSchedule for routine viral load testing1 \\n• Age 0 -24 years old: at month 3, then every 6 months \\n• Age      years old: at month 3, then month 12 and then annually \\n• Pregnant or breastfeeding: at confirmation of pregnancy (if already on ART) or 3 months after ART initiation (if ART initiate d during \\npregnancy/breastfeeding), and then every 6 months until complete cessation of breastfeeding \\n• Before any drug substitution (if no VL result available from the prior 6 months) \\n• Three months after any regimen modification (including single -drug substitutions) \\nVL < 200 copies/ml\\n VL 200 – 999 copies/ml\\n VL         copies/ml\\nIncreased risk of progression to \\ntreatment failure\\nSuspected treatment \\nfailure', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 157}),\n",
       " Document(page_content='VL < 200 copies/ml\\n VL 200 – 999 copies/ml\\n VL         copies/ml\\nIncreased risk of progression to \\ntreatment failure\\nSuspected treatment \\nfailure\\n• Discuss patient in MDT \\n• Assign a case manager \\n• Assess for and address likely causes of non -adherence2 \\n• Provide enhanced adherence support/intervention as appropriate (Section \\n5.4 of guidelines for enhanced adherence protocol) \\n• Assess for other causes of viremia and manage as needed3 \\n• Support daily witnessed ingestion by treatment buddy or healthcare worker\\n• After 3 months of excellent adherence, repeat VL \\nVL < 200 copies/ml (LDL)\\nVL 200 – 999 copies/ml\\nVL         copies/ml\\n• Continue ART regimen\\n• Routine adherence \\ncounselling and monitoring\\n• Routine VL monitoring\\n• Reassess adherence and other \\ncauses of viremia2,3', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 157}),\n",
       " Document(page_content='• Continue ART regimen\\n• Routine adherence \\ncounselling and monitoring\\n• Routine VL monitoring\\n• Reassess adherence and other \\ncauses of viremia2,3\\n• Repeat VL after another 3 months of \\nexcellent adherence\\nConfirms treatment failure: \\n• Begin treatment preparation for new regimen and \\ncontinue failing regimen until adherence \\npreparation completed \\n• Continue enhanced adherence support \\n• Take sample for CD4 count and assess for and \\nmanage any OIs \\n• If failing a DTG or PI based regimen a DRT is \\nrecommended in consult ation with the  regional or \\nNational HIV Clinical TWG or call Uliza Hotline \\n       (0726 460 000)  \\n• Schedule clinical appointment at 2 weeks after \\nregimen change to review adherence, side effects \\nand any other concerns', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 157}),\n",
       " Document(page_content='(0726 460 000)  \\n• Schedule clinical appointment at 2 weeks after \\nregimen change to review adherence, side effects \\nand any other concerns \\n• Repeat VL 3 months after regimen modification \\nConsult Regional or National HIV \\nClinical TWG or call Uliza Hotline \\n(0726 460 000)\\nVL 200 – 999 copies/ml\\n1. As part of treatment preparation, patients should be informed that \\nviral load is the recommended method of monitoring ART. VL results \\nshould always be discussed with patients, even when they are \\nundetectable. Goals of treatment and definition of success should be \\ndiscussed and adherence messaging reinforced \\n2. Common causes of poor adherence include: stigma, non -disclosure, \\ntravel, toxicities, alcohol or drug use, mental health disorder, religious', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 157}),\n",
       " Document(page_content='2. Common causes of poor adherence include: stigma, non -disclosure, \\ntravel, toxicities, alcohol or drug use, mental health disorder, religious \\nbeliefs, inadequate treatment preparation, chaotic lifestyle, lack of \\nsupport systems, and poor patient -provider relationship \\n3. Other common causes of treatment failure (beyond adherence) \\ninclude: inadequate dosing/dose adjustments, drug -drug \\ninteractions, drug -food interactions, impaired absorption (e.g. \\nchronic severe diarrhoea)  \\n Figure 6.6: Viral Load Monitoring of Patients on ART (1st Line or 2nd Line)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 157}),\n",
       " Document(page_content='Antiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 19 Non -adherence is the most frequent cause of treatment failure. As per the viral load \\nmonitoring algorithm, adherence issues must be addressed BEFORE confirming \\ntreatment failure.  \\nDaily witnessed ingestion by a treatment buddy or healthcare worker is recommended to confirm \\nexcellent adherence before repeating the VL. All adherence issues must be resolved before \\nswitching to a new regimen otherwise the patient will quickly fail the n ew regimen as well, and \\nsoon run out of viable ART options. An exception to this may be when the regimen itself is \\nthe primary cause of poor adherence  (e.g., side effects from one of the ARVs are not', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 158}),\n",
       " Document(page_content='the primary cause of poor adherence  (e.g., side effects from one of the ARVs are not \\nmanageable such as severe diarrhea with LPV/r that does not improve with symptom \\nmanagement), in which case the regimen may need to be modified to allow for perfect adherence. \\nThis should be done in consultation with the Regional or National HIV Clinical TWG.  \\nChapter 5 provides detailed guidance on adherence pr eparation, assessment, and support.  \\nTable 6.10: Recommended Second -line ART Regimens in Infants, Children, Adolescents and \\nAdults, excluding TB/HIV co -infection 1 \\nWeight/scenario  First -line ART  Second -line ART  \\n \\n< 30 kg  ABC (or AZT) + 3TC + DTG  DRT -based second -line2,3  \\nABC + 3TC + LPV/r  Take sample for DRT and change to AZT + \\n3TC + DTG while awaiting DRT results;', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 158}),\n",
       " Document(page_content='ABC + 3TC + LPV/r  Take sample for DRT and change to AZT + \\n3TC + DTG while awaiting DRT results; \\nmodify based on DRT results if indicated  \\nAZT + 3TC + LPV/r  Take sample for DRT and change to ABC \\n+ 3TC + DTG while awaiting DRT results; \\nmodify based on DRT results if indicated  \\nABC + 3TC + EFV  AZT + 3TC + DTG  \\nAZT + 3TC + EFV  ABC + 3TC + DTG  \\n \\n≥ 30 kg or ≥ 15 \\nyears old  TDF (or ABC) + 3TC + DTG (or PI/r)  DRT -based second -line2 \\nTDF (or ABC) + 3TC + EFV  TDF + 3TC +  DTG  \\nAZT + 3TC + EFV  TDF + 3TC + DTG  \\nPregnant and \\nBreastfeeding \\nwomen  TDF (or ABC) + 3TC + DTG  Take sample for DRT and change to TDF \\n+ 3TC + ATV/r while awaiting DRT \\nresults; modify based on DRT results if \\nindicated  \\nTDF (or ABC) + 3TC + PI/r  Take sample for DRT and change to TDF', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 158}),\n",
       " Document(page_content='results; modify based on DRT results if \\nindicated  \\nTDF (or ABC) + 3TC + PI/r  Take sample for DRT and change to TDF \\n+ 3TC + DTG while awaiting DRT results; \\nmodify based on DRT results if indicated  \\nTDF (or ABC) + 3TC + EFV  TDF + 3TC + DTG  \\nAZT + 3TC + EFV  TDF + 3TC + DTG  \\nHIV/HBV Co -\\ninfection  Always maintain TDF in order to treat the HBV as well as HIV  \\nTB/HIV Co -\\ninfection  Refer to Table 8.8: Recommended ART Regimens for Patients who Develop TB \\nwhile Failing  1st Line ART', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 158}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 20 Table 6.10 Cont.  \\n1. If any drug in the recommended 2nd line regimen is contraindicated or previously not tolerated, \\nconsult the Regional or National HIV Clinical TWG (Uliza Hotline 0726 460 000; \\nhttps://nhcsc.nascop.org/clinicalform ). Such patients may require DRT to select agents for the \\nsecond -line ART. Add itional drugs may be recommended on a case -by-case basis, including DRV/r, \\nATV/r, RAL, or ETR  \\n2. Patients failing DTG -based or PI -based first -line regimens should have a Drug Resistance Test \\n(DRT) ordered as soon as treatment failure is confirmed. The patient  summary and DRT results \\nshould be sent to the Regional or National HIV Clinical TWG', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 159}),\n",
       " Document(page_content='should be sent to the Regional or National HIV Clinical TWG \\n(https://nhcsc.nascop.org/clinicalform ) or call Uliza Hotline (0726 460 000) to determine the \\nmost suitable second -line regimen for the patient. The DRT results will be us ed to determine if \\nthere is true DTG or PI failure or if there is an underlying problem with non -adherence. Daily \\nwitnessed ingestion is recommended prior to performing DRT  \\nImportant Considerations for First -line Treatment Failure in Children  \\n● Second -line ART in infants and children is more complex to manage. These children and \\ntheir caregivers should undergo thorough clinical and psychosocial assessment to rule \\nout inter -current illness or non -adherence as the reason for a high viral load', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 159}),\n",
       " Document(page_content='out inter -current illness or non -adherence as the reason for a high viral load  \\n● All c hildren failing first -line should be discussed in the MDT and preferably with an \\nexperienced ART provider prior to change of ART to second -line. However, this should \\nnot cause undue delay in switching a failing regimen  \\n● The choices for infants and children failing an alternative first -line regimen are limited \\nand may need to be discussed with the Regional or National HIV Clinical TWG. Some of \\nthese children will require HIV DRT to determine the most suitable second -line regimen  \\nImportant considerations for s econd -line ART Treatment Failure  \\n● Patients failing second -line ART have limited options. ARVs used to construct a third -line', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 159}),\n",
       " Document(page_content='● Patients failing second -line ART have limited options. ARVs used to construct a third -line \\nregimen are often more expensive, will have increased pill burden and more side effects. \\nThese factors will exacerbate pre -existing poor adherence  \\n● Second -line treatment failure should be confirmed by viral load testing following the \\nviral load monitoring algorithm (Figure 6.6)  \\no After the first detectable VL ( \\uf065 50 copies/ml), assess for and address all causes of \\npoor adherence, and assess for all other possible causes of viremia.  \\no These patients should be discussed at an MDT session. Repeat the VL after 3 months \\nof excellent adherence (preferably with daily witn essed ingestion of the ARVs by a \\ntreatment buddy, relative, CHV, etc.).', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 159}),\n",
       " Document(page_content='of excellent adherence (preferably with daily witn essed ingestion of the ARVs by a \\ntreatment buddy, relative, CHV, etc.).  \\no If the second VL is still \\uf065 50 copies/ml then continue the failing second -line regimen \\nwhile reassessing adherence and other causes of viremia, implementing adherence \\nsupport systems as needed, and then repeat the VL after another 3 months.  \\no If viremia continues then consult the Regional or National HIV Clinical TWG (Uliza \\nHotline 0726 460 000; https://nhcsc.nascop.org/clinicalform ) using the national \\ncase summary form (Annex 9B). These patients will likely require DRT in order for \\nthe TWG to design the most suitable third -line regimen  \\n● Patients failing second -line ART require thorough assessment for barriers to adherence', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 159}),\n",
       " Document(page_content='the TWG to design the most suitable third -line regimen  \\n● Patients failing second -line ART require thorough assessment for barriers to adherence \\nand ongoing enhanced adherence support including  \\no Assigning a case manager  \\no More frequent adherence counselling by a trained counsellor  \\no Assessment and treatment of mental health and substance use disorders  \\no Provision of adherence support such as modified directly observed therapy, a \\ntreatment supporter, hom e visits etc.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 159}),\n",
       " Document(page_content='Antiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 21 Table 6.11: Possible Third -line ART in Children, Adolescents and Adults  \\n Possible 3rd Line Regimen  Comment  \\n \\nChildren  DTG + 3TC + DRV/r  Third line ART selection is based on DRT \\nresults  \\nNote that the Regional or National \\nHIV Clinical TWG may recommend \\nreusing some of the ARVs the \\npatient has already failed, even \\nwhen resistance is present  DTG + AZT + 3TC + DRV/r  \\nDTG + ABC (or TDF) + 3TC + DRV/r  \\nETV + 3TC + DRV/r  \\nAdults  DTG + 3TC + DRV/r  \\nDTG + AZT + 3TC + DRV/r  \\nDTG + TDF + 3TC + DRV/r  \\nDTG + TDF (or AZT) + 3TC  \\nETV + 3TC + DRV/r', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 160}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 22', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 161}),\n",
       " Document(page_content='Prevention of Mother to Child Transmission of HIV/Syphilis/Hepatitis B  \\n  7 - 1  \\n7. Prevention of Mother to Child Transmission of \\nHIV/Syphilis/Hepatitis B  \\nRoutine antenatal care (ANC) offers an important opportunity to provide high quality combined \\nHIV prevention throug h targeted health education and counselling; HIV testing for the woman, \\npartners and family members; linkage to HIV prevention and treatment; and to discuss and plan \\nfor future conception and contraception needs. Prevention of mother -to-child transmission of HIV \\n(PMTCT)/Syphilis/Hepatitis B should be offered as part of a comprehensive package of fully \\nintegrated, routine antenatal care interventions (Table 7.1).  \\nTable 7.1: Essential Package of Antenatal Care  \\nIntervention  Recommendation/Description', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 162}),\n",
       " Document(page_content='Table 7.1: Essential Package of Antenatal Care  \\nIntervention  Recommendation/Description  \\n \\nGroup & \\nIndividual \\nEducation  Include information on importance of at least 8  ANC visits, details of ANC services \\n(including health checks and treatment of any illness, medical tests including HIV, \\nsyphilis testing and hepatitis B, monitoring of maternal and fetal wellbeing, etc.), \\nnutrition, personal care, recognizing and responding to danger signs during \\npregnancy, birth preparedness including skilled birth attendance, post -natal care \\nincluding immunization, family pla nning and maternal and infant nutrition, HIV \\nprevention and treatment (HTS, preventing new infections during pregnancy \\nincluding PrEP where appropriate, ART for those who are HIV positive, monitoring of', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 162}),\n",
       " Document(page_content='including PrEP where appropriate, ART for those who are HIV positive, monitoring of \\nART and ARV prophylaxis and follow -up for HEIs) and t riple elimination (preventing \\nHIV/ syphilis/hepatitis B transmission from mother to child).  \\nCounselling  ● Pre-conception – Women in reproductive age who are known to be HIV positive \\nshould have pregnancy intention assessment visit at every visit. If they desire to \\nbecome pregnant, pregnancy should be planned i.e., attain viral load suppression, \\nimmune reconsti tution and have Iron and Folic Acid Supplementation (IFAS) \\nadministered prior to conception.  \\n● Women who are newly diagnosed with HIV and/or newly initiating ART require \\nmore intensive adherence counseling and HIV education, which may include a case \\nmanager  and/or mentor mother', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 162}),\n",
       " Document(page_content='more intensive adherence counseling and HIV education, which may include a case \\nmanager  and/or mentor mother  \\n● Birth preparedness: support the pregnant woman and her partner to develop an \\nindividual birth plan that includes place of delivery with skilled attendants, \\nemergency transport, birth companionship and readiness for infant care  \\n● Pregnan cy danger signs: offer information on returning to ANC as soon as possible \\nin case they develop fever, lower abdominal pain, severe headache, swollen feet, \\nconvulsions and per vaginal bleeding.  \\n● Maternal, infant and young child nutrition (MIYCN): All pregn ant women should \\nreceive information on proper nutrition during pregnancy and breastfeeding, safe', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 162}),\n",
       " Document(page_content='receive information on proper nutrition during pregnancy and breastfeeding, safe \\ninfant feeding and optimal nutrition practices. Promote exclusive breastfeeding for \\nthe first 6 months irrespective of HIV status, followed by complementary f eeding \\n(Table 7.7). During pregnancy, provide iron, folate and multivitamins; monitor for \\nanemia, advise on adequate caloric intake (HIV positive women require an \\nadditional 10% of recommended daily allowance (RDA))', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 162}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n7 - 2 Table 7.1 Cont.  \\nCounselling  ● HIV testing services  \\no All pregnant women (unless known HIV positive) should be counselled and \\ntested for HIV, syphilis and Hepatitis B during their first ANC visit and if \\nnegative, repeat HIV and syphilis testing in the third trimester.  \\no All pre gnant and breastfeeding mothers with continued HIV risk (Key \\npopulations) should be counseled and tested for HIV every 3 months until post -\\ncessation of breastfeeding.  \\no Pregnant and breastfeeding mothers should be educated and offered a self -test \\nkit for th eir sexual partner(s)  \\no At Labour and delivery, HIV testing should be done for all women with \\nunknown HIV status or that previously tested negative, even if tested during', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 163}),\n",
       " Document(page_content='unknown HIV status or that previously tested negative, even if tested during \\nthe third trimester  \\no All breastfeeding mothers (unless known HIV positive) should be co unselled \\nand tested at the 6 -week infant immunization visit. The HIV test (if negative) \\nshould be repeated every 6 months until complete cessation of breastfeeding. \\nNote:  key population mothers (FSWs and PWIDs) get retested every 3 months \\n(Table 2.5)  \\no Women should be counselled about the schedule for repeat HIV testing in \\npregnancy and postnatally as part of routine ANC and postnatal education  \\no All pregnant and breastfeeding women who are not tested, opt -out or decline \\nHIV, Syphilis or Hepatitis testing during the first contact should be offered', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 163}),\n",
       " Document(page_content='HIV, Syphilis or Hepatitis testing during the first contact should be offered \\ncounselling and testing in subsequent visits with appropriate linkage and \\nreferral for prevention, care and support services. Daily Witnessed Ingestion \\n(DWI) is advised to support Viral suppression for newly initi ated clients and \\nthose whose regimens are being switched. This is to support viral suppression \\namong women with high viral load.  \\no All HIV positive pregnant and breastfeeding women enrolled into care should \\nreceive counselling and support (including assiste d disclosure), case \\nmanagement linkage and follow -up for comprehensive treatment and \\nprevention (including lifelong ART)  \\no All Syphilis and Hepatitis B positive clients should be given appropriate care as', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 163}),\n",
       " Document(page_content='prevention (including lifelong ART)  \\no All Syphilis and Hepatitis B positive clients should be given appropriate care as \\ndefined in Table 7.3 “triple elimination”.  \\no All partn ers of pregnant and breastfeeding women should be offered HIV \\ntesting and counselling and all biological children if the mother is HIV positive  \\n● All pregnant and breastfeeding women should receive information on risk \\nreduction, including PrEP where appropri ate \\n● Post -partum contraception: counsel on contraception methods and help patient \\ndevelop a plan for effective contraception from 6 -weeks post -partum to avoid \\nunplanned pregnancies', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 163}),\n",
       " Document(page_content='Prevention of Mother to Child Transmission of HIV/Syphilis/Hepatitis B  \\n  7 - 3 7.1 Antiretroviral Therapy for HIV -positive Pregnant and Breastfeeding \\nWomen and Infant Prophylaxis  \\nThe goal of ART for HIV positive pregnant women is two -fold: to restore and maintain the \\nmother’s immune function and therefore general health, and secondly, to prevent transmission \\nof HIV in utero, at labour and delivery and during breastfeeding. To achieve this goal, the mother \\nmust take effective antiretroviral therapy to achieve viral suppression.  Table 7.2 summarizes \\nrecommendations for use of ART for HIV positive pregnant women.  \\nTable 7.2: Summary of Use of A RT for HIV Positive Pregnant and Breastfeeding Women  \\nOverall recommendations', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 164}),\n",
       " Document(page_content='Table 7.2: Summary of Use of A RT for HIV Positive Pregnant and Breastfeeding Women  \\nOverall recommendations  \\nWhen to start  ART should be initiated in all pregnant and breastfeeding women living with HIV, \\nregardless of gestation, WHO clinical stage and at any CD4 cell count and continued \\nlifelong. ART should be started, ideally, on same day as HIV diagnosis after \\nreadiness asse ssment with ongoing enhanced adherence support including \\ncommunity -based case management and support.  \\nWhat to start with \\n(first -line ART)  TDF/3TC/DTG  \\nInfant \\nprophylaxis  ● AZT+NVP for 6 weeks, NVP should be continued until 6 weeks after complete \\ncessation of breastfeeding  \\nFor more comprehensive information Refer to Table 7.3', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 164}),\n",
       " Document(page_content='cessation of breastfeeding  \\nFor more comprehensive information Refer to Table 7.3  \\nMonitoring       Viral load  monitoring during pregnancy and breast -feeding (Figure 6.6)  \\n● Whenever possible, use same -day point -of-care methods for viral load \\ntesting of pregnant and breastfeeding women to expedite the return of \\nresults and clinical decision -making. If this is not available, viral load \\nspecimens and results for pregnant and breastfeeding women should be \\ngiven priority across the laboratory referral process  (including specimen \\ncollection, testing and return of results).  \\n● For pregnant and breastfeeding women newly initiated on ART, obtain VL 3 \\nmonths after initiation, and then every 6 months until complete cessation of \\nbreastfeeding', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 164}),\n",
       " Document(page_content='months after initiation, and then every 6 months until complete cessation of \\nbreastfeeding  \\n● For HIV positive women already on ART at the time of confirming pregnancy \\nor breastfeeding, obtain a VL irrespective of when prior VL was done, and \\nthen every 6 months until complete cessation of breastfeeding  \\n● For pregnant or breastfeeding women with a VL ≥ 50 copies/ml: assess for \\nand address potential reasons for viremia, including intensifying adherence \\nsupport, repeat the VL after 3 months of excellent adherence, including \\ndaily witnessed ingestion, where feasible and appropriate  \\no If the repeat VL is 200 - 999 copies/ml consul t the Regional or National \\nHIV Clinical TWG  \\no If the repeat VL is ≥ 1,000 copies/ml, change to an effective regimen. \\nRefer to Table 6.10', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 164}),\n",
       " Document(page_content='HIV Clinical TWG  \\no If the repeat VL is ≥ 1,000 copies/ml, change to an effective regimen. \\nRefer to Table 6.10  \\no If the repeat VL is < 200 copies/ml (LDL) then continue routine \\nmonitoring', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 164}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n7 - 4 Table 7.2 Cont.  \\nScenario  \\nPre-conception planning \\nfor women already on \\nART (not yet pregnant)  Maintain ART  \\nCarry out a VL test if not done in the prior six months to confirm viral \\nsuppression (Figure 6.6)  \\nRefer to Table 4.8 for pre -conception care for women on ART who desire \\npregnancy, including laboratory screening, TT immunization, folate, etc.  \\nOn ART at the time of \\nconfirming \\npregnancy/breastfeeding  Maintain ART.  \\nCarry out a VL at first identification of pregnancy, irrespective of when a \\nprior viral load was done, to confirm viral suppression (Figure 6.6)  \\nManage the baby as HEI (Figure 2.1 for EID, and Table 7.3 for infant \\nprophylaxis)  \\nNot on ART at the time of', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 165}),\n",
       " Document(page_content='Manage the baby as HEI (Figure 2.1 for EID, and Table 7.3 for infant \\nprophylaxis)  \\nNot on ART at the time of \\nconfirming pregnancy  Prepare the patient and start on ART as soon as possible.  \\nART initiation should occur preferably on the same day HIV infection is \\nconfirmed. Perform VL 3 months after ART initiation.  \\nPregnant and breastfeeding women with a history of treatment \\ninterruption returning to care should have reasons for interruption \\nassessed and preferentially re -started on a DTG -containing regimen \\nunless the reason for interruption was DTG intolerance or failure. Viral \\nload monitoring in this case should be done after 3 months of initiation \\nand 6 months thereafter until cessation of breastfeeding . Additional \\nadherence support should be made available.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 165}),\n",
       " Document(page_content='and 6 months thereafter until cessation of breastfeeding . Additional \\nadherence support should be made available.  \\nNot on ART during \\nlabour and delivery  Start on ART during labour.  \\nAfter delivery, continue treatment preparation and adherence support and \\ncontinue ART  \\nManage the baby as HEI (Figure 2.1 for EID, a nd Table 7.3 for infant \\nprophylaxis)  \\nNot on ART during \\npost -\\npartum/breastfeeding  Prepare (readiness assessment) and start on ART as soon as possible \\npreferably on the same day HIV infection is confirmed.  \\nManage the baby as HEI (Figure 2.1 for EID, and Table 7.3 for infant \\nprophylaxis). Adherence support for both mother and infant, con sider \\ndaily witnessed ingestion (DWI) support.  \\nManaging labour and', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 165}),\n",
       " Document(page_content='prophylaxis). Adherence support for both mother and infant, con sider \\ndaily witnessed ingestion (DWI) support.  \\nManaging labour and \\ndelivery  Minimize vaginal examinations, use aseptic techniques to conduct delivery, \\navoid artificial rupture of membranes, monitor labour and avoid prolonged \\nlabour by use of the partograph, avoid unnecessary genital tract trauma  \\nNote that certain patient groups e.g., recent HIV infections, pregnant adolescent girls and young \\nwomen, women with previous children with HIV infection, patients with high viral load at time of \\npregnancy  confirmation, patients with poor social support systems, patients with history of \\ndefault from care and those with active co -morbidities etc. may require additional adherence and \\npsychosocial support', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 165}),\n",
       " Document(page_content='Prevention of Mother to Child Transmission of HIV/Syphilis/Hepatitis B  \\n  7 - 5 7.2. Syphilis elimination for Pregnant and Breastfeed ing Women and Infant \\nTreatment  \\nThe country has adopted triple elimination of HIV, Syphilis and Hepatitis B among pregnant and \\nbreastfeeding women. It is recommended that all pregnant women attending ANC and not aware \\nof their HIV status require a dual HIV syphilis test during their first trimester and a second HIV \\nSyphilis test in the 3rd trimester if the initial test was negative.   \\nAll women who test positive for syphilis at any point during pregnancy and breastfeeding should \\nbe treated with the appropria te regimen. (Table 7.3). All babies born of mothers who test positive', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 166}),\n",
       " Document(page_content='be treated with the appropria te regimen. (Table 7.3). All babies born of mothers who test positive \\nfor syphilis are suspected to be exposed to syphilis and should also be treated with the correct \\nregimen (Table 7.3). Ensure to perform contact tracing for all the sexual contacts and en sure they \\nare treated for syphilis.  \\nSymptoms of congenital syphilis may not become apparent for several weeks or months after \\nbirth.  \\n7.3. Hepatitis B elimination for Pregnant and Breastfeeding Women and Infant \\nProphylaxis  \\nRequires routine testing of pregnant women to identify women in need of antiviral treatment for \\ntheir own health and additional interventions to reduce Mother to Child Transmission of viral \\nhepatitis B.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 166}),\n",
       " Document(page_content='their own health and additional interventions to reduce Mother to Child Transmission of viral \\nhepatitis B.  \\nRegular screening should be done by incorporation of viral hepatitis screening as  part of the ANC \\nprofile. This is recommended for Hepatitis B & C which pose a big risk to both the mother and \\nfetus.  \\nFor pregnant and breastfeeding women who are found to be positive for HBsAg, offer appropriate \\ntreatment options of ARVs containing TDF/3TC or FTC containing regimens. This treatment also \\nacts as prophylaxis for HBV transmission from mother to child. All pregnant and breastfeeding \\nwomen without evidence of hepatitis B infection (HBsAg negative) should be vaccinated against \\nhepatitis B. (Chapter 9).', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 166}),\n",
       " Document(page_content='women without evidence of hepatitis B infection (HBsAg negative) should be vaccinated against \\nhepatitis B. (Chapter 9).  \\nHIV positive infants without evidence of infection should be vaccinated against Hepatitis B.  \\nInfants born of mothers who test positive for HBsAG should be treated using Hepatitis B \\nImmunoglobulin (Table 7.3).  \\nRefer to Chapter 9 f or management of HIV/HBV coinfection.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 166}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n7 - 6 Table 7.3: ARV Prophylaxis for HIV -Exposed Infants  \\nInfant Scenario  Infant Prophylaxis  Maternal Scenarios  \\nHIV Exposed \\nInfant  ● Infant prophylaxis  \\no AZT+NVP for 6 weeks, NVP + cotrimoxazole should be \\ncontinued until 6 weeks after complete cessation of \\nbreastfeeding  \\no Infant prophylaxis can be discontinued after a minimum \\nof 12 weeks on NVP if the child is not breastfeeding (death \\nof mother or separation with mother)  \\no The infant prophylaxis regimen applies to all infants \\nirrespective of age when identifying HIV exposure (e.g., \\nmother diagnosed HIV -positive in the  postpartum  period)  \\n● DBS or whole blood for PCR at 6 weeks or first contact, \\nfollowing EID algorithm (Figure 2.1)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 167}),\n",
       " Document(page_content='● DBS or whole blood for PCR at 6 weeks or first contact, \\nfollowing EID algorithm (Figure 2.1)  \\n● Birth testing (Figure 2.2) may be conducted in sites \\nwhere point of care has been implemented and when \\nmedically indicated  If mother not on ART, initiate \\nART as soon as possible \\n(preferably same day)  \\nIf mother is on ART for ≥ 3 \\nmonths and the VL is ≥ 50 \\ncopies/ml, intensify adherence, \\nrepeat the VL  \\n \\nIf VL <50 copies/ml, continue \\ncurrent regimen  \\nFollow Viral load algorithm \\nFigure 6.6  \\nTRIPLE ELIMINATION  \\nCONDITION in \\nmother  INFANT MANAGEMENT  MATERNAL MANAGEMENT  \\nSyphilis -VDRL \\nor diagnosed \\nwith Dual kit  Crystalline Penicillin 50,000 IU/kg BD (if <7 days) or TDS if \\n(>7 days old) for a total of 10 days.  Penicillin G 2.4 MU IM Stat or', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 167}),\n",
       " Document(page_content='with Dual kit  Crystalline Penicillin 50,000 IU/kg BD (if <7 days) or TDS if \\n(>7 days old) for a total of 10 days.  Penicillin G 2.4 MU IM Stat or \\nCeftriaxone 1gm IM daily for 8 -10 \\ndays in case of penicillin allergy.  \\nCongenital \\nsyphilis    \\nHepatitis B – \\nHbsAg test  Hepatitis B immunoglobulin 0.5ml IM within 12 hours after \\nbirth. Hepatitis B vaccine 0.5ml three doses at birth, 1 month \\nand 6 months.  Refer to viral hepatitis \\nmanagement guidelines  \\nNote: If child has contraindication or unable to tolerate NVP or AZT then give the tolerated drug up to complete \\ncessation of breastfeeding. If the infant is on AZT prophylaxis, give up to a minimum of 12 we eks or until maternal viral', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 167}),\n",
       " Document(page_content='cessation of breastfeeding. If the infant is on AZT prophylaxis, give up to a minimum of 12 we eks or until maternal viral \\nload is suppressed. In situations where neither AZT nor NVP are tolerated 3TC may be used as a third option if available.  \\nHIV exposed infants with TB infection, infant prophylaxis should include AZT plus 3TC fixed dose (60/30 mg ). For 12 \\nweeks or until maternal viral load is suppressed (3 -5.9 – 1 tab BD, 6 -9.9kg 1.5tab BD, 10 -13.9 kg 2 tabs BD).  For more \\ndetails, refer to Annex 10 A.  \\nAfter TB treatment, revert to NVP until 6 weeks post cessation of breastfeeding,  \\nHB monitoring should be done to all HEIs on AZT prophylaxis as per the recommendations (Table 6.7: management of \\nAZT associated bone marrow suppression)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 167}),\n",
       " Document(page_content='AZT associated bone marrow suppression)  \\nGroups considered higher risk for mother to child transmission who may need additional adherence and \\npsych ological support include:  \\n● All new HIV positives irrespective of time identified  \\n● HIV positive adolescent Girls and Young Women (AGYW) <19 yrs. including OVC  \\n● VL >200 copies/ml  \\n● Clients with stigma, declining treatment, poor adherence   \\n● PMTCT client with previous HIV infected infant  \\n● Client with active comorbidities - DM, OIs, malnourished (low MUAC), mental health etc.  \\n● Clients who sero -convert during ANC/PNC follow up  \\n● Poor socio -economic and family support structures   \\n● Those who drop of f ART  \\n● Key population – FSW, PWID  \\nAlcohol use and brewers/sellers', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 167}),\n",
       " Document(page_content='Prevention of Mother to Child Transmission of HIV/Syphilis/Hepatitis B  \\n  7 - 7 Table 7.4: Dosing of ARVs for Infant Prophylaxis from Birth to 12 Weeks of Age  \\nAge/Weight  Dosing of NVP (10mg/ml) OD  Dosing of AZT (10mg/ml) BD  \\nBirth to 6 weeks  \\nBirth weight < 2,000 g  2 mg/kg per dose, OD  4 mg/kg per dose, BD  \\nBirth weight 2,000 -2,499 g  10 mg (1 ml), OD  10 mg (1 ml), BD  \\nBirth weight ≥ 2,500 g  15 mg (1.5 ml), OD  15 mg (1.5 ml), BD  \\n> 6 weeks to 12 weeks of age*  \\nAny weight  20 mg (2 ml), OD  60 mg (6 ml), BD  \\n> 12 weeks (Table 7.5 and 7.6)  \\n*Dose adjustment required once child reaches 6 weeks of age  \\nIf older infant beyond 6 weeks of age is newly identified as HIV exposed infant, should be given', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 168}),\n",
       " Document(page_content='If older infant beyond 6 weeks of age is newly identified as HIV exposed infant, should be given \\nAZT+NVP for 6 weeks, NVP + cotrimoxazole should be continued until 6 weeks after complete \\ncessation of breastfeeding  \\nTable 7.5: NVP Dosing for Infant Prophylaxis beyond 12 Weeks of Age *  \\nAge  Dosing of NVP (10mg/ml) Once Daily  \\n12 weeks – 6 months  25 mg (2.5 ml), OD  \\n7 months – 9 months  30 mg (3 ml), OD  \\n10 months – 12 months  40 mg (4 ml), OD  \\n> 12 months  Consult the Regional or National HIV Clinical TWG (Uliza \\nHotline 0726 460 000; \\nhttps://nhcsc.nascop.org/clinicalform ) \\n* If child presents to facility late and has to be on AZT and NVP beyond 12 weeks of age \\nTable 7.6: AZT Dosing for Infant Prophylaxis beyond 12 Weeks of Age *', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 168}),\n",
       " Document(page_content='Table 7.6: AZT Dosing for Infant Prophylaxis beyond 12 Weeks of Age *  \\nWeight  Dosing of AZT: (10mg/ml syrup) Twice Daily  \\n3.0-5.9 kg  6 ml, BD  \\n6.0-9.9 kg  9 ml, BD  \\n10.0 -13.9 kg  12 ml, BD  \\n14.0 -19.9 kg  15 ml, BD  \\n* If child presents to facility late and has to be on AZT and NVP beyond 12 weeks of age  \\n7.4 Infant and Young Child Nutrition in the Context of HIV  \\n● Exclusive breastfeeding  involves giving the baby only breast milk with no other liquids \\n(including water) or solids for the first six months of life. Giving of vitamins, mineral \\nsupplements or medicines are permitted if prescribed.  \\n● Mixed feeding  is giving other liquids and/or foods together with breast milk to infants \\nunder 6 months of age and is not recommended.  Mixed feeding during thi s period is', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 168}),\n",
       " Document(page_content='under 6 months of age and is not recommended.  Mixed feeding during thi s period is \\nassociated with significantly higher risk of mother -to-child HIV transmission, diarrhoeal \\nand respiratory tract illnesses, among other consequences and should be prevented', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 168}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n7 - 8 ● All infants irrespective of HIV status should be exclusively breastfed f or the first 6 months \\nof life, with timely introduction of appropriate complementary foods after 6 months, and \\ncontinued breastfeeding up to 24 months or beyond.  \\n● Should mothers be physically separated from their infants (back to work), support them \\nto sust ain lactation and to exclusively breastfeed including mentorship on expressing \\nbreast milk (refer to current MIYCN Policy)  \\n● All mothers, irrespective of HIV status, should be encouraged and supported to \\nexclusively breastfeed for the first six months and co ntinue breastfeeding with \\nappropriate complementary feeding after 6 months, for a period of 24 months or beyond.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 169}),\n",
       " Document(page_content='appropriate complementary feeding after 6 months, for a period of 24 months or beyond. \\nBreastfeeding should ONLY stop once a nutritionally adequate and safe diet without \\nbreast milk can be sustained.  \\n● HIV positive mothers and HIV p ositive infants should always be on ART and given extra \\nattention for adherence support, VL monitoring and optimal retention in care  \\n● Breastfeeding mothers who do not know their HIV status or who previously tested HIV \\nnegative should be encouraged to be ret ested for HIV at the 6 -week immunization visit, \\nand then every 6 months thereafter until complete cessation of breastfeeding (Table 2.5)  \\n● Access for HIV testing and STI/HIV prevention interventions should be reinforced for \\npartners of pregnant and breastfee ding women', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 169}),\n",
       " Document(page_content='● Access for HIV testing and STI/HIV prevention interventions should be reinforced for \\npartners of pregnant and breastfee ding women  \\n● Mothers who are diagnosed with HIV while breastfeeding should immediately start \\nappropriate ART, giving extra attention to adherence support, VL monitoring, and optimal \\nretention in care. The infant should immediately start ARV prophylaxis and r eceive PCR \\ntesting (Table 7.3).  \\n● Mothers who decide to stop breastfeeding at any time should stop gradually within one \\nmonth (and only when a nutritionally adequate and safe diet without breast milk can be \\nsustained), and HIV positive mothers and HIV positi ve infants should continue with ART. \\nContinued breastfeeding is recommended for HIV positive infants for as long as the', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 169}),\n",
       " Document(page_content='Continued breastfeeding is recommended for HIV positive infants for as long as the \\nmother is willing and able to do so.  \\n● In special medical circumstances, determined by clinicians, where an infant cannot \\nbreastfeed, refe r to current MIYCN Policy and Breast Milk Substitute (BMS) Regulation \\nand Control Act, 2012.  \\n● Complimentary feeding means giving other foods to complement breast milk after six \\nmonths of exclusive breastfeeding. Complimentary feeds provide additional nutrit ional \\nvalue to meet the child’s increasing nutritional needs for growth (Table 7.7). \\nFurthermore, complementary feeding helps the child to gradually become accustomed \\nto eating family foods while breastfeeding continues to be an important source of', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 169}),\n",
       " Document(page_content='to eating family foods while breastfeeding continues to be an important source of \\nnutrien ts. It is worth noting that breastfeeding continues to have child growth/survival \\nbenefits for up to two years or longer. Emphasis should be made on consuming all the \\nseven (7) food groups for children in various meals.  \\no Cereal/tubers and roots  \\no Beans, pulses and nuts  \\no Dairy and dairy products  \\no Eggs and Flesh (meat/poultry/insects/organ meat)  \\no Vitamin A rich food (orange/yellow fruits) and green vegetables  \\no Fats and high sugar foods  \\n● Other fruits and vegetables', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 169}),\n",
       " Document(page_content='Prevention of Mother to Child Transmission of HIV/Syphilis/Hepatitis B  \\n  7 - 9 Table 7.7: Complementary Foods for Children 6 -24 Months Old  \\nFoods to Offer  \\nAge  Texture  Frequency  Amount of food per meal  \\n6 \\nmonths  Start with thick porridge or \\nwell mashed foods  \\n 2 times per day  2 tablespoons each feed, \\nincreasing to 3 tablespoons \\nin the 3rd to 4th week  \\n7-8 \\nmonths  Mashed/pureed family foods  \\nBy 8 months can begin \\nfinger foods  3 meals per day, plus \\nfrequent breastfeeds  \\n Increase amount gradually \\nto ½ of a 250 ml cup  \\nUse a separate plate/bowl  \\n9-11 \\nmonths  Finely chopped or mashed \\nfoods, and foods that baby \\ncan pick up  3 meals and 1 snack, \\nplus frequent \\nbreastfeeds  ¾ of a 250 ml cup/bowl  \\nUse a separate plate/bowl  \\n12-23', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 170}),\n",
       " Document(page_content='can pick up  3 meals and 1 snack, \\nplus frequent \\nbreastfeeds  ¾ of a 250 ml cup/bowl  \\nUse a separate plate/bowl  \\n12-23 \\nmonths  Cut food into small, soft \\npieces that child can pick up, \\nchew and swallow \\ncomfortably  3 meals and 2 snacks, \\nplus breastfeeds  One 250ml cup/bowl  \\nUse a separate plate/bowl  \\n24-59 \\nmonths  Cut food into small, soft \\npieces that child can pick up, \\nchew and swallow \\ncomfortably  3 meals and 2 snacks, \\nplus breastfeeds if still \\nbreastfeeding  1 ½ - 2 cups of 250ml \\ncup/bowl  \\nUse a separate plate/bowl', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 170}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n7 - 10', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 171}),\n",
       " Document(page_content='TB/HIV Co -infection, Prevention and Management  \\n8 - 1 \\n  \\n8. TB/HIV Co -infection, Prevention and \\nManagement  \\n \\nTB is a leading cause of morbidity and mortality among people living with HIV. Reducing this \\nburden of illness requires identifying TB early, providing pre -emptive and preventive  treatment \\nfor TB, and providing optimal treatment for both HIV and TB. Timely initiation of ART in \\ncombination with TB Preventive Therapy are effective ways to reduce the burden of TB in PLHIV.  \\nAll PLHIV should receive counselling about the risk of acquir ing TB, strategies for reducing \\nexposure to TB, recognizing clinical manifestations of TB and seeking care promptly, the risk of \\ntransmission of TB to others and TB preventive therapy to prevent TB disease.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 172}),\n",
       " Document(page_content='transmission of TB to others and TB preventive therapy to prevent TB disease.  \\nHealthcare settings present suitable conditions f or transmission of TB, particularly among \\nvulnerable individuals like PLHIV. All healthcare settings should develop and implement TB \\ninfection control guidelines to reduce the risk of transmission of TB between patients, visitors \\nand staff.  \\n8.1 TB Screenin g for PLHIV: Intensified Case Finding (ICF)  \\nTB screening and prevention services should be offered at every clinical visit. Symptom -based \\nTB screening using the ICF tool MUST be performed at every clinic visit to rule out active TB; \\npatients who screen pos itive (presumptive TB cases) must complete definitive diagnostic', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 172}),\n",
       " Document(page_content='patients who screen pos itive (presumptive TB cases) must complete definitive diagnostic \\npathways (Figure 8.1 and Table 8.1) and patients who screen negative should be evaluated for \\nTB preventive therapy (TPT).  \\nActive Case Finding (ACF) differs from ICF. ICF refers to TB screenin g among PLHIV, whereas \\nActive TB case finding (ACF) refers to special efforts made by the NTP or other partners that go \\nbeyond passive TB case finding at health facilities, in which communities or population groups \\nthat are underserved or at higher risk of  TB are actively reached for providing access to care, \\nincluding screening and testing', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 172}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n8 - 2      Intensified Case Finding Screening Questions       \\n●  If “Yes” to any question, take a detailed history, examine the patient and do sputum examination \\n(sputum smear or GeneXpert)  \\n● If “No” to questions 1 -5 above, consider TPT eligibility and work up for TB Preventive Therapy and \\nrepeat screening on subsequent visits  \\n● Questions 5 and 6 do not apply to adults  \\nThe following are the intensified case finding screening questions:  \\n● Cough of any duration (Y/N)  \\n● Fever (Y/N)  \\n● Noticeable weight loss/ Failure to thrive/ Poor weight gain (Y/N)  \\n● Night sweats (Y/N)  \\n● Reduced playfulness/ Lethargy/ Irritability (Y/N)  \\n● Contact with a TB case (Y/ N)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 173}),\n",
       " Document(page_content='TB/HIV Co -infection, Prevention and Management  \\n \\n8 - 3 \\n \\nIf yes, to any of the signs and symptoms above the patient requires a clinical review If no to all the signs and symptoms above\\nTake a comprehensive history and thorough examination. Decide on classification as a presumptive TB case\\nIs the client/patient a presumptive TB case?\\nIs a sample available for TB testing? • Evaluate and manage for other conditions\\n• Consider TB preventive therapy (TPT) as per LTBI guidelines\\nIs the GeneXpert available on site?\\n• Consider a CXR3\\n• Consider clinical \\ndiagnosis of TB\\nIs smear microscopy available on site?\\n• Obtain a sample1 for GeneXpert\\n• TB LAM should be considered for \\neligible PLHIV2\\no Positive TB LAM test – initiate \\nDS TB treatment. Review once \\nGeneXpert results received', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 174}),\n",
       " Document(page_content='• TB LAM should be considered for \\neligible PLHIV2\\no Positive TB LAM test – initiate \\nDS TB treatment. Review once \\nGeneXpert results received\\no NB: A negative TB LAM test \\ndoes not rule out TB• If yes, collect 2 samples; one for smear microscopy and an additional sample for \\nGeneXpert\\n• If smear microscopy is positive, start DS TB treatment and review the patient once \\nGeneXpert results as received\\n• TB LAM should be considered for eligible PLHIV2\\no Positive TB LAM test – initiate DS TB treatment. Evaluate once GeneXpert results \\nreceived\\no NB: A negative TB LAM test does not rule out TB• If not available, collect and refer sample for \\nGeneXpert\\n• TB LAM should be considered for eligible PLHIV2\\n• Positive TB LAM test – initiate DS TB treatment. \\nEvaluate once GeneXpert results received', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 174}),\n",
       " Document(page_content='• TB LAM should be considered for eligible PLHIV2\\n• Positive TB LAM test – initiate DS TB treatment. \\nEvaluate once GeneXpert results received\\n• NB: A negative TB LAM test does not rule out TB\\nGene Xpert ResultsDoes the client have any of the following symptoms?\\n4. Unintended weight loss\\n5. Chest Pain\\n6. BMI less than 18.5 or Z score   -21. Cough of any duration\\n2. Hotness of Body\\n3. Drenching night sweats\\nYES NOYES NOYES NOYES NOYES NOis the initial  test  for TB a has no smear  \\nSHOULD  BE USED  as sample  is & for \\nTB LAM  should  be used  among  PLHIV  as per TB LAM  SHOULD  be used  as an to', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 174}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n8 - 4 \\nMTB Detected\\nRifampicin Resistance Detected \\n(RR)MTB Detected\\nRifampicin Resistance not \\nDetected (TR)MTB not Detected \\n(N)MTB Detected 1\\nRifampicin Resistance \\ninditerminate (TI)MTB \\nDetected \\nTrace4Invalid/\\nError\\n1. Collect another \\nsample and repeat \\nGeneXpert test.\\n2. Treat as per the \\nrepeat results1. Collect a sample for FL & SL LPA, \\nculture and 1st and 2nd line DST\\n2. Conduct baseline work up on DR \\nTB treatment\\n3. Comprehensive review by a DR \\nTB clinical review team.\\n4. Start DR TB treatment as per the \\nguidelines.Patients at high risk of DR TB \\ngroups\\n1. Collect a sample of FL & SL \\nLPA, culture and 1st and 2nd \\nLine DST\\n2. Start DS TB treatment while \\nawaiting DST results.Patients at low  \\nrisk of DR TB \\ngroups', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 175}),\n",
       " Document(page_content='LPA, culture and 1st and 2nd \\nLine DST\\n2. Start DS TB treatment while \\nawaiting DST results.Patients at low  \\nrisk of DR TB \\ngroups\\n1. Start DS TB \\ntreatments.• If already on TB treatment (smear \\npositive, TB LAM positive), continue until \\nother diagnostic test results received and \\nreviewed even if MTB Not Detected\\n• NTM is likely if smear microscopy was \\npositive, and MTB not detected on \\nGeneXpert\\n- Send a sample for culture for definitive \\ndiagnosis of NTM\\n- Continue with TB treatment until \\nculture results received and reviewed\\n• Evaluate for other respiratory illnesses \\ne.g. asthma, pneumonias, COPD, \\nbronchiectasis and cancer as other \\npossible conditions\\n• Obtain a CXR and review with CXR3 report \\nand treat for TB as applicable\\n• Consider EPTB', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 175}),\n",
       " Document(page_content='bronchiectasis and cancer as other \\npossible conditions\\n• Obtain a CXR and review with CXR3 report \\nand treat for TB as applicable\\n• Consider EPTB\\n• Refer for further evaluation when a \\ndefinitive diagnosis is yet to be found\\n• Consider repeat GeneXpert1. Treat as DS TB\\n2. Immediately \\ncollect another \\nsample and \\nrepeat GeneXpert \\n(Ultra) test\\n3. Collect a sample \\nfor FL & SL LPA, \\nculture and 1st \\nand 2nd line DST\\n4. Revise regimen \\nbased on DST \\nresults.Based on DST results, DR \\nTB clinical team to adjust \\nregimen as necessary.Revised treatment based on DST \\nresults Follow up as per guidelines\\n• Follow up as per DR TB treatment \\nguidelines\\n• Mandatory clinical review meetings \\nfor Patients\\n• Monthly smears and cultures are \\nmandatory during the treatment \\nduration.Follow up:', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 175}),\n",
       " Document(page_content='guidelines\\n• Mandatory clinical review meetings \\nfor Patients\\n• Monthly smears and cultures are \\nmandatory during the treatment \\nduration.Follow up:\\n1. Clinical improvement assessment\\n2. Smear microscopy at months 2/3,5,6\\n3. If drug resistance is detected, treat \\nfor DR TB as per guidelines.DR TB DS TBGene Xpert Results', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 175}),\n",
       " Document(page_content='TB/HIV Co -infection, Prevention and Management  \\n \\n8 - 5 \\n \\nFootnotes\\n1 Samples for GeneXpert, sputum, CSF, Pleural aspirate, \\nPeriloneal fluid, synovial fluid, Gastric Aspirate, \\nNasopharyngeal aspirate, FNA, Lymph node biopsy, Pus, \\nstool\\n2 Indications for use of TB -LAM, as an adjunct test to \\nGeneXpert:\\n• PLHIV with advanced disease (WHO stage 3 or 4 or \\nCD4 count  200 cells/mm3 (or 25% for children \\n 5years old) with presumed TB\\n• PLHIV that have any danger signs of severe illness: \\nrespiratory rate ˃30breaths per minute, \\ntemperature ˃39°C, heart rate˃120beats per minute, \\nunable to walk unaided\\n• Currently admitted to hospital\\n3 All CHEST X -rays should be reported and the reports \\nreviewed by the clinician for definitive management. \\nRefer to the CXR algorithm for TB diagnosis', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 176}),\n",
       " Document(page_content='reviewed by the clinician for definitive management. \\nRefer to the CXR algorithm for TB diagnosis\\n4 MTB detected Trace – Results from sample with few \\nbacilli (paucibacillary TB).  Rifampicin resistance status.\\nHIV Testing, using the HTS algorithm 1, is \\nrecommended during TB screening and diagnosis.\\nScreening for diabetes is recommended among all \\nadult patients with TB disease\\nKey\\nCBR - Chest X -ray\\nDR TB - Drug Resistant TB\\nDS TB - Drug Susceptible TB\\nDST - Drug Susceptibility \\nTesting\\nEPTB   - Extra Pulmonary TB\\nFL - First LineLPA Line Probe Assay\\nMTB Mycobacteria \\nTuberculosis\\nNTM Non -Tuberculous \\nMycobacteria\\nTST Tuberculin Skin test\\nSL Second lineDR TB risk classification among \\npatients\\nHigh risk for DR TB*\\n1. All previously treated TB \\npatients: treatment failures,', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 176}),\n",
       " Document(page_content='SL Second lineDR TB risk classification among \\npatients\\nHigh risk for DR TB*\\n1. All previously treated TB \\npatients: treatment failures, \\nrelapses, treatment after loss to \\nfollow up\\n2. Contacts  of Drug Resistant TB \\npatients\\n3. TB patients with a positive \\nsmear result at month 2 or \\nmonth 5 of TB treatment\\n4. Patient who develops TB \\nsymptoms while on IPT or has \\nhad previous IPT exposure\\n5. Healthcare workers with 18 \\nsymptoms\\n6. Prisoners with TB symptoms\\n7. Refugees with TB symptoms\\nLow risk for DR TB\\nAll presumptive TB cases who are \\nNOT  in the high risk group\\n*ALL the high risk patients MUST  \\nbe prioritized to receive DST, \\nGeneXpert, FL and SL LPA, \\nculture and FL and SL DST.DS TB follow up and DR TB surveillance\\nPOSITIVE SMEAR \\nRESULT ATAction', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 176}),\n",
       " Document(page_content='GeneXpert, FL and SL LPA, \\nculture and FL and SL DST.DS TB follow up and DR TB surveillance\\nPOSITIVE SMEAR \\nRESULT ATAction\\nMonth 2/3 • Evaluate for adherence, and other causes of delayed conversion\\n• Request for all the following drug susceptibility tests (DST); GeneXpert, FL, LPA and \\nSL, LPA, Culture and FL and SL DST\\n• Continue with RHZE for one more month, or longer if DST results not received by then\\n• Adjust treatment regimen based on DST results\\n• Repeat smear microscopy at end of month 3. If smear positive continue with RHZE and \\nreview DST results and inform the SCTLC immediately\\n• Do not proceed to the continuation phase (RH) without a DST result confirming \\nsusceptibility to RH (rifampicin and isoniazid)\\nMonth 5 or', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 176}),\n",
       " Document(page_content='• Do not proceed to the continuation phase (RH) without a DST result confirming \\nsusceptibility to RH (rifampicin and isoniazid)\\nMonth 5 or \\nMonth 6• Declare treatment failure and stop anti -TB treatment\\n• Review by the sub county and county TB clinical review teams\\n• Evaluate for adherence, other causes of delayed conversion and treatment failure\\n• Request for GeneXpert, FL LPA and SL LPA, culture and FL and SL DST\\n• Review DST results and re -initiate treatment based on DST results and other clinical \\nfindings\\nDS TB follow up and DR TB surveillance\\nSmear Positive or \\nculture positive \\nat months 3 or \\nlater• Evaluate for adherence, and  other causes of delay conversion\\n• Request for the following drug susceptibility tests (DSTI) (GeneXpert, Culture and', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 176}),\n",
       " Document(page_content='• Request for the following drug susceptibility tests (DSTI) (GeneXpert, Culture and \\nFirst Line (FL) and SL DST, FL LPA and SL LPA) depending on the initial resistance \\npattern\\no Review by the sub county and county clinical review teams\\n▪ Evaluate for adherence, other causes of reversion and treatment failure\\n▪ Review the DST results\\no Declare failure if at the end of the extended intensive phase  (refer to DR TB \\nguidelines)\\no Send a case summary to the national clinical team after review by the county clinical \\nteam\\n• Do not proceed to the continuation phase (depending on treatment regimen) without a \\nDST result\\n• Declare treatment failure\\no Review by the sub county and county clinical review teams\\n▪ Evaluate for adherence, other causes of reversion and treatment failure', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 176}),\n",
       " Document(page_content='o Review by the sub county and county clinical review teams\\n▪ Evaluate for adherence, other causes of reversion and treatment failure\\n▪ Review the DST results\\n• Send a case summary to the national clinical team after review by the county clinical \\nteamMOH/DNTLDP/TBSDXALG/01\\nSeptember 2020Smear Positive \\nsmears and/or \\ncultures during \\ncontinuation \\nphase \\nFigure 8.1: TB diagnosis - GeneXpert Ultra algorithm', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 176}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 8 - 6 Table 8.1: TB Diagnosis in Children <10 Years Old  \\nALGORITHM FOR PULMONARY TB DIAGNOSIS IN CHILDREN  \\nHistory of \\npresenting \\nillness  For all children presenting to a health facility ask for the following suggestive \\nsymptoms  \\n● Cough  \\n● Fever  \\n● Poor weight gain  \\n● Lethargy or reduced playfulness  \\nSuspect TB if the child has two or more of these suggestive symptoms  \\nAsk for history of contact with adult/adolescent with chronic cough or TB within the \\nlast 2 years  \\nClinical \\nevaluation  Examine the child and check for:  \\n● Temperature > 37.5o (fever)  \\n● Weight (to confirm poor weight gain, weight loss) – check growth monitoring \\ncurve)  \\n● Respiratory rate (fast breathing)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 177}),\n",
       " Document(page_content='● Weight (to confirm poor weight gain, weight loss) – check growth monitoring \\ncurve)  \\n● Respiratory rate (fast breathing)  \\n● Respiratory system examination – any abnormal findings  \\nExamine other systems for abnormal signs suggestive of extra -pulmonary TB#  \\nInvesti gation\\ns Obtain specimen’ for Xpert MTB/RIF (and culture when indicated**)  \\nDo a chest Xray (where available)  \\nDo a Mantoux test** (where available)  \\nDo a HIV test  \\nDo other tests to diagnose extra -pulmonary TB where suspected#  \\nDiagnosis  Bacteriologically  \\nConfirmed TB:  \\nDiagnosis if \\nspecimen is \\npositive for MTB  Clinical Diagnosis of PTB:  \\nChild has two or more of the following suggestive symptoms  \\n● Persistent cough, fever, poor weight gain, lethargy  \\nPLUS, two or more of the following:', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 177}),\n",
       " Document(page_content='● Persistent cough, fever, poor weight gain, lethargy  \\nPLUS, two or more of the following:  \\n● Positive contact, abnormal respiratory signs, abnormal, \\npositive Mantoux  \\nNote: If the child has clinical signs suggestive of EPTB, refer to \\nEPTB diagnostic table*  \\nTreatment  Treat for TB as follows:  \\n● All children with bacteriologically confirmed TB \\n● All children with a clinical diagnosis of TB  \\nNB: In children who do not have an Xpert result, or their Xpert results is negative, but \\nthey have clinical signs and symptoms suggestive of TB they should be treated for TB  \\nAll forms of TB (Except TB meningitis, bone and joint TB) Treat for 6 months (2 RH ZE/ \\n4 RH)  \\nTB meningitis, bone and joint TB: Treat for 12 months ( 2 RHZE/ 10 RH)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 177}),\n",
       " Document(page_content='4 RH)  \\nTB meningitis, bone and joint TB: Treat for 12 months ( 2 RHZE/ 10 RH)  \\n*Specimen may include: Expectorated sputum (child > 5 years), induced sputum, nasopharyngeal \\naspirate and gastric aspirate. Attempt to obtain specimen in every child  \\n**Do a cultu re and DST for the following children:  \\n1. Rifampicin resistance detected by the Xpert test  \\n2. Refugees and children in contact with anyone who has Drug Resistant TB  \\n3. Those not responding to TB treatment  \\n4. Those with indeterminate Xpert results  \\n***This may include IGRA in facilities where it is available  \\n#Use IMCI guidelines to classify severity of disease', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 177}),\n",
       " Document(page_content='TB/HIV Co -infection, Prevention and Management  \\n \\n8 - 7 \\n Table 8.2: Drug Susceptible TB Treatment Regimen for Children, Adolescents and Adults  \\nTB disease category  Recommended regimen  \\nIntensive phase        Continuation phase  \\nAll forms of TB except TB meningitis, bone \\nand joint TB (osteoarticular TB)  2 RHZE  4 RH  \\nTB meningitis   \\nOsteoarticular TB  2 RHZE  10 RH  \\nDrug resistant TB  Refer to a DRTB Clinical Team  \\n● Follow up smears should be done for all bacteriologically confirmed pulmonary TB cases at end of \\nmonth 2, 5 and 6 of TB treatment using smear microscopy  \\n● Follow up of RR TB and DR TB should be done as per PMDT guidelines  \\n● Patients taking isoniazid containing regimen should also be given Pyridoxine (Vitamin B6) daily for', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 178}),\n",
       " Document(page_content='● Patients taking isoniazid containing regimen should also be given Pyridoxine (Vitamin B6) daily for \\nthe duration of treatment to reduce the risk of developing peripheral neuropathy (see Annex 10 for \\npyridoxine dosing)  \\nOnce TB treatment is started it should be completed; unless another definitive diagnosis (like lung \\ncancer) is established and TB is ruled out.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 178}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 8 - 8  \\nTB-LAM is a rapid point -of-care urine dip -stick test that can be performed at the bedside. LAM stands for \\nlipoarabinomannan, which  can be detected in urine when it sheds off of the TB  cell wall . \\nGeneXpert is the recommended initial diagnostic test for people with presumptive TB.\\nTB-LAM SHOULD NOT be used as an alternative test to GeneXpert, but can be performed  to help diagnose TB while \\nwaiting for GeneXpert test results. TB -LAM cannot detect resistance to rifampicin.\\nIndications for use of TB -LAM, as an adjunct test to GeneXpert:\\n• PLHIV with advanced disease (WHO stage 3 or 4 or CD4 count       cells/mm3 (or       for children     \\nyears old)) with presumed TB', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 179}),\n",
       " Document(page_content='• PLHIV with advanced disease (WHO stage 3 or 4 or CD4 count       cells/mm3 (or       for children     \\nyears old)) with presumed TB \\n• PLHIV that have any danger signs of severe illness: respiratory rate >30 breaths per minute, temperature >39°C, \\nheart rate >120 beats per minute, unable to walk unaided\\n• Currently admitted to hospital \\nLF-LAM Negative LF-LAM Positive\\nTB is not ruled out \\n• Evaluate the clinical response after 3–5 days of \\nantibiotic treatment, while awaiting GeneXpert \\nresultsTB is likely\\n• Initiate TB treatment\\n• Conduct additional investigations for TB \\nand other HIV related diseases as \\nappropriate\\n• Continue TB treatment even if GeneXpert \\nresults come back negative\\nClinical improvementClinical worsening or no \\nimprovement\\nTB is unlikely', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 179}),\n",
       " Document(page_content='• Continue TB treatment even if GeneXpert \\nresults come back negative\\nClinical improvementClinical worsening or no \\nimprovement\\nTB is unlikely\\n• Conduct additional investigations for TB and \\nother opportunistic illnesses\\n• Complete the course of parenteral antibiotics\\nNote: \\n• If GeneXpert results are positive for TB, \\ninitiate TB treatment irrespective of TB -LAM \\nresults or clinical improvement \\n• If GeneXpert results are negative for TB, \\nconsider TPTTB is likely\\n• Start TB treatment if patient is seriously \\nill or if GeneXpert results come back \\npositive (irrespective of TB -LAM results)\\n• Conduct additional investigations for TB \\nand other HIV -related diseases\\n• Complete the course of parenteral \\nantibiotics\\n \\nFigure 8.2: Use of TB-LAM for Diagnosis of TB among PLHIV', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 179}),\n",
       " Document(page_content='TB/HIV Co -infection, Prevention and Management  \\n \\n8 - 9 8.2. TB Preventive Therapy (TPT)  \\nThis section summarizes the current national recommendations for treatment of latent TB \\ninfections (LTBI) in the PLHIV population. These are in line with the updated World Health \\nOrganization guidelines which include the use of shorter, safer LTBI treatment options for an \\nexpanded at -risk population. For further guidance, refer to the national guidelines on LTBI \\nmanagement.  \\n8.2.1. Indications for TPT  \\nTPT should be provided to those p atients in whom TB is excluded (using the ICF tool) and meet \\nthe eligibility criteria to initiate TPT. The following client categories are eligible for TPT who \\nscreen negative for active TB', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 180}),\n",
       " Document(page_content='the eligibility criteria to initiate TPT. The following client categories are eligible for TPT who \\nscreen negative for active TB  \\n● All PLHIV above 12 months of age (children, adolescents and adults  including pregnant \\nand breastfeeding women)  \\n● All household contacts of persons with bacteriologically confirmed pulmonary TB            \\n● Prisoners and staff working in prison setting            \\n● Health care workers and other staff in health care setting  \\n● Other clinical risk groups as defined in LTBI guidelines  \\n*Neonates born to mothers with TB, or exposed to close contacts with TB should be given TPT \\nonce TB disease has been ruled out. BCG should be given 2 weeks after completion of TPT or anti -\\nTB treatment  \\nSummary of recommendations for TPT among the PLHIV', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 180}),\n",
       " Document(page_content='TB treatment  \\nSummary of recommendations for TPT among the PLHIV  \\n● PLHIV are at a much higher risk of getting TB disease compared to the general population  \\n● TB preventive therapy should be given to all PLHIV above 12 months of age who do not \\nhave active TB disease. This should be done irrespective of immune status, ART status, \\nprevious history of TB and pregnancy status.  \\n● Children aged <12 months living with HIV who are household contacts of a person with \\nbacteriologically confirmed pulmonary TB, and whom act ive TB has been ruled out \\nshould receive TB preventive therapy.  \\n● TPT may be given immediately following successful completion of TB treatment among \\nthe PLHIV.  \\n● Repeat TPT is not recommended among PLHIV except if a PLHIV becomes a', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 180}),\n",
       " Document(page_content='the PLHIV.  \\n● Repeat TPT is not recommended among PLHIV except if a PLHIV becomes a \\nhousehold contact of a perso n with bacteriologically confirmed pulmonary TB  \\n● PLHIV aged 15 years and above should be provided with 3 months of weekly Rifapentine \\nand Isoniazid (3HP), while those less than 15 years are given 6 months of daily INH (6H)  \\n● In PLHIV on PI/r -based ART, pregna nt women and those who do not tolerate 3HP should \\nbe given six months of daily INH (6H)  \\n● For eligible patients previously treated for TB, initiate TPT upon completion of their TB \\ntreatment.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 180}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 8 - 10 8.2.2. Contraindications to TPT  \\nPatients with the following should not receive TPT until the underlying issue(s) are \\naddressed  \\n● Active tuberculosis disease  \\n● Active hepatitis (acute or chronic)  \\n● Chronic alcohol abuse      \\n● Symptoms of peripheral neuropathy  \\n \\n8.2.3. Dose and Duration of TPT  \\nTable 8.3: Recommended TPT Regimens for PLHIV  \\nTarget populations  TPT Regimen  \\n● Adult PLHIV excluding patients \\non PI/r -based ARV regimens  Rifapentine and Isoniazid (3HP)  \\nOnce weekly for three months  \\n          (12 doses)  \\n● Adult PLHIV on PI/r -based ARV \\nregimens  \\n● All CALHIV aged below 15 years  \\n● Any patient with intolerance or \\ncontraindication to 3HP  \\n● Pregnant women  Isoniazid (6H)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 181}),\n",
       " Document(page_content='regimens  \\n● All CALHIV aged below 15 years  \\n● Any patient with intolerance or \\ncontraindication to 3HP  \\n● Pregnant women  Isoniazid (6H)  \\nOnce daily for 6 months  \\n● The 3RH (rifampicin and isoniazid) regimen is not recommended for PLHIV due \\nto drug - drug interactions  \\n● All TPT regimens should be given with Vitamin B6 (pyridoxine), if available, to \\nreduce the risk of developing peripheral neuropathy  \\n● Comprehensive health  education and adherence counselling should be \\nconducted prior to initiation of TPT  \\n● Dosing of TPT is in Annex 10  \\n \\n● Children should be weighed at each visit and correct weight -based dosing confirmed.  \\n● Clients on 3HP should receive weekly dose of pyridoxine, Those on Rifapentine and \\nIsoniazid regimen should be given pyridoxine once a week', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 181}),\n",
       " Document(page_content='● Clients on 3HP should receive weekly dose of pyridoxine, Those on Rifapentine and \\nIsoniazid regimen should be given pyridoxine once a week  \\n● The 3RH (rifampicin and isoniazid) regimen is not recommended for PLHIV due \\nto drug -drug interactions. 3RH is used in HIV negative populations', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 181}),\n",
       " Document(page_content='TB/HIV Co -infection, Prevention and Management  \\n \\n8 - 11 8.2.4. Follow -up of Patients on TPT  \\nPatients on TPT should be followed up on a monthly basis and their return -to-clinic dates \\nharmonized with any other routine schedules. During each clinic visit, conduct the following;  \\n● Symptom screening for active TB disease and update status  \\n● Assess and reinforce adherence to treatment  \\n● If a patient screens positive for TB while on TPT, stop TPT and manage according to \\nNational TB guidelines  \\n● Assess for any adverse drug reactions at each visit and intervene appropriately  \\n● Provide/update TPT appointment card  \\n● Document and update the relevant recording and reporting tools, e.g., ICF/TPT cards, \\nContact Management/TPT register', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 182}),\n",
       " Document(page_content='● Document and update the relevant recording and reporting tools, e.g., ICF/TPT cards, \\nContact Management/TPT register  \\n● Document outcome of TPT use e.g., completion in the relevant tools and/or EMR  \\n*Baseline liver function tests are not mandatory for patients initiating TPT. These may, however, be \\nconsidered on an individual ba sis, especially for patients taking other medications for chronic \\nmedical conditions or symptomatic patients suspected to have active hepatitis  \\n \\n8.3. Identifying and Managing Drug Toxicities from TPT  \\nThe management of drug toxicities should be based on severity, with appropriate grading of \\nindividual patients. The most common adverse drug reactions associated with TPT are peripheral \\nneuropathy, drug -induced liver injury (DILI), and rash.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 182}),\n",
       " Document(page_content='neuropathy, drug -induced liver injury (DILI), and rash.  \\n8.3.1 Periphe ral Neuropathy - Suspected drug: INH        \\nDiagnosis of Peripheral Neuropathy  \\n● Symptoms include: burning sensation, numbness, or tingling, usually starting at the feet \\non both sides  \\n● May have decreased sensation on examination  \\n● May develop weakness in severe cases  \\n● May be potentiated by other neurotoxic drugs, alcoholism, metabolic disease (e.g., \\ndiabetes), malnutrition and infections  \\n● Rarely severe enough to require drug withdrawal  \\nManagement of INH -induced Peripheral Neuropathy  \\n● Increase the dose of pyridoxine to 100 mg per day  \\n● For children give double the standard weight -based dose  \\n● Assess for other causes of peripheral neuropathy (e.g., diabetes, thyroid disorder, B12', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 182}),\n",
       " Document(page_content='● Assess for other causes of peripheral neuropathy (e.g., diabetes, thyroid disorder, B12 \\ndeficiency, syphilis, etc.)  \\n● Relief of symptoms can be achieved with analgesics, tricyclic antidepressants \\n(amitriptyline, nortriptyline), anticonvulsants (carbamazepine, phenytoin)  \\n● If symptoms do not improve, or there is any worsening, then discontinue TPT; symptoms \\nmay persist even  after discontinuing TPT', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 182}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 8 - 12 8.3.2 Drug -Induced Liver Injury (DILI) -Suspected drugs include Isoniazid (H), \\nRifapentine (P), Rifampicin (R)  \\n● Elevation of liver enzymes may occur in the first weeks of treatment  \\n● In asymptomatic patients, serum liver enzyme lev els do not need to be monitored \\nroutinely   \\n● All clients with gastrointestinal symptoms (nausea and vomiting, liver tenderness, \\nhepatomegaly or jaundice) should have their liver function assessed  \\n● Patients should be screened for other causes of liver injury  (the hepatitis viruses -A, B, C)  \\n● Table 8.4 shows the grading of liver injury and management of DILI  \\n● Once the drugs are discontinued, no attempt should be made to reintroduce these drugs', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 183}),\n",
       " Document(page_content='● Once the drugs are discontinued, no attempt should be made to reintroduce these drugs \\nuntil liver functions have normalized  \\n● An expert with experience in managing DILI should be involved in the further \\nmanagement of such cases  \\nDiagnosis of DILI  \\n● Jaundice, a bdominal pain, nausea, vomiting, anorexia, etc.  \\n● Abnormal liver enzymes  \\n \\nTable 8.4: Grading and Management of DILI  \\n Grade 1: Mild  Grade 2: Moderate  Grade 3: Severe  Grade 4: Life \\nthreatening  \\nALT (SGPT)  1.25 – 2.5 x ULN  2.6 – 5.0 x ULN  5.1 – 10.0 x ULN  > 10.0 x ULN  \\nAST (SGOT)  1.25 – 2.5 x ULN  2.6 – 5.0 x ULN  5.1 – 10.0 x ULN  > 10.0 x ULN  \\n  \\n  \\n  \\nACTION  Continue treatment \\nregimen;  \\npatients should have \\nweekly followed up \\nuntil resolution \\n(return to baseline) \\nor stabilization of', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 183}),\n",
       " Document(page_content='ACTION  Continue treatment \\nregimen;  \\npatients should have \\nweekly followed up \\nuntil resolution \\n(return to baseline) \\nor stabilization of \\nAST/ALT elevation  Continue treatment \\nregimen;  \\npatients should have \\nweekly followed up \\nuntil resolution \\n(return to baseline) \\nor stabilization of \\nAST/ALT elevation  Stop all drugs, \\nincluding TPT \\ndrugs;  \\nmeasure LFTs \\nweekly;  \\nTPT should not  \\nbe reintroduced \\nafter severe DILI1 Stop all drugs, \\nincluding TPT drugs;  \\nmeasure LFTs weekly. \\nTPT should not  be \\nreintroduced after life \\nthreatening DILI1 \\n \\n \\n1. PLHIV who develop DILI during treatment of active TB disease, may have anti -TBs reintroduced \\nafter toxicity is resolved in consultation with a senior clinician', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 183}),\n",
       " Document(page_content='TB/HIV Co -infection, Prevention and Management  \\n \\n8 - 13 8.3.3 Management of TPT -associated Rash - Suspected Drugs include Isoniazid (H), \\nRifapentin e (P), Rifampicin (R)  \\n● A rash may occasionally develop, usually within a few days following initiation of TPT. It \\nis often a relatively mild maculopapular rash with or without pruritus.  \\n● Flu-like and other systemic hypersensitivity reactions are rare amongst children. \\nHypersensitivity reactions in adults are usually mild and self -limiting  \\n● Rarely, rash may develop with severe exfoliation of the skin and Stevens -Johnson \\nsyndrome  \\n● Rash severity should be assessed and managed appropriately as shown in table  8.5  \\n \\nTable 8.5: Management of TPT -Associated Skin Rash  \\nSeverity  Characteristics  Action', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 184}),\n",
       " Document(page_content='Table 8.5: Management of TPT -Associated Skin Rash  \\nSeverity  Characteristics  Action  \\nMild  Dry; erythema +/ - fine \\npapules; pruritus; affecting \\n< 50% of body surface area  Continue TPT; close monitoring; symptomatic \\ntreatment with antihistamines +/ - topical steroids \\n(NOT oral steroids)  \\nModerate  Dry; erythema +/ - fine \\npapules; pruritus; affecting \\n≥ 50% of body surface area  Stop TPT; symptomatic treatment with \\nantihistamines +/ - topical steroids (NOT oral \\nsteroids); trial of desensitization after symptoms \\ncompletely resolved  \\nSevere  Mucosal involvement;  \\nblistering; associated \\nfever; any % of body \\nsurface area  Stop TPT; admission to hospital for supportive \\nmanagement (IV fluids, wound care, pain control, \\ninfection control, monitoring for super -infection);', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 184}),\n",
       " Document(page_content='management (IV fluids, wound care, pain control, \\ninfection control, monitoring for super -infection); \\npatient should NEVER be re -challenged;  \\ndocument and report adverse event and issue \\npatient alert card  \\n \\n8.4. ART for TB/HIV Co -infection  \\nAs with all PLHIV, those who are diagnosed with TB/HIV co -infection should be on ART and CPT \\nas part of the comprehensive package of care for PLHIV.  \\nTiming of ART for TB/HIV Co -infection  \\n● Patients who are not yet on ART  \\no Start TB treatment immediately  \\no Initiate ART as soon as anti -TB medications are tolerated, preferably within 2 \\nweeks  \\no For TB meningitis delay ART for 4 to 8 weeks  \\no Monitor closely for IRIS (Annex 16)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 184}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 8 - 14 ● Patients who are already on ART  \\no Start TB treatment immedi ately  \\no Continue ART, assessing for treatment failure and making any required \\nadjustments to the ART regimen based on drug -drug interactions (Table 8.7)  \\no Monitor closely for IRIS (Annex 16)  \\n● Patient being treated concurrently for TB and HIV require close monitoring for \\ntoxicity  \\n● MDR TB and HIV co -infection should be managed in settings where close toxicity \\nmonitoring and follow up by experienced clinicians or multi -disciplinary team is \\npossible       \\nPreferred ART regimens for patients with TB/HIV co -infecti on are summarized in Tables 8.6 - 8.8. \\nTable 8.6: Preferred ART Regimens for TB/HIV Co -infection for Patients Newly Initiating 1st', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 185}),\n",
       " Document(page_content='Table 8.6: Preferred ART Regimens for TB/HIV Co -infection for Patients Newly Initiating 1st \\nLine ART 1 \\nAge  Weight  1st Line ART if TB/HIV Co -infection  \\nBirth to 4 \\nweeks  Any  Start anti -TB treatment immediately; start ART after 4 weeks \\nof age, once tolerating anti -TB drugs (follow the regimen \\nrecommendations for children ≥ 4 weeks old)  \\n> 4 weeks to < \\n15 years  < 30 kg  ● ABC + 3TC + DTG  \\n● Increase DTG dosing frequency to twice daily for duration \\nof rifampicin -containing TB treatment and for an additional \\n2 weeks after TB treatment is completed, then revert to \\nonce daily dosing  \\n≥ 30 kg  ● Give TDF/3TC/DTG FDC morning + DTG 50mg evening for \\nduration of rifampicin -containing TB treatment and for an \\nadditional 2 weeks after TB treatment is completed, then', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 185}),\n",
       " Document(page_content='duration of rifampicin -containing TB treatment and for an \\nadditional 2 weeks after TB treatment is completed, then \\nrevert to TDF/3TC/DTG FDC once daily  \\n≥ 15 years  Any  ● Give TDF/3TC/DTG FDC morning + DTG 50mg evening for \\nduration of rifampicin -containing TB treatment and for an \\nadditional 2 weeks after TB treatmen t is completed, then \\nrevert to TDF/3TC/DTG FDC once daily  \\n1 Refer to Annex 10 for weight -based ARV dosing', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 185}),\n",
       " Document(page_content='TB/HIV Co -infection, Prevention and Management  \\n \\n8 - 15 Table 8.7: Preferred ART Regimens for Patients who Develop TB while Virally Suppressed on \\n1st Line ART 1,2 \\nCurrent \\nRegimen3  Recommended Substitution  \\nPI/r -based4 All ages  ● Switch from PI/r to DTG and continue this regimen even after \\ncompleting TB treatment. Follow DTG dosing as below  \\n● If it is not possible to switch to DTG:  \\no Children < 30 kg requiring PI/r -based ART should receive \\nLPV/r with additional ritonavir super -boosting for the duration \\nof rifampicin -based TB therapy, reverting to standard LPV/r \\ndosing 2 weeks after completing TB treatment  \\no Patients ≥ 30 kg who cannot switch to DTG should be switched \\nto EFV -based ART and maintained on EFV -based ART after \\ncompletion of TB treatment', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 186}),\n",
       " Document(page_content='to EFV -based ART and maintained on EFV -based ART after \\ncompletion of TB treatment  \\nRAL -based  All ages Switch from RAL to double -dose DTG dosing during TB treatment and \\nmaintain on DTG after completion of TB treatment  \\nDTG -based  All ages   \\nAdminister the double -dose of DTG (i.e., the standard weight -based \\ndose of DTG given twice daily) while taking rifampicin containing TB \\ntreatment. Two weeks after completion of TB treatment revert to the \\nrecommended DTG dose once daily.  \\n1 Always assess for HIV treatment failure in patients who develop TB after being on ART for ≥ 6 \\nmonths. For patients failing 1st line ART refer to Table 8.8 for recommended 2nd line regimens  \\n2 For patients on 2nd line ART, subsequent regimens, or nonstandard drugs who require regimen', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 186}),\n",
       " Document(page_content='2 For patients on 2nd line ART, subsequent regimens, or nonstandard drugs who require regimen \\nchange because of TB treatment, consult the Regional or National HIV Clinical TWG (Uliza Hotline \\n0726  460 000; https://nhcsc.nascop.org/clinicalform ) \\n3 NRTIs in the patient’s current regimen do not require any adjustments with anti -TB treatment  \\n4 Use “super -boosted” LPV/r by adding additional ritonavir to manage the drug interaction between \\nLPV/r and rifampicin (see Annex 10 for dosing recommendations)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 186}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 8 - 16 Table 8.8: Recommended ART Regimens for Patients who Develop TB while Failing 1st Line \\nART 1 \\nAge/  \\nScenario  First -line \\nART  Second -line ART  \\n< 30 kg \\nbody \\nweight  LPV/r -\\nbased 1st \\nline ● Start anti -TB immediately.  \\n● Change to DTG -based second -line immediately. Increase DTG dosing \\nfrequency to twice daily for duration of rifampicin -containing TB \\ntreatment and for an additional 2 weeks after TB treatment is completed, \\nthen revert to once daily dosin g  \\n● Immediately collect a sample for DRT2 \\n● Assess for and address reasons for treatment failure.  \\n● If unable to switch to DTG then use super -boosted LPV/r3 \\nABC (or \\nAZT) + \\n3TC + \\nDTG  ● Start anti -TB immediately', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 187}),\n",
       " Document(page_content='● If unable to switch to DTG then use super -boosted LPV/r3 \\nABC (or \\nAZT) + \\n3TC + \\nDTG  ● Start anti -TB immediately  \\n● Increase DTG dosing frequency to twice daily for duration of rifampicin -\\ncontaining TB treatment and for an additional 2 weeks after TB treatment \\nis completed, then revert to once daily dosing.  \\n● Follow the viral load monitoring algorithm (Figure 6.6), inclu ding \\nassessing for and addressing reasons for treatment failure, and collecting \\nDRT. Consult the Regional or National TWG to constitute a second -line \\nregimen based on DRT results  \\n≥ 30 kg or \\n≥ 15 years \\nold TDF (or \\nABC or \\nAZT) + 3TC \\n+ DTG  ● Start anti -TB immediately  \\n● Give TDF/3TC/DTG FDC morning + DTG 50mg evening for duration of', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 187}),\n",
       " Document(page_content='≥ 15 years \\nold TDF (or \\nABC or \\nAZT) + 3TC \\n+ DTG  ● Start anti -TB immediately  \\n● Give TDF/3TC/DTG FDC morning + DTG 50mg evening for duration of \\nrifampicin -containing TB treatment and for an additional 2 weeks after \\nTB treatment is completed, then revert to TDF/3TC/DTG FDC once daily  \\n● Follow the viral load monitoring algorithm (Figure 6.6), including \\nassessing for and addressing reasons for treatment failure, and collecting \\nDRT. Consult the Regional or National TWG to constitute a second -line \\nregimen based on DRT results  \\nTDF (or \\nABC or \\nAZT) + \\n3TC + EFV  ● Start anti -TB immediately  \\n● Continue current regimen while following the viral load monitoring \\nalgorithm (Figure 6.6), including assessing for and addressing reasons for \\ntreatment failure.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 187}),\n",
       " Document(page_content='algorithm (Figure 6.6), including assessing for and addressing reasons for \\ntreatment failure.  \\n● Once treatment failure is confirmed and patient ready to switch to 2nd \\nline, switch to TDF + 3TC + DTG (maintain the TDF, even if the patient was \\nalready on a TDF -containing regimen), increasing the DTG dose to twice \\ndaily for the duration of rifampicin -based TB therapy, switching back to \\nstandard DTG dose 2 weeks after rifampin is discontinued.  \\nPI/r -\\nbased 1st \\nline ● Start anti -TB immediately  \\n● Switch to TDF+3TC+DTG immediately. Give TDF/3TC/DTG FDC morning \\n+ DTG 50mg evening for duration of rifampicin -containing TB treatment \\nand for an additional 2 weeks after TB treatment is completed, then revert \\nto TDF/3TC/DTG FDC once daily  \\n● Immediately collect a sample for DRT2', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 187}),\n",
       " Document(page_content='and for an additional 2 weeks after TB treatment is completed, then revert \\nto TDF/3TC/DTG FDC once daily  \\n● Immediately collect a sample for DRT2  \\n● Assess for and address reasons for treatment failure.  \\nPregnant or \\nBreastfeeding  Follow the same recommendations as for ≥ 30 kg or ≥ 15 years old.   \\nHIV/HBV \\nCo-infection  Always maintain TDF or TAF in second -line instead of switching to a different NRTI and \\ninstead of adding an additional NRTI', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 187}),\n",
       " Document(page_content='TB/HIV Co -infection, Prevention and Management  \\n \\n8 - 17 Table 8.8 Cont.  \\n1. For patients on 2nd line ART, subsequent regimens, drug intolerance, or nonstandard drugs who require \\nregimen change because of TB treatment, consult the Regional or National HIV Clinical TWG (Uliza Hotline \\n0726 460 000; https://nhcsc.nascop.org/clinicalform ) \\n2. Contact  the Regional or National HIV Clinical TWG (Uliza Hotline 0726 460 000; \\nhttps://nhcsc.nascop.org/clinicalform ) for guidance on urgent collection of DRT samples  \\n3. Use “super -boosted” LPV/r by adding additional ritonavir to manage the drug interaction between LPV/r \\nand rifampicin (see Annex 10 for dosing recommendations). Two weeks after TB treatment is completed \\nthe child should go back to standard LPV/r dosing.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 188}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 8 - 18', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 189}),\n",
       " Document(page_content='TB/HIV Co -infection, Prevention and Management  \\n \\n9 - 1  \\n9. HBV/HIV and HCV/HIV Co -infection \\nPrevention and Management  \\n9.1 Hepatitis B/HIV Co -infection  \\nHIV and Hepatitis -B Virus (HBV) share infection transmission routes.  Acute HBV infection in HIV \\npositive people is associated with increased risk of chronicity, reduced chances of spontaneous \\nclearance, higher rates of replication and reactivation and therefore increased incidence of \\nchronic liver disease, cirrhosis and hep atocellular carcinoma (HCC). Additionally, HIV/HBV co -\\ninfection has been associated with rapid HIV disease progression and poorer HIV treatment \\noutcomes.  Other complications of HIV/HBV co -infection include increased incidence of drug -', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 190}),\n",
       " Document(page_content='outcomes.  Other complications of HIV/HBV co -infection include increased incidence of drug -\\nrelated hepatotoxicit y, drug -drug interactions and ART -related immune reconstitution hepatitis.  \\n9.1.1 Screening  \\nAll adolescents and adults living with HIV (plus children who did not complete routine childhood \\nimmunizations) should be screened for HBV infection, using HBsAg, as part of initial evaluation. \\nTo promote population -wide prevention, hepatitis B prevention should be integrated into \\nroutine HIV prevention and care programs. In this setting, other indications for HBsAg screening \\ncould include  \\n▪ Household and sexual contacts of HBsAg positive individuals  \\n▪ Pregnant women  \\n▪ Persons who inject drugs (PWID)  \\n▪ Men who have sex with men  \\n▪ Sex workers', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 190}),\n",
       " Document(page_content='▪ Pregnant women  \\n▪ Persons who inject drugs (PWID)  \\n▪ Men who have sex with men  \\n▪ Sex workers  \\n▪ Persons with multiple sexual partners  \\n▪ Prisoners  \\n▪ Blood donors  \\n▪ Unvaccinated healthcare providers  \\n \\nPLHIV on follow -up who presen t with signs of liver disease (jaundice, ascites, abnormal liver on \\npalpation, other signs of cirrhosis) or unexplained and persistent ALT elevation should also be \\nscreened for HBV as part of their work -up. \\n9.1.2 Prevention  \\nA. Vaccination : HBV vaccination reduces the risk of new (incident) HBV infection in PLHIV and \\nalso reduces the risk of new infections becoming chronic. Therefore;  \\n● HIV positive infants, children, adolescents and adults without evidence of hepatitis B', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 190}),\n",
       " Document(page_content='● HIV positive infants, children, adolescents and adults without evidence of hepatitis B \\ninfection (HBsAg negative)  should be vaccinated against hepatitis B (Table 9.1)  \\n● HIV exposed infants (HEI) should also receive hepatitis B vaccination as part of childhood \\nimmunization (Table 4.21)  \\n● As a strategy to reduce the population level burden of HBV infection, HIV prevention and \\ntreatment settings should integrate HBV prevention through vaccination. Thus, HBV \\nvaccination is recommended for the following groups who test HBsAg negative.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 190}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 9 - 2 o Babies and young children (through EPI and catch -up immunization for those who \\nmissed EPI vac cination)  \\no Household contacts of HBsAg positive people  \\no Sexual contacts of HBsAg positive people  \\no People on haemodialysis  \\no PWID  \\no Individuals with chronic liver disease and/or hepatitis C  \\no Inmates and prison personnel  \\no Healthcare workers  \\nTable 9.1: Hepatitis B Vaccination Schedule for HIV -positive Adolescents and Adults  \\nVaccine  Dose (intramuscular)  Schedule  \\nNon -adjuvanted formulation  Double the standard dose   \\n0, 1, 2, and 6 months  Adjuvanted formulation  Standard dose  \\n*Booster vaccination is not required for persons who have completed the full vaccination schedule', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 191}),\n",
       " Document(page_content='*Booster vaccination is not required for persons who have completed the full vaccination schedule  \\nB. General preventive measures:  General measures for infection prevention adopted by \\nPLHIV and in healthcare settings are effective in preventing HBV transmission. The se \\ninclude  \\n● Hand hygiene  \\n● Use of personal protective equipment  \\n● Medical waste management including safe disposal of used sharps  \\n● Disinfection and sterilization  \\n● General health advice against sharing of personal effects like towels, tooth -brushes, \\nrazors, combs and other grooming equipment  \\n● Harm reduction counselling and services for PWID as outlined in Chapter 12  \\n● Safer sex practices  \\n9.1.3 Treatment  \\nA. When to start ART', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 191}),\n",
       " Document(page_content='● Harm reduction counselling and services for PWID as outlined in Chapter 12  \\n● Safer sex practices  \\n9.1.3 Treatment  \\nA. When to start ART  \\nAll HIV infected patients who are co -infected with hepatitis B should be started on ART \\nirrespective of CD4 cell count, WHO clinical stage or stage of liver disease  \\n \\nThe general recommendations for treatment preparation, adherence counselling and support \\nand monitoring of therapy for PLHIV apply. However, because HBV positive patients are at higher \\nrisk of hepatotoxicity, closer monitoring of liver function (with ALT) is advised. Table 9.2 \\nprovides a summary of areas of focus during initial evaluation for HIV/HBV co -infected patients \\ninitiating therapy.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 191}),\n",
       " Document(page_content='TB/HIV Co -infection, Prevention and Management  \\n \\n9 - 3 B. Recommended first -line ART in HIV/HBV co -infection  \\nThe recommended first -line ART in adolescents and adults with HIV/HBV co -infection \\nis TDF + 3TC + DTG, including for women and adolescent girls of childbearing potential  \\n \\nTreatment with both TDF (or TAF) and 3TC is recommended as 3TC without TDF or TAF will \\nresult in rapid emergence of resistance. In case of renal impairment (as assessed by creatinine \\nclearance), the dose of TDF and 3TC should be adjusted (Table 9.3).  \\nTable 9.2: Summary of Initial Clinical and Labora tory Evaluation in HIV/HBV Co -infection  \\n Findings  Action  \\nHistory  Alcohol use, cigarette \\nsmoking, intravenous drug \\nuse, risky sexual practices, \\nanorexia, right upper', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 192}),\n",
       " Document(page_content='Findings  Action  \\nHistory  Alcohol use, cigarette \\nsmoking, intravenous drug \\nuse, risky sexual practices, \\nanorexia, right upper \\nquadrant pain, jaundice, early \\nsatiety, haematemesis, dark \\nstool, bleeding, pruritus  Assess, counsel and support to stop taking \\nalcohol; counsel and support smoking \\ncessation; counsel and provide or refer for \\nharm reduction interventions  \\ndiscuss or refer to a consultant for additional \\nevaluation and management  \\nPhysical \\nexamination  Enlarged liver, enlarged \\nspleen, ascites, scratch marks  Evidence of established chronic liver disease, \\ncloser follow -up due to increased risk of \\nhepatotoxicity.  \\ndiscuss or refer to a consultant for additional \\nevaluation and management  \\nALT  If elevated, may point to \\nactive liver disease. Exclude', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 192}),\n",
       " Document(page_content='discuss or refer to a consultant for additional \\nevaluation and management  \\nALT  If elevated, may point to \\nactive liver disease. Exclude \\nother causes of elevation of \\nliver enzymes  Every effort should be made to assess for \\nother liver function (albumin and INR), \\nespecially in symptomatic patients. However, \\nthis should not delay initiation of ART  \\nCreatinine  Calculate creatinine clearance  In HIV/HBV co -infection, TDF is indicated \\neven in patients with CrCl < 50 ml/min. In \\nsuch patients, avoid FDCs. Instead administer \\nthe ART as single drugs to allow for dosage \\nadjustment as shown in Table 9.3  \\nComorbidities  HCV antibody, random blood \\nsugar, lipid profile, alcoholic \\nand non -alcoholic liver \\ndisease, hepatocellular', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 192}),\n",
       " Document(page_content='Comorbidities  HCV antibody, random blood \\nsugar, lipid profile, alcoholic \\nand non -alcoholic liver \\ndisease, hepatocellular \\ncarcinoma (family history)  Consult/Refer the patient for additional \\ninvestigations where these are suspected', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 192}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 9 - 4 Table 9.3: Dose Adjustment of TDF and 3TC in Patients with Impaired Renal Function 1 \\nDrug  Creatinine clearance (ml/min)  Haemodialysis  \\n50 - 80 30-49 10-29 \\nTDF 33 mg/g \\ngranules  \\n(=1scoop)  245 mg (7.5 scoops of \\ngranules or 245mg \\nfilm -coated tablet) \\nonce daily  132 mg (4 \\nscoops of \\ngranules) once \\ndaily  65 mg (2 scoops \\nof granules once \\ndaily  16.5 mg (0.5 scoop) \\nafter each 4 hr session \\nof dialysis  \\n \\nTDF 300 mg  Unchanged: 300 mg \\nonce daily  300 mg every  \\n48 hrs  300 mg every 72 to 96 hours (twice \\nweekly). For patients getting hemodialysis, \\nadminister 300 mg once weekly after \\ncompletion of dialysis sessions 2 \\n3TC 300mg  Unchanged: 300 mg \\nonce daily or 150 mg \\nBD  150 mg once \\ndaily  150 mg once', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 193}),\n",
       " Document(page_content='completion of dialysis sessions 2 \\n3TC 300mg  Unchanged: 300 mg \\nonce daily or 150 mg \\nBD  150 mg once \\ndaily  150 mg once \\ndaily  50 mg first dose,  \\n25 mg once daily  \\n1 Patients with impaired renal function in whom the benefits of continued use of TDF outweighs the \\nrisks (such as in the management of HIV/HBV co -infection) should be managed with input from a \\nspecialist in internal/paediatric or renal medicine  \\n2 Assuming 3 haemodialysis sessions per week, each of approximately 4 hours duration or after 12 \\nhours cumulative haemodialysis  \\n \\nC. Follow -up/Monitoring  \\nFollow -up of HIV/HBV co -infected patients should be as for all other patients on ART. However, \\nconsider more frequent monitoring (using ALT) for patients with active liver disease (jaundice,', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 193}),\n",
       " Document(page_content='consider more frequent monitoring (using ALT) for patients with active liver disease (jaundice, \\nliver cirrhosis and features of portal hypertension) at baseline.  The presence of co -infection also \\nincreases the risk of drug -related hepatotoxicity from all classes of ARVs by 3 -5 times, especially \\nwhen anti -TB and ART are given simultaneously. Also, hepatic flare -up (AST > 5 times normal \\nvalue) can occur, often in th e initial 3 months.  \\nNote:  ALT elevations 5 -10 times normal can be tolerated in the first 3 months of ART as \\nlong as the patient is not severely symptomatic, remains stable without progression, and \\nthere is no evidence of synthetic dysfunction (INR normal,  glucose normal, albumin \\nnormal).', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 193}),\n",
       " Document(page_content='there is no evidence of synthetic dysfunction (INR normal,  glucose normal, albumin \\nnormal).  \\nPatients with persistently elevated ALT levels during follow -up should be referred to a \\nspecialist. Subsequent laboratory monitoring after baseline should be conducted every 6 \\nmonths. Patients should be counselled and supp orted to abstain from consuming alcohol.  \\nD. Stopping treatment, /treatment interruptions  \\nTDF -containing ART should not be stopped in a patient with HIV/HBV co -infection as this may \\nresult in a flare -up of the hepatitis. If the regimen must be stopped and another alternative for \\nsuppressing hepatitis B cannot be found, liver enzymes should be monitored and treatment re -\\ninstated as soon as possible.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 193}),\n",
       " Document(page_content='TB/HIV Co -infection, Prevention and Management  \\n \\n9 - 5 E. Second line for HIV/ HBV co -infected  \\nMaintain TDF + 3TC in the ART regimen for patients switc hing from TDF -based -therapy.  So, for \\nexample, if a patient with HIV/HBV co -infection fails TDF/3TC/EFV in first -line, they should \\nswitch to TDF/3TC/DTG in second -line.  \\nHIV/HBV co -infected patients failing second -line ART should be discussed in the MDT and  \\ndiscussed with the Regional or National HIV Clinical TWG (Uliza Hotline 0726 460 000.)  \\n9.2 Hepatitis C/HIV Co -infection  \\nIn Kenya, the prevalence of HCV infection is high in PWID (estimated to be 12 -16%). The \\nprevalence in the general population and among PLHIV is low (estimated to be < 3%), but likely', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 194}),\n",
       " Document(page_content='prevalence in the general population and among PLHIV is low (estimated to be < 3%), but likely \\nto be higher in HIV infected PWID due to shared routes of transmission. HIV/ HCV co -infection is \\nassociated with  \\n• Rapid progression of liver fibrosis  \\n• Higher risk of deteriorating liver disease even in the pres ence of controlled HIV disease  \\n• Worsened hepatotoxicity as a result of ART and other drugs used in the treatment of \\ncomorbidities  \\nThus, HIV -positive persons at risk of HCV co -infection should be identified and offered HCV \\ntreatment. The recent introduction of direct acting antiviral therapies (DAAs) for treatment of \\nHCV has simplified the management of HIV/HCV co -infection, making it possible to manage', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 194}),\n",
       " Document(page_content='HCV has simplified the management of HIV/HCV co -infection, making it possible to manage \\nuncomplicated HIV/HCV infection safely even in primary care settings.  \\nHowever, treatment for H CV is a rapidly evolving field of therapeutics. Providers are encouraged \\nto seek regular updates on the subject and, when in doubt, to discuss individual cases with \\nexperienced providers.  \\n9.2.1 Screening  \\nHCV serology should be offered to individuals at ri sk of HCV infection. These include  \\n● People who inject or use intranasal drugs  \\n● Persons who have had tattoos, body piercing or scarification procedures from \\nsettings with doubtful infection prevention precautions  \\n● Children born to HCV positive mothers', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 194}),\n",
       " Document(page_content='settings with doubtful infection prevention precautions  \\n● Children born to HCV positive mothers  \\nUp to 30 % of individuals who are infected with HCV spontaneously clear the infection. To confirm \\nchronic HCV infection, HCV positive individuals should be offered nucleic acid HCV RNA testing \\nto establish presence of chronic HCV infection.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 194}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 9 - 6 9.2.2 Prevention  \\nGeneral measures for prevention of blood -borne infections are effective in preventing HCV \\ntransmission.  \\n● Recommendations for healthcare settings  \\nTraining of healthcare providers on:  \\no Hand hygiene: including surgical hand preparation, hand -washing and use of gloves  \\no Safe handling and disposal of sharps and waste  \\no Effective disinfection and sterilization  \\no Provision of safe blood and blood products  \\n● Recommendations for PWID  \\no Harm reduction counselling and support (Table 12.1)  \\n● Recommendations for prevention of sexual transmission  \\no Correct and consistent condom use  \\no Access to prevention services for sex workers and other people at risk (including', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 195}),\n",
       " Document(page_content='o Correct and consistent condom use  \\no Access to prevention services for sex workers and other people at risk (including \\nscreening and treatment of STIs, frequent testing for HIV and HCV testing)  \\n \\n9.2.3 Treatment of HIV/HCV Co -infection  \\nTable 9.4: Summary of Initial Clinical and Laboratory Evaluation in HIV/HCV Co -infection  \\n Findings  Action  \\nHistory  Alcohol use, cigarette smoking, \\nintravenous drug use, risky sexual \\npractices, anorexia, right upper quadrant \\npain, jaundice, early satiety, haematemesis, \\ndark stool, bleeding, pruritus  Assess, counsel and support to stop \\ntaking alcohol; counsel and support \\nsmoking cessation; counsel provide \\nand refer for harm reduction \\ninterventions  \\nPhysical \\nexamination  Enlarged liver, enlarged spleen, ascites,', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 195}),\n",
       " Document(page_content='smoking cessation; counsel provide \\nand refer for harm reduction \\ninterventions  \\nPhysical \\nexamination  Enlarged liver, enlarged spleen, ascites, \\nscratch marks  Evidence of established chronic liver \\ndisease, closer follow -up due to \\nincreased risk of hepatotoxicity, \\ndiscuss or refer to a consultant for \\nadditional evaluation and management  \\nHCV RNA PCR  For confirmation of chronic HCV  \\ninfection  If available, at baseline  \\nHCV genotype  May be important for selecting appropriate \\nDAA regimen. (Current regimens pan -\\ngenotypic, so HCV genotype testing not \\nrequired)   \\nALT  If elevated, may point to active liver \\ndisease. Exclude other causes of elevation \\nof liver enzymes  Every effort should be made to assess \\nfor liver function (albumin and INR),', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 195}),\n",
       " Document(page_content='disease. Exclude other causes of elevation \\nof liver enzymes  Every effort should be made to assess \\nfor liver function (albumin and INR), \\nespecially in symptomatic patients. \\nHowever, this should not delay \\ninitiation of ART  \\nComorbidities  HBV, random blood su gar, lipid profile, \\nalcoholic and non -alcoholic liver disease,  \\nhepatocellular carcinoma (family history)  Consult/Refer the patient for \\nadditional investigations where these \\nare suspected', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 195}),\n",
       " Document(page_content='TB/HIV Co -infection, Prevention and Management  \\n \\n9 - 7 Table 9.5: Recommended DAA for the Treatment of HCV among PLHIV  \\nGenotype  DAA Regimen*  Duration of treatment  \\n1 and 4  Sofosbuvir + Ledipasvir (Harvoni)  12 weeks  \\nAll Sofosbuvir + Velpatasvir (Epclusa)  12 weeks  \\n* DAA regimen availability continues to evolve; this table just shows the most readily available regimens at \\ntime of publication. Always start DAA HCV therapy, and review most recent drug -drug interactions with \\nARVs.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 196}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 9 - 8', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 197}),\n",
       " Document(page_content='ARVs for Post -exposure Prophylaxis  \\n10 - 1  \\n10. ARVs for Post -exposure Prophylaxis  \\n \\n \\nAn ARV regimen, with preferably three -drugs, should be offered as post exposure prophylaxis as \\nsoon as possible (preferably within 72 hours) after an exposure.  \\n  \\n10.1 What is PEP?  \\nPost -exposure prophylaxis (PEP) is short -term use of antiretroviral treatment to reduce the \\nlikelihood of HIV infection after potential exposure.  \\nPeople can be accidentally exposed to HIV through healthcare work or due to exposures outside \\nhealthcare setting, for example, through unprotected sex or sexual assault among adults and \\nchildren. Healthcare workers are at increased risk of exposure to HIV through contact with', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 198}),\n",
       " Document(page_content='children. Healthcare workers are at increased risk of exposure to HIV through contact with \\ncontaminated blood and other body fluids  containing HIV through needle stick injuries and \\ninjuries by other sharp objects or through non -intact skin and mucous membranes.  \\n10.2 Recommended ARVs for PEP  \\nThree -drug regimens are preferred for PEP. However, if the person is unable to tolerate the thi rd \\ndrug, (usually the PI/r), two drugs  can be used.  \\nTable 10.1: Recommended ARVs for PEP  \\nAge  Weight  Preferred  Alternate  \\n \\n \\n<15 years  < 30kg  ABC + 3TC + DTG  ● AZT + 3TC + DTG  \\n● AZT+3TC and LPV/r may be used \\nas the third drug  \\n≥ 30 kg  TDF + 3TC /FTC + DTG  ● TDF+3TC/FTC and ATV/r may be \\nused as alternative third drug', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 198}),\n",
       " Document(page_content='● AZT+3TC and LPV/r may be used \\nas the third drug  \\n≥ 30 kg  TDF + 3TC /FTC + DTG  ● TDF+3TC/FTC and ATV/r may be \\nused as alternative third drug  \\n≥ 15 years  Any weight  TDF + 3TC/FTC + DTG  ● TDF+3TC/FTC and ATV/r may be \\nused as alternative third drug  \\n.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 198}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 10 - 2 10.3 Eligibility For PEP  \\nPEP should always be offered as soon as possible, preferably within 72 hours, after an exposure.  \\nPersons who present after 72 hours should be provided with other appropriate services including \\ncounselling and support.  \\nEligibilit y assessment for PEP is based on the type of exposure, HIV status of source where \\npossible and timing of seeking care.  \\nThe following include the eligibility criteria for PEP.  \\n● Exposed individual is HIV negative at baseline.  \\n● Exposure must have occurred within the past 72 hours.  \\n● Exposure to bodily fluids pose a significant risk (exposure and/or material):  \\n▪ Type of exposure:  mucous membrane (i.e.  sexual exposure; splashes to eye, nose, or', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 199}),\n",
       " Document(page_content='▪ Type of exposure:  mucous membrane (i.e.  sexual exposure; splashes to eye, nose, or \\noral cavity), non -intact skin, percutaneous injury or paren teral exposures  \\n▪ Material : blood, blood -stained body fluids, breast milk; semen; vaginal secretions; \\nsynovial, pleural, pericardial, amniotic fluids; CSF, and HIV cultures in laboratories  \\nExposures that do not require HIV PEP include:  \\n● When the exposed individual is already HIV positive.  \\n● Exposures to bodily fluids that do not pose a significant risk, i.e., tears, non -blood -stained \\nsaliva, urine, and sweat.  \\n10.4 Management and Follow Up  \\nPatients should be counselled and encouraged to complete the full course of PEP once a decision \\nhas been made to initiate PEP.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 199}),\n",
       " Document(page_content='Patients should be counselled and encouraged to complete the full course of PEP once a decision \\nhas been made to initiate PEP.  \\nFor occupational exposure, immediate care of the exposure site includes washing the site with \\nsoap and water and allow the wound  to bleed freely for several minutes  \\nNOTE: Do not do anything that will increase tissue damage such as squeezing, scrubbing, or \\ncutting the site further .', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 199}),\n",
       " Document(page_content='ARVs for Post -exposure Prophylaxis  \\n10 - 3 Table 10.2: Recommendations for PEP Management and Follow -up \\nConsiderations  Recommendation  \\nManagement at initial \\ncontact  ● Counsel on risks and benefits of PEP and obtain verbal consent for HIV \\ntesting.  \\n● Voluntary testing for both exposed and source individuals  \\n● Offer PEP as soon as high -risk exposure is established and the exposed \\nindividual tests HIV-negative at baseline (if HIV testing not feasible, \\noffer 1 -2 days of PEP to cover until HIV test performed)  \\n● Provide first aid in case of broken skin or other type of wound  \\nTime of initiation  As soon as possible after exposure, but no later than after 72 hours  \\nDuration of PEP  28 days (dispense all 28 days of treatment at the first visit if tested HIV negative)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 200}),\n",
       " Document(page_content='Duration of PEP  28 days (dispense all 28 days of treatment at the first visit if tested HIV negative)  \\nDose of PEP  Same as indicated for treatment; use weight -based dosing for children  \\nLaboratory \\ninvestigation at \\nbaseline  ● Conduct creatine testing (if TDF -containing regimen) and Hb (if AZT -\\ncontaining regimen), however PEP should be offered even when lab tests \\nare not available. Do not delay administration of PEP while waiting for lab \\nresults.  \\n● HBsAg testing is recommended. Do not del ay administration of PEP while \\nwaiting for lab results. If negative provide HBV vaccination  \\n● Pregnancy testing for women of childbearing potential in case of sexual \\nassault.  \\nFollow -up ● Follow up client at 7 days, 14 days, 28 days, and 12 weeks after starting \\nPEP', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 200}),\n",
       " Document(page_content='assault.  \\nFollow -up ● Follow up client at 7 days, 14 days, 28 days, and 12 weeks after starting \\nPEP  \\n● Assess for and manage side effects due to PEP  \\n● Follow -up HIV testing should be done at the completion of PEP and if \\nnegative, test again at 12 weeks  \\n● Link to HIV treatment if positive  \\nCounselling  Counselling at baseline should include:  \\n● Adherence counselling  \\n● Information on side effects  \\n● Risk reduction counselling  \\n● Trauma and mental health counselling  \\n● Specific support for sexual assault  \\nOther services for \\nsexual assault  ● STI prophylactic treatment to all (treat for vaginal/urethral discharge \\nsyndrome following the national STI algorithms)  \\n● Emergency contraception for non -pregnant women', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 200}),\n",
       " Document(page_content='syndrome following the national STI algorithms)  \\n● Emergency contraception for non -pregnant women  \\n● Tetanus toxoid for any physical injury of skin or mucous membranes  \\n● Documentation of clinic evidence of assault and collection of foren sic \\nevidence  \\nRefer to post -rape care guidelines for additional details', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 200}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 10 - 4 10.5 Risk reduction counselling  \\nTo reduce the risk of further HIV transmission, it is necessary to prevent transmission to sexual \\npartners and the children of breastfeeding mothers. R isk reduction counselling should form part \\nof each consultation with the individual. Measures to reduce transmission to another person may \\ninclude:  \\n● The use of condoms and safe injecting practices to prevent secondary transmission  \\n● Avoiding blood donation until confirmed HIV negative at 12 weeks post exposure  \\nTable 10.3 Considerations for special circumstances  \\nCircumstance   Recommendation  \\nBreastfeeding women  • Breastfeeding is not a contraindication for PEP  \\n• The risks and benefits of continuing breastfeeding while HIV', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 201}),\n",
       " Document(page_content='Breastfeeding women  • Breastfeeding is not a contraindication for PEP  \\n• The risks and benefits of continuing breastfeeding while HIV \\ntransmission risk is unknown and should be discussed with the \\nmother  \\nChildren  • HIV testing approaches for children should be in line with national \\nguidelines and age appropriate  \\n• Informed consent from the caregiver is needed  \\nAdolescents  • Requiring parental consent for adolescents can be a barrier to HIV \\ntesting, particularly in cases of sexual assault  \\n• HIV testing should be performed in accordance with national \\nguidelines and consenting requirements  \\n \\n10.6 Preventing HIV exposure  \\nTo avoid or minimize the risk of exposure to HIV the following infection prevention control (IPC) \\nmeasures are recommended:', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 201}),\n",
       " Document(page_content='To avoid or minimize the risk of exposure to HIV the following infection prevention control (IPC) \\nmeasures are recommended:  \\n• Precautions should be taken when handling contaminated body fluids including the use \\nof appropriate barriers such as gloves, gowns, and goggles.  \\n• Care with sharps including minimizing blind surgical procedures and proper handling \\nand disposal o f sharps.  \\n• Safe disposal of contaminated waste  \\n• Safe handling of soiled linen.  \\n• Adequate disinfection procedures  \\n• Universal Hepatitis B vaccination of non -immune at -risk groups including HCWs, police, \\nprison staff and rescue workers.  \\nIn cases that do not requi re PEP, the exposed person should be counselled about limiting future \\nexposure risk.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 201}),\n",
       " Document(page_content='Pre-Exposure Prophylaxis (PrEP)  \\n11 - 1  \\n11. Pre-Exposure Prophylaxis (PrEP)  \\n \\nPre-exposure prophylaxis (PrEP) is the use of antiretroviral medication to prevent the acquisition \\nof HIV infection by an uninfected person at ongoing risk of acquiring HIV infection.  \\nPrEP is recommended for use as follows:  \\n• Daily Oral PrEP for all indivi duals, irrespective of gender or sexual orientation who are at risk \\nof HIV infection.  \\n• Event -Driven (ED) PrEP is currently recommended for all people born male who are not \\ntaking exogenous estradiol -based gender affirming hormones  \\n11.1 Indications for PrEP and Criteria for Eligibility   \\n11.1.1 Indications for PrEP  \\nPrEP is indicated for;  \\n● HIV uninfected persons at ongoing risk of HIV acquisition', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 202}),\n",
       " Document(page_content='11.1.1 Indications for PrEP  \\nPrEP is indicated for;  \\n● HIV uninfected persons at ongoing risk of HIV acquisition  \\n● Some risk situations that place one at ongoing risk include individuals or sexual partner/s \\nwho is/are:  \\no HIV positive and: not on ART, or on ART < 6 months, on ART with viral non -suppression, \\nor on ART with suspected poor adherence  \\no In sero -discordant relat ionships trying to conceive  \\no Of unknown HIV status and at high -risk of HIV infection  \\no Engaging in transactional sex or sex work  \\no With history of recent or current sexually transmitted infections  \\no With recurrent use of Post -Exposure Prophylaxis  \\no With a history of sex whilst under the influence of alcohol or recreational drugs', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 202}),\n",
       " Document(page_content='o With recurrent use of Post -Exposure Prophylaxis  \\no With a history of sex whilst under the influence of alcohol or recreational drugs  \\no Inconsistent or no condom use or unable to negotiate condom use during intercourse \\nwith persons of unknown HIV status  \\no Using injection drugs where needles and/or syringes are  shared  \\n11.1.2 HIV Risk Assessment  \\nClients accessing health services should be screened for HIV risk and additionally provided with \\ninformation on HIV prevention options available including the availability of PrEP. This is in \\naddition to the use of HIV testing services (HTS), as clients ar e assessed for HIV risk before testing.  \\nThe risk assessment questions are enquiry of behavioural practices that may expose an individual \\nto HIV (Table 11.2).', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 202}),\n",
       " Document(page_content='The risk assessment questions are enquiry of behavioural practices that may expose an individual \\nto HIV (Table 11.2).  \\n A simple Risk Assessment Tool (RAST) is provided to guide the provider in generating a \\nconversat ion about HIV risk. Screening for HIV risk should be integrated within other service \\ndelivery points. HIV negative individuals who answer “yes” to any of the screening questions \\nshould be engaged in a discussion about the risks and benefits of PrEP. The cl ient then is evaluated \\nfor eligibility to receive PrEP.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 202}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 11 - 2 Table 11:1 HIV Screening questions  \\nScreening question refer to the past 6 months & include;  \\n• “Have you had sex with more than one person?”  \\n• “Have you had sex without a condom?”  \\n• “Have you had sex with a nyone whose HIV status you do not know?”  \\n• “Are any of your partners at risk of HIV?”  \\n• “Have you had sex with a person who has HIV?”  \\n• “Have you received a new diagnosis of a sexually transmitted infection?”  \\n• “Do you desire pregnancy?”  \\n• “Have you used or wanted t o use PEP or PrEP for sexual exposure to HIV?”  \\n• “Have you injected drugs that were not prescribed by healthcare provider? If yes, did \\nyou use syringes, needles or other drug preparation equipment that had already been', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 203}),\n",
       " Document(page_content='you use syringes, needles or other drug preparation equipment that had already been \\nused by another person?”  \\n• “Have you rece ived money, housing, food or gifts in exchange for sex?”  \\n• “Have you been forced to have sex against your will?”  \\n• “Have you been physically assaulted, including assault by a sexual partner?”  \\n11.1.3 Criteria for PrEP Eligibility  \\nTo be eligible for PrEP, individuals identified to be at risk of HIV infection from Risk Assessment \\nmust meet ALL the following criteria prior to initiating PrEP.  \\n● Confirmed HIV negative status through rapid antibody testing following the HTS algorithm.  \\n● Determine if the client is w illing to take PrEP as prescribed. (This is done by adherence', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 203}),\n",
       " Document(page_content='● Determine if the client is w illing to take PrEP as prescribed. (This is done by adherence \\neducation and counselling on the PrEP regimen to be given, and assessing the client’s \\nreadiness to follow the regimen.)  \\n● Does not have a current or recent (within the past one month) illness consistent with acute \\nHIV infection (fever, sore throat, muscle or joint pains, swollen glands, diarrhoea or headache) \\nin combination with a preceding high -risk exposure for HIV.  \\n● No contraindication to use of any of the ARVs recommended for PrEP e. g., TDF +/ - FTC (or \\n3TC) for those who choose oral PrEP.  \\n● Renal or liver disease  \\no Clients with renal and liver disease should receive further clinical and laboratory tests, \\nto determine the renal/liver function and extent of disease.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 203}),\n",
       " Document(page_content='to determine the renal/liver function and extent of disease.  \\nOther important factors  for screening  \\n1. Gender based violence (GBV) screening:  All clients accessing PrEP must be screened for \\ngender -based violence, especially intimate partner violence (IPV), and appropriate \\nintervention offered or client linked to appropriate.  \\n2. Mental Status Assessment:  Psychological issues that may influence adherence should be \\nassessed and addressed. It is important to carry out basic mental health evaluation and \\noffer appropriate referral as necessary.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 203}),\n",
       " Document(page_content='Pre-Exposure Prophylaxis (PrEP)  \\n11 - 3 HIV self -test (HIVST) should not be used as a de finitive HIV test for PrEP initiation and \\nfollow up monitoring.  \\n11.2 Package of PrEP Service  \\nPrEP should be offered as part of the comprehensive prevention package which includes \\nbehavioural, bio medical and structural components. Integration of PrEP serv ices is \\nrecommended within different service delivery points, including in the community, ANC and FP \\nclinics.  \\n \\n Client  seeking  any service  from the facility /Communit y\\n(See section  on PrEP Integration)\\n \\n \\n \\n \\nSCREEN  for ongoing  risk for HIV \\nTEST for HIV  \\n  \\nHIV Positive – link/refer\\nAdditional Screening:\\nGBV/HIV\\n \\n \\n \\n \\n \\n \\n \\n \\n \\n1 \\n \\nFigure 11.1 : Package of Service for PrEP', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 204}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 11 - 4 11.2.1 Pre -Initiation Checklist  \\nThis checklist is intended to help the service provider ensure all necessary screening and \\nassessments are done prior to PrEP initiation  \\nTable 11.2: Pre -Initiation Assessment Checklist  \\nITEM  Y/N  \\nScreening and Support for GBV   \\nHIV Testing   \\nCheck symptoms of acute viral infection in last 6 weeks   \\nBehavior risk assessment   \\nSubstance use and mental health screening   \\nPartner information   \\nPre-initiation education and understanding of PrEP   \\nClient readiness and willingness to adhere to prescribed PrEP and follow -up schedule   \\nSTI screening and treatment   \\nFor women  \\n✔ Pregnancy test, pregnancy intention and / or breastfeeding', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 205}),\n",
       " Document(page_content='STI screening and treatment   \\nFor women  \\n✔ Pregnancy test, pregnancy intention and / or breastfeeding  \\n✔ Screen for contraception use using appropriate contraceptive screening tool   \\n✔ Highlight the need for condom use   \\nDiscussed plans for continually accessing PrEP   \\nAdditional laboratory tests (Availability of these test should not delay initiation of PrEP)  \\n✔ Serum creatinine and creatinine clearance  \\n✔ HBsAg  \\n✔ HCV serology  \\nNB:  absence of these tests should not hinder initiation   \\nMedication history and potential drug interactions', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 205}),\n",
       " Document(page_content='Pre-Exposure Prophylaxis (PrEP)  \\n11 - 5 11.2.2 Pre -initiation client education  \\nThe following components should be discussed prior to PrEP initiation:  \\nTable 11.3: Client Education Checklist  \\nTopic  Check  \\n✔ Explain how PrEP works as part of combination HIV prevention  ✔  \\n✔ Explain the need for baseline and follow -up tests including regular HIV testing  ✔  \\n✔ Explain PrEP use: include the following: (refer to the different types of PrEP \\navailable for details)  \\no The medications used (show the client the pills or other PrEP options  \\no How the medications are used (frequency of dosing for the various options)  \\no Number of doses required to achieve efficacy (7 doses for daily oral PrEP, \\nloading dose for event driven oral PrEP)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 206}),\n",
       " Document(page_content='o Number of doses required to achieve efficacy (7 doses for daily oral PrEP, \\nloading dose for event driven oral PrEP)  \\no What to do when doses are missed (continue for daily doses)  \\no Discontinuation of PrEP, how and when it can be discontinued.  \\no Side effects and what to do in case these are experienced (including when to \\nconsult the clinician)   ✔  \\n✔ Discuss what to do in case client experiences symptoms of seroconversion (acute \\nHIV infect ion)   \\n✔ Discuss the Limitations of PrEP  \\no PrEP reduces but does not eliminate the risk of acquiring HIV.  \\no PrEP does not prevent pregnancies and STIs.   ✔  \\n✔ Risk reduction counselling and support education  \\no Managing mental health needs  \\no Couple counselling  \\no Access to, and consistent use of condoms and lubricants', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 206}),\n",
       " Document(page_content='o Managing mental health needs  \\no Couple counselling  \\no Access to, and consistent use of condoms and lubricants  \\no Access to and need for frequent HIV testing.  \\no Early access to ART  \\no VMMC  \\no STI screening and treatment  \\no Harm reduction for PWID  ✔  \\n \\n11.3 Recommended ARVs for PrEP  \\nThe preferred ARV regimen is Tenofovir 300mg/ Emtricitabine 200mg (TDF/FTC) given as one \\nfixed dose combination (FDC) tablet orally daily.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 206}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 11 - 6 Table 11.4: Antiretrovirals for Use in PrEP  \\nPrEP Dosing \\nStrategies  Preferred  Alternative  \\nDaily Oral PrEP  TDF/FTC (300 mg/200 mg) as FDC \\nonce daily  TDF/3TC (300 mg/300 mg) as FDC once \\ndaily  \\nEvent Driven Oral \\nPrEP    TDF/FTC (300 mg/200 mg) as FDC \\n– two pills taken between 2 and 24 \\nhours in advance of anticipated sex; \\nthen, a third pill 24 hours after the \\nfirst two pills and a fourth pill 48 \\nhours after the first two pills; 2 -1-1 TDF/3TC (300 mg/300 mg) as FDC – \\ntwo pills taken between 2 and 24 hours \\nin advance of anticipated sex; then, a \\nthird pill 24 hours after the first two \\npills and a fourth pill 48 hours after the \\nfirst two pills ; 2-1-1', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 207}),\n",
       " Document(page_content='in advance of anticipated sex; then, a \\nthird pill 24 hours after the first two \\npills and a fourth pill 48 hours after the \\nfirst two pills ; 2-1-1 \\n*Recommended Long -acting Products: These products are at different stages of approval and availability \\nin Kenya. The Ministry of Health will issue specific implementation guidelines when they become \\navailable.  \\n*Long Acting \\nCabotegravir \\nInjection  Initiation injections: 600 mg \\nIntramuscular (IM) x 2 doses given \\n1 month apart (the second \\ninitiation injection can be given up \\nto 7 days before or after the date \\nscheduled to receive injection)  \\nTHEN  \\nContinuation injections: 600 mg  IM \\nevery 2months   \\n*Dapivirine \\nvaginal ring  Dapivirine vaginal ring, 25mg, \\ninserted vaginally every 28 days.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 207}),\n",
       " Document(page_content='Continuation injections: 600 mg  IM \\nevery 2months   \\n*Dapivirine \\nvaginal ring  Dapivirine vaginal ring, 25mg, \\ninserted vaginally every 28 days.   \\nThe drugs can be taken with or without food, and can be stored at room temperature.  \\nPrescription intervals for daily oral PrEP  \\nThe first prescription should be for 30 days to allow for the first follow -up visit during which a \\nrepeat HIV test should be conducted, and adherence, tolerability and adverse effects assessed.   \\nDuring the one -month visit, if no major concerns are noted, PrEP should be prescribed for 2 \\nmonths and thereafter 3 -monthly. Clients with sub -optimal adherence and or other major \\nconcerns should be given monthly follow up visit.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 207}),\n",
       " Document(page_content='months and thereafter 3 -monthly. Clients with sub -optimal adherence and or other major \\nconcerns should be given monthly follow up visit.  \\nRemind individuals using daily oral PrEP that it takes 7 doses (equivalent to 7 days) o f \\ncontinuous PrEP use to achieve adequate levels of the ARVs in tissues for it to be \\neffective. During these days, safer sex practices should be encouraged (including \\nabstinence and condom use). This only applies for individuals born female. Those born \\nmal e can have protective levels as soon as 2 hours before sex but ideally 24 hours. This \\nis true even for people intending to take daily oral PrEP for ongoing exposure.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 207}),\n",
       " Document(page_content='Pre-Exposure Prophylaxis (PrEP)  \\n11 - 7 11.3.1 Schema for follow up for daily oral PrEP  \\nInitial Visit/First Contact\\nPerform a risk assessment to determine if PrEP is indicated:\\n• Discuss effective PrEP use and Clarify misinformation\\n• Perform Initial clinical and laboratory assessment:\\no Baseline HIV test and rule out symptoms of Acute \\nHIV infection.\\no Screen for STIs and risk of renal disease/Hepatitis \\nB/C infectionIf HIV Negative and meets eligibility for PrEP\\n• Offer adherence counselling and support. \\n• Prescribe 30 -day supply of PrEP (TDF 300 mg/FTC \\n200 mg OD) \\n• Discuss combination prevention and risk reduction.\\n• Offer other HIV prevention services e.g., condoms as \\nappropriate.\\n30 Day review\\n• Assess for adherence and offer adherence counselling and support.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 208}),\n",
       " Document(page_content='appropriate.\\n30 Day review\\n• Assess for adherence and offer adherence counselling and support.\\n• Ask about any side effects. Find out how the client is coping with the side effects if any. Reassure if minor.\\n• Assess for STIs, risk of acute HIV infection, and perform pregnancy test in women. \\n• Assess for risk of kidney disease, if available, obtain serum creatinine and calculate creatinine clearance \\n• Discuss risk reduction and provide condoms.\\n• Perform a repeat HIV test. (Discontinue PrEP for those who test positive and link to care for ART initiation) \\nGive a 60-day PrEP prescription for drug refill of PrEP. Schedule the 3 -month return visit.\\n3 monthly reviews \\n• Assess for adherence and offer adherence counselling and support. \\n• Ask about any side effects', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 208}),\n",
       " Document(page_content='3 monthly reviews \\n• Assess for adherence and offer adherence counselling and support. \\n• Ask about any side effects\\n• Assess for STIs, (and pregnancy in women) and acute HIV infection. \\n• Perform HIV test every 3 months (HIV self -test may be used followed by a \\nconfirmatory test in health facilities for those testing positive) \\n• Discuss risk reduction and provide condoms.\\nDo serum creatinine and calculate creatinine clearance within 3 months after initiation \\nand thereafter annually as recommended.\\n \\nFigure 11.2: Schema for Follow -up for Daily Oral PrEP  \\n \\n11.3.2 EVENT DRIVEN PrEP (ON DEMAND PrEP or 2+1+1 PrEP)  \\nWhat is event driven?  \\nAn “Event” refers to a sexual act. Event driven PrEP is where oral PrEP is to be used when an  \\nisolated sexual act is anticipated.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 208}),\n",
       " Document(page_content='An “Event” refers to a sexual act. Event driven PrEP is where oral PrEP is to be used when an  \\nisolated sexual act is anticipated.   \\nEvent -Driven PrEP is recommended for all people assigned male at birth not taking exogenous \\nestradiol -based gender affirming hormones', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 208}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 11 - 8 \\n \\nFigure 11.3 Schema for Event -Driven PrEP  \\nWhen is ED -PrEP considered most appropriate?  \\nEvent driven PrEP is most appropriate for men who:  \\n• Have infrequent sex (for example, sex less than 2 times per week on average).  \\n• Can plan for sex at least 2 hours in advance or who can delay sex for at least 2 hours.  \\n• Would find ED -PrEP more convenient  \\nClients on Event driven PrEP require follow up. Figure 11.4  shows the schema for follow up of \\nevent driven PrEP.  \\nAssess HIV risk and determine eligibility for oral PrEP\\nOffer PrEP and discuss dosing options.\\nDaily dosing if risk is more frequent \\nthan 2 times per week and sex cannot \\nbe predicted or delayed by 2 hours.Men who have sex with men on PrEP', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 209}),\n",
       " Document(page_content='Daily dosing if risk is more frequent \\nthan 2 times per week and sex cannot \\nbe predicted or delayed by 2 hours.Men who have sex with men on PrEP \\ncan switch from daily dosing to ED -\\nPrEP (and vice -versa)Event -driven dosing if sex can be \\npredicted (particularly for infrequent \\nsex)\\nFollow -up visit (1 month after initiation and/or every 3 months) \\n✓ Provide HIV testing and screen for STIs\\n✓ Offer counselling by discussing adherence dosing strategy during use, and if PrEP user \\ntransitions from one dosing strategy to another. \\n✓ Assess if HIV risk is likely to persist in the next few weeks and months. \\n✓ May require more active support in continuing PrEP, whichever dosing strategy is chosen.\\n \\nFigure 11.4 Schema for Initiation and Follow -up for Event -driven PrEP', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 209}),\n",
       " Document(page_content='Pre-Exposure Prophylaxis (PrEP)  \\n11 - 9 Changing between ED PrEP and daily oral PrEP  \\nMen can be offered the two dosing options: daily oral PrEP or Event driven PrEP.  \\n• Daily dosing is appropriate for those whose occurrence of sex cannot be predicted and for \\nthose whose potential exposures to HIV  are more frequent than 2 times per week, such \\nthat ED -PrEP would be taken so frequently that it would effectively resemble daily PrEP.  \\n• If sex continues beyond one day, a user of ED -PrEP can stay protected by taking another \\npill each day as long as sex co ntinues and stopping 2 days after the last sex act.  \\n• On the other hand, if an individual starts daily oral PrEP, but then sex becomes infrequent \\nand predictable, ED -PrEP can be used instead.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 210}),\n",
       " Document(page_content='• On the other hand, if an individual starts daily oral PrEP, but then sex becomes infrequent \\nand predictable, ED -PrEP can be used instead.  \\n \\n11.4 Managing Clinical and Laboratory Results on Initial and Fol low -up \\nAssessment  \\nTable 11.5 Initial & follow up laboratory test  \\nLaboratory Test  Guidelines for clients initiating \\nPrEP  Guidelines for clients on \\nfollow up  \\nHIV Rapid Test  Before initiating PrEP as per the National \\nHTS algorithm  At Month 1, Month 3, thereafter \\nevery 3months  \\nCreatinine Test  Test within 1 -3 months of PrEP Initiation  If client >50years – Screen every \\n6-12months  \\nClients of any age with renal \\ncomorbidity: recommended before  \\ninitiating PrEP  Screen every 6 -12months  \\nHepatitis B Surface', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 210}),\n",
       " Document(page_content='6-12months  \\nClients of any age with renal \\ncomorbidity: recommended before  \\ninitiating PrEP  Screen every 6 -12months  \\nHepatitis B Surface \\nAntigen (HBsAg)  Test once within 3 months of initiating PrEP. If negative, offer/refer for \\nimmunization   \\nHepatitis C Virus \\nSerology  Test once within 3months of PrEP \\ninitiation  Every 12 months for persons at \\nhigh risk of Hepatitis C infection', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 210}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 11 - 10 Table 11.6: Managing Clinical and Laboratory Results on Initial and Follow -up Assessment  \\nScreening  Action  \\nHIV -positive at \\ninitial evaluation  Do not start PrEP, counsel and link to care and treatment  \\nHIV -positive after \\ninitiation of PrEP  Discontinue PrEP, counsel and link to care and treatment. Take DBS or plasma \\nsample for drug resistance testing.  \\n \\nPositive STI Screen  Thorough genitourinary and anorectal examination, urine dipstick for urethritis, \\nserological testing for syphilis, full STI evaluation if resources available (refer to \\nSTI algorithm). Refer to guidelines on syndromic management of STIs.  \\nHBsAg -negative  Offer HBV vaccination', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 211}),\n",
       " Document(page_content='STI algorithm). Refer to guidelines on syndromic management of STIs.  \\nHBsAg -negative  Offer HBV vaccination  \\n \\nHBsAg -positive  This is not a contraindication to oral PrEP.  However, will require monitoring of \\nliver function and referral for management of liver disease.  \\nNB: TDF -based daily or event -driven oral PrEP can be safely offered to \\npersons with HBV infection.  \\nHepatitis C - \\nNegative  Continue PrEP and follow Hepatitis C testing algorithm.  \\nHepatitis C - \\nPositive  Continue PrEP, refer for Hepatitis C confirmatory testing and management with \\ndirectly acting antivirals (DAAs).  \\nFlu-like illness after \\ninitiating PrEP  Continue PrEP, test for HIV at first contact and after 28 days, and if negative,  \\ncontinue with usual follow -up', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 211}),\n",
       " Document(page_content='initiating PrEP  Continue PrEP, test for HIV at first contact and after 28 days, and if negative,  \\ncontinue with usual follow -up \\n \\n \\n \\n \\n \\n \\n \\nSide effects of PrEP  GIT - nausea, vomiting, weight loss: these are often mild, self -limiting and occur \\nduring the first 1 -2 months. Provide supportive counselling, offer symptomatic \\ntreatment e.g., anti -emetics like metoclopramide 10 mg 8 hourly for 3 to 5 days.  \\nRenal – individuals may experience transient increase in creatinine, and rarely \\nproteinuria and Fanconi’s syndrome (presenting as polyuria, bone pain and \\nweakness). Measure creatinine (and ca lculate estimated creatinine clearance) at \\ninitiation of PrEP and annually thereafter (or whenever indicated (symptom \\ndirected)).', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 211}),\n",
       " Document(page_content='initiation of PrEP and annually thereafter (or whenever indicated (symptom \\ndirected)).  \\nIf creatinine clearance (eGFR) < 50 ml/min do not start PrEP, recheck after 2 \\nweeks. Refer for evaluation of underlying renal  disease.  \\nIf the renal function returns to normal, reassess for PrEP and initiate/ continue \\nPrEP.  \\nPrEP should not be prescribed for individuals using nephrotoxic drugs like \\nacyclovir, aminoglycosides, retinoids etc. instead, offer alternative HIV \\nprevent ion services.  \\n \\nPregnancy or \\nBreastfeeding  \\n Pregnancy and breastfeeding are not contraindications to provision of PrEP.  \\nPregnant or breastfeeding women whose sexual partners are HIV positive or are \\nat high risk of HIV infection may benefit from PrEP as part of combination \\nprevention of HIV infection.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 211}),\n",
       " Document(page_content='at high risk of HIV infection may benefit from PrEP as part of combination \\nprevention of HIV infection.  \\nPrEP is also indicated for HIV -negative women in sero -different partnersh ips \\nwho wish to conceive. PrEP in these situations can be prescribed during the pre -\\nconception period and throughout pregnancy to reduce risk of sexual HIV \\ninfection.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 211}),\n",
       " Document(page_content='Pre-Exposure Prophylaxis (PrEP)  \\n11 - 11 Table 11.7: Summary of PrEP Initial and Follow -up Assessment  \\nVisit  Action  \\nFirst (Screening Visit) \\nClinician Visit  • HIV testing and counselling.  \\n• Evaluate for eligibility, willingness and readiness to take PrEP.  \\n• Educate about the risks, benefits, and limitations of different PrEP \\noptions  \\n• Educate client about recognizing symptoms of Acute  HIV Infection (AHI) \\nand what to do if such symptoms occur (i.e., urgently return for HIV \\ntesting)  \\n• Conduct behavior risk assessment  \\n• STI screening and treatment  \\n• Pregnancy, contraceptive use and counselling (for women); if pregnancy \\nsuspected, obtain a preg nancy test. However, pregnancy is not a \\ncontraindication to PrEP.  \\n• Adherence counselling', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 212}),\n",
       " Document(page_content='suspected, obtain a preg nancy test. However, pregnancy is not a \\ncontraindication to PrEP.  \\n• Adherence counselling  \\n• Discuss combination prevention.  \\n• Laboratory test; serum creatinine test and calculate Creatinine Clearance \\n(CrCl), HBsAg, pregnancy test, Hepatitis C (baseline investigations should \\nnot delay initiation of PrEP)  \\nIf no contraindication to TDF and the client is eligible and ready, \\nprescribe TDF/FTC one tablet once daily for 30 days (alternative \\nTDF/3TC one tablet once daily for 30 days, or TDF 300 mg once daily for \\n30 days); agree on a follow -up date before the prescription is finished  \\nVisit 2 (Month 1) \\nCounsellor/Clinician \\nVisit  • Counsellor/ Clinician visit  \\n• Assess for side effects and adverse effects', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 212}),\n",
       " Document(page_content='Visit 2 (Month 1) \\nCounsellor/Clinician \\nVisit  • Counsellor/ Clinician visit  \\n• Assess for side effects and adverse effects  \\n• Safety monitoring clinical assessment/ Review lab results  \\n• Conduct a HIV test as per the national algorithm  \\n• Behavioral risk assessment .  \\n• Review for PrEP continuation or discontinuation  \\n• Adherence and risk reduction counselling  \\n• Give a prescription for PrEP for 2 months.  \\n• Offer HBV vaccination if available and HBsAg negative (follow HBV \\nvaccination schedule complete series  \\nFollow up visits - \\nMonths 3, 6,  , 12, 15.….  \\nClinician/Counsellor -\\nled visits  • HIV testing and counselling  \\n• HIV risk assessment   \\n• Review for PrEP continuation or discontinuation  \\n• Assess for side effects and adverse effects', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 212}),\n",
       " Document(page_content='• HIV risk assessment   \\n• Review for PrEP continuation or discontinuation  \\n• Assess for side effects and adverse effects  \\n• Safety monitoring clinical assessment/ Review lab results  \\n• Adherence and risk reduction counselling  \\n• Give a prescription for PrEP for 3 months  \\n• Refill PrEP prescription  \\n• Serum creatinine and creatinine clearance', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 212}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 11 - 12 Table 11.7 Cont: Summary of PrEP Initial and Follow -up Assessment  \\nDuring every visit  \\n• Assess adherence  \\n• Reassess risk of HIV infection and offer risk reduction counselling  \\n• HIV testing should be repeated at month 1 and thereafter, every 3 months (this applies for both \\ndaily and Event driven PrEP)  \\n• Assess for adverse effects   \\n11.5 Contra -indications to Oral PrEP (daily or ED PrEP)  \\n• HIV infection or suspected acute HIV infection (i.e., flu -like symptoms in the last 4 weeks in \\ncombination with a preceding h igh-risk exposure for HIV)  \\n• Adolescents < 35 kg or age < 15 years  \\n• Impaired renal function (estimated creatinine clearance of <50 ml/min)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 213}),\n",
       " Document(page_content='• Adolescents < 35 kg or age < 15 years  \\n• Impaired renal function (estimated creatinine clearance of <50 ml/min)  \\n• Unable or unwilling to adhere to prescribed PrEP or follow -up schedule.  \\n11.6 Criteria for Discontinuing Oral PrEP  \\nPrEP should be discontinued if ANY of the following criteria are met.  \\n● Positive HIV test during follow up.  \\n● Change in risk status (no ongoing risk)  \\n● Renal dysfunction with creatinine clearance below 50 ml/min  \\n● Client request to stop.  \\n● Sustained non -adherence.  \\nDiscontinuing daily oral PrEP:   Users discontinuing PrEP due to no ongoing risk or requesting \\nto stop should continue PrEP for at least 7 days after the last potential exposure to HIV. Reasons \\nfor discontinuation should be documented in the client’s record.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 213}),\n",
       " Document(page_content='for discontinuation should be documented in the client’s record.  \\nDiscontinuing event –driven PrEP:  Event -driven PrEP can be stopped after two daily doses \\nfollowing the last sexual exposure.  \\n11.7 Restarting PrEP  \\nAny client restarting PrEP regardless of the preferred method should be assessed for HIV status \\nand a rapid HI V test conducted:  \\n● Daily Oral PrEP : Clients who stop PrEP for more than 7 days and wishes to restart should \\nbe assessed for resumption of PrEP similar to the assessment done for an initial (first) visit. \\nImportantly, conduct a HIV test before re -starting PrEP. If a high -risk exposure occurre d in \\nthe previous 7 days (i.e., acute HIV infection is suspected), defer PrEP and obtain repeat HIV', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 213}),\n",
       " Document(page_content='the previous 7 days (i.e., acute HIV infection is suspected), defer PrEP and obtain repeat HIV \\ntest after 4 weeks; if negative, PrEP can be prescribed if the other criteria are fulfilled. The \\nuse of condoms should be recommended during the waiting per iod.  \\n● Event driven Oral PrEP :  Clients who have stopped PrEP for more than a week and who are \\nrestarting ED -PrEP should commence with a double dose (two pills) of PrEP as new \\ninitiators. Risk assessment should be conducted. If a high -risk exposure occurred  in the \\nprevious 7 days (i.e., acute HIV infection is suspected), defer PrEP and obtain repeat HIV \\ntest after 4 weeks; if negative, PrEP can be prescribed if the other criteria are fulfilled. The \\nuse of condoms should be recommended during the waiting peri od.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 213}),\n",
       " Document(page_content='Pre-Exposure Prophylaxis (PrEP)  \\n11 - 13 11.8 Improving adherence to PrEP  \\nApproaches to improve adherence include:  \\n● Encourage ring users to keep ring in place continuously through the 28 -day period from \\ninitial insertion  \\n● Disclosure of PrEP use to a partner or trusted person  \\n● Use of reminder de vices like a cell phone alarm.  \\n● SMS reminders where available and feasible  \\n● Exploring and mitigation of other barriers to adherence  \\n● Peer support  \\n11.9 Monitoring Sero -conversion among PrEP users  \\nPrEP substantially reduce the risk of HIV acquisition.  The effi cacy of PrEP is correlated with \\nadherence.  Sero -conversion during use of PrEP should be monitored critically as it is increasing', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 214}),\n",
       " Document(page_content='adherence.  Sero -conversion during use of PrEP should be monitored critically as it is increasing \\nthe risk of developing drug resistance if clients continue the use of PrEP while HIV infected.  \\nFactors that lead to HIV seroco nversion among PrEP sero -converters include:  \\n● Inconsistency in use of PrEP (non -adherence).  \\n● Social -behavioral factors e.g., poverty, HIV stigma and relationship status that may affect \\nthe ability to use PrEP as prescribed.  \\n● Possible infections with drug res istant strains  \\n \\nWhat should be done upon identification of a PrEP sero -converter?  \\nHIV testing among PrEP should be conducted consistently as per the algorithm. Identification of \\nnew HIV positive diagnosis among PrEP users should be followed with:  \\n● Immediate discontinuation of PrEP', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 214}),\n",
       " Document(page_content='new HIV positive diagnosis among PrEP users should be followed with:  \\n● Immediate discontinuation of PrEP  \\n● Counselling of client on positive results  \\n● Linkage to care and ART (immediate ART initiation).  \\n● Assessment of barriers to adherence that may affect use of ART.  \\n● Document sero -conversion in client file, PrEP registers, and monthly reporting as \\nrequired.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 214}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 11 - 14', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 215}),\n",
       " Document(page_content='People Who Inject Drugs (PWID) and HIV  \\n12 - 1  \\n12. People Who Inject Drugs (PWID) and HIV  \\n \\n12.1 Introduction  \\nThe use of ART for HIV treatment in key populations should follow the same general principles \\nand recommendations as for all adults. Individuals within key populations groups may experience \\ndiscrimination and marginali zation that can impede their access to health care, including \\ntreatment for HIV, and frequently present late for treatment. It is important to ensure that people \\nfrom key populations have equitable access to HIV treatment and care.  Programs should ensure \\nthat missed opportunities are minimized and every single encounter with key populations is \\noptimally used. ART service delivery includes decentralization of HIV care and treatment and', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 216}),\n",
       " Document(page_content='optimally used. ART service delivery includes decentralization of HIV care and treatment and \\nintegration of ART services into other clinical services such as Medical ly Assisted Therapy and \\ndrop -in centers where appropriate capacity exists.  \\nPeople who inject drugs (PWID) are at increased risk of HIV infection. In Kenya, the HIV \\nprevalence among PWID is up to 4 times that of the general population. PWID also suffer a hi gher \\nburden of viral hepatitis (HBV and HCV), TB and sexually transmitted infections irrespective of \\ntheir HIV status. Despite this, PWID have limited access to HIV treatment and prevention services.  \\nEvery effort should be made to implement evidence -inform ed interventions in the comprehensive', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 216}),\n",
       " Document(page_content='Every effort should be made to implement evidence -inform ed interventions in the comprehensive \\npackage of measures targeting PWID, either in combination or (depending on site capacity) singly, \\nwith linkage to comprehensive care (Table 12.1).  \\nPackage of care for PWID  \\nPWID have complex needs related to drug dependency, psychosocial and medical \\ncomplications of injection and other substance use. When they require ART, anti -TB, or any \\nother therapy, they are at increased risk of adverse drug reactions, drug -drug interactions and \\nnon-adherence.  These patients a re best comprehensively managed by providers who have \\nreceived specific training in the management of injection drug users. Once identified, PWID', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 216}),\n",
       " Document(page_content='received specific training in the management of injection drug users. Once identified, PWID \\nshould be counselled and linked to programs with the capacity to offer comprehensive care for \\nsuch patients.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 216}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 12 - 2 Table 12.1: Comprehensive Package of Harm Reduction for PWID  \\nIntervention  Comment/Recommendations  \\nHIV testing services  PWID are at high risk of HIV infection, are likely to be diagnosed late and \\ntherefore have poorer treatment outcomes following ART i nitiation.  \\n● PWID should be offered HIV testing and counselling and be linked to \\ncomprehensive HIV treatment and prevention services including \\nharm reduction counselling and support.  \\n● Retest for HIV every 3 months if there is ongoing risk.  \\n● HIV self -testing should be integrated into drop -in centers (DICEs) \\nthrough both assisted and non -assisted approaches after initial \\ntesting by a provider.  \\n● HTS should also be offered to sexual partners  of PWID.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 217}),\n",
       " Document(page_content='testing by a provider.  \\n● HTS should also be offered to sexual partners  of PWID.   \\n \\nTargeted information, \\neducation, and \\ncommunication for PWID \\nand their sexual partners  PWID and sexual partners should be provided with information and \\ncounselling on risks related to drug use and risky sexual behavior. PWID \\nshould be informed of where and what harm -reduction services are \\navailable, and linked to appropriate services.  \\nPeer -based networks are effective in improving access and retention to \\nharm reduction care  \\n \\n \\nCondom provision  The correct and consistent use of condoms with condom -compatible \\nlubricants is recommended for all PWID to prevent unintended pregnancy \\nand sexual transmission of HIV and other STIs.  \\n \\n \\nPrevention and treatment of \\nsexually transmitted', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 217}),\n",
       " Document(page_content='and sexual transmission of HIV and other STIs.  \\n \\n \\nPrevention and treatment of \\nsexually transmitted \\ninfections  PWID may be at higher risk of STIs due to sex work or other risky sex \\npractices.  \\nSTIs, especially genital ulcer diseases increase the risk of HIV infection and \\ntransmission and are often a sign of unsafe sexual behavior or risk of HIV \\ntransmission.  \\nScreening, dia gnosis, treatment, and prevention of STIs should be offered \\nroutinely as part of comprehensive HIV prevention and care for PWID.  \\n \\n \\nPrevention, diagnosis, and \\ntreatment of TB  Independent of HIV infection, PWID have an increased risk of TB. HIV \\ninfection f urther increases this risk.  \\n● All PWID should be screened regularly for active TB using the', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 217}),\n",
       " Document(page_content='infection f urther increases this risk.  \\n● All PWID should be screened regularly for active TB using the \\nsymptom -based screening algorithm at each contact with healthcare \\nworkers.  \\n● Once active TB is ruled out, TPT should be provided to PWID living \\nwith HIV as per National guidelines for TPT.  \\n● PWID w ith active TB should receive standard TB treatment as per the \\nNational guidelines and be supported to complete treatment.  \\n● Anticipate and manage complications due to viral hepatitis or renal \\nimpairment.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 217}),\n",
       " Document(page_content='People Who Inject Drugs (PWID) and HIV  \\n12 - 3 Table 12.1 Cont.  \\nPrevention, vaccination, \\ndiagnosis, and treatment for \\nviral hepatitis  Hepatitis B and C disproportionately affect PWID due to overlapping risk \\nfactors of sexual transmission and sharing needles, syringes, and other \\ndrug use items.  \\nHarm reduction and behavioral interv entions are also effective in \\nreducing risk of infection/transmission of HBV and HCV.  \\n● Peer interventions should be offered to people who inject drugs to \\nreduce the incidence of viral hepatitis  \\n● PWID should be screened for HBV (by HBsAg) and HCV (by HCV \\nsero logy) at first contact  \\n● Hepatitis B  \\no Hepatitis B vaccination is recommended for those who are \\nHBsAg negative. A higher -dose HBV vaccine should be used', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 218}),\n",
       " Document(page_content='● Hepatitis B  \\no Hepatitis B vaccination is recommended for those who are \\nHBsAg negative. A higher -dose HBV vaccine should be used \\nwith the rapid regimen (day 0, 7, 21, and a booster at 12 \\nmonths). If the rapid regimen is not available, the standard \\nregimen should be offered. For PWID who are HIV positive, they \\nshould follow the dosing schedule in Table. 9.1  \\no HBV/HIV co -infected PWID should be started on TDF - or TAF - \\ncontaining ART (the current recommended first line is \\nTDF/3TC/ DTG) in addition to harm -reduction interventions to \\noptimize adherence and treatment outcomes.  \\n● Hepatitis C  \\no HCV/HIV co -infected PWID should be initiated on ART.  \\no Specific HCV antiviral therapy should be provided in \\nconsultation with expertise in the management of HCV infection', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 218}),\n",
       " Document(page_content='o Specific HCV antiviral therapy should be provided in \\nconsultation with expertise in the management of HCV infection \\n(refer to national guidelines on management of viral hepatitis)  \\n  \\nNeedle and syringe \\nprogrammes (NSPs)  NSPs help decrease drug -related risk behaviors, reduce quantity of \\ncontaminated needles in circulation, reduce risk of new HIV infections and \\nimprove referrals and linkage to HTS and HIV treatment and prevention \\nservices.  \\nNSPs are effective means for intr oducing combination prevention to PWID \\nincluding HTS, STI screening and treatment, condoms provision, OST, and \\nHIV treatment and prevention.  \\nAll PWID should be linked to NSPs to access sterile injecting \\nequipment  \\n \\nOpioid substitution therapy', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 218}),\n",
       " Document(page_content='HIV treatment and prevention.  \\nAll PWID should be linked to NSPs to access sterile injecting \\nequipment  \\n \\nOpioid substitution therapy \\n(OST)  OST usi ng methadone or another suitable alternative is effective in the \\ntreatment of opioid dependency, reducing risk behaviors related to drug \\nuse and therefore reducing HIV transmission and improving PWIDs’ \\nadherence to ART  \\nIdentify and link all PWID who have o pioid dependence for opioid \\nsubstitution therapy', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 218}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 12 - 4 Table 12.1 Cont.  \\nAntiretroviral therapy \\n(refer to Table 12.2 for \\ndetails)  • ART is effective in managing HIV infection in PWID. However, poor \\nadherence may interfere with ART success. Intensive support is \\nrequired including OST, enhanced counselling techniques and daily \\nwitnessed ingestion (DWI) when available.  \\n• Close monitoring of ART is necessary because of risk of drug -drug \\ninteractions, renal and liver toxicity.  \\n• HIV-positive PWID should be off ered comprehensive HIV treatment \\nand prevention services including ART. When ART is provided with \\nadditional targeted support, PWID can achieve and maintain viral \\nsuppression.  \\n• Oral PrEP is recommended as an additional prevention choice for', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 219}),\n",
       " Document(page_content='additional targeted support, PWID can achieve and maintain viral \\nsuppression.  \\n• Oral PrEP is recommended as an additional prevention choice for \\nPWID at substant ial risk of HIV infection as part of combination \\nprevention and harm reduction approaches.  \\nCommunity outreach  PWID face barriers to accessing formal facility -based health services due \\nto stigma, discrimination, and fear of victimization among other factors.  \\nOutreach either directly from the facility or through collaborations with \\ncommunity -based groups is an effe ctive means of delivering harm -\\nreduction interventions in addition to HIV treatment and prevention \\nservices.  \\nPeer -led, community -based approaches are particularly useful in \\nimproving adherence and retention.  \\n \\n12.3 ART in HIV positive PWID', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 219}),\n",
       " Document(page_content='services.  \\nPeer -led, community -based approaches are particularly useful in \\nimproving adherence and retention.  \\n \\n12.3 ART in HIV positive PWID  \\nAntiretroviral  therapy is part of the comprehensive care package for PWID living with HIV. ART \\nservice provision should follow the same general principles and recommendations as for all \\nadults.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 219}),\n",
       " Document(page_content='People Who Inject Drugs (PWID) and HIV  \\n12 - 5 Table 12.2: Summary of ART Recommendations for PWID  \\nCare and Support  Recom mendation/Additional Information  \\nWhen to start ART in \\nHIV positive PWID  ART should be initiated in all individuals with HIV regardless of WHO clinical \\nstage or CD4 cell count  \\nWhat to start (first -line \\nART)  Irrespective of OST, PWID with HIV infection should be initiated on a first -line \\nregimen of TDF + 3TC + DTG  including women of childbearing potential.  \\nTDF + 3TC + ATV/r may be offered as an alternative where DTG cannot be used. \\n(Table 6.3)  \\nTB Co -infecti on  ART should be started as soon as possible within two weeks of initiating TB \\ntreatment, regardless of CD4 cell count.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 220}),\n",
       " Document(page_content='TB Co -infecti on  ART should be started as soon as possible within two weeks of initiating TB \\ntreatment, regardless of CD4 cell count.  \\nFor PWID with TB/HIV co -infection on DTG, give TDF/3TC/DTG FDC given in \\nthe am + DTG 50mg given in the pm for duration of rifampicin -containing TB \\ntreatment and for an additional 2 weeks after TB treatment is completed, then \\nrevert to TDF/3TC/DTG FDC once daily.  \\nSecond -line \\nART  Patients failing DTG -based first line ART (including PWID) should be managed \\nas per the viral load  monitoring algorithm (Figure 6.6), including performing a \\nDRT for selection of a second -line regimen (Table 6.10)  \\nTreatment preparation \\nand adherence \\ncounselling and \\nsupport  Injection drug use is not a contra -indication to ART initiation. OST, though', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 220}),\n",
       " Document(page_content='Treatment preparation \\nand adherence \\ncounselling and \\nsupport  Injection drug use is not a contra -indication to ART initiation. OST, though \\nimp ortant in contributing to the success of ART in PWID, should not be a pre -\\nrequisite to initiation of ART. However, these patients benefit from additional \\npreparation and support to increase their chances of successful treatment \\nincluding:  \\n● Harm reduction in terventions  \\n● Thorough baseline assessment for important comorbid conditions like \\nAdvanced HIV Disease (AHD) including TB, hepatitis, renal impairment \\nand depression or other psychiatric disorders  \\n● Negotiation for, and access to daily witnessed ingestion (DWI ). \\n● Community outreach and support', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 220}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 12 - 6 Table 12.1 Cont.  \\nPreventing and \\nmanaging drug -drug \\ninteractions  Selection of drugs should take into consideration possible drug to drug \\ninteractions and their effects on opioids, OST and ART. Any interaction that \\nreduces the levels of methadone may induce withdrawal symptoms and \\nrequire an increased dose of methadone.  \\n● ARV interactions with methadone and opioids  \\no NRTIs  \\n▪ TDF, TAF, 3TC, FTC: no significant interactions  \\n▪ AZT levels are increased, with higher risk of AZT toxicity.  \\n▪ ABC levels are decreased, and methadone levels are \\ndecreased.  \\no NNRTIs  \\n▪ EFV: methadone levels are decreased and may induce \\nwithdrawal symptoms.  \\no PI/r: all boosted PIs decrease methadone levels.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 221}),\n",
       " Document(page_content='o NNRTIs  \\n▪ EFV: methadone levels are decreased and may induce \\nwithdrawal symptoms.  \\no PI/r: all boosted PIs decrease methadone levels.  \\n▪ LPV/r and methadone increase risk for prolonged QT \\nsyndrome and sudden cardiac death.  \\no INSTIs: no significant interactions  \\n● ARV interactions with buprenorphine  \\no ATV/r and DRV/r increase concentrations of buprenorphine or \\nits active metabolites and may increase risk of toxicity.  \\no EFV decreases buprenorphine levels substantially.  \\no No known significant interactions with other ARVs  \\n● Rifampicin and Rifapentine decrease levels of methadone and \\nbuprenorphine and may induce withdrawal symptoms.  \\n● INH can be used safely with methadone or bupr enorphine  \\n● Management of Drug -Drug Interactions (Annex 13)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 221}),\n",
       " Document(page_content='● INH can be used safely with methadone or bupr enorphine  \\n● Management of Drug -Drug Interactions (Annex 13)  \\n \\nMonitoring ART  ● PWID on ART require more frequent monitoring and support to ensure \\nadherence to treatment and harm reduction interventions, assessment for \\nand management of adverse drug reactions or drug -drug interactions  \\n● Ongoing monitoring should also include screening for other illicit \\nsubstance/drug use.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 221}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 1  \\n13. Annexes  \\n \\nAnnex 1: WHO Clinical Staging of HIV Infection in Infants and Children  \\nStage I  \\n• Asymptomatic  \\n• Persistent generalized lymphadenopathy  \\n• (PGL)  \\n• Unexplained, asymptomatic \\nhepatosplenomegaly  Stage II  \\n• Papular pruritic eruptions (PPE)  \\n• Seborrheic dermatitis  \\n• Fungal nail infections  \\n• Angular cheilitis  \\n• Linear gingival erythema  \\n• Extensive HPV or molluscum infection (>5% of \\nbody area/face)  \\n• Recurrent oral ulcerations (>2 episodes/ in 6 \\nmonths)  \\n• Parotid enlargement  \\n• Herpes zoster (>1 episode/12 months)  \\n• Recurrent or chronic upper respiratory infection \\n(URI): otitis media, otorrhea, sinusitis (>2 \\nepisodes/6 months)  \\nStage III  \\n• Unexplained moderate malnutrition ( -\\n2SD or Z score) not responding to', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 222}),\n",
       " Document(page_content='episodes/6 months)  \\nStage III  \\n• Unexplained moderate malnutrition ( -\\n2SD or Z score) not responding to \\nstandard therapy  \\n• Unexplained persistent diarrhoea (>14 \\ndays)  \\n• Unexplained persistent fever  \\n• (Intermittent or constant, > 1 mo.)  \\n• Oral candidiasis (outside neonatal \\nperiod)  \\n• Oral hairy Leucoplakia  \\n• Pulmonary tuberculosis  \\n• Severe recurrent presumed bacterial \\npneumonia (>2 episodes/12 months)  \\n• Acute necrotizing ulcerative gingivitis/  \\n• periodontitis  \\n• Lymphoid interstitial pneumonitis (LIP)  \\n• Unexplained anaemia (<8g/dL), \\nneutropenia (<1,000/mm3), or \\nthrombocytopenia (<30,000/mm3) for \\n>1 mo.  \\n• HIV-related cardiomyopathy  \\n• HIV-related nephropathy  Stage IV  \\n• Unexplained severe wasting or severe malnutrition \\n(-3', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 222}),\n",
       " Document(page_content='>1 mo.  \\n• HIV-related cardiomyopathy  \\n• HIV-related nephropathy  Stage IV  \\n• Unexplained severe wasting or severe malnutrition \\n(-3 \\nSD or Z score) not responding to standard \\ntherapy  \\n• Pneumocystis pneumonia  \\n• Recurrent severe bacterial infections (>2 \\nepisodes/12 months, excluding pneumonia)  \\n• Chronic orolabial or cutaneous HSV (lasting > 1 \\nmo.)  \\n• Extra -pulmonary tuberculosis  \\n• Kaposi’s sarcoma  \\n• Oesophageal candidiasis  \\n• CNS toxoplasmosis  \\n• Cryptococcal meningitis  \\n• Any disseminated endemic mycosis  \\n• Cryptosporidiosis or Isosporiasis (with \\ndiarrhoea > 1 month)  \\n• CMV infection of organ other than liver, spleen, \\nlymph nodes (and onset age >1 month)  \\n• Disseminated mycobacterial disease other \\nthan tuberculosis  \\n• Candida of trachea, bronchi or lungs', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 222}),\n",
       " Document(page_content='lymph nodes (and onset age >1 month)  \\n• Disseminated mycobacterial disease other \\nthan tuberculosis  \\n• Candida of trachea, bronchi or lungs  \\n• Acquired recto -vesicular fistula  \\n• Cerebral or B -cell non -Hodgkin’s lymphoma  \\n• Progressive multifocal leukoencephalopathy PML)  \\n• HIV encephalopathy  \\nNOTE: WHO Clinical Staging should be carried out only on children confirmed (by serology or DNA PCR) \\nto be HIV infected', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 222}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 2 Annex 2: WHO Clinical Staging of HIV Infection in Adolescents and Adults  \\nStage 1  \\n• Asymptomatic  \\n• Persistent Generalized  \\nLymphadenopathy (PGL)  Stage 2  \\n• Moderate unexplained weight loss (< 10% of presumed \\nor measured body weight)  \\n• Minor mucocutaneous manifestations (seborrheic \\ndermatitis, papular pruritic eruptions, fungal nail \\ninfections, recurrent oral ulcerations, angular cheilitis)  \\n• Herpes zoster  \\n• Recurrent upper respiratory tract infections (sinusitis, \\ntonsillitis, bronchitis, otitis m edia, pharyngitis)  \\nStage 3  \\n• Unexplained severe weight loss \\n(over  \\n• 10% of presumed or measured \\nbody weight)  \\n• Unexplained chronic diarrhoea for \\nlonger than one month  \\n• Unexplained persistent fever', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 223}),\n",
       " Document(page_content='(over  \\n• 10% of presumed or measured \\nbody weight)  \\n• Unexplained chronic diarrhoea for \\nlonger than one month  \\n• Unexplained persistent fever \\n(intermittent or constant for longer \\nthan one month)  \\n• Persistent oral candidiasis  \\n• Oral hairy leukoplakia  \\n• Pulmonary tuberculosis  \\n• Severe bacterial infections (e.g., \\npneumonia, empyema, \\npyomyositis, bone or joint \\ninfection, meningitis, bacteraemia)  \\n• Acute necrotizing ulcerative \\nstomatitis, gingivitis or \\nperiodontitis  \\n• Unexplained anaemia (below 8 \\ng/dl), neutropenia (below 0.5 x \\n109/l) and/or chronic \\nthrombocytopenia (below 50 x 109 \\n/l) Stage 4  \\nConditions where a presumptive diagnosis can be made \\nusing clinical signs or simple investigations:  \\n•   HIV wastin g syndrome  \\n•   Pneumocystis jirovecipneumonia (PCP)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 223}),\n",
       " Document(page_content='using clinical signs or simple investigations:  \\n•   HIV wastin g syndrome  \\n•   Pneumocystis jirovecipneumonia (PCP)  \\n•   Recurrent severe bacterial pneumonia (≥ 2 episodes \\nwithin 1 year)  \\n•   Cryptococcal meningitis  \\n•   Toxoplasmosis of the brain  \\n•   Chronic orolabial, genital or ano -rectal herpes simplex \\ninfection for > 1 month  \\n•   Kaposi’s sarcoma (KS)  \\n•   HIV encephalopathy  \\n•   Extra pulmonary tuberculosis (EPTB) Conditions \\nwhere confirmatory diagnostic testing is  \\nnecessary:  \\n•   Cryptosporidiosis, with diarrhoea > 1 month  \\n•   Isosporiasis  \\n•   Cryptococco sis (extra pulmonary)  \\n•   Disseminated non -tuberculous mycobacterial infection  \\n•   Cytomegalovirus (CMV) retinitis or infection of the \\norgans (other than liver, spleen, or lymph nodes)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 223}),\n",
       " Document(page_content='•   Cytomegalovirus (CMV) retinitis or infection of the \\norgans (other than liver, spleen, or lymph nodes)  \\n•   Progressive multifocal leukoencephalopathy (PML)  \\n•   Any disseminated mycosis (e.g., histoplasmosis, \\ncoccidiomycosis)  \\n•   Candidiasis of the esophagus or airways  \\n•   Non -typhoid salmonella (NTS) septicaemia  \\n•   Lymphoma cerebral or B cell Non -Hodgkin’s Lymphoma  \\n•   Invasive cervical cancer  \\n•   Visceral leishmaniasis  \\n•   Symptomatic HIV -associated nephropathy or HIV  \\nassociated cardiomyopathy', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 223}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 3 Annex 3: Normal Developmental Milestones in Children  \\nAGE  GROSS MOTOR  FINE MOTOR  WARNING SIGNS  \\n3 Months  Supine:  \\n● Pull to sit:  \\n● 45 o head lag still present  \\nSitting: Propped up  \\n● Flexed/C -Position  \\n● Hold head steady  \\nProne:  \\n● Bears weight on flexed arms  \\n● Lifts head 45 o turn head to side  Eyes:  \\n● Follow through 90 o in lying  \\nHands:  \\n● Open for longer  \\n● Shake a rattle when it is placed \\nin the hand (not intentional)  \\n● Mouthing begins  ● No visual fixation or following \\nasymmetry of tone or movement.  \\n● Floppy/stiff  \\n● Consistent fisting  \\n● Unstable to turn or lift head  \\n● Failure to smile  \\n● Poor sucking & swallowing  \\n6 Months  \\n Supine:  \\n● Pull to sit, no more head lag  \\n● Plays with feet  \\n● Rolls from back to tummy', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 224}),\n",
       " Document(page_content='● Poor sucking & swallowing  \\n6 Months  \\n Supine:  \\n● Pull to sit, no more head lag  \\n● Plays with feet  \\n● Rolls from back to tummy  \\nSitting:  \\n● Unaided supported by arms  \\nStanding:  \\n● Bears weight on legs, equal both sides  \\nProne:  \\n● Props self on straight arms, legs \\nextended, toes turned outwards  Eyes:  \\n● Follow through 180 o in lying  \\n● Focus on small objects  \\nHands:  \\n● Hands on midline  \\n● Banging blocks against the table \\nreaches and attains objects at \\nwill Holds and actively plays \\nwith rattle  ● Floppiness  \\n● No head control  \\n● Failure to use both hands  \\n●  Asymmetrical movement squint  \\n● Failure to turn to sound  \\n● Poor response to people  \\n9 Months  Sitting:  \\n● Sits without support lean forward  \\n● And sit up again without losing balance  \\nStanding:', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 224}),\n",
       " Document(page_content='● Poor response to people  \\n9 Months  Sitting:  \\n● Sits without support lean forward  \\n● And sit up again without losing balance  \\nStanding:  \\n● Remain standing for a few seconds by \\nholding onto an object, falls down again  \\nProne:  \\n● Baby starts to crawl  Eyes:  \\n● Extremely accurate vision  \\nHands:  \\n● Can pick up and button  \\n● Holds a block in each hand  \\n● Points  ● Unable to sit  \\n● Failure to use both hands  \\n● Fisting  \\n● Squint  \\n● Persistence of primitive reflexes  \\n12 Months  \\n Sitting:  \\n● Turns around to reach nearby toys  \\n● Sits down unaided from standing  \\nStanding: (Walking)  \\n● Walks forward if held by one hand  \\n● Walks around furniture sideways -cruising  \\nProne: (crawling)  \\n● Crawls  \\n● Pulls up to standing by holding onto object  Eyes:', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 224}),\n",
       " Document(page_content='● Walks around furniture sideways -cruising  \\nProne: (crawling)  \\n● Crawls  \\n● Pulls up to standing by holding onto object  Eyes:  \\n● Looks for toys when out of sight  \\nHands:  \\n● Able to pick up a button with thumb and \\nindex finger (pincer grasp)  \\n● Release on request  \\n● Hold with 1 hand and play with the other  \\n● Throws things into a container and take \\nit out again  ● Unable to bear \\nweight on legs  \\n● Not yet crawling and \\npulling to stand  \\n● Abnormal grasp  \\n● Failure to  respond to \\nsound  \\n● Unable to start with \\nsolids independently  \\n15 Months  \\n Sitting:  \\n● Stand up from sitting  \\n● Will climb on a chair and sit down  \\nStanding: (Walking)  \\n● Bend over to pick up an object  \\n● Squat and stand up again  \\n● Walks alone, broad base with arms in the airs  \\nProne: (crawling)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 224}),\n",
       " Document(page_content='● Bend over to pick up an object  \\n● Squat and stand up again  \\n● Walks alone, broad base with arms in the airs  \\nProne: (crawling)  \\n● Able to crawl fast and manage obstacles e.g., stairs  Eyes:  \\n● Hold crayon in a fist when \\nscribbling  \\n● Turn pages of a book roughly  \\n● Hold 2 small toys in 1 hand  \\n● Put lid back on container  ● Unable to bear \\nweight on legs  \\n● Not yet wal king  \\n● Abnormal grasp  \\n● Abnormal posture: \\nfloppy/spastic  \\n● Failure to respond to \\nsound  \\n● Not yet talking  \\n18 Months  ● Walking with more confidence  \\n● Walk, squat and pick up something, \\nstand up and walk again  \\n● Starts running, often falls  \\n● Take few steps backwards  \\n● Runs and change direction easily  \\n● Jump off step with 2 feet together  \\n● Stand and kick a ball', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 224}),\n",
       " Document(page_content='● Take few steps backwards  \\n● Runs and change direction easily  \\n● Jump off step with 2 feet together  \\n● Stand and kick a ball  \\n● Able to throw a ball  ● Build a 3 -cube tower  \\n● Scribbles  \\n● Holds the crayon in a fist  \\n● Turn pages of a book  \\n● Page through a book page by page  \\n● Obvious hand preference  \\n● Uses lines: I, _,0  \\n● Completes 3 -piece puzzle  \\n● Remove a sweet wrapper with little help  ● Failure to walk  \\n● Unable to pick up small \\nobjects e.g., buttons  \\n● Abnormal posture  \\n● Not yet talking  \\n● Unable to understand \\nsimple commands  \\n● Poor co -ordination  \\n36 Months  ● Walk forward and backward  \\n● Walks on tip toes  \\n● Walks on straight line  \\n● Jump 2 feet together  \\n● Able to climb on chair  \\n● Catch a big ball (hugging against chest)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 224}),\n",
       " Document(page_content='● Walks on tip toes  \\n● Walks on straight line  \\n● Jump 2 feet together  \\n● Able to climb on chair  \\n● Catch a big ball (hugging against chest)  \\n● Holds ball above head and throws  \\n● Runs and kicks ball  ● Copies the following shapes: _, I, O, T \\n● Start coloring in, go over the lines  \\n● Pencil grip:  \\n● Holding crayon to draw (still developing)  \\n● Builds a 9 -block tower  \\n● Thread big beads on a shoelace  \\n● Draw a man: at least 4 parts  ● Using only single \\nwords  \\n● Ataxia', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 224}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 4 Annex 4: Tanner Staging of Sexual Maturity in Adolescents  Annex 4 A: Tanner Staging of Sexual Maturity in Girls  \\nAge Range  \\n(Year)  \\n0-15 \\n8-15 \\n10-15 \\n10-17 \\n12-18 Tanner Staging in  \\n Annex 4 B: Tanner Staging of Sexual Maturity in Boys  \\nAge Range  \\n(Year)  \\n0-15 \\n \\n10-15 \\n \\n10-16 \\n \\nVariable  \\n(12-17) \\n13-18 Tanner Staging in', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 225}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 5 Annex 5: Age -Appropriate Disclosure for Children and Adolescents  \\nAge \\nCharacteristics  Stage of \\nDisclosure  Provider Actions  \\n0 - 4 years  No disclosure  At this stage no disclosure is done since the child is too young \\nto understand about HIV  \\n5 - 8 years  Partial disclosure  At this age the child can understand a lot. Define the virus as a \\ngerm and the CD4 as the soldier in the body that keeps fighting \\nand one has to take the drugs to strengthen the soldiers in the \\nbody  \\n9 to 12 years  Full disclosure  Full disclosure is important since most children at this stage \\nare able to understand more about HIV and would have heard \\nabout HIV as part of formal education at school  \\nFollow the following stages in the disclosure process  \\nStage 1', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 226}),\n",
       " Document(page_content='about HIV as part of formal education at school  \\nFollow the following stages in the disclosure process  \\nStage 1  \\nAssessing the child’s social support system to ensure \\navailability of sufficient support once disclosure is completed  \\nStage 2  \\nAssess the child’s prior knowledge about HIV including \\ninformation given at school, any myths and misconceptions. \\nOffer or reinforce accurate information  \\nStage 3  \\nUse an imaginary exercise or story to assess child’s reaction to \\ndisclosure of HIV status  \\nStage 4  \\nTell the child about their HIV status. Support parents to \\ndisclose to the child and clarify the mode of infect ion. Address \\nimmediate reactions and concerns a child might have  \\nPost -disclosure  \\n(1-2 weeks after', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 226}),\n",
       " Document(page_content='immediate reactions and concerns a child might have  \\nPost -disclosure  \\n(1-2 weeks after \\nfull disclosure)  Find out from the parent/guardian if they have observed \\nanything after disclosure, e.g., change in behavior  \\n• Introduce the child to tell their story and emerge as a hero \\n(a comic book may be a useful aid)  \\n• Link the child to a support group or with an older child \\nwho has been disclosed to  \\nNB: Find out how the child is doing at every visit after full \\ndisclosure', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 226}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 6 Annex 6: Transitioning from Adolescent to Adult HIV Services  \\nInitiate transition process for all children in \\npaediatric clinic who have attained 10 years of ageGoal 1 : for age 10 -12 years (early -adolescence)\\n•  Full disclosure\\n•  Understanding of the HIV\\n•  Understanding of HIV prevention measures\\n•  Link to an adolescent support group Has adolescent attained 13years and achieved Goal 1 \\nabove?\\nYes: Client is 13years and has achieved \\ngoals at early adolescence continue to \\ngoal 2No: Client is 13years and has \\nnot achieved goals 1 at early \\nadolescence\\nGoal 2 : for age 13 -16 years (mid -adolescence)\\n•  Understanding of the medication and adherence\\n•  Encourage appointment keeping', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 227}),\n",
       " Document(page_content='adolescence\\nGoal 2 : for age 13 -16 years (mid -adolescence)\\n•  Understanding of the medication and adherence\\n•  Encourage appointment keeping\\n•  Should be a member of a support group\\nHas adolescent attained 17years and achieved Goal 2 above?No: Client is 17 years and has not \\nachieved goals at mid adolescence\\nYes: Client is 17 years and has achieved goals at mid adolescence\\nGoal 3 : for age 17 -19 years (late -adolescence)\\n• Demonstrated understanding importance of medication adherence in last 2 -3 visits\\n• Prompt appointment keeping for 6months\\nHas adolescent attained 19years and achieved Goal 3 above?\\n Client chooses to transition\\n Transfer medical records\\n Orient adolescent in adult clinic\\n Follow up of transitioned adolescentsClient declines to transition', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 227}),\n",
       " Document(page_content='Transfer medical records\\n Orient adolescent in adult clinic\\n Follow up of transitioned adolescentsClient declines to transition\\n Continue psychosocial support to client as you prepare for transition to \\nadult clinic', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 227}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 7 Annex 7: 2018 HIV Testing Services Algorithm  \\nSCREENING\\nNON REACTIVE REACTIVE\\nREPORT NEGATIVE CONFIRMATORY TEST\\nNON REACTIVE REACTIVE\\nINCONCLUSIVE REPORT POSITIVE\\nREFER TO THE COMPREHENSIVE CARE CLINIC\\nSCREENING TEST SCREENING TEST\\nNON REACTIVE REACTIVE NON REACTIVE\\nCONFIRMATORY TEST\\nNON REACTIVE REACTIVE\\nREPORT INCONCLUSIVE REPORT POSITIVECollect DBS and \\nsend to laboratory \\nfor DNA PCRINCONCLUSIVE\\nRequest for retest \\nafter 2 weeks at \\nCCC\\nIf the result is still \\ninconclusive, \\ncollect DBS and \\nsend to the \\nlaboratory for DNA \\nPCREnroll to care and \\ntreatment \\nNB:  The use of TIE BREAKER is no longer recommendedRetesting in MCH, wards or \\nsettings without CCCs: To be \\ndone by a different service \\nprovider on a second \\nspecimen\\nREPORT NEGATIVE', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 228}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 8 Annex 8: HIV Education and Adherence Counselling Content Guide  \\nHIV Education and Adherence Counselling  \\nNote: for children/adolescents, the script below should be modified towards the caregiver  \\nSection 1: Introductions, climate setting, and review of objectives for the session  \\n• Ensure privacy and confidentiality  \\n• Introductions of all pa rticipants  \\n• Present the key message for each section using simple terms that the patient will understand, \\nusing analogies as appropriate  \\n• Use IEC material when available  \\n• Ask the patient if they have any questions at the end of each section, and then ask them to explain the \\nmain points back to you to confirm understanding', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 229}),\n",
       " Document(page_content='main points back to you to confirm understanding  \\n• If this is a follow -up session, review what they remember from previous sessions and adapt the \\nsession  to address their needs  \\nSection 2: HIV  \\n• What is HIV  \\n− HIV stands for “Human Immunodeficiency Virus”  \\n− HIV is a virus that attacks the body’s immune system.  The immune system protects the \\nbody from infections  \\n• How is HIV transmitted  \\n− Sexual contact  \\n− Needles  \\n− Exchange of blood and bodily fluids  \\n− Mother -to-child transmission  \\n• Why should family members be tested for HIV  \\n− Sexual partners are at risk for already having HIV  \\n− All children born to HIV positive mothers are at risk for already having HIV  \\n− Encouraging partners/children to test for HIV now is the best way to identify HIV early, so', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 229}),\n",
       " Document(page_content='− Encouraging partners/children to test for HIV now is the best way to identify HIV early, so \\nthey can also get into treatment  \\n− Starting treatment early will help them live long and productive lives  \\n− Whether they test positive or negative, they can be an impor tant source of support for your \\nown treatment', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 229}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 9 Annex 8: Cont.  \\nSection 3: Viral load  \\n• What is viral load  \\n- Viral load is the amount of HIV in your body  \\n- When your viral load is high it means you have a lot of HIV in your body; this causes damage to \\nyour body  \\n- Viral load is measured by a blood test  \\n \\n• How often is viral load measured  \\n- Viral load is measured after being on treatment for 3 months  \\n- After 3 months of treatment, we expect the amount of virus in your body to be undetectable; if \\nyour VL is detectable then we have to discuss the reasons  \\n- Having an “undetectable” VL means the test cannot measure the virus in your blood because \\nyour ART is working, but it does not mean you are no longer infected with HIV', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 230}),\n",
       " Document(page_content='your ART is working, but it does not mean you are no longer infected with HIV  \\n- Repeat viral load tests are done dependin g on how you are doing; if you are doing well on \\ntreatment then the viral load is measured again every 6 months (for children/adolescents and \\npregnant/breastfeeding) or annually  \\n- For HEI with positive PCR, we also measure viral load at the start of treatmen t \\n \\n• What do viral load measurements mean  \\n- After being on treatment for 3 or more months, your viral load should be undetectable  \\n- If your viral load is undetectable, it means your treatment is working well and you should \\ncontinue taking it the same; the virus is not damaging your body any more  \\n- If your viral load is detectable, it means your treatment is not working properly, usually because', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 230}),\n",
       " Document(page_content='- If your viral load is detectable, it means your treatment is not working properly, usually because \\nyou have been missing some of your pills; the virus is damaging your body and you and the clinic \\nteam will need to work together to figure out how to fix the problem  \\nSection 4: CD4 cells  \\n• What are CD4 cells  \\n- CD4 cells are the immune cells that protect the body from infections  \\n- CD4 cells are measured through a blood test, called CD4 count. For adults a normal CD4 count is \\nabove 500  \\n \\n• How are CD4 cells affected by HIV  \\n- HIV attacks and destroys CD4 cells  \\n- After years of constant attack from HIV, the CD4 count falls  \\n \\n• What happens when CD4 cells decrease  \\n- When the CD4 count falls too low (usually below 200), diseases called “opportunistic infections”', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 230}),\n",
       " Document(page_content='• What happens when CD4 cells decrease  \\n- When the CD4 count falls too low (usually below 200), diseases called “opportunistic infections” \\nare able to infect the body because the body cannot defend itself  \\n- Common opportunistic infections include: tuberculosis, pneumonia, skin problems, white spots \\nin the mouth, and chronic diarrhoea  \\n \\n• How often is CD4 count measured  \\n- CD4 count is measured for all patients at the beginning of treatment, to see if you are likely to get \\nany opportunistic infections  \\n- Once you start treatment for HIV, we do not need to check CD4 count frequently, but we will use \\nthe VL tes t to monitor your response to anti -retroviral treatment', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 230}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 10 Annex 8: Cont.  \\nSection 5: Antiretroviral therapy (ART)  \\n• What is ART:  \\n- ART is a combination of 3 or more different medicines  \\n- ART fights HIV, lowering the amount of virus in the body allowing the body to protect \\nitself against opportunistic infections  \\n- When the virus level is low then the CD4 count can increase  \\n- Increased CD4 count means the body is able to protect itself against opportunistic infections  \\n \\n• What are the benefits of ART:  \\n- After a few weeks of taking ART, you will begin to regain appetite and weight (if it has been \\naffected)  \\n- Many people report an increase in their energy levels and general sense of well being', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 231}),\n",
       " Document(page_content='affected)  \\n- Many people report an increase in their energy levels and general sense of well being  \\n- People can often return to work or school or care for their families  \\n- With ART,  people with HIV can live a long and healthy life if they take it properly  \\n \\n• When is ART started:  \\n- Everybody with HIV should start ART  \\n- Even if your CD4 count is high, the virus is doing damage inside of you and needs to be \\ncontrolled  \\n- ART should be started as soon as you are ready, preferably within 2 weeks  \\n- The longer you wait to start ART, the more time the virus can damage your body, increasing \\nyour chances of getting sick or even dying  \\n- Sometimes ART is started a few weeks later if you have certain infections, or if you do not \\nthink you are ready to take them properly', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 231}),\n",
       " Document(page_content='- Sometimes ART is started a few weeks later if you have certain infections, or if you do not \\nthink you are ready to take them properly  \\n \\n• Does ART cure HIV:  \\n- ART does not cure HIV  \\n- ART lowers the amount of virus in your body so your body can protect itself from infections  \\n- It does not remove the virus completely  \\n \\n• Can you still give HIV to others while taking ART:  \\n- Transmission of HIV is very unlikely once your viral load is undetectable  \\n- You should practice safer sex to reduce the risk for other infections as well, including \\ndisclosure of HIV status to sexual partners and consistent and correct condom use  \\n \\n• How long is ART taken for:  \\n- ART is a life -long treatment', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 231}),\n",
       " Document(page_content='• How long is ART taken for:  \\n- ART is a life -long treatment  \\n- Once you start ART, you need to take it every day for the rest of your life (either once a day, \\nor twice a day, depending on which drugs you are on)  \\n- You must take the ART as prescribed and never miss a dose otherwise the treatment might \\nfail and the drugs stop working against the virus', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 231}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 11 Annex 8: Cont.  \\nSection 6: Treatment failure  \\n• What happens if you stop taking ART:  \\n- When you stop taking ART the virus begins to increase in your body very quickly  \\n- The virus goes back to the same high level it was at before you started ART  \\n• What happens if you do not take ART regularly:  \\n- The virus begins to increase to high levels again  \\n• What happens if t he viral load increases:  \\n- When the virus is allowed to increase again, it will also affect your immunity and reduce your CD4 count \\nputting you at risk of opportunistic infections  \\n- When the virus is allowed to increase again, it can change and get stronger, a nd becomes resistance to \\nthe ART  \\n- When the virus becomes resistant, the ART does not work against the virus anymore', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 232}),\n",
       " Document(page_content='the ART  \\n- When the virus becomes resistant, the ART does not work against the virus anymore  \\n- The risk of resistance increases by not taking the ART correctly and by starting and stopping the \\nmedications several times  \\n- When resistance o ccurs, this is called treatment failure  \\n• What happens in treatment failure:  \\n- The ART no longer works because the virus has become resistant to it  \\n- If treatment fails, it is necessary to use stronger, more expensive ART, but it still may not work as well  \\n- With the stronger ART you may need to take more pills every day, and you may have more side effects  \\n- If you become resistant to the new ART as well, then there may not be any drugs that can work for you, \\nand the virus will increase quickly and your CD4 coun t will go way down', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 232}),\n",
       " Document(page_content='and the virus will increase quickly and your CD4 coun t will go way down  \\n- It is essential that you take your ART every day as prescribed so that you do not develop treatment \\nfailure, and can live a long and healthy life  \\nSection 7: ART side effects  \\n• What are the side -effects of ART:  \\n- Sometimes people can get side effects from taking ART  \\n- Side effects vary from person to person  \\n- Some people have none while other experience mild effects which are unpleasant but often manageable  \\n- Most side effects occur within the first few weeks of starting ART and then improve aft er a few weeks or \\nmonths  \\n- Some common side effects include:  \\n● Headache  \\n● Loss of appetite  \\n● Skin rash  \\n● Fatigue  \\n● Nausea, vomiting, diarrhoea  \\n● Muscle pains', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 232}),\n",
       " Document(page_content='- Some common side effects include:  \\n● Headache  \\n● Loss of appetite  \\n● Skin rash  \\n● Fatigue  \\n● Nausea, vomiting, diarrhoea  \\n● Muscle pains  \\n• What do you do if you notice any side effects:  \\n- If you develop any side effects, you should continue taking your ART as prescribed, without missing any \\ndoses, until you discuss with the clinician  \\n- If the side effects are mild then you can continue taking your ART without missing any doses, and then \\ndiscuss the side effects with the clinician at your next appointment  \\n- If the side effects are bothering you too much then return to the clinic immediately, even if you do not \\nhave a scheduled appointment, to discuss what to do next; you can also call the clinic if you are not able \\nto make it yourself immediately', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 232}),\n",
       " Document(page_content='have a scheduled appointment, to discuss what to do next; you can also call the clinic if you are not able \\nto make it yourself immediately  \\n- Severe side effects include rash all over your body, or rash in your mouth or eyes, constant vomiting, \\ninability to eat or retain food, or anything else that makes you think you should stop the ART. If this \\noccurs then contact the clinic immediately  \\n- The cl inician will help you manage the side effects, and occasionally the ART may need to be changed', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 232}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 12 Annex 8: Cont.  \\nSection 8: Adherence  \\n• What is adherence  \\n- Following a care plan as agreed with the healthcare team  \\n- Attending clinic appointments as scheduled  \\n- Picking up medicines and taking them as prescribed  \\n- Getting lab tests according to the recommended schedule  \\n- Following nutritional recommendations  \\n• How should ART be taken  \\n- You must take the correct dosage. If you take less than the dose prescribed the treatment will \\nnot be effective and will result in resistance and treatment failure. Never share your ART with \\nsomeone else  \\n- For children, the dosage keeps changing as they grow and gain weight  \\n- You must take ART the correct time of day:', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 233}),\n",
       " Document(page_content='someone else  \\n- For children, the dosage keeps changing as they grow and gain weight  \\n- You must take ART the correct time of day:  \\n• If your ART is supposed to be taken once per day, then pick a time when it will usually be \\nconvenient for you to remember, e.g., with breakfast every day.  \\n• If your ART is supposed to be taken twice per day, then you should set a convenient time to \\ntake your dr ugs approximately 12 hours apart (e.g., 8.00 am and 8.00 pm every day). It \\ndoes not have to be exactly 12 hours apart if your schedule does not allow; the most \\nimportant thing is to take them twice per day every day (e.g., you can take it at 6.00 am and \\n8.00 pm every day)  \\n- If you miss a dose of ART then take your dose as soon as you remember, as long as it is not', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 233}),\n",
       " Document(page_content='8.00 pm every day)  \\n- If you miss a dose of ART then take your dose as soon as you remember, as long as it is not \\nwithin a couple of hours of your next dose, and then return to your regular schedule. Do not \\ntake a double -dose of ART to make up for a missed dose  \\n- You must take ART according to dietary restrictions. Some ART should be taken with food, for \\nsome it does not matter, and a few require that you have an empty stomach. These dietary \\nrestrictions will be explained to you once your ART regimen is  selected  \\n- It is essential to take ART as prescribed and not miss any doses  \\n- Some medications (prescription, non -prescription, and herbal) interact with ART and make \\nthem ineffective. Be sure to tell your clinician and pharmacist the names of all the medicat ions', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 233}),\n",
       " Document(page_content='them ineffective. Be sure to tell your clinician and pharmacist the names of all the medicat ions \\n(including traditional/herbal) that you are taking, and any time you are given new medications. \\nAvoid use of alcohol  \\n• What usually interferes with good adherence (can apply to the patient or to the caregiver)  \\n- Stigma: it is hard to take ART correctly if you need to hide it because you are worried about \\npeople finding out you have HIV  \\n- Disclosure: it is hard to take ART correctly if the people closest to you, particularly family \\nmembers and close friends, do not know you have HIV  \\n- Change in rout ine: if your daily routine suddenly changes it may be difficult to remember to \\ntake your ART at the usual time', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 233}),\n",
       " Document(page_content='- Change in rout ine: if your daily routine suddenly changes it may be difficult to remember to \\ntake your ART at the usual time  \\n- Travel: frequent travel, or unexpected travel (such as for a funeral) may interfere with taking \\nART, particularly if you do not have enough drugs  with you for the entire trip  \\n- Alcohol and drug use: it is hard to remember to take ART when under the influence of alcohol \\nor other drugs  \\n- Caregiver changes: every time a child has a new caregiver, that person needs to learn about \\nhow and why ART is taken  \\n- Side effects: when people get side effects from ART they sometimes stop or reduce the amount \\nof ART they are taking, hoping it will reduce the side effects', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 233}),\n",
       " Document(page_content='of ART they are taking, hoping it will reduce the side effects  \\n- Pill burden/palatability: sometime the number of pills (or taste of syrups for children) makes it \\ndifficult to take ART correctly', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 233}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 13 Annex 8: Cont.  \\n- Distance: choosing an HIV clinic that is far away from your home can make it difficult to come to \\nappointments and pick drugs regularly  \\n- HIV knowledge: when people do not understand what HIV is, and why ART is important, they \\nmay not take their drugs properly. This also applies to children and adolescents, if they have \\nnot been told they have HIV and taught what it means  \\n- Mental health disorders: depression and other mental illnesses can make it difficult to t ake ART \\ncorrectly  \\n- Religious beliefs: some people stop taking ART after faith -healing, although there has never \\nbeen a case of someone being cured of HIV this way  \\n• What might make it difficult for you individually to take your ART as prescribed', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 234}),\n",
       " Document(page_content='been a case of someone being cured of HIV this way  \\n• What might make it difficult for you individually to take your ART as prescribed  \\n- Ask the patie nt: “Based on what you have learned so far, what challenges do you think you will \\nhave taken  ART correctly, every day, for the rest of your life?”  \\n- Discuss strategies to manage any expected barriers to adherence  \\n• What can help you take ART as prescribed  \\n- Disclosure: It is easier to take your ART properly when the people close to you know your HIV \\nstatus, so you do not have to try and hide your ART or miss doses to avoid being seen. Family \\nand friends can also provide additional support once they  are aware you have HIV and \\nunderstand more about it. We can help you disclose your HIV status to important family', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 234}),\n",
       " Document(page_content='understand more about it. We can help you disclose your HIV status to important family \\nmembers or friends when you are ready  \\n- Treatment supporter: Having a “treatment buddy” can help you take your ART correctly; ask a \\nfriend, par tner, or family member to remind you to take your ART. If possible, invite that \\nperson with you to some of your clinic appointments and counselling sessions so they can learn \\nabout ART, the importance of good adherence, side effects, etc.  \\n- SMS reminder syst em (if SMS reminder system in place at the facility): Receiving a regular SMS, \\ne.g., every week, can help you take your ART correctly. We enroll all our patients into this \\nservice for SMS reminders at our clinic, unless you do not want to receive them. The  messages', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 234}),\n",
       " Document(page_content='service for SMS reminders at our clinic, unless you do not want to receive them. The  messages \\nsimply ask how you are doing, and do not mention HIV, ART, the clinic, or anything else that \\nmay reveal your HIV status to others  \\n- Support group: Joining a support group will help you learn from other people how they \\novercome challenges in living with HIV and taking ART correctly. Some support groups also \\nhave economic activities to help increase your income. We have support groups based at the \\nhealth facility, and there are also support groups in the community  \\n- Other reminders:  \\n- Set a specific time of day to take your ART  \\n- Associate your ART with a specific event/s in your daily schedule (e.g., when you eat \\nbreakfast and dinner)  \\n- Set an alarm on your phone or watch', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 234}),\n",
       " Document(page_content='breakfast and dinner)  \\n- Set an alarm on your phone or watch  \\n• What happens if you miss an appointment?  \\n• The healthcare team will be concerned about you, and will try to contact you by phone  \\n- Confirm patient phone number and consent to call if misses an appointment or any urgent \\nlab results  \\n• If we cannot contact you by phone, we will try to call your treatment buddy  \\n- Confirm treatment buddy name and phone number, and consent to call if needed  \\n• If we cannot reach you or your treatment buddy, we may try and visit you at home, if we have \\nyour permission  \\n- Confirm locator information and consent to perform home visits if needed  \\n• Once you are back in care, we will work with you to figure out what caused you to miss an', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 234}),\n",
       " Document(page_content='• Once you are back in care, we will work with you to figure out what caused you to miss an \\nappointment and how it can be prevented in the future  \\n• You will not be punished for missing an appointment', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 234}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 14 Annex 8: Cont.  \\nSection 9: Other medications  \\n• What other medications will you take, in addition to ART:  \\n- CPT: all PLHIV should take cotrimoxazole preventive therapy once per day, in order to reduce \\nthe chance of getting other infections such as pneumonia, malaria, and diarrhoea  \\n- TPT: all PLHIV should receive 6 months of isoniazid preventive therapy (or another \\napproved TPT regimen), unless they have active TB disease, in order to prevent \\ndevelopment of TB  \\n• Other medications may be recommended for specific conditions  \\nSection 10: Nutrition  \\n• Why is nutrition important:  \\n- When the viral load is high, your body uses a lot of energy trying to fight the virus', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 235}),\n",
       " Document(page_content='Section 10: Nutrition  \\n• Why is nutrition important:  \\n- When the viral load is high, your body uses a lot of energy trying to fight the virus  \\n- If your nutrition is poor, you have more chance of getting other infections as well  \\n- You need to eat well so your body has everything it needs to fight HIV, and look healthy  \\n• What can you do to improve your nutrition?  \\n- Eat a balanced diet from a variety of foods.  \\n- Try not to eat a lot of sugar, red meat, or fatty/fried foods  \\n- Try to eat plenty of whole grains, vegetables, fruit, beans, and fish  \\n- Drink plenty of clean safe water  \\n- Physical activity and exercise is encouraged.  \\nSection 11: Follow -up \\n• How often will you need to come to the clinic', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 235}),\n",
       " Document(page_content='- Physical activity and exercise is encouraged.  \\nSection 11: Follow -up \\n• How often will you need to come to the clinic  \\n- Before starting ART: you should come to the clinic at least every week in order to get you prepared \\nfor ART so you can start as soon as possible  \\n- Soon after starting ART: after you start ART you should come to the clinic in 2 weeks in order to \\nsee if you have had any trouble taking your pills or have developed any side effects; then you can \\nbe seen after another two weeks for the same; then every month until your first viral load test  \\n- Once you have been on ART for a while: if your first viral load (after 3 months) is undetectable \\nthen you can be seen every 1 -6 months depending on other factors  that will be discussed with the \\nclinician', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 235}),\n",
       " Document(page_content='then you can be seen every 1 -6 months depending on other factors  that will be discussed with the \\nclinician  \\n- Unscheduled visits: if you ever have any concerns, feel unwell, or need to speak with any of the \\nclinic team then you can call or come to the clinic, even if you do not have an appointment \\nscheduled for that day  \\n• What will we be checking for during your clinic visits  \\n- At each visit you will be asked if you have had any illnesses since the last visit, if you have had any \\ntrouble taking your ART, and if you are experiencing any side effects. You may need a physic al \\nexam or blood tests at some visits  \\nSection 12: ART readiness assessment  \\n• Are you ready to start ART today?  \\n- Complete the ART Readiness Assessment (Table 5.4) for each patient to see if they should', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 235}),\n",
       " Document(page_content='• Are you ready to start ART today?  \\n- Complete the ART Readiness Assessment (Table 5.4) for each patient to see if they should \\nstart ART today, and if not, to identify what issues need to be addressed before starting \\nART', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 235}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 15 Annex 8: Cont.  \\nSection 13: Management plan  \\n• Which investigations will you have today  \\n- See Table 3.2 and Table 3.5 for recommended baseline and follow -up investigations \\nrespectively  \\n• Which medications will you start today  \\n- May include: ART; CPT; TPT; other  \\n• What else is required as you start or as you prepare to start ART  \\n- May include: assisted disclosure; support group referral; engagement of a treatment \\nbuddy; drug and alcohol counselling; depression management; referrals; other  \\n- For patients not starting ART today, management plan should include specific \\nstrategies to address any issues preventing/delaying ART initiation  \\n• When should you return to the clinic', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 236}),\n",
       " Document(page_content='strategies to address any issues preventing/delaying ART initiation  \\n• When should you return to the clinic  \\n- Book appointment date  for next visit, preferably with the same healthcare worker', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 236}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 16 Annex 9 A: Enhanced Adherence Counselling Content Guide  \\nEnhanced Adherence Counselling for Patients with Suspected or Confirmed Treatment Failure  \\nNote: for children/adolescents, the script below should be modified towards the caregiver  \\nSession 1  \\n• Assess patient’s understanding of ‘viral load’, ‘high viral load’ and ‘suppressed viral load’. Ask \\nthe patient to explain what each of these terms mean. Provide education if patient requires \\nmore explanation  \\n• Provide VL result and explanation of result:  \\n“You have a detectable viral load. There are several possible reasons for this such as problems with \\nadherence, dosing of your medications, interactions wit h other drugs or foods, or possible drug', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 237}),\n",
       " Document(page_content='adherence, dosing of your medications, interactions wit h other drugs or foods, or possible drug \\nresistance. It is very important for us to work with you determine which may apply to you.”  \\n• How does the patient feel concerning the result?  \\n• Explain the process of enhanced adherence:  \\n“Patients with a high viral load come for at least 3 adherence counselling sessions to discuss what \\nmight cause a high viral and to look for solutions on how adherence can be improved. Another \\nviral load test will be done after 3 months of good adherence to see if the ART can b e continued or \\nif we need to change treatment.”  \\n• Check whether the patient had previous problems with adherence and/or missed \\nappointments  \\n• Ask:  \\n“Why do you think your viral load is high?”', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 237}),\n",
       " Document(page_content='• Check whether the patient had previous problems with adherence and/or missed \\nappointments  \\n• Ask:  \\n“Why do you think your viral load is high?”  \\n• Sometimes the patient already knows why his/her VL is detectable. Sta rt by giving them a \\nchance to provide their own explanation. Often, they will admit that they are struggling with \\ntheir adherence  \\n• If they really don’t know why their VL is high you can say:  \\n“We notice that when people sometimes forget to take their ART everyday it gives the virus a chance \\nto multiply. Do you think that you sometimes forget your pills?”  \\nAssess for Possible Barriers to Adherence  \\nCognitive Barriers (HIV and ART knowledge)  \\n• Assess patient’s knowledge about HIV and ART; correct any misconceptions  \\n“What is HIV?”', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 237}),\n",
       " Document(page_content='Cognitive Barriers (HIV and ART knowledge)  \\n• Assess patient’s knowledge about HIV and ART; correct any misconceptions  \\n“What is HIV?”  \\n“What is the immune system and CD4 cells?”  \\n“What is ART and how does it work?”  \\n“Why is it important to be adherent? And how?”  \\n“Why do you have to come for follow -up appointments? What should you bring?”', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 237}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 17 Annex 9A: Cont.  \\nBehavioural Barriers  \\n• Review how the patient takes drugs  \\n“Please explain how you take your drugs, and at what time?”  \\n“How does treatment fit in your daily routines?”  \\n• Establish with the patient whether the time they are meant to take their medication is \\nappropriate or whether the time is a problem. For example, if the patient has chosen 9 pm, \\nbut is already asleep in bed by 9 pm, then that is not a good dosing time. If the time is a \\nproblem, then determine a new, more appropriate time with the patient based on their \\nschedule  \\n• Remind the patient/caregiver that a missed dose should be taken as soon as he/she \\nremembers (up to a couple of hours before the next scheduled dose). The next dose should \\nbe taken at the usual time', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 238}),\n",
       " Document(page_content='remembers (up to a couple of hours before the next scheduled dose). The next dose should \\nbe taken at the usual time  \\n“What reminder tools do you use? (e.g., mobile phone alarm)” “What do you do in case of visits, and \\ntravel?”  \\n• Travelling is always a risk for poor adherence or default from treatment. Encourage the patient \\nto plan, to make sure they have enough medication on hand  before and to remember to pack \\nit \\n• Make sure that all relevant information is on the patient’s appointment card and explain that \\nif they are ever away from home and they are about to run out of medication that they must go \\nto the closest ART clinic and sho w their appointment card  \\n“What do you do in case of side effects?”', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 238}),\n",
       " Document(page_content='to the closest ART clinic and sho w their appointment card  \\n“What do you do in case of side effects?”  \\n• Ask the patient if s/he has any side effects from the ARVs, and if they sometimes find it \\ndifficult to take ARVs  \\n• Due to the side effects, ask how s/he manages side effects and if it influences the way s/he \\ntakes the drugs.  \\n“What are the most difficult situations for you to take drugs?”  \\n• Check for alcohol or drug use. Ask the patient in a casual way (not in an accusing way) if they \\nsometimes use substances; emphasize treatment planning in case they do  \\n• “Taking alcohol or drugs sometimes makes it difficult for us to remember to take treatment. If \\npossible, it is best to limit your use, but if you are planning to take any alcohol or drugs, it is', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 238}),\n",
       " Document(page_content='possible, it is best to limit your use, but if you are planning to take any alcohol or drugs, it is \\nimportant to plan ahead so that you don’t for get to take your treatment”  \\n“If you feel your alcohol or drug use is affecting your adherence, are you ready to be referred to some \\nprofessionals that may help you work on that problem?”', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 238}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 18 Annex 9A: Cont.  \\n● Emotional Barriers  \\n• Review the patient’s motivation:  \\n“How do you feel about taking drugs every day?” \\n“What are your ambitions in life?”  \\n• You can use motivation cards for this: Ask the patient to think of his or her own personal \\ngoals/dreams for the future. What are the 3 most important things they  still want to achieve? \\nHave them write them in their own words on a notecard. Encourage the patient to read the \\nnotecard every day, preferably right before they take their medication  \\n• Mental health screening:  \\n- Depression is an important reason of non -adherence.  All patients with suspected or \\nconfirmed treatment failure should be screened for depression using the PHQ -9 tool', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 239}),\n",
       " Document(page_content='confirmed treatment failure should be screened for depression using the PHQ -9 tool \\n(Table 4.14)  \\n- The patient may be in any of the five stages of grief (because of their HIV diagnosis or for \\nother reasons): deni al and isolation; anger; bargaining; depression, or; acceptance. This \\nneeds to be assessed and addressed  \\nSocio -economical Barriers  \\n• Review the patient’s disclosure of their HIV status  \\n“Do you have any people in your life who you can talk to about your HIV status and ART?”  \\n• Discuss how the patient can enlist the support of their family, friends, and/or co -workers in \\nreminding them to take their medication if they have not already done so  \\n• Support from a treatment buddy: if the patient came with treatment buddy, assess their input', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 239}),\n",
       " Document(page_content='• Support from a treatment buddy: if the patient came with treatment buddy, assess their input \\ntowards adherence. If patient did not come with treatment buddy, explain the role of a treatment \\nbuddy and encourage the patient to come with a person they trust next visit  \\n• Support in family/community/support group: expl ore support systems, in addition to the \\ntreatment buddy, that the patient is currently using and options that the patient can start using. \\nDiscuss the advantages of joining a support group and any reasons the patient is hesitant to join  \\n• Profession, income generating resources: review the patient’s and family’s sources of income \\nand how well they cover their needs  \\n• Specific barriers to come to health centre on regular basis: ask the patient if they have any', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 239}),\n",
       " Document(page_content='and how well they cover their needs  \\n• Specific barriers to come to health centre on regular basis: ask the patient if they have any \\nchallenges getting to the clinic on regular basis. Help the patient develop strategies to overcome \\nthose challenges  \\n• Stigma and discrimination  \\n“Are you ever worried about people finding out your HIV status \\naccidentally?” “Do you feel like people treat you differently when they know \\nyour HIV status?”  \\n• Discuss if stigma is making it difficult for them to take their medications on time, or for them \\nto attend clinic appointments  \\n• Religious beliefs: find out if the patient has tried faith healing, or if they have ever stopped taking \\ntheir medicine because of their religious beliefs', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 239}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 19 Annex 9A: Cont.  \\nReferrals and Networking  \\n• Review the patient’s file to determine if they have been referred to other services. This includes \\nreferrals to social services, support groups, psychology services, nutrition services, medical \\nclinics, substance abuse groups, etc.  \\n• Ask the patient if they attended the appointments, check in on their experience with the \\nreferral services and re -organize referrals as necessary  \\n• Determine if the patient could benefit from a home visit  \\nDevelop Adherence Plan  \\n• Go through each of the adherence challenges identified during the session and assist the \\npatient to develop a plan that addresses each of the issues. It is important to let the patient \\ncome up with the solutions so that they can own them', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 240}),\n",
       " Document(page_content='come up with the solutions so that they can own them  \\n• Some examples of addressing adherence challenges:  \\n- Behavioural barriers: using a reminder tool; using a pill box; redefining the medication \\nschedule to fit with the patient’s daily schedule; keeping an emergency dose of drugs when \\naway from home  \\n- Refer to clinician in case of side effects  \\n- Socio -economical barriers: move on to disclosure process; identify a treatment buddy; join a \\nsupport group; refer to CBO/NGO to learn about income generating activities  \\n- Emotional barriers: emotional support or refer to clinician for mental health management  \\nAgree on a follow -up date for the next session  \\n \\nSession 2 (usually 2 weeks after Session 1, preferably with the same provider)  \\nReview Adherence Plan', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 240}),\n",
       " Document(page_content='Session 2 (usually 2 weeks after Session 1, preferably with the same provider)  \\nReview Adherence Plan  \\n• Ask the patient if he/she thinks adherence has improved since the last visit. Enquire in a \\nfriendly way if any doses have been missed  \\n• Review the patient’s barriers to adherence documented during the first session and if \\nstrategies identified have been taken up. If  not, discuss why  \\nIdentify Any New Issues  \\n• Discuss specific reasons why the patient may have missed their pills or a clinic \\nappointment since the last counselling session, and determine if it is a new issue that \\nwasn’t addressed during the first session  \\n• Discuss if other issues have come up because of implementing the adherence plan (e.g., \\nperhaps the disclosure process had unintended results)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 240}),\n",
       " Document(page_content='• Discuss if other issues have come up because of implementing the adherence plan (e.g., \\nperhaps the disclosure process had unintended results)  \\nReferrals and Networking  \\n• Follow -up on any referrals made during the previous session  \\n• Determine if the patient could benefit from a home visit  \\nDevelop Adherence Plan  \\n• Go through each of the adherence challenges identified during the session and assist the patient \\nto modify their original adherence plan to address each of the issues. It is important to let the \\npatient come up with the solutions so that they own them  \\n• Give another short motivational speech on how you believe in the patient! You know they can \\ndo this! Together you will make sure that they suppress their viral load!!', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 240}),\n",
       " Document(page_content='do this! Together you will make sure that they suppress their viral load!!  \\n• Agree on a follow -up date fo r the next session', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 240}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 20 Annex 9A: Cont.  \\nSession 3 (usually 2 weeks after Session 2, preferably with the same provider)  \\nReview Adherence Plan  \\n• Ask the patient if he/she thinks adherence has improved since the last visit. Enquire in a \\nfriendly way if any doses have been missed  \\n• Review the patient’s barriers to adherence documented during the first session and if \\nstrategies identified have been taken up. If not, discuss why  \\n \\nIdentify Any New Issues  \\n• Discuss specific reasons why the patient may have missed their pills or a clinic appointment \\nsince the last counselling session, and determine if it is a new issue that wasn’t addressed \\nduring the first session', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 241}),\n",
       " Document(page_content='since the last counselling session, and determine if it is a new issue that wasn’t addressed \\nduring the first session  \\n• Discuss if other issues have come up because of implementing the adherence plan (e.g., perhaps \\nthe disclosure process had unintended results)  \\n \\nReferrals and Networking  \\n• Follow -up on any referrals made during the previous session  \\n• Determine if the patient could benefit from a home visit  \\n \\nDevelop Adherence Plan  \\n• Go through each of the adherence challenges identified during the session and assist the patient \\nto modify their original adherence plan to address each of the issues. It is important to let the \\npatient come up with the solutions so that they own them  \\n• Give another short motivati onal speech on how you believe in the patient! You know they', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 241}),\n",
       " Document(page_content='• Give another short motivati onal speech on how you believe in the patient! You know they \\ncan do this! Together you will make sure that they suppress their viral load!!  \\n• Agree on a follow -up date for the next session  \\n \\nRepeat Viral Load  \\n• If the adherence is good: plan for the next VL testing after 3 months and explain possible ways \\nforward, emphasizing the roles of the patient, the support systems and the health facility. You \\ncan continue follow -up adherence counselling sessions during the 3 -month period if you and \\nthe patient think th ere would be a benefit to them  \\n“If your results come back and your VL is undetectable then you will be able to continue with same ART.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 241}),\n",
       " Document(page_content='“If your results come back and your VL is undetectable then you will be able to continue with same ART. \\nIf your viral load is still greater than 1,000 copies/ml then you will need to switch to a new regimen, \\nprobably after do ing some additional testing to see which regimen may work best for you. If your viral \\nload is detectable but less than 1,000 copies/ml we will discuss options, including changing regimens \\nor continuing to monitor.” (Adapt to individual patient/context)  \\n• If adherence challenges persist: plan further Enhanced Adherence Counselling Sessions before \\nrepeating the VL', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 241}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 21 Annex 9A: Cont.  \\nSession to Discuss Repeat Viral Load Results (after the repeat VL results are back, preferably with \\nthe same provider)  \\nDiscuss Viral Load Results  \\n• If suppressed (VL < 50 copies/ml) CONGRATULATE the patient!!!  \\n- Explain the way forward: will continue with same ART regimen and repeat the VL again in 6 \\nmonths  \\n• If viral load is ≥ 1,000 copies/ml  \\n- Explain the way forward: will probably need to switch to a new ART regimen after discussing \\nas an MDT, and additional testing to see which regimen may work for the patient  \\n- Summarize the case with the MDT; if the patient cannot switch to standard 2nd line ART, or \\nis failin g 2nd line ART, forward to the Regional or National HIV Clinical Technical Working \\nGroup for next steps', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 242}),\n",
       " Document(page_content='is failin g 2nd line ART, forward to the Regional or National HIV Clinical Technical Working \\nGroup for next steps  \\n• If viral load is 50 - 999 copies/ml  \\n- Explain the way forward: will reassess barriers to adherence, support systems, and other \\nreasons for viremia; once reason/s for viremia have been addressed then will repeat the viral \\nload after another 3 months of excellent adherence', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 242}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 22 Annex 9 B: Case Summary Form  \\n \\n \\nMINISTRY OF HEALTH  \\nNATIONAL AIDS AND STI CONTROL PROGRAMME  \\nCLINICAL SUMMARY FORM  \\nName of \\nFacility   MFL \\nCode   \\nPatient CCC \\nno.  \\n(Do not write \\nname )  Date   \\nPatient \\nDetails  Date of Birth:                  Enrollment Date:  \\n \\nGender:   Current Weight (Kg):                      Height (cm):  \\nClinician’s \\nName   \\nFacility \\nContacts  Tel:  Email:  \\n \\nWhat is the primary reason for this consultation:  \\n \\nClinical Evaluation: history, physical, diagnostics, working diagnosis ( excluding the information in \\nthe table below  \\n \\n \\n \\n \\n \\n \\nComplete the table below chronologically, including all ART regimens and laboratory results (and', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 243}),\n",
       " Document(page_content='the table below  \\n \\n \\n \\n \\n \\n \\nComplete the table below chronologically, including all ART regimens and laboratory results (and \\nany previous history available for transfer -in patients)  \\nDate  CD4  HB CrCl/  \\neGFR  Viral \\nLoad  Weight  \\n(z-score/BMI \\nfor children)  ARV \\nRegimen  Reason for \\nSwitch  New OI or other \\nclinical event', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 243}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 23 Annex 9 B: Cont.  \\nAdherence and Treatment Failure Evaluation  \\nParameters of Evaluation  Findings  \\n● Number and findings of adherence counseling/assessment \\nsessions done in the last 3 -6 months including the following:  \\no Findings from MMAS -8 \\no Adherence barriers identified  \\no Recommendations   \\nNumber of home visits conducted in last 3 -6 months, and findings   \\nDescribe support structures (e.g., treatment buddy, support group \\nattendance, caregivers) in place for this patient   \\nEvidence of adherence concerns (e.g., missed appointments, pill counts)   \\nDescribe daily witnessed ingestion done in last 3 -6 months (Who performed \\nit, which tool was used, how long was session done etc.)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 244}),\n",
       " Document(page_content='Describe daily witnessed ingestion done in last 3 -6 months (Who performed \\nit, which tool was used, how long was session done etc.)   \\nDescribe likely root cause/s of poor adherence for this patie nt (e.g., stigma, \\ndisclosure, side effects, alcohol or other drugs, mental health issues, \\ncaregiver changes, religious beliefs, inadequate preparation, etc.)   \\nEvaluation for other causes of treatment failure, e.g.:  \\n● Inadequate dosing/dose adjustments (particularly for children)  \\n● Drug -drug interactions  \\n● Drug -food interactions  \\n● Impaired absorption (e.g., chronic severe diarrhea)   \\nOther Relevant ART History  \\nComment on treatment interruptions, if any   \\nHas Drug Resistance Testing been done for this patient? If yes, state date \\ndone and attach the detailed results', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 244}),\n",
       " Document(page_content='Has Drug Resistance Testing been done for this patient? If yes, state date \\ndone and attach the detailed results   \\nHas facility multidisciplinary team discussed the patient’s case? If yes, \\ncomment on date, deliberations and recommendations (indicate how \\ntreatment failure was established and con firmed, proposed regimen and \\ndosage, current source of drugs if patient already on 3rd line)   \\nMDT members who participated in the case discussion (names and titles)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 244}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 24 Annex 9 C: Enhanced Adherence Counselling Form  \\nENHANCED ADHERENCE COUNSELLING FORM  \\n(To be completed by the counsellor)  \\n• Start each session by reviewing the adherence barriers and action plan from the previous session  \\n• For each session assess major barriers to adherence (cognitive, behavioral, emotional, socio -economic)  \\nSession #:   Date:   Adherence % (from pill count):   MMAS -8 Score:   \\nTreatment \\nmotivation:   \\n \\n \\n \\n \\n \\n \\n \\nBarriers to \\nadherence:   \\n \\n \\n \\nYour impression about patient’s \\ncurrent adherence:    ▢ Excellent                ▢ Unsure            ▢ Inadequate  \\nAdherence plan:   \\n \\n \\n \\n \\n \\n \\nNext appointment date:', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 245}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 25 Annex 9 D: Home Visit Checklist  \\nHOME VISIT CHECKLIST  \\nPatient Name  Tel No:  Sex: M            F     \\nFamily Member  Tel No:  Sex: M            F     \\nPhysical Landmark:   File No.  \\n \\nThis checklist is not all -inclusive but highlights critical areas that can affect adherence.  \\n Areas to Assess and Discuss  Comments  \\nI Is the patient independent in the activities of daily living (e.g., \\nfeeding, grooming, toileting) l  \\n2 Are the patient’s basic needs being met (e.g., clothing, shelter, food) l  \\n3 Has the patient disclosed their HIV status to other household members   \\n4 How are the patient’s ARVs stored and taken?   \\n5 Does the patient receive social support from household members   \\n6 Does the patient receive social support in the community e.g., linked to', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 246}),\n",
       " Document(page_content='5 Does the patient receive social support from household members   \\n6 Does the patient receive social support in the community e.g., linked to \\nOVC, income generating activities, community -based support group, CBO, \\ncash transfer program?   \\n7 Is the patient linked to non -clinical services (e.g., spiritual, legal \\nor nutritional)    \\n8 Does the patient have mental health issues that need to be addressed (use \\nPHQ9 to screen for depression), or use drugs or alcohol?   \\n9 Is the patient suffering from a stressful situation or significant loss/grief?   \\n10 Is the patient having any side -effects from the medications?', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 246}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 26 Annex 9 E: Management Protocol for Patients Switching to 3rd Line ART  \\nManagement Protocol for patients switching to 3rd line ART  \\n \\nPre – Initiation MDT Meeting  \\n• Confirm what 3rd line ARV regimen is prescribed, its availability and the management plan  \\n• Assign a case manager to patient  \\nInitiation of 3rd Line ART  \\n• Triage  \\no Record vital signs and take actions as needed  \\n \\n• Adherence support  \\no Conduct patient education on the new ART regimen: Treatment goals, dosing, drug \\ninteractions and potential side effects and adverse events  \\no Conduct adherence assessment and counselling  \\no Link patient to adherence support systems  \\n \\n• Clinical assessment  \\no Take history and conduct physical examination', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 247}),\n",
       " Document(page_content='o Link patient to adherence support systems  \\n \\n• Clinical assessment  \\no Take history and conduct physical examination  \\no Complete clinical encounter form and MOH 257 (Green Card)  \\no Manage any co -infection and co -morbidities  \\no Review for potential drug interactions and contraindications  \\no Conduct adherence assessment and review adherence support systems including \\ndaily witnessed ingestion plan  \\no Reinforce patient education messages on new regimen  \\n▪ Currently limited future treatment options  \\n▪ Need for perfect adherence (>95%)  \\n▪ Dosing schedule and timing  \\n▪ Potential side effects and what the patient should do  \\no Prescribe new regimen  for 2 weeks  \\no Confirm dosing as per the weight (for ≤15)  \\no Continue other medication e.g., CPT, OI treatment etc.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 247}),\n",
       " Document(page_content='o Prescribe new regimen  for 2 weeks  \\no Confirm dosing as per the weight (for ≤15)  \\no Continue other medication e.g., CPT, OI treatment etc.  \\n \\n• Dispensing  \\no Confirm ARV dosing as per the weight (for ≤15)  \\no Conduct medication use counselling  \\no Dispense 3rd Line ARVs for 2 weeks  \\no Check for possible drug interaction  \\n \\n• Community follow up  \\no Link all patients to support group, CHV/CHA  \\no Plan for home visits as required', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 247}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 27 Annex 9 E: cont.  \\nPatient Follow Up after Treatment Initiation  \\n● Frequency  \\no First follow -up should be within 2 weeks of initiation of 3rd line ART  \\no Subsequent visits should be monthly (or more frequent) until confirmed viral sup - \\npression at 6 months  \\no Thereafter, follow -up can be 1 -3 monthly  \\n \\n● Triage  \\no Record vital signs and take action as needed  \\n \\n● Adherence Support (adherence should be reinforced during every clinic visit, in addition to \\nenhanced adherence counselling sessions)  \\no Review and address knowledge deficits on new regimen  \\no Confirm understanding of adherence, conduct adherence assessment, and reinforce key \\nadherence messages  \\no Document reasons for missed doses and manage obstacles to perfect adherence. Review', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 248}),\n",
       " Document(page_content='adherence messages  \\no Document reasons for missed doses and manage obstacles to perfect adherence. Review \\nand reinforce adherence support systems  \\n \\n● Clinical Assessment  \\no Take history and conduct physical examination  \\no Complete Clinical Encounter Form and MOH 257 (blue card)  \\no Manage any co -infections and co -morbidities  \\no Evaluate for potential drug interactions  \\no Evaluate for and manage any drug side effects and adverse events  \\no Conduct adherence assessment and review adherence  support systems  \\no Reinforce patient education messages on new regimen  \\n▪ Review and address knowledge gaps on ART regimen  \\n▪ Need for perfect adherence (>95%)  \\n▪ Dosing schedule and timing  \\n▪ Potential side effects and what the patient should do  \\no Prescribe 3rd line ARVs', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 248}),\n",
       " Document(page_content='▪ Dosing schedule and timing  \\n▪ Potential side effects and what the patient should do  \\no Prescribe 3rd line ARVs  \\n \\n● Viral load should be conducted 3 months after change of regimen  \\n \\n● Dispensing  \\no Confirm ARV dosing as per the weight  \\no Conduct medication use counselling  \\no Dispense 3rd line ARVs  \\n \\n● Community Follow up  \\no Review linkage to community adherence support systems  \\no Conduct home visits as required  \\no Continue DOTS  \\n \\n● NOTE: 3rd line annual report with viral load, adherence, and outcomes to be sent to NASCOP', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 248}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 28 Annex 10 A: Dosing of Solid and Liquid Formulations for Twice -Daily Dosing in Infants and Children 4 Weeks of Age \\nand Older  1\\n \\nDrug  Strength of tablets  Number of tablets by weight band morning and evening  Strength of adult \\ntablet  Number of tablets \\nby weight band  \\n3–5.9 kg  6–9.9 kg  10–13.9 kg  14–19.9 kg  20–24.9 kg  25–34.9 kg  \\nAM PM AM PM AM PM AM PM AM PM AM PM \\nAZT/3TC  Tablet (dispersible) 60/30 mg  1 1 1.5 1.5 2 2 2.5 2.5 3 3 300 /150 mg  1 1 \\nAZT/3TC/NVP2 Tablet (dispersible) 60/30 mg/50 mg  1 1 1.5 1.5 2 2 2.5 2.5 3 3 300 /150 /200 mg  1 1 \\nABC/3TC  Tablet (dispersible) 120/60 mg  0.5 0.5 0.5 1 1 1 1 1.5 1.5 1.5 600 /300 mg  0.5 0.5 \\nABC/3TC/LPV/r  30/15/40/10 mg  2 2 3 3 4 4 5 5 6 6', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 249}),\n",
       " Document(page_content='ABC/3TC  Tablet (dispersible) 120/60 mg  0.5 0.5 0.5 1 1 1 1 1.5 1.5 1.5 600 /300 mg  0.5 0.5 \\nABC/3TC/LPV/r  30/15/40/10 mg  2 2 3 3 4 4 5 5 6 6    \\nSOLID SINGLE FORMULATIONS  \\nAZT  Tablet (dispersible) 60 mg  1 1 1.5 1.5 2 2 2.5 2.5 3 3 300 mg 1 1 \\nABC  Tablet (dispersible) 60 mg  1 1 1.5 1.5 2 2 2.5 2.5 3 3 300 mg  1 1 \\nNVP2 Tablet (dispersible) 50 mg  1 1 1.5 1.5 2 2 2.5 2.5 3 3 200 mg  1 1 \\nTablet 200 mg  – – – – 0.5 0.5 1 0.5 1 0.5 200 mg  1 1 \\n \\nLPV/r3 Tablet 100/25 mg  – – – – 2 1 2 2 2 2 100/25 mg  3 3 \\nTablet 200/50 mg  – – – – – – 1 1 1 1 200/50 mg  2 1 \\nGranules4 40/10 mg per sachet  2 2 3 3 4 4 5 5 6 6    \\nDRV5 Tablet 75 mg  – – – – 3 3 5 5 5 5    \\n \\nRAL6 Chewable tablets 25 mg  – – – – 3 3 4 4 6 6 400 mg  1 1 \\nChewable tablets 100 mg  – – – – – – 1 1 1.5 1.5 400 mg  1 1', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 249}),\n",
       " Document(page_content='RAL6 Chewable tablets 25 mg  – – – – 3 3 4 4 6 6 400 mg  1 1 \\nChewable tablets 100 mg  – – – – – – 1 1 1.5 1.5 400 mg  1 1 \\nGranules (100 mg/sachet)  0.25  0.25  0.5 0.5 – – – – – –  – – \\nLIQUID SINGLE FORMULATIONS  \\nAZT  10 mg/ml  6 ml  6 ml  9 ml  9 ml  12 ml  12 ml  – – – – – – – \\nABC  20 mg/ml  3 ml  3 ml  4 ml  4 ml  6 ml  6 ml  – – – – – – – \\n3TC  10 mg/ml  3 ml  3 ml  4 ml  4 ml  6 ml  6 ml  – – – – – – – \\nNVP2 10 mg/ml  5 ml  5 ml  8 ml  8 ml  10 ml  10 ml  – – – – – – – \\nDRV5 100 mg/ml  – – – – 2.5 ml  2.5 ml  3.5 ml  3.5 ml  – –    \\nNotes  1 For infants younger than 4 weeks of age refer to Table 10C for more accurate dosing information', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 249}),\n",
       " Document(page_content='Notes  1 For infants younger than 4 weeks of age refer to Table 10C for more accurate dosing information  \\n2 NVP dose escalation with half dose for 2 weeks when initiating ART is still recommended for infants > 2 weeks of age and not already on NVP prophylaxis to avoid toxicity from high initial \\nNVP levels. HEI already on NVP prophylaxis who are confirmed positive can initiate full dose (twice daily) NVP without dose escalation  \\n3 The LPV/r heat -stable tablet formulation must be swallowed whole and should not be split, chewed, dissolved or crushed. The adult 200/50 mg tablet may be used for patients 14 -24.9kg (1', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 249}),\n",
       " Document(page_content='tab am and 1 tab pm) and for patients 25 -34.9kg (2 tabs am and 1 tab pm) who are able to swallow them whole. The 100/25 mg tablet is smaller than the adult formulatio n and may be used \\nby children of lower weight  bands able to swallow tablets whole.  \\n4 LPV/r granule formulation can be used in infants over 2 weeks of age. Transition to tablets as soon as a child is able to swa llow tablets whole. The 4 -in-1 ABC/3TC/LPV/r may be used after \\n1 month of age if the combin ation is appropriate and once it becomes available.  \\n5 DRV must be administered with 0.5 ml of RTV 80 mg/mL oral suspension if less than 15 kg and with RTV 50 mg solid formulation in children 15 to 30 kg', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 249}),\n",
       " Document(page_content='Annexes  \\n13 - 29 6RAL granules are approved for use in newborn childre n, however the administration procedure is complex and the formulation has very limited availability. If this RAL must be use d, consult \\nthe regional/national clinical support center  \\n Annex 10 B: Simplified Dosing of Child -Friendly Solid and Oral Liquid For mulations for Once -Daily Dosing in \\nInfants and Children 4 Weeks of Age and Older1 \\nDrug  Strength of tablet  Number of tablets or capsules by weight band once \\ndaily  Strength of adult \\ntablet  Number of tablets or capsules \\nby weight band once daily  \\n3–5.9 \\nkg 6–9.9 \\nkg 10–13.9 \\nkg 14–19.9 \\nkg 20–24.9 kg   25–34.9 kg  \\nEFV2 Tablet (scored) 200 mg  – – 1 1.5 1.5 200 mg  2 \\nABC/3TC  Tablet (dispersible) 120/60 \\nmg 1 1.5 2 2.5 3 600 mg/300 mg  1', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 250}),\n",
       " Document(page_content='EFV2 Tablet (scored) 200 mg  – – 1 1.5 1.5 200 mg  2 \\nABC/3TC  Tablet (dispersible) 120/60 \\nmg 1 1.5 2 2.5 3 600 mg/300 mg  1 \\nDTG  Tablet (dispersible) 10 mg  0.5 1.5 2 2.5 33   \\nDTG  Tablet 50 mg  - - - - 1 50 mg  1 \\nDTG/TDF/  \\n3TC   - - - - - 50/300/300  1 \\nATV4 Capsules 100 mg  – – 1 2 2 300 mg  2 (100 mg) or 1 (300 mg)  \\n \\nTDF5 Oral powder 40 mg/scoop  – – 3 – –  \\n300 mg  1 (200 mg) d or 1 (300 mg)  \\nTablets 150 mg or 200 mg  – – – 1 (150 mg)  1 (200 mg)  \\nNotes  1For infants younger than 4 weeks of age refer to Table 10C for more accurate dosing information  \\n2EFV is not recommended for children younger than 3 years and weighing less than 10 kg. Where there are no suitable alternativ es, EFV may be used in children le ss than 3 years', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 250}),\n",
       " Document(page_content='weighing more than 3.5 kg (3.5 -5 kg two 50 mg capsules; 5 -7.5 kg three 50 mg capsules; 7.5 -15 kg one 200 mg capsule).  \\n3 DTG dispersible tablets have higher bioavailability than film tablets and doses are not interchangeable. Children can tr ansition to the 50 mg film tablet once they reach 20 kg. If unable to \\nswallow the tablets whole, the dispersible tablets may be given at a dose of 30 mg daily.  \\n4ATV is only approved for use in children 3 months and older. ATV single strength capsules shoul d be administered with RTV 100 mg for all weight bands. ATV powder formulation \\nenables administration of ATV to infants and children as young as 3 months. Infants and children 5 -10 kg should be given 200 mg of ATV powder (4 packets, 50 mg/ packet) with 80 \\nmg of RTV oral solution (1 ml)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 250}),\n",
       " Document(page_content='mg of RTV oral solution (1 ml)  \\n5TDF is can be used in children 2 years and older. Target dose: 8 mg/kg or 200 mg/m2 (maximum 300 m', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 250}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 30 Annex 10 C: Drug Dosing of Liquid Formulations for Twice -Daily Dosing in Infants Less than 4 Weeks of Age  \\nDrug  Strength of oral liquid  2-3 kg  3-4 kg  4-5 kg  \\nAZT  10 mg/mL  1 mL  1.5 mL  2 mL  \\nNVP1 10 mg/mL  1.5 mL  2 mL  3 mL  \\n3TC  10 mg/mL  0.5 mL  0.8 mL  1 mL  \\nNotes  1 NVP for treatment can be initiated with twice daily dosing for infants < 2 weeks of age (they do not require once -daily lead -in dosing)  \\n \\nAnnex 10 D: Simplified Dosing of INH and CTX Prophylaxis for Infants and Children Who Are at Least 4 Weeks of \\nAge \\nDrug  Strength of tablet or oral \\nliquid  Number of tablets or ml by weight band once daily  Strength of adult \\ntablet  Number of tablets \\nby weight band  \\n \\n3–5.9 kg   \\n6–9.9 kg', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 251}),\n",
       " Document(page_content='liquid  Number of tablets or ml by weight band once daily  Strength of adult \\ntablet  Number of tablets \\nby weight band  \\n \\n3–5.9 kg   \\n6–9.9 kg   \\n10–13.9 kg   \\n14–19.9 kg   \\n20–24.9 kg    \\n25–34.9 kg  \\nINH  100 mg  0.5 1 1.5 2 2.5 300 mg 1 \\nCTX  Suspension 200/40 per 5 ml  2.5 ml  5 ml  5 ml  10 ml  10 ml  – – \\nTablets (dispersible) 100/20 mg  1 2 2 4 4 – – \\nTablets (scored) 400/80 mg  – 0.5 0.5 1 1 400 mg/80 mg  2 \\nTablets (scored) 800/160 mg  – – – 0.5 0.5 800 mg/160 mg  1', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 251}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 31 Annex 10 E: TB Preventive Therapy dosing  \\nA. Daily INH for 6 months (6H)  \\nWeight (Kg)  Dose (mg)  Number of 100mg INH tablets  Number of 300mg (Adult) tablet  \\n<5 50 ½ tablet  - \\n5.1-9.9 100  1 tablet  - \\n10-13.9  150  1½ tablet  ½ tablet  \\n 14-19.9  200  2 tablets  - \\n20-24.9  250  2 ½ tablets  - \\n≥25  300  3 tablets  1 tablet  \\nAdult  300  3 tablets  1 tablet', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 252}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 32 Annex 10 E: Cont.  \\nB1. Daily INH for 6 months (6H)  \\nWeight (Kg)  Number of tablets (RH \\n75/50mg  How to reconstitute the medicine  \\nLess than 2  ¼  Dissolve one (1) tablet of RH in 20 ml of safe drinking water. Once fully \\ndissolved. Give 5ml (¼) of this solution measured with a syringe.  \\n2-2.9 ½  Dissolve one (1) tablet of RH is 20 ml of safe drinking water. Once fully \\ndissolved, give 10ml (½) of this solution measure d with a syringe.  \\n3-3.9 ¾  Dissolve one (1) tablet of RH in 20 ml of safe drinking water. Once fully \\ndissolved, give 15 ml (¾) of this solution measured with a syringe.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 253}),\n",
       " Document(page_content='dissolved, give 15 ml (¾) of this solution measured with a syringe.  \\nAfter giving the child their dose for that day, discard the rest of the solution. Pre pare a fresh solution. Prepare a fresh solution every day.  \\n4-7.9 1 Dissolve the tablet(s) of RH in 20mls of safe drinking water.  \\n \\nOnce fully dissolved, give ALL this solution to the child  8-11.9  2 \\n12-15.9  3 \\n16-24.9  4 \\nB2. Daily RH for 3 months (3RH) for children ≥25kgs (To use adult formulation)  \\nWeight (Kg)  Number of tablets (RH 150/75mg)  \\n25-39.9  2 \\n40-54.9  3 \\n55kg and above  4 \\nC.  Weekly 3HP (3HP) (For adults and adolescents ≥15 years)  \\n3HP products  No of Tablets  \\nRifapentine 150mg tabs  6 \\nIsoniazid 300mg tabs  3 \\nRifapentine 300mg+Isoniazid 200mg (FDC)  3', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 253}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 33 Annex 10 E: Cont.  \\nD. Dosage of Pyrldoxine (Vitamin B6)  \\nWeight (Kgs)  Dosage In mg  Number of 25mg tablets  Number of 50mg tablets  \\n<5 6.25mg  ½ Tablet 3 times a week, alternate days  - \\n5.0-79 12.5mg  Half a tablet  - \\n8.0-14.9  25mg  One tablet  Half of 50mg tablet  \\n15kg and above  50mg  Two tablets  One 50mg tablet  \\nAdults  50mg  Two tablets  One 50mg tablet', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 254}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 34 Annex 10 F: Ritonavir Dosing for Super -Boosting LPV/r in Children Taking Rifampicin  \\nDosing for RTV super -boosting of LPV/r for children receiving rifampicin -containing TB treatment*  \\nDrug  Strength of paediatric \\ntablets or oral liquid  Number of tablets or MLS by weight -band morning (AM) and evening (PM)  Strength of \\nadult tablet  Number of tablets \\nby weight band  \\n3–5.9 kg  6–9.9 kg  10–13.9 kg  14–19.9 kg  20–24.9 kg   25–34.9 kg  \\nAM PM AM PM AM PM AM PM AM PM  AM PM \\nFor children able to swallow tablets  \\nLPV/rb Tablet 100/25 mg  – – – – 2 1 2 2 2 2 100/25 mg  3 3 \\nRTV  Tablet 100 mg  – – – – 1 1 1 2 1 2  \\n \\n100 mg   \\n2  \\n2 Tablet 50 mg  – – – – 2 2 3 3 3 3 \\nTablet 25 mg  – – – – 4 4 6 6 6 6', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 255}),\n",
       " Document(page_content='RTV  Tablet 100 mg  – – – – 1 1 1 2 1 2  \\n \\n100 mg   \\n2  \\n2 Tablet 50 mg  – – – – 2 2 3 3 3 3 \\nTablet 25 mg  – – – – 4 4 6 6 6 6 \\nFor children unable to swallow tablets  \\nLPV/r  Oral solution 80/20 mg/ml  1 ml  1 ml  1.5 \\nml 1.5 ml  2 ml  2 ml  2.5 \\nml 2.5 \\nml 3 ml  3 ml  - - - \\nPellets 40 mg/10 mg  2 2 3 3 4 4 5 5 6 6 - - - \\nGranules 40 mg/10 mg \\nsachet  2 2 3 3 4 4 5 5 6 6 - - - \\nRTVe Oral solution 80 mg/ml  0.8 ml  0.8 ml  1.2 ml  1.2 ml  1.5 ml  1.5 ml  2 ml  2 ml  2.3 ml  2.3 ml  - - - \\nPowder 100 mg/packet  - - 1 1 1 1 1 2 1 2 - - - \\na Suggested RT V dose for super -boosting to achieve the same dose as LPV in mg, in a ratio equal or approaching to 1:1. This dosing approach is supported by a study which explored this \\napproach in young children receiving LPV/r12.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 255}),\n",
       " Document(page_content='approach in young children receiving LPV/r12. \\nb the LPV/r heat -stable t ablet formulation must be swallowed whole and should not be split, chewed, dissolved or crushed. Adult 200 / 50 tablet could be used for patients 14 -24.9kg (1 \\ntab am and 1 tab pm) and for patients 25 -34.9kg (2 tab am and 1 tab pm).  \\nc LPV/r liquid requires a cold chain during transport and storage.  \\nd LPV/r pellets formulation should not be used in infants younger than 3 months. More details on the administration of LPV/r pe llets can be found at \\nhttps://www.who.int/hiv/pub/toolkits/iattfactsheet -lopinavir -ritonavir/en/. The dosing schedule provided applies to equivalent solid dosage forms that may become available such as \\nLPV/r granules, which are approved by US FDA for use from 2 weeks of life.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 255}),\n",
       " Document(page_content='LPV/r granules, which are approved by US FDA for use from 2 weeks of life.  \\n  e RT V oral solution dosing is ba sed on the dosing tested in the trial that supports the use of super boosting', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 255}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 35 Annex 11: Overlapping toxicities between ARVs  \\nBone marrow \\nsuppression  Peripheral \\nneuropathy  Pancreatitis  Nephrotoxicity  Hepatotoxicity  Rash  Diarrhoea  Ocular effects  \\nAmphotericin B \\nCotrimoxazole \\nDapsone Flucytosine \\nGanciclovir \\nHydroxyurea \\nInterferon - \\nPrimaquine \\nPyrimethamine \\nZidovudine  Didanosine \\nIsoniazid \\nVincristine  Didanosine \\nLamivudine  \\n(esp. in \\nchildren)  \\nStavudine \\nCotrimoxazole \\nRitonavir \\nPentamidine  Acyclovir  \\nAdefo vir high dose \\nAminoglycosides \\nAmphotericin B \\nCidofovir  \\nFoscarnet \\nPentamidine \\nTenofovir  Abacavir  \\nAtazanavir \\nAtovaquone \\nCotrimoxazole \\nDapsone \\nEfavirenz \\nNevirapine \\nSulfadiazine \\nVoriconazole  Abacavir \\nAtazanavir \\nAtovaquone \\nCotrimoxazole \\nDapsone \\nEfavirenz \\nNevirapine \\nSulfadiazine', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 256}),\n",
       " Document(page_content='Efavirenz \\nNevirapine \\nSulfadiazine \\nVoriconazole  Abacavir \\nAtazanavir \\nAtovaquone \\nCotrimoxazole \\nDapsone \\nEfavirenz \\nNevirapine \\nSulfadiazine \\nVoriconazole  Atovaquone \\nClindamycin \\nLPV/r Ritonavir  Cidofovir Ethambutol \\nLinezolid Rifabutin \\nVoriconazole', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 256}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 36 Annex 12 A: Use of Nucleoside & Nucleotide Reverse Transcriptase Inhibitors \\nin Adults  \\nDrug name  Dose (in \\nadults)  Dietary \\nrestrictions  Major side effects  Comments  \\nZidovudine  \\n(AZT or ZDV)  \\n \\nAvailable in 300mg \\ntablets and as FDC \\nwith 3TC and 3TC/ \\nNVP  300mg/  \\ndose BD  No food \\nrestrictions  Bone marrow suppression), \\nincluding anaemia; \\ngranulocytopenia; headache; \\ngastrointestinal intolerance; \\nmyopathy; myositis; liver toxicity; \\ndiscoloured nails; lactic acidosis \\nand severe  \\nhepatomegaly with steatosis (fatal \\ncases have been reported)  Monitor for anaemia in  the \\nfirst 3 months of treatment  \\nLamivudine (3TC) \\nAvailable in 150mg  \\ntablet and as FDC \\nwith AZT and \\nAZT/NVP, D4T and \\nD4T/NVP and with', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 257}),\n",
       " Document(page_content='first 3 months of treatment  \\nLamivudine (3TC) \\nAvailable in 150mg  \\ntablet and as FDC \\nwith AZT and \\nAZT/NVP, D4T and \\nD4T/NVP and with \\nTDF and TDF/ EFV  150mg/ \\ndose BD \\nOR 300 \\nmg/dose \\nOD No food \\nrestrictions  Headache; fatigue; nausea; \\ndiarrhoea; skin rash; pancreatitis; \\nperipheral neuropathy; \\nhepatotoxicity/ hepatitis; lactic \\nacidosis and severe hepatomegaly \\nwith steatosis (rare fatal cases \\nhave been reported).  A well -tolerated drug. \\nAdjust dose in renal \\nimpairment.  \\nAlso active against hepatitis B. \\nIdeally, patients should be  \\nscreened for hepatitis B virus  \\n(HBV) before starting therapy; \\nexacerbation of hepatitis B has \\nbeen reported in patients on \\ndiscontinuation of 3TC.  \\nAbacavir (ABC) \\nAvailable in 300mg  \\ntablets and in \\ncombination with', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 257}),\n",
       " Document(page_content='been reported in patients on \\ndiscontinuation of 3TC.  \\nAbacavir (ABC) \\nAvailable in 300mg  \\ntablets and in \\ncombination with  \\n3TC and DTG  300mg/  \\ndose BD  \\n or 600mg \\nOD No food \\nrestrictions. \\nAlcohol \\nincreases \\nABC levels \\nby 41%  Hypersensitivity reaction \\n(potentially fatal) whose \\nsymptoms include fever, \\nfatigue, malaise, nausea, \\nvomiting, diarrhoea  \\nand abdominal pain or \\nrespiratory symptoms such as \\nshortness of breath, \\nlymphadenopathy, ulceration of \\nmucous  \\nmembranes and skin rash. Patients \\nsuspected of having \\nhypersensitivity reaction should \\nhave ABC stopped and never be \\nrestarted. Pancreatitis; lactic \\nacidosis with hepatic steatosis is \\nrare  Educate patient on \\nhypersensitivity reaction. \\nOnce hypersensitivity has \\noccurred, the patient should', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 257}),\n",
       " Document(page_content='acidosis with hepatic steatosis is \\nrare  Educate patient on \\nhypersensitivity reaction. \\nOnce hypersensitivity has \\noccurred, the patient should \\nnever be re -challenged with \\nABC.  \\n \\nAvoid alcohol while on ABC.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 257}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 37 Table 12 A: Cont.  \\nDrug name  Dose (in \\nadults)  Dietary \\nrestrictions  Major side effects  Comments  \\nEmtricitabine  \\n(FTC)  \\n \\nAvailable in 200mg \\ncapsules and as FDC \\nwith TDF and \\nTDF/EFV  200mg/  \\ndose OD  No food \\nrestrictions  Well tolerated. Lactic \\nacidosis and severe \\nhepatomegaly with \\nsteatosis (fatal cases have \\nbeen reported); headache; \\ndiarrhoea; nausea; rash; \\nskin discoloration  Effective against hepatitis B. \\nIdeally, patients should be \\nscreened for chronic hepatitis B \\nvirus (HBV) before starting \\ntherapy; exacerbation of Hepatitis \\nB has been reported in patients on \\ndiscontinuation of FTC  \\nDecrease dosage in patients with \\nrenal impairment Monitor renal \\nfunction if combined with TDF.  \\nWhen used in combination with', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 258}),\n",
       " Document(page_content='Decrease dosage in patients with \\nrenal impairment Monitor renal \\nfunction if combined with TDF.  \\nWhen used in combination with \\nTDF, should not be given to \\npatients with a creatinine \\nclearance of <30ml/min. Should \\nnot be used with or aft er failure of \\n3TC  \\nTenofovir \\ndisoproxil fumarate \\n(TDF)  \\n \\nAvailable in 300mg \\ntablets and as FDC \\nwith 3TC and 3TC/ \\nEFV  300mg/  \\ndose OD  No food \\nrestrictions  Lactic acidosis and severe \\nhepatomegaly with \\nsteatosis (fatal cases have \\nbeen reported with \\nnucleoside analogues); \\nrenal toxicity; Pancreatitis  Should not be used with ddI. \\nShould never be used in triple \\nnucleoside combinations  \\nwith 3TC+ddI/ABC.  Renal function \\nshould be monitored while on TDF  \\nIdeally, patients should be \\nscreened for chronic hepatitis B', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 258}),\n",
       " Document(page_content='with 3TC+ddI/ABC.  Renal function \\nshould be monitored while on TDF  \\nIdeally, patients should be \\nscreened for chronic hepatitis B \\nvirus (HBV) before starting \\ntherapy; Exacerbation of hepatitis \\nB has been reported in patients on \\ndiscontinuation of TDF  \\nWhen used in combination with \\n3TC, should not be given to \\npatients with a creatinine \\nclearance of <30ml/min.  \\nWhen used with ATV levels of ATV \\nreduced significantly therefore \\ncombine with RTV  \\nTenofovir \\nalafenamide (TAF)  \\n \\nVarious co -\\nformulations \\navailable or being \\ndeveloped  As TAF 25 \\nmg alone or \\nas part of \\nco-\\nformulated \\nFDC  No food \\nrestrictions  Well tolerated. GIT upsets, \\nraised serum creatinine, \\nproteinuria and renal \\ntoxicity (but to a lesser \\ndegree than TDF)  RTV and cobicistat increase TAF', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 258}),\n",
       " Document(page_content='raised serum creatinine, \\nproteinuria and renal \\ntoxicity (but to a lesser \\ndegree than TDF)  RTV and cobicistat increase TAF \\nlevels. DRV decreases TAF levels. \\nBoosted PI increase TAF levels but \\nthe PI levels are not affected.  \\nAvoid co -administration with \\nrifabutin, rifampicin and phenytoin', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 258}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 38 Annex 12 B: Use of Non -Nucleoside Reverse Transcriptase Inhibitors for Adults  \\nDrug name  Dose (in \\nadults)  Dietary \\nrestrictions  Major side effects  Comments  \\nEfavirenz (EFV) \\nAvailable in 200mg  \\n& 600mg tablets \\nand as FDC with \\nTDF/3TC  600mg \\nOD Best \\ntaken  \\nat \\nbedtime  Preferably \\ntaken on an \\nempty \\nstomach.  \\nCan be given \\nwith food, \\nbut avoid \\nhigh fat  \\nmeals which \\nincrease \\nabsorption.  CNS symptoms \\n(somnolence, insomnia, \\nabnormal dreams, \\nconfusion, \\nhallucination, amnesia, \\netc. Avoid in patients \\nwith history of \\npsychiatric disease);  \\nSkin rash; avoid use in \\nduring the first \\ntrimester  Can be used with rifampicin in TB \\npatients  \\nEtravirine (ETR) \\nAvailable in tablets  \\nof 200 mg   \\n200 mg \\nBD', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 259}),\n",
       " Document(page_content='during the first \\ntrimester  Can be used with rifampicin in TB \\npatients  \\nEtravirine (ETR) \\nAvailable in tablets  \\nof 200 mg   \\n200 mg \\nBD  \\nTake with \\nfood  Severe but rare: SJS and \\nerythema multiforme \\nCommon & minor: \\nRash, nausea, vomiting, \\ndiarrhoea, abdominal \\npain, hepatotoxicity, \\ndyslipidaemia and CNS \\ndisturbances (less than \\nEFV)  Avoid concurrent use with \\nrifampicin, and boosted tipranavir.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 259}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 39 Annex 12 C: Use of Protease Inhibitors in Adults  \\nDrug name  Dose (in \\nadults)  Dietary \\nrestrictions  Major side effects  Comments  \\nLopinavir/ritonav\\nir (LPV/r) \\nAvailable as \\n200mg  \\n+ 50mg RTV  [LPV 400 mg \\n+ RTV  \\n100 mg] 2 \\ntablets BD  Take with food. \\nModerate  \\nfat increases \\nbioavailability.  GI intolerance; \\nnausea; vomiting; \\ndiarrhoea  Tablets should be \\nswallowed whole  \\nAtazanavir  \\n(ATV)  \\n \\nAvailable in  \\n100mg, 150mg, \\n200 mg capsules  \\n \\nAvailable as FDC  \\nwith RTV  ATV 300mg / \\nRTV 100mg \\nOD Take with food. \\nTake 2 hours \\nbefore or 1  \\nhour after \\nantacids and \\nbuffered \\nmedications \\nsuch as buffered \\nddI (reduced \\nATV \\nconcentrations  \\nif administered \\ntogether)  Jaundice; headache; \\nfever; depression; \\nnausea; diarrhoea \\nand vomiting;', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 260}),\n",
       " Document(page_content='ddI (reduced \\nATV \\nconcentrations  \\nif administered \\ntogether)  Jaundice; headache; \\nfever; depression; \\nnausea; diarrhoea \\nand vomiting; \\nparaesthesia; \\nspontaneous \\nbleeding episodes \\nin haemop hiliacs.  Indirect \\nhyperbilirubinaemia. \\nWhen used with TDF \\nshould always be given \\nwith RTV. Experienced \\npatients should also be \\ngiven ATV/RTV.  \\nRitonavir  \\n(RTV)  \\n \\nAvailable as 100mg \\ncapsules  \\nCapsules should be \\nrefrigerated until \\ndispensed; stable \\nat room (up to \\n25ºC) for 30 days  Recommended \\nfor use as a \\nbooster of \\nother PIs  Administration \\nwith food \\nincreases \\nabsorption and \\nhelps reduce \\ngastrointestinal \\nside effects.  Exacerbation of liver \\ndisease; fat \\nredistribution and \\nlipid abnormalities; \\ndiarrhoea; \\nabdom inal \\ndiscomfort; \\nheadache; nausea; \\nparaesthesia;', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 260}),\n",
       " Document(page_content='disease; fat \\nredistribution and \\nlipid abnormalities; \\ndiarrhoea; \\nabdom inal \\ndiscomfort; \\nheadache; nausea; \\nparaesthesia;  \\nskin rash; \\nspontaneous \\nbleeding episodes in \\nhaemophiliacs.  Potent CYP450 inhibitor, \\nthus its use as a booster \\nof other PIs  \\nDarunavir (DRV)  DRV 600 \\nmg/ RTV \\n100 mg BID \\nOR \\n \\nDRV 800 \\nmg/ RTV 100 \\nmg OD (only \\nif PI naïve)  Take with a \\nmeal to limit \\nADR  GIT upsets, rash, \\ndyslipidaemia, \\nhepatitis. Caution \\nin patients with \\nsulphur allergy.  Metabolized by CYP3A \\nand is an inhibitor of \\nCYP3A. Contains sulphur \\nmoiety. Monitor liver \\nfunctions especially in \\npatients at risk  or with \\npre-existing liver  \\ndisease.  May cause \\nhormonal contraceptive \\nfailure.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 260}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 40 Annex 12 D: Integrase Strand Transfer Inhibitors - INSTIs  \\nDrug name  Dose (in adults)  Dietary \\nrestrictions  Major side effects  Comments  \\nDolutegravir \\n(DTG) Available \\nas DTG 50mg, \\n10mg dispersible \\ntablet  \\n \\nOr FDCs:  \\nABC/3TC/DTG \\n(600/300/50mg)  \\n \\nand \\n \\nTDF/3TC/DTG \\n(300/300/50mg)  50 mg once daily  \\n \\nIf co - \\nadministering with \\nEFV, \\ncarbamazepine, or \\nrifampicin, use \\nDTG 50 mg BD  \\n \\nIf suspected or \\nconfirmed INSTI \\nresistance use DTG \\n50 mg BD  No food \\nrestrictions  Rare - \\nHypersensitivity; \\nHepatotoxicity \\nespecially in those  \\nwith HBV and HCV  \\ninfection, fatigue  \\n \\nInsomnia, headache, \\ndiarrhea, nausea is \\ncommon but usually \\nminor and resolve \\nwith continued use  Interacts with  carbamazepine,', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 261}),\n",
       " Document(page_content='Insomnia, headache, \\ndiarrhea, nausea is \\ncommon but usually \\nminor and resolve \\nwith continued use  Interacts with  carbamazepine, \\nphenobarbital and phenytoin, \\nuse alternative \\nanticonvulsants.  \\n \\nAdminister DTG at least 2 \\nhours before or 6 hours after \\ntaking supplements or \\nantacids containing Mg, Al, Fe, \\nCa and Zn. For Ca or Fe, if DTG \\nis taken with a meal then dose \\nsepa ration is not required  \\nRaltegravir (RAL)  ADULT and CHILD \\nover 16 years, 400 \\nmg BD  No food \\nrestrictions  Nausea, vomiting, \\ndiarrhoea, \\nflatulence, \\nconstipation  \\nSevere skin (SJS \\nand TEN) and \\nhypersensitivity \\nreactions have \\nbeen reported  Contraindicated in \\nbreast - feeding mothers  \\nSafety in paediatric patients \\nhas not been established', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 261}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 41 Annex 13 A: Drug -Drug Interactions - NNRTIs  \\nDrugs Affected  Nevirapine (NVP)  Efavirenz (EFV)  \\nANTIRETROVIRALS  \\nDolutegravir  Co-administration not recommended because NVP \\ndecreases levels of DTG  Co-administration not recommended because EFV decreases \\nlevels of DTG.  If must be used together then increase DTG to \\n50 mg BD when co -administered with EFV  \\nRaltegravir  No interaction or not studied  Efavirenz decreases RAL plasma levels but it is unlikely to be \\nclinically sign ificant  \\nAtazanavir/ritonavir  Co-administration not recommended because ATV/r may \\nincrease the serum concentration of NVP leading to \\nincreased risk of toxicity, and NVP decreases the serum \\nconcentration of ATV/r which may lead to resistance and', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 262}),\n",
       " Document(page_content='increased risk of toxicity, and NVP decreases the serum \\nconcentration of ATV/r which may lead to resistance and \\ntreatment failure  Co-administration not recommended because EFV decreases \\nthe serum concentration of ATV/r which may lead to \\nresistance and treatment failure  \\nLopinavir/ritonavir  Co-administration not recommended because NVP \\ndecreases levels of LPV/r  AVOID : this combination increased risk of prolonged -QT \\nsyndrome and sudden cardiac death  \\nDarunavir/ ritonavir  No significant interaction when NVP is combined with \\nritonavir -boosted darunavir  Co-administration not recommended because DRV/r may \\nincrease the seru m concentration of EFV leading to increased \\nrisk of toxicity, and EFV decreases the serum concentration of', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 262}),\n",
       " Document(page_content='increase the seru m concentration of EFV leading to increased \\nrisk of toxicity, and EFV decreases the serum concentration of \\nDRV/r which may lead to resistance and treatment failure', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 262}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 42 Annex 13 A: Cont.  \\nANTIFUNGALS  \\nKetoconazole  Levels: ketoconazole ↓ 63%  \\nNVP ↑ 15 – 30%  \\nDose: Not recommended  No data  \\nVoriconazole  Metabolism of Voriconazole may be induced by NVP. \\nVoriconazole may inhibit NNRTI metabolism. Frequently \\nmonitor for NNRTI toxicity and antifungal outcome  Levels: EFV ↑ 44%  \\nVoriconazole ↓ 77%  \\nThis combination is not recommended  \\nFluconazole  NVP Levels: Cmax, AUC, and Cmin ↑ 100%  \\nFluconazole Levels: No change  \\nRisk of hepatotoxicity may increase with this combination. If \\nconcomitant use is necessary, recommend monitoring NVP \\ntoxicity  No clinically significant changes in EFV or \\nFluconazole concentrations  \\nANTI -MYCOBACTERIALS', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 263}),\n",
       " Document(page_content='toxicity  No clinically significant changes in EFV or \\nFluconazole concentrations  \\nANTI -MYCOBACTERIALS  \\nRifampicin  Levels: NVP ↓ 20% -58%. Virologic consequences are uncertain; \\nthe potential for additive hepatotoxicity exists. Use of this \\ncombination is not recommended; however, if used, co \\nadministration should be done with careful monitoring  Levels: EFV ↓ 25%.  \\nDose: Consider ↑ EFV to 800 mg QD  \\nClarithromycin  Levels: NVP ↑ 26%. Clarithromycin ↓ 30%. Monitor for efficacy \\nor use alternative agent  Levels: Clarithromycin ↓ 39%.  \\nMonitor for efficacy or use alternative agent  \\nBedaquiline (BDQ)  No dose adjustment required  Do not co -administer  \\nDelamanid (DLM)  No interaction expected  No interaction  \\nORAL CONTRACEPTIVES', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 263}),\n",
       " Document(page_content='Delamanid (DLM)  No interaction expected  No interaction  \\nORAL CONTRACEPTIVES  \\n Levels: ethinyl estradiol approx. 20%. Use alternative or \\nadditional methods.  Levels: Ethinyl estradiol   37%. No data on other \\ncomponents. Use alternative or additional methods', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 263}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 43 Annex 13 A: Cont.  \\nLIPID -LOWERING AGENTS  \\nSimvastatin  \\nLovastatin  No data  Levels: Simvastatin AUC    by 58%; EFV unchanged  \\nDose: Adjust simvastatin dose according to lipid responses, \\nnot to exceed the maximum recommended dose  \\nAtorvastatin  No data  Levels: Atorvastatin AUC   43%; EFV unchanged.  \\nDose: Adjust atorvastatin dose according to lipid responses, \\nnot to exceed the maximum recommended dose  \\nPravastatin  No data  No data  \\nANTI -HYPERTENSIVES   \\nAngiotensin -converting enzyme \\ninhibitors (ACEIs): E.g.  - Enalapril, \\nLisinopril  No known interactions  No known interactions  \\nAngiotensin II receptor blockers \\n(ARBs): e.g., Losartan, Telmisartan  Telmisartan, Candesartan: None  \\nLosartan: Potential interactions with all NNRTIs, net effect', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 264}),\n",
       " Document(page_content='(ARBs): e.g., Losartan, Telmisartan  Telmisartan, Candesartan: None  \\nLosartan: Potential interactions with all NNRTIs, net effect \\nof interaction difficult to predict, use with caution  Telmisartan, Candesartan: None  \\nLosartan: Potential interactions with all NNRTIs, net effect \\nof interaction difficult to predict, use with caution  \\nBeta blockers: e.g., Atenolol, \\nCarvedilol and Propranolol  No known interactions  No known interactions  \\nCalcium channel blockers (CCBs): \\ne.g., Nifedipine, Amlodipine and \\nFelodipine  Potential interaction with all NNRTIs: Metabolism of CCBs \\nis induced by EFV or NVP, blunting antihypertensive \\neffect: higher starting dose of CCB may be required  Potential intera ction with all NNRTIs: Metabolism of CCBs', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 264}),\n",
       " Document(page_content='effect: higher starting dose of CCB may be required  Potential intera ction with all NNRTIs: Metabolism of CCBs \\nis induced by EFV or NVP, blunting antihypertensive effect: \\nhigher starting dose of CCB may be required  \\nDiuretics: E.g., HCTZ, Indapamide. \\nFurosemide and Spironolactone  No known interactions  No known interactions  \\nOthers: Alpha blockers:  \\nMethyldopa, Hydralazine   No known interactions  No known interactions', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 264}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 44 Annex 13 A: Cont.  \\nANTICONVULSANTS  \\nCarbamazepine Phenobarbital \\nPhenytoin  Unknown  \\nUse with caution.  \\nMonitor anticonvulsant levels  Use with caution  \\nMonitor anticonvulsant levels  \\nMETHADONE  Levels: NVP unchanged. Methadone significantly. \\nOpiate withdrawal common when this combination \\nis used. Increased methadone dose often necessary. \\nTitrate methadone dose to effect  Levels: Methadone   60%  \\nOpiate withdrawal common, increase methadone dose often \\nnecessary. Titrate methadone dose to effect  \\nMISCELLANEOUS  No data  Monitor warfarin when used concomitantly', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 265}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 45 Annex 13 B: Drug -Drug Interactions – PIs \\nDrugs Affected  Atazanavir (ATV)  Ritonavir  \\n(RTV)  Darunavir (DRV)  Lopinavir (LPV)  \\nANTIRETROVIRALS  \\nEFV  Co-administration not \\nrecommended because EFV \\ndecreases the serum \\nconcentration of ATV/r which \\nmay lead to resistance and \\ntreatment failure  See interaction with specific \\nritonavir -boosted PI  Co-administration not \\nrecommended because DRV/r \\nmay increase the serum \\nconcentration of EFV leading to \\nincreased risk of toxicity, and EFV \\ndecreases the serum \\nconcentration of DRV/r which \\nmay lead to resistance and \\ntreatment failure  AVOID: this combination \\nincreased risk of \\nprolonged -QT syndrome \\nand sudden cardiac death  \\nETR  No significant interaction  See interaction with specific', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 266}),\n",
       " Document(page_content='increased risk of \\nprolonged -QT syndrome \\nand sudden cardiac death  \\nETR  No significant interaction  See interaction with specific \\nritonavir -boosted PI  No significant interaction  \\n No significant interaction  \\nDTG  No significant interaction  See interaction with specific \\nritonavir -boosted PI  No significant interaction  No significant interaction  \\nRAL  ATV/r may increase RAL levels \\nbut interaction in not clinically \\nsignificant  See interaction with specific \\nritonavir -boosted PI  No sign ificant interaction  No significant interaction', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 266}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 46 Annex 13 B: Cont.  \\nANTIFUNGALS  \\nItraconazole  Limited data, minimal effect  No data, but potential for bi - \\ndirectional inhibition between \\nItraconazole and RTV, monitor for \\ntoxicities  \\n \\nDose: dose adjustment for patients \\nreceiving  \\n>400 mg Itraconazole may be \\nneeded, or consider monitoring \\nItraconazole level  ↑ Levels of azoles and DRV  ↑ Levels: itraconazole when \\nadministered with LPV/r  \\n \\nDose: itraconazole  \\n– consider not to exceed \\n200 mg/day or monitor \\nlevel and toxicity  \\nKetoconazole  Limited data, minimal effect  Levels: Ketoconazole ↑ 3X \\nDose: Use with caution; do not \\nexceed 200 mg ketoconazole daily  ↑ levels of azoles and DRV  Levels: LPV AUC ↓ \\n13% Azole ↑ 3-fold.  \\nDose: Use with caution; do', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 267}),\n",
       " Document(page_content='exceed 200 mg ketoconazole daily  ↑ levels of azoles and DRV  Levels: LPV AUC ↓ \\n13% Azole ↑ 3-fold.  \\nDose: Use with caution; do \\nnot exceed 200 mg \\nketoconazole daily  \\nANTI -MYCOBACTERIALS  \\nRifampicin  Atazanavir AUC: decreased 72%; \\nCmax: decreased  \\n53%; Cmin:  \\ndecreased 98%  Levels: RTV ↓ 35%.  \\n \\nDose: No change. Increased liver \\ntoxicity possible. Co-administration \\nmay lead to loss of virologic response \\nis RTV sole PI. Alternate anti - \\nmycobacterial agents, such as \\nrifabutin, should be considered  ↓ levels of DRV  Levels: LPV AUC ↓ \\n75%. Should not be co \\nadministered as  \\na safe and effective dose of \\nLPV/ r that can be given \\nwith rifampicin has not \\nbeen established  \\nRifapentine  Do NOT co -administer  Do NOT co -administer  Do NOT co -administer  Do NOT co -administer', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 267}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 47 Annex 13 B: Cont.  \\nClarithromycin  Clarithromycin AUC:  \\nincreased 94%;  Levels; Clarithromycin  \\n↑ 77%  \\n \\nDose: Adjust clarithromycin \\ndose for moderate and severe \\nrenal impairment  ↑ levels of clarithromycin by  \\n59%  Levels: ↑  \\nClarithromycin AUC 77%  \\nDose: Adjust clarithromycin \\ndose for moderate and \\nsevere renal impairment  \\nBedaquiline \\n(BDQ)  Increases BDQ exposure and \\nincreases risk of prolonged QT \\nsyndrome, monitor for increased \\ntoxic effects by frequent ECG and \\ntransaminases assessment  Increases BDQ exposure, \\nmonitor for increased toxic \\neffects by frequent ECG and \\ntransamin ases assessment  Increases BDQ exposure, \\nmonitor for increased toxic \\neffects by frequent ECG and \\ntransaminases assessment  Do NOT co -administer', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 268}),\n",
       " Document(page_content='monitor for increased toxic \\neffects by frequent ECG and \\ntransaminases assessment  Do NOT co -administer \\nbecause of increased risk of \\nprolonged QT syndrome  \\n \\nIncreases BDQ exposure, \\nmonitor for increased toxic \\neffects  \\nDelamanid \\n(DLM)  Increases DLM exposure, monitor \\nfor increased toxic effects by \\nfrequent ECG and transaminases \\nassessment  Increases DLM exposure, \\nmonitor for increased toxic \\neffects by frequent ECG and \\ntransaminases assessment  Increases DLM exposur e, \\nmonitor for increased toxic \\neffects by frequent ECG and \\ntransaminases assessment  Do NOT co -administer \\nbecause of increased risk of \\nprolonged QT syndrome  \\n \\nIncreases DLM exposure, \\nmonitor for increased toxic \\neffects  \\nORAL CONTRACEPTIVES  \\n Ethinyl estradiol  \\nAUC: ↓ Levels: Ethinyl estradiol', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 268}),\n",
       " Document(page_content='Increases DLM exposure, \\nmonitor for increased toxic \\neffects  \\nORAL CONTRACEPTIVES  \\n Ethinyl estradiol  \\nAUC: ↓ Levels: Ethinyl estradiol  \\n↓ 40%.  \\n \\nUse alternative or additional \\nmethod  Ethinyl estradiol  \\nAUC:  ↓ 44%  Levels: Ethinyl estradiol  \\n↓ 42%  \\nUse alternative or \\nadditional method', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 268}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 48 Annex 13 B: Cont.  \\nLIPID -LOWERING AGENTS  \\nSimvastatin  \\nLovastatin  Avoid co - administration  Levels: potential  \\nfor large increase in statin \\nlevels. Avoid concomitant use  Avoid  Levels: Potential  \\nfor large increase in statin \\nlevels  \\nAvoid concomitant use  \\nAtorvastatin  Minimal interaction  Levels:  450% ↑ \\nwhen administered with \\nSQV/RTV combination. Use \\nlowest possible starting dose of \\natorvastatin with careful \\nmonitoring  ↑ AUC four -fold  Atorvastatin AUC ↑ \\n5.88 -fold. Use lowest possible \\nstarting  \\ndose of atorvastatin with \\ncareful monitoring  \\nPravastatin  Minimal interaction  Levels: 50% ↓ when \\nadministered  \\nwith SQV/RTV  \\ncombination  \\n \\nDose: Pravastatin dosage \\nadjustment based on lipid', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 269}),\n",
       " Document(page_content='administered  \\nwith SQV/RTV  \\ncombination  \\n \\nDose: Pravastatin dosage \\nadjustment based on lipid \\nresponse  ↑ AUC 81%  Pravastatin AUC  \\n↑ 33%; no dosage adjustment \\nnecessary  \\nANTI -HYPERTENSIVES  \\nAngiotensin -\\nconverting enzyme \\ninhibitors (ACEIs): \\nE.g. - Enalapril, \\nLisinopril  No known interactions  No known interactions  No known interactions  No known interactions', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 269}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 49 Annex 13 B: Cont.  \\nAngiotensin II \\nreceptor blockers \\n(ARBs): e.g., \\nLosartan, \\nTelmisartan  Telmisartan, Candesartan:  \\nNone  \\nLosartan: Potential \\ninteractions with all PIs, net \\neffect of interaction difficult \\nto predict, use with caution  Telmisartan, Candesartan:  None  \\nLosartan: Potential interactions \\nwith all PIs, net effect of \\ninteraction difficult to predict, \\nuse with caution  Telmisartan, Candesartan:  None  \\nLosartan: Potential interactions \\nwith all PIs, net effect of \\ninteraction difficult to predict, \\nuse with caution  Telmisartan, Candesartan:  \\nNone  \\nLosartan: Potential \\ninteractions with all PIs, net \\neffect of interaction difficult to \\npredict, use with caution  \\nBeta blockers: e.g., \\nAtenolol, Carvedilol', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 270}),\n",
       " Document(page_content='interactions with all PIs, net \\neffect of interaction difficult to \\npredict, use with caution  \\nBeta blockers: e.g., \\nAtenolol, Carvedilol \\nand Propranolol  Potential increase in B -\\nblocker effect, careful dose \\nadjustment and ECG where \\nindicated  Potential increase in B -blocker \\neffect, careful dose adjustment \\nand ECG where indicated  Potential increase in B -blocker \\neffect, careful dose adjustment \\nand ECG where indicated  Potential increase in B -blocker \\neffect, careful dose adjustment \\nand ECG where indicated  \\nCalcium channel \\nblockers (CCBs): e.g., \\nNifedipine, \\nAmlodipine and \\nFelodipine  Potential interaction with all \\nPIs: Metabolism of CCBs \\ninhibited, increasing \\nantihypertensive effect: \\nlower starting dose  of CCB \\nmay be required, monitor for', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 270}),\n",
       " Document(page_content='PIs: Metabolism of CCBs \\ninhibited, increasing \\nantihypertensive effect: \\nlower starting dose  of CCB \\nmay be required, monitor for \\nexcessive reduction in BP  Potential interaction with all \\nPIs: Metabolism of CCBs \\ninhibited, increasing \\nantihypertensive effect: lower \\nstarting dose of CCB may be \\nrequired, monitor for excessive \\nreduction in BP  Potential  interaction with all \\nPIs: Metabolism of CCBs \\ninhibited, increasing \\nantihypertensive effect: lower \\nstarting dose of CCB may be \\nrequired, monitor for excessive \\nreduction in BP  Potential interaction with all \\nPIs: Metabolism of CCBs \\ninhibited, increasing \\nanti hypertensive effect: lower \\nstarting dose of CCB may be \\nrequired, monitor for excessive \\nreduction in BP  \\nDiuretics: E.g., HCTZ, \\nIndapamide. \\nFurosemide and', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 270}),\n",
       " Document(page_content='starting dose of CCB may be \\nrequired, monitor for excessive \\nreduction in BP  \\nDiuretics: E.g., HCTZ, \\nIndapamide. \\nFurosemide and \\nSpironolactone  No known interactions  No known interactions  No known interactions  No known interactions  \\nOthers: Alpha \\nblockers:  \\nMethyldopa, \\nHydralazine   No known interactions  No known interactions  No known interactions  No known interactions', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 270}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 50 Annex 13 B: Cont.  \\nANTICONVULSANTS  \\nCarbamazepine \\nPhenobarbital \\nPhenytoin  Reduce ATV levels  Carbamazepine; ↑ \\nserum levels when  \\nco-administered with  \\nRTV  \\n \\nUse with caution  \\n \\nMonitor anticonvulsant levels  Avoid  Many possible  \\ninteractions: Carbamazepine:  \\n↑ levels when  \\nco-administered with RTV. Use \\nwith caution. Monitor \\nanticonvulsant levels. \\nPhenytoin : levels of LPV, RTV, \\nand ↓ levels of Phenytoin when \\nadministered together  \\nAvoid concomitant use or \\nmonitor LPV level  \\nOTHER DRUG  \\nMethadone  No interaction with unboosted \\nATV Increased metabolism of \\nmethadone with boosted ATV  Methadone ↓ 37%. Monitor and \\ntitrate dose if needed  \\n \\nMay require ↑', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 271}),\n",
       " Document(page_content='ATV Increased metabolism of \\nmethadone with boosted ATV  Methadone ↓ 37%. Monitor and \\ntitrate dose if needed  \\n \\nMay require ↑  \\nmethadone dose  ↓ levels of methadone by 16%  Methadone AUC  \\n↑ 53%. Opiate withdrawal may \\noccur  \\nMonitor and titrate dose if \\nneeded.  \\nMay require ↑  \\nmethadone dose', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 271}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 51 Annex 13 B: Cont.  \\nERECTILE DYSFUNCTION AGENTS  \\nSildenafil  Use reduced dose of sildenafil  Sildenafil AUC ↑ 11-fold. Use \\ncautiously Start with reduced \\ndose of 25 mg every  \\n48 hours and monitor for \\nadverse effects   Sildenafil AUC ↑ 11- fold in \\ncombination with RTV. Do not \\nexceed 25 mg every  \\n48 hours  \\nMiscellaneous  Decreased GI absorption of \\natazanavir due to reduced acidity  Theophylline ↓ 47%  \\nmonitor theophylline levels  \\n \\nRTV 100 mg bid significantly \\nincrease systemic exposure  \\nof inhaled (oral or nasal \\nfluticasone, may predispose \\npatients to systemic  \\ncorticosteroid effects. Co -\\nadministration not \\nrecommended unless benefit of \\nfluticasone outweighs the risk  Warfarin levels', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 272}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 52 Annex 13 C: Drug -Drug Interactions – INSTIs  \\nDrugs Affected  Dolutegravir (DTG)  Raltegravir (RAL)  \\nEfavirenz  Co-administration not recommended because \\nEFV decreases levels of DTG.  If must be used \\ntogether then increase DTG to 50 mg BD when \\nco-administered with EFV.  Efavirenz decreases RAL \\nplasma levels but it is unlikely \\nto be clinically significant  \\nEtravirine  Co-administration not recommended because \\nETR decreases levels of DTG, unless used in \\ncombination with a PI/r (which counteracts the \\ninteraction between DTG and ETR)  \\n \\nIf must be used together without a PI/r then \\nincrease DTG to 50 mg BD when co -\\nadministered with ETR. If used together with a', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 273}),\n",
       " Document(page_content='If must be used together without a PI/r then \\nincrease DTG to 50 mg BD when co -\\nadministered with ETR. If used together with a \\nPI/r then standard dose DTG is sufficient  Etravirine decreases RAL \\nplasma levels so co -\\nadministration when using \\nonce -daily RAL is not \\nrecommended.  Co -\\nadministration when using \\nstandard BD RAL dosing is \\nacceptable  \\nRifampicin  Increase DTG to 50 mg BD when co -\\nadministered with rifampicin (for children, use \\ndouble the standard weight -based DTG dose by \\nadministering twice daily).  \\n \\nThere is no known drug interaction between \\nDTG and rifabutin.  Increase RAL to 800 mg BD \\nwhen co -administered with \\nrifampicin (for children, use \\ndouble the standard weight -\\nbased RAL dose).  \\n \\nRifabutin may alter RA L \\nplasma levels but it is unlikely', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 273}),\n",
       " Document(page_content='rifampicin (for children, use \\ndouble the standard weight -\\nbased RAL dose).  \\n \\nRifabutin may alter RA L \\nplasma levels but it is unlikely \\nto be clinical significant.  \\nRifapentine  Potential decreased DTG levels when co -\\nadministered with once -weekly rifapentine – no \\ndose adjustment required unless viral load \\nbecomes detectable, in which case increase DTG \\nto twice daily until two weeks after completion \\nof rifapentine -based TPT  Potential increased RAL \\nlevels when co -administered \\nwith once -weekly rifapentine \\n– no dose adjustment \\nrequired but monitor for RAL \\ntoxicity  \\nBedaquiline (BDQ)  No interactions expected  No interactions expected  \\nDelamanid (DLM)  No interactions expected  No interactions expected  \\nMetformin  DTG may increase metformin plasma levels so', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 273}),\n",
       " Document(page_content='Delamanid (DLM)  No interactions expected  No interactions expected  \\nMetformin  DTG may increase metformin plasma levels so \\nmetformin dose may need to be decreased. Limit \\ndaily metformin dose to 1,000mg.  \\n \\nDTG does NOT require a dose adjustment is when \\nused with metformin.  No interaction', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 273}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 53 Annex 13 C: Cont.  \\nDrugs Affected  Dolutegravir (DTG)  Raltegravir (RAL)  \\nAnticonvulsants  \\n-Carbamazepine  \\n-Phenobarbital  \\n-Phenytoin  Avoid use of DTG with carbamazepine, \\nphenobarbital, or phenytoin because they \\ndecrease DTG plasma levels.  \\n \\nIf the DTG must be used in combination with any \\nof these anticonvulsants than increase DTG dose \\nto 50mg BD and monitor viral load.  No interaction  \\nMineral \\nsupplements and \\nantacids \\ncontaining cations \\n(e.g., calcium, iron, \\nzinc, magnesium, \\naluminum), \\nincluding prenatal \\nvitamins  Administer DTG at least 2 hours before or 6 \\nhours after taking any of these supplements \\n(note: if taking DTG with a meal then it is safe to \\ntake at th e same time as prenatal vitamins, \\ncalcium, or iron)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 274}),\n",
       " Document(page_content='(note: if taking DTG with a meal then it is safe to \\ntake at th e same time as prenatal vitamins, \\ncalcium, or iron)  \\n \\nThere are no drug -drug interactions between \\nDTG and proton pump inhibitors or H2 blockers \\nused for gastritis.  Do not use calcium, \\nmagnesium and aluminum \\ncontaining antacids with RAL.  \\nMethadone  No inter action  No interaction', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 274}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 54 Annex 14: Health Facility Assessment to Provide Community ART Distribution  \\nHealth Facility Assessment to Provide Community ART Distribution*  \\nFacility name:  MFL code:  Date of assessment:  \\nHealth system domains for community ART distribution  Yes/No  \\nLeadership:  \\nHas the facility identified a focal person to oversee community -based ART distribution?   \\nFinance:  \\nDoes the facility have resources to implement and monitor community -based ART distribution?   \\nHuman Resources for Health:  \\nHas the facility identified appropriate personnel to distribute ART (peer educators, lay \\ncounselors and /or Community Health Volunteers)?   \\nDoes the facility have capacity to train ART distributors?   \\nService Delivery:', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 275}),\n",
       " Document(page_content='counselors and /or Community Health Volunteers)?   \\nDoes the facility have capacity to train ART distributors?   \\nService Delivery:  \\nHas the facility achieved a routine viral load monitoring uptake of ≥ 90%?   \\nHas the facility established a facility -based system for fast -track ART distribution?   \\nCommodity Management:  \\nDoes the facility have ≥ three months of ART available on site?   \\nHas the facility identified a focal person to pre -pack and label ART for community distribution?   \\nHealth Information Systems:  \\nDoes the facility have an established system to monitor patient level outcomes, specifically \\nretention, loss to follow -up, mortalities an d viral load suppression?   \\nIs the facility able to establish recording and reporting systems for community ART?', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 275}),\n",
       " Document(page_content='Is the facility able to establish recording and reporting systems for community ART?   \\nAssessors’ recommendations:  \\n \\nFinal assessment outcome:  \\nFacility can initiate community ART distribution ▢  \\nFacility to implement assessors’ recommendations and be re -assessed thereafter ▢  \\nNames of assessors:  Signature of \\nassessors:  Name of health facility manager: \\nSignature of health facility manager:  \\n*None of these criteria are absolute requirements for implementation of community -based ART \\ndistribution; implementation can be considered even if some criteria are not met, as long as a plan is in \\nplace to address and monitor gaps', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 275}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 55 \\n Annex 15: Creatinine Clearance  \\nFormula for calculating creatinine clearance for adults : \\n \\n \\n \\n \\nFormula for calculating creatinine clearance for children and adolescents (up to 19 years \\nold):  \\n \\neGFR = k x height (cm)/ serum creatinine (mg/dL)  \\n \\nk = 0.45 for infants < 1 year old  \\nk = 0.55 for children (1 – 10 years)  \\nk = 0.55 for female adolescents (11 -19 years)  \\nk = 0.70 for male adolescents (11 -19 years)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 276}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 56 Annex 16: Immune Reconstitution Inflammatory Syndrome  \\nImmune Reconstitution Inflammatory Syndrome (IRIS)  \\nDefinition:  \\nIRIS is a paradoxical inflammatory reaction against a foreign antigen (alive or dead) in patients who \\nhave started ART with reconstitution (improved functioning) of their immune system. The immune \\nsystem, once it regains some function, is now able to respond against the foreign antigen.  \\nClassification:  \\n● Unmasked IRIS: appearance of a previously undiagnosed opportunistic infection (OI) following \\nART initiation (or switch of ART to a suppressive regimen)  \\n● Paradoxical IRIS: worsening of a previously diagnosed disease after ART initiation (or switch of \\nART to a suppressive regimen)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 277}),\n",
       " Document(page_content='● Paradoxical IRIS: worsening of a previously diagnosed disease after ART initiation (or switch of \\nART to a suppressive regimen)  \\nRisk Factors for IRIS:  \\n● 10-20% of patients who start ART with advanced immunosuppression (refer to Chapter 3) \\nexperience clinical deterioration during the first few months due to IRIS  \\n● High risk patients include:  \\no Advanced immunosuppression (WHO Stage 3 or 4, or CD4 count ≤ 200 cell/mm3 ( or CD4% ≤ \\n25% for children ≤ 5 years old))  \\no Patients with a diagnosed opportunistic infection like TB, MAC, CMV, and PCP  \\no Low baseline CD4 (CD4 count ≤ 50 cell/mm3 or CD4% ≤ 10%)  \\no High baseline viral load  \\no Substantial increase in CD4 count and drop in viral load after starting ART  \\nPatient evaluation:', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 277}),\n",
       " Document(page_content='o High baseline viral load  \\no Substantial increase in CD4 count and drop in viral load after starting ART  \\nPatient evaluation:  \\nIn addition to the clinical evaluation for PLHIV outlined in Table 3.1, emphasis should be placed on the \\nfollowing areas during the patient evaluation:  \\nHistory:  \\nSymptoms and current ARV history:  \\n• Specific systemic symptomatology  \\n• Date of ARV initiation  \\n• Regimen  \\n• Reason for substitution / switch from previous ART if not first line  \\n• Adherence to ART and other ongoing treatment  \\n• HIV viral load  \\n• CD4 count  \\nPrior History:  \\n• ARV toxicity  \\n• Drug -drug interaction  \\n• CD4 count  \\n• HIV viral load  History of treatment of opportunistic infections:  \\n• Date of initiation of treatment  \\n• Duration of therapy', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 277}),\n",
       " Document(page_content='• CD4 count  \\n• HIV viral load  History of treatment of opportunistic infections:  \\n• Date of initiation of treatment  \\n• Duration of therapy  \\n• Clinical response to treatment  \\n• Adherence to the OI treatment  \\n• Any default to treatment  \\n• Resistance to treatment', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 277}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 57 Annex 16: Cont.  \\nPhysical Examination:  \\nVital signs assessment:  Temperature, Heart Rate, Blood Pressure, Respiratory rate  \\nConduct a detailed systemic examination:  \\n• Emphasis should be placed on the system(s) which are primarily affected (Table 3.1)  \\n \\nInvestigations  \\n• All patients with advanced HIV disease should be screened for common OIs including TB, \\ncryptococcal meningitis and other common OIs depending of their presenting signs and \\nsymptoms  \\n. \\nDiagnosis of IRIS  \\n● IRIS should be suspected any time a patient has clinical deterioration weeks to months after \\nstarting ART (or switching to a suppressive ART regimen)  \\n● Clinical deterioration usually occurs within 4 -8 weeks of initiation or change of ART (but can be \\nmonths afterwards)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 278}),\n",
       " Document(page_content='● Clinical deterioration usually occurs within 4 -8 weeks of initiation or change of ART (but can be \\nmonths afterwards)  \\n● IRIS has varied clinical presentations due to multiple possible pathogens that the immune system \\nmay be reacting to, and various immune system reactions; there are generally clinical \\nmanifestations consistent with an inflammatory condition  \\n● A high level of suspicion is required when making a diagnosis of IRIS, which is generally one of \\nexclusion  \\n● Rule out the possibility of drug reaction, patient non -adherence to OI treatment, persistently active \\ninfection and/or drug resistance to OI treatment  \\n● There could be localized tissue inflammation with or without systemic inflammatory response  \\n \\nMajor and Minor Presentations of IRIS', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 278}),\n",
       " Document(page_content='● There could be localized tissue inflammation with or without systemic inflammatory response  \\n \\nMajor and Minor Presentations of IRIS  \\nMajor presentation  Minor presentation  \\nTuberculosis (TB)  \\nMycobacterium avium complex (MAC)  \\nCryptococcal meningitis  \\nCytomegalovirus (CMV) retinitis  \\nHepatitis B or C virus  \\nProgressive multifocal leukoencephalopathy \\n(PML)  \\nKaposi’s sarcoma  \\nCerebral toxoplasmosis  \\nAutoimmune diseases  Herpes simplex virus (HSV) and varicella \\nzoster virus (VZV)  \\nNonspecific dermatologic complic ations such \\nas folliculitis, oral and genital warts', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 278}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 58 Annex 16: Cont.  \\nManagement of IRIS  \\nIRIS management is dependent on severity of symptoms and the following general guidance is \\nrecommended:  \\nSeverity of \\nIRIS  Definition  Management  \\nMild  • Resolves over time \\nin most patients  \\n• Symptomatic \\ntreatment is often \\nsufficient  \\n • Treat the OI and manage the associated \\nsymptoms  \\n• Treat IRIS -associated inflammation:  \\no NSAIDS for discomfort associated with mild \\ninflammation / fevers  \\no Inhaled steroids for bronchospasm or \\ncough associated with mild pulmonary \\ninflammation  \\n• Surgical intervention:  \\no Drainage of abscesses  \\no Excision of inflamed and painful lymph \\nnodes  \\nSevere  • Threatens a \\npatient’s \\nfunctional state  \\n• Cause permanent \\ndisability', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 279}),\n",
       " ...]"
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "chunks"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "8e9d3dc5-59d5-4058-aae3-db2465629631",
   "metadata": {},
   "source": [
    "## Chunking wit LLM"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "e900a4d5-9823-4696-a6cc-ba083918f363",
   "metadata": {},
   "outputs": [],
   "source": [
    "from dotenv import load_dotenv\n",
    "load_dotenv()  # OPENAI_API_KEY from .env\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "fb9afb69-57b6-4955-8e1c-6d294c26b305",
   "metadata": {},
   "outputs": [],
   "source": [
    "from openai import OpenAI\n",
    "\n",
    "openai_client = OpenAI()\n",
    "\n",
    "\n",
    "def llm(prompt, model='gpt-4o-mini'):\n",
    "    messages = [\n",
    "        {\"role\": \"user\", \"content\": prompt}\n",
    "    ]\n",
    "\n",
    "    response = openai_client.responses.create(\n",
    "        model='gpt-4o-mini',\n",
    "        input=messages\n",
    "    )\n",
    "\n",
    "    return response.output_text"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "7d06a282-8f5b-458a-9448-f0eadea0a9c9",
   "metadata": {},
   "outputs": [],
   "source": [
    "prompt_template = \"\"\"\n",
    "Split the provided document into logical sections\n",
    "that make sense for a Q&A system.\n",
    "\n",
    "Each section should be self-contained and cover\n",
    "a specific topic or concept.\n",
    "\n",
    "<DOCUMENT>\n",
    "{document}\n",
    "</DOCUMENT>\n",
    "\n",
    "Use this format:\n",
    "\n",
    "## Section Name\n",
    "\n",
    "Section content with all relevant details\n",
    "\n",
    "---\n",
    "\n",
    "## Another Section Name\n",
    "\n",
    "Another section content\n",
    "\n",
    "---\n",
    "\"\"\".strip()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "f1162596-6344-4fbb-a8ae-b221823a1c6b",
   "metadata": {},
   "outputs": [],
   "source": [
    "def intelligent_chunking(text):\n",
    "    prompt = prompt_template.format(document=text)\n",
    "    response = llm(prompt)\n",
    "    sections = response.split('---')\n",
    "    sections = [s.strip() for s in sections if s.strip()]\n",
    "    return sections"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "f9575d54-ada2-44ba-88c0-c94e14540082",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[Document(page_content=' \\n \\n', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 0}),\n",
       " Document(page_content='', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 1}),\n",
       " Document(page_content='  \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n2022 Edition  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 2}),\n",
       " Document(page_content=' \\n  \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n© National AIDS & STI Control Program 2022  \\n \\nThis guideline document is a publication of the National AIDS & STI Control Program, Ministry of Health \\nKenya. No part of this publication may be reproduced, distributed, or transmitted in any form or by any \\nmeans, including photocopying or recording, without the prior written permission of the National AIDS and \\nSTI Contro l Program (NASCOP), Ministry of Health Kenya, except for non -commercial uses permitted by \\ncopyright law.  \\n \\nKenya HIV Prevention and Treatment Guidelines, 2022  edition contain relevant information required by \\nhealthcare providers in the use of ARVs as of the date of issue. All reasonable precautions have been taken \\nby NASCOP to verify the information contained in this guideline document.   \\n \\nFor clarifications contact National AIDS and STI Control Program (NASCOP) at P. O. Box 19361 - 00202, \\nNairobi Kenya, T el: +254 (020) 2630867, Email: info@nascop.or.ke, Website: www.nascop.or.ke  \\nThe recommended citation for this document is:  \\nMinistry of Health, National AIDS & STI Control Program. Kenya HIV Prevention and Treatment Guidelines, \\n2022  Edition. Nairobi, Kenya: NASCOP, Aug  2022. Print.  \\n \\n \\n \\nDesign and Layout: Collins Etemesi - NASCOP  \\nISBN: 13 -978 -9966 -038 -31-9\\n', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 3}),\n",
       " Document(page_content=' \\n \\ni Foreword  \\nKenya is committed to achieving the UNAIDS 95 –95–95 testing and treatment targets among \\npeople living with HIV within all sub -populations and age groups.  \\nThe 2022 edition of the ‘Guidelines on Use of Antiretroviral Drugs for Treating and Pr eventing \\nHIV Infection in Kenya’ is an update of the comprehensive HIV prevention, Care and treatment \\nguidelines released in 2018. These guidelines are aligned with the Ministry of Health’s mission of \\nproviding the highest standard of health for all Kenyan s and one of the Government of Kenya’s Big \\nFour Agenda on Universal Health Coverage .  \\nThe theme of the 2022 guidelines is refocusing efforts in the management of Advanced HIV \\nDisease to reduce HIV/AIDS related morbidity and mortality. While Kenya has made tremendous \\nprogress in HIV Prevention, Care and Treatment through introduction of better medicines, \\ndiagnostics and patient centered approaches in service delivery, Advanced HIV Disease continues \\nto be a challenge. These guidelines intend to widen access t o key diagnostics and medicines to \\nmanage the most common causes of illness and death. Further, emphasis on integrated delivery \\nof patient -centered HIV, TB, NCDs, mental health and sexual and reproductive health services has \\nbeen included.  \\nThese guidelines  provide key recommendations on  HIV testing services and linkage to prevention \\nand treatment; initial evaluation and follow up of PLHIV; standard package of care for PLHIV; \\nadherence preparation monitoring and support; antiretroviral therapy in infants, c hildren, \\nadolescents and adults; prevention of mother to child transmission of HIV, Syphilis and Viral \\nHepatitis; TB/HIV coinfection; Hepatitis B & C/HIV co -infection; use of ARVs for post and pre -\\nexposure prophylaxis for HIV uninfected populations; and HI V services for people who inject \\ndrugs.  \\nThe guidelines are an important tool meant to be used by service providers at all levels of the \\nhealth sector in Kenya. They are presented in a simplified manner using a public health approach \\nto HIV prevention and treatment.  \\nIt is my hope that this guidance document provides the much -needed framework and impetus to \\nmove towards universal access for HIV services and the agenda of ending AIDS by 2030 as a key \\nnational health strategic objective.  \\n \\n \\nDr. Patrick Amoth , EBS  \\nAg. Director General for Health , \\nMinistry of Health . \\n', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 4}),\n",
       " Document(page_content=' \\n \\nii Acknowledgement s \\n \\nThe 2022 Guidelines on Use of Antiretroviral Drugs for Treating and Preventing HIV Infection in \\nKenya has been a long -awaited document as the revision was greatly affected by the COVID -19 \\npandemic. The document has been updated through the collaborative effort of multiple \\nstakeholders, both individuals and institutions, that contributed to the extensive consultations \\nled by NASCOP HIV Care and Treatment Program.  \\n \\nWith much appreciation, I acknowledge all the institutions, both local and international, \\ngovernment ministries and departments whose staff spent long hours, both virtually and in \\nperson, in the review, writing and finalization of this document.  \\n \\nI take th is opportunity to appreciate the efforts of the Ministry of Health officers at NASCOP and \\nother institutions who coordinated and provided leadership during the review process. \\nCompliments to the guidelines review secretariat and the special task force who worked tirelessly \\nto ensure that the team produced a great quality document. Particular appreciation to the \\nNASCOP team and numerous TA’s who were instrumental in compiling the evidence review and \\ndeveloping the guidelines. Special thanks to the consultant s; Jeremy Penner, Irene Mukui, and \\nHerb Harwell for their dedication to this process.  \\n \\nFinancial support for the review process, printing and launch of this document was provided by \\nthe Global Fund, UNITAID through CHAI, the US government through the Cent ers for Disease \\nControl and Prevention and ICAP at Columbia University through the USAID -funded RISE -Kenya \\nProject, WHO and UNICEF - Kenya.  \\n \\n \\n \\nDr. Rose Wafula  \\nHead, National AIDS & STI Control Program  \\nMinistry of Health\\n', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 5}),\n",
       " Document(page_content=' \\n \\niii Table of Contents  \\nForeword  ................................ ................................ ................................ ................................ ................................ .......... i \\nAcknowledgements  ................................ ................................ ................................ ................................ ....................  ii \\nTable of Contents  ................................ ................................ ................................ ................................ ........................  iii \\nList of Figures  ................................ ................................ ................................ ................................ ...............................  ix \\nList of Tables  ................................ ................................ ................................ ................................ ................................ ..x \\nAcronyms and Abbreviations  ................................ ................................ ................................ ............................  xiii \\n1. Summary of Key Recommendations  ................................ ................................ ..................  1 \\n1.1 HIV Testing Services (HTS) and Linkage to Treatment and Prevention  ................................ ..... 1 \\n1.2 Initial Evaluation and Follow -up for PLHIV  ................................ ................................ .............................  1 \\n1.3 Standard Package of Care for PLHIV  ................................ ................................ ................................ ...........  2 \\n1.4 Adherence Preparation, Monitoring and Support  ................................ ................................ ................  4 \\n1.5 Antiretroviral Therapy for Infants, Children, Adolescents, and Adults  ................................ ....... 4 \\n1.6 Prevention of Mother to Child Transmission of HIV/Syphilis/HBV  ................................ .............  5 \\n1.7 TB/HIV Co -infection Prevention and Management  ................................ ................................ .............  6 \\n1.8 HBV/HIV and HCV/HIV Co -infection Prevention and Management  ................................ .............  7 \\n1.9 ARVs for Post -exposure Prophylaxis (PEP)  ................................ ................................ .............................  7 \\n1.10 Pre -Exposure Prophylaxis (PrEP)  ................................ ................................ ................................ .............  7 \\n1.11 People Who Inject Drugs (PWID) and HIV  ................................ ................................ ............................  8 \\n2. HIV Testing Services and Linkage to Treatment and Prevention  ...........................  1 \\n2.1 Settings for HIV Testing  ................................ ................................ ................................ ................................ .... 1 \\n2.1.1 Facility -based testing  ................................ ................................ ................................ ................................ ..........................  1 \\n2.1.2 Community –based testing  ................................ ................................ ................................ ................................ ................  2 \\n2.2 HTS strategies  ................................ ................................ ................................ ................................ .......................  2 \\n2.2.1 HIV Self -Testing (HIVST)  ................................ ................................ ................................ ................................ ...................  2 \\n2.2.2 Index Testing  ................................ ................................ ................................ ................................ ................................ ...........  2 \\n2.2.3 Voluntary Counselling and Testing (VCT):  ................................ ................................ ................................ ...............  2 \\n2.2.4 Social Network Strategy (SNS) - ................................ ................................ ................................ ................................ ...... 2 \\n2.3 Package of HI V Testing Services  ................................ ................................ ................................ ...................  5 \\n2.4 Age -Specific HIV Testing Algorithms  ................................ ................................ ................................ ..........  8 \\n2.4.1 Early Infant Diagnosis  ................................ ................................ ................................ ................................ .................  8 \\n2.4.2 Diagnosis of HIV Infection in the Older Child (≥ 18 months), Adolescents and Adults  ............  12 \\n2.4.3 HIV testing for Pregnant Women  ................................ ................................ ................................ .......................  14 \\n2.5 Retesting recommendations for HIV negative pe rsons  ................................ ................................ ... 17 \\n2.6 Inconclusive HIV status  ................................ ................................ ................................ ................................ .. 18 \\n2.7 Approach to Patients on ART with a Discrepant HIV Test Result  ................................ ...............  19 ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 6}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n \\niv 3. Initial Evaluation and Follow up  ................................ ................................ .........................  1 \\n3.1 Introduction  ................................ ................................ ................................ ................................ ...........................  1 \\n3.2 Initial Clinical Evaluation of PLHIV  ................................ ................................ ................................ ..............  1 \\n3.3 Initial Laboratory Evaluation of PLHIV  ................................ ................................ ................................ ...... 4 \\n3.4 Managem ent of Patients Who Present with Advanced HIV Disease  ................................ .............  6 \\n3.5 Follow -up of PLHIV after ART initiation  ................................ ................................ ................................ ... 8 \\n3.5.1 First 6 months after ART initiation  ................................ ................................ ................................ ..............................  9 \\n3.5.2 Differentiated Service Delivery for Patients beyond the 1st 6 months of ART  ................................ ....... 9 \\n3.6 Summary of clinical and laboratory monitoring of PLHIV on ART ................................ .............  11 \\n3.7 Differentiated Care for Chi ldren, Adolescents and Pregnant/ breastfeeding Women  ...... 13 \\n3.8 ART Prescription, Dispensing, and Distribution for clients establishe d on ART  .................  14 \\n4. Standard Package of Care for PLHIV ................................ ................................ ..................  1 \\n4.1 Antiretrovir al Therapy  ................................ ................................ ................................ ................................ ...... 4 \\n4.2 PHDP, GBV/IPV & HIV Education/Counselling  ................................ ................................ ......................  5 \\n4.2.1 Screening for Gender -Based Violence (GBV)/Intimate -Partner Violence (IPV)  ................................ .... 6 \\n4.2.2 HIV Education/Counselling  ................................ ................................ ................................ ................................ ..............  7 \\n4.3 Specific Opportun istic Infection Screening and Prevention  ................................ .............................  8 \\n4.3.1 Cotrimoxazole Preventive Therapy (CPT)  ................................ ................................ ................................ ................  8 \\n4.3.2 Tuberculosis (TB) Prevention and Management for PLHIV  ................................ ................................ ..........  11 \\n4.3.3 Cryptococcal Meningitis (CM) Screening and Treatment  ................................ ................................ ...............  11 \\n4.4 Reproductive Health Services  ................................ ................................ ................................ .....................  15 \\n4.4.1 Sexually Transmitted Infections  ................................ ................................ ................................ ................................ . 15 \\n4.4.2 Family Planning and Pre -Conception Counselling  ................................ ................................ .............................  15 \\n4.4.3 Maternal Healthcare  ................................ ................................ ................................ ................................ .........................  18 \\n4.5 Non -communicable Diseas es Screening and Management  ................................ ............................  18 \\n4.5.1 Metabolic Disorders  ................................ ................................ ................................ ................................ ..........................  18 \\n4.5.2 Cancer Prevention, Early Detection and Management among PLHIV  ................................ ......................  23 \\n4.6 Mental Health Screening and Management  ................................ ................................ ..........................  25 \\n4.6.1 Depre ssion  ................................ ................................ ................................ ................................ ................................ .............  25 \\n4.6.2 Alcohol and Drug Use/Addiction  ................................ ................................ ................................ ................................  28 \\n4.6.3 Anxiety ................................ ................................ ................................ ................................ ................................ .....................  31 \\n4.6.4 Stress and stress management  ................................ ................................ ................................ ................................ .... 32 \\n4.6.5 experiences o f Trauma  ................................ ................................ ................................ ................................ ....................  33 \\n4.6.6 Psychosis  ................................ ................................ ................................ ................................ ................................ ................  34 \\n4.6.7 Self -Care  ................................ ................................ ................................ ................................ ................................ ..................  34 \\n4.6.8 Wellbeing  ................................ ................................ ................................ ................................ ................................ ...............  35 ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 7}),\n",
       " Document(page_content=' \\n \\nv 4.7 Nutritional Services  ................................ ................................ ................................ ................................ .........  36 \\n4.7.1 Nutritional Assessment, Counselling and Support (NACS)  ................................ ................................ ............  36 \\n4.8 Prevention of Other Infections  ................................ ................................ ................................ ...................  40 \\n4.8.1 Immunizations  ................................ ................................ ................................ ................................ ................................ ..... 40 \\n4.8.2 Malaria  ................................ ................................ ................................ ................................ ................................ .....................  42 \\n4.8.3 Safe Water, Sanitation and Hygien e ................................ ................................ ................................ ..........................  42 \\n5. Adherence Preparation, Monitoring and Support  ................................ ........................  1 \\n5.1 Undetectable = Untransmittable (U=U)  ................................ ................................ ................................ ..... 5 \\n5.1.1 Benefits of U=U  ................................ ................................ ................................ ................................ ................................ ....... 5 \\n5.1.2 Considerations for implem entation of U=U within clinical settings  ................................ ............................  5 \\n5.1.3 Messaging to Patients on U=U  ................................ ................................ ................................ ................................ .........  5 \\n5.1.4 How patients can discuss U=U with others  ................................ ................................ ................................ ..............  6 \\n5.1.5 Counselling patients about other prevention combination interventions  ................................ ................  6 \\n5.1.6 Application of U=U in o ther settings  ................................ ................................ ................................ ............................  6 \\n5.2 ART Adherence Preparation and Support  ................................ ................................ ................................  7 \\n5.2.1 Treatment Preparation as Part of HIV Testing Services  ................................ ................................ ....................  7 \\n5.2.2 ART Treatment Preparation  ................................ ................................ ................................ ................................ ............  7 \\n5.2.3 Age -Specific Tr eatment Preparation and Support  ................................ ................................ .............................  13 \\n5.3 Adherence Monitoring, Counselling and Support During the First 3 Months of ART  ........ 20 \\n5.3.1 Adherence Monitoring  ................................ ................................ ................................ ................................ .....................  20 \\n5.3.2 Adherence Counselling and Support During the First 3 Months of ART  ................................ .................  25 \\n5.4 Adherence Monitoring, Counselling and Support for Patients with Suppressed Viral Load \\n< 200 copies/ml  ................................ ................................ ................................ ................................ ...... 29 \\n5.5 Adherence Monitoring, Counselling and Support for Patients with Unsuppressed Viral \\nLoad ≥ 200 copies/ml  ................................ ................................ ................................ ...........................  30 \\n5.5.1 Enhanced Adherence Assessments  ................................ ................................ ................................ ...........................  31 \\n5.5.2 Enhanced Adherence Counselling  ................................ ................................ ................................ ..............................  31 \\n5.6 Treatment Preparation for 2nd Line or 3rd Line ART  ................................ ................................ ..... 34 \\n5.7 Identifying, Tracing, and Supporting Patients who Default from Care  ................................ ..... 35 \\n6. Antiretroviral Therapy in Infants, Children, Adolescents, and Adults  .................  1 \\n6.1 Eligibility for ART  ................................ ................................ ................................ ................................ ................  1 \\n6.2 Timing of ART Initiation  ................................ ................................ ................................ ................................ ... 1 \\n6.3 First -Line ART for Infants, Children, Adolescents and Adults (including Pregnant and \\nBreastfeeding Women)  ................................ ................................ ................................ ...........................  3 \\n6.4 Dosing and Administration of Dolutegravir (DTG) ................................ ................................ ...............  5 \\n6.5 Monitoring and Changing ART  ................................ ................................ ................................ .......................  7 \\n6.5.1 Optimizing Therapy for Patients who have suppressed viral load on First Line ART .........................  7 ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 8}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n \\nvi 6.5.2 Changing ARVs Due to Adverse Drug Reactions  ................................ ................................ ................................ .... 9 \\n6.5.3 Changing ARVs Due to Drug -Drug Interactions  ................................ ................................ ................................ .. 16 \\n6.5.4 Changing ARVs Due to Treatment Failure  ................................ ................................ ................................ .............  17 \\n7. Prevention of Mother to Child Transmission of HIV/Syphilis/Hepatitis B  .........  1 \\n7.1 Antiretroviral Therapy for HIV -positive Pregnant and Breastfeeding Women and Infant \\nProphylaxis  ................................ ................................ ................................ ................................ ...................  3 \\n7.2. Syphilis elimination for Pregnant and Breastfeeding Women and Infant Treatment  .........  5 \\n7.3. Hepatitis B elimination for Pregnant and Breastfeeding Women and Infant Prophylaxis  5 \\n7.4 Infant and Young Child Nutrition in the Context of HIV  ................................ ................................ ..... 7 \\n8. TB/HIV Co -infection, Prevention  and Management  ................................ ....................  1 \\n8.1 TB Screening for PLHIV: Intensified Case Finding (ICF)  ................................ ................................ .... 1 \\n8.2. TB Preventive Therapy (TPT)  ................................ ................................ ................................ .......................  9 \\n8.2.1. Indications for TPT  ................................ ................................ ................................ ................................ ..............................  9 \\n8.2.2. Contraindications to TPT  ................................ ................................ ................................ ................................ ..............  10 \\n8.2.3. Dose and Duration of TPT  ................................ ................................ ................................ ................................ .............  10 \\n8.2.4. Follow -up of Patients on TPT  ................................ ................................ ................................ ................................ ...... 11 \\n8.3. Identifying and Managing Drug Toxicities from TPT  ................................ ................................ ...... 11 \\n8.3.1 Peripheral Neuropathy - Suspected drug: INH  ................................ ................................ ................................ ..... 11 \\n8.3.2 Drug -Induced Liver Injury (DILI) -Suspected drugs include Isoniazid (H), Rifapentine (P), \\nRifampicin (R)  ................................ ................................ ................................ ................................ ................................ .................  12 \\n8.3.3 Managemen t of TPT -associated Rash - Suspected Drugs include Isoniazid (H), Rifapentine (P), \\nRifampicin (R)  ................................ ................................ ................................ ................................ ................................ .................  13 \\n8.4. ART for TB/HIV Co -infect ion ................................ ................................ ................................ ......................  13 \\n9. HBV/HIV and HCV/HIV Co -infection Prevention and Management  .......................  1 \\n9.1 Hepatitis B/HIV Co -infection  ................................ ................................ ................................ ..........................  1 \\n9.1.1 Screening  ................................ ................................ ................................ ................................ ................................ ...................  1 \\n9.1.2 Prevention  ................................ ................................ ................................ ................................ ................................ ................  1 \\n9.1.3 Treatment  ................................ ................................ ................................ ................................ ................................ .................  2 \\n9.2 Hepatitis C/HIV Co -infection  ................................ ................................ ................................ ..........................  5 \\n9.2.1 Screening  ................................ ................................ ................................ ................................ ................................ ...................  5 \\n9.2.2 Prevention  ................................ ................................ ................................ ................................ ................................ ................  6 \\n9.2.3 Treatment of HIV/HCV Co -infection  ................................ ................................ ................................ ............................  6 \\n10. ARVs for Post -exposure Prophylaxis  ................................ ................................ .................  1 \\n10.1 What is P EP? ................................ ................................ ................................ ................................ ........................  1 \\n10.2 Recommended ARVs for PEP  ................................ ................................ ................................ .......................  1 \\n10.3 Eligibility For PEP  ................................ ................................ ................................ ................................ .............  2 \\n10.4 Management and Follow Up ................................ ................................ ................................ .........................  2 ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 9}),\n",
       " Document(page_content=' \\n \\nvii 10.5 Risk reduction cou nselling ................................ ................................ ................................ ............................  4 \\n10.6 Preventing HIV exposure  ................................ ................................ ................................ ...............................  4 \\n11. Pre-Exposure Prophylaxis (PrEP)  ................................ ................................ ......................  1 \\n11.1 Indications for PrEP and Criteria for Eligibility  ................................ ................................ ..................  1 \\n11.1.1 Indications for PrEP  ................................ ................................ ................................ ................................ ..........................  1 \\n11.1.2 HIV Risk Assessment  ................................ ................................ ................................ ................................ ........................  1 \\n11.1.3 Criteria for PrEP Eligibility  ................................ ................................ ................................ ................................ ............  2 \\n11.2 Package of PrEP Service  ................................ ................................ ................................ ................................ . 3 \\n11.2.1 Pre -Initiation Che cklist  ................................ ................................ ................................ ................................ ....................  4 \\n11.2.2 Pre -initiation client education  ................................ ................................ ................................ ................................ ..... 5 \\n11.3 Recommended ARVs for PrEP  ................................ ................................ ................................ .....................  5 \\n11.3.1 Schema for follow up for daily oral PrEP  ................................ ................................ ................................ ................  7 \\n11.3. 2 EVENT DRIVEN PrEP (ON DEMAND PrEP or 2+1+1 PrEP)  ................................ ................................ ...........  7 \\n11.4 Managing Clinical and Laboratory Results on Initial and Follow -up Asse ssment  ...............  9 \\n11.5 Contra -indications to Oral PrEP (daily or ED PrEP)  ................................ ................................ ....... 12 \\n11.6 Criteria for Discontinuing Oral PrEP  ................................ ................................ ................................ ..... 12 \\n11.7 Restarting PrEP  ................................ ................................ ................................ ................................ ...............  12 \\n11.8 Improving adherence to PrEP  ................................ ................................ ................................ ..................  13 \\n11.9 Monitoring Sero -conversion among PrEP users  ................................ ................................ ..............  13 \\n12. People Who Inject Drugs (PWID) and HIV ................................ ................................ ....... 1 \\n12.1 Intro duction  ................................ ................................ ................................ ................................ ........................  1 \\n12.3 ART in HIV positive PWID  ................................ ................................ ................................ .............................  4 \\n13. Annexes  ................................ ................................ ................................ ................................ ........  1 \\nAnnex 1: WHO Clinical Staging of HIV Infection in Infants and Children  ................................ ...........  1 \\nAnnex 2: WHO Clinical Staging of HIV Infection in Adolescents and Adults  ................................ ..... 2 \\nAnnex 3: Normal Developmental Miles tones in Children  ................................ ................................ .........  3 \\nAnnex 4: Tanner Staging of Sexual Maturity in Adolescents  ................................ ................................ ... 4 \\nAnnex 4 A: Tanner Staging of Sexual Maturity in Girls ................................ ................................ ................................ ... 4 \\nAnnex 4 B: Tanner Staging of Sexual Maturity in Boys  ................................ ................................ ................................ .. 4 \\nAnnex 5: Age -Appropriate Disclosure for Child ren and Adolescents  ................................ ..................  5 \\nAnnex 6: Transitioning from Adolescent to Adult HIV Services  ................................ .............................  6 \\nAnnex 7: 2018 HIV Testing Services Algorithm ................................ ................................ .............................  7 \\nAnnex 8: HIV Education and Adherence Counselling Content Guide  ................................ ...................  8 \\nAnnex 9 A: Enhanced Adherence Counselling Content Guide  ................................ ..............................  16 \\nAnnex 9 B: Case Summary Form  ................................ ................................ ................................ .......................  22 \\nAnnex 9 C: Enhanced Adherence Counselling Form  ................................ ................................ .................  24 \\nAnnex 9 D: Home Visit Checklist  ................................ ................................ ................................ .......................  25 ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 10}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n \\nviii Annex 9 E: Management Protocol for Patients Switc hing to 3rd Line ART  ................................ .... 26 \\nAnnex 10 A: Dosing of Solid and Liquid Formulations for Twice -Daily Dosing in Infants and \\nChildren 4 Week s of Age and Older  1 ................................ ................................ .............................  28 \\nAnnex 10 B: Simplified Dosing of Child -Friendly Solid and Oral Liquid Formulations for Once -\\nDaily Dosing in Infants and Children 4 Weeks of Age and Older1 ................................ ..... 29 \\nAnnex 10 C: Drug Dosing of Liquid Formulations for Twice -Daily Dosing in Infants Less than \\n4 Weeks of Age  ................................ ................................ ................................ ................................ .........  30 \\nAnnex 10 D: Simplified Dosing of INH and CTX Prophylaxis for Infants and Children Who Are \\nat Least 4 Weeks of Age  ................................ ................................ ................................ .......................  30 \\nAnn ex 10 E: TB Preventive Therapy dosing  ................................ ................................ ................................ . 31 \\nAnnex 10 F: Ritonavir Dosing for Super -Boosting LPV/r in Children Taking Rifampicin  ....... 34 \\nAnnex 11: Overlapping toxicities between AR Vs ................................ ................................ .......................  35 \\nAnnex 12 A: Use of Nucleoside & Nucleotide Reverse Transcriptase Inhibitors in Adults  ..... 36 \\nAnnex 12 B: Use of Non -Nucleoside Reverse Transcriptase Inhibitors for Adults  .....................  38 \\nAnnex 12 C: Use of Protease Inhibitors in Adults  ................................ ................................ ......................  39 \\nAnnex 12 D: Integrase Strand Transfer Inhibitors - INSTIs  ................................ ................................ .. 40 \\nAnnex 13 A: Drug -Drug Interactions - NNRTIs  ................................ ................................ ...........................  41 \\nAnnex 13 B: Drug -Drug Interactions – PIs ................................ ................................ ................................ .... 45 \\nAnnex 13 C: Drug -Drug Interactions – INSTIs  ................................ ................................ .............................  52 \\nAnnex 14: Health Facility Assessment to Provide Community ART Distribution  .......................  54 \\nAnnex 15: Creatinine Clearance  ................................ ................................ ................................ .........................  55 \\nAnnex 16: Immune Reconstitution Inflammatory Syndrome  ................................ ..............................  56 \\nAnnex 17: HTS Adult Screening Tool Enhancement  ................................ ................................ .................  59 \\nAnnex 18: List of Contributors and Affiliation  ................................ ................................ ............................  60 \\nAnnex 19: List of Participating Organizations and Agencies  ................................ ................................  62 \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 11}),\n",
       " Document(page_content=' \\n \\nix List of Figures  \\nFigure 2.1 Algorithm for Early Infant Diagnosis in Infants and Children < 18 months of age  ................................ .. 9 \\nFigure 2.2: Birth Testing Algor ithm  ................................ ................................ ................................ ................................ ....................  11 \\nFigure 2.3: HIV Testing Services Algorithm  ................................ ................................ ................................ ................................ .... 13 \\nFigure 2.4 Dual HIV/syphilis Testing Algorithm  ................................ ................................ ................................ ..........................  15 \\nFigure 2.5: Managing Patients on ART Who Present with a New Negative HIV Antibody Test  ............................  20 \\nFigure 4.1: Routine Screening for Cryptococcal Meningitis for HIV -infected Adults and Adolescents  .............  14 \\nFigure 4.2: Generalized Anxiety Disorder Assessment (GAD -7) ................................ ................................ ..........................  32 \\nFigure 4.3: Management of Severe Acute Malnutrition in Children  ................................ ................................ ....................  38 \\nFigure 4.4: Management of Malnutrition in Adults with HIV  ................................ ................................ ................................ . 39 \\nFigure 5.1: Adherence Preparation, Monitoring and Support  until Viral Load after 3 Months on ART  ...............  2 \\nFigure 5.2: Adherence Counselling and Education for Patients Preparing to Initiate 2nd Line or 3rd Line \\nART  ................................ ................................ ................................ ................................ ................................ ................................ .....................  34 \\nFigure 5.3: Ident ifying, Tracing and Supporting Patients who Default from Care  ................................ .......................  35 \\nFigure 6.1: Optimizing ART Regimens for Children and adolescents <15 years Weighing < 30 kg on First \\nLine ART  ................................ ................................ ................................ ................................ ................................ ................................ ..............  8 \\nFigure 6.2: Optimizing ART Regimens for Children and Adolescents Weighing ≥ 30 kg  or ≥ 15 years old on \\nFirst Line ART  ................................ ................................ ................................ ................................ ................................ ................................ ... 9 \\nFigure 6.3: General Principles for Managing Adverse Drug Reactions  ................................ ................................ ..............  11 \\nFigure 6.4: Managing Single Drug Substitutions for ART  ................................ ................................ ................................ .........  12 \\nFigure 6.5: Managing TDF -Associated Kidney Toxicity  ................................ ................................ ................................ ............  13 \\nFigure 6.6: Viral Load Monitoring of Patients on ART (1st Line or 2nd Line)  ................................ ...............................  18 \\nFigure 8.1: TB diagnosis - GeneXpert Ultra algorithm  ................................ ................................ ................................ ...................  5 \\nFigure 8.2: Use of TB -LAM for Diagnosis of TB among PLHIV  ................................ ................................ ................................ .. 8 \\nFigure 11.1 : Package of Service for PrEP  ................................ ................................ ................................ ................................ ............  3 \\nFigure 11.2: Schema for Follow -up for Daily Oral PrEP  ................................ ................................ ................................ ...............  7 \\nFigure 11.3 Schema for Event -Driven PrEP  ................................ ................................ ................................ ................................ ....... 8 \\nFigure 11.4 Schema for Initiation and Follow -up for Event -driven PrEP  ................................ ................................ ...........  8 \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 12}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n \\nx List of Tables  \\nTable 2.1: HTS Recommendations for Different Populations and Settings  ................................ ................................ ........ 3 \\nTable 2.2: Summary of HIV Testing Services Package  ................................ ................................ ................................ ..................  6 \\nTable 2.3: Presumptive Diagnosis of HIV in children <18 months while awaiting DNA PCR Results  ................  10 \\nTable 2 .4: Approaches to Improve Linkage to Treatment and Prevention Services  ................................ ..................  16 \\nTable 2.5: Recommendations for Retesting HIV Negative C lients  ................................ ................................ .......................  18 \\nTable 3.1: Initial Clinical Evaluation for PLHIV (History and Physical Examination)  ................................ ...................  2 \\nTable 3.2: Baseline Laboratory Investigatio ns for PLHIV  ................................ ................................ ................................ ...........  4 \\nTable 3.3: Differentiated Care Based on Initial Patient Presentation  ................................ ................................ ...................  7 \\nTable 3.4: Management of patients who are presenting well: WHO Stage 1 or 2, and CD4 count > 200 \\ncell/mm3  ................................ ................................ ................................ ................................ ................................ ................................ ............  8 \\nTable 3.5: Differentiated Follow -up of Patients Beyond the First 6 Months of ART  ................................ ......................  9 \\nTable 3.6: Summary of Clinical and Laboratory Monitoring for PLHIV1 ................................ ................................ ..........  11 \\nTable 4.1: Components of the Standard Package of Care for PLHIV  ................................ ................................ ......................  2 \\nTable 4.2: Domains and Components for PHDP Serv ices ................................ ................................ ................................ ............  5 \\nTable 4.2a: Components of screening for GBV/IPV (LIVES)  ................................ ................................ ................................ ...... 7 \\nTable 4.3: Co -trimoxazole Preventive therapy  ................................ ................................ ................................ ................................ . 8 \\nTable 4.4: Daily Dose of Cotrimoxazole Preventive Therapy  ................................ ................................ ................................ .... 9 \\nTable 4.5: Management of Drug -Associated Skin Rash  ................................ ................................ ................................ ................  9 \\nTable 4.6a: Standard Cotrimoxazole Desensitization Regimen (8 days)  ................................ ................................ ..........  10 \\nTable 4.6b: Rapid Cotrimoxazole Desensitization Regimen (6 hours)  ................................ ................................ ..............  10 \\nTable 4.7: Treatment of Cryptococcal Meningitis  ................................ ................................ ................................ ........................  12 \\nTable 4.8: Contraceptive Methods for PLHIV Based on WHO 2018 Medical Eligibility Criteria  ...........................  16 \\nTable 4.9: Pr e-Conception Counselling Messages and Services for PLHIV  ................................ ................................ ...... 17 \\nTable 4.10: Lifestyle Modifications to Prevent and Manage Cardiovascu lar Disease in PLHIV  ............................  19 \\nTable 4.11 : Hypertension Screening, Diagnosis, and Initial Management for Adult PLHIV  ................................ .... 20 \\nTable 4.12: Type 2 Diabetes Mellitus Screening, Dia gnosis, and Initial Management for PLHIV  .........................  21 \\nTable 4.12: Dyslipidemia Screening, Diagnosis, and Initial Management for PLHIV  ................................ ..................  22 \\nTable 4.13: Chronic Kidney Disease Screening, Diagnosis, and Initial Management for PLHIV  ...........................  23 \\nTable 4.15: Patient Health Questionnaire -9 (PHQ -9) for Depression Screening  ................................ ..........................  26 \\nTable 4.16: CRAFFT Screening Interview for Adolescents  ................................ ................................ ................................ ...... 28 \\nTable 4.17: CAGE -AID Screening Questions for Adults  ................................ ................................ ................................ .............  29 \\nTable 4.18: Addiction Support Based on Stages of Change  ................................ ................................ ................................ ..... 30 \\nTable 4.19: Interpretation of MUAC Results for Children and Pregnant/Lactating Women  ................................ .. 37 \\nTable 4.20: Interpretation of Z -scores for Children  ................................ ................................ ................................ ....................  37 \\nTable 4.21: Interpretation of BMI Results for Adults  ................................ ................................ ................................ .................  40 \\nTable 4.22: Kenya Expanded Program on Immunizations 2016 Schedule  ................................ ................................ ...... 40 ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 13}),\n",
       " Document(page_content=' \\n \\nxi Table 4.23: Vaccinations in Adolescents and Adults Living wit h HIV  ................................ ................................ ................  41 \\nTable 5.1: Treatment Preparation and Adherence Counselling Guide  ................................ ................................ .................  7 \\nTable 5.2: Components of HIV Education (see Annex 8 for detai led content guide)  ................................ ..................  10 \\nTable 5.3: Adherence Support and Retention Interventions  ................................ ................................ ................................ .. 11 \\nTable 5.4: ART Readiness Assessment Form  ................................ ................................ ................................ ................................ . 13 \\nTable 5 .5: Age -appropriate Involvement of Child/Adolescent in HIV Education and Adherence Counselling\\n ................................ ................................ ................................ ................................ ................................ ................................ ..............................  15 \\nTable 5.6: Unique Considerations for Caregivers, Children and Adolescents  ................................ ................................  16 \\nTable 5.7: Treatment Preparation and Support for Chil dren (≤ 9 years) and Caregivers  ................................ ....... 17 \\nTable 5.8: Treatment Preparation and Support for Adolescents (10 -19 years)  ................................ ...........................  18 \\nTable 5.9: Treatment Preparation and Support for Adults  ................................ ................................ ................................ ..... 19 \\nTable 5.10: Adherence Monitoring Strategies  ................................ ................................ ................................ ...............................  21 \\nTable 5.11: Morisky Medication Adherence Scale (MMAS -4) ................................ ................................ ................................  23 \\nTable 5.12: Morisky Medication Adherence Scale (MMAS -8) ................................ ................................ ................................  24 \\nTable 5.13: Adherence Rate Based on Pill Counts  ................................ ................................ ................................ .......................  25 \\nTable 5.14: Adherence Counselling and Support During the First 3 Months of ART  ................................ .................  26 \\nTable 5.15: Assessment for Barriers to Adherence  ................................ ................................ ................................ .....................  27 \\nTable 5.16: Adherence Counselling and Support for Patients with Viral Load < 50 copies/ml  ............................  29 \\nTable 5.17 Viral Load Monitoring Cut -Offs  ................................ ................................ ................................ ................................ ..... 30 \\nTable 5.18: Components of Enhanced Adherence Co unselling Sessions (Annex 9A for detailed content \\nguide)  ................................ ................................ ................................ ................................ ................................ ................................ .................  32 \\nTable 6.1: Special Considerat ions for Timing of ART Initiation  ................................ ................................ ...............................  2 \\nTable 6.2: Preferred First -line ART Regimens and Dosing for Children, Adolescents and Adults 1 .......................  3 \\nTable 6.3: Use of Alternative ARVs in First -Line Regimens 1 ................................ ................................ ................................ .... 4 \\nTable 6.4: Dosing and Administration of Dolutegravir  ................................ ................................ ................................ ................  5 \\nTable 6.5: Common Significant Adverse Drug Reactions  ................................ ................................ ................................ .........  10 \\nTable 6.6: ARV, CTX and Fluconazole Adjustments in Renal and Hepatic Impairment1 ................................ ...........  14 \\nTable 6.7: Management of AZT -Associated Bone Marrow Suppression  ................................ ................................ ...........  15 \\nTable 6.8: Management of Drug -Related Hepatotoxicity  ................................ ................................ ................................ .........  15 \\nTable 6.9: Diagnosis and Management of Abacavir Hypersensitivity Reaction  ................................ ............................  16 \\nTable 6.10: Recommended Second -line ART Regimens in Infants, Children, Adolescents and Adults, \\nexcluding TB/HIV co -infection 1 ................................ ................................ ................................ ................................ ...........................  19 \\nTable 6.11: Possible Third -line ART in Children, Adolescents and Adults  ................................ ................................ ...... 21 \\nTable 7.1: Essential Package of Antenatal Care  ................................ ................................ ................................ ...............................  1 \\nTable 7.2: Summary of Use of ART for HIV Positive Pregnant and Breastfeeding Women  ................................ ........ 3 \\nTable 7.3: ARV Prophylaxis for HIV -Exposed Infants  ................................ ................................ ................................ ...................  6 \\nTable 7.4: Dosing of ARVs for Infant Prophylaxis from Birth to 12 Weeks of Age  ................................ ..........................  7 \\nTable 7.5: NVP Dosing for Infant Prophylaxi s beyond 12 Weeks of Age *  ................................ ................................ ..........  7 \\nTable 7.6: AZT Dosing for Infant Prophylaxis beyond 12 Weeks of Age *  ................................ ................................ ..........  7 ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 14}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n \\nxii Table 7.7: Complementary Foods for Children 6 -24 Months Old  ................................ ................................ ...........................  9 \\nTable 8.1: TB Diagnosis in Children <10 Years Old  ................................ ................................ ................................ ........................  6 \\nTable 8.2: Drug Susceptible TB Treatment Regimen for Children, Adolescents and Adults  ................................ ...... 7 \\nTable 8.3: Recommended TPT Regimens for PLHIV  ................................ ................................ ................................ ..................  10 \\nTable 8.4: Grading and Management of DILI  ................................ ................................ ................................ ................................ .. 12 \\nTable 8.5: Management of TPT -Associated Skin Rash  ................................ ................................ ................................ ...............  13 \\nTable 8.6: Preferred ART Regimens for TB/HIV Co -infection for Patients Newly Initiating 1st Line ART 1 ... 14 \\nTable 8.7: Preferred ART Regimens for Patients who Develop TB while Virally Suppressed on 1st Line ART \\n1,2 ................................ ................................ ................................ ................................ ................................ ................................ ..........................  15 \\nTable 8.8: Recommended ART Regimens for Patients who Develop TB while Failing 1st Line ART 1 ..............  16 \\nTable 9.1: Hepatitis B Vaccination Schedule for HIV -positive Adolescents and Adults  ................................ ...............  2 \\nTable 9.2: Summary of Initial Clinical and Laboratory Evaluation in HIV/HBV Co -infection  ................................ ... 3 \\nTable 9.3: Dose Adjustment of TDF and  3TC in Patients with Impaired Renal Function 1 ................................ .........  4 \\nTable 9.4: Summary of Initial Clinical and Laboratory Evaluation in HIV/HCV Co -infection  ................................ ... 6 \\nTable 9.5: Recommended DAA for the Treatment of HCV among PLHIV  ................................ ................................ ............  7 \\nTable 10.1: Recommended ARVs for PEP  ................................ ................................ ................................ ................................ ...........  1 \\nTable 10.2: Recommendations for PEP Management and Follow -up ................................ ................................ ...................  3 \\nTable 10.3 Considerations for special circumstances  ................................ ................................ ................................ ...................  4 \\nTable 11:1 HIV Screening questions  ................................ ................................ ................................ ................................ .....................  2 \\nTable 11.2: Pre -Initiation Assessment Checklist  ................................ ................................ ................................ .............................  4 \\nTable 11.3: Client Education Checklist  ................................ ................................ ................................ ................................ .................  5 \\nTable 11.4: Antiretrovirals for Use in PrEP  ................................ ................................ ................................ ................................ ....... 6 \\nTable 11. 5 Initial & follow up laboratory test  ................................ ................................ ................................ ................................ ... 9 \\nTable 11.6: Managing Clinical and Laboratory Results on Initial and Follow -up Assessment  ..............................  10 \\nTable 11.7: Summary of PrEP Initial and Follow -up Assessment  ................................ ................................ ........................  11 \\nTable 11.7 Cont: Summary of PrEP Initial and Follow -up Assessment  ................................ ................................ .............  12 \\nTable 12.1: Comprehensive Package of Harm Reduction for PWID  ................................ ................................ ......................  2 \\nTable 12.2: Summary of ART Recommendations for PWID  ................................ ................................ ................................ ....... 5 ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 15}),\n",
       " Document(page_content=' \\n \\nxiii Acronyms and Abbreviations  \\nAbbreviations and Names of Antiretroviral Drugs  Other Acronyms and Abbreviations  \\n3TC  Lamivudine  HTS  HIV Testing Services  \\nABC  Abacavir  ICF  Intensified Case Finding  \\nATV  Atazanavir  IEC  Information, Education and Communication  \\nATV/r  Atazanavir/ritonavir  INH  Isoniazid  \\nAZT  Zidovudine  INSTI  Integrase Strand Transfer Inhibitor  \\nDRV  Darunavir  IPD  In-Patient Department  \\nDRV/r  Darunavir/ritonavir  IPT  Isoniazid Preventive Therapy  \\nDTG  Dolutegravir  IPV Intimate Partner Violence  \\nEFV  Efavirenz  IRIS  Immune Reconstitution Inflammatory \\nSyndrome  \\nETR  Etravirine  ITN  Insecticide Treated Mosquito Nets  \\nFTC  Emtricitabine  IUD  Intrauterine Device  \\nLPV  Lopinavir  KEPI  Kenya Expanded Program of Immunization  \\nLPV/r  Lopinavir/ritonavir  KS  Kaposi’s Sarcoma  \\nNVP        Nevirapine  LEEP  Loop Electrosurgical Excision Procedure  \\nRAL                                Raltegravir  L&D  Labor And Delivery  \\nRTV  Ritonavir  LIVES  Listen, Inquiry, Validate, Enhance Safety and \\nSupport  \\nTDF  Tenofovir Disoproxil Fumarate  LLV  Low Level Viremia  \\nOther Acronyms and Abbreviations  LRF  Laboratory Requisition Form  \\nACE -I Angiotensin -Converting Enzyme Inhibitor  LP Lumbar Puncture  \\nADR  Adverse Drug Reaction  MAC  Mycobacterium Avium Complex  \\nAIDS  Acquired Immunodeficiency Syndrome  MAT  Medically Assisted Therapy  \\nALT  Alanine Transaminase  MCH  Maternal Child Health  \\nALP  Alkaline Phosphatase  MNCH/FP  Maternal, Neonatal and Child Health/Family \\nPlanning  \\nAHI Acute Hiv Infection  MDT  Multi -Disciplinary Team  \\nANC  Antenatal Care  MEC  Medical Eligibility Criteria  \\nA&E  Accident And Emergency  MOH  Ministry of Health  \\nARB  Angiotensin -Receptor Blocker  MSM  Men Who Have Sex with Men  \\nART  Antiretroviral Therapy  MUAC  Mid -Upper Arm Circumference  \\nARV  Antiretroviral Drug(S)  NACS  Nutritional Assessment, Counselling and \\nSupport  \\nAST  Aspartate Transaminase  NASCOP  National AIDS And STI Control Program  \\nBD Twice Daily  NCD  Non -Communicable Diseases  \\nBF Breastfeeding  NHRL  National H IV Reference Laboratory  \\nBMI  Body Mass Index  NNRTI  Non -Nucleoside Reverse Transcriptase \\nInhibitor  \\nBP Blood Pressure  NRTI  Nucleoside Reverse Transcriptase Inhibitor  \\nCAG  Community Art Groups  NSP  Needle and Syringe Programmes  \\nCCC  Comprehensive Care Centre  NRTI  Nucleotide Reverse Transcriptase Inhibitor  \\nCrCl  Creatinine Clearance  OD  Once Daily  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 16}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n \\nxiv CHV  Community Health Volunteer  OI  Opportunistic Infection  \\nCITC  Client -Initiated HIV Testing and Counselling  OPD  Outpatient Department  \\nCM Cryptococcal Meningitis  OST  Opioid Substitution Therapy  \\nCMV  Cytomegalovirus  OVC  Orphans And Vulnerable Children  \\nCNS  Central Nervous System  PCP  Pneumocystis Jirovecii Pneumonia  \\nCPT  Cotrimoxazole Preventive Therapy  PCR  Polymerase Chain Reaction  \\nCrCl  Creatinine Clearance  PEP  Post -Exposure Prophylaxis  \\nCTX  Cotrimoxazole  PrEP  Pre-Exposure Prophylaxis  \\nCYP450  Cytochrome P450  PGL  Persistent Generalized Lymphadenopathy  \\nDAAs  Direct Acting Antiviral Therapies  PHQ -9  Patient Health Questionnaire -9 \\nDBS  Dried Blood Spot  PHDP  Positive Health, Dignity, and Prevention  \\nDICEs  Drop -In-Centres  PI  Protease Inhibitor  \\nDMS  Director of Medical Services  PITC  Provider Initiated HIV Testing and Counselling  \\nDNA  Deoxyribonucleic acid  PLHIV  People Living With HIV  \\nDOT  Directly observed therapy  PLLV  Persistent Low-level Viremia  \\nDS Double strength  PML                                 Progressive Multifocal Leukoencephalopathy  \\nDRT  Drug Resistance Testing  PMTCT                           Prevention of mother -to-child transmission  \\nED - PrEP  Event Driven PrEP  PPE                                  Papular Pruritic Eruptions  \\nEDTA  Ethylenediaminetetraacetic acid  PrEP  Pre-exposure Prophylaxis  \\nECP  Emergency contraceptive pill  PTB  Pulmonary Tuberculosis  \\nEID  Early Infant Diagnosis  PWID  People Who Inject Drugs  \\neMTCT  Elimination of Mother to Child Transmission  NHCSC  National HIV Clinical Support Centre  \\nEPTB  Extra -pulmonary Tuberculosis  RAST  Rapid Assessment Tool  \\nFDA  Food and Drug Administration  RNA  Ribonucleic Acid \\nFBC  Full Blood Count  RPR  Rapid Plasma Reagin  \\nFBS Fasting Blood Sugar  sCrAg  Serum Cryptococcal Antigen  \\nFDC  Fixed Dose Combination  SRH  Sexual and Reproductive Health  \\nFLP  Fasting Lipid Profile  SS  Single Strength  \\nFP  Family Planning  STI  Sexually Transmitted Infection  \\nFTC  Emtriciatabine  TB  Tuberculosis  \\nGIT  Gastro -intestinal tract  TB LAM  Tuberculosis Lipoarabinomannan  \\nGOK  Government of Kenya  TDF  Tenofovir  \\nGBV  Gender -Based Violence  TT Tetanus Toxoid  \\nHb  Hemoglobin  TWG  Technical Working Group  \\nHBV  Hepatitis B virus  ULN  Upper Limit of Normal  \\nHBsAg  Hepatitis B Surface Antigen  UTI Urinary Tract Infection  \\nHCV  Hepatitis C Virus  VIA  Visual Inspection with Acetic Acid  \\nHCW  Health Care Worker  VILI  Visual Inspection with Lugol’s Iodine  \\nHEI  HIV Exposed Infant  VL  Viral Load  \\nHIV  Human immunodeficiency Virus  VMMC  Voluntary Medical Male Circumcision  \\nHIVST  HIV Self-testing  WHO  World Health Organization  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 17}),\n",
       " Document(page_content='  \\nSummary of Key Recommendations  \\n1 - 1   \\n1. Summary of Key Recommendations  \\n \\n1.1 HIV Testing Services (HTS) and Linkage to Treatment and Prevention  \\n• HIV testing should be voluntary and conducted ethically in an environment where \\nConsent, Confidentiality, Counselling, Correct results, Connection (linkage) and Creating \\nan enabling environment can be assured  \\n• To optimize access to testing services, HIV testing can be conducted in 2 different settings:  \\n▪ Facility -based  \\n▪ Community -based  \\n• Targeted HIV testing is recommended which involves index client listing of contacts, HIV \\nself-testing and use of HTS screening tool to identify people at risk of HIV infection as \\neligible for testing  \\n• Serial testing, using ap proved rapid HIV antibody testing kits, is used to diagnose HIV \\ninfection in children older than 18 months, adolescents, and adults. An HIV -positive \\ndiagnosis will be made using three consecutive reactive assays  \\n \\n1.2 Initial Evaluation and Follow -up for PLHIV  \\n● Initial clinical evaluation of PLHIV entails CD4 monitoring, which is recommended for:  \\n▪ Baseline investigation for all PLHIV  \\n▪ Any patient with suspected treatment failure  \\n▪ Any patient returning to care after interrupting treatment for > 3 months  \\n▪ Any patient on fluconazole maintenance therapy or on dapsone as prophylaxis, to \\ndetermine when prophylaxis can be discontinued  \\n● Advanced HIV Disease is defined as:  \\n▪ Adults, adolescents, and children five years and older as having a CD4 cell count of \\nless than 200 cells/mm3 or \\n▪ WHO clinical stage 3 or 4 disease  \\n▪ All children younger than five years  \\n● All PLHIV presenting with Advanced HIV Disease (AHD) should be offered a package of \\ncare that includes timely initiation of ART, screening, diagnosis, prophyl axis, and \\nmanagement  of opportunistic infections.  \\n● Frequency of routine VL monitoring:  \\n▪ For PCR positive HEIs: at baseline (at the time of ART initiation)  \\n▪ Age 0 -24 years old: 3 months after ART initiation, and then every 6 months  \\n▪ Age ≥ 25 years old: 3 months after ART initiation, then at month 12, and then annually  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 18}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n1 - 2  ▪ Pregnant or breastfeeding: at confirmation of pregnancy (if already on ART) or 3 \\nmonths after ART initiation (if ART initiated during pregnancy/breastfeeding), and \\nthen every 6 months until c omplete cessation of breastfeeding  \\n▪ Before any drug substitution (if no VL result available from the prior 6 months)  \\n▪ Three months after any regimen modification (including single -drug substitution)  \\n● PLHIV should receive differentiated care based on initial e valuation (advanced vs. well) \\nand follow up (established vs not established on ART)  \\n \\n1.3 Standard Package of Care for PLHIV  \\nConsists of 8 components:  \\n1. Antiretroviral Therapy  \\n▪ All PLHIV are eligible for ART irrespective of CD4 cell count or percentage, WHO \\nclinical stage, age, pregnancy status, or comorbidities  \\n▪ ART should be initiated as soon as the patient is ready to start, preferably within \\ntwo weeks from time of HIV diagnosis (except for patients with cryptococcal \\nmeningitis or TB meningi tis) \\n2. Positive Health, Dignity, and Prevention, GBV/IPV & HIV Education and Counselling  \\n▪ All patients should be counselled and supported for disclosure of HIV status; \\npartner/ family testing and engagement; condom use; family planning; sexually \\ntransmitted infections screening; treatment adherence; and pre -exposure \\nprophylaxis for HIV -negative sexual partners  \\n▪ All females aged 15 -49 years and emancipated minors accessing HIV care services \\nshould be screened for Intimate Partner Violence (IPV) as p art of the standard \\npackage of care  \\n▪ All PLHIV should be provided with HIV education and counselling  \\n3. Screening for and Prevention of Specific Opportunistic Infections  \\nCotrimoxazole Preventive Therapy (CPT) is no longer recommended as life -long \\nprophylaxis, and is only recommended in the following sub populations, unless they \\nhave an allergy to sulfur drugs or develop toxicity from CPT  \\n● All HIV Exposed Infants  \\n● HIV infected children < 15 years of age  \\n● All PLHIV > 15 years of age:  \\no Living in malaria -endemic zones  (Refer to the National Guidelines for the \\nDiagnosis, Treatment and Prevention of Malaria in Kenya for the current Kenya \\nMalaria endemicity map)  \\no Presenting with WHO stage 3 or 4 event, or meeting the AHD criteria  \\no Suspected treatment fa ilure  \\n● All Pregnant and Breast -feeding women  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 19}),\n",
       " Document(page_content='  \\nSummary of Key Recommendations  \\n1 - 3  ▪ When dapsone (as a substitute for CPT) is being used as PCP prophylaxis, it is only \\nrecommended for patients in WHO Stage 4 and/or absolute CD4 count ≤ 200 \\ncells/mm3 (or CD4% ≤ 25% for children ≤ 5 years old), and should be discontinued \\nonce a patient achieves viral suppression and a sustained CD4 count of > 200 \\ncell/mm3 (or > 25% for children ≤ 5 years old) for at least 6 months  \\n▪ All PLHIV should be screened for TB at  every visit using the Intensified Case Finding \\n(ICF) tool and assessed for TB Preventive Therapy (TPT) if screened negative for TB  \\n▪ All adolescent and adult PLHIV with a baseline CD4 count of ≤ 200 cells/mm3 should \\nbe screened for cryptococcal infection us ing the serum CrAg test  \\n4. Reproductive Health Services  \\n▪ All PLHIV should be screened for STI at every clinic visit  \\n▪ Pregnancy status should be determined for all women of reproductive age at every \\nvisit and their contraception need determined and met  \\n▪ All HIV p ositive women between the ages of 18 - 65 years should be screened for \\ncervical cancer (HPV testing conducted every 2 years or Annually if using VIA -VILI)  \\n5. Screening for and Management of Non -Communicable Diseases  \\n▪ All PLHIV should be screened for hypertension, diabetes mellitus, dyslipidaemia, \\nand renal disease annually.  \\n▪ Routine screening should be provided for early detection of cervical cancer, breast \\ncancer, bowel cancer, and prostate cancer  \\n6. Mental Health Screening and Management  \\n▪ All PLHIV should receive basic screening for depression  and anxiety  before initiating \\nART, and annually thereafter, and whenever there is a clinical suspicion  \\n▪ All PLHIV should be provided for and linked with support structures to maintain \\ngeneral well -being  addressi ng issues that could affect their mental health  \\n▪ All adults and adolescents should be screened for alcohol and drug use before \\ninitiating ART and regularly during follow -up \\n▪ All caregivers should also receive baseline and follow -up screening for depression \\nand alcohol/drug use  \\n7. Nutrition Services  \\n▪ All PLHIV should receive nutritional assessment, counselling, and support tailored \\nto the individual needs of the patients  \\n▪ All infants irrespective of HIV status should be exclusively breastfed for the first 6 \\nmonths  of life, with timely introduction of appropriate complementary foods after \\n6 months, and continued breastfeeding up to 24 months or beyond  \\n8. Prevention of Other Infections  \\n▪ PLHIV (including children) should receive vaccinations as recommended by the \\nNational  Vaccines and Immunization Program  \\n▪ All PLHIV should receive vaccination for COVID -19 following national guidelines for \\nage and dosing  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 20}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n1 - 4  1.4 Adherence Preparation, Monitoring and Support  \\n• The adherence preparation, monitoring, and support that a patient requires should be \\ntailored to their level of adherence and the stage of ART initiation and follow -up \\n• All patients with durable viral suppression (2 consecutive viral load results with < 50 \\ncopies) should be offered messaging on Undetectable=Untrans mittable (U=U).  \\n• Whenever possible, follow -up should be provided by the same care provider or team of \\ncare providers (e.g., same clinician and counsellor) at every visit. This is particularly \\nimportant during the first 3 months in care  \\n• For all children/adol escents, the level of disclosure should be assessed at the first visit. \\nOngoing care should include a plan for age -appropriate disclosure  \\n• All patients are at risk of new or worsening barriers to adherence, so adherence \\nmonitoring, counselling and support s hould continue despite viral suppression  \\n• Every service delivery point that is providing ARVs for patients (whether ART, PEP, or \\nPrEP) must have a functional system for identifying patients who miss appointments and \\nfor taking action within 24 hours of a mi ssed appointment  \\n• In patients failing ART, do not change regimens until the reason/s for treatment failure \\nhave been identified and addressed (which should be done urgently using a case -\\nmanagement approach)  \\n1.5 Antiretroviral Therapy for Infants, Children, Adolescents, and Adults  \\n• The goal of ART is to suppress viral replication with the aim of reducing the patient’s VL \\nto undetectable levels (Viral Load <50 copies/LD L) \\n• All individuals with confirmed HIV infection are eligible for ART, irrespective of CD4 \\ncount/%, WHO clinical stage, age, pregnancy or breastfeeding status, co -infection status, \\nrisk group, or any other criteria, provided that the individual is willing and ready to start \\nART  \\n• ART should be started in all patients as soon as possible, even on the  same day as \\nconfirming their HIV diagnosis (and preferably within 2 weeks)  \\n• Preferred first -line ART for infants, children, adolescents and adults  \\n▪ Birth to 4 weeks: AZT + 3TC + NVP  \\n▪ > 4 weeks to < 15 years old  \\n▪ < 30 kg: ABC + 3TC + DTG  \\n▪ ≥ 30 kg: TDF + 3TC + DTG  \\n▪ ≥ 15 years old: TDF + 3TC + DTG  \\n• Children and adolescents who are virally suppressed but are NOT on the preferred first -\\nline ART regimen should be assessed for transition and transitioned to the preferred \\nregimen  \\n• Treatment failure is suspected when a pa tient has a VL ≥ 100 0 copies/ml after at least 3 \\nmonths of using ART. Treatment failure is only confirmed when VL is ≥ 1,000 copies/ml \\nafter assessing for and addressing poor adherence or other reasons for high VL, and then \\nrepeating VL after at least 3 mo nths of excellent adherence to allow for viral re -\\nsuppression  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 21}),\n",
       " Document(page_content='  \\nSummary of Key Recommendations  \\n1 - 5  • Persistent low -level viremia ( pLLV) is defined as having VL 200 - 999 copies/ml on two \\nor more consecutive measures. These patients are at increased risk of progression to \\ntreatment failure, dev elopment of ARV resistance and death and therefore require a \\nsimilar case management approach as patients with an initial VL ≥ 1,000 copies/ml  \\n• All PLHIV with a detectable VL ≥ 200 copies/ ml (unsuppressed) : assess for and address \\npotential reasons for virem ia, including intensifying adherence support, and repeat the \\nVL after 3 months of excellent adherence  \\n▪ If the repeat VL is < 200  copies/ml ( suppres sed) then continue routine \\nmonitoring  \\n▪ If the repeat VL is ≥ 1,000 copies/ml (suspected treatment failure), prepare for \\nchange to an effective regimen (Figure 5.2 and Table 6.10)  \\n▪ If the repeat VL is 200 - 999 copies/ml (low level viremia),  reassess adherence \\nand other causes of viremia and repeat VL after another 3 months of excellent \\nadherence  \\n1.6 Pre vention of Mother to Child Transmission of HIV/Syphilis/HBV  \\n• Prevention of mother -to-child transmission (PMTCT) of HIV,  Syphilis and Hepatitis B  \\n(triple elimination ) should be offered as part of a comprehensive package of fully \\nintegrated, routine antenatal  care interventions  \\n• All pregnant women, unless known positive, should be counseled and tested for HIV, \\nSyphilis (using the HIV -Syphilis dual test) and HBV during their first ANC visit, and if \\nnegative a repeat HIV -Syphilis dual test should be performed in the 3rd trimester.  \\n• Lifelong ART should be initiated in all pregnant and breastfeeding women living \\nwith HIV, regardless of gestational age, WHO clinical stage or CD4 count  \\n• ART should be started as soon as possible, ideally on the same day HIV diagnosis is  made, \\nwith ongoing enhanced adherence support  \\n• The preferred first line ART regimen for pregnant and breastfeeding women is TDF + 3TC \\n+ DTG  \\n• For pregnant and breastfeeding women newly initiated on ART, obtain VL 3 months after \\ninitiation, and then every 6 m onths until complete cessation of breastfeeding  \\n• For HIV positive women already on ART at the time of confirming pregnancy or \\nbreastfeeding, obtain a VL irrespective of when prior VL was done, and then every 6 \\nmonths until complete cessation of breastfeeding  \\n• For pregnant or breastfeeding women with a VL ≥ 200 copies/m l (unsuppressed ): assess \\nfor and address potential reasons for viremia, including intensifying adherence support, \\nand repeat the VL after 3 months of excellent adherence  \\n▪ If the repea t VL is < 200  copies/ml (suppressed) then continue routine \\nmonitoring  \\n▪ If the repeat VL is ≥ 1,000 copies/ml (treatment failure), prepare for change to \\nan effective regimen  \\n▪ If the repeat VL is 200  - 999 copies/ml ( low level viremia ), reassess adherence \\nand other causes of viremia and consult the Regional or National TWG  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 22}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n1 - 6  • All HIV exposed infants (HEI) should be tested with DNA PCR within 6 weeks of age or \\nfirst contact thereafter; if negative then another DNA PCR at 6 months, and if negative \\nthen  repeat DNA PCR at 12 months.  \\n• All HEI should receive infant ARV prophylaxis consisting of 6 weeks of AZT + NVP and \\nthereafter NVP should be continued until 6 weeks after complete cessation of \\nbreastfeeding  \\n• All infants irrespective of HIV status should be exclusively breastfed for the first 6 months \\nof life, with timely introduction of appropriate complementary foods after 6 months, and \\ncontinued breastfeeding up to 24 months or beyond  \\n \\n1.7 TB/HIV Co -infection Prevention and Management  \\n• All healthcare settings should implement TB infection control recommendations to \\nreduce the risk of transmission of TB among patients, visitors and staff  \\n• Symptom -based TB screening using the ICF tool MUST be performed for all PLHIV at \\nevery clinic visit  \\n▪ Patien ts who screen negative should be assessed for and provided with TB \\npreventive therapy (TPT)  \\n▪ Patients who screen positive (presumptive TB) must complete definitive diagnostic \\npathways  \\n• The GeneXpert Ultra MTB/Rif test is the preferred test for diagnosis of T B and \\nrifampicin resistance in all presumptive TB cases  \\n• TB-LAM can be used as an adjunct rapid point -of-care diagnostic test for PLHIV: with \\nadvanced HIV disease (WHO stage 3 or 4 or CD4 count ≤ 200 cells/mm3 (or CD4% ≤ 25% \\nfor children ≤ 5 years)) with presumptive TB, or; any danger signs of severe illness, or; \\ncurrently admitted to hospital  \\n• Patients diagnosed with TB/HIV co -infection should start anti -TB treatment immediately \\nand initiate ART as soon as anti -TB medications are tolerated, preferably within 2 weeks \\n(unless they have TB meningitis, in which case ART should be deferred for 4 to 8 weeks)  \\n• Patients with TB/HIV co -infection who are already on ART should start anti -TB treatment \\nimmediately and continu e ART, making any required adjustments to the ART regimen \\nbased on known drug -drug interactions and monitoring toxicity  \\n• Always assess for ART failure in patients who develop TB after being on ART for ≥ 6 \\nmonths  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 23}),\n",
       " Document(page_content='  \\nSummary of Key Recommendations  \\n1 - 7  1.8 HBV/HIV and HCV/HIV Co -infection Preve ntion and Management  \\n• All HIV positive adolescents and adults should be screened for HBV infection, using serum \\nHBsAg, as part of initial evaluation; children who did not complete routine childhood \\nimmunizations should also be screened for HBV and vaccinat ed if negative.  \\n• PLHIV without evidence of hepatitis B infection (HBsAg negative) should be vaccinated \\nagainst hepatitis B  \\n• The recommended first -line ART for adults with HIV/HBV co -infection is TDF+ 3TC + DTG  \\n• HCV serology should be offered to individuals at  risk of HCV infection  \\n• Direct acting antiviral therapies (DAAs) for treatment of HCV have simplified the \\nmanagement of HIV/HCV co -infection  \\n \\n1.9 ARVs for Post -exposure Prophylaxis (PEP)  \\n• PEP should be offered as soon as possible (< 72 hours) after high -risk exposure  \\n• The recommended ARV agents for PEP are  \\n▪  <15 years old  \\n▪ < 30 kg: ABC + 3TC + DTG  \\n▪ ≥ 30 kg: TDF + 3TC + DTG  \\n▪ ≥ 15 years old  \\n▪ TDF + 3TC + DTG  \\n \\n1.10 Pre -Exposure Prophylaxis (PrEP)  \\n• PrEP should be offered to HIV negative individuals at substantial ongoing risk of HIV \\ninfection (including the seronegative partner in a discordant relationship)  \\n•  PrEP works if taken as prescribed . However, it does not prevent other STIs or unintended \\npregnancies, therefore, additional protection should be of fered.  \\n• PrEP should only be offered to clients  ≥15 years of age who are sexually active after \\neligibility assessment using  the following parameters:  \\n▪ Laboratory: HIV negative  \\n▪ Medical (for oral PrEP): no contraindication to TDF; no severe renal diseases; wei ght \\n≥ 30 kg  \\n▪ Client readiness: client must be willing to take PrEP as prescribed, and adhere to \\nassociated follow up and HIV testing (at enrollment, at month 1 and thereafter every \\n3 months)  \\n• The recommended ARV regimen for Oral PrEP is TDF/FTC (alternative  TDF/3TC), \\navailable in two dosing strategies:  \\n▪ Daily oral PrEP: TDF (300 mg) + FTC (200 mg) once daily  \\n▪ Event -driven PrEP : Event driven PrEP is where oral PrEP is used in men having sex \\nwith men when an isolated sexual act is anticipated. The dose is two pills of TDF/FTC \\ntaken between 2 and 24 hours (preferably closer to 24h) before the anticipated \\nsexual act; then, a third pill taken 24 hours after the first two pills; and then a fourth \\npill taken 24 hours after the third pill (“2+1+1”).  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 24}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n1 - 8  1.11 People Who I nject Drugs (PWID) and HIV  \\n• PWID should be offered regular HIV testing and counselling and be linked to   \\ncomprehensive HIV treatment and prevention services including harm reduction \\ncounselling and support  \\n• The recommended first -line ART for adult PWID is T DF + 3TC + DTG  \\n• PWID should be offered screening, diagnosis, treatment and prevention of STIs as part of \\ncomprehensive HIV prevention and care  \\n• PWID should have the same access to TB prevention, screening and treatment services as \\nother populations at risk o f or living with HIV  \\n• PWID should be screened for HBV (by HBsAg) and HCV (by HCV serology) at first contact  \\n• All PWID should be linked to Needle and Syringe Programs (NSP) to access sterile \\ninjecting equipment  \\n• All PWID should be linked to Medically Assisted Therapy (MAT)  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 25}),\n",
       " Document(page_content='  \\nHIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 1   \\n2. HIV Testing Services and Linkage to Treatment \\nand Prevention  \\nHIV testing services (HTS) provide the first critical link to comprehensive HIV treatment and \\nprevention services such as voluntary medical male circumcision (VMMC), pre -exposure \\nprophylaxis (PrEP), post -exposure prophylaxis (P EP) and other combination HIV prevention \\nservices. In addition, this initial step also provides opportunities to offer other interventions such \\nas sexual and reproductive health services (SRH), TB screening and referral, and substance abuse \\nscreening and r eferral.  \\nHIV testing should be voluntary and conducted ethically in an environment where the six Cs \\nprinciples of Consent, Confidentiality, Counselling, Correct results, Connection (linkage) to care and \\nother appropriate post -test services and creating an  enabling environment are adhered to . \\nTargeted HIV testing  is the major strategic shift, involving index client listing of contacts, HIV self -\\ntesting and use of HIV screening tools to identify people at risk of HIV infection as eligible for \\ntesting, except in the case of PMTCT and key populations.  \\n2.1 Settings fo r HIV Testing  \\nIn Kenya, HTS is delivered in two broad settings: facility -based and community -based settings  \\n2.1.1 Facility -based testing  \\n● The HTS screening tool should be used to facilitate prioritization of testing for persons at risk \\nof HIV infection; those diagnosed with sexually transmitted infections, with multiple sexual \\npartners, key populations, and those with possible or known HIV exposures, such as sexual or \\nneedle sharing partner of a person living with HIV or of a person of unknown HIV status  \\n● Providers should undertake a thorough risk assessment using the validated NASCOP screening \\ntools (Annex 17) to identify clients at risk and those eligible for a HIV test.  \\n● HTS should be offered only to clients who consent  \\n● Clients who are not eli gible for testing should receive HIV prevention messages and be offered \\nservices as appropriate  \\n● Clients who test HIV positive should be linked to care while those who test negative should be \\nlinked to HIV prevention services  \\n● Patients starting HIV care shou ld receive disclosure counselling and support, and be offered \\nfamily, sexual and needle -sharing partner testing  \\nAs much as possible, HIV testing services should be integrated into care pathways at all service \\ndelivery points including adult and pediatric i npatient units, outpatient units, maternal and child \\nhealth clinics, SRH/family planning clinics, TB clinics, specialty clinics, gender -based violence \\n(GBV) care units and service delivery points for key and priority populations.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 26}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 2  2.1.2 Community –based t esting  \\nTargeted community based HTS offers additional opportunities to identify and link people to HIV \\ntreatment and prevention. This setting is especially important for testing children and partners of \\nindex clients through index testing , as well as  outreach to key and priority populations, orphans, \\nand vulnerable children (OVCs), adolescents, youth and targeted testing in workplaces.  \\n2.2 HTS strategies  \\nThe major HTS strategies to identify people living with HIV but unaware of their status are:  \\n2.2.1 HIV Self -Testing (HIVST)  \\n● HIVST allows individuals to collect their own specimen, perform the test, and interpret the \\nresults on their own, conducted either within a health facility, at home or in any other \\nconvenient place.  \\nHIVST can be  conducted with o r without direct assistance by a trained person.  \\n● HIVST is a screening test and is not sufficient to make an HIV -positive diagnosis. A reactive \\n(positive) self -test result should therefore be confirmed using the validated national testing \\nalgorithm by an H TS-trained service provider.  \\n● HIVST should be performed using MoH approved HIV rapid diagnostic test kits that are either \\nblood -based or oral fluid based.  \\n● HIVST may have the greatest benefit in reaching specific populations such as partners of newly \\ndiagnosed PLHIV; partners of pregnant women attending antenatal care (ANC); contacts of \\npatients treated for STIs; hard -to-reach populations such as men, adolescents, and young \\npeople, as well as key populations, such as MSM and sex workers.  \\nHIVST is a scr eening test and does not provide a diagnosis.  \\nAll reactive (positive) self -test results must be confirmed in a health facility according to \\nnationally set standards  \\n2.2.2 Index Testing  referred to as partner testing/partner notification services, is an approach \\nwhereby the exposed contacts (i.e., sexual partners, biological children and anyone with whom a \\nneedle was shared) of an HIV -positive person (i.e., index client), are elicited and offered HIV testing \\nservices  \\n2.2.3 Voluntary Counselling and Testin g (VCT):  This involves provision of targeted HIV \\ntesting to clients who willingly present to HTS facilities for testing for diverse reasons, including \\nself-assessed risk.  \\n2.2.4 Social Network Strategy (SNS) - this involves offering to index clients self -guided options \\nto informally extend links to HIV testing and other services to a broader set of social -, sexual -, \\nand injecting -network members who have an elevated risk of HIV infection. The index client for \\nSNS can either be PLHIV or HIV negative persons wi th increased risk for HIV infection . \\nProviding targeted HTS for different populations and in different settings increases opportunities \\nfor access to knowledge of HIV status and to a range of HIV treatment and prevention services. \\nTable 2.1 summarizes key recommendations for HTS for different sub -populations.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 27}),\n",
       " Document(page_content='  \\nHIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 3  Table 2.1: HTS R ecommendations for Different Populations and Settings  \\nPopulation  Recommendation  \\nBirth testing of \\ninfants born to \\nknown HIV - \\npositive mothers \\n(Figure 2.2)  ● Birth testing (HIV testing of infants at birth or at first contact within 2 weeks after \\nbirth) can be conducted where feasible and in settings wher e return of results is \\nfeasible within 24 hours and ART  can be initiated immediately*). Infants tested at \\nbirth must be tested at the 6 weeks immunization visit regardless of the results of \\nthe initial test at birth.  \\n● Infants with an initial positive HIV D NA PCR result should be presumed to be HIV \\ninfected and started on ART in line with national guidelines, with a new sample for \\nconfirmatory HIV DNA PCR and baseline viral load taken at the time of ART \\ninitiation (ART initiation is based on the initial HIV DNA PCR result)  \\nInfants and \\nchildren aged less \\nthan 18 months \\n(Figure 2.1)  ● HIV exposure status of all infants should be established at first contact.  \\n● To establish HIV exposure status of a child less than 18 months of age, conduct HIV \\nantibody testing for mothers with unknown status or who previously tested \\nnegative during antenatal care at the 6 -week immunization visit or first contact. If \\nthe mother declines to be tested or is not available for testing, then conduct a rapid \\nHIV antibo dy test for the child to determine exposure (if antibody test is positive \\nthis confirms HIV exposure)  \\n● When HIV exposure is confirmed, ARV prophylaxis should be started immediately.  \\n● All HEIs should have DNA PCR testing at the 6 -week immunization visit or fi rst \\ncontact thereafter.  \\n● Infants with an initial positive HIV DNA PCR result should be presumed to be HIV \\ninfected and started on ART in line with national guidelines, with a new sample for \\nconfirmatory HIV DNA PCR and baseline viral load taken at the time of ART \\ninitiation (ART initiation is based on the initial HIV DNA PCR result)  \\n● All HEI with initial HIV negative results should continue infant ARV prophylaxis \\nand be followed as HEIs, including additional PCR testing at 6 months and 12 \\nmonths, and antibody  testing at 18 months and every 6 months during \\nbreastfeeding, and at 6 weeks after complete cessation of breastfeeding  \\nChildren older \\nthan 18 months \\ntill age 9 years \\n(Figure 2.3)  ● Conduct HIV testing and counselling for all children of adults living with HIV as \\nsoon as possible after confirming the HIV positive status of the adult. Within health \\nfacilities, testing should be conducted at in -patient wards, nutrition clinics, and all \\nhigh HIV burden settings.  \\nAdolescents and \\nyoung people  \\n(10 - 24 years) \\n(Figure 2.3)  ● Targeted HIV testing services should be offered to adolescents and young people \\nwho are screened and found eligible for HIV test. HIV prevention services should \\nbe offered to clients who test negative while those who test positive should be \\nlinked to HIV care.  \\n● Adolescents aged above 10 years, should be tested with the written consent of a \\nparent or guardian, and are also required to give assent.  \\n● Adolescents who are e mancipated minors irrespective of age, can give their own \\nconsent.  \\n● All adolescents should be counselled on the potential benefits and risks of \\ndisclosure of their HIV status and empowered and supported to determine if, \\nwhen, how and to whom to disclose.  \\n● For sexually active adolescents, HIV testing and counselling should be offered to \\ntheir partners and children where appropriate.  \\n● All uncircumcised adolescent males who test HIV negative should be counselled \\nabout the prevention benefits of VMMC and linked t o VMMC services if they agree  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 28}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 4  Table 2.1 Cont.  \\nPregnant and \\nbreastfeeding \\nwomen  ● During the first ANC visit, HIV testing of pregnant women should be done \\nusing a dual test for HIV and syphilis, unless the woman is known to be living \\nwith HIV.  \\n● Women who test negative for both HIV and Syphilis should be offered a repeat \\nHIV-Syphilis dua l test in the third trimester.  \\n● Prevention services should be offered to all pregnant and breastfeeding \\nwomen who test HIV negative. They should be screened for eligibility and \\nwillingness for PrEP.  \\n● At labor and delivery, HIV testing should be done for all women with \\nunknown HIV status and those who previously tested negative (even if tested \\nnegative in the third trimester).  \\n● All breastfeeding mothers (unless known HIV positive) should be counselled \\nand tested at the 6 -week infant immunization visit. The HIV  test (if negative) \\nshould be repeated every 6 months until complete cessation of breastfeeding.  \\n● For mothers considered to be at high risk of HIV infection, retesting \\npostnatally should be done every 3 months; these include mothers \\ncategorized as key popul ation; in a HIV discordant relationship, or having \\nongoing sexual or injecting behavior that places her at risk, including new or \\nmultiple sexual partners.  \\n● Mothers should be counselled on the schedule for repeat HIV testing in \\npregnancy and postnatal as p art of routine ANC and postnatal education.  \\n● All pregnant and breastfeeding women who are not tested, opt -out or decline \\nHIV testing during the first contact should be offered HIV counselling and \\ntesting in subsequent visits with appropriate referral and li nkage for \\nprevention, care, and support services.  \\n● All HIV positive pregnant and breastfeeding women enrolled into care should \\nreceive counselling and support (assisted disclosure), case management and \\nfollow -up. It should also include linkage to general ca re for ANC, delivery and \\npost -natal care  \\n● All spouses/partners as well as children of pregnant and breastfeeding \\nwomen testing HIV positive should be offered HIV testing and counselling.  \\nSexual partners & \\nchildren of index \\nclients (HIV positive \\nperson who is newly \\ndiagnosed or already \\nin HIV care)  ● All PLHIV enrolled into HIV care should receive disclosure counselling and \\nbe supported to disclose their HIV status (assisted disclosure)  \\n● HIV testing and counselling (facility -based or community -based) should be \\nencouraged for all partners including  sexual partners, needle sharing \\npartners, and children of index clients, with appropriate linkage to \\ntreatment and prevention services.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 29}),\n",
       " Document(page_content='  \\nHIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 5  Table 2.1 Cont.  \\nKey and vulnerable \\npopulations  ● Conduct HIV testing and counselling for all clients from key and vulnerable \\npopulations presenting to the health facility irrespective of the reason for \\ntheir visit, or through targeted outreach and testing at key and vulnerable \\npopulation service delivery points (e.g., drop -in centers).  \\n● Key populations that test negati ve should be retested quarterly.  \\n● Link all who test HIV positive to treatment and prevention services.  \\n● Prevention services should be recommended, including consistent and \\ncorrect use of condoms and use of sterile needles and syringes.  They should \\nbe scree ned for eligibility and willingness for PrEP.  \\n● All uncircumcised males who test HIV negative should be counselled on the \\nprevention benefits of VMMC and linked to VMMC services if they consent  \\nTargeted HIV testing \\nand counselling of \\nadults  ● All adults eligible for testing should be offered HTS and encouraged to know \\ntheir HIV status and the status of their partners.  \\n● For those that test negative, re -testing is recommended if there is a new risk \\nexposure.  \\n● HIV positive adults should be counseled for  immediate ART initiation.  \\n● Link all adults identified as HIV positive to treatment and prevention services.  \\n● Clients who are not eligible for testing should receive HIV prevention \\nmessages and be offered services, as appropriate.  \\n● All males who test HIV nega tive should be counselled on the prevention \\nbenefits of VMMC and linked to VMMC services if they consent  \\n \\n2.3 Package of HIV Testing Services  \\nAn HIV testing and counselling session consists of:  \\n● A pre -test session  \\n● HIV testing  \\n● Assessment for other health -related conditions or needs (while HIV tests are running)  \\n● A post -test session (including index testing)  \\n● Referral and linkage to other appropriate health services (as part of the post -test session)  \\nThe HIV testing service package is summarized in Tab le 2.2.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 30}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 6  Table 2.2: Summary of HIV Testing Services Package  \\nPre- Test Counselling  \\nPre-test counselling may be provided to an individual or a couple presenting for HTS.  Group information \\ncan also be offered during pre -test.  \\nThe objectives of the pre -test counselling session are to:  \\n− Provide information on the benefits of knowing one’s H IV status, including outcomes for people \\non ART and undetectable = Untransmittable  (U=U).  \\n− Provide an explanation for the HIV testing process including time the session will take, \\nconfidentiality, and interpretation of test results  \\n− Obtain informed consent for HIV testing.  \\n− Explore the client’s risk of HIV infection.  \\n− Discuss the importance of disclosure to partners and other family members.  \\n− Explain the benefits of couple testing and partner services/index testing.  \\nProvide information on available post -test se rvices, including referrals for prevention or HIV care services  \\nPerform test.  \\nThe goal of HIV testing is to:  \\n• Provide accurate HIV diagnosis as per the nationally approved testing algorithm  \\n• Provide same day HIV test results  \\nDuring the 15 minutes as you wait for the test results:  \\n− Discuss Combination Prevention e.g., PrEP, PEP, Risk Reduction, STI treatment, condom \\ninformation and demonstration, VMMC, Elimination of Mother to Child Transmission of HIV \\n(eMTCT)  \\n− Screen, provide information and referrals for; Intimate Partner Violence (IPV), STI and cancer \\nscreening, Tuberculosis (TB), Family planning/c ontraceptive needs, etc.  \\n− Establishing number of sexual contacts and biological children for the purpose of index testing.  \\n− Document in the HTS, Lab, referral and linkage register (MOH 362).  \\nDiscuss further on index testing and HIVST as you perform the secon d and the third test, as per the national \\nalgorithm, for the clients who test positive with the screening test  \\nPost -test counselling  \\n− Check if the client is ready for results and help them to interpret.  \\n− Check what the client understands by the results.  \\n− Allow the client to share his/her initial reactions and verbalize their initial feelings.  \\n− Explore and acknowledge client’s immediate feelings and concerns.  \\nOffer necessary support  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 31}),\n",
       " Document(page_content='  \\nHIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 7  Table 2.2 Cont.  \\nNEGATIVE RESULT  \\n− Explain test results.  \\n− Review implications of being HIV negative.  \\n− Support clients to develop a risk reduction \\nplan (see HTS operational manual)  \\n− Provide information on methods to prevent \\nHIV acquisition.  \\n− Provide male and/or female condoms, \\nlubricant, and guidance on their use.  \\n− Emphasize on importance of knowing the \\nstatus of sexual partners and information \\nabout the availability of partner and couples \\ntesting services.  \\n− Referral and linkage to relevant HIV \\nprevention services  \\nExplain the need for repeat testing for people \\nwho tes t negative but report risky behavior \\nwithin the prior  4 weeks (i.e., unprotected sex \\nwith a partner of unknown status or Known HIV \\npositive status); if they test HIV negative again \\nafter 4 weeks  and are at  ongoing risk of HIV \\nacquisition , they should be ad vised to return for \\ntesting every 3 months  POSITIVE RESULT  \\n− Review implications of being HIV positive.  \\n− Help the index client to cope with emotions arising \\nfrom the diagnosis.  \\n− Discuss immediate concerns and help for the client \\nto decide who in his or her social network may be \\navailable to provide immediate support.  \\n− Discuss positive living.  \\n− Provide clear information on ART and its benefits \\nfor maintaining health and reducing the  risk of HIV \\ntransmission, as well as where and how to access \\nART  \\n− Refer clients who turn HIV positive to CCC for \\nlinkage to treatment.  \\n− Revisit index testing and HIVST to determine \\npartner notification plan/approach (refer to HTS \\noperational manual and APN S operational Manual).  \\n− Discussion of the risks and benefits of disclosure to \\npartners; couples counselling should be offered to \\nsupport mutual disclosure.  \\nEncourage and offer HIV testing for sexual partners, \\ninjecting partners, biological children, and oth er family \\nmembers, which can be done through couples testing, \\nfamily testing and/or assisted partner notification \\nservice.  \\nAssessment of other health related conditions  \\nAssess risk for sexually transmitted infections (STIs) and opportunistic infections that would also require \\nmanagement  \\nReferral and linkage to care  \\nObtain accurate locator information from the index client (physical location, phone number)  \\nPhysically escort the client for re -testing and linkage to ART  \\nDocument the outcomes of partner follow up(s)  \\nPost -Test Counseling in the Era of Test -and -Treat  \\nPost -test counselling should, at a minimum, include three key messages that being the ART treatment \\npreparation process for all PLHIV:  \\n− Treatment (called antiretroviral therapy or ART) is available and is recommended for everyone \\nwith HIV.  \\n− Starting treatment as soon as possible (preferably within two weeks from testing positive for \\nHIV) reduces the chance of your illness getting worse or of passing HIV to others. If  you take your \\nART properly and do not miss pills you can expect to live a long and productive life  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 32}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 8  2.4 Age -Specific HIV Testing Algorithms  \\n2.4.1  Early Infant Diagnosis  \\n2.4.1.1 Confirmation of HIV infection in HIV Exposed Infants and Children < 18 Months Old  \\nHIV expo sure  of an infant or child can occur in utero, at labour and delivery and through breast \\nmilk. Confirmation of HIV infection should immediately follow.  \\nAll HIV exposed infants (HEI) should be tested with DNA PCR within 6 weeks of age or first contact \\nthere after; if negative then another DNA PCR at 6 months, and if negative then repeat DNA PCR at \\n12 months.  \\nIf the HEI develops symptoms suggestive of HIV as per WHO staging criteria, an additional DNA \\nPCR test should be conducted immediately.  \\nAn antibody test  should be performed for all HEI at 18 months of age and every 6 months thereafter \\nduring breastfeeding, and at 6 weeks after complete cessation of breastfeeding (Figure 2.1).  \\n \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 33}),\n",
       " Document(page_content='  \\nHIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 9  \\nEstablish  HIV   of Infants  and  Children\\n< 18 months\\n•  Mother known HIV \\n•  HTS  for mothers  with  unkn own HIV \\n•  Rapid antibod y test on infant/child  if mother s HIV cannot  be \\nEstablish HIV infection for HIV Exposed Child at 6 weeks or at first \\ncontact  (includes child with negative DNA PCR result at birth)\\n• Collect a DBS for HIV DNA PCR test 1\\n• Start/continue infant  ARV prophylaxis\\n• Start CPT At L&D, MNCH/F P, \\nIPD, A&E,  CCC & \\nHIV DNA PCR test NEGATIVE\\nChild HIV -exposed\\n• Continue HEI follow -upHIV DNA PCR test POSITIVE\\nChild presumed HIV infected\\n• Discontinue infant ARV prophylaxis\\n• Start ART\\n• Offer comprehensive care including \\ncontinuation of CPT\\n• Collect new sample for confirmatory HIV DNA \\nPCR, baseline viral load and CD4%.  1Conduct DNA PCR  at 6 months of age or soonest contact \\nthereafter (or earlier if child develops symptoms \\nsuggestive of HIV -as per WHO staging criteria)1\\nConfirmatory HIV DNA \\nPCR test POSITIVE\\nChild confirmed HIV \\ninfected\\n• Continue ART and \\ncomprehensive care \\nand routine under -5 \\ncareConfirmatory HIV DNA PCR \\ntest NEGATIVE\\nChild presumed HIV infected\\n• Continue ART \\n• Collect and send a DBS \\nto NHRL and manage \\nas per the results from \\nNHRLHIV DNA PCR result NEGATIVE\\nChild HIV -exposed\\n• Continue HEI follow -up\\n• Conduct DNA PCR at 12 months of age  or \\nsoonest contact till 18 months of age (or earlier if \\nchild develops symptoms suggestive of HIV -as \\nper WHO staging criteria) 1\\nHIV DNA PCR result NEGATIVE\\nChild HIV -exposed\\n• Continue HEI follow -up\\n• Continue routine under -5 care\\n• Conduct HIV Antibody test at 18 months of age \\n• If breast feeding, do HIV antibody test every 6 months while breast \\nfeeding and 6 weeks after complete cessation of breastfeeding \\nIf HIV antibody test  is negative\\nChild HIV negative \\n• Stop CPT * \\n• Review at age 2 years and document vital status \\n• Continue routine  unde r-5 If HIV antibody test  is positive \\nChild confirmed HIV infected\\n• Start  ompre hensive  \\n• Continue CPT\\n• Continue routine  unde r-5 \\n1 Where Point of Care DNA PCR is available - EID should be done using the whole blood at the facility. \\nFor baseline viral load testing – If available, use point of care machine for viral load; If there is no point of care \\nmachine to do viral load - Take a plasma and send it to the VL testing laboratory\\n* Only after final antibody test negativeChild is HIV unexposed\\n  \\nFigure 2.1 Algorithm for Early Infant Diagnosis in Infants and Children < 18 months of age   \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 34}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 10  Presumptive Diagnosis of Severe HIV Disease in Children under 18 Months  \\nOccasionally, children less than 18 months of age present to hospital with severe illness; and a rapid \\nHIV antibody test confirm s HIV exposure. Lack of immediate availability of HIV DNA PCR results \\nfor confirmation of HIV could result in undue delay in starting life -saving ART. In such children, a \\npresumptive diagnosis of HIV infection can be made using the criteria in Table 2.3. A RT can be \\ninitiated while awaiting HIV DNA PCR results to confirm HIV infection.  \\nTable 2.3: Presumptive Diagnosis of HIV in children <18 months while awaiting DNA PCR \\nResults  \\nHIV antibody test positive AND symptomatic with;  \\n 2 or more of the following:  \\n● Oral candidiasis/thrush  \\n● Severe pneumonia  \\n● Severe sepsis  \\nOR any of the of following:  \\n● Any WHO Clinical Stage 4 condition  \\n● Recent maternal death (if likely to have been HIV -related) or advanced HIV disease in \\nmother  \\n● Child’s CD4% < 2 5% \\n \\n2.4.1.2  Birth Testing  \\nBirth testing is defined as HIV testing (with DNA PCR) at birth or around birth for infants born to \\nHIV-positive mothers. Birth testing has the potential to improve survival for infants who are \\ninfected during pregnancy, around labour and delivery by ident ifying them early for rapid ART \\ninitiation. Do not use cord blood for birth testing as this could result in false positive results.  \\nA DNA PCR test can be offered at birth or around birth where feasible.  \\nALL children initially tested at birth should be rete sted at 6 weeks of age and the EID \\nalgorithm followed (Figure 2.2.)  \\nConsiderations for providing birth testing:  \\nBirth testing may be prioritized for newborns who are at high risk of HIV acquisition including \\nthose born to:  \\n● Mothers who seroconvert during p regnancy.  \\n● Mothers who have unsuppressed or unknown viral loads during delivery.  \\n● Mothers who received a HIV positive diagnosis for the first time at or after 28 weeks \\ngestation or during labour and delivery  \\n● Mother on ART for less than 12 weeks prior to delivery  \\nBirth testing should be offered where this is feasible:  \\n● DNA PCR results can be returned the same  day e.g., where on site point of care is available.  \\n● ART regimens recommended for neonates as per national guidelines are available and can \\nbe initiated immed iately.  \\n● Follow -up of the newborn is done to ensure no lost to follow -up. ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 35}),\n",
       " Document(page_content='  \\nHIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 11  \\nInfant of known HIV positive mothers at birth (or \\nwithin 2 weeks of birth)\\n• Collect DBS for DNA PCR\\n• Start infant ARV prophylaxis immediately after \\nbirth.  \\nHIV DNA PCR positive HIV DNA PCR Negative \\n• Initiate ART immediately\\n• Book for follow up at 2 weeks of age. \\n• Offer comprehensive care for HIV infected child. \\n• Collect new sample for confirmatory HIV DNA \\nPCR, baseline viral load and CD4%.• Continue infant ARV prophylaxis and follow up \\nfor HIV exposed infants. \\n• Repeat DNA PCR test at 6 weeks. Follow the EID \\nalgorithm. \\nConfirmatory DNA PCR positive/ \\ndetectable Viral load \\n• Continue ART \\n• Provide comprehensive care. Confirmatory DNA PCR negative \\n• Continue ART \\n• Collect DBS for repeat PCR at 6 weeks of age \\nand manage as per EID algorithm \\n• Collect new sample send to NHRL. Manage as \\nper NHRL results \\nFigure 2.2: Birth Testing Algorithm  \\n \\n2.4.1.3  Use of Point of Care testing for Children  \\nPoint -of-care testing occurs at the health facility where care is being provided, with results being \\nreturned to the patient or caregiver on the same day as sample collection. Point of care DNA PCR \\ntesting for early infant diagnosis of HIV can reduce the turnaround time for testing and return of \\nresults and allow imme diate initiation of ART among infants.  Point of care DNA PCR testing can be \\nused to diagnose HIV infection as well as to confirm positive results.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 36}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 12  2.4.2  Diagnosis of HIV Infection in the Older Child (≥ 18 months), Adolescents and \\nAdults  \\n● Serial testing,  using approved rapid HIV antibody testing kits, is used to diagnose HIV infection \\nin children older than 18 months, adolescents, and adults, and (refer to Figure 2.3)  \\n● An HIV -positive diagnosis will be made using three consecutive reactive assays . This thr ee-\\ntest strategy as well as retesting aims to ensure that at least a 99% Positive Predictive Value \\n(PPV) is maintained, and false positive misdiagnosis is avoided.  \\n● Offer adequate information to all clients and obtain consent prior to the HIV test (verbal \\nconsent is adequate but should be documented by the health care worker in client records). \\nFor children below the age of 14 year who are not emancipated minors, a written consent from \\nthe guardian is recommended.  \\n● Individuals 15 years and older and emancipa ted minors can provide self -consent.  \\n● Clients who test positive should be linked to care and treatment. Counselling support, index \\nand family testing should be offered to these clients.  \\n● Clients who test negative should be counselled on HIV risk reduction b ehaviors and linked to \\ncombination HIV prevention services (such as VMMC, RH/FP, condoms, PrEP, etc.) depending \\non individual risk profile. Table 2.5 provides recommendations for re -testing those who test \\nHIV negative.  \\nHIV testing algorithm for children >1 8months, adolescents and adults.  \\nFigure 2.3 illustrates the serial testing algorithm. An HIV -positive diagnosis will be made using \\nthree consecutive reactive assays (Figure 2.3). All individuals are first tested on Assay 1 (A1). \\nAnyone with a non -reactive test result (A1−) is reported HIV -negative.  Individuals who are \\nreactive on Assay 1 (A1+) will then be tested on a separate and distinct Assay 2 (A2). Individuals \\nwho are reactive on both Assay 1 and Assay 2 (A1+; A2+) will then be tested on a separate an d \\ndistinct Assay 3 (A3). A positive HIV diagnosis is given when Assay 3 is reactive (A1+; A2+; A3+).  \\nIf Assay 3 is nonreactive (A1+; A2+; A3−), the status should be reported as HIV -inconclusive, and \\nthe individual should be asked to return in 14 days for retesting.   \\nIndividuals who are reactive on Assay 1 but non -reactive on Assay 2 (A1+; A2−) should be repeated \\non Assay 1. If repeat Assay 1 is non -reactive (A1+; A2−; repeat A1 –), the status should be reported \\nas HIV -negative.  If repeat Assay 1 is reactive (A1+; A2 –; repeat A1+), the status should be reported \\nas HIV -inconclusive, and the individual asked  to return in 14 days for retesting.   All clients with \\nHIV positive results will be referred to a Comprehensive Care Clinic for retesting prior to \\ninitiation of ART  \\nNOTE:  The three -test algorithm will be implemented after identification of the specific \\nassay. Meanwhile, the current algorithm continues being in use (Annex 7). Guidance will \\nbe issued before implementation.  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 37}),\n",
       " Document(page_content='  \\nHIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 13  \\nHIV TEST A1\\nNON -REACTIVE REACTIVE\\nREPORT NEGATIVE HIV TEST A2\\nNON -REACTIVE REACTIVE\\nHIV TEST A1 HIV TEST A3\\nNON -REACTIVE REACTIVE NON -REACTIVE REACTIVE\\nREPORT NEGATIVE\\nREPORT INCONCLUSIVE AND \\nRETEST IN 14 DAYS. \\nREPORT HIV POSITIVE AND REFER TO THE SECOND TESTER AT CCC/MCH\\nHIV TEST A1\\nNON -REACTIVE REACTIVE\\nREPORT INCONCLUSIVE AND \\nRETEST IN 14 DAYSHIV TEST A2\\nNON -REACTIVE REACTIVE\\nHIV TEST A1 HIV TEST A3\\nNON -REACTIVE REACTIVE NON -REACTIVE REACTIVE\\nREPORT NEGATIVEREPORT INCONCLUSIVE AND \\nRETEST IN 14 DAYSINITIATE ART\\nNote: \\n• The use of DNA PCR as a supplemental assay is no longer recommended\\n• For inconclusive HIV status, if reactivity remains the same after 14 days the individual should be \\nreported as HIV -negative and advised to retest after 3 months \\nFigure 2.3: HIV Testing Services Algorithm  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 38}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 14  Results interpretation  \\nRESULTS  INTERPRETATION  \\nA1- HIV-NEGATIVE  \\nA1+; A2+; A3+  HIV-POSITIVE  \\nA1+; A2 -; Repeat A1+  HIV-INCONCLUSIVE (retest after 14 days). If reactivity \\nremains the same after 14 days, the individual should be \\nreported as HIV -negative   \\nA1+; A2 -; Repeat A1 - HIV-NEGATIVE  \\nA1+; A2+; A3 - HIV- INCONCLUSIVE (Retest after 14 days). If reactivity \\nremains the same after 14 days, the individual should be \\nreported as HIV -negative  \\n \\n2.4.3  HIV testing for Pregnant Women  \\nFor pregnant women, the HIV/syphilis dual test should be used as the A1 test (Figure 2.4). The dual \\ntest kit is recommended for:  \\n● Pregnant women during their first ANC, unless the woman is known to be living with HIV.  \\n● For those who test negative for both HIV and Syphilis repeat testing should be conducted \\nin the third trimester using the HIV and syphilis dual test.  \\n● Partners accompanying pregnant women for the first -time during ANC  \\nHIV/Syphilis dual test should not be used for retesting women on ART or with  known positive HIV \\nstatus, or women diagnosed with syphilis during pregnancy.  \\nSee Figure 2.4 for the full algorithm when considering HIV and syphilis (TP) results concurrently.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 39}),\n",
       " Document(page_content='  \\nHIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 15  \\nTEST A1 (HIV/Syphillis)\\nHIV TEST A1 SYPHILIS TEST A1\\nREPORT NEGATIVE HIV TEST A2\\nNON -REACTIVE REACTIVE\\nHIV TEST A1 HIV TEST A3\\nNON -REACTIVE REACTIVE NON -REACTIVE REACTIVE\\nREPORT NEGATIVE REPORT INCONCLUSIVE \\nRETEST IN 14 DAYS.\\nREPORT HIV POSITIVE AND REFER TO THE SECOND TESTER AT CCC/MCH\\nHIV TEST A1\\nNON -REACTIVE REACTIVE\\nREPORT INCONCLUSIVE AND \\nRETEST IN 14 DAYSHIV TEST A2\\nNON -REACTIVE REACTIVE\\nHIV TEST A1 HIV TEST A3\\nNON -REACTIVE REACTIVE NON -REACTIVE REACTIVE\\nREPORT NEGATIVE REPORT INCONCLUSIVE AND \\nRETEST IN 14 DAYSINITIATE ARTNON -REACTIVE REACTIVE NON -REACTIVE REACTIVE\\nREPORT NEGATIVEREPORT POSITIVE AND \\nTREAT FOR SYPHILLIS\\nNote: \\n• The use of DNA PCR as a supplemental assay is no longer recommended\\n• For inconclusive HIV status, if reactivity remains the same after 14 days the individual should be \\nreported as HIV -negative and advised to retest after 3 months \\nFigure 2.4 Dual HIV/syphilis Testing Algorithm  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 40}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 16  RESULTS  INTERPRETATION  \\nA1 HIV -, Syphilis Test (TP) - HIV negative, syphilis negative  \\nA1 HIV -, Syphilis Test (TP)+  HIV negative, syphilis positive  \\nA1 HIV+, Syphilis Test (TP) - Syphilis negative and proceed with A2 for HIV  \\nA1 HIV+, Syphilis Test (TP)+  Syphilis positive and proceed with A2 for HIV  \\nA1 (HIV+); A2+; A3+  HIV-positive  \\nA1(HIV+); A2 -; Repeat A1+  HIV-inconclusive (retest after 14 days). If reactivity remains the same \\nafter 14 days, the individual should be reported as HIV -negative  \\nA1(HIV+); A2 -; Repeat A1 - HIV-negative  \\nA1(HIV+); A2+; A3 - HIV- inconclusive (retest after 14 days). If reactivity remains the same \\nafter 14 days, the individual should be reported as HIV -negative  \\nTable 2.4: Approaches to Improve Linkage to Treatment and Prevention Services  \\nkey area  Action  \\nInformation  ● Quality post -test counselling should include information about the nature and \\navailability of additional HIV -related services, description of the next steps in \\ntreatment and prevention including entire treatment plan and follow -up visits \\nand schedule.  \\n● The benefits of immediate assessment and early initiation of ART should be \\nemphasized.  \\n● Involve the patient in the decision -making process regarding treatment and \\nprevention (espe cially where and when to start ART)  \\nDisclosure  ● Disclosure to a trusted ‘significant other’ promotes linkage and adherence to \\ntreatment.  \\n● Encourage and help the patient to discuss HIV status with a trusted friend or close \\nrelative.  \\n● Encourage adolescents to identify and invite a supportive adult or friend to \\nsupport them.  \\n● For children, HIV status should be disclosed to children by age 12 years and the \\nprocess can start when a child is as young as 7 years old.  The health care provider \\nor the pa rent/caregiver/guardian can disclose to the child with appropriate \\nguidance and training. The aim of disclosure to children is to start to involve them \\nin the management of their own health and reduce stigma associated with HIV  \\nBarriers to \\nLinkage  ● During post -test counselling, identify and address any barriers to linkage  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 41}),\n",
       " Document(page_content='  \\nHIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 17  Table 2.4 Cont.  \\nSystems to \\nFacilitate \\nLinkage  ● The HTS provider is responsible for linkage into care.  \\n● Same day enrolment into care is expected. monitor linkage to treatment initiation \\nwithin 14 days of diagnosis, however allow follow up of clients to 90 days of a \\nHIV-positive diagnosis  \\n● For HIV negative clients link to HIV prevention services based on assessed risk  \\n● Linkage should be done to on -site treatment and prev ention services through \\npatient escorts. Where this is not possible (due to patient preference or the \\nservices are not available), the testing facility should book the appointment with \\nthe receiving facility and follow -up to ensure the patient registers at  the receiving \\nfacility. Provide the patient with referral information, referral form and contact \\ndetails of the facility.  \\n● Deploy retention and loss -to-follow up tracking system to ensure linkage is \\nsuccessful. These include enlisting the help of peer or b uddy systems, SMS \\nreminders, phone calls and community outreach workers to escort HIV positive \\nclients to enrolment.  \\n● Early preparation and assessment for ART, with early initiation of ART \\nstrengthens engagement in care.  \\nCare \\nCoordination \\nand \\nIntegration  ● Coordinate and treat mother -baby pairs, partners, and families together. \\nIntegrate common services offered to PLHIV (TB diagnosis and treatment, \\nSRH/FP, cervical cancer screening, nutrition etc.)  \\n● Where referrals are necessary, such referrals should be coor dinated \\n(communication and documentation between referring and receiving service \\ndelivery points)  \\nLinkage Register  ● Maintain a linkage register at all testing points in the facility and community.  \\n● Track and report on progress with linkage monthly  \\n● Discuss linkage at MDT meetings.  \\n \\n2.5 Retesting recommendations for HIV negative persons  \\nRetesting in this context refers to testing that occurs later after the initial test is negative.  \\nThe purpose of retesting is to:  \\n● Monitor the effectiveness of HIV prevention interventions  \\n● identify and treat new HIV infections as early as possible when prevention efforts fail.  \\nThe following are the recommendations for HIV retesting in different populations and settings in \\nKenya:  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 42}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 18  Table 2.5: Recommendations for Retesting HIV Negative Clients  \\nScenario/population  Recommendation for retesting  \\nGeneral population  All general population to be screened every 2 years \\nusing the approved NASCOP HTS screening tool and \\nthose eligible get tested  \\nKey populations (FSW, MsM, TG, \\nPWID)  Re-test every 3 months  \\nNegative partner in discordant  \\n \\n Retest HIV negative partner at the initiation of ART for the \\nHIV positive partner, at 6months and 12 months once \\nviral suppression is achieved.  \\nRetest a nnually if the positive partner remains virally \\nsuppressed.  \\nPregnant women  Test in first trimester or first contact; Re -test in the third \\ntrimester and, during labour and delivery.  \\nBreastfeeding mothers  Re-test 6 weeks after delivery, at 6 months then every 6 \\nmonths until complete cessation of breast feeding.  \\nFor mothers considered to be at high risk of HIV \\ninfection, retesting postnatally should be done every 3 \\nmonths  \\nPersons who had a most recent \\n(e.g., less than one month) high \\nrisk exposure to  HIV  Test at initial presentation and re -test at 4 weeks, after \\nwhich National testing guidelines apply  \\nSTI symptomatic patients or \\npatients with symptoms \\nsuggestive of acute HIV  Test at initial presentation and re -test at 4 weeks, after \\nwhich national te sting guidelines apply  \\nIndividuals on Pre -exposure \\nprophylaxis (PrEP)  Test at initiation of PrEP; Retest at month one, and then \\nevery 3 months  \\n2.6 Inconclusive HIV status  \\nAn HIV -inconclusive test status means that individuals had discrepant results on the test (for \\nexample, first test reactive, second test nonreactive, third test reactive) and so could not be given \\nan HIV -positive or HIV -negative diagnosis.  \\nInconclusive results are rare, but they may occur when  \\ni) cross -reactivity exists between kits or patient -related factors,  \\nii) the tester or test kit makes an error; and/or  \\niii) individuals are seroconverting and in the window period, when infection cannot be \\ndeterm ined.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 43}),\n",
       " Document(page_content='  \\nHIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 19  The window period is the time from exposure to HIV infection to when the body produces enough \\nHIV antibodies to be detected by an HIV antibody test. This time can vary across different types of \\ntests, where some tests may be able to detect antibodies earli er than another test, which can lead \\nto discrepant test results.  \\nAll people with an inconclusive HIV status should be encouraged to return in 14 days for retesting. \\nReceiving inconclusive results could be confusing and stressful for clients and may be dif ficult for \\nthe provider to explain. During post -test counselling, the provider needs to take time to explain \\ncarefully what an HIV -inconclusive status means, stating that it is neither HIV -positive nor HIV -\\nnegative, and that retesting in 14 days is needed to establish the correct diagnosis. Because \\ndefinitive diagnosis cannot be made on the day of testing, and immediate referral to HIV care or \\nART initiation is not appropriate, providers need to help clients make a clear plan for follow -up and \\nschedule an a ppointment for retesting. Also, clients should be informed about prevention options \\nand how to stay HIV -negative, as well as about the availability and benefits of ART.  \\nThose suspected of having an acute HIV infection1 – for example, if they report or pre sent with \\nsymptoms associated with acute HIV infection – should be followed up closely. This is a period of \\nhigh infectiousness due to high viral load, and clients need to be informed how to protect their \\npartners. Individuals at high ongoing risk of HIV c an be informed about PrEP and encouraged to \\ndiscuss options depending on their final HIV status when they come back for retesting.  \\n \\n2.7 Approach to Patients on ART with a Discrepant HIV Test Result  \\nHIV testing should not be performed to patients who are al ready enrolled into HIV care and \\non ART.  However, some patients self -refer for HIV antibody testing without disclosing that they \\nare known HIV positive and on ART. Figure 2.5 provides recommendations on managing patients \\nwho have a non -reactive antibody te st while on ART.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 44}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 20  \\nEducation/counselling  for patients who are on ART and present with a new negative HIV antibody test\\n• The new HIV antibody test may be a  false negative    the patient may still be HIV -infected but their antibody \\nlevels may be suppressed as a result of effective ART. This is more common for patients who start ART very \\nsoon after HIV infection\\n• Those with prior history of detectable viral loads, positive DNA PCR results, or low CD4 counts are almost \\nalways truly HIV positive\\n• Continue their ART until a special test is performed (a new sample for DNA PCR) at the National HIV \\nReference Laboratory (NHRL)\\n• Stopping ART before HIV status is confirmed could result in a rapid rise in viral load, decline in CD4, and \\nincreased risk of developing an opportunistic infection or dying\\n• Draw a sample for DNA PCR  and send to the NHRL  (preferably a whole blood EDTA sample following \\ncold -chain protocols within 24 hours of collection; DBS is acceptable if EDTA is not possible)\\n• Specify that this is a sample for confirming HIV status  of a patient who is on ART, and provide the dates \\nand results for all prior antibody tests, DNA PCR tests, and RNA viral load tests in the request form\\nIf HIV DNA PCR sample is positive\\n• This confirms the patient is HIV positive\\n• Provide additional counseling on the \\nreasons why the antibody test may have \\nbeen falsely negative and discourage the \\npatient from any repeat antibody testing\\n• Emphasize that the patient  s ART is \\nworking and the need for continued \\nexcellent adherenceIf HIV DNA PCR sample is negative\\n• The patient may be HIV negative, or it could be that the \\npatient is  HIV positive but the HIV DNA levels have been \\nsuppressed below the testing limit (this is more common if \\na DBS sample was used)\\n• Inform the patient that they may still be HIV positive and \\nneed to be monitored closely for an additional 6 months \\nbefore confirming they are HIV negative\\n• Inform the patient that ART should be stopped immediately\\n• They should return for HIV viral load performed at 1 \\nmonth, 3 months, and 6 months after stopping ART \\n(samples for HIV viral load should be sent to the designated \\nVL/EID network laboratory assigned to the requesting \\nfacility with all past details) \\nFigure 2.5: Managing Patients on ART Who Present with a New Negative HIV Antibody Test', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 45}),\n",
       " Document(page_content='  \\nInitial Evaluation and Follow up  \\n3 - 1   \\n3. Initial Evaluation and Follow up  \\n \\n3.1 Introduction  \\nAll PLHIV are eligible for ART irrespective of CD4 cell count or percentage, WHO clinical  stage, age, \\npregnancy status, or comorbidities. ART should be initiated as soon as the patient is ready to start, \\npreferably within two weeks from time of HIV diagnosis.  \\nIn order to provide targeted services based on clinical presentation, during the init ial evaluation \\nall PLHIV should be categorized as presenting with advanced HIV disease (AHD) or as presenting \\nwell (Table 3.3). Patients with advanced disease require more intensive evaluation for and \\nmanagement of OIs, and once ART is started, they are at  higher risk of developing immune \\nreconstitution inflammatory syndrome (IRIS, Annex 16).  \\nSimilarly, after at least 6 months on ART, PLHIV should be categorized as being either established \\nor not established on ART (clinically, virologically, and psychosoci ally) to best meet the specific \\nneeds of each patient for treatment and follow -up and improve patient outcomes through provision \\nof targeted differentiated care. Differentiated care minimizes inconvenience and unnecessary \\nfrequent follow -up, thus reducing costs and time related to clinic visits. It also allows resources to \\nbe focused on those patients who require additional attention.  \\n3.2 Initial Clinical Evaluation of PLHIV  \\nAll patients enrolling into HIV care should have a complete medical history taken, a thorough \\nphysical examination and appropriate laboratory investigations. Findings from this initial \\nevaluation should be documented legibly in a retrievable health record management format \\n(electronic or paper -based) to facilitate long -term follow -up of the patient. Table 3.1 summarizes \\nimportant aspects of the initial medical history and physical examination for PLHIV.  \\nThe initial visit provides the opportunity to establish a meaningful patient -provider relationship; \\nthe clinician should elicit concerns  and expectations with open, non -judgmental, and clear \\ncommunication.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 46}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 2  Table 3.1: Initial Clinical Evaluation for PLHIV (History and Physical Examination)  \\nHistory  Details for History taking  \\nCurrent and past \\nmedical history  ● Presenting complaints/current symptoms  \\no Also inquire about symptoms due to co -existing HIV -related and non -HIV-\\nrelated disease and co -morbidities that will require immediate intervention  \\n● History of TB and TB contacts  \\nComplete the Intensified Case Finding (ICF) tool  \\n● Date of first positive HIV test  \\n● Past and current co -morbidities (e.g., TB, cryptococcal meningitis, hypertension, \\ndiabetes, kidney, and liver disease)  \\no Document history of TB  \\n● Current medications,  \\no Establish current medications (prescription, non -prescription, and \\nherbal) likely to interact with ARVs  \\no Document ARV exposure history including previous or current ARV use \\n(including for PMTCT, PEP, PrEP, and ART)  \\n● Drug allergies, especially sulpha allergy  \\n● History of hospitalizations  \\no Establish reasons for hospitalizations  \\n● Family history of chronic disease or cancer  \\nEstablish nutritional history and adequacy of nutritional intake and household food \\nsecurity  \\nPsychosocial \\nhistory  ● Education, employment, family, marital status  \\n● Establish possible presence of mental health concerns  \\no Including past treatment for mental illnesses and any current \\nsymptoms of depression  \\n● Assess for disclosure and presence of self -stigma  \\no Encourage disclosure to trusted close relations and sexual partners  \\n● Substance use screening including alcohol, tobacco, miraa (khat), marijuana, \\nnarcotics, injection drug use (use the CRAFFT screening tool for adolescents and \\nthe CAGE -AID screening tool for adults to screen for alcohol and drug use \\ndisorders – see Tables 4.15 and 4.16)  \\n● Establish and document social support structures  \\n● Link to additional facility and community support resources, including \\npsychosocial support groups, peer mentors, harm reduction services for PWIDs, \\netc. \\nElicit and begin to address possible barriers to adherence  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 47}),\n",
       " Document(page_content='  \\nInitial Evaluation and Follow up  \\n3 - 3  Table 3.1 Cont.  \\nSexual and \\nreproductive \\nhistory  History  \\n● History of STIs  \\n● Current symptoms of STIs  \\n● Sexual practices  \\no Determine HIV status and disclosure to sexual partner(s)  \\no ART status of sexual partner/s  \\n● Pregnancy history and age of all living children  \\n● Menstrual history, family planning and plans for pregnancy  \\n● History of cervical cancer screening  \\n● Vaccination history (including COVID -19 vaccine)  \\nDiscuss:  \\n● Secondary prevention and avoidance of re -infection with STIs  \\n● Pregnancy intention and contraception needs  \\nEncourage contact tracing and HIV testing for sexual partners and all children < 15 \\nyears of age of HIV -infected women or whose mothers’ HIV status is unknown  \\nVital signs, and \\nanthropometric \\nmeasurements  ● Measure and record weight, height, MUAC (in children and pregnant women), \\ntemperature, pulse rate, BP, respiratory rate, and pulse oximetry  \\n● Calculate BMI as: Weight (kg)/ Height2(m); Use z -scores for children  \\n● Monitor growth trends for children  \\nGeneral \\nexamination  Examine the following:  \\n● Conjunctiva and palms for pallor or jaundice; swollen lymph nodes (cervical, \\naxillary, inguinal); mouth for Kaposi’s sarcoma (KS) lesions, oral hairy \\nleucoplakia, candidiasis, tooth decay; skin (for drug eruptions, herpes zoster, \\ndermatitis, pruritic papular eruptions (PPE), folliculitis, fungal infections, \\nmolluscum, and KS)  \\n● Assess developmental milestones for children  \\nSystemic \\nexamination  ● Central Nervous System  \\n● Mental State Examination (for mental status)  \\n● Abdomen   \\n● Respiratory  \\n● Cardiovascular  \\n● Genitourinary/ anorectal system (for ulcers, discharge, condylomata/warts, \\nprostate examination for men ≥ 45 years of age). Speculum examination with \\ncervical cancer screening for females  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 48}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 4  Table 3.1 Cont.  \\nSummary  List differential diagnosis and management plan for each problem (including \\ninvestigations, treatment, referrals, and follow -up) \\n● Assign and document the WHO Clinical Stage and manage presenting \\nillnesses  \\n● Growth and developmental milestone must be assessed and used for WHO \\nstaging in children  \\nDifferentiate between patients with advanced disease versus those who are clinically \\nwell, to guide acuity of follow -up \\n3.3 Initial Laboratory Evaluation of PLHIV  \\nThe comprehensiveness of laboratory tests will depend on presence and/or type of suspected \\nconcurrent illness. Table 3.2 summarizes the recommended baseline laboratory investigations for \\nall PLHIV. Additional investigations should be based on clinical indicati on. ART should not be \\ndelayed if a laboratory test is not available.  \\nTable 3.2: Baseline Laboratory Investigations for PLHIV  \\nHIV  \\nSpecific  Test  Comments  \\n● Confirm and \\ndocument positive \\nHIV test result  ● Positive status should be reconfirmed prior to ART \\ninitiation for all patients  \\n● Refer to current HIV testing algorithm  \\nCD4 cell count  ● For all patients  (CD4% for children ≤ 5 years old)  \\n● If CD4 ≤ 200 cells/mm3 in PLHIV >5 years, th en \\nlaboratories should automatically perform a serum \\ncryptococcal antigen (sCrAg) on the same sample to screen \\nfor cryptococcal infection  \\n● TB-LAM should also be conducted   \\nViral load (HIV -1 RNA)  ● Baseline viral load (VL) is recommended for infants after \\n1st PCR test is positive. Specimen for baseline VL can be \\ndrawn at the time of initiating ART; obtaining a VL should \\nnot delay ART initiation  \\nSerum Cryptococcal  \\nAntigen (sCrAg)  ● Obtain serum CrAg If CD4 ≤ 200 cells/mm3 in patients >5 \\nyears  as reflex testing by the laboratory  \\n● If positive, manage as per the cryptococcal meningitis \\nscreening algorithm (Figure 4.1)  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 49}),\n",
       " Document(page_content='  \\nInitial Evaluation and Follow up  \\n3 - 5  Table 3.2 Cont.  \\nOthers  Hb (preferably full  \\nblood count if available)  ● All patients especially if on AZT  \\n●  \\nPregnancy Test  ● Pregnancy status should be determined for all women of \\nreproductive age (based on history of last menstrual period, \\nand if uncertain, irregular, or delayed then a urine pregnancy \\ntest should be performed)  \\nTB- LAM  ● Conduct TB -LAM  on a urine sample if CD4 ≤ 200 cells/mm3 \\nin PLHIV >5 years, and if CD4% ≤ 25% in children < 5 years  \\n● Seriously ill patients  \\nUrinalysis (for protein  \\n& glucose)  ● All patients  \\nCreatinine  o All patients, especially those starting TDF. Calculate \\nCreatinine Clearance (CrCl), (Annex 15)  \\nSyphilis serology \\n(VDRL, TPHA, or RPR)  ● All patients with a history of being sexually active  \\nGlucose  ● All patients  \\nPlasma lipid profile  ● All patients  \\nHBsAg  ● All adolescent and adult patients (plus children who did not \\ncomplete routine childhood immunizations)  \\nHCV antibody  ● PWID or for patients with history of injection drug use  \\nALT  ● Not recommended as baseline investigation unless there is a \\nspecific clinical reason (e.g., patient with history of hepatitis, \\nsigns or symptoms of liver disease, or risk of liver disease - \\nalcoholics, HBV or HCV infection, hepatotoxic drugs such as \\nfluconazole, etc.)  \\nHPV testing  ● For women of reproductive age between 25 -49 years \\nconducted at baseline and every two years (refer to cancer \\nscreening guidelines)  \\n \\nIt is not possible for ALL facilities providing ART to offer all the laboratory tests recommended for \\nHIV treatment. If a facility does not have on -site capacity to carry out any test, arrangements \\nshould be made to transport specimens to a local or regional reference laboratory.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 50}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 6  3.4 Management of Patients Who Present with Advanced HIV Disease  \\nThe World hea lth organization (WHO) defines AHD for adults, adolescents, and children five years \\nand older as having a CD4 cell count of less than 200 cells/mm3 or WHO clinical stage III or IV \\ndisease. All children younger than five years living with HIV who are not al ready receiving ART and \\nnot clinically stable are considered to have AHD.  \\nAdvanced HIV Disease can occur in various settings including PLHIV newly presenting to care, \\nthose returning to care after treatment interruption and those on ART who have experienc ed \\ntreatment failure.  \\nPLHIV with AHD have immune suppression with reduced ability to fight opportunistic infections \\n(OI), other infectious and non -infectious diseases, and are therefore at increased risk of morbidity \\nand mortality. AHD is also associated with increased health -care costs, use of more health -care \\nservices and more frequent monitoring needs. Leading causes of mortality among adults with AHD \\ninclude immune reconstitution inflammatory syndrome, tuberculosis (TB), severe bacterial \\ninfections, cryptococcal disease, histoplasmosis, toxoplasmosis, and Pneumocystis Jirovecii \\npneumonia amongst others.  \\nCD4 testing criteria to diagnose AHD and determine eligibility for package for care:   \\n• New clients initiating ART:  \\no CD4 testing should be c onducted as a baseline test for ALL PLHIV  \\n• Patients who are treatment experienced:  \\no PLHIV ≥5 years of age and who had previously initiated ART and are reinitiating after >3 \\nmonths).  \\no Individuals who have documented persistent unsuppressed viral load (two viral load VL \\n>1,000 within 3 -6 months).  \\nPackage of Care for AHD  \\nAll PLHIV presenting  with Advanced HIV Disease (AHD) should be offered a package of care that \\nincludes timely initiation of ART, screening, diagnosis, prophylaxis, and management of \\nopportunistic infections.  \\nTable 3.3 provides a summary of definitions of well versus advanced disease and package of care \\nfor each at enrolment.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 51}),\n",
       " Document(page_content='  \\nInitial Evaluation and Follow up  \\n3 - 7  Table 3.3: Differentiated Care Based on Initial Patient Presentation  \\nAdults, adolescents, and children ≥ 5 years who Present with Advanced HIV Disease: WHO Stage \\n3 or 4, or CD4 count ≤ 200 cell/mm3  \\nAll children younger than five years at enrollment into care  \\nPackage of Care  ● Standard Package of Care (Chapter 4)  \\n● Intensive management of presenting illnesses and malnutrition  \\n● Priority for identification, management, and prevention of OIs, \\nincluding.  \\no GeneXpert ultra for TB diagnosis for all PLHIV with presumptive TB \\n(Figure 8.1)  \\no TB-LAM (Figure 8.2), in addition to GeneXpert ultra, for PLHIV with \\npresumptive TB who  \\n▪ Have CD4 ≤ 200 cells/mm3 and if CD4% ≤ 25% in children < 5 \\nyears  \\n▪ Have signs of severe illness, or  \\n▪ Are currently admitted to hospital  \\no Cryptococcal antigen screening for adolescents and adults with CD4 \\n≤ 200 cells/mm3 or clinical suspicion of meningitis (any age) (Figure \\n4.1)  \\no Cotrimoxazole Preventive Therapy (CPT)  \\no TB Preventiv e Therapy (TPT)  \\n● Immediate ART initiation unless they are suspected to have TB, TB \\nmeningitis, or cryptococcal meningitis;( Table 6.1)  \\n● Close monitoring for development of immune reconstitution \\ninflammatory syndrome (Annex 16)  \\nFocus of ART Preparation \\nCounselling  ● Immediate ART start is required to prevent further damage to the \\nimmune system.  \\n● Starting ART soon will decrease risk of disease progression, including \\nwasting and other infections  \\nFrequency of  \\nFollow -up ● Weekly follow -up until ART initiation, and then at week 2 and 4 after \\nART initiation, and then monthly until confirmed viral suppression.  \\n● More frequent visits or hospitalization may be required to stabilize \\nacute medical conditions and address psychosocial and other concerns  \\n● Referral for management of co -morbidities or concurrent infections \\nmay also be needed  \\nManagement of Opportunistic Infections in Patients with AHD  \\nCryptococcal Disease (CM)  \\nCryptococcal disease is one of the most important opportunistic infections among peop le living \\nwith AHD and is a major contributor to mortality.  \\nEarly diagnosis and treatment of cryptococcal meningitis is key to reducing mortality from \\ncryptococcal disease. Health -care professionals should have a low threshold for suspecting \\ncryptococcal meningitis among people with advanced HIV disease.  \\nScreening, prevention and treatment of  cryptococcal meningitis is described in Section 4.33.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 52}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 8  Tuberculosis (TB)  \\nTB is the most frequent life -threatening OI and a leading cause of death among PLHIV. TB remains \\nthe leading cause of mortality among PLHIV, despite substantial scale -up of ART, accounting for \\n30% of the AIDS -related deaths reported.  \\nScreening, prevention  and treatment of TB is described in Chapter 8.  \\nTable 3. 4: Management of patients who are presenting well : WHO Stage 1 or 2, and CD4 count \\n> 200 cell/mm3  \\nAdults, adolescents, and children ≥ 5 years who Present Well: WHO Stage 1 or 2, and CD4 count > \\n200 cell/mm3 \\nFocus of ART Preparation \\nCounselling  ● ART is the most important treatment to maintain good health and an \\nactive life  \\n● Starting ART soon will decrease risk of developing wasting and other \\ninfections  \\n● ART will reduce the risk of transmitting HIV to others  \\nFrequency of  \\nFollow -up ● Weekly follow -up until ART initiation, and then at week 2 and 4 after \\nART initiation, and then monthly until confirmed viral suppression  \\n● Additional visits as required to address any medical or psychosocial \\nconcerns  \\nAdults, adolescents, and children ≥ 5 years who Present Well: WHO Stage 1 or 2, and CD4 count > \\n200 cell/mm3 \\nLocation of Services  • Management at any ART service delivery point; all facility levels   \\n• Initial management and ART initiation by trained and experienced HCW  \\nFocus of Treatment \\nPreparation Counselling  • ART is the most important treatment to maintain good health and an \\nactive life  \\n• Starting ART soon will decrease risk of developing wasting and other \\ninfections  \\n• ART will reduce the risk of transmitting HIV to others  \\n \\n3.5 Follow -up of PLHIV after ART initiation   \\nFollow -up of patients on ART is determined by the duration the patient has been on treatment, how \\nwell they understand the treatment and their response to AR T. Follow -up includes scheduled \\nclinical appointments, unscheduled clinical assessments for patients with concerns/complaints, \\nroutine and as -needed laboratory monitoring.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 53}),\n",
       " Document(page_content='  \\nInitial Evaluation and Follow up  \\n3 - 9  3.5.1 First 6 months after ART initiation  \\nAfter ART initiation, patients need to be monitored closely for development of adverse drug events, \\nidentify and address barriers to adherence, and development of IRIS. A reasonable follow -up \\nschedule for most patients is 2 weeks and 4 weeks after ART initiation (Table 3. 5 and 3. 6).  \\nWhen possi ble, follow -up for a particular patient should be provided by the same care provider or \\nteam of care providers (e.g., same clinician and same counsellor) at every visit. This is particularly \\nimportant during the first 6 months in care.   \\n3.5.2 Differentiat ed Service Delivery for Patients beyond the 1st 6 months of ART  \\nFollow up of patients beyond 6 months of ART is described in table 3. 5. It also  provides the criteria \\nfor determining if a patient is established on ART.  \\nIn summary:  \\n● Patients who are not established on ART require closer follow -up.  \\n● Patients who are established on ART require less frequent facility follow -up, with up \\nto six months b etween clinical appointments  \\n \\nTable 3. 5: Differentiated Follow -up of Patients Beyond the First 6 Months of ART  \\nPatients NOT established on ART  \\nPatients with any of the following:  \\n● On treatment for < 6 months  \\n● Any active OIs (including TB) in the previous 6 months  \\n● Poor or questionable adherence to scheduled clinic visits in the previous 6 months.  \\n● Most recent VL ≥ 200 copies/ml  \\n● Children < 2 years  \\nPackage of \\nCare  ● Standard Package of Care  \\n● Case management to address reason/s for not being established on ART  \\nFocus of \\nCounselling  ● ART is the most important treatment to maintain good health and an active life  \\n● ART will reduce the risk of transmitting HIV to others   \\nFrequency of \\nFollow -up ● Every 1 -3 months, based on clinical judgment  \\n● Additional visits as required to address any medical or psychosocial concerns  \\n● If VL is detectable at 3 months they will need additional assessments for \\nand management of the reason/s for detectable viral load, with close \\nfollow -up until viral suppression is achieved (Chapter 5).  \\n● Patients with confirmed viral suppression can be followed up every 3 -6 \\nmonths based on patient preference and clinician judgment, with \\nadditional unscheduled visits any time the patient has a concern.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 54}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 10  Table 3. 5 Cont.  \\nPatients Established on ART  \\nPatients established on ART must have achieved ALL the following  \\n● On their current ART regimen for ≥ 6 months  \\n● Currently no active Illness or in the previous 6 months (patients with well controlled chronic \\nconditions should not be excluded)  \\n● Adherent to scheduled clinic visits for the previous 6 months  \\n● VL ≤200 copies/ml (LDL) within the last 6 months  \\nNote:  \\n● This definition should be applied to all populations, including those receiving second - \\nand third -line regimens, those with controlled comorbidities, children above 2 years *, \\nadolescents, pregnant and breastfeeding women, and key populations.  \\n● The client’s category can change at any time so there is a need for a reassessment at each \\nvisit. Clients should be categorized at every visit and managed based on their status.  \\nPackage of \\nCare  ● Standard Package of Care  \\n● Re-assessment of criteria at every clinical visit  \\nLocation of  \\nServices  ● Clinical review and ART prescription from any ART service delivery point; all \\nfacility levels  \\n● Distribution of ART between clinical appointments, which can be facility -based \\nor community -based  \\nFocus of  \\nCounselling  ● Encourage patient to continue with what is working  \\n● Reminders that any significant life event or change in daily routine could \\ninterfere with adherence  \\nFrequency of  \\nFollow -up ● Clinic appointments to be made at 6 months intervals  \\n● ART should be offered as refills lasting 3 months,  (through fast -track pick -up at \\nfacility or through community -based distribution). Patients on injectab le \\ncontraception should be provided FP through a fast -tracked process between \\nclinic follow -up visits; oral contraceptives and condoms should be distributed \\nwith ART  \\n● Additional visits as required to address any medical or psychosocial concerns  \\n● Closer follow -up may be arranged based on patient preference  \\n*  Children below 2 years are excluded as they require frequent dose adjustment  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 55}),\n",
       " Document(page_content='  \\nInitial Evaluation and Follow up  \\n3 - 11  3.6 Summary of clinical and laboratory monitoring of PLHIV on ART  \\nTable 3. 6 summarizes the recommended minimum routine follow -up schedule for PLHIV.  \\nAdditional clinical and laboratory follow -up should be performed whenever clinically indicated  \\nTable 3. 6: Summary of Clinical and Laboratory Monitoring for PLHIV1 \\n Initial  \\nVisit  ART  \\npreparation  Week  \\n(After \\nART)   \\nMonths (after ART)   \\n≥ 6 months  \\n \\nAppointment2,3   \\nEvery week4  \\n2  \\n4  \\n2  \\n3  \\n4  \\n5  \\n6 Every 1 -6 \\nmonths \\ndepending \\non stability  \\nHistory and \\nphysical exam5 ✔  ✔  ✔  ✔  ✔  ✔  ✔  ✔  ✔  At each \\nclinical visit  \\nAdherence \\nassessment and \\nsupport6 ✔  ✔  ✔  ✔  ✔  ✔  ✔  ✔  ✔  At each visit  \\nTB Screening  ✔  Every visit, using ICF screening tool  \\nCD4 count  ✔  ● Baseline, and then only if patient develops treatment failure (to assess \\nfor risk of OIs), or if defaults from care (off ART) for at least 6 months  \\n● For patients on prophylaxis using dapsone (documented CTX allergy), \\nrepeat CD4 every 6 months until CD4 >200 cells/mm3 for two \\nconsecutive measures 6 months apart and VL undetectable, after which \\ndapsone and CD4 monitoring can be discontinued  \\nHIV Viral Load   ● For PCR positive HEIs: baseline at the time of ART initiation  \\n● Age 0 -24 years: at month 3, then every 6 months  \\n● Age ≥ 25 years: at month 3, then month 12, then annually thereafter if \\nsuppressed  \\n● For all: before any drug substitution for patients on ART for a t least 6 \\nmonths with no valid VL, at month 3 after regimen modification, and \\nthen as per population group  \\n● Any patient with a detectable VL during routine monitoring, follow viral \\nload monitoring algorithm (Figure 6.6)  \\nHIV Viral Load \\n(pregnant/ \\nbreastfeeding)   ● If on ART at time of confirming pregnancy: VL done at confirmation of \\npregnancy (regardless of when previously done), then every 6 months \\nuntil complete cessation of breastfeeding  \\n● If starting ART during pregnancy or breastfeeding, VL at 3 months after \\ninitiation, and then every 6 months until complete cessation of \\nbreastfeeding  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 56}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 12  Table 3. 6 Cont.  \\nCrAg  ✔  Baseline for adults and adolescents with CD4 ≤ 200 cells/mm3 (as reflex \\ntesting by laboratory), then only if there is clinical suspicion of CM  \\nHb ✔  Baseline, then symptom directed; if on AZT, baseline then weeks 2, 4, and \\n12 \\nPregnancy \\nStatus  ✔  At every visit for women of reproductive age (by history +/ - urine \\npregnancy test)  \\nUrinalysis \\n(protein & \\nglucose)  ✔  Baseline, then annually if on TDF  \\nCreatinine  ✔  Baseline, then annually if on TDF  \\nGlucose  ✔  Baseline, then annually  \\nPlasma lipid \\nprofile  ✔  Baseline, then annually  \\nHBsAg  ✔  Baseline, followed by immunization for all patients who screen \\nnegative (after viral suppression is confirmed)  \\nSyphilis \\nserology \\n(VDRL, \\nTPHA, or \\nRPR)  ✔  Baseline, then annually in those at risk and as part of routine ANC profile  \\nDrug \\nResistance  \\nTesting   DRT recommended once treatment failure confirmed on a DTG - or PI -based \\n1st line regimen, or confirmed treatment failure on 2nd line or subsequent \\nregimens  \\nALT   Not recommended for routine baseline or follow -up unless specific clinical \\nindication  \\nCervical \\nCancer  All women should be screened for cervical cancer following the national guidelines.  \\nUsing HPV screening conducted every 2 years for HIV positive women in their \\nreproductive age (or annually if using VIA -VILI)  \\nHCV  Baseline for PWIDs or with a history of injection drug use  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 57}),\n",
       " Document(page_content='  \\nInitial Evaluation and Follow up  \\n3 - 13  Table 3. 6 Cont.  \\n1 Recommended investigation should not delay ART initiation.  \\n 2This is the recommended appointment schedule. Clinicians and patients should be encouraged to \\nschedule additional appointments as needed. Patients should be encouraged to return to the HIV \\nclinic for unscheduled appointment whenever  an acute issue arises, instead of seeking care at \\nanother facility. Early after initiation of ART, and after any regimen modification , every \\nappointment should include:  \\n− Continued adherence counselling and support (started at the initial visit)  \\n− Assessment of adherence and correct storage of medication  \\n−  Assessment for and management of early side effects of the drugs, and patient counselling \\non the same  \\n3 Patients who are adherent and virally suppressed at month 3, may not need subsequent \\nmonthly appointments until month 6.  \\n4 All PLHIV qualify for ART and should be initiated as soon as possible including same day and \\nwithin 2 weeks. For patients who do not  start ART on the same day as enrolment into HIV care, \\nthey should be followed up every week until ART initiation to address whatever issues are \\ndelaying ART initiation, for ongoing management of acute medical issues and for treatment \\npreparation and ART r eadiness assessment.  \\n4Refer to table 3.1 for detailed history and physical examinations.  \\n5children and adolescents, weight and height should be measured and recorded at every visit, \\nwith weight -based dosing of ARVs confirmed at every visit.  \\nIn adults, weig ht and height should be measured at the initial visit to determine nutritional status \\nand calculate the BMI, and thereafter, weight should be measured at every visit.  \\n6The first 2 -4 visits are critical for assessing and supporting adherence to ART, managi ng adverse \\ndrug reactions, and treating any acute illnesses including IRIS. Adherence should be assessed at \\nevery contact with the clinic. See Chapter 5 for specific adherence preparation, monitoring and \\nsupport procedures for each visit  \\nRequired laboratory tests are highly recommended for patient monitoring, but are not a pre -\\nrequisite for ART initiation.  \\nTargeted laboratory tests may be necessary to identify and manage inter -current diseases or \\nadverse drug reactions.  \\n3.7 Differentiated Care for Children, Adolescents and Pregnant/ breastfeeding \\nWomen  \\nChildren, adolescents, pregnant and breastfeeding women, and key populations face unique \\nchallenges in retention  and viral suppression and  hence may benefit more from different iated \\nservice delivery models  adapted to their needs.  \\nChildren:  Children’s care is dependent on family and care giver dynamics. Family centered \\napproaches to care where clinic visits for parents/caregivers and the child are synchronized, \\nshould be used.  A ssessment and categorization to determine establishment on ART should be \\nconducted for pairs and follow -up tailored to their situations. Weight -based dose adjustments \\nshould be incorporated in both the facility and community models (e.g., by using portable  weighing \\nscales if out of the health facility) to determine optimal doses for ARVs at each review.  Aligning \\nappointments with school calendar should be considered to avert disruption of treatment and \\nlearning of the child.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 58}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 14  Adolescents:  Adolescents requi re psychosocial support, ongoing adherence assessments and \\ncounselling which should be aligned with clinic visits, community follow -up as well as school \\ncalendar.  Considerations should be factored in during the clinical encounters with more focus to \\nthose  with adherence and viral suppression challenges. Adolescents and Youth Friendly services \\nthat incorporate life skills and extracurricular activities should be integrated where feasible.  \\nPregnant/breastfeeding women:  Pregnant and breastfeeding women who h ave been established \\non ART should have their HIV clinic appointments synchronized with Antenatal Care visits and with \\nfollow -up of the HIV -exposed infant. Those initiated on ART during pregnancy may need close \\nfollow up to support them in adherence, reten tion and achieving viral suppression. Breast feeding \\nwomen and their babies will have their clinical visit aligned with the immunization clinics schedule. \\nPsychosocial support groups are encouraged for both pregnant and breastfeeding mothers \\nincluding peer  to peer support.  \\n3.8 ART Prescription, Dispensing, and Distribution for clients established on \\nART  \\nPatients who are established on ART should be offered ART  refills of up to 3 months. The refill of \\nother associated commodities such as cotrimoxazole, TPT a nd condoms should be aligned to the \\nART refill schedule. Clients established on ART should receive their ART, CPT, family planning, and \\nany other chronic medicines through a distribution system that minimizes the burden on them \\n(travel costs, waiting times , inconvenience) and burden on the health facility (personnel time, \\nspace constraints, etc.). This must be on a voluntary basis (i.e., the client can choose to remain in \\nstandard care if they prefer).  \\nThe health facility is responsible for ART prescription , dispensing, and distribution for all patients \\nenrolled into care. ART distribution for patients established on ART can take place at the health \\nfacility or through a community distribution system, depending on patient preference and health \\nfacility syste ms and resources. The point of ART dispensing should be based on client ability \\nto access treatment with ease.  Models for ART refills include:  \\n● Facility -based  \\no Fast track facility -based refills  \\no Facility -based ART distribution groups  \\n● Community -based  \\no Community -based ART distribution groups  \\no Community ART distribution points  \\no Community pharmacy distribution  \\nFacility -based Fast Track System for ART Refills  \\nThe facility -based fast track system for ART  refills is a simple model implemented at the health \\nfacility. The client is still required to come to the clinic every 3 months for ART refill, however the \\nrefill appointments require minimal or no waiting time at the clinic.   Refer to DSD operational \\nmanual for detailed information on community models.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 59}),\n",
       " Document(page_content='  \\nInitial Evaluation and Follow up  \\n3 - 15  Facility -based ART Distribution Group  \\nFacility -based ART Distribution Groups are a model for ART distribution, whereby a group of \\nPLHIVs meet at a designated location within their health facility for drug refills and dispense \\ndrugs to their peers within the group while ensuring peer support and treatment literacy.  ART \\nrefills are done through the group every 3 months and  each client is required to attend their \\nclinical review appointment e very 6 months.   \\nThis model may provide clients with psychosocial support if they are not already part of a support \\ngroup. This may also be more convenient for clients who are in urban settings and would not wish \\nto be enrolled in a community -based group. F acility -based groups can be peer or HCW led.  \\nCommunity -based ART Distribution Models  \\nClients may receive ART refills through community -based distribution. All clients may also benefit \\nfrom home visits such as for adherence monitoring and support, on a case -by-case basis.  \\nClients can receive their ART refill through community -based models such as:  \\n● Community -based ART distribution groups  \\n● Community ART distribution points  \\n● Community pharmacy distribution  \\nBefore implementing a community -based ART distribution program, a health facility should work \\nwith the CHMT to design a program that meets the criteria listed in Annex 14, and the plan \\napproved by the County HIV Technical Working Group before implementation. Refer to DSD \\noperational manual for det ailed information on community models.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 60}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 16   ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 61}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 1   \\n4. Standard Package of Care for PLHIV  \\n \\nAll PLHIV should receive a package of services that are known to promote health, improve the \\nquality of life, prevent further HIV transmission, and prevent HIV disease progression and \\nmortality.  \\nThe standard package of care for PLHIV in cludes: antiretroviral therapy; Positive Health, Dignity \\nand Prevention (PHDP) services; screening and providing support in cases of gender -based \\nviolence (GBV) or intimate -partner violence (IPV); HIV education/counselling; screening and \\nprevention of spec ific opportunistic infections; reproductive health services; screening for and \\nmanagement of non -communicable diseases; mental health screening and management; \\nnutritional services; and prevention of other infections (Table 4.1).  \\nThe standard package of ca re should always be applied using a patient - and family -\\ncentered approach  in PLHIV management.  Patient -centered care includes: considering the \\nindividual patient’s health needs; eliciting and addressing the patient’s concerns and expectations; \\ninvolving th e patient’s (and their family and friends as appropriate) in decision -making, and; \\nrespecting the patient’s values and preferences. Family -centered care identifies, engages and \\nprovides care to all HIV -positive family members, prevents new infections among  family members \\nat risk, and promotes family support and awareness.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 62}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 2  Table 4.1: Components of the Standard Package of Care for PLHIV  \\nComponent of Standard Package of Care Sub components  \\nAntiretroviral therapy (ART)  ● ART initiation  \\n● Adherence assessment, counselling and support  \\n● Monitoring (clinical and laboratory)  \\nPositive health, dignity and prevention \\n(PHDP); gender -based violence (GBV) \\nand intimate -partner violence (IPV) \\nscreening; and HIV \\neducation/counselling  ● Disclosure  \\n● Index testing  \\n● Condom use  \\n● Family planning  \\n● STI screening, prevention, and treatment  \\n● Adherence counselling and support  \\n● Pre-exposure prophylaxis for HIV -negative sexual partners  \\n● GBV/IPV screening and support  \\n● HIV education/counselling  \\nSpecific opportunistic infection screening \\nand prevention  ● Cotrimoxazole preventive therapy  \\n● Tuberculosis (TB)  \\no Intensified case finding  \\no TB preventive therapy  \\no ART for TB/HIV co -infected patients  \\n● Cryptococcal meningitis  \\nReproductive health services  ● Sexually transmitted infections screening and management  \\n● Family planning and pre -conception services  \\n● Maternal healthcare  \\n● Cervical cancer screening  \\nNon -communicable diseases (NCD) \\nscreening and management  ● Hypertension  \\n● Diabetes mellitus  \\n● Dyslipidemia  \\n● Chronic kidney disease  \\n● Other NCDs  \\nMental health screening and management  ● Depression  \\n● Anxiety  \\n● Stress  \\n● Trauma  \\n● Alcohol and drug use/addiction  \\n● Self-care and wellbeing  \\nNutritional services  ● Assessment  \\n● Counselling and education  \\n● Management and support  \\nPrevention of other infections  ● Immunizations  \\n● Malaria  \\n● Safe water, sanitation and hygiene  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 63}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 3  Table 4.1 Cont.  \\nStandard Package of Care for HIV -Exposed and HIV -Infected Infants  \\n● Determine HIV status at first contact through HTS/EID and link to HIV care  \\n● Provide ARV prophylaxis for all HEIs and ART for all HIV -infected children ( confirming correct \\nweight -based dosing of ARVs at every visit ); perform clinical and laboratory assessment  \\n● Provide nutritional assessment, counselling and support (NACS, Section 4. 7) and monitor growth and \\ndevelopment of the child (Annex 3)  \\n● Ensure that all immunizations are provided following the national schedule (Section 4.8.1)  \\n● Clinical assessment at every visit, treat infections early, identify, manage and report adverse drug \\nreactions aggressively and refer appropriately where specialized care is required.  \\n● Screen for opportunistic infections and provide prophylaxis (cotrimoxazole, TB Preventive Therapy \\n(TPT), deworm every 6 months (starting at 1 year of age) and provide supplemen tal Vitamin A every 6 \\nmonths (starting at age 6 months)  \\n● Educate the caregiver on all aspects of care for the child including infant feeding, immunizations, \\npersonal hygiene, HIV education/counselling, adherence, availability of support for child disclosure , \\nand follow -up requirements  \\n● Adherence assessment, counselling and support  \\n● Provide age -appropriate psychosocial support for the family and child and refer to community -based \\nsupport programs as appropriate  \\n● Ensure that the caregiver and family members are r eceiving appropriate care, support and treatment  \\n● Provide intensive case management for mother/infant pair until 2 years postpartum; identify \\ndefaulters and prioritize this population for tracking  \\n● Enroll in Orphans and Vulnerable Children (OVC) program for social protection and other services.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 64}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 4  Table 4.1 Cont.  \\nStandard Package of Care for Adolescents Living with HIV  \\nClinical care  \\n● Provide immediate linkage to HIV care  \\n● Provide ART to all HIV -infected adolescents  \\n● Perform clinical and laboratory assessment  \\n● Clinical assessment at every visit, treat infections early and refer appropriately where specialized care \\nis required  \\n● Screen for opportunistic infections and provide prophylaxis (cotrimoxazole, TPT)  \\n● Provide NACS and monitor growth and  development  \\n● Provide/refer for HPV vaccine  \\nAdherence and psychosocial support  \\n● Perform a baseline and regular subsequent psychosocial assessment  \\n● Assess for and support disclosure of HIV status to the adolescent (Annex 5)  \\n● Enroll in age -appropriate psychosoci al support groups  \\n● Provide treatment literacy  \\n● Provide life skills counselling  \\n● Provide adherence counselling  \\n● Support appropriate transition into adult HIV treatment and prevention  \\n \\nPrevention of HIV transmission  \\n● Encourage index testing and support for disclosure  \\n● Assess for and manage drug and alcohol use  \\n● Perform a sexual risk assessment and STI screening and treatment, and linkage of sexual partner to \\nPrEP where applicable  \\n● Assess for and manage IPV  \\n● Provide reproductive health services, including pregnan cy screening, pregnancy intention assessment, \\nfamily planning and linkage to PMTCT for pregnant adolescents  \\nReferrals, linkages and support for continuum of care  \\n● Provide intra -facility & inter -facility referrals as needed for specialized care  \\n● Link with youth community groups, targeting youth both in and out of school  \\nOther services  \\nlegal centers, paralegal services, gender -based violence recovery centers, educational institutions, \\nbursary/scholarship programs, income generating activities, constituency development funds, vocational \\ntraining centers for skills development, etc.  \\n4.1 Antiretroviral Therapy  \\nART is recommended for all PLHIV, regardless of WHO stage, CD4 count, age, pregnancy status, \\nor comorbidities/co -infections. O nce a diagnosis of HIV infection is confirmed, ART should be \\ninitiated as soon as possible (preferably within 2 weeks), once patient readiness has been \\ndetermined. Other sections of these guidelines deal with initial evaluation and monitoring \\n(Chapter 3), patient preparation and adherence support (Chapter 5), and specific recommended \\nART regimens (Chapter 6).  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 65}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 5  4.2 PHDP, GBV/IPV & HIV Education/Counselling  \\nPHDP (Positive Health, Dignity and prevention) is a framework that emphasizes the health and \\nrights of P LHIV, including reducing risk of onward transmission of HIV.  Within PHDP are 7 core \\ndomains of services that should be provided at the health facility to PLHIV and caregivers (Table \\n4.2). Complementary community -based PHDP should also be implemented.  \\nTabl e 4.2: Domains and Components for PHDP Services  \\nPHDP Domain  Components  \\nDisclosure of HIV status  ● Assessment of disclosure status, particularly to sexual partners  \\n● Assisted disclosure  \\nNote: for children and adolescents, it is also necessary to evaluate for and \\nsupport age -appropriate HIV disclosure to the child/adolescent (Annex 5)  \\nIndex testing and \\nengagement  ● HIV testing of sexual and drug injecting partners  \\n● HIV testing of other family members at risk  \\n● Enrolment of positive partners/family members into HIV care  \\n● Engagement of negative partners and family members in care and \\nsupport for index patient, and PrEP as appropriate  \\nCondom use  ● Risk reduction counseling  \\n● Correct and consistent condom use  \\n● Provision of condoms at every visit  \\nFamily planning  ● Assessment of pregnancy intention  \\n● Pre-conception counselling  \\n● Dual contraception until ready for pregnancy  \\n(See Section 4.4.2 for specific clinical guidelines)  \\nSexually transmitted \\ninfections (STI)  ● Screening for symptoms of STIs  \\n● Prevention of STIs  \\n(See Section 4.4.1 for specific clinical guidelines)  \\nTreatment adherence  ● Benefits/importance of:  \\no Adherence to clinical care  \\no Adherence to ART  \\n● Messaging on Undetectable=Untransmissible (U=U)  \\n (Chapter 5)  \\nPre-exposure prophylaxis  ● Assess HIV -negative sexual partners for PrEP  \\n(Chapter 11)  \\nAdditional services that should be offered to PLHIV beyond the above components include screening for GBV and IPV \\nand HIV education/counseling services.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 66}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 6  4.2.1 Screening for Gender -Based Violence (GBV)/Intimate -Partner Violence (IPV)  \\nNational data (KDHS 2014) shows that 45% of women and 44 % of men aged 15 -49 years have \\nexperienced physical violence since age 15.; 14% of women and 6% of men age 15 -49 report \\nhaving experienced sexual violence at least once in their lifetime.  To identify these survivors \\nscreening is recommended. WHO recommends that facilities should meet the minimum \\nrequirement before starting to routinely screening clients.  \\nThe minimum require ments are:   \\n• A protocol or Standard Operating Procedure exists for providing post -GBV and Violence \\nAgainst Children  services  \\n• A questionnaire, with standard questions where providers can document responses,  \\n• Providers offer first -line support (LIVES)  \\n• Providers have received training on how to ask about GBV and Violence Against Children  \\n• Private setting, confidentiality ensured  \\n• A system for referrals or linkages to other services within the facility is in place  \\nIf any of these minimum requirements is mis sing, GBV and Violence Against Children  services are \\nconsidered inadequate, and providers should ensure to have these systems in place before \\nconducting routine enquiry or universal screening  \\nAll clients accessing HIV care services should be screened for a ny form of violence \\nincluding  IPV as part of the standard package of care for PLHIV.  \\nThe following script can be used for screening:  \\n “Many people do not realize that violence can lead to various serious health problems. Many \\npeople have problems with thei r husbands, partners or other people in their lives. Sometimes the \\npeople who love us can hurt us. Has this ever happened to you?”  \\nHas your partner ever:  \\n1. Insulted you or made you feel bad about yourself?  \\n2. Belittled or humiliated you in front of other people?   \\n3. Did things to scare or intimidate you on purpose  \\n4. Threatened to hurt you or someone you care about?  \\n5. Slapped you or thrown something at you that could hurt you?  \\n6. Kicked, dragged, beat you up?  \\n7. Chocked or  burned you on purpose?  \\n8. Threatened to use or actually used a gun, knife or other weapon against you?  \\n9. Physically forced you to have sexual intercourse when you did not want?  \\n10. Did you ever have sexual intercourse you did not want because you were afraid of w hat \\nhe might do?  \\n11. Forced you to do something sexual that you found degrading or humiliating?  \\nIf a survivor answers yes to any of these questions provide them with LIVES and do a mental \\nassessment  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 67}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 7  Table 4.2a: Components of screening for GBV/IPV (LIVES)  \\nListen  Listen to the client closely, with empathy and without judging  \\nInquire  Assess and respond to the client’s various needs and concerns  \\nValidate  Show the client that you understand and believe them. Assure the client that they \\nare not to blame  \\nEnhance safety  Discuss a plan to protect the client from further harm if violence occurs again  \\nSupport  Support the client by helping them to access information, services and social \\nsupport  \\nSupportive messages that may be helpful include:  \\n● “What happened to you is not your fault”  \\n● “Many women/men are in the same situation as you”  \\n● “You are not to blame.”  \\n● “Everybody deserves to feel safe at home if you feel like you are in immediate danger, we can \\ninvolve the police or local administration “  \\nMen, the  elderly, and children suffer different forms of violence and should be assessed if there \\nis any clinical suspicion. Key populations are particularly vulnerable to abuse, including MSM, \\ntransgender, and prisoners. For children art and play therapy is used during history taking and \\npsychological assessment.  \\n4.2.2 HIV Education/Counselling  \\nAll PLHIV and caregivers should receive focused education about HIV and its treatment to \\nempower them to succeed in management of the infection. Self -management is critica l to the \\nsuccessful treatment of any chronic illness, including HIV. Key messages for HIV education and \\nadherence counselling are described in Chapter 5 of these guidelines.  \\nIn addition, psychosocial counselling and support for PLHIV and caregivers should include:  \\n● Mitigation of fear, anger, self -stigma and discrimination  \\n● Alleviation of grief, bewilderment and stress among partners and family members  \\n● Behavior changes in support of healthy living and prevention of further HIV transmission  \\n● Skills -building on how to live a healthy and productive life  \\n● Identification and treatment of depression and substance abuse  \\nHIV education and counselling can be offered in multiple settings, including: facility -based \\nindividual, couples, family, and/or gro up counselling, and through community -based counselling \\nand peer support groups.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 68}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 8  4.3 Specific Opportunistic Infection Screening and Prevention  \\n4.3.1 Cotrimoxazole Preventive Therapy (CPT)  \\nCPT is no longer recommended as life -long prophylaxis, and is only recommended in the \\nfollowing sub populations, unless they have an allergy to sulfur drugs or develop toxicity from \\nCPT:  \\n● HIV exposed infants  \\n● HIV infected children and adolescents <15 years of age  \\n● PLHIV > 15 years of age:  \\no Living in malaria -endemic zones * \\no Presenting with WHO stage 3 or 4 event, or meeting the criteria AHD  \\no Suspected treatment failure  \\n● All Pregnant and Breast -feeding women  \\nFor HIV exposed and infected infants, CPT should start at 6 weeks of age. CPT is effective in AHD, \\nand preventing specific OIs for patients with low CD4 counts (PCP and toxoplasmosis), as well as \\nreducing the risk of common bacterial infections, sepsis, diarrhea illness and malaria.  \\n*Refer to the National Guidelines for the Diagnosis, Treatment and Prevention of Malaria in Kenya for the \\ncurrent Kenya Malaria endemicity map  \\nTable 4.3: Co -trimoxazole Preventive therapy  \\nSub -Population  Starting/Restarting criteria  Ending criteria  \\nHIV exposed Infants  All infants, starting 4 -6 weeks \\nafter birth  Child is confirmed HIV -negative  \\n \\nHIV-infected children \\nand adolescents ≤ 15 \\nyears old  All children  Attains 15 years of age  \\nPLHIV > 15 years old  Suspected treatment failure  \\nWHO Clinical Stage 3 and 4  Clinically stable:  \\no On ART for at least 12 months  \\no Showing no signs or symptoms of \\nWHO Clinical Stage 2,3 or 4  \\nHIV-positive \\nPregnant and \\nbreastfeeding women  All Clinically stable:  \\no On ART for at least 12 months  \\no Showing no signs or symptoms of \\nWHO Clinical Stage 2,3 or 4  \\no Not pregnant or breastfeeding  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 69}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 9  Table 4.4: Daily Dose of Cotrimoxazole Preventive Therapy  \\nWeight (kg)  If using oral suspension  \\n(240mg per 5ml)  If using single \\nstrength tablet 480 \\nmg (SS)  If using double strength \\ntablet 960 mg (DS)  \\n1 – 4 2.5 ml  ¼ SS tab  -- \\n5 – 8 5 ml  ½ SS tab  ¼ DS tab  \\n9 – 16 10 ml  1 SS tab  ½ DS tab  \\n17 – 30 15 ml  2 SS tabs  1 DS tab  \\n> 30  20 ml  2 SS tabs  1 DS tab  \\nAdult (any weight)   2 SS tabs  1 DS tab  \\nNote: If CrCl 15 -30 ml/min then use 50% of normal recommended dose; if CrCl < 15 ml/min then CTX should \\nbe avoided  \\nDuring pregnancy, CPT should be initiated irrespective of the gestational age and should \\ncontinue throughout pregnancy and breastfeeding. Additional intermittent preventive \\ntherapy (sulfadoxi ne-pyrimethamine (SP)) for malaria is not required for women already \\non CPT.  \\nCotrimoxazole can cause anaemia and neutropenia in some patients, as well as a skin rash.  \\nManagement of Patients with Cotrimoxazole Allergy  \\n● A rash may occasionally develop, usually about 7 -14 days following initiation of CPT. It \\nis often a relatively mild maculopapular rash with or without pruritus. Infrequently, rash \\nmay develop with severe exfoliation of the skin and Stevens -Johnson syndrome. Rash \\nseverity should b e assessed, with management based on severity (Table 4.5)  \\n● Desensitization is effective in the majority of patients with mild to moderate rash (Table \\n4.6a). The rapid desensitization regimen (Table 4.6 b) can be used in situations where \\ntreatment for PCP is needed  \\nTable 4.5: Management of Drug -Associated Skin Rash  \\nSeverity  Characteristics  Action  \\nMild  Dry; erythema +/ - fine \\npapules; pruritus; affecting \\n< 50% of body surface area  Continue CTX; close monitoring; symptomatic treatment with \\nantihistamines +/ - topical steroids (NOT oral steroids)  \\nModerate  Dry; erythema +/ - fine \\npapules; pruritus; affecting \\n≥ 50% of body surface area  Stop CTX; symptomatic treatment with antihistamines +/ - \\ntopical steroids (NOT oral steroids); trial of desensitization \\nafter symptoms completely resolved  \\nSevere  Mucosal involvement;  \\nblistering; associated fever; \\nany % of body surface area  Stop CTX; admission to hospital for supportive management (IV \\nfluids, wound care, pain control, infection control, monitoring \\nfor super -infection); patient should NEVER be re -challenged \\nwith CTX or other sulfa -containing drugs;  document and \\nreport adverse event and issue patient alert card  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 70}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 10   \\n \\n Cotrimoxazole Desensitization Protocols (for patients who have fully recovered from \\nmoderate reaction)  \\nTable 4.6a: Standard Cotrimoxazole \\nDesensitization Regimen (8 days)  Table 4.6b: Rapid Cotrimoxazole \\nDesensitization Regimen (6 hours)  \\n \\nDay  \\nDose of TMP/SMX Suspension  \\n(40/200 mg per 5ml)  \\nDay 1 0.5 ml  \\nDay 2 1 ml \\nDay 3 2 ml \\nDay 4 3 ml \\nDay 5 4 ml \\nDay 6 5 ml \\nDay 7 1 SS tablet  \\nDay 8 2 SS tablets/1 DS tablet per day  \\nNote: For children, continue up until they have \\nreached their recommended weight -based dosage  \\n  \\nHour  \\nDose of TMP/SMX Suspension \\n(40/200  mg per 5ml) \\nHour 0 0.5 ml \\nHour 1 1 ml \\nHour 2 2 ml \\nHour 3 3 ml \\nHour 4 4 ml \\nHour 5 5 ml \\nHour 6 1 SS tablet \\nNote: The rapid desensitization protocol should \\nnot be used for children because the cumulative \\ndosage will be too high  \\n \\n \\nDapsone as a Substitute for CPT  \\nIn situations of severe allergy to cotrimoxazole or when desensitization is not successful, \\ndapsone can be used instead of CTX. It is primarily effective as prophylaxis against PCP but does \\nnot have the other prophylactic benefits of cotrimoxazole.  \\nNote:  \\nDapsone will contribute to anaemia in most patients, and causes haemolytic anaemia in some \\npatients, so pati ents should have a baseline Hb before starting dapsone and Hb monitored every \\n1-2 weeks for the first couple of months.  \\nWhen dapsone (as a substitute for CPT) is being used as PCP prophylaxis, it is only \\nrecommended for patients in WHO Stage 4 and/or with  absolute CD4 count ≤ 200 \\ncells/mm3 (or CD4 % ≤ 25% for children ≤ 5 years old), and should be discontinued once \\na patient achieves a sustained CD4 count of > 200 cells/mm3 (or > 25% for children ≤ 5 \\nyears old) for at least 6 months.  \\nDapsone is NOT recomme nded during breastfeeding.  \\nDose of Dapsone  \\n● Available as 25 mg and 100 mg tabs  \\n● Children: 2 mg/kg once daily (maximum dose: 100 mg) OR 4 mg/kg once weekly \\n(maximum dose: 200 mg)  \\n● Adults: 100 mg once daily  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 71}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 11  4.3.2 Tuberculosis (TB) Prevention and Management for PLHIV  \\nAll PLHIV should be screened for TB at every visit using the Intensified Case Finding (ICF) tool.  \\nAll PLHIV older than 12 months of age who screen negative for TB should be provided with TB \\nPreventive Therapy (TPT) unless they have a s pecific contraindication.  All patients who receive \\na full course of TPT should have this clearly documented in their file (Section 8.2)  \\nFor PLHIV who have presumptive TB, GeneXpert ultra is the preferred testing platform to \\nconfirm the diagnosis, with TB -LAM used as an adjunct bedside test when indicated, while \\nawaiting GeneXpert ultra -results. All PLHIV qualify for ART, including patients with HIV/TB co -\\ninfection.  \\nChapter 8 provides specific guidelines for ICF, TPT, use of GeneXpert ultra and TB -LAM, and ART \\nfor patients with TB/HIV co -infection.  \\n4.3.3 Cryptococcal Meningitis (CM) Screening and Treatment  \\nAll adult and adolescent PLHIV with a baseline CD4 count of ≤ 200 cells/mm3   should be \\nscreened for cryptococcal infection (Figure 4.1). This should be a  reflex test performed by the \\nlaboratory as soon as the low CD4 count is noted, rather than requiring the clinician to order a \\nspecial test for screening.  \\nPLHIV, including children and adolescents, should receive cryptococcal screening if clinically \\nsuspec ted. For patients who are symptomatic for meningitis but screen serum CrAg negative, \\nalternative diagnoses for sub -acute meningitis should be explored, such as TB meningitis. All \\npatients with clinical meningitis should be assessed and managed at a facilit y that can perform \\nlumbar punctures.  \\nWhenever performing CSF CrAg for patients with symptomatic meningitis, CSF GeneXpert \\nultra for TB should be performed at the same time, as well as urine for TB -LAM . \\nFluconazole use during first trimester of pregnancy in creases the risk of birth defects. All \\npregnant women who screen positive with serum CrAg should be offered a lumbar puncture \\n(irrespective of symptoms) to determine if they have cryptococcal meningitis. If the CSF CrAg is \\npositive, they should be treated with 2 weeks of amphotericin B for induction (without \\nfluconazole), while consulting Uliza!  Hotline (0726 460 000; ulizanascop@gmail.com) to discuss \\nconsolidation/maintenance. Pregnant women with negative CSF CrAg should start ART \\nimmediately (without pre -emptive fluconazole therapy) and be monitored for symptoms of CM.  \\nTable 4. 7 provides detailed guidance on the use of amphotericin, fluconazole, flucytosine (once \\navailable), and therapeutic lumbar punctures for the treatment of symptomatic cryptococcal \\nmen ingitis  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 72}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 12  Table 4. 7: Treatment of Cryptococcal Meningitis  \\nTarget \\npopulation  Regimen  Induction (2 \\nweeks)1,2 Consolidation \\n(8 weeks)  Maintenance  When to start  \\nART  \\nAdults  Preferred  Ampho B 1.0 \\nmg/kg/day + \\nFluconazole \\n1,200 mg/day  Fluconazole6  \\n800 mg/day  Fluconazole 200 \\nmg/day for at \\nleast 1 year and \\nuntil CD4 count  \\n> 200 cells/mm3 \\nfor two measures  \\n6 months apart \\nAND VL is \\nundetectable  Defer ART until \\nafter completing  \\n5 weeks of CM \\ntreatment and \\nsymptoms have \\nresolved  Alternative  Fluconazole,3,4,5,6  \\n1,600 mg daily  Fluconazole6 \\n800 mg daily  \\nChildren and \\nadolescents  Preferred  Ampho B 1.0 \\nmg/kg/day + \\nFluconazole 12 \\nmg/kg/day (up \\nto max 800 \\nmg/day)  Fluconazole 6 -\\n12 mg/kg/day \\nup to  \\n800 mg/day  Fluconazole  \\n6mg/kg/day up \\nto 200 mg/day  \\nAlternative  Fluconazole3,4,5 \\n12 mg/kg/day \\n(up to max \\n1,600 mg/  \\nday)  Fluconazole 12 \\nmg/kg/day up \\nto \\n800 mg/day  Fluconazole  \\n6mg/kg/day up \\nto 200 mg/day  \\n1Amphotericin B should always be used for induction when available. If it is not possible to complete 2 weeks \\nof induction with ampho due to availability, toxicity or monitoring, then use a shorter duration of ampho and \\ncomplete the 14 -day induction period with the alternative regimen  \\n2Once available, flucytosine may become part of the  preferred and alternative induction regimens, given \\n100mg/kg per day divided into four doses per day  \\n3Fluconazole requires a dose adjustment for impaired renal function; when CrCl ≤ 50 ml/min then use 50% \\nof the standard recommended dose  \\n4Fluconazole shou ld not be used with rifabutin -based TB treatment  \\n5When using high -dose fluconazole check ALT after one week of treatment and based on symptoms \\nthereafter  \\n6Fluconazole is contraindicated in the first trimester of pregnancy. Amphotericin can be used. Please consult \\nexpert or National or Regional TWG.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 73}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 13  Managing and Monitoring for Amphotericin B Therapy  \\nAdults  \\n• Give 1 L of normal saline with 20 mmol of KCl over 2 -4 hours before each controlled \\ninfusion of Ampho B given with 1 litre of 5% dextrose. Add one to two tablets of 8 mEq \\nKCl orally twice daily. An additional one 8 mEq KCl tablets twice daily may be added in \\nthe second week. Include magnesium supplementation at 250 mg tablets of magnesium \\ntrisilicate twice daily (or 4 mEq tablets of magnesium chloride t wice daily)  \\nAdolescents and Children  \\n• Give 1 L of normal saline with 20 mmol of KCl over 2 -4 hours before each controlled \\ninfusion of Ampho B. Darrows or Ringer’s solutions can also be used  \\nNote: Avoid KCl replacement in patients with pre -existing renal imp airment or \\nhyperkalemia  \\n \\nManaging hypokalaemia and raised creatinine levels  \\n• Obtain a routine baseline and twice weekly potassium and creatinine:  \\n- If K < 3.3 mmol/L, administer 1 L of normal saline with KCl 40 mmol in normal saline \\nor 1 -2 tablets of 8mEq KCl every 8 hours. Add magnesium. Monitor potassium daily  \\n- If creatinine level increases > 2 -fold from baseline, omit dose of Ampho B, increase \\nhydration to 1 L every 8 hours. If there’s improvement, re -start Ampho B at 0.7 \\nmg/kg/day on alternate days. If n o improvement, discontinue Ampho B, give \\nfluconazole 1,600 mg/day to complete induction. Monitor creatinine daily  \\nTherapeutic lumbar punctures are a critical component of the management of CM and \\nshould be standard of care:  \\n• For all patients with symptomati c CM: perform daily therapeutic lumbar punctures:  \\n- If opening pressure is ≤ 40 cm: draw off enough CSF to reduce pressure to 20 cm  \\n- If opening pressure is > 40 cm: draw off enough CSF to reduce pressure by 50%  \\n- Continue daily LPs until pressure is normal for 3 consecutive days  \\n- Restart LPs if symptoms return  \\nIf measuring intracranial pressure is not possible (even using a giving set and tape measure), \\nthen perform daily therapeutic LPs until severe headache subsides, removing 10 -20 ml of CSF \\neach tim e \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 74}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 14  \\nNewly diagnosed HIV -infected adult or adolescent\\nCD4   200 cells/mm3\\nAutomatic/reflex CrAg \\nscreening\\nSerum CrAg POSITIVE Serum CrAg NEGATIVE\\nSymptom Screen: Progressive headache, fever, \\nmalaise, neck pain, confusion\\nSymptomatic: Admit and do \\nLumbar puncture to obtain CSF \\nfor CrAg and geneXpert• Asymptomatic1: Offer presumptive treatment for possible early CM with \\nfluconazole 1,600 mg per day for 2 weeks, followed by fluconazole 800 \\nmg per day for 8 weeks, followed by fluconazole 200 mg per day for at \\nleast 1 year and until CD4 count >200 cells/mm3 for two measures 6 \\nmonths apart and VL is undetectable (LDL <200copies/ml )\\n• Defer ART for 5 weeks2\\n• Monitor closely and perform LP if symptoms develop\\nNB: Lumber puncture for CSF CrAg is strongly recommended for pregnant \\nwomen irrespective of symptoms3\\nCSF CrAg positive: Treat for cryptococcal \\nmeningitis with amphotericin, fluconazole \\nand therapeutic LPs (Annex 7)\\nDefer ART until completed 5 weeks of \\ntreatment and has resolution of \\nsymptoms2• CSF CrAg negative: Offer pre -emptive therapy for non -meningeal \\ndisease with fluconazole 800 mg per day for 2 weeks, followed by \\nfluconazole 400 mg per day for 8 weeks, followed by fluconazole \\n200 mg for at least 1 year and until CD4 count >200 cells/mm3 for \\ntwo measures 6 months apart and VL is undetectable (LDL \\n<200copies/ml )\\n• Defer ART until completed 5 weeks of treatment and has \\nresolution of symptoms2\\nLP is recommended for all sCrAg positive patients irrespective of symptoms with management based on LP results. If \\nLP is not available to rule out meningeal disease then patients should be treated for possible CM, even if \\nasymptomatic\\nPatients with cryptococcal meningitis are at high risk of developing life-threatening IRIS;  deferring ART has \\nshown to improve survival for these specific \\nFluconazole use during pregnancy increases the risk of birth defects. All pregnant women who screen positive with \\nserum CrAg should be offered a lumbar puncture (irrespective of symptoms) to determine if they have cryptococcal \\nmeningitis\\nNote: \\n• Fluconazole requires a dose adjustment for impaired renal function; when CrCl      ml/min then use 50% of the \\nstandard recommended dose\\n• Fluconazole should not be used with rifabutin -based TB treatment\\n• When using high -dose fluconazole check ALT after one week of treatment and based on symptoms thereafter• No cryptococcal treatment required\\n• Initiate ART within 2 weeks \\nFigure 4.1: Routine Screening for Cryptococcal Meningitis for HIV -infected Adults and Adolescents  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 75}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 15  4.4 Reproductive Health Services  \\n4.4.1 Sexually Transmitted Infections  \\nScreening for syphilis using VDRL, TPHA, or RPR should be performed as a baseline investigation \\nfor all adolescent and adult PLHIV. Pregnant women should be screened for Syphilis during the \\nfirst ANC visit and 3rd trimester.  \\n \\nAll PLHIV should be assessed for symptoms of STIs using the National Algorithm s for Treating \\nCommon STI Syndromes (Kenya National guidelines for management and control of STIs, 2018. \\nAnnex 4). Sexual partners should be treated as well.  \\n \\nRisk reduction counselling and provision of condoms is an integral part of STI treatment.  \\n \\nPatien ts who have persistent signs and symptoms of STIs after syndromic treatment should \\nundergo diagnostic evaluation for definitive diagnosis and treatment.  \\n \\nAt initial diagnosis of HIV, all sex workers should be treated for presumptive gonorrhoea and \\nchlamydi a (following treatment recommendations of vaginal/urethral discharge syndrome as \\nper national STI guidelines), with presumptive treatment every quarter.  \\n \\n4.4.2 Family Planning and Pre -Conception Counselling  \\nPregnancy status should be determined for all wom en of reproductive age at every visit (based \\non history of last menstrual period and, if uncertain, irregular, or delayed, then a urine pregnancy \\ntest should be performed).  \\n \\nPregnancy intention should be determined for all women of reproductive age and the ir partners \\nso that appropriate family planning or pre -conception counselling can be provided.  \\n \\nFor patients who do not have an immediate desire to become pregnant, dual contraception \\n(defined as condoms plus another form of effective contraception) should  be provided \\nimmediately with follow -up appointments scheduled to ensure no interruption in contraception \\nprovision. Table 4.8  outlines contraception options for PLHIV based on the ARVs they are using.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 76}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 16  Table 4.8 : Contraceptive Methods for PLHIV Based on  WHO 2018 Medical Eligibility Criteria  \\nContraceptive Method  ARVs Being Used  Anti -TB \\nNRTI \\n(any)  NNRTI  \\nPI/r \\n(any)  INSTI  \\nRifampicin or \\nRifabutin  EFV \\nor \\nNVP  ETR  RAL  DTG*  \\nIM medroxyprogesterone (DMPA; Depo \\nProvera)  1 1 1 1 1 - 1 \\nNorethisterone enanthate (NET -EN; \\nnorethindrone)  1 2 1 2 1 - 2 \\nImplants  1 2 1 2 1 - 2 \\nCombined oral contraceptive (pill)  1 2 1 2 1 - 3 \\nIntrauterine \\ndevice (IUD)  Initiation  ● Category 2 for asymptomatic or mild HIV disease (WHO Stage 1 \\nor 2, or any WHO Stage once they are stable on ART)  \\n● Category 3 for women with advanced and symptomatic HIV \\ndisease UNTIL they are stable on ART and asymptomatic  \\nContinuation  Category 2 for all women regardless of symptomatic HIV (do not \\nrequire IUD to be removed)  \\nCondoms  No restrictions; use encouraged in combination with a hormonal \\ncontraception method or IUD as part of dual FP to prevent STI/HIV \\ntransmission  \\nEmergency contraceptive pill (ECP)  No restrictions; can be started up to 5 days after intercourse  \\nSterilization  No reason to deny; delay in case of acute HIV -related infection  \\nFertility awareness -based (FAB) methods  Can use if menstrual cycle is regular, although reliability is not as \\ngood as hormonal contraceptive methods or IUD. Encoura ge to use \\nin combination with condoms to prevent STI/HIV transmission  \\nLactational amenorrhoea method (LAM)  Effective for women who are less than 6 months post -partum, are \\nexclusively breastfeeding, and have not resumed menses. Encourage \\nto use in combinat ion with condoms to prevent STI/HIV \\ntransmission  \\nSpermicides and diaphragm  Use is not recommended; may increase risk of HIV transmission  \\nCategory 1: No restriction for the use of the contraceptive method  \\nCategory 2: Advantages of using the method generally outweigh the theoretical or proven risks  \\nCategory 3: The theoretical or proven risks usually outweigh the advantages of using the method  \\n*DTG was not included in the WHO 2018 MEC Guidelines, however, drug interactions between DTG and \\nhormonal con traception have not been identified  \\nFor patients who intend to become pregnant, the key pre -conception messages and services are \\npresented in Table 4. 9. \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 77}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 17  Table 4. 9: Pre -Conception Counselling Messages and Services for PLHIV  \\nScenario  Key Counselling Messag es Pre-conception Services (in \\naddition to the Standard Package of \\nCare for PLHIV)  \\nAll \\nwomen/couples \\nwith intention to \\nconceive  ● All PLHIV qualify for ART, with \\ninitiation preferably within 2 weeks \\nof HIV diagnosis  \\n● Deferring pregnancy until confirmed \\nviral suppression reduces risk of \\nvertical transmission to the baby, \\nimproves infant outcomes, and \\nreduces risk of cross -transmission to \\nthe sexual partner  \\n● Unprotected sex should be limited to \\ndays when ovulation is expected \\n(based on basal tempe rature \\nmonitoring, fertility calendar based \\non menstrual cycles, and/or fertility \\ncalendar app)  \\n● Routine ANC and delivery by a \\nskilled birth attendant improves \\noutcomes for mother and baby  ● ART for all PLHIV, including those \\nintending to become pregnant  \\n● Baseline investigations  \\no Hb (with management of \\nanaemia)  \\no Syphilis screening  \\no Cervical cancer screening  \\n● STI symptom screening  \\n● Nutritional assessment, \\ncounselling, and support  \\n● Folic acid supplementation  \\n● Standard VL monitoring (Figure \\n6.6)  \\n● PrEP for the HIV -negative partner  \\nAdditional \\nmessages for \\ndiscordant \\ncouples: male \\npartner HIV \\npositive  ● Defer unprotected sex until confirmed viral suppression in the HIV positive \\npartner  \\n● Discuss use of PrEP for the HIV-negative partner (Chapter 11)  \\n● In situations where viral suppression is challenging, consider specialist referral \\nfor additional options such as sperm washing and artificial insemination  \\nAdditional \\nmessages for \\ndiscordant \\ncouples: female \\npartner HIV \\npositive  ● Defer unprotected sex until confirmed viral suppression in the HIV -positive \\npartner  \\n● Discuss use of PrEP for the HIV -negative partner (Chapter 11)  \\n● Discuss self -insemination during the peri -ovulatory period, where \\nappropriate/as preferred  \\n● In situations where viral suppression is challenging, consider specialist referral \\nfor additional options such as artificial insemination  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 78}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 18  4.4.3 Maternal Healthcare  \\nMaternal healthcare begins with preconception counselling (Table 4. 9), and continues \\nthroughout pregnancy and breastfeeding. The standard package of antenatal and postnatal \\nservices in the context of HIV is described in Chapter 7 of these guidelines.  \\n4.5 Non -communicable Diseases Screening and Management  \\n4.5.1 Metabolic Disorders  \\nScreening, prevention and management of specific NCDs are included in the standard package of \\ncare for PLHIV because of their associated high morbidity and mortality. PLHIV are at higher risk \\nfor cardiovascular, liver and kidney disease because o f the chronic inflammatory state associated \\nwith HIV infection itself, and also as a side -effect of some of the ARVs.  \\nThe modifiable risk factors for cardiovascular disease include tobacco use and exposure to \\ntobacco smoke, unhealthy diets, overweight/obe sity, physical inactivity, harmful use of alcohol, \\nhypertension, diabetes, hyperlipidemia, infections such as rheumatic fever and HIV. Advancing \\nage, sex, race/ethnicity and family history are non -modifiable risk factors associated with \\ncardiovascular dise ases  \\nHIV and other chronic diseases require health systems that support chronic care and  \\nadherence; their management should be integrated at the health facility, including at the \\nprimary care level.  \\nLifestyle modifications are always the first line of prev ention and management for \\nhypertension, diabetes mellitus (DM), and dyslipidaemia (Table 4. 10). These are \\nrecommended for all patients to prevent these NCDs and should be integrated into routine HIV \\ntreatment and prevention. Recommendations for screening, diagnosis, and initial management \\nof hypertension, type 2 DM, dyslipidaemia, and chronic kidney disease (CKD) are provided in \\nTables 4.1 1-4.14. \\nFor comprehensive guidelines on prevention, diagnosis and management of diabetes and \\ncardiovascular diseases, re fer to Kenya National Clinical Guidelines for the Management of \\nDiabetes  and Kenya National Guidelines for Cardiovascular Diseases Management , respectively.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 79}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 19  Table 4. 10: Lifestyle Modifications to Prevent and Manage Cardiovascular Disease in PLHIV  \\nSmoking Cessation  \\n● Smoking cessation has multiple short -term and long -term benefits, including  \\no Reduced premature aging/wrinkling of skin  \\no Improved fitness and quicker recovery from common infections  \\no Reduced risk of respiratory infections and chronic lung disease  \\no Reduced risk of high blood pressure, diabetes, kidney disease, heart disease, and stroke  \\no Improved infant outcomes (for pregnant women)  \\no Reduced risk of cancers: lung, bladder, breast, mouth, throat, esophagus  \\no Better response to ART (better viral suppression)  \\no Reduced risk of developing TB or dying from TB  \\n● Tobacco dependence treatment and cessation programs should combine behavioral/counseling \\nsupport with pharmacotherapy treatment where necessary and available. For further details on \\ncessation interventions, refer to the Kenya National Guidelines for Tobacco Dependence \\nTreatment  \\nRefer to Table 4.1 8 for tips to assist a client to quit smoking  \\n \\nDietary Changes and Weight Loss  \\n● Weight loss to maintain a healthy BMI (nutritionists to be engaged in patient care)  \\n● Drink 8 glasses of water per day  \\n● Reduce/abstain from alcohol  \\n● Cut down sugar intake  \\n● Cut down red meat intake  \\n● Cut down consumption of fatty foods, fat for flavoring, and fried foods  \\n● Increase intake of whole grain s, vegetables, fruit, and beans  \\n● Increase intake of fish  \\n● Consume less than 5 g (just under a teaspoon) of salt per day  \\n \\nPhysical Activity  \\n● Active lifestyle with moderate -intensity physical activity  \\n● 30 minutes of aerobic activity such as brisk walking, at least 5 days per week  \\n \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 80}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 20  Table 4.1 1: Hypertension Screening, Diagnosis, and Initial Management for Adult PLHIV  \\nScreening  \\n● BP should be measured and recorded for every adult at every visit  \\nDiagnosis  \\n● Hypertension requiring intervention is defined as BP ≥ 140/90 mmHg on at least 3 different occasions  \\nAdditional Investigations for patients with hypertension  \\n● Urinalysis: to assess for kidney disease and diabetes  \\n● Creatinine, Na, K: to assess for kidney disease  \\n● Blood glucose: to assess for diabetes  \\n● Full blood count: anaemia may indicate chronic kidney disease  \\n● Lipid profile: dyslipidemia is a cardiovascular risk factor  \\n● ECG: to assess for cardiac pathology including cardiomegaly, ventricular dysfunction, ischemic heart \\ndisease, etc.  \\nManagement (treatment target is BP < 140/90 mmHg)  \\n● If baseline BP is 120 -139/80 -89 (pre -hypertension)  \\no Lifestyle modification, along with monthly BP monitoring  \\n \\n● If baseline BP is 140 -159/90 -99 \\no Lifestyle modification (Table 4.9) for up to 6 months, along with monthly BP monitoring  \\no If does not meet treatment target with lifestyle modifications, then add drugs to lifestyle \\nmodification  \\no In PLHIV without  kidney disease or diabetes, first -line antihypertensive therapy is a thiazide \\ndiuretic s uch as hydrochlorothiazide starting at 12.5 mg OD (maximum dose 25 mg OD) OR a \\ncalcium channel blocker such as amlodipine starting at 2.5 mg OD (maximum 10 mg OD)  \\no In PLHIV with kidney disease or diabetes the first antihypertensive should be an ACE -I or ARB  \\nsuch as enalapril 2.5 -10 mg OD (maximum dose is 20 mg BD); or, losartan 50 mg OD (maximum \\ndose is 100 mg OD), with referral to a physician if available  \\no Introduce one drug at a time. If the target blood pressure is not reached within one month after \\ninitia ting therapy, the dosage of the initial medication should be increased. Titrate to maximum \\nrecommended dosage (if tolerated) before adding an additional drug  \\no If inadequate response once dose has been titrated, an additional agent may be required e.g., \\nhydr ochlorothiazide starting at 12.5 mg OD (maximum dose 25 mg OD)  \\no If inadequate response to two agents, consider consultation with or referral to a physician  \\no Note: Calcium -channel blockers have known drug interactions with PIs and NNRTIs and \\nshould be used with caution (Annex 13). ACE -I and thiazide diuretics do not have significant \\ninteractions with ARVs  \\n \\n● If baseline BP ≥ 160/100 mmHg  \\no Initiate lifestyle modifications and introduce anti -hypertensive medications concurrently  \\n \\n \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 81}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 21  Table 4.1 2: Type 2 Diabetes Mellitus Screening, Diagnosis, and Initial Management for PLHIV  \\nScreening  \\n● Blood glucose (fasting or random) should be evaluated at baseline for all PLHIV, then annually if \\nbaseline screening is normal; urine dipstick for protein and glucose can be used if blood glucose \\ntesting is not available  \\nDiagnosis  \\n● Diabetes Mellitus is defined as fasting blood sugar ≥ 7.0 mmol/L, or random blood sugar ≥ 11.1 \\nmmol/L, or HbA1c > 6.5%, or oral glucose tolerance test ≥ 11.1 mmol/L  \\n● Abnormal results should be repeated to confirm the diagnosis, particularly for patients without \\nsymptoms of diabetes (such as polyuria, polydipsia, polyphagia, weight loss)  \\n \\nManagement (treatment target is HbA1c ≤ 7.0% or FBS 4 -7 mmol/L)  \\n● For patients with pre -diabetes (abnormal results but does not meet criteria above for diabetes) \\nmonitor FBS or HbA1c every 3 months and encourage lifestyle modifications (Table 4. 10) \\n \\n● For patients with diabetes, monitor HbA1c (or FBS if HbA1c is not available) every 3 months  \\n \\n● Lifestyle modification (weight loss, nutritional support to manage portion sizes and calculate \\nglycaemic index of various foods to hel p with control of blood sugar) for 3 -6 months  \\n \\n● If does not meet treatment target with lifestyle modifications then add drugs  \\no Metformin  \\n▪ Obtain baseline Creatinine; do NOT use metformin if creatinine clearance < 45 ml/min  \\n▪ Start with low dose (500 mg OD or BD) and titrate up every 1 -2 weeks until reaches 1 g BD (or \\nmaximum tolerated dose if less than 1 g BD)  \\n▪ Note:  DTG may increase metformin plasma levels: monitor blood glucose levels; dose reduction \\nof metformin may be required, and maximum daily dose of met formin should be 1g  \\no If does not meet treatment targets with metformin for 3 -6 months at maximum tolerated dose then \\nconsider adding drug from another class (such as sulphonylureas (gliclazide)) and/or specialist \\nconsultation. Some patients may require insu lin. \\no At every visit: A thorough history (to elicit features of hypoglycemia, other cardiovascular disease \\nrisk factors, neuropathy, diabetic foot ulcers) and a physical exam (for BP, neuropathy, foot ulcers)  \\n \\n● Additional routine screening for patients with diabetes  \\no Annual ophthalmology examination for diabetic retinopathy  \\no Annual urinalysis: start on an ACE -I/ARB if proteinuria develops (even if BP normal)  \\nNote : patients with DM are at increased risk of developing TB  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 82}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 22  Table 4.12: Dyslipidemia Screening, Diagnosis, and Initial Management for PLHIV  \\nScreening  \\n● Fasting lipid profile should be evaluated at baseline for all PLHIV, then annually if baseline screening \\nis normal  \\nDiagnosis  \\n● Dyslipidemia is defined as high fasting total cholesterol (>5.2 mmol/L), LDL (>3.4 mmol/L) or \\ntriglycerides (>2.2 mmol/L)  \\nManagement  \\n● Lifestyle modification for 3 -6 months (Table 4. 10) \\n● If the patient is on an ARV known to cause or exacerbate dyslipidemia (primarily LPV/r & EFV) then \\nconsider a single -drug substitution to a more lipid -friendly drug (such as ATV/r or DTG) as the \\ntreatment of choice before adding a lipid -lowering drug. Rule out treatment failure before making \\nsingle -drug substitutions (Figure 6.4)  \\n● If patient does not meet treatment  target with lifestyle modifications, then add drugs  \\no Atorvastatin: starting dose of 10 mg OD (maximum dose 20 mg once daily if patient is on a PI/r; \\nmaximum dose 80 mg once daily if not on a PI/r)  \\no Simvastatin and lovastatin are contraindicated in the presence of PI/r  \\no Allow at least 3 months before repeating fasting lipids and titrating dose  \\nOnce targets achieved can monitor lipids every 6 -12 months  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 83}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 23  Table 4.13: Chronic Kidney Disease Screening, Diagnosis, and Initial Management for PLHIV  \\nScreening  \\n● Urinalysis (for protein) and serum creatinine should be evaluated at baseline for all PLHIV and \\nmonitored annually  \\nDiagnosis  \\n● Impaired renal function is defined as creatinine clearance < 90 ml/min, or dipstick proteinuria ≥ 1 \\n(see Annex 15 for CrCl calculations)  \\n● Abnormal results should be repeated to confirm diagnosis  \\n● Chronic kidney disease is defined as evidence of kidney damage that persists for at least three \\nmonths  \\nManagement  \\n● Management depends on the cause of the renal impairment; additional investigations and/or \\nspecialist consultation may be required  \\n● Consultations with a physician is recommended  \\n● Treat dehydration promptly and aggressively  \\n● If on TDF -containing regimen, substitute with another ARV if C rCl<50 ml/min (see Section 6.5), \\nwith the exception of patients with HBV/HIV co -infection (Table 9.3 for renal dose adjustments of \\nTDF and 3TC for patients with HIV/HBV co -infection)  \\n● Avoid nephrotoxic drugs (e.g., aminoglycosides and NSAIDS)  \\n● Evaluate for a nd treat hypertension  \\n● All NRTIs except ABC require dose adjustments for renal impairment, depending on the severity \\n(Table 6.6 for specific dose adjustments). NNRTIs, PIs, and INSTIs do not require dose adjustments \\nfor impaired renal function  \\nNote: DTG may  cause a small rise in serum creatinine levels but this does NOT represent a \\ndecline in renal function, close monitoring is recommended.  \\nPatients at higher risk for renal disease and for developing TDF -associated renal toxicity include \\nthose with: pre-existing renal disease, hypertension, diabetes mellitus, severe wasting (weight \\nbelow 60 kg in adults), age > 45 years, WHO stage 3 or 4, CD4 < 200 cells/mm3, high HIV viral \\nload, and concomitant nephrotoxic agents.  \\nGlomerular disease directly related to HIV infection, commonly known as HIV -associated \\nnephropathy (HIVAN) is an important cause of chronic kidney disease among PLHIV.  \\nPrevention, early identification, and management of kidney disease is important to reduce \\nthe burden of dialysis and other c omplications.  \\n4.5.2 Cancer Prevention, Early Detection and Management among PLHIV  \\nPLHIV have a substantially higher risk for many cancers, mainly due to a weakened immune \\nsystem which impairs control of oncogenic viral infections. A high prevalence of thes e infections \\nand other modifiable risk factors (such as smoking, alcohol use, unhealthy diet and physical \\ninactivity) contributes to the elevated risk. PLHIV are far more likely than the general population \\nto be diagnosed with Kaposi Sarcoma, non -Hodgkin l ymphoma and other cancers (cervical, anal, \\nliver, lung and oral/throat) hence the importance of prioritizing screening and early diagnosis \\nprograms in this group.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 84}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 24  4.5.2.1 Specific Interventions for Cancer Control in PLHIV  \\nFour interventions are important f or cancer control among PLHIV:  \\n● Achieve viral suppression:  uncontrolled viral replication is a major risk factor for \\ncancer. All PLHIV should initiate ART, and be supported and monitored to achieve long -\\nterm viral suppression in order to reduce risk for can cer, and to improve treatment \\noutcomes for many cancers  \\n● Primary prevention through avoidance of modifiable risk factors  \\no Smoking cessation  \\no Avoidance of harmful use of alcohol  \\no Regular physical activity  \\no Healthy diets  \\no Vaccination: vaccination against Human Papillomavirus for girls 9 -14 years old are \\neligible in Kenya, Hepatitis B Vaccine for newborns and high -risk groups  \\n● Secondary prevention through screening and early diagnosis  \\no Screening: application of simple tests to detect cancer in asymptomatic individuals  \\n▪ Cervical cancer: all women LHIV who have been sexually active up to 49 years \\nold (25 -49 years in the general population), through either visual inspection \\nwith acetic acid (VIA) or PAP smear annually, or HPV testing every 2 years  \\n▪ Breast cancer: mammogram annually from 40 -55 years; mammogram every \\ntwo years from 56 -74 years; screening for younger women can be performed \\non an individual basis based on family history or other risk factors. Clinical \\nbreast exam can be used where mammogr am is not available  \\n▪ Prostate cancer: serum prostate specific antigen (PSA) annually for men 40 \\nyears and above; digital rectal examination can be used if PSA is not available, \\nand for all men with urinary symptoms  \\n▪ Colorectal cancer: fecal occult blood test ing of stool (guaiac or FIT) annually for \\neveryone 45 -75 years old, or colonoscopy every 10 years  \\n▪ Oral cancer: visual examination for everyone above 40 years with history of \\ntobacco use, known HPV infection or immunosuppression  \\no Early diagnosis: prompt diag nosis of cancer in symptomatic individuals  \\n▪ Breast: lump, asymmetry, skin changes, nipple changes, blood -stained \\ndischarge  \\n▪ Cervix: post -coital bleeding, excessive vaginal discharge  \\n▪ Colon and rectum: change in bowel habits, unexplained weight loss, anemia, \\nblood in stool  \\n▪ Oral: white or red lesions, growth, ulceration  \\n▪ Naso -pharynx: nosebleed, permanent blocked nose, deafness, lymph nodes in \\nupper neck  \\n▪ Larynx: persistent hoarseness of voice  \\n▪ Stomach: upper abdominal pain, indigestion, weight loss  \\n▪ Skin: irregular growths, lesions, or non -healing sores  \\n▪ Bladder: painful or frequent urination, blood in urine  \\n▪ Prostate: difficulty (long time) in urination, frequent nocturnal urination  \\n▪ Retinoblastoma: white spot in the pupil, convergent strabismus (in a child)  \\n▪ Testis: swelling of one testicle  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 85}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 25  ● Tertiary prevention : Cancer management, prevention of complications and treatment \\nof side effects and secondary cancers  \\nNote: For screening, diagnosis, and management recommendations refer to national \\nguidelines for prevent ion and management of cancers. For individual patient \\nmanagement, referral to regional and national hospitals with capacity for comprehensive \\noncology services may be warranted.  \\n4.6 Mental Health Screening and Management  \\nPLHIV are susceptible to psychological disturbances due to HIV itself and perceptions regarding \\nHIV in their environment. Some of the most common psychological disturbances include \\ndepression and suicide, anxiety, internalized stigma, post -traumatic stress disorder, cognitive \\ndifficulties such as dementia, and perceived lack of social support. Any of these can significantly \\ninterfere with a patient’s sense of well -being and their adherence. Depression and alcohol/drug \\naddiction are the most significant and are reviewed in this sect ion. For any patient with other \\nsuspected mental health disorders, such as anxiety, psychosis or post -traumatic stress disorder, \\nconsider formal screening and/or referral to a specialist.  \\n4.6.1 Depression  \\nDepression is one of the most common psychiatric il lnesses in the world, and chronic illness \\n(including HIV) is a strong risk factor for depression. PLHIV are 3 -6 times more likely to suffer \\nfrom depression than the general population, with significant disability and poorer treatment \\noutcomes if it is not identified and managed. Depression can be a significant contributing factor \\nto poor adherence and HIV treatment failure.  \\nAll PLHIV should receive basic screening for depression upon enrollment and thereafter \\nannually using the following two questions:  \\n● Duri ng the past two weeks have you often been bothered by feeling down, depressed, or \\nhopeless?  \\n● During the past two weeks have you often been bothered by little interest or pleasure in \\ndoing things?  \\nAll patients who answer “yes” to either or both of the questi ons above, and all patients with a \\ndetectable viral load after 3 or more months on ART (whether or not they had achieved viral \\nsuppression in the past), should undergo a more thorough screening for depression using the \\nPHQ -9 screening tool, with management  guided by the PHQ -9 score (Table 4.1 5). \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 86}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 26  Table 4.1 5: Patient Health Questionnaire -9 (PHQ -9) for Depression Screening  \\nPHQ -9 Depression Screening                               Name:  _________________________    Date: __________________  \\nAsk the patient the questions below for each of the 9 symptoms and circle the response for each question. After asking all \\nquestions, add the points for each column  at the bottom. The total score is the sum of the column totals. Interpretation \\nand management recommendations are provided at the bottom of the table.  \\nQuestion:  “Over the last 2 weeks, how often have you been \\nbothered by any of the following problems?”  Not at all  Several days  More than \\nhalf the days  Nearly every \\nday \\n 1. Little interest or pleasure in doing things  0 1 2 3 \\n2. Feeling down, depressed, or hopeless  0 1 2 3 \\n3. Trouble falling or staying asleep, or sleeping too much  0 1 2 3 \\n4. Feeling tired or having little energy  0 1 2 3 \\n5. Poor appetite or overeating  0 1 2 3 \\n6. Feeling bad about yourself, or that you are a failure, or that \\nyou have let yourself or your family down  0 1 2 3 \\n7. Trouble concentrating on things (linked with patient’s usual \\nactivities, such as reading the newspaper or listening to a radio \\nprogram)  0 1 2 3 \\n8. Moving or speaking so slowly that other people could have \\nnoticed. Or the opposite, being so fidgety or restless that you \\nhave been moving around a lot m ore than usual  0 1 2 3 \\n9. Thoughts that you would be better off dead or of hurting \\nyourself in some way  0 1 2 3 \\nTotal ____ = (add the points from each column)  0 +___  +___  +___  \\n \\nInterpretation of PHQ -9 Score and Recommended Management  \\nTotal Score  Provisional \\nDiagnosis  Recommended Management  \\n0-4 Depression unlikely  Repeat screening in future if new concerns that depression has developed  \\n5-9 Mild depression  ● Provide counselling support and continue to monitor; refer to mental \\nhealth team if available  \\n● If patient is on EFV, substitute with a different ARV after ruling out \\ntreatment failure (Figure 6.4)  \\n10-14 Moderate depression*  ● Provide supportive counselling (refer to a psychologist if available)  \\n● If patient is on EFV, substitute with a different ARV after ruling out \\ntreatment failure (Figure 6.4)  \\nand  \\n● Begin antidepressant medication (or, if unfamiliar with use of \\nantidepressants, then refer to an experienced clinician)  \\nand  \\n● Refer to a medical officer, psychiatrist, or mental health team if available  15-19 Moderate -severe \\ndepression*  \\n20-27 Severe depression*  \\n*Symptoms should be present for at least 2 weeks for a diagnosis of depression and before considering treatment with \\nantidepressant medication. Severe depression may require patients to start on anti -depressants immediately  \\nDepression is a known adverse drug reaction with EFV although it is often mild and temporary. Patients on \\nEFV who develop any persistent symptoms of depression should be switched to another ARV aft er ruling \\nout treatment failure (Figure 6.4).  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 87}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 27  Supportive Counselling for Depression  \\nPatients with mild depression should receive supportive counselling, which includes  \\n● Psycho -education on the following key messages  \\no Depression is common and can happen to anyone  \\no Depressed people often have exaggerated negative opinions about themselves, \\ntheir life and their future  \\no Effective treatment is possible  \\n● Counseling on self -management  \\no Continuing ART as prescribed  \\no Continuing activities that they used to find interesting/pleasurable  \\no Maintaining a regular sleep cycle  \\no Keeping physically active  \\no Participating in community/social events  \\no Returning to clinic if any thoughts of self -harm occur  \\n● Addressing psychosocial stressors  \\no Explore potential stressors in the patient ’s life  \\no Assist in problem -solving to reduce stressors  \\no Assess for and manage intimate partner violence  \\n● Reactivation of or referral to social networks, including peer support groups  \\n● Regular follow -up until symptoms improves and are stable  \\n \\nPharmacological Management of Depression  \\nPatients with moderate depression or worse should be treated with supportive counselling plus \\nan anti -depressant medication.  \\nFluoxetine is an antidepressant and does not have significant drug interactions with ARVs.  \\n● Starting dose for an adult is usually 20 mg once taken daily in the morning (can start with a \\nlower dose for patients who frequently have side -effects from medications). Dose can be \\ntitrated up by 20 mg every 2 -4 weeks as needed, up to a maximum of 80 mg p er day.  \\n● Common side -effects include GI upset, headaches, insomnia, and disturbances of the \\nmenstrual cycle. These usually resolve after 1 -2 weeks of continued use.  \\n● Full effect is not achieved until around 4 weeks of continued use. Once symptoms of \\ndepres sion resolve, antidepressants should be continued for at least another 6 months.  \\n● If/when the patient is ready to discontinue antidepressant therapy it should be discontinued \\nas a weekly taper (e.g., if the maintenance dose is 60mg then taper to 40mg, then 30mg, then \\n20mg, then 10mg and then stop), with close monitoring for recurrence of symptoms.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 88}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 28  4.6.2 Alcohol and Drug Use/Addiction  \\nAlcohol and other drug use are common among the general population and among PLHIV. \\nAlcohol and drug use can be a significant contributing factor to poor adherence and HIV \\ntreatment failure.  \\nAll adults and adolescents should be screened for alcohol and drug use before initiating ART and \\nevery year using the following three questions:  \\n● During the past 12 months, did you  drink any alcohol (more than a few sips)?  \\n● During the past 12 months, did you smoke any marijuana?  \\n● During the past 12 months, did you use anything else to get high?  \\nPatients who answer “yes” to any of the questions above, and all patients with a detectable  viral \\nload after 3 or more months on ART (whether or not they had achieved viral suppression in the \\npast), should undergo a more thorough screening.  \\nFor adolescents, use the CRAFFT screening tool (Table 4.1 6). For adults, use the CAGE -AID \\nscreening tool (Table 4.1 7). Anyone who screens positive on these tools should have further \\nassessment and management by clinical staff, ideally with experience in managing alcohol and \\ndrug use disorders. Table 4.1 8 gives some general guidance on management of addictions . The \\nNational Protocol for Treatment of Substance Use Disorders in Kenya provides more in -depth \\nguidance.   \\nTable 4.1 6: CRAFFT Screening Interview for Adolescents  \\nCRAFFT Screening for Alcohol and Drug Use Disorders for Adolescents  \\nAsk the patient the six questions below. Each question requires a yes/no response. Answering Yes to two \\nor more questions indicates an alcohol or drug use problem and requires further assessment and \\nmanagement.  \\n“I’m going to ask you a few questions that I ask all my patients . Please be honest. I will keep your \\nanswers confidential”  \\nQuestion  No Yes \\n1. Have you ever ridden in a Car driven by someone (including yourself) \\nwho was “high” or had been using alcohol or drugs?    \\n2. Do you ever use alcohol or drugs to Relax, feel better about yourself, or \\nfit in?    \\n3. Do you ever use Alcohol or drugs while you are alone?    \\n4. Do you ever Forget things you did while using alcohol or drugs?    \\n5. Do your Family or Friends ever tell you that you should cut down on \\nyour drinking or drug use?    \\n6. Have you ever gotten into Trouble while you were using alcohol or \\ndrugs?    \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 89}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 29  Table 4.1 7: CAGE -AID Screening Questions for Adults  \\nCAGE -AID Screening for Alcohol and Drug Use Disorders for Adults  \\nAsk the patient the four questions below. Each question requires a yes/no response. Answering Yes to two \\nor more questions indicates an alcohol or drug use problem and requires further assessment and \\nmanagement.  \\n“I’m going to ask you a few questions that I ask all my patients. Please be honest. I will keep your \\nanswers confidential”  \\nQuestion  No Yes \\n1. Have you felt you should Cut down on your drinking or drug use?    \\n2. Have people ever Annoyed you by criticizing your drinking or drug use?    \\n3. Have you ever felt bad or Guilty about your drinking or drug use?    \\n4. Have you ever had a drink or used drugs first thing in the morning to \\nsteady your nerves or to get rid of a hangover ( Eye opener)?    \\nIf referral to the mental health team is not immediately possible for those who screen positive, or as a \\nstarting point in supporting a patient while referral is being made, an assessment of whether the patient \\nwants to quit and targeted messages/support based on their stage of quitting may be benefi cial (Table \\n4.17). The National Protocol for Treatment of Substance Use Disorders in Kenya provides additional \\nresources for assessments and interventions.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 90}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 30  Table 4.1 8: Addiction Support Based on Stages of Change  \\nStage of Change  Counselling Approach  \\nPre-contemplation: not \\ncurrently considering \\nquitting; no immediate \\ndesire to quit  ● Acknowledge that not everyone is ready to think about quitting  \\n● Clarify that it is their decision  \\n● Listen to them describe the benefits they get from their alcohol or drug \\nuse (their motivation for continuing to use)  \\n● Explore why other people might think it is a good idea to quit  \\nContemplation: not sure if \\nhe/she wants to quit, or \\nthinking about quitting but \\nwith no immediate plan to \\nquit  ● Acknowledge that not everyone is ready to quite immediately  \\n● Clarify that it is their decision  \\n● Listen to them describe the benefits they get from the alcohol or drug use \\n(their motivation for continuing to use)  \\n● Listen to them describe the negative effects o f their alcohol or drug use \\n(their motivation for considering quitting)  \\n● Discuss any ideas they have on how they could go about quitting  \\nPreparation: would like to \\nquit within the next month  ● Congratulate them on their decision to quit  \\n● Listen to them describe the benefits they expect to get from quitting  \\n● Discuss any plan they have to try quitting  \\n● Discuss the challenges they may face with quitting  \\n● Problem -solve with them on overcoming challenges, including identifying \\nsupport systems  \\n● Encourage small ste ps towards quitting (e.g., avoiding situations that \\ntrigger use)  \\n● Acknowledge that they have the strength to succeed  \\nAction: actively trying to \\nquit, or has recently quit \\n(within past 6 months)  ● Listen to their experience with quitting  \\n● Congratulate them on the steps they have taken so far  \\n● Problem -solve with them on overcoming challenges, including identifying \\nsupport systems  \\n● Review the long -term benefits of quitting  \\nMaintenance: has quit (more \\nthan 6 months ago) and \\nwants to remain abstinent  ● Congratulate them on their success so far  \\n● Discuss potential for relapse and how to deal with it  \\n● Review the long -term benefits of maintaining abstinence from drug or \\nalcohol use  \\nRelapse  ● Acknowledge that relapse is common  \\n● Evaluate what triggered the relapse  \\n● Reassess motivation to quit and barriers to quitting  \\n● Problem -solve with them on overcoming challenges and what additional \\nsupport systems and strategies can be used  \\nAs indicated in the introduction of this section on mental health (Section 4.6), the following are \\nkey areas of concern in mental ill health and there needs to be a high index of suspicion in order \\nto identify these often -debilitating conditions that negatively affect an individual’s ability to cope \\nwith the tasks  of daily living. The last to items in this section contribute towards building \\nresilience which positively affects an individual’s mental health enabling them to positively \\ninteract with their environments   and live more meaningful lives.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 91}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 31  4.6.3 Anxiety  \\nAnxiety and other anxiety related disorders are mental health conditions that are often \\ncharacterized by experiences of one or several of the following:  \\n− Feelings of nervousness  \\n− Fear, or worry that interfere with the ability to sleep or otherwise function  \\n− A lack of appetite  \\n− Tremulousness and or frank trembling  \\n− Sweating and clamminess  of hands  \\n− Other symptoms may include a racing heart (rapid heartbeat ), difficulty breathing,  \\nheadaches, difficulty falling asleep, and difficulty concentrating.  \\nConcerns around anxiety, especially within the context of living with HIV or caring for persons \\nliving with HIV may reveal themselves during the history taking. These manifestations need to be \\ntaken seriously and addressed with sincerity and compassion.  \\nMany of these may require basic reassurance and support or even just a listening ear during the \\nevaluation session. These will go a long way in alleviating many patient’s anxieties and conc erns. \\nA quick screening tool can be used to assess whether the anxiety demonstrated or identified may \\nrequire further attention.  \\nThe Generalized Anxiety Disorder Assessment (GAD -7) is a seven -item instrument that is used to \\nmeasure or assess the severity of generalized anxiety disorder (GAD). Each item asks the \\nindividual to rate the severity of his or her symptoms over the past two weeks.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 92}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 32  \\nOver the last 2 weeks,  how \\noften have you been bothered \\nby the following problemsNot at all Several daysMore than half \\nthe daysNearly every \\nday\\n1. Feeling nervous, anxious or \\non edge\\n2. Not being able to stop or \\ncontrol worrying\\n3. Worrying too much about \\ndifferent things\\n4. Trouble Relaxing\\n5. Being so restless that it is \\nhard to sit still\\n6. Becoming easily annoyed or \\nirritable\\n7. Feeling afraid as if \\nsomething awful might \\nhappen\\n0 +1 +2 +3\\n0 +1 +2 +3\\n0 +1 +2 +3\\n0 +1 +2 +3\\n0 +1 +2 +3\\n0 +1 +2 +3\\n0 +1 +2 +3 \\nFigure 4.2: Generalized Anxiety Disorder Assessment (GAD -7) \\nThe following cut -offs correla te with level of anxiety severity:  \\n• Score 0 -4: Minimal Anxiety  \\n• Score 5 -9: Mild Anxiety  \\n• Score 10 -14: Moderate Anxiety  \\n• Score greater than 15: Severe Anxiety  \\nTreatment options can then be explored including referral to psychologists, psychiatrists for \\npossible  psychotherapy and medication if required  \\n4.6.4 Stress and stress management  \\nThis is a feeling of emotional or physical tension. The symptoms include ache and pains, \\npalpitations, exhaustion, insomnia, headache,  dizziness or shaking, digestive problems, we ak \\nimmune system, muscles tension or jaw tension.  \\nMany patients may experience these symptoms individually or in clusters and they interfere with \\nthe lives they are living. Sources of stress may be from difficulties in understanding issues around \\nHIV, from  addressing different concerns within themselves, from their significant others, from ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 93}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 33  their workplaces. These issues could be social, financial or environmental concerns and may be \\nsevere enough to negatively impact their lives. The stress may be so severe  as to be observed by \\nanyone interacting with the individual and may manifest in their behaviour and the symptoms \\nthey complain about. It is important for the health care worker to be calm, and assured as they \\naddress the patient’s concerns around stress. Further, a  screening tool can be used to assess the \\nneed for referral to more specialized mental health workers to provide much needed support.  \\n4.6.5 experiences of Trauma  \\nTrauma results from exposure to an incident or series of events that are emotionally disturbing \\nor life -threatening with lasting adverse effects on the individual’s functioning and mental, \\nphysical, social, emotional, and/or spiritual well -being. Past traumatic experiences in PLHIV must \\nbe addressed for their wellbeing.  \\nAssessi ng for Trauma - Primary Care PTSD Screen for DSM -5 (PC -PTSD -5) \\nThe Primary Care PTSD Screen for DSM -5 (PC -PTSD -5) is a screening tool designed to identify \\npersons with probable PTSD. Results of the screening should be considered \"positive\" if the \\nrespondent  answers \"yes\" to any 3 items in the questions listed below. Those screening positive \\nshould have further assessment with a structured interview for PTSD, preferably performed by a \\nmental health professional who has experience in diagnosing PTSD.  \\n“Sometim es things happen to people that are unusually or especially frightening, horrible, or \\ntraumatic. ” For example:  \\n1. A serious accident or fire  \\n2. A physical or sexual assault or abuse  \\n3. An earthquake or flood  \\n4. A war  \\n5. Seeing someone be killed or seriously injured  \\n7. Having a loved one die through homicide or suicide  \\n“If you have ever experienced this type of event, please answer the following in the past month, \\nhave you ” \\n• Had nightmares about the event(s) or thought about the event(s) when you did not want \\nto? \\n• Tried hard not to think about the event(s) or went out of your way to avoid situations that \\nreminded you of the event(s)?  \\n• Been constantly on guard, watchful, or easily startled?  \\n• Felt numb or detached from people, activities, or your surroundings?  \\n• Felt guil ty or unable to stop blaming yourself or others for the events(s) or any problems \\nthe event(s) may have caused?  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 94}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 34  4.6.6 Psychosis  \\nPsychosis is a mental disorder characterized by a disconnection from reality.  \\nPsychosis may occur as a result of a psychiatri c illness such as schizophrenia. In other instances, \\nit may be caused by a health condition, medication or drug use.  \\nSigns and Symptoms of psychosis  \\n• Marked behavioural changes  \\n• Neglecting usual responsibilities related to work, school, domestic or social activities  \\n• Agitated, aggressive behaviour, decreased or increased activity  \\n• Fixed false beliefs not shared by others in the person’s culture  \\n• Hearing voices or seeing things that are not there  \\n• Lack of realization that one is having mental health problems  \\nTreatment may include medication and talk therapy.  \\n4.6.7 Self -Care  \\nOverall, in the context of mental health, taking up self -care strategies will help individuals live \\nboth more responsibly, and more satisfactorily as this helps boost both physical and mental \\nhealth.  \\nSelf-care strategies include the following;  \\n− Getting regular exercise  \\n− Eating healthy, regular meals and staying well hydrated  \\n− Making sleep a priority. Many people struggle with this but just getting regular sleep with \\na constant waking and sleeping time contribute tremendously to good self-care  as well as \\ngood, well rested physical and mental health  \\n− Taking up a relaxing activity  \\n− Setting goals and priorities.  \\nThis allows for being realistic in one’s expectation in life and formulat ing realistic strategies to \\nachieve one’s goals  \\nPracticing gratitude  \\nReminding oneself that things that one is grateful for. The more specific one is, the easier it is to \\neven be grateful for them. Listing them down is a good way of getting such clarity  \\nFocusing on positivity  \\nThe calls for appreciating the good and positive things that have happened, are going on and are \\nplanned for in one’s life. The things to look forward to. This strategy also calls for the identification \\nand challenging of negative and unhelpful thoughts. Good friends and counsellors, as well as other \\nhealth workers with mental health skills can assist in this.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 95}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 35  Staying connected  \\nThis is extremely important. Increasingly in the present world disconnection is leading to more \\nand more phy sical and mental ill health. Staying connected with family and friends as well as \\nspiritual support systems enable  one to better manage their lives as they work towards being as \\nmentally healthy as possible.  \\n4.6.8 Wellbeing  \\nAccording to the WHO, mental hea lth is a state of well -being in which an individual realizes his or \\nher own abilities, can cope with the normal stresses of life, can work productively and is able to \\nmake a contribution to his or her community.  \\nSupport structures for wellbeing:  \\nThe suppor t structures for wellbeing are available at different levels of implementation which are:  \\n• Individual counselling  \\n• Group therapy  \\n• Networks of organizations providing support to different categories of populations in \\ndifferent age sets such as adolescents, me n, women etc.  \\nHealth workers in facilities should take the initiative to set up/ maintain these structures and \\nestablish referral systems for clients in need of these services. Referral for PLHIV should include \\nservices that address issues that potentially could affect the mental health of PLHIV such as social \\nand financial issues.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 96}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 36  4.7 Nutritional Services  \\nGood nutrition is a critical component of management of HIV because it contributes to: reducing \\nrisk and frequency of other infections; delaying progression from HIV infection to AIDS; a healthy \\nappearance and weight; gaining strength, maintaining and building muscle, and having energy to \\nremain active, and reducing side effects of ART.  \\n4.7.1 Nutritional Assessment, Counselling  and Support (NACS)  \\nAll PLHIV should receive nutritional assessment, counselling, and support  \\nAll PLHIV should receive nutritional assessment, counselling, and support tailored to the \\nindividual needs of the patients, including:  \\n● Nutrition assessment and diagnosis (timed with routine clinic visits, preferably monthly for \\nthe first year of life, and then quarterly up to 14 years old, and then every 3 -6 months)  \\no Anthropometric (Tables 4.1 9, 4.20 and 4.2 1 provide interpretation and required acti ons \\nfor anthropometric results for children and adults)  \\no Biochemical (investigations as listed in Table 3.2 for baseline and Table 3.5 for follow -up \\ninvestigations)  \\no Clinical (physical examination as described in Table 3.1 for initial evaluation)  \\no Dietary (24 -hour recall for food type/frequency and household food security)  \\no Environmental and psychosocial  \\no Functional (ability to care for self, bedridden, etc.)  \\n● Counselling and education  \\no Benefits of maintaining good nutritional status for a person living with HIV \\no Mother infant and young child nutrition (MIYCN) including exclusive breastfeeding  \\no Reassuring the client that it is possible to  \\no Attain/maintain good nutritional status  \\no Look well and live a healthy life  \\no Identifying locally available foods they can access given their own context, food safety \\nand food preparation  \\no Helping the client to plan meals and snacks with a variety of foods in order to meet their \\nenergy and nutrient needs and treatment plans  \\no Identifying any constraints, the client may face and f ind ways to minimize them  \\no Helping the client to understand the potential side effects and food interactions of the \\nmedicines they are taking, and help the client identify ways to manage these side effects  \\no Exploring with the client the cause(s) of poor appetite and appropriate responses (type \\nof food, disease, pain, depression, anxiety, or side effects of medications)  \\no Counsel on critical nutrition practices  \\nMessages: Critical Nutrition Practices (CNPs)  \\n1. Have periodic nutritional status assessments  \\n2. Increase energy intake through a balanced diet  \\n3. Maintain high levels of sanitation and food hygiene  \\n4. Practice positive living behaviors  \\n5. Carry out physical activity or exercises  \\n6. Drink plenty of clean, safe water  \\n7. Seek prompt treat ment for all opportunistic infections and manage diet -related symptoms  \\n8. Manage drug -food interactions and side effects  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 97}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 37  Support  \\no Therapeutic and supplementary foods to treat clinical malnutrition (food by prescription, \\ntherapeutic feeds, fortified blended flour): Figures 4. 3 and 4. 4 provide malnutrition \\nmanagement recommendations for adults and children; Table 4. 10 provides specific \\nnutritional recommendations for patients with non -communicable diseases  \\no Exclusive breastfeeding for the first 6 months of life; complementary foods for children \\naged 6 - 24 months with continued breastfeeding to prevent malnutrition (Table 7.7 \\nprovides complementary feeding recommendations)  \\no Micronutrient supplements to prevent vitamin and mineral deficiencie s \\no Food security and linkage to HIV sensitive social protection such as household food \\nsupport, home -based care, agricultural extension services, and economic strengthening \\nand livelihood support  \\nSome aspects of nutrition support (such as prescription of th erapeutic and supplementary foods) \\nshould be provided by a trained healthcare professional, however all aspects should be promoted \\nand supported at the community level.  \\nTable 4.1 9: Interpretation of MUAC Results for Children and Pregnant/Lactating Women  \\nMUAC Level by Age (cm)  Classification  Action to Take  \\n6-59 \\nmonths  5-9 yrs.  10-17 yrs.  \\n< 11.5  < 13.5  < 14.5 cm  Severe acute \\nmalnutrition  Irrespective of clinical signs, admission \\n(referral) for stabilization/therapeutic \\nrehabilitation  \\n11.5–12.5  13.5 -14.5  14.5 -18.5  Moderate acute \\nmalnutrition  Admission for supplementary feeding is \\nrecommended  \\n12.6–13.5    Mild acute \\nmalnutrition  Nutritional education and counselling  \\n> 13.5    Normal  Education and counselling of caregivers  \\nPregnant and Breastfeeding Women  \\n≤ 23  Malnourished  Provide nutritional support (Figure 4.3)  \\n> 23  Normal  Education and counselling  \\nTable 4. 20: Interpretation of Z -scores for Children  \\nRatio  Indicator   Z-score  Severity  \\nWeight/Age  Underweight  < - 3 Severe  \\nHeight/Age  Stunting  - 3 to - 2 Moderate  \\nWeight/Height  Wasting*  > - 2 to - 1 Mild  \\n> - 1 Normal  \\n*Children with weight/height z -score of -2 or less should be supported with therapeutic/supplementary \\nfoods    ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 98}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 38   \\nScreening\\nMeasure  anthropometry and check bilateral\\nPitting oedema\\nMedical History and Physical examination:\\n-  Evaluate nutritional status and health condition\\n-  Check for medical complications\\n-  Perform appetite test\\nIf SAM without  medical \\ncomplication and passed appetite \\ntestIf SAM with  medical complication \\nand/or failed  appetite test\\nMedical complication developed, decreased \\nappetite, weight loss or stagnant weight, \\noedema increase or no decreaseAdmission to \\nOutpatient careAdmission to \\nInpatient care\\nReferral for continuing treatment in out patient \\ncare:\\nAppetite returning (passed appetite test)\\nOedema decreasing,\\nMedical complication resolvingTreatment Treatment\\nSAM Treatment completed (based on discharge criteria):\\nDischarge to home or refer for supplementary feeding and other services\\n that address underlying causes of malnutritionTREATMENTADMISSION\\n \\nFigure 4. 3: Management of Severe Acute Malnutrition in Children  \\n Other medical complications that necessitate hospitalization  \\nIn addition to severe bilateral pitting oedema (+++), marasmic \\nkwashiorkor and poor appetite, the following complications \\nnecessitate inpatient care:  \\n✔ Intractable vomiting  \\n✔ Convulsions  \\n✔ Lethargy  \\n✔ Unconsciousness  \\n✔ Lower respiratory tract infection  \\n✔ High fever  \\n✔ Severe dehydration  \\n✔ Severe anaemia  \\n✔ Hypoglycaemia  \\n✔ Hypothermia  \\n✔ Eye signs of vitamin A deficiency  \\n✔ Skin lesions  \\nThe following complications require referral of patient for further \\nmedical evaluation:  \\n✔ No appetite (failed appetite test)  \\n✔ IMCI danger signs  \\n✔ Increase in or newly developed bilateral pitting oedema  \\n✔ Weight loss because of diarrhoea (r e-feeding or of other \\norigin)  \\n✔ Weight loss for three consecutive weeks  \\n✔ Static weight (no weight gain) for five consecutive weeks  \\n✔ Other signs of failure to respond to treatment  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 99}),\n",
       " Document(page_content=' Standard Package of Care for PLHIV  \\n 4 - 39 \\nA. Weight loss score\\n<5% – Low Risk\\n5-10% – Moderate Risk\\n>10% – High RiskUnplanned % weight loss in the last 1 -3mnthsB. Opportunistic Infections score\\nNo opportunistic infection\\nSub acute OI – Moderate Risk\\nAcute OI – High RiskOpportunistic infections statusC. Food intake score\\nAdequate Intake\\nLow intake – Moderate Intake\\nNausea/Vomiting Non/Fasted \\nfor >5 days – High RiskFood Intake/barriersD. Food Security score\\nLittle or No H/H Hunger = 0 -1\\nModerate H/H Hunger= 2 -3 (High Risk)\\nSevere H/H Hunger= 4 -6 (High Risk)Household hunger score a\\nPregnant & Postpartum women\\nMUAC (cm)<19\\n(SAM)\\n19.0 - 20.9\\n(MAM)\\n21.0 - 23.1\\n(HIGH \\nRISK)\\n>23.1\\n(NORMAL)Nutritional anemia (Hb < 11g/dl) – \\ndeficiency  of iron, folate, Vit. B12;\\nBitot spots due to Vitamin A \\ndeficiency; Pellagra due to vitamin \\nB1 deficiencyMicronutrient deficiency/diseases Other Adults\\nBMI (Kg/m2) b< 16\\n(SAM)\\n16 – 18.5\\n(MAM)\\n18.6 - 21.9\\n(HIGH \\nRISK)\\n22 – 24. \\n(NORMAL)\\nSEVERE MALNUTRITION (SAM)\\nSAM with medical complications \\nand cannot eat ( Clinical status or \\nfailed appetite test)\\nActions  c\\ni. Initiate Phase I therapeutic \\nfeeding until stable (Inpatient – \\nrescue phase feeding)Clinically stable, able to eat and \\ngood appetite\\nActions  c\\n i.  Initiate Phase II therapeutic \\nfeeding for nutritional \\nreconstitution\\nii.  Nutrition counselling & \\neducation\\niii.  Review (in or out patients) \\nweekly\\niv.  Transition to supplemental \\nfeeding upon recovery from \\nSAMActions  c\\ni. Nutrition counselling & \\neducation\\nii. Initiate supplemental \\nfeeding\\niii.  Multiple micronutrient \\nsupplementation\\niv.  Review monthly\\nv.  Post -discharge review every \\n2-3monthsMODERATE MALNUTRITION \\n(MAM)\\nActions  c\\ni.  Nutrition \\ncounselling & \\neducation\\nii.  Repeat nutrition \\nscreening every 2 -3 \\nmonthsNORMAL/LOW RISK\\nActions  c\\ni.   Nutrition counselling & \\neducation\\nii.   Multiple micronutrient \\nsupplementation\\niii.   Review nutrition status \\nand risk factors every \\n2-4 weeks until stable\\niv.  Repeat nutrition \\nscreening every 2 -3 \\nmonths once stable\\n v.  For pregnant or \\npostpartum mothers \\nenroll on FBPNORMAL/HIGH RISK\\nRefer food insecure \\nclients for livelihood\\na Refer to household food security assessment tool\\nb For overweight and obese, refer for counselling\\nc Implement local clinical policy and protocol\\nNUTRITIONAL \\nINTERVENTIONSNUTRITIONAL \\nDAIGNOSISNUTRITIONAL \\nASSESSMENT\\nRefer non responders for \\nfurther clinical assessment \\nand management \\nFigure 4. 4: Management of Malnutrition in Adults with HIV', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 100}),\n",
       " Document(page_content='  \\nGuidelines on Use of Antiretroviral Drugs for Tre ating and Preventing HIV Infection in Kenya  \\n \\n4 - 40 Table 4.2 1: Interpretation of BMI Results for Adults  \\nBMI Level  Classification  Action to Take  \\n< 16 Severe \\nmalnutrition  • Refer for facility -based therapeutic intervention; rehabilitation with \\ntherapeutic foods; counselling on intake issues and possible metabolic issues  \\n• Screen for TB  \\n16.0 –18.4 Mild/moderate \\nmalnutrition  ● Nutritional counselling and supplementary feeding  \\n● Screen for TB  \\n18.5 –25.0 Normal/ \\nrecommended  Nutritional counselling, consistent exercise to build muscles  \\n25.1 –30 Overweight  Nutritional counselling to reduce energy intake; aerobic physical activity to \\nreduce weight  \\n>30 Obese  Counselling to change lifestyle and reduce energy intake; aerobic physical activity \\nto reduce weight  \\n4.8 Prevention of Other Infections  \\n4.8.1 Immunizations  \\nAll children, regardless of HIV status, should be immunized following the full KEPI schedule, \\nwith a few exceptions for infants with severe immunosup pression (Table 4.2 2). For infants \\nliving with HIV and HEIs, an earlier dose of measles vaccines should be given at 6 months of age.  \\nTable 4.2 2: Kenya Expanded Program on Immunizations 2016 Schedule  \\nAge  Vaccines  \\nBirth  OPV1, BCG2 \\n6 weeks  OPV3, Pentavalent (DPT -HepB -HiB), Pneumococcal (PCV10), Rotavirus  \\n10 weeks  OPV3, Pentavalent (DPT -HepB -HiB), Pneumococcal (PCV10), Rotavirus  \\n14 weeks  IPV, Pentavalent (DPT -HepB -HiB), Pneumococcal (PCV10)  \\n6 months  Measles/Rubella (MR) - for HIV exposed and infected infants; Vitamin A  \\n9 months  Measles/Rubella (MR); Vitamin A; Yellow Fever4 \\n18 months  Measles/Rubella (MR); Vitamin A  \\n10 years (girls only)  HPV (2 doses at 6 months apart in the general population; 3 doses for \\nPLHIV, at month 0, 1 -2, and 6)  \\n11-12 years  Tdap (tetanus, diphtheria and pertussis)  \\n1Give OPV to all infants at birth or within the first two weeks of life. If missed in the neonatal period and the child \\nhas symptoms of advanced HIV disease (WHO Stage 3 or 4) or severe immunosuppressio n (CD4% < 25%) then \\ndefer BCG until virally suppressed on ART and with immune system recovery  \\n2Give BCG to all infants at birth or within the first two weeks of life. If missed in the neonatal period and the child \\nhas symptoms of advanced HIV disease (WHO Stage 3 or 4) or severe immunosuppression (CD4% < 25%) then \\ndefer BCG until virally suppressed on ART and with immune system recovery . Do not give BCG vaccine to babies \\nborn to smear positive mothers. Investigate to rule out TB, give TPT then vaccination d one two weeks after \\ncompletion of TPT  \\n3If HIV+ with symptoms of advanced HIV disease (WHO Stage 3 or 4) or severe immunosuppression (CD4% < 25%) \\nthen use IPV instead of OPV  \\n4Yellow fever vaccine is only routinely used in certain counties as specified by National Vaccines and Immunization \\nProgram; defer yellow fever vaccine if symptoms of advanced HIV disease (WHO Stage 3 or 4) or severe \\nimmunosuppression (CD4% < 25%), until virally suppressed on ART and with immune system recovery  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 101}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 41 PLHIV may have an inadequate response to immunizations, particularly before they achieve full \\nviral suppression. The ideal timing, dose, and frequency of re -immunizations for children on ART \\nare not well known. Providers will receive specific guidance or r evaccination from the National \\nVaccines and Immunization Program and NASCOP.  \\nRecommended vaccinations for adolescents and adults living with HIV are listed in Table 4.2 3. \\nTable 4.2 3: Vaccinations in Adolescents and Adults Living with HIV  \\nInfection  Vaccine  Live  \\n(Y/N)  Course  Comments  \\nCOVID -19 Various  N Variable  Follow national guidelines on dosing for the \\nspecific vaccine available  \\nHepatitis B  Subunit  N 4 doses (at  \\n0, 1, 2 and 6 \\nmonths)  Use double dose if non -adjuvanted; use standard \\ndose if adjuvanted  \\nPneumococcus  Conjugate  N 1 dose (PCV  \\n13)  \\nPreferable to polysaccharide  \\nPolysaccharide  N 1 dose  Use if >65 years and with co -morbidity other \\nthan HIV  \\nHuman \\nPapillomavirus \\n(HPV)  Virus -like \\nparticles   \\nN 3 doses (at \\nmonths 0, 1 -\\n2, and 6)  All girls at 9 -14 years old  \\nInfluenza  Inactivated  N 1 dose  Annually  \\nHepatitis A  Inactivated  N 2 - 3 doses  3 doses if CD4 count < 350 cells/mm3 at 0, 1 and \\n6 months. If CD4 count > 350 cells/mm3, give 2 \\ndoses at 0 and 6 months. For those at continued \\nrisk, one booster dose every 10 years  \\nAdditional Vaccines for Special Circumstances  \\nYellow fever  Live attenuated  Y 1 dose  Use only in patients <60 yrs of age and  CD4 > \\n200 cells/mm3 \\nTyphoid  Polysaccharide  N 1 dose  Give the ViCPS parenteral. Repeat every 3 years  \\nCholera  Subunit  N 2 doses  As indicated (usually in epidemics). 2 oral doses \\nof the non -replicating vaccine given 1 -6 weeks \\napart with a single booster dose at 2 years from \\nprimary vaccination  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 102}),\n",
       " Document(page_content='  \\nGuidelines on Use of Antiretroviral Drugs for Tre ating and Preventing HIV Infection in Kenya  \\n \\n4 - 42 4.8.2 Malaria  \\nChildren and adults living with HIV suffer heavier parasitaemia and more malaria morbidity with \\nadvanced HIV disease. Further, people with advanced immunosuppression are at risk of failure \\nof anti -malarial treatment. In pregnancy, there is increased risk of placental malaria,  severe \\nanaemia, premature delivery and perinatal mortality. Drug interactions between ARVs and \\nantimalarial drugs may further complicate management.  \\nRecommendations for malaria prevention for PLHIV include:  \\n● Offer cotrimoxazole preventive therapy (CPT) for  protection against malaria infection \\n(Table 4. 3: Co-trimoxazole Preventive therapy)  \\n● In areas of stable malaria transmission, PLHIV should have access to insecticide treated \\nmosquito nets (ITNs) or indoor residual spraying to reduce exposure to mosquito bi tes \\nand therefore malaria transmission  \\n● PLHIV travelling from non -malarious zones to malaria endemic areas should sleep under \\nITNs  \\n● Pregnant women with HIV living in areas of stable malaria transmission who are not able \\nto take CPT should be given at least t hree doses of sulfadoxine -pyrimethamine (SP) \\nintermittent preventive treatment for malaria as part of routine antenatal care  \\nNote:  SP should not be given to women who are taking CPT  \\n● PLHIV on CPT who develop fever should not be treated for an unconfirmed presumptive \\ndiagnosis of malaria. Laboratory confirmation of malaria should be obtained prior to \\ninitiation of anti -malarial therapy  \\n● PLHIV with malaria should receive standard antimalarial therapy according to national \\nguidelines.  Those on CPT should not be given sulfa -containing anti -malarial drugs. \\nPatients on ART receiving anti -malarial therapy should be monitored closely for adverse \\ndrug reactions  \\n4.8.3 Safe Water, Sanitation and Hygiene  \\nDiarrheal illnesses are common causes of morbidity and  mortality among PLHIV. These diseases \\nare often due to lack of access to safe drinking water, improper disposal of human and animal \\nwaste, and poor personal hygiene, leading to contamination of food and water.  \\nRecommendations for prevention of faecal -oral ly spread illnesses include:  \\n● Offer CPT for protection against some GI infections (Table 4.3: Co -trimoxazole \\nPreventive therapy)  \\n● Hand washing with soap and water after handling human or animal faeces, after using \\nthe toilet, and before food preparation or eating  \\n● Facilities for proper disposal of human waste.  \\n● Training on household -based water treatment methods and water storage containers \\nthat prevent direct hand contact with drinking water  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 103}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 1  \\n5. Adherence Preparation, Monitoring and \\nSupport  \\n \\nThe individual and population benefits of ART are dependent on high levels of adherence to the \\nprescribed medication, the accompanying medical advice and the follow -up plans. Adherence -\\nenhancing strategies should be implemented beginning at the point of HIV di agnosis (as part of \\npost -test counselling and linkage), continued during initial evaluation, and thereafter during the \\nentire follow -up period for ART.  \\n \\nTo avoid treatment failure and the need to switch patients to 2nd or 3rd line ART, it is key to have \\nan adherence support strategy in place before ART initiation, anticipating common and individual \\nbarriers to good adherence. Prevention of treatment failure starts at the time of HIV diagnosis. \\nThis is particularly important with the current recommendation t hat all PLHIV qualify for ART, \\nand ART should be initiated within 2 weeks of diagnosis. Adherence preparation must begin at \\ntime of HIV testing, and close follow -up is required after ART initiation.  \\n \\nThe adherence preparation, monitoring, and support that a patient requires should be tailored to \\ntheir level of adherence, the stage of ART initiation, and the follow -up stage that they are at (Figure \\n5.1).  \\n \\nWhenever possible, follow -up should be provided by the same care provider or team of care \\nproviders (e.g ., same clinician and same counsellor) at each visit. This is particularly important \\nduring the first few months of HIV care.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 104}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 2 \\nHTS post -test counselling: key treatment preparation messages for all patients who test positive\\n• Treatment is available and recommended for everyone with HIV\\n• Starting treatment early reduces your chance of becoming ill or infecting your sexual partner(s)\\n• With good adherence you can live a long and productive life\\nEnrolment Visit\\n• HIV education and adherence preparation for all patients/caregivers (Table 5.1)\\n• ART Readiness Assessment for all patients/caregivers (Table 5.4), along with \\nindividualized adherence support plan\\nReady to start ART Not ready to start ART\\n• Initiate ART\\n• Baseline investigations if not already completed\\n• Provide standard package of care and differentiated \\ncare based on initial presentation (advanced disease vs \\nwell)\\n• Book follow -up appointment for week 2 and 4 to \\nreview adherence and side -effects\\n• Continue adherence support plan• Weekly appointments  to review clinical \\nstatus, barriers to ART initiation, and provide \\nongoing HIV education and counselling\\n• Provide standard package of care\\n• Re-assessment of ART readiness at every \\nvisit, until ready (target is within 2 weeks)\\nFollow -up with adherence monitoring at every \\nvisit (Table 5.10) and counselling based on \\nlevel of adherence (Table 5.14) until first VL at \\n3 months\\nVL undetectable ( LDL <200copies/ml )\\n• Ongoing adherence assessment and \\ncounselling (Table 5.16)\\n• Continue routine VL monitoring as per \\nthe population groupVL       copies/ml\\n• Suspect poor adherence\\n• Assess for barriers to adherence (Table 5.15)\\n• Follow VL algorithm with enhanced \\nadherence assessment and interventions and \\nassessment for other causes of viremia \\n(Figure 6.6) \\nFigure 5.1: Adherence Preparation, Monitoring and Support until Viral Load after 3 Months on \\nART  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 105}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 3 Adherence is most difficult during the first few months of treatment: the patient is not yet in the \\nhabit of taking their medications every day, they are not familiar with common side -effects, and \\nthey have more challenges with disclosure and stigma,  all of which can interfere with adherence. \\nPoor adherence within the first few months of therapy is also the most risky period for \\ndevelopment of resistance mutations, when the viral load is still high.  \\n \\nFor these reasons, adherence preparation, monitorin g and support must be emphasized \\nduring the first few months of ART until the patient achieves full virological suppression,  \\nafter which adherence monitoring and support can continue at lower intensity.  \\n \\nPatient preparation and counselling should be a coll aborative process between the provider and \\nthe patient or caregiver, to enable the patient to initiate and continue lifelong treatment. This is \\nbest done when the same adherence counsellor follows an individual patient throughout the \\npreparation, initiatio n, and early ART period.  \\n \\nART can be initiated concurrently with the first adherence counselling session, even during \\nthe enrolment visit, especially for infants and for pregnant women. This may also apply to \\npatients with a good understanding of HIV and A RT and strong motivation for immediate \\nART initiation.  \\n \\nEach member of the multidisciplinary team should have the requisite training to provide \\ntreatment education and offer appropriate support to address potential barriers to adherence. \\nTreatment preparat ion and support can be offered at triage, consultation, pharmacy or any other \\nclinic station where confidentiality and privacy are assured and providers are adequately trained. \\nIt should also be incorporated into health talks, peer support group activities , and group \\ncounselling sessions.  \\n \\nBefore commencement of a counseling session, the counselor should ensure that adequate space is available \\nto conduct the counseling, that confidentiality can be maintained, and that tools such as psychosocial \\nassessment f orms, treatment literacy flip charts, PHDP flip charts, and tools to document the counseling \\nsessions are available.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 106}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 4 Persons living positively (adolescent and adult peer educators who can share personal \\nexperiences when needed) should be engaged to support patient education as indicated in the \\noperational guidance below.  \\nOperational Guidance: Meaningful Involvement of People Living with HIV  \\nFor best patient outcomes, PLHIV themselves should be engaged to lead facility -based and \\ncommunity -based HIV ed ucation and support systems. They are often referred to as “peer \\neducators”, “mentor mothers”, and “lay health workers” in these roles. PLHIV have successfully and \\nsignificantly contributed to: improving identification of people at risk for HIV or infected  with HIV; \\nincreasing linkage from testing to treatment; reducing onward transmission of HIV; providing \\npsychosocial support, and improving adherence and retention to care and ART.  \\n \\nIdentifying PLHIV to offer peer -led patient support:  \\n● PLHIV on ART for ≥ 1  year  \\n● Good adherence and undetectable VL  \\n● Positive attitude and interest in supporting peers  \\n \\nPreparing and supporting PLHIV to play a role in patient support systems:  \\n● Must be trained for the role they are expected to provide  \\n● Must have job aids and IEC material appropriate for their role  \\n● Must be supervised by healthcare professionals  \\n \\nPotential roles for PLHIV include  \\n● Supporting HIV self -testing  \\n● Providing HIV testing services  \\n● Acting as peer linkage supporters  \\n● Leading or contributing to facility -based or community -based support groups  \\n● Providing individual or group HIV education  \\n● Providing individual or group adherence counselling  \\n● Distribution of ART refills for stable patients  \\n \\nCompensation for PLHIV who contribute to patient support systems  \\n● Recognition (e.g., ID badges; certificates of service; acknowledgement at community forums)  \\n● Training opportunities with certification  \\n● Financial compensation (e.g., salaries; stipends; transportation allowances)  \\n● Priority consideration for em ployment opportunities  \\n \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 107}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 5 5.1 Undetectable = Untransmittable (U=U)  \\nART adherence resulting to durable viral suppression eliminates risk of sexual transmission of \\nHIV and is key to HIV epidemic control. Adoption of the Undetectable equals Untransmittable \\n(U=U) campaign is posed to revolutionize HIV treatment among PLHIV and fortify treatment -for-\\nprevention strategies. Multiple studies have showed that durable viral suppression of <50 \\ncopies/ml eliminates risk of sexual transmission of HIV. (Table 5. 17 Viral load cut -offs)  \\nThe framework of U=U offers a unique opportunity to dismantle HIV stigma and discrimination, \\nemphasizes the critical importance of antiretroviral therapy (ART), daily adherence, and \\ncontinuous engagement in medical care for  PLHIV.  \\nDefinitions:  \\n● Durably Undetectable: 2 consecutive viral load results of <50 copies/ml  \\n● Untransmittable: The finding established by various clinical trials and observational \\nstudies, that people who maintain an undetectable viral load have minimal HIV virus in their \\nblood and other body fluids secretions that they have “effectively no risk” of passing HIV to \\nothers through sex.  \\n5.1.1 Benefits of U=U  \\n● Diminish stigma associated with having HIV  \\n● Reduce barriers to HIV testing and treatment  \\n● Incre ase interest in starting and staying on ART  \\n● Improve self -esteem by removing the fear of being contagious  \\n● Support healthy sexuality regardless of HIV status  \\n● Reduce sex partners’ concerns  \\n5.1.2 Considerations for implementation of U=U within clinical setting s \\n● Viral load monitoring as per the recommended intervals for various populations  \\n● Continuous adherence monitoring and support at all clinical visits  \\n● STI screening at all visits  \\n● Messaging on U=U should be provided for all PLHIV as part of treatment literacy  \\n5.1.3 Messaging to Patients on U=U  \\n● Keeping your HIV undetectable helps you live a long and healthy life  \\n● To get your HIV to an undetectable level and to keep it undetectable, take antiretroviral \\nmedicines as prescribed  \\n● It may take up to 6 months o f taking HIV treatment medicines to bring your HIV viral load \\ndown to an undetectable level  \\n● If you are durably suppressed and you are taking your medications as prescribed, you can \\nbe sure you will not pass HIV through sex  \\n● People who keep their HIV at an undetectable level will not pass HIV to others through sex  \\n● If you stop taking HIV medicines, your HIV can rebound to a detectable level within 1 to 2 \\nweeks, and you may pass HIV to your sex partners  \\n● Keeping your HIV at durably suppressed level helps you sa fely conceive a child with your \\npartner  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 108}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 6 5.1.4 How patients can discuss U=U with others  \\n● Counsel patients to share information about the research on U=U as follows:  \\no In recent research studies that involved thousands of couples, no one who was on \\nHIV treatment and whose HIV was durably undetectable passed HIV to their HIV -\\nnegative sex partner  \\n● Advise patients that they can share the following personal information with current or \\npotential sex partners:  \\no When they last had a viral load test and if their viral load was undetectable  \\n● Individuals should tell their partner(s) that their HIV is undetectable only if they have \\ntaken HIV medicines consistently since their last test with an undetectable viral load  \\n5.1.5 Counselling patients about other preven tion combination interventions  \\n● PrEP:  PrEP is a safe and effective daily pill that prevents HIV infection. The partner without \\nHIV may decide to take PrEP if they:  \\no Are unsure that their partner’s HIV viral load is undetectable, especially if their \\npartner has only recently started ART  \\no Have mo re than 1 sexual partner  \\no Feel more secure with the added perception of protection provided by PrEP  \\n● PEP:  After a possible HIV exposure (e.g., Occupational exposure or if a sex partner with HIV \\nhas not consistently taken ART and is not virally suppressed), t he immediate initiation of \\nemergency PEP can prevent HIV infection  \\n● Condom use:  Condoms protect against other STIs, such as gonorrhea, chlamydia, and \\nsyphilis, and help prevent pregnancy.  \\nCounsel patients to find a prevention strategy that works for them:  \\n● If an individual who does not have HIV is unsure if their partner has an undetectable level of \\nvirus or is anxious about acquiring HIV, care providers should encourage that person to \\nchoose a prevention strategy that works for them, whether that is use of P rEP, emergency \\nPEP, condoms, or a combination of these strategies  \\nNote: Care providers should emphasize that no one should ever be compelled to have \\nsex without condoms  \\n5.1.6 Application of U=U in other settings  \\n● Breastfeeding:  Studies demonstrate that ART greatly reduces the risk of transmission \\nthrough breast milk. However, research has not established that people whose HIV is \\nundetectable do not transmit virus during breastfeeding. Prophylaxis should be provided \\nto HIV expose d infants during the breastfeeding period as per the guidelines regardless \\nof the viral load status  \\n● Injection drug use:  Studies demonstrate that ART greatly reduces the risk of \\ntransmission through sharing of injection drug use. However, research has not \\nestablished that people whose HIV is undetectable do not transmit virus through needle \\nsharing. All people who inject drugs should only use their own needles and not share \\nneedles or other paraphernalia with others  \\n● Needle stick injuries:  Research has not es tablished that people with undetectable viral \\nload do not transmit HIV to people who are stuck by needles containing their blood. HIV \\nPEP should be provided as per the guidelines  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 109}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 7 5.2 ART Adherence Preparation and Support  \\nPreparation for ART begins at the t ime of HIV diagnosis and continues until initiation of ART.  \\n5.2.1 Treatment Preparation as Part of HIV Testing Services  \\nWith the current treatment guidelines recommendation that all PLHIV qualify for ART, post -test \\ncounselling by the HTS provider should no w include three key messages that begin the ART \\ntreatment preparation process for all PLHIV  \\n● Treatment (called antiretroviral therapy (ART)) is available and is recommended for \\neveryone with HIV  \\n● Starting treatment as soon as possible (preferably within two weeks of testing positive \\nfor HIV) reduces the chance of your illness getting worse or of passing HIV to others  \\n● If you take your ART properly and do not miss pills you can expect to live a long and \\nproductive life  \\n \\n5.2.2 ART Treatment Preparatio n \\nART treatment preparation involves HIV education and counselling, including identifying likely \\nbarriers to adherence, a discussion of strategies and support systems to overcome possible \\nbarriers to adherence, and an individualized adherence plan, as summ arized in Table 5.1. The \\neducation and counseling sessions should be documented in patient charts.  \\nTable 5.1: Treatment Preparation and Adherence Counselling Guide  \\nHIV Education  \\n• Ask the patient what they know about HIV  \\n• Ask the patient what they know about treatment for HIV  \\n• Correct/clarify as needed, ensuring you cover:  \\no Modes of transmission and importance of testing partners/children  \\no HIV effect on the immune system and health  \\no HIV viral load and its relationship to health and to HIV transmission  \\no Goals of ART  \\no Relationship between adherence and viral suppression, treatment failure, and drug \\nresistance  \\no Consequences of drug resistance  \\n• Ensure the patient understands by asking them to explain it back to you  \\nBarriers to Adherence  \\n• Ask the patient what they think will be most difficult about taking ART every day  \\n• As the patient what they think will be most difficult about attending all clinic appointments  \\n• Discuss common reasons patients have trouble with excellent adherence and identify which may \\nbe most relevant for them, including:  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 110}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 8 Table 5.1 Cont.  \\n● Patient Factors  \\no Stigma and non -disclosure (having to hide \\ntheir ARV pill -taking)  \\no Lack of support systems  \\no Alcohol or drug use  \\no Depression or other psychiatric illness  \\no Loss or grief  \\no Cognitive disorders  \\no Change in daily routine  \\no Chaotic lifestyle; no consistent daily \\nroutine  \\no Forgetting to take pills  \\no Feeling better so does not think the ART is \\nneeded any more  \\no Feeling too sick to take ART  \\no Age (adolescents - impulsive, more \\nsusceptible to social pressure; children – \\ncaregiver dependent)  ● Provider/System Factors  \\no Side effects (many patients have side \\neffects when they first start their ART, \\nincluding nausea, headaches, and \\ndifficulty sleeping.  These side effects \\nalmost always resolve with continued \\nuse)  \\no Pill burden  \\no Poor patient -provider relationship  \\no Inadequate HIV education  \\no Cost of care (direct and indirect)  \\no ARV supply -chain limitations (stock -outs, \\nor low stock levels resulting in small refill \\nquantities)  \\nIndividualized Adherence Plan  \\n● Ask the patient what they can do to ensure excellent adherence  \\n● Ensure the adherence plan incorporates details of the patient’s specific ART regimen:  \\no Number of pills, frequency, food requirements/restrictions  \\no Common side effects  \\no Important drug interactions  \\n● Work with the patient to make an individualized adherence plan, which may include:  \\no Disclosing their HIV status to a close friend or family member who can help support their \\ntreatment; bringing their treatment buddy to clinic with them or to a session with a \\ncounsellor to learn more about HIV  \\no Disclosing their HIV status to household members so they do not have to hide pill -taking  \\no Combining pill taking with a consistent activity in their daily routine  \\no Keeping the ARVs in a place that they are lik ely to see every day  \\no Setting a daily alarm on their phone/watch/clock  \\no Connecting with a support group for additional counseling/education/support  \\no Getting treatment for alcohol or drug use  \\no Getting treatment for depression or other psychiatric illness  \\n● Discuss what to do if:  \\no Develops side effects  \\n▪ Discuss common and serious adverse events for their specific regimen  \\n▪ Encourage patient to return to clinic for any side effects rather than stopping ART  \\no Forgets to take a dose: take it late rather than skipping the dose completely  \\no Travels without their ART: go to the nearest health facility or call clinic for guidance  \\n● Ask the patient to summarize their individualized adherence plan  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 111}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 9 Table 5.1 Cont.  \\nOngoing Support at Subsequent Visits  \\n● Review the patient’s HIV knowledge  \\n● Review the patient’s motivation to take ART  \\n● Elicit any concerns the patient may have about their ART, side effects, visit schedule, or health  \\n● Review the ART dosing schedule and ask about any missed pills  \\n● Explore barriers to adherence that were previously identified or new ones that have developed  \\n● Explore any recent or expected changes in their life or daily routine  \\n● Discuss their individualized adherence plan and if any changes are required  \\n \\nHIV Education and Counselling  \\nHIV education should be a standard component of the enrolment visit. Prior to ART initiation, all \\npatients/caregivers must be provided with enough information to make an informed choice about \\nART initiation and adherence (Table 5.2), including for patients who initiate ART during the \\nenrolment visit. A detailed content guide for HIV education and adherence counselling is provided \\nin Annex 8. This information can be provided through group or individual counselling. The ART \\nReadiness Assessment an d the management plan should be completed for each patient \\nindividually (Table 5.4).  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 112}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 10 Table 5.2: Components of HIV Education (see Annex 8 for detailed content guide)  \\nComponent  Questions to be Covered  \\n \\nHIV ● What is HIV  \\n● How is HIV transmitted  \\n● Why should partners and family members be tested for HIV  \\n \\nViral load  ● What is viral load  \\n● How often is viral load measured  \\n● What do viral load measurements mean, including the goal of achieving viral suppression  \\n \\n \\nCD4 cells  ● What are CD4 cells  \\n● How are CD4 cells affected by HIV  \\n● What happens when CD4 cells decrease  \\n● How often is CD4 cell count measured  \\n \\n \\n \\nAntiretroviral \\ntherapy (ART)  ● What is ART  \\n● What are the benefits of ART  \\n● When is ART started  \\n● Does ART cure HIV  \\n● Can you still give HIV to others while taking ART  \\n● How long is ART taken  \\n \\n \\nTreatment failure  ● What happens if you stop taking ART  \\n● What happens if you do not take ART regularly  \\n● What happens if the viral load increases  \\n● What happens in treatment failure  \\n \\nART side effects  ● What are the side -effects of ART  \\n● What should you do if you notice any side effects  \\n \\n \\n \\nAdherence  ● What is adherence  \\n● How should ART be taken  \\n● What usually interferes with good adherence  \\n● What might make it difficult for you to take your ART as prescribed  \\n● What can help you take ART as prescribed  \\n● What happens if you miss an appointment  \\nOther medications  ●  What other medications will you take, in addition to ART (e.g., CPT, TPT)  \\n \\nNutrition  ● Why is nutrition important  \\n● What can you do to improve your nutrition  \\n \\nFollow -up ● How often will you need to come for clinic visits?  \\n● What will we be checking for during your clinic visits  \\nAdherence Support  \\nPsychosocial support for PLHIV and their families is essential for their well -being and good health \\noutcomes. HIV affects virtually every aspect of one’s life, as well as the lives of those close to them. \\nPLHIV need psychological and social support to deal with various issues that are common to \\nchronic illness as well as those that are unique to HIV. These include sti gma, bereavement, self -\\nimage, loss of earning capacity, life skills, and chronic illness, among others. Providing \\npsychosocial support entails identifying any needs that they may have and addressing them. In \\nsome cases, some of these needs can be anticipat ed and addressed even before they come to play \\nin the individual’s life.  \\nThe individualized patient management plan should include establishing appropriate adherence \\nsupport interventions (Table 5.3).  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 113}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 11 Table 5.3: Adherence Support and Retention Intervention s \\nStandard Adherence Support Interventions  \\nStructural \\ninterventions  ● Conduct a baseline psychosocial assessment to explore the various aspects of \\nthe client’s life that may influence their adherence to treatment and \\nprevention, and their general well -being. This teases out issues that need to \\nbe explored in detail during the counselling session e.g., disclosure, family \\nplanning, living circumstances etc.  \\n● Use a multidisciplinary team approach to develop and implement treatment \\nplans for each patien t \\n● Engage peer educators to lead HIV education and support services  \\n● Adequately prepare and assess the patient’s readiness to initiate and continue \\nwith ART  \\n● Implement a system for identifying and taking action when patients miss an \\nappointment  \\n● Formalize a sy stem for providing health talks and treatment literacy classes \\nfor patients  \\n● Formalize a system for linking patients to community -based resources, \\nincluding: community support groups, religious groups, CBOs, groups \\nsupporting income -generating activities, o rganizations providing food \\nsupport, NEPHAK, child welfare societies, community health volunteers/units, \\nschools, children’s homes etc.  \\n \\nHIV \\neducation \\nand \\ncounselling  ● Remind the patient about HIV disease, how ART works, the importance of \\nhigh -level adherence and the consequences of non -adherence  \\no Risk of ill health caused by HIV  \\no Role of ART in restoring and maintaining good health  \\no Link between adherence and viral load, CD4 and health  \\no Side effects of medications and how to avoid, recognize and manage them. \\nManage side effects aggressively  \\no Address misconceptions and beliefs about HIV and ART  \\n● Discuss and agree on a treatment plan with the patient. Gain commitment \\nfrom the patient to follow through  \\n● Discuss use of alcohol and drugs and  how to prevent these from affecting the \\ntreatment plan  \\n● It is important to maintain a non -judgmental attitude, establish trust with \\nparents/caregivers, and involve the child as they mature  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 114}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 12 Table 5.3 Cont.  \\nDisclosure and \\nstigma  ● Respect patient privacy and confidentiality  \\n● Discuss with the patient the role of disclosure to close family \\nmembers/trusted friend in promoting adherence  \\n● Offer to facilitate disclosure  \\n● For children/adolescents, discuss age -appropriate disclosure with the \\ncaregiver and off er to support the process (Annex 5)  \\n● Conduct stigma assessment and support appropriately  \\n \\nTreatment \\nsupporter  ● Encourage the patient to identify a treatment supporter/buddy who will \\nprovide the patient with encouragement and social support and even remind \\nthe patient to take medication  \\n● Invite the treatment supporter to at least one of the adherence counselling \\nsessions  \\n● Obtain consent from the patient to contact the treatment supporter if needed  \\nSupport group  ● Link the patient to psychosocial support groups and other community -based \\nsupport mechanisms (preferably through direct introduction)  \\no Support groups give confidence and encouragement and promote positive \\nattitude towards HIV status and may promote disclosure  \\no Support groups offer opportunities for additional counselling and \\nexperience sharing and are an avenue for developing/strengthening life \\nskills  \\no Some support groups engage in economic empowerment activities  \\no Support groups can be used for ART distribution to improve  convenience \\nto the patient  \\n● Develop population -specific support groups when possible (e.g., youth \\ngroups with peer educators for adolescents; children’s clubs; caregiver \\nsupport groups)  \\n● MDT members should be patrons to the support groups, to guide activiti es in \\nline with intended objectives  \\n \\nSMS reminder \\nsystem  ● Enroll patients into an automated SMS reminder system with their consent  \\n● Review the type of messages the patient may receive, the frequency of \\nmessages, and any actions the patient should take when receiving the \\nmessage  \\n● Ensure the system and messages maintain patient privacy and confidentiality  \\nOther reminder \\nstrategies  ● Encourage patient/caregiver to set a specific time of day to take ART, and to \\nassociate ART time with a specific event/s in their daily schedule  \\n● Encourage patient/caregiver to set an alarm on their phone  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 115}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 13 5.2.3 Age -Specific Treatment Preparation and Support  \\nTreatment preparation must be customized to the patient’s age, gender, needs and clinical status: \\nfor patients who present with advanced/symptomatic disease, the focus is on getting better; for \\npatients who present clinically well, the focus is on staying healthy. Specific needs for children, \\nadolescents, caregivers, pregnant and breastfeeding women and men should also be taken into \\nconsideration.  \\nThe HIV education and counselling sessions should be provided at every visit until the patient is \\nready and wi lling to start ART, as determined using the ART Readiness Assessment Form (Table \\n5.4). Each repeat session should begin with a review of what the patient remembers from the \\nprevious session as well as any key issues the counsellor documented in the patient ’s chart, so the \\nsession can be customized to meet their needs. ART preparation should not take more than 1 -2 \\nweeks except for special circumstances such as with uncontrolled mental health issues or \\nuntreated drug addictions. However, once the patient has initiated ART, continued HIV education, \\ncounselling and adherence support must be provided. The counselling sessions should preferably \\nbe conducted by the same counsellor, peer educator, social worker, nurse, community health \\nvolunteer, and/or clinician wh o is professionally certified to counsel based on a certified \\ncurriculum, and they possess the requisite competencies to provide quality counselling. In order \\nto prepare children and adolescents for ART, the counsellor should be trained in providing \\npsycho social support to this age group.  \\nTable 5.4: ART Readiness Assessment Form  \\nCriteria  Y N* \\nA. Psychosocial/Knowledge Criteria (applies to patients and caregivers)  \\n1. Understands the nature of HIV infection and benefits of ART?    \\n2. Has screened negative for alcohol or other drug use disorder, or is stable on \\ntreatment (see Section 4.6)    \\n3. Has screened negative for depression or other psychiatric illness, or is stable on \\ntreatment (see Section 4.6)    \\n4. Is willing to disclose/has disclosed HIV status, ideally to a family member or close \\nfriend?    \\n5. Has received demonstration of how to take/administer ART and other prescribed \\nmedication?    \\n6. Has received information on predictable side effects of ART and understands what \\nsteps to take in case of these side effects?    \\n7. For patients dependent on a caregiver: is the caregiver committed to long -term \\nsupport of the patient, daily administration of ART, and meets the criteria above?    \\n8. Other likely barriers to adherence have been identified and there is a plan in place \\nto address them (e.g., frequent travel for work, plan to deal with unexpected travel, \\ndistance from clinic, etc.)?    \\n9. Has the Patient/caregiver provided accurate locator information and contact details?    \\n10. Patient/caregiver feels ready to start ART today?    \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 116}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 14 Table 5.4 Cont.  \\nB. Support Systems Criteria (applies to patients and caregivers)  \\n1. Has identified convenient time/s of day for taking ART, and/or associated \\ndose/s with daily event/s?    \\n2. Treatment supporter has been identified and engaged in HIV education, or will \\nattend next counselling session?    \\n3. Is aware of support group meeting time/s?    \\n4. If facility has SMS reminder system: Has enrolled into SMS reminder system?    \\n5. Other support systems are in place or planned (e.g., setting phone alarm, pill box)?    \\nC. Medical Criteria (applies to patients)  \\n1. Newly diagnosed with TB: defer ART until patient tolerates anti -TB medication; \\ninitiate ART as soon as possible preferably within 2 weeks; for TB meningitis \\ndelay ART for 4 to 8 weeks); monitor closely for IRIS    \\n2. Newly diagnosed cryptococcal meningitis (CM), or symptoms consistent with CM \\n(progressive headache, fever, malaise, neck pain, confusion): defer ART until \\ncompleted 5 weeks of CM treatment, or until ruling out CM as the cause of \\nsymptoms; monitor closely f or IRIS    \\n*If the response to any of the psychosocial criteria or support systems criteria is “No”: develop a \\nstrategy to address the issue as quickly as possible and consider assigning a case manager. ART \\nmay be initiated with adequate adherence support while the criteria is being addressed, on a \\ncase -by-case basis  \\n \\nAt each visit up until ART initiation, every patient should be assessed for readiness to \\nstart ART (Table 5.4), with the patient/caregiver allowed to make the final decision on \\nwhether and when to start ART.  \\nSpecial Considerations when Counselling Children and Adolescents  \\nChildren and adolescents depend on caregivers to support their adherence so there are special \\nconsiderations for adherence preparation and support. All topics covered in the HIV Education \\nand Adherence Counselling sessions (Table 5.2 and Annex 8) should be covered with the \\ncaregiver, with involvement of the child/adolescent as appropriate based on the stage of \\ndisclosure and their developmental stage (Tab le 5.5).  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 117}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 15 Table 5.5: Age -appropriate Involvement of Child/Adolescent in HIV Education and \\nAdherence Counselling  \\nAge  Counselling Approach  \\n< 6 years old  The counselling sessions will focus on engaging all of the child’s \\ncaregivers  \\n6-12 years old  Both the caregiver and the child will be involved. The counselling will \\nfocus on the caregiver; younger children can be given a paper and pen \\nand asked to draw their family, school, etc., and talk about their \\nexperiences. Disclosure of HIV status to the child s hould commence by 5 \\nyears of age and be completed by 10 -12 years of age (Annex 5)  \\n> 12 years old with \\ncaregiver present  Most of the counselling can focus on the adolescent, who is often fully \\nresponsible for medication administration. However, it is neces sary to \\nkeep the caregiver coming and involved in supporting the adolescent. A \\nrecommended approach is to start with the caregiver alone, then see the \\ncaregiver and adolescent together, and then see the adolescent alone. \\nUse the HEADSSS tool* to facilitate  discussion  \\n> 12 years old \\nwithout the \\ncaregiver present  Use the HEADSSS tool* to facilitate discussion. Negotiate involvement \\nof a treatment supporter  \\n* HEADSSS assesses: Home; Education/Employment; Activities; Drugs; Sexuality; \\nSuicide/depression/self -image; Safety  \\n \\nIn addition to the standard HIV Education and Adherence Counselling topics, unique issues need \\nto be addressed for caregivers, children and adolescents (Table 5.6).  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 118}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 16 Table 5.6: Unique Considerations for Caregivers, Children and Adolescents  \\nCaregiver Barriers to Adherence  \\n• Frequently changing or multiple simultaneous caregivers  \\n• Loss or grief  \\n• Absent or sick caregiver  \\n• Poor understanding of HIV management due to inadequate counselling, elderly, or illiterate \\ncaregiver  \\n• Depression, alcohol and other drug use  \\n• Living far from the health facility  \\n• Economically unstable  \\n• Lack of affection between caregiver and child  \\n• Lack of support systems for the caregiver  \\nChild/Adolescent Barriers to Adherence  \\n• Level of disclosure (is the child/adolescent aware of their HIV status?)  \\n• Lack of understanding of disease/treatment  \\n• Developmental stage and emotional state  \\n• Child refusal to swallow medicine (do not allow refusal to take medicines: all activities should \\nbe stopped for the child until the dose is swallowed)  \\n• Stigmatization and discrimination  \\n• Low self -esteem  \\n• Depression  \\n• Defiance related to a troublesome caregiver -child relationship  \\n• Inadequate structures at school (day or boarding) to support adherence  \\n• Lack of support systems for the child/adolescent  \\nTreatment Barriers to Adherence  \\n• Large volumes of syrups  \\n• Bad taste of syrups  \\n• Pill burden  \\n• Confusing regimens combining syrups and tablets  \\n• Side effects  \\n• Dose adjustment requirements as the child grows  \\nFor all children/adolescents, the level of disclosure should be assessed at first visit and the \\nmanagement plan should include a plan for age -appropriate disclosure (Annex 5). Treatment \\npreparation and support se ssions should be customized to the patient’s age (Tables 5.7 -5.9).  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 119}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 17 Table 5.7: Treatment Preparation and Support for Children (≤   years) and Caregivers  \\nVisit  Standard of Care  \\nAt \\nenrolment \\ninto care  \\n Use the 5As (Assess, Assist, Advice, Agree, Arrange)  \\n• Perform a psychosocial assessment at enrolment to evaluate for possible \\npsychological, emotional and social adherence boosters and barriers  \\n• Assess growth and developmental milestones (Annex 3) to rule out growth \\nretardation, developmental challenges such as autism, deafness and any other \\nphysical challenge. Any child with developmental challenges should be referred for \\nappropriate care  \\n• Identify the primary caregiver as soon as possible after diagnosis of HIV in a child. In \\nthe absence of a caregiver, link the child to a community health volunteer or a peer \\neducator while a more permanent solution is sought, and link with Department of \\nChildren and Social Protection  \\n• The child and their caregiver, if also infected, should be enrolled in the sa me clinic, \\nand have appointments booked on the same clinic day for family -centered care  \\n• Provide HIV education and counselling to caregiver (and child as appropriate for age, \\nTable 5.5) as outlined in Table 5.2  \\n• Identify and establish appropriate adherence s upport interventions (Table 5.3), \\nincluding linkage to pediatric and caregiver support groups  \\n• Discuss benefits of disclosure of HIV status of the child and formulate a disclosure \\nplan for children aged 5 years and above (Annex 5)  \\n• Conduct readiness assessme nt to initiate ART (Table 5.4); ART should be initiated \\nsame day or the date of initiation agreed upon  \\n• Review ART dosing and timing (including having the caregiver demonstrate how they \\nmeasure and administer the ART)  \\n• Conclude the session by agreeing on a t reatment and follow -up plan  \\n• Where ART is initiated book the child to return within two weeks. Those unwilling to \\ninitiate should return weekly for further counselling on barriers to initiation  \\n• Identify referral needs and link as appropriate  \\n• Document sessi on in the patient’s chart  \\nTwo weeks \\nafter ART \\nInitiation  \\n • Review and reinforce the messages delivered at enrolment; confirm the caregiver’s \\nunderstanding of key messages  \\n• Review ART dosing, timing and reminders (including having the caregiver \\ndemonstrate how they measure and administer the ART)  \\n• Explore any barriers to adherence  \\n• Revisit benefits of disclosure and the individualized age -appropriate disclosure plan  \\n• Identify referral needs and link as appropriate  \\n• Document the session in the patien t’s chart  \\nFour weeks \\nafter ART \\nInitiation, \\nand further \\nfollow -up \\nvisits  \\n • Review and reinforce the messages delivered in previous sessions; confirm the \\ncaregiver’s understanding of key messages  \\n• Review ART dosing, timing and reminders (including having the caregiver \\ndemonstrate how they measure and administer the ART)  \\n• Explore any barriers to adherence  \\n• Revisit benefits of disclosure and the individualized age -appropriate disclosure plan  \\n• Identify referral needs and link as appropriate  \\n• Document the session in the patient’s chart  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 120}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 18 Table 5.8: Treatment Preparation and Support for Adolescents (10 -19 years)  \\nVisit  Standard of care  \\nAt \\nenrolment \\ninto care  Use the 5As (Assess, Assist, Advice, Agree, Arrange)  \\n• Perform a psychosocial assessment at enrolment to evaluate for possible psychological, \\nemotional and social adherence boosters and barriers  \\n• Assess growth and developmental milestones to rule out growth retardation, \\ndevelopmental challenges such as autism, deafness and any other physical challenge. \\nAny adolescent with developmental challenges should be referred for appropriate care  \\n• Identify the primary caregiver as soon as possible after diagnosis of HIV in an \\nadolescent. Adolescents older than 15 years and emancipated minors may not have or \\nmay not want the presence of a caregiver. In this case, the clinical team should explore \\nalternative options to support the adolescent until they are ready to disclose to their \\ncaregivers/guardian or identify someone to disclose to. The alterna tive options include \\nadolescent mentors, peer educators, social worker, nurses or community health \\nvolunteers as may be appropriate.  An adolescent can have both private and joint \\nsessions with the caregiver when deemed appropriate  \\n• The health provider shou ld explore Sexual and Reproductive Health (SRH) \\nunderstanding, fears and needs of the adolescent and prioritize interventions as \\nappropriate. SRH counseling should be introduced in a one -to-one session with the \\nadolescent. The care giver can be excused fro m the sexual and reproductive health \\nsession to enable adolescent to open up during the session  \\n• The adolescent and their caregiver, if also infected, should be enrolled in the same \\nclinic, and have appointments booked on the same clinic day for family -cent ered care  \\n• Provide HIV education and counselling to caregiver (and adolescent as appropriate for \\nage, Table 5.5) as outlined in Table 5.2  \\n• Identify and establish appropriate adherence support interventions (Table 5.3), \\nincluding linkage to adolescent and car egiver support groups  \\n• Discuss with the caregiver the benefits of disclosure of HIV status to the adolescent (if \\nnot aware of status) and formulate a disclosure plan for adolescents (see Annex 5 for \\nage-appropriate disclosure)  \\n• Conduct readiness assessment to initiate ART (Table 5.4); ART should be initiated \\nsame day or the date of initiation agreed upon  \\n• Review ART dosing and timing (including having the adolescent and/or caregiver \\ndemonstrate how they measure and administer the ART)  \\n• Conclude the session by agreeing on a treatment and follow -up plan  \\n• Where ART is initiated, book the adolescent to return within two weeks. Those \\nunwilling to initiate should return weekly for further counselling on barriers to \\ninitiation  \\n• Identify referral needs and li nk as appropriate  \\n• Document session in the patient’s chart  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 121}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 19 Table 5.8 Cont.  \\nTwo \\nweeks \\nafter ART \\ninitiation  • Review and reinforce the messages delivered at enrolment; confirm the adolescent’s \\nand/or caregiver’s understanding of key messages  \\n• Review ART dosing, timing and reminders (including having the adolescent and/or \\ncaregiver demonstrate how they measure and administer the ART)  \\n• Explore any barriers to adherence, including issues related to the school environment  \\n• Review support systems (including adol escent support group)  \\n• Revisit benefits of disclosure and the individualized age -appropriate disclosure plan  \\n• Review SRH needs  \\n• Identify referral needs and link as appropriate  \\n• Document the session in the patient’s chart  \\nFour \\nweeks \\nafter ART \\ninitiation, \\nand \\nfurther \\nfollow -up \\nvisits  \\n • Review and reinforce the messages delivered in previous sessions; confirm the \\nadolescent’s and/or caregiver’s understanding of key messages  \\n• Review ART dosing, timing and reminders (including having the adolescent a nd/or \\ncaregiver demonstrate how they measure and administer the ART)  \\n• Explore any barriers to adherence, including issues related to the school environment  \\n• Review support systems (including adolescent support group)  \\n• Revisit benefits of disclosure and the in dividualized age -appropriate disclosure plan  \\n• Review SRH needs  \\n• Link to psychosocial support group  \\n• Identify referral needs and link as appropriate  \\n• Document the session in the patient’s chart  \\nTable 5.9: Treatment Preparation and Support for Adults  \\nVisit  Standard of care  \\nAt \\nenrolment \\ninto HIV \\ncare  \\n Use the 5As (Assess, Assist, Advice, Agree, Arrange)  \\n● Perform a psychosocial assessment to evaluate adherence boosters and barriers e.g., \\nmental, emotional and social status assessments; refer for appropriate care if mental \\ndisorder diagnosed  \\n● Identify a treatment buddy (family member, friend, peer educator, community health \\nvolunteer, etc.) and involve them in HIV education and adherence counselling  \\n● Provide HIV education and counselling to patient  \\n● Identify and establish appropriate adherence support interventions (Table 5.3), \\nincluding linkage to a support g roup  \\n● Discuss benefits of disclosure of HIV status to a trusted family member/friend; how to \\ndisclose; and establish a disclosure plan  \\n● Discuss importance of child and sexual partner testing as well as assisted partner \\nnotification services (aPNS)  \\n● Discus pr evention methods such as condoms, PrEP, PEP, STI screening and treatment  \\n● Conduct an assessment of readiness to initiate ART (Table 5.4); ART should be initiated \\nsame day or the date of initiation agreed upon  \\n● Review ART dosing and timing  \\n● Conclude the sessi on by agreeing on a treatment and follow -up plan  \\n● Where ART is initiated, book the patient to return within two weeks. Those unwilling \\nto initiate should return weekly for further counselling on barriers to initiation  \\n● Document session in the patient’s cha rt ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 122}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 20 Table 5.9 Cont.  \\nTwo weeks \\nafter ART \\ninitiation  ● Review and reinforce the messages delivered at enrolment; confirm the patient’s \\nunderstanding of key messages  \\n● Review ART dosing, timing and reminders  \\n● Explore any barriers to adherence  \\n● Review support systems  \\n● Revisit benefits of disclosure, the disclosure plan and progress in aPNS  \\n● Document the session in the patient’s chart  \\nFour weeks \\nafter ART \\ninitiation, \\nand further \\nfollow -up \\nvisits  ● Review and reinforce the messages delivered in previous sessions; confirm the \\npatient’s understanding of key messages  \\n● Review ART dosing, timing and reminders  \\n● Explore any barriers to adherence  \\n● Review support systems  \\n● Revisit benefits of disclosure the disclosure plan,  and progress in aPNS  \\n● Document the session in the patient’s chart  \\n \\n5.3 Adherence Monitoring, Counselling and Support During the First 3 Months \\nof ART  \\n5.3.1 Adherence Monitoring  \\nOnce ART has been initiated, adherence should be assessed non-judgmentally by a trained \\nprovider during each visit (Table 5.10).  The objectives of this assessment are to evaluate and \\nreinforce the patient’s adherence to ART, to elicit any barriers to the same, and to develop a plan \\nwith the patient/caregiver to address any of the barriers identified. These may include incorrect \\nknowledge of HIV infection and ART, unsupportive psychosocial factors, difficult home or school \\nenvironment, substance use and poor motivation for taking medication. Patients/caregivers ne ed \\nto be counselled on the importance of being honest about their adherence in order for the \\nhealthcare team to serve them better.  \\nAdherence monitoring requires a combination of interventions. At every clinical visit, the MMAS -\\n4 should be administered as w ell as pill counts. MMAS -8 should be administered any time a \\nhealthcare worker suspects adherence problem (e.g., patients with suspected or confirmed \\ntreatment failure; patient who misses an appointment).  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 123}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 21 Table 5.10: Adherence Monitoring Strategies  \\nAdher ence \\nMonitoring \\nStrategy  Technique  Frequency  \\nSubjective (self -reported adherence)  \\nMorisky \\nMedication \\nAdherence Scale -4 Use Table 5.11 to assess adherence using a \\nstandardized questionnaire, and take action \\nas required  Every patient, every visit  \\nMorisky \\nMedication \\nAdherence Scale -8 Use Table 5.12 to assess adherence using a \\nstandardized questionnaire, and take action \\nas required  Any time a healthcare worker \\nsuspects adherence problems \\n(e.g., patients with suspected or \\nconfirmed treatment failure; \\npatient who misses an \\nappointment)  \\nAdherence \\nMonitoring \\nStrategy  Technique  Frequency  \\nObjective  \\n \\n \\n \\nPill counts  Ask the patient to bring all their pills with \\nthem to follow -up visits. Calculate how many \\npills should be remaining based on the \\nprevious prescription date and amount \\nprescribed, and compare to how many pills \\nare actually remaining. Excess pills are \\nassumed to be missed doses. Use Table 5.13 to \\ncalculate adherence rate and take action as \\nrequired  ● At every visit until confirmed \\nviral suppression  \\n● Any time a healthcare worker \\nsuspects adherence problems  \\n \\nPharmacy refill \\nrecords  Compare drug pick -up date with expected \\ndate of pick -up (based on number of pills \\ndispensed at last visit). If drug pick -up date is \\nlater than expected, it is assumed the patient \\nis missing doses equivalent to the number of \\ndays late  ● At every drug pick -up \\n● Any time a healthcare worker \\nsuspects adherence problems  \\nViral load  Follow the viral load monitoring algorithm \\n(Figure 6.6). Undetectable VL is the best \\nconfirmation of adequate adherence  ● Age 0 -24 years: at 3 months after \\nART initiation and then every 6 \\nmonths  \\n● Age ≥ 25 years: at month 3 after \\nART initiation and month 12 \\nthen annually  \\n● For pregnant and breastfeeding \\nwomen: at fir st ANC visit if \\nalready on ART, or 3 months \\nafter ART initiation if starting \\nART during pregnancy, and then \\nevery 6 months  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 124}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 22 Table 5:10 Cont.  \\n \\n \\nHome visit  Observe where and how a patient stores and takes \\ntheir medications and assess if they have extra \\nmedications because of missed doses. Home visits \\nmay also provide a better understanding of a \\npatient’s living situation and specific barriers to \\nadherence. Unscheduled home visits may be more \\nrevealing, but should only be conducted if the  patient \\nconsente d to home visits previously (preferably at \\nthe time of enrolment or initiation)  For patients with suspected or \\nconfirmed treatment failure, \\npatients who default from care, \\nor any time the MDT feels a \\nhome visit will contribute to \\npatient management  \\n \\nAccurately assessing adherence requires clinicians to develop a collaborative and non -\\njudgmental relationship with patients.  This is best done when one provider follows an \\nindividual patient longitudinally. The key to asking patients about their adherence is not in the \\nspecifics of the tool used but in taking the time to ask about adherence regularly and doing so in \\nan open and truly inquisitive manner. Otherwise, many patients will simply state what they \\nbelieve the clinician wants to hear: perfe ct adherence.  \\nEvery provider in each ART service delivery point should receive training and gain confidence in \\nassessing adherence and providing adherence support and counselling to the majority of patients \\nwho do not have significant barriers to adherence . However, patients with significant adherence \\nchallenges and multiple barriers to adherence should be referred to providers with additional \\ntraining and time to offer dedicated and enhanced adherence support and counselling. Involving \\nexperienced colleagu es at the same health facility should be done as soon as a concern is \\nidentified, and the patient should be discussed by the MDT to generate as many solutions as \\npossible. Consultation with Mental Health Teams or regional or national mentors may be require d \\nfor complex situations.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 125}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 23 Table 5.11: Morisky Medication Adherence Scale (MMAS -4) \\nMMAS -4: Ask the patient each question below. Circle the corresponding score for each response. \\nAfter completion of all questions, add up all the points that you have circle d for the total score.  \\nQuestion  Yes No \\n1. Do you ever forget to take your medicine?  1 0 \\n2. Are you careless at times about taking your medicine?  1 0 \\n3. Sometimes if you feel worse when you take the medicine, do you stop taking it?  1 0 \\n4. When you feel better do you sometimes stop taking your medicine?  1  0 \\nTotal Score (sum of all items)   \\nInterpretation of MMAS -4 Score  \\nMMAS -4 \\nScore  Adherence \\nRating  Action Required  \\n0 Good  Continue with routine monitoring, counselling and support  \\n \\n \\n1-2  \\n \\nInadequate  ● Discuss as an MDT  \\n● Assign a case manager  \\n● Assess for and address barriers to adherence (Table 5.15)  \\n● Engage treatment supporter in adherence counselling sessions  \\n● Follow up in 2 -4 weeks  \\n \\n \\n3-4  \\n \\nPoor  ● Discuss as an MDT  \\n● Assign a case manager  \\n● Assess for and address barriers to adherence (Table 5.15)  \\n● Engage treatment supporter in adherence counselling sessions  \\n● Implement DOTs  \\n● Follow up in 1 -2 weeks  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 126}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 24 Table 5.12: Morisky Medication Adherence Scale (MMAS -8) \\nMMAS -8: Ask the patient each question below. Circle the corresponding score for each \\nresponse. After completion of all questions, add up all the points that you have circled for the \\ntotal score.  \\nQuestion  Yes No \\n1. Do you ever forget to take your medicine?  1 0 \\n2. Are you careless at times about taking your medicine?  1 0 \\n3. Sometimes if you feel worse when you take the medicine, do you stop taking it?  1 0 \\n4. When you feel better do you sometimes stop taking your medicine?  1 0 \\n5. Did you take your medicine yesterday?  0 1 \\n6. When you feel like your symptoms are under control, do you sometimes stop \\ntaking your medicine?   \\n1  \\n0 \\n7. Taking medication every day is a real inconvenience for some people. Do you ever \\nfeel under pressure about sticking to your treatment plan?   \\n1  \\n0 \\n8. How often do you have difficulty remembering to take all your medications? \\n(Please circle the correct number)  \\n  A. Never/Rarely  \\n  B. Once in a while  \\n  C. Sometimes  \\n  D. Usually  \\n  E. All the time  Points: A. 0  \\nB. ¼ C. ½ D. ¾ \\nE. 1 \\nTotal Score (sum of all items)  \\nInterpretation of MMAS -8 Score  \\nMMAS -8 Score  Adherence Rating  Action Required  \\n0 Good  Continue with routine monitoring, counselling and support  \\n \\n \\n1-2  \\n \\nInadequate  ● Discuss as an MDT  \\n● Assign a case manager  \\n● Assess for and address barriers to adherence (Table 5.15)  \\n● Engage treatment supporter in adherence counselling \\nsessions  \\n● Follow up in 2 -4 weeks  \\n \\n \\n \\n3-8  \\n \\n \\nPoor  ● Discuss as an MDT  \\n● Assign a case manager  \\n● Assess for and address barriers to adherence (Table 5.15)  \\n● Engage treatment supporter in adherence counselling \\nsessions  \\n● Implement DOTs  \\n● Follow up in 1 -2 weeks  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 127}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 25 Table 5.13: Adherence Rate Based on Pill Counts  \\nMissed Doses per Month  % Of \\nMedications \\nTaken  Adherence  \\nRating  Action Required (see Table 5.10 for \\nmore details)  For once -\\ndaily \\nregimen  For BD  \\nregimen  \\n1 dose  1-3 doses  ≥ 95%  Good  Continue with routine monitoring, \\ncounselling and support  \\n2-4 doses  4-8 doses  85-94%  Inadequate  ● Discuss as an MDT  \\n● Assign a case manager  \\n● Assess for and address barriers to \\nadherence (Table 5.15)  \\n● Engage treatment supporter in \\nadherence counselling sessions  \\n● Follow up in 2 -4 weeks  \\n≥ 5 doses  ≥ 9 doses  < 85%  Poor  ● Discuss as an MDT  \\n● Assign a case manager  \\n● Assess for and address barriers to \\nadherence (Table 5.15)  \\n● Engage treatment supporter in \\nadherence counselling sessions  \\n● Implement DOTs  \\n● Follow up in 1 -2 weeks  \\n \\n5.3.2 Adherence Counselling and Support During the First 3 Months of ART  \\nAll patients recently initiated on ART need careful adherence monitoring and support to \\nensure they achieve virological suppression.  This is particularly important in the context of \\nrapid ART initiation. The intensity of counselling and support are dependent on the patients’ level \\nof adherence as assessed by the methods described i n section 5.2.1.  \\nTable 5.14 summarizes adherence counselling and support for patients from the time of ART \\ninitiation until the 3 -month viral load results are available. For patients who have inadequate or \\npoor adherence, Table 5.15 describes the assessmen t for barriers to adherence.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 128}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 26 Table 5.14: Adherence Counselling and Support During the First 3 Months of ART  \\nNo adherence concerns (based on adherence assessment and healthcare team opinion)  \\nCounselling: Group or \\nIndividual, at every visit (can be \\ndone by any member of the \\nhealthcare team, including the \\nclinician)  ● Review patient/caregiver HIV knowledge (Table 5.2, Annex 8) \\nand address any gaps  \\n● Review patient/caregiver understanding of ART \\nadministration (dosing, timing, frequency) and address any \\ngaps  \\n● Elicit any concerns the patient/caregiver has about ART, other \\nmedications, visit schedule, or health. Address any concerns or \\nengage another care team member who can address them  \\n● Explore any major recent or expected changes in the \\npatient’s/caregiver ’s life or daily routine that could disrupt \\nadherence  \\n● Update patient locator and contact information  \\nSupport  ● Encourage the patient/caregiver to continue with the support \\nsystems discussed and implemented already  \\n● Encourage introduction of additional standard support \\nsystems (Table 5.3), including supporting disclosure as needed  \\nInadequate or poor adherence (based on adherence assessment or healthcare team opinion)  \\nCounselling: Individual, at \\nevery visit until adherence is \\ngood (preferably by someone \\ntrained on adherence \\ncounselling)  ● Assess for and address potential barriers to adherence \\n(Table  5.15)  \\n● Review patient/caregiver HIV knowledge (Table 5.2, Annex 8) \\nand address any gaps  \\n● Review patient/caregiver understanding of ART administration \\n(dosing, timing, frequency) and address any gaps  \\n● Elicit any concerns the patient/caregiver has about ART, other \\nmedications, visit schedule, or health. Address any concerns or \\nengage another care team member who can addr ess them  \\n● Explore any major recent or expected changes in the \\npatient’s/caregiver’s life or daily routine that could disrupt \\nadherence  \\n● Update patient locator and contact information  \\nSupport  ● Review effectiveness of support systems they already have in \\nplace  \\n● Encourage introduction of additional standard and enhanced \\nsupport systems (Table 5.3), including supporting disclosure as \\nneeded, assigning a case manager and considering DOTs  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 129}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 27 Table 5.15: Assessment for Barriers to Adherence  \\nTheme  Assessment  \\nAwareness of  \\nHIV status  ● Has the patient/caregiver accepted HIV status?  \\n● For children/adolescents: is age -appropriate disclosure underway/complete?  \\n \\n \\nUnderstanding  \\nof HIV infection \\nand ART  ● How HIV affects the body and risk of transmission to sexual partners and \\nchildren during pregnancy and breastfeeding  \\n● ART and how it works  \\n● Understanding of side effects and what to do in case of side effects  \\no “Have you experienced any side effect since your last visit? Has this \\naffected the way you take your medicine?”  \\n● Benefits of adherence  \\n● Consequences of non -adherence including drug resistance and treatment \\nfailure  \\n \\nDaily routine  ● Review the patient’s/caregiver’s daily routine: “Tell me about your typical day”  \\n● Review how the patient takes medicine or how the caregiver administers it  \\no “Please tell me how you take each of your medicines?”  \\no “How does taking your medicine fit into your daily routine?”  \\n● If the patient’s/caregiver’s daily routine conflicts with medication schedule, \\nwork with t hem to find a new medication schedule that will be more \\nappropriate  \\n● Remind the patient/caregiver to take/give missed or delayed doses as soon as \\nhe/she remembers (up to 12 hours late if on a once -daily regimen, or up to 6 \\nhours late if on a twice - daily re gimen). The next dose should be taken at the \\nusual time  \\n● “What do you do in case of visits or travel?”  \\n● Remind the patient/caregiver to plan travel well, pack sufficient medicine; but \\nshould their medication get finished before they return, advise them to vi sit the \\nclosest ART centre and show their appointment card to get a refill  \\n● For orphans it is critical to assess who the primary caregiver is and their \\ncommitment  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 130}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 28 Table 5.15 Cont.  \\n \\n \\nPsychosocial \\ncircumstance  Home environment:  \\n● “Who do you live with?”  \\n● “Who is aware of your HIV status? Are there people in your life with whom you’ve \\ndiscussed your HIV status and ART use?”  \\no Discuss the usefulness of enlisting the support of family members, friends \\nor a treatment supporter/buddy in reminding them to take medication (for \\nchildren/adolescents, this includes teachers and/or supportive peers at \\nschool); offer assisted disclosure  \\no Encourage the patient to identify and bring a treatment supporter during \\nthe next visit  \\n● Support system (treatment buddy, psychos ocial support groups, etc.)  \\n● Any recent losses, grief  \\n● Changes in relationships with family members/friends  \\n● Screen the patient/caregiver for alcohol and substance abuse (Tables 4.15 and \\n4.16)  \\no Discuss impact on ability to remember to take medication  \\no Explore m otivation to stop and offer support/referral  \\no Encourage limiting use and planning ahead so as not to forget to take \\nmedication  \\n● Screen for intimate partner violence (Section 4.2.1)  \\n● Stigma and discrimination  \\no “Does it bother you people might find out about your HIV status?”  \\no “Do you feel that people treat you differently when they know your HIV \\nstatus?”  \\n● Discuss if stigma is interfering with taking medication on time or with keeping \\nclinic appointments  \\n● Beliefs: has the patient tried faith healing? Has th e patient ever stopped using \\nmedication because of religious beliefs?  \\nMental Health  \\nScreening  ● Screen patient/caregiver for depression using the PHQ -9 (Table 4.14) and \\nmanage/refer as required  \\n● Screen for other psychiatric conditions such as anxiety, post -traumatic stress \\ndisorder or psychosis, or refer to a mental health worker for assessment  \\nReferrals  ● Establish if the patient has been referred to other services (including nutrition, \\npsychosocial support services, other medical clinics, substance use treatment, \\netc.)  \\n● Did he/she attend the appointments? What was his/her experience? Do the \\nreferrals need to be re -organized?  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 131}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 29 5.4 Adherence Monitoring, Counselling and Support for Patients with  \\nSuppressed Viral Load < 200 copies/ml  \\nOnce a patient has confirmed viral suppression (with VL < 50 copies/ml or below the Lower \\nDetection Limit (LDL)) this is confirmation of adequate adherence to ART. The patient can be \\nreassured that they will do well if they continue to adhere. Ho wever, all patients are at risk of new \\nor worsening barriers to adherence, so adherence monitoring, counselling and support should \\ncontinue despite viral suppression, but at a lower intensity and frequency unless concerns are \\nidentified (Table 5.16). These  patients should also be educated on and assessed for qualification \\nas “stable patient” services such as less frequent facility visits, fast -track or community -based ART \\ndistribution, etc. (Table 3.5).  \\nTable 5.16: Adherence Counselling and Support for Pati ents with Viral Load < 50 copies/ml  \\nNo adherence concerns (based on adherence assessment or healthcare team opinion)  \\nCounselling: Group or \\nindividual, every visit \\n(can be done by any \\nmember of the \\nhealthcare team, \\nincluding the clinician)  • Elicit any concerns the patient/caregiver has about ART, other \\nmedications, visit schedule, or health. Address any concerns or engage \\nanother care team member who can address them  \\n• Explore any major recent or expected changes in the \\npatient’s/caregiver’s life or daily  routine that could disrupt adherence  \\n• Update patient locator and contact information  \\nSupport  • Encourage the patient/caregiver to continue with the support systems \\nthat are in place already  \\nInadequate or poor adherence (based on adherence assessment or healthcare team opinion)  \\nCounselling: Individual, \\nat every visit until \\nadherence is good \\n(preferably by someone \\ntrained on adherence \\ncounselling)  • Assess for and address potential barriers to adherence (Table \\n5.15)  \\n• Review patient/caregiver HIV knowledge (Table 5.2, Annex 8) and \\naddress any gaps  \\n• Review patient/caregiver understanding of ART administration \\n(dosing, timing, frequency) and address any gaps  \\n• Elicit any concerns the patient/caregiver has about ART, other \\nmedicatio ns, visit schedule, or health. Address any concerns or engage \\nanother care team member who can address them  \\n• Explore any major recent or expected changes in the \\npatient’s/caregiver’s life or daily routine that could disrupt adherence  \\n• Update patient locator and contact information  \\nSupport  • Review effectiveness of support systems the patient already has in \\nplace  \\n• Encourage introduction of additional standard and enhanced support \\nsystems (Table 5.3), including supporting disclosure as needed, \\nassigning a case manager and considering DOTs  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 132}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 30 Table 5.17 Viral Load Monitoring Cut -Offs  \\nClinical \\nDefinition  Category  Lab Value  Interpretation  Guidance  \\n• Suppressed  • LDL  \\n \\n \\n• Low Risk \\nLLV  • <50 \\nCopies/ml  \\n \\n• 50 – 199 \\nCopies/ml.  • Treatment Goal  \\n \\n \\n• Stable Client, \\nUntransmissible  • Continue Management  \\n \\n \\n• Continue management, \\nremind client of \\ntreatment goal  \\n• Enroll  in DSD  \\n \\n• Unsuppressed  • High Risk \\nLLV  • 200 -199 \\nCopies/ml  • Increased risk \\nof progression \\nto treatment \\nfailure  • Step down from DSD, \\ninstitute EAC, repeat VL \\nafter 3 months of \\nexcellent adherence  \\n \\n• Suspected \\nTreatment \\nFailure  • ≥1000 \\nCopies/ml  • Client at \\nincreased risk \\nof morbidity \\nand mortality  • Enroll Client in \\nspecialized clinic if \\navailable  \\n• Conduct EAC  \\n• Refer to VL algorithm  \\n \\n \\n5.5 Adherence Monitoring, Counselling and Support for Patients with \\nUnsuppressed Viral Load ≥ 200 copies/ml  \\nTreatment failure should be suspected whenever a patient has been on ART for at least 3 months \\nand has: a viral load ≥ 200 copies/ml; a decline in CD4 count or; a ny new or worsening clinical \\ncondition. Treatment failure is confirmed as per the viral load monitoring algorithm (Figure 6.6). \\nPoor adherence is often the most important factor in developing treatment failure, though there \\ncan be other causes. Adherence m ust be thoroughly assessed and all issues must be addressed \\nbefore switching patients to the next line of ART. Do not change regimens until the reason/s \\nfor treatment failure have been identified and addressed, and a repeat VL is ≥ 1,000 \\ncopies/ml after 3 months of excellent adherence . For patients with high -risk  persistent low -\\nlevel viremia (VL 200 - 999 copies/ml after additional assessment and intervention), consult the \\nRegional or National HIV Clinical TWG (Uliza Hotline 0726 460 000; \\nhttps://nh csc.nascop.org/clinicalform ). \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 133}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 31 5.5.1 Enhanced Adherence Assessments  \\nAs soon as treatment failure is suspected the patient/caregiver should be discussed by the facility \\nmulti -disciplinary team to develop a plan for assessing barriers to adherence (includin g \\nscheduling a home visit), and assessing other potential causes of treatment failure (e.g., \\ninadequate dosing/dose adjustments, drug -drug interactions, drug -food interactions, impaired \\nabsorption e.g., chronic severe diarrhoea).  \\nAll patients with suspecte d or confirmed treatment failure should have a thorough assessment of \\npotential barriers to adherence (Table 5.15).  \\nIf the patient has a caregiver, treatment buddy, and/or spouse/partner who is enrolled in HIV \\ncare, that person’s file should also be review ed to confirm their most recent viral load results and \\nadherence.  \\n5.5.2 Enhanced Adherence Counselling  \\nAdherence assessment and enhanced adherence counselling should begin as soon as a detectable \\nviral load ( ≥ 200 copies/ml) is received, preferably within 2 weeks.  \\nThe goal of Enhanced Adherence Counselling is to assess possible barriers to adherence in a non -\\njudgmental way and to help the patient construct an adherence plan with concrete objectives. It \\nis important not to focus solely on k nowledge of HIV and ART but also to review psychological, \\nemotional, and socio -economic factors that may contribute to poor adherence. In addition, \\nexploring the patient’s motivation for taking medication often highlights reasons for poor \\nadherence.  \\nAt lea st three sessions of Enhanced Adherence Counselling, spaced 2 -4 weeks apart, are \\nrecommended as the minimum number of sessions, but additional sessions can be added as \\nneeded (Table 5.1 8). If the adherence is evaluated as adequate, a repeat viral load is d one after \\nthree months of excellent adherence, and another Enhanced Adherence Counselling session is \\nconducted to discuss the viral load results. A detailed content guide for Enhanced Adherence \\nCounselling is provided in Annex 9.  \\nIt is preferable to have t he patient go through all adherence counselling sessions with the same \\ncounsellor in order to provide continuity, and that the session is documented to ensure follow -up \\nof all issues identified.  \\nIf adequate adherence cannot be achieved then consult with a senior clinician, discuss as an MDT, \\nor consult the Regional or National TWG.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 134}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 32 Table 5.1 8: Components of Enhanced Adherence Counselling Sessions (Annex 9A for detailed \\ncontent guide)  \\nEnhanced Adherence Counselling Sessions: Overview  \\n \\nSession 1  • Review understanding of viral load (VL) and discuss why the patient’s VL is \\nhigh  \\n• Review common cognitive, behavioral, emotional and socio -economic barriers \\nto adherence  \\no Stigma and non -disclosure  \\no Loss or grief  \\no Treatment literacy  \\no Medications: dosage, timing, storage  \\no Side effects  \\no Discuss risk reduction (e.g., for substance abuse)  \\no Motivation  \\no Mental health screening (screen for depression using PHQ -9, Table 4.14)  \\no Discuss patient’s support systems  \\n● Assist patient to develop adherence plan to address the ide ntified issues  \\n \\nSession 2  ● Review adherence plan from the first session and discuss any challenges  \\n● Identify other possible gaps and issues emerging  \\n● Assist patient to modify the adherence plan to address the identified issues  \\n \\n \\nSession 3  ● Review adherence plan from the first and second session and discuss any \\nchallenges  \\n● Identify other possible gaps and issues emerging  \\n● Assist patient to modify the adherence plan to address the identified issues  \\n● Decision on repeat VL based on current adherence  \\no If the adherence is good: plan repeat VL testing after three months of good \\nadherence and explain possible ways forward, emphasizing role of the \\npatient and the health facility  \\no If adherence challenges persist: consult with a senior clinician, discuss as \\nan MD T, or consult the Regional or National TWG before repeating the VL  \\n \\nSession to \\nDiscuss \\nRepeat Viral \\nLoad Results  ● Discuss result of the second VL test  \\n● Plan the way forward:  \\no If VL now < 200 copies/ml: continue current regimen with ongoing \\nenhanced adherence; repeat VL after 6 months  \\no If VL ≥ 1,000: prepare patient for change of regimen (Figure 5.2)  \\no If VL is 200 -999 copies/ml: perform another assessment for causes for \\nviremia and address any issues identified; repeat viral load after an \\nadditional 3 months of excellent adherence  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 135}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 33 Table 5.1 8 Cont.  \\nOther Enhanced Adherence Support Interventions (for patients failing or at high -risk of failing \\ntreatment)  \\nCase \\nmanagement  • Assign a case manager to all children and adolescents (those not achieving \\noptimum treatment outcomes); pregnant women, orphans, patients with alcohol \\nand substance abuse, patients with mental illness, patients with suspected or \\nconfirmed treatment failure, and any patients who the healthcare team feels has \\npoor adheren ce or is at high risk of defaulting from care  \\n• The case manager is the link between the patient and the MDT  \\n• Roles  of the case managers include:  \\no Coordinating multidisciplinary management for patients under case \\nmanagement  \\no Following up on appointment -keeping for their patients  \\no Organizing patient reminders (SMS, calling the day before) and other support \\nsystems  \\no Ensuring appropriate defaulter tracing  \\no Coordinating home visits to their patients  \\nDirectly \\nobserved \\ntherapy  • Patients with suspected treatment failure should have DOTs to ensure good \\nadherence before a viral load is repeated to confirm treatment failure  \\n• DOTs involve a healthcare provider, family member, treatment supporter or any \\ntrained peer observing the patient ingesting th eir prescribed ART on a daily basis  \\n• DOTs can be tapered off once the patient adopts consistent adherence -enhancing \\nbehaviours  and barriers to adherence are overcome  \\nHome visits  • Observe where and how a patient stores and takes their medications, and assess if \\nthey have extra medications because of missed doses  \\n• Home visits may also provide a better understanding of a patient’s living situation \\nand specific barriers to adherence  \\n• Unscheduled home visits may be more revealing, but should only be conducted if \\nthe patient consented to home visits previously (preferably at the time of enrolment  \\nor initiation)  \\nMonthly “high \\nviral load” \\nclinics  • Patients with suspected treatment failure should be booked for dedicated monthly \\nhigh viral load clinics  \\n• Children and adolescents in school who are unable to attend clinic monthly may \\nattend dedicated monthly clinics during mid -term and school holidays (at least \\nevery 6 weeks)  \\n• Comprehensive clinical and psychosocial evaluation should be conducted at e ach \\nvisit, appropriate investigations done and any opportunistic infections treated  \\n• Enhanced adherence counseling sessions should be conducted at each visit  \\n• Support groups for patients with viremia can be timed with “high viral load” clinic \\ndays  \\nSpecial \\nsupport \\ngroups  • For health facilities with several patients who are failing treatment or who are on \\n2nd line ART, special support groups can be established so these patients can work \\nthrough their adherence challenges together  \\n• Community support groups can also be engaged and linked to the facility for \\nsupporting patients with adherence challenges  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 136}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 34 Adherence support systems will need to be adapted to patients’ specific needs and the context \\n(Table 5.1 8). Special attention needs to be given to children, a dolescents, pregnant and \\nbreastfeeding women, patients with mental health disorders and substance users.  \\n5.6 Treatment Preparation for 2nd Line or 3rd Line ART  \\nAfter confirming treatment failure and making the decision to start 2nd line or 3rd line ART (ba sed \\non discussion as an MDT, and in consultation with the Regional or National HIV Clinical TWG), the \\npatient requires targeted counselling and education to prepare them for the new regimen and to \\nsupport ongoing adherence (Figure 5.2).  \\nReview patient file\\nAssess patient  s \\nknowledge and \\nunderstanding\\nProvide patient education\\nConstruct adherence plan\\nEnsure monthly \\ncounselling follow -up \\nsessionsEnsure a monthly follow -up counselling session during \\nclinic visits for the first 6months after initiating the new \\nregimen\\n• Follow up on problems identified during the previous \\nsessions\\n• Assess patient  s adherence and explore any reasons for \\npoor adherence. Identify strategies to overcome these \\nbarriers\\nRepeat VL after 3 months on new regimen\\n• If VL undetectable: adherence counselling every \\n3months\\n• If VL is detectable: discuss as MDT and consult Clinical \\nTWG• Confirm patient  s willingness to start new regimen\\n• Ensure that the patient understands the treatment plan \\n(drug regimen, dosing schedule, dietary restrictions, \\npotential side effects, what to do when missing doses or \\nexperiencing side effects)\\n• Prepare for situations that could impair good \\nadherence, and encourage disclosure of poor adherence\\n• Plan sessions with the pharmacist on medication \\nadherence, and nutritionist on nutritional aspects• Strengthen key messages on HIV and viral load\\n• Provide information on 2nd/3rd line ART: more complex \\nto take (more pills, twice -a-day dosing), very limited \\noptions if this fails\\n• Provide simple take -home IEC materials on 2nd  or 3rd  \\nline ART management• HIV, viral load and ART\\n• The importance of good adherence and potential \\nproblems of non -adherence\\n• Reasons for switching to 2nd or 3rd line ART: treatment \\nfailure with repeated high viral load• Review the patient file and all problems identified \\nduring Enhanced Adherence Counselling sessions\\n• Confirm all the barriers to adherence have been \\naddressed during Enhanced Adherence Counselling, if \\nnot – address remaining barriers before considering \\nchanging regimens\\n \\n \\nFigure 5.2: Adherence Counselling and Education for Patients Preparing to Initiate 2nd Line or \\n3rd Line ART  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 137}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 35 5.7 Identifying, Tracing, and Supporting Patients who Default from Care  \\nEvery service delivery point that is providing ARVs for patients (whether ART, PEP, or PrEP) must \\nhave a functional system for identifying patients who miss appointments and for taking action \\nwithin 24 hours of a missed appointment (Figure 5.3).  \\nEnter date of next appointment/TCA for each patient into the \\nappointment diary\\n• As patients arrive at the service delivery point their name should be \\nchecked off in the appointment diary for that day\\n• All patients who had appointments booked for the day but did not \\nattend clinic should be recorded in the patient follow -up register\\n• Patient/caregiver should be called within 24 hours of missed \\nappointment\\n• If no response, treatment buddy should be called\\n• Several attempts at phone tracing should be made if no response \\ninitially\\n• Update the patient follow -up register with phone call findings\\nPatient does not return \\nwithin time agreed upon \\nduring phone call, but still \\nable to reach by phonePatient returns to clinic \\nwithin 7 days, or returns \\non date agreed during \\nphone callUnable to reach by phone, \\nand does not return to \\nclinic within 7 daysPatient dead, transferred \\nout, or declines further \\ncontact: update patient \\nrecords/ registers with \\noutcome\\nReturns to clinic\\n• Assess for and address potential barriers to adherence \\n(Table 5.14) \\n• Review patient/caregiver HIV knowledge (Table 5.1, \\nAnnex 6) and address any gaps\\n• Elicit any concerns the patient/caregiver has about ART, \\nother medications, visit schedule, or health. Address any \\nconcerns or engage another care team member who can \\naddress them\\n• Explore any major recent or expected changes in the \\npatient s/caregiver  s life or daily routine that could disrupt \\nadherence\\n• Review effectiveness of facility and community support \\nsystems the patient already has in place\\n• Encourage introduction of additional standard  and \\nenhanced support systems (Table 5.2), including \\nsupporting disclosure as needed, assigning a case manager \\nand considering DOTs\\n• Review ART Readiness Assessment Form for re -initiation \\nof ART• Prioritized home visit, based on\\no Patient type (pregnant and \\nbreastfeeding women, child, co -\\nmorbidity)\\no Proximity to clinic\\n• Complete the home visit form\\n• Update the patient follow -up register with \\nhome visit findings\\n• Update appointment diary if agrees to \\nreturn to clinic\\nUnable to trace or does not return to clinic on \\nscheduled appointment date\\n• Discuss as MDT and develop follow -up/ \\nmanagement plan\\n• Update patient records/registers with \\noutcome\\n \\nFigure 5.3: Ident ifying, Tracing and Supporting Patients who Default from Care  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 138}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 36  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 139}),\n",
       " Document(page_content='  \\nAntiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 1  \\n6. Antiretroviral Therapy in Infants, Children, \\nAdolescents, and Adults  \\nART, while very effective in managing HIV disease, does not cure HIV infection. The goal of ART is \\nto suppress viral replication with the aim of reducing the  patient’s VL to undetectable levels. \\nUninterrupted ART with ongoing strict adherence will help maintain undetectable VL levels \\nthereby preventing damage to the body’s immune system, reducing AIDS -related morbidity and \\nmortality and the risk of sexual and vertical transmission of HIV.  \\n6.1 Eligibility for ART  \\nAll individuals with confirmed HIV infection are eligible for ART irrespective of CD4 \\ncount, WHO clinical stage, age, pregnancy or breastfeeding status, co -infection status, \\nrisk group, or any other cri teria.  \\n6.2 Timing of ART Initiation  \\nART should be started in all patients as soon as possible, preferably within 2 weeks of \\nconfirmation of HIV status, and even on the same day as testing positive for HIV if they are ready.  \\nART Readiness Criteria (Table 5.4) can be used to help determine any issues that need to be \\naddressed around the time of ART initiation. Same -day ART initiation (on the same day as testing \\nHIV-positive) has additional benefits for HIV prevention (e.g., for pregnant and breastfee ding \\nwomen, and the HIV positive partner in a discordant relationship), and is associated with \\nimproved retention, viral suppression, and survival. Special considerations for timing of ART \\ninitiation are listed in Table 6.1.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 140}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 2 Table 6.1: Special Considerat ions for Timing of ART Initiation  \\nPopulation  Timing of ART Initiation  Additional Notes  \\nPregnant and \\nbreastfeeding \\nwomen  Support ART initiation on the \\nsame day as testing positive for \\nHIV Intensive adherence counselling, \\nsupport and close follow -up \\nrequired because of limited time for \\npatient preparation  \\nInfants (< 12 months \\nold)  Support ART initiation on the \\nsame day as testing positive for \\nHIV. Treatment should \\ncommence following a first \\npositive PCR test. ALWAYS take a \\nsample for a confirmatory PCR \\ntest as soon as the first positive \\nPCR result is received, but do not \\ndelay ART initiation for the \\nsecond PCR result  Intensive adherence counselling, \\nsupport and close follow -up \\nrequired because of limited time for \\ncaregiver preparation  \\nPatients with strong \\nmotivation to start \\nART immediately  Support ART initiation as soon as \\nthe patient feels ready, preferably \\non the same day as testing \\npositive for HIV  Intensive adherence counselling, \\nsupport and close follow -up \\nrequired because of limited time for \\npatient preparation  \\nPatients with newly \\ndiagnosed TB  Start anti -TB treatment \\nimmediately and initiate ART as \\nsoon as anti -TB medications are \\ntolerated, preferably within 2 \\nweeks. For TB meningitis delay \\nART for 4 to 8 weeks  Monitor closely for IRIS (Annex 16)  \\nPatients with \\ncryptococcal \\nmeningitis  Defer ART until after completing \\n5 weeks of CM treatment  Monitor closely for IRIS (Annex 16)  \\n \\nPatients for whom \\nadherence will be \\nparticularly \\nchallenging  Start ART as soon as possible \\nwhile implementing additional \\nsupport systems (e.g., optional \\nenrolment of a PWID into a MAT \\nprogram; psychiatric treatment \\nfor a patient with mental illness; \\nenrolment into an OVC program \\nfor orphans etc.)  A case manager should be assigned \\nto all patients with complex \\nadherence challenges  \\nAll other patients  Start ART as soon as possible, \\npreferably within 2 weeks, \\nand even on the same day as \\ntesting positive for HIV if they \\nare ready  Continued adherence monitoring \\nand support is recommended after \\nART initiation for all patients  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 141}),\n",
       " Document(page_content='  \\nAntiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 3 6.3 First -Line ART for Infants, Children, Adolescents and Adults (including \\nPregnant and Breastfeeding Women)  \\nThe recommendations below apply to patients who are starting ART for the first time. Preferred \\nand alternative first line regimens are shown in Tables  6.2 and 6.3. ARVs for infant prophylaxis \\nare presented in the PMTCT chapter in Tables 7.3 to 7.6.  \\nAll patients must have their weight documented at every visit. Children and adolescents \\nless than 15 years must have correct weight -based dosing of ARVs conf irmed at every visit.  \\nInfants and children depend on their caregivers for adherence to medication. Caregivers should \\nbe adequately prepared for their role of administering ARVs to infants and children, including \\naddressing anticipated challenges such as dr ug palatability. It can be helpful for more than one \\ncaregiver to be informed about a child’s HIV status and receive instruction on administration of \\nART.  \\nCaregivers should always be shown and then asked to demonstrate how to measure and \\nadminister ARVs.  This should be done both at the time of prescribing the ART (by the clinician) \\nand at the time of dispensing the ART. Clinicians should ensure that the caregiver accompanying \\na child for clinical review is the same caregiver responsible for day -to-day ART a dministration.  \\nTable 6.2: Preferred First -line ART Regimens and Dosing for Children, Adolescents and \\nAdults 1 \\nAge  Weight  Preferred \\nRegimen  Dosing2 (correct weight -based dosing must \\nbe confirmed at every visit)  \\nBirth to 4 \\nweeks  Any  AZT + 3TC + NVP3 Refer to Annex 10 for weight -based dosing  \\n> 4 weeks to \\n< 15 years  < 30 kg  ABC + 3TC + DTG4 Refer to Annex 10 for weight -based dosing  \\n≥ 30 kg  TDF + 3TC + \\nDTG5,6 TDF/3TC/DTG (300/300/50mg): 1 tab once \\ndaily  \\n≥ 15 years  Any  TDF + 3TC + \\nDTG5,6 TDF/3TC/DTG (300/300/50mg): 1 tab once \\ndaily  \\n1 Patients currently on first -line regimens that are not included in the indicated preferred (Table 6.2) \\nor alternative (Table 6.3) regimens should be considered for regimen optimization as per Section \\n6.5.1  \\n2 See Annex 10 for weight -based dosing of all single -drug and fixed -dose combination formulations  \\n3 Infants who initiate ART at less than 4 weeks of age should initiate on AZT+3TC+NVP irrespective of \\nprevious ART exposure; metabolism of other ARVs is not well known for this age group. As soon as \\nthese infants become 4 weeks old, they should switch to ABC/3TC+DTG (dosing included in Annex \\n10). Consult the Regional or National HIV Clinical TWG (Uliza Hotline 0726 460 000, \\nulizanascop@gmail.com) in case of pre -term infants  \\n4 Once adolescents reach 30 kg, if virally suppressed they should be considered for transition as per \\nFigure 6.2  \\n5 TAF may become the preferred NRTI once fixed -dose combinations are available  \\n6 DTG/3TC dual therapy may be considered for HBV -negative pa tients once fixed -dose combinations \\nare available  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 142}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 4 Table 6.3: Use of Alternative ARVs in First -Line Regimens 1 \\nAge  Weight  Scenario and ARV \\nAffected  Alternative ARV to Use  \\nBirth to 4 \\nweeks   \\nAny  NVP: Develops \\nhypersensitivity reaction  Use RAL granules or LPV/r granules \\n(over 2 weeks of age) or defer ART until \\n4 weeks of age, then start ABC+3TC+DTG  \\nAZT: Infant Hb < 9.5 g/dL  Defer ART until 4 weeks of age, then \\nstart ABC+3TC+DTG  \\n> 4 weeks \\nto < 15 \\nyears   \\n \\n< 30 kg  ABC: Develops ABC \\nhypersensitivity reaction2 Use AZT (if Hb ≥ 9.5 g/dL); if Hb < 9.5 \\ng/dL consults Regional or National HIV \\nClinical TWG (call Uliza Hotline 0726 \\n460 000; ulizanascop@gmail.com)  \\nDTG: Unable to tolerate  Use LPV/r at standard weight -based BD \\ndosing, if 4-in-1 available this is \\npreferred  \\nDTG: Currently on \\nrifampicin -containing \\nanti -TB \\nmedications  Increase DTG dosing frequency to twice \\ndaily for duration of rifampicin -\\ncontaining TB treatment and for an \\nadditional 2 weeks after TB treatment is \\ncompleted, then revert to once daily \\ndosing3 \\n \\n \\n \\n≥ 30 kg  \\n \\n TDF: Impaired renal \\nfunction (CrCl ≤ 50 \\nml/min)  Use ABC4,5 or TAF (once available)  \\nDTG: Unable to tolerate  Use EFV (for PWID use ATV/r)  \\nDTG: Currently on \\nrifampicin -containing \\nanti -TB \\nmedications  Give TDF/3TC/DTG FDC morning + DTG \\n50mg evening for duration of rifampicin -\\ncontaining TB treatment and for an \\nadditional 2 weeks after TB treatment is \\ncompleted, then revert to TDF/3TC/DTG \\nFDC OD 3 \\n≥ 15 years  Any  TDF: Impaired renal \\nfunction (CrCl ≤ 50 \\nml/min)  Use ABC4,5 or TAF (once available)  \\nDTG: Unable to tolerate  Use EFV (for PWID use ATV/r)  \\nDTG: Currently on \\nrifampicin -containing \\nanti -TB \\nmedications  Give TDF/3TC/DTG FDC morning + DTG \\n50mg evening for duration of rifampicin -\\ncontaining TB treatment and for an \\nadditional 2 weeks after TB treatment is \\ncompleted, then revert to TDF/3TC/DTG \\nFDC OD 3 \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 143}),\n",
       " Document(page_content='  \\nAntiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 5 Table 6.3 Cont.  \\n1 For other scenarios that are not covered in this table, discuss as an MDT and consult the Regional or \\nNational HIV Clinical TWG (Uliza Hotline 0726 460 000; https://nhcsc.nascop.org/clinicalform ) \\n2 ABC hypersensitivity reaction (AHR) is rare in the Kenyan population. Table 6.9 provides the \\ndefinition and management of AHR  \\n3 The additional 2 weeks of higher -dose DTG is to counter the ongoing liver enzyme induction effect \\nof rifampicin, which continues for a short period after TB treatment is completed  \\n4 TAF may become the preferred NRTI once fixed -dose combinations are available  \\n5 DTG/3TC dual therapy may be considered for HBV -negative patients once fixed -dose combinations \\nare available  \\n6.4 Dosing and Administration of Dolutegravir (DTG)  \\nDTG is preferred in first line ART (in combination with other ARVs) for children, adolescents and \\nadults. DTG is well tolerated, highly efficacious, has a high genetic barrier to resistance and fewer \\ndrug -drug interactions.  \\nTable 6.4: Dosing and Administration of  Dolutegravir  \\nRecommended Dosing of DTG  \\n● < 20 kg body weight: Use weight -based dosing with dispersible 10mg DTG tablets as per Annex 10  \\n● ≥ 20 kg body weight: DTG 50 mg film -coated tablet once daily, preferably as a morning dose. It is also \\navailable as part of FDC. Those unable to swallow the film coated tablets whole refer to Annex 10  \\n● For patients taking rifampicin: Increase DTG dosing frequency to twice daily for duration of \\nrifampicin -containing TB treatment and for an additional 2 weeks after TB treatment is completed, \\nthen revert to once daily. (The additional 2 weeks of higher -dose DTG is to counter the ongoing liver \\nenzyme induction effect of rifampicin, which continues for a short period after TB treatment is \\ncompleted)  \\n● For patients w ith suspected or confirmed INSTI resistance (e.g., patients with prior history of failing a \\nRAL -based regimen): use DTG twice daily  \\n● DTG can be taken with or without food  \\nCommon Side Effects of DTG  \\n● The most common side effects of DTG are headache, nausea and diarrhea. These side effects usually \\nresolve after continued use for 1 -2 weeks. It is critical to inform patients / caregivers about these \\npotential side effects and their temporary nature, and encourage them to continue their ART and \\nconsult a HCW if concerned.  \\n● Some patients on DTG are more likely to develop insomnia. This may be reduced by taking DTG as a \\nmorning dose, or by taking DTG with a low -fat meal or on an empty stomach.  \\n● DTG may cause a small rise in serum creatinine levels bu t this does NOT represent a true decline in \\nrenal function.  \\n● Integrase inhibitors, including DTG, are associated with increased weight gain. Counsel patients about \\nhealthy eating and physical activity and the benefits of maintaining a healthy weight.  \\n● All ad verse events should be reported through the national pharmacovigilance mechanism. \\n(http://www.pv.pharmacyboardkenya.org/ ) ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 144}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 6 Table 6.4 Cont.  \\nPregnancy Safety of DTG  \\n● DTG is safe during pregnancy and breastfeeding. Pregnancy intention should be discussed with all \\nwomen initiating ART regardless of regimen. Women who do not wish to become pregnant should be \\noffered appropriate family planning counseling and methods.  \\nImportant Drug Interactions with DTG  \\n● Rifampicin  \\no Rifampicin lowers DTG levels: increase DTG to 50 mg twice daily for patients on rifampicin who \\nare > 20 kg in body weight. Children <20 kg taking DTG who require rifampicin should increase \\ntheir weight -appropriate DTG dose to twice daily.  \\no There are no significant drug interactions between DTG and other currently used anti -TB \\nmedications (including for MDR -TB) \\n● Mineral supplements, including: antacids containing calcium, zinc, magnesium or aluminum; iron \\nsupplements; prenatal vitamins (which contain iron and calcium)  \\no These supplements decrease the absorption of DTG: administer DTG at least 2 hours before or 6 \\nhours after taking any of these supplements  \\no Dose separation is not required for calcium and iron supplements (including prenatal vitamins) if \\nDTG is taken with a meal  \\no It is critical to educate patients about this important drug interact ion because many patients get \\nthese supplements and antacids over -the-counter without informing their healthcare provider  \\n● Carbamazepine, phenobarbital, phenytoin  \\no These anticonvulsants decrease DTG levels: use a different anticonvulsant if available  \\no If DTG must be co -administered with these drugs then increase to DTG to twice daily, although \\nthere is little data to guide this  \\no If valproic acid is available this can be used with DTG without dose adjustment  \\n● Metformin  \\no DTG increases levels of metformin; the levels of DTG are not affected: use a lower dose of \\nmetformin (often 50% of usual dose) and monitor glycemic control. Use a maximum daily dose of \\nmetformin 1 g  \\n● Other drug -drug interactions with DTG  \\no See Annex 13C  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 145}),\n",
       " Document(page_content='  \\nAntiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 7 6.5 Monitoring and Changing ART  \\nThe objectives of clinical and laboratory monitoring during ART are to identify and treat inter -\\ncurrent illnesses, assess for and manage adverse drug reactions, and evaluate response to \\ntreatment. Routine laboratory monitoring recommendations are described in Table 3.5; however, \\nadditional investigations should be ordered whenever there is clinical suspicion for which a \\nlaboratory test result may alter patient management.  \\nIndications for changing ART include optimizing therapy for patients who have undetectable viral \\nload, managing adverse drug reactions or toxicity, drug -drug interactions, co -morbidities and \\ntreatment failure.  \\n6.5.1 Optimizing Therapy for Patients who have suppressed viral load on First Line \\nART  \\nPatients who are virally suppressed o n first line ART may benefit from regimen optimization even \\nif they are currently tolerating their regimen well and have no drug -drug interactions requiring a \\nchange. Regimen modifications may be done for age/weight transitions among children and \\nadolescen ts <15 years and to simplify a regimen, prevent long -term toxicity and improve cost -\\neffectiveness. Dolutegravir has been shown to have superior tolerability and efficacy compared to \\nefavirenz and lopinavir and is now preferred as part of first line ART for  children, adolescents and \\nadults. While most adults in Kenya have switched over to a DTG -containing regimen, proactive \\nswitching of children is now also recommended with the availability of a pediatric dispersible \\ndolutegravir tablet.  \\nChildren and adolesc ents with suppressed viral load on first line ART and not on the \\nrecommended first line regimen as per Table 6.2 should be considered for optimization as \\nper Figures 6.1 and 6.2, such as when children grow and enter a new weight band.  This also \\nincludes PL HIV who recently initiated non -standard therapy (less than 3 months ago, before the \\nfirst VL is due). Decisions on regimen modification should be made following discussion with the \\npatient/caregiver.  \\nAlways discuss the possibility of new side effects when changing to a new ARV,  particularly \\nside effects common to all ARVs (headache, nausea, diarrhea) and any side effects specific to the \\nnew ARV. Reassure patients that most side effects resolve with continued use after 1 -2 weeks.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 146}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 8 \\nChildren weighing < 30  kg on a first line ART regimen OTHER than ABC/3TC + DTG\\nVL within last 6 months < \\n200 copies/ml (LDL)\\nNo VL result within last 6 \\nmonths\\nVL within last 6 months   \\n200 copies/ml\\nCollect sample for VL\\nVL   200 copies/ml\\n• Switch to ABC/3TC + DTG using the \\nweight -based dosing from Annex 10A -B\\n• Schedule clinical appointment at 2 weeks \\nafter regimen change to review \\nadherence, side effects and any other \\nconcerns\\n• Repeat VL 3 months after regimen \\nmodification followed by routine viral \\nload monitoring\\n• Switch regimen while assessing for reasons for viremia and \\nproviding enhanced adherence counselling\\n• If current regimen contains ABC: Switch to \\nAZT/3TC + DTG\\n• If current regimen contains AZT: Switch to \\nABC/3TC + DTG\\n• Use the weight -based dosing from Annex 10A -B\\n• For all patients on PI/r or DTG containing regimens: \\nsummarize case for TWG and take sample for DRT  – do not \\nwait for DRT results for making the regimen modification\\n• Schedule clinical appointment at 2 weeks after regimen \\nchange to review adherence, side effects and any other \\nconcerns\\n• Repeat VL 3 months after regimen modification\\n• If VL still   200  copies/ml then consult the \\nregional or national TWG\\n• If VL now < 200  copies/ml then continue routine \\nviral load monitoring\\nOn ART for < 3 months\\n On ART for     months\\nVL < 200 copies/ml  (LDL) \\nFigure 6.1: Optimizing ART Regimens for Children and adolescents <15 years Weighing < 30 kg \\non First Line ART  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 147}),\n",
       " Document(page_content='  \\nAntiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 9 \\nChildren and adolescents weighing      kg or       years old on a first line ART regimen OTHER \\nthan TDF/3TC/DTG\\nVL within last 6 months \\n< 200 copies/ml (LDL)\\nNo VL result within last 6 \\nmonths\\nVL within last 6 months   \\n200  copies/ml\\nCollect sample for VL\\nVL       copies/ml\\n• Switch to TDF/3TC/DTG (300/300/\\n50mg) 1 tab once daily\\n• Schedule clinical appointment at 2 weeks \\nafter regimen change to review \\nadherence, side effects and any other \\nconcerns\\n• Repeat VL 3 months after regimen \\nmodification followed by routine viral \\nload monitoring\\n• Switch regimen while assessing for reasons for viremia \\nand providing enhanced adherence counselling\\n• Switch to TDF/3TC/DTG (300/300/50mg) 1 tab once \\ndaily\\n• For all patients on PI/r or DTG containing regimens: \\nsummarize case for TWG and take sample for DRT  – do \\nnot wait for DRT results for making the regimen \\nmodification\\n• Schedule clinical appointment at 2 weeks after regimen \\nchange to review adherence, side effects and any other \\nconcerns\\n• Repeat VL 3 months after regimen modification\\n• If VL still       copies/ml then consult the \\nregional or national TWG\\n• If VL now < 200 copies/ml then continue routine \\nviral load monitoring\\nOn ART for < 3 months\\n On ART for     months\\nVL < 200 copies/ml (LDL) \\nFigure 6.2: Optimizing ART Regimens for Children and Adolescents Weighing ≥ 30 kg or ≥ 15 years \\nold on First Line ART  \\n6.5.2 Changing ARVs Due to Adverse Drug Reactions  \\nPatients starting ART should be educated on the potential side effects of ART and all ot her \\nprescribed medication.  ADRs can have a significant impact on patient adherence and must be \\nidentified early and managed aggressively. All ADRs should be reported to the Pharmacy and \\nPoisons Board using existing pharmacovigilance tools \\n(http://www.pv.pharmacyboardkenya.org/ ). Pharmacovigilance is particularly important for \\nmonitoring ADRs associated with any new ARVs that enter the national supply chain, as rare \\nADRs may appear in routine care, whi ch were not observed in the highly selected patients \\nparticipating in clinical trials.  \\nThe most common significant ADRs associated with ARVs that may require a drug substitution \\nare summarized in Table 6.5. General principles for managing ADRs are outlined  in Figure 6.3. \\nManaging specific ADRs is described in Tables 6.6 to 6.9.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 148}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 10  Table 6.5: Common Significant Adverse Drug Reactions  \\nARV \\nAgent   Adverse Drug Reaction   High Risk Situations/Comments  \\n NRTIs  \\n  ABC  ABC hypersensitivity \\nreaction (see Table 6.9)  Do not re -challenge  \\n \\n \\n \\nAZT  Anaemia, neutropenia  \\n(See Table 6.7)  Risk factors: CD4 count < 200 cells/mm3; BMI < 18.5 (or \\nbody weight < 50 kg); anaemia at baseline; concurrent use \\nof other drugs with similar ADR (cotrimoxazole, \\ngancyclovir, ribavirin)  \\nLactic acidosis  Risk factors: Pregnancy; obesity  \\nLipoatrophy  Risk factors: Low CD4 count  \\nTDF  Renal dysfunction  \\n(See Figure 6.5)  Risk factors: Underlying renal disease; age > 60 years; BMI \\n< 18.5 (or body weight < 50 kg); diabetes; hypertension; \\nconcomitant PI use or nephrotoxic drug  \\nAvoid in patients with CrCl< 50ml/minute unless no \\nsuitable alternative such as required to treat HIV/HBV co -\\ninfection if TAF is not available  \\nTAF  Weight gain  Risk factors: women; concomitant use of INSTIs  \\nProvide advice on healthy eating and physical activity to \\nmaintain a healthy weight (Table 4.9)  \\nNNRTIs  \\nAll \\nNNRTIs  Rash  \\n(NVP>>EFV>ETR)  Manage rash as per Table 4.4 \\n \\nEFV  CNS side -effects  Risk factors: Pre -existing psychiatric disorder  \\nGynaecomastia  Switch from EFV to an alternative, and consult if \\ngynecomastia does not improve  \\nNVP  Hepatotoxicity  \\n(See Table 6.8)  N/A.  \\nPIs \\nAll PIs \\nboosted \\nwith  \\nRTV  GI intolerance \\n(LPV/r>DRV/r>ATV/r)  Consult for recommendation on alternative regimen (R -\\nTWG or Uliza Hotline 0726 460 000, \\nhttps://nhcsc.nascop.org/clinicalform ) \\nDyslipidaemia \\n(LPV/r>DRV/r>ATV/r)  Risk factors: Obesity; sedentary lifestyle; diet high in \\nsaturated fats and cholesterol  \\nATV/r  Hyperbilirubinemia  This only requires drug substitution if cosmetic effect of \\njaundice is likely to interfere with patient adherence  \\nDRV/r  Rash/hypersensitivity  Risk factors: sulfa allergy  \\nINSTIs  \\nAll \\nINSTIs  Weight gain  Risk factors: women; concomitant use of TAF  \\nProvide advice on healthy eating and physical activity to \\nmaintain a healthy weight  \\nRash/hypersensitivity  Consult (Uliza Hotline 0726 460 000, \\nhttps://nhcsc.nascop.org/clinicalform ) \\n DTG   Insomnia   Give in the morning; if no improvement then try giving \\nwith low fat meal or on empty stomach  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 149}),\n",
       " Document(page_content='  \\nAntiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 11  \\nAlternative explanations for toxicity must be excluded before concluding a reaction is secondary to an ARV.\\nConsider other medications and herbal remedies and diseases including opportunistic infections, immune \\nreconstitution inflammatory syndrome (IRIS), or other illnesses\\n2. Evaluate concurrent medications & any concurrent new \\nor pre -existing condition Establish whether adverse \\nevent is due to:  \\n• other drugs or drug -drug interaction\\n• other medical condition\\n• Inter -current illness or IRIS\\nAdverse Drug Reaction \\nidentifiedPresentation due to other \\nmedical condition\\n3.  Determine seriousness of adverse event Manage condition, continue ART\\nLife-threatening  \\n(Grade 4) Severe\\n(Grade 3) Moderate \\n(Grade 2)Mild \\n(Grade 1)\\nImmediately discontinue\\nALL drugs, including ARVs  \\nand manage the medical \\nevent. The patient often \\nrequires hospitalization \\nWhen the patient is stabilised, \\nreintroduce ARVs using a \\nmodified regimen (substitute \\nthe offending drug) *Substitute the offending \\ndrug without \\ndiscontinuing ART *. \\nMonitor the patient \\ncloselyContinue ARVs as long as \\nfeasible,  offer \\nsymptomatic relief if \\nappropriate. If no \\nimprovement consider \\nsingle drug substitution*Continue ARVs, offer \\nsymptomatic relief (if \\nappropriate)\\nPatients identified with ADR, review the patient progress at every clinic visit and \\ndocument their outcomes \\nReport suspected/confirmed adverse drug events by filling the Pharmacovigilance\\nform or online at www.pv.pharmacykenya.org1. Patient/caregiver \\nreports  possible \\nadverse eventHistory or clinical \\nassessment suggest \\nadverse eventLab tests indicate \\npossible problem \\nrelated to ART\\n1. At every clinic  visit the patient on ART should be monitored clinically for toxicities using history \\n(history of symptoms that suggest toxicity) and physical examination (relevant signs). Patients should be asked \\nspecifically about ADR known to be associated with their current ART. laboratory assessment may be \\nused to confirm specific  \\n2.  Evaluate concurrent medications and establish whether the toxicity is attributable to an ARV, or to a non-ARV \\nmedication taken at the same time. Consider  other disease processes concurrent infectious processes or \\n3.  All toxicities should be graded. Manage the adverse event according to \\n* Follow single-drug substitution algorithm (Figu re \\n \\nFigure 6.3: General Principles for Managing Adverse Drug Reactions  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 150}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 12  \\nPatients with specific reason for stopping an ARV  1\\nVL within last 6 months < \\n200 copies/ml\\nNo VL result within last 6 \\nmonths 1\\nVL within last 6 months   \\n200 copies/ml\\nCollect sample for VL\\nVL       copies/ml\\n• Proceed with single drug substitution\\n• Schedule clinical appointment at 2 weeks after regimen change \\nto review adherence, side effects and any other concerns\\n• Repeat VL 3 months after regimen modification followed by \\nroutine viral load monitoring\\n• Do NOT  change the current regimen unless \\nimmediate change required for clinical reasons1\\n• Follow viral load monitoring algorithm (Figure 6.6)\\nOn ART for < 3 months\\n On ART for     months\\nVL < 200 copies/ml \\n1 If an ARV must be changed for clinical reasons (adverse \\ndrug reaction; drug -drug interaction; co -morbidity; etc) \\nbefore viral load results available, Urgently consult Uliza \\nHotline (0726 460 000) or Regional or National TWG\\n \\nFigure 6.4: Managing Single Drug Substitutions for ART  \\n \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 151}),\n",
       " Document(page_content='  \\nAntiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 13 \\nAt every clinic visit, assess for risk of kidney disease:\\n•  Age > 60 years\\n•  Concurrent HIV associated diseases (such as TB and other OIs)\\n•  Concurrent diabetes, hypertension, viral hepatitis\\n•  Concomitant use of nephrotoxic drugs (e.g. aminoglycosides, \\namphotericin and boosted PIs)\\n•  Wasting, low BMI\\n•  CD4 count < 200 cells/mm3\\nIf any risk factor present\\nObtain a dip stick urinalysis and serum creatinine and calculate \\ncreatinine clearance (CrCl in ml/min, see Annex 15)1\\n4,5CrCl   29\\nAVOID: if there is no \\nsuitable alternative; give \\nTDF 300 mg every 72 \\nhours, monitor CrCl \\nmonthly 2CrCl    90 \\nTDF 300 mg OD: re -\\nassess creatinine and CrCl \\nat 1 month, 3 months and \\nbi-annually thereafter if \\nnormal3CrCl = 50 -89\\nTDF 300 mg OD, monitor \\nmore closely for decline in \\nrenal function (monthly \\nduring the first year, and 3 \\nmonthly thereafter if CrCl \\nremains stable4,5CrCl = 30 -49\\nAVOID: if there is no \\nsuitable alternative; give \\nTDF 300 mg every 48 \\nhours, monitor closely \\nwith monthly CrCl for the \\nfirst year, and 3 monthly \\nthereafter if stable\\n1 DTG may cause a small rise in serum creatinine levels but this does NOT represent a true decline in renal function\\n2 Obtain biannual serum Cr and CrCl in patients at risk of renal disease and a CrCl      ml/min\\n3 Patients with a CrCl      ml/min do not require TDF dose adjustment.\\n4 Avoid the use of TDF in patients with CrCl < 50ml/min unless in HIV/HBV coinfection (in which case TAF or TDF should \\nbe used). If HBV  negative and on first line ART, substitute TDF with  ABC, TAF or DTG + 3TC dual therapy. If prior ART \\ntreatment failure or any other scenario consult the Regional or National HIV Clinical TWG (Uliza Hotline 0726 460 000).  \\n5 3TC also requires dose adjustment once CrCl < 50 ml/min\\n* For patients with decreased renal function, assess for other causes of renal impairment and refer to physician for review \\nFigure 6.5: Managing TDF -Associated Kidney Toxicity  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 152}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 14 Table 6.6: ARV, CTX and Fluconazole Adjustments in Renal and Hepatic Impairment1 \\nDrug  CrCl (ml/min)  Haemodialysis  Liver impairment  \\n15 - 50 <15  \\n \\nABC   \\nNo change  Reduce adult dose to 200 mg BD for \\nmoderate to severe liver impairment. \\nAVOID in severe hepatic impairment  \\nAZT  No change  300 mg/day  300 mg/day  Reduce dose by 50% or double \\ninterval of administration in \\nmoderate to severe impairment  \\nTDF2 AVOID unless \\nHBV+2 AVOID unless \\nHBV+2 300 mg every 7 \\ndays  No change  \\nTAF  No change  AVOID unless \\nHBV+2 No dose adjustment - \\nAdminister after \\ndialysis  No change  \\n3TC  150 mg OD  150 mg OD  75 mg OD  No change  \\nLPV  No change  No change, use with caution in \\nmoderate to severe impairment  RTV  \\nATV  \\nDRV  \\nRAL  No change  \\n No change in mild to moderate \\nimpairment. Use with caution in \\nsevere impairment  DTG  \\nEFV  No change  \\n Use with caution in mild to moderate \\nliver impairment. AVOID in severe \\nimpairment  \\nNVP  No change  AVOID  \\nETV  No change  Use with caution in severe liver \\nimpairment  \\nCTX  If CrCl > 30 ml/min then no dose adjustment \\nrequired; if 15 -30 ml/min then use 50% of normal \\nrecommended dose; if CrCl < 15 ml/min then CTX \\nshould be avoided  Use with caution in mild to moderate \\nliver impairment. AVOID in severe \\nimpairment  \\nFluconazole  If CrCl ≤ 50 ml/min then use 50% of normal \\nrecommended dose (no dose adjustment required \\nfor CrCl > 50 ml/min)  Use with caution  \\n1 Patients with evidence of renal or hepatic impairment should have access to regular monitoring of renal \\nand liver function  \\n2 TDF and renal impairment:  \\n● In acute kidney injury (AKI), interrupt TDF administration until the cause of AKI is established and \\ncorrected.  \\n● Avoid the use of TDF in patients with CrCl < 50ml/min unless in HIV/HBV coinfection (in which case \\nTAF or TDF should be used). For patients wit h HBV co -infection, the benefit of TDF or TAF for treating \\nHBV often outweighs the risks of renal impairment, so more severe levels of renal impairment are \\ntolerated. See Table 9.3 for TDF and TAF dose adjustments for patients with HBV/HIV co -infection. \\nThese patients should be managed in consultation with an experienced clinician  \\n● If HBV negative and on first line ART, substitute TDF with ABC, TAF or DTG + 3TC dual therapy, \\nfollowing the single drug substitution algorithm (Figure 6.4). If prior ART treatmen t failure or any other \\nscenario consult the Regional or National HIV Clinical TWG (Uliza Hotline 0726 460 000; \\nhttps://nhcsc.nascop.org/clinicalform ) \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 153}),\n",
       " Document(page_content='  \\nAntiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 15 Table 6.7: Management of AZT -Associated Bone Marrow Suppression  \\nTest  Result  Action  \\n \\nHb (g/dL)  > 8.5 (and decrease \\nfrom pre -AZT \\nbaseline)  Retain AZT, repeat Hb at week 1, 2, 4 and 12 (if accessing \\nfollow -up Hb is difficult then consider substituting to an \\nalternative ARV immediately)  \\n≤ 8.5  Switch from AZT to an alternative ARV  \\n \\nNeutrophils  \\n(x 109/L) 1.0 – 1.5 (and decrease \\nfrom pre -AZT baseline, \\nif available)  If receiving cotrimoxazole consider withholding unless \\nessential. Retain AZT, repeat at week 1, 2, 4 and 12 (if \\naccessing follow -up neutrophils is difficult then \\nconsider s witching to an alternative ARV immediately)  \\n≤ 1.0  Switch from AZT to an alternative ARV  \\nNote:  \\n● Patients with baseline Hb of < 9.5 g/dL should not be initiated on AZT; patients who develop \\nanaemia while on AZT should be managed as per this table  \\n● AZT -associated bone marrow suppression occurs early in the course of treatment, usually within \\n3 months of initiating ART  \\n● All patients with anaemia and/or neutropenia, whether on AZT or not, should be evaluated for \\nother likely causes of anaemia/neutropenia and managed appropriately  \\n \\nTable 6.8: Management of Drug -Related Hepatotoxicity  \\nALT  <2.5 x Upper Limit of Normal (ULN)  2.5 – 5 x ULN  > 5 x ULN  \\nAction  Retain regimen, repeat in 2 weeks  Retain regimen, \\nrepeat in 1 week  Discontinue offending drug/s  \\nConsult senior clinician for \\nnext step  \\nNote: All patients with acute increase in liver enzymes should be evaluated for other likely causes of \\nhepatitis/hepatotoxicity and managed appropriately  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 154}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 16 Table 6.9: Diagnosis and Management of Abacavir Hypersensitivity Reaction  \\nDiagnosis  \\nWithin 3 weeks of initiating an ABC -containing regimen , patient develops any 2 of the following \\nsymptom groups concurrently  \\n• Fever  \\n• Erythematous and/or pruritic rash  \\n• Respiratory symptoms (shortness of breath and/or sore throat and/or cough)  \\n• GI symptoms: nausea and/or vomiting and/or diarrhea  \\n• Extreme fatigue and/or body pain preventing normal activities  \\nAND: there is not a more likely alternative explanation for the symptoms  \\nManagement  \\n• Stop ABC immediately and substitute with an alternative ARV  \\n• Patient must NEVER be re -challenged with ABC – a single dose could result in a fatal \\nhypersensitivity reaction  \\n• Clearly mark file and educate patient about avoiding ABC in future  \\n• Issue an Adverse Event alert card  \\nNote:  \\n• ABC hypersensitivity reaction is rare in our population: always consider other more likely possible \\ndiagnoses  \\n• Symptoms generally get worse within hours after each dose of ABC  \\n \\n \\n6.5.3 Changing ARVs Due to Drug -Drug Interactions  \\nPatients must be asked about other medications (including non -prescription and herbal \\nmedicine) they are taking at every visit. Some common drugs have specific drug -drug interactions \\nthat may require dose adjustment or substitution o f the ARV or the other interacting drugs. \\nCommon medications that interact with specific ARVs include: rifampicin, rifabutin, antacids, \\nmultivitamin/mineral supplements, methadone, several anti -fungal, anti -convulsant, calcium -\\nchannel blockers, some anti -depressants, some statins, and some anti -malarial. Annex 13 \\nprovides common drug -drug interactions and management recommendations. It is \\nrecommended practice to check for interactions whenever a new medicine is started.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 155}),\n",
       " Document(page_content='  \\nAntiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 17 6.5.4 Changing ARVs Due to Treatmen t Failure  \\nViral load is the test of choice for monitoring response to ART and identifying treatment failure. \\nFirst VL should be performed 3 months after ART initiation for all PLHIV.   \\nTreatment failure should be suspected when a new or recurrent HIV -associ ated condition \\nindicating severe immunodeficiency (WHO stage III or IV condition) develops after at least 6 \\nmonths on ART. Treatment failure should always be confirmed with VL testing.  \\nFrequency of routine VL monitoring for specific populations is:  \\n● Age 0-24 years old: at 3 months after ART initiation and then every 6 months  \\n● Age ≥ 25 years old: at 3 months after ART initiation, then at month 12 and then \\nannually  \\n● Pregnant or breastfeeding: at confirmation of pregnancy (if already on ART) or 3 \\nmonths after ART initiation (if ART initiated during pregnancy/ breastfeeding), and \\nthen every 6 months until cessation of breastfeeding  \\n● Before making any drug substitution (if no VL results from the prior 6 months)  \\n● Three months after any regimen modification (includin g single -drug substitutions), \\nand then as per population group  \\n● For any patient with a detectable VL follow the viral load monitoring algorithm \\n(Figure 6.6)  \\n \\nInterpreting Viral Load Results and Defining Treatment Failure (Figure 6.6)  \\nThe goal for ART is t o achieve sustained viral suppression defined as below the Lower Detection \\nLimit (LDL), < 50 copies/ml is considered as suppressed.  See Table 5.17  \\nPersistent low -level viremia (PLLV) is defined as having between 200 -999 copies/ml on \\ntwo consecutive measures.  These patients are at increased risk of progression to treatment \\nfailure, development of resistance and death and therefore require a similar case management \\napproach as patients with VL ≥ 1,000 copies/ml, and consultation with the Re gional or National \\nHIV Clinical TWG (Uliza Hotline 0726 460 000; https://nhcsc.nascop.org/clinicalform ).  \\nTreatment failure is suspected when a patient has a high VL ≥ 1,000 copies/ml after at least \\n3 months of using ART.  Treatment failure is only confirmed when VL is ≥ 1,000 copies/ml after \\nassessing for and addressing poor adherence or other reasons for high VL, and then repeating VL \\nafter at least 3 months of enhanced adherence to allow for viral re -suppression.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 156}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 18 \\nSchedule for routine viral load testing1 \\n• Age 0 -24 years old: at month 3, then every 6 months \\n• Age      years old: at month 3, then month 12 and then annually \\n• Pregnant or breastfeeding: at confirmation of pregnancy (if already on ART) or 3 months after ART initiation (if ART initiate d during \\npregnancy/breastfeeding), and then every 6 months until complete cessation of breastfeeding \\n• Before any drug substitution (if no VL result available from the prior 6 months) \\n• Three months after any regimen modification (including single -drug substitutions) \\nVL < 200 copies/ml\\n VL 200 – 999 copies/ml\\n VL         copies/ml\\nIncreased risk of progression to \\ntreatment failure\\nSuspected treatment \\nfailure\\n• Discuss patient in MDT \\n• Assign a case manager \\n• Assess for and address likely causes of non -adherence2 \\n• Provide enhanced adherence support/intervention as appropriate (Section \\n5.4 of guidelines for enhanced adherence protocol) \\n• Assess for other causes of viremia and manage as needed3 \\n• Support daily witnessed ingestion by treatment buddy or healthcare worker\\n• After 3 months of excellent adherence, repeat VL \\nVL < 200 copies/ml (LDL)\\nVL 200 – 999 copies/ml\\nVL         copies/ml\\n• Continue ART regimen\\n• Routine adherence \\ncounselling and monitoring\\n• Routine VL monitoring\\n• Reassess adherence and other \\ncauses of viremia2,3\\n• Repeat VL after another 3 months of \\nexcellent adherence\\nConfirms treatment failure: \\n• Begin treatment preparation for new regimen and \\ncontinue failing regimen until adherence \\npreparation completed \\n• Continue enhanced adherence support \\n• Take sample for CD4 count and assess for and \\nmanage any OIs \\n• If failing a DTG or PI based regimen a DRT is \\nrecommended in consult ation with the  regional or \\nNational HIV Clinical TWG or call Uliza Hotline \\n       (0726 460 000)  \\n• Schedule clinical appointment at 2 weeks after \\nregimen change to review adherence, side effects \\nand any other concerns \\n• Repeat VL 3 months after regimen modification \\nConsult Regional or National HIV \\nClinical TWG or call Uliza Hotline \\n(0726 460 000)\\nVL 200 – 999 copies/ml\\n1. As part of treatment preparation, patients should be informed that \\nviral load is the recommended method of monitoring ART. VL results \\nshould always be discussed with patients, even when they are \\nundetectable. Goals of treatment and definition of success should be \\ndiscussed and adherence messaging reinforced \\n2. Common causes of poor adherence include: stigma, non -disclosure, \\ntravel, toxicities, alcohol or drug use, mental health disorder, religious \\nbeliefs, inadequate treatment preparation, chaotic lifestyle, lack of \\nsupport systems, and poor patient -provider relationship \\n3. Other common causes of treatment failure (beyond adherence) \\ninclude: inadequate dosing/dose adjustments, drug -drug \\ninteractions, drug -food interactions, impaired absorption (e.g. \\nchronic severe diarrhoea)  \\n Figure 6.6: Viral Load Monitoring of Patients on ART (1st Line or 2nd Line)  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 157}),\n",
       " Document(page_content='  \\nAntiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 19 Non -adherence is the most frequent cause of treatment failure. As per the viral load \\nmonitoring algorithm, adherence issues must be addressed BEFORE confirming \\ntreatment failure.  \\nDaily witnessed ingestion by a treatment buddy or healthcare worker is recommended to confirm \\nexcellent adherence before repeating the VL. All adherence issues must be resolved before \\nswitching to a new regimen otherwise the patient will quickly fail the n ew regimen as well, and \\nsoon run out of viable ART options. An exception to this may be when the regimen itself is \\nthe primary cause of poor adherence  (e.g., side effects from one of the ARVs are not \\nmanageable such as severe diarrhea with LPV/r that does not improve with symptom \\nmanagement), in which case the regimen may need to be modified to allow for perfect adherence. \\nThis should be done in consultation with the Regional or National HIV Clinical TWG.  \\nChapter 5 provides detailed guidance on adherence pr eparation, assessment, and support.  \\nTable 6.10: Recommended Second -line ART Regimens in Infants, Children, Adolescents and \\nAdults, excluding TB/HIV co -infection 1 \\nWeight/scenario  First -line ART  Second -line ART  \\n \\n< 30 kg  ABC (or AZT) + 3TC + DTG  DRT -based second -line2,3  \\nABC + 3TC + LPV/r  Take sample for DRT and change to AZT + \\n3TC + DTG while awaiting DRT results; \\nmodify based on DRT results if indicated  \\nAZT + 3TC + LPV/r  Take sample for DRT and change to ABC \\n+ 3TC + DTG while awaiting DRT results; \\nmodify based on DRT results if indicated  \\nABC + 3TC + EFV  AZT + 3TC + DTG  \\nAZT + 3TC + EFV  ABC + 3TC + DTG  \\n \\n≥ 30 kg or ≥ 15 \\nyears old  TDF (or ABC) + 3TC + DTG (or PI/r)  DRT -based second -line2 \\nTDF (or ABC) + 3TC + EFV  TDF + 3TC +  DTG  \\nAZT + 3TC + EFV  TDF + 3TC + DTG  \\nPregnant and \\nBreastfeeding \\nwomen  TDF (or ABC) + 3TC + DTG  Take sample for DRT and change to TDF \\n+ 3TC + ATV/r while awaiting DRT \\nresults; modify based on DRT results if \\nindicated  \\nTDF (or ABC) + 3TC + PI/r  Take sample for DRT and change to TDF \\n+ 3TC + DTG while awaiting DRT results; \\nmodify based on DRT results if indicated  \\nTDF (or ABC) + 3TC + EFV  TDF + 3TC + DTG  \\nAZT + 3TC + EFV  TDF + 3TC + DTG  \\nHIV/HBV Co -\\ninfection  Always maintain TDF in order to treat the HBV as well as HIV  \\nTB/HIV Co -\\ninfection  Refer to Table 8.8: Recommended ART Regimens for Patients who Develop TB \\nwhile Failing  1st Line ART  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 158}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 20 Table 6.10 Cont.  \\n1. If any drug in the recommended 2nd line regimen is contraindicated or previously not tolerated, \\nconsult the Regional or National HIV Clinical TWG (Uliza Hotline 0726 460 000; \\nhttps://nhcsc.nascop.org/clinicalform ). Such patients may require DRT to select agents for the \\nsecond -line ART. Add itional drugs may be recommended on a case -by-case basis, including DRV/r, \\nATV/r, RAL, or ETR  \\n2. Patients failing DTG -based or PI -based first -line regimens should have a Drug Resistance Test \\n(DRT) ordered as soon as treatment failure is confirmed. The patient  summary and DRT results \\nshould be sent to the Regional or National HIV Clinical TWG \\n(https://nhcsc.nascop.org/clinicalform ) or call Uliza Hotline (0726 460 000) to determine the \\nmost suitable second -line regimen for the patient. The DRT results will be us ed to determine if \\nthere is true DTG or PI failure or if there is an underlying problem with non -adherence. Daily \\nwitnessed ingestion is recommended prior to performing DRT  \\nImportant Considerations for First -line Treatment Failure in Children  \\n● Second -line ART in infants and children is more complex to manage. These children and \\ntheir caregivers should undergo thorough clinical and psychosocial assessment to rule \\nout inter -current illness or non -adherence as the reason for a high viral load  \\n● All c hildren failing first -line should be discussed in the MDT and preferably with an \\nexperienced ART provider prior to change of ART to second -line. However, this should \\nnot cause undue delay in switching a failing regimen  \\n● The choices for infants and children failing an alternative first -line regimen are limited \\nand may need to be discussed with the Regional or National HIV Clinical TWG. Some of \\nthese children will require HIV DRT to determine the most suitable second -line regimen  \\nImportant considerations for s econd -line ART Treatment Failure  \\n● Patients failing second -line ART have limited options. ARVs used to construct a third -line \\nregimen are often more expensive, will have increased pill burden and more side effects. \\nThese factors will exacerbate pre -existing poor adherence  \\n● Second -line treatment failure should be confirmed by viral load testing following the \\nviral load monitoring algorithm (Figure 6.6)  \\no After the first detectable VL ( \\uf065 50 copies/ml), assess for and address all causes of \\npoor adherence, and assess for all other possible causes of viremia.  \\no These patients should be discussed at an MDT session. Repeat the VL after 3 months \\nof excellent adherence (preferably with daily witn essed ingestion of the ARVs by a \\ntreatment buddy, relative, CHV, etc.).  \\no If the second VL is still \\uf065 50 copies/ml then continue the failing second -line regimen \\nwhile reassessing adherence and other causes of viremia, implementing adherence \\nsupport systems as needed, and then repeat the VL after another 3 months.  \\no If viremia continues then consult the Regional or National HIV Clinical TWG (Uliza \\nHotline 0726 460 000; https://nhcsc.nascop.org/clinicalform ) using the national \\ncase summary form (Annex 9B). These patients will likely require DRT in order for \\nthe TWG to design the most suitable third -line regimen  \\n● Patients failing second -line ART require thorough assessment for barriers to adherence \\nand ongoing enhanced adherence support including  \\no Assigning a case manager  \\no More frequent adherence counselling by a trained counsellor  \\no Assessment and treatment of mental health and substance use disorders  \\no Provision of adherence support such as modified directly observed therapy, a \\ntreatment supporter, hom e visits etc.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 159}),\n",
       " Document(page_content='  \\nAntiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 21 Table 6.11: Possible Third -line ART in Children, Adolescents and Adults  \\n Possible 3rd Line Regimen  Comment  \\n \\nChildren  DTG + 3TC + DRV/r  Third line ART selection is based on DRT \\nresults  \\nNote that the Regional or National \\nHIV Clinical TWG may recommend \\nreusing some of the ARVs the \\npatient has already failed, even \\nwhen resistance is present  DTG + AZT + 3TC + DRV/r  \\nDTG + ABC (or TDF) + 3TC + DRV/r  \\nETV + 3TC + DRV/r  \\nAdults  DTG + 3TC + DRV/r  \\nDTG + AZT + 3TC + DRV/r  \\nDTG + TDF + 3TC + DRV/r  \\nDTG + TDF (or AZT) + 3TC  \\nETV + 3TC + DRV/r  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 160}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 22   ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 161}),\n",
       " Document(page_content='  \\nPrevention of Mother to Child Transmission of HIV/Syphilis/Hepatitis B  \\n  7 - 1  \\n7. Prevention of Mother to Child Transmission of \\nHIV/Syphilis/Hepatitis B  \\nRoutine antenatal care (ANC) offers an important opportunity to provide high quality combined \\nHIV prevention throug h targeted health education and counselling; HIV testing for the woman, \\npartners and family members; linkage to HIV prevention and treatment; and to discuss and plan \\nfor future conception and contraception needs. Prevention of mother -to-child transmission of HIV \\n(PMTCT)/Syphilis/Hepatitis B should be offered as part of a comprehensive package of fully \\nintegrated, routine antenatal care interventions (Table 7.1).  \\nTable 7.1: Essential Package of Antenatal Care  \\nIntervention  Recommendation/Description  \\n \\nGroup & \\nIndividual \\nEducation  Include information on importance of at least 8  ANC visits, details of ANC services \\n(including health checks and treatment of any illness, medical tests including HIV, \\nsyphilis testing and hepatitis B, monitoring of maternal and fetal wellbeing, etc.), \\nnutrition, personal care, recognizing and responding to danger signs during \\npregnancy, birth preparedness including skilled birth attendance, post -natal care \\nincluding immunization, family pla nning and maternal and infant nutrition, HIV \\nprevention and treatment (HTS, preventing new infections during pregnancy \\nincluding PrEP where appropriate, ART for those who are HIV positive, monitoring of \\nART and ARV prophylaxis and follow -up for HEIs) and t riple elimination (preventing \\nHIV/ syphilis/hepatitis B transmission from mother to child).  \\nCounselling  ● Pre-conception – Women in reproductive age who are known to be HIV positive \\nshould have pregnancy intention assessment visit at every visit. If they desire to \\nbecome pregnant, pregnancy should be planned i.e., attain viral load suppression, \\nimmune reconsti tution and have Iron and Folic Acid Supplementation (IFAS) \\nadministered prior to conception.  \\n● Women who are newly diagnosed with HIV and/or newly initiating ART require \\nmore intensive adherence counseling and HIV education, which may include a case \\nmanager  and/or mentor mother  \\n● Birth preparedness: support the pregnant woman and her partner to develop an \\nindividual birth plan that includes place of delivery with skilled attendants, \\nemergency transport, birth companionship and readiness for infant care  \\n● Pregnan cy danger signs: offer information on returning to ANC as soon as possible \\nin case they develop fever, lower abdominal pain, severe headache, swollen feet, \\nconvulsions and per vaginal bleeding.  \\n● Maternal, infant and young child nutrition (MIYCN): All pregn ant women should \\nreceive information on proper nutrition during pregnancy and breastfeeding, safe \\ninfant feeding and optimal nutrition practices. Promote exclusive breastfeeding for \\nthe first 6 months irrespective of HIV status, followed by complementary f eeding \\n(Table 7.7). During pregnancy, provide iron, folate and multivitamins; monitor for \\nanemia, advise on adequate caloric intake (HIV positive women require an \\nadditional 10% of recommended daily allowance (RDA))  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 162}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n7 - 2 Table 7.1 Cont.  \\nCounselling  ● HIV testing services  \\no All pregnant women (unless known HIV positive) should be counselled and \\ntested for HIV, syphilis and Hepatitis B during their first ANC visit and if \\nnegative, repeat HIV and syphilis testing in the third trimester.  \\no All pre gnant and breastfeeding mothers with continued HIV risk (Key \\npopulations) should be counseled and tested for HIV every 3 months until post -\\ncessation of breastfeeding.  \\no Pregnant and breastfeeding mothers should be educated and offered a self -test \\nkit for th eir sexual partner(s)  \\no At Labour and delivery, HIV testing should be done for all women with \\nunknown HIV status or that previously tested negative, even if tested during \\nthe third trimester  \\no All breastfeeding mothers (unless known HIV positive) should be co unselled \\nand tested at the 6 -week infant immunization visit. The HIV test (if negative) \\nshould be repeated every 6 months until complete cessation of breastfeeding. \\nNote:  key population mothers (FSWs and PWIDs) get retested every 3 months \\n(Table 2.5)  \\no Women should be counselled about the schedule for repeat HIV testing in \\npregnancy and postnatally as part of routine ANC and postnatal education  \\no All pregnant and breastfeeding women who are not tested, opt -out or decline \\nHIV, Syphilis or Hepatitis testing during the first contact should be offered \\ncounselling and testing in subsequent visits with appropriate linkage and \\nreferral for prevention, care and support services. Daily Witnessed Ingestion \\n(DWI) is advised to support Viral suppression for newly initi ated clients and \\nthose whose regimens are being switched. This is to support viral suppression \\namong women with high viral load.  \\no All HIV positive pregnant and breastfeeding women enrolled into care should \\nreceive counselling and support (including assiste d disclosure), case \\nmanagement linkage and follow -up for comprehensive treatment and \\nprevention (including lifelong ART)  \\no All Syphilis and Hepatitis B positive clients should be given appropriate care as \\ndefined in Table 7.3 “triple elimination”.  \\no All partn ers of pregnant and breastfeeding women should be offered HIV \\ntesting and counselling and all biological children if the mother is HIV positive  \\n● All pregnant and breastfeeding women should receive information on risk \\nreduction, including PrEP where appropri ate \\n● Post -partum contraception: counsel on contraception methods and help patient \\ndevelop a plan for effective contraception from 6 -weeks post -partum to avoid \\nunplanned pregnancies  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 163}),\n",
       " Document(page_content='  \\nPrevention of Mother to Child Transmission of HIV/Syphilis/Hepatitis B  \\n  7 - 3 7.1 Antiretroviral Therapy for HIV -positive Pregnant and Breastfeeding \\nWomen and Infant Prophylaxis  \\nThe goal of ART for HIV positive pregnant women is two -fold: to restore and maintain the \\nmother’s immune function and therefore general health, and secondly, to prevent transmission \\nof HIV in utero, at labour and delivery and during breastfeeding. To achieve this goal, the mother \\nmust take effective antiretroviral therapy to achieve viral suppression.  Table 7.2 summarizes \\nrecommendations for use of ART for HIV positive pregnant women.  \\nTable 7.2: Summary of Use of A RT for HIV Positive Pregnant and Breastfeeding Women  \\nOverall recommendations  \\nWhen to start  ART should be initiated in all pregnant and breastfeeding women living with HIV, \\nregardless of gestation, WHO clinical stage and at any CD4 cell count and continued \\nlifelong. ART should be started, ideally, on same day as HIV diagnosis after \\nreadiness asse ssment with ongoing enhanced adherence support including \\ncommunity -based case management and support.  \\nWhat to start with \\n(first -line ART)  TDF/3TC/DTG  \\nInfant \\nprophylaxis  ● AZT+NVP for 6 weeks, NVP should be continued until 6 weeks after complete \\ncessation of breastfeeding  \\nFor more comprehensive information Refer to Table 7.3  \\nMonitoring       Viral load  monitoring during pregnancy and breast -feeding (Figure 6.6)  \\n● Whenever possible, use same -day point -of-care methods for viral load \\ntesting of pregnant and breastfeeding women to expedite the return of \\nresults and clinical decision -making. If this is not available, viral load \\nspecimens and results for pregnant and breastfeeding women should be \\ngiven priority across the laboratory referral process  (including specimen \\ncollection, testing and return of results).  \\n● For pregnant and breastfeeding women newly initiated on ART, obtain VL 3 \\nmonths after initiation, and then every 6 months until complete cessation of \\nbreastfeeding  \\n● For HIV positive women already on ART at the time of confirming pregnancy \\nor breastfeeding, obtain a VL irrespective of when prior VL was done, and \\nthen every 6 months until complete cessation of breastfeeding  \\n● For pregnant or breastfeeding women with a VL ≥ 50 copies/ml: assess for \\nand address potential reasons for viremia, including intensifying adherence \\nsupport, repeat the VL after 3 months of excellent adherence, including \\ndaily witnessed ingestion, where feasible and appropriate  \\no If the repeat VL is 200 - 999 copies/ml consul t the Regional or National \\nHIV Clinical TWG  \\no If the repeat VL is ≥ 1,000 copies/ml, change to an effective regimen. \\nRefer to Table 6.10  \\no If the repeat VL is < 200 copies/ml (LDL) then continue routine \\nmonitoring  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 164}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n7 - 4 Table 7.2 Cont.  \\nScenario  \\nPre-conception planning \\nfor women already on \\nART (not yet pregnant)  Maintain ART  \\nCarry out a VL test if not done in the prior six months to confirm viral \\nsuppression (Figure 6.6)  \\nRefer to Table 4.8 for pre -conception care for women on ART who desire \\npregnancy, including laboratory screening, TT immunization, folate, etc.  \\nOn ART at the time of \\nconfirming \\npregnancy/breastfeeding  Maintain ART.  \\nCarry out a VL at first identification of pregnancy, irrespective of when a \\nprior viral load was done, to confirm viral suppression (Figure 6.6)  \\nManage the baby as HEI (Figure 2.1 for EID, and Table 7.3 for infant \\nprophylaxis)  \\nNot on ART at the time of \\nconfirming pregnancy  Prepare the patient and start on ART as soon as possible.  \\nART initiation should occur preferably on the same day HIV infection is \\nconfirmed. Perform VL 3 months after ART initiation.  \\nPregnant and breastfeeding women with a history of treatment \\ninterruption returning to care should have reasons for interruption \\nassessed and preferentially re -started on a DTG -containing regimen \\nunless the reason for interruption was DTG intolerance or failure. Viral \\nload monitoring in this case should be done after 3 months of initiation \\nand 6 months thereafter until cessation of breastfeeding . Additional \\nadherence support should be made available.  \\nNot on ART during \\nlabour and delivery  Start on ART during labour.  \\nAfter delivery, continue treatment preparation and adherence support and \\ncontinue ART  \\nManage the baby as HEI (Figure 2.1 for EID, a nd Table 7.3 for infant \\nprophylaxis)  \\nNot on ART during \\npost -\\npartum/breastfeeding  Prepare (readiness assessment) and start on ART as soon as possible \\npreferably on the same day HIV infection is confirmed.  \\nManage the baby as HEI (Figure 2.1 for EID, and Table 7.3 for infant \\nprophylaxis). Adherence support for both mother and infant, con sider \\ndaily witnessed ingestion (DWI) support.  \\nManaging labour and \\ndelivery  Minimize vaginal examinations, use aseptic techniques to conduct delivery, \\navoid artificial rupture of membranes, monitor labour and avoid prolonged \\nlabour by use of the partograph, avoid unnecessary genital tract trauma  \\nNote that certain patient groups e.g., recent HIV infections, pregnant adolescent girls and young \\nwomen, women with previous children with HIV infection, patients with high viral load at time of \\npregnancy  confirmation, patients with poor social support systems, patients with history of \\ndefault from care and those with active co -morbidities etc. may require additional adherence and \\npsychosocial support  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 165}),\n",
       " Document(page_content='  \\nPrevention of Mother to Child Transmission of HIV/Syphilis/Hepatitis B  \\n  7 - 5 7.2. Syphilis elimination for Pregnant and Breastfeed ing Women and Infant \\nTreatment  \\nThe country has adopted triple elimination of HIV, Syphilis and Hepatitis B among pregnant and \\nbreastfeeding women. It is recommended that all pregnant women attending ANC and not aware \\nof their HIV status require a dual HIV syphilis test during their first trimester and a second HIV \\nSyphilis test in the 3rd trimester if the initial test was negative.   \\nAll women who test positive for syphilis at any point during pregnancy and breastfeeding should \\nbe treated with the appropria te regimen. (Table 7.3). All babies born of mothers who test positive \\nfor syphilis are suspected to be exposed to syphilis and should also be treated with the correct \\nregimen (Table 7.3). Ensure to perform contact tracing for all the sexual contacts and en sure they \\nare treated for syphilis.  \\nSymptoms of congenital syphilis may not become apparent for several weeks or months after \\nbirth.  \\n7.3. Hepatitis B elimination for Pregnant and Breastfeeding Women and Infant \\nProphylaxis  \\nRequires routine testing of pregnant women to identify women in need of antiviral treatment for \\ntheir own health and additional interventions to reduce Mother to Child Transmission of viral \\nhepatitis B.  \\nRegular screening should be done by incorporation of viral hepatitis screening as  part of the ANC \\nprofile. This is recommended for Hepatitis B & C which pose a big risk to both the mother and \\nfetus.  \\nFor pregnant and breastfeeding women who are found to be positive for HBsAg, offer appropriate \\ntreatment options of ARVs containing TDF/3TC or FTC containing regimens. This treatment also \\nacts as prophylaxis for HBV transmission from mother to child. All pregnant and breastfeeding \\nwomen without evidence of hepatitis B infection (HBsAg negative) should be vaccinated against \\nhepatitis B. (Chapter 9).  \\nHIV positive infants without evidence of infection should be vaccinated against Hepatitis B.  \\nInfants born of mothers who test positive for HBsAG should be treated using Hepatitis B \\nImmunoglobulin (Table 7.3).  \\nRefer to Chapter 9 f or management of HIV/HBV coinfection.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 166}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n7 - 6 Table 7.3: ARV Prophylaxis for HIV -Exposed Infants  \\nInfant Scenario  Infant Prophylaxis  Maternal Scenarios  \\nHIV Exposed \\nInfant  ● Infant prophylaxis  \\no AZT+NVP for 6 weeks, NVP + cotrimoxazole should be \\ncontinued until 6 weeks after complete cessation of \\nbreastfeeding  \\no Infant prophylaxis can be discontinued after a minimum \\nof 12 weeks on NVP if the child is not breastfeeding (death \\nof mother or separation with mother)  \\no The infant prophylaxis regimen applies to all infants \\nirrespective of age when identifying HIV exposure (e.g., \\nmother diagnosed HIV -positive in the  postpartum  period)  \\n● DBS or whole blood for PCR at 6 weeks or first contact, \\nfollowing EID algorithm (Figure 2.1)  \\n● Birth testing (Figure 2.2) may be conducted in sites \\nwhere point of care has been implemented and when \\nmedically indicated  If mother not on ART, initiate \\nART as soon as possible \\n(preferably same day)  \\nIf mother is on ART for ≥ 3 \\nmonths and the VL is ≥ 50 \\ncopies/ml, intensify adherence, \\nrepeat the VL  \\n \\nIf VL <50 copies/ml, continue \\ncurrent regimen  \\nFollow Viral load algorithm \\nFigure 6.6  \\nTRIPLE ELIMINATION  \\nCONDITION in \\nmother  INFANT MANAGEMENT  MATERNAL MANAGEMENT  \\nSyphilis -VDRL \\nor diagnosed \\nwith Dual kit  Crystalline Penicillin 50,000 IU/kg BD (if <7 days) or TDS if \\n(>7 days old) for a total of 10 days.  Penicillin G 2.4 MU IM Stat or \\nCeftriaxone 1gm IM daily for 8 -10 \\ndays in case of penicillin allergy.  \\nCongenital \\nsyphilis    \\nHepatitis B – \\nHbsAg test  Hepatitis B immunoglobulin 0.5ml IM within 12 hours after \\nbirth. Hepatitis B vaccine 0.5ml three doses at birth, 1 month \\nand 6 months.  Refer to viral hepatitis \\nmanagement guidelines  \\nNote: If child has contraindication or unable to tolerate NVP or AZT then give the tolerated drug up to complete \\ncessation of breastfeeding. If the infant is on AZT prophylaxis, give up to a minimum of 12 we eks or until maternal viral \\nload is suppressed. In situations where neither AZT nor NVP are tolerated 3TC may be used as a third option if available.  \\nHIV exposed infants with TB infection, infant prophylaxis should include AZT plus 3TC fixed dose (60/30 mg ). For 12 \\nweeks or until maternal viral load is suppressed (3 -5.9 – 1 tab BD, 6 -9.9kg 1.5tab BD, 10 -13.9 kg 2 tabs BD).  For more \\ndetails, refer to Annex 10 A.  \\nAfter TB treatment, revert to NVP until 6 weeks post cessation of breastfeeding,  \\nHB monitoring should be done to all HEIs on AZT prophylaxis as per the recommendations (Table 6.7: management of \\nAZT associated bone marrow suppression)  \\nGroups considered higher risk for mother to child transmission who may need additional adherence and \\npsych ological support include:  \\n● All new HIV positives irrespective of time identified  \\n● HIV positive adolescent Girls and Young Women (AGYW) <19 yrs. including OVC  \\n● VL >200 copies/ml  \\n● Clients with stigma, declining treatment, poor adherence   \\n● PMTCT client with previous HIV infected infant  \\n● Client with active comorbidities - DM, OIs, malnourished (low MUAC), mental health etc.  \\n● Clients who sero -convert during ANC/PNC follow up  \\n● Poor socio -economic and family support structures   \\n● Those who drop of f ART  \\n● Key population – FSW, PWID  \\nAlcohol use and brewers/sellers  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 167}),\n",
       " Document(page_content='  \\nPrevention of Mother to Child Transmission of HIV/Syphilis/Hepatitis B  \\n  7 - 7 Table 7.4: Dosing of ARVs for Infant Prophylaxis from Birth to 12 Weeks of Age  \\nAge/Weight  Dosing of NVP (10mg/ml) OD  Dosing of AZT (10mg/ml) BD  \\nBirth to 6 weeks  \\nBirth weight < 2,000 g  2 mg/kg per dose, OD  4 mg/kg per dose, BD  \\nBirth weight 2,000 -2,499 g  10 mg (1 ml), OD  10 mg (1 ml), BD  \\nBirth weight ≥ 2,500 g  15 mg (1.5 ml), OD  15 mg (1.5 ml), BD  \\n> 6 weeks to 12 weeks of age*  \\nAny weight  20 mg (2 ml), OD  60 mg (6 ml), BD  \\n> 12 weeks (Table 7.5 and 7.6)  \\n*Dose adjustment required once child reaches 6 weeks of age  \\nIf older infant beyond 6 weeks of age is newly identified as HIV exposed infant, should be given \\nAZT+NVP for 6 weeks, NVP + cotrimoxazole should be continued until 6 weeks after complete \\ncessation of breastfeeding  \\nTable 7.5: NVP Dosing for Infant Prophylaxis beyond 12 Weeks of Age *  \\nAge  Dosing of NVP (10mg/ml) Once Daily  \\n12 weeks – 6 months  25 mg (2.5 ml), OD  \\n7 months – 9 months  30 mg (3 ml), OD  \\n10 months – 12 months  40 mg (4 ml), OD  \\n> 12 months  Consult the Regional or National HIV Clinical TWG (Uliza \\nHotline 0726 460 000; \\nhttps://nhcsc.nascop.org/clinicalform ) \\n* If child presents to facility late and has to be on AZT and NVP beyond 12 weeks of age \\nTable 7.6: AZT Dosing for Infant Prophylaxis beyond 12 Weeks of Age *  \\nWeight  Dosing of AZT: (10mg/ml syrup) Twice Daily  \\n3.0-5.9 kg  6 ml, BD  \\n6.0-9.9 kg  9 ml, BD  \\n10.0 -13.9 kg  12 ml, BD  \\n14.0 -19.9 kg  15 ml, BD  \\n* If child presents to facility late and has to be on AZT and NVP beyond 12 weeks of age  \\n7.4 Infant and Young Child Nutrition in the Context of HIV  \\n● Exclusive breastfeeding  involves giving the baby only breast milk with no other liquids \\n(including water) or solids for the first six months of life. Giving of vitamins, mineral \\nsupplements or medicines are permitted if prescribed.  \\n● Mixed feeding  is giving other liquids and/or foods together with breast milk to infants \\nunder 6 months of age and is not recommended.  Mixed feeding during thi s period is \\nassociated with significantly higher risk of mother -to-child HIV transmission, diarrhoeal \\nand respiratory tract illnesses, among other consequences and should be prevented  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 168}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n7 - 8 ● All infants irrespective of HIV status should be exclusively breastfed f or the first 6 months \\nof life, with timely introduction of appropriate complementary foods after 6 months, and \\ncontinued breastfeeding up to 24 months or beyond.  \\n● Should mothers be physically separated from their infants (back to work), support them \\nto sust ain lactation and to exclusively breastfeed including mentorship on expressing \\nbreast milk (refer to current MIYCN Policy)  \\n● All mothers, irrespective of HIV status, should be encouraged and supported to \\nexclusively breastfeed for the first six months and co ntinue breastfeeding with \\nappropriate complementary feeding after 6 months, for a period of 24 months or beyond. \\nBreastfeeding should ONLY stop once a nutritionally adequate and safe diet without \\nbreast milk can be sustained.  \\n● HIV positive mothers and HIV p ositive infants should always be on ART and given extra \\nattention for adherence support, VL monitoring and optimal retention in care  \\n● Breastfeeding mothers who do not know their HIV status or who previously tested HIV \\nnegative should be encouraged to be ret ested for HIV at the 6 -week immunization visit, \\nand then every 6 months thereafter until complete cessation of breastfeeding (Table 2.5)  \\n● Access for HIV testing and STI/HIV prevention interventions should be reinforced for \\npartners of pregnant and breastfee ding women  \\n● Mothers who are diagnosed with HIV while breastfeeding should immediately start \\nappropriate ART, giving extra attention to adherence support, VL monitoring, and optimal \\nretention in care. The infant should immediately start ARV prophylaxis and r eceive PCR \\ntesting (Table 7.3).  \\n● Mothers who decide to stop breastfeeding at any time should stop gradually within one \\nmonth (and only when a nutritionally adequate and safe diet without breast milk can be \\nsustained), and HIV positive mothers and HIV positi ve infants should continue with ART. \\nContinued breastfeeding is recommended for HIV positive infants for as long as the \\nmother is willing and able to do so.  \\n● In special medical circumstances, determined by clinicians, where an infant cannot \\nbreastfeed, refe r to current MIYCN Policy and Breast Milk Substitute (BMS) Regulation \\nand Control Act, 2012.  \\n● Complimentary feeding means giving other foods to complement breast milk after six \\nmonths of exclusive breastfeeding. Complimentary feeds provide additional nutrit ional \\nvalue to meet the child’s increasing nutritional needs for growth (Table 7.7). \\nFurthermore, complementary feeding helps the child to gradually become accustomed \\nto eating family foods while breastfeeding continues to be an important source of \\nnutrien ts. It is worth noting that breastfeeding continues to have child growth/survival \\nbenefits for up to two years or longer. Emphasis should be made on consuming all the \\nseven (7) food groups for children in various meals.  \\no Cereal/tubers and roots  \\no Beans, pulses and nuts  \\no Dairy and dairy products  \\no Eggs and Flesh (meat/poultry/insects/organ meat)  \\no Vitamin A rich food (orange/yellow fruits) and green vegetables  \\no Fats and high sugar foods  \\n● Other fruits and vegetables    ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 169}),\n",
       " Document(page_content='  \\nPrevention of Mother to Child Transmission of HIV/Syphilis/Hepatitis B  \\n  7 - 9 Table 7.7: Complementary Foods for Children 6 -24 Months Old  \\nFoods to Offer  \\nAge  Texture  Frequency  Amount of food per meal  \\n6 \\nmonths  Start with thick porridge or \\nwell mashed foods  \\n 2 times per day  2 tablespoons each feed, \\nincreasing to 3 tablespoons \\nin the 3rd to 4th week  \\n7-8 \\nmonths  Mashed/pureed family foods  \\nBy 8 months can begin \\nfinger foods  3 meals per day, plus \\nfrequent breastfeeds  \\n Increase amount gradually \\nto ½ of a 250 ml cup  \\nUse a separate plate/bowl  \\n9-11 \\nmonths  Finely chopped or mashed \\nfoods, and foods that baby \\ncan pick up  3 meals and 1 snack, \\nplus frequent \\nbreastfeeds  ¾ of a 250 ml cup/bowl  \\nUse a separate plate/bowl  \\n12-23 \\nmonths  Cut food into small, soft \\npieces that child can pick up, \\nchew and swallow \\ncomfortably  3 meals and 2 snacks, \\nplus breastfeeds  One 250ml cup/bowl  \\nUse a separate plate/bowl  \\n24-59 \\nmonths  Cut food into small, soft \\npieces that child can pick up, \\nchew and swallow \\ncomfortably  3 meals and 2 snacks, \\nplus breastfeeds if still \\nbreastfeeding  1 ½ - 2 cups of 250ml \\ncup/bowl  \\nUse a separate plate/bowl  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 170}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n7 - 10  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 171}),\n",
       " Document(page_content=' \\nTB/HIV Co -infection, Prevention and Management  \\n8 - 1 \\n  \\n8. TB/HIV Co -infection, Prevention and \\nManagement  \\n \\nTB is a leading cause of morbidity and mortality among people living with HIV. Reducing this \\nburden of illness requires identifying TB early, providing pre -emptive and preventive  treatment \\nfor TB, and providing optimal treatment for both HIV and TB. Timely initiation of ART in \\ncombination with TB Preventive Therapy are effective ways to reduce the burden of TB in PLHIV.  \\nAll PLHIV should receive counselling about the risk of acquir ing TB, strategies for reducing \\nexposure to TB, recognizing clinical manifestations of TB and seeking care promptly, the risk of \\ntransmission of TB to others and TB preventive therapy to prevent TB disease.  \\nHealthcare settings present suitable conditions f or transmission of TB, particularly among \\nvulnerable individuals like PLHIV. All healthcare settings should develop and implement TB \\ninfection control guidelines to reduce the risk of transmission of TB between patients, visitors \\nand staff.  \\n8.1 TB Screenin g for PLHIV: Intensified Case Finding (ICF)  \\nTB screening and prevention services should be offered at every clinical visit. Symptom -based \\nTB screening using the ICF tool MUST be performed at every clinic visit to rule out active TB; \\npatients who screen pos itive (presumptive TB cases) must complete definitive diagnostic \\npathways (Figure 8.1 and Table 8.1) and patients who screen negative should be evaluated for \\nTB preventive therapy (TPT).  \\nActive Case Finding (ACF) differs from ICF. ICF refers to TB screenin g among PLHIV, whereas \\nActive TB case finding (ACF) refers to special efforts made by the NTP or other partners that go \\nbeyond passive TB case finding at health facilities, in which communities or population groups \\nthat are underserved or at higher risk of  TB are actively reached for providing access to care, \\nincluding screening and testing   ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 172}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n8 - 2      Intensified Case Finding Screening Questions       \\n●  If “Yes” to any question, take a detailed history, examine the patient and do sputum examination \\n(sputum smear or GeneXpert)  \\n● If “No” to questions 1 -5 above, consider TPT eligibility and work up for TB Preventive Therapy and \\nrepeat screening on subsequent visits  \\n● Questions 5 and 6 do not apply to adults  \\nThe following are the intensified case finding screening questions:  \\n● Cough of any duration (Y/N)  \\n● Fever (Y/N)  \\n● Noticeable weight loss/ Failure to thrive/ Poor weight gain (Y/N)  \\n● Night sweats (Y/N)  \\n● Reduced playfulness/ Lethargy/ Irritability (Y/N)  \\n● Contact with a TB case (Y/ N)  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 173}),\n",
       " Document(page_content=' \\nTB/HIV Co -infection, Prevention and Management  \\n \\n8 - 3 \\n \\nIf yes, to any of the signs and symptoms above the patient requires a clinical review If no to all the signs and symptoms above\\nTake a comprehensive history and thorough examination. Decide on classification as a presumptive TB case\\nIs the client/patient a presumptive TB case?\\nIs a sample available for TB testing? • Evaluate and manage for other conditions\\n• Consider TB preventive therapy (TPT) as per LTBI guidelines\\nIs the GeneXpert available on site?\\n• Consider a CXR3\\n• Consider clinical \\ndiagnosis of TB\\nIs smear microscopy available on site?\\n• Obtain a sample1 for GeneXpert\\n• TB LAM should be considered for \\neligible PLHIV2\\no Positive TB LAM test – initiate \\nDS TB treatment. Review once \\nGeneXpert results received\\no NB: A negative TB LAM test \\ndoes not rule out TB• If yes, collect 2 samples; one for smear microscopy and an additional sample for \\nGeneXpert\\n• If smear microscopy is positive, start DS TB treatment and review the patient once \\nGeneXpert results as received\\n• TB LAM should be considered for eligible PLHIV2\\no Positive TB LAM test – initiate DS TB treatment. Evaluate once GeneXpert results \\nreceived\\no NB: A negative TB LAM test does not rule out TB• If not available, collect and refer sample for \\nGeneXpert\\n• TB LAM should be considered for eligible PLHIV2\\n• Positive TB LAM test – initiate DS TB treatment. \\nEvaluate once GeneXpert results received\\n• NB: A negative TB LAM test does not rule out TB\\nGene Xpert ResultsDoes the client have any of the following symptoms?\\n4. Unintended weight loss\\n5. Chest Pain\\n6. BMI less than 18.5 or Z score   -21. Cough of any duration\\n2. Hotness of Body\\n3. Drenching night sweats\\nYES NOYES NOYES NOYES NOYES NOis the initial  test  for TB a has no smear  \\nSHOULD  BE USED  as sample  is & for \\nTB LAM  should  be used  among  PLHIV  as per TB LAM  SHOULD  be used  as an to  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 174}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n8 - 4 \\nMTB Detected\\nRifampicin Resistance Detected \\n(RR)MTB Detected\\nRifampicin Resistance not \\nDetected (TR)MTB not Detected \\n(N)MTB Detected 1\\nRifampicin Resistance \\ninditerminate (TI)MTB \\nDetected \\nTrace4Invalid/\\nError\\n1. Collect another \\nsample and repeat \\nGeneXpert test.\\n2. Treat as per the \\nrepeat results1. Collect a sample for FL & SL LPA, \\nculture and 1st and 2nd line DST\\n2. Conduct baseline work up on DR \\nTB treatment\\n3. Comprehensive review by a DR \\nTB clinical review team.\\n4. Start DR TB treatment as per the \\nguidelines.Patients at high risk of DR TB \\ngroups\\n1. Collect a sample of FL & SL \\nLPA, culture and 1st and 2nd \\nLine DST\\n2. Start DS TB treatment while \\nawaiting DST results.Patients at low  \\nrisk of DR TB \\ngroups\\n1. Start DS TB \\ntreatments.• If already on TB treatment (smear \\npositive, TB LAM positive), continue until \\nother diagnostic test results received and \\nreviewed even if MTB Not Detected\\n• NTM is likely if smear microscopy was \\npositive, and MTB not detected on \\nGeneXpert\\n- Send a sample for culture for definitive \\ndiagnosis of NTM\\n- Continue with TB treatment until \\nculture results received and reviewed\\n• Evaluate for other respiratory illnesses \\ne.g. asthma, pneumonias, COPD, \\nbronchiectasis and cancer as other \\npossible conditions\\n• Obtain a CXR and review with CXR3 report \\nand treat for TB as applicable\\n• Consider EPTB\\n• Refer for further evaluation when a \\ndefinitive diagnosis is yet to be found\\n• Consider repeat GeneXpert1. Treat as DS TB\\n2. Immediately \\ncollect another \\nsample and \\nrepeat GeneXpert \\n(Ultra) test\\n3. Collect a sample \\nfor FL & SL LPA, \\nculture and 1st \\nand 2nd line DST\\n4. Revise regimen \\nbased on DST \\nresults.Based on DST results, DR \\nTB clinical team to adjust \\nregimen as necessary.Revised treatment based on DST \\nresults Follow up as per guidelines\\n• Follow up as per DR TB treatment \\nguidelines\\n• Mandatory clinical review meetings \\nfor Patients\\n• Monthly smears and cultures are \\nmandatory during the treatment \\nduration.Follow up:\\n1. Clinical improvement assessment\\n2. Smear microscopy at months 2/3,5,6\\n3. If drug resistance is detected, treat \\nfor DR TB as per guidelines.DR TB DS TBGene Xpert Results \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 175}),\n",
       " Document(page_content=' \\nTB/HIV Co -infection, Prevention and Management  \\n \\n8 - 5 \\n \\nFootnotes\\n1 Samples for GeneXpert, sputum, CSF, Pleural aspirate, \\nPeriloneal fluid, synovial fluid, Gastric Aspirate, \\nNasopharyngeal aspirate, FNA, Lymph node biopsy, Pus, \\nstool\\n2 Indications for use of TB -LAM, as an adjunct test to \\nGeneXpert:\\n• PLHIV with advanced disease (WHO stage 3 or 4 or \\nCD4 count  200 cells/mm3 (or 25% for children \\n 5years old) with presumed TB\\n• PLHIV that have any danger signs of severe illness: \\nrespiratory rate ˃30breaths per minute, \\ntemperature ˃39°C, heart rate˃120beats per minute, \\nunable to walk unaided\\n• Currently admitted to hospital\\n3 All CHEST X -rays should be reported and the reports \\nreviewed by the clinician for definitive management. \\nRefer to the CXR algorithm for TB diagnosis\\n4 MTB detected Trace – Results from sample with few \\nbacilli (paucibacillary TB).  Rifampicin resistance status.\\nHIV Testing, using the HTS algorithm 1, is \\nrecommended during TB screening and diagnosis.\\nScreening for diabetes is recommended among all \\nadult patients with TB disease\\nKey\\nCBR - Chest X -ray\\nDR TB - Drug Resistant TB\\nDS TB - Drug Susceptible TB\\nDST - Drug Susceptibility \\nTesting\\nEPTB   - Extra Pulmonary TB\\nFL - First LineLPA Line Probe Assay\\nMTB Mycobacteria \\nTuberculosis\\nNTM Non -Tuberculous \\nMycobacteria\\nTST Tuberculin Skin test\\nSL Second lineDR TB risk classification among \\npatients\\nHigh risk for DR TB*\\n1. All previously treated TB \\npatients: treatment failures, \\nrelapses, treatment after loss to \\nfollow up\\n2. Contacts  of Drug Resistant TB \\npatients\\n3. TB patients with a positive \\nsmear result at month 2 or \\nmonth 5 of TB treatment\\n4. Patient who develops TB \\nsymptoms while on IPT or has \\nhad previous IPT exposure\\n5. Healthcare workers with 18 \\nsymptoms\\n6. Prisoners with TB symptoms\\n7. Refugees with TB symptoms\\nLow risk for DR TB\\nAll presumptive TB cases who are \\nNOT  in the high risk group\\n*ALL the high risk patients MUST  \\nbe prioritized to receive DST, \\nGeneXpert, FL and SL LPA, \\nculture and FL and SL DST.DS TB follow up and DR TB surveillance\\nPOSITIVE SMEAR \\nRESULT ATAction\\nMonth 2/3 • Evaluate for adherence, and other causes of delayed conversion\\n• Request for all the following drug susceptibility tests (DST); GeneXpert, FL, LPA and \\nSL, LPA, Culture and FL and SL DST\\n• Continue with RHZE for one more month, or longer if DST results not received by then\\n• Adjust treatment regimen based on DST results\\n• Repeat smear microscopy at end of month 3. If smear positive continue with RHZE and \\nreview DST results and inform the SCTLC immediately\\n• Do not proceed to the continuation phase (RH) without a DST result confirming \\nsusceptibility to RH (rifampicin and isoniazid)\\nMonth 5 or \\nMonth 6• Declare treatment failure and stop anti -TB treatment\\n• Review by the sub county and county TB clinical review teams\\n• Evaluate for adherence, other causes of delayed conversion and treatment failure\\n• Request for GeneXpert, FL LPA and SL LPA, culture and FL and SL DST\\n• Review DST results and re -initiate treatment based on DST results and other clinical \\nfindings\\nDS TB follow up and DR TB surveillance\\nSmear Positive or \\nculture positive \\nat months 3 or \\nlater• Evaluate for adherence, and  other causes of delay conversion\\n• Request for the following drug susceptibility tests (DSTI) (GeneXpert, Culture and \\nFirst Line (FL) and SL DST, FL LPA and SL LPA) depending on the initial resistance \\npattern\\no Review by the sub county and county clinical review teams\\n▪ Evaluate for adherence, other causes of reversion and treatment failure\\n▪ Review the DST results\\no Declare failure if at the end of the extended intensive phase  (refer to DR TB \\nguidelines)\\no Send a case summary to the national clinical team after review by the county clinical \\nteam\\n• Do not proceed to the continuation phase (depending on treatment regimen) without a \\nDST result\\n• Declare treatment failure\\no Review by the sub county and county clinical review teams\\n▪ Evaluate for adherence, other causes of reversion and treatment failure\\n▪ Review the DST results\\n• Send a case summary to the national clinical team after review by the county clinical \\nteamMOH/DNTLDP/TBSDXALG/01\\nSeptember 2020Smear Positive \\nsmears and/or \\ncultures during \\ncontinuation \\nphase \\nFigure 8.1: TB diagnosis - GeneXpert Ultra algorithm', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 176}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 8 - 6 Table 8.1: TB Diagnosis in Children <10 Years Old  \\nALGORITHM FOR PULMONARY TB DIAGNOSIS IN CHILDREN  \\nHistory of \\npresenting \\nillness  For all children presenting to a health facility ask for the following suggestive \\nsymptoms  \\n● Cough  \\n● Fever  \\n● Poor weight gain  \\n● Lethargy or reduced playfulness  \\nSuspect TB if the child has two or more of these suggestive symptoms  \\nAsk for history of contact with adult/adolescent with chronic cough or TB within the \\nlast 2 years  \\nClinical \\nevaluation  Examine the child and check for:  \\n● Temperature > 37.5o (fever)  \\n● Weight (to confirm poor weight gain, weight loss) – check growth monitoring \\ncurve)  \\n● Respiratory rate (fast breathing)  \\n● Respiratory system examination – any abnormal findings  \\nExamine other systems for abnormal signs suggestive of extra -pulmonary TB#  \\nInvesti gation\\ns Obtain specimen’ for Xpert MTB/RIF (and culture when indicated**)  \\nDo a chest Xray (where available)  \\nDo a Mantoux test** (where available)  \\nDo a HIV test  \\nDo other tests to diagnose extra -pulmonary TB where suspected#  \\nDiagnosis  Bacteriologically  \\nConfirmed TB:  \\nDiagnosis if \\nspecimen is \\npositive for MTB  Clinical Diagnosis of PTB:  \\nChild has two or more of the following suggestive symptoms  \\n● Persistent cough, fever, poor weight gain, lethargy  \\nPLUS, two or more of the following:  \\n● Positive contact, abnormal respiratory signs, abnormal, \\npositive Mantoux  \\nNote: If the child has clinical signs suggestive of EPTB, refer to \\nEPTB diagnostic table*  \\nTreatment  Treat for TB as follows:  \\n● All children with bacteriologically confirmed TB \\n● All children with a clinical diagnosis of TB  \\nNB: In children who do not have an Xpert result, or their Xpert results is negative, but \\nthey have clinical signs and symptoms suggestive of TB they should be treated for TB  \\nAll forms of TB (Except TB meningitis, bone and joint TB) Treat for 6 months (2 RH ZE/ \\n4 RH)  \\nTB meningitis, bone and joint TB: Treat for 12 months ( 2 RHZE/ 10 RH)  \\n*Specimen may include: Expectorated sputum (child > 5 years), induced sputum, nasopharyngeal \\naspirate and gastric aspirate. Attempt to obtain specimen in every child  \\n**Do a cultu re and DST for the following children:  \\n1. Rifampicin resistance detected by the Xpert test  \\n2. Refugees and children in contact with anyone who has Drug Resistant TB  \\n3. Those not responding to TB treatment  \\n4. Those with indeterminate Xpert results  \\n***This may include IGRA in facilities where it is available  \\n#Use IMCI guidelines to classify severity of disease   \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 177}),\n",
       " Document(page_content=' \\nTB/HIV Co -infection, Prevention and Management  \\n \\n8 - 7 \\n Table 8.2: Drug Susceptible TB Treatment Regimen for Children, Adolescents and Adults  \\nTB disease category  Recommended regimen  \\nIntensive phase        Continuation phase  \\nAll forms of TB except TB meningitis, bone \\nand joint TB (osteoarticular TB)  2 RHZE  4 RH  \\nTB meningitis   \\nOsteoarticular TB  2 RHZE  10 RH  \\nDrug resistant TB  Refer to a DRTB Clinical Team  \\n● Follow up smears should be done for all bacteriologically confirmed pulmonary TB cases at end of \\nmonth 2, 5 and 6 of TB treatment using smear microscopy  \\n● Follow up of RR TB and DR TB should be done as per PMDT guidelines  \\n● Patients taking isoniazid containing regimen should also be given Pyridoxine (Vitamin B6) daily for \\nthe duration of treatment to reduce the risk of developing peripheral neuropathy (see Annex 10 for \\npyridoxine dosing)  \\nOnce TB treatment is started it should be completed; unless another definitive diagnosis (like lung \\ncancer) is established and TB is ruled out.  \\n \\n \\n \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 178}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 8 - 8  \\nTB-LAM is a rapid point -of-care urine dip -stick test that can be performed at the bedside. LAM stands for \\nlipoarabinomannan, which  can be detected in urine when it sheds off of the TB  cell wall . \\nGeneXpert is the recommended initial diagnostic test for people with presumptive TB.\\nTB-LAM SHOULD NOT be used as an alternative test to GeneXpert, but can be performed  to help diagnose TB while \\nwaiting for GeneXpert test results. TB -LAM cannot detect resistance to rifampicin.\\nIndications for use of TB -LAM, as an adjunct test to GeneXpert:\\n• PLHIV with advanced disease (WHO stage 3 or 4 or CD4 count       cells/mm3 (or       for children     \\nyears old)) with presumed TB \\n• PLHIV that have any danger signs of severe illness: respiratory rate >30 breaths per minute, temperature >39°C, \\nheart rate >120 beats per minute, unable to walk unaided\\n• Currently admitted to hospital \\nLF-LAM Negative LF-LAM Positive\\nTB is not ruled out \\n• Evaluate the clinical response after 3–5 days of \\nantibiotic treatment, while awaiting GeneXpert \\nresultsTB is likely\\n• Initiate TB treatment\\n• Conduct additional investigations for TB \\nand other HIV related diseases as \\nappropriate\\n• Continue TB treatment even if GeneXpert \\nresults come back negative\\nClinical improvementClinical worsening or no \\nimprovement\\nTB is unlikely\\n• Conduct additional investigations for TB and \\nother opportunistic illnesses\\n• Complete the course of parenteral antibiotics\\nNote: \\n• If GeneXpert results are positive for TB, \\ninitiate TB treatment irrespective of TB -LAM \\nresults or clinical improvement \\n• If GeneXpert results are negative for TB, \\nconsider TPTTB is likely\\n• Start TB treatment if patient is seriously \\nill or if GeneXpert results come back \\npositive (irrespective of TB -LAM results)\\n• Conduct additional investigations for TB \\nand other HIV -related diseases\\n• Complete the course of parenteral \\nantibiotics\\n \\nFigure 8.2: Use of TB-LAM for Diagnosis of TB among PLHIV  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 179}),\n",
       " Document(page_content='  \\nTB/HIV Co -infection, Prevention and Management  \\n \\n8 - 9 8.2. TB Preventive Therapy (TPT)  \\nThis section summarizes the current national recommendations for treatment of latent TB \\ninfections (LTBI) in the PLHIV population. These are in line with the updated World Health \\nOrganization guidelines which include the use of shorter, safer LTBI treatment options for an \\nexpanded at -risk population. For further guidance, refer to the national guidelines on LTBI \\nmanagement.  \\n8.2.1. Indications for TPT  \\nTPT should be provided to those p atients in whom TB is excluded (using the ICF tool) and meet \\nthe eligibility criteria to initiate TPT. The following client categories are eligible for TPT who \\nscreen negative for active TB  \\n● All PLHIV above 12 months of age (children, adolescents and adults  including pregnant \\nand breastfeeding women)  \\n● All household contacts of persons with bacteriologically confirmed pulmonary TB            \\n● Prisoners and staff working in prison setting            \\n● Health care workers and other staff in health care setting  \\n● Other clinical risk groups as defined in LTBI guidelines  \\n*Neonates born to mothers with TB, or exposed to close contacts with TB should be given TPT \\nonce TB disease has been ruled out. BCG should be given 2 weeks after completion of TPT or anti -\\nTB treatment  \\nSummary of recommendations for TPT among the PLHIV  \\n● PLHIV are at a much higher risk of getting TB disease compared to the general population  \\n● TB preventive therapy should be given to all PLHIV above 12 months of age who do not \\nhave active TB disease. This should be done irrespective of immune status, ART status, \\nprevious history of TB and pregnancy status.  \\n● Children aged <12 months living with HIV who are household contacts of a person with \\nbacteriologically confirmed pulmonary TB, and whom act ive TB has been ruled out \\nshould receive TB preventive therapy.  \\n● TPT may be given immediately following successful completion of TB treatment among \\nthe PLHIV.  \\n● Repeat TPT is not recommended among PLHIV except if a PLHIV becomes a \\nhousehold contact of a perso n with bacteriologically confirmed pulmonary TB  \\n● PLHIV aged 15 years and above should be provided with 3 months of weekly Rifapentine \\nand Isoniazid (3HP), while those less than 15 years are given 6 months of daily INH (6H)  \\n● In PLHIV on PI/r -based ART, pregna nt women and those who do not tolerate 3HP should \\nbe given six months of daily INH (6H)  \\n● For eligible patients previously treated for TB, initiate TPT upon completion of their TB \\ntreatment.  \\n      \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 180}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 8 - 10 8.2.2. Contraindications to TPT  \\nPatients with the following should not receive TPT until the underlying issue(s) are \\naddressed  \\n● Active tuberculosis disease  \\n● Active hepatitis (acute or chronic)  \\n● Chronic alcohol abuse      \\n● Symptoms of peripheral neuropathy  \\n \\n8.2.3. Dose and Duration of TPT  \\nTable 8.3: Recommended TPT Regimens for PLHIV  \\nTarget populations  TPT Regimen  \\n● Adult PLHIV excluding patients \\non PI/r -based ARV regimens  Rifapentine and Isoniazid (3HP)  \\nOnce weekly for three months  \\n          (12 doses)  \\n● Adult PLHIV on PI/r -based ARV \\nregimens  \\n● All CALHIV aged below 15 years  \\n● Any patient with intolerance or \\ncontraindication to 3HP  \\n● Pregnant women  Isoniazid (6H)  \\nOnce daily for 6 months  \\n● The 3RH (rifampicin and isoniazid) regimen is not recommended for PLHIV due \\nto drug - drug interactions  \\n● All TPT regimens should be given with Vitamin B6 (pyridoxine), if available, to \\nreduce the risk of developing peripheral neuropathy  \\n● Comprehensive health  education and adherence counselling should be \\nconducted prior to initiation of TPT  \\n● Dosing of TPT is in Annex 10  \\n \\n● Children should be weighed at each visit and correct weight -based dosing confirmed.  \\n● Clients on 3HP should receive weekly dose of pyridoxine, Those on Rifapentine and \\nIsoniazid regimen should be given pyridoxine once a week  \\n● The 3RH (rifampicin and isoniazid) regimen is not recommended for PLHIV due \\nto drug -drug interactions. 3RH is used in HIV negative populations   \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 181}),\n",
       " Document(page_content='  \\nTB/HIV Co -infection, Prevention and Management  \\n \\n8 - 11 8.2.4. Follow -up of Patients on TPT  \\nPatients on TPT should be followed up on a monthly basis and their return -to-clinic dates \\nharmonized with any other routine schedules. During each clinic visit, conduct the following;  \\n● Symptom screening for active TB disease and update status  \\n● Assess and reinforce adherence to treatment  \\n● If a patient screens positive for TB while on TPT, stop TPT and manage according to \\nNational TB guidelines  \\n● Assess for any adverse drug reactions at each visit and intervene appropriately  \\n● Provide/update TPT appointment card  \\n● Document and update the relevant recording and reporting tools, e.g., ICF/TPT cards, \\nContact Management/TPT register  \\n● Document outcome of TPT use e.g., completion in the relevant tools and/or EMR  \\n*Baseline liver function tests are not mandatory for patients initiating TPT. These may, however, be \\nconsidered on an individual ba sis, especially for patients taking other medications for chronic \\nmedical conditions or symptomatic patients suspected to have active hepatitis  \\n \\n8.3. Identifying and Managing Drug Toxicities from TPT  \\nThe management of drug toxicities should be based on severity, with appropriate grading of \\nindividual patients. The most common adverse drug reactions associated with TPT are peripheral \\nneuropathy, drug -induced liver injury (DILI), and rash.  \\n8.3.1 Periphe ral Neuropathy - Suspected drug: INH        \\nDiagnosis of Peripheral Neuropathy  \\n● Symptoms include: burning sensation, numbness, or tingling, usually starting at the feet \\non both sides  \\n● May have decreased sensation on examination  \\n● May develop weakness in severe cases  \\n● May be potentiated by other neurotoxic drugs, alcoholism, metabolic disease (e.g., \\ndiabetes), malnutrition and infections  \\n● Rarely severe enough to require drug withdrawal  \\nManagement of INH -induced Peripheral Neuropathy  \\n● Increase the dose of pyridoxine to 100 mg per day  \\n● For children give double the standard weight -based dose  \\n● Assess for other causes of peripheral neuropathy (e.g., diabetes, thyroid disorder, B12 \\ndeficiency, syphilis, etc.)  \\n● Relief of symptoms can be achieved with analgesics, tricyclic antidepressants \\n(amitriptyline, nortriptyline), anticonvulsants (carbamazepine, phenytoin)  \\n● If symptoms do not improve, or there is any worsening, then discontinue TPT; symptoms \\nmay persist even  after discontinuing TPT  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 182}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 8 - 12 8.3.2 Drug -Induced Liver Injury (DILI) -Suspected drugs include Isoniazid (H), \\nRifapentine (P), Rifampicin (R)  \\n● Elevation of liver enzymes may occur in the first weeks of treatment  \\n● In asymptomatic patients, serum liver enzyme lev els do not need to be monitored \\nroutinely   \\n● All clients with gastrointestinal symptoms (nausea and vomiting, liver tenderness, \\nhepatomegaly or jaundice) should have their liver function assessed  \\n● Patients should be screened for other causes of liver injury  (the hepatitis viruses -A, B, C)  \\n● Table 8.4 shows the grading of liver injury and management of DILI  \\n● Once the drugs are discontinued, no attempt should be made to reintroduce these drugs \\nuntil liver functions have normalized  \\n● An expert with experience in managing DILI should be involved in the further \\nmanagement of such cases  \\nDiagnosis of DILI  \\n● Jaundice, a bdominal pain, nausea, vomiting, anorexia, etc.  \\n● Abnormal liver enzymes  \\n \\nTable 8.4: Grading and Management of DILI  \\n Grade 1: Mild  Grade 2: Moderate  Grade 3: Severe  Grade 4: Life \\nthreatening  \\nALT (SGPT)  1.25 – 2.5 x ULN  2.6 – 5.0 x ULN  5.1 – 10.0 x ULN  > 10.0 x ULN  \\nAST (SGOT)  1.25 – 2.5 x ULN  2.6 – 5.0 x ULN  5.1 – 10.0 x ULN  > 10.0 x ULN  \\n  \\n  \\n  \\nACTION  Continue treatment \\nregimen;  \\npatients should have \\nweekly followed up \\nuntil resolution \\n(return to baseline) \\nor stabilization of \\nAST/ALT elevation  Continue treatment \\nregimen;  \\npatients should have \\nweekly followed up \\nuntil resolution \\n(return to baseline) \\nor stabilization of \\nAST/ALT elevation  Stop all drugs, \\nincluding TPT \\ndrugs;  \\nmeasure LFTs \\nweekly;  \\nTPT should not  \\nbe reintroduced \\nafter severe DILI1 Stop all drugs, \\nincluding TPT drugs;  \\nmeasure LFTs weekly. \\nTPT should not  be \\nreintroduced after life \\nthreatening DILI1 \\n \\n \\n1. PLHIV who develop DILI during treatment of active TB disease, may have anti -TBs reintroduced \\nafter toxicity is resolved in consultation with a senior clinician  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 183}),\n",
       " Document(page_content='  \\nTB/HIV Co -infection, Prevention and Management  \\n \\n8 - 13 8.3.3 Management of TPT -associated Rash - Suspected Drugs include Isoniazid (H), \\nRifapentin e (P), Rifampicin (R)  \\n● A rash may occasionally develop, usually within a few days following initiation of TPT. It \\nis often a relatively mild maculopapular rash with or without pruritus.  \\n● Flu-like and other systemic hypersensitivity reactions are rare amongst children. \\nHypersensitivity reactions in adults are usually mild and self -limiting  \\n● Rarely, rash may develop with severe exfoliation of the skin and Stevens -Johnson \\nsyndrome  \\n● Rash severity should be assessed and managed appropriately as shown in table  8.5  \\n \\nTable 8.5: Management of TPT -Associated Skin Rash  \\nSeverity  Characteristics  Action  \\nMild  Dry; erythema +/ - fine \\npapules; pruritus; affecting \\n< 50% of body surface area  Continue TPT; close monitoring; symptomatic \\ntreatment with antihistamines +/ - topical steroids \\n(NOT oral steroids)  \\nModerate  Dry; erythema +/ - fine \\npapules; pruritus; affecting \\n≥ 50% of body surface area  Stop TPT; symptomatic treatment with \\nantihistamines +/ - topical steroids (NOT oral \\nsteroids); trial of desensitization after symptoms \\ncompletely resolved  \\nSevere  Mucosal involvement;  \\nblistering; associated \\nfever; any % of body \\nsurface area  Stop TPT; admission to hospital for supportive \\nmanagement (IV fluids, wound care, pain control, \\ninfection control, monitoring for super -infection); \\npatient should NEVER be re -challenged;  \\ndocument and report adverse event and issue \\npatient alert card  \\n \\n8.4. ART for TB/HIV Co -infection  \\nAs with all PLHIV, those who are diagnosed with TB/HIV co -infection should be on ART and CPT \\nas part of the comprehensive package of care for PLHIV.  \\nTiming of ART for TB/HIV Co -infection  \\n● Patients who are not yet on ART  \\no Start TB treatment immediately  \\no Initiate ART as soon as anti -TB medications are tolerated, preferably within 2 \\nweeks  \\no For TB meningitis delay ART for 4 to 8 weeks  \\no Monitor closely for IRIS (Annex 16)  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 184}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 8 - 14 ● Patients who are already on ART  \\no Start TB treatment immedi ately  \\no Continue ART, assessing for treatment failure and making any required \\nadjustments to the ART regimen based on drug -drug interactions (Table 8.7)  \\no Monitor closely for IRIS (Annex 16)  \\n● Patient being treated concurrently for TB and HIV require close monitoring for \\ntoxicity  \\n● MDR TB and HIV co -infection should be managed in settings where close toxicity \\nmonitoring and follow up by experienced clinicians or multi -disciplinary team is \\npossible       \\nPreferred ART regimens for patients with TB/HIV co -infecti on are summarized in Tables 8.6 - 8.8. \\nTable 8.6: Preferred ART Regimens for TB/HIV Co -infection for Patients Newly Initiating 1st \\nLine ART 1 \\nAge  Weight  1st Line ART if TB/HIV Co -infection  \\nBirth to 4 \\nweeks  Any  Start anti -TB treatment immediately; start ART after 4 weeks \\nof age, once tolerating anti -TB drugs (follow the regimen \\nrecommendations for children ≥ 4 weeks old)  \\n> 4 weeks to < \\n15 years  < 30 kg  ● ABC + 3TC + DTG  \\n● Increase DTG dosing frequency to twice daily for duration \\nof rifampicin -containing TB treatment and for an additional \\n2 weeks after TB treatment is completed, then revert to \\nonce daily dosing  \\n≥ 30 kg  ● Give TDF/3TC/DTG FDC morning + DTG 50mg evening for \\nduration of rifampicin -containing TB treatment and for an \\nadditional 2 weeks after TB treatment is completed, then \\nrevert to TDF/3TC/DTG FDC once daily  \\n≥ 15 years  Any  ● Give TDF/3TC/DTG FDC morning + DTG 50mg evening for \\nduration of rifampicin -containing TB treatment and for an \\nadditional 2 weeks after TB treatmen t is completed, then \\nrevert to TDF/3TC/DTG FDC once daily  \\n1 Refer to Annex 10 for weight -based ARV dosing  \\n \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 185}),\n",
       " Document(page_content='  \\nTB/HIV Co -infection, Prevention and Management  \\n \\n8 - 15 Table 8.7: Preferred ART Regimens for Patients who Develop TB while Virally Suppressed on \\n1st Line ART 1,2 \\nCurrent \\nRegimen3  Recommended Substitution  \\nPI/r -based4 All ages  ● Switch from PI/r to DTG and continue this regimen even after \\ncompleting TB treatment. Follow DTG dosing as below  \\n● If it is not possible to switch to DTG:  \\no Children < 30 kg requiring PI/r -based ART should receive \\nLPV/r with additional ritonavir super -boosting for the duration \\nof rifampicin -based TB therapy, reverting to standard LPV/r \\ndosing 2 weeks after completing TB treatment  \\no Patients ≥ 30 kg who cannot switch to DTG should be switched \\nto EFV -based ART and maintained on EFV -based ART after \\ncompletion of TB treatment  \\nRAL -based  All ages Switch from RAL to double -dose DTG dosing during TB treatment and \\nmaintain on DTG after completion of TB treatment  \\nDTG -based  All ages   \\nAdminister the double -dose of DTG (i.e., the standard weight -based \\ndose of DTG given twice daily) while taking rifampicin containing TB \\ntreatment. Two weeks after completion of TB treatment revert to the \\nrecommended DTG dose once daily.  \\n1 Always assess for HIV treatment failure in patients who develop TB after being on ART for ≥ 6 \\nmonths. For patients failing 1st line ART refer to Table 8.8 for recommended 2nd line regimens  \\n2 For patients on 2nd line ART, subsequent regimens, or nonstandard drugs who require regimen \\nchange because of TB treatment, consult the Regional or National HIV Clinical TWG (Uliza Hotline \\n0726  460 000; https://nhcsc.nascop.org/clinicalform ) \\n3 NRTIs in the patient’s current regimen do not require any adjustments with anti -TB treatment  \\n4 Use “super -boosted” LPV/r by adding additional ritonavir to manage the drug interaction between \\nLPV/r and rifampicin (see Annex 10 for dosing recommendations)  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 186}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 8 - 16 Table 8.8: Recommended ART Regimens for Patients who Develop TB while Failing 1st Line \\nART 1 \\nAge/  \\nScenario  First -line \\nART  Second -line ART  \\n< 30 kg \\nbody \\nweight  LPV/r -\\nbased 1st \\nline ● Start anti -TB immediately.  \\n● Change to DTG -based second -line immediately. Increase DTG dosing \\nfrequency to twice daily for duration of rifampicin -containing TB \\ntreatment and for an additional 2 weeks after TB treatment is completed, \\nthen revert to once daily dosin g  \\n● Immediately collect a sample for DRT2 \\n● Assess for and address reasons for treatment failure.  \\n● If unable to switch to DTG then use super -boosted LPV/r3 \\nABC (or \\nAZT) + \\n3TC + \\nDTG  ● Start anti -TB immediately  \\n● Increase DTG dosing frequency to twice daily for duration of rifampicin -\\ncontaining TB treatment and for an additional 2 weeks after TB treatment \\nis completed, then revert to once daily dosing.  \\n● Follow the viral load monitoring algorithm (Figure 6.6), inclu ding \\nassessing for and addressing reasons for treatment failure, and collecting \\nDRT. Consult the Regional or National TWG to constitute a second -line \\nregimen based on DRT results  \\n≥ 30 kg or \\n≥ 15 years \\nold TDF (or \\nABC or \\nAZT) + 3TC \\n+ DTG  ● Start anti -TB immediately  \\n● Give TDF/3TC/DTG FDC morning + DTG 50mg evening for duration of \\nrifampicin -containing TB treatment and for an additional 2 weeks after \\nTB treatment is completed, then revert to TDF/3TC/DTG FDC once daily  \\n● Follow the viral load monitoring algorithm (Figure 6.6), including \\nassessing for and addressing reasons for treatment failure, and collecting \\nDRT. Consult the Regional or National TWG to constitute a second -line \\nregimen based on DRT results  \\nTDF (or \\nABC or \\nAZT) + \\n3TC + EFV  ● Start anti -TB immediately  \\n● Continue current regimen while following the viral load monitoring \\nalgorithm (Figure 6.6), including assessing for and addressing reasons for \\ntreatment failure.  \\n● Once treatment failure is confirmed and patient ready to switch to 2nd \\nline, switch to TDF + 3TC + DTG (maintain the TDF, even if the patient was \\nalready on a TDF -containing regimen), increasing the DTG dose to twice \\ndaily for the duration of rifampicin -based TB therapy, switching back to \\nstandard DTG dose 2 weeks after rifampin is discontinued.  \\nPI/r -\\nbased 1st \\nline ● Start anti -TB immediately  \\n● Switch to TDF+3TC+DTG immediately. Give TDF/3TC/DTG FDC morning \\n+ DTG 50mg evening for duration of rifampicin -containing TB treatment \\nand for an additional 2 weeks after TB treatment is completed, then revert \\nto TDF/3TC/DTG FDC once daily  \\n● Immediately collect a sample for DRT2  \\n● Assess for and address reasons for treatment failure.  \\nPregnant or \\nBreastfeeding  Follow the same recommendations as for ≥ 30 kg or ≥ 15 years old.   \\nHIV/HBV \\nCo-infection  Always maintain TDF or TAF in second -line instead of switching to a different NRTI and \\ninstead of adding an additional NRTI  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 187}),\n",
       " Document(page_content='  \\nTB/HIV Co -infection, Prevention and Management  \\n \\n8 - 17 Table 8.8 Cont.  \\n1. For patients on 2nd line ART, subsequent regimens, drug intolerance, or nonstandard drugs who require \\nregimen change because of TB treatment, consult the Regional or National HIV Clinical TWG (Uliza Hotline \\n0726 460 000; https://nhcsc.nascop.org/clinicalform ) \\n2. Contact  the Regional or National HIV Clinical TWG (Uliza Hotline 0726 460 000; \\nhttps://nhcsc.nascop.org/clinicalform ) for guidance on urgent collection of DRT samples  \\n3. Use “super -boosted” LPV/r by adding additional ritonavir to manage the drug interaction between LPV/r \\nand rifampicin (see Annex 10 for dosing recommendations). Two weeks after TB treatment is completed \\nthe child should go back to standard LPV/r dosing.  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 188}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 8 - 18 ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 189}),\n",
       " Document(page_content='  \\nTB/HIV Co -infection, Prevention and Management  \\n \\n9 - 1  \\n9. HBV/HIV and HCV/HIV Co -infection \\nPrevention and Management  \\n9.1 Hepatitis B/HIV Co -infection  \\nHIV and Hepatitis -B Virus (HBV) share infection transmission routes.  Acute HBV infection in HIV \\npositive people is associated with increased risk of chronicity, reduced chances of spontaneous \\nclearance, higher rates of replication and reactivation and therefore increased incidence of \\nchronic liver disease, cirrhosis and hep atocellular carcinoma (HCC). Additionally, HIV/HBV co -\\ninfection has been associated with rapid HIV disease progression and poorer HIV treatment \\noutcomes.  Other complications of HIV/HBV co -infection include increased incidence of drug -\\nrelated hepatotoxicit y, drug -drug interactions and ART -related immune reconstitution hepatitis.  \\n9.1.1 Screening  \\nAll adolescents and adults living with HIV (plus children who did not complete routine childhood \\nimmunizations) should be screened for HBV infection, using HBsAg, as part of initial evaluation. \\nTo promote population -wide prevention, hepatitis B prevention should be integrated into \\nroutine HIV prevention and care programs. In this setting, other indications for HBsAg screening \\ncould include  \\n▪ Household and sexual contacts of HBsAg positive individuals  \\n▪ Pregnant women  \\n▪ Persons who inject drugs (PWID)  \\n▪ Men who have sex with men  \\n▪ Sex workers  \\n▪ Persons with multiple sexual partners  \\n▪ Prisoners  \\n▪ Blood donors  \\n▪ Unvaccinated healthcare providers  \\n \\nPLHIV on follow -up who presen t with signs of liver disease (jaundice, ascites, abnormal liver on \\npalpation, other signs of cirrhosis) or unexplained and persistent ALT elevation should also be \\nscreened for HBV as part of their work -up. \\n9.1.2 Prevention  \\nA. Vaccination : HBV vaccination reduces the risk of new (incident) HBV infection in PLHIV and \\nalso reduces the risk of new infections becoming chronic. Therefore;  \\n● HIV positive infants, children, adolescents and adults without evidence of hepatitis B \\ninfection (HBsAg negative)  should be vaccinated against hepatitis B (Table 9.1)  \\n● HIV exposed infants (HEI) should also receive hepatitis B vaccination as part of childhood \\nimmunization (Table 4.21)  \\n● As a strategy to reduce the population level burden of HBV infection, HIV prevention and \\ntreatment settings should integrate HBV prevention through vaccination. Thus, HBV \\nvaccination is recommended for the following groups who test HBsAg negative.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 190}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 9 - 2 o Babies and young children (through EPI and catch -up immunization for those who \\nmissed EPI vac cination)  \\no Household contacts of HBsAg positive people  \\no Sexual contacts of HBsAg positive people  \\no People on haemodialysis  \\no PWID  \\no Individuals with chronic liver disease and/or hepatitis C  \\no Inmates and prison personnel  \\no Healthcare workers  \\nTable 9.1: Hepatitis B Vaccination Schedule for HIV -positive Adolescents and Adults  \\nVaccine  Dose (intramuscular)  Schedule  \\nNon -adjuvanted formulation  Double the standard dose   \\n0, 1, 2, and 6 months  Adjuvanted formulation  Standard dose  \\n*Booster vaccination is not required for persons who have completed the full vaccination schedule  \\nB. General preventive measures:  General measures for infection prevention adopted by \\nPLHIV and in healthcare settings are effective in preventing HBV transmission. The se \\ninclude  \\n● Hand hygiene  \\n● Use of personal protective equipment  \\n● Medical waste management including safe disposal of used sharps  \\n● Disinfection and sterilization  \\n● General health advice against sharing of personal effects like towels, tooth -brushes, \\nrazors, combs and other grooming equipment  \\n● Harm reduction counselling and services for PWID as outlined in Chapter 12  \\n● Safer sex practices  \\n9.1.3 Treatment  \\nA. When to start ART  \\nAll HIV infected patients who are co -infected with hepatitis B should be started on ART \\nirrespective of CD4 cell count, WHO clinical stage or stage of liver disease  \\n \\nThe general recommendations for treatment preparation, adherence counselling and support \\nand monitoring of therapy for PLHIV apply. However, because HBV positive patients are at higher \\nrisk of hepatotoxicity, closer monitoring of liver function (with ALT) is advised. Table 9.2 \\nprovides a summary of areas of focus during initial evaluation for HIV/HBV co -infected patients \\ninitiating therapy.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 191}),\n",
       " Document(page_content='  \\nTB/HIV Co -infection, Prevention and Management  \\n \\n9 - 3 B. Recommended first -line ART in HIV/HBV co -infection  \\nThe recommended first -line ART in adolescents and adults with HIV/HBV co -infection \\nis TDF + 3TC + DTG, including for women and adolescent girls of childbearing potential  \\n \\nTreatment with both TDF (or TAF) and 3TC is recommended as 3TC without TDF or TAF will \\nresult in rapid emergence of resistance. In case of renal impairment (as assessed by creatinine \\nclearance), the dose of TDF and 3TC should be adjusted (Table 9.3).  \\nTable 9.2: Summary of Initial Clinical and Labora tory Evaluation in HIV/HBV Co -infection  \\n Findings  Action  \\nHistory  Alcohol use, cigarette \\nsmoking, intravenous drug \\nuse, risky sexual practices, \\nanorexia, right upper \\nquadrant pain, jaundice, early \\nsatiety, haematemesis, dark \\nstool, bleeding, pruritus  Assess, counsel and support to stop taking \\nalcohol; counsel and support smoking \\ncessation; counsel and provide or refer for \\nharm reduction interventions  \\ndiscuss or refer to a consultant for additional \\nevaluation and management  \\nPhysical \\nexamination  Enlarged liver, enlarged \\nspleen, ascites, scratch marks  Evidence of established chronic liver disease, \\ncloser follow -up due to increased risk of \\nhepatotoxicity.  \\ndiscuss or refer to a consultant for additional \\nevaluation and management  \\nALT  If elevated, may point to \\nactive liver disease. Exclude \\nother causes of elevation of \\nliver enzymes  Every effort should be made to assess for \\nother liver function (albumin and INR), \\nespecially in symptomatic patients. However, \\nthis should not delay initiation of ART  \\nCreatinine  Calculate creatinine clearance  In HIV/HBV co -infection, TDF is indicated \\neven in patients with CrCl < 50 ml/min. In \\nsuch patients, avoid FDCs. Instead administer \\nthe ART as single drugs to allow for dosage \\nadjustment as shown in Table 9.3  \\nComorbidities  HCV antibody, random blood \\nsugar, lipid profile, alcoholic \\nand non -alcoholic liver \\ndisease, hepatocellular \\ncarcinoma (family history)  Consult/Refer the patient for additional \\ninvestigations where these are suspected  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 192}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 9 - 4 Table 9.3: Dose Adjustment of TDF and 3TC in Patients with Impaired Renal Function 1 \\nDrug  Creatinine clearance (ml/min)  Haemodialysis  \\n50 - 80 30-49 10-29 \\nTDF 33 mg/g \\ngranules  \\n(=1scoop)  245 mg (7.5 scoops of \\ngranules or 245mg \\nfilm -coated tablet) \\nonce daily  132 mg (4 \\nscoops of \\ngranules) once \\ndaily  65 mg (2 scoops \\nof granules once \\ndaily  16.5 mg (0.5 scoop) \\nafter each 4 hr session \\nof dialysis  \\n \\nTDF 300 mg  Unchanged: 300 mg \\nonce daily  300 mg every  \\n48 hrs  300 mg every 72 to 96 hours (twice \\nweekly). For patients getting hemodialysis, \\nadminister 300 mg once weekly after \\ncompletion of dialysis sessions 2 \\n3TC 300mg  Unchanged: 300 mg \\nonce daily or 150 mg \\nBD  150 mg once \\ndaily  150 mg once \\ndaily  50 mg first dose,  \\n25 mg once daily  \\n1 Patients with impaired renal function in whom the benefits of continued use of TDF outweighs the \\nrisks (such as in the management of HIV/HBV co -infection) should be managed with input from a \\nspecialist in internal/paediatric or renal medicine  \\n2 Assuming 3 haemodialysis sessions per week, each of approximately 4 hours duration or after 12 \\nhours cumulative haemodialysis  \\n \\nC. Follow -up/Monitoring  \\nFollow -up of HIV/HBV co -infected patients should be as for all other patients on ART. However, \\nconsider more frequent monitoring (using ALT) for patients with active liver disease (jaundice, \\nliver cirrhosis and features of portal hypertension) at baseline.  The presence of co -infection also \\nincreases the risk of drug -related hepatotoxicity from all classes of ARVs by 3 -5 times, especially \\nwhen anti -TB and ART are given simultaneously. Also, hepatic flare -up (AST > 5 times normal \\nvalue) can occur, often in th e initial 3 months.  \\nNote:  ALT elevations 5 -10 times normal can be tolerated in the first 3 months of ART as \\nlong as the patient is not severely symptomatic, remains stable without progression, and \\nthere is no evidence of synthetic dysfunction (INR normal,  glucose normal, albumin \\nnormal).  \\nPatients with persistently elevated ALT levels during follow -up should be referred to a \\nspecialist. Subsequent laboratory monitoring after baseline should be conducted every 6 \\nmonths. Patients should be counselled and supp orted to abstain from consuming alcohol.  \\nD. Stopping treatment, /treatment interruptions  \\nTDF -containing ART should not be stopped in a patient with HIV/HBV co -infection as this may \\nresult in a flare -up of the hepatitis. If the regimen must be stopped and another alternative for \\nsuppressing hepatitis B cannot be found, liver enzymes should be monitored and treatment re -\\ninstated as soon as possible.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 193}),\n",
       " Document(page_content='  \\nTB/HIV Co -infection, Prevention and Management  \\n \\n9 - 5 E. Second line for HIV/ HBV co -infected  \\nMaintain TDF + 3TC in the ART regimen for patients switc hing from TDF -based -therapy.  So, for \\nexample, if a patient with HIV/HBV co -infection fails TDF/3TC/EFV in first -line, they should \\nswitch to TDF/3TC/DTG in second -line.  \\nHIV/HBV co -infected patients failing second -line ART should be discussed in the MDT and  \\ndiscussed with the Regional or National HIV Clinical TWG (Uliza Hotline 0726 460 000.)  \\n9.2 Hepatitis C/HIV Co -infection  \\nIn Kenya, the prevalence of HCV infection is high in PWID (estimated to be 12 -16%). The \\nprevalence in the general population and among PLHIV is low (estimated to be < 3%), but likely \\nto be higher in HIV infected PWID due to shared routes of transmission. HIV/ HCV co -infection is \\nassociated with  \\n• Rapid progression of liver fibrosis  \\n• Higher risk of deteriorating liver disease even in the pres ence of controlled HIV disease  \\n• Worsened hepatotoxicity as a result of ART and other drugs used in the treatment of \\ncomorbidities  \\nThus, HIV -positive persons at risk of HCV co -infection should be identified and offered HCV \\ntreatment. The recent introduction of direct acting antiviral therapies (DAAs) for treatment of \\nHCV has simplified the management of HIV/HCV co -infection, making it possible to manage \\nuncomplicated HIV/HCV infection safely even in primary care settings.  \\nHowever, treatment for H CV is a rapidly evolving field of therapeutics. Providers are encouraged \\nto seek regular updates on the subject and, when in doubt, to discuss individual cases with \\nexperienced providers.  \\n9.2.1 Screening  \\nHCV serology should be offered to individuals at ri sk of HCV infection. These include  \\n● People who inject or use intranasal drugs  \\n● Persons who have had tattoos, body piercing or scarification procedures from \\nsettings with doubtful infection prevention precautions  \\n● Children born to HCV positive mothers  \\nUp to 30 % of individuals who are infected with HCV spontaneously clear the infection. To confirm \\nchronic HCV infection, HCV positive individuals should be offered nucleic acid HCV RNA testing \\nto establish presence of chronic HCV infection.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 194}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 9 - 6 9.2.2 Prevention  \\nGeneral measures for prevention of blood -borne infections are effective in preventing HCV \\ntransmission.  \\n● Recommendations for healthcare settings  \\nTraining of healthcare providers on:  \\no Hand hygiene: including surgical hand preparation, hand -washing and use of gloves  \\no Safe handling and disposal of sharps and waste  \\no Effective disinfection and sterilization  \\no Provision of safe blood and blood products  \\n● Recommendations for PWID  \\no Harm reduction counselling and support (Table 12.1)  \\n● Recommendations for prevention of sexual transmission  \\no Correct and consistent condom use  \\no Access to prevention services for sex workers and other people at risk (including \\nscreening and treatment of STIs, frequent testing for HIV and HCV testing)  \\n \\n9.2.3 Treatment of HIV/HCV Co -infection  \\nTable 9.4: Summary of Initial Clinical and Laboratory Evaluation in HIV/HCV Co -infection  \\n Findings  Action  \\nHistory  Alcohol use, cigarette smoking, \\nintravenous drug use, risky sexual \\npractices, anorexia, right upper quadrant \\npain, jaundice, early satiety, haematemesis, \\ndark stool, bleeding, pruritus  Assess, counsel and support to stop \\ntaking alcohol; counsel and support \\nsmoking cessation; counsel provide \\nand refer for harm reduction \\ninterventions  \\nPhysical \\nexamination  Enlarged liver, enlarged spleen, ascites, \\nscratch marks  Evidence of established chronic liver \\ndisease, closer follow -up due to \\nincreased risk of hepatotoxicity, \\ndiscuss or refer to a consultant for \\nadditional evaluation and management  \\nHCV RNA PCR  For confirmation of chronic HCV  \\ninfection  If available, at baseline  \\nHCV genotype  May be important for selecting appropriate \\nDAA regimen. (Current regimens pan -\\ngenotypic, so HCV genotype testing not \\nrequired)   \\nALT  If elevated, may point to active liver \\ndisease. Exclude other causes of elevation \\nof liver enzymes  Every effort should be made to assess \\nfor liver function (albumin and INR), \\nespecially in symptomatic patients. \\nHowever, this should not delay \\ninitiation of ART  \\nComorbidities  HBV, random blood su gar, lipid profile, \\nalcoholic and non -alcoholic liver disease,  \\nhepatocellular carcinoma (family history)  Consult/Refer the patient for \\nadditional investigations where these \\nare suspected  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 195}),\n",
       " Document(page_content='  \\nTB/HIV Co -infection, Prevention and Management  \\n \\n9 - 7 Table 9.5: Recommended DAA for the Treatment of HCV among PLHIV  \\nGenotype  DAA Regimen*  Duration of treatment  \\n1 and 4  Sofosbuvir + Ledipasvir (Harvoni)  12 weeks  \\nAll Sofosbuvir + Velpatasvir (Epclusa)  12 weeks  \\n* DAA regimen availability continues to evolve; this table just shows the most readily available regimens at \\ntime of publication. Always start DAA HCV therapy, and review most recent drug -drug interactions with \\nARVs.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 196}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 9 - 8  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 197}),\n",
       " Document(page_content='  \\nARVs for Post -exposure Prophylaxis  \\n10 - 1  \\n10. ARVs for Post -exposure Prophylaxis  \\n \\n \\nAn ARV regimen, with preferably three -drugs, should be offered as post exposure prophylaxis as \\nsoon as possible (preferably within 72 hours) after an exposure.  \\n  \\n10.1 What is PEP?  \\nPost -exposure prophylaxis (PEP) is short -term use of antiretroviral treatment to reduce the \\nlikelihood of HIV infection after potential exposure.  \\nPeople can be accidentally exposed to HIV through healthcare work or due to exposures outside \\nhealthcare setting, for example, through unprotected sex or sexual assault among adults and \\nchildren. Healthcare workers are at increased risk of exposure to HIV through contact with \\ncontaminated blood and other body fluids  containing HIV through needle stick injuries and \\ninjuries by other sharp objects or through non -intact skin and mucous membranes.  \\n10.2 Recommended ARVs for PEP  \\nThree -drug regimens are preferred for PEP. However, if the person is unable to tolerate the thi rd \\ndrug, (usually the PI/r), two drugs  can be used.  \\nTable 10.1: Recommended ARVs for PEP  \\nAge  Weight  Preferred  Alternate  \\n \\n \\n<15 years  < 30kg  ABC + 3TC + DTG  ● AZT + 3TC + DTG  \\n● AZT+3TC and LPV/r may be used \\nas the third drug  \\n≥ 30 kg  TDF + 3TC /FTC + DTG  ● TDF+3TC/FTC and ATV/r may be \\nused as alternative third drug  \\n≥ 15 years  Any weight  TDF + 3TC/FTC + DTG  ● TDF+3TC/FTC and ATV/r may be \\nused as alternative third drug  \\n.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 198}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 10 - 2 10.3 Eligibility For PEP  \\nPEP should always be offered as soon as possible, preferably within 72 hours, after an exposure.  \\nPersons who present after 72 hours should be provided with other appropriate services including \\ncounselling and support.  \\nEligibilit y assessment for PEP is based on the type of exposure, HIV status of source where \\npossible and timing of seeking care.  \\nThe following include the eligibility criteria for PEP.  \\n● Exposed individual is HIV negative at baseline.  \\n● Exposure must have occurred within the past 72 hours.  \\n● Exposure to bodily fluids pose a significant risk (exposure and/or material):  \\n▪ Type of exposure:  mucous membrane (i.e.  sexual exposure; splashes to eye, nose, or \\noral cavity), non -intact skin, percutaneous injury or paren teral exposures  \\n▪ Material : blood, blood -stained body fluids, breast milk; semen; vaginal secretions; \\nsynovial, pleural, pericardial, amniotic fluids; CSF, and HIV cultures in laboratories  \\nExposures that do not require HIV PEP include:  \\n● When the exposed individual is already HIV positive.  \\n● Exposures to bodily fluids that do not pose a significant risk, i.e., tears, non -blood -stained \\nsaliva, urine, and sweat.  \\n10.4 Management and Follow Up  \\nPatients should be counselled and encouraged to complete the full course of PEP once a decision \\nhas been made to initiate PEP.  \\nFor occupational exposure, immediate care of the exposure site includes washing the site with \\nsoap and water and allow the wound  to bleed freely for several minutes  \\nNOTE: Do not do anything that will increase tissue damage such as squeezing, scrubbing, or \\ncutting the site further . \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 199}),\n",
       " Document(page_content='  \\nARVs for Post -exposure Prophylaxis  \\n10 - 3 Table 10.2: Recommendations for PEP Management and Follow -up \\nConsiderations  Recommendation  \\nManagement at initial \\ncontact  ● Counsel on risks and benefits of PEP and obtain verbal consent for HIV \\ntesting.  \\n● Voluntary testing for both exposed and source individuals  \\n● Offer PEP as soon as high -risk exposure is established and the exposed \\nindividual tests HIV-negative at baseline (if HIV testing not feasible, \\noffer 1 -2 days of PEP to cover until HIV test performed)  \\n● Provide first aid in case of broken skin or other type of wound  \\nTime of initiation  As soon as possible after exposure, but no later than after 72 hours  \\nDuration of PEP  28 days (dispense all 28 days of treatment at the first visit if tested HIV negative)  \\nDose of PEP  Same as indicated for treatment; use weight -based dosing for children  \\nLaboratory \\ninvestigation at \\nbaseline  ● Conduct creatine testing (if TDF -containing regimen) and Hb (if AZT -\\ncontaining regimen), however PEP should be offered even when lab tests \\nare not available. Do not delay administration of PEP while waiting for lab \\nresults.  \\n● HBsAg testing is recommended. Do not del ay administration of PEP while \\nwaiting for lab results. If negative provide HBV vaccination  \\n● Pregnancy testing for women of childbearing potential in case of sexual \\nassault.  \\nFollow -up ● Follow up client at 7 days, 14 days, 28 days, and 12 weeks after starting \\nPEP  \\n● Assess for and manage side effects due to PEP  \\n● Follow -up HIV testing should be done at the completion of PEP and if \\nnegative, test again at 12 weeks  \\n● Link to HIV treatment if positive  \\nCounselling  Counselling at baseline should include:  \\n● Adherence counselling  \\n● Information on side effects  \\n● Risk reduction counselling  \\n● Trauma and mental health counselling  \\n● Specific support for sexual assault  \\nOther services for \\nsexual assault  ● STI prophylactic treatment to all (treat for vaginal/urethral discharge \\nsyndrome following the national STI algorithms)  \\n● Emergency contraception for non -pregnant women  \\n● Tetanus toxoid for any physical injury of skin or mucous membranes  \\n● Documentation of clinic evidence of assault and collection of foren sic \\nevidence  \\nRefer to post -rape care guidelines for additional details  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 200}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 10 - 4 10.5 Risk reduction counselling  \\nTo reduce the risk of further HIV transmission, it is necessary to prevent transmission to sexual \\npartners and the children of breastfeeding mothers. R isk reduction counselling should form part \\nof each consultation with the individual. Measures to reduce transmission to another person may \\ninclude:  \\n● The use of condoms and safe injecting practices to prevent secondary transmission  \\n● Avoiding blood donation until confirmed HIV negative at 12 weeks post exposure  \\nTable 10.3 Considerations for special circumstances  \\nCircumstance   Recommendation  \\nBreastfeeding women  • Breastfeeding is not a contraindication for PEP  \\n• The risks and benefits of continuing breastfeeding while HIV \\ntransmission risk is unknown and should be discussed with the \\nmother  \\nChildren  • HIV testing approaches for children should be in line with national \\nguidelines and age appropriate  \\n• Informed consent from the caregiver is needed  \\nAdolescents  • Requiring parental consent for adolescents can be a barrier to HIV \\ntesting, particularly in cases of sexual assault  \\n• HIV testing should be performed in accordance with national \\nguidelines and consenting requirements  \\n \\n10.6 Preventing HIV exposure  \\nTo avoid or minimize the risk of exposure to HIV the following infection prevention control (IPC) \\nmeasures are recommended:  \\n• Precautions should be taken when handling contaminated body fluids including the use \\nof appropriate barriers such as gloves, gowns, and goggles.  \\n• Care with sharps including minimizing blind surgical procedures and proper handling \\nand disposal o f sharps.  \\n• Safe disposal of contaminated waste  \\n• Safe handling of soiled linen.  \\n• Adequate disinfection procedures  \\n• Universal Hepatitis B vaccination of non -immune at -risk groups including HCWs, police, \\nprison staff and rescue workers.  \\nIn cases that do not requi re PEP, the exposed person should be counselled about limiting future \\nexposure risk.  \\n \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 201}),\n",
       " Document(page_content='  \\nPre-Exposure Prophylaxis (PrEP)  \\n11 - 1  \\n11. Pre-Exposure Prophylaxis (PrEP)  \\n \\nPre-exposure prophylaxis (PrEP) is the use of antiretroviral medication to prevent the acquisition \\nof HIV infection by an uninfected person at ongoing risk of acquiring HIV infection.  \\nPrEP is recommended for use as follows:  \\n• Daily Oral PrEP for all indivi duals, irrespective of gender or sexual orientation who are at risk \\nof HIV infection.  \\n• Event -Driven (ED) PrEP is currently recommended for all people born male who are not \\ntaking exogenous estradiol -based gender affirming hormones  \\n11.1 Indications for PrEP and Criteria for Eligibility   \\n11.1.1 Indications for PrEP  \\nPrEP is indicated for;  \\n● HIV uninfected persons at ongoing risk of HIV acquisition  \\n● Some risk situations that place one at ongoing risk include individuals or sexual partner/s \\nwho is/are:  \\no HIV positive and: not on ART, or on ART < 6 months, on ART with viral non -suppression, \\nor on ART with suspected poor adherence  \\no In sero -discordant relat ionships trying to conceive  \\no Of unknown HIV status and at high -risk of HIV infection  \\no Engaging in transactional sex or sex work  \\no With history of recent or current sexually transmitted infections  \\no With recurrent use of Post -Exposure Prophylaxis  \\no With a history of sex whilst under the influence of alcohol or recreational drugs  \\no Inconsistent or no condom use or unable to negotiate condom use during intercourse \\nwith persons of unknown HIV status  \\no Using injection drugs where needles and/or syringes are  shared  \\n11.1.2 HIV Risk Assessment  \\nClients accessing health services should be screened for HIV risk and additionally provided with \\ninformation on HIV prevention options available including the availability of PrEP. This is in \\naddition to the use of HIV testing services (HTS), as clients ar e assessed for HIV risk before testing.  \\nThe risk assessment questions are enquiry of behavioural practices that may expose an individual \\nto HIV (Table 11.2).  \\n A simple Risk Assessment Tool (RAST) is provided to guide the provider in generating a \\nconversat ion about HIV risk. Screening for HIV risk should be integrated within other service \\ndelivery points. HIV negative individuals who answer “yes” to any of the screening questions \\nshould be engaged in a discussion about the risks and benefits of PrEP. The cl ient then is evaluated \\nfor eligibility to receive PrEP.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 202}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 11 - 2 Table 11:1 HIV Screening questions  \\nScreening question refer to the past 6 months & include;  \\n• “Have you had sex with more than one person?”  \\n• “Have you had sex without a condom?”  \\n• “Have you had sex with a nyone whose HIV status you do not know?”  \\n• “Are any of your partners at risk of HIV?”  \\n• “Have you had sex with a person who has HIV?”  \\n• “Have you received a new diagnosis of a sexually transmitted infection?”  \\n• “Do you desire pregnancy?”  \\n• “Have you used or wanted t o use PEP or PrEP for sexual exposure to HIV?”  \\n• “Have you injected drugs that were not prescribed by healthcare provider? If yes, did \\nyou use syringes, needles or other drug preparation equipment that had already been \\nused by another person?”  \\n• “Have you rece ived money, housing, food or gifts in exchange for sex?”  \\n• “Have you been forced to have sex against your will?”  \\n• “Have you been physically assaulted, including assault by a sexual partner?”  \\n11.1.3 Criteria for PrEP Eligibility  \\nTo be eligible for PrEP, individuals identified to be at risk of HIV infection from Risk Assessment \\nmust meet ALL the following criteria prior to initiating PrEP.  \\n● Confirmed HIV negative status through rapid antibody testing following the HTS algorithm.  \\n● Determine if the client is w illing to take PrEP as prescribed. (This is done by adherence \\neducation and counselling on the PrEP regimen to be given, and assessing the client’s \\nreadiness to follow the regimen.)  \\n● Does not have a current or recent (within the past one month) illness consistent with acute \\nHIV infection (fever, sore throat, muscle or joint pains, swollen glands, diarrhoea or headache) \\nin combination with a preceding high -risk exposure for HIV.  \\n● No contraindication to use of any of the ARVs recommended for PrEP e. g., TDF +/ - FTC (or \\n3TC) for those who choose oral PrEP.  \\n● Renal or liver disease  \\no Clients with renal and liver disease should receive further clinical and laboratory tests, \\nto determine the renal/liver function and extent of disease.  \\nOther important factors  for screening  \\n1. Gender based violence (GBV) screening:  All clients accessing PrEP must be screened for \\ngender -based violence, especially intimate partner violence (IPV), and appropriate \\nintervention offered or client linked to appropriate.  \\n2. Mental Status Assessment:  Psychological issues that may influence adherence should be \\nassessed and addressed. It is important to carry out basic mental health evaluation and \\noffer appropriate referral as necessary.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 203}),\n",
       " Document(page_content='  \\nPre-Exposure Prophylaxis (PrEP)  \\n11 - 3 HIV self -test (HIVST) should not be used as a de finitive HIV test for PrEP initiation and \\nfollow up monitoring.  \\n11.2 Package of PrEP Service  \\nPrEP should be offered as part of the comprehensive prevention package which includes \\nbehavioural, bio medical and structural components. Integration of PrEP serv ices is \\nrecommended within different service delivery points, including in the community, ANC and FP \\nclinics.  \\n \\n Client  seeking  any service  from the facility /Communit y\\n(See section  on PrEP Integration)\\n \\n \\n \\n \\nSCREEN  for ongoing  risk for HIV \\nTEST for HIV  \\n  \\nHIV Positive – link/refer\\nAdditional Screening:\\nGBV/HIV\\n \\n \\n \\n \\n \\n \\n \\n \\n \\n1 \\n \\nFigure 11.1 : Package of Service for PrEP  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 204}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 11 - 4 11.2.1 Pre -Initiation Checklist  \\nThis checklist is intended to help the service provider ensure all necessary screening and \\nassessments are done prior to PrEP initiation  \\nTable 11.2: Pre -Initiation Assessment Checklist  \\nITEM  Y/N  \\nScreening and Support for GBV   \\nHIV Testing   \\nCheck symptoms of acute viral infection in last 6 weeks   \\nBehavior risk assessment   \\nSubstance use and mental health screening   \\nPartner information   \\nPre-initiation education and understanding of PrEP   \\nClient readiness and willingness to adhere to prescribed PrEP and follow -up schedule   \\nSTI screening and treatment   \\nFor women  \\n✔ Pregnancy test, pregnancy intention and / or breastfeeding  \\n✔ Screen for contraception use using appropriate contraceptive screening tool   \\n✔ Highlight the need for condom use   \\nDiscussed plans for continually accessing PrEP   \\nAdditional laboratory tests (Availability of these test should not delay initiation of PrEP)  \\n✔ Serum creatinine and creatinine clearance  \\n✔ HBsAg  \\n✔ HCV serology  \\nNB:  absence of these tests should not hinder initiation   \\nMedication history and potential drug interactions   \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 205}),\n",
       " Document(page_content='  \\nPre-Exposure Prophylaxis (PrEP)  \\n11 - 5 11.2.2 Pre -initiation client education  \\nThe following components should be discussed prior to PrEP initiation:  \\nTable 11.3: Client Education Checklist  \\nTopic  Check  \\n✔ Explain how PrEP works as part of combination HIV prevention  ✔  \\n✔ Explain the need for baseline and follow -up tests including regular HIV testing  ✔  \\n✔ Explain PrEP use: include the following: (refer to the different types of PrEP \\navailable for details)  \\no The medications used (show the client the pills or other PrEP options  \\no How the medications are used (frequency of dosing for the various options)  \\no Number of doses required to achieve efficacy (7 doses for daily oral PrEP, \\nloading dose for event driven oral PrEP)  \\no What to do when doses are missed (continue for daily doses)  \\no Discontinuation of PrEP, how and when it can be discontinued.  \\no Side effects and what to do in case these are experienced (including when to \\nconsult the clinician)   ✔  \\n✔ Discuss what to do in case client experiences symptoms of seroconversion (acute \\nHIV infect ion)   \\n✔ Discuss the Limitations of PrEP  \\no PrEP reduces but does not eliminate the risk of acquiring HIV.  \\no PrEP does not prevent pregnancies and STIs.   ✔  \\n✔ Risk reduction counselling and support education  \\no Managing mental health needs  \\no Couple counselling  \\no Access to, and consistent use of condoms and lubricants  \\no Access to and need for frequent HIV testing.  \\no Early access to ART  \\no VMMC  \\no STI screening and treatment  \\no Harm reduction for PWID  ✔  \\n \\n11.3 Recommended ARVs for PrEP  \\nThe preferred ARV regimen is Tenofovir 300mg/ Emtricitabine 200mg (TDF/FTC) given as one \\nfixed dose combination (FDC) tablet orally daily.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 206}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 11 - 6 Table 11.4: Antiretrovirals for Use in PrEP  \\nPrEP Dosing \\nStrategies  Preferred  Alternative  \\nDaily Oral PrEP  TDF/FTC (300 mg/200 mg) as FDC \\nonce daily  TDF/3TC (300 mg/300 mg) as FDC once \\ndaily  \\nEvent Driven Oral \\nPrEP    TDF/FTC (300 mg/200 mg) as FDC \\n– two pills taken between 2 and 24 \\nhours in advance of anticipated sex; \\nthen, a third pill 24 hours after the \\nfirst two pills and a fourth pill 48 \\nhours after the first two pills; 2 -1-1 TDF/3TC (300 mg/300 mg) as FDC – \\ntwo pills taken between 2 and 24 hours \\nin advance of anticipated sex; then, a \\nthird pill 24 hours after the first two \\npills and a fourth pill 48 hours after the \\nfirst two pills ; 2-1-1 \\n*Recommended Long -acting Products: These products are at different stages of approval and availability \\nin Kenya. The Ministry of Health will issue specific implementation guidelines when they become \\navailable.  \\n*Long Acting \\nCabotegravir \\nInjection  Initiation injections: 600 mg \\nIntramuscular (IM) x 2 doses given \\n1 month apart (the second \\ninitiation injection can be given up \\nto 7 days before or after the date \\nscheduled to receive injection)  \\nTHEN  \\nContinuation injections: 600 mg  IM \\nevery 2months   \\n*Dapivirine \\nvaginal ring  Dapivirine vaginal ring, 25mg, \\ninserted vaginally every 28 days.   \\nThe drugs can be taken with or without food, and can be stored at room temperature.  \\nPrescription intervals for daily oral PrEP  \\nThe first prescription should be for 30 days to allow for the first follow -up visit during which a \\nrepeat HIV test should be conducted, and adherence, tolerability and adverse effects assessed.   \\nDuring the one -month visit, if no major concerns are noted, PrEP should be prescribed for 2 \\nmonths and thereafter 3 -monthly. Clients with sub -optimal adherence and or other major \\nconcerns should be given monthly follow up visit.  \\nRemind individuals using daily oral PrEP that it takes 7 doses (equivalent to 7 days) o f \\ncontinuous PrEP use to achieve adequate levels of the ARVs in tissues for it to be \\neffective. During these days, safer sex practices should be encouraged (including \\nabstinence and condom use). This only applies for individuals born female. Those born \\nmal e can have protective levels as soon as 2 hours before sex but ideally 24 hours. This \\nis true even for people intending to take daily oral PrEP for ongoing exposure.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 207}),\n",
       " Document(page_content='  \\nPre-Exposure Prophylaxis (PrEP)  \\n11 - 7 11.3.1 Schema for follow up for daily oral PrEP  \\nInitial Visit/First Contact\\nPerform a risk assessment to determine if PrEP is indicated:\\n• Discuss effective PrEP use and Clarify misinformation\\n• Perform Initial clinical and laboratory assessment:\\no Baseline HIV test and rule out symptoms of Acute \\nHIV infection.\\no Screen for STIs and risk of renal disease/Hepatitis \\nB/C infectionIf HIV Negative and meets eligibility for PrEP\\n• Offer adherence counselling and support. \\n• Prescribe 30 -day supply of PrEP (TDF 300 mg/FTC \\n200 mg OD) \\n• Discuss combination prevention and risk reduction.\\n• Offer other HIV prevention services e.g., condoms as \\nappropriate.\\n30 Day review\\n• Assess for adherence and offer adherence counselling and support.\\n• Ask about any side effects. Find out how the client is coping with the side effects if any. Reassure if minor.\\n• Assess for STIs, risk of acute HIV infection, and perform pregnancy test in women. \\n• Assess for risk of kidney disease, if available, obtain serum creatinine and calculate creatinine clearance \\n• Discuss risk reduction and provide condoms.\\n• Perform a repeat HIV test. (Discontinue PrEP for those who test positive and link to care for ART initiation) \\nGive a 60-day PrEP prescription for drug refill of PrEP. Schedule the 3 -month return visit.\\n3 monthly reviews \\n• Assess for adherence and offer adherence counselling and support. \\n• Ask about any side effects\\n• Assess for STIs, (and pregnancy in women) and acute HIV infection. \\n• Perform HIV test every 3 months (HIV self -test may be used followed by a \\nconfirmatory test in health facilities for those testing positive) \\n• Discuss risk reduction and provide condoms.\\nDo serum creatinine and calculate creatinine clearance within 3 months after initiation \\nand thereafter annually as recommended.\\n \\nFigure 11.2: Schema for Follow -up for Daily Oral PrEP  \\n \\n11.3.2 EVENT DRIVEN PrEP (ON DEMAND PrEP or 2+1+1 PrEP)  \\nWhat is event driven?  \\nAn “Event” refers to a sexual act. Event driven PrEP is where oral PrEP is to be used when an  \\nisolated sexual act is anticipated.   \\nEvent -Driven PrEP is recommended for all people assigned male at birth not taking exogenous \\nestradiol -based gender affirming hormones  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 208}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 11 - 8 \\n \\nFigure 11.3 Schema for Event -Driven PrEP  \\nWhen is ED -PrEP considered most appropriate?  \\nEvent driven PrEP is most appropriate for men who:  \\n• Have infrequent sex (for example, sex less than 2 times per week on average).  \\n• Can plan for sex at least 2 hours in advance or who can delay sex for at least 2 hours.  \\n• Would find ED -PrEP more convenient  \\nClients on Event driven PrEP require follow up. Figure 11.4  shows the schema for follow up of \\nevent driven PrEP.  \\nAssess HIV risk and determine eligibility for oral PrEP\\nOffer PrEP and discuss dosing options.\\nDaily dosing if risk is more frequent \\nthan 2 times per week and sex cannot \\nbe predicted or delayed by 2 hours.Men who have sex with men on PrEP \\ncan switch from daily dosing to ED -\\nPrEP (and vice -versa)Event -driven dosing if sex can be \\npredicted (particularly for infrequent \\nsex)\\nFollow -up visit (1 month after initiation and/or every 3 months) \\n✓ Provide HIV testing and screen for STIs\\n✓ Offer counselling by discussing adherence dosing strategy during use, and if PrEP user \\ntransitions from one dosing strategy to another. \\n✓ Assess if HIV risk is likely to persist in the next few weeks and months. \\n✓ May require more active support in continuing PrEP, whichever dosing strategy is chosen.\\n \\nFigure 11.4 Schema for Initiation and Follow -up for Event -driven PrEP  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 209}),\n",
       " Document(page_content='  \\nPre-Exposure Prophylaxis (PrEP)  \\n11 - 9 Changing between ED PrEP and daily oral PrEP  \\nMen can be offered the two dosing options: daily oral PrEP or Event driven PrEP.  \\n• Daily dosing is appropriate for those whose occurrence of sex cannot be predicted and for \\nthose whose potential exposures to HIV  are more frequent than 2 times per week, such \\nthat ED -PrEP would be taken so frequently that it would effectively resemble daily PrEP.  \\n• If sex continues beyond one day, a user of ED -PrEP can stay protected by taking another \\npill each day as long as sex co ntinues and stopping 2 days after the last sex act.  \\n• On the other hand, if an individual starts daily oral PrEP, but then sex becomes infrequent \\nand predictable, ED -PrEP can be used instead.  \\n \\n11.4 Managing Clinical and Laboratory Results on Initial and Fol low -up \\nAssessment  \\nTable 11.5 Initial & follow up laboratory test  \\nLaboratory Test  Guidelines for clients initiating \\nPrEP  Guidelines for clients on \\nfollow up  \\nHIV Rapid Test  Before initiating PrEP as per the National \\nHTS algorithm  At Month 1, Month 3, thereafter \\nevery 3months  \\nCreatinine Test  Test within 1 -3 months of PrEP Initiation  If client >50years – Screen every \\n6-12months  \\nClients of any age with renal \\ncomorbidity: recommended before  \\ninitiating PrEP  Screen every 6 -12months  \\nHepatitis B Surface \\nAntigen (HBsAg)  Test once within 3 months of initiating PrEP. If negative, offer/refer for \\nimmunization   \\nHepatitis C Virus \\nSerology  Test once within 3months of PrEP \\ninitiation  Every 12 months for persons at \\nhigh risk of Hepatitis C infection  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 210}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 11 - 10 Table 11.6: Managing Clinical and Laboratory Results on Initial and Follow -up Assessment  \\nScreening  Action  \\nHIV -positive at \\ninitial evaluation  Do not start PrEP, counsel and link to care and treatment  \\nHIV -positive after \\ninitiation of PrEP  Discontinue PrEP, counsel and link to care and treatment. Take DBS or plasma \\nsample for drug resistance testing.  \\n \\nPositive STI Screen  Thorough genitourinary and anorectal examination, urine dipstick for urethritis, \\nserological testing for syphilis, full STI evaluation if resources available (refer to \\nSTI algorithm). Refer to guidelines on syndromic management of STIs.  \\nHBsAg -negative  Offer HBV vaccination  \\n \\nHBsAg -positive  This is not a contraindication to oral PrEP.  However, will require monitoring of \\nliver function and referral for management of liver disease.  \\nNB: TDF -based daily or event -driven oral PrEP can be safely offered to \\npersons with HBV infection.  \\nHepatitis C - \\nNegative  Continue PrEP and follow Hepatitis C testing algorithm.  \\nHepatitis C - \\nPositive  Continue PrEP, refer for Hepatitis C confirmatory testing and management with \\ndirectly acting antivirals (DAAs).  \\nFlu-like illness after \\ninitiating PrEP  Continue PrEP, test for HIV at first contact and after 28 days, and if negative,  \\ncontinue with usual follow -up \\n \\n \\n \\n \\n \\n \\n \\nSide effects of PrEP  GIT - nausea, vomiting, weight loss: these are often mild, self -limiting and occur \\nduring the first 1 -2 months. Provide supportive counselling, offer symptomatic \\ntreatment e.g., anti -emetics like metoclopramide 10 mg 8 hourly for 3 to 5 days.  \\nRenal – individuals may experience transient increase in creatinine, and rarely \\nproteinuria and Fanconi’s syndrome (presenting as polyuria, bone pain and \\nweakness). Measure creatinine (and ca lculate estimated creatinine clearance) at \\ninitiation of PrEP and annually thereafter (or whenever indicated (symptom \\ndirected)).  \\nIf creatinine clearance (eGFR) < 50 ml/min do not start PrEP, recheck after 2 \\nweeks. Refer for evaluation of underlying renal  disease.  \\nIf the renal function returns to normal, reassess for PrEP and initiate/ continue \\nPrEP.  \\nPrEP should not be prescribed for individuals using nephrotoxic drugs like \\nacyclovir, aminoglycosides, retinoids etc. instead, offer alternative HIV \\nprevent ion services.  \\n \\nPregnancy or \\nBreastfeeding  \\n Pregnancy and breastfeeding are not contraindications to provision of PrEP.  \\nPregnant or breastfeeding women whose sexual partners are HIV positive or are \\nat high risk of HIV infection may benefit from PrEP as part of combination \\nprevention of HIV infection.  \\nPrEP is also indicated for HIV -negative women in sero -different partnersh ips \\nwho wish to conceive. PrEP in these situations can be prescribed during the pre -\\nconception period and throughout pregnancy to reduce risk of sexual HIV \\ninfection.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 211}),\n",
       " Document(page_content='  \\nPre-Exposure Prophylaxis (PrEP)  \\n11 - 11 Table 11.7: Summary of PrEP Initial and Follow -up Assessment  \\nVisit  Action  \\nFirst (Screening Visit) \\nClinician Visit  • HIV testing and counselling.  \\n• Evaluate for eligibility, willingness and readiness to take PrEP.  \\n• Educate about the risks, benefits, and limitations of different PrEP \\noptions  \\n• Educate client about recognizing symptoms of Acute  HIV Infection (AHI) \\nand what to do if such symptoms occur (i.e., urgently return for HIV \\ntesting)  \\n• Conduct behavior risk assessment  \\n• STI screening and treatment  \\n• Pregnancy, contraceptive use and counselling (for women); if pregnancy \\nsuspected, obtain a preg nancy test. However, pregnancy is not a \\ncontraindication to PrEP.  \\n• Adherence counselling  \\n• Discuss combination prevention.  \\n• Laboratory test; serum creatinine test and calculate Creatinine Clearance \\n(CrCl), HBsAg, pregnancy test, Hepatitis C (baseline investigations should \\nnot delay initiation of PrEP)  \\nIf no contraindication to TDF and the client is eligible and ready, \\nprescribe TDF/FTC one tablet once daily for 30 days (alternative \\nTDF/3TC one tablet once daily for 30 days, or TDF 300 mg once daily for \\n30 days); agree on a follow -up date before the prescription is finished  \\nVisit 2 (Month 1) \\nCounsellor/Clinician \\nVisit  • Counsellor/ Clinician visit  \\n• Assess for side effects and adverse effects  \\n• Safety monitoring clinical assessment/ Review lab results  \\n• Conduct a HIV test as per the national algorithm  \\n• Behavioral risk assessment .  \\n• Review for PrEP continuation or discontinuation  \\n• Adherence and risk reduction counselling  \\n• Give a prescription for PrEP for 2 months.  \\n• Offer HBV vaccination if available and HBsAg negative (follow HBV \\nvaccination schedule complete series  \\nFollow up visits - \\nMonths 3, 6,  , 12, 15.….  \\nClinician/Counsellor -\\nled visits  • HIV testing and counselling  \\n• HIV risk assessment   \\n• Review for PrEP continuation or discontinuation  \\n• Assess for side effects and adverse effects  \\n• Safety monitoring clinical assessment/ Review lab results  \\n• Adherence and risk reduction counselling  \\n• Give a prescription for PrEP for 3 months  \\n• Refill PrEP prescription  \\n• Serum creatinine and creatinine clearance  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 212}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 11 - 12 Table 11.7 Cont: Summary of PrEP Initial and Follow -up Assessment  \\nDuring every visit  \\n• Assess adherence  \\n• Reassess risk of HIV infection and offer risk reduction counselling  \\n• HIV testing should be repeated at month 1 and thereafter, every 3 months (this applies for both \\ndaily and Event driven PrEP)  \\n• Assess for adverse effects   \\n11.5 Contra -indications to Oral PrEP (daily or ED PrEP)  \\n• HIV infection or suspected acute HIV infection (i.e., flu -like symptoms in the last 4 weeks in \\ncombination with a preceding h igh-risk exposure for HIV)  \\n• Adolescents < 35 kg or age < 15 years  \\n• Impaired renal function (estimated creatinine clearance of <50 ml/min)  \\n• Unable or unwilling to adhere to prescribed PrEP or follow -up schedule.  \\n11.6 Criteria for Discontinuing Oral PrEP  \\nPrEP should be discontinued if ANY of the following criteria are met.  \\n● Positive HIV test during follow up.  \\n● Change in risk status (no ongoing risk)  \\n● Renal dysfunction with creatinine clearance below 50 ml/min  \\n● Client request to stop.  \\n● Sustained non -adherence.  \\nDiscontinuing daily oral PrEP:   Users discontinuing PrEP due to no ongoing risk or requesting \\nto stop should continue PrEP for at least 7 days after the last potential exposure to HIV. Reasons \\nfor discontinuation should be documented in the client’s record.  \\nDiscontinuing event –driven PrEP:  Event -driven PrEP can be stopped after two daily doses \\nfollowing the last sexual exposure.  \\n11.7 Restarting PrEP  \\nAny client restarting PrEP regardless of the preferred method should be assessed for HIV status \\nand a rapid HI V test conducted:  \\n● Daily Oral PrEP : Clients who stop PrEP for more than 7 days and wishes to restart should \\nbe assessed for resumption of PrEP similar to the assessment done for an initial (first) visit. \\nImportantly, conduct a HIV test before re -starting PrEP. If a high -risk exposure occurre d in \\nthe previous 7 days (i.e., acute HIV infection is suspected), defer PrEP and obtain repeat HIV \\ntest after 4 weeks; if negative, PrEP can be prescribed if the other criteria are fulfilled. The \\nuse of condoms should be recommended during the waiting per iod.  \\n● Event driven Oral PrEP :  Clients who have stopped PrEP for more than a week and who are \\nrestarting ED -PrEP should commence with a double dose (two pills) of PrEP as new \\ninitiators. Risk assessment should be conducted. If a high -risk exposure occurred  in the \\nprevious 7 days (i.e., acute HIV infection is suspected), defer PrEP and obtain repeat HIV \\ntest after 4 weeks; if negative, PrEP can be prescribed if the other criteria are fulfilled. The \\nuse of condoms should be recommended during the waiting peri od.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 213}),\n",
       " Document(page_content='  \\nPre-Exposure Prophylaxis (PrEP)  \\n11 - 13 11.8 Improving adherence to PrEP  \\nApproaches to improve adherence include:  \\n● Encourage ring users to keep ring in place continuously through the 28 -day period from \\ninitial insertion  \\n● Disclosure of PrEP use to a partner or trusted person  \\n● Use of reminder de vices like a cell phone alarm.  \\n● SMS reminders where available and feasible  \\n● Exploring and mitigation of other barriers to adherence  \\n● Peer support  \\n11.9 Monitoring Sero -conversion among PrEP users  \\nPrEP substantially reduce the risk of HIV acquisition.  The effi cacy of PrEP is correlated with \\nadherence.  Sero -conversion during use of PrEP should be monitored critically as it is increasing \\nthe risk of developing drug resistance if clients continue the use of PrEP while HIV infected.  \\nFactors that lead to HIV seroco nversion among PrEP sero -converters include:  \\n● Inconsistency in use of PrEP (non -adherence).  \\n● Social -behavioral factors e.g., poverty, HIV stigma and relationship status that may affect \\nthe ability to use PrEP as prescribed.  \\n● Possible infections with drug res istant strains  \\n \\nWhat should be done upon identification of a PrEP sero -converter?  \\nHIV testing among PrEP should be conducted consistently as per the algorithm. Identification of \\nnew HIV positive diagnosis among PrEP users should be followed with:  \\n● Immediate discontinuation of PrEP  \\n● Counselling of client on positive results  \\n● Linkage to care and ART (immediate ART initiation).  \\n● Assessment of barriers to adherence that may affect use of ART.  \\n● Document sero -conversion in client file, PrEP registers, and monthly reporting as \\nrequired.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 214}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 11 - 14  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 215}),\n",
       " Document(page_content='  \\nPeople Who Inject Drugs (PWID) and HIV  \\n12 - 1  \\n12. People Who Inject Drugs (PWID) and HIV  \\n \\n12.1 Introduction  \\nThe use of ART for HIV treatment in key populations should follow the same general principles \\nand recommendations as for all adults. Individuals within key populations groups may experience \\ndiscrimination and marginali zation that can impede their access to health care, including \\ntreatment for HIV, and frequently present late for treatment. It is important to ensure that people \\nfrom key populations have equitable access to HIV treatment and care.  Programs should ensure \\nthat missed opportunities are minimized and every single encounter with key populations is \\noptimally used. ART service delivery includes decentralization of HIV care and treatment and \\nintegration of ART services into other clinical services such as Medical ly Assisted Therapy and \\ndrop -in centers where appropriate capacity exists.  \\nPeople who inject drugs (PWID) are at increased risk of HIV infection. In Kenya, the HIV \\nprevalence among PWID is up to 4 times that of the general population. PWID also suffer a hi gher \\nburden of viral hepatitis (HBV and HCV), TB and sexually transmitted infections irrespective of \\ntheir HIV status. Despite this, PWID have limited access to HIV treatment and prevention services.  \\nEvery effort should be made to implement evidence -inform ed interventions in the comprehensive \\npackage of measures targeting PWID, either in combination or (depending on site capacity) singly, \\nwith linkage to comprehensive care (Table 12.1).  \\nPackage of care for PWID  \\nPWID have complex needs related to drug dependency, psychosocial and medical \\ncomplications of injection and other substance use. When they require ART, anti -TB, or any \\nother therapy, they are at increased risk of adverse drug reactions, drug -drug interactions and \\nnon-adherence.  These patients a re best comprehensively managed by providers who have \\nreceived specific training in the management of injection drug users. Once identified, PWID \\nshould be counselled and linked to programs with the capacity to offer comprehensive care for \\nsuch patients.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 216}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 12 - 2 Table 12.1: Comprehensive Package of Harm Reduction for PWID  \\nIntervention  Comment/Recommendations  \\nHIV testing services  PWID are at high risk of HIV infection, are likely to be diagnosed late and \\ntherefore have poorer treatment outcomes following ART i nitiation.  \\n● PWID should be offered HIV testing and counselling and be linked to \\ncomprehensive HIV treatment and prevention services including \\nharm reduction counselling and support.  \\n● Retest for HIV every 3 months if there is ongoing risk.  \\n● HIV self -testing should be integrated into drop -in centers (DICEs) \\nthrough both assisted and non -assisted approaches after initial \\ntesting by a provider.  \\n● HTS should also be offered to sexual partners  of PWID.   \\n \\nTargeted information, \\neducation, and \\ncommunication for PWID \\nand their sexual partners  PWID and sexual partners should be provided with information and \\ncounselling on risks related to drug use and risky sexual behavior. PWID \\nshould be informed of where and what harm -reduction services are \\navailable, and linked to appropriate services.  \\nPeer -based networks are effective in improving access and retention to \\nharm reduction care  \\n \\n \\nCondom provision  The correct and consistent use of condoms with condom -compatible \\nlubricants is recommended for all PWID to prevent unintended pregnancy \\nand sexual transmission of HIV and other STIs.  \\n \\n \\nPrevention and treatment of \\nsexually transmitted \\ninfections  PWID may be at higher risk of STIs due to sex work or other risky sex \\npractices.  \\nSTIs, especially genital ulcer diseases increase the risk of HIV infection and \\ntransmission and are often a sign of unsafe sexual behavior or risk of HIV \\ntransmission.  \\nScreening, dia gnosis, treatment, and prevention of STIs should be offered \\nroutinely as part of comprehensive HIV prevention and care for PWID.  \\n \\n \\nPrevention, diagnosis, and \\ntreatment of TB  Independent of HIV infection, PWID have an increased risk of TB. HIV \\ninfection f urther increases this risk.  \\n● All PWID should be screened regularly for active TB using the \\nsymptom -based screening algorithm at each contact with healthcare \\nworkers.  \\n● Once active TB is ruled out, TPT should be provided to PWID living \\nwith HIV as per National guidelines for TPT.  \\n● PWID w ith active TB should receive standard TB treatment as per the \\nNational guidelines and be supported to complete treatment.  \\n● Anticipate and manage complications due to viral hepatitis or renal \\nimpairment.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 217}),\n",
       " Document(page_content='  \\nPeople Who Inject Drugs (PWID) and HIV  \\n12 - 3 Table 12.1 Cont.  \\nPrevention, vaccination, \\ndiagnosis, and treatment for \\nviral hepatitis  Hepatitis B and C disproportionately affect PWID due to overlapping risk \\nfactors of sexual transmission and sharing needles, syringes, and other \\ndrug use items.  \\nHarm reduction and behavioral interv entions are also effective in \\nreducing risk of infection/transmission of HBV and HCV.  \\n● Peer interventions should be offered to people who inject drugs to \\nreduce the incidence of viral hepatitis  \\n● PWID should be screened for HBV (by HBsAg) and HCV (by HCV \\nsero logy) at first contact  \\n● Hepatitis B  \\no Hepatitis B vaccination is recommended for those who are \\nHBsAg negative. A higher -dose HBV vaccine should be used \\nwith the rapid regimen (day 0, 7, 21, and a booster at 12 \\nmonths). If the rapid regimen is not available, the standard \\nregimen should be offered. For PWID who are HIV positive, they \\nshould follow the dosing schedule in Table. 9.1  \\no HBV/HIV co -infected PWID should be started on TDF - or TAF - \\ncontaining ART (the current recommended first line is \\nTDF/3TC/ DTG) in addition to harm -reduction interventions to \\noptimize adherence and treatment outcomes.  \\n● Hepatitis C  \\no HCV/HIV co -infected PWID should be initiated on ART.  \\no Specific HCV antiviral therapy should be provided in \\nconsultation with expertise in the management of HCV infection \\n(refer to national guidelines on management of viral hepatitis)  \\n  \\nNeedle and syringe \\nprogrammes (NSPs)  NSPs help decrease drug -related risk behaviors, reduce quantity of \\ncontaminated needles in circulation, reduce risk of new HIV infections and \\nimprove referrals and linkage to HTS and HIV treatment and prevention \\nservices.  \\nNSPs are effective means for intr oducing combination prevention to PWID \\nincluding HTS, STI screening and treatment, condoms provision, OST, and \\nHIV treatment and prevention.  \\nAll PWID should be linked to NSPs to access sterile injecting \\nequipment  \\n \\nOpioid substitution therapy \\n(OST)  OST usi ng methadone or another suitable alternative is effective in the \\ntreatment of opioid dependency, reducing risk behaviors related to drug \\nuse and therefore reducing HIV transmission and improving PWIDs’ \\nadherence to ART  \\nIdentify and link all PWID who have o pioid dependence for opioid \\nsubstitution therapy  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 218}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 12 - 4 Table 12.1 Cont.  \\nAntiretroviral therapy \\n(refer to Table 12.2 for \\ndetails)  • ART is effective in managing HIV infection in PWID. However, poor \\nadherence may interfere with ART success. Intensive support is \\nrequired including OST, enhanced counselling techniques and daily \\nwitnessed ingestion (DWI) when available.  \\n• Close monitoring of ART is necessary because of risk of drug -drug \\ninteractions, renal and liver toxicity.  \\n• HIV-positive PWID should be off ered comprehensive HIV treatment \\nand prevention services including ART. When ART is provided with \\nadditional targeted support, PWID can achieve and maintain viral \\nsuppression.  \\n• Oral PrEP is recommended as an additional prevention choice for \\nPWID at substant ial risk of HIV infection as part of combination \\nprevention and harm reduction approaches.  \\nCommunity outreach  PWID face barriers to accessing formal facility -based health services due \\nto stigma, discrimination, and fear of victimization among other factors.  \\nOutreach either directly from the facility or through collaborations with \\ncommunity -based groups is an effe ctive means of delivering harm -\\nreduction interventions in addition to HIV treatment and prevention \\nservices.  \\nPeer -led, community -based approaches are particularly useful in \\nimproving adherence and retention.  \\n \\n12.3 ART in HIV positive PWID  \\nAntiretroviral  therapy is part of the comprehensive care package for PWID living with HIV. ART \\nservice provision should follow the same general principles and recommendations as for all \\nadults.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 219}),\n",
       " Document(page_content='  \\nPeople Who Inject Drugs (PWID) and HIV  \\n12 - 5 Table 12.2: Summary of ART Recommendations for PWID  \\nCare and Support  Recom mendation/Additional Information  \\nWhen to start ART in \\nHIV positive PWID  ART should be initiated in all individuals with HIV regardless of WHO clinical \\nstage or CD4 cell count  \\nWhat to start (first -line \\nART)  Irrespective of OST, PWID with HIV infection should be initiated on a first -line \\nregimen of TDF + 3TC + DTG  including women of childbearing potential.  \\nTDF + 3TC + ATV/r may be offered as an alternative where DTG cannot be used. \\n(Table 6.3)  \\nTB Co -infecti on  ART should be started as soon as possible within two weeks of initiating TB \\ntreatment, regardless of CD4 cell count.  \\nFor PWID with TB/HIV co -infection on DTG, give TDF/3TC/DTG FDC given in \\nthe am + DTG 50mg given in the pm for duration of rifampicin -containing TB \\ntreatment and for an additional 2 weeks after TB treatment is completed, then \\nrevert to TDF/3TC/DTG FDC once daily.  \\nSecond -line \\nART  Patients failing DTG -based first line ART (including PWID) should be managed \\nas per the viral load  monitoring algorithm (Figure 6.6), including performing a \\nDRT for selection of a second -line regimen (Table 6.10)  \\nTreatment preparation \\nand adherence \\ncounselling and \\nsupport  Injection drug use is not a contra -indication to ART initiation. OST, though \\nimp ortant in contributing to the success of ART in PWID, should not be a pre -\\nrequisite to initiation of ART. However, these patients benefit from additional \\npreparation and support to increase their chances of successful treatment \\nincluding:  \\n● Harm reduction in terventions  \\n● Thorough baseline assessment for important comorbid conditions like \\nAdvanced HIV Disease (AHD) including TB, hepatitis, renal impairment \\nand depression or other psychiatric disorders  \\n● Negotiation for, and access to daily witnessed ingestion (DWI ). \\n● Community outreach and support  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 220}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 12 - 6 Table 12.1 Cont.  \\nPreventing and \\nmanaging drug -drug \\ninteractions  Selection of drugs should take into consideration possible drug to drug \\ninteractions and their effects on opioids, OST and ART. Any interaction that \\nreduces the levels of methadone may induce withdrawal symptoms and \\nrequire an increased dose of methadone.  \\n● ARV interactions with methadone and opioids  \\no NRTIs  \\n▪ TDF, TAF, 3TC, FTC: no significant interactions  \\n▪ AZT levels are increased, with higher risk of AZT toxicity.  \\n▪ ABC levels are decreased, and methadone levels are \\ndecreased.  \\no NNRTIs  \\n▪ EFV: methadone levels are decreased and may induce \\nwithdrawal symptoms.  \\no PI/r: all boosted PIs decrease methadone levels.  \\n▪ LPV/r and methadone increase risk for prolonged QT \\nsyndrome and sudden cardiac death.  \\no INSTIs: no significant interactions  \\n● ARV interactions with buprenorphine  \\no ATV/r and DRV/r increase concentrations of buprenorphine or \\nits active metabolites and may increase risk of toxicity.  \\no EFV decreases buprenorphine levels substantially.  \\no No known significant interactions with other ARVs  \\n● Rifampicin and Rifapentine decrease levels of methadone and \\nbuprenorphine and may induce withdrawal symptoms.  \\n● INH can be used safely with methadone or bupr enorphine  \\n● Management of Drug -Drug Interactions (Annex 13)  \\n \\nMonitoring ART  ● PWID on ART require more frequent monitoring and support to ensure \\nadherence to treatment and harm reduction interventions, assessment for \\nand management of adverse drug reactions or drug -drug interactions  \\n● Ongoing monitoring should also include screening for other illicit \\nsubstance/drug use.  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 221}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 1  \\n13. Annexes  \\n \\nAnnex 1: WHO Clinical Staging of HIV Infection in Infants and Children  \\nStage I  \\n• Asymptomatic  \\n• Persistent generalized lymphadenopathy  \\n• (PGL)  \\n• Unexplained, asymptomatic \\nhepatosplenomegaly  Stage II  \\n• Papular pruritic eruptions (PPE)  \\n• Seborrheic dermatitis  \\n• Fungal nail infections  \\n• Angular cheilitis  \\n• Linear gingival erythema  \\n• Extensive HPV or molluscum infection (>5% of \\nbody area/face)  \\n• Recurrent oral ulcerations (>2 episodes/ in 6 \\nmonths)  \\n• Parotid enlargement  \\n• Herpes zoster (>1 episode/12 months)  \\n• Recurrent or chronic upper respiratory infection \\n(URI): otitis media, otorrhea, sinusitis (>2 \\nepisodes/6 months)  \\nStage III  \\n• Unexplained moderate malnutrition ( -\\n2SD or Z score) not responding to \\nstandard therapy  \\n• Unexplained persistent diarrhoea (>14 \\ndays)  \\n• Unexplained persistent fever  \\n• (Intermittent or constant, > 1 mo.)  \\n• Oral candidiasis (outside neonatal \\nperiod)  \\n• Oral hairy Leucoplakia  \\n• Pulmonary tuberculosis  \\n• Severe recurrent presumed bacterial \\npneumonia (>2 episodes/12 months)  \\n• Acute necrotizing ulcerative gingivitis/  \\n• periodontitis  \\n• Lymphoid interstitial pneumonitis (LIP)  \\n• Unexplained anaemia (<8g/dL), \\nneutropenia (<1,000/mm3), or \\nthrombocytopenia (<30,000/mm3) for \\n>1 mo.  \\n• HIV-related cardiomyopathy  \\n• HIV-related nephropathy  Stage IV  \\n• Unexplained severe wasting or severe malnutrition \\n(-3 \\nSD or Z score) not responding to standard \\ntherapy  \\n• Pneumocystis pneumonia  \\n• Recurrent severe bacterial infections (>2 \\nepisodes/12 months, excluding pneumonia)  \\n• Chronic orolabial or cutaneous HSV (lasting > 1 \\nmo.)  \\n• Extra -pulmonary tuberculosis  \\n• Kaposi’s sarcoma  \\n• Oesophageal candidiasis  \\n• CNS toxoplasmosis  \\n• Cryptococcal meningitis  \\n• Any disseminated endemic mycosis  \\n• Cryptosporidiosis or Isosporiasis (with \\ndiarrhoea > 1 month)  \\n• CMV infection of organ other than liver, spleen, \\nlymph nodes (and onset age >1 month)  \\n• Disseminated mycobacterial disease other \\nthan tuberculosis  \\n• Candida of trachea, bronchi or lungs  \\n• Acquired recto -vesicular fistula  \\n• Cerebral or B -cell non -Hodgkin’s lymphoma  \\n• Progressive multifocal leukoencephalopathy PML)  \\n• HIV encephalopathy  \\nNOTE: WHO Clinical Staging should be carried out only on children confirmed (by serology or DNA PCR) \\nto be HIV infected  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 222}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 2 Annex 2: WHO Clinical Staging of HIV Infection in Adolescents and Adults  \\nStage 1  \\n• Asymptomatic  \\n• Persistent Generalized  \\nLymphadenopathy (PGL)  Stage 2  \\n• Moderate unexplained weight loss (< 10% of presumed \\nor measured body weight)  \\n• Minor mucocutaneous manifestations (seborrheic \\ndermatitis, papular pruritic eruptions, fungal nail \\ninfections, recurrent oral ulcerations, angular cheilitis)  \\n• Herpes zoster  \\n• Recurrent upper respiratory tract infections (sinusitis, \\ntonsillitis, bronchitis, otitis m edia, pharyngitis)  \\nStage 3  \\n• Unexplained severe weight loss \\n(over  \\n• 10% of presumed or measured \\nbody weight)  \\n• Unexplained chronic diarrhoea for \\nlonger than one month  \\n• Unexplained persistent fever \\n(intermittent or constant for longer \\nthan one month)  \\n• Persistent oral candidiasis  \\n• Oral hairy leukoplakia  \\n• Pulmonary tuberculosis  \\n• Severe bacterial infections (e.g., \\npneumonia, empyema, \\npyomyositis, bone or joint \\ninfection, meningitis, bacteraemia)  \\n• Acute necrotizing ulcerative \\nstomatitis, gingivitis or \\nperiodontitis  \\n• Unexplained anaemia (below 8 \\ng/dl), neutropenia (below 0.5 x \\n109/l) and/or chronic \\nthrombocytopenia (below 50 x 109 \\n/l) Stage 4  \\nConditions where a presumptive diagnosis can be made \\nusing clinical signs or simple investigations:  \\n•   HIV wastin g syndrome  \\n•   Pneumocystis jirovecipneumonia (PCP)  \\n•   Recurrent severe bacterial pneumonia (≥ 2 episodes \\nwithin 1 year)  \\n•   Cryptococcal meningitis  \\n•   Toxoplasmosis of the brain  \\n•   Chronic orolabial, genital or ano -rectal herpes simplex \\ninfection for > 1 month  \\n•   Kaposi’s sarcoma (KS)  \\n•   HIV encephalopathy  \\n•   Extra pulmonary tuberculosis (EPTB) Conditions \\nwhere confirmatory diagnostic testing is  \\nnecessary:  \\n•   Cryptosporidiosis, with diarrhoea > 1 month  \\n•   Isosporiasis  \\n•   Cryptococco sis (extra pulmonary)  \\n•   Disseminated non -tuberculous mycobacterial infection  \\n•   Cytomegalovirus (CMV) retinitis or infection of the \\norgans (other than liver, spleen, or lymph nodes)  \\n•   Progressive multifocal leukoencephalopathy (PML)  \\n•   Any disseminated mycosis (e.g., histoplasmosis, \\ncoccidiomycosis)  \\n•   Candidiasis of the esophagus or airways  \\n•   Non -typhoid salmonella (NTS) septicaemia  \\n•   Lymphoma cerebral or B cell Non -Hodgkin’s Lymphoma  \\n•   Invasive cervical cancer  \\n•   Visceral leishmaniasis  \\n•   Symptomatic HIV -associated nephropathy or HIV  \\nassociated cardiomyopathy  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 223}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 3 Annex 3: Normal Developmental Milestones in Children  \\nAGE  GROSS MOTOR  FINE MOTOR  WARNING SIGNS  \\n3 Months  Supine:  \\n● Pull to sit:  \\n● 45 o head lag still present  \\nSitting: Propped up  \\n● Flexed/C -Position  \\n● Hold head steady  \\nProne:  \\n● Bears weight on flexed arms  \\n● Lifts head 45 o turn head to side  Eyes:  \\n● Follow through 90 o in lying  \\nHands:  \\n● Open for longer  \\n● Shake a rattle when it is placed \\nin the hand (not intentional)  \\n● Mouthing begins  ● No visual fixation or following \\nasymmetry of tone or movement.  \\n● Floppy/stiff  \\n● Consistent fisting  \\n● Unstable to turn or lift head  \\n● Failure to smile  \\n● Poor sucking & swallowing  \\n6 Months  \\n Supine:  \\n● Pull to sit, no more head lag  \\n● Plays with feet  \\n● Rolls from back to tummy  \\nSitting:  \\n● Unaided supported by arms  \\nStanding:  \\n● Bears weight on legs, equal both sides  \\nProne:  \\n● Props self on straight arms, legs \\nextended, toes turned outwards  Eyes:  \\n● Follow through 180 o in lying  \\n● Focus on small objects  \\nHands:  \\n● Hands on midline  \\n● Banging blocks against the table \\nreaches and attains objects at \\nwill Holds and actively plays \\nwith rattle  ● Floppiness  \\n● No head control  \\n● Failure to use both hands  \\n●  Asymmetrical movement squint  \\n● Failure to turn to sound  \\n● Poor response to people  \\n9 Months  Sitting:  \\n● Sits without support lean forward  \\n● And sit up again without losing balance  \\nStanding:  \\n● Remain standing for a few seconds by \\nholding onto an object, falls down again  \\nProne:  \\n● Baby starts to crawl  Eyes:  \\n● Extremely accurate vision  \\nHands:  \\n● Can pick up and button  \\n● Holds a block in each hand  \\n● Points  ● Unable to sit  \\n● Failure to use both hands  \\n● Fisting  \\n● Squint  \\n● Persistence of primitive reflexes  \\n12 Months  \\n Sitting:  \\n● Turns around to reach nearby toys  \\n● Sits down unaided from standing  \\nStanding: (Walking)  \\n● Walks forward if held by one hand  \\n● Walks around furniture sideways -cruising  \\nProne: (crawling)  \\n● Crawls  \\n● Pulls up to standing by holding onto object  Eyes:  \\n● Looks for toys when out of sight  \\nHands:  \\n● Able to pick up a button with thumb and \\nindex finger (pincer grasp)  \\n● Release on request  \\n● Hold with 1 hand and play with the other  \\n● Throws things into a container and take \\nit out again  ● Unable to bear \\nweight on legs  \\n● Not yet crawling and \\npulling to stand  \\n● Abnormal grasp  \\n● Failure to  respond to \\nsound  \\n● Unable to start with \\nsolids independently  \\n15 Months  \\n Sitting:  \\n● Stand up from sitting  \\n● Will climb on a chair and sit down  \\nStanding: (Walking)  \\n● Bend over to pick up an object  \\n● Squat and stand up again  \\n● Walks alone, broad base with arms in the airs  \\nProne: (crawling)  \\n● Able to crawl fast and manage obstacles e.g., stairs  Eyes:  \\n● Hold crayon in a fist when \\nscribbling  \\n● Turn pages of a book roughly  \\n● Hold 2 small toys in 1 hand  \\n● Put lid back on container  ● Unable to bear \\nweight on legs  \\n● Not yet wal king  \\n● Abnormal grasp  \\n● Abnormal posture: \\nfloppy/spastic  \\n● Failure to respond to \\nsound  \\n● Not yet talking  \\n18 Months  ● Walking with more confidence  \\n● Walk, squat and pick up something, \\nstand up and walk again  \\n● Starts running, often falls  \\n● Take few steps backwards  \\n● Runs and change direction easily  \\n● Jump off step with 2 feet together  \\n● Stand and kick a ball  \\n● Able to throw a ball  ● Build a 3 -cube tower  \\n● Scribbles  \\n● Holds the crayon in a fist  \\n● Turn pages of a book  \\n● Page through a book page by page  \\n● Obvious hand preference  \\n● Uses lines: I, _,0  \\n● Completes 3 -piece puzzle  \\n● Remove a sweet wrapper with little help  ● Failure to walk  \\n● Unable to pick up small \\nobjects e.g., buttons  \\n● Abnormal posture  \\n● Not yet talking  \\n● Unable to understand \\nsimple commands  \\n● Poor co -ordination  \\n36 Months  ● Walk forward and backward  \\n● Walks on tip toes  \\n● Walks on straight line  \\n● Jump 2 feet together  \\n● Able to climb on chair  \\n● Catch a big ball (hugging against chest)  \\n● Holds ball above head and throws  \\n● Runs and kicks ball  ● Copies the following shapes: _, I, O, T \\n● Start coloring in, go over the lines  \\n● Pencil grip:  \\n● Holding crayon to draw (still developing)  \\n● Builds a 9 -block tower  \\n● Thread big beads on a shoelace  \\n● Draw a man: at least 4 parts  ● Using only single \\nwords  \\n● Ataxia  \\n   \\n \\n \\n \\n \\n \\n \\n', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 224}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 4 Annex 4: Tanner Staging of Sexual Maturity in Adolescents  Annex 4 A: Tanner Staging of Sexual Maturity in Girls  \\nAge Range  \\n(Year)  \\n0-15 \\n8-15 \\n10-15 \\n10-17 \\n12-18 Tanner Staging in  \\n Annex 4 B: Tanner Staging of Sexual Maturity in Boys  \\nAge Range  \\n(Year)  \\n0-15 \\n \\n10-15 \\n \\n10-16 \\n \\nVariable  \\n(12-17) \\n13-18 Tanner Staging in  \\n \\n \\n', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 225}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 5 Annex 5: Age -Appropriate Disclosure for Children and Adolescents  \\nAge \\nCharacteristics  Stage of \\nDisclosure  Provider Actions  \\n0 - 4 years  No disclosure  At this stage no disclosure is done since the child is too young \\nto understand about HIV  \\n5 - 8 years  Partial disclosure  At this age the child can understand a lot. Define the virus as a \\ngerm and the CD4 as the soldier in the body that keeps fighting \\nand one has to take the drugs to strengthen the soldiers in the \\nbody  \\n9 to 12 years  Full disclosure  Full disclosure is important since most children at this stage \\nare able to understand more about HIV and would have heard \\nabout HIV as part of formal education at school  \\nFollow the following stages in the disclosure process  \\nStage 1  \\nAssessing the child’s social support system to ensure \\navailability of sufficient support once disclosure is completed  \\nStage 2  \\nAssess the child’s prior knowledge about HIV including \\ninformation given at school, any myths and misconceptions. \\nOffer or reinforce accurate information  \\nStage 3  \\nUse an imaginary exercise or story to assess child’s reaction to \\ndisclosure of HIV status  \\nStage 4  \\nTell the child about their HIV status. Support parents to \\ndisclose to the child and clarify the mode of infect ion. Address \\nimmediate reactions and concerns a child might have  \\nPost -disclosure  \\n(1-2 weeks after \\nfull disclosure)  Find out from the parent/guardian if they have observed \\nanything after disclosure, e.g., change in behavior  \\n• Introduce the child to tell their story and emerge as a hero \\n(a comic book may be a useful aid)  \\n• Link the child to a support group or with an older child \\nwho has been disclosed to  \\nNB: Find out how the child is doing at every visit after full \\ndisclosure  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 226}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 6 Annex 6: Transitioning from Adolescent to Adult HIV Services  \\nInitiate transition process for all children in \\npaediatric clinic who have attained 10 years of ageGoal 1 : for age 10 -12 years (early -adolescence)\\n•  Full disclosure\\n•  Understanding of the HIV\\n•  Understanding of HIV prevention measures\\n•  Link to an adolescent support group Has adolescent attained 13years and achieved Goal 1 \\nabove?\\nYes: Client is 13years and has achieved \\ngoals at early adolescence continue to \\ngoal 2No: Client is 13years and has \\nnot achieved goals 1 at early \\nadolescence\\nGoal 2 : for age 13 -16 years (mid -adolescence)\\n•  Understanding of the medication and adherence\\n•  Encourage appointment keeping\\n•  Should be a member of a support group\\nHas adolescent attained 17years and achieved Goal 2 above?No: Client is 17 years and has not \\nachieved goals at mid adolescence\\nYes: Client is 17 years and has achieved goals at mid adolescence\\nGoal 3 : for age 17 -19 years (late -adolescence)\\n• Demonstrated understanding importance of medication adherence in last 2 -3 visits\\n• Prompt appointment keeping for 6months\\nHas adolescent attained 19years and achieved Goal 3 above?\\n Client chooses to transition\\n Transfer medical records\\n Orient adolescent in adult clinic\\n Follow up of transitioned adolescentsClient declines to transition\\n Continue psychosocial support to client as you prepare for transition to \\nadult clinic\\n \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 227}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 7 Annex 7: 2018 HIV Testing Services Algorithm  \\nSCREENING\\nNON REACTIVE REACTIVE\\nREPORT NEGATIVE CONFIRMATORY TEST\\nNON REACTIVE REACTIVE\\nINCONCLUSIVE REPORT POSITIVE\\nREFER TO THE COMPREHENSIVE CARE CLINIC\\nSCREENING TEST SCREENING TEST\\nNON REACTIVE REACTIVE NON REACTIVE\\nCONFIRMATORY TEST\\nNON REACTIVE REACTIVE\\nREPORT INCONCLUSIVE REPORT POSITIVECollect DBS and \\nsend to laboratory \\nfor DNA PCRINCONCLUSIVE\\nRequest for retest \\nafter 2 weeks at \\nCCC\\nIf the result is still \\ninconclusive, \\ncollect DBS and \\nsend to the \\nlaboratory for DNA \\nPCREnroll to care and \\ntreatment \\nNB:  The use of TIE BREAKER is no longer recommendedRetesting in MCH, wards or \\nsettings without CCCs: To be \\ndone by a different service \\nprovider on a second \\nspecimen\\nREPORT NEGATIVE\\n \\n \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 228}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 8 Annex 8: HIV Education and Adherence Counselling Content Guide  \\nHIV Education and Adherence Counselling  \\nNote: for children/adolescents, the script below should be modified towards the caregiver  \\nSection 1: Introductions, climate setting, and review of objectives for the session  \\n• Ensure privacy and confidentiality  \\n• Introductions of all pa rticipants  \\n• Present the key message for each section using simple terms that the patient will understand, \\nusing analogies as appropriate  \\n• Use IEC material when available  \\n• Ask the patient if they have any questions at the end of each section, and then ask them to explain the \\nmain points back to you to confirm understanding  \\n• If this is a follow -up session, review what they remember from previous sessions and adapt the \\nsession  to address their needs  \\nSection 2: HIV  \\n• What is HIV  \\n− HIV stands for “Human Immunodeficiency Virus”  \\n− HIV is a virus that attacks the body’s immune system.  The immune system protects the \\nbody from infections  \\n• How is HIV transmitted  \\n− Sexual contact  \\n− Needles  \\n− Exchange of blood and bodily fluids  \\n− Mother -to-child transmission  \\n• Why should family members be tested for HIV  \\n− Sexual partners are at risk for already having HIV  \\n− All children born to HIV positive mothers are at risk for already having HIV  \\n− Encouraging partners/children to test for HIV now is the best way to identify HIV early, so \\nthey can also get into treatment  \\n− Starting treatment early will help them live long and productive lives  \\n− Whether they test positive or negative, they can be an impor tant source of support for your \\nown treatment  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 229}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 9 Annex 8: Cont.  \\nSection 3: Viral load  \\n• What is viral load  \\n- Viral load is the amount of HIV in your body  \\n- When your viral load is high it means you have a lot of HIV in your body; this causes damage to \\nyour body  \\n- Viral load is measured by a blood test  \\n \\n• How often is viral load measured  \\n- Viral load is measured after being on treatment for 3 months  \\n- After 3 months of treatment, we expect the amount of virus in your body to be undetectable; if \\nyour VL is detectable then we have to discuss the reasons  \\n- Having an “undetectable” VL means the test cannot measure the virus in your blood because \\nyour ART is working, but it does not mean you are no longer infected with HIV  \\n- Repeat viral load tests are done dependin g on how you are doing; if you are doing well on \\ntreatment then the viral load is measured again every 6 months (for children/adolescents and \\npregnant/breastfeeding) or annually  \\n- For HEI with positive PCR, we also measure viral load at the start of treatmen t \\n \\n• What do viral load measurements mean  \\n- After being on treatment for 3 or more months, your viral load should be undetectable  \\n- If your viral load is undetectable, it means your treatment is working well and you should \\ncontinue taking it the same; the virus is not damaging your body any more  \\n- If your viral load is detectable, it means your treatment is not working properly, usually because \\nyou have been missing some of your pills; the virus is damaging your body and you and the clinic \\nteam will need to work together to figure out how to fix the problem  \\nSection 4: CD4 cells  \\n• What are CD4 cells  \\n- CD4 cells are the immune cells that protect the body from infections  \\n- CD4 cells are measured through a blood test, called CD4 count. For adults a normal CD4 count is \\nabove 500  \\n \\n• How are CD4 cells affected by HIV  \\n- HIV attacks and destroys CD4 cells  \\n- After years of constant attack from HIV, the CD4 count falls  \\n \\n• What happens when CD4 cells decrease  \\n- When the CD4 count falls too low (usually below 200), diseases called “opportunistic infections” \\nare able to infect the body because the body cannot defend itself  \\n- Common opportunistic infections include: tuberculosis, pneumonia, skin problems, white spots \\nin the mouth, and chronic diarrhoea  \\n \\n• How often is CD4 count measured  \\n- CD4 count is measured for all patients at the beginning of treatment, to see if you are likely to get \\nany opportunistic infections  \\n- Once you start treatment for HIV, we do not need to check CD4 count frequently, but we will use \\nthe VL tes t to monitor your response to anti -retroviral treatment  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 230}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 10 Annex 8: Cont.  \\nSection 5: Antiretroviral therapy (ART)  \\n• What is ART:  \\n- ART is a combination of 3 or more different medicines  \\n- ART fights HIV, lowering the amount of virus in the body allowing the body to protect \\nitself against opportunistic infections  \\n- When the virus level is low then the CD4 count can increase  \\n- Increased CD4 count means the body is able to protect itself against opportunistic infections  \\n \\n• What are the benefits of ART:  \\n- After a few weeks of taking ART, you will begin to regain appetite and weight (if it has been \\naffected)  \\n- Many people report an increase in their energy levels and general sense of well being  \\n- People can often return to work or school or care for their families  \\n- With ART,  people with HIV can live a long and healthy life if they take it properly  \\n \\n• When is ART started:  \\n- Everybody with HIV should start ART  \\n- Even if your CD4 count is high, the virus is doing damage inside of you and needs to be \\ncontrolled  \\n- ART should be started as soon as you are ready, preferably within 2 weeks  \\n- The longer you wait to start ART, the more time the virus can damage your body, increasing \\nyour chances of getting sick or even dying  \\n- Sometimes ART is started a few weeks later if you have certain infections, or if you do not \\nthink you are ready to take them properly  \\n \\n• Does ART cure HIV:  \\n- ART does not cure HIV  \\n- ART lowers the amount of virus in your body so your body can protect itself from infections  \\n- It does not remove the virus completely  \\n \\n• Can you still give HIV to others while taking ART:  \\n- Transmission of HIV is very unlikely once your viral load is undetectable  \\n- You should practice safer sex to reduce the risk for other infections as well, including \\ndisclosure of HIV status to sexual partners and consistent and correct condom use  \\n \\n• How long is ART taken for:  \\n- ART is a life -long treatment  \\n- Once you start ART, you need to take it every day for the rest of your life (either once a day, \\nor twice a day, depending on which drugs you are on)  \\n- You must take the ART as prescribed and never miss a dose otherwise the treatment might \\nfail and the drugs stop working against the virus  \\n \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 231}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 11 Annex 8: Cont.  \\nSection 6: Treatment failure  \\n• What happens if you stop taking ART:  \\n- When you stop taking ART the virus begins to increase in your body very quickly  \\n- The virus goes back to the same high level it was at before you started ART  \\n• What happens if you do not take ART regularly:  \\n- The virus begins to increase to high levels again  \\n• What happens if t he viral load increases:  \\n- When the virus is allowed to increase again, it will also affect your immunity and reduce your CD4 count \\nputting you at risk of opportunistic infections  \\n- When the virus is allowed to increase again, it can change and get stronger, a nd becomes resistance to \\nthe ART  \\n- When the virus becomes resistant, the ART does not work against the virus anymore  \\n- The risk of resistance increases by not taking the ART correctly and by starting and stopping the \\nmedications several times  \\n- When resistance o ccurs, this is called treatment failure  \\n• What happens in treatment failure:  \\n- The ART no longer works because the virus has become resistant to it  \\n- If treatment fails, it is necessary to use stronger, more expensive ART, but it still may not work as well  \\n- With the stronger ART you may need to take more pills every day, and you may have more side effects  \\n- If you become resistant to the new ART as well, then there may not be any drugs that can work for you, \\nand the virus will increase quickly and your CD4 coun t will go way down  \\n- It is essential that you take your ART every day as prescribed so that you do not develop treatment \\nfailure, and can live a long and healthy life  \\nSection 7: ART side effects  \\n• What are the side -effects of ART:  \\n- Sometimes people can get side effects from taking ART  \\n- Side effects vary from person to person  \\n- Some people have none while other experience mild effects which are unpleasant but often manageable  \\n- Most side effects occur within the first few weeks of starting ART and then improve aft er a few weeks or \\nmonths  \\n- Some common side effects include:  \\n● Headache  \\n● Loss of appetite  \\n● Skin rash  \\n● Fatigue  \\n● Nausea, vomiting, diarrhoea  \\n● Muscle pains  \\n• What do you do if you notice any side effects:  \\n- If you develop any side effects, you should continue taking your ART as prescribed, without missing any \\ndoses, until you discuss with the clinician  \\n- If the side effects are mild then you can continue taking your ART without missing any doses, and then \\ndiscuss the side effects with the clinician at your next appointment  \\n- If the side effects are bothering you too much then return to the clinic immediately, even if you do not \\nhave a scheduled appointment, to discuss what to do next; you can also call the clinic if you are not able \\nto make it yourself immediately  \\n- Severe side effects include rash all over your body, or rash in your mouth or eyes, constant vomiting, \\ninability to eat or retain food, or anything else that makes you think you should stop the ART. If this \\noccurs then contact the clinic immediately  \\n- The cl inician will help you manage the side effects, and occasionally the ART may need to be changed  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 232}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 12 Annex 8: Cont.  \\nSection 8: Adherence  \\n• What is adherence  \\n- Following a care plan as agreed with the healthcare team  \\n- Attending clinic appointments as scheduled  \\n- Picking up medicines and taking them as prescribed  \\n- Getting lab tests according to the recommended schedule  \\n- Following nutritional recommendations  \\n• How should ART be taken  \\n- You must take the correct dosage. If you take less than the dose prescribed the treatment will \\nnot be effective and will result in resistance and treatment failure. Never share your ART with \\nsomeone else  \\n- For children, the dosage keeps changing as they grow and gain weight  \\n- You must take ART the correct time of day:  \\n• If your ART is supposed to be taken once per day, then pick a time when it will usually be \\nconvenient for you to remember, e.g., with breakfast every day.  \\n• If your ART is supposed to be taken twice per day, then you should set a convenient time to \\ntake your dr ugs approximately 12 hours apart (e.g., 8.00 am and 8.00 pm every day). It \\ndoes not have to be exactly 12 hours apart if your schedule does not allow; the most \\nimportant thing is to take them twice per day every day (e.g., you can take it at 6.00 am and \\n8.00 pm every day)  \\n- If you miss a dose of ART then take your dose as soon as you remember, as long as it is not \\nwithin a couple of hours of your next dose, and then return to your regular schedule. Do not \\ntake a double -dose of ART to make up for a missed dose  \\n- You must take ART according to dietary restrictions. Some ART should be taken with food, for \\nsome it does not matter, and a few require that you have an empty stomach. These dietary \\nrestrictions will be explained to you once your ART regimen is  selected  \\n- It is essential to take ART as prescribed and not miss any doses  \\n- Some medications (prescription, non -prescription, and herbal) interact with ART and make \\nthem ineffective. Be sure to tell your clinician and pharmacist the names of all the medicat ions \\n(including traditional/herbal) that you are taking, and any time you are given new medications. \\nAvoid use of alcohol  \\n• What usually interferes with good adherence (can apply to the patient or to the caregiver)  \\n- Stigma: it is hard to take ART correctly if you need to hide it because you are worried about \\npeople finding out you have HIV  \\n- Disclosure: it is hard to take ART correctly if the people closest to you, particularly family \\nmembers and close friends, do not know you have HIV  \\n- Change in rout ine: if your daily routine suddenly changes it may be difficult to remember to \\ntake your ART at the usual time  \\n- Travel: frequent travel, or unexpected travel (such as for a funeral) may interfere with taking \\nART, particularly if you do not have enough drugs  with you for the entire trip  \\n- Alcohol and drug use: it is hard to remember to take ART when under the influence of alcohol \\nor other drugs  \\n- Caregiver changes: every time a child has a new caregiver, that person needs to learn about \\nhow and why ART is taken  \\n- Side effects: when people get side effects from ART they sometimes stop or reduce the amount \\nof ART they are taking, hoping it will reduce the side effects  \\n- Pill burden/palatability: sometime the number of pills (or taste of syrups for children) makes it \\ndifficult to take ART correctly  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 233}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 13 Annex 8: Cont.  \\n- Distance: choosing an HIV clinic that is far away from your home can make it difficult to come to \\nappointments and pick drugs regularly  \\n- HIV knowledge: when people do not understand what HIV is, and why ART is important, they \\nmay not take their drugs properly. This also applies to children and adolescents, if they have \\nnot been told they have HIV and taught what it means  \\n- Mental health disorders: depression and other mental illnesses can make it difficult to t ake ART \\ncorrectly  \\n- Religious beliefs: some people stop taking ART after faith -healing, although there has never \\nbeen a case of someone being cured of HIV this way  \\n• What might make it difficult for you individually to take your ART as prescribed  \\n- Ask the patie nt: “Based on what you have learned so far, what challenges do you think you will \\nhave taken  ART correctly, every day, for the rest of your life?”  \\n- Discuss strategies to manage any expected barriers to adherence  \\n• What can help you take ART as prescribed  \\n- Disclosure: It is easier to take your ART properly when the people close to you know your HIV \\nstatus, so you do not have to try and hide your ART or miss doses to avoid being seen. Family \\nand friends can also provide additional support once they  are aware you have HIV and \\nunderstand more about it. We can help you disclose your HIV status to important family \\nmembers or friends when you are ready  \\n- Treatment supporter: Having a “treatment buddy” can help you take your ART correctly; ask a \\nfriend, par tner, or family member to remind you to take your ART. If possible, invite that \\nperson with you to some of your clinic appointments and counselling sessions so they can learn \\nabout ART, the importance of good adherence, side effects, etc.  \\n- SMS reminder syst em (if SMS reminder system in place at the facility): Receiving a regular SMS, \\ne.g., every week, can help you take your ART correctly. We enroll all our patients into this \\nservice for SMS reminders at our clinic, unless you do not want to receive them. The  messages \\nsimply ask how you are doing, and do not mention HIV, ART, the clinic, or anything else that \\nmay reveal your HIV status to others  \\n- Support group: Joining a support group will help you learn from other people how they \\novercome challenges in living with HIV and taking ART correctly. Some support groups also \\nhave economic activities to help increase your income. We have support groups based at the \\nhealth facility, and there are also support groups in the community  \\n- Other reminders:  \\n- Set a specific time of day to take your ART  \\n- Associate your ART with a specific event/s in your daily schedule (e.g., when you eat \\nbreakfast and dinner)  \\n- Set an alarm on your phone or watch  \\n• What happens if you miss an appointment?  \\n• The healthcare team will be concerned about you, and will try to contact you by phone  \\n- Confirm patient phone number and consent to call if misses an appointment or any urgent \\nlab results  \\n• If we cannot contact you by phone, we will try to call your treatment buddy  \\n- Confirm treatment buddy name and phone number, and consent to call if needed  \\n• If we cannot reach you or your treatment buddy, we may try and visit you at home, if we have \\nyour permission  \\n- Confirm locator information and consent to perform home visits if needed  \\n• Once you are back in care, we will work with you to figure out what caused you to miss an \\nappointment and how it can be prevented in the future  \\n• You will not be punished for missing an appointment  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 234}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 14 Annex 8: Cont.  \\nSection 9: Other medications  \\n• What other medications will you take, in addition to ART:  \\n- CPT: all PLHIV should take cotrimoxazole preventive therapy once per day, in order to reduce \\nthe chance of getting other infections such as pneumonia, malaria, and diarrhoea  \\n- TPT: all PLHIV should receive 6 months of isoniazid preventive therapy (or another \\napproved TPT regimen), unless they have active TB disease, in order to prevent \\ndevelopment of TB  \\n• Other medications may be recommended for specific conditions  \\nSection 10: Nutrition  \\n• Why is nutrition important:  \\n- When the viral load is high, your body uses a lot of energy trying to fight the virus  \\n- If your nutrition is poor, you have more chance of getting other infections as well  \\n- You need to eat well so your body has everything it needs to fight HIV, and look healthy  \\n• What can you do to improve your nutrition?  \\n- Eat a balanced diet from a variety of foods.  \\n- Try not to eat a lot of sugar, red meat, or fatty/fried foods  \\n- Try to eat plenty of whole grains, vegetables, fruit, beans, and fish  \\n- Drink plenty of clean safe water  \\n- Physical activity and exercise is encouraged.  \\nSection 11: Follow -up \\n• How often will you need to come to the clinic  \\n- Before starting ART: you should come to the clinic at least every week in order to get you prepared \\nfor ART so you can start as soon as possible  \\n- Soon after starting ART: after you start ART you should come to the clinic in 2 weeks in order to \\nsee if you have had any trouble taking your pills or have developed any side effects; then you can \\nbe seen after another two weeks for the same; then every month until your first viral load test  \\n- Once you have been on ART for a while: if your first viral load (after 3 months) is undetectable \\nthen you can be seen every 1 -6 months depending on other factors  that will be discussed with the \\nclinician  \\n- Unscheduled visits: if you ever have any concerns, feel unwell, or need to speak with any of the \\nclinic team then you can call or come to the clinic, even if you do not have an appointment \\nscheduled for that day  \\n• What will we be checking for during your clinic visits  \\n- At each visit you will be asked if you have had any illnesses since the last visit, if you have had any \\ntrouble taking your ART, and if you are experiencing any side effects. You may need a physic al \\nexam or blood tests at some visits  \\nSection 12: ART readiness assessment  \\n• Are you ready to start ART today?  \\n- Complete the ART Readiness Assessment (Table 5.4) for each patient to see if they should \\nstart ART today, and if not, to identify what issues need to be addressed before starting \\nART  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 235}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 15 Annex 8: Cont.  \\nSection 13: Management plan  \\n• Which investigations will you have today  \\n- See Table 3.2 and Table 3.5 for recommended baseline and follow -up investigations \\nrespectively  \\n• Which medications will you start today  \\n- May include: ART; CPT; TPT; other  \\n• What else is required as you start or as you prepare to start ART  \\n- May include: assisted disclosure; support group referral; engagement of a treatment \\nbuddy; drug and alcohol counselling; depression management; referrals; other  \\n- For patients not starting ART today, management plan should include specific \\nstrategies to address any issues preventing/delaying ART initiation  \\n• When should you return to the clinic  \\n- Book appointment date  for next visit, preferably with the same healthcare worker  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 236}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 16 Annex 9 A: Enhanced Adherence Counselling Content Guide  \\nEnhanced Adherence Counselling for Patients with Suspected or Confirmed Treatment Failure  \\nNote: for children/adolescents, the script below should be modified towards the caregiver  \\nSession 1  \\n• Assess patient’s understanding of ‘viral load’, ‘high viral load’ and ‘suppressed viral load’. Ask \\nthe patient to explain what each of these terms mean. Provide education if patient requires \\nmore explanation  \\n• Provide VL result and explanation of result:  \\n“You have a detectable viral load. There are several possible reasons for this such as problems with \\nadherence, dosing of your medications, interactions wit h other drugs or foods, or possible drug \\nresistance. It is very important for us to work with you determine which may apply to you.”  \\n• How does the patient feel concerning the result?  \\n• Explain the process of enhanced adherence:  \\n“Patients with a high viral load come for at least 3 adherence counselling sessions to discuss what \\nmight cause a high viral and to look for solutions on how adherence can be improved. Another \\nviral load test will be done after 3 months of good adherence to see if the ART can b e continued or \\nif we need to change treatment.”  \\n• Check whether the patient had previous problems with adherence and/or missed \\nappointments  \\n• Ask:  \\n“Why do you think your viral load is high?”  \\n• Sometimes the patient already knows why his/her VL is detectable. Sta rt by giving them a \\nchance to provide their own explanation. Often, they will admit that they are struggling with \\ntheir adherence  \\n• If they really don’t know why their VL is high you can say:  \\n“We notice that when people sometimes forget to take their ART everyday it gives the virus a chance \\nto multiply. Do you think that you sometimes forget your pills?”  \\nAssess for Possible Barriers to Adherence  \\nCognitive Barriers (HIV and ART knowledge)  \\n• Assess patient’s knowledge about HIV and ART; correct any misconceptions  \\n“What is HIV?”  \\n“What is the immune system and CD4 cells?”  \\n“What is ART and how does it work?”  \\n“Why is it important to be adherent? And how?”  \\n“Why do you have to come for follow -up appointments? What should you bring?”  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 237}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 17 Annex 9A: Cont.  \\nBehavioural Barriers  \\n• Review how the patient takes drugs  \\n“Please explain how you take your drugs, and at what time?”  \\n“How does treatment fit in your daily routines?”  \\n• Establish with the patient whether the time they are meant to take their medication is \\nappropriate or whether the time is a problem. For example, if the patient has chosen 9 pm, \\nbut is already asleep in bed by 9 pm, then that is not a good dosing time. If the time is a \\nproblem, then determine a new, more appropriate time with the patient based on their \\nschedule  \\n• Remind the patient/caregiver that a missed dose should be taken as soon as he/she \\nremembers (up to a couple of hours before the next scheduled dose). The next dose should \\nbe taken at the usual time  \\n“What reminder tools do you use? (e.g., mobile phone alarm)” “What do you do in case of visits, and \\ntravel?”  \\n• Travelling is always a risk for poor adherence or default from treatment. Encourage the patient \\nto plan, to make sure they have enough medication on hand  before and to remember to pack \\nit \\n• Make sure that all relevant information is on the patient’s appointment card and explain that \\nif they are ever away from home and they are about to run out of medication that they must go \\nto the closest ART clinic and sho w their appointment card  \\n“What do you do in case of side effects?”  \\n• Ask the patient if s/he has any side effects from the ARVs, and if they sometimes find it \\ndifficult to take ARVs  \\n• Due to the side effects, ask how s/he manages side effects and if it influences the way s/he \\ntakes the drugs.  \\n“What are the most difficult situations for you to take drugs?”  \\n• Check for alcohol or drug use. Ask the patient in a casual way (not in an accusing way) if they \\nsometimes use substances; emphasize treatment planning in case they do  \\n• “Taking alcohol or drugs sometimes makes it difficult for us to remember to take treatment. If \\npossible, it is best to limit your use, but if you are planning to take any alcohol or drugs, it is \\nimportant to plan ahead so that you don’t for get to take your treatment”  \\n“If you feel your alcohol or drug use is affecting your adherence, are you ready to be referred to some \\nprofessionals that may help you work on that problem?”  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 238}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 18 Annex 9A: Cont.  \\n● Emotional Barriers  \\n• Review the patient’s motivation:  \\n“How do you feel about taking drugs every day?” \\n“What are your ambitions in life?”  \\n• You can use motivation cards for this: Ask the patient to think of his or her own personal \\ngoals/dreams for the future. What are the 3 most important things they  still want to achieve? \\nHave them write them in their own words on a notecard. Encourage the patient to read the \\nnotecard every day, preferably right before they take their medication  \\n• Mental health screening:  \\n- Depression is an important reason of non -adherence.  All patients with suspected or \\nconfirmed treatment failure should be screened for depression using the PHQ -9 tool \\n(Table 4.14)  \\n- The patient may be in any of the five stages of grief (because of their HIV diagnosis or for \\nother reasons): deni al and isolation; anger; bargaining; depression, or; acceptance. This \\nneeds to be assessed and addressed  \\nSocio -economical Barriers  \\n• Review the patient’s disclosure of their HIV status  \\n“Do you have any people in your life who you can talk to about your HIV status and ART?”  \\n• Discuss how the patient can enlist the support of their family, friends, and/or co -workers in \\nreminding them to take their medication if they have not already done so  \\n• Support from a treatment buddy: if the patient came with treatment buddy, assess their input \\ntowards adherence. If patient did not come with treatment buddy, explain the role of a treatment \\nbuddy and encourage the patient to come with a person they trust next visit  \\n• Support in family/community/support group: expl ore support systems, in addition to the \\ntreatment buddy, that the patient is currently using and options that the patient can start using. \\nDiscuss the advantages of joining a support group and any reasons the patient is hesitant to join  \\n• Profession, income generating resources: review the patient’s and family’s sources of income \\nand how well they cover their needs  \\n• Specific barriers to come to health centre on regular basis: ask the patient if they have any \\nchallenges getting to the clinic on regular basis. Help the patient develop strategies to overcome \\nthose challenges  \\n• Stigma and discrimination  \\n“Are you ever worried about people finding out your HIV status \\naccidentally?” “Do you feel like people treat you differently when they know \\nyour HIV status?”  \\n• Discuss if stigma is making it difficult for them to take their medications on time, or for them \\nto attend clinic appointments  \\n• Religious beliefs: find out if the patient has tried faith healing, or if they have ever stopped taking \\ntheir medicine because of their religious beliefs  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 239}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 19 Annex 9A: Cont.  \\nReferrals and Networking  \\n• Review the patient’s file to determine if they have been referred to other services. This includes \\nreferrals to social services, support groups, psychology services, nutrition services, medical \\nclinics, substance abuse groups, etc.  \\n• Ask the patient if they attended the appointments, check in on their experience with the \\nreferral services and re -organize referrals as necessary  \\n• Determine if the patient could benefit from a home visit  \\nDevelop Adherence Plan  \\n• Go through each of the adherence challenges identified during the session and assist the \\npatient to develop a plan that addresses each of the issues. It is important to let the patient \\ncome up with the solutions so that they can own them  \\n• Some examples of addressing adherence challenges:  \\n- Behavioural barriers: using a reminder tool; using a pill box; redefining the medication \\nschedule to fit with the patient’s daily schedule; keeping an emergency dose of drugs when \\naway from home  \\n- Refer to clinician in case of side effects  \\n- Socio -economical barriers: move on to disclosure process; identify a treatment buddy; join a \\nsupport group; refer to CBO/NGO to learn about income generating activities  \\n- Emotional barriers: emotional support or refer to clinician for mental health management  \\nAgree on a follow -up date for the next session  \\n \\nSession 2 (usually 2 weeks after Session 1, preferably with the same provider)  \\nReview Adherence Plan  \\n• Ask the patient if he/she thinks adherence has improved since the last visit. Enquire in a \\nfriendly way if any doses have been missed  \\n• Review the patient’s barriers to adherence documented during the first session and if \\nstrategies identified have been taken up. If  not, discuss why  \\nIdentify Any New Issues  \\n• Discuss specific reasons why the patient may have missed their pills or a clinic \\nappointment since the last counselling session, and determine if it is a new issue that \\nwasn’t addressed during the first session  \\n• Discuss if other issues have come up because of implementing the adherence plan (e.g., \\nperhaps the disclosure process had unintended results)  \\nReferrals and Networking  \\n• Follow -up on any referrals made during the previous session  \\n• Determine if the patient could benefit from a home visit  \\nDevelop Adherence Plan  \\n• Go through each of the adherence challenges identified during the session and assist the patient \\nto modify their original adherence plan to address each of the issues. It is important to let the \\npatient come up with the solutions so that they own them  \\n• Give another short motivational speech on how you believe in the patient! You know they can \\ndo this! Together you will make sure that they suppress their viral load!!  \\n• Agree on a follow -up date fo r the next session  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 240}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 20 Annex 9A: Cont.  \\nSession 3 (usually 2 weeks after Session 2, preferably with the same provider)  \\nReview Adherence Plan  \\n• Ask the patient if he/she thinks adherence has improved since the last visit. Enquire in a \\nfriendly way if any doses have been missed  \\n• Review the patient’s barriers to adherence documented during the first session and if \\nstrategies identified have been taken up. If not, discuss why  \\n \\nIdentify Any New Issues  \\n• Discuss specific reasons why the patient may have missed their pills or a clinic appointment \\nsince the last counselling session, and determine if it is a new issue that wasn’t addressed \\nduring the first session  \\n• Discuss if other issues have come up because of implementing the adherence plan (e.g., perhaps \\nthe disclosure process had unintended results)  \\n \\nReferrals and Networking  \\n• Follow -up on any referrals made during the previous session  \\n• Determine if the patient could benefit from a home visit  \\n \\nDevelop Adherence Plan  \\n• Go through each of the adherence challenges identified during the session and assist the patient \\nto modify their original adherence plan to address each of the issues. It is important to let the \\npatient come up with the solutions so that they own them  \\n• Give another short motivati onal speech on how you believe in the patient! You know they \\ncan do this! Together you will make sure that they suppress their viral load!!  \\n• Agree on a follow -up date for the next session  \\n \\nRepeat Viral Load  \\n• If the adherence is good: plan for the next VL testing after 3 months and explain possible ways \\nforward, emphasizing the roles of the patient, the support systems and the health facility. You \\ncan continue follow -up adherence counselling sessions during the 3 -month period if you and \\nthe patient think th ere would be a benefit to them  \\n“If your results come back and your VL is undetectable then you will be able to continue with same ART. \\nIf your viral load is still greater than 1,000 copies/ml then you will need to switch to a new regimen, \\nprobably after do ing some additional testing to see which regimen may work best for you. If your viral \\nload is detectable but less than 1,000 copies/ml we will discuss options, including changing regimens \\nor continuing to monitor.” (Adapt to individual patient/context)  \\n• If adherence challenges persist: plan further Enhanced Adherence Counselling Sessions before \\nrepeating the VL  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 241}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 21 Annex 9A: Cont.  \\nSession to Discuss Repeat Viral Load Results (after the repeat VL results are back, preferably with \\nthe same provider)  \\nDiscuss Viral Load Results  \\n• If suppressed (VL < 50 copies/ml) CONGRATULATE the patient!!!  \\n- Explain the way forward: will continue with same ART regimen and repeat the VL again in 6 \\nmonths  \\n• If viral load is ≥ 1,000 copies/ml  \\n- Explain the way forward: will probably need to switch to a new ART regimen after discussing \\nas an MDT, and additional testing to see which regimen may work for the patient  \\n- Summarize the case with the MDT; if the patient cannot switch to standard 2nd line ART, or \\nis failin g 2nd line ART, forward to the Regional or National HIV Clinical Technical Working \\nGroup for next steps  \\n• If viral load is 50 - 999 copies/ml  \\n- Explain the way forward: will reassess barriers to adherence, support systems, and other \\nreasons for viremia; once reason/s for viremia have been addressed then will repeat the viral \\nload after another 3 months of excellent adherence  \\n \\n \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 242}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 22 Annex 9 B: Case Summary Form  \\n \\n \\nMINISTRY OF HEALTH  \\nNATIONAL AIDS AND STI CONTROL PROGRAMME  \\nCLINICAL SUMMARY FORM  \\nName of \\nFacility   MFL \\nCode   \\nPatient CCC \\nno.  \\n(Do not write \\nname )  Date   \\nPatient \\nDetails  Date of Birth:                  Enrollment Date:  \\n \\nGender:   Current Weight (Kg):                      Height (cm):  \\nClinician’s \\nName   \\nFacility \\nContacts  Tel:  Email:  \\n \\nWhat is the primary reason for this consultation:  \\n \\nClinical Evaluation: history, physical, diagnostics, working diagnosis ( excluding the information in \\nthe table below  \\n \\n \\n \\n \\n \\n \\nComplete the table below chronologically, including all ART regimens and laboratory results (and \\nany previous history available for transfer -in patients)  \\nDate  CD4  HB CrCl/  \\neGFR  Viral \\nLoad  Weight  \\n(z-score/BMI \\nfor children)  ARV \\nRegimen  Reason for \\nSwitch  New OI or other \\nclinical event  \\n         \\n         \\n         \\n         \\n         \\n         \\n \\n  \\n', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 243}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 23 Annex 9 B: Cont.  \\nAdherence and Treatment Failure Evaluation  \\nParameters of Evaluation  Findings  \\n● Number and findings of adherence counseling/assessment \\nsessions done in the last 3 -6 months including the following:  \\no Findings from MMAS -8 \\no Adherence barriers identified  \\no Recommendations   \\nNumber of home visits conducted in last 3 -6 months, and findings   \\nDescribe support structures (e.g., treatment buddy, support group \\nattendance, caregivers) in place for this patient   \\nEvidence of adherence concerns (e.g., missed appointments, pill counts)   \\nDescribe daily witnessed ingestion done in last 3 -6 months (Who performed \\nit, which tool was used, how long was session done etc.)   \\nDescribe likely root cause/s of poor adherence for this patie nt (e.g., stigma, \\ndisclosure, side effects, alcohol or other drugs, mental health issues, \\ncaregiver changes, religious beliefs, inadequate preparation, etc.)   \\nEvaluation for other causes of treatment failure, e.g.:  \\n● Inadequate dosing/dose adjustments (particularly for children)  \\n● Drug -drug interactions  \\n● Drug -food interactions  \\n● Impaired absorption (e.g., chronic severe diarrhea)   \\nOther Relevant ART History  \\nComment on treatment interruptions, if any   \\nHas Drug Resistance Testing been done for this patient? If yes, state date \\ndone and attach the detailed results   \\nHas facility multidisciplinary team discussed the patient’s case? If yes, \\ncomment on date, deliberations and recommendations (indicate how \\ntreatment failure was established and con firmed, proposed regimen and \\ndosage, current source of drugs if patient already on 3rd line)   \\nMDT members who participated in the case discussion (names and titles)   \\n \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 244}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 24 Annex 9 C: Enhanced Adherence Counselling Form  \\nENHANCED ADHERENCE COUNSELLING FORM  \\n(To be completed by the counsellor)  \\n• Start each session by reviewing the adherence barriers and action plan from the previous session  \\n• For each session assess major barriers to adherence (cognitive, behavioral, emotional, socio -economic)  \\nSession #:   Date:   Adherence % (from pill count):   MMAS -8 Score:   \\nTreatment \\nmotivation:   \\n \\n \\n \\n \\n \\n \\n \\nBarriers to \\nadherence:   \\n \\n \\n \\nYour impression about patient’s \\ncurrent adherence:    ▢ Excellent                ▢ Unsure            ▢ Inadequate  \\nAdherence plan:   \\n \\n \\n \\n \\n \\n \\nNext appointment date:   \\n \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 245}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 25 Annex 9 D: Home Visit Checklist  \\nHOME VISIT CHECKLIST  \\nPatient Name  Tel No:  Sex: M            F     \\nFamily Member  Tel No:  Sex: M            F     \\nPhysical Landmark:   File No.  \\n \\nThis checklist is not all -inclusive but highlights critical areas that can affect adherence.  \\n Areas to Assess and Discuss  Comments  \\nI Is the patient independent in the activities of daily living (e.g., \\nfeeding, grooming, toileting) l  \\n2 Are the patient’s basic needs being met (e.g., clothing, shelter, food) l  \\n3 Has the patient disclosed their HIV status to other household members   \\n4 How are the patient’s ARVs stored and taken?   \\n5 Does the patient receive social support from household members   \\n6 Does the patient receive social support in the community e.g., linked to \\nOVC, income generating activities, community -based support group, CBO, \\ncash transfer program?   \\n7 Is the patient linked to non -clinical services (e.g., spiritual, legal \\nor nutritional)    \\n8 Does the patient have mental health issues that need to be addressed (use \\nPHQ9 to screen for depression), or use drugs or alcohol?   \\n9 Is the patient suffering from a stressful situation or significant loss/grief?   \\n10 Is the patient having any side -effects from the medications?   \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 246}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 26 Annex 9 E: Management Protocol for Patients Switching to 3rd Line ART  \\nManagement Protocol for patients switching to 3rd line ART  \\n \\nPre – Initiation MDT Meeting  \\n• Confirm what 3rd line ARV regimen is prescribed, its availability and the management plan  \\n• Assign a case manager to patient  \\nInitiation of 3rd Line ART  \\n• Triage  \\no Record vital signs and take actions as needed  \\n \\n• Adherence support  \\no Conduct patient education on the new ART regimen: Treatment goals, dosing, drug \\ninteractions and potential side effects and adverse events  \\no Conduct adherence assessment and counselling  \\no Link patient to adherence support systems  \\n \\n• Clinical assessment  \\no Take history and conduct physical examination  \\no Complete clinical encounter form and MOH 257 (Green Card)  \\no Manage any co -infection and co -morbidities  \\no Review for potential drug interactions and contraindications  \\no Conduct adherence assessment and review adherence support systems including \\ndaily witnessed ingestion plan  \\no Reinforce patient education messages on new regimen  \\n▪ Currently limited future treatment options  \\n▪ Need for perfect adherence (>95%)  \\n▪ Dosing schedule and timing  \\n▪ Potential side effects and what the patient should do  \\no Prescribe new regimen  for 2 weeks  \\no Confirm dosing as per the weight (for ≤15)  \\no Continue other medication e.g., CPT, OI treatment etc.  \\n \\n• Dispensing  \\no Confirm ARV dosing as per the weight (for ≤15)  \\no Conduct medication use counselling  \\no Dispense 3rd Line ARVs for 2 weeks  \\no Check for possible drug interaction  \\n \\n• Community follow up  \\no Link all patients to support group, CHV/CHA  \\no Plan for home visits as required  \\n \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 247}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 27 Annex 9 E: cont.  \\nPatient Follow Up after Treatment Initiation  \\n● Frequency  \\no First follow -up should be within 2 weeks of initiation of 3rd line ART  \\no Subsequent visits should be monthly (or more frequent) until confirmed viral sup - \\npression at 6 months  \\no Thereafter, follow -up can be 1 -3 monthly  \\n \\n● Triage  \\no Record vital signs and take action as needed  \\n \\n● Adherence Support (adherence should be reinforced during every clinic visit, in addition to \\nenhanced adherence counselling sessions)  \\no Review and address knowledge deficits on new regimen  \\no Confirm understanding of adherence, conduct adherence assessment, and reinforce key \\nadherence messages  \\no Document reasons for missed doses and manage obstacles to perfect adherence. Review \\nand reinforce adherence support systems  \\n \\n● Clinical Assessment  \\no Take history and conduct physical examination  \\no Complete Clinical Encounter Form and MOH 257 (blue card)  \\no Manage any co -infections and co -morbidities  \\no Evaluate for potential drug interactions  \\no Evaluate for and manage any drug side effects and adverse events  \\no Conduct adherence assessment and review adherence  support systems  \\no Reinforce patient education messages on new regimen  \\n▪ Review and address knowledge gaps on ART regimen  \\n▪ Need for perfect adherence (>95%)  \\n▪ Dosing schedule and timing  \\n▪ Potential side effects and what the patient should do  \\no Prescribe 3rd line ARVs  \\n \\n● Viral load should be conducted 3 months after change of regimen  \\n \\n● Dispensing  \\no Confirm ARV dosing as per the weight  \\no Conduct medication use counselling  \\no Dispense 3rd line ARVs  \\n \\n● Community Follow up  \\no Review linkage to community adherence support systems  \\no Conduct home visits as required  \\no Continue DOTS  \\n \\n● NOTE: 3rd line annual report with viral load, adherence, and outcomes to be sent to NASCOP  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 248}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 28 Annex 10 A: Dosing of Solid and Liquid Formulations for Twice -Daily Dosing in Infants and Children 4 Weeks of Age \\nand Older  1\\n \\nDrug  Strength of tablets  Number of tablets by weight band morning and evening  Strength of adult \\ntablet  Number of tablets \\nby weight band  \\n3–5.9 kg  6–9.9 kg  10–13.9 kg  14–19.9 kg  20–24.9 kg  25–34.9 kg  \\nAM PM AM PM AM PM AM PM AM PM AM PM \\nAZT/3TC  Tablet (dispersible) 60/30 mg  1 1 1.5 1.5 2 2 2.5 2.5 3 3 300 /150 mg  1 1 \\nAZT/3TC/NVP2 Tablet (dispersible) 60/30 mg/50 mg  1 1 1.5 1.5 2 2 2.5 2.5 3 3 300 /150 /200 mg  1 1 \\nABC/3TC  Tablet (dispersible) 120/60 mg  0.5 0.5 0.5 1 1 1 1 1.5 1.5 1.5 600 /300 mg  0.5 0.5 \\nABC/3TC/LPV/r  30/15/40/10 mg  2 2 3 3 4 4 5 5 6 6    \\nSOLID SINGLE FORMULATIONS  \\nAZT  Tablet (dispersible) 60 mg  1 1 1.5 1.5 2 2 2.5 2.5 3 3 300 mg 1 1 \\nABC  Tablet (dispersible) 60 mg  1 1 1.5 1.5 2 2 2.5 2.5 3 3 300 mg  1 1 \\nNVP2 Tablet (dispersible) 50 mg  1 1 1.5 1.5 2 2 2.5 2.5 3 3 200 mg  1 1 \\nTablet 200 mg  – – – – 0.5 0.5 1 0.5 1 0.5 200 mg  1 1 \\n \\nLPV/r3 Tablet 100/25 mg  – – – – 2 1 2 2 2 2 100/25 mg  3 3 \\nTablet 200/50 mg  – – – – – – 1 1 1 1 200/50 mg  2 1 \\nGranules4 40/10 mg per sachet  2 2 3 3 4 4 5 5 6 6    \\nDRV5 Tablet 75 mg  – – – – 3 3 5 5 5 5    \\n \\nRAL6 Chewable tablets 25 mg  – – – – 3 3 4 4 6 6 400 mg  1 1 \\nChewable tablets 100 mg  – – – – – – 1 1 1.5 1.5 400 mg  1 1 \\nGranules (100 mg/sachet)  0.25  0.25  0.5 0.5 – – – – – –  – – \\nLIQUID SINGLE FORMULATIONS  \\nAZT  10 mg/ml  6 ml  6 ml  9 ml  9 ml  12 ml  12 ml  – – – – – – – \\nABC  20 mg/ml  3 ml  3 ml  4 ml  4 ml  6 ml  6 ml  – – – – – – – \\n3TC  10 mg/ml  3 ml  3 ml  4 ml  4 ml  6 ml  6 ml  – – – – – – – \\nNVP2 10 mg/ml  5 ml  5 ml  8 ml  8 ml  10 ml  10 ml  – – – – – – – \\nDRV5 100 mg/ml  – – – – 2.5 ml  2.5 ml  3.5 ml  3.5 ml  – –    \\nNotes  1 For infants younger than 4 weeks of age refer to Table 10C for more accurate dosing information  \\n2 NVP dose escalation with half dose for 2 weeks when initiating ART is still recommended for infants > 2 weeks of age and not already on NVP prophylaxis to avoid toxicity from high initial \\nNVP levels. HEI already on NVP prophylaxis who are confirmed positive can initiate full dose (twice daily) NVP without dose escalation  \\n3 The LPV/r heat -stable tablet formulation must be swallowed whole and should not be split, chewed, dissolved or crushed. The adult 200/50 mg tablet may be used for patients 14 -24.9kg (1 \\ntab am and 1 tab pm) and for patients 25 -34.9kg (2 tabs am and 1 tab pm) who are able to swallow them whole. The 100/25 mg tablet is smaller than the adult formulatio n and may be used \\nby children of lower weight  bands able to swallow tablets whole.  \\n4 LPV/r granule formulation can be used in infants over 2 weeks of age. Transition to tablets as soon as a child is able to swa llow tablets whole. The 4 -in-1 ABC/3TC/LPV/r may be used after \\n1 month of age if the combin ation is appropriate and once it becomes available.  \\n5 DRV must be administered with 0.5 ml of RTV 80 mg/mL oral suspension if less than 15 kg and with RTV 50 mg solid formulation in children 15 to 30 kg  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 249}),\n",
       " Document(page_content='  \\nAnnexes  \\n13 - 29 6RAL granules are approved for use in newborn childre n, however the administration procedure is complex and the formulation has very limited availability. If this RAL must be use d, consult \\nthe regional/national clinical support center  \\n Annex 10 B: Simplified Dosing of Child -Friendly Solid and Oral Liquid For mulations for Once -Daily Dosing in \\nInfants and Children 4 Weeks of Age and Older1 \\nDrug  Strength of tablet  Number of tablets or capsules by weight band once \\ndaily  Strength of adult \\ntablet  Number of tablets or capsules \\nby weight band once daily  \\n3–5.9 \\nkg 6–9.9 \\nkg 10–13.9 \\nkg 14–19.9 \\nkg 20–24.9 kg   25–34.9 kg  \\nEFV2 Tablet (scored) 200 mg  – – 1 1.5 1.5 200 mg  2 \\nABC/3TC  Tablet (dispersible) 120/60 \\nmg 1 1.5 2 2.5 3 600 mg/300 mg  1 \\nDTG  Tablet (dispersible) 10 mg  0.5 1.5 2 2.5 33   \\nDTG  Tablet 50 mg  - - - - 1 50 mg  1 \\nDTG/TDF/  \\n3TC   - - - - - 50/300/300  1 \\nATV4 Capsules 100 mg  – – 1 2 2 300 mg  2 (100 mg) or 1 (300 mg)  \\n \\nTDF5 Oral powder 40 mg/scoop  – – 3 – –  \\n300 mg  1 (200 mg) d or 1 (300 mg)  \\nTablets 150 mg or 200 mg  – – – 1 (150 mg)  1 (200 mg)  \\nNotes  1For infants younger than 4 weeks of age refer to Table 10C for more accurate dosing information  \\n2EFV is not recommended for children younger than 3 years and weighing less than 10 kg. Where there are no suitable alternativ es, EFV may be used in children le ss than 3 years \\nweighing more than 3.5 kg (3.5 -5 kg two 50 mg capsules; 5 -7.5 kg three 50 mg capsules; 7.5 -15 kg one 200 mg capsule).  \\n3 DTG dispersible tablets have higher bioavailability than film tablets and doses are not interchangeable. Children can tr ansition to the 50 mg film tablet once they reach 20 kg. If unable to \\nswallow the tablets whole, the dispersible tablets may be given at a dose of 30 mg daily.  \\n4ATV is only approved for use in children 3 months and older. ATV single strength capsules shoul d be administered with RTV 100 mg for all weight bands. ATV powder formulation \\nenables administration of ATV to infants and children as young as 3 months. Infants and children 5 -10 kg should be given 200 mg of ATV powder (4 packets, 50 mg/ packet) with 80 \\nmg of RTV oral solution (1 ml)  \\n5TDF is can be used in children 2 years and older. Target dose: 8 mg/kg or 200 mg/m2 (maximum 300 m  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 250}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 30 Annex 10 C: Drug Dosing of Liquid Formulations for Twice -Daily Dosing in Infants Less than 4 Weeks of Age  \\nDrug  Strength of oral liquid  2-3 kg  3-4 kg  4-5 kg  \\nAZT  10 mg/mL  1 mL  1.5 mL  2 mL  \\nNVP1 10 mg/mL  1.5 mL  2 mL  3 mL  \\n3TC  10 mg/mL  0.5 mL  0.8 mL  1 mL  \\nNotes  1 NVP for treatment can be initiated with twice daily dosing for infants < 2 weeks of age (they do not require once -daily lead -in dosing)  \\n \\nAnnex 10 D: Simplified Dosing of INH and CTX Prophylaxis for Infants and Children Who Are at Least 4 Weeks of \\nAge \\nDrug  Strength of tablet or oral \\nliquid  Number of tablets or ml by weight band once daily  Strength of adult \\ntablet  Number of tablets \\nby weight band  \\n \\n3–5.9 kg   \\n6–9.9 kg   \\n10–13.9 kg   \\n14–19.9 kg   \\n20–24.9 kg    \\n25–34.9 kg  \\nINH  100 mg  0.5 1 1.5 2 2.5 300 mg 1 \\nCTX  Suspension 200/40 per 5 ml  2.5 ml  5 ml  5 ml  10 ml  10 ml  – – \\nTablets (dispersible) 100/20 mg  1 2 2 4 4 – – \\nTablets (scored) 400/80 mg  – 0.5 0.5 1 1 400 mg/80 mg  2 \\nTablets (scored) 800/160 mg  – – – 0.5 0.5 800 mg/160 mg  1    \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 251}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 31 Annex 10 E: TB Preventive Therapy dosing  \\nA. Daily INH for 6 months (6H)  \\nWeight (Kg)  Dose (mg)  Number of 100mg INH tablets  Number of 300mg (Adult) tablet  \\n<5 50 ½ tablet  - \\n5.1-9.9 100  1 tablet  - \\n10-13.9  150  1½ tablet  ½ tablet  \\n 14-19.9  200  2 tablets  - \\n20-24.9  250  2 ½ tablets  - \\n≥25  300  3 tablets  1 tablet  \\nAdult  300  3 tablets  1 tablet  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 252}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 32 Annex 10 E: Cont.  \\nB1. Daily INH for 6 months (6H)  \\nWeight (Kg)  Number of tablets (RH \\n75/50mg  How to reconstitute the medicine  \\nLess than 2  ¼  Dissolve one (1) tablet of RH in 20 ml of safe drinking water. Once fully \\ndissolved. Give 5ml (¼) of this solution measured with a syringe.  \\n2-2.9 ½  Dissolve one (1) tablet of RH is 20 ml of safe drinking water. Once fully \\ndissolved, give 10ml (½) of this solution measure d with a syringe.  \\n3-3.9 ¾  Dissolve one (1) tablet of RH in 20 ml of safe drinking water. Once fully \\ndissolved, give 15 ml (¾) of this solution measured with a syringe.  \\nAfter giving the child their dose for that day, discard the rest of the solution. Pre pare a fresh solution. Prepare a fresh solution every day.  \\n4-7.9 1 Dissolve the tablet(s) of RH in 20mls of safe drinking water.  \\n \\nOnce fully dissolved, give ALL this solution to the child  8-11.9  2 \\n12-15.9  3 \\n16-24.9  4 \\nB2. Daily RH for 3 months (3RH) for children ≥25kgs (To use adult formulation)  \\nWeight (Kg)  Number of tablets (RH 150/75mg)  \\n25-39.9  2 \\n40-54.9  3 \\n55kg and above  4 \\nC.  Weekly 3HP (3HP) (For adults and adolescents ≥15 years)  \\n3HP products  No of Tablets  \\nRifapentine 150mg tabs  6 \\nIsoniazid 300mg tabs  3 \\nRifapentine 300mg+Isoniazid 200mg (FDC)  3 \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 253}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 33 Annex 10 E: Cont.  \\nD. Dosage of Pyrldoxine (Vitamin B6)  \\nWeight (Kgs)  Dosage In mg  Number of 25mg tablets  Number of 50mg tablets  \\n<5 6.25mg  ½ Tablet 3 times a week, alternate days  - \\n5.0-79 12.5mg  Half a tablet  - \\n8.0-14.9  25mg  One tablet  Half of 50mg tablet  \\n15kg and above  50mg  Two tablets  One 50mg tablet  \\nAdults  50mg  Two tablets  One 50mg tablet  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 254}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 34 Annex 10 F: Ritonavir Dosing for Super -Boosting LPV/r in Children Taking Rifampicin  \\nDosing for RTV super -boosting of LPV/r for children receiving rifampicin -containing TB treatment*  \\nDrug  Strength of paediatric \\ntablets or oral liquid  Number of tablets or MLS by weight -band morning (AM) and evening (PM)  Strength of \\nadult tablet  Number of tablets \\nby weight band  \\n3–5.9 kg  6–9.9 kg  10–13.9 kg  14–19.9 kg  20–24.9 kg   25–34.9 kg  \\nAM PM AM PM AM PM AM PM AM PM  AM PM \\nFor children able to swallow tablets  \\nLPV/rb Tablet 100/25 mg  – – – – 2 1 2 2 2 2 100/25 mg  3 3 \\nRTV  Tablet 100 mg  – – – – 1 1 1 2 1 2  \\n \\n100 mg   \\n2  \\n2 Tablet 50 mg  – – – – 2 2 3 3 3 3 \\nTablet 25 mg  – – – – 4 4 6 6 6 6 \\nFor children unable to swallow tablets  \\nLPV/r  Oral solution 80/20 mg/ml  1 ml  1 ml  1.5 \\nml 1.5 ml  2 ml  2 ml  2.5 \\nml 2.5 \\nml 3 ml  3 ml  - - - \\nPellets 40 mg/10 mg  2 2 3 3 4 4 5 5 6 6 - - - \\nGranules 40 mg/10 mg \\nsachet  2 2 3 3 4 4 5 5 6 6 - - - \\nRTVe Oral solution 80 mg/ml  0.8 ml  0.8 ml  1.2 ml  1.2 ml  1.5 ml  1.5 ml  2 ml  2 ml  2.3 ml  2.3 ml  - - - \\nPowder 100 mg/packet  - - 1 1 1 1 1 2 1 2 - - - \\na Suggested RT V dose for super -boosting to achieve the same dose as LPV in mg, in a ratio equal or approaching to 1:1. This dosing approach is supported by a study which explored this \\napproach in young children receiving LPV/r12. \\nb the LPV/r heat -stable t ablet formulation must be swallowed whole and should not be split, chewed, dissolved or crushed. Adult 200 / 50 tablet could be used for patients 14 -24.9kg (1 \\ntab am and 1 tab pm) and for patients 25 -34.9kg (2 tab am and 1 tab pm).  \\nc LPV/r liquid requires a cold chain during transport and storage.  \\nd LPV/r pellets formulation should not be used in infants younger than 3 months. More details on the administration of LPV/r pe llets can be found at \\nhttps://www.who.int/hiv/pub/toolkits/iattfactsheet -lopinavir -ritonavir/en/. The dosing schedule provided applies to equivalent solid dosage forms that may become available such as \\nLPV/r granules, which are approved by US FDA for use from 2 weeks of life.  \\n  e RT V oral solution dosing is ba sed on the dosing tested in the trial that supports the use of super boosting', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 255}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 35 Annex 11: Overlapping toxicities between ARVs  \\nBone marrow \\nsuppression  Peripheral \\nneuropathy  Pancreatitis  Nephrotoxicity  Hepatotoxicity  Rash  Diarrhoea  Ocular effects  \\nAmphotericin B \\nCotrimoxazole \\nDapsone Flucytosine \\nGanciclovir \\nHydroxyurea \\nInterferon - \\nPrimaquine \\nPyrimethamine \\nZidovudine  Didanosine \\nIsoniazid \\nVincristine  Didanosine \\nLamivudine  \\n(esp. in \\nchildren)  \\nStavudine \\nCotrimoxazole \\nRitonavir \\nPentamidine  Acyclovir  \\nAdefo vir high dose \\nAminoglycosides \\nAmphotericin B \\nCidofovir  \\nFoscarnet \\nPentamidine \\nTenofovir  Abacavir  \\nAtazanavir \\nAtovaquone \\nCotrimoxazole \\nDapsone \\nEfavirenz \\nNevirapine \\nSulfadiazine \\nVoriconazole  Abacavir \\nAtazanavir \\nAtovaquone \\nCotrimoxazole \\nDapsone \\nEfavirenz \\nNevirapine \\nSulfadiazine \\nVoriconazole  Atovaquone \\nClindamycin \\nLPV/r Ritonavir  Cidofovir Ethambutol \\nLinezolid Rifabutin \\nVoriconazole  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 256}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 36 Annex 12 A: Use of Nucleoside & Nucleotide Reverse Transcriptase Inhibitors \\nin Adults  \\nDrug name  Dose (in \\nadults)  Dietary \\nrestrictions  Major side effects  Comments  \\nZidovudine  \\n(AZT or ZDV)  \\n \\nAvailable in 300mg \\ntablets and as FDC \\nwith 3TC and 3TC/ \\nNVP  300mg/  \\ndose BD  No food \\nrestrictions  Bone marrow suppression), \\nincluding anaemia; \\ngranulocytopenia; headache; \\ngastrointestinal intolerance; \\nmyopathy; myositis; liver toxicity; \\ndiscoloured nails; lactic acidosis \\nand severe  \\nhepatomegaly with steatosis (fatal \\ncases have been reported)  Monitor for anaemia in  the \\nfirst 3 months of treatment  \\nLamivudine (3TC) \\nAvailable in 150mg  \\ntablet and as FDC \\nwith AZT and \\nAZT/NVP, D4T and \\nD4T/NVP and with \\nTDF and TDF/ EFV  150mg/ \\ndose BD \\nOR 300 \\nmg/dose \\nOD No food \\nrestrictions  Headache; fatigue; nausea; \\ndiarrhoea; skin rash; pancreatitis; \\nperipheral neuropathy; \\nhepatotoxicity/ hepatitis; lactic \\nacidosis and severe hepatomegaly \\nwith steatosis (rare fatal cases \\nhave been reported).  A well -tolerated drug. \\nAdjust dose in renal \\nimpairment.  \\nAlso active against hepatitis B. \\nIdeally, patients should be  \\nscreened for hepatitis B virus  \\n(HBV) before starting therapy; \\nexacerbation of hepatitis B has \\nbeen reported in patients on \\ndiscontinuation of 3TC.  \\nAbacavir (ABC) \\nAvailable in 300mg  \\ntablets and in \\ncombination with  \\n3TC and DTG  300mg/  \\ndose BD  \\n or 600mg \\nOD No food \\nrestrictions. \\nAlcohol \\nincreases \\nABC levels \\nby 41%  Hypersensitivity reaction \\n(potentially fatal) whose \\nsymptoms include fever, \\nfatigue, malaise, nausea, \\nvomiting, diarrhoea  \\nand abdominal pain or \\nrespiratory symptoms such as \\nshortness of breath, \\nlymphadenopathy, ulceration of \\nmucous  \\nmembranes and skin rash. Patients \\nsuspected of having \\nhypersensitivity reaction should \\nhave ABC stopped and never be \\nrestarted. Pancreatitis; lactic \\nacidosis with hepatic steatosis is \\nrare  Educate patient on \\nhypersensitivity reaction. \\nOnce hypersensitivity has \\noccurred, the patient should \\nnever be re -challenged with \\nABC.  \\n \\nAvoid alcohol while on ABC.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 257}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 37 Table 12 A: Cont.  \\nDrug name  Dose (in \\nadults)  Dietary \\nrestrictions  Major side effects  Comments  \\nEmtricitabine  \\n(FTC)  \\n \\nAvailable in 200mg \\ncapsules and as FDC \\nwith TDF and \\nTDF/EFV  200mg/  \\ndose OD  No food \\nrestrictions  Well tolerated. Lactic \\nacidosis and severe \\nhepatomegaly with \\nsteatosis (fatal cases have \\nbeen reported); headache; \\ndiarrhoea; nausea; rash; \\nskin discoloration  Effective against hepatitis B. \\nIdeally, patients should be \\nscreened for chronic hepatitis B \\nvirus (HBV) before starting \\ntherapy; exacerbation of Hepatitis \\nB has been reported in patients on \\ndiscontinuation of FTC  \\nDecrease dosage in patients with \\nrenal impairment Monitor renal \\nfunction if combined with TDF.  \\nWhen used in combination with \\nTDF, should not be given to \\npatients with a creatinine \\nclearance of <30ml/min. Should \\nnot be used with or aft er failure of \\n3TC  \\nTenofovir \\ndisoproxil fumarate \\n(TDF)  \\n \\nAvailable in 300mg \\ntablets and as FDC \\nwith 3TC and 3TC/ \\nEFV  300mg/  \\ndose OD  No food \\nrestrictions  Lactic acidosis and severe \\nhepatomegaly with \\nsteatosis (fatal cases have \\nbeen reported with \\nnucleoside analogues); \\nrenal toxicity; Pancreatitis  Should not be used with ddI. \\nShould never be used in triple \\nnucleoside combinations  \\nwith 3TC+ddI/ABC.  Renal function \\nshould be monitored while on TDF  \\nIdeally, patients should be \\nscreened for chronic hepatitis B \\nvirus (HBV) before starting \\ntherapy; Exacerbation of hepatitis \\nB has been reported in patients on \\ndiscontinuation of TDF  \\nWhen used in combination with \\n3TC, should not be given to \\npatients with a creatinine \\nclearance of <30ml/min.  \\nWhen used with ATV levels of ATV \\nreduced significantly therefore \\ncombine with RTV  \\nTenofovir \\nalafenamide (TAF)  \\n \\nVarious co -\\nformulations \\navailable or being \\ndeveloped  As TAF 25 \\nmg alone or \\nas part of \\nco-\\nformulated \\nFDC  No food \\nrestrictions  Well tolerated. GIT upsets, \\nraised serum creatinine, \\nproteinuria and renal \\ntoxicity (but to a lesser \\ndegree than TDF)  RTV and cobicistat increase TAF \\nlevels. DRV decreases TAF levels. \\nBoosted PI increase TAF levels but \\nthe PI levels are not affected.  \\nAvoid co -administration with \\nrifabutin, rifampicin and phenytoin  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 258}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 38 Annex 12 B: Use of Non -Nucleoside Reverse Transcriptase Inhibitors for Adults  \\nDrug name  Dose (in \\nadults)  Dietary \\nrestrictions  Major side effects  Comments  \\nEfavirenz (EFV) \\nAvailable in 200mg  \\n& 600mg tablets \\nand as FDC with \\nTDF/3TC  600mg \\nOD Best \\ntaken  \\nat \\nbedtime  Preferably \\ntaken on an \\nempty \\nstomach.  \\nCan be given \\nwith food, \\nbut avoid \\nhigh fat  \\nmeals which \\nincrease \\nabsorption.  CNS symptoms \\n(somnolence, insomnia, \\nabnormal dreams, \\nconfusion, \\nhallucination, amnesia, \\netc. Avoid in patients \\nwith history of \\npsychiatric disease);  \\nSkin rash; avoid use in \\nduring the first \\ntrimester  Can be used with rifampicin in TB \\npatients  \\nEtravirine (ETR) \\nAvailable in tablets  \\nof 200 mg   \\n200 mg \\nBD  \\nTake with \\nfood  Severe but rare: SJS and \\nerythema multiforme \\nCommon & minor: \\nRash, nausea, vomiting, \\ndiarrhoea, abdominal \\npain, hepatotoxicity, \\ndyslipidaemia and CNS \\ndisturbances (less than \\nEFV)  Avoid concurrent use with \\nrifampicin, and boosted tipranavir.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 259}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 39 Annex 12 C: Use of Protease Inhibitors in Adults  \\nDrug name  Dose (in \\nadults)  Dietary \\nrestrictions  Major side effects  Comments  \\nLopinavir/ritonav\\nir (LPV/r) \\nAvailable as \\n200mg  \\n+ 50mg RTV  [LPV 400 mg \\n+ RTV  \\n100 mg] 2 \\ntablets BD  Take with food. \\nModerate  \\nfat increases \\nbioavailability.  GI intolerance; \\nnausea; vomiting; \\ndiarrhoea  Tablets should be \\nswallowed whole  \\nAtazanavir  \\n(ATV)  \\n \\nAvailable in  \\n100mg, 150mg, \\n200 mg capsules  \\n \\nAvailable as FDC  \\nwith RTV  ATV 300mg / \\nRTV 100mg \\nOD Take with food. \\nTake 2 hours \\nbefore or 1  \\nhour after \\nantacids and \\nbuffered \\nmedications \\nsuch as buffered \\nddI (reduced \\nATV \\nconcentrations  \\nif administered \\ntogether)  Jaundice; headache; \\nfever; depression; \\nnausea; diarrhoea \\nand vomiting; \\nparaesthesia; \\nspontaneous \\nbleeding episodes \\nin haemop hiliacs.  Indirect \\nhyperbilirubinaemia. \\nWhen used with TDF \\nshould always be given \\nwith RTV. Experienced \\npatients should also be \\ngiven ATV/RTV.  \\nRitonavir  \\n(RTV)  \\n \\nAvailable as 100mg \\ncapsules  \\nCapsules should be \\nrefrigerated until \\ndispensed; stable \\nat room (up to \\n25ºC) for 30 days  Recommended \\nfor use as a \\nbooster of \\nother PIs  Administration \\nwith food \\nincreases \\nabsorption and \\nhelps reduce \\ngastrointestinal \\nside effects.  Exacerbation of liver \\ndisease; fat \\nredistribution and \\nlipid abnormalities; \\ndiarrhoea; \\nabdom inal \\ndiscomfort; \\nheadache; nausea; \\nparaesthesia;  \\nskin rash; \\nspontaneous \\nbleeding episodes in \\nhaemophiliacs.  Potent CYP450 inhibitor, \\nthus its use as a booster \\nof other PIs  \\nDarunavir (DRV)  DRV 600 \\nmg/ RTV \\n100 mg BID \\nOR \\n \\nDRV 800 \\nmg/ RTV 100 \\nmg OD (only \\nif PI naïve)  Take with a \\nmeal to limit \\nADR  GIT upsets, rash, \\ndyslipidaemia, \\nhepatitis. Caution \\nin patients with \\nsulphur allergy.  Metabolized by CYP3A \\nand is an inhibitor of \\nCYP3A. Contains sulphur \\nmoiety. Monitor liver \\nfunctions especially in \\npatients at risk  or with \\npre-existing liver  \\ndisease.  May cause \\nhormonal contraceptive \\nfailure.  \\n   \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 260}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 40 Annex 12 D: Integrase Strand Transfer Inhibitors - INSTIs  \\nDrug name  Dose (in adults)  Dietary \\nrestrictions  Major side effects  Comments  \\nDolutegravir \\n(DTG) Available \\nas DTG 50mg, \\n10mg dispersible \\ntablet  \\n \\nOr FDCs:  \\nABC/3TC/DTG \\n(600/300/50mg)  \\n \\nand \\n \\nTDF/3TC/DTG \\n(300/300/50mg)  50 mg once daily  \\n \\nIf co - \\nadministering with \\nEFV, \\ncarbamazepine, or \\nrifampicin, use \\nDTG 50 mg BD  \\n \\nIf suspected or \\nconfirmed INSTI \\nresistance use DTG \\n50 mg BD  No food \\nrestrictions  Rare - \\nHypersensitivity; \\nHepatotoxicity \\nespecially in those  \\nwith HBV and HCV  \\ninfection, fatigue  \\n \\nInsomnia, headache, \\ndiarrhea, nausea is \\ncommon but usually \\nminor and resolve \\nwith continued use  Interacts with  carbamazepine, \\nphenobarbital and phenytoin, \\nuse alternative \\nanticonvulsants.  \\n \\nAdminister DTG at least 2 \\nhours before or 6 hours after \\ntaking supplements or \\nantacids containing Mg, Al, Fe, \\nCa and Zn. For Ca or Fe, if DTG \\nis taken with a meal then dose \\nsepa ration is not required  \\nRaltegravir (RAL)  ADULT and CHILD \\nover 16 years, 400 \\nmg BD  No food \\nrestrictions  Nausea, vomiting, \\ndiarrhoea, \\nflatulence, \\nconstipation  \\nSevere skin (SJS \\nand TEN) and \\nhypersensitivity \\nreactions have \\nbeen reported  Contraindicated in \\nbreast - feeding mothers  \\nSafety in paediatric patients \\nhas not been established  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 261}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 41 Annex 13 A: Drug -Drug Interactions - NNRTIs  \\nDrugs Affected  Nevirapine (NVP)  Efavirenz (EFV)  \\nANTIRETROVIRALS  \\nDolutegravir  Co-administration not recommended because NVP \\ndecreases levels of DTG  Co-administration not recommended because EFV decreases \\nlevels of DTG.  If must be used together then increase DTG to \\n50 mg BD when co -administered with EFV  \\nRaltegravir  No interaction or not studied  Efavirenz decreases RAL plasma levels but it is unlikely to be \\nclinically sign ificant  \\nAtazanavir/ritonavir  Co-administration not recommended because ATV/r may \\nincrease the serum concentration of NVP leading to \\nincreased risk of toxicity, and NVP decreases the serum \\nconcentration of ATV/r which may lead to resistance and \\ntreatment failure  Co-administration not recommended because EFV decreases \\nthe serum concentration of ATV/r which may lead to \\nresistance and treatment failure  \\nLopinavir/ritonavir  Co-administration not recommended because NVP \\ndecreases levels of LPV/r  AVOID : this combination increased risk of prolonged -QT \\nsyndrome and sudden cardiac death  \\nDarunavir/ ritonavir  No significant interaction when NVP is combined with \\nritonavir -boosted darunavir  Co-administration not recommended because DRV/r may \\nincrease the seru m concentration of EFV leading to increased \\nrisk of toxicity, and EFV decreases the serum concentration of \\nDRV/r which may lead to resistance and treatment failure  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 262}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 42 Annex 13 A: Cont.  \\nANTIFUNGALS  \\nKetoconazole  Levels: ketoconazole ↓ 63%  \\nNVP ↑ 15 – 30%  \\nDose: Not recommended  No data  \\nVoriconazole  Metabolism of Voriconazole may be induced by NVP. \\nVoriconazole may inhibit NNRTI metabolism. Frequently \\nmonitor for NNRTI toxicity and antifungal outcome  Levels: EFV ↑ 44%  \\nVoriconazole ↓ 77%  \\nThis combination is not recommended  \\nFluconazole  NVP Levels: Cmax, AUC, and Cmin ↑ 100%  \\nFluconazole Levels: No change  \\nRisk of hepatotoxicity may increase with this combination. If \\nconcomitant use is necessary, recommend monitoring NVP \\ntoxicity  No clinically significant changes in EFV or \\nFluconazole concentrations  \\nANTI -MYCOBACTERIALS  \\nRifampicin  Levels: NVP ↓ 20% -58%. Virologic consequences are uncertain; \\nthe potential for additive hepatotoxicity exists. Use of this \\ncombination is not recommended; however, if used, co \\nadministration should be done with careful monitoring  Levels: EFV ↓ 25%.  \\nDose: Consider ↑ EFV to 800 mg QD  \\nClarithromycin  Levels: NVP ↑ 26%. Clarithromycin ↓ 30%. Monitor for efficacy \\nor use alternative agent  Levels: Clarithromycin ↓ 39%.  \\nMonitor for efficacy or use alternative agent  \\nBedaquiline (BDQ)  No dose adjustment required  Do not co -administer  \\nDelamanid (DLM)  No interaction expected  No interaction  \\nORAL CONTRACEPTIVES  \\n Levels: ethinyl estradiol approx. 20%. Use alternative or \\nadditional methods.  Levels: Ethinyl estradiol   37%. No data on other \\ncomponents. Use alternative or additional methods  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 263}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 43 Annex 13 A: Cont.  \\nLIPID -LOWERING AGENTS  \\nSimvastatin  \\nLovastatin  No data  Levels: Simvastatin AUC    by 58%; EFV unchanged  \\nDose: Adjust simvastatin dose according to lipid responses, \\nnot to exceed the maximum recommended dose  \\nAtorvastatin  No data  Levels: Atorvastatin AUC   43%; EFV unchanged.  \\nDose: Adjust atorvastatin dose according to lipid responses, \\nnot to exceed the maximum recommended dose  \\nPravastatin  No data  No data  \\nANTI -HYPERTENSIVES   \\nAngiotensin -converting enzyme \\ninhibitors (ACEIs): E.g.  - Enalapril, \\nLisinopril  No known interactions  No known interactions  \\nAngiotensin II receptor blockers \\n(ARBs): e.g., Losartan, Telmisartan  Telmisartan, Candesartan: None  \\nLosartan: Potential interactions with all NNRTIs, net effect \\nof interaction difficult to predict, use with caution  Telmisartan, Candesartan: None  \\nLosartan: Potential interactions with all NNRTIs, net effect \\nof interaction difficult to predict, use with caution  \\nBeta blockers: e.g., Atenolol, \\nCarvedilol and Propranolol  No known interactions  No known interactions  \\nCalcium channel blockers (CCBs): \\ne.g., Nifedipine, Amlodipine and \\nFelodipine  Potential interaction with all NNRTIs: Metabolism of CCBs \\nis induced by EFV or NVP, blunting antihypertensive \\neffect: higher starting dose of CCB may be required  Potential intera ction with all NNRTIs: Metabolism of CCBs \\nis induced by EFV or NVP, blunting antihypertensive effect: \\nhigher starting dose of CCB may be required  \\nDiuretics: E.g., HCTZ, Indapamide. \\nFurosemide and Spironolactone  No known interactions  No known interactions  \\nOthers: Alpha blockers:  \\nMethyldopa, Hydralazine   No known interactions  No known interactions  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 264}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 44 Annex 13 A: Cont.  \\nANTICONVULSANTS  \\nCarbamazepine Phenobarbital \\nPhenytoin  Unknown  \\nUse with caution.  \\nMonitor anticonvulsant levels  Use with caution  \\nMonitor anticonvulsant levels  \\nMETHADONE  Levels: NVP unchanged. Methadone significantly. \\nOpiate withdrawal common when this combination \\nis used. Increased methadone dose often necessary. \\nTitrate methadone dose to effect  Levels: Methadone   60%  \\nOpiate withdrawal common, increase methadone dose often \\nnecessary. Titrate methadone dose to effect  \\nMISCELLANEOUS  No data  Monitor warfarin when used concomitantly  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 265}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 45 Annex 13 B: Drug -Drug Interactions – PIs \\nDrugs Affected  Atazanavir (ATV)  Ritonavir  \\n(RTV)  Darunavir (DRV)  Lopinavir (LPV)  \\nANTIRETROVIRALS  \\nEFV  Co-administration not \\nrecommended because EFV \\ndecreases the serum \\nconcentration of ATV/r which \\nmay lead to resistance and \\ntreatment failure  See interaction with specific \\nritonavir -boosted PI  Co-administration not \\nrecommended because DRV/r \\nmay increase the serum \\nconcentration of EFV leading to \\nincreased risk of toxicity, and EFV \\ndecreases the serum \\nconcentration of DRV/r which \\nmay lead to resistance and \\ntreatment failure  AVOID: this combination \\nincreased risk of \\nprolonged -QT syndrome \\nand sudden cardiac death  \\nETR  No significant interaction  See interaction with specific \\nritonavir -boosted PI  No significant interaction  \\n No significant interaction  \\nDTG  No significant interaction  See interaction with specific \\nritonavir -boosted PI  No significant interaction  No significant interaction  \\nRAL  ATV/r may increase RAL levels \\nbut interaction in not clinically \\nsignificant  See interaction with specific \\nritonavir -boosted PI  No sign ificant interaction  No significant interaction  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 266}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 46 Annex 13 B: Cont.  \\nANTIFUNGALS  \\nItraconazole  Limited data, minimal effect  No data, but potential for bi - \\ndirectional inhibition between \\nItraconazole and RTV, monitor for \\ntoxicities  \\n \\nDose: dose adjustment for patients \\nreceiving  \\n>400 mg Itraconazole may be \\nneeded, or consider monitoring \\nItraconazole level  ↑ Levels of azoles and DRV  ↑ Levels: itraconazole when \\nadministered with LPV/r  \\n \\nDose: itraconazole  \\n– consider not to exceed \\n200 mg/day or monitor \\nlevel and toxicity  \\nKetoconazole  Limited data, minimal effect  Levels: Ketoconazole ↑ 3X \\nDose: Use with caution; do not \\nexceed 200 mg ketoconazole daily  ↑ levels of azoles and DRV  Levels: LPV AUC ↓ \\n13% Azole ↑ 3-fold.  \\nDose: Use with caution; do \\nnot exceed 200 mg \\nketoconazole daily  \\nANTI -MYCOBACTERIALS  \\nRifampicin  Atazanavir AUC: decreased 72%; \\nCmax: decreased  \\n53%; Cmin:  \\ndecreased 98%  Levels: RTV ↓ 35%.  \\n \\nDose: No change. Increased liver \\ntoxicity possible. Co-administration \\nmay lead to loss of virologic response \\nis RTV sole PI. Alternate anti - \\nmycobacterial agents, such as \\nrifabutin, should be considered  ↓ levels of DRV  Levels: LPV AUC ↓ \\n75%. Should not be co \\nadministered as  \\na safe and effective dose of \\nLPV/ r that can be given \\nwith rifampicin has not \\nbeen established  \\nRifapentine  Do NOT co -administer  Do NOT co -administer  Do NOT co -administer  Do NOT co -administer  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 267}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 47 Annex 13 B: Cont.  \\nClarithromycin  Clarithromycin AUC:  \\nincreased 94%;  Levels; Clarithromycin  \\n↑ 77%  \\n \\nDose: Adjust clarithromycin \\ndose for moderate and severe \\nrenal impairment  ↑ levels of clarithromycin by  \\n59%  Levels: ↑  \\nClarithromycin AUC 77%  \\nDose: Adjust clarithromycin \\ndose for moderate and \\nsevere renal impairment  \\nBedaquiline \\n(BDQ)  Increases BDQ exposure and \\nincreases risk of prolonged QT \\nsyndrome, monitor for increased \\ntoxic effects by frequent ECG and \\ntransaminases assessment  Increases BDQ exposure, \\nmonitor for increased toxic \\neffects by frequent ECG and \\ntransamin ases assessment  Increases BDQ exposure, \\nmonitor for increased toxic \\neffects by frequent ECG and \\ntransaminases assessment  Do NOT co -administer \\nbecause of increased risk of \\nprolonged QT syndrome  \\n \\nIncreases BDQ exposure, \\nmonitor for increased toxic \\neffects  \\nDelamanid \\n(DLM)  Increases DLM exposure, monitor \\nfor increased toxic effects by \\nfrequent ECG and transaminases \\nassessment  Increases DLM exposure, \\nmonitor for increased toxic \\neffects by frequent ECG and \\ntransaminases assessment  Increases DLM exposur e, \\nmonitor for increased toxic \\neffects by frequent ECG and \\ntransaminases assessment  Do NOT co -administer \\nbecause of increased risk of \\nprolonged QT syndrome  \\n \\nIncreases DLM exposure, \\nmonitor for increased toxic \\neffects  \\nORAL CONTRACEPTIVES  \\n Ethinyl estradiol  \\nAUC: ↓ Levels: Ethinyl estradiol  \\n↓ 40%.  \\n \\nUse alternative or additional \\nmethod  Ethinyl estradiol  \\nAUC:  ↓ 44%  Levels: Ethinyl estradiol  \\n↓ 42%  \\nUse alternative or \\nadditional method  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 268}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 48 Annex 13 B: Cont.  \\nLIPID -LOWERING AGENTS  \\nSimvastatin  \\nLovastatin  Avoid co - administration  Levels: potential  \\nfor large increase in statin \\nlevels. Avoid concomitant use  Avoid  Levels: Potential  \\nfor large increase in statin \\nlevels  \\nAvoid concomitant use  \\nAtorvastatin  Minimal interaction  Levels:  450% ↑ \\nwhen administered with \\nSQV/RTV combination. Use \\nlowest possible starting dose of \\natorvastatin with careful \\nmonitoring  ↑ AUC four -fold  Atorvastatin AUC ↑ \\n5.88 -fold. Use lowest possible \\nstarting  \\ndose of atorvastatin with \\ncareful monitoring  \\nPravastatin  Minimal interaction  Levels: 50% ↓ when \\nadministered  \\nwith SQV/RTV  \\ncombination  \\n \\nDose: Pravastatin dosage \\nadjustment based on lipid \\nresponse  ↑ AUC 81%  Pravastatin AUC  \\n↑ 33%; no dosage adjustment \\nnecessary  \\nANTI -HYPERTENSIVES  \\nAngiotensin -\\nconverting enzyme \\ninhibitors (ACEIs): \\nE.g. - Enalapril, \\nLisinopril  No known interactions  No known interactions  No known interactions  No known interactions  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 269}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 49 Annex 13 B: Cont.  \\nAngiotensin II \\nreceptor blockers \\n(ARBs): e.g., \\nLosartan, \\nTelmisartan  Telmisartan, Candesartan:  \\nNone  \\nLosartan: Potential \\ninteractions with all PIs, net \\neffect of interaction difficult \\nto predict, use with caution  Telmisartan, Candesartan:  None  \\nLosartan: Potential interactions \\nwith all PIs, net effect of \\ninteraction difficult to predict, \\nuse with caution  Telmisartan, Candesartan:  None  \\nLosartan: Potential interactions \\nwith all PIs, net effect of \\ninteraction difficult to predict, \\nuse with caution  Telmisartan, Candesartan:  \\nNone  \\nLosartan: Potential \\ninteractions with all PIs, net \\neffect of interaction difficult to \\npredict, use with caution  \\nBeta blockers: e.g., \\nAtenolol, Carvedilol \\nand Propranolol  Potential increase in B -\\nblocker effect, careful dose \\nadjustment and ECG where \\nindicated  Potential increase in B -blocker \\neffect, careful dose adjustment \\nand ECG where indicated  Potential increase in B -blocker \\neffect, careful dose adjustment \\nand ECG where indicated  Potential increase in B -blocker \\neffect, careful dose adjustment \\nand ECG where indicated  \\nCalcium channel \\nblockers (CCBs): e.g., \\nNifedipine, \\nAmlodipine and \\nFelodipine  Potential interaction with all \\nPIs: Metabolism of CCBs \\ninhibited, increasing \\nantihypertensive effect: \\nlower starting dose  of CCB \\nmay be required, monitor for \\nexcessive reduction in BP  Potential interaction with all \\nPIs: Metabolism of CCBs \\ninhibited, increasing \\nantihypertensive effect: lower \\nstarting dose of CCB may be \\nrequired, monitor for excessive \\nreduction in BP  Potential  interaction with all \\nPIs: Metabolism of CCBs \\ninhibited, increasing \\nantihypertensive effect: lower \\nstarting dose of CCB may be \\nrequired, monitor for excessive \\nreduction in BP  Potential interaction with all \\nPIs: Metabolism of CCBs \\ninhibited, increasing \\nanti hypertensive effect: lower \\nstarting dose of CCB may be \\nrequired, monitor for excessive \\nreduction in BP  \\nDiuretics: E.g., HCTZ, \\nIndapamide. \\nFurosemide and \\nSpironolactone  No known interactions  No known interactions  No known interactions  No known interactions  \\nOthers: Alpha \\nblockers:  \\nMethyldopa, \\nHydralazine   No known interactions  No known interactions  No known interactions  No known interactions  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 270}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 50 Annex 13 B: Cont.  \\nANTICONVULSANTS  \\nCarbamazepine \\nPhenobarbital \\nPhenytoin  Reduce ATV levels  Carbamazepine; ↑ \\nserum levels when  \\nco-administered with  \\nRTV  \\n \\nUse with caution  \\n \\nMonitor anticonvulsant levels  Avoid  Many possible  \\ninteractions: Carbamazepine:  \\n↑ levels when  \\nco-administered with RTV. Use \\nwith caution. Monitor \\nanticonvulsant levels. \\nPhenytoin : levels of LPV, RTV, \\nand ↓ levels of Phenytoin when \\nadministered together  \\nAvoid concomitant use or \\nmonitor LPV level  \\nOTHER DRUG  \\nMethadone  No interaction with unboosted \\nATV Increased metabolism of \\nmethadone with boosted ATV  Methadone ↓ 37%. Monitor and \\ntitrate dose if needed  \\n \\nMay require ↑  \\nmethadone dose  ↓ levels of methadone by 16%  Methadone AUC  \\n↑ 53%. Opiate withdrawal may \\noccur  \\nMonitor and titrate dose if \\nneeded.  \\nMay require ↑  \\nmethadone dose  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 271}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 51 Annex 13 B: Cont.  \\nERECTILE DYSFUNCTION AGENTS  \\nSildenafil  Use reduced dose of sildenafil  Sildenafil AUC ↑ 11-fold. Use \\ncautiously Start with reduced \\ndose of 25 mg every  \\n48 hours and monitor for \\nadverse effects   Sildenafil AUC ↑ 11- fold in \\ncombination with RTV. Do not \\nexceed 25 mg every  \\n48 hours  \\nMiscellaneous  Decreased GI absorption of \\natazanavir due to reduced acidity  Theophylline ↓ 47%  \\nmonitor theophylline levels  \\n \\nRTV 100 mg bid significantly \\nincrease systemic exposure  \\nof inhaled (oral or nasal \\nfluticasone, may predispose \\npatients to systemic  \\ncorticosteroid effects. Co -\\nadministration not \\nrecommended unless benefit of \\nfluticasone outweighs the risk  Warfarin levels   ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 272}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 52 Annex 13 C: Drug -Drug Interactions – INSTIs  \\nDrugs Affected  Dolutegravir (DTG)  Raltegravir (RAL)  \\nEfavirenz  Co-administration not recommended because \\nEFV decreases levels of DTG.  If must be used \\ntogether then increase DTG to 50 mg BD when \\nco-administered with EFV.  Efavirenz decreases RAL \\nplasma levels but it is unlikely \\nto be clinically significant  \\nEtravirine  Co-administration not recommended because \\nETR decreases levels of DTG, unless used in \\ncombination with a PI/r (which counteracts the \\ninteraction between DTG and ETR)  \\n \\nIf must be used together without a PI/r then \\nincrease DTG to 50 mg BD when co -\\nadministered with ETR. If used together with a \\nPI/r then standard dose DTG is sufficient  Etravirine decreases RAL \\nplasma levels so co -\\nadministration when using \\nonce -daily RAL is not \\nrecommended.  Co -\\nadministration when using \\nstandard BD RAL dosing is \\nacceptable  \\nRifampicin  Increase DTG to 50 mg BD when co -\\nadministered with rifampicin (for children, use \\ndouble the standard weight -based DTG dose by \\nadministering twice daily).  \\n \\nThere is no known drug interaction between \\nDTG and rifabutin.  Increase RAL to 800 mg BD \\nwhen co -administered with \\nrifampicin (for children, use \\ndouble the standard weight -\\nbased RAL dose).  \\n \\nRifabutin may alter RA L \\nplasma levels but it is unlikely \\nto be clinical significant.  \\nRifapentine  Potential decreased DTG levels when co -\\nadministered with once -weekly rifapentine – no \\ndose adjustment required unless viral load \\nbecomes detectable, in which case increase DTG \\nto twice daily until two weeks after completion \\nof rifapentine -based TPT  Potential increased RAL \\nlevels when co -administered \\nwith once -weekly rifapentine \\n– no dose adjustment \\nrequired but monitor for RAL \\ntoxicity  \\nBedaquiline (BDQ)  No interactions expected  No interactions expected  \\nDelamanid (DLM)  No interactions expected  No interactions expected  \\nMetformin  DTG may increase metformin plasma levels so \\nmetformin dose may need to be decreased. Limit \\ndaily metformin dose to 1,000mg.  \\n \\nDTG does NOT require a dose adjustment is when \\nused with metformin.  No interaction  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 273}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 53 Annex 13 C: Cont.  \\nDrugs Affected  Dolutegravir (DTG)  Raltegravir (RAL)  \\nAnticonvulsants  \\n-Carbamazepine  \\n-Phenobarbital  \\n-Phenytoin  Avoid use of DTG with carbamazepine, \\nphenobarbital, or phenytoin because they \\ndecrease DTG plasma levels.  \\n \\nIf the DTG must be used in combination with any \\nof these anticonvulsants than increase DTG dose \\nto 50mg BD and monitor viral load.  No interaction  \\nMineral \\nsupplements and \\nantacids \\ncontaining cations \\n(e.g., calcium, iron, \\nzinc, magnesium, \\naluminum), \\nincluding prenatal \\nvitamins  Administer DTG at least 2 hours before or 6 \\nhours after taking any of these supplements \\n(note: if taking DTG with a meal then it is safe to \\ntake at th e same time as prenatal vitamins, \\ncalcium, or iron)  \\n \\nThere are no drug -drug interactions between \\nDTG and proton pump inhibitors or H2 blockers \\nused for gastritis.  Do not use calcium, \\nmagnesium and aluminum \\ncontaining antacids with RAL.  \\nMethadone  No inter action  No interaction  \\n \\n \\n \\n \\n \\n \\n \\n \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 274}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 54 Annex 14: Health Facility Assessment to Provide Community ART Distribution  \\nHealth Facility Assessment to Provide Community ART Distribution*  \\nFacility name:  MFL code:  Date of assessment:  \\nHealth system domains for community ART distribution  Yes/No  \\nLeadership:  \\nHas the facility identified a focal person to oversee community -based ART distribution?   \\nFinance:  \\nDoes the facility have resources to implement and monitor community -based ART distribution?   \\nHuman Resources for Health:  \\nHas the facility identified appropriate personnel to distribute ART (peer educators, lay \\ncounselors and /or Community Health Volunteers)?   \\nDoes the facility have capacity to train ART distributors?   \\nService Delivery:  \\nHas the facility achieved a routine viral load monitoring uptake of ≥ 90%?   \\nHas the facility established a facility -based system for fast -track ART distribution?   \\nCommodity Management:  \\nDoes the facility have ≥ three months of ART available on site?   \\nHas the facility identified a focal person to pre -pack and label ART for community distribution?   \\nHealth Information Systems:  \\nDoes the facility have an established system to monitor patient level outcomes, specifically \\nretention, loss to follow -up, mortalities an d viral load suppression?   \\nIs the facility able to establish recording and reporting systems for community ART?   \\nAssessors’ recommendations:  \\n \\nFinal assessment outcome:  \\nFacility can initiate community ART distribution ▢  \\nFacility to implement assessors’ recommendations and be re -assessed thereafter ▢  \\nNames of assessors:  Signature of \\nassessors:  Name of health facility manager: \\nSignature of health facility manager:  \\n*None of these criteria are absolute requirements for implementation of community -based ART \\ndistribution; implementation can be considered even if some criteria are not met, as long as a plan is in \\nplace to address and monitor gaps  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 275}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 55 \\n Annex 15: Creatinine Clearance  \\nFormula for calculating creatinine clearance for adults : \\n \\n \\n \\n \\nFormula for calculating creatinine clearance for children and adolescents (up to 19 years \\nold):  \\n \\neGFR = k x height (cm)/ serum creatinine (mg/dL)  \\n \\nk = 0.45 for infants < 1 year old  \\nk = 0.55 for children (1 – 10 years)  \\nk = 0.55 for female adolescents (11 -19 years)  \\nk = 0.70 for male adolescents (11 -19 years)  \\n \\n', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 276}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 56 Annex 16: Immune Reconstitution Inflammatory Syndrome  \\nImmune Reconstitution Inflammatory Syndrome (IRIS)  \\nDefinition:  \\nIRIS is a paradoxical inflammatory reaction against a foreign antigen (alive or dead) in patients who \\nhave started ART with reconstitution (improved functioning) of their immune system. The immune \\nsystem, once it regains some function, is now able to respond against the foreign antigen.  \\nClassification:  \\n● Unmasked IRIS: appearance of a previously undiagnosed opportunistic infection (OI) following \\nART initiation (or switch of ART to a suppressive regimen)  \\n● Paradoxical IRIS: worsening of a previously diagnosed disease after ART initiation (or switch of \\nART to a suppressive regimen)  \\nRisk Factors for IRIS:  \\n● 10-20% of patients who start ART with advanced immunosuppression (refer to Chapter 3) \\nexperience clinical deterioration during the first few months due to IRIS  \\n● High risk patients include:  \\no Advanced immunosuppression (WHO Stage 3 or 4, or CD4 count ≤ 200 cell/mm3 ( or CD4% ≤ \\n25% for children ≤ 5 years old))  \\no Patients with a diagnosed opportunistic infection like TB, MAC, CMV, and PCP  \\no Low baseline CD4 (CD4 count ≤ 50 cell/mm3 or CD4% ≤ 10%)  \\no High baseline viral load  \\no Substantial increase in CD4 count and drop in viral load after starting ART  \\nPatient evaluation:  \\nIn addition to the clinical evaluation for PLHIV outlined in Table 3.1, emphasis should be placed on the \\nfollowing areas during the patient evaluation:  \\nHistory:  \\nSymptoms and current ARV history:  \\n• Specific systemic symptomatology  \\n• Date of ARV initiation  \\n• Regimen  \\n• Reason for substitution / switch from previous ART if not first line  \\n• Adherence to ART and other ongoing treatment  \\n• HIV viral load  \\n• CD4 count  \\nPrior History:  \\n• ARV toxicity  \\n• Drug -drug interaction  \\n• CD4 count  \\n• HIV viral load  History of treatment of opportunistic infections:  \\n• Date of initiation of treatment  \\n• Duration of therapy  \\n• Clinical response to treatment  \\n• Adherence to the OI treatment  \\n• Any default to treatment  \\n• Resistance to treatment  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 277}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 57 Annex 16: Cont.  \\nPhysical Examination:  \\nVital signs assessment:  Temperature, Heart Rate, Blood Pressure, Respiratory rate  \\nConduct a detailed systemic examination:  \\n• Emphasis should be placed on the system(s) which are primarily affected (Table 3.1)  \\n \\nInvestigations  \\n• All patients with advanced HIV disease should be screened for common OIs including TB, \\ncryptococcal meningitis and other common OIs depending of their presenting signs and \\nsymptoms  \\n. \\nDiagnosis of IRIS  \\n● IRIS should be suspected any time a patient has clinical deterioration weeks to months after \\nstarting ART (or switching to a suppressive ART regimen)  \\n● Clinical deterioration usually occurs within 4 -8 weeks of initiation or change of ART (but can be \\nmonths afterwards)  \\n● IRIS has varied clinical presentations due to multiple possible pathogens that the immune system \\nmay be reacting to, and various immune system reactions; there are generally clinical \\nmanifestations consistent with an inflammatory condition  \\n● A high level of suspicion is required when making a diagnosis of IRIS, which is generally one of \\nexclusion  \\n● Rule out the possibility of drug reaction, patient non -adherence to OI treatment, persistently active \\ninfection and/or drug resistance to OI treatment  \\n● There could be localized tissue inflammation with or without systemic inflammatory response  \\n \\nMajor and Minor Presentations of IRIS  \\nMajor presentation  Minor presentation  \\nTuberculosis (TB)  \\nMycobacterium avium complex (MAC)  \\nCryptococcal meningitis  \\nCytomegalovirus (CMV) retinitis  \\nHepatitis B or C virus  \\nProgressive multifocal leukoencephalopathy \\n(PML)  \\nKaposi’s sarcoma  \\nCerebral toxoplasmosis  \\nAutoimmune diseases  Herpes simplex virus (HSV) and varicella \\nzoster virus (VZV)  \\nNonspecific dermatologic complic ations such \\nas folliculitis, oral and genital warts  \\n \\n   \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 278}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 58 Annex 16: Cont.  \\nManagement of IRIS  \\nIRIS management is dependent on severity of symptoms and the following general guidance is \\nrecommended:  \\nSeverity of \\nIRIS  Definition  Management  \\nMild  • Resolves over time \\nin most patients  \\n• Symptomatic \\ntreatment is often \\nsufficient  \\n • Treat the OI and manage the associated \\nsymptoms  \\n• Treat IRIS -associated inflammation:  \\no NSAIDS for discomfort associated with mild \\ninflammation / fevers  \\no Inhaled steroids for bronchospasm or \\ncough associated with mild pulmonary \\ninflammation  \\n• Surgical intervention:  \\no Drainage of abscesses  \\no Excision of inflamed and painful lymph \\nnodes  \\nSevere  • Threatens a \\npatient’s \\nfunctional state  \\n• Cause permanent \\ndisability  \\n• Potentially lead to \\ndeath  \\nExamples:  \\n• Decline in \\npulmonary \\ncapacity from TB \\nor MAC infection  \\n• Neurologic \\ncomplications \\nfrom cryptococcal \\ninfection  \\n• Loss of vision from \\nCMV retinitis \\ninfection  • Treat the OI and manage the associated \\nsymptoms  \\n• Manage t he IRIS -associated inflammation:  \\no If NOT KS: give 1 to 2 mg/kg prednisone for \\n1 to 2 weeks. Follow with a period of \\nindividualized tapering of the dose  \\no Do not use corticosteroids for the \\nmanagement of KS -related IRIS  \\n• Closely monitor patients on corticosteroid \\ntherapy for:  \\no Hyperglycemia  \\no Hypertension  \\no Mental status changes  \\no Avascular necrosis  \\no Worsening of an existing infection  \\no Predisposition to a new infection (e.g., TB \\nand CMV)  \\n    \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 279}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 59 Annex 17: HTS Adult Screening Tool Enhancement  \\n  \\nCounty: …………………………………………. Sub -County Name: ………………………………….  \\n \\nFacility Name:……………………………… Facility MFL Code: ……………………………………  \\n1 Today’s Date                                              Gender                                             AGE  \\n \\n………………………….                            \\n2 Have you ever tested for HIV Before?  \\nIf yes, what was the HIV result?         Positive                      Negative  \\nIf positive, Date of ART initiation. ……………………. (Not eligible for testing)  \\nIf Negative, when is the most recent HIV test?   Months              Years  \\n \\n3 If negative or status unknown, determine  behavioural risk of HIV acquisition  by \\nasking the following questions:  \\n• Unprotected sex within the last 3 months  \\n• Unknown status of the sexual partners  \\n• New sexual partner within the last 3 months  \\n• Multiple sexual partners  \\n• intergenerational relationships  \\n• Symptoms of sexually transmitted infection (refer to MoH syndromic \\nchart) or history of STI  \\n• Pregnancy for females  \\n• Assessing h istory of recurrent illnesses without resolution of symptoms, \\nacute or chronic febrile illness (symptoms ≥ 14 days) and any other \\nconditions suggestive of HIV  \\n4 Possible Risk exposures:  \\n• Defilement  \\n• Traditional /non -medical procedures e.g., scarification, plastic tooth \\nextraction , Circumcision, uvulectomy etc.  \\n5 If Risk noted or clinical assessment suggest HIV, eligible for testing  \\n6. If No risk noted and assessment does not suggest, not eligible  \\nName  Institutions  \\n \\n  \\n M\\nM\\nM  F \\n  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 280}),\n",
       " Document(page_content=\" Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 60 Annex 1 8: List of Contributors and Affiliation  \\n  Name  Affiliation    Name  Affiliation  \\n1 Abraham Katana  CDC  61 Jonah Magare  MOH NASCOP  \\n2 Adrian Gardner  Moi University  62 Jonah Maswai   DoD  \\n3 Agnes Langat  CDC  63 Jonah Onentiah  MOH NASCOP  \\n4 Alice Njoroge  Kajiado County  64 Jonathan Mwangi  CDC  \\n5 Ambrose Juma  MOH NASCOP  65 Joseph Mbuthia  Mater Hospital  \\n6 Anne Marie \\nMacharia  KNH  66 Joseph Nkuranga  UON  \\n7 Anthony Wachira  MOH NASCOP  67 Judith Lusike  CHAI  \\n8 Appolonia Aoko  CDC  68 Julius Kisio  Murang'a County  \\n9 Barbara Mambo  MOH NASCOP  69 Julius Oliech  CDC  \\n10 Brandwell Mwangi  CHAI  70 Justine Odionyi  EGPAF  \\n11 Brenda Opanga  MOH NASCOP  71 Justus Ogada  CHAI  \\n12 Celestine \\nImuuraget  DOD  72 Kenneth Masamaro  CDC  \\n13 Christine Kisia  WHO  73 Lazarus Momanyi  MOH NASCOP  \\n14 Claver Kimathi  Isiolo County  74 Lennah Nyabiage  CDC  \\n15 Collins Etemesi  MOH NASCOP  75 Leonard Kingwara  MOH NHRL  \\n16 Dalton Wamalwa  UON  76 Leonard Soo  USAID  \\n17 Daniel Kimani  CDC  77 Loice Achieng Ombajo  UON  \\n18 Daniel Were  JHPIEGO  78 Margaret Ndubi  UNAIDS  \\n19 Davis Karambi  CHAI  79 Mary Mugambi  MOH NASCOP  \\n20 Deborah Carpenter  CDC  80 Mary Nyangasi  MOH NCCP  \\n21 Deborah Goldstein  USAID  81 Marybeth Maritim  UON  \\n22 Deborah Ikonge  MOH NASCOP  82 Maureen Inimah  MOH NASCOP  \\n23 Dennis Osiemo  USAID  83 Maureen Syowai  ICAP at Columbia \\nUniversity  \\n24 Diana Marangu  UoN  84 Mike Ekisa  Kakamega County  \\n25 Dinah Mamai   CHS  85 Muthoni Karanja  DOD  \\n26 Dorcus Abuya  UNICEF  86 Nancy Bowen  MOH NHRL  \\n27 Doreen Muriithi  JHPIEGO  87 Nandita Sugandhi  ICAP at Columbia \\nUniversity  \\n28 Dorothy Mwagae  MOH NASCOP  88 Natella Rakhmanina  EGPAF  \\n29 Douglas Gaitho  AKUH  89 Nelson Otwoma  NEPHAK  \\n30 Dunstan Achwoka  USAID  90 Newton Omale  MOH NASCOP  \\n31 Edith Apondi  AMPATH Plus  91 Odylia Muhenje  CDC  \\n32 Elaine Abrams   ICAP at Columbia \\nUniversity  92 Pacific Akinyi  MOH NASCOP  \\n33 Elizabeth Irungu  JHPIEGO  93 Patricia Oluoch  USAID  \\n34 Elizabeth Katiku  CDC  94 Patricia Ongwen  JHPIEGO  \", metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 281}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 61 35 Elizabeth Mueni  NMS  95 Philip Kimani  CHAI  \\n36 Elizabeth Onyango  MOH NCD  96 Rogers Simiyu  EGPAF  \\n37 Elizabeth Washika  MOH NASCOP  97 Rose Ayugi  MOH NASCOP  \\n38 Emma Momanyi  CIHEB  98 Rose Wafula  MOH NASCOP  \\n39 Eric Mutua  MOH NASCOP  99 Ruby Fayorsey                  ICAP at Columbia \\nUniversity  \\n40 Evelyn Ngugi  CDC  100  Ruth Kamau  MOH NASCOP  \\n41 Everline Ashiono  USAID Dumisha Afya  101  Ruth Korir  Mathari Hospital  \\n42 Felicistas Makokha  NyaWest RTWG  102  Ruth Musyoki  MOH NASCOP  \\n43 Francis Ndwiga  MOH NASCOP  103  Ruth Nduati  UoN  \\n44 Frank Basiye  CDC  104  Salome Okutoyi  USAID  \\n45 George Siberry  USAID  105  Sarafuina Sikwata  MOH NASCOP  \\n46 Grace Rabut  MOH NASCOP  106  Sarah Masyuko  MOH NASCOP  \\n47 Helen Chun  CDC  107  Shobha Vakil                     ICAP at Columbia \\nUniversity  \\n48 Herb Herwell  CHAI  108  Sospeter Gitonga  MOH NASCOP  \\n49 Herman Wayenga  CDC  109  Steve Oyule  DoD  \\n50 Immaculate \\nMutisya  CDC  110  Susan Njogo  ARC Kenya  \\n51 Irene Mukui  DnDI  111  Teresa Simiyu  USAID  \\n52 Isabella Yonga  USAID  112  Terezah Alwar  UNICEF  \\n53 Ivy Kasirye  WHO  113  Vakil, Shobha  ICAP  \\n54 Jafred Mwangi  MOH NASCOP  114  Valeria Makory  MOH NASCOP  \\n55 James Wagude  NyaWest RTWG  115  Valerie Obare  MOH NASCOP  \\n56 Janet Muema  MOH NASCOP  116  Veronica Irungu  CHS  \\n57 Japheth Gituku  MOH NASCOP  117  Virginia Karanja  CHS  \\n58 Jeremy Penner  UBC  118  Wangui Kamau  KNH  \\n59 Joan -Paula Bor  MOH NCCP  119  Wanjiku Ndegwa  MOH NASCOP  \\n60 John Mungai  CHAI  120  Winifred Nyanya  MOH NASCOP  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 282}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 62 Annex 19: List of Participating Organizations and Agencies  \\nContributing Organizations  \\nCenter for Health Solutions  \\nAga Khan University Hospital  \\nAMPATH Plus  \\nARC Kenya  \\nCenter for Disease Control  \\nCIHEB Kenya  \\nClinton Health Access Initiative  \\nCouncil of Governors  \\nDepartment of Defence  \\nDnDI  \\nEGPAF  \\nICAP at Columbia University  \\nJHPIEGO  \\nKenyatta Nati onal Hospital  \\nMater Hospital  Mathari National TRH  \\nMOH Department of NCD  \\nMOH Division of NCCP  \\nMOH NASCOP  \\nMOH NHRL  \\nMOH NLTP  \\nMoi University  \\nNairobi Metropolis Services  \\nNEPHAK  \\nUCSF  \\nUNICEF  \\nUniversity of British Columbia  \\nUniversity of Nairobi  \\nUSAID  \\nWorld Health Organization  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 283}),\n",
       " Document(page_content=' \\n63 - 264   \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 284}),\n",
       " Document(page_content=' \\n  \\n', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 285})]"
      ]
     },
     "execution_count": 11,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "documents"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "id": "90b40334-11fa-46e2-b9db-600992282296",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "aa9cdb0185fa41ca83adf00f6df0a680",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Processing docs:   0%|          | 0/286 [00:00<?, ?it/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Total chunks created: 1317\n"
     ]
    }
   ],
   "source": [
    "from tqdm.auto import tqdm\n",
    "from concurrent.futures import ThreadPoolExecutor, as_completed\n",
    "\n",
    "guides_chunks = []\n",
    "\n",
    "def process_doc(doc):\n",
    "    \"\"\"\n",
    "    Splits a single document into sections and returns a list of section dicts.\n",
    "    \"\"\"\n",
    "    doc_content = doc.page_content\n",
    "    doc_metadata = doc.metadata\n",
    "    sections = intelligent_chunking(doc_content)\n",
    "    return [{**doc_metadata, 'section': section} for section in sections]\n",
    "\n",
    "# Use ThreadPoolExecutor to process multiple docs in parallel\n",
    "with ThreadPoolExecutor() as executor:\n",
    "    futures = [executor.submit(process_doc, doc) for doc in documents]\n",
    "    \n",
    "    # Create a tqdm progress bar with total=len(futures)\n",
    "    for future in tqdm(as_completed(futures), total=len(futures), desc=\"Processing docs\"):\n",
    "        # future.result() blocks until the future is done\n",
    "        guides_chunks.extend(future.result())\n",
    "\n",
    "print(f\"Total chunks created: {len(guides_chunks)}\")\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "id": "f98dafab-73db-4417-ae3a-e1cecd70b761",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Embedding"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "id": "4c4bdf41-4487-4163-ad7a-cd4ca3b17431",
   "metadata": {},
   "outputs": [],
   "source": [
    "embeddings = HuggingFaceEmbeddings(\n",
    "    model_name=\"sentence-transformers/all-MiniLM-L6-v2\"\n",
    ")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "id": "87537556-e949-4a71-a383-95c9a838020a",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 1,\n",
       "  'section': \"Sure! Please provide the document you'd like me to split into sections.\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 0,\n",
       "  'section': \"It appears that there is no content provided within the `<DOCUMENT>` tags. If you have a specific text or document that you would like to split into logical sections for a Q&A system, please provide that content, and I'll be glad to assist you!\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 5,\n",
       "  'section': \"## Acknowledgements\\n\\nThe 2022 Guidelines on Use of Antiretroviral Drugs for Treating and Preventing HIV Infection in Kenya has been a long-awaited document, with its revision significantly affected by the COVID-19 pandemic. This document has been updated through the collaborative effort of multiple stakeholders, including individuals and institutions involved in extensive consultations led by NASCOP's HIV Care and Treatment Program.\\n\\nI acknowledge all the institutions, both local and international, as well as government ministries and departments whose staff dedicated long hours, both virtually and in person, to the review, writing, and finalization of this document.\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 5,\n",
       "  'section': '## Contributions to the Document\\n\\nThis opportunity allows me to appreciate the efforts of the Ministry of Health officers at NASCOP and other institutions that coordinated and provided leadership during the review process. Special thanks to the guidelines review secretariat and the task force who worked tirelessly to produce a high-quality document. \\n\\nParticular appreciation goes to the NASCOP team and various technical advisors who were instrumental in compiling the evidence review and developing the guidelines. Notable acknowledgments to the consultants; Jeremy Penner, Irene Mukui, and Herb Harwell for their dedication to this process.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 5,\n",
       "  'section': '## Financial Support\\n\\nFinancial support for the review process, printing, and launch of this document was generously provided by various organizations. This includes the Global Fund, UNITAID through CHAI, the US government through the Centers for Disease Control and Prevention, ICAP at Columbia University through the USAID-funded RISE-Kenya Project, as well as WHO and UNICEF - Kenya.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 5,\n",
       "  'section': '## Contact Information\\n\\nDr. Rose Wafula  \\nHead, National AIDS & STI Control Program  \\nMinistry of Health'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 3,\n",
       "  'section': '## Introduction\\n\\nThis guideline document is a publication of the National AIDS & STI Control Program, Ministry of Health Kenya. It emphasizes the importance of the information provided and details the copyright restrictions on reproduction and distribution.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 3,\n",
       "  'section': '## Purpose of the Guidelines\\n\\nThe Kenya HIV Prevention and Treatment Guidelines, 2022 edition, contain crucial information required by healthcare providers for the use of ARVs as of the date of issue.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 3,\n",
       "  'section': '## Verification of Information\\n\\nNASCOP has taken reasonable precautions to verify the information contained in this guideline document to ensure its accuracy and reliability.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 3,\n",
       "  'section': '## Contact Information\\n\\nFor clarifications, contact the National AIDS and STI Control Program (NASCOP) at:\\n- P.O. Box 19361 - 00202, Nairobi, Kenya\\n- Tel: +254 (020) 2630867\\n- Email: info@nascop.or.ke\\n- Website: www.nascop.or.ke'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 3,\n",
       "  'section': '## Citation\\n\\nThe recommended citation for this document is:\\nMinistry of Health, National AIDS & STI Control Program. Kenya HIV Prevention and Treatment Guidelines, 2022 Edition. Nairobi, Kenya: NASCOP, Aug 2022. Print.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 3,\n",
       "  'section': '## Design and Layout Information\\n\\nThe document layout was designed by Collins Etemesi - NASCOP, and it includes the ISBN: 13 -978 -9966 -038 -31-9.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 4,\n",
       "  'section': '## Foreword\\n\\nKenya is committed to achieving the UNAIDS 95–95–95 testing and treatment targets among people living with HIV within all sub-populations and age groups. The 2022 edition of the ‘Guidelines on Use of Antiretroviral Drugs for Treating and Preventing HIV Infection in Kenya’ is an update of the comprehensive HIV prevention, care, and treatment guidelines released in 2018. These guidelines align with the Ministry of Health’s mission of providing the highest standard of health for all Kenyans and one of the Government of Kenya’s Big Four Agenda on Universal Health Coverage.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 4,\n",
       "  'section': '## Focus of the Guidelines\\n\\nThe theme of the 2022 guidelines is to refocus efforts in the management of Advanced HIV Disease to reduce HIV/AIDS-related morbidity and mortality. Despite significant progress in HIV prevention, care, and treatment through improved medicines, diagnostics, and patient-centered service delivery, Advanced HIV Disease remains a challenge. The guidelines aim to widen access to key diagnostics and medications to manage the most common causes of illness and death.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 4,\n",
       "  'section': '## Integrated Services\\n\\nThe guidelines emphasize the integrated delivery of patient-centered HIV, TB, NCDs, mental health, and sexual and reproductive health services. They provide key recommendations on various aspects of HIV care, including HIV testing services, linkage to prevention and treatment, and patient evaluation.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 4,\n",
       "  'section': '## Key Recommendations\\n\\nThese guidelines provide key recommendations on:  \\n- HIV testing services and linkage to prevention and treatment  \\n- Initial evaluation and follow-up of PLHIV  \\n- Standard package of care for PLHIV  \\n- Adherence preparation, monitoring, and support  \\n- Antiretroviral therapy in infants, children, adolescents, and adults  \\n- Prevention of mother-to-child transmission of HIV, syphilis, and viral hepatitis  \\n- TB/HIV co-infection management  \\n- Hepatitis B & C/HIV co-infection management  \\n- Use of ARVs for post and pre-exposure prophylaxis for HIV-uninfected populations  \\n- HIV services for people who inject drugs'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 4,\n",
       "  'section': '## Purpose of the Guidelines\\n\\nThe guidelines are an essential tool meant for use by service providers at all levels of the health sector in Kenya. They are presented in a simplified manner, utilizing a public health approach to HIV prevention and treatment.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 4,\n",
       "  'section': '## Conclusion\\n\\nIt is hoped that this guidance document provides the much-needed framework and impetus to move towards universal access to HIV services and supports the agenda of ending AIDS by 2030 as a key national health strategic objective.\\n\\nDr. Patrick Amoth, EBS  \\nAg. Director General for Health, Ministry of Health.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 2,\n",
       "  'section': '## Kenya HIV Prevention and Treatment Guidelines, 2022\\n\\nThis section outlines the purpose and scope of the Kenya HIV Prevention and Treatment Guidelines for the year 2022, detailing the importance of these guidelines in the context of public health and disease management in Kenya.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 2,\n",
       "  'section': '## HIV Prevention Strategies\\n\\nThis section covers the various strategies recommended for the prevention of HIV transmission in Kenya, including safe sex practices, condom distribution, pre-exposure prophylaxis (PrEP), and harm reduction for people who inject drugs.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 2,\n",
       "  'section': '## HIV Testing and Counseling\\n\\nThis section provides information on the guidelines for HIV testing and counseling services, emphasizing the importance of confidential and accessible testing, as well as support mechanisms for individuals who test positive.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 2,\n",
       "  'section': '## Antiretroviral Therapy (ART)\\n\\nThis section discusses antiretroviral therapy (ART), including treatment initiation criteria, types of ART medications, adherence strategies, and monitoring guidelines for individuals living with HIV.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 2,\n",
       "  'section': '## Care and Support Services\\n\\nThis section outlines the care and support services available for individuals living with HIV, including mental health support, nutritional guidance, and community-based resources to enhance the quality of life for patients.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 2,\n",
       "  'section': '## Special Populations\\n\\nThis section addresses the unique considerations and approaches needed for special populations affected by HIV, such as women, children, and adolescents, and key populations at higher risk.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 2,\n",
       "  'section': '## Monitoring and Evaluation\\n\\nThis section highlights the importance of monitoring and evaluating the effectiveness of HIV prevention and treatment programs, including metrics for success and ways to improve service delivery.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 2,\n",
       "  'section': '## Policy and Legal Framework\\n\\nThis section presents an overview of the policies and legal frameworks that support HIV prevention and treatment efforts in Kenya, including human rights considerations and anti-discrimination laws.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 2,\n",
       "  'section': '## Training and Capacity Building\\n\\nThis section focuses on the training and capacity-building initiatives intended for healthcare providers, ensuring they are equipped to deliver effective HIV prevention and treatment services according to the updated guidelines.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 2,\n",
       "  'section': '## Community Engagement\\n\\nThis section discusses the role of community engagement in the successful implementation of HIV prevention and treatment strategies, encouraging the involvement of local communities in program development and execution.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 2,\n",
       "  'section': '## Future Directions\\n\\nThis section looks at future directions and emerging trends in HIV prevention and treatment, considering ongoing research, technological advancements, and the importance of adaptation to new challenges in public health.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 6,\n",
       "  'section': '## Foreword\\n\\nThis section typically provides an introduction to the document, outlining its purpose and significance.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 6,\n",
       "  'section': '## Acknowledgements\\n\\nHere, the contributions of individuals or organizations that assisted in the creation of the document are recognized.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 6,\n",
       "  'section': '## Table of Contents\\n\\nThis section lists all the main sections and subsections of the document for easy navigation.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 6,\n",
       "  'section': '## List of Figures\\n\\nA compilation of all figures included in the document, with corresponding page numbers.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 6,\n",
       "  'section': '## List of Tables\\n\\nA compilation of all tables found within the document, with corresponding page numbers.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 6,\n",
       "  'section': '## Acronyms and Abbreviations\\n\\nA listing of abbreviations used throughout the document, providing clarity on terminology.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 6,\n",
       "  'section': '## Summary of Key Recommendations\\n\\nThis section summarizes critical recommendations related to HIV testing and treatment, including:\\n\\n1.1 HIV Testing Services (HTS) and Linkage to Treatment and Prevention  \\n1.2 Initial Evaluation and Follow -up for PLHIV  \\n1.3 Standard Package of Care for PLHIV  \\n1.4 Adherence Preparation, Monitoring, and Support  \\n1.5 Antiretroviral Therapy for Infants, Children, Adolescents, and Adults  \\n1.6 Prevention of Mother to Child Transmission of HIV/Syphilis/HBV  \\n1.7 TB/HIV Co-infection Prevention and Management  \\n1.8 HBV/HIV and HCV/HIV Co-infection Prevention and Management  \\n1.9 ARVs for Post-exposure Prophylaxis (PEP)  \\n1.10 Pre-Exposure Prophylaxis (PrEP)  \\n1.11 People Who Inject Drugs (PWID) and HIV'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 6,\n",
       "  'section': '## HIV Testing Services and Linkage to Treatment and Prevention\\n\\nThis section delves into HIV testing services, including settings and strategies used:\\n\\n2.1 Settings for HIV Testing  \\n2.1.1 Facility-based testing  \\n2.1.2 Community-based testing  \\n2.2 HTS strategies  \\n2.2.1 HIV Self-Testing (HIVST)  \\n2.2.2 Index Testing  \\n2.2.3 Voluntary Counselling and Testing (VCT)  \\n2.2.4 Social Network Strategy (SNS)  \\n2.3 Package of HIV Testing Services  \\n2.4 Age-Specific HIV Testing Algorithms  \\n2.4.1 Early Infant Diagnosis  \\n2.4.2 Diagnosis of HIV Infection in the Older Child (≥ 18 months), Adolescents, and Adults  \\n2.4.3 HIV testing for Pregnant Women  \\n2.5 Retesting recommendations for HIV negative persons  \\n2.6 Inconclusive HIV status  \\n2.7 Approach to Patients on ART with a Discrepant HIV Test Result'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 18,\n",
       "  'section': '## Summary of Key Recommendations\\n\\nThis section provides an overview of key recommendations regarding HIV testing, linkage to treatment, and care for people living with HIV (PLHIV).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 18,\n",
       "  'section': '## HIV Testing Services (HTS) and Linkage to Treatment and Prevention\\n\\n• HIV testing should be voluntary and conducted ethically, ensuring that Consent, Confidentiality, Counselling, Correct results, Connection (linkage), and Creating an enabling environment are prioritized.  \\n• To enhance access to testing services, HIV testing can be conducted in two different settings:  \\n  - Facility-based  \\n  - Community-based  \\n• Targeted HIV testing is recommended, involving index client listing of contacts, HIV self-testing, and utilizing HTS screening tools to identify at-risk individuals for testing.  \\n• Serial testing, using approved rapid HIV antibody testing kits, is utilized to diagnose HIV infection in individuals older than 18 months, adolescents, and adults. An HIV-positive diagnosis will be made using three consecutive reactive assays.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 18,\n",
       "  'section': '## Initial Evaluation and Follow-Up for PLHIV\\n\\n● The initial clinical evaluation of PLHIV involves CD4 monitoring, which is recommended for the following:  \\n  - Baseline investigation for all PLHIV  \\n  - Any patient with suspected treatment failure  \\n  - Any patient returning to care after interrupting treatment for more than three months  \\n  - Any patient on fluconazole maintenance therapy or on dapsone as prophylaxis to determine when prophylaxis can be discontinued  \\n\\n● Advanced HIV Disease is defined as:  \\n  - Adults, adolescents, and children five years and older having a CD4 cell count of less than 200 cells/mm³ or  \\n  - WHO clinical stage 3 or 4 disease  \\n  - All children younger than five years  \\n\\n● All PLHIV presenting with Advanced HIV Disease (AHD) should be offered a comprehensive care package that includes timely initiation of ART, screening, diagnosis, prophylaxis, and management of opportunistic infections.  \\n\\n● Frequency of routine viral load (VL) monitoring:  \\n  - For PCR positive HIV-exposed infants (HEIs): at baseline (at the time of ART initiation)  \\n  - Age 0 - 24 years old: 3 months after ART initiation and then every 6 months  \\n  - Age ≥ 25 years old: 3 months after ART initiation, then at month 12, and then annually'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 11,\n",
       "  'section': '## Management Protocol for Patients Switching to 3rd Line ART\\n\\nThis section provides guidelines for managing patients who are being transitioned to third line antiretroviral therapy (ART). A well-defined management protocol is essential to ensure the effectiveness of the treatment and to monitor any adverse effects.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 11,\n",
       "  'section': '## Dosing of Solid and Liquid Formulations for Infants and Children\\n\\nThis section covers various dosing protocols for solid and liquid formulations intended for infants and children aged 4 weeks and older. The dosing is categorized into:\\n\\n### Twice-Daily Dosing \\nDetails on the dosing procedures and recommendations for administration of medications in solid and liquid forms.\\n\\n### Once-Daily Dosing\\nA simplified approach to dosing child-friendly medications for once-daily intake.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 11,\n",
       "  'section': '## Drug Dosing for Infants Less than 4 Weeks of Age\\n\\nThis section outlines the specific dosing guidelines for liquid formulations administered to infants who are less than 4 weeks old. It is critical to ensure that dosing is both safe and effective for this vulnerable age group.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 11,\n",
       "  'section': '## Prophylaxis Dosing for Infants and Children\\n\\nThis section discusses the simplified dosing of isoniazid (INH) and cotrimoxazole (CTX) prophylaxis for infants and children who are at least 4 weeks of age. Proper prophylactic measures are vital in preventing opportunistic infections.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 11,\n",
       "  'section': '## Tuberculosis (TB) Preventive Therapy Dosing\\n\\nHere, the dosing guidelines for TB preventive therapy are outlined. Effective dosing is crucial for reducing the incidence of TB among populations at risk.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 11,\n",
       "  'section': '## Ritonavir Dosing for Super-Boosting LPV/r in Children Taking Rifampicin\\n\\nThis section provides guidance on the appropriate dosing of ritonavir for boosting lopinavir/ritonavir (LPV/r) in children who are concurrently taking rifampicin, highlighting the need for careful management of drug interactions.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 11,\n",
       "  'section': '## Overlapping Toxicities Between Antiretroviral Medications\\n\\nThis section addresses the potential overlapping toxicities that may occur between various antiretroviral (ARV) medications. Understanding these toxicities is essential for the safe management of patients undergoing ART.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 11,\n",
       "  'section': '## Use of Antiretroviral Classes in Adults\\n\\nThis section contains subsections on the use of different classes of antiretroviral drugs in adults:\\n\\n### Nucleoside & Nucleotide Reverse Transcriptase Inhibitors\\nGuidelines and recommendations for the use of these inhibitors.\\n\\n### Non-Nucleoside Reverse Transcriptase Inhibitors\\nInformation on the application of non-nucleoside inhibitors in treatment approaches.\\n\\n### Protease Inhibitors\\nDetails regarding the use of protease inhibitors and their clinical implications for adult patients.\\n\\n### Integrase Strand Transfer Inhibitors (INSTIs)\\nGuidance on the use of INSTIs, highlighting their role in modern treatment regimens.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 11,\n",
       "  'section': '## Drug-Drug Interactions Among Antiretrovirals\\n\\nThis section covers the potential drug-drug interactions between various classes of antiretrovirals:\\n\\n### NNRTIs\\nDetails the interactions associated with non-nucleoside reverse transcriptase inhibitors.\\n\\n### PIs\\nDiscusses interactions specifically related to protease inhibitors.\\n\\n### INSTIs\\nCovers drug interactions pertaining to integrase strand transfer inhibitors.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 11,\n",
       "  'section': '## Health Facility Assessment for Community ART Distribution\\n\\nGuidelines are provided here for assessing health facilities capable of distributing community ART. This is important for ensuring accessibility and continuity of care for patients.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 11,\n",
       "  'section': '## Creatinine Clearance\\n\\nThis section discusses the assessment of creatinine clearance, which is a critical parameter for evaluating renal function in patients undergoing ART.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 11,\n",
       "  'section': '## Immune Reconstitution Inflammatory Syndrome\\n\\nDetails on immune reconstitution inflammatory syndrome (IRIS), including its causes, symptoms, and management strategies.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 11,\n",
       "  'section': '## HTS Adult Screening Tool Enhancement\\n\\nThis section includes enhancements to the adult screening tool used in HIV testing services (HTS), aimed at optimizing the screening process for better outcomes.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 11,\n",
       "  'section': '## List of Contributors and Affiliation\\n\\nThis section provides a list of contributors involved in the creation of the guidelines, along with their affiliations.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 11,\n",
       "  'section': '## List of Participating Organizations and Agencies\\n\\nHere, a comprehensive list of organizations and agencies that participated in the development of the guidelines is provided, reflecting the collaborative effort in fighting HIV.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 9,\n",
       "  'section': '## Changing ARVs Due to Adverse Drug Reactions\\n\\nDetails on when and how to switch antiretroviral therapies (ARVs) in response to adverse drug reactions.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 9,\n",
       "  'section': '## Changing ARVs Due to Drug-Drug Interactions\\n\\nGuidelines for revising ARV regimens based on interactions with other medications.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 9,\n",
       "  'section': '## Changing ARVs Due to Treatment Failure\\n\\nInformation on identifying treatment failure and adjusting ARV therapy accordingly.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 9,\n",
       "  'section': '## Prevention of Mother to Child Transmission of HIV/Syphilis/Hepatitis B\\n\\nOverview of strategies to prevent the transmission of HIV, syphilis, and hepatitis B from mother to child.\\n\\n### Antiretroviral Therapy for HIV-positive Pregnant and Breastfeeding Women and Infant Prophylaxis\\n\\nRecommendations for effective antiretroviral therapy for HIV-positive women and their infants.\\n\\n### Syphilis Elimination for Pregnant and Breastfeeding Women and Infant Treatment\\n\\nGuidelines for the prevention and treatment of syphilis in pregnant and breastfeeding women.\\n\\n### Hepatitis B Elimination for Pregnant and Breastfeeding Women and Infant Prophylaxis\\n\\nProtocols for managing hepatitis B in pregnant and breastfeeding women.\\n\\n### Infant and Young Child Nutrition in the Context of HIV\\n\\nNutritional guidelines for infants and young children affected by HIV.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 9,\n",
       "  'section': '## TB/HIV Co-infection, Prevention and Management\\n\\nGuidance on managing tuberculosis (TB) in individuals living with HIV.\\n\\n### TB Screening for PLHIV: Intensified Case Finding (ICF)\\n\\nMethods and importance of screening for TB in people living with HIV.\\n\\n### TB Preventive Therapy (TPT)\\n\\nDetailed recommendations on the preventive therapy for TB in HIV-positive individuals.\\n\\n#### Indications for TPT\\n\\nCriteria for when TB preventive therapy should be initiated.\\n\\n#### Contraindications to TPT\\n\\nConditions under which TB preventive therapy should not be administered.\\n\\n#### Dose and Duration of TPT\\n\\nRecommendations on the appropriate dosages and duration for TB preventive therapy.\\n\\n#### Follow-up of Patients on TPT\\n\\nGuidelines for monitoring patients undergoing TB preventive therapy.\\n\\n### Identifying and Managing Drug Toxicities from TPT\\n\\nInformation on the potential toxicities associated with TB preventive therapy and their management.\\n\\n#### Peripheral Neuropathy - Suspected Drug: INH\\n\\nDetails on managing peripheral neuropathy suspected to be caused by isoniazid (INH).\\n\\n#### Drug-Induced Liver Injury (DILI) - Suspected Drugs\\n\\nManagement of liver injury potentially due to isoniazid (H), rifapentine (P), and rifampicin (R).\\n\\n#### Management of TPT-associated Rash\\n\\nGuidelines for addressing rash reactions from drugs like isoniazid, rifapentine, and rifampicin.\\n\\n### ART for TB/HIV Co-infection\\n\\nRecommendations for antiretroviral therapy specifically tailored for those with both TB and HIV.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 9,\n",
       "  'section': '## HBV/HIV and HCV/HIV Co-infection Prevention and Management\\n\\nStrategies for managing co-infection with hepatitis B (HBV) and C (HCV) in HIV-positive individuals.\\n\\n### Hepatitis B/HIV Co-infection\\n\\nOverview of screening, prevention, and treatment approaches for individuals co-infected with HBV and HIV.\\n\\n#### Screening\\n\\nGuidelines on screening for hepatitis B in HIV-positive populations.\\n\\n#### Prevention\\n\\nPreventive measures aimed at reducing the risk of hepatitis B in HIV-infected individuals.\\n\\n#### Treatment\\n\\nTreatment options available for those co-infected with HIV and HBV.\\n\\n### Hepatitis C/HIV Co-infection\\n\\nSimilar to HBV, managing co-infection with hepatitis C in those living with HIV.\\n\\n#### Screening\\n\\nRecommendations for screening for hepatitis C in HIV-positive patients.\\n\\n#### Prevention\\n\\nStrategies to prevent hepatitis C infection in individuals with HIV.\\n\\n#### Treatment of HIV/HCV Co-infection\\n\\nTreatment protocols for managing HIV in tandem with hepatitis C infection.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 9,\n",
       "  'section': '## ARVs for Post-exposure Prophylaxis\\n\\nInformation surrounding post-exposure prophylaxis (PEP) for HIV.\\n\\n### What is PEP?\\n\\nA definition and overview of post-exposure prophylaxis for HIV.\\n\\n### Recommended ARVs for PEP\\n\\nList of antiretroviral medications recommended for PEP.\\n\\n### Eligibility For PEP\\n\\nCriteria that determine eligibility for receiving post-exposure prophylaxis.\\n\\n### Management and Follow-Up\\n\\nGuidelines for the management and follow-up care of individuals on PEP.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 8,\n",
       "  'section': '## Nutritional Services\\n\\n### 4.7 Nutritional Assessment, Counselling and Support (NACS)\\nDetails regarding nutritional assessments, counseling techniques, and support services aimed at improving patient health through tailored nutrition plans.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 8,\n",
       "  'section': '## Prevention of Other Infections\\n\\n### 4.8 Prevention of Other Infections\\nGeneral strategies for preventing infections that may affect patient health, with a focus on specific areas.\\n\\n#### 4.8.1 Immunizations\\nInformation on vaccination protocols to protect against infections.\\n\\n#### 4.8.2 Malaria\\nStrategies for the prevention and treatment of malaria.\\n\\n#### 4.8.3 Safe Water, Sanitation and Hygiene\\nGuidelines for ensuring safe water access, sanitation, and hygiene practices to prevent infection.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 8,\n",
       "  'section': '## Adherence Preparation, Monitoring and Support\\n\\n### 5. Adherence Preparation, Monitoring and Support\\nGuidance on supporting patients in adhering to antiretroviral therapy (ART) through preparation and follow-up.\\n\\n#### 5.1 Undetectable = Untransmittable (U=U)\\nExploration of the U=U concept and its implications for patients and healthcare providers.\\n\\n##### 5.1.1 Benefits of U=U\\nAdvantages of understanding and implementing the U=U message in patient care.\\n\\n##### 5.1.2 Considerations for implementation of U=U within clinical settings\\nPractical approaches for integrating U=U into practice.\\n\\n##### 5.1.3 Messaging to Patients on U=U\\nEffective communication strategies to convey U=U to patients.\\n\\n##### 5.1.4 How patients can discuss U=U with others\\nEncouragement for patients to share U=U information within their communities.\\n\\n##### 5.1.5 Counselling patients about other prevention combination interventions\\nAdvice on combining U=U messaging with other preventive measures.\\n\\n##### 5.1.6 Application of U=U in other settings\\nContexts outside clinical care where U=U principles can be applied.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 8,\n",
       "  'section': '### 5.2 ART Adherence Preparation and Support\\nConsiderations for preparation and ongoing support for patients beginning ART.\\n\\n#### 5.2.1 Treatment Preparation as Part of HIV Testing Services\\nIntegration of treatment preparation within HIV testing protocols.\\n\\n#### 5.2.2 ART Treatment Preparation\\nSteps for preparing patients for ART initiation.\\n\\n#### 5.2.3 Age-Specific Treatment Preparation and Support\\nTailored strategies for different age groups regarding ART preparation.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 8,\n",
       "  'section': '### 5.3 Adherence Monitoring, Counselling and Support During the First 3 Months of ART\\nStrategies for ensuring adherence in the initial phase of ART.\\n\\n#### 5.3.1 Adherence Monitoring\\nApproaches to monitor patient adherence effectively.\\n\\n#### 5.3.2 Adherence Counselling and Support During the First 3 Months of ART\\nCounseling techniques specific to the first three months of ART.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 8,\n",
       "  'section': '### 5.4 Adherence Monitoring, Counselling and Support for Patients with Suppressed Viral Load < 200 copies/ml\\nGuidelines for supporting patients who have achieved viral suppression.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 8,\n",
       "  'section': '### 5.5 Adherence Monitoring, Counselling and Support for Patients with Unsuppressed Viral Load ≥ 200 copies/ml\\nInterventions for patients who have not achieved viral suppression.\\n\\n#### 5.5.1 Enhanced Adherence Assessments\\nTechniques for conducting in-depth adherence assessments.\\n\\n#### 5.5.2 Enhanced Adherence Counselling\\nEffective counseling strategies for patients with unsuppressed viral loads.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 8,\n",
       "  'section': '### 5.6 Treatment Preparation for 2nd Line or 3rd Line ART\\nGuidelines for preparing patients for second or third-line ART regimens.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 8,\n",
       "  'section': '### 5.7 Identifying, Tracing, and Supporting Patients who Default from Care\\nStrategies for re-engaging patients who have fallen out of care.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 8,\n",
       "  'section': \"## Antiretroviral Therapy in Infants, Children, Adolescents, and Adults\\n\\n### 6. Antiretroviral Therapy in Infants, Children, Adolescents, and Adults\\nOverview of ART protocols across various age groups.\\n\\n#### 6.1 Eligibility for ART\\nCriteria for determining who is eligible for ART.\\n\\n#### 6.2 Timing of ART Initiation\\nGuidelines on when to initiate ART treatment.\\n\\n#### 6.3 First-Line ART for Infants, Children, Adolescents and Adults (including Pregnant and Breastfeeding Women)\\nRecommended first-line ART regimens based on patient demographics.\\n\\n#### 6.4 Dosing and Administration of Dolutegravir (DTG)\\nInstructions for the proper dosing and administration of Dolutegravir.\\n\\n#### 6.5 Monitoring and Changing ART\\nProtocols for monitoring patients' responses to ART and making necessary adjustments.\\n\\n##### 6.5.1 Optimizing Therapy for Patients who have suppressed viral load on First Line ART\\nStrategies for enhancing therapy for patients who have achieved viral suppression on first-line ART.\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 15,\n",
       "  'section': '## Guidelines Overview\\n\\nKenya HIV Prevention and Treatment Guidelines, 2022 provide comprehensive strategies and recommendations for the prevention and treatment of HIV and its co-infections.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 15,\n",
       "  'section': '## Tables on Childhood Nutrition and TB Management\\n\\n**Table 7.7**: Complementary Foods for Children 6 - 24 Months Old  \\n**Table 8.1**: TB Diagnosis in Children <10 Years Old  \\n**Table 8.2**: Drug Susceptible TB Treatment Regimen for Children, Adolescents, and Adults  \\n**Table 8.3**: Recommended TPT Regimens for PLHIV  \\n**Table 8.4**: Grading and Management of DILI  \\n**Table 8.5**: Management of TPT-Associated Skin Rash  \\n**Table 8.6**: Preferred ART Regimens for TB/HIV Co-infection for Patients Newly Initiating 1st Line ART  \\n**Table 8.7**: Preferred ART Regimens for Patients who Develop TB while Virally Suppressed on 1st Line ART  \\n**Table 8.8**: Recommended ART Regimens for Patients who Develop TB while Failing 1st Line ART'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 15,\n",
       "  'section': '## Hepatitis B and C Co-Infection Management\\n\\n**Table 9.1**: Hepatitis B Vaccination Schedule for HIV-positive Adolescents and Adults  \\n**Table 9.2**: Summary of Initial Clinical and Laboratory Evaluation in HIV/HBV Co-infection  \\n**Table 9.3**: Dose Adjustment of TDF and 3TC in Patients with Impaired Renal Function  \\n**Table 9.4**: Summary of Initial Clinical and Laboratory Evaluation in HIV/HCV Co-infection  \\n**Table 9.5**: Recommended DAA for the Treatment of HCV among PLHIV'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 15,\n",
       "  'section': '## Post-Exposure Prophylaxis (PEP)\\n\\n**Table 10.1**: Recommended ARVs for PEP  \\n**Table 10.2**: Recommendations for PEP Management and Follow-up  \\n**Table 10.3**: Considerations for Special Circumstances'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 15,\n",
       "  'section': '## HIV Screening and Pre-Exposure Prophylaxis (PrEP)\\n\\n**Table 11.1**: HIV Screening Questions  \\n**Table 11.2**: Pre-Initiation Assessment Checklist  \\n**Table 11.3**: Client Education Checklist  \\n**Table 11.4**: Antiretrovirals for Use in PrEP  \\n**Table 11.5**: Initial & Follow-Up Laboratory Tests  \\n**Table 11.6**: Managing Clinical and Laboratory Results on Initial and Follow-Up Assessment  \\n**Table 11.7**: Summary of PrEP Initial and Follow-Up Assessment'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 15,\n",
       "  'section': '## Harm Reduction Strategies\\n\\n**Table 12.1**: Comprehensive Package of Harm Reduction for PWID  \\n**Table 12.2**: Summary of ART Recommendations for PWID'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 7,\n",
       "  'section': '## Initial Evaluation and Follow up\\n\\nThis section covers the initial clinical and laboratory evaluations required for people living with HIV (PLHIV), management of advanced HIV disease, and subsequent follow-up care after ART initiation.\\n\\n### 3.1 Introduction\\nAn overview of the importance of initial evaluations for PLHIV.\\n\\n### 3.2 Initial Clinical Evaluation of PLHIV\\nDetailed guidelines on assessing the clinical status of PLHIV upon diagnosis.\\n\\n### 3.3 Initial Laboratory Evaluation of PLHIV\\nInformation about the necessary laboratory tests to be conducted.\\n\\n### 3.4 Management of Patients Who Present with Advanced HIV Disease\\nStrategies and protocols for managing patients diagnosed with advanced stages of HIV.\\n\\n### 3.5 Follow-up of PLHIV after ART initiation\\nGuidance on the follow-up procedures post-ART initiation.\\n\\n#### 3.5.1 First 6 months after ART initiation\\nKey monitoring practices during the initial six months on ART.\\n\\n#### 3.5.2 Differentiated Service Delivery for Patients beyond the 1st 6 months of ART\\nTailored approaches for PLHIV beyond the first six months of treatment.\\n\\n### 3.6 Summary of clinical and laboratory monitoring of PLHIV on ART\\nA recap of the ongoing monitoring required for PLHIV on ART.\\n\\n### 3.7 Differentiated Care for Children, Adolescents and Pregnant/Breastfeeding Women\\nSpecial considerations for vulnerable populations within the PLHIV community.\\n\\n### 3.8 ART Prescription, Dispensing, and Distribution for clients established on ART\\nProtocols surrounding the prescription and distribution of ART.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 7,\n",
       "  'section': '## Standard Package of Care for PLHIV\\n\\nThis section outlines the standard comprehensive care package for PLHIV, encompassing various health services.\\n\\n### 4.1 Antiretroviral Therapy\\nDetails about the types of ART available and their administration.\\n\\n### 4.2 PHDP, GBV/IPV & HIV Education/Counselling\\nClarity on the importance of education and counseling in managing HIV.\\n\\n#### 4.2.1 Screening for Gender-Based Violence (GBV)/Intimate-Partner Violence (IPV)\\nGuidelines for screening and managing instances of violence.\\n\\n#### 4.2.2 HIV Education/Counselling\\nEducational frameworks designed to inform and empower PLHIV.\\n\\n### 4.3 Specific Opportunistic Infection Screening and Prevention\\nNecessary screenings to prevent opportunistic infections.\\n\\n#### 4.3.1 Cotrimoxazole Preventive Therapy (CPT)\\nProtocols for administering preventive therapy.\\n\\n#### 4.3.2 Tuberculosis (TB) Prevention and Management for PLHIV\\nStrategies for preventing and managing TB in PLHIV.\\n\\n#### 4.3.3 Cryptococcal Meningitis (CM) Screening and Treatment\\nGuidelines for CM-specific screening and intervention.\\n\\n### 4.4 Reproductive Health Services\\nOverview of reproductive health services for PLHIV.\\n\\n#### 4.4.1 Sexually Transmitted Infections\\nManagement protocols for STIs among PLHIV.\\n\\n#### 4.4.2 Family Planning and Pre-Conception Counselling\\nInformation regarding family planning options for PLHIV.\\n\\n#### 4.4.3 Maternal Healthcare\\nGuidelines for pregnant women living with HIV.\\n\\n### 4.5 Non-communicable Diseases Screening and Management\\nInformation about screening for non-communicable diseases in PLHIV.\\n\\n#### 4.5.1 Metabolic Disorders\\nProtocols surrounding the management of metabolic issues.\\n\\n#### 4.5.2 Cancer Prevention, Early Detection and Management among PLHIV\\nBest practices for cancer screening and management in PLHIV.\\n\\n### 4.6 Mental Health Screening and Management\\nFocus on mental health issues prevalent among PLHIV.\\n\\n#### 4.6.1 Depression\\nApproaches to identify and treat depression in PLHIV.\\n\\n#### 4.6.2 Alcohol and Drug Use/Addiction\\nGuidelines for addressing substance abuse.\\n\\n#### 4.6.3 Anxiety\\nManagement strategies for anxiety disorders among PLHIV.\\n\\n#### 4.6.4 Stress and stress management\\nTechniques for managing stress in the context of living with HIV.\\n\\n#### 4.6.5 Experiences of Trauma\\nAddressing trauma-related issues in PLHIV.\\n\\n#### 4.6.6 Psychosis\\nGuidelines for identifying and managing psychosis in HIV patients.\\n\\n#### 4.6.7 Self-Care\\nEncouragement and methods for fostering self-care among PLHIV.\\n\\n#### 4.6.8 Wellbeing\\nPromoting overall wellbeing for individuals living with HIV.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 10,\n",
       "  'section': '## Risk Reduction Counseling\\n\\nThis section discusses the strategies and counseling methods aimed at reducing the risk of HIV exposure. It highlights various behavioral changes, safe practices, and community resources to aid individuals in minimizing their risk.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 10,\n",
       "  'section': '## Preventing HIV Exposure\\n\\nThis section focuses on preventive measures to reduce the chance of HIV infection. It includes information on safe sex practices, needle exchange programs, and other strategies for individuals to protect themselves.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 10,\n",
       "  'section': '## Pre-Exposure Prophylaxis (PrEP)\\n\\nThis section provides an overview of Pre-Exposure Prophylaxis (PrEP), a preventive strategy for individuals at high risk of HIV infection.\\n\\n### Indications for PrEP and Criteria for Eligibility\\n\\nThis subsection outlines who should consider PrEP and the specific criteria used to determine eligibility.\\n\\n### Indications for PrEP\\n\\nDetails the clinical scenarios and populations that can benefit from PrEP.\\n\\n### HIV Risk Assessment\\n\\nDiscusses the evaluation processes to identify individuals at risk of HIV and the corresponding recommendations for PrEP.\\n\\n### Criteria for PrEP Eligibility\\n\\nExplains the specific criteria that must be met for an individual to be eligible for PrEP.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 10,\n",
       "  'section': '## Package of PrEP Service\\n\\nThis section covers the comprehensive set of services provided to individuals starting PrEP, including additional support resources.\\n\\n### Pre-Initiation Checklist\\n\\nA preparatory checklist that individuals and providers can use before starting PrEP.\\n\\n### Pre-Initiation Client Education\\n\\nFocuses on the education materials and sessions provided to new clients prior to initiating PrEP.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 10,\n",
       "  'section': '## Recommended ARVs for PrEP\\n\\nLists the antiretroviral medications recommended for use in PrEP, including their effectiveness and suitability.\\n\\n### Schema for Follow Up for Daily Oral PrEP\\n\\nProvides a schedule and guidelines for regular follow-ups for clients on daily oral PrEP.\\n\\n### Event Driven PrEP (On Demand PrEP or 2+1+1 PrEP)\\n\\nDescribes the alternative event-driven PrEP regimen, detailing recommendations for use.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 10,\n",
       "  'section': '## Managing Clinical and Laboratory Results on Initial and Follow-Up Assessment\\n\\nThis section discusses how to interpret and manage clinical and laboratory results for individuals starting and continuing PrEP.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 10,\n",
       "  'section': '## Contraindications to Oral PrEP\\n\\nLists the medical conditions and situations where oral PrEP should not be prescribed.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 10,\n",
       "  'section': '## Criteria for Discontinuing Oral PrEP\\n\\nOutlines the specific circumstances or health events that may warrant the discontinuation of PrEP.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 10,\n",
       "  'section': '## Restarting PrEP\\n\\nDetails the guidelines and considerations for individuals who wish to restart PrEP after a break.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 10,\n",
       "  'section': '## Improving Adherence to PrEP\\n\\nDiscusses strategies and interventions aimed at helping individuals adhere to their PrEP regimen.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 10,\n",
       "  'section': '## Monitoring Sero-Conversion among PrEP Users\\n\\nCovers the protocols for monitoring HIV sero-conversion in individuals using PrEP.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 10,\n",
       "  'section': '## People Who Inject Drugs (PWID) and HIV\\n\\nThis section explores the unique considerations and challenges faced by people who inject drugs in relation to HIV.\\n\\n### Introduction\\n\\nAn introduction to the specific issues surrounding HIV risks and prevention among PWID.\\n\\n### ART in HIV Positive PWID\\n\\nDiscusses the antiretroviral therapy (ART) management specifically tailored for HIV-positive individuals who inject drugs.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 10,\n",
       "  'section': '## Annexes\\n\\nA comprehensive set of additional resources and materials that complement the main content.\\n\\n### Annex 1: WHO Clinical Staging of HIV Infection in Infants and Children\\n\\nOutlines the classifications of HIV infection stages in younger populations.\\n\\n### Annex 2: WHO Clinical Staging of HIV Infection in Adolescents and Adults\\n\\nDetails HIV infection stages tailored for adolescents and adults.\\n\\n### Annex 3: Normal Developmental Milestones in Children\\n\\nDescribes the developmental milestones for children and how they relate to HIV care.\\n\\n### Annex 4: Tanner Staging of Sexual Maturity in Adolescents\\n\\nFocuses on the Tanner stages, which are used to assess sexual maturity.\\n\\n#### Annex 4 A: Tanner Staging of Sexual Maturity in Girls\\n\\n#### Annex 4 B: Tanner Staging of Sexual Maturity in Boys\\n\\nDetailed staging for sexual maturity specific to each gender.\\n\\n### Annex 5: Age-Appropriate Disclosure for Children and Adolescents\\n\\nGuidelines around how and when to disclose HIV status to younger individuals.\\n\\n### Annex 6: Transitioning from Adolescent to Adult HIV Services\\n\\nProvides a framework for ensuring a smooth transition of care for young people with HIV.\\n\\n### Annex 7: 2018 HIV Testing Services Algorithm\\n\\nAn algorithm designed to guide HIV testing service processes.\\n\\n### Annex 8: HIV Education and Adherence Counselling Content Guide\\n\\nOffers a content guide for educational sessions and adherence counseling.\\n\\n### Annex 9 A: Enhanced Adherence Counselling Content Guide\\n\\nDetailed content for adherence counseling aimed at improving outcomes for individuals on PrEP.\\n\\n### Annex 9 B: Case Summary Form\\n\\nA form template for summarizing individual client cases involved in PrEP.\\n\\n### Annex 9 C: Enhanced Adherence Counselling Form\\n\\nSpecific forms used during adherence counseling sessions.\\n\\n### Annex 9 D: Home Visit Checklist\\n\\nA checklist for healthcare providers conducting home visits to clients on PrEP.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 16,\n",
       "  'section': '## Acronyms and Abbreviations\\n\\nThis section covers various acronyms and abbreviations used in the context of antiretroviral therapy and healthcare related to HIV/AIDS.\\n\\n- **3TC**: Lamivudine\\n- **ABC**: Abacavir\\n- **ATV**: Atazanavir\\n- **ATV/r**: Atazanavir/ritonavir\\n- **AZT**: Zidovudine\\n- **DRV**: Darunavir\\n- **DRV/r**: Darunavir/ritonavir\\n- **DTG**: Dolutegravir\\n- **EFV**: Efavirenz\\n- **ETR**: Etravirine\\n- **FTC**: Emtricitabine\\n- **LPV**: Lopinavir\\n- **LPV/r**: Lopinavir/ritonavir\\n- **NVP**: Nevirapine\\n- **RAL**: Raltegravir\\n- **RTV**: Ritonavir\\n- **TDF**: Tenofovir Disoproxil Fumarate'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 16,\n",
       "  'section': '## Other Acronyms and Abbreviations\\n\\nAdditional acronyms and terms relevant to healthcare and HIV/AIDS management.\\n\\n- **HTS**: HIV Testing Services\\n- **ICF**: Intensified Case Finding\\n- **IEC**: Information, Education and Communication\\n- **INH**: Isoniazid\\n- **INSTI**: Integrase Strand Transfer Inhibitor\\n- **IPD**: In-Patient Department\\n- **IPT**: Isoniazid Preventive Therapy\\n- **IPV**: Intimate Partner Violence\\n- **IRIS**: Immune Reconstitution Inflammatory Syndrome\\n- **ITN**: Insecticide Treated Mosquito Nets\\n- **IUD**: Intrauterine Device\\n- **KEPI**: Kenya Expanded Program of Immunization\\n- **KS**: Kaposi’s Sarcoma\\n- **LEEP**: Loop Electrosurgical Excision Procedure\\n- **L&D**: Labor And Delivery\\n- **LIVES**: Listen, Inquiry, Validate, Enhance Safety and Support\\n- **LLV**: Low Level Viremia\\n- **LRF**: Laboratory Requisition Form\\n- **LP**: Lumbar Puncture\\n- **MAC**: Mycobacterium Avium Complex\\n- **MAT**: Medically Assisted Therapy\\n- **MCH**: Maternal Child Health\\n- **MNCH/FP**: Maternal, Neonatal and Child Health/Family Planning\\n- **MDT**: Multi-Disciplinary Team\\n- **MEC**: Medical Eligibility Criteria\\n- **MOH**: Ministry of Health\\n- **MSM**: Men Who Have Sex with Men\\n- **NACS**: Nutritional Assessment, Counselling and Support\\n- **NCD**: Non-Communicable Diseases\\n- **NHRL**: National HIV Reference Laboratory\\n- **NNRTI**: Non-Nucleoside Reverse Transcriptase Inhibitor\\n- **NRTI**: Nucleoside Reverse Transcriptase Inhibitor\\n- **NSP**: Needle and Syringe Programmes'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 16,\n",
       "  'section': '## Laboratory and Clinical Measures\\n\\nThis section lists laboratory tests and clinical measures relevant to patient management and monitoring.\\n\\n- **ALT**: Alanine Transaminase\\n- **ALP**: Alkaline Phosphatase\\n- **AST**: Aspartate Transaminase\\n- **CrCl**: Creatinine Clearance\\n- **BMI**: Body Mass Index\\n- **BP**: Blood Pressure\\n- **BD**: Twice Daily\\n- **OD**: Once Daily\\n- **A&E**: Accident And Emergency\\n- **ANC**: Antenatal Care\\n- **AHI**: Acute HIV Infection\\n- **ADR**: Adverse Drug Reaction\\n- **AIDS**: Acquired Immunodeficiency Syndrome'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 16,\n",
       "  'section': 'This structure ensures that each section is self-contained and addresses specific topics relevant to a Q&A system.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 19,\n",
       "  'section': '## Introduction to Kenya HIV Prevention and Treatment Guidelines, 2022\\n\\nThis section outlines the key points regarding the guidelines for the prevention and treatment of HIV in Kenya, highlighting the importance of timely care and monitoring for individuals living with HIV (PLHIV).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 19,\n",
       "  'section': '## Monitoring Pregnant and Breastfeeding Individuals\\n\\n- **Timing of Viral Load Testing**: \\n  - At confirmation of pregnancy (if already on ART) or 3 months after ART initiation (if ART is started during pregnancy/breastfeeding).\\n  - Continue testing every 6 months until complete cessation of breastfeeding.\\n  \\n- **Drug Substitution Monitoring**: \\n  - Perform before any drug substitution if no viral load result is available from the prior 6 months.\\n  - Conduct testing three months after any regimen modification (including single-drug substitutions).\\n\\n- **Differentiated Care**: \\n  - PLHIV should receive differentiated care based on initial evaluation (advanced vs. well) and follow-up (established vs. not established on ART).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 19,\n",
       "  'section': '## Standard Package of Care for PLHIV\\n\\nThis section details the components of the standard package of care provided to individuals living with HIV.\\n\\n### 1. Antiretroviral Therapy (ART)\\n- **Eligibility**: All PLHIV are eligible for ART regardless of CD4 cell count, WHO clinical stage, age, pregnancy status, or comorbidities.\\n- **Initiation of ART**: Should be initiated as soon as the patient is ready, preferably within two weeks of HIV diagnosis (exceptions apply to patients with cryptococcal meningitis or TB meningitis).\\n\\n### 2. Positive Health, Dignity, and Prevention\\n- **Counseling**: Patients should receive counseling for HIV status disclosure, partner/family testing and engagement, condom use, family planning, STI screening, treatment adherence, and pre-exposure prophylaxis for HIV-negative partners.\\n- **Screening for IPV**: All females aged 15-49 years and emancipated minors accessing HIV care services should be screened for Intimate Partner Violence (IPV) as part of the care package.\\n- **HIV Education**: All PLHIV should receive education and counseling about HIV.\\n\\n### 3. Screening for and Prevention of Specific Opportunistic Infections\\n- **Cotrimoxazole Preventive Therapy (CPT)**: \\n  - No longer recommended as life-long prophylaxis, but is advised for specific subpopulations unless contraindicated.\\n  \\n- **Target Groups for CPT**:\\n  - All HIV Exposed Infants.\\n  - HIV infected children under 15 years of age.\\n  - All PLHIV over 15 years of age living in malaria-endemic zones or presenting with WHO stage 3 or 4 events or suspected treatment failure.\\n  - Pregnant and breastfeeding women.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 13,\n",
       "  'section': '## HIV Testing Services\\n\\nThis section covers the recommendations for HIV testing services tailored to various populations and settings, along with a summary of the HIV testing services package and presumptive diagnosis of HIV in children under 18 months.\\n\\n- Table 2.1: HTS Recommendations for Different Populations and Settings\\n- Table 2.2: Summary of HIV Testing Services Package\\n- Table 2.3: Presumptive Diagnosis of HIV in children <18 months while awaiting DNA PCR Results'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 13,\n",
       "  'section': '## Linkage to Treatment and Prevention Services\\n\\nThis section discusses approaches to improve linkage to treatment and prevention services for individuals who test positive for HIV and provides recommendations for retesting HIV-negative clients.\\n\\n- Table 2.4: Approaches to Improve Linkage to Treatment and Prevention Services\\n- Table 2.5: Recommendations for Retesting HIV Negative Clients'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 13,\n",
       "  'section': '## Clinical Evaluation and Management of PLHIV\\n\\nThis section details the initial clinical evaluation and baseline laboratory investigations for people living with HIV (PLHIV), as well as differentiated care based on patient presentation and follow-up management.\\n\\n- Table 3.1: Initial Clinical Evaluation for PLHIV (History and Physical Examination)\\n- Table 3.2: Baseline Laboratory Investigations for PLHIV\\n- Table 3.3: Differentiated Care Based on Initial Patient Presentation\\n- Table 3.4: Management of patients who are presenting well: WHO Stage 1 or 2, and CD4 count > 200 cell/mm3\\n- Table 3.5: Differentiated Follow-up of Patients Beyond the First 6 Months of ART\\n- Table 3.6: Summary of Clinical and Laboratory Monitoring for PLHIV'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 13,\n",
       "  'section': '## Standard Package of Care\\n\\nThis section outlines the components of the standard package of care for PLHIV, including domains and components for prevention, health, and drug-related services along with management strategies for various conditions associated with HIV.\\n\\n- Table 4.1: Components of the Standard Package of Care for PLHIV\\n- Table 4.2: Domains and Components for PHDP Services\\n- Table 4.2a: Components of screening for GBV/IPV (LIVES)\\n- Table 4.3: Co-trimoxazole Preventive therapy\\n- Table 4.4: Daily Dose of Cotrimoxazole Preventive Therapy\\n- Table 4.5: Management of Drug-Associated Skin Rash\\n- Table 4.6a: Standard Cotrimoxazole Desensitization Regimen (8 days)\\n- Table 4.6b: Rapid Cotrimoxazole Desensitization Regimen (6 hours)\\n- Table 4.7: Treatment of Cryptococcal Meningitis'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 13,\n",
       "  'section': '## Family Planning and Health Maintenance\\n\\nThis section provides information on contraceptive methods, pre-conception counseling, lifestyle modifications, and screenings for comorbid conditions in PLHIV.\\n\\n- Table 4.8: Contraceptive Methods for PLHIV Based on WHO 2018 Medical Eligibility Criteria\\n- Table 4.9: Pre-Conception Counselling Messages and Services for PLHIV\\n- Table 4.10: Lifestyle Modifications to Prevent and Manage Cardiovascular Disease in PLHIV\\n- Table 4.11: Hypertension Screening, Diagnosis, and Initial Management for Adult PLHIV\\n- Table 4.12: Type 2 Diabetes Mellitus Screening, Diagnosis, and Initial Management for PLHIV\\n- Table 4.12: Dyslipidemia Screening, Diagnosis, and Initial Management for PLHIV\\n- Table 4.13: Chronic Kidney Disease Screening, Diagnosis, and Initial Management for PLHIV'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 13,\n",
       "  'section': '## Mental Health and Addiction Support\\n\\nThis section examines mental health screenings for depression and substance use disorders, along with support strategies based on stages of change.\\n\\n- Table 4.15: Patient Health Questionnaire -9 (PHQ-9) for Depression Screening\\n- Table 4.16: CRAFFT Screening Interview for Adolescents\\n- Table 4.17: CAGE-AID Screening Questions for Adults\\n- Table 4.18: Addiction Support Based on Stages of Change'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 13,\n",
       "  'section': '## Nutritional Assessment\\n\\nThis section focuses on methods for the nutritional assessment of children and pregnant/lactating women, including the interpretation of relevant metrics.\\n\\n- Table 4.19: Interpretation of MUAC Results for Children and Pregnant/Lactating Women\\n- Table 4.20: Interpretation of Z-scores for Children\\n- Table 4.21: Interpretation of BMI Results for Adults'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 13,\n",
       "  'section': '## Immunization Schedule\\n\\nThis section provides details regarding the Kenya Expanded Program on Immunizations and the required vaccination schedule for children.\\n\\n- Table 4.22: Kenya Expanded Program on Immunizations 2016 Schedule'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 20,\n",
       "  'section': '## Summary of Key Recommendations\\n\\n1. **Dapsone Use for PCP Prophylaxis**\\n   - Recommended only for patients in WHO Stage 4 and/or absolute CD4 count ≤ 200 cells/mm³ (or CD4% ≤ 25% for children ≤ 5 years old).\\n   - Should be discontinued once a patient achieves viral suppression and sustained CD4 count of > 200 cells/mm³ (or > 25% for children ≤ 5 years old) for at least 6 months.\\n\\n2. **Screening for TB**\\n   - All PLHIV should be screened for TB at every visit using the Intensified Case Finding (ICF) tool.\\n   - TB Preventive Therapy (TPT) should be assessed if screened negative for TB.\\n\\n3. **Screening for Cryptococcal Infection**\\n   - All adolescent and adult PLHIV with a baseline CD4 count of ≤ 200 cells/mm³ should be screened using the serum CrAg test.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 20,\n",
       "  'section': '## Reproductive Health Services\\n\\n- **STI Screening**\\n  - All PLHIV should be screened for STIs at every clinic visit.\\n\\n- **Pregnancy and Contraception**\\n  - Pregnancy status must be determined for all women of reproductive age at every visit, along with their contraception needs.\\n\\n- **Cervical Cancer Screening**\\n  - All HIV-positive women aged 18-65 years should be screened for cervical cancer (HPV testing every 2 years or annually if using VIA-VILI).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 20,\n",
       "  'section': '## Screening for and Management of Non-Communicable Diseases\\n\\n- **Annual Screening**\\n  - All PLHIV should be screened annually for hypertension, diabetes mellitus, dyslipidaemia, and renal disease.\\n\\n- **Cancer Screening**\\n  - Routine screening should be provided for early detection of cervical cancer, breast cancer, bowel cancer, and prostate cancer.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 20,\n",
       "  'section': '## Mental Health Screening and Management\\n\\n- **Depression and Anxiety Screening**\\n  - Basic screening for depression and anxiety should be conducted before initiating ART, and annually thereafter or whenever there is clinical suspicion.\\n\\n- **Support Structures**\\n  - PLHIV should be linked with support structures to maintain general well-being and address issues affecting mental health.\\n\\n- **Substance Use Screening**\\n  - Adults and adolescents should be screened for alcohol and drug use before initiating ART and regularly during follow-up.\\n  - Caregivers should also receive baseline and follow-up screening for depression and alcohol/drug use.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 20,\n",
       "  'section': '## Nutrition Services\\n\\n- **Nutritional Assessment**\\n  - All PLHIV should receive nutritional assessment, counselling, and tailored support.\\n\\n- **Infant Feeding Guidelines**\\n  - All infants, irrespective of HIV status, should be exclusively breastfed for the first 6 months of life. Timely introduction of appropriate complementary foods should occur after 6 months, with continued breastfeeding up to 24 months or beyond.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 20,\n",
       "  'section': '## Prevention of Other Infections\\n\\n- **Vaccinations**\\n  - PLHIV (including children) should receive vaccinations as recommended by the National Vaccines and Immunization Program.\\n\\n- **COVID-19 Vaccination**\\n  - All PLHIV should receive COVID-19 vaccination following national guidelines for age and dosing.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 25,\n",
       "  'section': '## HIV Testing and Counseling for PWID\\n\\nPeople Who Inject Drugs (PWID) should be offered regular HIV testing and counseling. This ensures they are linked to comprehensive HIV treatment and prevention services, including harm reduction counseling and support.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 25,\n",
       "  'section': '## Recommended First-Line ART for PWID\\n\\nThe recommended first-line Antiretroviral Therapy (ART) for adult PWID is TDF + 3TC + DTG. This combination is vital for effective HIV management in this population.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 25,\n",
       "  'section': '## STI Prevention and Care for PWID\\n\\nPWID should receive screening, diagnosis, treatment, and prevention of Sexually Transmitted Infections (STIs) as part of a comprehensive approach to HIV prevention and care.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 25,\n",
       "  'section': '## TB Services for PWID\\n\\nPWID should have equitable access to TB prevention, screening, and treatment services, similar to other populations at risk of or living with HIV.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 25,\n",
       "  'section': '## Hepatitis Screening for PWID\\n\\nAt first contact, PWID should be screened for Hepatitis B Virus (HBV) using HBsAg and for Hepatitis C Virus (HCV) through HCV serology tests.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 25,\n",
       "  'section': '## Needle and Syringe Programs (NSP)\\n\\nAll PWID should be linked to Needle and Syringe Programs (NSP) to obtain sterile injecting equipment, which reduces the risk of HIV transmission.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 25,\n",
       "  'section': '## Medically Assisted Therapy (MAT) for PWID\\n\\nAll PWID should be linked to Medically Assisted Therapy (MAT) to assist in their treatment and recovery from substance use disorders.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 14,\n",
       "  'section': '## Vaccinations in Adolescents and Adults Living with HIV\\n\\nTable 4.23 provides details about vaccinations specifically designed for adolescents and adults who are living with HIV.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 14,\n",
       "  'section': '## Treatment Preparation and Adherence Counseling\\n\\n### Treatment Preparation and Adherence Counseling Guide\\nTable 5.1 outlines a comprehensive guide for treatment preparation and adherence counseling.\\n\\n### Components of HIV Education\\nTable 5.2 lists the essential components of HIV education, with further details available in Annex 8.\\n\\n### Adherence Support and Retention Interventions\\nTable 5.3 discusses various interventions aimed at supporting adherence and retention in treatment.\\n\\n### ART Readiness Assessment\\nTable 5.4 presents the ART Readiness Assessment Form, a tool to evaluate readiness for antiretroviral therapy.\\n\\n### Age-Appropriate Involvement in Education and Counseling\\nTable 5.5 highlights the involvement of children and adolescents in HIV education and adherence counseling.\\n\\n### Unique Considerations for Caregivers\\nTable 5.6 addresses the unique considerations that caregivers should be aware of when supporting children and adolescents.\\n\\n### Treatment Preparation and Support for Children\\nTable 5.7 details treatment preparation and support strategies for children aged 9 years and younger.\\n\\n### Treatment Preparation and Support for Adolescents\\nTable 5.8 covers treatment preparation and support for adolescents aged 10 to 19 years.\\n\\n### Treatment Preparation and Support for Adults\\nTable 5.9 outlines treatment preparation and support mechanisms tailored for adults.\\n\\n### Adherence Monitoring Strategies\\nTable 5.10 presents various strategies for monitoring adherence to treatment.\\n\\n### Morisky Medication Adherence Scales\\nTables 5.11 and 5.12 provide information on the Morisky Medication Adherence Scales (MMAS-4 and MMAS-8).\\n\\n### Adherence Rate and Monitoring\\nTable 5.13 shows adherence rates based on pill counts.\\n\\n### Initial Adherence Counseling\\nTable 5.14 offers insights into adherence counseling and support during the first three months of ART.\\n\\n### Assessment for Barriers to Adherence\\nTable 5.15 describes methods for assessing barriers to adherence to treatment.\\n\\n### Tailored Adherence Counseling\\nTable 5.16 focuses on adherence counseling and support for patients with a viral load of less than 50 copies/ml.\\n\\n### Viral Load Monitoring\\nTable 5.17 details the cut-offs for viral load monitoring.\\n\\n### Enhanced Adherence Counseling\\nTable 5.18 outlines the components of enhanced adherence counseling sessions, with further content available in Annex 9A.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 14,\n",
       "  'section': '## ART Initiation and Regimens\\n\\n### Timing of ART Initiation\\nTable 6.1 discusses special considerations for the timing of ART initiation.\\n\\n### Preferred First-Line ART Regimens\\nTable 6.2 provides a list of preferred first-line ART regimens and dosing for children, adolescents, and adults.\\n\\n### Alternative ARVs in First-Line Regimens\\nTable 6.3 highlights the use of alternative antiretroviral drugs in first-line regimens.\\n\\n### Dolutegravir Dosing and Administration\\nTable 6.4 provides detailed dosing and administration guidelines for Dolutegravir.\\n\\n### Adverse Drug Reactions\\nTable 6.5 lists common significant adverse drug reactions associated with ART.\\n\\n### Renal and Hepatic Adjustments\\nTable 6.6 discusses adjustments of ARVs, CTX, and Fluconazole in cases of renal and hepatic impairment.\\n\\n### Management of AZT-Associated Issues\\nTable 6.7 focuses on the management of bone marrow suppression associated with AZT.\\n\\n### Drug-Related Hepatotoxicity Management\\nTable 6.8 outlines management strategies for drug-related hepatotoxicity.\\n\\n### Abacavir Hypersensitivity Reaction Management\\nTable 6.9 describes diagnosis and management of abacavir hypersensitivity reactions.\\n\\n### Recommended Second-Line ART Regimens\\nTable 6.10 presents recommended second-line ART regimens in infants, children, adolescents, and adults, excluding TB/HIV co-infection.\\n\\n### Possible Third-Line ART\\nTable 6.11 discusses possible third-line ART options for children, adolescents, and adults.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 14,\n",
       "  'section': '## Antenatal and Infant Care\\n\\n### Essential Package of Antenatal Care\\nTable 7.1 outlines the essential package for antenatal care.\\n\\n### ART Use for HIV Positive Pregnant Women\\nTable 7.2 summarizes the use of ART for HIV positive pregnant and breastfeeding women.\\n\\n### ARV Prophylaxis for HIV-Exposed Infants\\nTable 7.3 details ARV prophylaxis for infants who have been exposed to HIV.\\n\\n### Dosing of ARVs for Infant Prophylaxis\\nTable 7.4 provides dosing instructions for ARVs for infant prophylaxis from birth to 12 weeks of age.\\n\\n### NVP and AZT Dosing for Infants\\nTables 7.5 and 7.6 lay out dosing recommendations for NVP and AZT for infant prophylaxis beyond 12 weeks of age.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 23,\n",
       "  'section': '## HIV Exposed Infants Testing and Treatment\\n\\n- All HIV exposed infants (HEI) should be tested with DNA PCR within 6 weeks of age or first contact thereafter; if negative, then another DNA PCR at 6 months, and if negative again, repeat DNA PCR at 12 months.\\n- All HEI should receive infant ARV prophylaxis, consisting of 6 weeks of AZT + NVP, and thereafter, NVP should be continued until 6 weeks after complete cessation of breastfeeding.\\n- All infants, irrespective of HIV status, should be exclusively breastfed for the first 6 months of life, followed by timely introduction of appropriate complementary foods after 6 months, and continued breastfeeding up to 24 months or beyond.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 23,\n",
       "  'section': '## TB/HIV Co-infection Prevention and Management\\n\\n- All healthcare settings should implement TB infection control recommendations to reduce the risk of transmission of TB among patients, visitors, and staff.\\n- Symptom-based TB screening using the ICF tool MUST be performed for all PLHIV at every clinic visit:\\n  - Patients who screen negative should be assessed for and provided with TB preventive therapy (TPT).\\n  - Patients who screen positive (presumptive TB) must complete definitive diagnostic pathways.\\n- The GeneXpert Ultra MTB/Rif test is the preferred test for diagnosis of TB and rifampicin resistance in all presumptive TB cases.\\n- TB-LAM can be used as an adjunct rapid point-of-care diagnostic test for PLHIV with advanced HIV disease (WHO stage 3 or 4 or CD4 count ≤ 200 cells/mm³ or CD4% ≤ 25% for children ≤ 5 years) and with presumptive TB, or with any danger signs of severe illness, or if currently admitted to hospital.\\n- Patients diagnosed with TB/HIV co-infection should start anti-TB treatment immediately and initiate ART as soon as anti-TB medications are tolerated, preferably within 2 weeks (unless they have TB meningitis, in which case ART should be deferred for 4 to 8 weeks).\\n- Patients with TB/HIV co-infection who are already on ART should start anti-TB treatment immediately and continue ART, making any required adjustments to the ART regimen based on known drug-drug interactions and monitoring toxicity.\\n- Always assess for ART failure in patients who develop TB after being on ART for ≥ 6 months.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 21,\n",
       "  'section': '## Adherence Preparation, Monitoring and Support\\n\\n• The adherence preparation, monitoring, and support that a patient requires should be tailored to their level of adherence and the stage of ART initiation and follow-up.  \\n• All patients with durable viral suppression (2 consecutive viral load results with < 50 copies) should be offered messaging on Undetectable=Untransmittable (U=U).  \\n• Whenever possible, follow-up should be provided by the same care provider or team of care providers (e.g., same clinician and counselor) at every visit. This is particularly important during the first 3 months in care.  \\n• For all children/adolescents, the level of disclosure should be assessed at the first visit. Ongoing care should include a plan for age-appropriate disclosure.  \\n• All patients are at risk of new or worsening barriers to adherence, so adherence monitoring, counseling, and support should continue despite viral suppression.  \\n• Every service delivery point that is providing ARVs for patients (whether ART, PEP, or PrEP) must have a functional system for identifying patients who miss appointments and for taking action within 24 hours of a missed appointment.  \\n• In patients failing ART, do not change regimens until the reasons for treatment failure have been identified and addressed (which should be done urgently using a case-management approach).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 21,\n",
       "  'section': '## Antiretroviral Therapy for Infants, Children, Adolescents, and Adults\\n\\n• The goal of ART is to suppress viral replication with the aim of reducing the patient’s viral load (VL) to undetectable levels (Viral Load <50 copies/LDL).  \\n• All individuals with confirmed HIV infection are eligible for ART, irrespective of CD4 count/%, WHO clinical stage, age, pregnancy or breastfeeding status, co-infection status, risk group, or any other criteria, provided that the individual is willing and ready to start ART.  \\n• ART should be started in all patients as soon as possible, even on the same day as confirming their HIV diagnosis (and preferably within 2 weeks).  \\n• Preferred first-line ART for infants, children, adolescents, and adults:  \\n  - Birth to 4 weeks: AZT + 3TC + NVP  \\n  - > 4 weeks to < 15 years old:  \\n    - < 30 kg: ABC + 3TC + DTG  \\n    - ≥ 30 kg: TDF + 3TC + DTG  \\n  - ≥ 15 years old: TDF + 3TC + DTG  \\n• Children and adolescents who are virally suppressed but are NOT on the preferred first-line ART regimen should be assessed for transition and transitioned to the preferred regimen.  \\n• Treatment failure is suspected when a patient has a VL ≥ 1000 copies/ml after at least 3 months of using ART. Treatment failure is only confirmed when VL is ≥ 1,000 copies/ml after assessing for and addressing poor adherence or other reasons for high VL, and then repeating VL after at least 3 months of excellent adherence to allow for viral re-suppression.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 12,\n",
       "  'section': '## List of Figures\\n\\nThis section lists the figures included in the document, along with their corresponding page numbers. The figures cover various algorithms and management strategies related to health diagnoses and treatments.\\n\\n1. **Figure 2.1**: Algorithm for Early Infant Diagnosis in Infants and Children < 18 months of age — Page 9\\n2. **Figure 2.2**: Birth Testing Algorithm — Page 11\\n3. **Figure 2.3**: HIV Testing Services Algorithm — Page 13\\n4. **Figure 2.4**: Dual HIV/Syphilis Testing Algorithm — Page 15\\n5. **Figure 2.5**: Managing Patients on ART Who Present with a New Negative HIV Antibody Test — Page 20\\n6. **Figure 4.1**: Routine Screening for Cryptococcal Meningitis for HIV-infected Adults and Adolescents — Page 14\\n7. **Figure 4.2**: Generalized Anxiety Disorder Assessment (GAD-7) — Page 32\\n8. **Figure 4.3**: Management of Severe Acute Malnutrition in Children — Page 38\\n9. **Figure 4.4**: Management of Malnutrition in Adults with HIV — Page 39\\n10. **Figure 5.1**: Adherence Preparation, Monitoring and Support until Viral Load after 3 Months on ART — Page 2\\n11. **Figure 5.2**: Adherence Counselling and Education for Patients Preparing to Initiate 2nd Line or 3rd Line ART — Page 34\\n12. **Figure 5.3**: Identifying, Tracing and Supporting Patients who Default from Care — Page 35\\n13. **Figure 6.1**: Optimizing ART Regimens for Children and Adolescents <15 years Weighing < 30 kg on First Line ART — Page 8\\n14. **Figure 6.2**: Optimizing ART Regimens for Children and Adolescents Weighing ≥ 30 kg or ≥ 15 years old on First Line ART — Page 9\\n15. **Figure 6.3**: General Principles for Managing Adverse Drug Reactions — Page 11\\n16. **Figure 6.4**: Managing Single Drug Substitutions for ART — Page 12\\n17. **Figure 6.5**: Managing TDF-Associated Kidney Toxicity — Page 13\\n18. **Figure 6.6**: Viral Load Monitoring of Patients on ART (1st Line or 2nd Line) — Page 18\\n19. **Figure 8.1**: TB Diagnosis - GeneXpert Ultra algorithm — Page 5\\n20. **Figure 8.2**: Use of TB-LAM for Diagnosis of TB among PLHIV — Page 8\\n21. **Figure 11.1**: Package of Service for PrEP — Page 3\\n22. **Figure 11.2**: Schema for Follow-Up for Daily Oral PrEP — Page 7\\n23. **Figure 11.3**: Schema for Event-Driven PrEP — Page 8\\n24. **Figure 11.4**: Schema for Initiation and Follow-Up for Event-Driven PrEP — Page 8'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 12,\n",
       "  'section': '## Algorithms for Diagnosis and Management\\n\\nThis section provides various algorithms aimed at diagnosing and managing health conditions, particularly in the context of HIV and associated complications.\\n\\n- **Figure 2.1**: Details the early diagnosis of HIV in infants and children under 18 months.\\n- **Figure 2.2**: Describes the birth testing algorithm for HIV.\\n- **Figure 2.3**: Outlines the steps for HIV testing services.\\n- **Figure 2.4**: Provides guidance on dual HIV/syphilis testing.\\n- **Figure 4.1**: Discusses routine screening for cryptococcal meningitis in HIV-infected individuals.\\n- **Figure 8.1**: Details the TB diagnosis using the GeneXpert Ultra algorithm.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 12,\n",
       "  'section': '## Patient Management and Treatment\\n\\nThis section focuses on patient management strategies and treatment adherence, particularly related to ART (Antiretroviral Therapy) and malnutrition.\\n\\n- **Figure 2.5**: Managing patients on ART who have a new negative HIV antibody test.\\n- **Figure 5.1**: Offers guidelines for adherence preparation, monitoring, and support.\\n- **Figure 5.2**: Discusses adherence counseling for patients preparing for 2nd or 3rd line ART.\\n- **Figure 5.3**: Describes strategies for identifying and supporting patients who default from care.\\n- **Figure 4.3 and 4.4**: Provide management strategies for severe acute malnutrition in children and adults with HIV, respectively.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 12,\n",
       "  'section': '## Optimizing ART Regimens \\n\\nThis section includes guidance on optimizing ART regimens for specific populations, including children and adolescents.\\n\\n- **Figure 6.1**: Describes ART regimen optimization for children and adolescents weighing less than 30 kg.\\n- **Figure 6.2**: Discusses ART optimization for children weighing 30 kg or more or those aged 15 years and older.\\n- **Figure 6.3 to 6.5**: Offer general principles for managing adverse drug reactions, drug substitutions, and specific kidney toxicity associated with TDF.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 12,\n",
       "  'section': '## TB Diagnosis and Management \\n\\nThis section provides algorithms and schemas pertinent to the diagnosis and management of tuberculosis (TB) among people living with HIV.\\n\\n- **Figure 8.2**: Discusses the use of TB-LAM for the diagnosis of TB in PLHIV.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 12,\n",
       "  'section': '## PrEP Services and Follow-Up\\n\\nThis section covers the package of services and schemas for Pre-Exposure Prophylaxis (PrEP) and follow-up care.\\n\\n- **Figure 11.1**: Provides an overview of the package of services for PrEP.\\n- **Figure 11.2**: Discusses the follow-up schema for daily oral PrEP.\\n- **Figure 11.3 and 11.4**: Provide schemas for event-driven PrEP initiation and follow-up.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 26,\n",
       "  'section': '## HIV Testing Services Overview\\n\\nHIV testing services (HTS) provide the first critical link to comprehensive HIV treatment and prevention services such as voluntary medical male circumcision (VMMC), pre-exposure prophylaxis (PrEP), post-exposure prophylaxis (PEP), and other combination HIV prevention services. This initial step also offers opportunities for additional interventions, including sexual and reproductive health services (SRH), TB screening and referral, and substance abuse screening and referral.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 26,\n",
       "  'section': '## Ethical Considerations in HIV Testing\\n\\nHIV testing should be voluntary and conducted ethically, adhering to the six Cs principles: Consent, Confidentiality, Counselling, Correct results, Connection (linkage) to care, and creating an enabling environment. Targeted HIV testing represents a strategic shift that involves index client listing of contacts, HIV self-testing, and the use of HIV screening tools to identify people at risk of HIV infection who are eligible for testing, with certain exceptions for PMTCT and key populations.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 26,\n",
       "  'section': '## Settings for HIV Testing\\n\\nIn Kenya, HTS is delivered in two broad settings: facility-based and community-based settings.\\n\\n### Facility-based Testing\\n\\n- The HTS screening tool should facilitate the prioritization of testing for persons at risk of HIV infection, including those diagnosed with sexually transmitted infections, individuals with multiple sexual partners, key populations, and those with possible or known HIV exposures.\\n- Providers should conduct thorough risk assessments using validated NASCOP screening tools (Annex 17) to identify clients at risk and those eligible for HIV testing.\\n- HTS should only be offered to clients who consent. Individuals not eligible for testing should receive HIV prevention messages and be offered appropriate services.\\n- Clients who test HIV positive should be linked to care, while those who test negative should be connected to HIV prevention services.\\n- Patients initiating HIV care should receive disclosure counselling and support, alongside offers for family, sexual, and needle-sharing partner testing.\\n\\nAs much as possible, HIV testing services should be integrated into care pathways at all service delivery points, including adult and pediatric inpatient units, outpatient units, maternal and child health clinics, SRH/family planning clinics, TB clinics, specialty clinics, gender-based violence (GBV) care units, and service delivery points for key and priority populations.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 22,\n",
       "  'section': '## Summary of Key Recommendations\\n\\nPersistent low-level viremia (pLLV) is defined as having a viral load (VL) of 200 - 999 copies/ml on two or more consecutive measures. These patients are at increased risk of progression to treatment failure, development of ARV resistance, and death. Therefore, they require a similar case management approach as patients with an initial VL of ≥ 1,000 copies/ml.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 22,\n",
       "  'section': '## Managing Detectable Viral Load\\n\\nAll people living with HIV (PLHIV) with a detectable VL ≥ 200 copies/ml (unsuppressed) should be assessed for and have potential reasons for viremia addressed. This includes:\\n\\n- Intensifying adherence support.\\n- Repeating the VL after 3 months of excellent adherence.\\n\\n### Follow-up Actions\\n\\n- If the repeat VL is < 200 copies/ml (suppressed), routine monitoring may continue.\\n- If the repeat VL is ≥ 1,000 copies/ml (suspected treatment failure), prepare for a change to an effective regimen.\\n- If the repeat VL is between 200 - 999 copies/ml (low-level viremia), reassess adherence and other causes of viremia, and repeat the VL after another 3 months of excellent adherence.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 22,\n",
       "  'section': '## Prevention of Mother-to-Child Transmission\\n\\nPrevention of mother-to-child transmission (PMTCT) of HIV, Syphilis, and Hepatitis B (triple elimination) should be offered as part of a comprehensive package of fully integrated, routine antenatal care interventions.\\n\\n### Testing and Treatment Protocols\\n\\n- All pregnant women, unless known positive, should be counseled and tested for HIV, Syphilis (using the HIV-Syphilis dual test), and HBV during their first antenatal care (ANC) visit. If negative, a repeat HIV-Syphilis dual test should be performed in the third trimester.\\n- Lifelong ART (Antiretroviral Therapy) should be initiated in all pregnant and breastfeeding women living with HIV, regardless of gestational age, WHO clinical stage, or CD4 count.\\n- ART should be started as soon as possible, ideally on the same day HIV diagnosis is made, with ongoing enhanced adherence support.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 22,\n",
       "  'section': '## ART Regimen for Pregnant and Breastfeeding Women\\n\\nThe preferred first-line ART regimen for pregnant and breastfeeding women is TDF + 3TC + DTG.\\n\\n### Monitoring Viral Load\\n\\n- For pregnant and breastfeeding women newly initiated on ART, obtain VL 3 months after initiation, and then every 6 months until complete cessation of breastfeeding.\\n- For HIV positive women already on ART at the time of confirming pregnancy or breastfeeding, obtain a VL irrespective of when prior VL was done, and then every 6 months until complete cessation of breastfeeding.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 22,\n",
       "  'section': '## Management of Unsuppressed Viral Load in Pregnant and Breastfeeding Women\\n\\nFor pregnant or breastfeeding women with a VL ≥ 200 copies/ml (unsuppressed), assess for and address potential reasons for viremia, including:\\n\\n- Intensifying adherence support.\\n- Repeating the VL after 3 months of excellent adherence.\\n\\n### Follow-up Actions\\n\\n- If the repeat VL is < 200 copies/ml (suppressed), continue routine monitoring.\\n- If the repeat VL is ≥ 1,000 copies/ml (treatment failure), prepare for a change to an effective regimen.\\n- If the repeat VL is between 200 - 999 copies/ml (low-level viremia), reassess adherence and other causes of viremia, and consult the Regional or National TWG (Technical Working Group).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 27,\n",
       "  'section': '## Community-Based Testing\\n\\nTargeted community-based HIV testing services (HTS) offer additional opportunities to identify and link people to HIV treatment and prevention. This setting is especially important for testing children and partners of index clients through index testing, as well as outreach to key and priority populations, orphans, vulnerable children (OVCs), adolescents, youth, and targeted testing in workplaces.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 27,\n",
       "  'section': '## HTS Strategies\\n\\nThe major HTS strategies to identify people living with HIV but unaware of their status include:\\n\\n### HIV Self-Testing (HIVST)\\n\\n- **Definition**: HIVST allows individuals to collect their own specimen, perform the test, and interpret the results on their own, either within a health facility, at home, or in any other convenient place.\\n- **Procedure**: HIVST can be conducted with or without direct assistance from a trained person.\\n- **Limitations**: HIVST is a screening test and is not sufficient to make an HIV-positive diagnosis. A reactive (positive) self-test result should be confirmed using the validated national testing algorithm by an HTS-trained service provider.\\n- **Testing Kits**: HIVST should be performed using Ministry of Health approved HIV rapid diagnostic test kits that are either blood-based or oral fluid based.\\n- **Target Populations**: HIVST may have the greatest benefit in reaching specific populations such as partners of newly diagnosed individuals living with HIV (PLHIV), partners of pregnant women attending antenatal care (ANC), contacts of patients treated for STIs, hard-to-reach populations (e.g., men, adolescents, and young people), and key populations (e.g., men who have sex with men and sex workers).\\n\\n**Note**: All reactive (positive) self-test results must be confirmed in a health facility according to nationally set standards.\\n\\n### Index Testing\\n\\nIndex testing, also referred to as partner testing or partner notification services, is an approach whereby the exposed contacts (i.e., sexual partners, biological children, and anyone with whom a needle was shared) of an HIV-positive individual (i.e., index client) are identified and offered HIV testing services.\\n\\n### Voluntary Counselling and Testing (VCT)\\n\\nThis involves the provision of targeted HIV testing to clients who willingly present to HTS facilities for testing for diverse reasons, including self-assessed risk.\\n\\n### Social Network Strategy (SNS)\\n\\nThis involves offering index clients self-guided options to informally extend links to HIV testing and other services to a broader set of social, sexual, and injecting network members who have an elevated risk of HIV infection. The index client for SNS can either be PLHIV or HIV-negative persons with increased risk for HIV infection.\\n\\nProviding targeted HTS for different populations and in different settings increases opportunities for access to knowledge of HIV status and to a range of HIV treatment and prevention services. \\n\\n**Table 2.1** summarizes key recommendations for HTS for different sub-populations.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 17,\n",
       "  'section': '## Abbreviations and Acronyms\\n\\nThis section provides a comprehensive list of abbreviations and acronyms commonly used in the Kenya HIV Prevention and Treatment Guidelines, 2022. Understanding these terms is essential for interpreting the guidelines accurately.\\n\\n- **CHV**: Community Health Volunteer  \\n- **OI**: Opportunistic Infection  \\n- **CITC**: Client-Initiated HIV Testing and Counselling  \\n- **OPD**: Outpatient Department  \\n- **CM**: Cryptococcal Meningitis  \\n- **OST**: Opioid Substitution Therapy  \\n- **CMV**: Cytomegalovirus  \\n- **OVC**: Orphans And Vulnerable Children  \\n- **CNS**: Central Nervous System  \\n- **PCP**: Pneumocystis Jirovecii Pneumonia  \\n- **CPT**: Cotrimoxazole Preventive Therapy  \\n- **PCR**: Polymerase Chain Reaction  \\n- **CrCl**: Creatinine Clearance  \\n- **PEP**: Post-Exposure Prophylaxis  \\n- **CTX**: Cotrimoxazole  \\n- **PrEP**: Pre-Exposure Prophylaxis  \\n- **CYP450**: Cytochrome P450  \\n- **PGL**: Persistent Generalized Lymphadenopathy  \\n- **DAAs**: Direct Acting Antiviral Therapies  \\n- **PHQ-9**: Patient Health Questionnaire - 9  \\n- **DBS**: Dried Blood Spot  \\n- **PHDP**: Positive Health, Dignity, and Prevention  \\n- **DICEs**: Drop-In-Centres  \\n- **PI**: Protease Inhibitor  \\n- **DMS**: Director of Medical Services  \\n- **PITC**: Provider Initiated HIV Testing and Counselling  \\n- **DNA**: Deoxyribonucleic acid  \\n- **PLHIV**: People Living With HIV  \\n- **DOT**: Directly Observed Therapy  \\n- **DS**: Double Strength  \\n- **PML**: Progressive Multifocal Leukoencephalopathy  \\n- **DRT**: Drug Resistance Testing  \\n- **PMTCT**: Prevention of Mother-to-Child Transmission  \\n- **ED-PrEP**: Event Driven PrEP  \\n- **PPE**: Papular Pruritic Eruptions  \\n- **EDTA**: Ethylenediaminetetraacetic Acid  \\n- **PrEP**: Pre-exposure Prophylaxis  \\n- **ECP**: Emergency Contraceptive Pill  \\n- **PTB**: Pulmonary Tuberculosis  \\n- **EID**: Early Infant Diagnosis  \\n- **PWID**: People Who Inject Drugs  \\n- **eMTCT**: Elimination of Mother to Child Transmission  \\n- **NHCSC**: National HIV Clinical Support Centre  \\n- **EPTB**: Extra-Pulmonary Tuberculosis  \\n- **RAST**: Rapid Assessment Tool  \\n- **FDA**: Food and Drug Administration  \\n- **RNA**: Ribonucleic Acid  \\n- **FBC**: Full Blood Count  \\n- **RPR**: Rapid Plasma Reagin  \\n- **FBS**: Fasting Blood Sugar  \\n- **sCrAg**: Serum Cryptococcal Antigen  \\n- **FDC**: Fixed Dose Combination  \\n- **SRH**: Sexual and Reproductive Health  \\n- **FLP**: Fasting Lipid Profile  \\n- **SS**: Single Strength  \\n- **FP**: Family Planning  \\n- **STI**: Sexually Transmitted Infection  \\n- **FTC**: Emtricitabine  \\n- **TB**: Tuberculosis  \\n- **GIT**: Gastro-Intestinal Tract  \\n- **TB LAM**: Tuberculosis Lipoarabinomannan  \\n- **GOK**: Government of Kenya  \\n- **TDF**: Tenofovir  \\n- **GBV**: Gender-Based Violence  \\n- **TT**: Tetanus Toxoid  \\n- **Hb**: Hemoglobin  \\n- **TWG**: Technical Working Group  \\n- **HBV**: Hepatitis B Virus  \\n- **ULN**: Upper Limit of Normal  \\n- **HBsAg**: Hepatitis B Surface Antigen  \\n- **UTI**: Urinary Tract Infection  \\n- **HCV**: Hepatitis C Virus  \\n- **VIA**: Visual Inspection with Acetic Acid  \\n- **HCW**: Health Care Worker  \\n- **VILI**: Visual Inspection with Lugol’s Iodine  \\n- **HEI**: HIV Exposed Infant  \\n- **VL**: Viral Load  \\n- **HIV**: Human Immunodeficiency Virus  \\n- **VMMC**: Voluntary Medical Male Circumcision  \\n- **HIVST**: HIV Self-Testing  \\n- **WHO**: World Health Organization'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 17,\n",
       "  'section': '## Key Concepts in HIV Prevention and Treatment\\n\\nThis section covers fundamental concepts related to HIV prevention and treatment based on the guidelines.\\n\\n1. **HIV Testing**: Important for both individuals and partners, includes Client-Initiated and Provider-Initiated methods.\\n2. **Pre-Exposure Prophylaxis (PrEP)**: A preventive approach for individuals at high risk of contracting HIV, enabling them to stay HIV-free.\\n3. **Treatment of HIV**: Comprehensive antiretroviral therapy aimed at controlling the virus, improving quality of life, and reducing transmission.\\n4. **Opportunistic Infections (OIs)**: Infections that occur more frequently in individuals with weakened immune systems due to HIV.\\n5. **Mother-to-Child Transmission**: Strategies to prevent HIV transmission during childbirth and breastfeeding.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 17,\n",
       "  'section': '## Access to HIV Services\\n\\nThis section discusses the different avenues for accessing HIV services.\\n\\n1. **Healthcare Facilities**: Clinics and hospitals provide essential services, including testing, counseling, and treatment.\\n2. **Community Health Volunteers (CHVs)**: Important players in providing outreach services and education within communities.\\n3. **Drop-In Centers (DICEs)**: Centers specifically designed for people at risk, offering a range of services including counseling and treatment.\\n4. **National Support Services**: Initiatives led by the Government of Kenya and NGOs to enhance healthcare delivery for those affected by HIV.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 17,\n",
       "  'section': '## Guidelines for Healthcare Workers\\n\\nGuidelines for healthcare workers on the best practices for HIV prevention and management.\\n\\n1. **Informed Consent**: Ensuring that clients understand the importance of testing and counseling.\\n2. **Confidentiality**: Maintaining privacy and trust in handling sensitive health information.\\n3. **Continued Education**: Ongoing training to keep healthcare workers updated on the latest guidelines and treatment options.\\n4. **Referral Systems**: Establishing effective networks for referring patients needing specialized care or treatment.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 17,\n",
       "  'section': '## Conclusion\\n\\nSummarizes the importance of comprehensive HIV prevention and treatment guidelines for improving health outcomes in Kenya.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 24,\n",
       "  'section': '## HBV/HIV and HCV/HIV Co-infection Prevention and Management\\n\\n• All HIV positive adolescents and adults should be screened for HBV infection, using serum HBsAg, as part of initial evaluation; children who did not complete routine childhood immunizations should also be screened for HBV and vaccinated if negative.  \\n• PLHIV without evidence of hepatitis B infection (HBsAg negative) should be vaccinated against hepatitis B.  \\n• The recommended first-line ART for adults with HIV/HBV co-infection is TDF + 3TC + DTG.  \\n• HCV serology should be offered to individuals at risk of HCV infection.  \\n• Direct acting antiviral therapies (DAAs) for treatment of HCV have simplified the management of HIV/HCV co-infection.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 24,\n",
       "  'section': '## ARVs for Post-exposure Prophylaxis (PEP)\\n\\n• PEP should be offered as soon as possible (< 72 hours) after high-risk exposure.  \\n• The recommended ARV agents for PEP are:  \\n  - **<15 years old**  \\n    - < 30 kg: ABC + 3TC + DTG  \\n    - ≥ 30 kg: TDF + 3TC + DTG  \\n  - **≥ 15 years old**  \\n    - TDF + 3TC + DTG'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 24,\n",
       "  'section': '## Pre-Exposure Prophylaxis (PrEP)\\n\\n• PrEP should be offered to HIV negative individuals at substantial ongoing risk of HIV infection (including the seronegative partner in a discordant relationship).  \\n• PrEP works if taken as prescribed, but it does not prevent other STIs or unintended pregnancies; therefore, additional protection should be offered.  \\n• PrEP should only be offered to clients ≥15 years of age who are sexually active after eligibility assessment using the following parameters:  \\n  - **Laboratory**: HIV negative  \\n  - **Medical** (for oral PrEP): no contraindication to TDF; no severe renal diseases; weight ≥ 30 kg  \\n  - **Client readiness**: client must be willing to take PrEP as prescribed and adhere to associated follow-up and HIV testing (at enrollment, at month 1, and thereafter every 3 months).  \\n• The recommended ARV regimen for Oral PrEP is TDF/FTC (alternative TDF/3TC), available in two dosing strategies:  \\n  - **Daily oral PrEP**: TDF (300 mg) + FTC (200 mg) once daily.  \\n  - **Event-driven PrEP**: Event-driven PrEP is where oral PrEP is used in men having sex with men when an isolated sexual act is anticipated. The dose is two pills of TDF/FTC taken between 2 and 24 hours (preferably closer to 24h) before the anticipated sexual act; then, a third pill taken 24 hours after the first two pills; and then a fourth pill taken 24 hours after the third pill (“2+1+1”).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 33,\n",
       "  'section': '## Kenya HIV Prevention and Treatment Guidelines, 2022\\n\\nOverview of the Kenyan guidelines for HIV prevention and treatment, focusing on their importance and updates for effective management.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 33,\n",
       "  'section': '## Age-Specific HIV Testing Algorithms\\n\\nDescription of the algorithms used for HIV testing specific to different age groups.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 33,\n",
       "  'section': '## Early Infant Diagnosis\\n\\nDetails on the processes involved in diagnosing HIV in infants, particularly those exposed to HIV.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 33,\n",
       "  'section': '## Confirmation of HIV Infection in HIV Exposed Infants and Children < 18 Months Old\\n\\nInformation on the confirmation procedures for HIV infection in infants and children under 18 months, including the timing and types of tests to be conducted.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 33,\n",
       "  'section': '## Testing Protocols for HIV Exposed Infants (HEIs)\\n\\nRecommendations for testing HIV exposed infants, including:\\n- Initial testing with DNA PCR at 6 weeks of age.\\n- Follow-up testing schedules (6 months, 12 months).\\n- Additional testing for symptomatic infants.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 33,\n",
       "  'section': '## Antibody Testing for HIV Exposed Infants\\n\\nGuidelines on performing antibody tests for all HIV exposed infants at 18 months of age, during breastfeeding, and after breastfeeding cessation.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 33,\n",
       "  'section': '## Summary of Testing Recommendations\\n\\nA summary of the necessary steps and timing for diagnosing HIV in infants and children under various circumstances, highlighting the importance of regular testing.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 28,\n",
       "  'section': '## HIV Testing for Infants Born to HIV-Positive Mothers\\n\\nBirth testing (HIV testing of infants at birth or at first contact within 2 weeks after birth) can be conducted where feasible and in settings where return of results is feasible within 24 hours and ART can be initiated immediately. Infants tested at birth must be tested at the 6-week immunization visit regardless of the results of the initial test at birth.\\n\\n- Infants with an initial positive HIV DNA PCR result should be presumed to be HIV infected and started on ART in line with national guidelines, with a new sample for confirmatory HIV DNA PCR and baseline viral load taken at the time of ART initiation.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 28,\n",
       "  'section': '## HIV Testing for Infants and Children Under 18 Months\\n\\n- HIV exposure status of all infants should be established at first contact.\\n- To establish HIV exposure status of a child less than 18 months of age, conduct HIV antibody testing for mothers with unknown status or who previously tested negative during antenatal care at the 6-week immunization visit or first contact. If the mother declines to be tested or is not available for testing, conduct a rapid HIV antibody test for the child. \\n- When HIV exposure is confirmed, ARV prophylaxis should be started immediately.\\n- All HIV-exposed infants (HEIs) should have DNA PCR testing at the 6-week immunization visit or first contact thereafter. \\n- Infants with an initial positive HIV DNA PCR result should be presumed to be HIV infected and started on ART according to national guidelines.\\n- HEIs with initial HIV negative results should continue infant ARV prophylaxis and be monitored, including additional PCR testing at 6 months and 12 months, and antibody testing at 18 months and every 6 months during breastfeeding.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 28,\n",
       "  'section': \"## HIV Testing for Children Aged 18 Months to 9 Years\\n\\n- Conduct HIV testing and counselling for all children of adults living with HIV as soon as possible after confirming the adult's HIV positive status. \\n- Testing should be conducted in health facilities, at inpatient wards, nutrition clinics, and all high HIV burden settings.\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 28,\n",
       "  'section': '## HIV Testing for Adolescents and Young People (10 - 24 Years)\\n\\n- Targeted HIV testing services should be offered to adolescents and young people who are screened and found eligible for HIV testing. \\n- HIV prevention services should be provided to clients who test negative, while those who test positive should be linked to HIV care.\\n- Adolescents aged above 10 years need written consent from a parent or guardian and are also required to give assent. \\n- Emancipated minors can give their own consent regardless of age.\\n- All adolescents should receive counselling about the benefits and risks of disclosing their HIV status, empowering them to decide if, when, how, and to whom to disclose.\\n- For sexually active adolescents, HIV testing and counselling should be offered to their partners and children where appropriate.\\n- Uncircumcised adolescent males who test HIV negative should be counselled about the prevention benefits of Voluntary Medical Male Circumcision (VMMC) and linked to VMMC services if they agree.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 31,\n",
       "  'section': '## HIV Testing Services Overview\\n\\nThe document outlines the components of HIV Testing Services (HTS), detailing the process of delivering testing services to individuals and couples. Key aspects include the objectives of pre-test counselling, the testing process, and post-test support.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 31,\n",
       "  'section': '## Pre-Test Counselling\\n\\nPre-test counselling may be provided to an individual or a couple presenting for HIV Testing Services (HTS). Group information can also be offered during pre-test sessions. The objectives include:\\n\\n- Providing information on the benefits of knowing one’s HIV status, including outcomes for people on ART and the concept of undetectable = Untransmittable (U=U).\\n- Explaining the HIV testing process, including session duration, confidentiality, and test result interpretation.\\n- Obtaining informed consent for HIV testing.\\n- Exploring the client’s risk of HIV infection.\\n- Discussing the importance of disclosure to partners and family members.\\n- Explaining the benefits of couple testing and partner services/index testing.\\n- Providing information about available post-test services, including referrals for prevention or HIV care services.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 31,\n",
       "  'section': '## Goals of HIV Testing\\n\\nThe primary goals of HIV testing include:\\n\\n- Providing an accurate HIV diagnosis as per the nationally approved testing algorithm.\\n- Ensuring same-day HIV test results.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 31,\n",
       "  'section': '## During the Waiting Period\\n\\nWhile clients await test results (approximately 15 minutes), healthcare providers should:\\n\\n- Discuss Combination Prevention methods, including PrEP, PEP, Risk Reduction, STI treatments, condom usage, Voluntary Medical Male Circumcision (VMMC), and Elimination of Mother to Child Transmission (eMTCT).\\n- Screen and provide information and referrals for Intimate Partner Violence (IPV), STI and cancer screenings, Tuberculosis (TB), and family planning/contraceptive needs.\\n- Establish the number of sexual contacts and biological children for index testing purposes.\\n- Document in the HTS, Lab, referral, and linkage register (MOH 362).\\n\\nIn cases where clients test positive, further discussions on index testing and HIV Self-Testing (HIVST) should follow.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 31,\n",
       "  'section': \"## Post-Test Counselling\\n\\nPost-test counselling should involve the following steps:\\n\\n- Checking if the client is ready to receive their test results and assisting them with interpretation.\\n- Ensuring the client understands the results.\\n- Allowing the client to express their initial reactions and feelings.\\n- Exploring and acknowledging the client’s immediate feelings and concerns.\\n- Offering necessary support based on the client's emotional needs.\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 29,\n",
       "  'section': '## HIV Testing for Pregnant and Breastfeeding Women\\n\\n- During the first ANC visit, HIV testing of pregnant women should be done using a dual test for HIV and syphilis, unless the woman is known to be living with HIV.  \\n- Women who test negative for both HIV and syphilis should be offered a repeat HIV-syphilis dual test in the third trimester.  \\n- Prevention services should be offered to all pregnant and breastfeeding women who test HIV negative. They should be screened for eligibility and willingness for PrEP.  \\n- At labor and delivery, HIV testing should be done for all women with unknown HIV status and those who previously tested negative (even if tested negative in the third trimester).  \\n- All breastfeeding mothers (unless known HIV positive) should be counselled and tested at the 6-week infant immunization visit. The HIV test (if negative) should be repeated every 6 months until complete cessation of breastfeeding.  \\n- For mothers considered to be at high risk of HIV infection, retesting postnatally should be done every 3 months. These include mothers categorized as key populations, in an HIV discordant relationship, or having ongoing sexual or injecting behavior that places her at risk, including new or multiple sexual partners.  \\n- Mothers should be counselled on the schedule for repeat HIV testing in pregnancy and postnatal as part of routine ANC and postnatal education.  \\n- All pregnant and breastfeeding women who are not tested, opt-out, or decline HIV testing during the first contact should be offered HIV counselling and testing in subsequent visits with appropriate referral and linkage for prevention, care, and support services.  \\n- All HIV positive pregnant and breastfeeding women enrolled in care should receive counselling and support (assisted disclosure), case management, and follow-up, including linkage to general care for ANC, delivery, and post-natal care.  \\n- All spouses/partners as well as children of pregnant and breastfeeding women testing HIV positive should be offered HIV testing and counselling.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 29,\n",
       "  'section': '## HIV Testing for Sexual Partners and Children of Index Clients\\n\\n- All people living with HIV (PLHIV) enrolled in HIV care should receive disclosure counselling and be supported to disclose their HIV status (assisted disclosure).  \\n- HIV testing and counselling (facility-based or community-based) should be encouraged for all partners, including sexual partners, needle-sharing partners, and children of index clients, with appropriate linkage to treatment and prevention services.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 30,\n",
       "  'section': '## HIV Testing for Key and Vulnerable Populations\\n\\n- Conduct HIV testing and counselling for all clients from key and vulnerable populations presenting to the health facility, regardless of the reason for their visit, or through targeted outreach at service delivery points (e.g., drop-in centers).\\n- Key populations that test negative should be retested quarterly.\\n- Link all who test HIV positive to treatment and prevention services.\\n- Recommend prevention services, including consistent and correct use of condoms and the use of sterile needles and syringes. Screen for eligibility and willingness for PrEP.\\n- Counsel all uncircumcised males who test HIV negative on the prevention benefits of Voluntary Medical Male Circumcision (VMMC) and link them to VMMC services if they consent.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 30,\n",
       "  'section': '## Targeted HIV Testing and Counselling for Adults\\n\\n- Offer HIV Testing Services (HTS) to all adults eligible for testing and encourage them to know their HIV status and that of their partners.\\n- Recommend re-testing for those who test negative if there is a new risk exposure.\\n- Counsel HIV positive adults for immediate Antiretroviral Therapy (ART) initiation.\\n- Link all adults identified as HIV positive to treatment and prevention services.\\n- Provide HIV prevention messages and services to clients who are not eligible for testing.\\n- Counsel all males who test HIV negative on the prevention benefits of VMMC and link them to VMMC services if they consent.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 30,\n",
       "  'section': '## Package of HIV Testing Services\\n\\nAn HIV testing and counselling session consists of:\\n- A pre-test session\\n- HIV testing\\n- Assessment for other health-related conditions or needs (while HIV tests are running)\\n- A post-test session (including index testing)\\n- Referral and linkage to other appropriate health services (as part of the post-test session)\\n\\nThe HIV testing service package is summarized in Table 2.2.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 38,\n",
       "  'section': '## HIV Testing Services Overview\\n\\nThis section provides an overview of the HIV testing services and the process of linkage to treatment and prevention. It encompasses various testing protocols, including the interpretation of test results.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 38,\n",
       "  'section': '## HIV Test Results Interpretation\\n\\nThis section outlines the interpretation of results from different HIV tests (A1, A2, A3). The outcomes are categorized into three types: Non-Reactive, Reactive, and Inconclusive. \\n\\n- **Non-Reactive**: Indicates no evidence of HIV infection.\\n- **Reactive**: Requires further validation or action.\\n- **Inconclusive**: Indicates uncertainty, requiring a retest in 14 days.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 38,\n",
       "  'section': '## Reporting of HIV Test Results\\n\\nThis section details how different test results influence reporting:\\n\\n- **Non-Reactive Results**: Report as negative.\\n- **Reactive Results**: Refer to the second tester at CCC/MCH.\\n- **Inconclusive Results**: Advise retest in 14 days. If retest is still inconclusive, report as HIV-negative and recommend retesting after 3 months.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 38,\n",
       "  'section': '## Recommendations for HIV Testing Procedures\\n\\nThis section stipulates important recommendations regarding testing procedures:\\n\\n- The use of DNA PCR as a supplemental assay is no longer recommended.\\n- Follow-up protocols for individuals with inconclusive results.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 38,\n",
       "  'section': '## Summary of Testing Algorithms\\n\\nThis section summarizes the HIV Testing Services Algorithm, outlining the flow from initial testing through to final results, emphasizing the need for follow-up based on different test outcomes.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 32,\n",
       "  'section': '## HIV Testing Services Overview\\n\\nThis section encompasses the processes and recommendations involved in HIV testing services, focusing on both negative and positive results.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 32,\n",
       "  'section': '## Negative Result Management\\n\\n- Explain test results and review the implications of being HIV negative.\\n- Support clients in developing a risk reduction plan (refer to the HTS operational manual).\\n- Provide information on methods to prevent HIV acquisition.\\n- Distribute male and/or female condoms, lubricant, and guidance on proper usage.\\n- Emphasize the importance of knowing the status of sexual partners and the availability of partner and couples testing services.\\n- Refer clients to relevant HIV prevention services.\\n- Explain the need for repeat testing for individuals who test negative but report risky behavior within the prior 4 weeks (e.g., unprotected sex). Advise them to return for testing every 3 months if they continue to be at risk.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 32,\n",
       "  'section': '## Positive Result Management\\n\\n- Review the implications of being HIV positive.\\n- Help the client cope with emotions stemming from the diagnosis.\\n- Discuss immediate concerns and identify potential social support within the client’s network.\\n- Provide guidance on positive living.\\n- Share clear information on ART (antiretroviral therapy) and its benefits for health maintenance and reducing HIV transmission risk.\\n- Refer clients who test HIV positive to a care and treatment center (CCC) for linkage to treatment.\\n- Revisit index testing and HIV self-testing (HIVST) to determine a partner notification plan.\\n- Discuss the risks and benefits of disclosing HIV status to partners and offer couples counseling for mutual disclosure.\\n- Encourage testing for sexual partners, injecting partners, biological children, and other family members through various testing methods.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 32,\n",
       "  'section': '## Health Assessments and Care Referral\\n\\n- Assess risks for sexually transmitted infections (STIs) and opportunistic infections that require management.\\n- Ensure proper referral and linkage to care.\\n- Gather accurate locator information from index clients (including physical location and phone number).\\n- Physically escort the client for re-testing and linkage to ART.\\n- Document the outcomes of partner follow-up(s).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 32,\n",
       "  'section': '## Post-Test Counseling\\n\\nPost-test counseling should include essential messages that prepare individuals living with HIV (PLHIV) for ART treatment:\\n\\n- Treatment (antiretroviral therapy or ART) is available and is recommended for everyone with HIV.\\n- Starting treatment as soon as possible (preferably within two weeks of testing positive) reduces deterioration of health and the risk of HIV transmission. Adhering to ART can lead to a long and productive life.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 40,\n",
       "  'section': '## HIV Testing Services Overview\\n\\nThis section provides information on the various HIV testing services, specifically focusing on HIV Test A1, which includes multiple testing outcomes including negative, reactive, and inconclusive results.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 40,\n",
       "  'section': '## Testing Results Interpretation\\n\\nThis part details the interpretation of different results:\\n- **Non-Reactive Results**: Indicates a negative HIV status.\\n- **Reactive Results**: Indicates a positive HIV status and the need for further action.\\n- **Inconclusive Results**: Requires retesting in 14 days to confirm status.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 40,\n",
       "  'section': '## Follow-Up Procedures for Positive Results\\n\\nThis section describes the necessary steps following a reactive test result:\\n- Report the individual as HIV positive and refer them to the second tester at CCC/MCH.\\n- Treatment initiation recommendation and optional further testing for syphilis.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 40,\n",
       "  'section': '## Retesting Protocols\\n\\nThis section outlines the protocols for inconclusive results:\\n- If the status remains the same upon retesting after 14 days, the individual should be reported as HIV negative.\\n- Recommendations for retesting after three months are provided.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 40,\n",
       "  'section': '## Important Notes\\n\\nThis section includes crucial information regarding testing methodologies:\\n- The use of DNA PCR as a supplemental assay is no longer recommended for HIV testing.\\n- Emphasis on accurate interpretation and timely follow-up.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 36,\n",
       "  'section': '## HIV Testing Services and Linkage to Treatment and Prevention\\n\\nThis section outlines the procedures for testing infants of known HIV-positive mothers immediately after birth and the necessary follow-up actions based on test results.\\n\\n- **Infant of known HIV positive mothers at birth (or within 2 weeks of birth)**\\n  - Collect DBS for DNA PCR.\\n  - Start infant ARV prophylaxis immediately after birth.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 36,\n",
       "  'section': '## Testing Outcomes for HIV DNA PCR\\n\\nThis section covers the guidelines based on the HIV DNA PCR test outcomes for infants born to HIV-positive mothers.\\n\\n- **HIV DNA PCR Positive**\\n  - Initiate ART immediately.\\n  - Book for follow-up at 2 weeks of age.\\n  - Offer comprehensive care for HIV-infected children.\\n\\n- **HIV DNA PCR Negative**\\n  - Continue infant ARV prophylaxis and follow up for HIV-exposed infants.\\n  - Repeat DNA PCR test at 6 weeks following the EID algorithm.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 36,\n",
       "  'section': '## Confirmatory Testing and Management\\n\\nThis section provides details on the management of infants based on confirmatory test results.\\n\\n- **Confirmatory DNA PCR Positive / Detectable Viral Load**\\n  - Continue ART.\\n  - Provide comprehensive care.\\n\\n- **Confirmatory DNA PCR Negative**\\n  - Continue ART.\\n  - Collect DBS for repeat PCR at 6 weeks and manage as per EID algorithm.\\n  - Collect new sample and send to NHRL. Manage as per NHRL results.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 36,\n",
       "  'section': '## Point of Care Testing for Children\\n\\nThis section discusses the use of point-of-care testing for the early diagnosis of HIV in infants.\\n\\n- **Use of Point-of-Care Testing**\\n  - Point-of-care testing occurs at the health facility where care is being provided.\\n  - Results are returned to the patient or caregiver on the same day as sample collection.\\n  - Point-of-care DNA PCR testing for early infant diagnosis can reduce turnaround time for testing and return of results.\\n  - Allows immediate initiation of ART among infants.\\n  - Used to diagnose HIV infection and to confirm positive results.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 35,\n",
       "  'section': '## Presumptive Diagnosis of Severe HIV Disease in Children under 18 Months\\n\\nOccasionally, children less than 18 months of age present to hospital with severe illness; and a rapid HIV antibody test confirms HIV exposure. Lack of immediate availability of HIV DNA PCR results for confirmation of HIV could result in undue delay in starting life-saving ART. In such children, a presumptive diagnosis of HIV infection can be made using the criteria in Table 2.3. ART can be initiated while awaiting HIV DNA PCR results to confirm HIV infection.\\n\\n**Table 2.3: Presumptive Diagnosis of HIV in children <18 months while awaiting DNA PCR Results**\\n- HIV antibody test positive AND symptomatic with 2 or more of the following:\\n  - Oral candidiasis/thrush\\n  - Severe pneumonia\\n  - Severe sepsis\\n- OR any of the following:\\n  - Any WHO Clinical Stage 4 condition\\n  - Recent maternal death (if likely to have been HIV-related) or advanced HIV disease in mother\\n  - Child’s CD4% < 25%'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 35,\n",
       "  'section': '## Birth Testing\\n\\nBirth testing is defined as HIV testing (with DNA PCR) at birth or around birth for infants born to HIV-positive mothers. Birth testing has the potential to improve survival for infants who are infected during pregnancy, around labor, and delivery by identifying them early for rapid ART initiation. Do not use cord blood for birth testing as this could result in false positive results. A DNA PCR test can be offered at birth or around birth where feasible.\\n\\nALL children initially tested at birth should be retested at 6 weeks of age and the EID algorithm followed.\\n\\n### Considerations for Providing Birth Testing:\\nBirth testing may be prioritized for newborns who are at high risk of HIV acquisition including those born to:\\n- Mothers who seroconvert during pregnancy.\\n- Mothers who have unsuppressed or unknown viral loads during delivery.\\n- Mothers who received a HIV positive diagnosis for the first time at or after 28 weeks gestation or during labor and delivery.\\n- Mother on ART for less than 12 weeks prior to delivery.\\n\\nBirth testing should be offered where this is feasible:\\n- DNA PCR results can be returned the same day (e.g., where on-site point of care is available).\\n- ART regimens recommended for neonates as per national guidelines are available and can be initiated immediately.\\n- Follow-up of the newborn is done to ensure no loss to follow-up.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 34,\n",
       "  'section': '## HIV Testing for Infants and Children\\n\\nThis section provides guidelines for establishing HIV infection in infants and children under 18 months. It outlines the steps to take when the mother’s HIV status is known or unknown.\\n\\n### Key Steps\\n- For mothers with known HIV, initiate HIV testing services (HTS) for infants.\\n- For mothers with unknown HIV status, perform HTS to ascertain maternal HIV status.\\n- Conduct a rapid antibody test on the infant/child if maternal HIV status cannot be determined.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 34,\n",
       "  'section': '## Early Infant Diagnosis Protocol\\n\\nThis section details the protocols for diagnosing HIV in infants at 6 weeks or during the first contact, including necessary tests and treatment initiation.\\n\\n### Actions at 6 Weeks or First Contact\\n- Collect a dried blood spot (DBS) for HIV DNA PCR testing.\\n- Start or continue ARV prophylaxis for the infant.\\n- Initiate Cotrimoxazole Preventive Therapy (CPT).\\n\\n#### Follow-up based on HIV DNA PCR Results\\n- **Negative Result**: Continue follow-up for HIV-exposed infant (HEI).\\n- **Positive Result**: Assume HIV infection and discontinue ARV prophylaxis, start ART, offer comprehensive care, and collect samples for further testing.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 34,\n",
       "  'section': '## Confirmatory Testing for HIV\\n\\nThis section covers the steps for confirming HIV infection in children based on follow-up testing.\\n\\n### Confirmatory Testing Steps\\n1. If HIV DNA PCR is positive, continue ART and comprehensive care.\\n2. If HIV DNA PCR is negative, continue ART and collect a DBS sample for further laboratories.\\n\\n### Code for Follow-up\\n- Continue routine follow-up with HIV-exposed infants based on results and symptoms as per WHO criteria.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 34,\n",
       "  'section': '## Long-term Follow-up and Care \\n\\nThis section outlines the plans for routine care of HIV-exposed children as they grow.\\n\\n### Actions Based on HIV Antibody Tests\\n- Conduct HIV antibody test at 18 months of age.\\n- If breastfeeding, test every 6 months during breastfeeding and up to 6 weeks after complete cessation.\\n\\n#### Outcomes of Antibody Tests\\n- **Negative Result**: Stop CPT, review at age 2, and continue routine under-5 care.\\n- **Positive Result**: Confirm HIV infection, start comprehensive care, and continue CPT.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 34,\n",
       "  'section': '## Testing and Laboratory Procedures\\n\\nThis section discusses the laboratory processes involved in HIV testing for infants and children and the logistics regarding sample collection.\\n\\n### Laboratory Requirements\\n- Use the whole blood for EID at point of care when available.\\n- For baseline viral load testing, utilize point-of-care machines if available; otherwise, send plasma samples to the relevant laboratory for analysis.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 34,\n",
       "  'section': '## Algorithm for Early Infant Diagnosis\\n\\nThis section provides a visual representation (referred to as Figure 2.1) of the steps involved in the early infant diagnosis process for children under 18 months. \\n\\n### Note\\nAdditional details regarding the algorithm may include specifics on timing, methods, and expected outcomes based on different test results.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 37,\n",
       "  'section': '## HIV Diagnosis in Older Children, Adolescents, and Adults\\n\\nSerial testing using approved rapid HIV antibody testing kits is utilized to diagnose HIV infection in individuals aged 18 months and older. An HIV-positive diagnosis requires three consecutive reactive assays to maintain a Positive Predictive Value (PPV) of at least 99%, thereby minimizing false positives.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 37,\n",
       "  'section': '## Consent Requirements for HIV Testing\\n\\nAll clients must be adequately informed about the test and provide consent prior to testing. Verbal consent is sufficient and must be documented. For children under 14 years not considered emancipated minors, written consent from a guardian is recommended. Individuals aged 15 years and older, as well as emancipated minors, can provide self-consent.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 37,\n",
       "  'section': '## Post-Test Procedures for Positive and Negative Results\\n\\nClients testing positive must be linked to care and treatment, with counseling support and options for index and family testing offered. Clients who test negative should receive counseling on HIV risk reduction behaviors and be connected to combination HIV prevention services based on individual risk profiles.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 37,\n",
       "  'section': '## HIV Testing Algorithm Overview\\n\\nThe testing algorithm for individuals over 18 months involves three distinct assays. Initial testing occurs with Assay 1 (A1). If the result is non-reactive (A1−), the individual is considered HIV-negative. If reactive (A1+), subsequent testing on Assay 2 (A2) is carried out. A positive diagnosis is confirmed with three reactive results (A1+, A2+, A3+). Nonreactive results on Assay 3 (A1+, A2+, A3−) result in an inconclusive status, requiring retesting in 14 days.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 37,\n",
       "  'section': '## Handling Inconclusive and Negative Results\\n\\nFor individuals who test A1+ but A2−, a repeat of Assay 1 is required. If the repeat result is non-reactive, the individual is reported as HIV-negative. If it remains reactive, the status is recorded as HIV-inconclusive, and retesting is advised after 14 days. Clients with confirmed positive results are referred to a Comprehensive Care Clinic for further testing before ART initiation.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 37,\n",
       "  'section': '## Implementation of the Testing Algorithm\\n\\nThe three-test algorithm will only be implemented following the identification of the specific assay. Until then, the current algorithm will remain in use, with additional guidance to be provided before the new protocol is enacted.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 39,\n",
       "  'section': '## Results Interpretation\\n\\nResults interpretation of HIV testing includes the following classifications:\\n\\n- **HIV-NEGATIVE:** A1- \\n- **HIV-POSITIVE:** A1+; A2+; A3+\\n- **HIV-INCONCLUSIVE:** \\n  - A1+; A2 -; Repeat A1+\\n  - A1+; A2+; A3 - (Retest after 14 days. If reactivity remains the same, the individual should be reported as HIV-negative.)\\n  \\nIf an individual tests A1+ and A2- after retesting A1 and it remains positive, they are classified as HIV-Negative.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 39,\n",
       "  'section': '## HIV Testing for Pregnant Women\\n\\nFor pregnant women, the HIV/syphilis dual test is recommended as the A1 test. The guidelines are as follows:\\n\\n- The dual test kit should be used for:\\n  - Pregnant women during their first antenatal clinic (ANC) visit, unless the woman is known to be living with HIV.\\n  - For women who test negative for both HIV and Syphilis, repeat testing should be conducted in the third trimester using the HIV/syphilis dual test.\\n  - Partners accompanying pregnant women for the first time during ANC.\\n\\n- The HIV/Syphilis dual test should not be used for:\\n  - Retesting women on antiretroviral therapy (ART) or with a known positive HIV status.\\n  - Women diagnosed with syphilis during pregnancy.\\n\\nRefer to Figure 2.4 for the full algorithm on how to consider HIV and syphilis (TP) results concurrently.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 41,\n",
       "  'section': '## HIV Test Results Interpretation\\n\\nThis section provides a guide for interpreting HIV test results based on various scenarios of HIV and syphilis test outcomes. \\n\\n- **A1 HIV -, Syphilis Test (TP) -**: HIV negative, syphilis negative\\n- **A1 HIV -, Syphilis Test (TP)+**: HIV negative, syphilis positive\\n- **A1 HIV+, Syphilis Test (TP) -**: Syphilis negative; proceed with A2 for HIV\\n- **A1 HIV+, Syphilis Test (TP)+**: Syphilis positive; proceed with A2 for HIV\\n- **A1 (HIV+); A2+; A3+**: HIV-positive\\n- **A1(HIV+); A2 -; Repeat A1+**: HIV-inconclusive (retest after 14 days). If reactivity remains the same after 14 days, the individual is reported as HIV-negative.\\n- **A1(HIV+); A2 -; Repeat A1 -**: HIV-negative\\n- **A1(HIV+); A2+; A3 -**: HIV-inconclusive (retest after 14 days). If reactivity remains the same after 14 days, the individual is reported as HIV-negative.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 41,\n",
       "  'section': \"## Approaches to Improve Linkage to Treatment and Prevention Services\\n\\nThis section outlines key strategies for enhancing the linkage to HIV treatment and prevention services.\\n\\n### Information\\n- Quality post-test counselling should impart details about additional HIV-related services, treatment plans, and follow-up visits.\\n- Emphasize the benefits of immediate assessment and early initiation of ART.\\n- Involve the patient in decision-making regarding their treatment and prevention, especially concerning the timing of ART initiation.\\n\\n### Disclosure\\n- Disclosure to a trusted 'significant other' enhances linkage and adherence to treatment.\\n- Encourage patients to discuss their HIV status with a trusted friend or close relative.\\n- Adolescents should be supported in identifying a supportive adult or friend.\\n- For children, disclose HIV status by age 12, starting the process as young as 7, with appropriate guidance. This aims to involve children in their health management and reduce HIV stigma.\\n\\n### Barriers to Linkage\\n- During post-test counselling, identify and address any barriers affecting linkage to treatment and prevention services.\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 43,\n",
       "  'section': '## Recommendations for Retesting HIV Negative Clients\\n\\n### General Population\\nAll general population to be screened every 2 years using the approved NASCOP HTS screening tool and those eligible get tested.\\n\\n### Key Populations\\n- **FSW (Female Sex Workers), MsM (Men who have sex with Men), TG (Transgender individuals), PWID (People Who Inject Drugs)**: Re-test every 3 months.\\n\\n### Discordant Couples\\n- **Negative partner** in discordant relationships: \\n  - Retest HIV negative partner at the initiation of ART for the HIV positive partner, at 6 months, and 12 months once viral suppression is achieved.\\n  - Retest annually if the positive partner remains virally suppressed.\\n\\n### Pregnant Women\\n- Test in the first trimester or first contact; re-test in the third trimester and during labor and delivery.\\n\\n### Breastfeeding Mothers\\n- Re-test 6 weeks after delivery, at 6 months, then every 6 months until complete cessation of breastfeeding.\\n- For mothers considered to be at high risk of HIV infection, retesting postnatally should be done every 3 months.\\n\\n### Individuals with High-Risk Exposure\\n- Persons who had a most recent (e.g., less than one month) high-risk exposure to HIV: Test at initial presentation and re-test at 4 weeks, after which national testing guidelines apply.\\n\\n### STI Symptomatic Patients\\n- Patients with symptoms suggestive of acute HIV: Test at initial presentation and re-test at 4 weeks, after which national testing guidelines apply.\\n\\n### Individuals on Pre-Exposure Prophylaxis (PrEP)\\n- Test at initiation of PrEP; re-test at month one, and then every 3 months.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 43,\n",
       "  'section': '## Inconclusive HIV Status\\n\\nAn HIV-inconclusive test status means that individuals had discrepant results on the test (for example, first test reactive, second test nonreactive, third test reactive) and could not be given an HIV-positive or HIV-negative diagnosis. \\n\\nInconclusive results are rare, but they may occur when:\\n1. Cross-reactivity exists between kits or patient-related factors.\\n2. The tester or test kit makes an error.\\n3. Individuals are seroconverting and in the window period, when infection cannot be determined.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 44,\n",
       "  'section': '## HIV Testing Window Period\\n\\nThe window period is the time from exposure to HIV infection to when the body produces enough HIV antibodies to be detected by an HIV antibody test. This timeframe can vary across different types of tests, with some able to detect antibodies earlier than others, leading to potentially discrepant test results.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 44,\n",
       "  'section': '## Follow-up for Inconclusive Results\\n\\nAll individuals with an inconclusive HIV status should be encouraged to return in 14 days for retesting. Receiving inconclusive results can be confusing and stressful for clients, and it may be difficult for the provider to explain. During post-test counseling, the provider should clearly explain what an HIV-inconclusive status means, stating that it is neither HIV-positive nor HIV-negative. Retesting in 14 days is necessary for an accurate diagnosis. \\n\\nProviders must assist clients in making a clear follow-up plan and schedule an appointment for retesting. Furthermore, clients should be informed about prevention options, how to stay HIV-negative, and the benefits of ART.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 44,\n",
       "  'section': '## Management of Suspected Acute HIV Infection\\n\\nIndividuals suspected of having an acute HIV infection—usually those presenting symptoms associated with acute HIV—should be closely monitored. This is a period of high infectiousness due to elevated viral load, and clients need to be educated on how to protect their partners. Those at high ongoing risk for HIV can be informed about PrEP and encouraged to discuss options based on their final HIV status during subsequent retesting.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 44,\n",
       "  'section': '## Testing Protocol for Patients on ART\\n\\nHIV testing should not be conducted for patients who are already enrolled in HIV care and receiving ART. However, some patients may self-refer for HIV antibody testing without disclosing their known HIV-positive status and ART usage. Recommendations for managing patients who have a non-reactive antibody test while on ART are provided in Figure 2.5.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 42,\n",
       "  'section': '## HIV Testing Services and Linkage to Treatment and Prevention\\n\\nThis section outlines the responsibilities and processes involved in linking clients to care after receiving an HIV test result.\\n\\n- The HIV testing services (HTS) provider is responsible for facilitating linkage into care.\\n- Same-day enrollment into care is expected, with a monitoring period for treatment initiation within 14 days post-diagnosis. Follow-ups can extend up to 90 days for clients who are HIV positive.\\n- For individuals who test HIV negative, linkage to HIV prevention services should be based on assessed risk.\\n- Linkages should ideally direct clients to on-site treatment and prevention services through patient escorts. If this is not feasible due to patient preference or unavailability of services, the testing facility should book an appointment with the receiving facility and follow up to confirm the patient registers there. Provide the patient with appropriate referral information, including a referral form and contact details of the facility.\\n- Implement retention and loss-to-follow-up tracking systems to ensure successful linkage. Strategies include using peer or buddy systems, SMS reminders, phone calls, and community outreach workers to assist HIV-positive clients with enrollment.\\n- Early assessment for antiretroviral therapy (ART) and initiating ART early can enhance client engagement in care.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 42,\n",
       "  'section': '## Care Coordination and Integration\\n\\nThis section discusses the importance of coordinating care and services for people living with HIV (PLHIV) and their families.\\n\\n- It is crucial to coordinate the treatment of mother-baby pairs, partners, and family groups collectively.\\n- Common services for PLHIV, such as tuberculosis (TB) diagnosis and treatment, sexual and reproductive health/family planning (SRH/FP), cervical cancer screening, and nutritional support, should be integrated.\\n- Any necessary referrals must be coordinated effectively, ensuring proper communication and documentation between the referring and receiving service delivery points.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 42,\n",
       "  'section': '## Linkage Register\\n\\nThis section describes the management and tracking of linkages to care for patients who test for HIV.\\n\\n- Maintain a linkage register at all testing points, including within the facility and the community.\\n- Track and report progress on linkage efforts on a monthly basis.\\n- Linkage progress should be discussed in multi-disciplinary team (MDT) meetings to ensure accountability and improvement in services.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 42,\n",
       "  'section': '## Retesting Recommendations for HIV Negative Persons\\n\\nThis section outlines the recommendations for retesting individuals who initially test negative for HIV.\\n\\n- Retesting serves to monitor the effectiveness of HIV prevention interventions and to identify and treat new HIV infections at the earliest opportunity if prevention efforts fail.\\n- Specific recommendations for HIV retesting in different populations and settings in Kenya will be detailed further (not included in this excerpt).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 46,\n",
       "  'section': '## Initial Evaluation and Follow-Up\\n\\nAll PLHIV are eligible for ART irrespective of CD4 cell count or percentage, WHO clinical stage, age, pregnancy status, or comorbidities. ART should be initiated as soon as the patient is ready to start, preferably within two weeks from the time of HIV diagnosis. \\n\\nIn order to provide targeted services based on clinical presentation, during the initial evaluation, all PLHIV should be categorized as presenting with advanced HIV disease (AHD) or as presenting well. Patients with advanced disease require more intensive evaluation for and management of opportunistic infections (OIs). Once ART is started, they are also at higher risk of developing immune reconstitution inflammatory syndrome (IRIS).\\n\\nAfter at least 6 months on ART, PLHIV should be categorized as being either established or not established on ART (clinically, virologically, and psychosocially) to best meet specific patient needs for treatment and follow-up, improving patient outcomes through the provision of targeted differentiated care. Differentiated care minimizes inconvenience and unnecessary frequent follow-up, thereby reducing costs and time related to clinic visits while allowing resources to be focused on patients who require additional attention.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 46,\n",
       "  'section': '## Initial Clinical Evaluation of PLHIV\\n\\nAll patients enrolling in HIV care should have a complete medical history taken, a thorough physical examination, and appropriate laboratory investigations. Findings from this initial evaluation should be documented legibly in a retrievable health record management format (electronic or paper-based) to facilitate long-term follow-up of the patient. \\n\\nThe initial visit also provides an opportunity to establish a meaningful patient-provider relationship; the clinician should elicit concerns and expectations with open, non-judgmental, and clear communication. \\n\\nTable 3.1 summarizes important aspects of the initial medical history and physical examination for PLHIV.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 49,\n",
       "  'section': '## Summary of Management Plans for PLHIV\\n\\nThis section outlines the key components for the differential diagnosis and management of presenting illnesses in patients living with HIV (PLHIV). It includes guidelines for assigning and documenting the WHO Clinical Stage, management of presenting illnesses, and the assessment of growth and developmental milestones in children. The goal is to differentiate between patients with advanced disease and those who are clinically well to guide the acuity of follow-up care.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 49,\n",
       "  'section': '## Initial Laboratory Evaluation of PLHIV\\n\\nThis section discusses the initial laboratory evaluations required for PLHIV, emphasizing that the comprehensiveness of these evaluations depends on the suspected concurrent illnesses. A baseline laboratory investigation table (Table 3.2) is provided to summarize recommended tests for all PLHIV, along with additional investigations based on clinical indications. Importantly, it states that antiretroviral therapy (ART) should not be delayed if laboratory tests are unavailable.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 49,\n",
       "  'section': '## Baseline Laboratory Investigations for PLHIV\\n\\nThis section details the specific laboratory tests recommended for baseline evaluation of PLHIV:\\n\\n- **Confirm and document positive HIV test result**: Positive status must be confirmed before initiating ART for all patients, following the current HIV testing algorithm.\\n  \\n- **CD4 cell count**: Required for all patients; for children ≤ 5 years, CD4% should be determined. If CD4 is ≤ 200 cells/mm³ in patients over 5 years, a serum cryptococcal antigen (sCrAg) test should be performed simultaneously to screen for cryptococcal infection.\\n\\n- **Viral load (HIV-1 RNA)**: A baseline viral load is recommended for infants after the 1st PCR test is positive. The specimen for baseline VL can be drawn during ART initiation, not delaying the start of treatment.\\n\\n- **Serum Cryptococcal Antigen (sCrAg)**: This should be obtained if CD4 is ≤ 200 cells/mm³ in patients over 5 years as reflex testing. If positive, management should follow the cryptococcal meningitis screening algorithm.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 45,\n",
       "  'section': '## Education/Counselling for Patients on ART with New Negative HIV Antibody Test\\n\\n- The new HIV antibody test may be a false negative; the patient may still be HIV-infected but their antibody levels may be suppressed due to effective ART. This is particularly common for patients who start ART very soon after HIV infection.\\n- Patients with a prior history of detectable viral loads, positive DNA PCR results, or low CD4 counts are almost always truly HIV positive.\\n- Continue ART until a special test (DNA PCR) is performed at the National HIV Reference Laboratory (NHRL).\\n- Stopping ART before HIV status is confirmed could result in a rapid rise in viral load, a decline in CD4, and an increased risk of developing an opportunistic infection or death.\\n- Draw a sample for DNA PCR and send it to the NHRL (preferably a whole blood EDTA sample following cold-chain protocols within 24 hours of collection; DBS is acceptable if EDTA is not possible).\\n- Specify that this is a sample for confirming the HIV status of a patient on ART, and provide the dates and results for all prior antibody tests, DNA PCR tests, and RNA viral load tests in the request form.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 45,\n",
       "  'section': \"## Protocol for Positive HIV DNA PCR Sample\\n\\n- A positive HIV DNA PCR sample confirms that the patient is HIV positive.\\n- Provide additional counseling on the reasons why the antibody test may have been falsely negative and discourage the patient from any repeat antibody testing.\\n- Emphasize that the patient's ART is effective and stress the importance of continued excellent adherence.\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 45,\n",
       "  'section': '## Protocol for Negative HIV DNA PCR Sample\\n\\n- A negative HIV DNA PCR sample may mean the patient is HIV negative, but it could also indicate that the patient is HIV positive with DNA levels suppressed below the testing limit (more common if a DBS sample was used).\\n- Inform the patient that they may still be HIV positive and that they need to be monitored closely for an additional 6 months before confirming they are HIV negative.\\n- Inform the patient that ART should be stopped immediately.\\n- They should return for HIV viral load tests at 1 month, 3 months, and 6 months after stopping ART. Samples for viral load should be sent to the designated VL/EID network laboratory associated with the requesting facility, including all past details.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 51,\n",
       "  'section': '## Overview of Advanced HIV Disease (AHD)\\n\\nThe World Health Organization (WHO) defines Advanced HIV Disease (AHD) for adults, adolescents, and children five years and older as having a CD4 cell count of less than 200 cells/mm³ or being at WHO clinical stage III or IV. All children younger than five years living with HIV who are not already receiving ART and are not clinically stable are also considered to have AHD.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 51,\n",
       "  'section': '## Settings for AHD Presentation\\n\\nAdvanced HIV Disease can occur in various settings, including:\\n\\n- People Living with HIV (PLHIV) newly presenting to care\\n- Those returning to care after treatment interruption\\n- PLHIV on ART who have experienced treatment failure'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 51,\n",
       "  'section': '## Risks Associated with AHD\\n\\nPLHIV with AHD experience immune suppression, which reduces their ability to fight opportunistic infections (OIs), other infectious and non-infectious diseases. This results in an increased risk of morbidity and mortality. \\n\\nLeading causes of mortality among adults with AHD include:\\n\\n- Immune reconstitution inflammatory syndrome\\n- Tuberculosis (TB)\\n- Severe bacterial infections\\n- Cryptococcal disease\\n- Histoplasmosis\\n- Toxoplasmosis\\n- Pneumocystis Jirovecii pneumonia\\n\\nAdditionally, AHD is associated with increased healthcare costs, a higher usage of healthcare services, and more frequent monitoring needs.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 51,\n",
       "  'section': '## CD4 Testing Criteria for AHD Diagnosis\\n\\nThe criteria for CD4 testing to diagnose AHD and determine eligibility for a package of care include:\\n\\n- **New clients initiating ART:** \\n  - CD4 testing should be conducted as a baseline test for all PLHIV.\\n\\n- **Patients who are treatment experienced:** \\n  - PLHIV ≥5 years of age who had previously initiated ART and are reinitiating after more than 3 months.\\n  - Individuals with documented persistent unsuppressed viral load (two viral loads >1,000 within 3-6 months).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 51,\n",
       "  'section': '## Package of Care for AHD\\n\\nAll PLHIV presenting with Advanced HIV Disease (AHD) should be offered a comprehensive package of care, which includes:\\n\\n- Timely initiation of ART\\n- Screening and diagnosis\\n- Prophylaxis\\n- Management of opportunistic infections\\n\\nA summary of definitions for well versus advanced disease and the package of care for each at enrollment can be found in Table 3.3.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 47,\n",
       "  'section': '## Initial Clinical Evaluation for PLHIV\\n\\nThis section covers the details necessary for the initial clinical evaluation of People Living with HIV (PLHIV), focusing on history and physical examination.\\n\\n### History Details for History Taking\\n\\n- **Current and Past Medical History**  \\n  - Presenting complaints/current symptoms  \\n  - Inquire about symptoms related to co-existing HIV-related and non-HIV-related diseases and co-morbidities needing immediate intervention.\\n  - History of TB and TB contacts (use the Intensified Case Finding (ICF) tool).\\n  - Document the date of the first positive HIV test.\\n  - Note past and current co-morbidities (e.g., TB, cryptococcal meningitis, hypertension, diabetes, kidney, and liver disease).\\n  - Document current medications, including prescription, non-prescription, and herbal medications that might interact with ARVs.\\n  - Record history of drug allergies, especially sulpha allergy.\\n  - Take note of history of hospitalizations and establish reasons for these hospitalizations.\\n  - Document family history of chronic diseases or cancer.\\n  - Establish nutritional history, adequacy of nutritional intake, and household food security.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 47,\n",
       "  'section': \"## Psychosocial History\\n\\nThis section focuses on gathering psychosocial information that can impact a patient's treatment and adherence to HIV management.\\n\\n- **Education, Employment, Family, Marital Status**  \\n- Assess for possible mental health concerns, including any history of treatment for mental illnesses and current symptoms of depression.\\n- Evaluate the potential for disclosure of HIV status and the presence of self-stigma. Encourage disclosure to trusted individuals and sexual partners.\\n- Conduct substance use screening, which includes alcohol, tobacco, miraa (khat), marijuana, and narcotics. \\n  - Utilize the CRAFFT screening tool for adolescents and the CAGE-AID screening tool for adults.\\n- Document social support structures that are available to the patient.\\n- Link patients to additional facility and community support resources, including psychosocial support groups, peer mentors, and harm reduction services for People Who Inject Drugs (PWIDs).\\n- Elicit and begin to address possible barriers to adherence to treatment.\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 53,\n",
       "  'section': '## Tuberculosis (TB) in PLHIV\\n\\nTB is the most frequent life-threatening opportunistic infection (OI) and a leading cause of death among people living with HIV (PLHIV). It remains the leading cause of mortality among PLHIV, accounting for 30% of AIDS-related deaths reported, despite significant scale-up of antiretroviral therapy (ART). Screening, prevention, and treatment of TB are described in Chapter 8.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 53,\n",
       "  'section': '## Management of Patients Who Present Well\\n\\nThis section outlines the management of adults, adolescents, and children aged 5 years and older who present well with WHO Stage 1 or 2 and a CD4 count greater than 200 cell/mm³.\\n\\n### Focus of ART Preparation Counseling\\n- ART is the most important treatment for maintaining good health and an active life.\\n- Starting ART soon decreases the risk of developing wasting and other infections.\\n- ART reduces the risk of transmitting HIV to others.\\n\\n### Frequency of Follow-up\\n- Weekly follow-up until ART initiation, then at weeks 2 and 4 after ART initiation, and monthly until confirmed viral suppression.\\n- Additional visits as required to address any medical or psychosocial concerns.\\n\\n### Location of Services\\n- Management can take place at any ART service delivery point, across all facility levels.\\n- Initial management and ART initiation should be conducted by trained and experienced health care workers (HCWs).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 53,\n",
       "  'section': '## Follow-up of PLHIV After ART Initiation\\n\\nFollow-up for patients on ART depends on the duration they have been on treatment, their understanding of the treatment, and their response to ART. Follow-up includes:\\n- Scheduled clinical appointments.\\n- Unscheduled clinical assessments for patients with concerns or complaints.\\n- Routine and as-needed laboratory monitoring.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 48,\n",
       "  'section': '## Initial Evaluation and Follow Up\\n\\nThis section covers the initial evaluation of the patient, especially focusing on the assessment of sexual and reproductive history, vital signs, anthropometric measurements, general examination, and systemic examination.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 48,\n",
       "  'section': '## Sexual and Reproductive History\\n\\n- **History of STIs**  \\n  - Current symptoms of STIs  \\n  - Sexual practices  \\n    - Determine HIV status and disclosure to sexual partner(s)  \\n    - ART status of sexual partner/s  \\n\\n- **Pregnancy history and age of all living children**  \\n- **Menstrual history, family planning, and plans for pregnancy**  \\n- **History of cervical cancer screening**  \\n- **Vaccination history (including COVID-19 vaccine)**  \\n\\n**Discuss:**  \\n- Secondary prevention and avoidance of re-infection with STIs  \\n- Pregnancy intention and contraception needs  \\n- Encourage contact tracing and HIV testing for sexual partners and all children under 15 years of age of HIV-infected women or whose mothers’ HIV status is unknown'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 48,\n",
       "  'section': '## Vital Signs and Anthropometric Measurements\\n\\n- Measure and record:\\n  - Weight\\n  - Height\\n  - Mid-Upper Arm Circumference (MUAC) in children and pregnant women\\n  - Temperature\\n  - Pulse rate\\n  - Blood Pressure (BP)\\n  - Respiratory rate\\n  - Pulse oximetry  \\n\\n- **Calculate BMI:**  \\n  - Formula: Weight (kg) / Height² (m)\\n  \\n- Use z-scores for children  \\n- Monitor growth trends for children'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 48,\n",
       "  'section': '## General Examination\\n\\n- Examine for:\\n  - Conjunctiva and palms for pallor or jaundice\\n  - Swollen lymph nodes (cervical, axillary, inguinal)\\n  - Mouth for Kaposi’s sarcoma (KS) lesions, oral hairy leucoplakia, candidiasis, tooth decay\\n  - Skin for drug eruptions, herpes zoster, dermatitis, pruritic papular eruptions (PPE), folliculitis, fungal infections, molluscum, and KS  \\n- Assess developmental milestones for children'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 48,\n",
       "  'section': '## Systemic Examination\\n\\n- **Central Nervous System**\\n- **Mental State Examination** (for mental status)  \\n- **Abdomen Examination**\\n- **Respiratory Examination**\\n- **Cardiovascular Examination**\\n- **Genitourinary/Anorectal System:**  \\n  - Check for ulcers, discharge, condylomata/warts  \\n  - Prostate examination for men aged ≥ 45 years  \\n  - Speculum examination with cervical cancer screening for females'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 50,\n",
       "  'section': '## Initial Evaluation and Follow-Up\\n\\nThis section outlines the initial evaluations and follow-up procedures for patients starting on ART treatment.\\n\\n### Recommended Laboratory Tests  \\n- **Hb (Full Blood Count)**: Conduct for all patients, especially those on AZT.  \\n- **Pregnancy Test**: Determine pregnancy status for all women of reproductive age. Conduct a urine pregnancy test if unsure or if menstrual history is irregular or delayed.  \\n- **TB-LAM**: Perform on urine samples for PLHIV with CD4 ≤ 200 cells/mm³ (adults) or CD4% ≤ 25% (children under 5 years) and for seriously ill patients.  \\n- **Urinalysis (for protein & glucose)**: Conduct for all patients.  \\n- **Creatinine**: Test all patients, particularly those starting TDF, and calculate Creatinine Clearance (CrCl).  \\n- **Syphilis Serology (VDRL, TPHA, or RPR)**: Conduct for all sexually active patients.  \\n- **Glucose**: Test required for all patients.  \\n- **Plasma Lipid Profile**: Conduct for all patients.  \\n- **HBsAg**: Test for all adolescent and adult patients, and for children who did not complete routine childhood immunizations.  \\n- **HCV Antibody**: Recommended for People Who Inject Drugs (PWID) or patients with a history of injection drug use.  \\n- **ALT**: Generally not recommended as a baseline investigation unless there are specific clinical indications (e.g., history of hepatitis or signs of liver disease).  \\n- **HPV Testing**: Conduct for women aged 25-49 at baseline and every two years, as per cancer screening guidelines.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 50,\n",
       "  'section': '## Laboratory Capacity and Testing Limitations\\n\\nThis section discusses the limitations of laboratory testing for ART facilities and suggests alternatives for testing.\\n\\n### Testing Capacity  \\nIt is acknowledged that not all facilities providing ART are equipped to offer the complete range of recommended laboratory tests for HIV treatment. \\n\\n### Alternative Arrangements  \\nIf on-site testing is unavailable, facilities must arrange for the transportation of specimens to local or regional reference laboratories to ensure all tests can be performed as needed.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 57,\n",
       "  'section': '## Baseline Testing Guidelines\\n\\n- **CrAg**: Baseline for adults and adolescents with CD4 ≤ 200 cells/mm³ (as reflex testing by laboratory), then only if there is clinical suspicion of CM.\\n- **Hb**: Baseline, then symptom directed; if on AZT, baseline then weeks 2, 4, and 12.\\n- **Pregnancy Status**: At every visit for women of reproductive age (by history +/- urine pregnancy test).\\n- **Urinalysis (protein & glucose)**: Baseline, then annually if on TDF.\\n- **Creatinine**: Baseline, then annually if on TDF.\\n- **Glucose**: Baseline, then annually.\\n- **Plasma lipid profile**: Baseline, then annually.\\n- **HBsAg**: Baseline, followed by immunization for all patients who screen negative (after viral suppression is confirmed).\\n- **Syphilis serology (VDRL, TPHA, or RPR)**: Baseline, then annually in those at risk and as part of routine ANC profile.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 57,\n",
       "  'section': '## Drug Resistance Testing\\n\\n- **Drug Resistance Testing**: Recommended once treatment failure confirmed on a DTG or PI-based 1st line regimen, or confirmed treatment failure on 2nd line or subsequent regimens.\\n- **ALT**: Not recommended for routine baseline or follow-up unless specific clinical indication.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 57,\n",
       "  'section': '## Cervical Cancer Screening\\n\\n- **Cervical Cancer**: All women should be screened for cervical cancer following the national guidelines.\\n- **HPV Screening**: Conducted every 2 years for HIV positive women in their reproductive age (or annually if using VIA-VILI).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 57,\n",
       "  'section': '## HCV Screening\\n\\n- **HCV**: Baseline for people who inject drugs (PWIDs) or with a history of injection drug use.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 55,\n",
       "  'section': '## Patients Established on ART\\n\\nPatients established on ART must have achieved ALL the following:\\n- On their current ART regimen for ≥ 6 months\\n- Currently no active illness or in the previous 6 months (patients with well-controlled chronic conditions should not be excluded)\\n- Adherent to scheduled clinic visits for the previous 6 months\\n- VL ≤200 copies/ml (LDL) within the last 6 months\\n\\n**Note:**\\n- This definition should be applied to all populations, including those receiving second- and third-line regimens, those with controlled comorbidities, children above 2 years, adolescents, pregnant and breastfeeding women, and key populations.\\n- The client’s category can change at any time, so there is a need for reassessment at each visit. Clients should be categorized at every visit and managed based on their status.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 55,\n",
       "  'section': '## Package of Care\\n\\n- **Standard Package of Care**: Includes a re-assessment of criteria at every clinical visit.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 55,\n",
       "  'section': '## Location of Services\\n\\n- Clinical review and ART prescription can be provided from any ART service delivery point at all facility levels.\\n- Distribution of ART can occur between clinical appointments, which may be facility-based or community-based.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 55,\n",
       "  'section': '## Focus of Counselling\\n\\n- Encourage patients to continue with what is working.\\n- Reminders that any significant life event or change in daily routine could interfere with adherence.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 55,\n",
       "  'section': '## Frequency of Follow-up\\n\\n- Clinic appointments should be made at 6-month intervals.\\n- ART should be offered as refills lasting 3 months, either through fast-track pick-up at the facility or community-based distribution.\\n- Patients on injectable contraception should be provided Family Planning (FP) through a fast-tracked process between clinic follow-up visits; oral contraceptives and condoms should be distributed with ART.\\n- Additional visits may be required to address any medical or psychosocial concerns.\\n- Closer follow-up may be arranged based on patient preference.\\n\\n**Note:** Children below 2 years are excluded as they require frequent dose adjustment.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 61,\n",
       "  'section': '## Kenya HIV Prevention Guidelines\\n\\nThis section covers the strategies and recommendations for preventing HIV transmission in Kenya. It includes information on safe sex practices, use of pre-exposure prophylaxis (PrEP), and the importance of regular testing for individuals at higher risk.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 61,\n",
       "  'section': '## Kenya HIV Treatment Guidelines\\n\\nThis section details the treatment protocols for individuals living with HIV in Kenya. It discusses antiretroviral therapy (ART), adherence to medication regimens, and the importance of viral load suppression.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 61,\n",
       "  'section': '## Testing and Diagnosis\\n\\nThis section focuses on the methods and protocols for HIV testing and diagnosis in Kenya. It includes information on different types of tests available, counseling services, and the significance of early diagnosis for effective treatment.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 61,\n",
       "  'section': '## Key Populations\\n\\nThis section addresses the specific considerations and tailored interventions for key populations at higher risk of HIV, including men who have sex with men (MSM), sex workers, and people who inject drugs (PWID).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 61,\n",
       "  'section': '## Community Engagement and Education\\n\\nThis section outlines the approaches for engaging communities in HIV prevention and treatment efforts. It emphasizes the role of education, awareness campaigns, and community-based organizations in promoting health interventions.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 61,\n",
       "  'section': '## Monitoring and Evaluation\\n\\nThis section highlights the importance of monitoring and evaluating HIV programs and strategies. It includes details on data collection, outcome measurement, and using findings to improve services and interventions.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 61,\n",
       "  'section': '## Policy Framework\\n\\nThis section discusses the policy context within which HIV prevention and treatment operates in Kenya. It provides insights into government initiatives, international partnerships, and funding mechanisms that support the national response to HIV.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 54,\n",
       "  'section': '## Initial Evaluation and Follow-Up\\n\\nAfter ART initiation, patients need to be monitored closely for the development of adverse drug events, identify and address barriers to adherence, and monitor for the development of immune reconstitution inflammatory syndrome (IRIS). A reasonable follow-up schedule for most patients is 2 weeks and 4 weeks after ART initiation. When possible, follow-up for a particular patient should be provided by the same care provider or team of care providers (e.g., same clinician and same counselor) at every visit. This is particularly important during the first 6 months in care.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 54,\n",
       "  'section': '## Follow-Up for Patients Beyond the First 6 Months of ART\\n\\nFollow-up of patients beyond 6 months of ART is crucial and is further detailed in Table 3.5. It provides the criteria for determining if a patient is established on ART.\\n\\n### Summary of Follow-Up Requirements:\\n- **Patients Not Established on ART**: Require closer follow-up.\\n- **Patients Established on ART**: Require less frequent facility follow-up, with intervals of up to six months between clinical appointments.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 54,\n",
       "  'section': '## Differentiated Follow-Up Criteria for Patients Not Established on ART\\n\\n### Patients with the Following Conditions:\\n- On treatment for less than 6 months.\\n- Any active opportunistic infections (OIs) including tuberculosis (TB) in the previous 6 months.\\n- Poor or questionable adherence to scheduled clinic visits in the previous 6 months.\\n- Most recent viral load (VL) ≥ 200 copies/ml.\\n- Children under 2 years.\\n\\n### Package of Care:\\n- **Standard Package of Care**: Case management to address reasons for not being established on ART.\\n\\n### Focus of Counseling:\\n- ART is the most important treatment to maintain good health and an active life.\\n- ART will reduce the risk of transmitting HIV to others.\\n\\n### Frequency of Follow-Up:\\n- Every 1-3 months, based on clinical judgment.\\n- Additional visits may be required to address any medical or psychosocial concerns.\\n- If VL is detectable at 3 months, additional assessments for management of the reasons for detectable viral load will be necessary.\\n- Patients with confirmed viral suppression can be followed up every 3-6 months based on patient preference and clinician judgment, along with additional unscheduled visits as needed.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 62,\n",
       "  'section': '## Standard Package of Care for PLHIV\\n\\nAll PLHIV should receive a package of services that are known to promote health, improve the quality of life, prevent further HIV transmission, and prevent HIV disease progression and mortality. The standard package of care for PLHIV includes: antiretroviral therapy; Positive Health, Dignity and Prevention (PHDP) services; screening and providing support in cases of gender-based violence (GBV) or intimate-partner violence (IPV); HIV education/counseling; screening and prevention of specific opportunistic infections; reproductive health services; screening for and management of non-communicable diseases; mental health screening and management; nutritional services; and prevention of other infections.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 62,\n",
       "  'section': '## Patient-Centered Care\\n\\nThe standard package of care should always be applied using a patient- and family-centered approach in PLHIV management. Patient-centered care includes considering the individual patient’s health needs, eliciting and addressing the patient’s concerns and expectations, involving the patient’s (and their family and friends as appropriate) in decision-making, and respecting the patient’s values and preferences.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 62,\n",
       "  'section': '## Family-Centered Care\\n\\nFamily-centered care identifies, engages, and provides care to all HIV-positive family members. It prevents new infections among family members at risk and promotes family support and awareness.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 60,\n",
       "  'section': '## Initial Evaluation and Follow-Up\\n\\nThis section outlines the protocols for evaluating and following up on patients receiving ART (Antiretroviral Therapy). It mentions the importance of clinical reviews and adherence to scheduled appointments.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 60,\n",
       "  'section': '## Facility-Based ART Distribution Groups\\n\\nFacility-based ART Distribution Groups are a model for ART distribution where a group of People Living with HIV (PLHIVs) gather at a designated location within a health facility for drug refills. \\n\\n- **Support and Literacy**: During these sessions, clients dispense drugs to their peers while providing psychosocial support and promoting treatment literacy.\\n- **Refill Schedule**: ART refills are conducted every three months, and clients must attend clinical review appointments every six months.\\n- **Convenience for Clients**: This model is particularly beneficial for clients in urban areas who may prefer not to be part of a community-based group. \\n- **Leadership**: These groups can be led by peers or healthcare workers (HCWs).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 60,\n",
       "  'section': '## Community-Based ART Distribution Models\\n\\nCommunity-based ART Distribution Models provide an alternative method for clients to receive their ART refills.\\n\\n- **Types of Distribution**: Clients can receive ART refills through various community-based models, including:\\n  - Community-based ART distribution groups\\n  - Community ART distribution points\\n  - Community pharmacy distribution\\n- **Home Visits**: Clients may also benefit from home visits for adherence monitoring and support, on a case-by-case basis.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 60,\n",
       "  'section': '## Implementation Guidelines for Community-Based Programs\\n\\nBefore starting a community-based ART distribution program, health facilities must collaborate with the County Health Management Team (CHMT) to create a tailored program.\\n\\n- **Program Design**: The program must meet specific criteria, as outlined in Annex 14.\\n- **Approval**: A plan must be approved by the County HIV Technical Working Group prior to implementation. \\n\\nFor more detailed information on these community models, refer to the DSD operational manual.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 59,\n",
       "  'section': '## Adolescents and Youth Support\\n\\nAdolescents require psychosocial support, ongoing adherence assessments, and counseling aligned with clinic visits, community follow-up, and the school calendar. Considerations should be factored in during clinical encounters, focusing particularly on those facing adherence and viral suppression challenges. Services for adolescents and youth should also incorporate life skills and extracurricular activities where feasible.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 59,\n",
       "  'section': '## Pregnant and Breastfeeding Women\\n\\nPregnant and breastfeeding women established on ART should synchronize their HIV clinic appointments with Antenatal Care visits and follow-up for the HIV-exposed infant. Those initiated on ART during pregnancy may need close follow-up to support adherence, retention, and achieving viral suppression. Clinical visits for breastfeeding women and their babies should align with immunization schedules. Psychosocial support groups, including peer-to-peer support, are encouraged for both pregnant and breastfeeding mothers.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 59,\n",
       "  'section': '## ART Prescription, Dispensing, and Distribution\\n\\nPatients established on ART should be offered ART refills of up to 3 months. Other associated commodities like cotrimoxazole, TPT, and condoms should be synced with the ART refill schedule. Clients established on ART should receive their ART, CPT, family planning, and any other chronic medicines through a distribution system that minimizes their burden (travel costs, waiting times, inconvenience) and that of the health facility (personnel time, space constraints, etc.). Participation in this system must be voluntary, allowing clients the option to remain in standard care if preferred.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 59,\n",
       "  'section': '## Health Facility Responsibilities\\n\\nThe health facility is responsible for ART prescription, dispensing, and distribution for all patients enrolled in care. ART distribution can occur at the health facility or through community distribution systems, depending on patient preference and the health facility’s resources. The dispensing point should ensure ease of access to treatment for clients.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 59,\n",
       "  'section': '## Models for ART Refills\\n\\nFacility-based and community-based models are available for ART refills:\\n\\n### Facility-based Models\\n- Fast track facility-based refills\\n- Facility-based ART distribution groups\\n\\n### Community-based Models\\n- Community-based ART distribution groups\\n- Community ART distribution points\\n- Community pharmacy distribution'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 59,\n",
       "  'section': '## Facility-based Fast Track System for ART Refills\\n\\nThe facility-based fast track system allows clients to come to the clinic every 3 months for ART refills with minimal or no waiting time. For detailed information on community models, refer to the DSD operational manual.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 58,\n",
       "  'section': '## Initial Evaluation and Follow-Up\\n\\n1. Recommended investigations should not delay ART initiation. Patients are encouraged to return to the HIV clinic for unscheduled appointments whenever an acute issue arises, rather than seeking care elsewhere.\\n\\n2. Early after initiation of ART, and after any regimen modification, every appointment should include:\\n   - Continued adherence counseling and support (started at the initial visit)\\n   - Assessment of adherence and correct storage of medication\\n   - Assessment for and management of early side effects of the drugs, and patient counseling on the same\\n\\n3. Patients who are adherent and virally suppressed at month 3 may not need subsequent monthly appointments until month 6.\\n\\n4. All PLHIV qualify for ART and should be initiated as soon as possible, including same day or within 2 weeks. Patients who do not start ART on the same day as enrollment into HIV care should be followed up weekly until ART initiation to address any issues delaying ART and for ongoing management of acute medical issues.\\n\\n5. In children and adolescents, weight and height should be measured and recorded at every visit, with weight-based dosing of ARVs confirmed. In adults, weight and height should be measured at the initial visit to determine nutritional status and calculate BMI, with weight measured at every visit thereafter.\\n\\n6. The first 2-4 visits are critical for assessing and supporting adherence to ART, managing adverse drug reactions, and treating acute illnesses, including IRIS. Adherence should be assessed at every contact with the clinic.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 58,\n",
       "  'section': '## Required Laboratory Tests\\n\\nRequired laboratory tests are highly recommended for patient monitoring but are not a prerequisite for ART initiation. Targeted laboratory tests may be necessary to identify and manage inter-current diseases or adverse drug reactions.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 58,\n",
       "  'section': '## Differentiated Care for Children, Adolescents, and Pregnant/Breastfeeding Women\\n\\nChildren, adolescents, pregnant and breastfeeding women, and key populations face unique challenges in retention and viral suppression and may benefit from differentiated service delivery models tailored to their needs.\\n\\n- **Children:** Care for children is dependent on family and caregiver dynamics. Family-centered approaches should be used, where clinic visits for parents/caregivers and the child are synchronized. Assessment and categorization should determine establishment on ART, with follow-ups tailored to their situations. Weight-based dose adjustments should be incorporated in both facility and community models (e.g., using portable weighing scales if outside the health facility) to determine optimal doses for ARVs at each review. Aligning appointments with the school calendar should be considered to avert disruptions in treatment and learning for the child.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 52,\n",
       "  'section': \"## Initial Evaluation and Follow-up\\n\\nThis section outlines the initial care and follow-up protocols for adults, adolescents, and children aged 5 years and older presenting with advanced HIV disease (WHO Stage 3 or 4, or CD4 count ≤ 200 cell/mm³) as well as all children younger than five years.\\n\\nKey components of the care package include:\\n- Standard Package of Care (refer to Chapter 4).\\n- Intensive management of presenting illnesses and malnutrition.\\n- Priority focus on the identification, management, and prevention of opportunistic infections (OIs).\\n  - GeneXpert ultra for TB diagnosis for all PLHIV with presumptive TB.\\n  - TB-LAM for individuals with presumptive TB who meet specific criteria.\\n  - Cryptococcal antigen screening for adolescents and adults with clinical suspicion of meningitis.\\n  - Cotrimoxazole Preventive Therapy (CPT) and TB Preventive Therapy (TPT).\\n- Immediate initiation of ART unless there's a suspicion of TB, TB meningitis, or cryptococcal meningitis.\\n- Close monitoring for the development of immune reconstitution inflammatory syndrome.\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 52,\n",
       "  'section': '## Focus of ART Preparation\\n\\nThis section emphasizes the importance of counseling and preparation before the initiation of Antiretroviral Therapy (ART).\\n\\n- Immediate ART initiation is crucial to prevent further immune system damage.\\n- Early ART can decrease the risk of disease progression and associated complications, such as wasting and increased susceptibility to infections.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 52,\n",
       "  'section': '## Frequency of Follow-up\\n\\nIn this section, the recommended frequency of follow-up visits after ART initiation is detailed:\\n\\n- Weekly follow-ups until ART initiation.\\n- Follow-ups at week 2 and 4 after ART initiation, transitioning to monthly visits once confirmed viral suppression is achieved.\\n- More frequent visits or hospitalizations may be necessary to stabilize acute medical conditions and address psychosocial concerns.\\n- Referrals may be needed for co-morbidities or concurrent infections.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 52,\n",
       "  'section': '## Management of Opportunistic Infections in Patients with AHD\\n\\nThis section discusses the management of opportunistic infections, particularly cryptococcal disease, which is significant in patients living with advanced HIV disease.\\n\\n- Cryptococcal disease is a leading cause of mortality in this population.\\n- Early diagnosis and treatment of cryptococcal meningitis is critical to reducing mortality rates.\\n- Healthcare professionals should maintain a vigilant approach when suspecting cryptococcal meningitis in individuals with AHD.\\n- Detailed procedures for screening, prevention, and treatment of cryptococcal meningitis are addressed in Section 4.33.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 56,\n",
       "  'section': '## Initial Evaluation and Follow-up\\n\\nThis section provides an overview of the initial evaluation and follow-up schedule for People Living with HIV (PLHIV) on Antiretroviral Therapy (ART).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 56,\n",
       "  'section': '## Summary of Clinical and Laboratory Monitoring for PLHIV\\n\\nThe summary highlights the recommended minimum routine follow-up schedule for PLHIV on ART, indicating various assessments to be made throughout the treatment process.\\n\\n### Minimum Routine Follow-up Schedule\\n\\n| Appointment        | Initial Visit | ART Preparation | Week After ART | 2 Months | 4 Months | 2 Months | 3 Months | 4 Months | 5 Months | 6 Months | Every 1-6 Months (depending on stability) |\\n|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 56,\n",
       "  'section': '--|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 56,\n",
       "  'section': '|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 56,\n",
       "  'section': '--|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 56,\n",
       "  'section': '--|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 56,\n",
       "  'section': '-|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 56,\n",
       "  'section': '-|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 56,\n",
       "  'section': '-|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 56,\n",
       "  'section': '-|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 56,\n",
       "  'section': '-|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 56,\n",
       "  'section': '-|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 56,\n",
       "  'section': '-|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 56,\n",
       "  'section': '-|\\n| History and physical exam | ✔             | ✔               | ✔               | ✔        | ✔        | ✔        | ✔        | ✔        | ✔        | ✔        | At each clinical visit                      |\\n| Adherence assessment and support | ✔             | ✔               | ✔               | ✔        | ✔        | ✔        | ✔        | ✔        | ✔        | ✔        | At each visit                               |\\n| TB Screening       | ✔             | -               | -               | -        | -        | -        | -        | -        | -        | -        | Every visit, using ICF screening tool      |\\n| CD4 Count          | ✔             | -               | -               | -        | -        | -        | -        | -        | -        | -        | Baseline; then only if clinically indicated |\\n| HIV Viral Load     | -             | -               | Baseline        | -        | -        | -        | -        | -        | -        | -        | Various based on age and clinical factors   |'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 56,\n",
       "  'section': '## CD4 Count Monitoring Guidelines\\n\\nThis section details the recommendations for CD4 count monitoring, including when and how often to assess levels based on various patient conditions.\\n\\n### Guidelines for CD4 Count\\n\\n- **Follow-up for Treatment Failure**: Conduct CD4 count only if the patient develops treatment failure or defaults from care for at least 6 months.\\n- **Patients on Dapsone**: For patients on prophylaxis due to documented CTX allergy, repeat CD4 every 6 months until:\\n  - CD4 > 200 cells/mm³ for two consecutive measures 6 months apart\\n  - HIV Viral Load undetectable\\n- **Discontinuation of Monitoring**: CD4 monitoring and dapsone can be discontinued after the above criteria are met.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 56,\n",
       "  'section': '## HIV Viral Load Monitoring Criteria\\n\\nThis section outlines the criteria and schedule for monitoring HIV Viral Load in patients on ART.\\n\\n### Monitoring Schedule by Age Group\\n\\n- **For PCR Positive HEIs**: Baseline at the time of ART initiation.\\n- **Age 0-24 Years**: At month 3, then every 6 months.\\n- **Age ≥ 25 Years**: At month 3, then month 12, then annually thereafter if suppressed.\\n\\n### Monitoring and Response Actions\\n\\n- Conduct before any drug substitution for patients on ART for at least 6 months with no valid viral load.\\n- Continue monitoring as per population groups.\\n- For any patient with a detectable viral load during routine monitoring, follow the viral load monitoring algorithm.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 56,\n",
       "  'section': '## HIV Viral Load Monitoring in Pregnant/Breastfeeding Women\\n\\nThis section describes adaptions for monitoring HIV Viral Load in pregnant or breastfeeding women on ART.\\n\\n### Screening and Follow-up Procedures\\n\\n1. **If on ART at Confirmation of Pregnancy**:\\n   - Viral Load test done at confirmation of pregnancy (regardless of prior testing).\\n   - Follow-up every 6 months until complete cessation of breastfeeding.\\n  \\n2. **If Starting ART During Pregnancy or Breastfeeding**:\\n   - Initial Viral Load test at 3 months after initiation, followed by testing every 6 months until complete cessation of breastfeeding.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 63,\n",
       "  'section': '## Kenya HIV Prevention and Treatment Guidelines Overview\\n\\nThe document outlines the components of the Standard Package of Care for People Living with HIV (PLHIV) as per the 2022 guidelines in Kenya.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 63,\n",
       "  'section': '## Antiretroviral Therapy (ART)\\n\\nThis section covers the components of ART, including:\\n- **ART initiation**\\n- **Adherence assessment, counselling, and support**\\n- **Monitoring (clinical and laboratory)**'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 63,\n",
       "  'section': '## Positive Health, Dignity and Prevention (PHDP)\\n\\nThis section emphasizes the importance of positive health and dignity, including:\\n- **Disclosure**\\n- **Index testing**\\n- **Condom use**\\n- **Family planning**\\n- **STI screening, prevention, and treatment**\\n- **Adherence counselling and support**\\n- **Pre-exposure prophylaxis for HIV-negative sexual partners**\\n- **Gender-based violence (GBV) and intimate-partner violence (IPV) screening and support**\\n- **HIV education/counselling**'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 63,\n",
       "  'section': '## Specific Opportunistic Infection Screening and Prevention\\n\\nDetails on the management of opportunistic infections, including:\\n- **Cotrimoxazole preventive therapy**\\n- **Tuberculosis (TB)**\\n  - Intensified case finding\\n  - TB preventive therapy\\n  - ART for TB/HIV co-infected patients\\n- **Cryptococcal meningitis**'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 63,\n",
       "  'section': '## Reproductive Health Services\\n\\nThis section outlines the reproductive health services available, such as:\\n- **Sexually transmitted infections screening and management**\\n- **Family planning and pre-conception services**\\n- **Maternal healthcare**\\n- **Cervical cancer screening**'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 63,\n",
       "  'section': '## Non-Communicable Diseases (NCD) Screening and Management\\n\\nThis section focuses on NCDs, addressing:\\n- **Hypertension**\\n- **Diabetes mellitus**\\n- **Dyslipidemia**\\n- **Chronic kidney disease**\\n- **Other NCDs**'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 63,\n",
       "  'section': '## Mental Health Screening and Management\\n\\nComponents for mental health care include:\\n- **Depression**\\n- **Anxiety**\\n- **Stress**\\n- **Trauma**\\n- **Alcohol and drug use/addiction**\\n- **Self-care and wellbeing**'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 63,\n",
       "  'section': '## Nutritional Services\\n\\nDetails regarding nutritional support, which encompasses:\\n- **Assessment**\\n- **Counselling and education**\\n- **Management and support**'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 63,\n",
       "  'section': '## Prevention of Other Infections\\n\\nThis section highlights preventive measures against other infections, including:\\n- **Immunizations**\\n- **Malaria prevention**\\n- **Safe water, sanitation, and hygiene**'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 64,\n",
       "  'section': '## Standard Package of Care for PLHIV\\n\\nThis section outlines the general care protocols and standards for People Living with HIV (PLHIV), emphasizing the importance of comprehensive assessments, treatment, and support.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 64,\n",
       "  'section': \"## Standard Package of Care for HIV-Exposed and HIV-Infected Infants\\n\\nThis section details the specific protocols for the care of infants who are either HIV-exposed or HIV-infected, covering various aspects such as testing, treatment, nutrition, immunizations, and psychosocial support.\\n\\n### Key Components:\\n- **HIV Status Determination**: Assess HIV status at first contact through HIV Testing Services (HTS) and Early Infant Diagnosis (EID), and link to HIV care.\\n- **ARV Prophylaxis and ART**: Provide antiretroviral (ARV) prophylaxis for all HIV-exposed infants (HEIs) and antiretroviral therapy (ART) for all diagnosed HIV-infected children, ensuring weight-based dosing is administered correctly at every visit.\\n- **Nutritional Support**: Conduct nutritional assessments and offer counseling and support, while monitoring the child's growth and development.\\n- **Immunizations**: Ensure all immunizations are provided according to the national schedule.\\n- **Clinical Assessment**: Perform clinical evaluations at each visit, treating any infections early and managing adverse drug reactions effectively.\\n- **Screening for Opportunistic Infections**: Screen for opportunistic infections and provide necessary prophylactic treatments, including cotrimoxazole and TB Preventive Therapy (TPT).\\n- **Educating Caregivers**: Offer education to caregivers about child care, including infant feeding, hygiene practices, adherence to treatment, and available support systems.\\n- **Adherence Support**: Conduct adherence assessments and provide counseling support as needed.\\n- **Psychosocial Support**: Offer age-appropriate psychosocial support for the child and family, along with referrals to community-based programs.\\n- **Family Care**: Ensure caregivers and family members receive appropriate care, support, and treatment.\\n- **Intensive Case Management**: Implement intensive case management for mother-infant pairs until 2 years postpartum, tracking and prioritizing those who are at risk of defaulting.\\n- **OVC Program Enrollment**: Enroll eligible families in Orphans and Vulnerable Children (OVC) programs for additional social protection and services.\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 68,\n",
       "  'section': '## Standard Package of Care for PLHIV\\n\\nThis section outlines the comprehensive care package for People Living with HIV (PLHIV), emphasizing the components necessary for effective support and management.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 68,\n",
       "  'section': '## Screening for Gender-Based Violence (GBV) and Intimate Partner Violence (IPV)\\n\\n### LIVES Framework\\n1. **Listen**: Listen to the client closely, with empathy and without judging.\\n2. **Inquire**: Assess and respond to the client’s various needs and concerns.\\n3. **Validate**: Show the client that you understand and believe them. Assure them they are not to blame.\\n4. **Enhance safety**: Discuss a plan to protect the client from further harm if violence occurs again.\\n5. **Support**: Help the client access information, services, and social support.\\n\\n### Supportive Messages\\n- “What happened to you is not your fault.”\\n- “Many women/men are in the same situation as you.”\\n- “You are not to blame.”\\n- “Everybody deserves to feel safe at home. If you feel like you are in immediate danger, we can involve the police or local administration.”\\n\\n### Vulnerable Populations\\nMen, the elderly, and children suffer different forms of violence and should be assessed if there is any clinical suspicion. Key populations, including MSM, transgender individuals, and prisoners, are particularly vulnerable to abuse. For children, art and play therapy are used during history-taking and psychological assessments.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 68,\n",
       "  'section': '## HIV Education and Counselling\\n\\nAll PLHIV and caregivers should receive focused education about HIV and its treatment to empower them in effectively managing the infection. \\n\\n### Key Messages for Education and Counselling\\n- Self-management is critical to the successful treatment of chronic illness, including HIV.\\n- Education and adherence counselling should focus on:\\n  - Mitigation of fear, anger, self-stigma, and discrimination.\\n  - Alleviation of grief, bewilderment, and stress among partners and family members.\\n  - Behaviour changes to support healthy living and prevent further HIV transmission.\\n  - Skills-building on how to live a healthy and productive life.\\n  - Identification and treatment of depression and substance abuse.\\n\\n### Settings for Counselling\\nHIV education and counselling can be provided in various settings, including facility-based individual, couples, family, and/or group counselling, as well as through community-based counselling and peer support groups.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 66,\n",
       "  'section': '## Standard Package of Care for PLHIV\\n\\nThe document outlines the Standard Package of Care for People Living with HIV (PLHIV), emphasizing the importance of health and rights, particularly through the Positive Health, Dignity, and Prevention (PHDP) framework.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 66,\n",
       "  'section': '## PHDP Framework\\n\\nPHDP (Positive Health, Dignity, and Prevention) is a comprehensive framework focusing on the health and rights of PLHIV. It aims to reduce the risk of onward transmission of HIV. The framework comprises 7 core domains of services that should be implemented in health facilities for PLHIV and their caregivers, alongside complementary community-based PHDP services.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 66,\n",
       "  'section': '## PHDP Domains and Components\\n\\nTable 4.2 outlines the specific domains and components for PHDP services:\\n\\n### Disclosure of HIV Status\\n- Assessment of disclosure status, especially to sexual partners.\\n- Assisted disclosure.\\n- For children and adolescents, evaluation and support for age-appropriate HIV disclosure.\\n\\n### Index Testing and Engagement\\n- HIV testing for sexual and drug-injecting partners and other at-risk family members.\\n- Enrollment of positive partners and family members into HIV care.\\n- Engagement of negative partners and family members in support for the index patient and PrEP.\\n\\n### Condom Use\\n- Risk reduction counseling.\\n- Encouragement of correct and consistent condom use.\\n- Provision of condoms at every visit.\\n\\n### Family Planning\\n- Assessment of pregnancy intentions.\\n- Pre-conception counseling.\\n- Recommendation for dual contraception until ready for pregnancy.\\n\\n### Sexually Transmitted Infections (STI)\\n- Screening for STI symptoms.\\n- Prevention strategies for STIs.\\n\\n### Treatment Adherence\\n- Emphasis on the benefits of adherence to clinical care and ART.\\n- Messaging on Undetectable=Untransmissible (U=U).\\n\\n### Pre-Exposure Prophylaxis (PrEP)\\n- Assessment of HIV-negative sexual partners for the utilization of PrEP.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 66,\n",
       "  'section': '## Additional Services\\n\\nThe document further notes that beyond the aforementioned components, additional services for PLHIV should include screening for Gender-Based Violence (GBV) and Intimate Partner Violence (IPV), as well as comprehensive HIV education and counseling services.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 67,\n",
       "  'section': '## Screening for Gender-Based Violence (GBV)/Intimate-Partner Violence (IPV)\\n\\nNational data (KDHS 2014) shows that 45% of women and 44% of men aged 15-49 years have experienced physical violence since age 15. Additionally, 14% of women and 6% of men in the same age bracket report having experienced sexual violence at least once in their lifetime. To identify these survivors, screening is recommended.\\n\\nThe WHO recommends that facilities meet certain minimum requirements before implementing routine screening of clients. These requirements include:\\n\\n- A protocol or Standard Operating Procedure for providing post-GBV and Violence Against Children services\\n- A questionnaire with standard questions for documentation\\n- First-line support (LIVES) offered by providers\\n- Providers trained in how to inquire about GBV and Violence Against Children\\n- A private setting ensuring confidentiality\\n- A system for referrals or linkages to other services within the facility\\n\\nIf any of these minimum requirements are missing, GBV and Violence Against Children services are considered inadequate. Providers should have these systems in place before conducting routine inquiries or universal screenings.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 67,\n",
       "  'section': '## Screening Clients Accessing HIV Care Services\\n\\nAll clients accessing HIV care services should be screened for any form of violence, including IPV, as part of the standard package of care for People Living with HIV (PLHIV).\\n\\n### Screening Script\\n\\nThe following script can be used when screening:\\n\\n“Many people do not realize that violence can lead to various serious health problems. Many people have problems with their husbands, partners, or other people in their lives. Sometimes the people who love us can hurt us. Has this ever happened to you?”\\n\\nThe specific questions to ask include:\\n\\n1. Has your partner ever insulted you or made you feel bad about yourself?\\n2. Has your partner belittled or humiliated you in front of others?\\n3. Did your partner do things to scare or intimidate you on purpose?\\n4. Has your partner threatened to hurt you or someone you care about?\\n5. Has your partner slapped you or thrown something at you that could hurt you?\\n6. Has your partner kicked, dragged, or beaten you up?\\n7. Has your partner choked or burned you on purpose?\\n8. Has your partner threatened to use or actually used a gun, knife, or other weapon against you?\\n9. Has your partner physically forced you to have sexual intercourse when you did not want?\\n10. Did you ever have sexual intercourse you did not want because you were afraid of what he might do?\\n11. Has your partner forced you to do something sexual that you found degrading or humiliating?\\n\\nIf a survivor answers yes to any of these questions, provide them with LIVES and conduct a mental assessment.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 69,\n",
       "  'section': '## Kenya HIV Prevention and Treatment Guidelines, 2022\\n\\nA brief introduction to the guidelines focusing on the prevention and treatment of HIV in Kenya.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 69,\n",
       "  'section': '## Specific Opportunistic Infection Screening and Prevention\\n\\nOverview of the strategies recommended for screening and prevention of opportunistic infections in individuals with HIV.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 69,\n",
       "  'section': '## Cotrimoxazole Preventive Therapy (CPT)\\n\\n### Recommendations\\nCPT is no longer recommended as lifelong prophylaxis and is only suggested in specific subpopulations unless contraindications exist.\\n\\n### Subpopulations for CPT\\n- **HIV exposed infants**\\n- **HIV infected children and adolescents <15 years of age**\\n- **People Living with HIV (PLHIV) > 15 years of age**:\\n  - Living in malaria-endemic zones\\n  - Presenting with WHO stage 3 or 4 event or meeting the criteria for Advanced HIV Disease (AHD)\\n  - Suspected treatment failure\\n- **All pregnant and breastfeeding women**\\n\\n### Timing for CPT\\nCPT should start at 6 weeks of age for HIV exposed and infected infants.\\n\\n### Effectiveness of CPT\\nCPT is effective in AHD, preventing specific opportunistic infections (OIs) in patients with low CD4 counts (e.g., PCP and toxoplasmosis), and reduces the risk of common bacterial infections, sepsis, diarrhea, and malaria.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 69,\n",
       "  'section': '## Co-trimoxazole Preventive Therapy Table\\n\\n### Sub-population\\n- **HIV exposed Infants**\\n  - **Starting/Restarting criteria**: All infants, starting 4-6 weeks after birth\\n  - **Ending criteria**: Child is confirmed HIV-negative\\n\\n- **HIV-infected children and adolescents ≤ 15 years old**\\n  - **Starting/Restarting criteria**: All children\\n  - **Ending criteria**: Attains 15 years of age\\n\\n- **PLHIV > 15 years old**\\n  - **Starting/Restarting criteria**: Suspected treatment failure, WHO Clinical Stage 3 and 4\\n  - **Ending criteria**: Clinically stable:\\n    - On ART for at least 12 months\\n    - Showing no signs or symptoms of WHO Clinical Stage 2, 3 or 4\\n\\n- **HIV-positive Pregnant and breastfeeding women**\\n  - **Starting/Restarting criteria**: All\\n  - **Ending criteria**: Clinically stable:\\n    - On ART for at least 12 months\\n    - Showing no signs or symptoms of WHO Clinical Stage 2, 3 or 4\\n    - Not pregnant or breastfeeding'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 65,\n",
       "  'section': '## Standard Package of Care for Adolescents Living with HIV\\n\\n### Clinical Care\\n- Provide immediate linkage to HIV care.\\n- Provide ART to all HIV-infected adolescents.\\n- Perform clinical and laboratory assessments.\\n- Conduct clinical assessment at every visit, treat infections early, and refer appropriately for specialized care.\\n- Screen for opportunistic infections and provide prophylaxis (cotrimoxazole, TPT).\\n- Provide nutrition assessment and support (NACS) and monitor growth and development.\\n- Provide/refer for HPV vaccine.\\n\\n### Adherence and Psychosocial Support\\n- Perform a baseline and regular subsequent psychosocial assessment.\\n- Assess for and support the disclosure of HIV status to the adolescent (refer to Annex 5).\\n- Enroll in age-appropriate psychosocial support groups.\\n- Provide treatment literacy.\\n- Provide life skills counseling.\\n- Provide adherence counseling.\\n- Support appropriate transition into adult HIV treatment and prevention.\\n\\n### Prevention of HIV Transmission\\n- Encourage index testing and support for disclosure.\\n- Assess for and manage drug and alcohol use.\\n- Perform a sexual risk assessment and STI screening and treatment, and link sexual partners to PrEP where applicable.\\n- Assess for and manage intimate partner violence (IPV).\\n- Provide reproductive health services, including pregnancy screening, pregnancy intention assessment, family planning, and linkage to prevention of mother-to-child transmission (PMTCT) for pregnant adolescents.\\n\\n### Referrals, Linkages, and Support for Continuum of Care\\n- Provide intra-facility and inter-facility referrals as needed for specialized care.\\n- Link with youth community groups, targeting youth both in and out of school.\\n\\n### Other Services\\n- Connect to various support services, including legal centers, paralegal services, gender-based violence recovery centers, educational institutions, bursary/scholarship programs, income-generating activities, constituency development funds, vocational training centers for skills development, etc.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 65,\n",
       "  'section': '## Antiretroviral Therapy (ART)\\n\\nART is recommended for all People Living with HIV (PLHIV), regardless of WHO stage, CD4 count, age, pregnancy status, or comorbidities/co-infections. Once a diagnosis of HIV infection is confirmed, ART should be initiated as soon as possible (preferably within 2 weeks), once patient readiness has been determined. \\n\\nOther sections of these guidelines deal with:\\n- Initial evaluation and monitoring (Chapter 3).\\n- Patient preparation and adherence support (Chapter 5).\\n- Specific recommended ART regimens (Chapter 6).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 72,\n",
       "  'section': '## Standard Package of Care for PLHIV\\n\\nOverview of the standard care protocols for people living with HIV (PLHIV).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 72,\n",
       "  'section': '## Tuberculosis (TB) Prevention and Management for PLHIV\\n\\nAll PLHIV should be screened for TB at every visit using the Intensified Case Finding (ICF) tool.  \\nAll PLHIV older than 12 months who screen negative for TB should be provided with TB Preventive Therapy (TPT) unless there are specific contraindications. Documentation of receiving a full course of TPT must be maintained in patient files.\\n\\nFor those with presumptive TB, GeneXpert ultra is the preferred testing method, with TB-LAM used as an additional bedside test while awaiting results. All PLHIV, including those with HIV/TB co-infection, are eligible for ART. Chapter 8 offers detailed guidelines on ICF, TPT, GeneXpert ultra, TB-LAM, and ART for TB/HIV co-infection.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 72,\n",
       "  'section': '## Cryptococcal Meningitis (CM) Screening and Treatment\\n\\nAll adult and adolescent PLHIV with a baseline CD4 count of ≤ 200 cells/mm³ should be screened for cryptococcal infection as a reflex test performed by the laboratory. PLHIV should also receive cryptococcal screening if clinically suspected.\\n\\nFor symptomatic patients with negative serum CrAg, alternative diagnoses like TB meningitis should be considered. Patients with clinical meningitis must be assessed at a facility that can perform lumbar punctures. \\n\\nWhen conducting CSF CrAg tests for symptomatic meningitis, CSF GeneXpert ultra for TB and urine TB-LAM tests should be performed concurrently. \\n\\nFluconazole use during the first trimester of pregnancy may increase the risk of birth defects. Pregnant women who screen positive with serum CrAg should undergo a lumbar puncture to check for cryptococcal meningitis. If CSF CrAg is positive, treat with 2 weeks of amphotericin B without fluconazole, while consulting the Uliza! Hotline for further guidance. If negative, they should begin ART immediately and be monitored for symptoms of CM. \\n\\nTable 4.7 contains detailed guidance on the use of amphotericin, fluconazole, flucytosine (when available), and therapeutic lumbar punctures in managing symptomatic cryptococcal meningitis.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 75,\n",
       "  'section': '## Overview of HIV Management for Newly Diagnosed Patients\\n\\nThis section outlines the initial management steps for adults or adolescents who are newly diagnosed with HIV, particularly focusing on those with a CD4 count of 200 cells/mm³.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 75,\n",
       "  'section': '## CrAg Screening Protocol\\n\\nDiscusses the automatic/reflex screening for Cryptococcus antigen (CrAg) and actions based on the screening results, including:\\n\\n- **Symptomatic Patients**: Admission and lumbar puncture for CSF analysis.\\n- **Asymptomatic Patients**: Presumptive treatment protocols for possible cryptococcal meningitis.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 75,\n",
       "  'section': '## Treatment for CrAg Positive Patients\\n\\nDetails treatment procedures for patients with positive CrAg, including:\\n\\n- Initial treatment for cryptococcal meningitis, using amphotericin and fluconazole.\\n- Recommendations for therapeutic lumbar punctures.\\n- Deferment of antiretroviral therapy (ART) until completion of a 5-week treatment regimen.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 75,\n",
       "  'section': '## Treatment for CrAg Negative Patients\\n\\nCovers the management of asymptomatic patients with a negative CrAg result, including:\\n\\n- Pre-emptive therapy protocols, with specific fluconazole dosing guidelines.\\n- The need to defer ART until the completion of treatment and resolution of symptoms.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 75,\n",
       "  'section': '## Importance of Lumbar Puncture\\n\\nEmphasizes the necessity of lumbar punctures for all CrAg positive patients, with a focus on management emanating from LP results. Highlights treatment decisions when LP is unavailable.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 75,\n",
       "  'section': '## Risks and Special Considerations\\n\\nDescribes the risks associated with cryptococcal meningitis, particularly regarding the development of Immune Reconstitution Inflammatory Syndrome (IRIS), and the significance of deferring ART to enhance survival.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 75,\n",
       "  'section': '## Considerations for Pregnant Women\\n\\nAddresses the unique considerations for pregnant women who test positive for serum CrAg, including the need for lumbar puncture irrespective of symptoms and caution regarding fluconazole usage during pregnancy due to potential birth defects risks.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 75,\n",
       "  'section': '## Special Dosing Recommendations\\n\\nProvides specifics on dose adjustments for fluconazole based on renal function, interactions with other medications, and monitoring guidelines after high-dose fluconazole use.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 75,\n",
       "  'section': '## Conclusion on Treatment Initiation\\n\\nStates that no cryptococcal treatment is required for CrAg negative patients and emphasizes the initiation of ART within 2 weeks after determining the CrAg status.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 73,\n",
       "  'section': '## Treatment of Cryptococcal Meningitis in Adults\\n\\nThis section provides the treatment regimens for adults diagnosed with cryptococcal meningitis. \\n\\n**Preferred Regimen:**\\n- Induction (2 weeks): Ampho B 1.0 mg/kg/day + Fluconazole 1,200 mg/day\\n- Consolidation (8 weeks): Fluconazole 800 mg/day\\n- Maintenance: Fluconazole 200 mg/day for at least 1 year or until CD4 count > 200 cells/mm³ for two measures 6 months apart and VL is undetectable.\\n\\n**When to start ART:**\\n- Defer ART until after completing 5 weeks of cryptococcal meningitis treatment and resolution of symptoms.\\n\\n**Alternative Regimen:**\\n- Induction: Fluconazole 1,600 mg daily\\n- Consolidation: Fluconazole 800 mg daily'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 73,\n",
       "  'section': '## Treatment of Cryptococcal Meningitis in Children and Adolescents\\n\\nThis section details the treatment approach for children and adolescents with cryptococcal meningitis.\\n\\n**Preferred Regimen:**\\n- Induction (2 weeks): Ampho B 1.0 mg/kg/day + Fluconazole 12 mg/kg/day (up to max 800 mg/day)\\n- Consolidation (8 weeks): Fluconazole 6 - 12 mg/kg/day up to 800 mg/day\\n- Maintenance: Fluconazole 6 mg/kg/day up to 200 mg/day\\n\\n**Alternative Regimen:**\\n- Induction: Fluconazole 12 mg/kg/day (up to max 1,600 mg/day)\\n- Consolidation: Fluconazole 12 mg/kg/day up to 800 mg/day\\n- Maintenance: Fluconazole 6 mg/kg/day up to 200 mg/day'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 73,\n",
       "  'section': '## Important Considerations for Amphotericin B and Fluconazole\\n\\nThis section outlines critical considerations regarding the use of Amphotericin B and Fluconazole in treatment regimens.\\n\\n1. Amphotericin B should be used for induction when available. If not possible due to availability, toxicity, or monitoring, a shorter duration should be combined with an alternative regimen to complete the 14-day induction.\\n   \\n2. Once available, flucytosine may be incorporated into the preferred and alternative induction regimens, administered as 100 mg/kg per day divided into four doses.\\n\\n3. Fluconazole requires a dose adjustment for patients with impaired renal function; when CrCl ≤ 50 ml/min, use 50% of the standard recommended dose.\\n\\n4. Fluconazole should not be used with rifabutin-based TB treatment.\\n\\n5. High-dose Fluconazole requires monitoring; check ALT after one week of treatment and based on symptoms thereafter.\\n\\n6. Fluconazole is contraindicated in the first trimester of pregnancy. Amphotericin B can be used; consult expert or National or Regional TWG.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 78,\n",
       "  'section': '## Standard Package of Care for PLHIV\\n\\nThis section outlines the essential components of care for people living with HIV (PLHIV). It emphasizes the importance of Antiretroviral Therapy (ART) and adherence to routine health checks to optimize health outcomes.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 78,\n",
       "  'section': '## Pre-Conception Counselling Overview\\n\\nThis section discusses the significance of pre-conception counselling for women and couples with an intention to conceive. The focus is on ART initiation, managing viral suppression, and reducing transmission risks.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 78,\n",
       "  'section': '## Key Counselling Messages for All PLHIV Intending to Conceive\\n\\nThis section details the critical messages for all PLHIV who plan to conceive. It includes the importance of ART, viral suppression, timing of unprotected sex, and the role of prenatal care.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 78,\n",
       "  'section': '## Pre-Conception Services for All PLHIV\\n\\nThis section outlines additional pre-conception services for PLHIV, including necessary health assessments and support services aimed at improving maternal and infant health outcomes.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 78,\n",
       "  'section': '## Additional Messages for Discordant Couples: Male Partner HIV Positive\\n\\nThis section provides specific guidance for discordant couples where the male partner is HIV positive. It covers delaying unprotected sex, discussing HIV prevention options, and referral for specialized treatments when needed.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 78,\n",
       "  'section': '## Additional Messages for Discordant Couples: Female Partner HIV Positive\\n\\nThis section addresses the unique considerations for discordant couples with the female partner being HIV positive. It includes advice on self-insemination and the challenges of maintaining viral suppression, along with recommendations for specialist referrals.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 76,\n",
       "  'section': '## Standard Package of Care for PLHIV\\n\\nThis section provides an overview of the essential care guidelines tailored for individuals living with HIV (PLHIV).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 76,\n",
       "  'section': '## Reproductive Health Services\\n\\nDetails the reproductive health services available for PLHIV, focusing on sexually transmitted infections and family planning.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 76,\n",
       "  'section': '### 4.4.1 Sexually Transmitted Infections\\n\\n- Screening for syphilis is essential for all adolescent and adult PLHIV using VDRL, TPHA, or RPR as a baseline investigation. Pregnant women should be screened during the first ANC visit and the third trimester.\\n- All PLHIV must be evaluated for STI symptoms following the National Algorithm for Treating Common STI Syndromes (Kenya National guidelines for management and control of STIs, 2018, Annex 4). Treatment for sexual partners is also recommended.\\n- Risk reduction counseling and condom provision are critical components of STI treatment.\\n- Patients exhibiting persistent signs and symptoms of STIs after syndromic treatment should receive further diagnostic evaluation for definitive diagnosis and treatment.\\n- At the initial HIV diagnosis, all sex workers should be treated for presumptive gonorrhea and chlamydia, following national STI guidelines’ recommendations, with presumptive treatment every quarter.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 76,\n",
       "  'section': '### 4.4.2 Family Planning and Pre-Conception Counselling\\n\\n- Pregnancy status should be assessed for all women of reproductive age during every visit. If uncertain, a urine pregnancy test should be conducted.\\n- It’s important to determine pregnancy intentions for all women of reproductive age and their partners to provide suitable family planning or pre-conception counseling.\\n- For patients not wanting to become pregnant immediately, dual contraception (condoms plus another effective method) should be provided right away, with follow-up appointments to ensure consistent contraception provision. Table 4.8 outlines contraception options for PLHIV based on the ARVs they are using.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 71,\n",
       "  'section': '## Cotrimoxazole Desensitization Protocols\\n\\nThis section outlines the protocols for desensitization to cotrimoxazole for patients who have fully recovered from a moderate reaction.\\n\\n### Standard Cotrimoxazole Desensitization Regimen (8 days)\\n\\n#### Dosage Schedule\\n- **Day 1**: 0.5 ml\\n- **Day 2**: 1 ml\\n- **Day 3**: 2 ml\\n- **Day 4**: 3 ml\\n- **Day 5**: 4 ml\\n- **Day 6**: 5 ml\\n- **Day 7**: 1 SS tablet\\n- **Day 8**: 2 SS tablets or 1 DS tablet per day\\n\\n**Note**: For children, continue up until they have reached their recommended weight-based dosage.\\n\\n### Rapid Cotrimoxazole Desensitization Regimen (6 hours)\\n\\n#### Dosage Schedule\\n- **Hour 0**: 0.5 ml\\n- **Hour 1**: 1 ml\\n- **Hour 2**: 2 ml\\n- **Hour 3**: 3 ml\\n- **Hour 4**: 4 ml\\n- **Hour 5**: 5 ml\\n- **Hour 6**: 1 SS tablet\\n\\n**Note**: The rapid desensitization protocol should not be used for children due to the high cumulative dosage.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 71,\n",
       "  'section': '## Dapsone as a Substitute for Cotrimoxazole Prophylaxis Therapy (CPT)\\n\\nThis section explains the use of dapsone as an alternative to cotrimoxazole for patients with severe allergy or unsuccessful desensitization.\\n\\n### Indications and Limitations\\n- Dapsone is effective only as prophylaxis against PCP but lacks the other prophylactic benefits of cotrimoxazole.\\n- It may contribute to anemia in most patients and can cause hemolytic anemia in some. A baseline hemoglobin (Hb) level should be checked before starting treatment, and Hb should be monitored every 1-2 weeks for the first couple of months.\\n\\n### Patient Selection Criteria\\n- Dapsone is recommended only for patients in WHO Stage 4 and/or with absolute CD4 count ≤ 200 cells/mm³ (or CD4 % ≤ 25% for children ≤ 5 years old).\\n- The drug should be discontinued once a patient achieves a sustained CD4 count of > 200 cells/mm³ (or > 25% for children ≤ 5 years old) for at least 6 months.\\n- Dapsone is NOT recommended during breastfeeding.\\n\\n### Dosage Information\\n- **Available forms**: 25 mg and 100 mg tablets\\n- **Children**: 2 mg/kg once daily (maximum dose: 100 mg) or 4 mg/kg once weekly (maximum dose: 200 mg)\\n- **Adults**: 100 mg once daily'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 80,\n",
       "  'section': '## Standard Package of Care for PLHIV\\n\\nOverview of care protocols for people living with HIV (PLHIV), including recommended lifestyle modifications to improve health outcomes.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 80,\n",
       "  'section': '## Smoking Cessation\\n\\n### Benefits of Smoking Cessation\\n- Reduced premature aging/wrinkling of skin\\n- Improved fitness and quicker recovery from common infections\\n- Reduced risk of respiratory infections and chronic lung disease\\n- Reduced risk of high blood pressure, diabetes, kidney disease, heart disease, and stroke\\n- Improved infant outcomes for pregnant women\\n- Reduced risk of various cancers (lung, bladder, breast, mouth, throat, esophagus)\\n- Better response to ART (better viral suppression)\\n- Reduced risk of developing TB or dying from TB\\n\\n### Treatment and Support\\n- Tobacco dependence treatment should combine behavioral/counseling support with pharmacotherapy where applicable.\\n- For additional details on cessation interventions, refer to the Kenya National Guidelines for Tobacco Dependence Treatment.\\n- Refer to Table 4.18 for tips to assist clients in quitting smoking.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 80,\n",
       "  'section': '## Dietary Changes and Weight Loss\\n\\n### Recommendations for Healthy Diet\\n- Achieve and maintain a healthy BMI with help from nutritionists.\\n- Drink 8 glasses of water per day.\\n- Reduce or abstain from alcohol consumption.\\n- Cut down on sugar intake.\\n- Limit red meat consumption.\\n- Reduce the intake of fatty foods, fat for flavoring, and fried foods.\\n- Increase consumption of whole grains, vegetables, fruits, and beans.\\n- Increase fish intake.\\n- Limit salt consumption to less than 5g (approximately a teaspoon) per day.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 80,\n",
       "  'section': '## Physical Activity\\n\\n### Guidelines for Physical Activity\\n- Adopt an active lifestyle with moderate-intensity physical activity.\\n- Engage in at least 30 minutes of aerobic activity (e.g., brisk walking) at least 5 days per week.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 74,\n",
       "  'section': '## Standard Package of Care for PLHIV\\n\\nOverview of the standard care package for people living with HIV (PLHIV), serving as a guideline for appropriate treatment strategies.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 74,\n",
       "  'section': '## Managing and Monitoring for Amphotericin B Therapy\\n\\n### Adults\\n- Administer 1 L of normal saline with 20 mmol of KCl over 2-4 hours before each controlled infusion of Amphotericin B (Ampho B), given with 1 L of 5% dextrose.\\n- Add one to two tablets of 8 mEq KCl orally twice daily. An additional one 8 mEq KCl tablet twice daily may be added in the second week.\\n- Include magnesium supplementation at 250 mg of magnesium trisilicate twice daily (or 4 mEq of magnesium chloride twice daily).\\n\\n### Adolescents and Children\\n- Administer 1 L of normal saline with 20 mmol of KCl over 2-4 hours before each controlled infusion of Ampho B. Alternatives such as Darrows or Ringer’s solutions can be used.\\n- **Note:** Avoid KCl replacement in patients with pre-existing renal impairment or hyperkalemia.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 74,\n",
       "  'section': '## Managing Hypokalemia and Raised Creatinine Levels\\n\\n- Obtain a routine baseline and monitor potassium and creatinine levels twice weekly.\\n  \\n### Hypokalemia Management\\n- If potassium (K) < 3.3 mmol/L:\\n  - Administer 1 L of normal saline with KCl 40 mmol or 1-2 tablets of 8 mEq KCl every 8 hours.\\n  - Add magnesium supplementation and monitor potassium levels daily.\\n\\n### Raised Creatinine Management\\n- If creatinine level increases > 2-fold from baseline:\\n  - Omit dose of Ampho B and increase hydration to 1 L every 8 hours.\\n  - If improvements are seen, re-start Ampho B at 0.7 mg/kg/day on alternate days.\\n  - If no improvement, discontinue Ampho B and give fluconazole 1,600 mg/day to complete induction, monitoring creatinine daily.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 74,\n",
       "  'section': '## Therapeutic Lumbar Punctures\\n\\nA critical component of managing cryptococcal meningitis (CM) that should be standardized in care.\\n\\n### Guidelines for Therapeutic Lumbar Punctures\\n- For all patients with symptomatic CM, perform daily therapeutic lumbar punctures (LPs):\\n  - If opening pressure is ≤ 40 cm, draw off enough cerebrospinal fluid (CSF) to reduce pressure to 20 cm.\\n  - If opening pressure is > 40 cm, draw off enough CSF to reduce pressure by 50%.\\n  - Continue daily LPs until normal pressure is maintained for three consecutive days.\\n  - Restart LPs if symptoms return.\\n\\n### Alternative Measures\\n- If measuring intracranial pressure is not possible, perform daily therapeutic LPs until severe headaches subside, removing 10-20 ml of CSF each time.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 70,\n",
       "  'section': '## Standard Package of Care for PLHIV\\n\\nThis section outlines the standard package of care for people living with HIV (PLHIV), focusing on the administration of Cotrimoxazole Preventive Therapy (CPT).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 70,\n",
       "  'section': '## Cotrimoxazole Preventive Therapy Dosage\\n\\n### Daily Dose Table\\n\\n| Weight (kg) | If using oral suspension (240mg per 5ml) | If using single strength tablet 480 mg (SS) | If using double strength tablet 960 mg (DS) |\\n|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 70,\n",
       "  'section': '-|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 70,\n",
       "  'section': '-|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 70,\n",
       "  'section': '|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 70,\n",
       "  'section': '|\\n| 1 – 4      | 2.5 ml                                    | ¼ SS tab                                   | --                                          |\\n| 5 – 8      | 5 ml                                      | ½ SS tab                                   | ¼ DS tab                                   |\\n| 9 – 16     | 10 ml                                     | 1 SS tab                                   | ½ DS tab                                   |\\n| 17 – 30    | 15 ml                                     | 2 SS tabs                                  | 1 DS tab                                   |\\n| > 30       | 20 ml                                     | 2 SS tabs                                  | 1 DS tab                                   |\\n| Adult (any weight) |                                   | 2 SS tabs                                  | 1 DS tab                                   |\\n\\n**Notes:**\\n- If Creatinine Clearance (CrCl) is between 15 - 30 ml/min, use 50% of the normal recommended dose.\\n- If CrCl < 15 ml/min, Cotrimoxazole (CTX) should be avoided.\\n- During pregnancy, CPT should be initiated regardless of gestational age and continued throughout pregnancy and breastfeeding. Additional intermittent preventive therapy for malaria is not required for women on CPT.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 70,\n",
       "  'section': '## Side Effects of Cotrimoxazole\\n\\nThis section highlights common side effects associated with Cotrimoxazole, including anemia, neutropenia, and skin rash.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 70,\n",
       "  'section': '## Management of Patients with Cotrimoxazole Allergy\\n\\n### Rash Management Guidelines\\n\\n- A rash may develop 7-14 days after starting CPT, usually mild and maculopapular. Severe cases may lead to exfoliation and Stevens-Johnson syndrome.\\n- Management should be based on rash severity as outlined below.\\n\\n### Severity Characteristics and Actions\\n\\n| Severity | Characteristics | Action |\\n|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 70,\n",
       "  'section': '-|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 70,\n",
       "  'section': '--|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 70,\n",
       "  'section': '--|\\n| Mild     | Dry; erythema +/- fine papules; pruritus; affecting < 50% of body surface area | Continue CTX; close monitoring; symptomatic treatment with antihistamines +/- topical steroids (NOT oral steroids) |\\n| Moderate | Dry; erythema +/- fine papules; pruritus; affecting ≥ 50% of body surface area | Stop CTX; symptomatic treatment with antihistamines +/- topical steroids (NOT oral steroids); consider desensitization after symptoms resolve |\\n| Severe   | Mucosal involvement; blistering; associated fever; any % of body surface area | Stop CTX; admission to hospital for supportive management; do not re-challenge patient with CTX or other sulfa-containing drugs; document and report adverse event |'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 70,\n",
       "  'section': '## Desensitization Procedures\\n\\nThis section describes the effectiveness of desensitization in patients experiencing mild to moderate rash and includes details on a rapid desensitization regimen for those needing treatment for Pneumocystis pneumonia (PCP).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 83,\n",
       "  'section': '## Dyslipidemia Screening for PLHIV\\n\\n● Fasting lipid profile should be evaluated at baseline for all PLHIV, then annually if baseline screening is normal.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 83,\n",
       "  'section': '## Diagnosis of Dyslipidemia\\n\\n● Dyslipidemia is defined as high fasting total cholesterol (>5.2 mmol/L), LDL (>3.4 mmol/L) or triglycerides (>2.2 mmol/L).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 83,\n",
       "  'section': '## Initial Management of Dyslipidemia\\n\\n### Lifestyle Modifications\\n● Implement lifestyle modification for 3-6 months.\\n\\n### ARV Considerations\\n● If the patient is on an ARV known to cause or exacerbate dyslipidemia (primarily LPV/r & EFV), consider a single-drug substitution to a more lipid-friendly drug (such as ATV/r or DTG) before adding a lipid-lowering drug. Ensure to rule out treatment failure before making single-drug substitutions.\\n\\n### Pharmacological Treatment\\n● If patient does not meet treatment target with lifestyle modifications, then add drugs:\\n  - Atorvastatin: starting dose of 10 mg OD (maximum dose 20 mg once daily if patient is on a PI/r; maximum dose 80 mg once daily if not on a PI/r).\\n  - Simvastatin and lovastatin are contraindicated in the presence of PI/r.\\n  - Allow at least 3 months before repeating fasting lipids and titrating dose.\\n\\n### Monitoring\\n● Once targets achieved, can monitor lipids every 6-12 months.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 81,\n",
       "  'section': '## Kenya HIV Prevention and Treatment Guidelines, 2022\\n\\nOverview of the guidelines and their importance in the management of HIV.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 81,\n",
       "  'section': '## Hypertension Screening\\n\\n- BP should be measured and recorded for every adult at every visit to ensure early detection.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 81,\n",
       "  'section': '## Hypertension Diagnosis\\n\\n- Hypertension requiring intervention is defined as BP ≥ 140/90 mmHg on at least 3 different occasions.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 81,\n",
       "  'section': '## Additional Investigations for Hypertension\\n\\n- **Urinalysis:** To assess for kidney disease and diabetes.\\n- **Creatinine, Na, K:** To assess kidney disease.\\n- **Blood Glucose:** To assess for diabetes.\\n- **Full Blood Count:** To check for anemia, which may indicate chronic kidney disease.\\n- **Lipid Profile:** To evaluate dyslipidemia as a cardiovascular risk factor.\\n- **ECG:** To assess for cardiac pathology including cardiomegaly, ventricular dysfunction, ischemic heart disease, etc.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 81,\n",
       "  'section': '## Management of Hypertension\\n\\n### Treatment Target\\n\\n- The treatment target is BP < 140/90 mmHg.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 81,\n",
       "  'section': '### Management for Pre-Hypertension (BP 120-139/80-89)\\n\\n- Lifestyle modification, along with monthly BP monitoring.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 81,\n",
       "  'section': '### Management for Stage 1 Hypertension (BP 140-159/90-99)\\n\\n- Lifestyle modification (refer to Table 4.9) for up to 6 months, along with monthly BP monitoring.\\n- If the target is not met, add antihypertensive drugs:\\n  - **For PLHIV without kidney disease or diabetes:** First-line is a thiazide diuretic (e.g., hydrochlorothiazide 12.5 mg OD, max 25 mg OD) or a calcium channel blocker (e.g., amlodipine 2.5 mg OD, max 10 mg OD).\\n  - **For PLHIV with kidney disease or diabetes:** First choice is an ACE-I or ARB (e.g., enalapril 2.5-10 mg OD, max 20 mg BD; or losartan 50 mg OD, max 100 mg OD).\\n- Introduce one drug at a time. Increase dosage if target BP not reached within one month, then consider adding an additional agent.\\n- Consult or refer to a physician if inadequate response to two agents is observed.\\n- Note: Calcium channel blockers have known drug interactions with PIs and NNRTIs and should be used with caution.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 81,\n",
       "  'section': '### Management for Stage 2 Hypertension (BP ≥ 160/100)\\n\\n- Initiate lifestyle modifications and introduce anti-hypertensive medications concurrently.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 79,\n",
       "  'section': '## Maternal Healthcare\\n\\nMaternal healthcare begins with preconception counselling and continues throughout pregnancy and breastfeeding. The standard package of antenatal and postnatal services in the context of HIV is described in Chapter 7 of these guidelines.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 79,\n",
       "  'section': '## Non-communicable Diseases Screening and Management\\n\\n### Metabolic Disorders\\n\\nScreening, prevention, and management of specific non-communicable diseases (NCDs) are included in the standard package of care for People Living with HIV (PLHIV) because of their associated high morbidity and mortality. PLHIV are at a higher risk for cardiovascular, liver, and kidney diseases due to the chronic inflammatory state associated with HIV infection and as a side effect of some Antiretroviral Treatments (ARVs).\\n\\n#### Modifiable and Non-modifiable Risk Factors\\n\\nThe modifiable risk factors for cardiovascular disease include:\\n- Tobacco use and exposure to tobacco smoke\\n- Unhealthy diets\\n- Overweight/obesity\\n- Physical inactivity\\n- Harmful use of alcohol\\n- Hypertension\\n- Diabetes\\n- Hyperlipidemia\\n- Infections such as rheumatic fever and HIV\\n\\nNon-modifiable risk factors include:\\n- Advancing age\\n- Sex\\n- Race/ethnicity\\n- Family history\\n\\n### Health System Integration\\n\\nHIV and other chronic diseases require health systems that support chronic care and adherence. Management should be integrated at health facilities, including at the primary care level. Lifestyle modifications are always the first line of prevention and management for hypertension, diabetes mellitus (DM), and dyslipidaemia. These recommendations should be integrated into routine HIV treatment and prevention.\\n\\n### Recommendations for Screening and Management\\n\\nRecommendations for screening, diagnosis, and initial management of hypertension, type 2 DM, dyslipidaemia, and chronic kidney disease (CKD) are provided in specified tables. For comprehensive guidelines on prevention, diagnosis, and management of diabetes and cardiovascular diseases, refer to the Kenya National Clinical Guidelines for the Management of Diabetes and the Kenya National Guidelines for Cardiovascular Diseases Management, respectively.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 86,\n",
       "  'section': '## Standard Package of Care for PLHIV\\n\\nThis section outlines the essential care package for people living with HIV (PLHIV), focusing on tertiary prevention. It emphasizes cancer management, prevention of complications, treatment of side effects, and secondary cancers. For specific screening, diagnosis, and management recommendations, it advises referring to national guidelines and suggests that patients may need to be referred to regional and national hospitals that offer comprehensive oncology services.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 86,\n",
       "  'section': '## Mental Health Screening and Management\\n\\nPLHIV are prone to psychological disturbances due to both the disease itself and societal perceptions surrounding it. This section highlights common issues such as depression, anxiety, internalized stigma, post-traumatic stress disorder (PTSD), cognitive challenges, and perceived lack of social support. The discussion encompasses how these issues can adversely affect well-being and treatment adherence, with a particular focus on depression and substance abuse.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 86,\n",
       "  'section': '## Depression in PLHIV\\n\\nDepression is prevalent among PLHIV, who face a significantly increased risk—3 to 6 times more likely than the general population—which can result in substantial disability and poor treatment outcomes if not addressed. This section discusses the importance of identifying and managing depression as it can severely impact adherence to treatment and overall health.\\n\\n### Screening for Depression\\n\\nIt is recommended that all PLHIV undergo basic screening for depression upon enrollment and annually thereafter. The screening process includes two questions aimed at assessing the patient\\'s mental state over the previous two weeks. If patients respond \"yes\" to either question, further screening with the PHQ-9 tool is advised, especially for those with detectable viral loads after several months on antiretroviral therapy (ART).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 86,\n",
       "  'section': '## PHQ-9 Screening and Management\\n\\nThis subsection details the PHQ-9 screening tool used for diagnosing depression among PLHIV. The management strategies are guided by the PHQ-9 score to ensure tailored care and support for those identified as needing further mental health intervention. This approach is critical for improving health outcomes in PLHIV and ensuring adherence to ART.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 77,\n",
       "  'section': '## Contraceptive Methods for PLHIV\\n\\nThis section describes various contraceptive methods for People Living with HIV (PLHIV) based on the WHO 2018 Medical Eligibility Criteria. The table includes contraceptive methods alongside the types of antiretroviral (ARV) medications being used.\\n\\n| Contraceptive Method | NRTI (any) | NNRTI | PI/r (any) | INSTI | Rifampicin/Rifabutin | EFV/NVP | ETR | RAL | DTG* |\\n|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 77,\n",
       "  'section': '-|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 77,\n",
       "  'section': '--|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 77,\n",
       "  'section': '--|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 77,\n",
       "  'section': '|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 77,\n",
       "  'section': '-|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 77,\n",
       "  'section': '-|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 77,\n",
       "  'section': '|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 77,\n",
       "  'section': '--|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 77,\n",
       "  'section': '--|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 77,\n",
       "  'section': '--|\\n| IM medroxyprogesterone (DMPA; Depo Provera) | 1         | 1      | 1          | 1     | 1                    | -       | 1   | -   | 1   |\\n| Norethisterone enanthate (NET-EN; norethindrone) | 1         | 2      | 1          | 2     | 1                    | -       | 2   | -   | 2   |\\n| Implants             | 1         | 2      | 1          | 2     | 1                    | -       | 2   | -   | 2   |\\n| Combined oral contraceptive (pill) | 1         | 2      | 1          | 2     | 1                    | -       | 3   | -   | 2   |\\n| Intrauterine device (IUD) | Category 2 for asymptomatic or mild HIV disease. |'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 77,\n",
       "  'section': '|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 77,\n",
       "  'section': '|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 77,\n",
       "  'section': '|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 77,\n",
       "  'section': '|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 77,\n",
       "  'section': '|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 77,\n",
       "  'section': '|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 77,\n",
       "  'section': '|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 77,\n",
       "  'section': '|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 77,\n",
       "  'section': '## Category Definitions for Contraceptive Methods\\n\\nThis section defines the categories used to specify the eligibility for different contraceptive methods with respect to HIV:\\n\\n- **Category 1**: No restriction for the use of the contraceptive method.\\n- **Category 2**: Advantages of using the method generally outweigh the theoretical or proven risks.\\n- **Category 3**: The theoretical or proven risks usually outweigh the advantages of using the method.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 77,\n",
       "  'section': '## Specific Contraceptive Recommendations\\n\\nThis section provides specific recommendations on the use of various contraceptive methods for PLHIV:\\n\\n- **IUD**  \\n  - **Initiation**: Category 2 for asymptomatic or mild HIV disease (WHO Stage 1 or 2).  \\n  - **Continuation**: Category 2 for all women regardless of symptomatic HIV (do not require IUD to be removed).\\n  \\n- **Condoms**: No restrictions; use encouraged in combination with a hormonal contraceptive method or IUD as part of dual family planning (FP) to prevent STI/HIV transmission.\\n\\n- **Emergency contraceptive pill (ECP)**: No restrictions; can be started up to 5 days after intercourse.\\n\\n- **Sterilization**: No reason to deny; delay in case of acute HIV-related infection.\\n\\n- **Fertility awareness-based (FAB) methods**: Can use if menstrual cycle is regular, although reliability is not as good as hormonal contraceptive methods or an IUD. Encourage to use in combination with condoms to prevent STI/HIV transmission.\\n\\n- **Lactational amenorrhoea method (LAM)**: Effective for women who are less than 6 months postpartum, exclusively breastfeeding, and have not resumed menses. Encourage to use in combination with condoms to prevent STI/HIV transmission.\\n\\n- **Spermicides and diaphragm**: Use is not recommended; may increase the risk of HIV transmission.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 77,\n",
       "  'section': '## Pre-Conception Messages and Services\\n\\nThis section outlines key pre-conception messages and services for patients who intend to become pregnant, as presented in Table 4.9. Details on these messages can help ensure the health of both the mother and the child in the context of HIV.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 89,\n",
       "  'section': '## Kenya HIV Prevention and Treatment Guidelines Overview\\n\\nThe document discusses the guidelines for HIV prevention and treatment in Kenya, specifically focusing on the impact of alcohol and drug use on treatment adherence and outcomes.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 89,\n",
       "  'section': '## Alcohol and Drug Use in PLHIV\\n\\nAlcohol and other drug use are prevalent among the general population and people living with HIV (PLHIV). These substances can significantly affect adherence to antiretroviral therapy (ART) and lead to HIV treatment failure.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 89,\n",
       "  'section': '## Screening for Alcohol and Drug Use\\n\\nAll adults and adolescents should be screened for alcohol and drug use prior to initiating ART and annually thereafter. The screening involves three key questions regarding alcohol consumption, marijuana use, and other drug use within the last 12 months.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 89,\n",
       "  'section': '## Additional Screening for Positive Responses\\n\\nPatients who respond “yes” to any of the initial screening questions or those with a detectable viral load after 3 months on ART require more thorough screening. Specific tools are recommended for adolescents and adults:\\n- **Adolescents:** CRAFFT screening tool\\n- **Adults:** CAGE-AID screening tool\\n\\nAnyone screening positive should receive further assessment and management by trained clinical staff.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 89,\n",
       "  'section': '## CRAFFT Screening Tool for Adolescents\\n\\nThe CRAFFT screening tool includes six questions that require yes/no responses. A positive response to two or more questions indicates a problem with alcohol or drug use and necessitates further assessment. Patients are encouraged to answer confidentially.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 89,\n",
       "  'section': '## Management of Alcohol and Drug Use Disorders\\n\\nManagement guidance for individuals with addiction issues is provided in Table 4.1 8 of the guidelines. The National Protocol for Treatment of Substance Use Disorders in Kenya offers more comprehensive advice on management strategies.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 89,\n",
       "  'section': '## Conclusion\\n\\nThe guidelines emphasize the importance of identifying and managing alcohol and drug use to improve adherence to HIV treatment and overall health outcomes for PLHIV.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 82,\n",
       "  'section': '## Standard Package of Care for PLHIV\\n\\nOverview of care guidelines and recommendations for People Living with HIV (PLHIV).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 82,\n",
       "  'section': '## Type 2 Diabetes Mellitus Screening for PLHIV\\n\\n### Screening\\n- Blood glucose (fasting or random) should be evaluated at baseline for all PLHIV.\\n- Annual reevaluation is necessary if baseline screening is normal.\\n- Urine dipstick for protein and glucose can be utilized if blood glucose testing is not available.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 82,\n",
       "  'section': '## Type 2 Diabetes Mellitus Diagnosis for PLHIV\\n\\n### Diagnosis Criteria\\n- Diabetes Mellitus is defined by any of the following:\\n  - Fasting blood sugar ≥ 7.0 mmol/L\\n  - Random blood sugar ≥ 11.1 mmol/L\\n  - HbA1c > 6.5%\\n  - Oral glucose tolerance test ≥ 11.1 mmol/L\\n- Abnormal results should be repeated to confirm diagnosis, especially for asymptomatic patients.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 82,\n",
       "  'section': '## Management of Diabetes for PLHIV\\n\\n### Treatment Targets\\n- Aim for HbA1c ≤ 7.0% or fasting blood sugar (FBS) between 4 - 7 mmol/L.\\n\\n### Pre-Diabetes Management\\n- For patients with pre-diabetes (abnormal results but not meeting diabetes criteria):\\n  - Monitor FBS or HbA1c every 3 months.\\n  - Encourage lifestyle modifications (see Table 4.10).\\n\\n### Diabetes Management\\n- For patients with diabetes:\\n  - Monitor HbA1c (or FBS if HbA1c is not available) every 3 months.\\n\\n### Lifestyle Modifications\\n- Implement lifestyle changes such as weight loss and nutritional support.\\n- Calculate glycaemic index of various foods for blood sugar control over a period of 3 - 6 months.\\n\\n### Medication Management\\n- If treatment targets are not met after lifestyle modifications, add medications:\\n  - **Metformin**:\\n    - Obtain baseline creatinine; do NOT use if creatinine clearance < 45 ml/min.\\n    - Start low dose (500 mg OD or BD) and titrate every 1 - 2 weeks until reaching 1 g BD (or max tolerated dose).\\n    - Be cautious: DTG may increase metformin plasma levels; monitor blood glucose.\\n  - If targets are not achieved with metformin after 3 - 6 months, consider other classes of drugs (e.g., sulphonylureas) or consult a specialist. Some patients may require insulin.\\n\\n### Regular Monitoring\\n- At every visit:\\n  - Conduct thorough history and physical exam to evaluate for hypoglycemia, cardiovascular disease risk factors, neuropathy, diabetic foot ulcers, and blood pressure.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 82,\n",
       "  'section': '## Additional Routine Screening for Diabetic Patients\\n\\n### Recommended Screening\\n- Annual ophthalmology examination for diabetic retinopathy.\\n- Annual urinalysis: initiate treatment with an ACE-I/ARB if proteinuria develops, even with normal blood pressure.\\n\\n### Note\\n- Patients with diabetes are at increased risk of developing tuberculosis (TB).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 92,\n",
       "  'section': '## Standard Package of Care for PLHIV\\n\\nThis section outlines the holistic care and support required for individuals living with HIV.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 92,\n",
       "  'section': '## Understanding Anxiety\\n\\nAnxiety and anxiety-related disorders are prevalent mental health conditions. They are characterized by a range of symptoms, including:\\n\\n- Feelings of nervousness\\n- Fear or worry that disrupts sleep and functioning\\n- A lack of appetite\\n- Trembling or tremulousness\\n- Sweating and clamminess of hands\\n\\nOther symptoms might include a racing heart, difficulty breathing, headaches, trouble falling asleep, and difficulty concentrating.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 92,\n",
       "  'section': \"## Addressing Anxiety in PLHIV\\n\\nConcerns regarding anxiety in the context of living with or caring for persons living with HIV may emerge during history-taking. It's essential to take these concerns seriously and engage with sincerity and compassion. \\n\\nMany concerns may be alleviated through basic reassurance, support, or even just by offering a listening ear during evaluation sessions.\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 92,\n",
       "  'section': '## Screening for Anxiety\\n\\nA quick screening tool can help determine whether identified anxiety requires further attention. The Generalized Anxiety Disorder Assessment (GAD-7) is a seven-item questionnaire designed to measure the severity of generalized anxiety disorder. Each item prompts the individual to rate the severity of their symptoms over the past two weeks.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 90,\n",
       "  'section': '## Standard Package of Care for PLHIV\\n\\nThis section outlines the recommended comprehensive care approach for individuals living with HIV. It emphasizes the importance of providing holistic services including medical treatment, psychological support, and lifestyle guidance.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 90,\n",
       "  'section': '## CAGE-AID Screening Questions for Adults\\n\\nThis section presents the CAGE-AID screening tool, which is used to assess individuals for potential alcohol and drug use disorders. The screening consists of four questions that require yes or no responses. A positive screen (two or more \"Yes\" answers) indicates the need for further assessment.\\n\\n### Screening Questions:\\n\\n1. Have you felt you should Cut down on your drinking or drug use?\\n2. Have people ever Annoyed you by criticizing your drinking or drug use?\\n3. Have you ever felt bad or Guilty about your drinking or drug use?\\n4. Have you ever had a drink or used drugs first thing in the morning to steady your nerves or to get rid of a hangover (Eye opener)?'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 90,\n",
       "  'section': '## Confidentiality Assurance\\n\\nThis section emphasizes the importance of confidentiality in the screening process. Patients are encouraged to answer honestly, knowing their responses will be kept confidential.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 90,\n",
       "  'section': '## Management Following Positive Screening\\n\\nThis section details the steps to take when a patient screens positive for substance use issues. If immediate referral to a mental health team is not possible, healthcare providers should assess the patient’s desire to quit and provide targeted support based on their stage of quitting.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 90,\n",
       "  'section': '## Additional Resources for Substance Use Disorders\\n\\nThis section highlights the National Protocol for Treatment of Substance Use Disorders in Kenya, directing health professionals to access additional resources for effective assessments and interventions related to substance use.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 84,\n",
       "  'section': '## Standard Package of Care for PLHIV\\n\\nThis section outlines the essential care guidelines for people living with HIV (PLHIV), focusing on the management of chronic kidney disease.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 84,\n",
       "  'section': '## Chronic Kidney Disease Screening, Diagnosis, and Initial Management for PLHIV\\n\\n### Screening\\n- **Urinalysis** (for protein) and **serum creatinine** should be evaluated at baseline for all PLHIV and monitored annually.\\n\\n### Diagnosis\\n- **Impaired renal function** is defined as creatinine clearance < 90 ml/min, or dipstick proteinuria ≥ 1 (see Annex 15 for CrCl calculations).\\n- Abnormal results should be **repeated to confirm diagnosis**.\\n- **Chronic kidney disease** is defined as evidence of kidney damage that persists for at least three months.\\n\\n### Management\\n- Management depends on the cause of the renal impairment; additional investigations and/or specialist consultation may be required.\\n- Consultations with a physician are recommended.\\n- Treat dehydration promptly and aggressively.\\n- If on a *TDF*-containing regimen, substitute with another ARV if CrCl < 50 ml/min (with exceptions for patients with HBV/HIV co-infection).\\n- Avoid **nephrotoxic drugs** (e.g., aminoglycosides and NSAIDs).\\n- Evaluate for and treat **hypertension**.\\n- All NRTIs except ABC require **dose adjustments** for renal impairment. NNRTIs, PIs, and INSTIs do not require dose adjustments for impaired renal function.\\n\\n**Note**: DTG may cause a small rise in serum creatinine levels, which does NOT represent a decline in renal function; close monitoring is recommended.\\n\\nPatients at higher risk for renal disease include those with:\\n- Pre-existing renal disease\\n- Hypertension\\n- Diabetes mellitus\\n- Severe wasting (weight below 60 kg in adults)\\n- Age > 45 years\\n- WHO stage 3 or 4\\n- CD4 < 200 cells/mm3\\n- High HIV viral load\\n- Concomitant nephrotoxic agents.\\n\\n**HIV-associated nephropathy (HIVAN)** is a significant cause of chronic kidney disease among PLHIV. Prevention, early identification, and management of kidney disease is crucial to reduce the burden of dialysis and other complications.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 84,\n",
       "  'section': '## Cancer Prevention, Early Detection, and Management among PLHIV\\n\\nPLHIV face a substantially higher risk for many cancers due to a weakened immune system, which impairs control over oncogenic viral infections. This elevated risk is influenced by a high prevalence of viral infections and modifiable risk factors such as smoking, alcohol use, unhealthy diet, and physical inactivity. \\n\\nPLHIV are significantly more likely than the general population to be diagnosed with:\\n- Kaposi Sarcoma\\n- Non-Hodgkin lymphoma\\n- Other cancers (cervical, anal, liver, lung, and oral/throat).\\n\\nThis highlights the importance of prioritizing **screening and early diagnosis programs** for this group.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 93,\n",
       "  'section': '## Anxiety Assessment Tool\\n\\nThis section introduces the Generalized Anxiety Disorder Assessment (GAD-7), which is designed to evaluate the level of anxiety in individuals. The assessment consists of seven items that participants respond to based on how often they\\'ve experienced problems over the last two weeks. The response options range from \"Not at all\" to \"Nearly every day.\" \\n\\n### Questions in the GAD-7:\\n1. Feeling nervous, anxious, or on edge\\n2. Not being able to stop or control worrying\\n3. Worrying too much about different things\\n4. Trouble relaxing\\n5. Being so restless that it is hard to sit still\\n6. Becoming easily annoyed or irritable\\n7. Feeling afraid as if something awful might happen\\n\\n### Scoring:\\n- Score 0-4: Minimal Anxiety\\n- Score 5-9: Mild Anxiety\\n- Score 10-14: Moderate Anxiety\\n- Score greater than 15: Severe Anxiety\\n\\nFollowing the assessment, treatment options such as referrals to psychologists or psychiatrists for possible psychotherapy and medication can be explored if necessary.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 93,\n",
       "  'section': '## Stress and Stress Management\\n\\nThis section discusses the concept of stress, defined as a feeling of emotional or physical tension. It outlines various symptoms associated with stress, which may include:\\n\\n- Aches and pains\\n- Palpitations\\n- Exhaustion\\n- Insomnia\\n- Headaches\\n- Dizziness or shaking\\n- Digestive problems\\n- Weak immune system\\n- Muscle or jaw tension\\n\\nPatients may experience these symptoms individually or in clusters, and they can significantly interfere with daily life. Additionally, potential sources of stress may arise from challenges related to understanding HIV, addressing personal concerns, or dealing with issues involving significant others.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 87,\n",
       "  'section': '## Patient Health Questionnaire - 9 (PHQ-9) Overview\\n\\nThe PHQ-9 is a tool used for screening depression in patients. It consists of 9 questions assessing the frequency of depressive symptoms over the past two weeks. Each question is rated on a scale from 0 (not at all) to 3 (nearly every day).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 87,\n",
       "  'section': '## PHQ-9 Questions\\n\\nThe following questions are to be asked to the patient to assess depressive symptoms:\\n\\n1. Little interest or pleasure in doing things\\n2. Feeling down, depressed, or hopeless\\n3. Trouble falling or staying asleep, or sleeping too much\\n4. Feeling tired or having little energy\\n5. Poor appetite or overeating\\n6. Feeling bad about yourself\\n7. Trouble concentrating on things\\n8. Moving or speaking slowly, or being restless\\n9. Thoughts of being better off dead or of hurting yourself\\n\\nPatients respond to each question, which contributes to their overall score.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 87,\n",
       "  'section': '## Scoring and Interpretation\\n\\nAfter completing the questionnaire, the total score is calculated by adding up the points for each response. The total score will help to interpret the severity of depression.\\n\\n### Score Ranges and Recommendations:\\n- **0-4:** Depression unlikely\\n  - Recommendation: Repeat screening in the future if new concerns arise.\\n  \\n- **5-9:** Mild depression\\n  - Recommendation: Provide counseling support and continue to monitor; refer to a mental health team if available. Consider substituting ARV if the patient is on EFV.\\n  \\n- **10-14:** Moderate depression\\n  - Recommendation: Provide supportive counseling, refer to a psychologist if available, and consider starting antidepressant medication. Refer to a medical officer, psychiatrist, or mental health team if available.\\n\\n- **15-27:** Moderate-severe to severe depression\\n  - Recommendation: Symptoms present for at least 2 weeks before considering treatment with antidepressants. Severe cases may require immediate initiation of antidepressants.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 87,\n",
       "  'section': '## Considerations for Antiretroviral Therapy (ARV)\\n\\nEFV (efavirenz) is known to potentially cause depression as an adverse drug reaction, though often mild and temporary. If patients on EFV experience persistent depressive symptoms, they should be switched to another ARV after ruling out treatment failure, following established clinical guidelines.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 96,\n",
       "  'section': '## Staying Connected\\n\\nThis section emphasizes the importance of staying connected with family, friends, and spiritual support systems. It highlights that disconnection can lead to increased physical and mental health issues, and maintaining these connections aids individuals in managing their lives and achieving mental health.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 96,\n",
       "  'section': '## Wellbeing\\n\\nAccording to the WHO, mental health is defined as a state of well-being in which individuals realize their own abilities, cope with the normal stresses of life, work productively, and contribute to their community.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 96,\n",
       "  'section': '## Support Structures for Wellbeing\\n\\nThis section outlines available support structures for wellbeing at different levels of implementation, including:\\n- Individual counselling\\n- Group therapy\\n- Networks of organizations providing support to various population categories, such as adolescents, men, and women.\\n\\nHealth workers in facilities are encouraged to initiate and maintain these support structures and establish referral systems for clients in need of services.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 96,\n",
       "  'section': '## Referral Systems for PLHIV\\n\\nThis section discusses the importance of referral systems for People Living with HIV (PLHIV). It outlines that referrals should include services addressing issues that may affect their mental health, such as social and financial challenges.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 85,\n",
       "  'section': '## Specific Interventions for Cancer Control in PLHIV\\n\\nFour interventions are important for cancer control among PLHIV:\\n\\n### Achieve Viral Suppression\\nUncontrolled viral replication is a major risk factor for cancer. All PLHIV should initiate ART, and be supported and monitored to achieve long-term viral suppression in order to reduce the risk of cancer and improve treatment outcomes for many cancers.\\n\\n### Primary Prevention through Avoidance of Modifiable Risk Factors\\n- **Smoking Cessation**\\n- **Avoidance of Harmful Use of Alcohol**\\n- **Regular Physical Activity**\\n- **Healthy Diets**\\n- **Vaccination**\\n  - Vaccination against Human Papillomavirus for girls 9-14 years old is eligible in Kenya.\\n  - Hepatitis B Vaccine for newborns and high-risk groups.\\n\\n### Secondary Prevention through Screening and Early Diagnosis\\n- **Screening:**\\n  - **Cervical Cancer:** All women living with HIV who have been sexually active up to 49 years old (25-49 years in the general population), through either visual inspection with acetic acid (VIA) or PAP smear annually, or HPV testing every 2 years.\\n  - **Breast Cancer:** Mammogram annually from 40-55 years; mammogram every two years from 56-74 years; screening for younger women can be performed on an individual basis based on family history or other risk factors. Clinical breast exam can be used where mammogram is not available.\\n  - **Prostate Cancer:** Serum prostate-specific antigen (PSA) annually for men 40 years and above; digital rectal examination can be used if PSA is not available, and for all men with urinary symptoms.\\n  - **Colorectal Cancer:** Fecal occult blood testing of stool (guaiac or FIT) annually for everyone 45-75 years old, or colonoscopy every 10 years.\\n  - **Oral Cancer:** Visual examination for everyone above 40 years with a history of tobacco use, known HPV infection, or immunosuppression.\\n\\n- **Early Diagnosis:**\\n  Prompt diagnosis of cancer in symptomatic individuals includes:\\n  - **Breast:** Lump, asymmetry, skin changes, nipple changes, blood-stained discharge.\\n  - **Cervix:** Post-coital bleeding, excessive vaginal discharge.\\n  - **Colon and Rectum:** Change in bowel habits, unexplained weight loss, anemia, blood in stool.\\n  - **Oral:** White or red lesions, growth, ulceration.\\n  - **Naso-pharynx:** Nosebleed, permanent blocked nose, deafness, lymph nodes in upper neck.\\n  - **Larynx:** Persistent hoarseness of voice.\\n  - **Stomach:** Upper abdominal pain, indigestion, weight loss.\\n  - **Skin:** Irregular growths, lesions, or non-healing sores.\\n  - **Bladder:** Painful or frequent urination, blood in urine.\\n  - **Prostate:** Difficulty (long time) in urination, frequent nocturnal urination.\\n  - **Retinoblastoma:** White spot in the pupil, convergent strabismus (in a child).\\n  - **Testis:** Swelling of one testicle.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 88,\n",
       "  'section': '## Standard Package of Care for PLHIV\\n\\nThis section outlines the comprehensive care approach for People Living with HIV (PLHIV), specifically focusing on depression management strategies, both supportive and pharmacological.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 88,\n",
       "  'section': '## Supportive Counselling for Depression\\n\\nPatients with mild depression should receive supportive counselling, which includes:\\n\\n- **Psycho-education on the following key messages**:\\n  - Depression is common and can happen to anyone.\\n  - Depressed people often have exaggerated negative opinions about themselves, their life, and their future.\\n  - Effective treatment is possible.\\n\\n- **Counseling on self-management**:\\n  - Continuing ART as prescribed.\\n  - Continuing activities that they used to find interesting/pleasurable.\\n  - Maintaining a regular sleep cycle.\\n  - Keeping physically active.\\n  - Participating in community/social events.\\n  - Returning to clinic if any thoughts of self-harm occur.\\n\\n- **Addressing psychosocial stressors**:\\n  - Explore potential stressors in the patient’s life.\\n  - Assist in problem-solving to reduce stressors.\\n  - Assess for and manage intimate partner violence.\\n\\n- **Reactivation of or referral to social networks**, including peer support groups.\\n\\n- **Regular follow-up** until symptoms improve and are stable.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 88,\n",
       "  'section': '## Pharmacological Management of Depression\\n\\nPatients with moderate depression or worse should be treated with supportive counselling plus an antidepressant medication.\\n\\n- **Fluoxetine** is an antidepressant that does not have significant drug interactions with ARVs:\\n  - Starting dose for an adult is usually 20 mg taken daily in the morning (can start with a lower dose for patients who frequently have side effects from medications).\\n  - Dose can be titrated up by 20 mg every 2-4 weeks as needed, up to a maximum of 80 mg per day.\\n\\n- **Common side effects** include:\\n  - GI upset\\n  - Headaches\\n  - Insomnia\\n  - Disturbances of the menstrual cycle.\\n  \\n  These usually resolve after 1-2 weeks of continued use.\\n\\n- **Full effect** is not achieved until around 4 weeks of continued use. Once symptoms of depression resolve, antidepressants should be continued for at least another 6 months.\\n\\n- **Discontinuation of therapy**: If the patient is ready to discontinue antidepressant therapy, it should be tapered weekly (e.g., maintenance dose of 60mg taper to 40mg, then 30mg, then 20mg, then 10mg, and then stop), with close monitoring for recurrence of symptoms.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 95,\n",
       "  'section': '## Psychosis\\n\\nPsychosis is a mental disorder characterized by a disconnection from reality. It may occur due to a psychiatric illness such as schizophrenia, or it can be triggered by a health condition, medication, or drug use. \\n\\n**Signs and Symptoms of Psychosis:**\\n- Marked behavioral changes\\n- Neglecting usual responsibilities related to work, school, domestic, or social activities\\n- Agitated, aggressive behavior, or decreased/increased activity\\n- Fixed false beliefs not shared by others in the person’s culture\\n- Hearing voices or seeing things that are not there\\n- Lack of realization that one is experiencing mental health problems\\n\\n**Treatment**\\nTreatment may include medication and talk therapy.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 95,\n",
       "  'section': '## Self-Care\\n\\nIn the context of mental health, adopting self-care strategies is essential for individuals to lead responsible and satisfying lives, boosting both physical and mental health.\\n\\n**Self-Care Strategies:**\\n- **Regular Exercise:** Engaging in physical activity on a consistent basis.\\n- **Healthy Eating:** Consuming nutritious meals and staying well-hydrated.\\n- **Sleep Hygiene:** Making sleep a priority by maintaining a consistent sleep schedule.\\n- **Relaxing Activities:** Participating in activities that promote relaxation.\\n- **Setting Goals and Priorities:** Formulating realistic expectations and strategies to achieve personal goals.\\n\\n**Practicing Gratitude:** \\nReminding oneself of things to be grateful for, with specificity aiding clarity. Listing these items can be beneficial.\\n\\n**Focusing on Positivity:**\\nEncouraging the appreciation of good and positive occurrences in life, while also identifying and challenging negative thoughts. Support from friends, counselors, or health workers with mental health expertise can be valuable.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 94,\n",
       "  'section': '## Standard Package of Care for PLHIV\\n\\nThis section discusses the care package designed for people living with HIV (PLHIV), focusing on addressing various issues that could affect their lives, including social, financial, and environmental concerns.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 94,\n",
       "  'section': \"## Impact of Stress on PLHIV\\n\\nStress can significantly impact the lives of PLHIV, leading to observable behavioral changes and a variety of symptoms. Health care workers need to remain calm and assured when addressing patients' stress-related concerns. Utilizing a screening tool can help assess the need for referrals to specialized mental health professionals.\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 94,\n",
       "  'section': '## Experiences of Trauma in PLHIV\\n\\nTrauma consists of events that are emotionally disturbing or life-threatening, with lasting effects on an individual’s well-being. Addressing past traumatic experiences is crucial for the overall health of PLHIV.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 94,\n",
       "  'section': '## Assessing for Trauma\\n\\n### Primary Care PTSD Screen for DSM-5 (PC-PTSD-5)\\n\\nThe PC-PTSD-5 is a screening tool used to identify individuals who may have post-traumatic stress disorder (PTSD). A positive result occurs when an individual answers \"yes\" to any three of the designated questions related to traumatic experiences.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 94,\n",
       "  'section': '## Examples of Traumatic Events\\n\\nThis section provides examples of specific traumatic events that could impact individuals, including:\\n\\n1. A serious accident or fire\\n2. A physical or sexual assault or abuse\\n3. Natural disasters, such as earthquakes or floods\\n4. Exposure to war\\n5. Witnessing violence, such as seeing someone being killed or injured\\n6. The death of a loved one by homicide or suicide'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 94,\n",
       "  'section': '## Questions for PTSD Screening\\n\\nThe section lists questions aimed at assessing PTSD symptoms in individuals who have experienced trauma. The questions inquire about:\\n\\n- Nightmares or unwanted thoughts about the traumatic event\\n- Efforts to avoid reminders of the event\\n- Increased vigilance or startle response\\n- Feelings of detachment or numbness\\n- Guilt related to the event or its aftermath'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 91,\n",
       "  'section': \"## Addiction Support Based on Stages of Change\\n\\nThe guidelines outline different counselling approaches based on the individual's stage in the process of change regarding substance use. These stages are:\\n\\n### Pre-contemplation:\\n- Not currently considering quitting; no immediate desire to quit.\\n  - Acknowledge that not everyone is ready to think about quitting.\\n  - Clarify that it is their decision.\\n  - Listen to them describe the benefits they get from their alcohol or drug use.\\n  - Explore why other people might think it is a good idea to quit.\\n\\n### Contemplation:\\n- Not sure if they want to quit or thinking about quitting but with no immediate plan.\\n  - Acknowledge that not everyone is ready to quit immediately.\\n  - Clarify that it is their decision.\\n  - Listen to both the benefits and the negative effects they associate with their substance use.\\n  - Discuss any ideas they have about quitting.\\n\\n### Preparation:\\n- Would like to quit within the next month.\\n  - Congratulate them on their decision.\\n  - Listen to expected benefits from quitting.\\n  - Discuss their quitting plan and potential challenges.\\n  - Problem-solve and identify support systems.\\n  - Encourage small steps towards quitting.\\n\\n### Action:\\n- Actively trying to quit or has recently quit (within the past 6 months).\\n  - Listen to their experiences.\\n  - Congratulate their efforts thus far.\\n  - Problem-solve on overcoming challenges and review long-term benefits.\\n\\n### Maintenance:\\n- Has quit (more than 6 months ago) and wants to remain abstinent.\\n  - Congratulate them on their ongoing success.\\n  - Discuss potential for relapse and coping strategies.\\n  - Review the long-term benefits of maintaining abstinence.\\n\\n### Relapse:\\n- Acknowledge that relapse is common.\\n  - Evaluate triggers.\\n  - Reassess their motivation and barriers.\\n  - Problem-solve on overcoming challenges and identify additional support strategies.\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 91,\n",
       "  'section': \"## Mental Health Concerns\\n\\nThis section discusses key areas of concern related to mental health, emphasizing the need for awareness and early identification of conditions that impact daily living. The following points are highlighted:\\n\\n- Importance of having a high index of suspicion for mental health issues.\\n- Recognition that mental health conditions can be debilitating.\\n- Conditions negatively affect an individual's ability to cope with daily tasks.\\n- Building resilience is crucial in positively influencing mental health.\\n- Resilience contributes to meaningful interactions and a more fulfilling life.\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 98,\n",
       "  'section': '## Standard Package of Care for PLHIV\\n\\nThis section outlines the necessary support components for people living with HIV (PLHIV). It includes therapeutic and supplementary foods to manage malnutrition, breastfeeding recommendations, micronutrient supplementation, and linkage to food security and social protection.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 98,\n",
       "  'section': '## Nutrition Support Recommendations\\n\\nThis section discusses specific nutritional interventions for adults and children with clinical malnutrition. It emphasizes the role of healthcare professionals in providing therapeutic foods and the importance of community support for these services.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 98,\n",
       "  'section': '## Malnutrition Management for Children and Pregnant/Lactating Women\\n\\nThis section presents the interpretation of Mid-Upper Arm Circumference (MUAC) results for children and pregnant/lactating women, including classifications and recommended actions based on specific MUAC levels.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 98,\n",
       "  'section': '## Nutritional Support for Pregnant and Breastfeeding Women\\n\\nThis section highlights the nutritional needs and support for pregnant and breastfeeding women based on their MUAC levels and provides guidance for education and counselling.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 98,\n",
       "  'section': \"## Interpretation of Z-scores for Children\\n\\nThis section outlines the Z-score indicators for assessing children's nutritional status, including classifications for underweight, stunting, and wasting, along with recommended interventions based on these scores.\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 97,\n",
       "  'section': '## Nutritional Services in HIV Management\\n\\nGood nutrition is a critical component of management of HIV as it contributes to reducing risk and frequency of other infections, delaying progression from HIV infection to AIDS, maintaining a healthy appearance and weight, gaining strength, building muscle, having energy to remain active, and reducing side effects of ART.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 97,\n",
       "  'section': '## Nutritional Assessment, Counselling, and Support (NACS)\\n\\nAll People Living with HIV (PLHIV) should receive a tailored nutritional assessment, counselling, and support that includes:\\n\\n- **Nutrition Assessment and Diagnosis**: \\n   - Timed with routine clinic visits (monthly for the first year, quarterly up to age 14, and every 3-6 months thereafter).\\n   - Types of assessments include:\\n     - Anthropometric measurements (interpretation and actions provided in specific tables).\\n     - Biochemical testing (baseline and follow-up investigations).\\n     - Clinical examinations (initial evaluation).\\n     - Dietary recall (24-hour recall for food type/frequency and household food security).\\n     - Environmental and psychosocial evaluations.\\n     - Functional assessments (ability to care for self, bedridden status, etc.).\\n\\n- **Counselling and Education**:\\n   - Benefits of good nutritional status for those living with HIV.\\n   - Guidance on Mother Infant and Young Child Nutrition (MIYCN), including exclusive breastfeeding.\\n   - Strategies for maintaining good nutritional status and overall health.\\n   - Identification of available local foods in the client’s context and ensuring food safety.\\n   - Meal and snack planning to meet energy and nutrient needs.\\n   - Addressing constraints impacting nutrition.\\n   - Education on side effects and food interactions related to medications.\\n   - Exploration of causes of poor appetite and appropriate responses (influences including food type, disease states, etc.).\\n   - Counselling on critical nutrition practices.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 97,\n",
       "  'section': '## Critical Nutrition Practices (CNPs)\\n\\n1. Have periodic nutritional status assessments.\\n2. Increase energy intake through a balanced diet.\\n3. Maintain high levels of sanitation and food hygiene.\\n4. Practice positive living behaviors.\\n5. Engage in physical activity or exercises.\\n6. Drink plenty of clean, safe water.\\n7. Seek prompt treatment for all opportunistic infections and manage diet-related symptoms.\\n8. Manage drug-food interactions and side effects.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 99,\n",
       "  'section': '## Screening for Severe Acute Malnutrition (SAM)\\n\\nMeasure anthropometry and check for bilateral pitting oedema. Conduct a medical history and physical examination to evaluate nutritional status and health condition, check for medical complications, and perform an appetite test.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 99,\n",
       "  'section': '## SAM Management Pathway\\n\\nIf the patient is diagnosed with SAM without medical complications and passes the appetite test, they should be admitted to outpatient care. If the patient has SAM with medical complications and/or fails the appetite test, they should be admitted to inpatient care.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 99,\n",
       "  'section': '## Admission Criteria for Inpatient Care\\n\\nThe following conditions necessitate hospitalization for SAM:\\n\\n- Intractable vomiting\\n- Convulsions\\n- Lethargy\\n- Unconsciousness\\n- Lower respiratory tract infection\\n- High fever\\n- Severe dehydration\\n- Severe anaemia\\n- Hypoglycaemia\\n- Hypothermia\\n- Eye signs of vitamin A deficiency\\n- Skin lesions'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 99,\n",
       "  'section': '## Referral Criteria for Further Medical Evaluation\\n\\nPatients should be referred for further medical evaluation if they exhibit any of the following:\\n\\n- No appetite (failed appetite test)\\n- IMCI danger signs\\n- Increase in or newly developed bilateral pitting oedema\\n- Weight loss due to diarrhoea (re-feeding or of other origin)\\n- Weight loss for three consecutive weeks\\n- Static weight (no weight gain) for five consecutive weeks\\n- Other signs of failure to respond to treatment'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 99,\n",
       "  'section': '## Treatment and Discharge Criteria\\n\\nOnce treatment for SAM is completed based on discharge criteria, patients can either be discharged to home or referred for supplementary feeding and other services that address underlying causes of malnutrition.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 99,\n",
       "  'section': '## Monitoring Recovery\\n\\nPatients should be monitored for the following indicators of recovery:\\n\\n- Appetite returning after passing the appetite test\\n- Decreases in oedema\\n- Resolution of medical complications'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 104,\n",
       "  'section': '## Adherence Importance in ART\\n\\nThe individual and population benefits of Antiretroviral Therapy (ART) are highly dependent on achieving high levels of adherence to the prescribed medication, medical advice, and follow-up plans. Implementation of adherence-enhancing strategies should take place starting from the point of HIV diagnosis, during post-test counseling and linkage, and continue through initial evaluation and throughout the entire follow-up period for ART.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 104,\n",
       "  'section': '## Strategies for Adherence Support\\n\\nTo avoid treatment failure and the need to switch patients to second or third line ART, it is critical to have an adherence support strategy established before the initiation of ART. This involves anticipating common and individual barriers to adherence. Prevention of treatment failure is essential and should start at the time of HIV diagnosis. Current recommendations state that all people living with HIV (PLHIV) qualify for ART and that it should be initiated within two weeks of diagnosis.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 104,\n",
       "  'section': '## Timing of Adherence Preparation\\n\\nAdherence preparation must commence at the time of HIV testing. Close follow-up is required post-ART initiation to ensure effective treatment. The level of adherence preparation, monitoring, and support a patient requires should be tailored according to their adherence level, the stage of ART initiation, and their follow-up stage.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 104,\n",
       "  'section': '## Consistency in Care Provider\\n\\nWhenever possible, follow-up care should be provided by the same clinician or team of care providers during each visit. This consistency is particularly crucial during the first few months of HIV care to ensure better patient support and adherence to treatment.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 106,\n",
       "  'section': '## Adherence Challenges During Initial Treatment\\n\\nAdherence is most difficult during the first few months of treatment. Patients face challenges such as forming the habit of daily medication intake, unfamiliarity with common side effects, and issues related to disclosure and stigma. This period is also associated with a higher risk of developing resistance mutations, as the viral load remains high.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 106,\n",
       "  'section': '## Importance of Adherence Preparation and Support\\n\\nAdherence preparation, monitoring, and support should be prioritized during the initial months of ART until the patient achieves full virological suppression. After this point, adherence monitoring and support can be maintained at a lower intensity.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 106,\n",
       "  'section': '## Collaborative Patient Preparation and Counseling\\n\\nPatient preparation and counseling should be a collaborative effort between the healthcare provider and the patient or caregiver. This approach empowers the patient to initiate and maintain lifelong treatment. Consistency in counseling is important; having the same adherence counselor follow the patient throughout the preparation, initiation, and early ART phase is beneficial.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 106,\n",
       "  'section': '## Initiation of ART with Counseling\\n\\nART can be initiated concurrently with the first adherence counseling session, even during the enrollment visit. This is particularly suitable for infants, pregnant women, and patients who possess a strong understanding of HIV and ART, along with a strong motivation for immediate treatment.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 106,\n",
       "  'section': '## Multidisciplinary Team Training and Support\\n\\nEach member of the multidisciplinary team must be adequately trained to provide treatment education and address potential barriers to adherence. Treatment preparation and support can occur at various clinic points, including triage, consultations, and pharmacies, ensuring confidentiality and privacy.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 106,\n",
       "  'section': '## Counseling Session Preparation\\n\\nBefore beginning a counseling session, the counselor should ensure that adequate space is available for conducting the session, that confidentiality can be maintained, and that necessary tools (such as psychosocial assessment forms, treatment literacy flip charts, and documentation tools) are accessible.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 105,\n",
       "  'section': '## HTS Post-Test Counselling\\n\\nKey treatment preparation messages for all patients who test positive for HIV include:\\n- Treatment is available and recommended for everyone with HIV.\\n- Starting treatment early reduces the chance of becoming ill or infecting sexual partners.\\n- With good adherence, individuals can live a long and productive life.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 105,\n",
       "  'section': '## Enrolment Visit\\n\\nDuring the enrolment visit, the following steps are taken:\\n- HIV education and adherence preparation for all patients/caregivers (refer to Table 5.1).\\n- ART (Antiretroviral Therapy) Readiness Assessment for all patients/caregivers (refer to Table 5.4), along with an individualized adherence support plan.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 105,\n",
       "  'section': '## Ready to Start ART\\n\\nFor patients who are ready to start ART:\\n- Initiate ART.\\n- Conduct baseline investigations if not already completed.\\n- Provide the standard package of care and differentiated care based on initial presentation (advanced disease vs. well).\\n- Book follow-up appointments for weeks 2 and 4 to review adherence and side effects.\\n- Continue the adherence support plan.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 105,\n",
       "  'section': '## Not Ready to Start ART\\n\\nFor patients who are not ready to start ART:\\n- Schedule weekly appointments to review clinical status, barriers to ART initiation, and provide ongoing HIV education and counselling.\\n- Provide the standard package of care.\\n- Re-assess ART readiness at every visit until the patient is ready (target readiness is within 2 weeks).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 105,\n",
       "  'section': '## Follow-up and Adherence Monitoring\\n\\nFollow-up visits include:\\n- Adherence monitoring at every visit (refer to Table 5.10).\\n- Counselling based on the level of adherence (refer to Table 5.14) until the first viral load (VL) is measured at 3 months.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 105,\n",
       "  'section': '## Viral Load Undetectable (LDL <200 copies/ml)\\n\\nFor patients with an undetectable VL:\\n- Continue ongoing adherence assessment and counselling (refer to Table 5.16).\\n- Maintain routine VL monitoring as per the population group.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 105,\n",
       "  'section': '## Suspected Poor Adherence\\n\\nIn cases of suspected poor adherence:\\n- Assess for barriers to adherence (refer to Table 5.15).\\n- Follow the VL algorithm with enhanced adherence assessment and interventions, along with an assessment for other causes of viremia (refer to Figure 6.6).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 112,\n",
       "  'section': '## Adherence Preparation, Monitoring and Support\\n\\nThis section outlines the necessary steps for ongoing support during subsequent visits with HIV patients. Key activities include:\\n- Reviewing the patient’s knowledge about HIV.\\n- Assessing the patient’s motivation to continue taking Anti-Retroviral Therapy (ART).\\n- Addressing any concerns the patient may have regarding their ART, potential side effects, visit schedule, or overall health.\\n- Checking the ART dosing schedule and inquiring about any missed doses.\\n- Identifying barriers to adherence that may have been previously noted or new ones that may have arisen.\\n- Discussing any recent or anticipated changes in the patient’s daily routine or life circumstances.\\n- Evaluating the individualized adherence plan and determining if any modifications are necessary.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 112,\n",
       "  'section': '## HIV Education and Counselling\\n\\nThis section emphasizes the importance of HIV education as an integral part of the enrolment process. All patients and their caregivers must receive comprehensive information to make informed decisions regarding ART initiation and adherence. Key points include:\\n- Providing essential information before the initiation of ART (as detailed in Table 5.2).\\n- Offering both group and individual counselling sessions.\\n- Completing the ART Readiness Assessment and the management plan for each patient individually (reflected in Table 5.4).\\n- Ensuring that even patients who begin ART during the enrolment visit receive adequate education and support.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 107,\n",
       "  'section': '## Overview of Peer Engagement in HIV Support\\n\\nPersons living positively (PLHIV), including adolescent and adult peer educators, should be engaged to support patient education. This involvement aims to enhance patient outcomes by leveraging their personal experiences to guide others.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 107,\n",
       "  'section': '## Operational Guidance: Meaningful Involvement of PLHIV\\n\\nPLHIV should lead both facility-based and community-based HIV education and support systems. They play a crucial role as peer educators, mentor mothers, and lay health workers, contributing to improving the identification of people at risk for HIV, increasing linkage from testing to treatment, reducing onward transmission, providing psychosocial support, and enhancing adherence and retention to care and antiretroviral therapy (ART).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 107,\n",
       "  'section': '## Identifying PLHIV for Peer-led Support\\n\\nTo effectively offer peer-led patient support, the following criteria should be used to identify PLHIV:\\n\\n- On ART for ≥ 1 year\\n- Displaying good adherence and an undetectable viral load (VL)\\n- Possessing a positive attitude and an interest in supporting peers'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 107,\n",
       "  'section': '## Preparing and Supporting PLHIV in Patient Support Roles\\n\\nTo prepare PLHIV for their roles in patient support systems, the following measures must be taken:\\n\\n- Provide training specific to their intended roles\\n- Equip them with job aids and informational, educational, and communication (IEC) materials suitable for their responsibilities\\n- Ensure supervision by healthcare professionals'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 107,\n",
       "  'section': '## Potential Roles for PLHIV\\n\\nPLHIV can engage in various roles to bolster patient support, including:\\n\\n- Supporting HIV self-testing\\n- Providing HIV testing services\\n- Acting as peer linkage supporters\\n- Leading or contributing to facility-based or community-based support groups\\n- Offering individual or group HIV education\\n- Providing individual or group adherence counseling\\n- Distributing ART refills for stable patients'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 107,\n",
       "  'section': '## Compensation for PLHIV in Support Systems\\n\\nRecognition and compensation for PLHIV who contribute to patient support systems can include:\\n\\n- Recognition methods such as ID badges, certificates of service, and acknowledgment at community forums\\n- Training opportunities that offer certification\\n- Financial compensation options like salaries, stipends, and transportation allowances\\n- Priority consideration for related employment opportunities'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 101,\n",
       "  'section': '## Guidelines on Use of Antiretroviral Drugs for Treating and Preventing HIV Infection in Kenya\\n\\nThis section outlines the general guidelines for the administration of antiretroviral drugs in the context of HIV treatment and prevention strategies in Kenya.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 101,\n",
       "  'section': '## BMI Interpretation for Adults\\n\\n### Table 4.2 1: Interpretation of BMI Results for Adults  \\n**BMI Level** | **Classification** | **Action to Take**'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 101,\n",
       "  'section': '|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 101,\n",
       "  'section': '|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 101,\n",
       "  'section': '< 16 | Severe malnutrition | • Refer for facility-based therapeutic intervention; rehabilitation with therapeutic foods; counselling on intake issues and possible metabolic issues. • Screen for TB  \\n16.0 – 18.4 | Mild/moderate malnutrition | ● Nutritional counselling and supplementary feeding. ● Screen for TB  \\n18.5 – 25.0 | Normal/recommended | Nutritional counselling, consistent exercise to build muscles  \\n25.1 – 30 | Overweight | Nutritional counselling to reduce energy intake; aerobic physical activity to reduce weight  \\n>30 | Obese | Counselling to change lifestyle and reduce energy intake; aerobic physical activity to reduce weight'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 101,\n",
       "  'section': '## Prevention of Other Infections \\n\\nThis section covers preventive measures for other infections among individuals living with HIV.\\n\\n### 4.8.1 Immunizations\\n\\nAll children, regardless of HIV status, should be immunized following the full KEPI schedule, with important considerations for infants with severe immunosuppression.\\n\\n### Table 4.2 2: Kenya Expanded Program on Immunizations 2016 Schedule  \\n**Age** | **Vaccines**'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 101,\n",
       "  'section': '|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 101,\n",
       "  'section': 'Birth | OPV1, BCG  \\n6 weeks | OPV3, Pentavalent (DPT-HepB-HiB), Pneumococcal (PCV10), Rotavirus  \\n10 weeks | OPV3, Pentavalent (DPT-HepB-HiB), Pneumococcal (PCV10), Rotavirus  \\n14 weeks | IPV, Pentavalent (DPT-HepB-HiB), Pneumococcal (PCV10)  \\n6 months | Measles/Rubella (MR) - for HIV exposed and infected infants; Vitamin A  \\n9 months | Measles/Rubella (MR); Vitamin A; Yellow Fever  \\n18 months | Measles/Rubella (MR); Vitamin A  \\n10 years (girls only) | HPV (2 doses at 6 months apart in the general population; 3 doses for PLHIV, at month 0, 1-2, and 6)  \\n11-12 years | Tdap (tetanus, diphtheria and pertussis)  \\n\\n#### Notes for Immunizations:\\n1. OPV should be given to all infants at birth or within the first two weeks of life. If missed and the child shows symptoms of advanced HIV disease, defer BCG until the child is virally suppressed on ART.\\n   \\n2. BCG should be administered to all infants at birth or within the first two weeks. If missed, defer until the child is virally suppressed and with immune system recovery, especially if born to smear-positive mothers.\\n\\n3. For HIV-positive children with symptoms of advanced HIV disease or severe immunosuppression, IPV should be used instead of OPV.\\n\\n4. Yellow fever vaccine is routinely used in certain counties; defer if there are symptoms of advanced HIV disease until the child is virally suppressed on ART.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 103,\n",
       "  'section': '## Guidelines on Use of Antiretroviral Drugs for Treating and Preventing HIV Infection in Kenya\\n\\nThis document outlines the recommended guidelines for the use of antiretroviral drugs in the context of treating and preventing HIV infection in Kenya.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 103,\n",
       "  'section': '## Malaria and HIV\\n\\nChildren and adults living with HIV suffer from heavier parasitaemia and greater malaria morbidity, particularly with advanced HIV disease. Individuals with advanced immunosuppression face a heightened risk of failure of anti-malarial treatment. Additionally, pregnant women are at increased risk for placental malaria, severe anemia, premature delivery, and perinatal mortality. Drug interactions between ARVs and antimalarial medications can complicate management.\\n\\n### Recommendations for Malaria Prevention for PLHIV:\\n- **Cotrimoxazole Preventive Therapy (CPT):** Offer CPT as a protection against malaria infection.\\n- **Insecticide-Treated Mosquito Nets (ITNs):** Ensure access to ITNs or indoor residual spraying in areas with stable malaria transmission to reduce mosquito bites and transmission risks.\\n- **Travel Advice:** PLHIV traveling from non-malarious zones to endemic areas should sleep under ITNs.\\n- **Pregnant Women:** Those unable to take CPT should receive at least three doses of sulfadoxine-pyrimethamine (SP) as part of routine antenatal care. Note: SP should not be given to women on CPT.\\n- **Fever Management:** PLHIV on CPT who develop fever should not receive presumptive anti-malarial treatment without laboratory confirmation.\\n- **Antimalarial Treatment:** Those diagnosed with malaria should receive standard antimalarial therapy, and those on CPT should not be given sulfa-containing drugs. Patients on ART receiving antimalarial therapy should be monitored closely for adverse reactions.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 103,\n",
       "  'section': '## Safe Water, Sanitation, and Hygiene\\n\\nDiarrheal illnesses are prevalent among PLHIV, often stemming from inadequate access to safe drinking water and poor sanitation and hygiene practices, which can lead to the contamination of food and water sources.\\n\\n### Recommendations for Prevention of Fecal-Oral Spread Illnesses:\\n- **Cotrimoxazole Preventive Therapy (CPT):** Provide CPT to offer protection against gastrointestinal infections.\\n- **Hand Hygiene:** Promote hand washing with soap and water, particularly after handling faeces, using the toilet, and before food preparation or eating.\\n- **Waste Disposal:** Ensure facilities are available for the proper disposal of human waste.\\n- **Water Treatment Education:** Train individuals on household water treatment methods and the use of storage containers that minimize direct hand contact with drinking water.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 110,\n",
       "  'section': '## Adherence Preparation, Monitoring and Support\\n\\nThis section provides an overview of the importance of adherence preparation prior to ART initiation, emphasizing the process that begins at HIV diagnosis.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 110,\n",
       "  'section': '## ART Adherence Preparation and Support\\n\\nPreparation for antiretroviral therapy (ART) starts at the time of HIV diagnosis and continues until ART initiation.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 110,\n",
       "  'section': '## Treatment Preparation as Part of HIV Testing Services\\n\\nIn this section, the guidelines recommend that all people living with HIV (PLHIV) qualify for ART, highlighting the importance of post-test counseling by the HIV Testing Services (HTS) provider.\\n\\n- **Key Messages for ART Treatment Preparation:**\\n  1. Treatment (ART) is available and recommended for everyone with HIV.\\n  2. Starting treatment as soon as possible (preferably within two weeks of testing positive) reduces health risks and transmission.\\n  3. Proper adherence to ART can lead to a long and productive life.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 110,\n",
       "  'section': '## ART Treatment Preparation\\n\\nThis section details the components of ART treatment preparation, including education and counseling.\\n\\n- **Components of ART Treatment Preparation:**\\n  - HIV education and counseling\\n  - Identification of barriers to adherence\\n  - Discussion of strategies and support systems\\n  - Development of an individualized adherence plan\\n\\nDocumentation of these education and counseling sessions in patient charts is also important.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 110,\n",
       "  'section': \"## Treatment Preparation and Adherence Counseling Guide\\n\\nA summary of the essential components of HIV education and adherence counseling.\\n\\n- **HIV Education:**\\n  - Assess the patient's knowledge about HIV and its treatment.\\n  - Cover key topics such as modes of transmission, the impact of HIV on health, and the goals of ART.\\n  - Discuss the relationship between adherence, viral suppression, treatment failure, and drug resistance.\\n\\n- **Barriers to Adherence:**\\n  - Discuss potential difficulties the patient may face regarding daily ART adherence and attending appointments.\\n  - Identify common reasons for non-adherence and personalize the discussion to the patient's specific concerns.\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 108,\n",
       "  'section': '## Adherence Preparation, Monitoring and Support\\n\\nThis section covers the overarching topic of adherence preparation, monitoring, and support for people living with HIV (PLHIV). It sets the stage for understanding the importance of antiretroviral therapy (ART) and its relation to HIV epidemic control.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 108,\n",
       "  'section': '## Undetectable = Untransmittable (U=U)\\n\\nThis subsection discusses the concept of U=U, emphasizing that adherence to ART leading to durable viral suppression eliminates the risk of sexual transmission of HIV. It details the significance of this campaign in HIV treatment and epidemic control.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 108,\n",
       "  'section': '### Definitions\\n\\n- **Durably Undetectable**: Defined as having two consecutive viral load results of <50 copies/ml.\\n- **Untransmittable**: Established through various clinical trials that those with an undetectable viral load have effectively no risk of transmitting HIV to others through sex.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 108,\n",
       "  'section': '## Benefits of U=U\\n\\nThis subsection outlines the advantages of the U=U campaign, including:\\n\\n- Diminishing stigma associated with having HIV.\\n- Reducing barriers to HIV testing and treatment.\\n- Increasing interest in starting and adhering to ART.\\n- Improving self-esteem by alleviating fears of being contagious.\\n- Supporting healthy sexuality regardless of HIV status.\\n- Reducing concerns for sexual partners.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 108,\n",
       "  'section': '## Considerations for Implementation of U=U within Clinical Settings\\n\\nThis section highlights key considerations for implementing the U=U message in clinical environments:\\n\\n- Regular viral load monitoring for various populations.\\n- Continuous adherence monitoring and support during clinical visits.\\n- STI screening at every visit.\\n- Providing U=U messaging as part of treatment literacy for all PLHIV.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 108,\n",
       "  'section': '## Messaging to Patients on U=U\\n\\nThis subsection presents specific messaging aimed at patients, including:\\n\\n- The importance of keeping HIV undetectable for a long and healthy life.\\n- Steps to achieve and maintain an undetectable viral load through prescribed ART.\\n- The time frame required to achieve undetectable levels.\\n- Assurance that adherence to medication prevents transmission during sex.\\n- Consequences of discontinuing medication regarding viral load and transmission risks.\\n- The role of maintaining a suppressed viral load in safe conception efforts.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 111,\n",
       "  'section': '## Patient Factors Affecting Adherence\\n\\n- Stigma and non-disclosure (having to hide their ARV pill-taking)\\n- Lack of support systems\\n- Alcohol or drug use\\n- Depression or other psychiatric illness\\n- Loss or grief\\n- Cognitive disorders\\n- Change in daily routine\\n- Chaotic lifestyle; no consistent daily routine\\n- Forgetting to take pills\\n- Feeling better and not thinking the ART is needed anymore\\n- Feeling too sick to take ART\\n- Age factors (adolescents being impulsive and susceptible to social pressure; children being caregiver dependent)'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 111,\n",
       "  'section': '## Provider/System Factors Affecting Adherence\\n\\n- Side effects (nausea, headaches, difficulty sleeping, which usually resolve with continued use)\\n- Pill burden\\n- Poor patient-provider relationship\\n- Inadequate HIV education\\n- Cost of care (direct and indirect)\\n- ARV supply chain limitations (stock-outs or low stock levels resulting in small refill quantities)'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 111,\n",
       "  'section': \"## Individualized Adherence Plan\\n\\n- Ask the patient what they can do to ensure excellent adherence.\\n- The adherence plan should include details of the patient's specific ART regimen:\\n  - Number of pills\\n  - Frequency\\n  - Food requirements/restrictions\\n  - Common side effects\\n  - Important drug interactions\\n\\n### Strategies for the Adherence Plan\\n\\n- Disclose HIV status to a close friend or family member for support\\n- Bring a treatment buddy to the clinic or counseling sessions\\n- Disclose HIV status to household members to avoid hiding pill-taking\\n- Combine pill-taking with a daily routine activity\\n- Keep ARVs in a visible location\\n- Set a daily alarm on a phone/watch/clock\\n- Connect with a support group for additional counsel/education/support\\n- Seek treatment for alcohol or drug use\\n- Seek treatment for depression or other psychiatric illnesses\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 111,\n",
       "  'section': '## Addressing Issues in Medication Adherence\\n\\n- Discuss what to do if:\\n  - **Develops side effects**: Discuss common and serious adverse events for their regimen, and encourage the patient to return to the clinic if they experience side effects rather than stopping ART.\\n  - **Forgets to take a dose**: Instruct to take it late rather than skip it completely.\\n  - **Travels without ART**: Go to the nearest health facility or call the clinic for guidance.\\n\\n- Ask the patient to summarize their individualized adherence plan.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 102,\n",
       "  'section': '## Standard Package of Care for PLHIV\\n\\nThis section outlines the standard package of care for people living with HIV (PLHIV), focusing on immunization responses and recommendations for vaccination timelines, particularly for children on antiretroviral therapy (ART). Providers are directed to consult the National Vaccines and Immunization Program and NASCOP for guidance on revaccination.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 102,\n",
       "  'section': '## Vaccinations for Adolescents and Adults Living with HIV\\n\\nThis section presents a list of recommended vaccinations for adolescents and adults living with HIV, detailing the type of vaccine, whether it is live or not, the vaccination course, and specific comments related to each vaccine.\\n\\n### Recommended Vaccinations\\n\\n1. **COVID-19**  \\n   - **Vaccine Type**: Various  \\n   - **Live**: No  \\n   - **Course**: Variable  \\n   - **Comments**: Follow national guidelines on dosing for the specific vaccine available.\\n\\n2. **Hepatitis B**  \\n   - **Vaccine Type**: Subunit  \\n   - **Live**: No  \\n   - **Course**: 4 doses (at 0, 1, 2, and 6 months)  \\n   - **Comments**: Use double dose if non-adjuvanted; use standard dose if adjuvanted.\\n\\n3. **Pneumococcus**  \\n   - **Vaccine Type**: Conjugate  \\n   - **Live**: No  \\n   - **Course**: 1 dose (PCV 13)  \\n   - **Comments**: Preferable to polysaccharide.\\n\\n4. **Polysaccharide**  \\n   - **Vaccine Type**: Polysaccharide  \\n   - **Live**: No  \\n   - **Course**: 1 dose  \\n   - **Comments**: Use if >65 years and with co-morbidity other than HIV.\\n\\n5. **Human Papillomavirus (HPV)**  \\n   - **Vaccine Type**: Virus-like particles  \\n   - **Live**: No  \\n   - **Course**: 3 doses (at months 0, 1-2, and 6)  \\n   - **Comments**: All girls at 9-14 years old.\\n\\n6. **Influenza**  \\n   - **Vaccine Type**: Inactivated  \\n   - **Live**: No  \\n   - **Course**: 1 dose  \\n   - **Comments**: Annually.\\n\\n7. **Hepatitis A**  \\n   - **Vaccine Type**: Inactivated  \\n   - **Live**: No  \\n   - **Course**: 2-3 doses  \\n   - **Comments**: 3 doses if CD4 count < 350 cells/mm³ at 0, 1, and 6 months. If CD4 count > 350 cells/mm³, give 2 doses at 0 and 6 months. For those at continued risk, one booster dose every 10 years.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 102,\n",
       "  'section': '## Additional Vaccines for Special Circumstances\\n\\nThis section details additional vaccines recommended for specific circumstances among PLHIV, ensuring personalized care based on patient health status.\\n\\n### Specialized Vaccinations\\n\\n1. **Yellow Fever**  \\n   - **Vaccine Type**: Live attenuated  \\n   - **Live**: Yes  \\n   - **Course**: 1 dose  \\n   - **Comments**: Use only in patients <60 years of age with CD4 > 200 cells/mm³.\\n\\n2. **Typhoid**  \\n   - **Vaccine Type**: Polysaccharide  \\n   - **Live**: No  \\n   - **Course**: 1 dose  \\n   - **Comments**: Give the ViCPS parenteral. Repeat every 3 years.\\n\\n3. **Cholera**  \\n   - **Vaccine Type**: Subunit  \\n   - **Live**: No  \\n   - **Course**: 2 doses  \\n   - **Comments**: As indicated (usually in epidemics). 2 oral doses of the non-replicating vaccine given 1-6 weeks apart with a single booster dose at 2 years from primary vaccination.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 100,\n",
       "  'section': '## Standard Package of Care for PLHIV\\n\\nThis section provides an overview of the standard assessments and scoring systems used to evaluate the care of people living with HIV (PLHIV).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 100,\n",
       "  'section': '## Weight Loss Score\\n\\n- **Low Risk:** <5% weight loss in the last 1-3 months\\n- **Moderate Risk:** 5-10% weight loss in the last 1-3 months\\n- **High Risk:** >10% weight loss in the last 1-3 months'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 100,\n",
       "  'section': '## Opportunistic Infections Score\\n\\n- **No Opportunistic Infection:** Low Risk\\n- **Sub Acute Opportunistic Infection:** Moderate Risk\\n- **Acute Opportunistic Infection:** High Risk'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 100,\n",
       "  'section': '## Food Intake Score\\n\\n- **Adequate Intake:** Low Risk\\n- **Low Intake:** Moderate Risk\\n- **Nausea/Vomiting or Fasted for >5 Days:** High Risk'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 100,\n",
       "  'section': '## Food Security Score\\n\\n- **Little or No Household Hunger:** 0-1 (Low Risk)\\n- **Moderate Household Hunger:** 2-3 (High Risk)\\n- **Severe Household Hunger:** 4-6 (High Risk)'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 100,\n",
       "  'section': '## Nutritional Assessment for Pregnant & Postpartum Women\\n\\n- **MUAC (cm) <19:** Severe Acute Malnutrition (SAM)\\n- **MUAC (cm) 19.0 - 20.9:** Moderate Acute Malnutrition (MAM)\\n- **MUAC (cm) 21.0 - 23.1:** High Risk\\n- **MUAC (cm) >23.1:** Normal\\n\\nMicronutrient deficiencies include:\\n- **Nutritional Anemia:** Hb < 11g/dl due to deficiencies of iron, folate, Vit. B12. \\n- **Bitot spots:** Due to Vitamin A deficiency\\n- **Pellagra:** Due to Vitamin B1 deficiency'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 100,\n",
       "  'section': '## Nutritional Assessment for Other Adults\\n\\n- **BMI (Kg/m²) < 16:** Severe Acute Malnutrition (SAM)\\n- **BMI (Kg/m²) 16 – 18.5:** Moderate Acute Malnutrition (MAM)\\n- **BMI (Kg/m²) 18.6 - 21.9:** High Risk\\n- **BMI (Kg/m²) 22 – 24:** Normal'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 100,\n",
       "  'section': '## Management of Severe Malnutrition (SAM)\\n\\n### Actions\\n- Initiate Phase I therapeutic feeding until clinical stability is achieved.\\n\\n### Additional Steps\\n- If clinically stable, able to eat, and has a good appetite:\\n  - Move to Phase II therapeutic feeding for nutritional reconstitution.\\n  - Provide nutrition counselling and education.\\n  - Conduct weekly reviews, transitioning to supplemental feeding post-recovery.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 100,\n",
       "  'section': '## Management of Moderate Malnutrition (MAM)\\n\\n### Actions\\n- Nutrition counselling and education.\\n- Repeat nutrition screening every 2-3 months.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 100,\n",
       "  'section': '## Management of Normal/Low Risk Nutrition\\n\\n### Actions\\n- Nutrition counselling and education.\\n- Multiple micronutrient supplementation.\\n- Weekly reviews of nutrition status and risk factors until stability.\\n- For pregnant or postpartum mothers, enroll in the Food-Based Programming Network (FBP).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 100,\n",
       "  'section': '## Referral and Assessment Procedures\\n\\n- **Food Insecure Clients:** Refer for livelihood support.\\n- **Non-Responders:** Refer for further clinical assessment and management.\\n- **For Overweight and Obese Individuals:** Refer for counselling as per local clinical policy and protocol.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 100,\n",
       "  'section': '## Nutritional Interventions \\n\\nDetails related to nutritional interventions are emphasized throughout the assessment scores and actions for various levels of malnutrition.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 100,\n",
       "  'section': '## Nutritional Diagnosis\\n\\nDiagnosis processes related to nutritional status are integral to ongoing management efforts and interventions.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 100,\n",
       "  'section': '## Nutritional Assessment\\n\\nHighlighting the importance of continuous nutrition screening and assessment as part of the overall care plan for individuals with HIV.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 100,\n",
       "  'section': '## Conclusion\\n\\nThis document outlines the comprehensive framework for assessing and managing malnutrition in PLHIV, ensuring a targeted and effective approach to care.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 109,\n",
       "  'section': '## Discussing U=U with Others\\n\\n● Counsel patients to share information about the research on U=U as follows:  \\n  - In recent research studies that involved thousands of couples, no one who was on HIV treatment and whose HIV was durably undetectable passed HIV to their HIV-negative sex partner.  \\n● Advise patients that they can share the following personal information with current or potential sex partners:  \\n  - When they last had a viral load test and if their viral load was undetectable.  \\n● Individuals should tell their partner(s) that their HIV is undetectable only if they have taken HIV medicines consistently since their last test with an undetectable viral load.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 109,\n",
       "  'section': '## Counseling on Prevention Combination Interventions\\n\\n### PrEP\\n- PrEP is a safe and effective daily pill that prevents HIV infection. The partner without HIV may decide to take PrEP if they:  \\n  - Are unsure that their partner’s HIV viral load is undetectable, especially if their partner has only recently started ART.  \\n  - Have more than one sexual partner.  \\n  - Feel more secure with the added perception of protection provided by PrEP.\\n\\n### PEP\\n- After a possible HIV exposure (e.g., occupational exposure or if a sex partner with HIV has not consistently taken ART and is not virally suppressed), the immediate initiation of emergency PEP can prevent HIV infection.\\n\\n### Condom Use\\n- Condoms protect against other STIs, such as gonorrhea, chlamydia, and syphilis, and help prevent pregnancy.  \\nCounsel patients to find a prevention strategy that works for them:  \\n- If an individual who does not have HIV is unsure if their partner has an undetectable level of virus or is anxious about acquiring HIV, care providers should encourage that person to choose a prevention strategy that works for them, whether that is use of PrEP, emergency PEP, condoms, or a combination of these strategies.  \\n- Note: Care providers should emphasize that no one should ever be compelled to have sex without condoms.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 109,\n",
       "  'section': '## Application of U=U in Other Settings\\n\\n### Breastfeeding\\n- Studies demonstrate that ART greatly reduces the risk of transmission through breast milk. However, research has not established that people whose HIV is undetectable do not transmit the virus during breastfeeding. Prophylaxis should be provided to HIV-exposed infants during the breastfeeding period as per the guidelines, regardless of the viral load status.\\n\\n### Injection Drug Use\\n- Studies demonstrate that ART greatly reduces the risk of transmission through sharing of injection drug use. However, research has not established that people whose HIV is undetectable do not transmit the virus through needle sharing. All people who inject drugs should only use their own needles and not share needles or other paraphernalia with others.\\n\\n### Needle Stick Injuries\\n- Research has not established that people with undetectable viral load do not transmit HIV to people who are stuck by needles containing their blood. HIV PEP should be provided as per the guidelines.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 114,\n",
       "  'section': '## Adherence Preparation and Support Interventions\\n\\nThis section outlines the standard adherence support interventions for individuals undergoing treatment and prevention, focusing on a variety of structural interventions.\\n\\n- Conduct a baseline psychosocial assessment to explore aspects of the client’s life that may influence their adherence to treatment and overall well-being, covering issues such as disclosure, family planning, and living circumstances.\\n- Use a multidisciplinary team approach to develop and implement tailored treatment plans for each patient.\\n- Engage peer educators to lead HIV education and support services.\\n- Adequately prepare and assess patients’ readiness to initiate and continue Antiretroviral Therapy (ART).\\n- Implement a system to identify and take action when patients miss appointments.\\n- Formalize a system for providing health talks and treatment literacy classes for patients.\\n- Establish a system for linking patients to community-based resources, including support groups, churches, income-generating organizations, food support, and child welfare societies.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 114,\n",
       "  'section': '## HIV Education and Counseling\\n\\nThis section details the components of HIV education and counseling that are essential for patient adherence to treatment.\\n\\n- Remind patients about HIV disease and the mechanism of ART, emphasizing the importance of high-level adherence and the consequences of non-adherence, such as:\\n  - Risk of health deterioration due to HIV.\\n  - The role of ART in restoring and maintaining health.\\n  - The connection between adherence, viral load, CD4 counts, and overall health.\\n  - Side effects of medications, including management strategies for avoidance and recognition.\\n  - Addressing misconceptions and beliefs regarding HIV and ART.\\n- Collaboratively discuss and agree on a treatment plan with the patient, ensuring their commitment to follow through.\\n- Discuss the impacts of alcohol and drugs on treatment plans and strategies to prevent them from interfering.\\n- Maintain a non-judgmental approach, foster trust with parents/caregivers, and involve children as they mature in the discussion.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 118,\n",
       "  'section': '## Adherence Preparation and Monitoring\\n\\nThis section discusses the processes involved in preparing, monitoring, and supporting adherence to HIV treatment, particularly focusing on age-appropriate strategies for counseling.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 118,\n",
       "  'section': '## Age-Appropriate Counseling Approaches\\n\\nThis section outlines specific counseling approaches based on the age of the child or adolescent.\\n\\n### For Children Under 6 Years Old\\n- Focus on engaging all of the child’s caregivers in counseling sessions.\\n\\n### For Children Aged 6-12 Years\\n- Involvement of both the caregiver and the child.\\n- Counseling primarily targets the caregiver.\\n- Younger children can participate by drawing and discussing their experiences.\\n- Disclosure of HIV status should start by age 5 and be completed by age 10-12.\\n\\n### For Adolescents Aged Over 12 with Caregiver Present\\n- Most counseling focuses on the adolescent, who is responsible for their medication.\\n- Caregiver involvement is crucial.\\n- Recommended approach includes sessions alone with the caregiver, joint sessions, and then sessions with the adolescent alone.\\n- Use the HEADSSS tool to facilitate discussions.\\n\\n### For Adolescents Aged Over 12 without Caregiver Present\\n- Use the HEADSSS tool to facilitate discussions.\\n- Negotiate the involvement of a treatment supporter.\\n\\n*HEADSSS assesses: Home; Education/Employment; Activities; Drugs; Sexuality; Suicide/depression/self-image; Safety.*'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 118,\n",
       "  'section': '## Unique Issues for Caregivers, Children, and Adolescents\\n\\nThis section highlights the unique issues that must be addressed for caregivers, children, and adolescents beyond standard HIV education and adherence counseling topics.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 116,\n",
       "  'section': \"## Adherence Preparation, Monitoring and Support\\n\\nThis section emphasizes the importance of tailoring treatment preparation to the patient's age, gender, needs, and clinical status. It highlights the difference in focus for patients with advanced/symptomatic disease versus those who are clinically well. The necessity of considering specific needs for various demographics, such as children, adolescents, caregivers, pregnant and breastfeeding women, and men, is discussed.\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 116,\n",
       "  'section': \"## Treatment Preparation for ART\\n\\nThis section outlines the importance of HIV education and counselling sessions provided at every visit until the patient is ready to begin ART, based on the ART Readiness Assessment Form (Table 5.4). It elaborates on the structure of these sessions, stressing the necessity of reviewing prior sessions to customize future meetings according to the patient's needs.\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 116,\n",
       "  'section': '## Duration of ART Preparation\\n\\nA concise discussion on the timing of ART preparation is provided, indicating that it should not exceed 1-2 weeks, except in special circumstances like uncontrolled mental health issues or untreated drug addictions. Continuous HIV education, counselling, and support are emphasized once the patient starts ART.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 116,\n",
       "  'section': '## Qualified Counsellors and Support Providers\\n\\nThis section identifies the qualifications necessary for individuals providing counselling and support. It specifies that preferably the same qualified counsellor, peer educator, social worker, nurse, community health volunteer, or clinician should conduct sessions, all of whom must have professional certification based on a recognized curriculum.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 116,\n",
       "  'section': '## Special Considerations for Children and Adolescents\\n\\nHere, the need for counsellors to be specially trained in psycho-social support for children and adolescents is highlighted. This ensures that younger patients receive appropriate support during their treatment journey.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 116,\n",
       "  'section': \"## ART Readiness Assessment Form (Table 5.4)\\n\\nThis segment introduces the ART Readiness Assessment Form, listing criteria that must be met by patients and caregivers before beginning ART. It covers aspects such as understanding HIV, mental health stability, willingness to disclose HIV status, and support mechanisms. Each criterion emphasizes the patient's preparedness and highlights potential barriers that need addressing for successful adherence to treatment.\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 115,\n",
       "  'section': '## Disclosure and Stigma\\n\\n- Respect patient privacy and confidentiality.\\n- Discuss with the patient the role of disclosure to close family members/trusted friends in promoting adherence.\\n- Offer to facilitate disclosure.\\n- For children/adolescents, discuss age-appropriate disclosure with the caregiver and offer to support the process (Annex 5).\\n- Conduct stigma assessment and support appropriately.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 115,\n",
       "  'section': '## Treatment Supporter\\n\\n- Encourage the patient to identify a treatment supporter/buddy who will provide encouragement and social support and remind the patient to take medication.\\n- Invite the treatment supporter to at least one of the adherence counselling sessions.\\n- Obtain consent from the patient to contact the treatment supporter if needed.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 115,\n",
       "  'section': '## Support Group\\n\\n- Link the patient to psychosocial support groups and other community-based support mechanisms (preferably through direct introduction).\\n  - Support groups give confidence and encouragement, promote a positive attitude towards HIV status, and may promote disclosure.\\n  - They offer opportunities for additional counselling and experience sharing and are avenues for developing/strengthening life skills.\\n  - Some support groups engage in economic empowerment activities.\\n  - Support groups can be used for ART distribution to improve convenience for the patient.\\n- Develop population-specific support groups where possible (e.g., youth groups with peer educators for adolescents, children’s clubs, caregiver support groups).\\n- MDT members should be patrons of the support groups, guiding activities in line with intended objectives.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 115,\n",
       "  'section': '## SMS Reminder System\\n\\n- Enroll patients into an automated SMS reminder system with their consent.\\n- Review the type of messages the patient may receive, the frequency of messages, and any actions the patient should take when receiving the message.\\n- Ensure the system and messages maintain patient privacy and confidentiality.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 115,\n",
       "  'section': '## Other Reminder Strategies\\n\\n- Encourage patient/caregiver to set a specific time of day to take ART and to associate ART time with specific events in their daily schedule.\\n- Encourage patient/caregiver to set an alarm on their phone.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 119,\n",
       "  'section': '## Caregiver Barriers to Adherence  \\n\\n- Frequently changing or multiple simultaneous caregivers  \\n- Loss or grief  \\n- Absent or sick caregiver  \\n- Poor understanding of HIV management due to inadequate counseling, elderly, or illiterate caregiver  \\n- Depression, alcohol, and other drug use  \\n- Living far from the health facility  \\n- Economically unstable  \\n- Lack of affection between caregiver and child  \\n- Lack of support systems for the caregiver'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 119,\n",
       "  'section': '## Child/Adolescent Barriers to Adherence  \\n\\n- Level of disclosure (is the child/adolescent aware of their HIV status?)  \\n- Lack of understanding of disease/treatment  \\n- Developmental stage and emotional state  \\n- Child refusal to swallow medicine (do not allow refusal to take medicines: all activities should be stopped for the child until the dose is swallowed)  \\n- Stigmatization and discrimination  \\n- Low self-esteem  \\n- Depression  \\n- Defiance related to a troublesome caregiver-child relationship  \\n- Inadequate structures at school (day or boarding) to support adherence  \\n- Lack of support systems for the child/adolescent'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 119,\n",
       "  'section': '## Treatment Barriers to Adherence  \\n\\n- Large volumes of syrups  \\n- Bad taste of syrups  \\n- Pill burden  \\n- Confusing regimens combining syrups and tablets  \\n- Side effects  \\n- Dose adjustment requirements as the child grows'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 119,\n",
       "  'section': '## Disclosure and Management Planning  \\n\\nFor all children/adolescents, the level of disclosure should be assessed at the first visit. The management plan should include a plan for age-appropriate disclosure (Annex 5). Treatment preparation and support sessions should be customized to the patient’s age (Tables 5.7-5.9).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 113,\n",
       "  'section': '## Overview of HIV\\n\\nHIV (Human Immunodeficiency Virus) is a virus that attacks the immune system, specifically targeting CD4 cells. Understanding HIV is crucial for prevention and management. Key questions covered in this section include:\\n- What is HIV?\\n- How is HIV transmitted?\\n- Why should partners and family members be tested for HIV?'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 113,\n",
       "  'section': \"## Understanding Viral Load\\n\\nViral load refers to the amount of HIV in a person's blood. Monitoring viral load is an essential part of HIV treatment. Key questions covered in this section include:\\n- What is viral load?\\n- How often is viral load measured?\\n- What do viral load measurements mean, including the goal of achieving viral suppression?\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 113,\n",
       "  'section': \"## Role of CD4 Cells\\n\\nCD4 cells are vital for a functioning immune system. Their relationship with HIV is critical for understanding the disease's progression. Key questions covered in this section include:\\n- What are CD4 cells?\\n- How are CD4 cells affected by HIV?\\n- What happens when CD4 cells decrease?\\n- How often is the CD4 cell count measured?\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 113,\n",
       "  'section': '## Antiretroviral Therapy (ART)\\n\\nART is the standard treatment for HIV and has a profound impact on health outcomes. Key questions covered in this section include:\\n- What is ART?\\n- What are the benefits of ART?\\n- When is ART started?\\n- Does ART cure HIV?\\n- Can you still give HIV to others while taking ART?\\n- How long is ART taken?'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 113,\n",
       "  'section': '## Treatment Failure\\n\\nUnderstanding treatment failure is crucial for effective management of HIV. It involves recognizing the consequences of inconsistent treatment. Key questions covered in this section include:\\n- What happens if you stop taking ART?\\n- What happens if you do not take ART regularly?\\n- What happens if the viral load increases?\\n- What happens in treatment failure?'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 113,\n",
       "  'section': '## ART Side Effects\\n\\nAwareness of potential side effects helps in managing treatment effectively. Key questions covered in this section include:\\n- What are the side effects of ART?\\n- What should you do if you notice any side effects?'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 113,\n",
       "  'section': '## Adherence to Treatment\\n\\nAdherence to ART is vital for its effectiveness. This section covers the importance of consistent medication intake. Key questions include:\\n- What is adherence?\\n- How should ART be taken?\\n- What usually interferes with good adherence?\\n- What might make it difficult for you to take your ART as prescribed?\\n- What can help you take ART as prescribed?\\n- What happens if you miss an appointment?'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 113,\n",
       "  'section': '## Other Medications\\n\\nIn addition to ART, patients may be prescribed other medications for comprehensive treatment. Key questions covered in this section include:\\n- What other medications will you take, in addition to ART (e.g., CPT, TPT)?'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 113,\n",
       "  'section': '## Importance of Nutrition\\n\\nNutrition plays a critical role in supporting the health of individuals living with HIV. Key questions covered in this section include:\\n- Why is nutrition important?\\n- What can you do to improve your nutrition?'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 113,\n",
       "  'section': '## Follow-Up Care\\n\\nRegular follow-up appointments are essential for effective monitoring and treatment adaptation. Key questions covered in this section include:\\n- How often will you need to come for clinic visits?\\n- What will we be checking for during your clinic visits?'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 113,\n",
       "  'section': '## Adherence Support\\n\\nProviding psychosocial support is vital for the well-being of people living with HIV (PLHIV). This section discusses the holistic needs of PLHIV and includes:\\n- The importance of psychosocial support.\\n- Common issues faced by PLHIV, including stigma and self-image.\\n- The need for individualized patient management plans to address these issues.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 123,\n",
       "  'section': \"## Kenya HIV Prevention and Treatment Guidelines Overview\\n\\nThis section introduces the Kenya HIV Prevention and Treatment Guidelines, providing a context for the guidelines' application in HIV management and patient care.\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 123,\n",
       "  'section': '## Follow-Up Recommendations Post-ART Initiation\\n\\n### Two Weeks After ART Initiation\\n- Review and reinforce the messages delivered at enrolment; confirm the patient’s understanding of key messages.\\n- Review ART dosing, timing, and reminders.\\n- Explore any barriers to adherence.\\n- Review support systems.\\n- Revisit benefits of disclosure, the disclosure plan, and progress in aPNS.\\n- Document the session in the patient’s chart.\\n\\n### Four Weeks After ART Initiation, and Further Follow-Up Visits\\n- Review and reinforce messages from previous sessions; confirm understanding of key messages.\\n- Review ART dosing, timing, and reminders.\\n- Explore any barriers to adherence.\\n- Review support systems.\\n- Revisit benefits of disclosure, the disclosure plan, and progress in aPNS.\\n- Document the session in the patient’s chart.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 123,\n",
       "  'section': '## Adherence Monitoring, Counseling, and Support During the First 3 Months of ART\\n\\n### Adherence Monitoring\\n- Adherence should be assessed non-judgmentally by a trained provider during each visit.\\n- Objectives include evaluating and reinforcing the patient’s adherence to ART, identifying barriers, and developing a plan to address those barriers.\\n- Common barriers include incorrect knowledge of HIV and ART, unsupportive psychosocial factors, difficult home or school environment, substance use, and poor motivation for taking medication.\\n- It is important for patients/caregivers to be honest about adherence for effective healthcare support.\\n\\n### Monitoring Techniques\\n- At every clinical visit, the MMAS-4 should be administered, along with pill counts.\\n- The MMAS-8 should be administered any time a healthcare worker suspects an adherence problem, such as in cases of suspected or confirmed treatment failure or missed appointments.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 122,\n",
       "  'section': '## Adherence Preparation for Adolescents\\n\\nTwo weeks after ART initiation:\\n- Review and reinforce the messages delivered at enrolment; confirm the adolescent’s and/or caregiver’s understanding of key messages.\\n- Review ART dosing, timing and reminders (including having the adolescent and/or caregiver demonstrate how they measure and administer the ART).\\n- Explore any barriers to adherence, including issues related to the school environment.\\n- Review support systems (including adolescent support group).\\n- Revisit benefits of disclosure and the individualized age-appropriate disclosure plan.\\n- Review Sexual and Reproductive Health (SRH) needs.\\n- Identify referral needs and link as appropriate.\\n- Document the session in the patient’s chart.\\n\\nFour weeks after ART initiation and further follow-up visits:\\n- Review and reinforce the messages delivered in previous sessions; confirm understanding of key messages.\\n- Repeat reviews of ART dosing, timing and reminders.\\n- Continue exploring barriers to adherence, especially in the school environment.\\n- Review support systems and revisit benefits of disclosure.\\n- Link to psychosocial support group.\\n- Document the session in the patient’s chart.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 122,\n",
       "  'section': '## Treatment Preparation for Adults\\n\\nAt enrolment into HIV care:\\n- Use the 5As (Assess, Assist, Advice, Agree, Arrange).\\n- Perform a psychosocial assessment to evaluate adherence boosters and barriers (mental, emotional, and social status assessments); refer for care if mental disorders are diagnosed.\\n- Identify a treatment buddy (family member, friend, etc.) and involve them in HIV education and adherence counselling.\\n- Provide HIV education and counselling.\\n- Identify and establish appropriate adherence support interventions, including linkage to a support group.\\n- Discuss benefits of disclosure of HIV status to a trusted person and establish a disclosure plan.\\n- Discuss importance of partner testing and assisted partner notification services (aPNS).\\n- Discuss prevention methods (condoms, PrEP, PEP, STI screening and treatment).\\n- Conduct an assessment of readiness to initiate ART; ART should be initiated the same day or upon agreement of a start date.\\n- Review ART dosing and timing.\\n- Conclude the session by agreeing on a treatment and follow-up plan.\\n- Where ART is initiated, schedule a return visit within two weeks; those unwilling to initiate should return weekly for further counselling.\\n- Document the session in the patient’s chart.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 121,\n",
       "  'section': '## Treatment Preparation and Support for Adolescents (10-19 years)\\n\\n### Standard of Care at Enrolment into Care\\n\\n- **5As Framework**: Utilize Assess, Assist, Advice, Agree, Arrange.\\n- **Psychosocial Assessment**: Evaluate potential psychological, emotional, and social adherence boosters and barriers.\\n- **Growth and Developmental Assessment**: Check for growth retardation and developmental challenges (e.g., autism, deafness). Refer adolescents with developmental issues to appropriate care.\\n\\n### Caregiver Identification\\n\\n- **Primary Caregiver**: Identify the primary caregiver post-HIV diagnosis. Consider that adolescents over 15 years and emancipated minors may prefer not to involve a caregiver.\\n- **Support Options**: Explore alternative support systems such as adolescent mentors, peer educators, social workers, nurses, or community health volunteers; allow private and joint sessions as needed.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 121,\n",
       "  'section': \"## Sexual and Reproductive Health (SRH)\\n\\n### SRH Counseling\\n\\n- **Understanding and Needs**: Explore the adolescent's understanding, fears, and needs regarding sexual and reproductive health.\\n- **One-on-One Sessions**: Introduce SRH counseling in individual sessions, allowing caregivers to be excused to encourage openness.\\n\\n### Family-Centered Care\\n\\n- Both the adolescent and their caregiver (if also infected) should be enrolled at the same clinic and have synchronized appointment days for comprehensive family-centered care.\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 121,\n",
       "  'section': '## Education and Support Interventions\\n\\n### HIV Education and Counseling\\n\\n- Provide age-appropriate HIV education and counseling for both the caregiver and the adolescent (see Table 5.2).\\n\\n### Adherence Support\\n\\n- **Interventions**: Identify and establish necessary adherence support interventions (see Table 5.3).\\n- **Support Groups**: Facilitate linkage to adolescent and caregiver support groups.\\n\\n### Disclosure Planning\\n\\n- Discuss the benefits of disclosing HIV status to the adolescent (if they are unaware) and create an age-appropriate disclosure plan.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 121,\n",
       "  'section': '## Antiretroviral Therapy (ART) Readiness and Initiation\\n\\n### Readiness Assessment\\n\\n- Conduct readiness assessments to initiate ART (see Table 5.4). ART initiation should occur the same day or on an agreed date.\\n\\n### Dosing and Administration\\n\\n- Review ART dosing and administration, ensuring that the adolescent and/or caregiver can demonstrate the measurement and administration process.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 121,\n",
       "  'section': '## Follow-Up and Referrals\\n\\n### Treatment and Follow-Up Plan\\n\\n- Conclude the session by agreeing on a comprehensive treatment and follow-up plan.\\n\\n### Appointment Scheduling\\n\\n- After ART initiation, schedule a return visit for the adolescent within two weeks. If unwilling to initiate ART, arrange weekly counseling sessions to address barriers to initiation.\\n\\n### Referral Needs\\n\\n- Identify any additional referral needs and make appropriate links.\\n\\n### Documentation\\n\\n- Document all details from the session in the patient’s chart.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 120,\n",
       "  'section': '## Adherence Preparation and Support for Children and Caregivers\\n\\nThis section outlines the key processes involved in preparing for adherence to treatment in children diagnosed with HIV and their caregivers.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 120,\n",
       "  'section': '## Enrollment into Care\\n\\n- **5As Approach**: Utilize the 5As (Assess, Assist, Advice, Agree, Arrange) for effective adherence support.\\n- **Psychosocial Assessment**: Evaluate psychological, emotional, and social factors that may influence adherence.\\n- **Growth and Development**: Assess growth milestones to identify issues such as growth retardation or developmental challenges. Refer children with challenges to appropriate care.\\n- **Identify Caregivers**: Determine the primary caregiver post-diagnosis and link the child to a community volunteer if necessary.\\n- **Family-Centered Care**: Enroll both child and caregiver in the same clinic for appointments.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 120,\n",
       "  'section': '## Education and Counseling\\n\\n- **HIV Education**: Provide tailored education and counseling for the caregiver and child, appropriate to age.\\n- **Adherence Support Interventions**: Identify specific adherence support options, including pediatric and caregiver support groups.\\n- **Disclosure Planning**: Discuss benefits of disclosing HIV status, especially for children aged 5 years and older. Formulate a disclosure plan.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 120,\n",
       "  'section': '## Initiation of Antiretroviral Therapy (ART)\\n\\n- **Readiness Assessment**: Conduct an assessment to gauge readiness for ART initiation.\\n- **ART Dosing Review**: Review ART dosing and timing, ensuring the caregiver can demonstrate measurement and administration.\\n- **Treatment Plan**: Agree on a treatment and follow-up plan. Schedule a return visit within two weeks after ART initiation, or weekly for further counseling if the child is hesitant to start.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 120,\n",
       "  'section': \"## Follow-Up Sessions after ART Initiation\\n\\n### Two Weeks After ART Initiation\\n\\n- **Reinforcement of Key Messages**: Review and reinforce messages from enrollment. Confirm caregiver understanding.\\n- **Barriers to Adherence**: Explore any obstacles to adherence.\\n- **Review of Disclosure Plan**: Revisit the disclosure plan tailored for the child's age. Identify and link any referral needs.\\n- **Documentation**: Document the session in the patient’s chart.\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 120,\n",
       "  'section': '### Four Weeks After ART Initiation and Further Follow-Up\\n\\n- **Continued Reinforcement**: Reiterate key messages and confirm caregiver understanding again.\\n- **Review ART Procedures**: Review dosing, timing, and adherence reminders. Ensure caregiver can demonstrate ART administration.\\n- **Barrier Exploration**: Continue to explore barriers to adherence.\\n- **Disclosure Revisit**: Revisit the individualized disclosure plan.\\n- **Referral Needs**: Identify and link any further referral needs.\\n- **Session Documentation**: Document each session in the patient’s chart.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 124,\n",
       "  'section': '## Adherence Preparation, Monitoring, and Support\\n\\nThis section discusses the importance of preparing for, monitoring, and providing support for adherence to medication regimens.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 124,\n",
       "  'section': '## Adherence Monitoring Strategies\\n\\n### Subjective Monitoring\\n\\n- **Morisky Medication Adherence Scale - 4**\\n  - **Technique**: Use a standardized questionnaire to assess adherence and take action as necessary.\\n  - **Frequency**: Every patient, every visit.\\n\\n- **Morisky Medication Adherence Scale - 8**\\n  - **Technique**: Utilize a standardized questionnaire to assess adherence when suspected problems arise (e.g., treatment failure, missed appointments).\\n  - **Frequency**: Any time a healthcare worker suspects adherence problems.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 124,\n",
       "  'section': '## Objective Monitoring\\n\\n### Pill Counts\\n\\n- **Technique**: Patients bring all their pills to follow-up visits. Calculate the expected remaining pills based on the previous prescription and compare to the actual remaining pills. Excess pills indicate missed doses.\\n- **Frequency**: At every visit until confirmed viral suppression and anytime adherence problems are suspected.\\n\\n### Pharmacy Refill Records\\n\\n- **Technique**: Compare the drug pick-up date with the expected pick-up date (based on the number of pills dispensed). A delayed pick-up suggests missed doses equivalent to the days late.\\n- **Frequency**: At every drug pick-up and when adherence issues are suspected.\\n\\n### Viral Load Monitoring\\n\\n- **Technique**: Follow the viral load monitoring algorithm. An undetectable viral load indicates adequate adherence.\\n- **Frequency**: \\n  - Ages 0 - 24 years: every 3 months after ART initiation and then every 6 months.\\n  - Ages ≥ 25 years: at month 3 after ART initiation, month 12, then annually.\\n  - Pregnant and breastfeeding women: first ANC visit if on ART or 3 months after ART initiation during pregnancy, then every 6 months.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 125,\n",
       "  'section': '## Home Visit Assessments\\n\\nHome visits involve observing where and how a patient stores and takes their medications. It helps assess if they have extra medications due to missed doses. Such visits provide a better understanding of a patient’s living situation and specific barriers to adherence. Unsanctioned home visits may offer more revealing insights but should only be conducted if the patient has consented to them previously, preferably at the time of enrollment or treatment initiation. They are particularly important for patients with suspected or confirmed treatment failure, those who have defaulted from care, or any time the multidisciplinary team (MDT) believes a home visit will aid in patient management.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 125,\n",
       "  'section': '## Developing Patient Relationships\\n\\nAccurately assessing adherence requires clinicians to foster a collaborative and non-judgmental relationship with patients. This is best achieved when a single provider follows a patient longitudinally. The key to discussing adherence is not only in the tools used but also in regularly asking patients about their adherence in an open and inquisitive manner. Many patients may otherwise report what they think the clinician wants to hear, often indicating perfect adherence.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 125,\n",
       "  'section': '## Training and Support for Providers\\n\\nEvery provider at each Antiretroviral Therapy (ART) service delivery point should receive training and develop confidence in assessing adherence and providing support and counselling to patients without significant barriers to adherence. However, patients facing substantial challenges should be referred to trained providers who can dedicate more time to offer enhanced adherence support and counselling. Identifying concerns should lead to involving experienced colleagues within the same health facility, as well as discussions within the MDT to explore solutions. For complex situations, consultations with Mental Health Teams or regional or national mentors may be necessary.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 126,\n",
       "  'section': '## Adherence Preparation, Monitoring and Support\\n\\nThis section outlines the importance of preparation, monitoring, and support in medication adherence among patients.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 126,\n",
       "  'section': \"## Morisky Medication Adherence Scale (MMAS -4)\\n\\nThe Morisky Medication Adherence Scale (MMAS -4) is a questionnaire designed to assess a patient's adherence to their medication regimen. Patients respond to four questions with 'Yes' or 'No', with corresponding scores assigned for each answer.\\n\\n### MMAS -4 Questions\\n1. Do you ever forget to take your medicine? (Yes = 1, No = 0)\\n2. Are you careless at times about taking your medicine? (Yes = 1, No = 0)\\n3. Sometimes if you feel worse when you take the medicine, do you stop taking it? (Yes = 1, No = 0)\\n4. When you feel better do you sometimes stop taking your medicine? (Yes = 1, No = 0)\\n\\n### Total Score\\nCalculate the total score by summing the points circled for each question.\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 126,\n",
       "  'section': '## Interpretation of MMAS -4 Score\\n\\nThe interpretation of the MMAS -4 total score helps determine the level of medication adherence and necessary actions.\\n\\n### Adherence Ratings and Actions\\n- **Score 0 (Good)**  \\n  Action Required: Continue with routine monitoring, counselling, and support.\\n\\n- **Score 1-2 (Inadequate)**  \\n  Actions Required: \\n  - Discuss as a multidisciplinary team (MDT)\\n  - Assign a case manager\\n  - Assess for and address barriers to adherence (see Table 5.15)\\n  - Engage a treatment supporter in counselling sessions\\n  - Follow up in 2-4 weeks.\\n\\n- **Score 3-4 (Poor)**  \\n  Actions Required: \\n  - Discuss as an MDT\\n  - Assign a case manager\\n  - Assess for and address barriers to adherence (see Table 5.15)\\n  - Engage a treatment supporter in counselling sessions\\n  - Implement Directly Observed Therapy (DOTs)\\n  - Follow up in 1-2 weeks.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 132,\n",
       "  'section': '## Adherence Preparation, Monitoring, and Support\\n\\nThis section discusses the importance of adherence monitoring, counseling, and support for patients undergoing Antiretroviral Therapy (ART). It outlines the protocols for managing patients who have achieved viral suppression.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 132,\n",
       "  'section': '## Monitoring Patients with Suppressed Viral Load\\n\\nThis section explains the process for monitoring patients whose viral load is below 200 copies/ml, specifically those who have confirmed viral suppression (VL < 50 copies/ml). It highlights the need for ongoing adherence monitoring and support regardless of viral suppression status, though at a reduced frequency unless issues are identified.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 132,\n",
       "  'section': '## Patient Education on Stability and Services\\n\\nThe section provides insight into educating patients on qualifying as “stable patients” which may include access to services like less frequent facility visits and fast-track ART distribution. This is tied to ongoing adherence monitoring and support.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 132,\n",
       "  'section': '## Adherence Counseling for No Concerns\\n\\nIn this section, specific counseling strategies for patients with no identified adherence concerns are outlined. It emphasizes routine check-ins and encouraging existing support systems, while also addressing any questions or changes in the patient’s life.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 132,\n",
       "  'section': '## Adherence Counseling for Inadequate Adherence\\n\\nThis section addresses how to counsel patients with poor adherence. It details individualized strategies for assessing and addressing barriers, enhancing understanding of ART, and reinforcing support systems.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 132,\n",
       "  'section': '## Support Systems for Patients\\n\\nThis portion discusses the importance of reviewing existing support systems for patients and exploring additional strategies, including potentially introducing a case manager or utilizing Directly Observed Therapy (DOT).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 128,\n",
       "  'section': '## Adherence Preparation, Monitoring and Support\\n\\nThis section discusses adherence rates based on pill counts and the actions required based on the number of missed doses per month. It provides a clear framework for evaluating medication adherence and outlines the necessary steps for intervention depending on the adherence rating.\\n\\n### Adherence Rate Based on Pill Counts\\n\\n- **1 missed dose (once-daily regimen) / 1-3 doses (BD regimen)**:\\n  - **% Medications Taken**: ≥ 95%\\n  - **Adherence Rating**: Good\\n  - **Action Required**: Continue with routine monitoring, counselling, and support.\\n\\n- **2-4 missed doses (once-daily regimen) / 4-8 doses (BD regimen)**:\\n  - **% Medications Taken**: 85-94%\\n  - **Adherence Rating**: Inadequate\\n  - **Action Required**: \\n    - Discuss as an MDT\\n    - Assign a case manager\\n    - Assess for and address barriers to adherence\\n    - Engage treatment supporter in adherence counselling sessions\\n    - Follow up in 2 - 4 weeks\\n\\n- **≥ 5 missed doses (once-daily regimen) / ≥ 9 doses (BD regimen)**:\\n  - **% Medications Taken**: < 85%\\n  - **Adherence Rating**: Poor\\n  - **Action Required**: \\n    - Discuss as an MDT\\n    - Assign a case manager\\n    - Assess for and address barriers to adherence\\n    - Engage treatment supporter in adherence counselling sessions\\n    - Implement Directly Observed Therapy (DOTs)\\n    - Follow up in 1 - 2 weeks'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 128,\n",
       "  'section': \"## Adherence Counselling and Support During the First 3 Months of ART\\n\\nThis section emphasizes the importance of adherence counselling and support for patients newly initiated on Antiretroviral Therapy (ART) to achieve virological suppression, especially during rapid ART initiation.\\n\\n### Key Points\\n\\n- All patients recently starting ART require careful adherence monitoring and support for the first three months until viral load results are available.\\n- The intensity of counselling and support should be tailored based on the patient's adherence levels, assessed using methods outlined in the document.\\n- Table 5.14 summarizes the necessary counselling and support strategies for patients during this initial period.\\n- For those identified with inadequate or poor adherence, Table 5.15 provides a strategy for assessing barriers to adherence.\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 130,\n",
       "  'section': '## Adherence Preparation, Monitoring and Support\\n\\nThis section provides an overview of the importance of adherence to HIV treatment, outlining strategies for preparation, monitoring, and support.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 130,\n",
       "  'section': '## Awareness of HIV Status\\n\\n- **Assessment Questions:**\\n  - Has the patient/caregiver accepted HIV status?\\n  - For children/adolescents: Is age-appropriate disclosure underway/complete?'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 130,\n",
       "  'section': '## Understanding of HIV Infection and ART\\n\\n- **Key Concepts:**\\n  - How HIV affects the body and the risk of transmission to sexual partners and children during pregnancy and breastfeeding.\\n  - The mechanism of ART (Antiretroviral Therapy) and its effects.\\n- **Understanding Side Effects:**\\n  - Importance of recognizing side effects and knowing responses: \\n    - “Have you experienced any side effect since your last visit? Has this affected the way you take your medicine?”\\n- **Education on Adherence:**\\n  - Benefits of adherence to treatment.\\n  - Consequences of non-adherence, including drug resistance and treatment failure.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 130,\n",
       "  'section': \"## Daily Routine Assessment\\n\\n- **Reviewing Patient's Routine:**\\n  - Assess the patient's/caregiver's daily routine: “Tell me about your typical day.”\\n  - Discuss how the patient takes medicine or how the caregiver administers it:\\n    - “Please tell me how you take each of your medicines?”\\n    - “How does taking your medicine fit into your daily routine?”\\n- **Adjustment Strategies:**\\n  - If conflicts exist between the patient's routine and medication schedule, collaborate to find a new schedule.\\n  - Remind the patient/caregiver about missed or delayed doses:\\n    - Up to 12 hours late for once-daily regimens or up to 6 hours late for twice-daily regimens.\\n    - The next dose should be taken at the usual time.\\n- **Travel Considerations:**\\n  - “What do you do in case of visits or travel?”\\n  - Advise planning ahead for travel and packing sufficient medicine.\\n  - If medication runs out during travel, instruct visiting the closest ART center with the appointment card for a refill.\\n- **Special Consideration for Orphans:**\\n  - Identify who the primary caregiver is for orphans and assess their commitment.\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 127,\n",
       "  'section': '## Morisky Medication Adherence Scale (MMAS-8) Overview\\n\\nThe Morisky Medication Adherence Scale (MMAS-8) is a tool used to assess patient adherence to prescribed medication regimens. The scale consists of eight questions that evaluate various aspects of medication-taking behavior.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 127,\n",
       "  'section': '## MMAS-8 Questions and Scoring\\n\\nPatients are asked a series of questions, and their responses determine their adherence score:\\n\\n1. **Do you ever forget to take your medicine?**  \\n   Yes: 1 | No: 0  \\n   \\n2. **Are you careless at times about taking your medicine?**  \\n   Yes: 1 | No: 0  \\n   \\n3. **Sometimes if you feel worse when you take the medicine, do you stop taking it?**  \\n   Yes: 1 | No: 0  \\n   \\n4. **When you feel better do you sometimes stop taking your medicine?**  \\n   Yes: 1 | No: 0  \\n   \\n5. **Did you take your medicine yesterday?**  \\n   Yes: 0 | No: 1  \\n   \\n6. **When you feel like your symptoms are under control, do you sometimes stop taking your medicine?**  \\n   Yes: 1 | No: 0  \\n   \\n7. **Do you ever feel under pressure about sticking to your treatment plan?**  \\n   Yes: 1 | No: 0  \\n   \\n8. **How often do you have difficulty remembering to take all your medications?**  \\n   A. Never/Rarely: 0  \\n   B. Once in a while: ¼  \\n   C. Sometimes: ½  \\n   D. Usually: ¾  \\n   E. All the time: 1  \\n\\nThe total score is calculated by summing the points from all questions.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 127,\n",
       "  'section': '## Interpretation of MMAS-8 Score\\n\\nThe total score obtained from the MMAS-8 has implications for patient care:\\n\\n- **Score 0 (Good adherence)**:  \\n  - Continue with routine monitoring, counselling, and support.\\n\\n- **Score 1-2 (Inadequate adherence)**:  \\n  - Discuss as a Multidisciplinary Team (MDT).  \\n  - Assign a case manager.  \\n  - Assess and address barriers to adherence.  \\n  - Engage a treatment supporter in counselling sessions.  \\n  - Follow up in 2-4 weeks.\\n\\n- **Score 3-8 (Poor adherence)**:  \\n  - Discuss as a MDT.  \\n  - Assign a case manager.  \\n  - Assess and address barriers to adherence.  \\n  - Engage a treatment supporter in counselling sessions.  \\n  - Implement Directly Observed Therapy (DOTs).  \\n  - Follow up in 1-2 weeks.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 129,\n",
       "  'section': '## Adherence Counselling and Support During the First 3 Months of ART\\n\\n### No Adherence Concerns\\nCounselling: \\n- Group or individual sessions at every visit, conducted by any healthcare team member, including clinicians.\\n- Review patient/caregiver HIV knowledge (refer to Table 5.2, Annex 8) and address any gaps.\\n- Review patient/caregiver understanding of ART administration (dosing, timing, frequency) and address any gaps.\\n- Elicit concerns the patient/caregiver may have about ART, other medications, visit schedules, or health, and address these concerns or involve another team member if necessary.\\n- Explore any major recent or expected changes in the patient’s/caregiver’s life that could disrupt adherence.\\n- Update patient locator and contact information.\\n\\nSupport:\\n- Encourage continuation of existing support systems discussed and implemented previously.\\n- Promote the introduction of additional standard support systems (refer to Table 5.3), including support for disclosure as needed.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 129,\n",
       "  'section': '## Inadequate or Poor Adherence\\n\\n### Counselling\\n- Conduct individual sessions at every visit until adherence is improved (preferably by a trained adherence counsellor).\\n- Assess and address potential barriers to adherence (refer to Table 5.15).\\n- Review patient/caregiver HIV knowledge (refer to Table 5.2, Annex 8) and address any gaps.\\n- Review patient/caregiver understanding of ART administration (dosing, timing, frequency) and address any gaps.\\n- Elicit concerns the patient/caregiver may have about ART, other medications, visit schedules, or health, and address these concerns or involve another team member if necessary.\\n- Explore any major recent or expected changes in the patient’s/caregiver’s life that could disrupt adherence.\\n- Update patient locator and contact information.\\n\\n### Support\\n- Review the effectiveness of existing support systems in place.\\n- Encourage the introduction of additional standard and enhanced support systems (refer to Table 5.3), including support for disclosure, assigning a case manager, and considering directly observed therapies (DOTs).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 135,\n",
       "  'section': '## Enhanced Adherence Counselling Sessions: Overview\\n\\nThis section provides an overview of the Enhanced Adherence Counselling (EAC) Sessions, aimed at improving adherence to HIV treatment. The sessions are structured to address various barriers patients may face in adhering to their treatment plans.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 135,\n",
       "  'section': \"## Session 1\\n\\n- **Review of viral load (VL)**: Discuss the patient's high viral load and its implications.\\n- **Barriers to adherence**: Explore cognitive, behavioral, emotional, and socio-economic barriers which may include:\\n  - Stigma and non-disclosure\\n  - Loss or grief\\n  - Treatment literacy\\n  - Medications: dosage, timing, storage\\n  - Side effects\\n  - Risk reduction (e.g., for substance abuse)\\n  - Motivation\\n  - Mental health screening (using PHQ-9)\\n  - Patient’s support systems\\n- **Development of adherence plan**: Assist the patient in creating an adherence plan to tackle the issues identified.\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 135,\n",
       "  'section': \"## Session 2\\n\\n- **Review of adherence plan**: Discuss challenges stemming from the first session's adherence plan.\\n- **Identify gaps**: Explore new issues or gaps that may have emerged.\\n- **Modification of adherence plan**: Assist the patient in adjusting the adherence plan to address these new issues.\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 135,\n",
       "  'section': \"## Session 3\\n\\n- **Review of adherence plan**: Analyze challenges from the previous sessions and update the plan as necessary.\\n- **Decision-making on repeat VL**:\\n  - If adherence is good: Plan for repeat VL testing after three months and explain patient's role and health facility's role.\\n  - If adherence challenges persist: Consult with a senior clinician or the relevant technical working group before repeating VL testing.\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 135,\n",
       "  'section': '## Session to Discuss Repeat Viral Load Results\\n\\n- **Discussion of VL results**: Analyze the results from the second VL test.\\n- **Plan for the way forward**:\\n  - If VL is < 200 copies/ml: Continue the current regimen with ongoing adherence strategies; repeat VL in 6 months.\\n  - If VL is ≥ 1,000 copies/ml: Prepare the patient for a regimen change.\\n  - If VL is between 200 - 999 copies/ml: Assess further for causes of viremia and address identified issues; repeat VL after an additional 3 months of excellent adherence.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 134,\n",
       "  'section': '## Adherence Preparation, Monitoring and Support\\n\\nThis section covers the importance of adherence in treatment and the protocols for assessing and addressing barriers to adherence in patients undergoing treatment for HIV.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 134,\n",
       "  'section': '## Enhanced Adherence Assessments\\n\\nAs soon as treatment failure is suspected, the patient/caregiver should be discussed by the facility multi-disciplinary team to develop a plan for assessing barriers to adherence. This includes:\\n\\n- Scheduling a home visit\\n- Evaluating other potential causes of treatment failure such as:\\n  - Inadequate dosing or dose adjustments\\n  - Drug-drug interactions\\n  - Drug-food interactions\\n  - Impaired absorption (e.g., chronic severe diarrhea)\\n\\nAll patients with suspected or confirmed treatment failure should undergo a thorough assessment of potential barriers to adherence.\\n\\nIf the patient has a caregiver or treatment buddy enrolled in HIV care, their file should be reviewed to confirm the most recent viral load results and adherence.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 134,\n",
       "  'section': '## Enhanced Adherence Counselling\\n\\nEnhanced adherence counselling should commence as soon as a detectable viral load (≥ 200 copies/ml) is noted, preferably within 2 weeks. The goals of this counselling include:\\n\\n- Assessing possible barriers to adherence in a non-judgmental way\\n- Helping the patient develop an adherence plan with clear objectives\\n\\nThe focus should not only be on the knowledge of HIV and ART but also include psychological, emotional, and socio-economic factors contributing to poor adherence. Evaluating the patient’s motivation for medication can reveal underlying reasons for non-adherence.\\n\\nAt least three sessions of Enhanced Adherence Counselling spaced 2-4 weeks apart are recommended. If adherence is deemed adequate, a repeat viral load test is conducted after three months, followed by an additional counselling session to discuss results.\\n\\nContinuity is emphasized by having the patient work with the same counsellor throughout the sessions. Documentation of each session is crucial to ensure follow-up on all identified issues.\\n\\nIf adequate adherence is not achieved, consult with a senior clinician, discuss as a multi-disciplinary team (MDT), or consult the Regional or National Technical Working Group (TWG).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 134,\n",
       "  'section': '## References and Additional Information\\n\\nA detailed content guide for Enhanced Adherence Counselling is found in Annex 9, which provides additional frameworks and support for conducting adherence counselling.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 131,\n",
       "  'section': \"## Psychosocial Circumstances\\n\\n- **Home Environment:**  \\n  - “Who do you live with?”  \\n  - “Who is aware of your HIV status? Are there people in your life with whom you’ve discussed your HIV status and ART use?”  \\n    - Discuss the usefulness of enlisting the support of family members, friends, or a treatment supporter/buddy in reminding them to take medication (for children/adolescents, this includes teachers and/or supportive peers at school); offer assisted disclosure.  \\n    - Encourage the patient to identify and bring a treatment supporter during the next visit.\\n\\n- **Support System:**  \\n  - Treatment buddy, psychosocial support groups, etc.\\n\\n- **Recent Losses or Grief:**  \\n  - Impact of any recent losses on the patient's mental health.\\n\\n- **Changes in Relationships:**  \\n  - Relationship dynamics with family members/friends.\\n\\n- **Screening for Alcohol and Substance Abuse:**  \\n  - Discuss the impact on the ability to remember to take medication.  \\n  - Explore motivation to stop and offer support/referral.  \\n  - Encourage limiting use and planning ahead to ensure medication adherence.\\n\\n- **Screen for Intimate Partner Violence:**  \\n  - Reference Section 4.2.1 for details.\\n\\n- **Stigma and Discrimination:**  \\n  - Questions to assess feelings regarding stigma:\\n    - “Does it bother you people might find out about your HIV status?”  \\n    - “Do you feel that people treat you differently when they know your HIV status?”  \\n  - Discuss if stigma is interfering with taking medication on time or with keeping clinic appointments.\\n\\n- **Beliefs and Faith Healing:**  \\n  - Has the patient tried faith healing?  \\n  - Has the patient ever stopped using medication because of religious beliefs?\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 131,\n",
       "  'section': '## Mental Health Screening\\n\\n- **Depression Screening:**  \\n  - Screen patient/caregiver for depression using the PHQ-9 (Table 4.14) and manage/refer as required.\\n\\n- **Screening for Other Psychiatric Conditions:**  \\n  - Conditions such as anxiety, post-traumatic stress disorder, or psychosis should be assessed or referred to a mental health worker for further evaluation.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 131,\n",
       "  'section': '## Referrals\\n\\n- **Establishing Referrals:**  \\n  - Determine if the patient has been referred to other services (including nutrition, psychosocial support services, other medical clinics, substance use treatment, etc.).\\n\\n- **Follow-Up on Appointments:**  \\n  - Did he/she attend the appointments?  \\n  - What was his/her experience?  \\n  - Do the referrals need to be re-organized?'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 133,\n",
       "  'section': '## Viral Load Monitoring Cut-Offs\\n\\nThis section outlines the clinical definitions and interpretations related to viral load monitoring in HIV treatment.\\n\\n- **Suppressed (Low Risk)**\\n  - **Lab Value:** <50 Copies/ml \\n  - **Interpretation:** Treatment Goal; Stable Client, Untransmissible\\n  - **Guidance:** Continue management, remind client of treatment goal, enroll in DSD.\\n\\n- **Unsuppressed (High Risk)**\\n  - **Lab Value:** 200 - 999 Copies/ml \\n  - **Interpretation:** Increased risk of progression to treatment failure.\\n  - **Guidance:** Step down from DSD, institute Enhanced Adherence Counseling (EAC), repeat VL after 3 months of excellent adherence.\\n\\n- **Suspected Treatment Failure**\\n  - **Lab Value:** ≥1000 Copies/ml \\n  - **Interpretation:** Client at increased risk of morbidity and mortality.\\n  - **Guidance:** Enroll client in specialized clinic if available, conduct EAC, refer to VL algorithm.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 133,\n",
       "  'section': '## Adherence Monitoring, Counselling, and Support\\n\\nThis section describes the procedures for monitoring adherence and providing support to patients with an unsuppressed viral load of ≥200 copies/ml.\\n\\n- **Diagnosis of Treatment Failure:**\\n  - To suspect treatment failure, the patient must have been on ART for at least 3 months with either:\\n    - Viral load ≥ 200 copies/ml\\n    - Decline in CD4 count\\n    - Any new or worsening clinical condition.\\n\\n- **Assessment of Adherence:**\\n  - Poor adherence is often the primary factor in treatment failure. \\n  - Adherence must be thoroughly assessed and any issues addressed before considering a switch to the next line of ART.\\n\\n- **Regimen Change Protocol:**\\n  - Do not change regimens until the reasons for treatment failure have been identified and addressed.\\n  - A repeat VL must be ≥ 1,000 copies/ml after 3 months of confirmed excellent adherence.\\n\\n- **Consultation:**\\n  - For patients with high-risk persistent low-level viremia (VL 200 - 999 copies/ml), consult the Regional or National HIV Clinical Technical Working Group (TWG) via the Uliza Hotline (0726 460 000) or the website (https://nhcsc.nascop.org/clinicalform).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 136,\n",
       "  'section': '## Adherence Preparation, Monitoring, and Support\\n\\nThis section outlines strategies to enhance adherence for patients who may be at risk of failing treatment. It emphasizes the importance of individual support tailored to specific patient needs.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 136,\n",
       "  'section': '## Case Management\\n\\n- **Purpose**: Assign a case manager to children, adolescents, pregnant women, or patients with specific challenges (e.g., alcohol and substance abuse, mental illness, suspected or confirmed treatment failure).\\n- **Role of Case Managers**:\\n  - Coordinate multidisciplinary management for patients.\\n  - Follow up on appointment-keeping.\\n  - Organize patient reminders (e.g., SMS, calls).\\n  - Ensure appropriate defaulter tracing.\\n  - Facilitate home visits to patients.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 136,\n",
       "  'section': '## Directly Observed Therapy (DOT)\\n\\n- **Purpose**: Monitor patients with suspected treatment failure to ensure adherence before confirming treatment failure with a viral load test.\\n- **Implementation**:\\n  - Involves observation by a healthcare provider, family member, treatment supporter, or trained peer during medication ingestion.\\n  - Can be tapered off once the patient demonstrates consistent adherence and overcomes barriers.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 136,\n",
       "  'section': \"## Home Visits\\n\\n- **Objectives**:\\n  - Assess how and where a patient stores and takes medications, determining if they have excess medications from missed doses.\\n  - Gain a deeper understanding of the patient's living circumstances and adherence barriers.\\n- **Considerations**:\\n  - Unscheduled visits may yield more insights but should only occur with prior patient consent.\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 136,\n",
       "  'section': '## Monthly \"High Viral Load\" Clinics\\n\\n- **Purpose**: For patients with suspected treatment failure to receive dedicated and regular care.\\n- **Attendance**:\\n  - Children and adolescents who cannot attend monthly clinics should have sessions scheduled during school breaks (every 6 weeks).\\n- **Activities at Each Visit**:\\n  - Comprehensive clinical and psychosocial evaluations.\\n  - Appropriate investigations and treatment of opportunistic infections.\\n  - Enhanced adherence counseling sessions.\\n  - Timed support groups for patients experiencing viremia.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 136,\n",
       "  'section': '## Special Support Groups\\n\\n- **Objective**: Establish groups for patients failing treatment or on second-line ART to collaboratively address adherence challenges.\\n- **Community Engagement**: Link health facilities with community support groups to further assist patients with adherence issues.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 137,\n",
       "  'section': '## Adherence Support Systems\\n\\nAdherence support systems will need to be adapted to patients’ specific needs and the context. Special attention should be given to distinct groups such as children, adolescents, pregnant and breastfeeding women, patients with mental health disorders, and substance users.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 137,\n",
       "  'section': '## Treatment Preparation for 2nd Line or 3rd Line ART\\n\\nAfter confirming treatment failure and making the decision to start 2nd line or 3rd line ART, it is essential to provide targeted counselling and education to prepare patients for the new regimen and to support ongoing adherence. This preparation includes:\\n\\n- Reviewing the patient file\\n- Assessing patient knowledge and understanding\\n- Providing patient education\\n- Constructing an adherence plan\\n- Ensuring monthly counselling follow-up sessions during the first six months after initiating the new regimen'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 137,\n",
       "  'section': '## Follow-Up and Adherence Assessment\\n\\nDuring the monthly follow-up counselling sessions:\\n\\n- Follow up on problems identified during previous sessions.\\n- Assess patient adherence and explore any reasons for poor adherence.\\n- Identify strategies to overcome these barriers.\\n- Repeat viral load (VL) tests after 3 months on the new regimen.\\n\\nIf the VL is undetectable, continue with adherence counselling every 3 months. If the VL is detectable, discuss with the Multidisciplinary Team (MDT) and consult the Clinical Technical Working Group (TWG).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 137,\n",
       "  'section': '## Patient Understanding and Treatment Plan\\n\\nIt is crucial to ensure that the patient:\\n\\n- Confirms willingness to start the new regimen.\\n- Understands the treatment plan, including drug regimen, dosing schedule, dietary restrictions, and potential side effects.\\n- Prepares for situations that could impair good adherence and encourages the disclosure of poor adherence.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 137,\n",
       "  'section': '## Coordination with Healthcare Providers\\n\\nPlan sessions with other healthcare providers, including:\\n\\n- Pharmacists on medication adherence\\n- Nutritionists on nutritional aspects related to HIV treatment\\n\\nStrengthen key messages about HIV and viral load, emphasizing the importance of good adherence and the potential problems associated with non-adherence.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 137,\n",
       "  'section': '## Information on 2nd and 3rd Line ART\\n\\nProvide patients with clear information about 2nd and 3rd line ART, including:\\n\\n- The complexity involved in taking these regimens (more pills, twice-a-day dosing)\\n- The limited options available if these fail\\n- Simple take-home IEC materials on 2nd or 3rd line ART management addressing:\\n  - The importance of good adherence\\n  - Reasons for switching to 2nd or 3rd line ART due to treatment failure with repeated high viral loads.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 137,\n",
       "  'section': \"## Enhanced Adherence Counselling\\n\\nBefore considering changing regimens, it's important to review the patient file to confirm that all problems identified during Enhanced Adherence Counselling sessions have been addressed. If any barriers remain, they should be resolved before making treatment adjustments.\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 139,\n",
       "  'section': '## Overview of HIV in Kenya\\n\\nThis section provides a brief introduction to the state of HIV in Kenya, including statistics, prevalence rates, and the demographic groups most affected by the virus.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 139,\n",
       "  'section': '## Prevention Strategies\\n\\nThis section outlines various strategies recommended for preventing HIV transmission, including condom use, pre-exposure prophylaxis (PrEP), and education programs aimed at high-risk populations.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 139,\n",
       "  'section': '## Treatment Guidelines\\n\\nDetails about the antiretroviral therapy (ART) guidelines in Kenya, including first-line and second-line treatment options, adherence strategies, and monitoring protocols for individuals living with HIV.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 139,\n",
       "  'section': '## Testing and Diagnosis\\n\\nInformation on recommended HIV testing methods, including rapid tests and laboratory testing, as well as guidelines for counseling and follow-up after diagnosis.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 139,\n",
       "  'section': '## Care and Support Services\\n\\nAn overview of the care and support services available for individuals with HIV, including psychosocial support, nutritional guidance, and linkage to various health services.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 139,\n",
       "  'section': '## Special Populations\\n\\nThis section addresses the unique considerations for specific populations, such as pregnant women, children, and key affected populations like men who have sex with men and sex workers.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 139,\n",
       "  'section': '## Data Collection and Monitoring\\n\\nDetails on the importance of data collection in HIV programs, including indicators for success, reporting requirements, and methods used for monitoring program effectiveness.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 139,\n",
       "  'section': '## Community Engagement\\n\\nDiscussion on the role of community involvement in HIV prevention and treatment efforts, highlighting successful models and strategies for increasing participation and awareness.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 139,\n",
       "  'section': '## Policy and Advocacy\\n\\nAn examination of the policy landscape surrounding HIV in Kenya, including key legislation, advocacy efforts, and the importance of human rights in combating stigma and discrimination.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 139,\n",
       "  'section': '## Future Directions\\n\\nInsights into emerging trends in HIV research and treatment, anticipated challenges, and recommended areas of focus for future HIV prevention and treatment initiatives in Kenya.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 140,\n",
       "  'section': '## Antiretroviral Therapy Overview\\n\\nAntiretroviral Therapy (ART) is a critical intervention in managing HIV disease, though it does not cure HIV infection. The primary goal of ART is to suppress viral replication, aiming to reduce the patient’s viral load (VL) to undetectable levels. Continuous and strict adherence to ART is essential for maintaining undetectable VL levels, which helps protect the immune system, lowers AIDS-related morbidity and mortality, and reduces the risk of both sexual and vertical transmission of HIV.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 140,\n",
       "  'section': '## Eligibility for ART\\n\\nAll individuals with a confirmed HIV infection are eligible for ART, regardless of their CD4 count, WHO clinical stage, age, pregnancy or breastfeeding status, co-infection status, risk group, or any other criteria. This inclusivity ensures that all patients have access to necessary treatment.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 140,\n",
       "  'section': '## Timing of ART Initiation\\n\\nART should be initiated as soon as possible for all patients, preferably within two weeks of HIV status confirmation. In some cases, ART can be started on the same day as the positive test result if the individual is prepared. Utilizing ART Readiness Criteria can assist in identifying any concerns that need to be addressed during the ART initiation. Initiating ART on the same day as testing positive has several benefits for HIV prevention, especially for pregnant and breastfeeding women, as well as for HIV-positive partners in discordant relationships. It is also linked to better retention, viral suppression, and survival rates. Special considerations for ART initiation timing can be found in Table 6.1.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 141,\n",
       "  'section': '## ART Initiation for Pregnant and Breastfeeding Women\\n\\nSupport ART initiation on the same day as testing positive for HIV. Intensive adherence counselling, support, and close follow-up are required because of limited time for patient preparation.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 141,\n",
       "  'section': '## ART Initiation for Infants (< 12 months old)\\n\\nSupport ART initiation on the same day as testing positive for HIV. Treatment should commence following a first positive PCR test. ALWAYS take a sample for a confirmatory PCR test as soon as the first positive PCR result is received, but do not delay ART initiation for the second PCR result. Intensive adherence counselling, support, and close follow-up are required because of limited time for caregiver preparation.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 141,\n",
       "  'section': '## ART Initiation for Patients with Strong Motivation\\n\\nSupport ART initiation as soon as the patient feels ready, preferably on the same day as testing positive for HIV. Intensive adherence counselling, support, and close follow-up are required because of limited time for patient preparation.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 141,\n",
       "  'section': '## ART Initiation for Patients with Newly Diagnosed TB\\n\\nStart anti-TB treatment immediately and initiate ART as soon as anti-TB medications are tolerated, preferably within 2 weeks. For TB meningitis, delay ART for 4 to 8 weeks. Monitor closely for IRIS (see Annex 16).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 141,\n",
       "  'section': '## ART Initiation for Patients with Cryptococcal Meningitis\\n\\nDefer ART until after completing 5 weeks of Cryptococcal Meningitis treatment. Monitor closely for IRIS (see Annex 16).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 141,\n",
       "  'section': '## ART Initiation for Patients with Complex Adherence Challenges\\n\\nStart ART as soon as possible while implementing additional support systems (e.g., optional enrolment of a person who injects drugs (PWID) into a medication-assisted treatment (MAT) program; psychiatric treatment for a patient with mental illness; enrolment into an orphaned and vulnerable children (OVC) program for orphans, etc.). A case manager should be assigned to all patients with complex adherence challenges.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 141,\n",
       "  'section': '## ART Initiation for All Other Patients\\n\\nStart ART as soon as possible, preferably within 2 weeks, and even on the same day as testing positive for HIV if they are ready. Continued adherence monitoring and support is recommended after ART initiation for all patients.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 146,\n",
       "  'section': '## Antiretroviral Therapy Overview\\n\\nAntiretroviral therapy (ART) is essential for infants, children, adolescents, and adults living with HIV. It is important for managing the viral load and improving overall health.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 146,\n",
       "  'section': '## Monitoring and Changing ART\\n\\nThe primary goals of clinical and laboratory monitoring during ART are to:\\n- Identify and treat intercurrent illnesses\\n- Assess and manage adverse drug reactions\\n- Evaluate the response to treatment\\n\\nRoutine laboratory monitoring is detailed in Table 3.5. Additional tests may be necessary based on clinical suspicion for better patient management.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 146,\n",
       "  'section': '## Indications for Changing ART\\n\\nChanges to ART may be necessary in cases of:\\n- Optimizing therapy for patients with undetectable viral loads\\n- Managing adverse drug reactions or toxicity\\n- Addressing drug-drug interactions\\n- Managing co-morbidities\\n- Responding to treatment failure'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 146,\n",
       "  'section': '## Optimizing Therapy for Suppressed Viral Load\\n\\nPatients on first-line ART who are virally suppressed may benefit from regimen optimization. This includes:\\n- Moving to a simplified regimen\\n- Preventing long-term toxicity\\n- Improving cost-effectiveness\\n\\nDolutegravir is preferred for its superior tolerability and efficacy compared to other agents like efavirenz and lopinavir.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 146,\n",
       "  'section': '## Pediatric Considerations in ART Optimization\\n\\nChildren and adolescents under 15 years should consider regimen optimization when transitioning through age/weight bands. Optimization should be discussed, especially for those not on the recommended first-line regimen.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 146,\n",
       "  'section': '## Communication with Patients and Caregivers\\n\\nWhen modifying regimens, always ensure discussions with the patient or caregiver regarding:\\n- Potential new side effects associated with the new ARV\\n- Common side effects (headache, nausea, diarrhea) and any specific to the chosen ARV\\n- Reassurance that most side effects tend to resolve within 1-2 weeks of continued use'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 145,\n",
       "  'section': '## Pregnancy Safety of DTG\\n\\nDTG is safe during pregnancy and breastfeeding. Pregnancy intention should be discussed with all women initiating ART regardless of regimen. Women who do not wish to become pregnant should be offered appropriate family planning counseling and methods.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 145,\n",
       "  'section': '## Important Drug Interactions with DTG\\n\\n### Rifampicin\\n- Rifampicin lowers DTG levels: \\n  - Increase DTG to 50 mg twice daily for patients on rifampicin who are > 20 kg in body weight.\\n  - Children <20 kg taking DTG who require rifampicin should increase their weight-appropriate DTG dose to twice daily.\\n- There are no significant drug interactions between DTG and other currently used anti-TB medications (including for MDR-TB).\\n\\n### Mineral Supplements\\n- Antacids containing calcium, zinc, magnesium, or aluminum; iron supplements; and prenatal vitamins (which contain iron and calcium) decrease the absorption of DTG:\\n  - Administer DTG at least 2 hours before or 6 hours after taking any of these supplements.\\n  - Dose separation is not required for calcium and iron supplements if DTG is taken with a meal.\\n  - Educating patients about this interaction is critical, as many obtain these supplements and antacids over-the-counter without informing their healthcare provider.\\n\\n### Anticonvulsants\\n- Carbamazepine, phenobarbital, and phenytoin decrease DTG levels:\\n  - Use a different anticonvulsant if available.\\n  - If DTG must be co-administered with these drugs, increase to DTG to twice daily, although there is little data to guide this.\\n  - If valproic acid is available, it can be used with DTG without dose adjustment.\\n\\n### Metformin\\n- DTG increases levels of metformin; the levels of DTG are not affected:\\n  - Use a lower dose of metformin (often 50% of usual dose) and monitor glycemic control.\\n  - Use a maximum daily dose of metformin 1 g.\\n\\n### Other Drug-Drug Interactions\\n- See Annex 13C for more information on other drug-drug interactions with DTG.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 138,\n",
       "  'section': '## Adherence Preparation, Monitoring and Support\\n\\nThis section outlines the key components necessary for effective adherence preparation, monitoring, and support within an ARV service delivery point, including appointment tracking and patient follow-up protocols.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 138,\n",
       "  'section': \"## Identifying and Tracing Patients who Miss Appointments\\n\\nEvery service delivery point providing ARVs (ART, PEP, or PrEP) must implement a system for identifying patients who miss their appointments. Actions should be taken within 24 hours of a missed appointment. Key steps include:\\n\\n- Entering the date of the next appointment/TCA into the appointment diary for each patient.\\n- Checking off patients' names in the appointment diary as they arrive at the service delivery point.\\n- Recording all patients who missed appointments in the patient follow-up register.\\n- Calling the patient or caregiver within 24 hours of the missed appointment.\\n- If there is no response, reaching out to the treatment buddy.\\n- Making several attempts at phone tracing if there is no initial response.\\n- Updating the patient follow-up register with the findings from the phone calls.\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 138,\n",
       "  'section': '## Managing Re-Engagement with Patients\\n\\nThis section discusses the actions to take when re-engaging patients who have missed appointments and outlines the follow-up process:\\n\\n- If a patient does not return within the agreed timeframe but is reachable by phone, encourage their return.\\n- If they return to the clinic:\\n  - Assess and address potential barriers to adherence.\\n  - Review HIV knowledge and address any gaps.\\n  - Discuss concerns related to ART, medications, or health and involve care team members as necessary.\\n  - Explore changes in the patient’s life that could disrupt adherence.\\n  - Review existing support systems and encourage additional support structures as needed.\\n- If unable to reach the patient by phone or they do not return within 7 days, update the records.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 138,\n",
       "  'section': '## Home Visit Preparations\\n\\nFor patients who are prioritized for a home visit based on specific criteria (e.g., pregnant women, children, or those with comorbidities), the following steps should be taken:\\n\\n- Complete a home visit form.\\n- Update the patient follow-up register with the findings from the home visit.\\n- Update the appointment diary if the patient agrees to return to the clinic.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 138,\n",
       "  'section': '## Management Plan for Unreached Patients\\n\\nThis section addresses the next steps when patients cannot be traced or do not return to the clinic:\\n\\n- Discuss the situation as a multi-disciplinary team (MDT) and develop a follow-up or management plan.\\n- Update the patient records/registers with any outcomes from these discussions.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 148,\n",
       "  'section': '## Antiretroviral Therapy Overview for Different Age Groups\\n\\nThis section outlines the management of antiretroviral therapy (ART) in infants, children, adolescents, and adults, focusing on specific age and weight criteria.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 148,\n",
       "  'section': '## Viral Load Monitoring and Regimen Changes\\n\\nIn this section, procedures for monitoring viral load (VL) and adjusting ART regimens for children and adolescents weighing ≥ 30 kg or ≥ 15 years old are discussed. Key steps include:\\n- Determining VL status within the last 6 months and its implications.\\n- Actions based on VL results, such as switching to TDF/3TC/DTG.\\n- Scheduling follow-up appointments and further monitoring as needed.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 148,\n",
       "  'section': '## Management of Adverse Drug Reactions (ADRs)\\n\\nThis section addresses how to identify and manage adverse drug reactions associated with ART. Key points include:\\n- Patient education on potential side effects.\\n- The importance of early identification and aggressive management of ADRs.\\n- Reporting ADRs to the Pharmacy and Poisons Board.\\n- Monitoring for rare ADRs related to new ARVs in the national supply chain.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 148,\n",
       "  'section': '## Summary of Significant ADRs and Management Principles\\n\\nA summary of common significant ADRs associated with ARVs that may necessitate drug substitution is provided here. General principles for managing ADRs and specific management guidelines can be found in accompanying tables and figures.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 148,\n",
       "  'section': '## Additional Resources for Pharmacovigilance\\n\\nThis section serves as a resource for accessing pharmacovigilance tools and emphasizes the importance of ongoing monitoring for ADRs arising from new antiretrovirals.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 142,\n",
       "  'section': '## Antiretroviral Therapy Overview\\n\\nAntiretroviral therapy (ART) is crucial for treating HIV in various populations, including infants, children, adolescents, and adults. Recommendations for first-line ART regimens are essential for individuals starting treatment and cover both preferred and alternative options.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 142,\n",
       "  'section': \"## First-Line ART for Infants\\n\\nFor infants up to 4 weeks of age, the recommended regimen is AZT + 3TC + NVP. The specific dosing guidelines must be referenced from Annex 10, taking into account the infant's weight.\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 142,\n",
       "  'section': '## First-Line ART for Children and Adolescents\\n\\nChildren aged over 4 weeks and under 15 years are prescribed ART based on their weight. \\n- For those weighing less than 30 kg: the preferred regimen is ABC + 3TC + DTG.\\n- For those weighing 30 kg or more: the regimen is TDF + 3TC + DTG. Dosage for TDF/3TC/DTG is 1 tablet once daily.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 142,\n",
       "  'section': '## First-Line ART for Adults\\n\\nAdults aged 15 years and older should follow the same regimen as adolescents weighing 30 kg or more: TDF + 3TC + DTG, which is also dosed at 1 tablet once daily.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 142,\n",
       "  'section': '## Weight Monitoring and Adherence\\n\\nIt is crucial for all patients to have their weight documented at every visit. For children and adolescents under 15, confirmation of correct weight-based dosing of ARVs must occur at each visit. Caregivers play an essential role in medication adherence, and their preparation is vital for managing challenges such as drug palatability.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 142,\n",
       "  'section': '## Caregiver Education and Administration\\n\\nCaregivers need to be shown how to measure and administer ARVs properly. This instruction should occur both during the prescribing phase by the clinician and at the time of dispensing the medication. It is important that the caregiver who attends clinical reviews is the one responsible for day-to-day ART administration.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 142,\n",
       "  'section': '## Recommendations for Regimen Optimization \\n\\nPatients currently on first-line regimens not included in the preferred or alternative regimens should be evaluated for regimen optimization as indicated in Section 6.5.1.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 142,\n",
       "  'section': '## Special Considerations for Infants and Adolescents\\n\\nInfants starting ART under 4 weeks should initially begin with AZT+3TC+NVP. As they reach 4 weeks, they should transition to ABC/3TC + DTG. Adolescents weighing 30 kg should be considered for a regimen transition if they are virally suppressed.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 144,\n",
       "  'section': '## Antiretroviral Therapy: Overview and Context\\n\\nThis section discusses the context of antiretroviral therapy (ART) use in different populations, including infants, children, adolescents, and adults. It emphasizes the need for multidisciplinary team (MDT) consultations for scenarios not covered in specific tables, as well as the importance of contacting the Regional or National HIV Clinical Technical Working Group (TWG) for guidance.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 144,\n",
       "  'section': '## ABC Hypersensitivity Reaction Management\\n\\nABC hypersensitivity reaction (AHR) is rare in the Kenyan population. This section refers to Table 6.9 for the definition and management strategies for AHR, underscoring the importance of being aware of this reaction and having a management plan in place.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 144,\n",
       "  'section': \"## Dolutegravir (DTG) Dosing and Administration\\n\\n### Recommended Dosing of DTG\\n\\nThis section provides detailed information on the dosing and administration of Dolutegravir (DTG) based on the patient's weight and specific health scenarios. \\n\\n- For patients < 20 kg: Use weight-based dosing with dispersible 10mg DTG tablets as specified in Annex 10.\\n- For patients ≥ 20 kg: Administer DTG 50 mg film-coated tablet once daily, preferably in the morning. Options for fixed-dose combinations (FDC) are also available.\\n- Special instructions for patients taking rifampicin: Increase dosing frequency to twice daily during TB treatment and for an additional 2 weeks afterward.\\n- Dosage adjustments for patients with suspected or confirmed integrase strand transfer inhibitor (INSTI) resistance.\\n\\n### Food Considerations\\n\\nDTG can be taken with or without food, which provides flexibility for administration.\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 144,\n",
       "  'section': '## Common Side Effects of DTG\\n\\nThis section outlines common side effects associated with DTG, including:\\n\\n- Headache, nausea, and diarrhea, which usually resolve after 1-2 weeks of continued use. Patients should be informed of these potential side effects.\\n- Insomnia may be experienced by some patients, which can be alleviated by taking DTG in the morning or with low-fat meals.\\n- A small rise in serum creatinine levels, which does not indicate a true decline in renal function.\\n- The association of integrase inhibitors, including DTG, with increased weight gain; patients should be counseled on maintaining a healthy lifestyle.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 144,\n",
       "  'section': '## Reporting Adverse Events\\n\\nAll adverse events should be reported through the national pharmacovigilance mechanism. Additional information can be found at the provided link (http://www.pv.pharmacyboardkenya.org/), emphasizing the importance of monitoring and reporting for patient safety.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 143,\n",
       "  'section': \"## Alternative ARVs in First-Line Regimens for Infants (Birth to 4 Weeks)\\n\\n- **NVP (Nevirapine)**: If the infant develops a hypersensitivity reaction, use RAL (Raltegravir) granules or LPV/r (Lopinavir/ritonavir) granules (over 2 weeks of age) or defer ART until 4 weeks of age, then start ABC (Abacavir) + 3TC (Lamivudine) + DTG (Dolutegravir).\\n  \\n- **AZT (Zidovudine)**: If the infant's hemoglobin (Hb) is < 9.5 g/dL, defer ART until 4 weeks of age, then start ABC + 3TC + DTG.\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 143,\n",
       "  'section': '## Alternative ARVs for Children Aged > 4 Weeks to < 15 Years (< 30 kg)\\n\\n- **ABC**: If the child develops an ABC hypersensitivity reaction, use AZT (if Hb ≥ 9.5 g/dL); if Hb < 9.5 g/dL, consult the Regional or National HIV Clinical TWG (call Uliza Hotline 0726 460 000; ulizanascop@gmail.com).\\n\\n- **DTG**: If the child is unable to tolerate DTG, use LPV/r at standard weight-based BD (twice daily) dosing; if a 4-in-1 formulation is available, this is preferred.\\n\\n- **DTG with Rifampicin**: If the child is currently on rifampicin-containing anti-TB medications, increase DTG dosing frequency to twice daily during TB treatment and for an additional 2 weeks after, then revert to once daily dosing.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 143,\n",
       "  'section': '## Alternative ARVs for Children Aged > 4 Weeks to < 15 Years (≥ 30 kg)\\n\\n- **TDF (Tenofovir)**: If there is impaired renal function (CrCl ≤ 50 ml/min), use ABC or TAF (Tenofovir alafenamide, once available).\\n\\n- **DTG**: If the child is unable to tolerate DTG, use EFV (Efavirenz; for people who inject drugs - PWID, use ATV/r).\\n\\n- **DTG with Rifampicin**: Provide TDF/3TC/DTG FDC (fixed-dose combination) in the morning plus DTG 50mg in the evening for the duration of rifampicin-containing TB treatment and for an additional 2 weeks, then revert to TDF/3TC/DTG FDC once daily.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 143,\n",
       "  'section': '## Alternative ARVs for Adolescents and Adults (≥ 15 Years)\\n\\n- **TDF**: If there is impaired renal function (CrCl ≤ 50 ml/min), use ABC or TAF (once available).\\n\\n- **DTG**: If unable to tolerate DTG, use EFV (for PWID, use ATV/r).\\n\\n- **DTG with Rifampicin**: Administer TDF/3TC/DTG FDC in the morning plus DTG 50mg in the evening for the duration of rifampicin-containing TB treatment and for an additional 2 weeks after TB treatment, then revert to TDF/3TC/DTG FDC once daily.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 152,\n",
       "  'section': '## Assessing Risk of Kidney Disease in HIV Patients\\n\\nAt every clinic visit, assess for risk of kidney disease based on the following criteria:\\n- Age > 60 years\\n- Concurrent HIV-associated diseases (such as TB and other opportunistic infections)\\n- Concurrent diabetes, hypertension, or viral hepatitis\\n- Concomitant use of nephrotoxic drugs (e.g., aminoglycosides, amphotericin, and boosted protease inhibitors)\\n- Wasting or low BMI\\n- CD4 count < 200 cells/mm³'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 152,\n",
       "  'section': '## Steps to Monitor Kidney Function\\n\\nIf any risk factor is present:\\n- Obtain a dipstick urinalysis and serum creatinine.\\n- Calculate creatinine clearance (CrCl in ml/min).\\n\\n**Monitoring Guidelines:**\\n1. If CrCl > 90 ml/min:  \\n   - Use TDF 300 mg daily; reassess creatinine and CrCl at 1 month, 3 months, and bi-annually thereafter if normal.  \\n   \\n2. If CrCl = 50 - 89 ml/min:  \\n   - Use TDF 300 mg daily; monitor closely for decline in renal function (monthly during the first year, and every 3 months thereafter if CrCl remains stable).\\n\\n3. If CrCl = 30 - 49 ml/min:  \\n   - Avoid use if there is no suitable alternative; if necessary, give TDF 300 mg every 48 hours and closely monitor with monthly CrCl for the first year and every 3 months thereafter if stable.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 152,\n",
       "  'section': \"## Managing TDF-Associated Kidney Toxicity\\n\\n**Important Considerations:**\\n- DTG may cause a small rise in serum creatinine levels, but this does NOT indicate a true decline in renal function.\\n- Patients with CrCl < 50 ml/min do not require a dose adjustment for TDF unless there's concurrent HIV/HBV co-infection.\\n- If HBV negative and on first-line ART, substitute TDF with ABC, TAF, or DTG + 3TC dual therapy.\\n- For patients with decreased renal function, assess for other causes of renal impairment and refer to a physician for review.\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 152,\n",
       "  'section': '## Hotline for Clinical Consultation\\n\\nIn cases of prior ART treatment failure or other concerns, consult the Regional or National HIV Clinical Technical Working Group (TWG) at the Uliza Hotline: 0726 460 000.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 155,\n",
       "  'section': '## Diagnosis and Management of Abacavir Hypersensitivity Reaction\\n\\n### Diagnosis  \\nWithin 3 weeks of initiating an ABC-containing regimen, the patient develops any 2 of the following symptom groups concurrently:  \\n- Fever  \\n- Erythematous and/or pruritic rash  \\n- Respiratory symptoms (shortness of breath and/or sore throat and/or cough)  \\n- GI symptoms: nausea and/or vomiting and/or diarrhea  \\n- Extreme fatigue and/or body pain preventing normal activities  \\n\\nAND: there is not a more likely alternative explanation for the symptoms.\\n\\n### Management  \\n- Stop ABC immediately and substitute with an alternative ARV.  \\n- The patient must NEVER be re-challenged with ABC; a single dose could result in a fatal hypersensitivity reaction.  \\n- Clearly mark the file and educate the patient about avoiding ABC in the future.  \\n- Issue an Adverse Event alert card.  \\n\\n### Note  \\n- ABC hypersensitivity reaction is rare in our population; always consider other more likely possible diagnoses.  \\n- Symptoms generally worsen within hours after each dose of ABC.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 155,\n",
       "  'section': '## Changing ARVs Due to Drug-Drug Interactions\\n\\nPatients must be asked about other medications (including non-prescription and herbal medicine) they are taking at every visit. Some common drugs have specific drug-drug interactions that may require dose adjustment or substitution of the ARV or the other interacting drugs.\\n\\n### Common Medications That Interact with Specific ARVs Include:  \\n- Rifampicin  \\n- Rifabutin  \\n- Antacids  \\n- Multivitamin/mineral supplements  \\n- Methadone  \\n- Several anti-fungals  \\n- Anti-convulsants  \\n- Calcium-channel blockers  \\n- Some anti-depressants  \\n- Some statins  \\n- Some anti-malarials  \\n\\nAnnex 13 provides common drug-drug interactions and management recommendations. It is recommended practice to check for interactions whenever a new medicine is started.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 147,\n",
       "  'section': '## HIV Viral Load Monitoring for Children on ART\\n\\nThis section covers the guidelines for monitoring viral loads (VL) in children weighing less than 30 kg on a first-line Antiretroviral Therapy (ART) regimen that is not ABC/3TC + DTG. Continuous monitoring is vital, and actions are based on the VL results obtained within the last 6 months.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 147,\n",
       "  'section': '## Actions for VL Results\\n\\nThis segment outlines specific actions based on different VL results:\\n\\n1. **VL < 200 copies/ml (LDL):**\\n   - No immediate action needed; continue routine monitoring. \\n\\n2. **No VL result within last 6 months:**\\n   - Collect sample for VL testing.\\n\\n3. **VL ≥ 200 copies/ml:**\\n   - Switch to ABC/3TC + DTG using weight-based dosing from Annex 10A-B.\\n   - Schedule a clinical appointment in 2 weeks to review adherence, side effects, and other concerns.\\n   - Repeat VL in 3 months after any regimen modification.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 147,\n",
       "  'section': '## Switching Regimens\\n\\nThis section addresses guidelines for switching regimens when VL results indicate viremia.\\n\\n1. **Viral Load ≥ 200 copies/ml:**\\n   - Assess reasons for viremia and provide enhanced adherence counseling. \\n\\n2. **If the current regimen contains ABC:**\\n   - Switch to AZT/3TC + DTG.\\n\\n3. **If the current regimen contains AZT:**\\n   - Switch to ABC/3TC + DTG.\\n\\n4. **Weight-based dosing:**\\n   - Follow dosing guidelines from Annex 10A-B for switching.\\n\\n5. **For patients on PI/r or DTG regimens:**\\n   - Summarize the case for the Technical Working Group (TWG) and take a sample for Drug Resistance Testing (DRT) without waiting for DRT results to modify the regimen.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 147,\n",
       "  'section': '## Follow-up Actions \\n\\nThis section outlines the post-switch actions:\\n\\n- **Clinical Appointment:**\\n   - Schedule an appointment 2 weeks post-regimen change to evaluate adherence and side effects.\\n\\n- **Follow-up VL Testing:**\\n   - Repeat VL in 3 months after the regimen modification.\\n  \\n- **Consultation with TWG:**\\n   - If VL remains ≥ 200 copies/ml, consult the regional or national TWG.\\n   - If VL drops to < 200 copies/ml, continue with routine viral load monitoring.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 147,\n",
       "  'section': '## Art Duration and Viral Load Context\\n\\nThis section discusses considerations for children on ART for less than 3 months and their VL outcomes:\\n\\n- If on ART for less than 3 months:\\n  - Monitor VL outcomes as per guidelines mentioned above; special considerations may apply based on adherence and regimen introduction.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 147,\n",
       "  'section': \"## Decision Flow for Treatment Modification\\n\\nProvide an overview of the decision-making process when assessing children's ART regimens:\\n\\n- Start with VL monitoring results to guide the treatment strategy.\\n- Adjust regimens based on VL results and adherence evaluations.\\n- Ensure continuous follow-up and support through clinical appointments and monitoring.\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 150,\n",
       "  'section': '## Antiretroviral Therapy Overview\\n\\nAntiretroviral therapy (ART) is crucial in managing HIV across different age groups, including infants, children, adolescents, and adults. This therapy involves several medications aimed at controlling HIV replication and improving the quality of life for those affected.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 150,\n",
       "  'section': '## Assessing Adverse Drug Reactions (ADRs)\\n\\nAlternative explanations for toxicity must be excluded before concluding that a reaction is secondary to an ARV. It is important to consider:\\n\\n- Other medications and herbal remedies\\n- Diseases, including opportunistic infections\\n- Immune reconstitution inflammatory syndrome (IRIS)\\n- Other illnesses'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 150,\n",
       "  'section': '## Evaluating Concurrent Medications\\n\\nWhen assessing an adverse event, evaluate:\\n\\n- Concurrent medications and any new or pre-existing conditions\\n- Possible drug-drug interactions\\n- Other medical conditions and inter-current illnesses or IRIS'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 150,\n",
       "  'section': '## Grading Seriousness of Adverse Events\\n\\nAdverse events can be classified into different grades, which determine how to proceed:\\n\\n1. **Life-threatening (Grade 4)**\\n   - Immediately discontinue all drugs, including ARVs, and manage the medical event, typically requiring hospitalization.\\n\\n2. **Severe (Grade 3)**\\n   - When stabilized, reintroduce ARVs with a modified regimen by substituting the offending drug.\\n\\n3. **Moderate (Grade 2)**\\n   - Substitute the offending drug without discontinuing ART, and monitor the patient closely.\\n\\n4. **Mild (Grade 1)**\\n   - Continue ARVs as long as feasible and offer symptomatic relief if appropriate.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 150,\n",
       "  'section': '## Monitoring Patients for Toxicities\\n\\nAt every clinic visit, patients on ART should be monitored clinically for ADRs using:\\n\\n- Patient history: Symptoms suggesting toxicity\\n- Physical examination: Relevant signs\\n- Laboratory assessments to confirm specific issues\\n\\nDiagnosis and management of toxicities should follow a systematic approach to evaluate whether the toxicity stems from an ARV or another source.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 150,\n",
       "  'section': '## Management of Adverse Drug Reactions\\n\\nFor patients identified with ADRs:\\n\\n- Review patient progress at each clinic visit.\\n- Document outcomes meticulously.\\n- Report suspected or confirmed adverse drug events using the Pharmacovigilance form at www.pv.pharmacykenya.org.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 150,\n",
       "  'section': '## General Principles for Managing Adverse Drug Reactions\\n\\nAlways follow established guidelines and algorithms for single-drug substitution when managing ADRs. This ensures a structured approach to patient care and improves overall treatment outcomes.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 156,\n",
       "  'section': '## Antiretroviral Therapy in Infants, Children, Adolescents, and Adults\\n\\nThis section discusses the importance and protocol of antiretroviral therapy (ART) monitoring in different age groups and specific populations.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 156,\n",
       "  'section': '## Monitoring Viral Load\\n\\nViral load (VL) is the test of choice for monitoring response to ART and identifying treatment failure. Key points include:\\n\\n- **Initial Testing**: First VL should be performed 3 months after ART initiation for all people living with HIV (PLHIV).\\n- **Suspecting Treatment Failure**: Treatment failure should be suspected when a new or recurrent HIV-associated condition indicating severe immunodeficiency (WHO stage III or IV) develops after at least 6 months on ART.\\n- **Confirmation**: Treatment failure should always be confirmed with VL testing.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 156,\n",
       "  'section': '## Frequency of Routine VL Monitoring\\n\\nThe frequency of VL monitoring varies by age and specific conditions:\\n\\n- **Age 0-24 years**: VL at 3 months after ART initiation, then every 6 months.\\n- **Age ≥ 25 years**: VL at 3 months after ART initiation, then at month 12 and annually thereafter.\\n- **Pregnant or Breastfeeding Individuals**: VL at confirmation of pregnancy (if already on ART) or 3 months after ART initiation, and then every 6 months until cessation of breastfeeding.\\n- **Drug Substitutions**: Before making any drug substitutions (if no VL results from the prior 6 months), and three months after any regimen modification.\\n- **Patients with Detectable VL**: Follow the viral load monitoring algorithm.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 156,\n",
       "  'section': '## Interpreting Viral Load Results \\n\\nUnderstanding VL results is vital for confirming treatment outcomes. Key definitions and indicators include:\\n\\n- **Sustained Viral Suppression**: Achieving a VL below the Lower Detection Limit (LDL), defined as < 50 copies/ml.\\n- **Persistent Low-Level Viremia (PLLV)**: Defined as having 200 - 999 copies/ml on two consecutive measures, necessitating case management similar to those with VL ≥ 1,000 copies/ml.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 156,\n",
       "  'section': '## Defining Treatment Failure\\n\\nTreatment failure is defined based on specific VL outcomes:\\n\\n- **Suspicion of Treatment Failure**: A high VL ≥ 1,000 copies/ml after at least 3 months on ART indicates treatment failure.\\n- **Confirmation Steps**: Treatment failure is confirmed only when VL is ≥ 1,000 copies/ml after addressing poor adherence or other reasons for high VL, with a follow-up VL test after improved adherence and at least 3 months of treatment.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 156,\n",
       "  'section': \"## Consultation Resources\\n\\nFor additional support and guidance, consult with the Regional or National HIV Clinical Technical Working Group (TWG) via the Uliza Hotline: 0726 460 000 or visit [NASCOP's Clinical Form](https://nhcsc.nascop.org/clinicalform).\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 149,\n",
       "  'section': '## Adverse Drug Reactions for ARV Agents\\n\\nThis section outlines the common significant adverse drug reactions (ADRs) associated with various antiretroviral (ARV) agents, categorized by their drug class.\\n\\n### NRTIs\\n- **ABC**: ABC hypersensitivity reaction. Do not re-challenge.\\n  \\n- **AZT**: \\n  - **Adverse Effects**: Anaemia, neutropenia.\\n  - **High Risk Situations**: CD4 count < 200 cells/mm3; BMI < 18.5 or body weight < 50 kg; anaemia at baseline; concurrent use of other drugs with similar ADR (cotrimoxazole, gancyclovir, ribavirin).\\n  - **Additional Risks**: Lactic acidosis (Risk factors: Pregnancy; obesity), Lipoatrophy (Risk factors: Low CD4 count).\\n  \\n- **TDF**: \\n  - **Adverse Effects**: Renal dysfunction.\\n  - **High Risk Situations**: Underlying renal disease; age > 60 years; BMI < 18.5 or body weight < 50 kg; diabetes; hypertension; concomitant PI use or nephrotoxic drug.\\n  - **Caution**: Avoid in patients with CrCl< 50ml/min unless treating HIV/HBV co-infection if TAF is unavailable.\\n  \\n- **TAF**: \\n  - **Adverse Effects**: Weight gain.\\n  - **High Risk Situations**: Women; concomitant use of INSTIs.\\n  - **Recommendations**: Provide advice on healthy eating and physical activity.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 149,\n",
       "  'section': '## NNRTIs and Their Adverse Effects\\n\\nThis section presents information on adverse drug reactions associated with Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs).\\n\\n- **All NNRTIs**: Common reaction is rash (NVP >> EFV > ETR). Manage rash as per specific protocols.\\n\\n- **EFV**: \\n  - **Adverse Effects**: CNS side effects.\\n  - **High Risk Situations**: Pre-existing psychiatric disorders.\\n  - **Other Effects**: Gynaecomastia (consult for alternative if symptoms persist).\\n\\n- **NVP**: \\n  - **Adverse Effects**: Hepatotoxicity. No additional risk factors reported.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 149,\n",
       "  'section': '## Protease Inhibitors (PIs) Adverse Reactions\\n\\nThis section highlights the significant side effects and risk factors associated with Protease Inhibitors.\\n\\n- **All PIs (boosted with RTV)**: \\n  - **Adverse Effects**: GI intolerance (LPV/r > DRV/r > ATV/r).\\n  - **Recommendations**: Consult for alternative regimen (R-TWG or Uliza Hotline).\\n  - **Other Effects**: Dyslipidaemia (risk factors: Obesity; sedentary lifestyle; diet high in saturated fats).\\n\\n- **ATV/r**: \\n  - **Specific Reaction**: Hyperbilirubinemia—requires drug substitution only if jaundice affects adherence.\\n\\n- **DRV/r**: \\n  - **Adverse Effects**: Rash/hypersensitivity.\\n  - **High Risk Situations**: Sulfa allergy.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 149,\n",
       "  'section': '## Integrase Strand Transfer Inhibitors (INSTIs) Adverse Reactions\\n\\nThis section outlines the adverse reactions associated with Integrase Strand Transfer Inhibitors (INSTIs).\\n\\n- **All INSTIs**: \\n  - **Common Reaction**: Weight gain (risk factors: women; concomitant use of TAF).\\n  - **Recommendations**: Provide advice on healthy eating and physical activity.\\n  - **Other Reaction**: Rash/hypersensitivity (consult Uliza Hotline for guidance).\\n\\n- **DTG**: \\n  - **Adverse Effect**: Insomnia. \\n  - **Recommendations**: Administer in the morning; consider low fat meal or empty stomach to improve conditions.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 153,\n",
       "  'section': '## ARV Adjustments in Renal and Hepatic Impairment\\n\\nThis section covers the adjustments required for various antiretroviral (ARV) medications based on renal and hepatic impairment. \\n\\n- **ABC**:  \\n  - CrCl 15 - 50 ml/min: No change  \\n  - CrCl <15 ml/min: Reduce adult dose to 200 mg BD for moderate to severe liver impairment.  \\n  - AVOID in severe hepatic impairment.\\n\\n- **AZT**:  \\n  - CrCl 15 - 50 ml/min: No change  \\n  - CrCl <15 ml/min: 300 mg/day; reduce dose by 50% or double the interval in moderate to severe impairment.\\n\\n- **TDF**:  \\n  - AVOID unless HBV+  \\n  - CrCl 15 - 50 ml/min: 300 mg every 7 days  \\n  - CrCl <15 ml/min: No change\\n\\n- **TAF**:  \\n  - No change in all conditions  \\n  - Administer after dialysis in severe impairment.\\n\\n- **3TC**:  \\n  - 150 mg OD: No change across all conditions.\\n\\n- **LPV**:  \\n  - No change; use with caution in moderate to severe impairment.\\n\\n- **EFV & NVP**:  \\n  - EFV: No change; use with caution in mild to moderate liver impairment. AVOID in severe impairment.  \\n  - NVP: No change; AVOID in severe impairment.\\n\\n- **Fluconazole**:  \\n  - CrCl ≤ 50 ml/min: Use 50% of normal recommended dose (no adjustment for CrCl > 50 ml/min).  \\n  - Use with caution.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 153,\n",
       "  'section': '## Renal Monitoring Recommendations\\n\\nThis section outlines the necessary monitoring guidelines for patients with renal or hepatic impairment.\\n\\n- Patients with evidence of renal or hepatic impairment should have access to regular monitoring of renal and liver function.  \\n- In acute kidney injury (AKI), interrupt TDF administration until the cause is established and corrected.  \\n- Avoid TDF in patients with CrCl < 50 ml/min unless in HIV/HBV co-infection; if HBV co-infection is present, benefits may outweigh risks.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 153,\n",
       "  'section': '## TDF and TAF Use in HBV/HIV Co-infection\\n\\nGuidelines regarding TDF and TAF use in patients with HBV/HIV co-infection.\\n\\n- For patients with HBV co-infection, the benefit of TDF or TAF often outweighs the risks of renal impairment, allowing for toleration of more severe levels of renal impairment. \\n- Consult Table 9.3 for dose adjustments for patients with HBV/HIV co-infection and manage these patients in consultation with an experienced clinician.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 153,\n",
       "  'section': '## Switching ART Medication\\n\\nInstructions on switching ART medications based on specific conditions.\\n\\n- If HBV negative and on first-line ART, substitute TDF with ABC, TAF, or DTG + 3TC dual therapy using the single drug substitution algorithm.\\n- In cases of prior ART treatment failure or other scenarios, consult the Regional or National HIV Clinical TWG at the Uliza Hotline (0726 460 000) or via the NHC website.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 157,\n",
       "  'section': \"## Routine Viral Load Testing Schedule\\n\\nKenya's HIV Prevention and Treatment Guidelines (2022) outline the schedule for routine viral load (VL) testing based on age and specific circumstances:\\n\\n- **Age 0 - 24 years**: at month 3, then every 6 months.\\n- **Age 25 years and older**: at month 3, then month 12, and then annually.\\n- **Pregnant or breastfeeding**: at confirmation of pregnancy (for those already on ART) or 3 months after ART initiation (if started during pregnancy/breastfeeding), and then every 6 months until complete cessation of breastfeeding.\\n- **Before any drug substitution**: if no VL result is available from the prior 6 months.\\n- **Three months after any regimen modification**: including single-drug substitutions.\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 157,\n",
       "  'section': '## Interpretation of Viral Load Results\\n\\nThe interpretation of viral load results is crucial for managing HIV treatment:\\n\\n- **VL < 200 copies/ml**: Indicates successful viral suppression.\\n- **VL 200 – 999 copies/ml**: May suggest increased risk of progression to treatment failure; further assessment is necessary.\\n- **VL ≥ 1000 copies/ml**: Indicates suspected treatment failure.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 157,\n",
       "  'section': '## Management of Patients with Viral Load Results\\n\\nFor managing patients based on viral load results, specific steps are suggested:\\n\\n- **For VL 200 – 999 copies/ml**: \\n  - Discuss the patient in a Multi-Disciplinary Team (MDT).\\n  - Assign a case manager.\\n  - Assess and address likely causes of non-adherence.\\n  - Provide enhanced adherence support/intervention as needed.\\n  - Support daily witnessed ingestion by treatment buddy or healthcare worker.\\n\\n- **For VL ≥ 1000 copies/ml**: \\n  - Begin treatment preparation for a new regimen while continuing with the failing regimen until preparation is complete.\\n  - Continue enhanced adherence support.\\n  - Take CD4 count and manage any opportunistic infections (OIs).\\n  - Schedule clinical appointment at 2 weeks after regimen change to review adherence and side effects.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 157,\n",
       "  'section': '## Common Causes of Poor Adherence\\n\\nThe guidelines emphasize understanding the common causes of poor adherence, which include:\\n\\n- Stigma and non-disclosure.\\n- Travel and toxicities.\\n- Alcohol or drug use.\\n- Mental health disorders and religious beliefs.\\n- Inadequate treatment preparation.\\n- Chaotic lifestyle and lack of support systems.\\n- Poor patient-provider relationship.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 157,\n",
       "  'section': '## Other Causes of Treatment Failure\\n\\nIn addition to adherence issues, the document notes other causes of treatment failure, such as:\\n\\n- Inadequate dosing or dosing adjustments.\\n- Drug-drug interactions and drug-food interactions.\\n- Impaired absorption (e.g., chronic severe diarrhea).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 157,\n",
       "  'section': '## Contact Information for Consultation\\n\\nHealthcare providers are encouraged to consult the Regional or National HIV Clinical Technical Working Group (TWG) or contact the Uliza Hotline (0726 460 000) for guidance on managing patients with suspected treatment failure or complex cases.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 161,\n",
       "  'section': '## Introduction to HIV in Kenya\\n\\nThis section provides an overview of the current state of HIV in Kenya, including statistics on prevalence, target populations, and the impact of HIV on public health in the country.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 161,\n",
       "  'section': '## Prevention Strategies\\n\\nIn this section, various prevention strategies will be discussed, including condom distribution, pre-exposure prophylaxis (PrEP), and community-based interventions aimed at reducing HIV transmission.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 161,\n",
       "  'section': '## Treatment Guidelines\\n\\nThis section outlines the recommended guidelines for the treatment of HIV, including antiretroviral therapy (ART) protocols, patient monitoring, and adherence strategies.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 161,\n",
       "  'section': '## Testing and Diagnosis\\n\\nDetailed information on HIV testing methodologies, diagnostic criteria, and the importance of early detection will be covered in this section.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 161,\n",
       "  'section': '## Special Populations\\n\\nThis section focuses on specific demographics that may face higher risks of HIV, such as key populations, adolescents, and pregnant women, along with tailored interventions for these groups.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 161,\n",
       "  'section': '## Stigma and Mental Health\\n\\nDiscussion on the impact of stigma associated with HIV, its effect on mental health, and strategies to address these issues within the community.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 161,\n",
       "  'section': '## Policy and Implementation\\n\\nThis section examines the policies in place to support HIV prevention and treatment efforts, including governmental and non-governmental organization roles in implementation.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 161,\n",
       "  'section': '## Resources and Support Services\\n\\nAn overview of available resources for individuals living with HIV, including healthcare services, counseling, and support groups.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 161,\n",
       "  'section': '## Conclusion\\n\\nSummarizes the key points discussed in the guidelines, emphasizing the importance of integrated approaches to HIV prevention and treatment in Kenya.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 154,\n",
       "  'section': '## Antiretroviral Therapy Management for AZT-Associated Bone Marrow Suppression\\n\\n### Test Results and Actions\\n\\n- **Hemoglobin (Hb) Levels**\\n  - **Result:** > 8.5 (and decrease from pre-AZT baseline)  \\n    **Action:** Retain AZT, repeat Hb at week 1, 2, 4, and 12. If accessing follow-up Hb is difficult, consider substituting to an alternative ARV immediately.\\n  \\n  - **Result:** ≤ 8.5  \\n    **Action:** Switch from AZT to an alternative ARV.\\n\\n- **Neutrophil Levels**\\n  - **Result:** 1.0 – 1.5 (and decrease from pre-AZT baseline, if available)  \\n    **Action:** If receiving cotrimoxazole, consider withholding unless essential. Retain AZT, repeat at week 1, 2, 4, and 12. If accessing follow-up neutrophils is difficult, consider switching to an alternative ARV immediately.\\n  \\n  - **Result:** ≤ 1.0  \\n    **Action:** Switch from AZT to an alternative ARV.\\n\\n### Notes\\n- Patients with a baseline Hb of < 9.5 g/dL should not be initiated on AZT; those who develop anaemia on AZT should be managed as per the specified guidelines.\\n- AZT-associated bone marrow suppression often occurs early, typically within 3 months of starting ART.\\n- All patients with anaemia and/or neutropenia, regardless of AZT use, should be evaluated for other potential causes and managed appropriately.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 154,\n",
       "  'section': '## Management of Drug-Related Hepatotoxicity\\n\\n### ALT Levels and Actions\\n\\n- **Result:** < 2.5 x Upper Limit of Normal (ULN)  \\n  **Action:** Retain regimen, repeat in 2 weeks.\\n\\n- **Result:** 2.5 – 5 x ULN  \\n  **Action:** Retain regimen, repeat in 1 week.\\n\\n- **Result:** > 5 x ULN  \\n  **Action:** Discontinue offending drug(s) and consult a senior clinician for further steps.\\n\\n### Notes\\n- All patients with an acute increase in liver enzymes should be evaluated for other likely causes of hepatitis/hepatotoxicity and managed appropriately.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 117,\n",
       "  'section': '## Support Systems Criteria\\n\\nThis section outlines the criteria for support systems applicable to patients and caregivers in the context of HIV treatment. It includes the following points:\\n1. Identification of convenient times for taking ART and/or associating doses with daily events.\\n2. Engagement of a treatment supporter in HIV education or attendance at the next counseling session.\\n3. Awareness of support group meeting times.\\n4. Enrollment in an SMS reminder system if the facility offers one.\\n5. Additional support systems planned or in place, such as setting phone alarms or using a pill box.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 117,\n",
       "  'section': '## Medical Criteria\\n\\nThis section details the medical criteria that apply to patients starting ART. Key points include:\\n1. For patients newly diagnosed with TB, ART should be deferred until they can tolerate anti-TB medication, with initiation ideally within 2 weeks; in the case of TB meningitis, ART should be delayed for 4 to 8 weeks, with close monitoring for Immune Reconstitution Inflammatory Syndrome (IRIS).\\n2. For newly diagnosed cryptococcal meningitis (CM) or symptoms consistent with CM (e.g., progressive headache, fever, malaise, neck pain, confusion), ART should be deferred until the completion of 5 weeks of CM treatment or until CM is ruled out; close monitoring for IRIS is required.\\n\\nIf any responses to the psychosocial or support systems criteria are \"No\", a strategy should be developed to address the issue promptly, possibly involving a case manager. ART may still be initiated with adequate adherence support while resolving these criteria on a case-by-case basis.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 117,\n",
       "  'section': '## Patient Readiness Assessment\\n\\nIn this section, it is highlighted that during each visit leading up to ART initiation, every patient should be assessed for their readiness to start ART. It is important that the patient or caregiver is given the final decision on when and whether to start ART.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 117,\n",
       "  'section': '## Special Considerations for Children and Adolescents\\n\\nThis section emphasizes the need for special considerations when counseling children and adolescents. Key points include:\\n- Children and adolescents depend on caregivers for adherence support, making caregiver involvement critical.\\n- All topics from the HIV Education and Adherence Counseling sessions should be covered with the caregiver, involving the child/adolescent appropriately based on disclosure stage and developmental stage.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 160,\n",
       "  'section': '## Antiretroviral Therapy Overview\\n\\nThis section provides a general understanding of antiretroviral therapy (ART) for various age groups, including infants, children, adolescents, and adults. ART is crucial in managing HIV infections and ensuring the health and well-being of those affected.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 160,\n",
       "  'section': '## Third-line ART Regimens in Children\\n\\nThis subsection outlines possible third-line ART regimens specifically for children. The selection of a third-line regimen is typically based on drug resistance test (DRT) results. \\n\\n- **Options:**\\n  - DTG + 3TC + DRV/r\\n  - DTG + AZT + 3TC + DRV/r\\n  - DTG + ABC (or TDF) + 3TC + DRV/r\\n  - ETV + 3TC + DRV/r\\n\\n**Note:** The Regional or National HIV Clinical Technical Working Group (TWG) may recommend reusing some ARVs even when there is evidence of resistance.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 160,\n",
       "  'section': '## Third-line ART Regimens in Adults\\n\\nThis subsection details possible third-line ART regimens for adults, emphasizing that clinicians should consider resistance levels when selecting treatment options.\\n\\n- **Options:**\\n  - DTG + 3TC + DRV/r\\n  - DTG + AZT + 3TC + DRV/r\\n  - DTG + TDF + 3TC + DRV/r\\n  - DTG + TDF (or AZT) + 3TC\\n  - ETV + 3TC + DRV/r'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 160,\n",
       "  'section': '## Key Considerations for Third-line ART Selection\\n\\nThis section discusses critical considerations when selecting third-line ART regimens for both children and adults, emphasizing the importance of DRT results and the recommendations from clinical guidelines.\\n\\n**Important Note:** Customization of regimens may occur based on the patient’s individual history with ARVs, including previous failures.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 151,\n",
       "  'section': '## HIV Treatment Guidelines Overview\\n\\nThis section provides a summary of the key points from the Kenya HIV Prevention and Treatment Guidelines, 2022.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 151,\n",
       "  'section': '## Viral Load Monitoring Criteria\\n\\nThis section outlines the conditions under which viral load (VL) testing is conducted for patients on antiretroviral therapy (ART):\\n\\n- Patients with specific reasons for stopping an ARV should have:\\n  - VL within the last 6 months < 200 copies/ml\\n  - No VL result within the last 6 months\\n  - VL within the last 6 months ≥ 200 copies/ml'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 151,\n",
       "  'section': '## Actions for Viral Load Results\\n\\nIn this section, the actions to take based on viral load results are detailed:\\n\\n- For VL < 200 copies/ml and on ART for less than 3 months:\\n  - Proceed with single drug substitution if necessary.\\n  - Schedule a clinical appointment 2 weeks after the regimen change to review adherence, side effects, and any other concerns.\\n  - Repeat VL testing 3 months after medication modification, followed by routine VL monitoring.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 151,\n",
       "  'section': '## Guidelines for ART Regimen Changes\\n\\nThis section highlights the protocols for changing ART regimens based on clinical reasons:\\n\\n- Do not change the current regimen unless an immediate change is required for clinical reasons.\\n- If an ARV must be changed before VL results are available due to adverse drug reactions, drug-drug interactions, or co-morbidities, urgently consult the Uliza Hotline (0726 460 000) or contact the Regional or National Technical Working Group (TWG).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 151,\n",
       "  'section': '## Managing Single Drug Substitutions \\n\\nThis section includes the visual reference (Figure 6.4) for managing single drug substitutions for ART in relation to viral load results:\\n\\n- Ensure ongoing assessment of adherence, side effects, and potential concerns, especially after any regimen changes.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 162,\n",
       "  'section': '## Prevention Overview\\n\\nThe prevention of Mother to Child Transmission (PMTCT) of HIV, Syphilis, and Hepatitis B is critical during routine antenatal care (ANC). This is an important opportunity to provide high-quality combined HIV prevention through education, counseling, and testing. Services are directed toward women, partners, and family members, aiming to prevent transmission as part of a comprehensive package of integrated ANC interventions.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 162,\n",
       "  'section': '## Essential Package of Antenatal Care\\n\\n### Group & Individual Education\\n- Importance of at least 8 ANC visits.\\n- Details of ANC services, including:\\n  - Health checks and treatment of any illness.\\n  - Medical tests (HIV, syphilis, hepatitis B).\\n  - Monitoring maternal and fetal wellbeing.\\n- Nutritional guidance and personal care.\\n- Recognizing danger signs during pregnancy and preparing for birth.\\n- Post-natal care including immunization and family planning.\\n- HIV prevention strategies (HTS, PrEP, ART).\\n- Triple elimination approach for preventing transmission from mother to child for HIV, syphilis, and hepatitis B.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 162,\n",
       "  'section': '## Counseling Measures\\n\\n### Pre-Conception\\n- Women of reproductive age known to be HIV positive should have pregnancy intention assessments at every visit.\\n- If pregnancy is desired, planning should include:\\n  - Attaining viral load suppression.\\n  - Immune reconstitution.\\n  - Administration of Iron and Folic Acid Supplementation (IFAS) prior to conception.\\n\\n### For Newly Diagnosed Women\\n- Intensive adherence counseling and HIV education are essential for women newly diagnosed with HIV or starting ART, potentially involving case managers or mentor mothers.\\n\\n### Birth Preparedness\\n- Support for developing an individualized birth plan covering:\\n  - Place of delivery with skilled attendants.\\n  - Emergency transport.\\n  - Birth companionship.\\n  - Readiness for infant care.\\n\\n### Pregnancy Danger Signs\\n- Education provided on signs requiring immediate ANC return, including:\\n  - Fever.\\n  - Lower abdominal pain.\\n  - Severe headache.\\n  - Swollen feet.\\n  - Convulsions.\\n  - Per vaginal bleeding.\\n\\n### Maternal, Infant, and Young Child Nutrition (MIYCN)\\n- Pregnant women receive information on nutrition during pregnancy and breastfeeding.\\n- Promotion of exclusive breastfeeding for the first 6 months regardless of HIV status.\\n- Complementary feeding guidance thereafter.\\n- Nutritional supplements such as iron, folate, and multivitamins provided.\\n- Monitoring for anemia and advising on adequate caloric intake, particularly noting that HIV positive women require an additional 10% of recommended daily allowance (RDA).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 159,\n",
       "  'section': '## Second-Line Regimen Management\\n\\nIf any drug in the recommended second-line regimen is contraindicated or previously not tolerated, consult the Regional or National HIV Clinical TWG (Uliza Hotline 0726 460 000; https://nhcsc.nascop.org/clinicalform). Such patients may require a Drug Resistance Test (DRT) to select agents for the second-line ART. Additional drugs may be recommended on a case-by-case basis, including DRV/r, ATV/r, RAL, or ETR.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 159,\n",
       "  'section': '## First-Line Treatment Failure in Adults\\n\\nPatients failing DTG-based or PI-based first-line regimens should have a Drug Resistance Test (DRT) ordered as soon as treatment failure is confirmed. The patient summary and DRT results should be sent to the Regional or National HIV Clinical TWG (https://nhcsc.nascop.org/clinicalform) or call Uliza Hotline (0726 460 000) to determine the most suitable second-line regimen. The DRT results will help ascertain if there is true DTG or PI failure or if there is an underlying problem with non-adherence. Daily witnessed ingestion is recommended prior to performing DRT.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 159,\n",
       "  'section': '## Important Considerations for First-Line Treatment Failure in Children\\n\\nSecond-line ART in infants and children is more complex to manage. These children and their caregivers should undergo thorough clinical and psychosocial assessment to rule out inter-current illness or non-adherence as the reason for a high viral load. All children failing first-line should be discussed in the MDT and preferably with an experienced ART provider before changing to second-line ART. This should not cause undue delay in switching a failing regimen. The choices for infants and children failing an alternative first-line regimen are limited and may need discussion with the Regional or National HIV Clinical TWG. Some of these children will require HIV DRT to determine the most suitable second-line regimen.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 159,\n",
       "  'section': '## Important Considerations for Second-Line ART Treatment Failure\\n\\nPatients failing second-line ART have limited options, as ARVs used to construct a third-line regimen are often more expensive and come with increased pill burden and more side effects, which may exacerbate pre-existing poor adherence. Second-line treatment failure should be confirmed by viral load testing following the viral load monitoring algorithm. After the first detectable VL (≥ 50 copies/ml), assess and address all causes of poor adherence and other possible causes of viremia. \\n\\nThese patients should be discussed at an MDT session. Repeat the viral load after 3 months of excellent adherence (preferably with daily witnessed ingestion). If the testing shows viremia continues then consult the Regional or National HIV Clinical TWG using the national case summary form. These patients will likely require DRT to design the most suitable third-line regimen.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 159,\n",
       "  'section': '## Enhanced Adherence Support for Patients Failing Second-Line ART\\n\\nPatients failing second-line ART require thorough assessment for barriers to adherence. Ongoing enhanced adherence support may include:\\n\\n- Assigning a case manager\\n- More frequent adherence counseling by a trained counselor\\n- Assessment and treatment of mental health and substance use disorders\\n- Provision of adherence support such as modified directly observed therapy, treatment supporters, home visits, etc.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 158,\n",
       "  'section': '## Antiretroviral Therapy Overview\\n\\nAntiretroviral Therapy (ART) is essential for managing HIV infections in various populations, including infants, children, adolescents, and adults. Adherence to therapy is critical, as non-adherence is the most frequent cause of treatment failure.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 158,\n",
       "  'section': '## Importance of Adherence\\n\\nNon-adherence must be addressed before confirming treatment failure. Daily witnessed ingestion of medication by a treatment buddy or healthcare worker is recommended to ensure excellent adherence before repeating the viral load (VL) test. All adherence issues should be resolved before considering a regimen switch to avoid rapid failure of the new regimen.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 158,\n",
       "  'section': '## Modifications Based on Regimen Issues\\n\\nIf the current regimen is the primary cause of poor adherence (e.g., manageable side effects), modification may be necessary. Such changes should be conducted in consultation with the Regional or National HIV Clinical Technical Working Group (TWG).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 158,\n",
       "  'section': '## Guidance on Adherence and Support\\n\\nDetailed guidance regarding adherence preparation, assessment, and support can be found in Chapter 5 of the referenced document.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 158,\n",
       "  'section': '## Recommended Second-line ART Regimens\\n\\n### For infants, children, and adolescents (weight/scenario: < 30 kg)\\n\\n| First-line ART                       | Second-line ART                            |\\n|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 158,\n",
       "  'section': '--|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 158,\n",
       "  'section': '-|\\n| ABC (or AZT) + 3TC + DTG             | DRT-based second-line                      |\\n| ABC + 3TC + LPV/r                    | Change to AZT + 3TC + DTG while awaiting DRT results; modify based on DRT results if indicated |\\n| AZT + 3TC + LPV/r                    | Change to ABC + 3TC + DTG while awaiting DRT results; modify based on DRT results if indicated |\\n| ABC + 3TC + EFV                      | AZT + 3TC + DTG                           |\\n| AZT + 3TC + EFV                      | ABC + 3TC + DTG                           |\\n\\n### For adolescents and adults (≥ 30 kg or ≥ 15 years old)\\n\\n| First-line ART                       | Second-line ART                            |\\n|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 158,\n",
       "  'section': '--|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 158,\n",
       "  'section': '-|\\n| TDF (or ABC) + 3TC + DTG (or PI/r)  | DRT-based second-line                      |\\n| TDF (or ABC) + 3TC + EFV            | TDF + 3TC + DTG                           |\\n| AZT + 3TC + EFV                      | TDF + 3TC + DTG                           |\\n\\n### For Pregnant and Breastfeeding Women\\n\\n| First-line ART                       | Second-line ART                            |\\n|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 158,\n",
       "  'section': '--|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 158,\n",
       "  'section': '-|\\n| TDF (or ABC) + 3TC + DTG             | Change to TDF + 3TC + ATV/r while awaiting DRT results; modify based on DRT results if indicated |\\n| TDF (or ABC) + 3TC + PI/r            | Change to TDF + 3TC + DTG while awaiting DRT results; modify based on DRT results if indicated |\\n| TDF (or ABC) + 3TC + EFV             | TDF + 3TC + DTG                           |\\n| AZT + 3TC + EFV                      | TDF + 3TC + DTG                           |'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 158,\n",
       "  'section': '## Co-infections Guidance\\n\\n### HIV/HBV Co-infection\\nMaintain TDF in order to treat both HBV and HIV.\\n\\n### TB/HIV Co-infection\\nRefer to Table 8.8 for recommended ART regimens for patients who develop TB while failing the first-line ART.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 164,\n",
       "  'section': '## Prevention of Mother to Child Transmission of HIV/Syphilis/Hepatitis B\\n\\nOverview of strategies to prevent mother-to-child transmission of HIV, syphilis, and hepatitis B during pregnancy and breastfeeding.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 164,\n",
       "  'section': '## Antiretroviral Therapy (ART) for HIV-Positive Pregnant and Breastfeeding Women\\n\\nThe goal of ART for HIV positive pregnant women is two-fold: to restore and maintain the mother’s immune function and general health, and to prevent transmission of HIV in utero, at labour and delivery, and during breastfeeding.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 164,\n",
       "  'section': '## Recommendations for Use of ART\\n\\n### When to Start ART\\n- ART should be initiated in all pregnant and breastfeeding women living with HIV, regardless of gestation, WHO clinical stage, and CD4 cell count.\\n- Ideally, ART should be started on the same day as HIV diagnosis after readiness assessment with ongoing enhanced adherence support.\\n\\n### What to Start With (First-line ART)\\n- Recommended regimen: TDF/3TC/DTG\\n\\n### Infant Prophylaxis\\n- AZT + NVP for 6 weeks; NVP should continue until 6 weeks after complete cessation of breastfeeding.\\n\\nFor more comprehensive information, refer to Table 7.3.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 164,\n",
       "  'section': '## Monitoring Viral Load During Pregnancy and Breastfeeding\\n\\n### General Recommendations\\n- Whenever possible, use same-day point-of-care methods for viral load testing. \\n- Prioritize viral load specimens and results for pregnant and breastfeeding women across the laboratory referral process.\\n\\n### Monitoring Schedule\\n- For women newly initiated on ART: Obtain viral load 3 months after initiation, then every 6 months until breastfeeding cessation.\\n- For women already on ART at the time of confirming pregnancy or breastfeeding: Obtain a viral load regardless of when the prior viral load was done, then every 6 months until breastfeeding cessation.\\n\\n### Addressing Viremia\\n- For viral loads ≥ 50 copies/ml: Assess and address potential reasons for viremia.\\n   - If repeat viral load is 200-999 copies/ml, consult the Regional or National HIV Clinical TWG.\\n   - If repeat viral load is ≥ 1,000 copies/ml, change to an effective regimen.\\n   - If repeat viral load is < 200 copies/ml (LDL), continue routine monitoring.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 171,\n",
       "  'section': '## Overview of HIV in Kenya\\n\\nThis section provides a general understanding of the HIV epidemic in Kenya, including statistics on prevalence, demographics of affected populations, and the overall impact on public health in the country.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 171,\n",
       "  'section': '## Prevention Strategies\\n\\nDetails various prevention strategies employed in Kenya, including educational programs, condom distribution, HIV testing services, and the role of Pre-Exposure Prophylaxis (PrEP) in reducing new infections.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 171,\n",
       "  'section': '## Treatment Guidelines\\n\\nOutlines the current treatment protocols for individuals living with HIV in Kenya, including antiretroviral therapy (ART) recommendations, monitoring guidelines, and management of co-infections and comorbidities.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 171,\n",
       "  'section': '## Key Populations\\n\\nFocuses on the key populations most affected by HIV in Kenya—such as men who have sex with men (MSM), sex workers, and people who inject drugs (PWID)—and the tailored approaches necessary for effectively engaging these groups in prevention and treatment efforts.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 171,\n",
       "  'section': '## Stigma and Discrimination\\n\\nDiscusses the social stigma associated with HIV in Kenya, its impact on testing and treatment adherence, and initiatives to combat discrimination against people living with HIV.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 171,\n",
       "  'section': '## Policy Framework\\n\\nDescribes the policy framework supporting HIV prevention and treatment in Kenya, including national and county-level strategies, funding sources, and collaboration with NGOs and international partners.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 171,\n",
       "  'section': '## Monitoring and Evaluation\\n\\nDetails the systems in place for monitoring and evaluating the effectiveness of HIV interventions in Kenya, including outcome indicators and feedback mechanisms for improving services.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 171,\n",
       "  'section': '## Community Engagement\\n\\nThis section emphasizes the importance of community involvement in HIV prevention and treatment programs, highlighting successful case studies and strategies used to engage community leaders and organizations.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 171,\n",
       "  'section': '## Resources and Support Services\\n\\nProvides information about various resources and support services available for individuals living with HIV, including counseling, support groups, and access to medical care.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 166,\n",
       "  'section': '## Prevention of Mother to Child Transmission of HIV/Syphilis/Hepatitis B\\n\\nThis section introduces the overarching goal of preventing the transmission of HIV, syphilis, and Hepatitis B from mothers to their children.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 166,\n",
       "  'section': '## Syphilis Elimination for Pregnant and Breastfeeding Women\\n\\nThe country has adopted triple elimination of HIV, syphilis, and Hepatitis B among pregnant and breastfeeding women. It is recommended that all pregnant women attending ANC and not aware of their HIV status undergo a dual HIV-syphilis test during their first trimester and a second test in the third trimester if the initial test was negative. \\n\\nAll women who test positive for syphilis at any point during pregnancy and breastfeeding should be treated with the appropriate regimen. Babies born to mothers who test positive for syphilis are suspected to be exposed and should also be treated accordingly. \\n\\nIt is necessary to perform contact tracing for all sexual contacts to ensure they receive treatment for syphilis. Be aware that symptoms of congenital syphilis may not become apparent for several weeks or months after birth.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 166,\n",
       "  'section': '## Hepatitis B Elimination for Pregnant and Breastfeeding Women\\n\\nThis section discusses routine testing of pregnant women to identify those needing antiviral treatments for their health and interventions to prevent the Mother to Child Transmission of Hepatitis B. Routine screening should be incorporated into the ANC profile for both Hepatitis B and C, which pose significant risks to the mother and fetus.\\n\\nFor pregnant and breastfeeding women who test positive for HBsAg, appropriate ARV treatment options, such as TDF/3TC or FTC-containing regimens, should be offered. This treatment serves as prophylaxis against HBV transmission from mother to child. \\n\\nAll pregnant and breastfeeding women without evidence of Hepatitis B infection (HBsAg negative) should receive vaccination against Hepatitis B. Additionally, HIV-positive infants without evidence of infection should also be vaccinated. \\n\\nInfants born to mothers who test positive for HBsAg should be treated with Hepatitis B Immunoglobulin. For management of HIV/HBV coinfection, refer to Chapter 9.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 165,\n",
       "  'section': '## Pre-conception Planning for Women on ART\\n\\nFor women already on ART who are not yet pregnant, maintain ART. It is essential to carry out a viral load (VL) test if it has not been done in the prior six months to confirm viral suppression. Refer to Table 4.8 for pre-conception care, which includes laboratory screening, TT immunization, folate, and other relevant information.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 165,\n",
       "  'section': '## ART Management During Pregnancy\\n\\n### On ART at Time of Pregnancy/Breastfeeding\\nFor those on ART when pregnancy is confirmed, maintain the current ART regimen. A VL test should be conducted at the first identification of pregnancy, regardless of the timing of prior tests, to ensure viral suppression. The baby should be managed as a HIV-exposed infant (HEI) according to specific guidelines.\\n\\n### Not on ART at Time of Pregnancy Confirmation\\nPatients who are not on ART when pregnancy is confirmed should be prepared and started on ART as soon as possible, preferably the same day HIV infection is confirmed. Perform a VL test 3 months after ART initiation.\\n\\n### History of Treatment Interruption\\nPregnant and breastfeeding women with a history of treatment interruption returning to care should have reasons assessed and should preferably restart on a Dolutegravir (DTG)-containing regimen unless there was an intolerance or failure related to DTG. VL monitoring in this case should occur after 3 months of initiation and 6 months thereafter until cessation of breastfeeding. Additional adherence support is necessary.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 165,\n",
       "  'section': '## ART Management During Labor and Delivery\\n\\nFor patients who are not on ART during labor and delivery, they should be started on ART during labor. After delivery, continue to provide treatment preparation and adherence support. The newborn should be managed as a HEI according to established guidelines.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 165,\n",
       "  'section': '## ART Management During Postpartum/Breastfeeding\\n\\nFor patients not on ART during the postpartum or breastfeeding period, prepare (readiness assessment) and initiate ART as soon as possible, ideally the same day HIV infection is confirmed. Adherence support for both mother and infant should be provided, which may include daily witnessed ingestion (DWI) support.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 165,\n",
       "  'section': '## Managing Labor and Delivery\\n\\nIn managing labor and delivery, minimize vaginal examinations, use aseptic techniques, avoid artificial rupture of membranes, monitor labor, and prevent prolonged labor using a partograph. Avoid unnecessary trauma to the genital tract. Certain patient groups, such as those with recent HIV infections, pregnant adolescent girls, and patients with high viral loads or poor social support systems, may require additional adherence and psychosocial support.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 163,\n",
       "  'section': '## HIV Testing Services for Pregnant Women\\n\\n- All pregnant women (unless known HIV positive) should be counselled and tested for HIV, syphilis, and Hepatitis B during their first ANC visit. \\n- If the initial tests are negative, repeat testing for HIV and syphilis should occur in the third trimester.\\n- Pregnant and breastfeeding mothers with continued HIV risk (Key populations) should be counselled and tested for HIV every 3 months until post-cessation of breastfeeding.\\n- At labor and delivery, HIV testing should be conducted for all women with unknown HIV status or those that previously tested negative, even if tested during the third trimester.\\n- All breastfeeding mothers (unless known HIV positive) should be counselled and tested at the 6-week infant immunization visit, with tests repeated every 6 months until complete cessation of breastfeeding.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 163,\n",
       "  'section': '## Counselling and Support for Pregnant Women\\n\\n- Women should receive counselling about the schedule for repeat HIV testing during pregnancy and postnatally as part of routine ANC and postnatal education.\\n- Pregnant and breastfeeding women who decline or opt-out of HIV, Syphilis, or Hepatitis testing during their first contact should be offered counselling and testing during subsequent visits.\\n- Daily Witnessed Ingestion (DWI) is advised to support viral suppression for newly initiated clients and those whose regimens are being switched.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 163,\n",
       "  'section': '## Care for HIV Positive Pregnant and Breastfeeding Women\\n\\n- All HIV positive pregnant and breastfeeding women enrolled in care should receive counselling and support, including assisted disclosure, case management linkage, and follow-up for comprehensive treatment and prevention (including lifelong ART).\\n- All Syphilis and Hepatitis B positive clients should receive appropriate care as outlined in Table 7.3 “triple elimination.”'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 163,\n",
       "  'section': '## Partner and Child Testing Recommendations\\n\\n- Partners of pregnant and breastfeeding women should be offered HIV testing and counselling.\\n- All biological children of HIV positive mothers should also receive testing.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 163,\n",
       "  'section': '## Risk Reduction and Contraception Education\\n\\n- All pregnant and breastfeeding women should receive information on risk reduction, including PrEP where appropriate.\\n- Post-partum contraception: Counsel on contraception methods and assist patients in developing a plan for effective contraception from 6 weeks post-partum to avoid unplanned pregnancies.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 172,\n",
       "  'section': '## TB/HIV Co-infection Overview\\n\\nTB is a leading cause of morbidity and mortality among people living with HIV (PLHIV). Reducing this burden of illness requires early identification of TB, preventive treatment, and optimal treatment for both HIV and TB. Timely initiation of ART along with TB Preventive Therapy are effective strategies to minimize the impact of TB in PLHIV.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 172,\n",
       "  'section': '## Counseling for PLHIV\\n\\nAll PLHIV should receive counseling regarding the risk of acquiring TB, strategies to reduce exposure, recognition of clinical manifestations, and the need for seeking care promptly. Information should also include the risk of TB transmission to others and available TB preventive therapy to help prevent TB disease.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 172,\n",
       "  'section': '## Infection Control in Healthcare Settings\\n\\nHealthcare environments are conducive to the transmission of TB, especially among vulnerable groups such as PLHIV. Therefore, all healthcare settings are encouraged to develop and implement TB infection control guidelines to minimize the risk of transmission among patients, visitors, and staff.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 172,\n",
       "  'section': '## TB Screening for PLHIV: Intensified Case Finding (ICF)\\n\\nTB screening and prevention services must be offered at every clinical visit for PLHIV. Symptom-based TB screening using the Intensified Case Finding (ICF) tool is essential at each appointment to rule out active TB. Patients who screen positive, categorized as presumptive TB cases, must complete definitive diagnostic pathways, while those who screen negative should be evaluated for TB preventive therapy (TPT).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 172,\n",
       "  'section': '## Differentiating ICF from Active Case Finding (ACF)\\n\\nIntensified Case Finding (ICF) is specifically designed for TB screening among PLHIV. In contrast, Active Case Finding (ACF) involves more vigorous efforts by the National Tuberculosis Program (NTP) or partners to reach underserved or high-risk populations outside of health facilities for screening and testing.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 173,\n",
       "  'section': '## Intensified Case Finding Screening Guidelines\\n\\nThis section outlines the methodology for intensified case finding for patients suspected of having TB. If a patient answers \"Yes\" to any of the screening questions, further action is required.\\n\\n- Take a detailed history\\n- Conduct a patient examination\\n- Perform a sputum examination (either sputum smear or GeneXpert)\\n\\nIf a patient answers \"No\" to questions 1-5, consider the eligibility for TB Preventive Therapy (TPT) and ensure that screening is repeated during subsequent visits. Note that questions 5 and 6 do not apply to adults.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 173,\n",
       "  'section': '## Screening Questions\\n\\nThe following are the intensified case finding screening questions that should be asked:\\n\\n1. Cough of any duration (Y/N)\\n2. Fever (Y/N)\\n3. Noticeable weight loss / Failure to thrive / Poor weight gain (Y/N)\\n4. Night sweats (Y/N)\\n5. Reduced playfulness / Lethargy / Irritability (Y/N)\\n6. Contact with a TB case (Y/N)'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 173,\n",
       "  'section': \"## Eligibility for TB Preventive Therapy\\n\\nIn the case where a patient's responses to the initial screening questions are negative (Questions 1-5), consideration should be given to the patient's eligibility for TB Preventive Therapy (TPT). This includes evaluating their risk factors and health history.\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 173,\n",
       "  'section': '## Follow-Up Procedures\\n\\nIf screening questions suggest potential TB infection or if a \"Yes\" response is received, follow-up actions include:\\n\\n- Detailed history-taking\\n- Physical examination of the patient\\n- Sputum testing to confirm TB infection \\n\\nReassess eligibility for TB Preventive Therapy in subsequent visits based on evolving clinical information and screening results.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 167,\n",
       "  'section': '## Introduction to HIV Prevention and Treatment Guidelines\\n\\nThe 2022 Kenya HIV Prevention and Treatment Guidelines outline the strategies for preventing and managing HIV in exposed infants and their mothers. This document provides essential protocols to ensure the health of both, including necessary prophylactic treatments and follow-up actions.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 167,\n",
       "  'section': '## ARV Prophylaxis for HIV-Exposed Infants\\n\\n### Infant Scenario\\nInfant prophylaxis is critical for newborns exposed to HIV. The following treatments are recommended:\\n- **Prophylactic Regimen**: \\n  - Start with AZT (Zidovudine) and NVP (Nevirapine) for 6 weeks.\\n  - Continue NVP and cotrimoxazole until 6 weeks after complete cessation of breastfeeding.\\n  - In cases where breastfeeding ceases and the infant has been on NVP for at least 12 weeks, prophylaxis may be discontinued.\\n\\n### Testing Protocol\\n- DBS or whole blood for PCR testing should be conducted at 6 weeks or during the first contact, following the Early Infant Diagnosis (EID) algorithm.\\n- Birth testing may occur in facilities with point-of-care implementation when medically indicated.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 167,\n",
       "  'section': '## Maternal Management\\n\\n### ART Initiation and Monitoring\\n- **If Mother is Not on ART**: Initiate ART immediately, preferably on the same day.\\n- **If Mother is on ART for ≥ 3 Months**:\\n  - If viral load (VL) is ≥ 50 copies/ml, intensify adherence and repeat the VL test.\\n  - If VL < 50 copies/ml, continue with the current regimen.\\n  \\nRefer to the Viral Load Algorithm for detailed management options.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 167,\n",
       "  'section': '## Triple Elimination Condition\\n\\n### Management for Syphilis\\n- For mothers diagnosed with syphilis:\\n  - Administer Crystalline Penicillin (50,000 IU/kg BD for infants <7 days or TDS for infants >7 days old) for a total of 10 days.\\n  - Alternatives include Penicillin G (2.4 MU IM stat) or Ceftriaxone (1gm IM daily for 8-10 days in cases of penicillin allergy).\\n\\n### Management for Hepatitis B\\n- Conduct HbsAg testing.\\n- Administer Hepatitis B immunoglobulin (0.5ml IM) within 12 hours after birth, plus three doses of Hepatitis B vaccine (0.5ml at birth, 1 month, and 6 months).\\n\\n### Special Considerations\\n- If an infant cannot tolerate NVP or AZT, use another tolerated drug until breastfeeding ceases.\\n- In cases with TB infection, infant prophylaxis should include a combination of AZT plus 3TC fixed dose, maintained until maternal viral load is suppressed.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 167,\n",
       "  'section': '## High-Risk Groups and Support Needs\\n\\nHigher-risk groups for mother-to-child transmission may require additional psychological and adherence support, including:\\n- All new HIV positive individuals.\\n- HIV positive adolescent girls and young women under 19 years, including orphans and vulnerable children (OVC).\\n- Individuals with VL > 200 copies/ml, or those who experience stigma, treatment declines, or poor adherence.\\n- Clients with previous HIV-infected infants, active comorbidities, or poor socio-economic and family support structures.\\n- Key populations, including female sex workers (FSW) and people who inject drugs (PWID).\\n\\nConsider alcohol use and mental health factors when assessing support needs.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 169,\n",
       "  'section': '## Breastfeeding Guidelines for Infants\\n\\nAll infants, irrespective of HIV status, should be exclusively breastfed for the first 6 months of life. After this period, appropriate complementary foods should be introduced, and breastfeeding should continue up to 24 months or beyond.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 169,\n",
       "  'section': '## Support for Nursing Mothers\\n\\nMothers who need to be physically separated from their infants (e.g., for work) should be supported to sustain lactation and exclusively breastfeed, including mentorship on expressing breast milk (refer to the current MIYCN Policy). All mothers, regardless of their HIV status, should be encouraged and supported to exclusively breastfeed for the first six months.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 169,\n",
       "  'section': '## Guidelines for HIV Positive Mothers and Infants\\n\\nHIV positive mothers and infants should always be on antiretroviral therapy (ART) with extra attention given to adherence support, viral load (VL) monitoring, and retention in care. Breastfeeding mothers who do not know their HIV status or have tested negative should be encouraged to retest for HIV at the 6-week immunization visit and then every 6 months until breastfeeding ceases.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 169,\n",
       "  'section': '## HIV Testing and Immediate Care for New Diagnoses\\n\\nAccess to HIV testing and STI/HIV prevention interventions should be reinforced for partners of pregnant and breastfeeding women. Mothers diagnosed with HIV while breastfeeding should immediately start appropriate ART, with infants beginning ARV prophylaxis and receiving PCR testing.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 169,\n",
       "  'section': '## Gradual Cessation of Breastfeeding\\n\\nMothers who choose to stop breastfeeding should do so gradually within one month, ensuring that a nutritionally adequate and safe diet without breast milk can be sustained. HIV positive mothers and infants should continue with ART. Continued breastfeeding is recommended for HIV positive infants for as long as the mother is willing and able.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 169,\n",
       "  'section': '## Special Medical Circumstances\\n\\nIn special medical circumstances determined by clinicians, where an infant cannot breastfeed, refer to the current MIYCN Policy and the Breast Milk Substitute (BMS) Regulation and Control Act of 2012.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 169,\n",
       "  'section': \"## Complementary Feeding\\n\\nComplementary feeding means providing additional foods to complement breast milk after six months of exclusive breastfeeding. Such feeds are essential for meeting the child's nutritional needs for growth and should help the child become accustomed to family foods. Breastfeeding continues to provide significant benefits for child growth and survival up to two years or longer.\\n\\n### Food Groups for Complementary Feeding\\n\\nEmphasis should be placed on consuming all seven food groups during various meals:\\n- Cereal/tubers and roots\\n- Beans, pulses, and nuts\\n- Dairy and dairy products\\n- Eggs and flesh (meat/poultry/insects/organ meat)\\n- Vitamin A-rich foods (orange/yellow fruits) and green vegetables\\n- Fats and high sugar foods\\n- Other fruits and vegetables\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 170,\n",
       "  'section': '## Prevention of Mother to Child Transmission of HIV/Syphilis/Hepatitis B\\n\\nThis section focuses on the strategies and guidelines to prevent the transmission of HIV, syphilis, and hepatitis B from mother to child during pregnancy and childbirth.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 170,\n",
       "  'section': '## Complementary Foods for Children 6 - 24 Months Old\\n\\nThis section provides detailed guidance on the types of complementary foods suitable for children aged 6 to 24 months, including texture and feeding frequency.\\n\\n### Foods to Offer\\n\\n| Age           | Texture                                               | Frequency                        | Amount of Food per Meal            |\\n|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 170,\n",
       "  'section': '|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 170,\n",
       "  'section': '|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 170,\n",
       "  'section': '-|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 170,\n",
       "  'section': '-|\\n| 6 months      | Start with thick porridge or well mashed foods       | 2 times per day                  | 2 tablespoons each feed, increasing to 3 tablespoons in the 3rd to 4th week |\\n| 7-8 months    | Mashed/pureed family foods; begin finger foods by 8 months | 3 meals per day, plus frequent breastfeeds | Increase gradually to ½ of a 250 ml cup, use a separate plate/bowl |\\n| 9-11 months   | Finely chopped or mashed foods, and foods that baby can pick up | 3 meals and 1 snack, plus frequent breastfeeds | ¾ of a 250 ml cup/bowl, use a separate plate/bowl |\\n| 12-23 months  | Cut food into small, soft pieces that child can pick up, chew, and swallow comfortably | 3 meals and 2 snacks, plus breastfeeds | One 250ml cup/bowl, use a separate plate/bowl |\\n| 24-59 months  | Cut food into small, soft pieces that child can pick up, chew, and swallow comfortably | 3 meals and 2 snacks, plus breastfeeds if still breastfeeding | 1 ½ - 2 cups of 250ml cup/bowl, use a separate plate/bowl |'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 168,\n",
       "  'section': '## Prevention of Mother to Child Transmission of HIV/Syphilis/Hepatitis B\\n\\nThis section discusses the overarching strategies to prevent the transmission of HIV, syphilis, and hepatitis B from mothers to their infants.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 168,\n",
       "  'section': '## Dosing of ARVs for Infant Prophylaxis from Birth to 12 Weeks of Age\\n\\n### Age/Weight Dosing Guidelines\\n- **Birth to 6 weeks**\\n  - **Birth weight < 2,000 g:** \\n    - NVP: 2 mg/kg per dose, OD\\n    - AZT: 4 mg/kg per dose, BD\\n  - **Birth weight 2,000 - 2,499 g:** \\n    - NVP: 10 mg (1 ml), OD\\n    - AZT: 10 mg (1 ml), BD\\n  - **Birth weight ≥ 2,500 g:** \\n    - NVP: 15 mg (1.5 ml), OD\\n    - AZT: 15 mg (1.5 ml), BD\\n\\n- **> 6 weeks to 12 weeks of age**\\n  - **Any weight:** \\n    - NVP: 20 mg (2 ml), OD\\n    - AZT: 60 mg (6 ml), BD\\n\\n**Note:** Dose adjustment required once the child reaches 6 weeks of age. If an older infant beyond 6 weeks is identified as HIV exposed, administer AZT+NVP for 6 weeks, continue NVP + cotrimoxazole until 6 weeks after breastfeeding cessation.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 168,\n",
       "  'section': '## NVP Dosing for Infant Prophylaxis beyond 12 Weeks of Age\\n\\n### Age Dosing Guidelines\\n- **12 weeks – 6 months:** 25 mg (2.5 ml), OD\\n- **7 months – 9 months:** 30 mg (3 ml), OD\\n- **10 months – 12 months:** 40 mg (4 ml), OD\\n- **> 12 months:** Consult the Regional or National HIV Clinical TWG for guidance.\\n\\n**Note:** If a child presents late and needs AZT and NVP beyond 12 weeks, follow appropriate guidelines.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 168,\n",
       "  'section': '## AZT Dosing for Infant Prophylaxis beyond 12 Weeks of Age\\n\\n### Weight Dosing Guidelines\\n- **3.0-5.9 kg:** 6 ml, BD\\n- **6.0-9.9 kg:** 9 ml, BD\\n- **10.0 -13.9 kg:** 12 ml, BD\\n- **14.0 -19.9 kg:** 15 ml, BD\\n\\n**Note:** If a child presents late and needs AZT and NVP beyond 12 weeks, follow the specified protocol.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 168,\n",
       "  'section': '## Infant and Young Child Nutrition in the Context of HIV\\n\\n### Key Nutrition Concepts\\n- **Exclusive Breastfeeding:** This involves providing the baby only breast milk (no other liquids or solids) for the first six months, with permitted vitamins, mineral supplements, or medicines if prescribed.\\n- **Mixed Feeding:** This practice of giving other liquids or foods along with breast milk to infants under 6 months is not recommended due to the increased risk of mother-to-child HIV transmission and other health issues.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 178,\n",
       "  'section': '## TB/HIV Co-infection Overview\\n\\nThis section discusses the co-infection of tuberculosis (TB) and human immunodeficiency virus (HIV), focusing on the importance of understanding both diseases and their interactions for effective management and treatment.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 178,\n",
       "  'section': '## Drug Susceptible TB Treatment Regimen\\n\\n### Drug Susceptible TB Treatment Regimen for Children, Adolescents, and Adults\\n\\n#### TB Disease Categories\\n\\n- **All forms of TB (except TB meningitis, bone and joint TB)**\\n  - **Intensive phase:** 2 RHZE \\n  - **Continuation phase:** 4 RH\\n\\n- **TB Meningitis**\\n  - **Intensive phase:** 2 RHZE \\n  - **Continuation phase:** 10 RH\\n\\n- **Osteoarticular TB**\\n  - **Intensive phase:** 2 RHZE \\n  - **Continuation phase:** 10 RH\\n\\n- **Drug Resistant TB**\\n  - Refer to a DRTB Clinical Team'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 178,\n",
       "  'section': '## Follow-Up Procedures\\n\\nThis section outlines the necessary follow-up procedures for TB treatment, including smear tests and guidelines for resistant TB cases.\\n\\n- Follow-up smears should be done for all bacteriologically confirmed pulmonary TB cases at the end of month 2, 5, and 6 using smear microscopy.\\n- Follow-up of RR TB and DR TB should be done as per PMDT guidelines.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 178,\n",
       "  'section': '## Additional Recommendations for Treatment\\n\\nThis section provides further recommendations for patients undergoing TB treatment to prevent complications.\\n\\n- Patients taking isoniazid-containing regimens should be given Pyridoxine (Vitamin B6) daily to reduce the risk of developing peripheral neuropathy. (Refer to Annex 10 for pyridoxine dosing).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 178,\n",
       "  'section': '## Treatment Completion Guidelines\\n\\nThis section emphasizes the importance of completing TB treatment.\\n\\n- Once TB treatment is initiated, it should be completed unless another definitive diagnosis (such as lung cancer) is established and TB is ruled out.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 175,\n",
       "  'section': '## Overview of HIV Prevention and Treatment Guidelines\\n\\nThis section provides an overview of the Kenya HIV Prevention and Treatment Guidelines, 2022, highlighting the importance of early detection and effective treatment strategies for HIV and associated conditions.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 175,\n",
       "  'section': '## GeneXpert Test Results Interpretation\\n\\nThis section outlines the different outcomes from GeneXpert testing for tuberculosis (TB) and the subsequent actions based on the results:\\n\\n- **MTB Detected, Rifampicin Resistance Detected (RR)**: Initiate drug-resistant TB (DR TB) protocols.\\n- **MTB Detected, Rifampicin Resistance not Detected (TR)**: Continue with standard TB treatment.\\n- **MTB Not Detected (N)**: Evaluate for other conditions or potential non-tuberculous mycobacteria (NTM).\\n- **Indeterminate Results (TI)**: Collect another sample and repeat the GeneXpert test.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 175,\n",
       "  'section': '## Management of Drug-Resistant TB\\n\\nThis section details the steps to be taken for patients diagnosed with drug-resistant TB:\\n\\n1. **High-Risk Groups**:\\n   - Collect samples for first-line (FL) and second-line (SL) line drug susceptibility testing (DST).\\n   - Conduct a comprehensive review by a DR TB clinical team.\\n   - Start DR TB treatment as per the guidelines.\\n\\n2. **Low-Risk Groups**:\\n   - Initiate drug-sensitive (DS) TB treatment while awaiting DST results.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 175,\n",
       "  'section': '## Treatment Protocol for Existing TB Patients\\n\\nProvides guidance for patients already on TB treatment when test results are pending:\\n\\n- Continue existing TB treatment (especially if smear-positive).\\n- If MTB not detected, consider NTM diagnosis; send cultures for definitive results.\\n- Evaluate for other respiratory illnesses (e.g., asthma, pneumonia).\\n- Conduct chest X-ray (CXR) evaluations, considering extrapulmonary TB (EPTB).\\n- Refer for further evaluation if no definitive diagnosis is achieved.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 175,\n",
       "  'section': '## Revised Treatment Based on Drug Susceptibility Testing (DST)\\n\\nThis section discusses the steps to be taken following DST results:\\n\\n1. Treat as DS TB.\\n2. Collect another sample for retesting with the GeneXpert (Ultra).\\n3. Adjust treatment regimen based on findings from DST results.\\n4. Follow up as per the guidelines for DR TB management.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 175,\n",
       "  'section': '## Follow-Up Protocols\\n\\nThis section emphasizes the requisite follow-up actions during and after TB treatment:\\n\\n- Regular clinical improvement assessments.\\n- Mandatory smear microscopy at specified intervals (months 2/3, 5, and 6).\\n- Monthly smears and cultures during the treatment duration.\\n- If drug resistance develops, initiate DR TB treatment per established guidelines.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 177,\n",
       "  'section': '## Understanding TB Diagnosis in Children\\n\\nThis section outlines the symptoms and history to consider when diagnosing pulmonary TB in children under 10 years old. Symptoms include cough, fever, poor weight gain, and lethargy. A history of contact with adults or adolescents with chronic cough or TB in the past two years is also crucial.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 177,\n",
       "  'section': '## Clinical Evaluation for TB\\n\\nClinical evaluation involves examining the child for specific signs of TB, such as:\\n- Temperature over 37.5°C\\n- Poor weight gain or weight loss, checked against a growth monitoring curve\\n- Increased respiratory rate\\n- Abnormal findings during a respiratory system examination\\n\\nAdditional evaluations should include checking other systems for signs suggestive of extra-pulmonary TB.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 177,\n",
       "  'section': '## Investigations for TB Diagnosis\\n\\nRecommended investigations include:\\n- Specimen collection for Xpert MTB/RIF testing, and culture if indicated\\n- Chest X-ray, if available\\n- Mantoux test, if applicable\\n- HIV testing\\n- Additional tests for suspected extra-pulmonary TB'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 177,\n",
       "  'section': '## TB Diagnosis Criteria\\n\\nDiagnosis can be categorized as follows:\\n- **Bacteriologically Confirmed TB:** Positive specimen for MTB.\\n- **Clinical Diagnosis of PTB:** Presence of two or more suggestive symptoms (persistent cough, fever, poor weight gain, lethargy) along with positive contact history or other abnormal respiratory signs.\\n\\nIf extra-pulmonary TB is suspected, refer to the specific diagnostic guidelines for EPTB.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 177,\n",
       "  'section': '## TB Treatment Guidelines\\n\\nTreatment protocols include:\\n- All children with bacteriologically confirmed TB and those with clinical signs suggestive of TB should be treated.\\n- Treatment Duration:\\n  - For all forms of TB (except TB meningitis, bone and joint TB): 6 months (2 RH ZE/ 4 RH).\\n  - For TB meningitis and bone/joint TB: 12 months (2 RH ZE/ 10 RH).\\n\\nIn cases where an Xpert result is absent or negative but clinical signs of TB are present, treatment should still commence.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 177,\n",
       "  'section': '## Special Considerations for Testing\\n\\nFor certain children, culture and Drug Susceptibility Testing (DST) may be warranted, particularly if:\\n1. Rifampicin resistance is detected by the Xpert test.\\n2. The child is a refugee or has been in contact with anyone with Drug Resistant TB.\\n3. There is no response to TB treatment.\\n4. Results from the Xpert test are indeterminate.\\n\\nIn facilities where available, IGRA testing may also be conducted. Always refer to IMCI guidelines for the severity classification of disease.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 176,\n",
       "  'section': '## TB/HIV Co-infection: Overview\\n\\nThis section discusses the co-infection of tuberculosis (TB) and HIV, including implications for diagnosis and treatment.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 176,\n",
       "  'section': '## Footnotes and Key Terms\\n\\n1. **Samples for GeneXpert testing:** Includes sputum, CSF, pleural aspirate, peritoneal fluid, synovial fluid, gastric aspirate, nasopharyngeal aspirate, FNA, lymph node biopsy, pus, and stool.\\n  \\n2. **Indications for TB-LAM:** Used as an adjunct test to GeneXpert for persons living with HIV (PLHIV) who are presumed to have TB if they meet certain clinical criteria, such as advanced disease or severe illness signs.\\n\\n3. **CXR Reporting:** All chest X-rays must be reported, and results reviewed by a clinician for confirmed management.\\n\\n4. **Test Results Interpretation:** Includes the identification of Mycobacterium tuberculosis (MTB) and rifampicin resistance status.\\n\\n5. **HIV Testing and Screening:** Recommended during TB screening and diagnosis and for diabetes screening among adults with TB. \\n\\n**Key Abbreviations:**\\n- CBR: Chest X-ray\\n- DR TB: Drug Resistant TB\\n- DS TB: Drug Susceptible TB\\n- DST: Drug Susceptibility Testing\\n- EPTB: Extra Pulmonary TB\\n- FL: First Line LPA Line Probe Assay\\n- MTB: Mycobacterium Tuberculosis \\n- NTM: Non-Tuberculous Mycobacteria\\n- TST: Tuberculin Skin test\\n- SL: Second line'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 176,\n",
       "  'section': '## Risk Classification for Drug Resistant TB (DR TB)\\n\\n### High-Risk Group for DR TB\\n- Previously treated TB patients (treatment failures, relapses).\\n- Contacts of Drug Resistant TB patients.\\n- Positive smear results at month 2 or 5 of treatment.\\n- Patients developing TB symptoms while on IPT.\\n- Healthcare workers showing symptoms.\\n- Prisoners and refugees with TB symptoms.\\n\\n### Low-Risk Group for DR TB\\n- All presumptive TB cases not in the high-risk category.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 176,\n",
       "  'section': '## Management of Positive Smear Results\\n\\n### Positive Smear Result at Month 2/3\\n- Evaluate for adherence; check for other causes of delayed conversion.\\n- Request for drug susceptibility tests (DST) and continue RHZE regimen.\\n- Adjust treatment based on DST results.\\n- Review smear results for further action.\\n\\n### Positive Smear Result at Month 5/6\\n- Declare treatment failure, stop anti-TB treatment.\\n- Review by TB clinical teams and evaluate reasons for failure.\\n- Request re-evaluation through GeneXpert and DST.\\n\\n### Subsequent Actions for Smear Positive or Culture Positive Results\\n- Continue evaluation regarding adherence and treatment efficacy.\\n- Request appropriate DST tests depending on initial resistance patterns.\\n- Declare treatment failure if necessary and communicate findings to the national clinical team.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 176,\n",
       "  'section': '## TB Diagnosis and Treatment Guidelines\\n\\nThis section highlights the protocols and algorithms available for TB diagnosis, including the GeneXpert Ultra algorithm.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 176,\n",
       "  'section': 'These sections refine the content into focused areas that can assist in a Q&A context, making it manageable for users looking for specific information about TB/HIV co-infection management.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 174,\n",
       "  'section': '## TB/HIV Co-Infection Overview\\n\\nThis section provides a general understanding of the co-infection of Tuberculosis (TB) and HIV, emphasizing the importance of identifying signs and symptoms in patients.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 174,\n",
       "  'section': '## Clinical Review Requirements\\n\\nIf a patient exhibits any signs or symptoms of TB, they require a clinical review. In cases where no signs or symptoms are present, a comprehensive history and thorough examination should be conducted to classify the patient as a presumptive TB case.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 174,\n",
       "  'section': '## Assessing Presumptive TB Cases\\n\\nKey evaluation steps for identifying presumptive TB cases include:\\n\\n- Determine if a sample is available for TB testing.\\n- Manage and evaluate for other conditions.\\n- Consider TB preventive therapy (TPT) as per Latent TB Infection (LTBI) guidelines.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 174,\n",
       "  'section': '## Diagnostic Options: GeneXpert and Smear Microscopy\\n\\n- If GeneXpert testing is available on site, follow specific diagnostic protocols:\\n  - Consider chest X-Ray (CXR).\\n  - Employ clinical diagnosis of TB.\\n\\n- If smear microscopy is available, obtain a sample for GeneXpert testing and conduct further evaluations based on the results.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 174,\n",
       "  'section': '## Managing Positive and Negative Test Results\\n\\n- In cases of a positive TB LAM test for eligible People Living with HIV (PLHIV):\\n  - Initiate Directly Observed Treatment Short-course (DS TB) treatment and evaluate upon receipt of GeneXpert results.\\n\\n- For a negative TB LAM test:\\n  - It does not rule out TB. Hence, further clinical evaluation is necessary.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 174,\n",
       "  'section': '## Symptoms to Consider for TB Diagnosis\\n\\nClinicians should inquire about the following symptoms when evaluating patients:\\n\\n1. Unintended weight loss\\n2. Chest pain\\n3. Body temperature elevation\\n4. Drenching night sweats\\n5. Cough of any duration\\n6. BMI less than 18.5 or Z score less than -2'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 174,\n",
       "  'section': '## Summary of Testing Protocols\\n\\nThis section outlines the testing protocols to be followed for TB diagnosis among patients, emphasizing the necessity of proper sample collection, referral for GeneXpert, and adherence to TB LAM testing guidelines in PLHIV.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 181,\n",
       "  'section': '## Contraindications to TPT\\n\\nPatients with the following conditions should not receive Tuberculosis Preventive Therapy (TPT) until the underlying issues are addressed:\\n- Active tuberculosis disease\\n- Active hepatitis (acute or chronic)\\n- Chronic alcohol abuse\\n- Symptoms of peripheral neuropathy'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 181,\n",
       "  'section': '## Dose and Duration of TPT\\n\\n### Recommended TPT Regimens for PLHIV\\n\\n**Target Populations and Regimens:**\\n- **Adult PLHIV (excluding patients on PI/r-based ARV regimens):** Rifapentine and Isoniazid (3HP) - Once weekly for three months (12 doses).\\n- **Adult PLHIV on PI/r-based ARV regimens, all CALHIV aged below 15 years, any patient with intolerance or contraindication to 3HP, and pregnant women:** Isoniazid (6H) - Once daily for 6 months.\\n- Note: The 3RH (rifampicin and isoniazid) regimen is not recommended for PLHIV due to drug-drug interactions.\\n\\n### Additional Recommendations\\n- All TPT regimens should be given with Vitamin B6 (pyridoxine), if available, to reduce the risk of developing peripheral neuropathy.\\n- Comprehensive health education and adherence counselling should be conducted prior to the initiation of TPT.\\n- Dosing of TPT is detailed in Annex 10.\\n\\n### Special Considerations for Children\\n- Children should be weighed at each visit, and correct weight-based dosing should be confirmed.\\n- Clients on 3HP should receive a weekly dose of pyridoxine. Those on the Rifapentine and Isoniazid regimen should also be given pyridoxine once a week.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 181,\n",
       "  'section': '## Important Notes on TPT Regimens\\n\\nThe 3RH (rifampicin and isoniazid) regimen is specifically not recommended for PLHIV due to potential drug-drug interactions, and it is generally used in HIV-negative populations.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 179,\n",
       "  'section': '## TB-LAM Overview\\n\\nTB-LAM is a rapid point-of-care urine dip-stick test used for diagnosing tuberculosis (TB). The test detects lipoarabinomannan (LAM), a component shed from the TB cell wall, found in urine. It is designed to be performed at the bedside.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 179,\n",
       "  'section': '## GeneXpert Diagnostic Test\\n\\nGeneXpert is the recommended initial diagnostic test for individuals with presumptive TB. TB-LAM should not be used as an alternative to GeneXpert but can assist in diagnosing TB while waiting for GeneXpert results. It is important to note that TB-LAM cannot detect rifampicin resistance.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 179,\n",
       "  'section': '## Indications for TB-LAM Use\\n\\nTB-LAM is indicated as an adjunct test to GeneXpert for:\\n- People Living with HIV (PLHIV) with advanced disease (WHO stage 3 or 4 or with a low CD4 count).\\n- PLHIV exhibiting severe illness danger signs (e.g., respiratory rate >30 breaths/min, temperature >39°C, heart rate >120 beats/min, or unable to walk unaided).\\n- PLHIV currently admitted to the hospital.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 179,\n",
       "  'section': '## Interpreting TB-LAM Results\\n\\n### LF-LAM Negative\\n\\n- TB is not ruled out.\\n- Evaluate clinical response after 3–5 days of antibiotic treatment while awaiting GeneXpert results.\\n\\n### LF-LAM Positive\\n\\n- TB is likely.\\n- Initiate TB treatment.\\n- Conduct additional investigations for TB and other HIV-related diseases as needed.\\n- Continue TB treatment even if GeneXpert results are negative.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 179,\n",
       "  'section': '## Clinical Response Assessment\\n\\n- **Clinical improvement**: Continue monitoring and adjust treatment as necessary.\\n- **Clinical worsening or no improvement**: TB is unlikely. Conduct additional investigations for TB and other opportunistic illnesses and complete the antibiotic course.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 179,\n",
       "  'section': '## Actions Based on GeneXpert Results\\n\\n- If GeneXpert results are positive for TB, initiate TB treatment regardless of TB-LAM results.\\n- If GeneXpert results are negative, consider TB prophylaxis (TPT).\\n- TB treatment should begin if the patient is seriously ill or if GeneXpert results are positive. Additional investigations for TB and HIV-related diseases should also be conducted. Complete the parenteral antibiotic course.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 179,\n",
       "  'section': '## Summary of TB-LAM Use among PLHIV\\n\\n- TB-LAM serves as a rapid diagnostic tool alongside GeneXpert for PLHIV.\\n- Proper interpretation of TB-LAM results and appropriate clinical actions are crucial in managing patients with suspected TB.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 180,\n",
       "  'section': '## TB/HIV Co-infection: Prevention and Management\\n\\nThis document discusses the current strategies and guidelines for the prevention and management of TB in individuals with HIV (PLHIV). It emphasizes the importance of TB preventive therapy (TPT) and provides concise recommendations aligned with national and World Health Organization guidelines.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 180,\n",
       "  'section': '## TB Preventive Therapy (TPT)\\n\\nThis section summarizes the national recommendations for the treatment of latent TB infections (LTBI) in the PLHIV population. It aligns with the updated WHO guidelines and highlights the use of shorter, safer LTBI treatment options for an expanded at-risk population.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 180,\n",
       "  'section': '## Indications for TPT\\n\\nTPT should be provided to patients in whom TB is excluded using the ICF tool. Eligible client categories include:\\n\\n- All PLHIV above 12 months of age (children, adolescents, and adults, including pregnant and breastfeeding women)\\n- All household contacts of persons with bacteriologically confirmed pulmonary TB\\n- Prisoners and staff working in prison settings\\n- Healthcare workers and other staff in healthcare settings\\n- Other clinical risk groups as defined in LTBI guidelines\\n\\n*Note: Neonates born to mothers with TB or exposed to close contacts with TB should receive TPT once TB disease has been ruled out. BCG vaccination should occur 2 weeks after completing TPT or anti-TB treatment.*'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 180,\n",
       "  'section': '## Summary of Recommendations for TPT among the PLHIV\\n\\n- **Higher Risk**: PLHIV are at a significantly higher risk of developing TB disease compared to the general population.\\n- **Eligibility**: TPT should be administered to all PLHIV above 12 months of age without active TB disease, irrespective of immune status, ART status, previous history of TB, or pregnancy status.\\n- **Children Aged <12 Months**: Those living with HIV who are household contacts of someone with bacteriologically confirmed pulmonary TB (with active TB ruled out) should receive TPT.\\n- **Post-TB Treatment**: TPT may commence immediately following successful completion of TB treatment among PLHIV.\\n- **Repeat TPT**: Not recommended, except for PLHIV who become a household contact of a person with bacteriologically confirmed pulmonary TB.\\n- **Therapy Regimen**: \\n   - PLHIV aged 15 years and above should receive 3 months of weekly Rifapentine and Isoniazid (3HP).\\n   - Those younger than 15 years should receive 6 months of daily Isoniazid (6H).\\n   - For PLHIV on PI/r-based ART, pregnant women, and those intolerant to 3HP, six months of daily Isoniazid (6H) is recommended.\\n- **TPT for Previously Treated Patients**: Initiate upon completion of TB treatment.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 188,\n",
       "  'section': '## TB/HIV Co-infection: Prevention and Management\\n\\nThis section covers the basic guidelines and recommendations for managing TB/HIV co-infection, particularly focusing on clinical consultation and drug regimens.\\n\\n1. For patients on 2nd line ART whose regimens, drug intolerances, or nonstandard drugs require a change due to TB treatment, it is advised to consult the Regional or National HIV Clinical Technical Working Group (TWG). For assistance, contact the Uliza Hotline at 0726 460 000 or visit [NASCOP Clinical Form](https://nhcsc.nascop.org/clinicalform).\\n\\n2. In urgent cases regarding the collection of Drug Resistance Testing (DRT) samples, reach out to the Regional or National HIV Clinical TWG at the same Uliza Hotline number or online resources.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 188,\n",
       "  'section': '## Drug Management Strategies\\n\\nThis section highlights specific strategies for managing drug interactions between TB medications and antiretroviral treatments.\\n\\n1. To manage the interaction between lopinavir/ritonavir (LPV/r) and rifampicin, use “super-boosted” LPV/r by adding additional ritonavir. Refer to Annex 10 for specific dosing recommendations.\\n\\n2. It is important to revert to the standard LPV/r dosing regimen for the child two weeks after the completion of TB treatment.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 184,\n",
       "  'section': '## Management of TPT-Associated Rash\\n\\nThis section discusses the management of skin rashes associated with Tuberculosis Preventive Therapy (TPT). Rashes may occur shortly after starting TPT, often presenting as mild maculopapular rashes with or without itching. \\n\\n### Characteristics of Rashes  \\n- **Flu-like systemic reactions** are rare in children; typically mild and self-limiting in adults.  \\n- Serious reactions like severe exfoliation or Stevens-Johnson syndrome may occur but are uncommon.  \\n\\n### Management Table (Table 8.5)  \\nSeverity classifications and corresponding actions for rash management:\\n\\n| Severity | Characteristics | Action |\\n|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 184,\n",
       "  'section': '-|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 184,\n",
       "  'section': '-|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 184,\n",
       "  'section': '--|\\n| Mild | Dry; erythema +/− fine papules; pruritus; affecting < 50% of body surface area | Continue TPT; monitor closely; symptomatic treatment with antihistamines +/− topical steroids (NOT oral steroids) |\\n| Moderate | Dry; erythema +/− fine papules; pruritus; affecting ≥ 50% of body surface area | Stop TPT; symptomatic treatment with antihistamines +/− topical steroids (NOT oral steroids); trial of desensitization after symptoms resolve |\\n| Severe | Mucosal involvement; blistering; associated fever; any % of body surface area | Stop TPT; admit to hospital for supportive care (IV fluids, wound care, pain control, infection control); NEVER re-challenge; document adverse event and issue patient alert card |'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 184,\n",
       "  'section': '## ART for TB/HIV Co-Infection\\n\\nThis section outlines the importance of Antiretroviral Therapy (ART) for People Living with HIV (PLHIV) who are diagnosed with TB/HIV co-infection. A comprehensive care package, including ART and Cotrimoxazole Preventive Therapy (CPT), is essential.\\n\\n### Timing of ART Initiation  \\n- **For patients not yet on ART**:  \\n  - Commence TB treatment immediately.  \\n  - Initiate ART as soon as anti-TB medications are well tolerated, ideally within 2 weeks.  \\n  - For TB meningitis, ART initiation should be delayed for 4 to 8 weeks.  \\n  - Close monitoring for Immune Reconstitution Inflammatory Syndrome (IRIS) is essential.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 182,\n",
       "  'section': '## TB/HIV Co-infection Prevention and Management\\n\\nThis section provides an overview of the guidelines for managing patients with TB/HIV co-infection, specifically focusing on the use of Tuberculosis Preventive Therapy (TPT).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 182,\n",
       "  'section': '## Follow-up of Patients on TPT\\n\\nPatients on TPT should be followed up on a monthly basis, aligning their return-to-clinic dates with other routine schedules. During each visit, conduct the following:\\n\\n- Symptom screening for active TB disease and update status\\n- Assess and reinforce adherence to treatment\\n- If a patient screens positive for TB while on TPT, stop TPT and manage according to National TB guidelines\\n- Assess for any adverse drug reactions at each visit and intervene appropriately\\n- Provide/update TPT appointment card\\n- Document and update the relevant recording and reporting tools (e.g., ICF/TPT cards, Contact Management/TPT register)\\n- Document outcomes of TPT use, such as completion, in the relevant tools and/or EMR\\n\\n*Note: Baseline liver function tests are not mandatory for patients starting TPT but may be considered on an individual basis, especially for those on other medications for chronic conditions or with symptoms suggestive of active hepatitis.*'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 182,\n",
       "  'section': '## Identifying and Managing Drug Toxicities from TPT\\n\\nThis section discusses the management of drug toxicities associated with TPT, focusing on the most common adverse drug reactions.\\n\\n### Common Adverse Drug Reactions\\n- Peripheral Neuropathy\\n- Drug-Induced Liver Injury (DILI)\\n- Rash'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 182,\n",
       "  'section': '## Peripheral Neuropathy\\n\\n### Suspected Drug: INH\\n\\n#### Diagnosis of Peripheral Neuropathy\\n- Symptoms include burning sensation, numbness, or tingling, typically starting at the feet on both sides.\\n- May exhibit decreased sensation upon examination.\\n- Severe cases can lead to weakness.\\n- Symptoms may be exacerbated by other neurotoxic drugs, alcoholism, metabolic diseases (e.g., diabetes), malnutrition, and infections.\\n- Rarely severe enough to necessitate drug withdrawal.\\n\\n#### Management of INH-induced Peripheral Neuropathy\\n- Increase the dose of pyridoxine to 100 mg per day.\\n- For children, administer double the standard weight-based dose.\\n- Assess for other causes of peripheral neuropathy (e.g., diabetes, thyroid disorder, B12 deficiency, syphilis, etc.).\\n- Symptom relief can be achieved with analgesics, tricyclic antidepressants (e.g., amitriptyline, nortriptyline), or anticonvulsants (e.g., carbamazepine, phenytoin).\\n- If symptoms do not improve or worsen, discontinue TPT, as symptoms may persist even after cessation of therapy.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 183,\n",
       "  'section': '## Drug-Induced Liver Injury (DILI) Overview\\n\\nSuspected drugs that may cause DILI include Isoniazid (H), Rifapentine (P), and Rifampicin (R). Elevation of liver enzymes may occur in the first weeks of treatment. It is important to note:\\n\\n- In asymptomatic patients, serum liver enzyme levels do not need to be monitored routinely.\\n- Clients with gastrointestinal symptoms (e.g., nausea, vomiting, liver tenderness, hepatomegaly, or jaundice) should have their liver function assessed.\\n- Screening for other causes of liver injury (such as hepatitis viruses A, B, and C) is essential.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 183,\n",
       "  'section': '## Diagnosis of DILI\\n\\nDILI can be diagnosed based on the following indicators:\\n\\n- Symptoms such as jaundice, abdominal pain, nausea, vomiting, and anorexia.\\n- The presence of abnormal liver enzymes.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 183,\n",
       "  'section': '## Grading and Management of DILI\\n\\nThe management of DILI is categorized by severity, as shown in Table 8.4:\\n\\n### Grading of DILI:\\n\\n- **Grade 1: Mild**\\n  - ALT (SGPT) 1.25 – 2.5 x ULN\\n  - AST (SGOT) 1.25 – 2.5 x ULN\\n  - **Action:** Continue treatment regimen; patients should have weekly follow-up until resolution (return to baseline) or stabilization of AST/ALT elevation.\\n\\n- **Grade 2: Moderate**\\n  - ALT (SGPT) 2.6 – 5.0 x ULN\\n  - AST (SGOT) 2.6 – 5.0 x ULN\\n  - **Action:** Continue treatment regimen; weekly follow-up until resolution or stabilization.\\n\\n- **Grade 3: Severe**\\n  - ALT (SGPT) 5.1 – 10.0 x ULN\\n  - AST (SGOT) 5.1 – 10.0 x ULN\\n  - **Action:** Stop all drugs, including TPT drugs; measure liver function tests (LFTs) weekly. TPT should not be reintroduced after severe DILI.\\n\\n- **Grade 4: Life-threatening**\\n  - ALT (SGPT) > 10.0 x ULN\\n  - AST (SGOT) > 10.0 x ULN\\n  - **Action:** Stop all drugs, including TPT drugs; measure LFTs weekly. TPT should not be reintroduced after life-threatening DILI.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 183,\n",
       "  'section': '## Reintroduction of Drugs after DILI\\n\\nPatients living with HIV (PLHIV) who develop DILI during the treatment of active TB disease may have anti-TB medications reintroduced after toxicity is resolved, but this should be done in consultation with a senior clinician.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 190,\n",
       "  'section': '## TB/HIV Co-infection Prevention and Management\\n\\nOverview of the relationship and implications of TB and HIV co-infection, including prevention and management strategies.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 190,\n",
       "  'section': '## HBV/HIV and HCV/HIV Co-infection Prevention and Management\\n\\n### 9.1 Hepatitis B/HIV Co-infection\\n\\nDiscussion on how HIV and Hepatitis B Virus (HBV) share transmission routes, the risks associated with co-infection, and the implications for liver health and HIV treatment outcomes.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 190,\n",
       "  'section': '### 9.1.1 Screening\\n\\nGuidelines for screening individuals with HIV for HBV infection. Recommendations include routine screenings for specific at-risk populations and those with signs of liver disease.\\n\\n- **Target populations for screening**:\\n  - Adolescents and adults living with HIV\\n  - Children who did not complete routine immunizations\\n  - Household and sexual contacts of HBsAg positive individuals\\n  - Pregnant women\\n  - Persons who inject drugs (PWID)\\n  - Men who have sex with men\\n  - Sex workers\\n  - Persons with multiple sexual partners\\n  - Prisoners\\n  - Blood donors\\n  - Unvaccinated healthcare providers'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 190,\n",
       "  'section': '### 9.1.2 Prevention\\n\\nStrategies for preventing HBV infection among people living with HIV (PLHIV). Emphasis on vaccination and targeted interventions to reduce HBV incidence.\\n\\n- **Vaccination**: \\n  - Importance of HBV vaccination in reducing the risk of new infections and chronicity among PLHIV.\\n  - Recommendations include:\\n    - Vaccination for HIV positive infants, children, adolescents, and adults without evidence of HBV infection (HBsAg negative).\\n    - Vaccination for HIV exposed infants (HEI) as part of childhood immunization.\\n    - Integration of HBV vaccination campaigns within HIV prevention and treatment programs for at-risk groups.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 186,\n",
       "  'section': '## TB/HIV Co-infection Overview\\n\\nThis section provides a general introduction to the co-infection of Tuberculosis (TB) and Human Immunodeficiency Virus (HIV), emphasizing the importance of managing both conditions simultaneously.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 186,\n",
       "  'section': '## Preferred ART Regimens for TB Patients on 1st Line ART\\n\\nThis section details the preferred Antiretroviral Therapy (ART) regimens for patients who develop TB while being virally suppressed on first-line ART. \\n\\n### Current Regimen Options:\\n1. **PI/r-based:**\\n   - **Substitution:** \\n     - Switch from PI/r to DTG (Dolutegravir) and continue this regimen after completing TB treatment.\\n     - If switching to DTG is not possible:\\n       - **Children < 30 kg:** Use LPV/r with additional ritonavir super-boosting during rifampicin-based TB therapy, revert to standard dosing 2 weeks post TB treatment.\\n       - **Patients ≥ 30 kg:** Switch to EFV-based ART and maintain after TB treatment completion.\\n\\n2. **RAL-based:**\\n   - **Substitution:** \\n     - Switch from RAL (Raltegravir) to double-dose DTG during TB treatment and maintain DTG post TB treatment.\\n\\n3. **DTG-based:**\\n   - **Substitution:** \\n     - Administer double-dose DTG while on rifampicin-containing TB treatment, reverting to the standard once-daily dose after TB treatment.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 186,\n",
       "  'section': '## Recommendations for Assessment and Follow-up\\n\\nThis section summarizes important follow-up actions and assessments that should be taken for patients with TB/HIV co-infection.\\n\\n- Always assess for HIV treatment failure in patients developing TB after 6 months on ART. \\n- For patients failing 1st line ART, refer to the recommended 2nd line regimens (see Table 8.8).\\n- For adjustments in second-line ART or nonstandard drugs needing changes due to TB treatment, consult the Regional or National HIV Clinical TWG. Contact info available: Uliza Hotline 0726 460 000; [Nascop Clinical Form](https://nhcsc.nascop.org/clinicalform).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 186,\n",
       "  'section': '## Special Considerations for NRTIs and Drug Interactions\\n\\nThis section outlines the considerations necessary regarding Nucleoside Reverse Transcriptase Inhibitors (NRTIs) and interactions with anti-TB treatments.\\n\\n- NRTIs in the patient’s current regimen do not require adjustments when undergoing anti-TB treatment.\\n- Special note on managing the interaction between LPV/r and rifampicin using “super-boosted” LPV/r, which involves additional ritonavir (refer to Annex 10 for dosing recommendations).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 185,\n",
       "  'section': '## Patients on ART and TB Treatment\\n\\nPatients who are already on ART should start TB treatment immediately. They must continue ART while assessing for treatment failure and making any necessary adjustments to the ART regimen based on drug-drug interactions. Close monitoring for Immune Reconstitution Inflammatory Syndrome (IRIS) is also essential. Those being treated concurrently for TB and HIV require close monitoring for toxicity. Multidrug-resistant (MDR) TB and HIV co-infection should be managed in settings where experienced clinicians or a multidisciplinary team can provide close toxicity monitoring and follow-up.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 185,\n",
       "  'section': '## Preferred ART Regimens for TB/HIV Co-infection\\n\\nThe preferred ART regimens for patients with TB/HIV co-infection are summarized based on age and weight:\\n\\n- **Birth to 4 weeks:** \\n  - Start anti-TB treatment immediately, and begin ART after 4 weeks of age once the patient can tolerate anti-TB drugs, following regimen recommendations for children aged ≥ 4 weeks.\\n\\n- **Age > 4 weeks to < 15 years:**  \\n  - **Weight < 30 kg:** \\n    - ABC + 3TC + DTG with increased DTG dosing frequency to twice daily for the duration of rifampicin-containing TB treatment and for an additional 2 weeks after TB treatment completion, reverting to once daily dosing afterward.\\n  - **Weight ≥ 30 kg:** \\n    - TDF/3TC/DTG fixed-dose combination (FDC) in the morning plus DTG 50mg in the evening during rifampicin-containing TB treatment and for an additional 2 weeks post-treatment, then reverting to TDF/3TC/DTG FDC once daily.\\n\\n- **Age ≥ 15 years:**  \\n  - Any weight:\\n    - TDF/3TC/DTG FDC in the morning plus DTG 50mg in the evening during the rifampicin-containing TB treatment and for an additional 2 weeks post-treatment, then reverting to TDF/3TC/DTG FDC once daily.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 185,\n",
       "  'section': '## Weight-Based ARV Dosing\\n\\nFor specific ARV dosing guidance based on weight, refer to Annex 10. This section outlines the detailed recommendations for the administration of antiretroviral medications, ensuring appropriate dosing tailored to individual patient needs.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 187,\n",
       "  'section': '## Recommended ART Regimens for Patients with TB and First-Line ART Failure\\n\\nThis section outlines specific ART (Antiretroviral Therapy) regimens for patients who develop tuberculosis (TB) while failing on first-line ART based on their age and body weight.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 187,\n",
       "  'section': '## Patients Under 30 kg Body Weight\\n\\nFor patients under 30 kg, the recommendations are as follows:\\n\\n- **First-Line ART**: LPV/r-based regimen\\n- **Actions**:\\n  - Start anti-TB treatment immediately.\\n  - Change to an DTG (Dolgtegravir) based second-line regimen immediately, increasing the DTG dosing frequency to twice daily during rifampicin-containing TB treatment and for an additional 2 weeks after TB treatment completion, then revert to once daily.\\n  - Immediately collect a sample for Drug Resistance Testing (DRT).\\n  - Assess and address reasons for treatment failure.\\n  \\nIf unable to switch to DTG, use super-boosted LPV/r (Lopinavir/ritonavir).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 187,\n",
       "  'section': '## Patients 30 kg or Older or 15 Years and Older\\n\\nFor patients aged 15 years and older or weighing 30 kg or more, the treatment recommendations include:\\n\\n- **ART Regimens**: \\n  - TDF (Tenofovir Disoproxil Fumarate) + 3TC (Lamivudine) + DTG\\n  - TDF (or ABC or AZT) + 3TC + EFV (Efavirenz)\\n  \\n- **Actions** (for TDF/3TC/DTG):\\n  - Start anti-TB treatment immediately.\\n  - Administer TDF/3TC/DTG fixed-dose combination (FDC) in the morning and DTG 50mg in the evening during TB treatment and for an additional 2 weeks after TB treatment completion, then revert to TDF/3TC/DTG FDC once daily.\\n  - Follow the viral load monitoring algorithm and assess treatment failure reasons, including collecting DRT samples.\\n\\nFor patients on TDF/3TC/EFV:\\n- Start anti-TB treatment immediately and continue the current regimen, monitoring for treatment failure.\\n- Upon confirmation of treatment failure and readiness to switch, transition to TDF + 3TC + DTG, maintaining TDF throughout.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 187,\n",
       "  'section': '## PI/r-Based First-Line ART\\n\\nFor patients on a PI/r (Protease Inhibitor/ritonavir) based first-line ART, the following is recommended:\\n\\n- **Actions**:\\n  - Start anti-TB treatment immediately.\\n  - Immediately switch to TDF + 3TC + DTG.\\n  - Administer TDF/3TC/DTG FDC in the morning and DTG 50mg in the evening during TB treatment and for an additional 2 weeks thereafter, then revert to once daily dosing.\\n  - Immediately collect a sample for DRT.\\n  - Assess and address reasons for treatment failure.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 187,\n",
       "  'section': '## Recommendations for Pregnant or Breastfeeding Patients\\n\\nPregnant or breastfeeding patients should follow the same recommendations as for patients aged 15 years and older or those weighing 30 kg or more.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 187,\n",
       "  'section': '## Recommendations for HIV/HBV Co-infection\\n\\nFor patients co-infected with HIV and HBV (Hepatitis B Virus), ensure the following:\\n\\n- Always maintain TDF or TAF (Tenofovir Alafenamide) in the second-line regimen instead of switching to a different NRTI or adding an additional NRTI in the treatment plan.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 191,\n",
       "  'section': '## Hepatitis B Vaccination Schedule for HIV-positive Individuals\\n\\n**Target Groups for Vaccination:**\\n\\n- Babies and young children (through EPI and catch-up immunization for those who missed EPI vaccination)\\n- Household contacts of HBsAg positive individuals\\n- Sexual contacts of HBsAg positive individuals\\n- People on haemodialysis\\n- People Who Inject Drugs (PWID)\\n- Individuals with chronic liver disease and/or hepatitis C\\n- Inmates and prison personnel\\n- Healthcare workers\\n\\n**Vaccine Dosing Schedule:**\\n\\n| Vaccine                     | Dose (intramuscular)              | Schedule            |\\n|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 191,\n",
       "  'section': '-|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 191,\n",
       "  'section': '--|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 191,\n",
       "  'section': '|\\n| Non-adjuvanted formulation  | Double the standard dose          | 0, 1, 2, and 6 months |\\n| Adjuvanted formulation      | Standard dose                     | 0, 1, 2, and 6 months |\\n\\n*Booster vaccination is not required for persons who have completed the full vaccination schedule.*'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 191,\n",
       "  'section': '## General Preventive Measures for HBV Transmission\\n\\n**Infection Prevention Measures:**\\n\\n- Hand hygiene\\n- Use of personal protective equipment (PPE)\\n- Medical waste management, including safe disposal of used sharps\\n- Disinfection and sterilization\\n- General health advice against sharing personal items like towels, toothbrushes, razors, and combs\\n- Harm reduction counselling and services for PWID, as outlined in Chapter 12\\n- Safer sex practices'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 191,\n",
       "  'section': '## Treatment Recommendations for HIV and Hepatitis B Co-infection\\n\\n**Initiation of Antiretroviral Therapy (ART):**\\n\\n- All HIV-infected patients co-infected with hepatitis B should start ART regardless of CD4 cell count, WHO clinical stage, or stage of liver disease.\\n\\n**Monitoring and Support:**\\n\\n- General recommendations for treatment preparation, adherence counselling, support, and therapy monitoring for People Living with HIV (PLHIV) still apply. \\n- Due to the higher risk of hepatotoxicity in HBV positive patients, closer monitoring of liver function (measured by ALT levels) is advised. \\n\\n**Initial Evaluation Focus Areas:**\\n\\n- Table 9.2 provides a summary of focus areas during the initial evaluation for HIV/HBV co-infected patients initiating therapy.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 192,\n",
       "  'section': '## TB/HIV Co-Infection: Overview\\n\\nThis section provides an overview of the complexities involved in managing individuals with both TB and HIV infections, emphasizing the importance of integrated care.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 192,\n",
       "  'section': '## Recommended First-Line ART in HIV/HBV Co-Infection\\n\\nThe recommended first-line ART for adolescents and adults with HIV/HBV co-infection is TDF + 3TC + DTG, including for women and adolescent girls of childbearing potential. Treatment with both TDF (or TAF) and 3TC is crucial, as using 3TC alone can lead to rapid resistance. Adjustments must be made in cases of renal impairment based on creatinine clearance.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 192,\n",
       "  'section': '## Initial Clinical and Laboratory Evaluation in HIV/HBV Co-Infection\\n\\n### Findings and Suggested Actions\\n\\n- **History**: Assess for alcohol use, smoking, intravenous drug use, risky sexual practices, and gastroenterological symptoms. Counsel and provide support for cessation and harm reduction.\\n\\n- **Physical Examination**: Observe for enlarged liver, spleen, ascites, or scratch marks, indicating chronic liver disease. Recommend closer follow-up due to increased hepatotoxicity risk.\\n\\n- **ALT Levels**: Elevated levels may indicate active liver disease. Exclude other causes but do not delay ART initiation.\\n\\n- **Creatinine Levels**: Calculate creatinine clearance. TDF is indicated even for patients with CrCl < 50 ml/min, requiring single drug administration for dosage adjustments.\\n\\n- **Comorbidities**: Consider investigating HCV, random blood sugar, lipid profile, and liver diseases in patient history.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 192,\n",
       "  'section': '## Management Considerations for HIV/HBV Co-Infection\\n\\nIn managing patients with HIV/HBV co-infection, it is essential to address any accompanying comorbidities and tailor treatment plans accordingly. Consultations and referrals may be necessary for additional evaluations.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 192,\n",
       "  'section': '## Key Points on ART Dosing Adjustments \\n\\nIn cases of renal impairment, specific adjustments to ART dosing are mandatory to prevent toxicity and ensure effectiveness. Detailed dosage guidelines are found in Table 9.3, which outlines the necessary adjustments based on creatinine clearance levels.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 192,\n",
       "  'section': '## Conclusion\\n\\nEffective management of individuals with TB/HIV co-infection requires a comprehensive approach with careful consideration of ART regimen selection, initial evaluations, and necessary adjustments for comorbid conditions. Integration of care strategies is critical for optimal patient outcomes.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 189,\n",
       "  'section': '## Overview of Kenya HIV Prevention and Treatment Guidelines\\n\\nThe Kenya HIV Prevention and Treatment Guidelines, 2022 provide comprehensive protocols aimed at reducing the incidence of HIV and ensuring effective management of HIV-positive individuals. The guidelines are designed to align with international standards while being adaptable to local contexts.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 189,\n",
       "  'section': '## Key HIV Prevention Strategies\\n\\nThis section outlines essential strategies for HIV prevention, including:\\n\\n- Promoting condom use among at-risk populations.\\n- Providing pre-exposure prophylaxis (PrEP) for high-risk individuals.\\n- Implementing regular HIV testing and counseling services.\\n- Fostering needle and syringe exchange programs to reduce transmission among injecting drug users.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 189,\n",
       "  'section': '## Treatment Protocols for HIV-Positive Individuals\\n\\nDetailing the treatment protocols, this section covers:\\n\\n- Initiation of antiretroviral therapy (ART) for all individuals diagnosed with HIV, regardless of CD4 count.\\n- Importance of adherence to ART for viral suppression and overall health.\\n- Regular follow-up appointments and monitoring for ART efficacy and side effects.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 189,\n",
       "  'section': '## Care and Support Services\\n\\nThis section discusses the importance of holistic care and support for individuals living with HIV, including:\\n\\n- Mental health support and counseling services.\\n- Nutritional support to enhance overall health and ART efficacy.\\n- Linkage to social services for economic empowerment.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 189,\n",
       "  'section': '## Role of Community Engagement\\n\\nAddressing the role of community in HIV prevention and treatment, this section emphasizes:\\n\\n- The significance of community education and awareness programs.\\n- Involvement of local organizations and peer educators in outreach efforts.\\n- Strategies for reducing stigma and discrimination against people living with HIV.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 189,\n",
       "  'section': '## Monitoring and Evaluation Framework\\n\\nThis section focuses on the framework for monitoring and evaluating the effectiveness of HIV interventions, highlighting:\\n\\n- Key performance indicators for HIV prevention and treatment services.\\n- The importance of data collection and analysis to inform policy and program adjustments.\\n- Strategies for stakeholder collaboration in monitoring outcomes.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 189,\n",
       "  'section': '## Future Directions and Recommendations\\n\\nFinally, this section outlines future directions for HIV policy and practice, including:\\n\\n- Emphasis on innovative approaches to reach underserved populations.\\n- Continuous updates to guidelines based on emerging research and epidemiological data.\\n- Advocacy for increased funding and resources to support HIV initiatives within Kenya.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 197,\n",
       "  'section': '## Background on HIV in Kenya\\n\\nThis section provides an overview of the HIV epidemic in Kenya, its prevalence, and the demographics affected. It highlights the significance of understanding the local context to inform prevention and treatment guidelines.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 197,\n",
       "  'section': '## Key Prevention Strategies\\n\\nThis section outlines the primary strategies employed in Kenya to prevent HIV transmission. It covers methods such as condom distribution, pre-exposure prophylaxis (PrEP), and education initiatives aimed at high-risk populations.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 197,\n",
       "  'section': '## Treatment Guidelines\\n\\nHere, the document details the recommended approaches for treating HIV in Kenya. It includes information on antiretroviral therapy (ART), monitoring, and the integration of services for co-infections.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 197,\n",
       "  'section': '## Target Populations\\n\\nThis section identifies specific groups targeted by the guidelines, such as men who have sex with men (MSM), sex workers, and adolescents. It discusses tailored interventions for these populations.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 197,\n",
       "  'section': '## Monitoring and Evaluation\\n\\nThis section describes the methods and metrics used to monitor the effectiveness of HIV prevention and treatment interventions. It emphasizes the importance of data collection and analysis for improving strategies.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 197,\n",
       "  'section': '## Future Directions\\n\\nIn this section, the guidelines address future challenges and opportunities in the fight against HIV in Kenya. It includes discussions on emerging research, potential policy changes, and community engagement efforts.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 194,\n",
       "  'section': '## TB/HIV Co-infection: Prevention and Management\\n\\nMaintain TDF + 3TC in the ART regimen for patients switching from TDF-based therapy. For example, if a patient with HIV/HBV co-infection fails TDF/3TC/EFV in first-line treatment, they should switch to TDF/3TC/DTG in second-line therapy. HIV/HBV co-infected patients failing second-line ART should be discussed in the MDT and consulted with the Regional or National HIV Clinical TWG (Uliza Hotline 0726 460 000).'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 194,\n",
       "  'section': '## Hepatitis C/HIV Co-infection\\n\\nIn Kenya, the prevalence of HCV infection is high among people who inject drugs (PWID), estimated at 12-16%. The prevalence in the general population and among people living with HIV (PLHIV) is low (estimated to be < 3%), but is likely higher in HIV-infected PWID due to shared transmission routes. HIV/HCV co-infection is associated with:\\n\\n- Rapid progression of liver fibrosis\\n- Higher risk of deteriorating liver disease, even with controlled HIV disease\\n- Worsened hepatotoxicity from ART and other drugs used for comorbidities\\n\\nThus, HIV-positive persons at risk of HCV co-infection should be identified and offered HCV treatment. The recent introduction of direct-acting antiviral therapies (DAAs) has simplified the management of HIV/HCV co-infection, making it feasible to manage uncomplicated cases safely even in primary care settings. However, the treatment landscape for HCV is rapidly evolving, and providers should seek regular updates and discuss individual cases with experienced providers when in doubt.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 194,\n",
       "  'section': '## Screening for HCV Infection\\n\\nHCV serology should be offered to individuals at risk of HCV infection, including:\\n\\n- People who inject or use intranasal drugs\\n- Persons who have had tattoos, body piercings, or scarification procedures in settings with questionable infection prevention measures\\n- Children born to HCV positive mothers\\n\\nUp to 30% of individuals infected with HCV can spontaneously clear the infection. To confirm chronic HCV infection, HCV positive individuals should be offered nucleic acid HCV RNA testing to establish the presence of a chronic infection.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 196,\n",
       "  'section': '## TB/HIV Co-infection Overview\\n\\nThis section provides a brief introduction to the complexities of co-infection with tuberculosis (TB) and human immunodeficiency virus (HIV). It highlights the increased risks and health challenges faced by patients who are co-infected, emphasizing the importance of integrated care and management strategies.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 196,\n",
       "  'section': '## Recommended Direct-Acting Antivirals (DAA) for HCV Treatment among PLHIV\\n\\nThis section details the recommended DAA regimens for the treatment of hepatitis C virus (HCV) in individuals living with HIV (PLHIV). \\n\\n### Recommended Regimens:\\n\\n- **Genotypes 1 and 4**: \\n  - **DAA Regimen**: Sofosbuvir + Ledipasvir (Harvoni)\\n  - **Duration of Treatment**: 12 weeks\\n  \\n- **All Genotypes**:\\n  - **DAA Regimen**: Sofosbuvir + Velpatasvir (Epclusa)\\n  - **Duration of Treatment**: 12 weeks\\n\\n*Note: The availability of DAA regimens is subject to change. It is crucial to initiate DAA therapy for HCV and to consult the latest drug-drug interaction data with antiretroviral (ARV) medications.*'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 196,\n",
       "  'section': '## Importance of Reviewing Drug-Drug Interactions\\n\\nThis section emphasizes the necessity of reviewing drug-drug interactions between DAA regimens and antiretroviral treatments. Ensuring compatibility can enhance treatment efficacy and patient safety in those co-infected with TB and HIV.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 195,\n",
       "  'section': '## Prevention of HIV and HCV Transmission\\n\\nGeneral measures for the prevention of blood-borne infections are effective in preventing HCV transmission.\\n\\n### Recommendations for Healthcare Settings\\n- Training of healthcare providers on:\\n  - Hand hygiene: including surgical hand preparation, hand-washing, and use of gloves\\n  - Safe handling and disposal of sharps and waste\\n  - Effective disinfection and sterilization\\n  - Provision of safe blood and blood products\\n\\n### Recommendations for People Who Inject Drugs (PWID)\\n- Harm reduction counselling and support (Table 12.1)\\n\\n### Recommendations for Prevention of Sexual Transmission\\n- Correct and consistent condom use\\n- Access to prevention services for sex workers and other people at risk, including:\\n  - Screening and treatment of STIs\\n  - Frequent testing for HIV and HCV testing'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 195,\n",
       "  'section': '## Treatment of HIV/HCV Co-Infection\\n\\n### Initial Clinical and Laboratory Evaluation in HIV/HCV Co-Infection\\n\\n| **Findings**          | **Action**                                                                                       |\\n|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 195,\n",
       "  'section': '--|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 195,\n",
       "  'section': '--|\\n| **History**           | Assess, counsel, and support to stop taking alcohol; counsel and support smoking cessation; provide and refer for harm reduction interventions.  |\\n| **Physical Examination** | Evidence of established chronic liver disease; closer follow-up due to increased risk of hepatotoxicity; discuss or refer to a consultant for additional evaluation and management. |\\n| **HCV RNA PCR**      | For confirmation of chronic HCV infection; if available, at baseline.                           |\\n| **HCV Genotype**     | May be important for selecting appropriate Direct-Acting Antiviral (DAA) regimen; current regimens are pan-genotypic, so testing is not required. |\\n| **ALT**              | If elevated, may point to active liver disease; exclude other causes of elevation of liver enzymes; assess liver function (albumin and INR) in symptomatic patients, but this should not delay initiation of ART. |\\n| **Comorbidities**     | Consult/Refer the patient for additional investigations where conditions such as HBV, alcoholic and non-alcoholic liver disease, or hepatocellular carcinoma are suspected. |'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 201,\n",
       "  'section': '## Risk Reduction Counselling\\n\\nTo reduce the risk of further HIV transmission, it is necessary to prevent transmission to sexual partners and the children of breastfeeding mothers. Risk reduction counselling should form part of each consultation with the individual. Measures to reduce transmission may include:\\n- The use of condoms and safe injecting practices to prevent secondary transmission\\n- Avoiding blood donation until confirmed HIV negative at 12 weeks post-exposure'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 201,\n",
       "  'section': '## Special Circumstances Considerations\\n\\n### Breastfeeding Women\\n- Breastfeeding is not a contraindication for PEP.\\n- Discuss the risks and benefits of continuing breastfeeding while HIV transmission risk is unknown with the mother.\\n\\n### Children\\n- HIV testing approaches for children should align with national guidelines and be age-appropriate.\\n- Informed consent from the caregiver is needed.\\n\\n### Adolescents\\n- Requiring parental consent for adolescents can be a barrier to HIV testing, particularly in cases of sexual assault.\\n- HIV testing should be performed in accordance with national guidelines and consenting requirements.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 201,\n",
       "  'section': '## Preventing HIV Exposure\\n\\nTo avoid or minimize the risk of exposure to HIV, the following infection prevention control (IPC) measures are recommended:\\n- Precautions when handling contaminated body fluids, including the use of appropriate barriers such as gloves, gowns, and goggles.\\n- Care with sharps, including minimizing blind surgical procedures and proper handling and disposal of sharps.\\n- Safe disposal of contaminated waste.\\n- Safe handling of soiled linen.\\n- Adequate disinfection procedures.\\n- Universal Hepatitis B vaccination of non-immune at-risk groups, including healthcare workers, police, prison staff, and rescue workers.\\n\\nIn cases that do not require PEP, the exposed person should be counselled about limiting future exposure risk.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 204,\n",
       "  'section': '## Pre-Exposure Prophylaxis (PrEP)\\n\\nPre-Exposure Prophylaxis (PrEP) is a preventive approach aimed at individuals at high risk of HIV infection. It is crucial to note that HIV self-testing (HIVST) should not be used as a definitive HIV test for PrEP initiation and follow-up monitoring.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 204,\n",
       "  'section': '## Package of PrEP Service\\n\\nPrEP should be integrated into a comprehensive prevention package that includes behavioral, biomedical, and structural components. It is recommended that PrEP services be delivered within various service points, including community settings, antenatal care (ANC), and family planning (FP) clinics.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 204,\n",
       "  'section': '## Service Integration\\n\\nClients seeking any service from healthcare facilities or community settings should be screened for ongoing risk of HIV. \\n\\n1. **Screen:** Assess the risk for ongoing HIV exposure.\\n2. **Test:** Conduct HIV testing for those at risk.\\n\\nIf the result is HIV positive, link or refer the individual to appropriate services. Additional screenings for gender-based violence (GBV) and HIV should also be conducted.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 204,\n",
       "  'section': '## Figure 11.1: Package of Service for PrEP\\n\\nThis figure illustrates the essential components of the service package for PrEP, emphasizing the importance of comprehensive integration and support for clients.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 198,\n",
       "  'section': '## ARVs for Post-exposure Prophylaxis\\n\\nAn ARV regimen, with preferably three drugs, should be offered as post-exposure prophylaxis as soon as possible (preferably within 72 hours) after an exposure.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 198,\n",
       "  'section': '## What is PEP?\\n\\nPost-exposure prophylaxis (PEP) is short-term use of antiretroviral treatment to reduce the likelihood of HIV infection after potential exposure. People can be accidentally exposed to HIV through healthcare work or due to exposures outside the healthcare setting, for example, through unprotected sex or sexual assault among adults and children. Healthcare workers are at increased risk of exposure to HIV through contact with contaminated blood and other body fluids containing HIV through needle stick injuries and injuries by other sharp objects or through non-intact skin and mucous membranes.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 198,\n",
       "  'section': '## Recommended ARVs for PEP\\n\\nThree-drug regimens are preferred for PEP. However, if the person is unable to tolerate the third drug (usually the PI/r), two drugs can be used.\\n\\n### Table 10.1: Recommended ARVs for PEP\\n\\n- **Age: <15 years**\\n  - **Weight: <30kg**\\n    - Preferred: ABC + 3TC + DTG\\n    - Alternate: AZT + 3TC + DTG; AZT + 3TC and LPV/r may be used as the third drug.\\n  \\n- **Age: ≥30 kg**\\n  - Preferred: TDF + 3TC/FTC + DTG\\n  - Alternate: TDF + 3TC/FTC and ATV/r may be used as alternative third drug.\\n  \\n- **Age: ≥15 years**\\n  - Any weight: TDF + 3TC/FTC + DTG\\n  - Alternate: TDF + 3TC/FTC and ATV/r may be used as alternative third drug.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 199,\n",
       "  'section': '## Eligibility For PEP\\n\\nPEP should always be offered as soon as possible, preferably within 72 hours, after an exposure. Persons who present after 72 hours should be provided with other appropriate services including counselling and support. Eligibility assessment for PEP is based on the type of exposure, HIV status of source where possible, and timing of seeking care. The following include the eligibility criteria for PEP:\\n\\n- Exposed individual is HIV negative at baseline.\\n- Exposure must have occurred within the past 72 hours.\\n- Exposure to bodily fluids poses a significant risk (exposure and/or material):\\n  - **Type of exposure:** mucous membrane (i.e., sexual exposure; splashes to eye, nose, or oral cavity), non-intact skin, percutaneous injury, or parenteral exposures.\\n  - **Material:** blood, blood-stained body fluids, breast milk; semen; vaginal secretions; synovial, pleural, pericardial, amniotic fluids; CSF, and HIV cultures in laboratories.\\n\\nExposures that do not require HIV PEP include:\\n- When the exposed individual is already HIV positive.\\n- Exposures to bodily fluids that do not pose a significant risk, i.e., tears, non-blood-stained saliva, urine, and sweat.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 199,\n",
       "  'section': '## Management and Follow Up\\n\\nPatients should be counselled and encouraged to complete the full course of PEP once a decision has been made to initiate PEP. For occupational exposure, immediate care of the exposure site includes washing the site with soap and water and allowing the wound to bleed freely for several minutes. \\n\\n**NOTE:** Do not do anything that will increase tissue damage such as squeezing, scrubbing, or cutting the site further.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 193,\n",
       "  'section': \"## Dose Adjustment of TDF and 3TC in Patients with Impaired Renal Function\\n\\nThis section outlines the recommended dosages for Tenofovir Disoproxil Fumarate (TDF) and Lamivudine (3TC) based on patients' creatinine clearance levels and their need for haemodialysis.\\n\\n- **TDF:**\\n  - **Creatinine clearance (ml/min):**\\n    - 50 - 80: 33 mg/g granules (1 scoop) or 245 mg (7.5 scoops of granules or 245 mg film-coated tablet) once daily.\\n    - 30 - 49: 132 mg (4 scoops of granules) once daily.\\n    - 10 - 29: 65 mg (2 scoops of granules) once daily.\\n    - Haemodialysis: 16.5 mg (0.5 scoop) after each 4-hour session of dialysis.\\n  - **TDF 300 mg:**\\n    - Unchanged: 300 mg once daily.\\n    - 300 mg every 48 hrs for 30-49 clearance.\\n    - 300 mg every 72 to 96 hours (twice weekly) for 10-29 clearance.\\n    - For patients getting haemodialysis, administer 300 mg once weekly after completion of dialysis sessions.\\n  \\n- **3TC 300 mg:**\\n  - Unchanged: 300 mg once daily or 150 mg BD.\\n  - 150 mg once daily for 30-49 clearance.\\n  - 150 mg once daily for 10-29 clearance.\\n  - Haemodialysis: 50 mg first dose, 25 mg once daily.\\n\\n> Note: Patients with impaired renal function and HIV/HBV co-infection should be managed with specialist input.\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 193,\n",
       "  'section': '## Follow-up/Monitoring\\n\\nThis section discusses the follow-up and monitoring protocols for HIV/HBV co-infected patients on ART.\\n\\n- Monitor these patients similar to other patients on ART, but consider more frequent monitoring using ALT for those with active liver disease (e.g., jaundice, cirrhosis).\\n- Co-infection increases the risk of drug-related hepatotoxicity from all classes of ARVs by 3-5 times, particularly when anti-TB and ART are combined.\\n- Hepatic flare-ups (AST > 5 times normal) can occur in the first 3 months of treatment.\\n- ALT elevations of 5-10 times normal can be tolerated during the first 3 months of ART if the patient is stable and asymptomatic, and without synthetic dysfunction.\\n- Patients with persistently elevated ALT should be referred to a specialist. Continuous laboratory monitoring after baseline should occur every 6 months.\\n- Patients should be advised to abstain from alcohol.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 193,\n",
       "  'section': '## Stopping Treatment/Treatment Interruptions\\n\\nThis section provides guidance on the management of treatment interruptions for patients with HIV/HBV co-infection.\\n\\n- TDF-containing ART should not be stopped to avoid potential hepatitis flare-ups.\\n- If treatment must be halted and no alternative suppressive therapy for hepatitis B is available, liver enzymes should be monitored closely.\\n- Treatment should be reinstated as soon as possible to mitigate risks associated with treatment interruptions.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 202,\n",
       "  'section': '## Pre-Exposure Prophylaxis (PrEP)\\n\\nPre-exposure prophylaxis (PrEP) is the use of antiretroviral medication to prevent the acquisition of HIV infection by an uninfected person at ongoing risk of acquiring HIV infection. PrEP is recommended for use as follows:  \\n- **Daily Oral PrEP** for all individuals, irrespective of gender or sexual orientation who are at risk of HIV infection.  \\n- **Event-Driven (ED) PrEP** is currently recommended for all people born male who are not taking exogenous estradiol-based gender affirming hormones.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 202,\n",
       "  'section': '## Indications for PrEP and Criteria for Eligibility\\n\\n### Indications for PrEP\\n\\nPrEP is indicated for:  \\n- HIV uninfected persons at ongoing risk of HIV acquisition.  \\n- Some risk situations that place an individual at ongoing risk include partners who are:  \\n  - HIV positive and: not on ART, or on ART for less than 6 months, on ART with viral non-suppression, or on ART with suspected poor adherence.  \\n  - In sero-discordant relationships trying to conceive.  \\n  - Of unknown HIV status and at high risk of HIV infection.  \\n  - Engaging in transactional sex or sex work.  \\n  - With a history of recent or current sexually transmitted infections.  \\n  - With recurrent use of Post-Exposure Prophylaxis.  \\n  - With a history of sex while under the influence of alcohol or recreational drugs.  \\n  - Inconsistent or no condom use or unable to negotiate condom use during intercourse with persons of unknown HIV status.  \\n  - Using injection drugs where needles and/or syringes are shared.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 202,\n",
       "  'section': '### HIV Risk Assessment\\n\\nClients accessing health services should be screened for HIV risk and provided with information on available HIV prevention options, including PrEP. This occurs in addition to using HIV testing services (HTS), as clients are assessed for HIV risk before testing. \\n\\nThe risk assessment questions inquire about behavioral practices that may expose an individual to HIV. A simple Risk Assessment Tool (RAST) is provided to guide the provider in discussions about HIV risk. Screening for HIV risk should be integrated within other service delivery points. \\n\\nHIV negative individuals who answer “yes” to any of the screening questions should engage in a discussion about the risks and benefits of PrEP. The client will then be evaluated for eligibility to receive PrEP.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 205,\n",
       "  'section': '## Pre-Initiation Checklist for PrEP\\n\\nThis section outlines the checklist intended for service providers to ensure all necessary screenings and assessments are completed prior to the initiation of Pre-Exposure Prophylaxis (PrEP).\\n\\n### Assessment Checklist\\n| ITEM                                               | Y/N |\\n|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 205,\n",
       "  'section': '-|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 205,\n",
       "  'section': '--|\\n| Screening and Support for Gender-Based Violence (GBV) |     |\\n| HIV Testing                                        |     |\\n| Check symptoms of acute viral infection in last 6 weeks |     |\\n| Behavior risk assessment                            |     |\\n| Substance use and mental health screening           |     |\\n| Partner information                                 |     |\\n| Pre-initiation education and understanding of PrEP  |     |\\n| Client readiness and willingness to adhere to prescribed PrEP and follow-up schedule |     |\\n| STI screening and treatment                         |     |\\n| **For Women**                                      |     |\\n| ✔ Pregnancy test, pregnancy intention and/or breastfeeding |     |\\n| ✔ Screen for contraception use using appropriate contraceptive screening tool |     |\\n| ✔ Highlight the need for condom use                 |     |\\n| Discussed plans for continually accessing PrEP      |     |\\n| Additional laboratory tests (Availability of these test should not delay initiation of PrEP) |     |\\n| ✔ Serum creatinine and creatinine clearance         |     |\\n| ✔ HBsAg                                            |     |\\n| ✔ HCV serology                                     |     |\\n| **NB:** Absence of these tests should not hinder initiation |     |\\n| Medication history and potential drug interactions   |     |'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 200,\n",
       "  'section': '## ARVs for Post-exposure Prophylaxis\\n\\nThis section provides guidelines on the administration of antiretroviral (ARV) medications for post-exposure prophylaxis (PEP) in cases of potential HIV exposure.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 200,\n",
       "  'section': \"## Recommendations for PEP Management and Follow-up\\n\\n### Management at Initial Contact\\n- Counsel on risks and benefits of PEP and obtain verbal consent for HIV testing.\\n- Conduct voluntary testing for both exposed and source individuals.\\n- Offer PEP as soon as high-risk exposure is established and the exposed individual tests HIV-negative at baseline. If HIV testing isn't feasible, offer 1-2 days of PEP to cover until the HIV test is performed.\\n- Provide first aid in case of broken skin or other types of wounds.\\n\\n### Time of Initiation\\n- PEP should be initiated as soon as possible after exposure, but no later than 72 hours.\\n\\n### Duration of PEP\\n- The treatment duration for PEP is 28 days. All 28 days of treatment should be dispensed at the first visit if the patient is tested HIV negative.\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 200,\n",
       "  'section': '## PEP Dosage and Laboratory Investigations\\n\\n### Dose of PEP\\n- The dosing is the same as that indicated for HIV treatment; weight-based dosing should be used for children. \\n\\n### Laboratory Investigation at Baseline\\n- Conduct creatinine testing (if using a TDF-containing regimen) and hemoglobin (Hb) testing (if using an AZT-containing regimen). PEP should be offered even if lab tests are not available. Do not delay PEP administration for lab results.\\n- HBsAg testing is recommended; PEP administration should not be delayed. If negative, provide HBV vaccination.\\n- For women of childbearing potential, a pregnancy test should be conducted in cases of sexual assault.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 200,\n",
       "  'section': '## Follow-up Care\\n\\n### Follow-up Schedule\\n- Follow up with the client at 7 days, 14 days, 28 days, and 12 weeks after starting PEP.\\n- Assess and manage side effects due to PEP.\\n- Conduct follow-up HIV testing upon completion of PEP; if negative, test again at 12 weeks.\\n- If the follow-up test is positive, link the individual to HIV treatment.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 200,\n",
       "  'section': '## Counselling and Support\\n\\n### Counselling at Baseline\\n- Provide adherence counselling, information on side effects, risk reduction counselling, trauma and mental health counselling, and specific support for sexual assault victims.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 200,\n",
       "  'section': '## Additional Services for Sexual Assault Survivors\\n\\n- Offer STI prophylactic treatment to all patients, treating for vaginal/urethral discharge syndrome according to national STI algorithms.\\n- Provide emergency contraception for non-pregnant women.\\n- Administer tetanus toxoid for any physical injury of skin or mucous membranes.\\n- Document clinic evidence of assault and collect forensic evidence.\\n- Refer to post-rape care guidelines for additional details.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 203,\n",
       "  'section': '## HIV Screening Questions\\n\\nScreening questions refer to the past 6 months and include:  \\n- “Have you had sex with more than one person?”  \\n- “Have you had sex without a condom?”  \\n- “Have you had sex with anyone whose HIV status you do not know?”  \\n- “Are any of your partners at risk of HIV?”  \\n- “Have you had sex with a person who has HIV?”  \\n- “Have you received a new diagnosis of a sexually transmitted infection?”  \\n- “Do you desire pregnancy?”  \\n- “Have you used or wanted to use PEP or PrEP for sexual exposure to HIV?”  \\n- “Have you injected drugs that were not prescribed by a healthcare provider? If yes, did you use syringes, needles, or other drug preparation equipment that had already been used by another person?”  \\n- “Have you received money, housing, food, or gifts in exchange for sex?”  \\n- “Have you been forced to have sex against your will?”  \\n- “Have you been physically assaulted, including assault by a sexual partner?”'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 203,\n",
       "  'section': '## Criteria for PrEP Eligibility\\n\\nTo be eligible for PrEP, individuals identified to be at risk of HIV infection from Risk Assessment must meet ALL of the following criteria prior to initiating PrEP:  \\n- Confirmed HIV negative status through rapid antibody testing following the HTS algorithm.  \\n- Determine if the client is willing to take PrEP as prescribed, which involves adherence education and counseling on the PrEP regimen and assessing the client’s readiness to follow the regimen.  \\n- Does not have a current or recent (within the past one month) illness consistent with acute HIV infection (fever, sore throat, muscle or joint pains, swollen glands, diarrhea, or headache) in combination with a preceding high-risk exposure for HIV.  \\n- No contraindication to use of any of the ARVs recommended for PrEP, e.g., TDF ± FTC (or 3TC) for those who choose oral PrEP.  \\n- Renal or liver disease: Clients with renal and liver disease should receive further clinical and laboratory tests to determine the renal/liver function and extent of disease.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 203,\n",
       "  'section': '## Additional Screening Factors\\n\\n1. **Gender-Based Violence (GBV) Screening:**  \\n   All clients accessing PrEP must be screened for gender-based violence, especially intimate partner violence (IPV), and appropriate intervention offered or client linked to appropriate services.  \\n\\n2. **Mental Status Assessment:**  \\n   Psychological issues that may influence adherence should be assessed and addressed. It is important to carry out a basic mental health evaluation and offer appropriate referral as necessary.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 209,\n",
       "  'section': '## Event-Driven PrEP Overview\\n\\nEvent-driven PrEP (ED-PrEP) is a preventive strategy primarily suited for men who engage in infrequent sexual activity. It is most beneficial for individuals who have sex less than twice a week and can plan or delay sexual encounters by at least two hours.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 209,\n",
       "  'section': '## Eligibility Criteria for Event-Driven PrEP\\n\\nEvent-driven PrEP is appropriate for men who:\\n\\n- Have infrequent sex (averaging less than 2 times per week).\\n- Can plan for sex at least 2 hours in advance or delay sex for at least 2 hours.\\n- Find ED-PrEP more convenient than daily dosing.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 209,\n",
       "  'section': '## Dosing Strategies for PrEP\\n\\nWhen assessing HIV risk:\\n\\n- Offer daily dosing if sexual activity is more frequent than twice a week and cannot be predicted or delayed by two hours.\\n- Men who have sex with men can transition between daily dosing and event-driven dosing based on their sexual activity patterns.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 209,\n",
       "  'section': '## Follow-Up for Clients on ED-PrEP\\n\\nClients utilizing Event-driven PrEP require regular follow-up:\\n\\n- Schedule a follow-up visit one month after initiation and then every three months.\\n- Conduct HIV testing and screen for STIs during follow-up visits.\\n- Discuss adherence and dosing strategy consistently with the user.\\n- Assess ongoing HIV risk to determine if continued use of PrEP is necessary.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 209,\n",
       "  'section': \"## Support for PrEP Users\\n\\nClients may require additional support in maintaining their PrEP regimen, regardless of the chosen dosing strategy. It's essential to provide counseling that addresses:\\n\\n- Adherence to the dosing schedule.\\n- Transitioning between dosing methods, if necessary.\\n- Continuing assessment of HIV risk over time to ensure the relevance of the PrEP strategy.\"},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 206,\n",
       "  'section': '## Pre-Exposure Prophylaxis (PrEP) Overview\\n\\nPre-Exposure Prophylaxis (PrEP) is a preventive treatment for individuals at high risk of contracting HIV. It involves taking medication to significantly reduce the risk of infection as part of a broader combination of HIV prevention strategies.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 206,\n",
       "  'section': '## Pre-Initiation Client Education\\n\\nPrior to PrEP initiation, the following components should be discussed with clients:\\n\\n### Client Education Checklist\\n\\n- **Explain How PrEP Works**  \\n  Discuss the role of PrEP in combination HIV prevention.\\n  \\n- **Baseline and Follow-Up Tests**  \\n  Explain the necessity for initial and ongoing HIV testing.\\n\\n- **PrEP Use**  \\n  - **Medications Used**: Demonstrate the pills or other PrEP options.\\n  - **Usage Frequency**: Outline dosing for various PrEP options.\\n  - **Efficacy Doses**: Clarify the number of doses needed for effectiveness (7 doses for daily oral PrEP, loading dose for event-driven oral PrEP).\\n  - **Missed Doses**: Instructions on what to do if doses are missed.\\n  - **Discontinuation**: Guidance on how and when to discontinue PrEP.\\n  - **Side Effects**: Discuss potential side effects and when to consult a clinician.\\n\\n- **Symptoms of Seroconversion**  \\n  Discuss what to do if the client experiences symptoms of acute HIV infection.\\n\\n- **Limitations of PrEP**  \\n  - PrEP reduces, but does not eliminate, the risk of acquiring HIV.\\n  - PrEP does not prevent pregnancies or STIs.\\n  \\n- **Risk Reduction Counseling and Support Education**  \\n  - Managing mental health needs\\n  - Couple counseling\\n  - Providing access to and consistent use of condoms and lubricants\\n  - The need for frequent HIV testing\\n  - Early access to ART\\n  - Voluntary Medical Male Circumcision (VMMC)\\n  - STI screening and treatment\\n  - Harm reduction strategies for people who inject drugs (PWID)'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 206,\n",
       "  'section': '## Recommended Antiretrovirals (ARVs) for PrEP\\n\\nThe preferred ARV regimen for PrEP is Tenofovir 300mg/Emtricitabine 200mg (TDF/FTC), provided as one fixed-dose combination (FDC) tablet taken orally on a daily basis.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 210,\n",
       "  'section': '## Pre-Exposure Prophylaxis (PrEP) Overview\\n\\nPrEP is a preventative strategy to reduce the risk of HIV infection in individuals who are at high risk. It involves taking medication before potential exposure to HIV.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 210,\n",
       "  'section': '## Dosing Options for PrEP\\n\\nMen can choose between two primary dosing options for PrEP: daily oral PrEP and event-driven PrEP (ED-PrEP).\\n\\n- **Daily Oral PrEP**: Suitable for individuals whose sexual activity is unpredictable or occurs more than twice per week. This regimen ensures consistent protection.\\n\\n- **Event-Driven PrEP (ED-PrEP)**: Ideal for those who have infrequent and predictable sexual encounters. It requires taking a pill before and after sexual activity.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 210,\n",
       "  'section': '## Transitioning Between Dosing Options\\n\\nIndividuals may switch between daily oral PrEP and ED-PrEP based on their sexual activity.\\n\\n- If sexual activity is continuous beyond one day while on ED-PrEP, additional pills can be taken daily until two days after the last sexual encounter.\\n\\n- Conversely, if a user on daily oral PrEP begins to engage in infrequent sex, they can transition to ED-PrEP.'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 210,\n",
       "  'section': '## Clinical and Laboratory Management\\n\\n### Initial Assessment and Follow-Up Guidelines\\n\\n#### Initial Laboratory Tests for PrEP Initiation\\n\\n| Laboratory Test                       | Guidelines for Clients Initiating PrEP                  |\\n|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 210,\n",
       "  'section': '|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 210,\n",
       "  'section': '-|\\n| HIV Rapid Test                        | Before initiating PrEP as per the National HTS algorithm |\\n| Creatinine Test                       | Test within 1-3 months of PrEP Initiation             |\\n| Hepatitis B Surface Antigen (HBsAg)  | Test once within 3 months of initiating PrEP          |\\n| Hepatitis C Virus Serology            | Test once within 3 months of PrEP initiation          |\\n\\n#### Follow-Up Laboratory Tests for Clients on PrEP\\n\\n| Laboratory Test                       | Guidelines for Clients on Follow-Up                 |\\n|'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 210,\n",
       "  'section': '|'},\n",
       " ...]"
      ]
     },
     "execution_count": 15,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "guides_chunks"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "id": "23b111a3-a752-4b21-900d-a9bffb9778d7",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Dropping existing table 'kenya-arv-guidelines'...\n",
      "Creating new vectorstore...\n",
      "Generating embeddings...\n",
      "✓ Created table with 286 records\n",
      "✓ Vectorstore created successfully!\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "[2026-02-12T13:06:05Z WARN  lance::dataset] No existing dataset at /Users/itsmuriuki/Desktop/cdss-notebooks/kenya-hiv-cdss/kenya_arv_guidelines_lancedb/kenya-arv-guidelines.lance, it will be created\n"
     ]
    }
   ],
   "source": [
    "from langchain_community.vectorstores import LanceDB\n",
    "from langchain_openai import OpenAIEmbeddings\n",
    "from langchain.schema import Document\n",
    "import lancedb\n",
    "import pyarrow as pa\n",
    "\n",
    "\n",
    "# LanceDB configuration\n",
    "db_path = \"./kenya_arv_guidelines_lancedb\"\n",
    "table_name = \"kenya-arv-guidelines\"\n",
    "\n",
    "# Connect to LanceDB\n",
    "db = lancedb.connect(db_path)\n",
    "\n",
    "# Drop existing table if it exists (for fresh start)\n",
    "if table_name in db.table_names():\n",
    "    print(f\"Dropping existing table '{table_name}'...\")\n",
    "    db.drop_table(table_name)\n",
    "\n",
    "# Create vectorstore using add_texts method\n",
    "print(\"Creating new vectorstore...\")\n",
    "\n",
    "# Extract texts and metadatas\n",
    "texts = [doc.page_content for doc in documents]\n",
    "metadatas = [doc.metadata for doc in documents]\n",
    "\n",
    "# Generate embeddings manually\n",
    "print(\"Generating embeddings...\")\n",
    "vectors = embeddings.embed_documents(texts)\n",
    "\n",
    "# Create the table manually with proper schema\n",
    "data = []\n",
    "for i, (text, metadata, vector) in enumerate(zip(texts, metadatas, vectors)):\n",
    "    data.append({\n",
    "        \"text\": text,\n",
    "        \"vector\": vector,\n",
    "        \"id\": str(i),\n",
    "        \"source\": metadata.get(\"source\", \"\"),\n",
    "        \"page\": metadata.get(\"page\", 0)\n",
    "    })\n",
    "\n",
    "# Create table\n",
    "table = db.create_table(table_name, data=data, mode=\"overwrite\")\n",
    "print(f\"✓ Created table with {len(data)} records\")\n",
    "\n",
    "# Now create the LanceDB vectorstore wrapper\n",
    "vectorstore = LanceDB(\n",
    "    connection=table,\n",
    "    embedding=embeddings\n",
    ")\n",
    "faq_index = vectorstore\n",
    "faq_vindex = table\n",
    "print(\"✓ Vectorstore created successfully!\")\n",
    "\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "3b7d0a3e-ba8e-414b-880e-b595883b3f64",
   "metadata": {},
   "source": [
    "## Add Search"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "id": "25b66590-2b25-4b24-9459-9bb693c4bedc",
   "metadata": {},
   "outputs": [],
   "source": [
    "# We will index this data by putting it inside a search engine. This allows us to quickly find relevant information when users ask questions. In particular, we will:\n",
    "# Build a lexical search for exact matches and keywords\n",
    "# Implement semantic search using embeddings\n",
    "# Combine them with a hybrid search"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "61779fb9-9669-47a3-b0fa-d84a34e6589c",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "id": "1f9140af-d183-4576-b1bf-962422048b14",
   "metadata": {},
   "outputs": [],
   "source": [
    "def text_search(query: str):\n",
    "    \"\"\"Search the Kenya ARV guidelines by semantic similarity. Use for clinical or guideline questions.\"\"\"\n",
    "    return faq_index.similarity_search(query, k=5)\n",
    "\n",
    "def vector_search(query):\n",
    "    q = embedding_model.encode(query)\n",
    "    return faq_vindex.search(q, num_results=5)\n",
    "\n",
    "def hybrid_search(query):\n",
    "    text_results = text_search(query)\n",
    "    vector_results = vector_search(query)\n",
    "    \n",
    "    # Combine and deduplicate results\n",
    "    seen_ids = set()\n",
    "    combined_results = []\n",
    "\n",
    "    for result in text_results + vector_results:\n",
    "        if result['filename'] not in seen_ids:\n",
    "            seen_ids.add(result['filename'])\n",
    "            combined_results.append(result)\n",
    "    \n",
    "    return combined_results"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "e09e08d8-9ff1-4c31-8559-ac194903ff13",
   "metadata": {},
   "source": [
    "## Agent and tools"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "id": "3ea325ff-fa36-4ef7-aa2f-674dad4e70f7",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "First-line antiretroviral therapy (ART) regimens for the treatment of HIV typically include a combination of antiretroviral medications from different classes to ensure effective viral suppression and prevent resistance. The recommended first-line regimens often include:\n",
      "\n",
      "1. **Integrase Strand Transfer Inhibitors (INSTIs)**: These are currently favored due to their efficacy and favorable side effect profile.\n",
      "   - **Bictegravir/Emtricitabine/Tenofovir alafenamide (BIC/FTC/TAF)** \n",
      "   - **Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC)** (for those who are HLA-B*5701 negative)\n",
      "   - **Dolutegravir/Emtricitabine/Tenofovir disoproxil fumarate (DTG/FTC/TDF)**\n",
      "\n",
      "2. **Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)**: These are another option, though typically used in specific cases or in patients with certain viral characteristics.\n",
      "   - **Efavirenz/Emtricitabine/Tenofovir disoproxil fumarate (EFV/FTC/TDF)** \n",
      "\n",
      "3. **Nucleoside Reverse Transcriptase Inhibitors (NRTIs)**: Often included in combinations for various regimens, though not typically as monotherapy.\n",
      "   - **Abacavir (ABC)**\n",
      "   - **Lamivudine (3TC)**\n",
      "   - **Emtricitabine (FTC)**\n",
      "   - **Tenofovir disoproxil fumarate (TDF)**\n",
      "   - **Tenofovir alafenamide (TAF)**\n",
      "\n",
      "The specific regimen may vary based on individual patient factors, such as co-morbidities, potential drug interactions, and patient preference. It's essential for patients to work closely with their healthcare provider to determine the best regimen for their specific situation. Additionally, guidelines may evolve, so it's advisable to refer to the latest reprints from relevant health authorities or organizations, such as the U.S. Department of Health and Human Services (DHHS).\n"
     ]
    }
   ],
   "source": [
    "import openai\n",
    "\n",
    "openai_client = openai.OpenAI()\n",
    "\n",
    "user_prompt = \"What are the first-line ART regimens?\"\n",
    "\n",
    "chat_messages = [\n",
    "    {\"role\": \"user\", \"content\": user_prompt}\n",
    "]\n",
    "\n",
    "response = openai_client.responses.create(\n",
    "    model='gpt-4o-mini',\n",
    "    input=chat_messages,\n",
    ")\n",
    "\n",
    "print(response.output_text)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "8b442c67-8347-4a7b-a312-59b061bdde87",
   "metadata": {},
   "source": [
    "## Function Calling with OpenAI"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "id": "37defd25-70b5-4456-893c-54d5e9ec6afe",
   "metadata": {},
   "outputs": [],
   "source": [
    "from typing import List\n",
    "from langchain.schema import Document\n",
    "def arv_text_search(query: str) -> List[Document]:\n",
    "    \"\"\"\n",
    "    Perform a text-based similarity search on the Kenya ARV Guidelines vectorstore.\n",
    "\n",
    "    Args:\n",
    "        query (str): Clinical or guideline-related search query\n",
    "\n",
    "    Returns:\n",
    "        List[Document]: Top 5 guideline sections matching the query\n",
    "    \"\"\"\n",
    "    return vectorstore.similarity_search(query, k=5)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "id": "2420c9e0-e334-464d-9d75-7c89ad637d43",
   "metadata": {},
   "outputs": [],
   "source": [
    "text_search_tool = {\n",
    "    \"type\": \"function\",\n",
    "    \"name\": \"arv_text_search\",\n",
    "    \"description\": \"Search the Kenya ART / ARV clinical guidelines knowledge base\",\n",
    "    \"parameters\": {\n",
    "        \"type\": \"object\",\n",
    "        \"properties\": {\n",
    "            \"query\": {\n",
    "                \"type\": \"string\",\n",
    "                \"description\": \"Clinical question or search text related to ARV regimens, eligibility, dosing, monitoring, or guidelines.\"\n",
    "            }\n",
    "        },\n",
    "        \"required\": [\"query\"],\n",
    "        \"additionalProperties\": False\n",
    "    }\n",
    "}\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "id": "5fdf804d-4ef2-4d81-867d-74683c6724f0",
   "metadata": {},
   "outputs": [],
   "source": [
    "system_prompt = \"\"\"\n",
    "You are a clinical decision support assistant specialized in Kenya ART (ARV) guidelines.\n",
    "Provide accurate, guideline-based answers for HIV treatment, regimens, dosing, eligibility,\n",
    "monitoring, and special populations. If information is not found in the guidelines, say so clearly.\n",
    "\"\"\"\n",
    "\n",
    "question = \"What are the recommended first-line ART regimens for adults?\"\n",
    "\n",
    "chat_messages = [\n",
    "    {\"role\": \"system\", \"content\": system_prompt},\n",
    "    {\"role\": \"user\", \"content\": question}\n",
    "]\n",
    "\n",
    "response = openai_client.responses.create(\n",
    "    model=\"gpt-4o-mini\",\n",
    "    input=chat_messages,\n",
    "    tools=[text_search_tool]\n",
    ")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "id": "b598ab20-c3a9-4d9c-a14d-b46d0297a04d",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Response(id='resp_06f536e96e84f14300698dd049d728819783409f86db439048', created_at=1770901577.0, error=None, incomplete_details=None, instructions=None, metadata={}, model='gpt-4o-mini-2024-07-18', object='response', output=[ResponseFunctionToolCall(arguments='{\"query\":\"first-line ART regimens for adults\"}', call_id='call_RFonMQesDEqRRVm1gm4PdeFA', name='arv_text_search', type='function_call', id='fc_06f536e96e84f14300698dd04a567881979f5c1fe0d40bcfa4', status='completed')], parallel_tool_calls=True, temperature=1.0, tool_choice='auto', tools=[FunctionTool(name='arv_text_search', parameters={'type': 'object', 'properties': {'query': {'type': 'string', 'description': 'Clinical question or search text related to ARV regimens, eligibility, dosing, monitoring, or guidelines.'}}, 'required': ['query'], 'additionalProperties': False}, strict=True, type='function', description='Search the Kenya ART / ARV clinical guidelines knowledge base')], top_p=1.0, background=False, conversation=None, max_output_tokens=None, max_tool_calls=None, previous_response_id=None, prompt=None, prompt_cache_key=None, reasoning=Reasoning(effort=None, generate_summary=None, summary=None), safety_identifier=None, service_tier='default', status='completed', text=ResponseTextConfig(format=ResponseFormatText(type='text'), verbosity='medium'), top_logprobs=0, truncation='disabled', usage=ResponseUsage(input_tokens=137, input_tokens_details=InputTokensDetails(cached_tokens=0), output_tokens=23, output_tokens_details=OutputTokensDetails(reasoning_tokens=0), total_tokens=160), user=None, billing={'payer': 'developer'}, completed_at=1770901578, frequency_penalty=0.0, presence_penalty=0.0, prompt_cache_retention=None, store=True)"
      ]
     },
     "execution_count": 23,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "response"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "id": "f9cc0b67-7d12-4226-a5dc-3633e13234be",
   "metadata": {},
   "outputs": [],
   "source": [
    "import json\n",
    "\n",
    "call = response.output[0]\n",
    "\n",
    "arguments = json.loads(call.arguments)\n",
    "results = text_search(**arguments)\n",
    "\n",
    "results_serializable = [\n",
    "    {\n",
    "        \"page_content\": doc.page_content,\n",
    "        \"metadata\": doc.metadata\n",
    "    }\n",
    "    for doc in results\n",
    "]\n",
    "\n",
    "call_output = {\n",
    "    \"type\": \"function_call_output\",\n",
    "    \"call_id\": call.call_id,\n",
    "    \"output\": json.dumps(results_serializable, ensure_ascii=False),\n",
    "}"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "id": "07d941fe-8bde-4a20-8cc4-89c4869f9d86",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "The recommended first-line ART regimens for adults in Kenya, as per the latest guidelines, include:\n",
      "\n",
      "### Preferred First-Line Regimens:\n",
      "1. **TDF + 3TC + DTG**\n",
      "   - **Dosing**: TDF/3TC/DTG (300/300/50mg): 1 tablet once daily.\n",
      "\n",
      "### Note on Regimen Selection:\n",
      "- All adults initiating ART should be assessed for their eligibility and readiness for treatment, and the above regimens are preferred for their efficacy and tolerability.\n",
      "- Special considerations are made for women who are pregnant or breastfeeding, ensuring their regimens do not compromise maternal or fetal health.\n",
      "\n",
      "For additional details on specific populations or alternative regimens, please refer to the guidelines or consult with a healthcare professional.\n"
     ]
    }
   ],
   "source": [
    "chat_messages.append(call)\n",
    "chat_messages.append(call_output)\n",
    "\n",
    "response = openai_client.responses.create(\n",
    "    model='gpt-4o-mini',\n",
    "    input=chat_messages,\n",
    "    tools=[text_search_tool]\n",
    ")\n",
    "\n",
    "print(response.output_text)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "cdf749be-1ef1-43e9-9a16-9235954810ed",
   "metadata": {},
   "source": [
    "## System Prompt: Instructions"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "id": "2cca97b5-6843-4b59-ac58-c64e67c0e4f6",
   "metadata": {},
   "outputs": [],
   "source": [
    "chat_messages = [\n",
    "    {\"role\": \"system\", \"content\": system_prompt},\n",
    "    {\"role\": \"user\", \"content\": question}\n",
    "]\n",
    "\n",
    "response = openai_client.responses.create(\n",
    "    model='gpt-4o-mini',\n",
    "    input=chat_messages,\n",
    "    tools=[text_search_tool]\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "id": "60c35a76-cd23-4654-9e6d-0b87396557e4",
   "metadata": {},
   "outputs": [],
   "source": [
    "system_prompt = \"\"\"\n",
    "You are a helpful assistant for a course.\n",
    "\n",
    "Before answering any question, first use the search tool to look for relevant information in the course materials.\n",
    "\n",
    "If the search returns relevant results:\n",
    "- Base your answer strictly on that information.\n",
    "- Be clear and specific.\n",
    "\n",
    "If the search does not return relevant results:\n",
    "- Clearly tell the user that the information was not found in the course materials.\n",
    "- Provide general guidance or best practices instead.\n",
    "\"\"\"\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "id": "7ea9a3e1-ca0b-4a4b-ac12-39596306c295",
   "metadata": {},
   "outputs": [],
   "source": [
    "# allows multiple search queries\n",
    "system_prompt = \"\"\"\n",
    "You are a helpful assistant for a course.\n",
    "\n",
    "Before answering any question, always search the course materials for relevant information.\n",
    "\n",
    "If the initial search does not return enough information:\n",
    "- Refine the query or try alternative search terms.\n",
    "- Perform multiple searches if necessary.\n",
    "\n",
    "Use the collected search results to provide a complete and accurate answer.\n",
    "If no relevant information is found after searching, clearly state this and offer general guidance instead.\n",
    "\"\"\"\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "af492b2e-e12d-4b05-819f-7b0945e22592",
   "metadata": {},
   "source": [
    "## Pydantic AI"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "id": "c8e9565b-3108-4f33-b62d-317ff3d9dd9a",
   "metadata": {},
   "outputs": [],
   "source": [
    "from typing import List, Any\n",
    "from pydantic_ai import Agent\n",
    "\n",
    "def arv_text_search(query: str) -> List[str]:\n",
    "    \"\"\"\n",
    "    Perform a text-based search on the Kenya ART (ARV) guidelines index.\n",
    "\n",
    "    Args:\n",
    "        query (str): Clinical or guideline-related search query\n",
    "                     (e.g. regimens, dosing, eligibility, monitoring).\n",
    "\n",
    "    Returns:\n",
    "        List[str]: A list of up to 5 search results from the ARV guidelines index as plain text.\n",
    "    \"\"\"\n",
    "    docs = faq_index.similarity_search(query, k=5)\n",
    "    # Convert Document objects to plain text\n",
    "    return [doc.page_content for doc in docs]\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "id": "6f25a538-6f7f-45d6-817f-98bef44a1faa",
   "metadata": {},
   "outputs": [],
   "source": [
    "from pydantic_ai import Agent\n",
    "\n",
    "agent = Agent(\n",
    "    'openai:gpt-4o-mini',\n",
    "    name=\"hiv_agent\",\n",
    "    system_prompt=system_prompt,\n",
    "    tools=[arv_text_search],  # Use the updated function\n",
    ")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "id": "d7fe739f-0042-4e45-8dbf-0bd53e1de7dd",
   "metadata": {},
   "outputs": [],
   "source": [
    "question = \"Can a newly diagnosed patient be started on ART immediately?\"\n",
    "\n",
    "result = await agent.run(question)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "id": "cfe4c814-be89-4d7f-a142-e6e34867aa78",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "AgentRunResult(output=\"Yes, a newly diagnosed patient can be started on Antiretroviral Therapy (ART) immediately. According to the Kenya ART guidelines:\\n\\n1. **Eligibility for ART**: All individuals with confirmed HIV infection are eligible for ART irrespective of their CD4 count, clinical stage, age, or any co-infection status.\\n\\n2. **Timing of ART Initiation**: ART should ideally be initiated as soon as possible, preferably within 2 weeks of confirmation of HIV status. Patients can even start ART on the same day as their HIV diagnosis if they are ready to do so.\\n\\n3. **Same-Day ART Initiation**: There are additional benefits associated with same-day ART start, including improved retention in care, enhanced viral suppression, and better health outcomes.\\n\\n4. **Readiness for ART**: While laboratory tests are often recommended for monitoring, they are not prerequisites for the initiation of ART. There is an emphasis on ensuring that any issues preventing or delaying ART initiation are addressed promptly.\\n\\nIn summary, immediate initiation of ART is not only permissible but is often recommended, supporting the patient's overall health and reducing the risk of HIV transmission.\")"
      ]
     },
     "execution_count": 32,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "result"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "id": "0734d709-5cc4-4870-8c78-db9143b400fc",
   "metadata": {},
   "outputs": [],
   "source": [
    "# eligibility\n",
    "question = \"Who is eligible to start ART according to Kenya guidelines?\"\n",
    "\n",
    "# timing\n",
    "question = \"When should ART be initiated after HIV diagnosis?\"\n",
    "\n",
    "# regimen selection\n",
    "question = \"What is the recommended first-line ART regimen for adults?\"\n",
    "\n",
    "results = await agent.run(question)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "id": "36bc871a-7c46-4991-a379-6eae22e3f9df",
   "metadata": {},
   "outputs": [],
   "source": [
    "question = \"Can you give me first line treatments for different pupoulation groups between children and adults and women in child bearing age vs those in menopouse\"\n",
    "\n",
    "result = await agent.run(question)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "id": "3daff9e8-f58f-43cf-889a-c2358b6e9312",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "AgentRunResult(output=\"The recommended first-line ART regimen for adults is as follows:\\n\\n- For adults aged 15 years and older, the preferred first-line regimen is:\\n  - **TDF (Tenofovir Disoproxil Fumarate) + 3TC (Lamivudine) + DTG (Dolutegravir)**\\n  \\nThis regimen is generally administered as a fixed-dose combination pill containing TDF/3TC/DTG, typically dosed at 1 tab once daily.\\n\\nIt's important to note that all patients starting ART should have their weight documented at every visit, and appropriate dosing based on their weight needs to be confirmed. \\n\\nIf there are any specific factors or conditions that might modify this regimen (such as co-infections or individual patient needs), consulting the guidelines would provide additional recommendations.\")"
      ]
     },
     "execution_count": 35,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "results"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "id": "a825a407-7a44-44f3-8d61-1b9149b0b19e",
   "metadata": {},
   "outputs": [],
   "source": [
    "import asyncio\n",
    "\n",
    "# result = asyncio.run(agent.run(question))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "id": "1f4fdc03-84ed-4456-98a9-9451289c200b",
   "metadata": {},
   "outputs": [
    {
     "ename": "SyntaxError",
     "evalue": "invalid syntax (1947214667.py, line 1)",
     "output_type": "error",
     "traceback": [
      "  \u001b[36mCell\u001b[39m\u001b[36m \u001b[39m\u001b[32mIn[37]\u001b[39m\u001b[32m, line 1\u001b[39m\n\u001b[31m    \u001b[39m\u001b[31m---\u001b[39m\n       ^\n\u001b[31mSyntaxError\u001b[39m\u001b[31m:\u001b[39m invalid syntax\n"
     ]
    }
   ],
   "source": [
    "---"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "f6e487ac-472a-4c36-bcf1-bf1afa00f412",
   "metadata": {},
   "outputs": [],
   "source": [
    "results.new_messages()\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "ea7d63d3-3ffa-44d0-b566-9ada6c8c6b51",
   "metadata": {},
   "source": [
    "## Evaluation"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "7e4e4e00-3eeb-4c3f-bccd-bdfbd9fb6b90",
   "metadata": {},
   "source": [
    "### Logging"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "55cae36e-6201-49cf-92ce-5a4e39c4b957",
   "metadata": {},
   "outputs": [],
   "source": [
    "question = \"When should ART be initiated after HIV diagnosis?\"\n",
    "result = await agent.run(question)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "6c563164-76a9-4c97-a44f-fc6ef5c748df",
   "metadata": {},
   "outputs": [],
   "source": [
    "from pydantic_ai.messages import ModelMessagesTypeAdapter\n",
    "\n",
    "\n",
    "def log_entry(agent, messages, source=\"user\"):\n",
    "    tools = []\n",
    "\n",
    "    for ts in agent.toolsets:\n",
    "        tools.extend(ts.tools.keys())\n",
    "\n",
    "    dict_messages = ModelMessagesTypeAdapter.dump_python(messages)\n",
    "\n",
    "    return {\n",
    "        \"agent_name\": agent.name,\n",
    "        \"system_prompt\": agent._instructions,\n",
    "        \"provider\": agent.model.system,\n",
    "        \"model\": agent.model.model_name,\n",
    "        \"tools\": tools,\n",
    "        \"messages\": dict_messages,\n",
    "        \"source\": source\n",
    "    }"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "9d118989-87a9-4da1-8317-66d8e5054420",
   "metadata": {},
   "outputs": [],
   "source": [
    "# write logs to a folder\n",
    "\n",
    "import json\n",
    "import secrets\n",
    "from pathlib import Path\n",
    "from datetime import datetime\n",
    "\n",
    "\n",
    "LOG_DIR = Path('logs')\n",
    "LOG_DIR.mkdir(exist_ok=True)\n",
    "\n",
    "\n",
    "def serializer(obj):\n",
    "    if isinstance(obj, datetime):\n",
    "        return obj.isoformat()\n",
    "    raise TypeError(f\"Type {type(obj)} not serializable\")\n",
    "\n",
    "\n",
    "def log_interaction_to_file(agent, messages, source='user'):\n",
    "    entry = log_entry(agent, messages, source)\n",
    "\n",
    "    ts = entry['messages'][-1]['timestamp']\n",
    "    ts_str = ts.strftime(\"%Y%m%d_%H%M%S\")\n",
    "    rand_hex = secrets.token_hex(3)\n",
    "\n",
    "    filename = f\"{agent.name}_{ts_str}_{rand_hex}.json\"\n",
    "    filepath = LOG_DIR / filename\n",
    "\n",
    "    with filepath.open(\"w\", encoding=\"utf-8\") as f_out:\n",
    "        json.dump(entry, f_out, indent=2, default=serializer)\n",
    "\n",
    "    return filepath"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "663c24ba-9bf2-4714-8cb9-7017b3246f67",
   "metadata": {},
   "outputs": [],
   "source": [
    "question = input()\n",
    "result = await agent.run(question)\n",
    "print(result.output)\n",
    "log_interaction_to_file(agent, result.new_messages())"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "7f356b2c-7c1d-417f-b06c-c3643aa43466",
   "metadata": {},
   "outputs": [],
   "source": [
    "question = input()\n",
    "result = await agent.run(question)\n",
    "print(result.output)\n",
    "log_interaction_to_file(agent, result.new_messages())"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "f6c257eb-2039-4501-a4ea-892418626dae",
   "metadata": {},
   "outputs": [],
   "source": [
    "question = input()\n",
    "result = await agent.run(question)\n",
    "print(result.output)\n",
    "log_interaction_to_file(agent, result.new_messages())"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "92b643a8-12d3-4f44-a7e5-41fd83020fd3",
   "metadata": {},
   "source": [
    "## Adding References"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "02c59d22-a178-4d48-90b9-85c4a58a8323",
   "metadata": {},
   "outputs": [],
   "source": [
    "system_prompt = \"\"\"\n",
    "You are a helpful clinical decision support assistant for HIV care in Kenya.\n",
    "\n",
    "Use the search tool to find relevant information from the Kenya ARV Guidelines and related clinical documents before answering questions.\n",
    "\n",
    "If you find specific guidance through search, use it to provide accurate, guideline-aligned answers.\n",
    "\n",
    "Always include references by citing the filename of the source material you used.\n",
    "When citing the reference, replace the filename with the page\n",
    "\n",
    "Format references as:\n",
    "[DOCUMENT TITLE][PAGE]\n",
    "\n",
    "If the search does not return relevant results, clearly state that the guidelines do not specify this and provide safe, general clinical guidance consistent with standard HIV care principles.\n",
    "\n",
    "Do not make up recommendations that are not supported by the guidelines.\n",
    "\"\"\".strip()\n",
    "\n",
    "# Create ARV clinical assistant agent\n",
    "agent = Agent(\n",
    "    \"openai:gpt-4o-mini\",\n",
    "    name=\"arv_guidelines_agent_v2\",\n",
    "    system_prompt=system_prompt,\n",
    "    tools=[arv_text_search],\n",
    ")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "082125b7-7a75-4682-8748-45ac771e8b12",
   "metadata": {},
   "outputs": [],
   "source": [
    "question = input()\n",
    "result = await agent.run(question)\n",
    "print(result.output)\n",
    "log_interaction_to_file(agent, result.new_messages())"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "07eb4501-da77-4303-ada1-547f849e5f06",
   "metadata": {},
   "source": [
    "## LLM as a Judge "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "dabcd094-51d0-4e83-9818-26c88039bb97",
   "metadata": {},
   "outputs": [],
   "source": [
    "evaluation_prompt = \"\"\"\n",
    "Use this checklist to evaluate the quality and safety of an AI agent's answer (<ANSWER>) to a clinical question (<QUESTION>).\n",
    "The full agent interaction log (<LOG>) is provided for context.\n",
    "\n",
    "For each checklist item, determine whether the condition is met.\n",
    "\n",
    "Checklist:\n",
    "\n",
    "- instructions_follow: The agent followed all instructions defined in <INSTRUCTIONS>\n",
    "- instructions_avoid: The agent avoided actions explicitly disallowed (e.g. hallucinating guidelines, giving unsafe advice)\n",
    "- answer_relevant: The response directly addresses the clinical question asked\n",
    "- answer_clear: The answer is clinically clear, accurate, and easy to understand\n",
    "- answer_guideline_aligned: The response is aligned with Kenya ARV Guidelines or explicitly states when guidance is unavailable\n",
    "- answer_citations: The response includes proper citations to source documents when required\n",
    "- completeness: The response covers all key clinical considerations relevant to the question\n",
    "- tool_call_search: The search tool was invoked when guideline lookup was required\n",
    "\n",
    "For each item, output true or false and provide a brief justification based on the answer and log.\n",
    "\"\"\".strip()\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "8c7dadf8-2ba1-4946-a4df-57f965e7e8e9",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Pydantic class with the expected response structure\n",
    "from pydantic import BaseModel\n",
    "\n",
    "class EvaluationCheck(BaseModel):\n",
    "    check_name: str\n",
    "    justification: str\n",
    "    check_pass: bool\n",
    "\n",
    "class EvaluationChecklist(BaseModel):\n",
    "    checklist: list[EvaluationCheck]\n",
    "    summary: str"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "dc84a984-51f4-4c1d-b65c-9659be77ea10",
   "metadata": {},
   "outputs": [],
   "source": [
    "eval_agent = Agent(\n",
    "    'openai:gpt-4o-mini',\n",
    "    name='eval_agent',\n",
    "    system_prompt=evaluation_prompt,\n",
    "    output_type=EvaluationChecklist,\n",
    ")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "d0756b45-960c-476f-8834-08498f25476b",
   "metadata": {},
   "outputs": [],
   "source": [
    "user_prompt_format = \"\"\"\n",
    "<INSTRUCTIONS>{instructions}</INSTRUCTIONS>\n",
    "<QUESTION>{question}</QUESTION>\n",
    "<ANSWER>{answer}</ANSWER>\n",
    "<LOG>{log}</LOG>\n",
    "\"\"\".strip()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "35ec3fc1-a498-4260-a8e9-668f0a1fe563",
   "metadata": {},
   "outputs": [],
   "source": [
    "#  helper function for loading JSON log files\n",
    "def load_log_file(log_file):\n",
    "    with open(log_file, 'r') as f_in:\n",
    "        log_data = json.load(f_in)\n",
    "        log_data['log_file'] = log_file\n",
    "        return log_data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "7f28eaa1-cf95-4f07-92c6-9cfa807297c6",
   "metadata": {},
   "outputs": [],
   "source": [
    "log_record = load_log_file(\"./logs/arv_guidelines_agent_v2_20260210_234813_125259.json\")\n",
    "\n",
    "instructions = log_record['system_prompt']\n",
    "question = log_record['messages'][0]['parts'][0]['content']\n",
    "answer = log_record['messages'][-1]['parts'][0]['content']\n",
    "log = json.dumps(log_record['messages'])\n",
    "\n",
    "user_prompt = user_prompt_format.format(\n",
    "    instructions=instructions,\n",
    "    question=question,\n",
    "    answer=answer,\n",
    "    log=log\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "73f67878-8f3f-4482-b047-f574b9cd6f93",
   "metadata": {},
   "outputs": [],
   "source": [
    "result = await eval_agent.run(user_prompt, output_type=EvaluationChecklist)\n",
    "\n",
    "checklist = result.output\n",
    "print(checklist.summary)\n",
    "\n",
    "for check in checklist.checklist:\n",
    "    print(check)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "c3b9d975-6cfd-4802-85a1-89512d355905",
   "metadata": {},
   "outputs": [],
   "source": [
    "def simplify_log_messages(messages):\n",
    "    log_simplified = []\n",
    "\n",
    "    for m in messages:\n",
    "        parts = []\n",
    "    \n",
    "        for original_part in m['parts']:\n",
    "            part = original_part.copy()\n",
    "            kind = part['part_kind']\n",
    "    \n",
    "            if kind == 'user-prompt':\n",
    "                del part['timestamp']\n",
    "            if kind == 'tool-call':\n",
    "                del part['tool_call_id']\n",
    "            if kind == 'tool-return':\n",
    "                del part['tool_call_id']\n",
    "                del part['metadata']\n",
    "                del part['timestamp']\n",
    "                # Replace actual search results with placeholder to save tokens\n",
    "                part['content'] = 'RETURN_RESULTS_REDACTED'\n",
    "            if kind == 'text':\n",
    "                del part['id']\n",
    "    \n",
    "            parts.append(part)\n",
    "    \n",
    "        message = {\n",
    "            'kind': m['kind'],\n",
    "            'parts': parts\n",
    "        }\n",
    "    \n",
    "        log_simplified.append(message)\n",
    "    return log_simplified"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "89bfafa5-ecfc-4cef-bc79-bd6451502149",
   "metadata": {},
   "outputs": [],
   "source": [
    "async def evaluate_log_record(eval_agent, log_record):\n",
    "    messages = log_record['messages']\n",
    "\n",
    "    instructions = log_record['system_prompt']\n",
    "    question = messages[0]['parts'][0]['content']\n",
    "    answer = messages[-1]['parts'][0]['content']\n",
    "\n",
    "    log_simplified = simplify_log_messages(messages)\n",
    "    log = json.dumps(log_simplified)\n",
    "\n",
    "    user_prompt = user_prompt_format.format(\n",
    "        instructions=instructions,\n",
    "        question=question,\n",
    "        answer=answer,\n",
    "        log=log\n",
    "    )\n",
    "\n",
    "    result = await eval_agent.run(user_prompt, output_type=EvaluationChecklist)\n",
    "    return result.output \n",
    "\n",
    "\n",
    "log_record = load_log_file('./logs/arv_guidelines_agent_v2_20260210_234618_fcc937.json')\n",
    "eval1 = await evaluate_log_record(eval_agent, log_record)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "d701a46b-d000-4d0a-ada1-56e48e9be788",
   "metadata": {},
   "source": [
    "## Data Generation and Evaluation"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "12f765d2-de3d-4c7f-9bc9-1ba0a339a7f1",
   "metadata": {},
   "outputs": [],
   "source": [
    "question_generation_prompt = \"\"\"\n",
    "You are helping to create test questions for an AI agent that answers questions about Kenya HIV care and ARV guidelines.\n",
    "\n",
    "Based on the provided ARV guideline content, generate realistic clinical or guideline-related questions that healthcare workers or students might ask.\n",
    "\n",
    "The questions should:\n",
    "\n",
    "- Be natural and varied in style\n",
    "- Range from simple to complex\n",
    "- Include both specific guideline questions (e.g., regimens, dosing, monitoring, eligibility) and general HIV care questions\n",
    "\n",
    "Generate one question for each guideline record provided.\n",
    "\"\"\".strip()\n",
    "\n",
    "from pydantic import BaseModel\n",
    "\n",
    "class QuestionsList(BaseModel):\n",
    "    questions: list[str]\n",
    "\n",
    "arv_question_generator = Agent(\n",
    "    \"openai:gpt-4o-mini\",\n",
    "    name=\"arv_question_generator\",\n",
    "    system_prompt=question_generation_prompt,\n",
    "    output_type=QuestionsList,\n",
    ")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "7600e866-f56e-423d-a415-99cfb840c759",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Sample 10 records\n",
    "import random\n",
    "\n",
    "source = guides_chunks if 'guides_chunks' in dir() and len(guides_chunks) > 10 else chunks\n",
    "sample = random.sample(source, min(10, len(source)))\n",
    "prompt_docs = [d['section'] for d in sample if d.get('section')]\n",
    "prompt = json.dumps(prompt_docs)\n",
    "\n",
    "result = await arv_question_generator.run(prompt)\n",
    "questions = result.output.questions"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "587c6e11-4488-46c1-8ca4-094a32c690e9",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Iterate over each of the question, ask our agent and log the results\n",
    "from tqdm.auto import tqdm\n",
    "\n",
    "for q in tqdm(questions):\n",
    "    print(q)\n",
    "\n",
    "    result = await agent.run(q)\n",
    "    print(result.output)\n",
    "\n",
    "    log_interaction_to_file(\n",
    "        agent,\n",
    "        result.new_messages(),\n",
    "        source='ai-generated'\n",
    "    )\n",
    "\n",
    "    print()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "028ea702-db32-46e0-9c57-c7123e6de9bd",
   "metadata": {},
   "outputs": [],
   "source": [
    "eval_set = []\n",
    "\n",
    "for log_file in LOG_DIR.glob('*.json'):\n",
    "    if 'arv_guidelines_agent_v2' not in log_file.name:\n",
    "        continue\n",
    "\n",
    "    log_record = load_log_file(log_file)\n",
    "    if log_record['source'] != 'ai-generated':\n",
    "        continue\n",
    "\n",
    "    eval_set.append(log_record)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "1efb679a-aaec-440a-bc13-ca1b0e214803",
   "metadata": {},
   "outputs": [],
   "source": [
    "print(len(eval_set))\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "f7160b72-d120-4ee2-9b4a-8dfd08912dcb",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Eavluating AI generated logs\n",
    "eval_results = []\n",
    "\n",
    "for log_record in tqdm(eval_set):\n",
    "    eval_result = await evaluate_log_record(eval_agent, log_record)\n",
    "    eval_results.append((log_record, eval_result))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "37f237fb-72b9-4165-9e21-bf2221c45de2",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Transform the data to later load it into pandas\n",
    "rows = []\n",
    "\n",
    "for log_record, eval_result in eval_results:\n",
    "    messages = log_record['messages']\n",
    "\n",
    "    row = {\n",
    "        'file': log_record['log_file'].name,\n",
    "        'question': messages[0]['parts'][0]['content'],\n",
    "        'answer': messages[-1]['parts'][0]['content'],\n",
    "    }\n",
    "\n",
    "    checks = {c.check_name: c.check_pass for c in eval_result.checklist}\n",
    "    row.update(checks)\n",
    "\n",
    "    rows.append(row)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "cea363cf-cfc6-4f42-88a7-bea9b6c48c0d",
   "metadata": {},
   "outputs": [],
   "source": [
    "# each row is a key-value dictionary - Create a pandas dataframe \n",
    "import pandas as pd\n",
    "\n",
    "df_evals = pd.DataFrame(rows)\n",
    "df_evals.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "ac596bcf-f609-4b8f-9022-f1cfda762e7c",
   "metadata": {},
   "outputs": [],
   "source": [
    "df_evals"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "bca3e2a8-d3dc-4595-aeb8-078972d1344d",
   "metadata": {},
   "outputs": [],
   "source": [
    "df_evals_clean.dtypes"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "c906c2b5-cb24-4556-9fea-a80db2e1617d",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Convert True/False or string \"True\"/\"False\" to numeric (1/0)\n",
    "df_evals_clean = df_evals.replace({\"True\": 1, \"False\": 0, True: 1, False: 0})\n",
    "\n",
    "# Calculate mean only for numeric columns\n",
    "pass_rates = df_evals_clean.mean(numeric_only=True)\n",
    "\n",
    "# Convert to percentages for readability\n",
    "pass_rates = (pass_rates * 100).round(1)\n",
    "\n",
    "print(pass_rates)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "243eeff1-17e2-4b32-a37d-386348c383be",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Only 81% of responses follow instructions completely\n",
    "# 100% responses avoid forbidden actions \n",
    "# 90% responses are relevant and clear\n",
    "# 77% include proper citations (great)\n",
    "# 86% of responses are complete\n",
    "# 81% responses use the search tool\n",
    "\n",
    "\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "5c383469-a53a-4a1e-93d3-acb15d911433",
   "metadata": {},
   "source": [
    "## Evaluating functions and tools"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "69a522de-3829-40be-b968-ce2e2655d44e",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Precision and Recall: How many relevant results were retrieved vs. how many relevant results were missed\n",
    "# Hit Rate: Percentage of queries that return at least one relevant result\n",
    "# MRR (Mean Reciprocal Rank): Reflects the position of the first relevant result in the ranking"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "d3054aa1-3518-43ba-905c-04edcf3f3f6b",
   "metadata": {},
   "outputs": [],
   "source": [
    "def evaluate_search_quality(search_function, test_queries):\n",
    "    results = []\n",
    "    \n",
    "    for query, expected_docs in test_queries:\n",
    "        search_results = search_function(query, num_results=5)\n",
    "        \n",
    "        # Calculate hit rate\n",
    "        relevant_found = any(doc['filename'] in expected_docs for doc in search_results)\n",
    "        \n",
    "        # Calculate MRR\n",
    "        for i, doc in enumerate(search_results):\n",
    "            if doc['filename'] in expected_docs:\n",
    "                mrr = 1 / (i + 1)\n",
    "                break\n",
    "        else:\n",
    "            mrr = 0\n",
    "            \n",
    "        results.append({\n",
    "            'query': query,\n",
    "            'hit': relevant_found,\n",
    "            'mrr': mrr\n",
    "        })\n",
    "    return results"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "b837b42c-f712-4956-98fd-044f0a840975",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python (kenya-hiv-cdss)",
   "language": "python",
   "name": "kenya-hiv-cdss"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.4"
  },
  "widgets": {
   "application/vnd.jupyter.widget-state+json": {
    "state": {
     "0c3e4cbd414f4f51ab5c7faa4e2068a1": {
      "model_module": "@jupyter-widgets/base",
      "model_module_version": "2.0.0",
      "model_name": "LayoutModel",
      "state": {
       "_model_module": "@jupyter-widgets/base",
       "_model_module_version": "2.0.0",
       "_model_name": "LayoutModel",
       "_view_count": null,
       "_view_module": "@jupyter-widgets/base",
       "_view_module_version": "2.0.0",
       "_view_name": "LayoutView",
       "align_content": null,
       "align_items": null,
       "align_self": null,
       "border_bottom": null,
       "border_left": null,
       "border_right": null,
       "border_top": null,
       "bottom": null,
       "display": null,
       "flex": null,
       "flex_flow": null,
       "grid_area": null,
       "grid_auto_columns": null,
       "grid_auto_flow": null,
       "grid_auto_rows": null,
       "grid_column": null,
       "grid_gap": null,
       "grid_row": null,
       "grid_template_areas": null,
       "grid_template_columns": null,
       "grid_template_rows": null,
       "height": null,
       "justify_content": null,
       "justify_items": null,
       "left": null,
       "margin": null,
       "max_height": null,
       "max_width": null,
       "min_height": null,
       "min_width": null,
       "object_fit": null,
       "object_position": null,
       "order": null,
       "overflow": null,
       "padding": null,
       "right": null,
       "top": null,
       "visibility": null,
       "width": "20px"
      }
     },
     "1edc8bd936904e3d8ff979a21a43680c": {
      "model_module": "@jupyter-widgets/controls",
      "model_module_version": "2.0.0",
      "model_name": "FloatProgressModel",
      "state": {
       "_dom_classes": [],
       "_model_module": "@jupyter-widgets/controls",
       "_model_module_version": "2.0.0",
       "_model_name": "FloatProgressModel",
       "_view_count": null,
       "_view_module": "@jupyter-widgets/controls",
       "_view_module_version": "2.0.0",
       "_view_name": "ProgressView",
       "bar_style": "success",
       "description": "",
       "description_allow_html": false,
       "layout": "IPY_MODEL_0c3e4cbd414f4f51ab5c7faa4e2068a1",
       "max": 1,
       "min": 0,
       "orientation": "horizontal",
       "style": "IPY_MODEL_4247dcaaf59a4fb0a7648a1aac8855b8",
       "tabbable": null,
       "tooltip": null,
       "value": 0
      }
     },
     "2d345a3aab784625bc982a686529bd1d": {
      "model_module": "@jupyter-widgets/controls",
      "model_module_version": "2.0.0",
      "model_name": "ProgressStyleModel",
      "state": {
       "_model_module": "@jupyter-widgets/controls",
       "_model_module_version": "2.0.0",
       "_model_name": "ProgressStyleModel",
       "_view_count": null,
       "_view_module": "@jupyter-widgets/base",
       "_view_module_version": "2.0.0",
       "_view_name": "StyleView",
       "bar_color": null,
       "description_width": ""
      }
     },
     "37dc0d93fd154464b4630766dc82d1c9": {
      "model_module": "@jupyter-widgets/base",
      "model_module_version": "2.0.0",
      "model_name": "LayoutModel",
      "state": {
       "_model_module": "@jupyter-widgets/base",
       "_model_module_version": "2.0.0",
       "_model_name": "LayoutModel",
       "_view_count": null,
       "_view_module": "@jupyter-widgets/base",
       "_view_module_version": "2.0.0",
       "_view_name": "LayoutView",
       "align_content": null,
       "align_items": null,
       "align_self": null,
       "border_bottom": null,
       "border_left": null,
       "border_right": null,
       "border_top": null,
       "bottom": null,
       "display": null,
       "flex": null,
       "flex_flow": null,
       "grid_area": null,
       "grid_auto_columns": null,
       "grid_auto_flow": null,
       "grid_auto_rows": null,
       "grid_column": null,
       "grid_gap": null,
       "grid_row": null,
       "grid_template_areas": null,
       "grid_template_columns": null,
       "grid_template_rows": null,
       "height": null,
       "justify_content": null,
       "justify_items": null,
       "left": null,
       "margin": null,
       "max_height": null,
       "max_width": null,
       "min_height": null,
       "min_width": null,
       "object_fit": null,
       "object_position": null,
       "order": null,
       "overflow": null,
       "padding": null,
       "right": null,
       "top": null,
       "visibility": null,
       "width": null
      }
     },
     "40284b805555425a8418eaf81a6709c1": {
      "model_module": "@jupyter-widgets/controls",
      "model_module_version": "2.0.0",
      "model_name": "HTMLStyleModel",
      "state": {
       "_model_module": "@jupyter-widgets/controls",
       "_model_module_version": "2.0.0",
       "_model_name": "HTMLStyleModel",
       "_view_count": null,
       "_view_module": "@jupyter-widgets/base",
       "_view_module_version": "2.0.0",
       "_view_name": "StyleView",
       "background": null,
       "description_width": "",
       "font_size": null,
       "text_color": null
      }
     },
     "41257a7770404cea804d2088f729eca4": {
      "model_module": "@jupyter-widgets/base",
      "model_module_version": "2.0.0",
      "model_name": "LayoutModel",
      "state": {
       "_model_module": "@jupyter-widgets/base",
       "_model_module_version": "2.0.0",
       "_model_name": "LayoutModel",
       "_view_count": null,
       "_view_module": "@jupyter-widgets/base",
       "_view_module_version": "2.0.0",
       "_view_name": "LayoutView",
       "align_content": null,
       "align_items": null,
       "align_self": null,
       "border_bottom": null,
       "border_left": null,
       "border_right": null,
       "border_top": null,
       "bottom": null,
       "display": null,
       "flex": null,
       "flex_flow": null,
       "grid_area": null,
       "grid_auto_columns": null,
       "grid_auto_flow": null,
       "grid_auto_rows": null,
       "grid_column": null,
       "grid_gap": null,
       "grid_row": null,
       "grid_template_areas": null,
       "grid_template_columns": null,
       "grid_template_rows": null,
       "height": null,
       "justify_content": null,
       "justify_items": null,
       "left": null,
       "margin": null,
       "max_height": null,
       "max_width": null,
       "min_height": null,
       "min_width": null,
       "object_fit": null,
       "object_position": null,
       "order": null,
       "overflow": null,
       "padding": null,
       "right": null,
       "top": null,
       "visibility": null,
       "width": null
      }
     },
     "4247dcaaf59a4fb0a7648a1aac8855b8": {
      "model_module": "@jupyter-widgets/controls",
      "model_module_version": "2.0.0",
      "model_name": "ProgressStyleModel",
      "state": {
       "_model_module": "@jupyter-widgets/controls",
       "_model_module_version": "2.0.0",
       "_model_name": "ProgressStyleModel",
       "_view_count": null,
       "_view_module": "@jupyter-widgets/base",
       "_view_module_version": "2.0.0",
       "_view_name": "StyleView",
       "bar_color": null,
       "description_width": ""
      }
     },
     "4686d436a8884729a364e4e6a028b889": {
      "model_module": "@jupyter-widgets/base",
      "model_module_version": "2.0.0",
      "model_name": "LayoutModel",
      "state": {
       "_model_module": "@jupyter-widgets/base",
       "_model_module_version": "2.0.0",
       "_model_name": "LayoutModel",
       "_view_count": null,
       "_view_module": "@jupyter-widgets/base",
       "_view_module_version": "2.0.0",
       "_view_name": "LayoutView",
       "align_content": null,
       "align_items": null,
       "align_self": null,
       "border_bottom": null,
       "border_left": null,
       "border_right": null,
       "border_top": null,
       "bottom": null,
       "display": null,
       "flex": null,
       "flex_flow": null,
       "grid_area": null,
       "grid_auto_columns": null,
       "grid_auto_flow": null,
       "grid_auto_rows": null,
       "grid_column": null,
       "grid_gap": null,
       "grid_row": null,
       "grid_template_areas": null,
       "grid_template_columns": null,
       "grid_template_rows": null,
       "height": null,
       "justify_content": null,
       "justify_items": null,
       "left": null,
       "margin": null,
       "max_height": null,
       "max_width": null,
       "min_height": null,
       "min_width": null,
       "object_fit": null,
       "object_position": null,
       "order": null,
       "overflow": null,
       "padding": null,
       "right": null,
       "top": null,
       "visibility": null,
       "width": null
      }
     },
     "6ce139d252c24712931698f3c2dc4770": {
      "model_module": "@jupyter-widgets/controls",
      "model_module_version": "2.0.0",
      "model_name": "FloatProgressModel",
      "state": {
       "_dom_classes": [],
       "_model_module": "@jupyter-widgets/controls",
       "_model_module_version": "2.0.0",
       "_model_name": "FloatProgressModel",
       "_view_count": null,
       "_view_module": "@jupyter-widgets/controls",
       "_view_module_version": "2.0.0",
       "_view_name": "ProgressView",
       "bar_style": "success",
       "description": "",
       "description_allow_html": false,
       "layout": "IPY_MODEL_8c751b7141e74dfa9f224ef9e9359b8d",
       "max": 286,
       "min": 0,
       "orientation": "horizontal",
       "style": "IPY_MODEL_2d345a3aab784625bc982a686529bd1d",
       "tabbable": null,
       "tooltip": null,
       "value": 286
      }
     },
     "7e52755ad06a496da5d99b5e6ab388dd": {
      "model_module": "@jupyter-widgets/controls",
      "model_module_version": "2.0.0",
      "model_name": "HTMLModel",
      "state": {
       "_dom_classes": [],
       "_model_module": "@jupyter-widgets/controls",
       "_model_module_version": "2.0.0",
       "_model_name": "HTMLModel",
       "_view_count": null,
       "_view_module": "@jupyter-widgets/controls",
       "_view_module_version": "2.0.0",
       "_view_name": "HTMLView",
       "description": "",
       "description_allow_html": false,
       "layout": "IPY_MODEL_37dc0d93fd154464b4630766dc82d1c9",
       "placeholder": "​",
       "style": "IPY_MODEL_84d4f0f92d6b4ed9adc4b5b76911b107",
       "tabbable": null,
       "tooltip": null,
       "value": "Processing docs: 100%"
      }
     },
     "7fc9d3e8f585436d8b0e9559935183a4": {
      "model_module": "@jupyter-widgets/controls",
      "model_module_version": "2.0.0",
      "model_name": "HTMLModel",
      "state": {
       "_dom_classes": [],
       "_model_module": "@jupyter-widgets/controls",
       "_model_module_version": "2.0.0",
       "_model_name": "HTMLModel",
       "_view_count": null,
       "_view_module": "@jupyter-widgets/controls",
       "_view_module_version": "2.0.0",
       "_view_name": "HTMLView",
       "description": "",
       "description_allow_html": false,
       "layout": "IPY_MODEL_4686d436a8884729a364e4e6a028b889",
       "placeholder": "​",
       "style": "IPY_MODEL_b19ee0e254574e7ba0d3ac8fa47d3b2b",
       "tabbable": null,
       "tooltip": null,
       "value": " 0/0 [00:00&lt;?, ?it/s]"
      }
     },
     "84d4f0f92d6b4ed9adc4b5b76911b107": {
      "model_module": "@jupyter-widgets/controls",
      "model_module_version": "2.0.0",
      "model_name": "HTMLStyleModel",
      "state": {
       "_model_module": "@jupyter-widgets/controls",
       "_model_module_version": "2.0.0",
       "_model_name": "HTMLStyleModel",
       "_view_count": null,
       "_view_module": "@jupyter-widgets/base",
       "_view_module_version": "2.0.0",
       "_view_name": "StyleView",
       "background": null,
       "description_width": "",
       "font_size": null,
       "text_color": null
      }
     },
     "8c751b7141e74dfa9f224ef9e9359b8d": {
      "model_module": "@jupyter-widgets/base",
      "model_module_version": "2.0.0",
      "model_name": "LayoutModel",
      "state": {
       "_model_module": "@jupyter-widgets/base",
       "_model_module_version": "2.0.0",
       "_model_name": "LayoutModel",
       "_view_count": null,
       "_view_module": "@jupyter-widgets/base",
       "_view_module_version": "2.0.0",
       "_view_name": "LayoutView",
       "align_content": null,
       "align_items": null,
       "align_self": null,
       "border_bottom": null,
       "border_left": null,
       "border_right": null,
       "border_top": null,
       "bottom": null,
       "display": null,
       "flex": null,
       "flex_flow": null,
       "grid_area": null,
       "grid_auto_columns": null,
       "grid_auto_flow": null,
       "grid_auto_rows": null,
       "grid_column": null,
       "grid_gap": null,
       "grid_row": null,
       "grid_template_areas": null,
       "grid_template_columns": null,
       "grid_template_rows": null,
       "height": null,
       "justify_content": null,
       "justify_items": null,
       "left": null,
       "margin": null,
       "max_height": null,
       "max_width": null,
       "min_height": null,
       "min_width": null,
       "object_fit": null,
       "object_position": null,
       "order": null,
       "overflow": null,
       "padding": null,
       "right": null,
       "top": null,
       "visibility": null,
       "width": null
      }
     },
     "8f6f30d4e3c14103adcc6f8336feb672": {
      "model_module": "@jupyter-widgets/base",
      "model_module_version": "2.0.0",
      "model_name": "LayoutModel",
      "state": {
       "_model_module": "@jupyter-widgets/base",
       "_model_module_version": "2.0.0",
       "_model_name": "LayoutModel",
       "_view_count": null,
       "_view_module": "@jupyter-widgets/base",
       "_view_module_version": "2.0.0",
       "_view_name": "LayoutView",
       "align_content": null,
       "align_items": null,
       "align_self": null,
       "border_bottom": null,
       "border_left": null,
       "border_right": null,
       "border_top": null,
       "bottom": null,
       "display": null,
       "flex": null,
       "flex_flow": null,
       "grid_area": null,
       "grid_auto_columns": null,
       "grid_auto_flow": null,
       "grid_auto_rows": null,
       "grid_column": null,
       "grid_gap": null,
       "grid_row": null,
       "grid_template_areas": null,
       "grid_template_columns": null,
       "grid_template_rows": null,
       "height": null,
       "justify_content": null,
       "justify_items": null,
       "left": null,
       "margin": null,
       "max_height": null,
       "max_width": null,
       "min_height": null,
       "min_width": null,
       "object_fit": null,
       "object_position": null,
       "order": null,
       "overflow": null,
       "padding": null,
       "right": null,
       "top": null,
       "visibility": null,
       "width": null
      }
     },
     "958faa34da7442aa92c0cb0e651b8a60": {
      "model_module": "@jupyter-widgets/base",
      "model_module_version": "2.0.0",
      "model_name": "LayoutModel",
      "state": {
       "_model_module": "@jupyter-widgets/base",
       "_model_module_version": "2.0.0",
       "_model_name": "LayoutModel",
       "_view_count": null,
       "_view_module": "@jupyter-widgets/base",
       "_view_module_version": "2.0.0",
       "_view_name": "LayoutView",
       "align_content": null,
       "align_items": null,
       "align_self": null,
       "border_bottom": null,
       "border_left": null,
       "border_right": null,
       "border_top": null,
       "bottom": null,
       "display": null,
       "flex": null,
       "flex_flow": null,
       "grid_area": null,
       "grid_auto_columns": null,
       "grid_auto_flow": null,
       "grid_auto_rows": null,
       "grid_column": null,
       "grid_gap": null,
       "grid_row": null,
       "grid_template_areas": null,
       "grid_template_columns": null,
       "grid_template_rows": null,
       "height": null,
       "justify_content": null,
       "justify_items": null,
       "left": null,
       "margin": null,
       "max_height": null,
       "max_width": null,
       "min_height": null,
       "min_width": null,
       "object_fit": null,
       "object_position": null,
       "order": null,
       "overflow": null,
       "padding": null,
       "right": null,
       "top": null,
       "visibility": null,
       "width": null
      }
     },
     "95d13f9134cb4e97b2ba3a1f640156a5": {
      "model_module": "@jupyter-widgets/controls",
      "model_module_version": "2.0.0",
      "model_name": "HBoxModel",
      "state": {
       "_dom_classes": [],
       "_model_module": "@jupyter-widgets/controls",
       "_model_module_version": "2.0.0",
       "_model_name": "HBoxModel",
       "_view_count": null,
       "_view_module": "@jupyter-widgets/controls",
       "_view_module_version": "2.0.0",
       "_view_name": "HBoxView",
       "box_style": "",
       "children": [
        "IPY_MODEL_7e52755ad06a496da5d99b5e6ab388dd",
        "IPY_MODEL_6ce139d252c24712931698f3c2dc4770",
        "IPY_MODEL_9fdc881dcd3c4993b70ad52f5d545f47"
       ],
       "layout": "IPY_MODEL_958faa34da7442aa92c0cb0e651b8a60",
       "tabbable": null,
       "tooltip": null
      }
     },
     "98edaa91b60d484ab606f712a2423d5e": {
      "model_module": "@jupyter-widgets/base",
      "model_module_version": "2.0.0",
      "model_name": "LayoutModel",
      "state": {
       "_model_module": "@jupyter-widgets/base",
       "_model_module_version": "2.0.0",
       "_model_name": "LayoutModel",
       "_view_count": null,
       "_view_module": "@jupyter-widgets/base",
       "_view_module_version": "2.0.0",
       "_view_name": "LayoutView",
       "align_content": null,
       "align_items": null,
       "align_self": null,
       "border_bottom": null,
       "border_left": null,
       "border_right": null,
       "border_top": null,
       "bottom": null,
       "display": null,
       "flex": null,
       "flex_flow": null,
       "grid_area": null,
       "grid_auto_columns": null,
       "grid_auto_flow": null,
       "grid_auto_rows": null,
       "grid_column": null,
       "grid_gap": null,
       "grid_row": null,
       "grid_template_areas": null,
       "grid_template_columns": null,
       "grid_template_rows": null,
       "height": null,
       "justify_content": null,
       "justify_items": null,
       "left": null,
       "margin": null,
       "max_height": null,
       "max_width": null,
       "min_height": null,
       "min_width": null,
       "object_fit": null,
       "object_position": null,
       "order": null,
       "overflow": null,
       "padding": null,
       "right": null,
       "top": null,
       "visibility": null,
       "width": null
      }
     },
     "9fdc881dcd3c4993b70ad52f5d545f47": {
      "model_module": "@jupyter-widgets/controls",
      "model_module_version": "2.0.0",
      "model_name": "HTMLModel",
      "state": {
       "_dom_classes": [],
       "_model_module": "@jupyter-widgets/controls",
       "_model_module_version": "2.0.0",
       "_model_name": "HTMLModel",
       "_view_count": null,
       "_view_module": "@jupyter-widgets/controls",
       "_view_module_version": "2.0.0",
       "_view_name": "HTMLView",
       "description": "",
       "description_allow_html": false,
       "layout": "IPY_MODEL_98edaa91b60d484ab606f712a2423d5e",
       "placeholder": "​",
       "style": "IPY_MODEL_f6cf331fec4342da813fdd65ec427458",
       "tabbable": null,
       "tooltip": null,
       "value": " 286/286 [07:35&lt;00:00,  1.50s/it]"
      }
     },
     "b139854af3cf4fb69cade2c9ee08e023": {
      "model_module": "@jupyter-widgets/controls",
      "model_module_version": "2.0.0",
      "model_name": "HBoxModel",
      "state": {
       "_dom_classes": [],
       "_model_module": "@jupyter-widgets/controls",
       "_model_module_version": "2.0.0",
       "_model_name": "HBoxModel",
       "_view_count": null,
       "_view_module": "@jupyter-widgets/controls",
       "_view_module_version": "2.0.0",
       "_view_name": "HBoxView",
       "box_style": "",
       "children": [
        "IPY_MODEL_c6a2387cc9a1473d9db66c7d42a1d91f",
        "IPY_MODEL_1edc8bd936904e3d8ff979a21a43680c",
        "IPY_MODEL_7fc9d3e8f585436d8b0e9559935183a4"
       ],
       "layout": "IPY_MODEL_8f6f30d4e3c14103adcc6f8336feb672",
       "tabbable": null,
       "tooltip": null
      }
     },
     "b19ee0e254574e7ba0d3ac8fa47d3b2b": {
      "model_module": "@jupyter-widgets/controls",
      "model_module_version": "2.0.0",
      "model_name": "HTMLStyleModel",
      "state": {
       "_model_module": "@jupyter-widgets/controls",
       "_model_module_version": "2.0.0",
       "_model_name": "HTMLStyleModel",
       "_view_count": null,
       "_view_module": "@jupyter-widgets/base",
       "_view_module_version": "2.0.0",
       "_view_name": "StyleView",
       "background": null,
       "description_width": "",
       "font_size": null,
       "text_color": null
      }
     },
     "c6a2387cc9a1473d9db66c7d42a1d91f": {
      "model_module": "@jupyter-widgets/controls",
      "model_module_version": "2.0.0",
      "model_name": "HTMLModel",
      "state": {
       "_dom_classes": [],
       "_model_module": "@jupyter-widgets/controls",
       "_model_module_version": "2.0.0",
       "_model_name": "HTMLModel",
       "_view_count": null,
       "_view_module": "@jupyter-widgets/controls",
       "_view_module_version": "2.0.0",
       "_view_name": "HTMLView",
       "description": "",
       "description_allow_html": false,
       "layout": "IPY_MODEL_41257a7770404cea804d2088f729eca4",
       "placeholder": "​",
       "style": "IPY_MODEL_40284b805555425a8418eaf81a6709c1",
       "tabbable": null,
       "tooltip": null,
       "value": ""
      }
     },
     "f6cf331fec4342da813fdd65ec427458": {
      "model_module": "@jupyter-widgets/controls",
      "model_module_version": "2.0.0",
      "model_name": "HTMLStyleModel",
      "state": {
       "_model_module": "@jupyter-widgets/controls",
       "_model_module_version": "2.0.0",
       "_model_name": "HTMLStyleModel",
       "_view_count": null,
       "_view_module": "@jupyter-widgets/base",
       "_view_module_version": "2.0.0",
       "_view_name": "StyleView",
       "background": null,
       "description_width": "",
       "font_size": null,
       "text_color": null
      }
     }
    },
    "version_major": 2,
    "version_minor": 0
   }
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
